[
    "The sample is a record of a clinical trial with a phase 1/phase 2 designation. The trial is focused on breast cancer and includes a list of ICD-10 codes associated with the disease. The trial is testing the effectiveness of three drugs - trastuzumab, paclitaxel, and myocet. The eligibility criteria for the trial includes women between the ages of 18-70 with metastatic or locally advanced breast cancer, HER2 overexpression, and at least one measurable lesion. The exclusion criteria includes prior treatment for advanced breast cancer, prior treatment with Herceptin, bone or central nervous system metastasis as the only site of disease, and a history of another malignancy within 5 years of the study.",
    "The sample is a clinical trial for breast cancer patients in phases 1 and 2. The trial is testing the effectiveness of the drugs Myocet, Taxotere, and Herceptin on breast cancer tumors that overexpress HER2neu. The trial has specific eligibility criteria, including a confirmed diagnosis of breast cancer stages II and IIIA, no evidence of metastasis, and adequate cardiac, hepatic, and renal function. Patients must also be over 18 years old and have a performance status (Karnofsky index) of at least 80. Exclusion criteria include prior systemic therapy for breast cancer, prior treatment with anthracyclines or taxanes, and serious comorbidities such as congestive heart failure or uncontrolled hypertension. The trial is not open to males.",
    "The sample is a clinical trial for patients with pancreatic cancer in phase 1/phase 2. The trial is testing the effectiveness of the drugs vismodegib and gemcitabine hydrochloride. The eligibility criteria include having histologically or cytologically confirmed adenocarcinoma of the pancreas, measurable disease, and either newly diagnosed chemo-na\u00efve metastatic pancreatic cancer or recurrent disease after curative-intent surgery which has now recurred and is metastatic. Patients must also meet certain age, performance status, and blood count requirements, and have no active bleeding or pathological condition that carries high risk of bleeding. Women of child-bearing potential and men must use at least one form of contraception for the duration of study participation. The exclusion criteria include no prior chemotherapy for metastatic pancreatic cancer, known brain metastases, and clinically active liver disease.",
    "The sample is a clinical trial for the treatment of diabetic macular edema. The trial is in phase 1/phase 2 and involves the drug ranibizumab. The eligibility criteria include being over 18 years old, having a diagnosis of diabetes mellitus, clinical evidence of retinal thickening due to macular edema, and previous history of two consecutive intravitreal bevacizumab injections for the treatment of diabetic macular edema with incomplete resolution of central subfield thickening. The trial also has exclusion criteria, such as pregnancy, participation in another ocular investigation or trial simultaneously, and uncontrolled glaucoma.",
    "The sample is a clinical trial for type 1 diabetes, with a combination of phase 1 and phase 2. The trial involves the use of etanercept and placebo drugs. The eligibility criteria for the trial include subjects aged 3-18 years with T1DM, positive GAD 65 and/or islet cell antibody, HbA1c at diagnosis above 6%, insulin regimen with 3 injections of insulin daily, normal white blood count and platelets, normal ALT and AST, creatinine less than 1.8 mg/dl, and T1DM duration equal or less than 4 weeks. The exclusion criteria include infection requiring IV antibiotics at diagnosis or within the past 14 days from study entry, BMI over 85th percentile for age and gender, unstable household, unable to provide compliance with study drug, insulin and study visits, evidence of psychiatric disease in the potential study subject and/or primary care taker, and chronic diseases, including additional autoimmune disorders with the exception of euthyroid autoimmune thyroiditis.",
    "The sample is a clinical trial for patients with multiple myeloma in phase 1/phase 2. The trial is testing the drug hll1-dox, which is the doxorubicin conjugate of milatuzumab. The eligibility criteria include being at least 18 years old, having measurable disease, and having been refractory or relapsed to at least two prior standard systemic anti-myeloma treatment regimens, one of which must include either thalidomide, lenalidomide or bortezomib. Patients must also have adequate performance status, life expectancy of at least 6 months, and meet certain hematologic, cardiac, renal, and hepatic function requirements. Exclusion criteria include pregnancy or lactation, eligibility for stem cell transplant, and prior treatment with certain therapeutic agents or investigational agents within 4 weeks. Patients must also not have persistent \u2265 Grade 2 toxicity from prior treatments and must not have a history of allergic or adverse reactions to anthracycline/anthracenedione agents.",
    "The sample is a clinical trial for patients with progressive or recurrent glioblastoma, a type of brain tumor. The trial is in phase 1/phase 2 and involves the drug tandutinib. The eligibility criteria include having a confirmed diagnosis of glioblastoma, measurable disease, and a Karnofsky performance status of 60-100%. Patients must also meet various medical requirements, such as having certain blood counts and no active infections. Additionally, patients must not have any other serious medical conditions or be taking certain medications. The trial also includes a feasibility study for patients planning to undergo surgical resection or biopsy.",
    "The sample is a clinical trial for patients with non-small cell lung cancer or lung cancer in advanced stages. The trial is in phase 1/phase 2 and the treatment involves a combination of abt-751 and carboplatin. The eligibility criteria include being at least 18 years old, having a confirmed diagnosis of NSCLC, having at least one measurable lesion, and having no known curative treatment that has progressed despite therapy for recurrent/metastatic disease or prior therapy was discontinued due to intolerable toxicities. The trial also requires adequate hematologic, renal, and hepatic function, as well as an Eastern Cooperative Oncology Group (ECOG) Performance Score of 0-1. The exclusion criteria include any other malignancy within 3 years except in situ carcinoma, untreated central nervous system (CNS) metastasis, and concurrent anti-cancer therapy or radiotherapy.",
    "The sample is a record of a clinical trial with a phase 1/phase 2 designation. The trial is focused on metastatic colorectal cancer and includes a list of ICD-10 codes for the disease. The trial involves the use of three drugs: azd2171, folfox (5-fluorouracil, leucovorin, oxaliplatin), and placebo cediranib. The eligibility criteria for the trial include having metastatic colorectal cancer, a WHO performance status of 0-1, and a life expectancy of 12 weeks or longer. The exclusion criteria include having uncontrolled brain metastases, inappropriate laboratory test values, and poorly controlled hypertension.",
    "The sample is a record of a clinical trial with a phase 1/phase 2 designation. The trial is focused on non-small-cell lung cancer and involves the use of three drugs: pemetrexed, cisplatin, and carboplatin. The trial has a set of inclusion and exclusion criteria that participants must meet in order to be eligible to participate. The inclusion criteria include having inoperable non-small-cell lung cancer, no weight loss greater than 10% in the 3 months prior to enrolling in the trial, and adequate kidney, liver, and lung function. The exclusion criteria include having had previous surgery to remove a lung tumor, previous chemotherapy or radiation therapy for lung cancer, inability to take vitamin supplementation, having had a heart attack within the past 6 months, and having an active infection.",
    "The sample is a record of a clinical trial with a combination of phase 1 and phase 2. The trial is focused on pancreatic neoplasms and adenocarcinoma, with corresponding ICD-10 codes. The trial involves the use of two drugs, gemcitabine and etanercept. The eligibility criteria for the trial include having a pathological diagnosis of recurring or metastatic pancreatic adenocarcinoma, no prior chemotherapy, immunology treatments or hormonal treatments, measurable disease, and being over 18 years old. However, there are also exclusion criteria, such as being pregnant or nursing, having psychiatric disorders that would interfere with consent ability, having known brain or leptomeningeal disease, and having a history of myocardial infarction within the previous six months. Additionally, any concurrent illness that would constitute a hazard to participation in the study, known sensitivity to gemcitabine or etanercept, and prior treatment with etanercept are also exclusion criteria.",
    "The sample is a clinical trial with a combination of phase 1 and phase 2. The trial is focused on diabetes mellitus and involves a list of icd-10 codes for the disease. The drugs being tested are viaject\u00ae25, viaject\u00ae7, and insulin lispro. The eligibility criteria for the trial include being between the ages of 19 and 65, having a body mass index between 18 and 28 kg/m2, being diagnosed with type 1 diabetes mellitus for at least 1 year, having insulin antibody less than or equal to 10 \u00b5U/mL at screening, being a non-smoker, and providing signed and dated informed consent. The exclusion criteria include having type 2 diabetes mellitus, a C-peptide value of >1.0 ng/mL, an HbA1c value of > 10.0%, a history of hypersensitivity to any of the components in the study medication, a history of severe or multiple allergies, treatment with any other investigational drug in the last 3 months before study entry, and any systemic treatment with drugs known to interfere with glucose metabolism such as systemic corticoids, non-selective beta-blockers, and monoamine oxidase (MAO) inhibitors within 3 months prior to randomization. Other exclusion criteria include changes in concomitant medication other than insulin or insulin analogues in the last 3 weeks prior to randomization, use of non-prescription drugs within 3 weeks prior to the first dose of the test drug, progressive disease likely to prove fatal, current drug or alcohol abuse, significant cardiovascular, respiratory, gastrointestinal, hepatic, renal, neurological, psychiatric and/or hematological disease, clinically significant abnormal hematology or biochemistry screening tests, any serious systemic infectious disease during the four weeks prior to the first dose of study drug, history of any illness that might confound the results of the trial or pose a risk in administering the trial drug to the subject, blood donation within the last 30 days, lactating women, pregnant women or women intending to become pregnant during the study, sexually active women not using adequate contraceptive methods, positive serology for HIV, Hepatitis B or Hepatitis C, abnormal ECG, safety lab or physical examination results that are deemed clinically significant by the Investigator, and lack of compliance or other reasons which prevent the participation of the subject in the study.",
    "The sample is a clinical trial for patients with locally advanced or metastatic pancreatic adenocarcinoma. The trial is divided into two phases, phase 1 and phase 2. The patients must meet certain eligibility criteria, including having a previously unirradiated, measurable lesion and adequate hepatic and renal function. They must also have a baseline performance status of Eastern Cooperative Oncology Group (ECOG) 0, 1, or 2. The patients must not have certain exclusion criteria, such as active CNS metastases or known hypersensitivity to 5-FU. The trial involves the use of two drugs, capecitabine and PHY906, and patients must discontinue any herbal medicines or supplements at least 7 days prior to study entry. The trial aims to evaluate the safety and efficacy of the drugs in treating pancreatic cancer.",
    "The sample is a clinical trial for ovarian cancer patients in phase 1/phase 2. The trial is for patients with recurrent epithelial ovarian cancer, primary peritoneal carcinomatosis or fallopian tube cancer who have platinum-resistant or platinum refractory disease. The trial involves the drug decitabine and has eligibility criteria including measurable or detectable disease, age over 18, written informed consent, and acceptable organ function. Exclusion criteria include not having participated in any clinical trial involving conventional or investigational drugs or devices within the previous 3 weeks, having grade 2 or greater neuropathy, having additional active cancer in addition to the epithelial ovarian cancer within the last 5 years, and having an additional uncontrolled serious medical condition or psychiatric illness.",
    "The sample is a clinical trial for kidney transplant patients with high levels of anti-HLA antibodies. The trial is in phase 1/phase 2 and involves the use of IVIG and Rituximab drugs. The eligibility criteria include having a PRA of >30%, being eligible for transplantation at Cedars-Sinai Medical Center, and having adequate liver function. Exclusion criteria include a history of severe allergic reactions, HIV, Hepatitis B and/or Hepatitis C, and significant cardiac or pulmonary disease. The patients will be monitored for anti-HLA antibody and undergo various tests throughout the trial.",
    "The sample is a record of a clinical trial with a phase 1/phase 2 designation. The trial is focused on breast cancer and includes a list of ICD-10 codes associated with the disease. The trial involves the drugs panobinostat and trastuzumab. The eligibility criteria for the trial include being over 18 years old, having confirmed HER2+ ve metastatic breast cancer, having prior treatment and progression on trastuzumab, having adequate laboratory values, and having an Eastern Cooperative Oncology Group (ECOG) performance status of <2. The exclusion criteria include having active central nervous system (CNS) disease or brain metastases, impaired heart function or clinically significant heart disease, impairment of gastrointestinal (GI) function, ongoing diarrhea, liver or renal disease with impaired hepatic or renal functions, concomitant use of any anti-cancer therapy or certain drugs, being a female patient who is pregnant or breast feeding, and not being willing to use an effective method of birth control.",
    "The sample is a record from a clinical trial table that includes information about the phase of the trial, diseases being studied, corresponding ICD-10 codes, drugs being tested, and eligibility criteria for patients to participate in the trial. In this particular sample, the trial is a combination of phase 1 and phase 2, and is focused on pancreatic cancer. The drugs being tested are everolimus, cetuximab, irinotecan, and capecitabine, oxaliplatine. The eligibility criteria include factors such as patient age, performance status, blood counts, liver function, and previous treatments. The exclusion criteria include factors such as active or previous history of malignant neoplasm, serious medical conditions, and hypersensitivity to the treatment.",
    "The sample is a clinical trial for prostate cancer patients in phase 1/phase 2. The trial includes patients with histologically or cytologically confirmed adenocarcinoma of the prostate and androgen-independent disease progression. Patients must have a castrate testosterone level of < 40 ng/dl and a PSA level of at least 4 ng/ml, and rising on two consecutive measurements at least 2 weeks apart prior to study entry. Patients must be off anti-androgens for at least four weeks, and six weeks for bicalutamide, without evidence of response; or have evidence of progression since anti-androgen withdrawal. Patients must have adequate bone marrow, liver, and renal function, and must have recovered from acute toxicities from chemotherapy or radiotherapy administered prior to entering this study. Patients must have a MUGA scan or 2-d echocardiogram indicating an ejection fraction of > 50% within 42 days prior to first dose of study drug. Patients with reproductive potential must use an adequate contraceptive method during treatment and for three months after completing treatment. Patients must have the ability to understand and willingness to sign a written informed consent document. Exclusion criteria include patients who have had chemotherapy or radiotherapy within 4 weeks prior to entering the study or those who have not recovered from adverse events due to agents administered more than 4 weeks earlier, patients who have had two or more prior chemotherapy treatment(s), patients receiving any other investigational agent(s), patients with symptomatic brain metastases or actively receiving any therapy for brain metastasis, active second malignancy in the last 5 years except for non-melanoma skin cancer or carcinoma-in-situ, history of cardiac disease, with New York Heart Association Class II or greater, or clinical evidence of congestive heart failure, history of hypersensitivity reactions attributed to a conventional formulation of doxorubicin HCL, the components of Doxil, docetaxel or other drugs formulated with polysorbate 80, and uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.",
    "The sample is a clinical trial for liver cancer patients in phase 1/phase 2. The trial involves the use of two drugs, doxorubicin-eluting beads and everolimus. The eligibility criteria for patients include having confirmed hepatocellular carcinoma, being in intermediate stage B according to the Barcelona Clinic Liver Cancer classification, having a Child-Pugh score of less than 8, and not having tumor involvement of more than 50% of the whole liver. Patients must also meet certain patient characteristics such as having a WHO performance status of 0-1, hemoglobin levels of at least 90 g/L, and platelet counts of at least 100 x 10^9/L. Patients must not have certain medical conditions such as active heart disease, hypertension, or bleeding diathesis. They must also not have any serious non-healing wounds or history of hemoptysis. Patients must not have any other prior or concurrent malignancy that is distinct in primary site or histology from HCC, except carcinoma in situ of the cervix, treated nonmelanoma skin cancer, superficial bladder tumor (Ta, Tis, T1), or any cancer curatively treated > 3 years prior to entry. The trial also has certain prior concurrent therapy requirements such as at least 4 weeks since prior transarterial embolization/chemoembolization, radiofrequency ablation, cryoablation, radiation therapy or percutaneous ethanol injection. Patients must not have any concurrent anticancer drugs or investigational drugs. They must also not have any concurrent known strong CYP3A4 inhibitors or inducers.",
    "The sample is a record from a clinical trial table that includes information about the phase of the trial, diseases being studied, ICD-10 codes of the diseases, drugs being used, and eligibility criteria for participants. In this particular sample, the trial is in phase 1/phase 2 and is studying the effects of docetaxel on various types of cancer, including recurrent non-small cell lung cancer, recurrent prostate cancer, and stage III and IV prostate and non-small cell lung cancer. The eligibility criteria include having measurable disease, a performance status of ECOG 0-2 or Karnofsky 60-100%, and meeting various laboratory and medical criteria. The sample also includes a list of ICD-10 codes for the diseases being studied and a detailed list of inclusion and exclusion criteria for participants.",
    "The sample is a record from a clinical trial table that includes information about the trial's phase, diseases being studied, icd-10 codes of the diseases, drugs being used, and eligibility criteria for participants. In this particular trial, the phase is a combination of phase 1 and phase 2, and the diseases being studied are melanoma, malignant melanoma, and experimental melanoma. The icd-10 codes associated with these diseases are also listed. The drugs being used in the trial include dmf5 melanoma reactive til, cyclophosphamide, fludarabine, and aldesleukin. The eligibility criteria for participants include having measurable metastatic melanoma that is refractory to standard treatment, being HLA-A 0201 positive, having a clinical performance status of Eastern Cooperative Oncology Group (ECOG) 0 or 1, and meeting various hematology, serology, and chemistry requirements. There are also exclusion criteria, such as having a history of severe immediate hypersensitivity reaction to any of the agents used in the study or having a documented penicillin allergy.",
    "The sample is a clinical trial for patients with metastatic breast cancer in phase 1/phase 2. The trial is testing the drug amrubicin. The eligibility criteria include being a female over 18 years old with a histologic diagnosis of HER2-negative breast cancer, evidence of metastatic or locally advanced, inoperable breast cancer, and having received a minimum of 1 and maximum of 2 prior metastatic breast cancer chemotherapy regimens. Patients must also have measurable disease per RECIST criteria version 1.1 and left ventricular ejection fraction (LVEF) \u00b350% by echocardiogram (ECHO) or multiple gated acquisition scan (MUGA). The exclusion criteria include any concurrent therapy with other investigational, chemotherapeutic, or hormonal therapy, prior treatment with >=3 regimens of cytotoxic therapy in the advanced disease setting, and major surgery or systemic therapy <=3 weeks of study treatment.",
    "The sample is a clinical trial for phase 1/phase 2 of a drug called cetuximab for the treatment of head and neck cancer. The trial is looking for patients who are over 18 years old, have histologically proven squamous cell carcinoma of the oral cavity, oropharynx, hypopharynx or larynx, and are selected for a primary surgical treatment. Patients must not have distant metastases, active second malignancy during the last 5 years, or prior or concurrent evidence of uncontrolled severe pathology precluding administration of surgery. Patients must have a life expectancy of more than 3 months, not be pregnant or nursing, and must use effective contraception if fertile. They must also have signed informed consent and have a performance status ECOG 0-1. Patients with nasopharynx cancer, past or current malignancy other than HNSCC, performance status ECOG above 2, concurrent chronic systemic immune therapy, chemotherapy, or hormone therapy not indicated in the study protocol, use of any investigational agents within 4 weeks prior to entry, previous exposure to EGFR targeting therapy, or known grade hypersensitivity to cetuximab are excluded from the trial.",
    "The sample is a clinical trial for the treatment of chronic myeloid leukemia (CML) and acute lymphoblastic leukemia (ALL) using the drugs dasatinib and bms-833923. The trial is in phase 1/phase 2 and the eligibility criteria include being over 18 years old, having a diagnosis of CML with a positive Philadelphia chromosome, and having a resistance or suboptimal response to imatinib, dasatinib, or nilotinib without a known T315I/A Abl-kinase mutation. The trial also has exclusion criteria, such as having a known Abl-kinase T315I or T315A mutation, uncontrolled medical disorders or active infections, and significant cardiovascular disease. Prior therapies for CML or Ph+ ALL are permitted with certain restrictions. The diseases are listed as 'leukemia' and the icd-10 codes are provided.",
    "The sample is a clinical trial for patients with recurrent glioblastoma multiforme, glioma, astrocytoma, or brain tumor. The trial is in phase 1/phase 2 and the treatment involves a combination of itv depocyt and temozolomide. The eligibility criteria include being between 18 and 85 years old, having a Karnofsky performance status of at least 60%, having a platelet count and ANC within a certain range, having adequate liver and renal function, and having recovered from prior therapy. Patients must also have a histological diagnosis of recurrent GBM and failed initial surgical resection followed by standard adjuvant therapy. Exclusion criteria include having received more than one other systemic or ITV adjuvant chemotherapy regimen in addition to temozolomide, having a Karnofsky performance status less than 60%, and having certain medical conditions or contraindications to the treatment. Patients or their legal guardians must sign an informed consent document.",
    "The sample is a clinical trial for the treatment of malignant melanoma. The trial is in phase 1/phase 2 and the table contains information about the diseases, icd-10 codes, drugs, and eligibility criteria. The inclusion criteria include having a confirmed diagnosis of melanoma that has been previously treated with chemotherapy or IL-2, having measurable disease, and having adequate renal, liver, and bone marrow function. The exclusion criteria include having received more than three systemic treatment regimens for malignant melanoma, having a second malignancy within the last 5 years, being pregnant or lactating, having known HIV, having acute medical problems, and having any underlying medical conditions that would contraindicate therapy with the study treatment. Patients with brain metastases are eligible if they are clinically and neurologically stable for at least 4 weeks since therapy and either off corticosteroids or on a stable dose of corticosteroids.",
    "The sample is a record of a clinical trial with a phase 1/phase 2 designation. The trial is focused on pulmonary disease, specifically chronic obstructive pulmonary disease, and the associated ICD-10 codes are J44.9, J44.1, and J44.0. The drug being tested is uk-369,003. The eligibility criteria for the trial include meeting GOLD criteria 2 to 4 and having a 10 pack year history of smoking. Women of childbearing potential are excluded from the trial.",
    "The sample is a clinical trial for a drug called amd3100. The trial is in phase 1/phase 2 and is focused on treating various types of leukemia, myelodysplastic syndromes, multiple myeloma, lymphoma, and Hodgkin disease. The trial involves a donor who is a 6/6 HLA-matched sibling willing to donate peripheral blood stem cells for transplant, and a recipient who must have one of the specified diagnoses and a 6/6 HLA-matched sibling willing to donate PBSC for transplant. Both the donor and recipient must meet certain eligibility criteria, including age, adequate organ function, and HIV and HTLV seronegativity. The trial also requires compliance with the study regimen and prohibits active infections or alcohol/substance abuse.",
    "The sample is a record of a clinical trial with a phase 1/phase 2 designation, focused on the disease glioblastoma multiforme. The icd-10 codes associated with the disease are listed as [\"['L51.0', 'L51.8', 'L51.9']\"]. The trial involves the drugs bcnu wafer, irinotecan, and bevacizumab. The eligibility criteria for the trial are listed, including requirements such as a histopathologically proven diagnosis of GBM, prior treatment with standard doses of Temodar, a KPS score greater than 50, and a predicted life expectancy of more than 3 months. The exclusion criteria are also listed, including prior exposure to VEGF inhibitors or Irinotecan, recent intracranial or GI bleeding, and uncontrolled concurrent illness that would limit compliance with study requirements.",
    "The sample is a clinical trial for lymphoma, specifically large-cell diffuse and B-cell lymphoma. It is a phase 1/phase 2 trial and includes a list of drugs such as bortezomib, cyclophosphamide, doxorubicin, vincristine, prednisolone, and lenograstim. The eligibility criteria for the trial includes confirmation of DLBCL, age 70 or younger, previously untreated, ECOG performance status of 0-2, advanced stage, measurable disease, and normal liver function. Exclusion criteria includes platelet count less than 75,000/microL, absolute neutrophil count less than 1,500/microlL, and other medical or psychiatric illnesses that may interfere with participation in the study.",
    "The sample is a clinical trial for patients with castration-resistant prostate cancer. The trial is in phase 1/phase 2 and the patients must have a rising PSA level above the androgen-deprivation therapy (ADT) nadir. The patients must have only received one prior chemotherapy regimen, which must contain docetaxel as a single agent or in combination with other agents. The trial involves treatment with cabazitaxel plus bavituximab. The eligibility criteria include being 18 years or older with a life expectancy of at least 3 months, having an Eastern Cooperative Oncology Group (ECOG) performance status \u2264 2, and having adequate hematologic, renal, and hepatic function. The exclusion criteria include a history of bleeding diathesis or coagulopathy, ongoing therapy with oral or parenteral anticoagulants, and major surgery within 28 days of Study Day 1.",
    "The sample is a clinical trial for Alzheimer's disease, with a combination of phase 1 and phase 2. The trial involves testing the effectiveness of the drugs ly2886721 and placebo on participants with mild Alzheimer's disease or mild cognitive impairment due to Alzheimer's disease. The eligibility criteria include meeting certain criteria for Alzheimer's disease or mild cognitive impairment, having a certain score on the Mini Mental State Examination, and having a positive scan for the presence of amyloid beta. Women must be postmenopausal, and men must use an approved barrier method of contraception if their partners are pregnant or of childbearing potential. The exclusion criteria include having certain medical conditions, being in another drug or device study, and having a history of alcohol or drug abuse.",
    "The sample is a clinical trial for the treatment of multiple myeloma, a type of cancer. The trial is in phase 1/phase 2 and involves the drugs bortezomib, lenalidomide, and dexamethasone. The eligibility criteria for participants include being diagnosed with multiple myeloma, not having received prior systemic therapy for the treatment of multiple myeloma, having a Karnofsky performance status of greater than or equal to 60, and being 18 years or older. Exclusion criteria include having certain medical conditions or prior malignancies, being pregnant or breastfeeding, and having a serious medical or psychiatric illness likely to interfere with participation in the study. The trial also includes a list of ICD-10 codes for multiple myeloma and a list of diseases.",
    "The sample is a clinical trial for leukemia and lymphoma patients in phase 1/phase 2. The trial is testing the effectiveness of a drug called laromustine. The eligibility criteria for the trial includes having a diagnosis of certain hematologic malignancies, having an ECOG performance status of 0-2, and meeting certain medical requirements such as having a creatinine level of \u2264 2.0 mg/dL and no uncontrolled infections. Patients must also not be pregnant or nursing, and fertile patients must use effective contraception. The trial requires patients to have had at least 2 weeks since prior cytotoxic therapy, and they cannot be receiving any other concurrent standard or investigational treatment for this cancer.",
    "The sample is a clinical trial for the treatment of scleroderma, a disease that affects the skin and connective tissues. The trial is in phase 1/phase 2 and involves the use of the drugs abatacept and placebo. The trial is looking for participants who have been diagnosed with diffuse systemic sclerosis, are 18 years or older, have adequate renal, pulmonary, and cardiovascular function, and are willing to use effective contraception if they are of childbearing potential. Participants cannot have other connective tissue diseases or overlap syndromes, cannot have used certain disease modifying agents or investigational agents within 90 days of the screening visit, cannot have HIV, Hepatitis B or Hepatitis C infection, cannot have used prednisone greater than 10mg daily for 28 days prior to the screening visit, and cannot be breastfeeding or pregnant.",
    "The sample is a record of a clinical trial with a phase 1/phase 2 designation. The trial is focused on breast neoplasms, with a list of associated ICD-10 codes. The trial involves the use of two drugs, exemestane and sunitinib malate. The eligibility criteria for the trial include being at least 18 years old, having estrogen and/or progesterone receptor positive adenocarcinoma of the breast with evidence of unresectable, locally recurrent, or metastatic disease, being postmenopausal, having an ECOG score of </=1, and having evaluable and measurable disease. The exclusion criteria include having HER2 positive disease not previously treated with herceptin, having received any prior anti-angiogenic therapy, endocrine or cytotoxic anti-cancer therapy in the metastatic disease setting, and having received radiation therapy within 2 weeks of first study treatment.",
    "The sample is a clinical trial for patients with relapsed multiple myeloma that has progressed following therapies that included bortezomib and an IMiD (thalidomide or lenalidomide) either alone or in any combination. The trial is for phase 1/phase 2 and the drug being tested is cep-18770. The eligibility criteria include having measurable disease, a life expectancy of more than 3 months, an ECOG performance status of 0, 1, or 2, adequate hepatic organ function, and meeting specific ranges for ANC, hemoglobin level, and platelet count. Patients must also have been independent of granulocyte-colony stimulating factor (G-CSF) or granulocyte macrophage-colony stimulating factor (GM-CSF) support for more than 1 week and independent of platelet transfusion for more than 1 week. Patients must have received, or may have received, an allogeneic and/or autologous transplant. There are also exclusion criteria, such as having nonmeasurable multiple myeloma, having received glucocorticoid therapy within the last 2 weeks prior to the first dose of study drug, and having plasma cell leukemia.",
    "The sample is a clinical trial for patients with castrate-resistant prostate cancer. The trial is in phase 1/phase 2 and involves the use of three drugs: bez235, prednisone, and abiraterone acetate. The eligibility criteria include having confirmed adenocarcinoma of the prostate, radiographic evidence of disease, castrate levels of testosterone, and progressive disease. Patients must also have an Eastern Cooperative Oncology Group (ECOG) performance status \u2264 2 and adequate bone marrow and organ function. Exclusion criteria include previous treatment with PI3K and/or mTOR inhibitors, active uncontrolled or symptomatic CNS metastases, and a concurrent malignancy or history of malignancy in the last 3 years. Patients must also not have active cardiac disease or a history of cardiac dysfunction, and must not have a history of active major depressive episodes, bipolar disorder, or other psychiatric disorders.",
    "The sample is a clinical trial for pancreatic cancer patients in phase 1/phase 2. The trial involves the use of two drugs, hydroxychloroquine and gemcitabine, and has eligibility criteria that include biopsy-proven adenocarcinoma of the pancreas, a Karnofsky performance status of 70 or greater, and normal renal, hepatic, and hematologic function. Exclusion criteria include prior chemotherapy or radiotherapy for pancreatic cancer, evidence of metastasis to distant organs, and concurrent malignancies with evidence of active or measurable disease. The trial also requires participants to use adequate contraception and excludes patients with immune deficiency or porphyria.",
    "The sample is a clinical trial for advanced breast cancer patients who have not responded to available therapies. The trial is in phase 1/phase 2 and involves the drugs hki-272 and trastuzumab. The eligibility criteria include having HER2 positive breast cancer, at least one measurable target lesion, adequate performance status, and adequate cardiac, kidney, and liver function. Exclusion criteria include having extensive visceral disease, active central nervous system metastases, or significant cardiac disease or dysfunction. The trial also requires subjects to use acceptable methods of birth control and not have any other cancer within 5 years, except for certain exceptions.",
    "The sample is a clinical trial for a drug called PB1023 or placebo for the treatment of type 2 diabetes. The trial is a combination of phase 1 and phase 2. The trial is looking for males or post-menopausal or surgically sterile females between the ages of 18-75 who have been diagnosed with type 2 diabetes for at least 6 months and have stable glucose levels while taking one or two oral antihyperglycemic agents. The trial is also looking for participants with a fasting plasma glucose level between 115 mg/dL and 269 mg/dL, a fasting C-peptide level of at least 0.8 ng/mL, and a BMI of 40 kg/m2 or less. The trial has exclusion criteria, including not taking non-oral antihyperglycemic agents, not having a known allergy to GLP-1 receptor analog/agonist, not having unstable cardiovascular disease, not having a history of pancreatitis or severe gastrointestinal disease, not having a personal or family history of medullary thyroid tumors or Multiple Endocrine Neoplasia Syndrome Type 2, not having poor glucose control, not having clinically significant renal and/or hepatic dysfunction, not having an absolute requirement for corticosteroids, not being pregnant or lactating, not having a known history or active alcohol or drug abuse, not testing positive for HIV, Hepatitis B surface antigen or Hepatitis C antibodies, not participating in any other study within 30 days prior to screening, and not having any other medical or psychiatric condition that would place the subject at increased risk.",
    "The sample is a clinical trial for ulcerative colitis, with a combination of phase 1 and phase 2. The trial involves testing the effectiveness of two drugs, placebo and he3286, on patients with mild-to-moderate ulcerative colitis. The eligibility criteria include being between 18-65 years old, having a Mayo Scoring System score of 4-9, and having a stable dose of certain medications for at least a certain period of time. Exclusion criteria include having certain medical conditions or taking certain medications. Patients must provide written consent and be able to follow instructions.",
    "The sample is a record from a clinical trial table that includes information about the trial's phase, diseases being studied, icd-10 codes of the diseases, drugs being used, and eligibility criteria for patients. In this particular sample, the trial is in phase 1/phase 2 and is studying pancreatic cancer. The drugs being used are azd0530 and gemcitabine hydrochloride. The eligibility criteria include having a confirmed diagnosis of pancreatic adenocarcinoma, having unresectable, locally advanced, or metastatic disease, and having no known brain metastases. Patients must also meet certain performance, hematopoietic, hepatic, renal, cardiovascular, pulmonary, gastrointestinal, and immunologic criteria. Additionally, patients must not be pregnant or nursing, must have negative pregnancy test results, and must use effective contraception if fertile. Prior concurrent therapy is also listed, including restrictions on certain drugs before, during, and after the study treatment.",
    "The sample is a clinical trial for a drug called imatinib, which is being tested on healthy male non-smoking subjects aged 18-55 years with a history of seasonal allergic rhinitis caused by Timothy grass pollen allergy. The trial is in phase 1/phase 2 and the subjects must meet certain inclusion criteria, such as having a positive skin prick test to Timothy grass pollen and demonstrating symptomatic worsening within one hour after nasal allergen challenge. The trial also has exclusion criteria, such as having respiratory disease other than mild stable asthma, recent nasal surgery, or use of medication that would affect the response to the allergen challenge. The trial will also monitor adverse events and non-tolerable symptoms resulting from the allergen challenge.",
    "The sample is a clinical trial for the treatment of multiple myeloma, a type of cancer. The trial is in phase 1/phase 2 and involves the use of two drugs, carfilzomib and lenalidomide, along with dexamethasone. The eligibility criteria for the trial include having newly diagnosed, previously untreated multiple myeloma, measurable disease, and a life expectancy of more than 3 months. Participants must also have adequate liver and kidney function, and meet other health requirements. Exclusion criteria include having certain types of cancer, recent surgery, or significant medical conditions that may interfere with the trial. Participants must also agree to adhere to all study requirements and undergo regular laboratory monitoring.",
    "The sample is a record of a clinical trial with a phase 1/phase 2 designation. The trial is focused on the treatment of prostatic neoplasms, which are identified by a list of ICD-10 codes. The drugs being tested in the trial are docetaxel, prednisone, and su011248. The eligibility criteria for the trial include having confirmed adenocarcinoma of the prostate, progressive hormone-refractory prostate cancer, and an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. The exclusion criteria include prior thalidomide or anti-angiogenic treatment, prior chemotherapy, uncontrolled pain or urinary obstruction, history of cardiac dysfunction, and CNS involvement.",
    "The sample is a clinical trial for patients with myelodysplastic syndromes (MDS) or leukemia. The trial is in phase 1/phase 2 and involves the drugs azacitidine and lenalidomide. The eligibility criteria include a diagnosis of MDS meeting certain criteria, a life expectancy of at least 3 months, and an ECOG performance status of 0-2. Patients must not be pregnant or nursing, and must use effective contraception during the study. They must also meet certain medical criteria, such as having a platelet count of at least 50,000/mm^3 and no serious medical conditions that would preclude study participation. Prior concurrent therapy is also restricted.",
    "The sample is a clinical trial for patients with newly diagnosed acute myeloid leukemia who are eligible for intensive induction chemotherapy. The trial is in phase 1/phase 2 and involves the use of clofarabine, cytarabine, and idarubicin. The eligibility criteria include being at least 18 years old, having no certain genetic mutations, having adequate renal and hepatic functions, and understanding the potential risks and benefits of the study. Female patients must meet certain criteria related to menopause or contraception, and male patients must meet certain criteria related to contraception. Exclusion criteria include having certain medical conditions or being pregnant or lactating.",
    "The sample is a clinical trial for left ventricular diastolic dysfunction, with a combination of phase 1 and phase 2. The trial involves the drugs BNP (nesiritide) and placebo. The eligibility criteria for the trial include having an ejection fraction of greater than 50% with moderate or severe diastolic dysfunction as assessed by Doppler echocardiography, and no signs or symptoms of congestive heart failure or hospitalization for heart failure. Exclusion criteria include recent myocardial infarction or unstable angina, significant valvular stenosis or cardiomyopathy, sustained ventricular tachycardia or fibrillation, and abnormal levels of various blood markers.",
    "The sample is a clinical trial for HIV infections in phase 1/phase 2. The trial is testing the effectiveness of lopinavir/ritonavir and saquinavir drugs on patients with HIV who have specific protease mutations and have been on continuous therapy with a protease inhibitor for at least 6 months. The trial has inclusion and exclusion criteria, including having a certain viral load, no change in antiretroviral therapy since genotypic resistance testing, and not having any significant diseases other than HIV that may interfere with the study. Patients must also have a telephone or other reliable method of communication with study staff and be willing to swallow study medications. Exclusion criteria include certain abnormal laboratory values, acute opportunistic or serious bacterial infections, chemotherapy for active cancer, and pregnancy or breastfeeding.",
    "The sample is a clinical trial with a combination of phase 1 and phase 2. The trial is focused on treating diseases such as graft versus host disease, leukemia, myelodysplastic syndromes, and myelodysplastic/myeloproliferative diseases. The trial involves the use of drugs such as busulfan, cyclophosphamide, methotrexate, and tacrolimus. The eligibility criteria for the trial include confirmed diagnosis of certain diseases, no suitable HLA genotypically identical sibling or fully matched HLA-A, -B, -C, and -DRB1 unrelated donor available, and no active CNS involvement with disease. The patient characteristics include a Karnofsky performance status of 50-100%, no symptomatic coronary artery disease or symptomatic congestive heart failure, no hepatic disease with transaminases or bilirubin > 2 times upper limit of normal except for isolated hyperbilirubinemia attributed to Gilbert's syndrome, no severe hypoxemia with room air P_AO_2 < 70, supplemental oxygen-dependence, or DLCO < 60% predicted, no impaired renal function with creatinine > 2 times upper limit of normal or creatinine clearance < 50% normal, not HIV seropositive, not pregnant or breast-feeding, and fertile patients must use effective contraception. The prior concurrent therapy includes no prior allogeneic or autologous bone marrow, peripheral blood stem cell, or umbilical cord blood transplantation using a high-dose total-body irradiation regimen.",
    "The sample is a record of a clinical trial for a drug called tki258, which is being tested on patients with locally advanced or metastatic melanoma that is refractory to standard therapy or for which no curative standard therapy exists. The trial is in phase 1/phase 2 and the record includes a list of diseases and their corresponding icd-10 codes. The eligibility criteria for the trial are also listed, including requirements for confirmed diagnosis, measurable disease, age, laboratory requirements, and performance status. The record also includes exclusion criteria, such as concurrent therapy with other investigational agents, uncontrolled central nervous system metastases, and impaired cardiac function. Other medical or psychiatric conditions that may increase the risk associated with study participation or study-drug administration are also listed as exclusion criteria.",
    "The sample is a record from a clinical trial table that includes information about the trial's phase, diseases being studied, icd-10 codes associated with those diseases, drugs being tested, and eligibility criteria for participants. In this particular sample, the trial is in phase 1/phase 2 and is studying non-hodgkin's lymphoma, chronic lymphocytic leukemia, and multiple myeloma. The icd-10 codes associated with these diseases are also listed. The drug being tested is gs-9219. The eligibility criteria for participants include having relapsed or refractory CLL, NHL, or MM, having an ECOG Performance Status of 0, 1, or 2, and having adequate organ function. There are also exclusion criteria listed, such as having AIDS-related lymphoma, recent anticancer therapy, or uncontrolled concurrent illness.",
    "The sample is a clinical trial for patients with non-Hodgkin Lymphoma or chronic lymphocytic leukemia. The trial is in phase 1/phase 2 and involves the use of cyclophosphamide and fludarabine phosphate drugs. The eligibility criteria include having measurable disease, acceptable organ function, and being off prednisone or other immunosuppressive medications for at least 3 days prior to Day 0. The trial also requires the availability of a related HLA-haploidentical natural killer cell adult donor. The donor must be in good health and able to give informed consent. The trial has exclusion criteria such as pregnancy, lactation, active serious infection, and allergy to rituximab or IL-2. The trial also has donor selection criteria, including being HIV-1, HIV-2 negative, and Hepatitis B and C negative.",
    "The sample is a clinical trial for sickle cell disease, with a phase 1/phase 2 designation. The trial is testing the effectiveness of sodium nitrite injection, usp as a treatment for acute pain associated with vaso-occlusive crisis in patients aged 8 to 23 years old. The eligibility criteria include a diagnosis of sickle cell disease, severe pain requiring hospitalization, and informed consent from a legal representative or the patient if they are 18 years or older. Exclusion criteria include pregnancy, significant acute or chronic concomitant diseases, and a history of allergy to nitrites or other substances characterized by dyspnea and cyanosis.",
    "The sample is a clinical trial with a phase 1/phase 2 designation, focused on treating malignant glioma (anaplastic astrocytoma or glioblastoma multiforme) that has progressed or recurred following radiation therapy and/or chemotherapy. The trial involves the use of the drugs ixabepilone and anticonvulsant. The eligibility criteria include having measurable progressive or recurrent malignant glioma, having recovered from severe toxicity of prior therapy, having a Karnofsky performance status of at least 60%, and meeting certain blood count and liver function requirements. Patients must also have no concurrent malignancy except for certain types of skin and breast cancer, and must be maintained on a stable corticosteroid regimen. Exclusion criteria include serious concurrent infection or medical illness, pregnancy or breastfeeding, and receiving certain medications that are known to be moderate to significant inhibitors of CYP3A4.",
    "The sample is a clinical trial for the treatment of follicular lymphoma, a type of cancer. The trial is in phase 1/phase 2 and involves the use of three drugs: rituximab, bortezomib, and ibritumomab tiuxetan. The eligibility criteria for the trial include having histologically confirmed follicular lymphoma, being CD20+ at the time of diagnosis or subsequently, and having gone more than 4 weeks without prior rituximab treatment. Exclusion criteria include having AIDS-related lymphoma, a history or evidence of CNS involvement, being pregnant or nursing, and having serious medical or psychiatric illness that would preclude study participation.",
    "The sample is a record from a clinical trial table that includes information about the trial's phase, diseases being studied, associated ICD-10 codes, drugs being used, and eligibility criteria for participants. In this particular sample, the trial is in phase 1/phase 2 and is focused on studying HIV infections. The associated ICD-10 code is \"Z21\". The trial is using a combination of drugs including gpo-vir z30 tablet, lamivudine, nevirapine, and zidovudine. The eligibility criteria for participants include being between 6 and 30 kilograms, being HIV infected, receiving a specific HAART regimen, agreeing to use two forms of contraception, being able to swallow study drugs, and being willing to be hospitalized for a 12-hour intensive PK study. There are also exclusion criteria listed, such as certain abnormal laboratory values, a history of immunologic failure, and being pregnant.",
    "The sample is a record from a clinical trial table that includes information about the trial's phase, diseases being studied, icd-10 codes of those diseases, drugs being used, and eligibility criteria for participants. In this particular sample, the trial is in phase 1/phase 2 and is studying metastatic bladder cancer. The icd-10 codes associated with the disease are listed, as well as the drugs being used in the trial. The eligibility criteria for participants are also listed, including requirements for age, prior treatment, and exclusion criteria such as brain metastases and fluid collection in the lungs or abdomen.",
    "The sample is a record from a clinical trial table that includes information about the phase of the trial, diseases being studied, ICD-10 codes associated with those diseases, drugs being used, and eligibility criteria for participants. In this particular sample, the trial is in phase 1/phase 2 and is focused on studying graft failure. The ICD-10 codes associated with the disease are T86.831 and T86.821. The drugs being used in the trial are fludarabine, campath 1h, and fk506. The eligibility criteria for participants include a diagnosis of engraftment failure, availability of a healthy donor, age between birth and 65, and negative pregnancy test for women of childbearing potential. There are also exclusion criteria, such as uncontrolled intercurrent infection and active CNS disease from hematological disorder.",
    "The sample is a record of a clinical trial with a combination of phase 1 and phase 2. The trial is focused on acute lymphoblastic leukemia, and the table includes a list of icd-10 codes for the disease. The trial involves the use of two drugs, vincristine sulfate liposomes injection and dexamethasone. The eligibility criteria for the trial include having previously treated, relapsed or refractory ALL, having a performance status of \u22643, and having adequate liver and renal function. Patients with a prior history of stem cell transplant are also eligible. The exclusion criteria include having an active serious infection, treatment with any investigational agents or chemotherapy agents in the last 21 days before study entry, and concurrent treatment with other anti-cancer agents other than dexamethasone. Pregnant and/or lactating women, or fertile men or women not willing to use contraception are also excluded.",
    "The sample is a clinical trial for rheumatoid arthritis, in which the phase is a combination of phase 1 and phase 2. The trial involves the drug rituximab and has a list of inclusion and exclusion criteria for participants. Inclusion criteria include a diagnosis of RA, positive for rheumatoid factor and/or anticyclic citrullinated peptide, and active RA with at least four swollen joints and at least four tender joints. Exclusion criteria include allergy to methotrexate, previous exposure to anti-CD20 monoclonal antibody, and previous use of a biologic agent. Participants must also be willing to adhere to the study requirements and use acceptable forms of contraception. The trial does not allow participants who have certain abnormal laboratory values, require certain medications, have any psychiatric disorder that would prevent informed consent, or have any condition or treatment that may place them at unacceptable risk during the study. Pregnant women are also excluded from the trial.",
    "This sample is a clinical trial for a drug called mifepristone, which is being tested on individuals with HIV-1 infection and a CD4 count of 350 cells/mm3 or more. The trial is in phase 1/phase 2 and the eligibility criteria include having a viral load of 2000 copies/ml or more, using acceptable forms of contraception during the study and for 30 days after stopping study medication, and having a body weight of at least 40 kg. However, there are also exclusion criteria, such as having a history of autoimmune endocrine disease, active hepatitis B or C, or current hormonal contraception or intrauterine use. The sample also includes a list of diseases (in this case, only HIV infections), their corresponding ICD-10 codes, and the eligibility criteria for the trial.",
    "The sample is a record of a clinical trial with a phase 1/phase 2 designation. The trial is focused on patients with multiple myeloma, a type of cancer. The trial is testing the effectiveness of the drug simvastatine. The eligibility criteria for the trial include patients in need of treatment with stable or progressive disease, age 18 or older, performance status less than 3, and life expectancy greater than 3 months. Exclusion criteria include pregnancy, patients incapable of giving personal consent, renal insufficiency with creatinine clearance below 25 ml/min, alanine aminotransferase levels above 2.5 times the upper reference limit, thyroxine levels below the lower reference limit, known familial muscle disease or previous myopathy, creatinine kinase levels above 10 times the upper reference limit, and medication with drugs known to interact with simvastatine.",
    "The sample is a clinical trial for Parkinson's disease, in which the phase is a combination of phase 1 and phase 2. The trial involves testing the effectiveness of two drugs, levodopa and carbidopa solution for sc administration and placebo, on subjects who experience motor fluctuations associated with LD/CD dosing. The trial has specific eligibility criteria, including a modified Hoehn and Yahr stage of less than 5, stable levodopa/dopa decarboxylase inhibitor therapy, and being age 30 or older. Women must be postmenopausal, surgically sterilized, or using adequate birth control. The trial also has exclusion criteria, such as clinically significant medical or surgical conditions, clinically significant psychiatric illness, and having undergone a neurosurgical intervention for Parkinson's disease.",
    "The sample is a clinical trial for small cell lung cancer patients who have relapsed after completing their first-line chemotherapy. The trial is a combination of two drugs, topotecan and vorinostat, and is in phase 1/phase 2. The trial has specific inclusion and exclusion criteria, including age, performance status, life expectancy, and adequate organ function. Patients with certain medical conditions or prior treatment with an HDAC inhibitor are excluded from the trial. Pregnant or breastfeeding women are also excluded.",
    "The sample is a record from a clinical trial table that includes information about the phase of the trial, diseases being studied, ICD-10 codes associated with those diseases, drugs being tested, and eligibility criteria for participants. In this particular sample, the trial is a combination of phase 1 and phase 2, and the disease being studied is heart failure. The inclusion criteria for participants include being between 18 and 85 years old, having chronic systolic heart failure due to primary/idiopathic dilated cardiomyopathy, coronary artery disease or hypertension, and stable for at least 30 days prior to screening, having a left ventricular ejection fraction \u2264 40%, and being on unchanging doses of heart failure medications for 2 weeks prior to randomization. The exclusion criteria include having participated in any investigational drug study within 30 days preceding randomization, having a heart rate <50 or \u2265 90 BPM at baseline prior to randomization, and having a history of worsening heart failure within 30 days prior to screening.",
    "The sample is a clinical trial with a combination of phase 1 and phase 2. The trial is focused on treating advanced breast cancer and advanced malignant solid tumors using the drugs HKI-272 and paclitaxel. The trial has specific eligibility criteria for participants, including good performance status, normal ejection fraction, adequate cardiac, kidney, and liver function, and adequate blood counts. Participants must also have at least one measurable target lesion and a negative pregnancy test for female subjects. The trial has exclusion criteria as well, including major surgery, radiotherapy, chemotherapy, or investigational agents within two weeks of treatment day 1, bone or skin as the only site of disease, active central nervous system metastases, significant cardiac disease or dysfunction, significant gastrointestinal disorder, inability or unwillingness to swallow HKI-272 capsules, and more. The trial has different inclusion criteria for part 1 and part 2, and part 2 has additional exclusion criteria.",
    "The sample is a clinical trial for kidney transplantation and kidney disease patients. The trial is in phase 1/phase 2 and involves a list of drugs including alemtuzumab, sirolimus, tacrolimus, and methylprednisolone. The eligibility criteria for the trial includes having received a kidney transplant with a primary cadaveric or non-HLA-identical living donor kidney, receiving only a kidney and no other organs, being able to take medications by mouth, and being willing to use acceptable methods of contraception. Exclusion criteria include having received an HLA-identical living-donor kidney transplant, having a PRA value greater than 10%, having received a non-heart-beating donor allograft, and having a history of cancer or lymphoma.",
    "The sample is a record from a clinical trial table and includes information about the phase of the trial, which is a combination of phase 1 and phase 2. The diseases being studied are breast cancer, including male breast cancer, recurrent breast cancer, stage iiib breast cancer, stage iiic breast cancer, and stage iv breast cancer. The icd-10 codes associated with these diseases are also listed. The drugs being tested are vorinostat and trastuzumab. The eligibility criteria for participants are also included, which includes factors such as not being pregnant or nursing, having no active infections, and having no history of allergic reactions to the study drugs. The criteria also specify that participants must have measurable disease and meet certain medical criteria, such as having normal liver and heart function.",
    "The sample is a clinical trial for patients with metastatic solid tumor malignancy, specifically prostate cancer. The trial is divided into two phases, phase 1 and phase 2. The trial involves the use of a drug called 2-deoxyglucose. The eligibility criteria for the trial include having a histologically proven metastatic solid tumor malignancy without a standard option of therapy, having prostate cancer with metastatic disease and progression after initial hormonal therapy, and having an estimated life expectancy of at least 6 months. Patients must also meet certain health criteria, such as having an ANC >1500/\u00b5l, hemoglobin > 10 g/dl, and platelet count >100,000/\u00b5l, and adequate renal function. Exclusion criteria include having a known infection with HIV, a history of glucose intolerance, ongoing coagulopathies and/or receiving oral anticoagulants, and known brain metastases. Women of childbearing potential must have a negative pregnancy test and both men and women of childbearing potential must consent to using effective contraception while on treatment and for 3 months thereafter.",
    "The sample is a clinical trial for a drug called vildagliptin, which is being tested on healthy volunteers and patients with type 2 diabetes. The trial is in phase 1/phase 2 and the disease being studied is diabetes mellitus, type 2. The trial is looking at the effects of the drug on patients who are already taking metformin and/or sufonylurea. The eligibility criteria include being a non-smoking, Caucasian or African American male or female between the ages of 30 and 65. Exclusion criteria include a history of type 1 diabetes or insulin use, coagulation abnormalities, abnormal heart conditions, and pregnancy or breastfeeding. Other protocol-defined inclusion/exclusion criteria may also apply.",
    "The sample is a clinical trial for a drug called combretastatin a4 phosphate, which is being tested for its effectiveness in treating age-related macular degeneration (AMD) with choroidal neovascularization (CNV). The trial is in phase 1/phase 2 and the table includes information on the diseases being treated, the icd-10 codes associated with those diseases, the drugs being used, and the eligibility criteria for participants. The eligibility criteria include age, medical history, and ophthalmic criteria, among others. The trial has both inclusion and exclusion criteria, and patients must be able to give written informed consent.",
    "The sample is a clinical trial for treating metastatic renal cell carcinoma using a combination of gefitinib and sunitinib. The trial is in phase 1/phase 2 and the eligibility criteria include having histologically confirmed renal cell carcinoma with measurable disease and having failed one prior immunotherapy or having no prior systemic therapy for metastatic RCC. The exclusion criteria include having RCC without any clear cell component, a history of or known brain metastases, and uncontrolled hypertension or other significant cardiac events within the 12 months prior to study entry. The diseases are listed as 'carcinoma, renal cell' and the icd-10 codes are listed as a string of codes.",
    "The sample is a clinical trial for a drug called nilotinib, which is being tested on patients with chronic myelogenous leukemia or acute lymphoblastic leukemia (philadelphia chromosome positive). The trial is in phase 1/phase 2 and the table includes information on the diseases being treated, the icd-10 codes associated with those diseases, the drugs being used, and the eligibility criteria for patients to participate in the trial. The eligibility criteria include factors such as the patient's performance status, history of cardiovascular disease, gastrointestinal function, and other medical conditions that could pose safety risks. The sample also includes exclusion criteria, such as recent chemotherapy or radiation therapy, pregnancy or breastfeeding, and a history of other primary malignancies.",
    "The sample is a record of a clinical trial with a combination of phase 1 and phase 2. The trial is focused on type 1 diabetes and involves the use of sitagliptin and insulin as drugs. The eligibility criteria for the trial include a diagnosis of diabetes according to the WHO report of 1999, age at onset between 25-70 years, disease duration of less than 3 years, and a fasting C-peptide level of 0.2 nmol/L or more. The exclusion criteria include insulin requirements more than 0.8 units/kg/day, evidence of chronic or acute infection affecting blood glucose control, history of any malignancy, pregnancy or breastfeeding, secondary diabetes, congestive heart failure requiring pharmacologic treatment, renal disease or dysfunction, and concurrent medical conditions that may interfere with the interpretation of efficacy and safety data during the study.",
    "The sample is a record from a clinical trial table that includes information about the phase of the trial, diseases being studied, icd-10 codes of the diseases, drugs being tested, and eligibility criteria for participants. In this particular sample, the trial is in phase 1/phase 2 and is focused on type II diabetes. The icd-10 codes associated with the disease are listed, as well as the drugs being tested, which include placebo, sitagliptin, and lez763. The eligibility criteria for participants are also listed, including age, weight, BMI, and medical history. Inclusion and exclusion criteria are also provided, such as not being a smoker and not having a history of drug or alcohol abuse.",
    "The sample is a record from a clinical trial table that includes information about the phase of the trial, diseases being studied, icd-10 codes of the diseases, drugs being used, and eligibility criteria for participants. In this particular record, the trial is in phase 1/phase 2 and is focused on non-small cell lung cancer. The drugs being used are belinostat and erlotinib. The eligibility criteria include having a signed consent form, being diagnosed with non-small cell lung cancer, having a performance status of ECOG \u2264 2, having acceptable liver, kidney, and bone marrow function, and meeting other medical requirements. The exclusion criteria include having received experimental drugs within the last 4 weeks, having received anti-cancer therapy within the last 3 weeks, and having certain medical conditions that could affect the trial procedures.",
    "The sample is a clinical trial for prostate cancer patients in phase 1/phase 2. The trial includes patients with castrate-resistant prostate cancer (CRPC) and metastatic disease. The trial involves the use of two drugs, temsirolimus and casodex (bicalutamide). The eligibility criteria include having a confirmed diagnosis of adenocarcinoma of the prostate, rising PSA levels, failure of previous treatments, and a castrate level of testosterone. Patients must also have a life expectancy of more than 6 months and meet certain performance status requirements. There are also exclusion criteria, such as prior treatment with mTOR inhibitors or chemotherapy for prostate cancer, and certain medical conditions that would make a patient ineligible for the trial.",
    "The sample is a table that contains information about a clinical trial. It includes the phase of the trial (phase I, phase II, or phase III), a list of diseases being studied, the corresponding ICD-10 codes for those diseases, a list of drugs being tested, and the eligibility criteria for participants. The eligibility criteria include age, disease stage, previous treatments, organ function, and other medical conditions. The sample also includes specific exclusion criteria, such as prior therapy with certain drugs, significant cardiovascular disease, and active infections. The table is divided into two parts, one for the Phase I/II component and one for the Phase II component, with different inclusion and exclusion criteria for each.",
    "The sample is a clinical trial for patients with multiple myeloma in phase 1/phase 2. The trial includes a list of drugs such as carfilzomib, cyclophosphamide, and dexamethasone. The eligibility criteria include being a newly diagnosed MM patient, having measurable disease, being at least 18 years old, having a life expectancy of at least 3 months, and having an ECOG performance status of 0-2. The trial also has exclusion criteria such as previous treatment with anti-myeloma therapy, major surgery within 21 days prior to randomization, and significant neuropathy. The sample also includes a list of diseases and their corresponding ICD-10 codes.",
    "The sample is a record from a clinical trial table that includes information about the trial's phase, diseases being studied, icd-10 codes associated with those diseases, drugs being tested, and eligibility criteria for participants. In this particular sample, the trial is in phase 1/phase 2 and is focused on diabetes mellitus and diabetic nephropathy. The icd-10 codes associated with these diseases are listed, as well as the drug being tested (pirfenidone). The eligibility criteria for participants are also listed, including requirements for age, kidney function, blood pressure, and medical history. There are also exclusion criteria, such as a history of certain medical conditions or plans to receive a kidney transplant within a year.",
    "The sample is a record from a clinical trial table. It includes information about the phase of the trial, which is a combination of phase 1 and phase 2. The trial is focused on heart failure, which is listed as the disease. The icd-10 codes associated with the disease are also included. The trial involves two drugs, trv120027 and placebo. The eligibility criteria for the trial are listed under inclusion and exclusion criteria, which include specific medical conditions and requirements for blood pressure and heart rate.",
    "The sample is a record from a clinical trial table that includes information about the phase of the trial (phase 1/phase 2), a list of diseases (lymphoma, hodgkin disease, lymphoma non-hodgkin), a list of icd-10 codes of diseases, a list of drugs (pci-24781), and eligibility criteria for the trial. The eligibility criteria include age, ability to swallow oral capsules, estimated life expectancy, ECOG performance status, and willingness to sign a written informed consent. The exclusion criteria include prior treatment with an HDAC inhibitor, creatinine clearance, total bilirubin, AST and ALT levels, platelet count, ANC, malabsorption, corticosteroids, concurrent therapeutic anticoagulation, uncontrolled illness, risk factors for or use of drugs known to prolong QTc interval, history of myocardial infarction, acute coronary syndromes, coronary angioplasty and/or stenting, known HIV infection, and other medical or psychiatric illness or organ dysfunction. Pregnant or lactating women and sexually active men who are unwilling to use adequate contraceptive protection during the course of the study are also excluded.",
    "The sample is a clinical trial for patients with solid tumors and hematologic malignancies who have delayed methotrexate clearance. The trial is in phase 1/phase 2 and involves the drugs voraxaze (glucarpidase) and placebo. The eligibility criteria include having an Eastern Cooperative Oncology Group (ECOG) performance status of 0-2 and providing IRB-approved signed informed consent. Exclusion criteria include having medical or psychiatric illnesses that may interfere with participation, receiving medications that may interfere with methotrexate excretion or enhance toxicity, having uncontrolled cardiac disease, or having known hypersensitivity to any of the study drug components. The diseases are listed as 'hematologic malignancy' and 'solid tumor', and the icd-10 codes for the diseases are also provided.",
    "The sample is a record from a clinical trial table that includes information about the phase of the trial, diseases being studied, icd-10 codes of the diseases, drugs being used, and eligibility criteria for participants. In this particular sample, the trial is in phase 1/phase 2 and is studying non-alcoholic steatohepatitis and increased iron storage/disturbed distribution. The icd-10 code for the disease is K75.81. The drug being used is exjade. The eligibility criteria for participants include having elevated liver enzymes and serum ferritin levels, liver histology consistent with a diagnosis of NASH, and not having certain exclusion criteria such as alcohol intake over 140 g/week, established liver cirrhosis, or anemia. There are several other exclusion criteria listed as well.",
    "The sample is a clinical trial for patients with head and neck cancer in phase 1/phase 2. The trial involves the use of two drugs, docetaxel and everolimus. The eligibility criteria include having histologically confirmed squamous cell carcinoma of the head and neck, measurable disease by RECIST criteria, and an ECOG performance status of 0-1. Patients must also meet certain medical requirements, such as having normal levels of urea and creatinine, and not having any uncontrolled infections. Additionally, patients must not have received prior chemotherapy for any cancer except for head and neck cancer, and must not have received prior therapy with any erbB inhibitors or taxanes. The trial also has certain exclusion criteria, such as not being pregnant or nursing, and not having any mental condition that would render the patient unable to understand the nature, scope, and possible consequences of the study.",
    "The sample is a clinical trial for patients with relapsed or resistant diffuse large B cell lymphoma. The trial is in phase 1/phase 2 and involves the use of two drugs, azacytidine and vorinostat. The eligibility criteria include having measurable disease, being over 18 years old, having a certain performance status, and having normal organ and marrow function. Women of childbearing potential must have a negative pregnancy test and agree to use contraception during the study. The exclusion criteria include having received certain previous treatments, having a currently active second malignancy, and having uncontrolled illness. Pregnant and lactating women are also excluded.",
    "The sample is a record from a table that contains information about clinical trials. It includes the phase of the trial, which can be either phase 1 or phase 2, as well as a list of diseases and their corresponding ICD-10 codes. The sample also includes a list of drugs being tested in the trial, which are lapatinib, carboplatin, and paclitaxel. Additionally, the sample provides the eligibility criteria for the trial, including inclusion criteria such as having relapsed ovarian or metastatic breast cancer and measurable disease, and exclusion criteria such as prior treatment with certain therapies and concomitant medication requirements.",
    "The sample is a record from a clinical trial table. It includes information about the phase of the trial, which is a combination of phase 1 and phase 2. The trial is focused on the disease type 2 diabetes mellitus, which is identified by a list of ICD-10 codes. The trial involves several drugs, including gk1-399 (formerly ttp399) and a placebo. The eligibility criteria for the trial include being between the ages of 18 and 75, having a diagnosis of T2DM, being on a stable dose of background medication for diabetes, and having a BMI between 20-40 kg/m2. The exclusion criteria include having type 1 diabetes, a recent heart attack or stroke, uncontrolled blood pressure, or significant kidney disease.",
    "The sample is a clinical trial for a drug called DPK-060 1% ointment and its placebo for the treatment of atopic dermatitis. The trial is in phase 1/phase 2 and the eligibility criteria include having a clinical diagnosis of atopic dermatitis, having treatable eczematous lesions of a total area of at least 25 cm2, and using an appropriate method of contraception for female patients of childbearing potential. Exclusion criteria include having significant clinical illness within the two weeks prior to the first dose, having had previous local or systemic antimicrobial therapy within the last four weeks prior to the first application of the investigational product, and having any surgical or medical condition which might interfere with the absorption, distribution, metabolism or excretion of the drug. The trial also excludes patients who had had systemic treatment for atopic dermatitis or other topical or transdermal treatments on the site of eczema within 14 days prior to first application of DPK-060 1% or placebo ointment and/or topical treatment with tar, any corticosteroid, topical immunomodulators or oral treatment with any corticosteroids within 14 days prior to first application and/or oral antihistamines within 14 days of the first dose. Other exclusion criteria include having a diagnosis of other skin diseases likely to adversely affect the outcome of the study, having a history or evidence of significant cardiac, renal, hepatic or endocrine disease, having significant hypersensitivity or allergy, being immunocompromised, having lice or scabies, having tinea corporis, having hypersensitivity to the ingredients of the vehicle, having prominent tattoos at sites of application of DPK-060 1% or placebo ointment, having donated blood exceeding 450 mL during the three months prior to first dose, having participated in a clinical study during the 12 weeks prior to first dose, having ongoing alcohol or drug abuse, and having a positive pregnancy test or lactation.",
    "The sample is a record from a clinical trial table that includes information about the phase of the trial, diseases being studied, icd-10 codes of the diseases, drugs being tested, and eligibility criteria for participants. In this particular sample, the trial is in phase 1/phase 2 and is focused on studying primary Hepatocellular Carcinoma (HCC) and liver neoplasms. The drug being tested is talaporfin sodium. The eligibility criteria for participants include having a diagnosis of HCC, having at least 1 but no more than 3 lesions in the liver, having an ECOG performance status of 0-2, and meeting certain hematologic, liver, and renal function requirements. There are also exclusion criteria, such as having lesions larger than 8 cm in diameter and more than 40% of parenchymal disease involvement, known sensitivity to porphyrin type drugs, and concurrent participation in another clinical trial involving experimental treatment.",
    "The sample is a clinical trial for the treatment of glioblastoma multiforme, a type of brain cancer. The trial is in phase 1/phase 2 and involves the use of a combination of drugs called mpc-6827 and carboplatin. The eligibility criteria for the trial include having a histologically proven WHO Grade IV glioblastoma multiforme, evidence of measurable recurrent or residual primary tumor by contrast-enhanced MRI, and a Performance Scale of Karnofsky > 60%, ECOG < 2 or WHO < 2. Exclusion criteria include hypersensitivity to Cremophor EL, evidence of current/active intratumor hemorrhage by MRI, and prior treatment with platinum-based chemotherapy.",
    "The sample is a clinical trial for patients with advanced hepatocellular carcinoma. The trial is a combination of temsirolimus and sorafenib drugs. The eligibility criteria include patients who are at least 18 years old, have a life expectancy of at least 12 weeks, have confirmed advanced HCC, and have at least one tumor lesion that can be accurately measured. Patients must have an ECOG PS of 0, 1 or 2 or a Karnofsky Performance Status > 70 %, and a cirrhotic status of Child-Pugh class A or B. Patients must also meet certain laboratory criteria, such as having white blood cells \u2265 3,000/mm\u00b3 and platelets \u2265 100,000/mm\u00b3. Exclusion criteria include patients who are currently receiving chemotherapy, immunotherapy or radiotherapy, have a known history of HIV seropositivity, or have uncontrolled diabetes. Patients must also be willing and able to comply with the protocol.",
    "The sample is a record of a clinical trial with a phase 1/phase 2 designation. The trial is focused on treating three diseases: myelofibrosis, polycythemia vera, and thrombocytosis. The diseases are identified by their corresponding ICD-10 codes. The drug being tested is ruxolitinib. The eligibility criteria for the trial include being diagnosed with PMF or Post-PV/ET MF, requiring therapy for myelofibrosis, and having adequate bone marrow reserve. The exclusion criteria include having received anti-cancer medications or investigational therapy in the past 14 days.",
    "The sample is a clinical trial for a drug combination of safinamide and levodopa for patients diagnosed with idiopathic Parkinson's disease. The trial is a phase 1/phase 2 trial and the eligibility criteria include being male or female, aged 30 years or older, having a BMI between 18-32 kg/m2, and being a levodopa-responsive patient with a stable dose of levodopa/carbidopa. The trial also requires a normal or non-hazardous 12-lead electrocardiogram recording, a negative beta-HCG test for females, and the ability to maintain an accurate dosing diary. The exclusion criteria include co-administration of certain drugs, being in a late stage of Parkinson's disease, having any indication of forms of Parkinsonism other than idiopathic Parkinson's disease, and having clinically relevant allergies or diseases that would exclude the subject from the study.",
    "The sample is a record from a clinical trial table that includes information about the trial's phase, diseases being studied, ICD-10 codes associated with those diseases, drugs being used, and eligibility criteria for participants. In this particular sample, the trial is studying prostate neoplasms and is in phase 1/phase 2. The drugs being used are abiraterone acetate, abiraterone acetate, and prednisone/prednisolone or dexamethasone. The eligibility criteria for participants include having confirmed adenocarcinoma of the prostate, no prior chemotherapy for prostate cancer, ongoing androgen deprivation therapy, and demonstrating disease progression after antiandrogen withdrawal. There are also exclusion criteria, such as having active psychiatric illnesses or uncontrolled autoimmune disease that may require corticosteroid therapy during the study.",
    "The sample is a record from a table that contains information about clinical trials. It pertains to a trial that is in phase 1/phase 2 and involves patients with severe combined immunodeficiency disease, severe primary immunodeficiency disorder, undefined T cell deficiency disorder, or Wiskott-Aldrich syndrome. The trial requires patients to have an HLA mismatched family member or an HLA matched or mismatched unrelated donor, and they must meet certain health criteria such as having a life expectancy greater than 6 weeks and a Lansky/Karnofsky score of at least 70%. The trial excludes patients with an HLA matched related donor, symptomatic cardiac disease, known allergy to rat serum products, severe infection, HIV positive, or pregnant. The record also includes a list of icd-10 codes, drugs, and eligibility criteria.",
    "The sample is a record of a clinical trial with a combination of phase 1 and phase 2. The trial is focused on treating non-small cell lung cancer, specifically stage IIIA non-resectable or stage IIIB without pleural effusion. The trial drug being tested is called s-3304. The eligibility criteria for the trial includes having a performance status of 0-1, adequate organ function, and being clinically indicated and able to receive conventional chemoradiation therapy. Patients with prior history of cancer, other serious intercurrent illness including HIV/AIDS, or contraindicated for paclitaxel/carboplatin or thoracic irradiation treatment are excluded from the trial. The diseases and their corresponding ICD-10 codes are also listed in the record.",
    "The sample is a clinical trial for lupus nephritis, with a phase 1/phase 2 designation. The trial is looking at the effectiveness of the drug nkt-01 in treating the disease. The eligibility criteria for participants include being between the ages of 18-70, having a diagnosis of SLE according to the ACR criteria, having sufficient signs to diagnose active SLE nephritis, and meeting certain laboratory values. Exclusion criteria include chronic infections, liver toxicity, pregnancy or lactation, anemia, and history of malignancy. Participants cannot have major and active SLE organ involvement other than the kidney, and cannot have participated in another trial within the last 6 months.",
    "The sample is a record from a clinical trial table that includes information about the trial's phase, diseases being studied, corresponding ICD-10 codes, drugs being tested, and eligibility criteria for participants. In this particular sample, the trial is in both phase 1 and phase 2 and is focused on ovarian and primary peritoneal cancer. The ICD-10 codes associated with these diseases are listed, as well as the drugs being tested in each phase of the trial. The eligibility criteria for participants are also provided, including requirements for diagnosis, prior treatment, and measurable disease. Exclusion criteria are also listed, such as having received more than two lines of therapy for the cancer or being pregnant or breastfeeding.",
    "The sample is a clinical trial for ovarian cancer patients who have previously undergone platinum-based chemotherapy. The trial is in phase 1/phase 2 and the drug being tested is vandetanib. The eligibility criteria include having a documented invasive epithelial ovarian carcinoma, cancer of the fallopian tube or the peritoneum that is refractory to platinum-based chemotherapy or with partially platinum sensitive disease. Patients must also have received at least one previous platinum- and taxane-based chemotherapy regimen. Exclusion criteria include brain metastases or spinal cord compression, concomitant medications that may cause QTc prolongation or induce Torsades de Pointes or induce CYP3A4 function, and more than two prior lines of chemotherapy. The trial requires planned therapy with pegylated liposomal doxorubicin 50 mg/m\u00b2 for recurrent platinum-refractory ovarian cancer.",
    "The sample is a clinical trial for a vaccine for influenza. The trial is a combination of phase 1 and phase 2. The trial is looking for male or non-pregnant female participants between the ages of 18 and 40 who are in good health and able to understand and comply with the study procedures. The trial has a list of exclusion criteria, including allergies to vaccine components, immunosuppression, neoplastic disease, and long-term use of certain steroids. Participants must provide informed consent and be available for all study visits. The trial is looking to evaluate the safety and efficacy of the vaccine.",
    "The sample is a clinical trial for patients with non-small cell lung cancer in stages IIIA or IIIB. The trial is a combination of chemotherapy and thoracic conformal radiotherapy. Patients must meet certain eligibility criteria, including having an Eastern Cooperative Oncology Group (ECOG) performance status of 0-1, certain blood counts, lung function, and kidney and liver function within normal limits. Patients must also not have certain medical conditions or recent surgeries, and cannot be participating in any other experimental drug studies or receiving other antineoplastic or antitumor agents.",
    "The sample is a clinical trial for patients with acute myeloid leukemia, myelodysplastic syndrome, or multiple myeloma. The trial is in phase 1/phase 2 and the drug being tested is chr-2797 (tosedostat), an aminopeptidase inhibitor. The eligibility criteria include signed informed consent, recovery from prior therapies, adequate bone marrow, hepatic and renal function, and a negative pregnancy test for female patients with reproductive potential. Exclusion criteria include concurrent illness, psychiatric disorders, and pregnancy or breastfeeding. The trial aims to evaluate the safety and efficacy of chr-2797 in treating these diseases.",
    "The sample is a record of a clinical trial with a phase 1/phase 2 designation. The trial is focused on prostate cancer and the icd-10 codes associated with it. The drug being tested is called odm-201. The eligibility criteria for the trial include having a confirmed diagnosis of adenocarcinoma of the prostate, ongoing androgen deprivation therapy, progressive metastatic disease, and adequate bone marrow, hepatic, and renal function. The exclusion criteria include having known metastases in the brain, a history of other malignancy within the previous 5 years, known gastrointestinal disease or procedure that affects absorption, and not being able to swallow the study drug.",
    "The sample is a clinical trial for ovarian cancer patients in phase 1/phase 2. The trial involves the use of drugs such as carboplatin, cyclophosphamide, etoposide, paclitaxel, and topotecan hydrochloride. The eligibility criteria for the trial include having histologically proven stage IIIC ovarian epithelial cancer, being chemosensitive to 6-8 courses of standard dose adjuvant chemotherapy, and having achieved at least partial response (PR) following six courses of standard dose chemotherapy. Patients must also meet certain patient characteristics such as being between the ages of 18 and 65, having a performance status of ECOG 0 or 1, and having no active infections or other malignancies within the past 5 years. The trial excludes patients who have no microscopic disease present following induction chemotherapy or who have histologically proven newly diagnosed stage IV ovarian epithelial cancer. Prior concurrent therapy is not specified, and patients must not be taking concurrent nitroglycerin preparations or antiarrhythmic drugs.",
    "The sample is a clinical trial for the treatment of metastatic malignant melanoma using the drugs karenitecin and valproic acid. The trial is divided into two phases, phase 1 and phase 2. The eligibility criteria for both phases include having cytologically/histologically-documented metastatic malignant melanoma, being at least 18 years old, having an ECOG performance status of 0-2, and being able to give informed consent and follow the study guidelines. Additionally, subjects must have no major impairment of hematological function and use an effective method of contraception during the study and three months following termination of treatment. The exclusion criteria for both phases include having evidence of significant active infection, inadequate renal or hepatic function, being pregnant or nursing, having uncontrolled CNS metastasis or a history of seizures, and having been previously treated with more than 2 prior chemotherapy regimens. The criteria for phase 2 also include having previously received any immunotherapy regimens. Subjects with stable CNS metastasis are eligible for both phases.",
    "The sample is a clinical trial for ovarian cancer patients who have previously undergone platinum-based chemotherapy. The trial is a combination of phase 1 and phase 2, and the treatment involves a combination of lenvatinib, carboplatin, and gemcitabine. The eligibility criteria include being a female over 18 years old with confirmed ovarian cancer that was sensitive to one prior platinum-based chemotherapy regimen for Stage III or Stage IV disease. Participants must also have documentation of biochemical relapse defined by CA125 criteria and have recovered from the effects of any major surgery within 28 days from the first dose of study treatment. The exclusion criteria include being pregnant, having proteinuria greater than 1+ on urine dipstick testing, having ovarian nonepithelial cancer, and having any other uncontrolled infection or medical condition that would interfere with the conduct of the study.",
    "The sample is a clinical trial with a combination of phase 1 and phase 2. The trial is focused on treating hepatocellular carcinoma, and the drugs used are mapatumumab, placebo, and sorafenib. The eligibility criteria include having Child-Pugh Class A, measurable disease demonstrating intratumoral arterial enhancement, adequate bone marrow, renal and liver function, performance status of 0, 1 or 2 on the Eastern Cooperative Oncology Group (ECOG) Scale, and age 18 years or older. The exclusion criteria include having any co-morbid condition that in the judgment of the investigator renders the subject at high risk of treatment complications or reduces the possibility of assessing clinical effect, received prior investigational or non-investigational cytotoxic chemotherapy, hormonal therapy, biological therapy, history of organ allograft, previously received mapatumumab or sorafenib, underwent resection, radiofrequency ablation, radiation or chemoembolization within 4 weeks before enrollment or not recovered from such treatments, need for concomitant anticancer therapy, major surgery within 4 weeks before enrollment, minor surgery within 2 weeks before enrollment, systemic steroids within 1 week before enrollment except steroids used as part of an antiemetic regimen or maintenance-dose steroids for non-cancerous disease, hepatic encephalopathy, per the investigator's evaluation, history of clinically significant gastrointestinal bleeding requiring procedural intervention within 4 weeks before enrollment, gastrointestinal disease resulting in an inability to take oral medication or a requirement for intravenous hyperalimentation, history of any infection requiring hospitalization or intravenous antibiotics within 2 weeks before enrollment, known brain or spinal cord metastases unless adequately treated, known human immunodeficiency virus infection, unstable angina, myocardial infarction, cerebrovascular accident, >= Class II congestive heart failure according to the New York Heart Association Classification for Congestive Heart Failure within 6 months before enrollment, cardiac arrhythmias requiring anti-arrhythmic therapy other than beta blockers or digoxin, uncontrolled hypertension, using and unable to discontinue use of concomitant strong CYP3A4 inducers, pregnant female or nursing mother, males who do not agree to use effective contraception during the study and for a period of 60 days following the final dose of study agent, subject is currently enrolled in or has not yet completed at least 30 days since ending other investigational device or drug study(s) or subject is receiving other investigational agents, acute or chronic severe renal insufficiency, and hepatitis B virus deoxyribonucleic acid (DNA) levels >2,000 international units/mL.",
    "The sample is a record from a clinical trial table that includes information about the phase of the trial, diseases being studied, icd-10 codes of the diseases, drugs being tested, and eligibility criteria for patients to participate in the trial. In this particular sample, the trial is a combination of phase 1 and phase 2, and the disease being studied is colorectal neoplasms. The icd-10 codes associated with the disease are listed, as well as the drugs being tested, which include bevacizumab, ag-013726, and ag-013736 (axitinib). The eligibility criteria for patients to participate in the trial are also listed, including requirements for previous chemotherapy, measurable disease, and controlled hypertension. Additionally, there are exclusion criteria listed, such as prior treatment with anti-angiogenesis agents or radiation.",
    "The sample is a clinical trial for ovarian cancer patients who have failed at least one prior platinum-based chemotherapy regimen. The trial is a combination of phase 1 and phase 2, and the drugs being tested are sorafenib and topotecan. The eligibility criteria include having histologically-confirmed epithelial ovarian cancer, measurable disease according to RECIST or detectable disease by CA-125, ascites and/or pleural effusion attributed to tumor, and solid and/or cystic abnormalities on radiographic imaging. Patients must also have failed at least one prior platinum-based chemotherapeutic regimen and have no more than 3 prior treatment regimens for epithelial ovarian cancer. The exclusion criteria include no known or suspected allergy to sorafenib or any agent given in the course of this trial, no prior treatment with anti-angiogenesis therapy, no active CNS metastases, and no treatment with any investigational agent within 30 days prior to being registered for protocol therapy.",
    "The sample is a record of a clinical trial that is in phase 1/phase 2. The trial is focused on the treatment of multiple sclerosis using smoked cannabis. The eligibility criteria for the trial include a diagnosis of clinically definite multiple sclerosis, moderate or severe spasticity, and being 21 years or older. However, there are also exclusion criteria, such as preexisting pulmonary or cardiac conditions, inability to abstain from tobacco or marijuana smoking, and a history of abuse of recreational drugs. The sample also includes a list of icd-10 codes for the disease and the inclusion and exclusion criteria for the trial.",
    "The sample is a record from a clinical trial table that includes information about the trial's phase, diseases being studied, icd-10 codes of the diseases, drugs being tested, and eligibility criteria for participants. In this particular sample, the trial is in phase 1/phase 2 and is studying urinary bladder neoplasms. The icd-10 codes associated with the disease are listed as \"['D30.3', 'C67.5', 'C67.9', 'C79.11', 'C67.0', 'C67.1', 'D41.4']\". The drug being tested is lenalidomide. The eligibility criteria for participants include being over 18 years old, having a Karnofsky Performance Status of \u2265 70%, having histological or cytological proof of transitional cell carcinoma of the urothelial tract, having measurable disease according to RECIST or unresectable disease (cT4b), and meeting certain laboratory value requirements. There are also exclusion criteria, such as having received prior lenalidomide or having a clinically significant infection.",
    "The sample is a clinical trial for patients with advanced non-small cell lung cancer. The trial is in phase 1/phase 2 and involves the use of carboplatin, hydroxychloroquine, and paclitaxel as drugs. The eligibility criteria include having a confirmed diagnosis of advanced non-small cell lung cancer, with no component of squamous cell carcinoma, and measurable disease. Patients must also have an ECOG performance status of 0-1 and meet certain laboratory values. They cannot have certain medical conditions or ongoing infections, and must not be pregnant or nursing. Prior concurrent therapy is also taken into consideration.",
    "The sample is a record of a clinical trial with a phase 1/phase 2 designation. The trial is focused on the disease of acute ischemic stroke and includes a list of ICD-10 codes associated with the disease. The trial involves the drugs mrx-801 and placebo. The eligibility criteria for the trial include having an acute ischemic stroke with occlusion demonstrated by transcranial Doppler ultrasound and being eligible for tPA. The exclusion criteria include having a right to left cardiac shunt, moderate to severe COPD, and uncontrolled hypertension.",
    "The sample is a clinical trial for type 1 diabetes mellitus, with a phase 1/phase 2 designation. The trial involves the drug lisofylline and has a list of inclusion and exclusion criteria for participants. Inclusion criteria include being between the ages of 18 and 45, having a clinical diagnosis of type 1 diabetes for at least 2 years, and being on a stable dose of insulin for at least 3 months. Exclusion criteria include having significant stomach, liver, kidney, or heart disease, a personal or family history of long QTc syndrome, and a history of drug or alcohol abuse.",
    "The sample is a record from a clinical trial table that includes information about the phase of the trial (phase 1/phase 2), the disease being studied (recurrent childhood acute lymphoblastic leukemia), the corresponding ICD-10 codes, the drugs being used in the trial (l-asparaginase, doxorubicin hydrochloride, therapeutic hydrocortisone, vincristine sulfate, cytarabine, prednisone, pegaspargase, dexrazoxane hydrochloride, methotrexate, etoposide, cyclophosphamide, leucovorin calcium), and the eligibility criteria for participants. The eligibility criteria include specific requirements related to the diagnosis of B lymphoblastic leukemia, performance status, blood count, liver and kidney function, heart function, and other health factors. Participants must also have recovered from prior treatments and not be receiving any other concurrent therapies or investigational drugs.",
    "The sample is a clinical trial for asthma patients in phase 1/phase 2. The trial involves testing the effectiveness of two drugs, active and placebo, on patients with mild bronchial asthma who are currently being treated only with intermittent short-acting beta-agonist therapy by inhalation. The trial has inclusion criteria such as a BMI between 18.5 and 35 kg/m2, nonsmoking for \u2265 one year, and a pre-bronchodilator FEV1 \u2265 75% of predicted at screening. The trial also has exclusion criteria such as hypertension, respiratory tract infection and/or exacerbation of asthma within prior 4 weeks, and history of life-threatening asthma. The trial requires patients to undergo methacholine testing and have a provocation concentration of methacholine resulting in a 20% fall in FEV1 (PC20 methacholine) of \u2264 8 mg/ml at screening. The sample also includes a list of icd-10 codes of diseases associated with asthma.",
    "The sample is a clinical trial table that contains information about the phase of the trial, diseases being studied, icd-10 codes of the diseases, drugs being tested, and eligibility criteria for patients to participate in the trial. The phase of the trial is a combination of phase 1 and phase 2. The diseases being studied include advanced nonhematological malignancies, non-small cell lung cancer, small cell lung cancer, metastatic breast cancer, head and neck squamous cell carcinoma, and gastroesophageal adenocarcinoma. The icd-10 codes associated with these diseases are also listed. The drug being tested is mln8237 (alisertib). The eligibility criteria for patients to participate in the trial include being 18 years or older, having a confirmed metastatic and/or advanced solid tumor, having an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1, and meeting other specific requirements. Patients who meet any of the exclusion criteria are not eligible to participate in the trial.",
    "The sample is a clinical trial for patients with intermittent claudication, a symptom of peripheral artery disease (PAD). The trial is in phase 1/phase 2 and involves the use of trans sodium crocetinate (TSC) and 0.9% normal saline as drugs. The eligibility criteria include being aged 40 or older, having a 6-month history of walking limitation or symptoms of IC, and having a diagnosis of PAD secondary to atherosclerosis. Patients must also have a peak walking time of at least 1 minute but no more than 12 minutes on an exercise treadmill test. The trial has various exclusion criteria, including pregnancy or lactation, critical limb ischemia, and recent cardiovascular surgery or intervention. Patients must be willing and able to comply with all study-related procedures and provide written, signed, informed consent.",
    "The sample is a clinical trial with a phase 1/phase 2 design, involving patients with recurrent small cell lung cancer or unspecified adult solid tumors. The trial is testing the effectiveness of obatoclax mesylate and topotecan hydrochloride as treatments for these cancers. The eligibility criteria include having a confirmed diagnosis of the cancer, not having progressive brain metastases or leptomeningeal involvement, having a certain level of performance status and blood counts, and not being pregnant or nursing. Patients must also have recovered from prior chemotherapy or radiotherapy and cannot be receiving any other investigational agents or anticancer therapy. The exclusion criteria include having a history of allergic reactions to similar compounds, having concurrent uncontrolled illnesses, and having a history of seizure disorder or other neurological dysfunction.",
    "The sample is a clinical trial for the treatment of metastatic melanoma. The trial is in phase 1/phase 2 and involves the drug combination of mpc-6827 and temozolomide. The eligibility criteria for the trial include having histologically proven melanoma, measurable metastases, and a performance score of Karnofsky \u2265 60%, or Eastern Cooperative Oncology Group (ECOG) \u2264 2, or WHO \u2264 2. Exclusion criteria include having hypersensitivity to Cremophor EL, ocular melanoma, primary intradural melanoma or leptomeningeal involvement, cardiovascular disease, cerebrovascular disease, uncontrolled hypertension, and a cardiac ejection fraction < 50%. The trial requires completion of any radiation therapy for brain metastases at least 4 weeks prior to starting the study drug and a minimum of 4 weeks since prior surgical resection or major surgical procedure and a minimum of 2 weeks since chemotherapy/biochemotherapy. If steroids are needed, the subject must be on a stable or decreasing dose of steroids for at least 1 week.",
    "The sample is a clinical trial for a drug called dasatinib, which is being tested on patients with chronic myeloid leukemia who have either developed resistance to imatinib mesylate or cannot tolerate it. The trial is in phase 1/phase 2 and the patients must meet certain eligibility criteria, such as having a specific performance status and being between the ages of 20 and 75. Women of childbearing potential must use contraception throughout the study and for up to 3 months after it ends. There are also exclusion criteria, such as having uncontrolled cardiovascular disease or a history of significant bleeding disorder unrelated to CML. The sample includes a list of diseases, icd-10 codes, and drugs being studied, as well as the eligibility and exclusion criteria for the trial.",
    "The sample is a record of a clinical trial with a combination of phase 1 and phase 2. The trial is focused on the treatment of hepatitis B and liver transplantation. The diseases involved are hepatitis B and liver transplantation. The icd-10 codes associated with these diseases are also listed. The drugs used in the trial are adefovir dipivoxil and hepatitis B vaccination. The eligibility criteria for the trial are listed under inclusion and exclusion criteria. The inclusion criteria include recipients who have not tested positive for hepatitis B surface antigen, have received liver transplantation with hepatitis B core antibody positive grafts, have received adefovir treatment post transplantation, and have not reached the 18 month post transplantation time period. The exclusion criteria include recipients with hepatitis B surface antigen positivity prior to liver transplant, grafts from hepatitis B surface antigen positive patients, previous intolerance to ADV therapy, pre-transplant creatinine > 1.6 mg/dL, patients younger than 21 years of age, and patients who are pregnant or breastfeeding.",
    "The sample is a record from a clinical trial table that includes information about the phase of the trial, diseases being studied, corresponding ICD-10 codes, drugs being tested, and eligibility criteria for participants. In this particular sample, the trial is in phase 1/phase 2 and is studying adenocarcinoma and neoplasms. The ICD-10 codes associated with these diseases are listed. The drug being tested is torisel. The eligibility criteria for participants include having a histological diagnosis of advanced cancer that is recurrent or refractory to standard therapy or for whom standard therapy is not available. There are also exclusion criteria listed, such as subjects receiving enzyme-inducing anticonvulsants and having pulmonary hypertension or pneumonitis.",
    "The sample is a clinical trial table that contains information about the phase of the trial, diseases being studied, icd-10 codes of the diseases, drugs being used, and eligibility criteria for the participants. The phase of the trial can be either phase I, phase II, or phase III. The diseases being studied include brain and central nervous system tumors, melanoma, and solid tumors. The icd-10 codes associated with these diseases are also listed. The drugs being used in the trial include ps-341 (velcade) and temozolomide. The eligibility criteria for the participants are also listed, including histologically proven malignancy, no available effective therapy, adequate performance status, and adequate baseline organ system function. The inclusion and exclusion criteria for both phase I and phase II are also listed.",
    "The sample is a clinical trial for patients with leukemia that has relapsed or is refractory to prior induction therapy. The trial is in phase 1/phase 2 and involves the drugs clofarabine, cytarabine, and methotrexate. The eligibility criteria include a confirmed diagnosis of acute myeloid leukemia, acute lymphoblastic leukemia, or acute leukemia of ambiguous lineage with certain characteristics, as well as specific patient characteristics such as performance status, life expectancy, and organ function. Patients must have recovered from prior therapy and meet certain time requirements since their last treatment. The trial does not allow concurrent chemotherapy or immunomodulating agents.",
    "The sample is a clinical trial for lung cancer patients in phase 1/phase 2. The trial includes patients with selected Stage IIIB or Stage IV advanced non-small cell lung cancer or recurrent disease after previous surgery and/or radiation. The trial involves the use of two drugs, bevacizumab and bortezomib. The eligibility criteria include having an Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-2, no history of or active brain metastases, and having received one or two prior systemic therapies, one of which contained a platinum compound. The trial also has exclusion criteria, such as patients with squamous histology, serious medical or psychiatric illness likely to interfere with participation, and pregnant or nursing women. The patients must provide voluntary written informed consent before participating in the trial.",
    "The sample is a clinical trial for HIV infections, with a phase 1/phase 2 designation. The trial involves the use of various forms of the drug raltegravir, and the eligibility criteria include documentation of HIV-1 infection, unchanged therapeutic regimen for at least 12 weeks, and HIV RNA of 1,000 copies/mL or greater at screening. Participants must also be willing to take the assigned raltegravir preparation and provide informed consent. Exclusion criteria include a history of lactic acidosis, treatment for active tuberculosis, and any clinically significant diseases that could compromise the outcome of the study. The trial also has specific exclusion criteria for participants in different stages of the trial.",
    "The sample is a clinical trial for malignant pleural mesothelioma, in which patients are eligible if they are over 18 years old, have not received previous chemotherapy, and are medically suitable for limited surgical intervention. The trial involves the use of chemotherapy and allows for radiotherapy for palliation. Patients must have a WHO performance status of 2 or less and adequate organ function. Exclusion criteria include active uncontrolled infection, severe cardiac dysfunction, uncorrectable bleeding tendency, and impaired renal function. The trial also excludes patients with previous successful pleurodesis, symptomatic CNS metastases, and those with serious disabling conditions.",
    "The sample is a clinical trial for the treatment of Tourette's Syndrome using a drug called ecopipam. The trial is a combination of phase 1 and phase 2. The eligibility criteria for the trial includes having Tourette's Syndrome for at least 5 years, exhibiting both motor and vocal tics, and having a minimum score of 20 on the Yale Global Tic Severity Score. Participants must also be at least 18 years old and meet certain contraceptive requirements. Exclusion criteria includes having unstable medical illness, a history of attempted suicide, or a first-degree relative with a major depressive episode resulting in hospitalization or suicide. Participants must not have had previous treatment with ecopipam or certain other medications.",
    "The sample is a clinical trial for advanced non-small cell lung cancer patients who have progressed after treatment with at least one chemotherapy regimen. The trial is a combination of phase 1 and phase 2, and the drugs being tested are docetaxel and npi-2358 + docetaxel. The eligibility criteria include being 18 years or older, having an ECOG performance status of 1 or less, and having resolved adverse events from prior treatments to grade 2 or less. The trial excludes patients with certain medical histories, infections, or who are pregnant or breastfeeding. The sample also includes a list of diseases (cancer) and their corresponding ICD-10 codes, as well as the inclusion and exclusion criteria for the trial.",
    "The sample is a clinical trial for lung cancer patients in phase 1/phase 2. The trial involves the drugs everolimus and gefitinib. The eligibility criteria include having histologically confirmed non-small cell lung cancer, measurable or evaluable indicator lesions, and progressive disease after receiving at least one prior chemotherapy regimen that included cisplatin or carboplatin and docetaxel. Patients must also meet certain age, performance status, and medical criteria, and cannot have uncontrolled brain or leptomeningeal metastases. Prior concurrent therapy is also restricted. The sample includes a detailed list of eligibility criteria for the trial.",
    "The sample is a record from a clinical trial table that includes information about the phase of the trial, the disease being studied (in this case, lymphoma), the ICD-10 codes associated with the disease, the drug being tested (pegylated liposomal doxorubicin hydrochloride), and the eligibility criteria for participants. The eligibility criteria include specific disease characteristics, patient characteristics, and prior concurrent therapy restrictions. The sample also includes detailed information about the specific eligibility criteria, such as the patient's performance status, life expectancy, hematopoietic, hepatic, renal, and cardiovascular health, as well as other factors that could impact their ability to participate in the trial.",
    "The sample is a clinical trial for patients with Malignant Bowel Obstruction caused by primary ovarian cancer, primary peritoneal cancer, or fallopian tube cancer. The trial is in phase 1/phase 2 and involves the use of cisplatin and paclitaxel as treatment. The eligibility criteria include hospital admission and diagnosis, non-surgical candidacy, understanding and willingness to sign a consent form, ECOG performance status of 0, 1, or 2, and adequate hematological, renal, and hepatic function. Exclusion criteria include other causes of MBO, recent chemotherapy, and various medical conditions that may be aggravated by treatment. The trial also requires CT confirmation of bowel obstruction and the presence of at least two of four symptoms.",
    "The sample is a clinical trial for patients with HIV infections, in which the drugs tipranavir capsules and ritonavir capsules are being tested. The trial is a combination of phase 1 and phase 2. The eligibility criteria include being between the ages of 18 and 60, having a negative pregnancy test result, and a BMI between 18 and 29 kg/m2. Patients must also have a documented HIV-1 RNA load of less than 50 copies/mL for at least 3 months and be on a stable ZDV or ABC regimen for at least 6 months. Exclusion criteria include being pregnant or breastfeeding, using any other investigational medicine within 30 days before Day 0, and having a history of illness that might confound the results of the study or pose additional risks in administering TPV/r.",
    "The sample is a record from a clinical trial table that includes information about the phase of the trial, the diseases being studied, the ICD-10 codes associated with those diseases, the drugs being tested, and the eligibility criteria for participants. In this particular sample, the trial is a combination of phase 1 and phase 2, and the diseases being studied are \"healthy\" and \"opioid-induced constipation\". The ICD-10 codes associated with these diseases are also listed. The drugs being tested are \"td-1211\" and \"placebo\". The eligibility criteria for participants include being between 18 and 65 years old, willingness to stop all laxatives during the screening and treatment period, and not having any clinically significant findings or medical disorders associated with diarrhea or intermittent loose stools.",
    "The sample is a clinical trial for patients with prostate cancer in phase 1/phase 2. The trial includes patients who are at least 18 years old and have metastatic disease with evidence of radiographic progression or serologically. Patients must have had prior treatment with bilateral orchiectomy or other primary hormonal therapy and evidence of treatment failure. Patients must have received prior therapy with docetaxel alone or in combination with either prednisone or estramustine. Patients must not have received radiotherapy < 3 weeks prior to randomization. The trial includes inclusion and exclusion criteria related to the patient's health status, medical history, and allergies. The trial also includes criteria related to the patient's performance status, hematologic, renal, and hepatic function, and contraceptive use.",
    "The sample is a record of a clinical trial with a phase 1/phase 2 designation. The trial is focused on the treatment of primary open-angle glaucoma and ocular hypertension. The diseases are listed along with their corresponding ICD-10 codes. The trial involves the use of three drugs: opa-6566, placebo, and latanoprost. The eligibility criteria for the trial are also listed, including inclusion criteria such as a diagnosis of bilateral primary open-angle glaucoma and ocular hypertension, and exclusion criteria such as any form of glaucoma other than primary open-angle glaucoma in either eye and other ocular conditions as defined by the protocol.",
    "The sample is a record from a clinical trial table that includes information about the phase of the trial, diseases being studied, corresponding ICD-10 codes, drugs being tested, and eligibility criteria for participants. In this particular sample, the trial is in phase 1/phase 2 and is focused on studying myocardial infarction. The ICD-10 codes associated with the disease are listed, as well as the drugs being tested (lovaza\u00ae and a placebo containing corn oil). The eligibility criteria for participants are also listed, including requirements such as having had an acute myocardial infarction, having undergone urgent or emergent PCI, and having the capacity for informed consent. There are also exclusion criteria listed, such as a history of drug or alcohol abuse, known pregnancy, or severe liver or renal insufficiency.",
    "The sample is a clinical trial for patients with non-small cell lung cancer in phase 1/phase 2. The trial involves the use of drugs such as docetaxel, cisplatin, and sti571. The eligibility criteria for the trial include having histologically or cytologically recurrent or advanced NSCLC, having at least one measurable target lesion, and not having received prior chemotherapy treatment for this disease. Patients with brain metastasis must be neurologically stable for at least 1-2 weeks prior to study enrollment. The exclusion criteria include any prior treatment with a biologic response modifier or chemotherapeutic agent for this disease, any concomitant malignancy except non-melanoma skin cancer or in-situ carcinoma of the cervix, and uncontrolled inter-current medical illness.",
    "The sample is a clinical trial with a combination of phase 1 and phase 2. The trial is focused on treating aplastic anemia, menorrhagia, and amenorrhea. The trial involves the use of two drugs, lo-ovral oral contraceptive pills and placebo - sugar pill. The eligibility criteria for the trial include women aged 12-55 years who have a uterus and at least one functioning ovary, diagnosed with bone marrow failure, and other diseases that require treatment with chemotherapy or stem cell transplantation with platelet counts less than 50,000 microliters at study entry, and do not desire pregnancy for the duration of the study. The exclusion criteria include age less than 12 years, postmenopausal women, history of liver disease that precludes OCP use, history of thrombosis, thromboembolism and/or thrombophilia, currently on 2 or more tablets of any oral contraceptive pills per day at study entry, having 2 or more depo medroxyprogesterone acetate injections in the past 12 months or having depo medroxyprogesterone acetate injection in the past 90 days, leuprolide acetate injection in the past 30 days, smoker over the age of 35, women with estrogen dependent tumor e.g. breast cancer, pregnancy, underlying sickle cell anemia, women who are taking chemotherapeutic agents known to cause ovarian failure such as alkylating agents, and allergy to any medication in this protocol.",
    "The sample is a record of a clinical trial with a phase 1/phase 2 designation. The trial is focused on treating head and neck cancer and squamous cell cancer using the drugs zalutumumab and cisplatin. The trial includes a list of inclusion and exclusion criteria for patients, such as having locoregionally advanced squamous cell carcinoma of the oral cavity, oropharynx, hypopharynx or larynx, and not having prior treatment with radiotherapy or chemotherapy in the head and neck area. The table also includes a list of icd-10 codes for the diseases being treated.",
    "The sample is a clinical trial for patients with type 2 diabetes and incipient or overt nephropathy. The trial is in phase 1/phase 2 and involves the use of the drug aliskiren. The eligibility criteria include being between 30-80 years old, having a glomerular filtration rate of at least 40ml per minute, and having a blood pressure between 135/85 mm Hg and 170/105 mm Hg. Patients must also be on stable antihypertensive medications for at least 8 weeks prior to the trial and must be willing to discontinue any prohibited medications. Exclusion criteria include severe hypertension, kidney disease not caused by diabetes or hypertension, and a history of drug or alcohol abuse within the past 12 months. Other protocol-defined inclusion/exclusion criteria may also apply.",
    "The sample is a clinical trial for bladder cancer patients in phase 1/phase 2. The trial includes patients with initial presentation or recurrence of Stage Ta, T1 or Tis, any grade, bladder cancer after transurethral resection of bladder tumor (TURBT). The trial requires patients to have undergone TURBT within 42 days prior to Day 1/Week 1 and have a Karnofsky Performance Status greater than or equal to 80%. Patients must also have a life expectancy of at least 3 years, be 18 years or older, and have acceptable liver and renal function. The trial also requires patients to have acceptable hematologic status and a urinalysis showing no clinically significant abnormalities except those attributable to bladder cancer. Patients must agree to use an effective contraceptive method during the treatment period of the study if they are of child-producing potential. The trial has exclusion criteria, including a history or previous diagnosis of bladder fibrosis, total bladder capacity estimated at cystoscopy to be less than 150 mL, urinary incontinence of a severity that would compromise the ability of the patient to retain the study drug intravesical instillation for two hours, and severe irritative voiding symptoms such as urgency, frequency, or nocturia. Other exclusion criteria include known other malignant disease except squamous or basal cell skin cancer unless the malignancy has been in complete remission off therapy for at least 5 years, major surgery, other than TURBT and diagnostic surgery, within 28 days prior to Day 1/Week 1, and active, uncontrolled bacterial, viral, or fungal infections, including urinary tract infection. The trial also excludes patients who have received treatment with radiation therapy, surgery, chemotherapy, or investigational therapy within one (1) month prior to Day 1/Week 1 on study (two [2] months for nitrosureas or MMC), unless given as standard treatment for bladder cancer and provided that patient is free of all treatment-related toxicities as of Day 1/Week 1. Other exclusion criteria include known infection with human immunodeficiency virus (HIV), known active infection with hepatitis B or hepatitis C, serious disease that could compromise protocol objectives in the opinion of the Investigator and/or the Sponsor (Halozyme), history of a hypersensitivity or idiosyncratic reaction to, or other contraindication to, mitomycin, known allergy to bee or vespid venom, known coagulation disorder or bleeding tendency, treatment with heparin or anticipation of heparin treatment during the treatment period in this study, and unwillingness or inability to comply with procedures required in this protocol.",
    "The sample is a clinical trial with a combination of three drugs, belinostat, paclitaxel, and carboplatin, for patients with solid carcinomas that have no known curative therapy. The trial is divided into different phases, and the sample is from phase 1/phase 2. The diseases included in the trial are ovarian cancer, epithelial ovarian cancer, fallopian tube cancer, and bladder cancer, with corresponding ICD-10 codes. The eligibility criteria include signed consent, confirmed diagnosis, acceptable liver, renal, and bone marrow function, acceptable coagulation status, negative pregnancy test, and more. The exclusion criteria include recent treatment with investigational agents or anticancer therapy, active infection, concurrent second malignancy, and more.",
    "The sample is a record from a clinical trial table that includes information about the phase of the trial (phase 1/phase 2), a list of diseases (recurrent pediatric all, relapsed pediatric all, acute lymphoblastic leukemia, refractory pediatric all), a list of icd-10 codes of diseases, a list of drug names (abt-751, dexamethasone, peg-asparaginase, doxorubicin, cytarabine, methotrexate, cyclophosphamide, 6-thioguanine), and eligibility criteria for patients to participate in the trial. The eligibility criteria include age, diagnosis, performance level, prior therapy, reproductive function, and exclusion criteria such as drug allergies, renal function, liver/pancreatic function, cardiac function, and infection.",
    "The sample is a clinical trial with a combination of phase 1 and phase 2. The trial is focused on treating various diseases such as leukemia, lymphoma, multiple myeloma, myelodysplastic syndromes, and others. The trial involves the use of two drugs, cyclophosphamide and fludarabine phosphate. The eligibility criteria for the trial include being in remission for certain types of leukemia, having high-risk cytogenetics, and having failed or been intolerant to Imatinib mesylate for chronic myelogenous leukemia. Patients must also have adequate performance status, be between the ages of 18 and 70, and have certain organ function requirements. Exclusion criteria include having an available, medically suitable, 5-6/6 HLA-A, B, DRB1 matched sibling donor, being eligible for autologous transplantation, and having acquired or inherited bone marrow failure syndromes such as aplastic anemia and Fanconi anemia.",
    "The sample is a clinical trial for patients with leukemia or myelodysplastic syndromes in any phase of the disease, including remission or relapse. The trial involves unmanipulated allogeneic bone marrow or peripheral blood stem cell transplantation with the use of fludarabine and treosulfan drugs. Patients must have a donor available who is either HLA-identical or HLA-matched unrelated donor by high-resolution DNA typing with a single allele mismatch allowed. Patients must also meet certain eligibility criteria, including having a performance status of Karnofsky 70-100% or Lansky 70-100%, and meeting specific hematopoietic, hepatic, renal, cardiovascular, and pulmonary requirements. Patients must not have any other disease that would severely limit life expectancy, be pregnant or nursing, have HIV positivity, or have any known hypersensitivity to the study drugs. Prior concurrent therapy is also taken into consideration.",
    "The sample is a record from a clinical trial table that includes information about the phase of the trial, the disease being studied (in this case, graft versus host disease), the ICD-10 codes associated with the disease, the drugs being used in the trial (rapamycin and tacrolimus), and the eligibility criteria for participants. The eligibility criteria include age, having received a specific type of stem cell transplant, being on tacrolimus for GVHD prophylaxis, and being deemed eligible for tapering off of tacrolimus by the primary BMT physician. There are also exclusion criteria, such as ongoing GVHD and allergy to rapamycin. Women of childbearing potential must have a negative pregnancy test before starting treatment.",
    "The sample is a clinical trial for the treatment of multiple myeloma, a type of cancer. The trial is in phase 1/phase 2 and involves the use of two drugs, bortezomib and sorafenib. The eligibility criteria for participants include having received no more than 2 prior regimens for the treatment of multiple myeloma, being defined as Relapsed or Refractory Disease, having an ECOG performance status of 0, 1, or 2, and meeting certain laboratory values for blood counts, kidney function, and liver function. Participants must also have measurable or evaluable disease. Exclusion criteria include having > grade 1 peripheral neuropathy, recent thrombolic or embolic events, and other medical conditions that could interfere with participation in the trial. Women who are pregnant or lactating are ineligible, and all patients of childbearing potential must use adequate contraception while receiving study treatment.",
    "The sample is a clinical trial for patients with metastatic prostate cancer in phase 1/phase 2. The trial involves the use of two drugs, dasatinib and docetaxel, and has specific eligibility criteria for patients to participate. These criteria include having confirmed adenocarcinoma of the prostate that is clinically refractory to hormone therapy, evidence of progressive metastatic disease, and measurable disease on imaging or bone scan with a certain level of serum prostate specific antigen (PSA). Patients must also have a certain Eastern Cooperative Oncology Group performance status and testosterone levels, and must not have certain exclusion criteria such as known brain metastases or clinically-significant cardiovascular disease. The trial has restrictions on prior therapy for metastatic disease, including limitations on prior chemotherapy and radiotherapy.",
    "The sample is a record from a clinical trial table that includes information about the phase of the trial, diseases being studied, icd-10 codes of the diseases, drugs being tested, and eligibility criteria for participants. In this particular sample, the trial is a combination of phase 1 and phase 2, and the disease being studied is obesity. The icd-10 codes associated with obesity are listed, as well as the drug being tested, which is tesofensine. The eligibility criteria for participants are also listed, including age, BMI, and various medical conditions that would exclude someone from participating in the trial.",
    "The sample is a clinical trial for patients with metastatic castration-resistant prostate cancer. The trial is in phase 1/phase 2 and the drug being tested is temsirolimus. The eligibility criteria include having evidence of chemotherapy-refractory metastatic CRPC, having received prior Docetaxel-based or Mitoxantrone-based chemotherapy, and having an ECOG performance status of 0-2. Patients must also meet various medical criteria such as having certain blood counts, liver function, and cholesterol levels. Patients with a history of a prior malignancy are eligible provided they were treated with curative intent and have been disease-free for the appropriate time period. Patients must not have received prior treatment with AVASTIN, temsirolimus, everolimus or sirolimus. The trial excludes patients with certain medical conditions such as significant cardiovascular disease, history of stroke or transient ischemic attack, and known pulmonary hypertension or pneumonitis. Patients must also not be taking certain medications or supplements.",
    "The sample is a clinical trial with a combination of phase 1 and phase 2. The trial is focused on HIV-1 infection and involves a list of drugs, including tbr-652 and its various dosages. The eligibility criteria for the trial include having no clinically significant findings on screening evaluations, being antiretroviral treatment-experienced, having a CD4 cell count of at least 250 cells/mm3, and having two separate qualifying plasma HIV 1 RNA levels of at least 5,000 copies/mL within 45 days prior to the first dose. The trial also has a list of exclusion criteria, including the presence of CXCR4- or dual/mixed-tropic HIV 1 virus, active CDC category C disease, and history of infection with hepatitis B or hepatitis C virus. The trial also prohibits the use of certain medications, including immunomodulating agents and experimental medications, within a certain timeframe prior to the first dose of study medication.",
    "The sample is a record from a clinical trial table that includes information about the trial phase, diseases being studied, corresponding ICD-10 codes, drugs being tested, and eligibility criteria for participants. In this particular sample, the trial is for patients with hepatocellular carcinoma and the drug being tested is rad001. The inclusion criteria include having measurable disease, no more than 2 prior systemic chemotherapy and biologic regimens, and a CLIP score of equal to or less than 3, among other requirements. Exclusion criteria include prior treatment with an mTor inhibitor, known hypersensitivity to RAD001, and a positive dipstick for urine protein.",
    "The sample is a clinical trial for patients with myeloma, a type of cancer. The trial is in phase 1/phase 2 and involves the use of four different drugs: trisenox (arsenic trioxide), velcade (bortezomib), melphalan, and vitamin c (ascorbic acid). The eligibility criteria for the trial include having primary refractory disease, consolidation of a partial remission, or relapsing after prior therapy. Patients must also be under 75 years old, have a Zubrod performance status of <2, and meet certain medical criteria such as having a left ventricular ejection fraction >40% and no uncontrolled arrhythmias or symptomatic cardiac disease. Patients must also be HIV-negative and have a negative Beta human chorionic gonadotrophin (hCG) test in a woman with child bearing potential. The trial has exclusion criteria as well, such as having a corrected QT interval greater than 470 msec or being in complete remission.",
    "The sample is a clinical trial for a combination treatment of HKI-272 and vinorelbine for patients with advanced malignant solid tumors or stage IV ErbB-2-positive breast cancer. The trial is divided into two parts, with different eligibility criteria for each part. The inclusion criteria for both parts include a confirmed diagnosis of the respective cancer type, prior treatment with at least one antineoplastic chemotherapy regimen for metastatic disease, and at least one measurable lesion. The exclusion criteria include prior treatment with certain drugs or cumulative doses of certain drugs, as well as having received more than a certain number of prior antineoplastic treatment regimens.",
    "The sample is a clinical trial for breast cancer patients in phase 1/phase 2. The trial is testing the effectiveness of the drugs docetaxel and epirubicin hydrochloride. The eligibility criteria for the trial include having histologically confirmed invasive adenocarcinoma of the breast, meeting certain criteria such as T4, NX, M0 or any T, N2-N3, M0, and having no evidence of metastatic disease. Patients must also meet certain patient characteristics such as being female, having a certain performance status, and having no other significant medical conditions. Patients must not have received prior treatment for breast cancer and must not be receiving any other concurrent investigational drugs or anticancer treatment.",
    "The sample is a record from a clinical trial table that includes information about the phase of the trial, the disease being studied (in this case, kidney transplantation), the ICD-10 codes associated with the disease, the drug being tested (aeb071), and the eligibility criteria for participants. The eligibility criteria include requirements for age, type of kidney transplant, and exclusion criteria such as certain medical conditions or infections. The sample also notes that there may be additional inclusion/exclusion criteria defined by the protocol.",
    "The sample is a clinical trial for a vaginal gel called dapivirine (tmc120) for HIV-negative women who are willing to use the experimental gel and be randomized to a study group that includes the possibility of being assigned to a placebo group. The trial is in phase 1/phase 2 and the disease being studied is HIV infections. The inclusion criteria include being willing to undergo pelvic examinations with colposcopy and photographic documentation, having a regular menstrual cycle, and being sexually abstinent from randomization until completion of Day 7 evaluations. The exclusion criteria include being currently pregnant or breast-feeding, having laboratory confirmed gonorrhea, chlamydia, trichomonas, syphilis, or vaginal candidiasis or clinically diagnosed genital ulcer disease or active HSV-2 lesions, and requiring treatment for tuberculosis (TB) within 21 days prior to randomization.",
    "The sample is a clinical trial for small cell lung cancer patients in phase 1/phase 2. The trial involves the use of three drugs, vorinostat, carboplatin, and etoposide. The eligibility criteria include having measurable disease, being chemotherapy naive, having a life expectancy of greater than 3 months, and having adequate organ and marrow function. Patients with known brain metastases, peripheral neuropathy CTC grade >2, uncontrolled intercurrent illness, and other malignancies in the last 5 years are excluded. Pregnant women and patients with known HIV, Hepatitis B, Hepatitis C, or active Hepatitis A are also excluded. The trial requires patients to sign a written informed consent document and use adequate contraception during the study.",
    "The sample is a clinical trial for lung cancer patients in phase 1/phase 2. The trial is testing the effectiveness of the drug celecoxib. The eligibility criteria for patients include having non-small cell lung cancer that is inoperable stage IIB or unresectable stage IIIA or IIIB, with no evidence of hematogenous metastases. Patients must also meet certain age and performance status requirements, have a certain life expectancy, and meet specific hematopoietic, hepatic, and renal criteria. Patients cannot have active gastrointestinal ulcers or bleeding within the past 3 months, no other malignancy within the past 3 years except nonmelanoma skin cancer, no known hypersensitivity to celecoxib, and no prior allergic-type reactions to sulfonamides or aspirin. Patients cannot be pregnant or nursing, must have a negative pregnancy test, and fertile patients must use effective contraception. The trial excludes patients who have had prior neoadjuvant chemotherapy, prior thoracic radiotherapy, or prior complete or subtotal tumor resection. Patients cannot take concurrent chemotherapy, corticosteroids, NSAIDs, lithium, furosemide, or angiotensin-converting enzyme inhibitors, but concurrent aspirin (325 mg/day) for cardioprotection is allowed.",
    "The sample is a clinical trial for patients with active rheumatoid arthritis in combination with a stable dose of methotrexate. The trial is in phase 1/phase 2 and the patients must be aged between 18-75 years. The trial includes a list of diseases and their corresponding icd-10 codes, a list of drugs, and eligibility criteria for inclusion and exclusion. The inclusion criteria include having a diagnosis of active rheumatoid arthritis of stages I, II or III, and a disease duration of at least 6 months prior to randomization. The exclusion criteria include current treatment with anti-TNF-\u03b1 or anti IL-1 therapy, congestive heart failure, poorly controlled diabetes mellitus, and major chronic inflammatory autoimmune diseases like psoriasis, psoriatic arthritis, spondyloarthropathy, inflammatory bowel disease or SLE that can mimic rheumatoid arthritis diagnosis or that can interfere with efficacy evaluation in the study. Pregnant or breastfeeding women will also be excluded.",
    "The sample is a clinical trial for sickle cell disease, with a phase 1/phase 2 designation. The trial involves the drugs eptifibatide and placebo. The eligibility criteria include being between the ages of 18 and 55, having a confirmed diagnosis of sickle cell anemia or sickle beta zero thalassemia, having certain laboratory values within normal ranges, experiencing sudden onset of pain, having adequate intravenous access, and being willing to give informed consent. Exclusion criteria include having certain medical conditions or histories, being pregnant or breastfeeding, being on certain medications, or having received investigational drugs within the past 4 weeks.",
    "The sample is a clinical trial for patients with juvenile myelomonocytic leukemia (JMML) who have relapsed or have residual disease after allogeneic hematopoietic cell transplant (HCT). The trial is in phase 1/phase 2 and involves the use of drugs such as cyclosporine, cytarabine, and methotrexate. The eligibility criteria include patients aged 0-18 with JMML, who are at least 6 months from their first HCT if clinically stable, and have adequate major organ function. The trial requires written informed consent and excludes patients with active uncontrolled infection within one week of HCT.",
    "The sample is a clinical trial for the treatment of multiple myeloma, a type of cancer. The trial is in phase 1/phase 2 and involves the drugs kw-2478 and bortezomib. The eligibility criteria include having a confirmed diagnosis of multiple myeloma and having had one to three prior unsuccessful treatments. Participants must also have an ECOG performance status of \u2264 2, a life expectancy of at least 3 months, and adequate hematologic status, liver and renal function. Exclusion criteria include no anti-cancer treatment for \u2265 4 weeks and no bortezomib treatment \u2265 60 days prior to receiving study drug, any other severe, acute or chronic illness, no other prior or concurrent malignancy, and no immunosuppressant therapy.",
    "The sample is a clinical trial for colorectal cancer patients in phase 1/phase 2. The trial is testing the effectiveness of three drugs, (folpi) picoplatin with 5-fu and leucovorin, folpi, and folfox. The eligibility criteria for the trial include having metastatic colorectal adenocarcinoma, not having received prior systemic therapy for metastatic cancer, having an ECOG performance score of 0 or 1, and having a life expectancy of more than 3 months. The trial also requires measurable disease, defined by the RECIST criteria, and certain blood count levels. Women of childbearing potential must have a negative pregnancy test and agree to use appropriate birth control methods while on the study. The exclusion criteria include having concurrent use of EGFR inhibitors or anti-VEGF agents, having clinically significant obstructive symptoms or intestinal bleeding, and having a history of serious cardiac disease.",
    "The sample is a clinical trial for a drug called xpf-002 and a placebo, for patients with primary or inherited erythromelalgia. The trial is a combination of phase 1 and phase 2. The table includes information about the diseases being studied, the icd-10 codes associated with them, the drugs being tested, and the eligibility criteria for participants. The eligibility criteria include having a BMI between 18-40 kg/m2, experiencing flares of pain in the feet or hands caused by erythromelalgia, being generally healthy apart from the pain, and being willing to comply with all study procedures and restrictions. The exclusion criteria include not being in constant pain, having coexistent pain from other conditions, having HIV, Hepatitis B or C, having a history of major psychiatric disturbance, and using any other investigational drug in the 30 days prior to dosing.",
    "The sample is a clinical trial for patients with metastatic colorectal cancer in phase 1/phase 2. The trial involves the use of three drugs: capecitabine, gefitinib, and oxaliplatin. The eligibility criteria include confirmation of the colorectal cancer diagnosis, measurable disease, no CNS metastases, and certain hematopoietic, hepatic, renal, cardiovascular, and pulmonary requirements. Patients must also meet certain age and performance status requirements, have a life expectancy of more than 3 months, and not have any other significant clinical disorder or laboratory finding that would preclude study participation. Prior concurrent therapy is also specified.",
    "The sample is a clinical trial for a drug called rose-010 and a placebo, aimed at treating constipation-predominant irritable bowel syndrome (IBS) in females aged 18-65 years old. The trial is a combination of phase 1 and phase 2. The eligibility criteria include a previous diagnosis of IBS according to Rome III criteria, with symptoms of recurrent abdominal pain or discomfort for at least six months prior to diagnosis and currently at least three days per month in the last three months associated with two or more specific symptoms. The patients must also have constipation-predominant type IBS, as defined by specific criteria, and a normal rectal exam result. Females of childbearing potential must use an acceptable method of contraception during the study. The exclusion criteria include pregnancy or breastfeeding, structural or metabolic diseases/conditions that affect the gastrointestinal system, and inability to withdraw medications 48 hours prior to the study. The trial also excludes patients who have participated in another clinical study within the past 30 days.",
    "The sample is a clinical trial for a drug called \"human secretin\" for the treatment of chronic pancreatitis. The trial is a combination of phase 1 and phase 2. The eligibility criteria for the trial include being between the ages of 18-70, having documented chronic pancreatitis, and using opioid analgesics for chronic pain from CP. The exclusion criteria include having abnormal serum amylase and/or lipase indicative of acute pancreatitis within 30 days of study enrollment, exhibiting signs and/or symptoms of an episode of acute pancreatitis, and having severe cardiac, pulmonary, or renal disease. Pregnant women, nursing mothers, or women of childbearing potential not employing appropriate contraception are also excluded. The sample includes a detailed list of inclusion and exclusion criteria for the trial.",
    "The sample is a clinical trial table that includes information about the phase of the trial (phase I, phase II, or phase III), a list of diseases, a list of ICD-10 codes of diseases, a list of drug names, and eligibility criteria. The diseases listed in the sample include recurrent childhood anaplastic astrocytoma, recurrent childhood brain stem glioma, recurrent childhood ependymoma, recurrent childhood giant cell glioblastoma, recurrent childhood glioblastoma, recurrent childhood gliosarcoma, and recurrent childhood medulloblastoma. The eligibility criteria include requirements for patients to have a histological diagnosis of malignant CNS tumor, measurable disease, and adequate general condition for the study. Patients with uncontrolled infection or any significant medical illnesses that cannot be adequately controlled with appropriate therapy are excluded from the study.",
    "The sample is a record of a clinical trial that is in phase 1/phase 2. The trial is focused on treating proliferative diabetic retinopathy using the drug ranibizumab. The eligibility criteria for the trial include being 18 years or older, having diabetic neovascularization that was previously treated with full panretinal photocoagulation and has persisted for at least three months, and having no known sensitivity to ranibizumab or other anti-VEGF injections. Patients must also not be pregnant and must provide evidence of using two types of birth control while enrolled in the study. The trial has exclusion criteria such as uncontrolled glaucoma, prior enrollment in the study, and any other condition that the investigator believes would pose a significant hazard to the subject if the investigational therapy were initiated.",
    "The sample is a record from a clinical trial table that includes information about the trial phase, diseases being studied, ICD-10 codes for those diseases, drugs being used, and eligibility criteria for participants. In this particular sample, the trial is for melanoma and is in phase 1/phase 2. The eligibility criteria include having stage IV or unresectable stage III melanoma, adequate organ function, and measurable disease by RECIST criteria. There are also exclusion criteria, such as having had major surgery or radiation therapy within 4 weeks of starting the study treatment, and having a history of active CHF or LVEF<50% at screening echocardiogram.",
    "The sample is a record from a clinical trial table that includes information about the phase of the trial, diseases being studied, corresponding ICD-10 codes, drugs being used, and eligibility criteria for patients. In this particular sample, the trial is in phase 1/phase 2 and is studying leukemia and lymphoma. The ICD-10 codes associated with these diseases are listed. The drugs being used in the trial are pentostatin, tacrolimus, and methotrexate. The eligibility criteria for patients include receiving allogeneic hematopoietic transplants from an unrelated or one antigen mismatched related donor, having certain types of cancer, meeting certain health criteria, and not having certain exclusions such as HIV seropositivity or uncontrolled infection.",
    "The sample is a record from a clinical trial table that includes information about the trial's phase, diseases being studied, ICD-10 codes associated with those diseases, drugs being tested, and eligibility criteria for participants. In this particular sample, the trial is in phase 1/phase 2 and is studying metastatic melanoma. The ICD-10 codes associated with the disease are listed, as well as the drug being tested (temozolomide). The eligibility criteria for participants are also listed, including requirements such as having had at least one prior systemic therapy, negative pregnancy test, and recovered from all toxic effects of prior therapy. Exclusion criteria are also listed, such as having a life expectancy of less than 4 months or being pregnant or nursing.",
    "The sample is a clinical trial for phase 1/phase 2 of treatment for head and neck cancer. The trial involves the use of drugs such as carboplatin, rad001, and paclitaxel. The eligibility criteria for patients include having locally advanced disease, no known brain metastases, and a WHO performance status of 0-2. Patients must also meet certain medical requirements such as having a platelet count of at least 100,000/mm\u00b3 and a creatinine clearance of at least 60 mL/min. Additionally, patients must not have any preexisting neuropathy \u2265 grade 2 or uncontrolled diseases such as diabetes or hypertension. Prior therapy for this cancer is not allowed, and patients must not be receiving concurrent CYP3A4 strong inhibitors or anti-coagulant therapy.",
    "The sample is a clinical trial for patients with adult glioblastoma or gliosarcoma, or recurrent adult brain neoplasm. The trial is in phase 1/phase 2 and involves the drugs sorafenib tosylate and temsirolimus. The eligibility criteria include having had no more than two prior systemic chemotherapy regimens, evidence of tumor progression following radiation therapy or the most recent anti-tumor therapy, and a performance status of 0, 1, or 2. Patients must also meet various medical criteria, such as having certain blood counts and no uncontrolled infections. The trial has exclusion criteria, such as prior intratumoral chemotherapy or evidence of bleeding diathesis or coagulopathy.",
    "The sample is a clinical trial for head and neck cancer patients in phase 1/phase 2. The trial involves the use of drugs such as carboplatin, cisplatin, docetaxel, fluorouracil, and lapatinib ditosylate. The eligibility criteria include having newly diagnosed squamous cell carcinoma of the larynx or hypopharynx, being in a certain stage of the disease, having no distant metastasis, and meeting certain patient characteristics such as having normal cardiac function and being able to swallow oral agents. Patients must also not have received any other anticancer therapy or investigational agents while on the study. The sample also includes a list of icd-10 codes for the diseases being studied and the eligibility criteria for the trial.",
    "The sample is a clinical trial for rheumatoid arthritis, in which the phase is a combination of phase 1 and phase 2. The trial includes a list of diseases and their corresponding ICD-10 codes, as well as a list of drugs. The eligibility criteria for the trial include being between the ages of 18-75, having stable RA for at least 3 months, and being on a stable dose of methotrexate for at least 8 weeks prior to randomization. Other criteria include negative results for HIV, hepatitis B and C, and being judged as otherwise healthy by the investigator. Exclusion criteria include a history of alcohol or drug abuse, recent use of certain medications, and any medical or psychiatric condition that may place the subject at unacceptable risk for study participation.",
    "The sample is a clinical trial for non-small cell lung cancer patients in phase 1/phase 2. The trial includes patients with stage II or III non-small cell lung cancer, or stage IV non-small cell lung cancer that will be treated with curative intent. The trial will use the drugs etoposide and cisplatin. The eligibility criteria include having measurable disease, being evaluated by a surgeon and deemed inoperable, having no active malignancy within the past 5 years (except for non-melanoma skin cancers or carcinoma in situ of the cervix), being 18 years or older, having a life expectancy of greater than 6 months, having an Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2, having normal organ and marrow function, and having a Forced expiratory volume (FEV1) of 1 L or greater OR 50% or greater of predicted. The exclusion criteria include having a primary tumor size greater than 6cm, having a prior history of thoracic radiotherapy, not being able to receive any other study agents, having a history of pulmonary fibrosis, having a history of allergic reactions attributed to compounds of similar chemical or biologic composition to cisplatin or etoposide, having a primary tumor less than 1.5 cm beyond hilar lymphadenopathy (if any) and 1.5 cm from proximal bronchial tree, having uncontrolled intercurrent illness, being pregnant or breast feeding, having a history of a different malignancy (except for certain circumstances), being HIV-positive individuals on combination antiretroviral therapy, and planned to receive certain medications.",
    "The sample is a record of a clinical trial with a phase 1/phase 2 designation. The trial is focused on the treatment of multiple sclerosis, with a list of icd-10 codes provided. The trial involves the use of inhaled cannabis, oral THC, oral placebo, and inhaled placebo as drugs. The eligibility criteria for the trial include a diagnosis of clinically definite multiple sclerosis, moderate or severe spasticity, age 21 or older, and living close to the Sacramento, CA area. The exclusion criteria include preexisting pulmonary and cardiac conditions, inability to abstain from tobacco or marijuana smoking, history of abuse of recreational drugs, and inability to provide informed consent. Additionally, there are criteria related to psychiatric illness, recent cannabis use, and contraception for females of childbearing potential.",
    "The sample is a clinical trial for patients with metastatic pancreatic cancer. The trial is in phase 1/phase 2 and involves two groups of patients: one group receiving ipi-926 plus gemcitabine and the other group receiving placebo plus gemcitabine. The eligibility criteria include being 18 years or older, having pathologically confirmed metastatic pancreatic adenocarcinoma, having at least one radiologically evaluable metastatic lesion, having an ECOG score of 0 or 1, having a life expectancy of at least 3 months, agreeing to use adequate methods of birth control, being able to adhere to the study visit schedule, and voluntarily signing an informed consent form. The exclusion criteria include having islet cell, acinar cell carcinoma, non-adenocarcinoma, adenocarcinoma originated from biliary tree or cystadenocarcinoma, having prior treatment with chemotherapy for pancreatic cancer, having known central nervous system metastases, having inadequate hematologic, hepatic, or renal function, having an external biliary drain, having a history of stroke, unstable angina, myocardial infarction, or ventricular arrhythmia requiring medication or mechanical control within the last 6 months, having a venous thromboembolic event requiring anticoagulation not appropriately anticoagulated or have NCI CTCAE Grade 2 or greater bleeding episode in the 3 weeks prior to administration of IPI-926, having concurrent administration of medications or foods known to inhibit CYP3A activity to a clinically relevant degree, having presence of active infection or systemic use of antibiotics within 72 hours of treatment, having significant co-morbid condition or disease which in the judgment of the Investigator would place the patient at undue risk or interfere with the study, having known human immunodeficiency virus (HIV) positivity, being known hypersensitive to gemcitabine, IPI-926, or their excipients, or being pregnant or lactating women.",
    "The sample is a record from a clinical trial table. It includes information about the phase of the trial, which is a combination of phase 1 and phase 2. The disease being studied is malignant melanoma, and the icd-10 codes associated with it are listed. The drugs being tested are imexon and dtic. The eligibility criteria for the trial are also listed, including requirements for the patient's health status, ability to perform daily activities, and projected life expectancy. The exclusion criteria are also listed, which include prior chemotherapy for the stage III or IV disease and brain metastases.",
    "The sample is a clinical trial for patients with leukemia or myelodysplastic syndromes in phase 1/phase 2. The trial is testing the effectiveness of the drug cytarabine for patients who are not suitable for intensive chemotherapy regimens. The eligibility criteria include having a diagnosis of AML or high-risk myelodysplastic syndromes, being in good health with no serious medical conditions, and not having any other concurrent experimental drugs or anticancer therapy. Patients must also have a negative pregnancy test and use effective contraception if fertile. The trial excludes patients with a history of significant neurologic or psychiatric disorder, active serious infections, active peptic ulcer disease, or bleeding diathesis. Prior chemotherapy is not allowed, and patients must have stopped taking hydroxyurea at least 2 days prior to enrollment. The trial also excludes patients taking therapeutic doses of anticoagulants.",
    "The sample is a clinical trial for patients with metastatic pancreatic cancer in phase 1/phase 2. The trial is testing the effectiveness of gemcitabine and albumin-bound paclitaxel as a treatment for the disease. The eligibility criteria for the trial include having no prior therapy for metastatic disease, acceptable blood counts and chemistry levels, acceptable coagulation status, a Karnofsky performance status of 70 or higher, and one or more measurable metastatic tumors. Patients must also have no clinically significant abnormalities in urinalysis results and must be willing to comply with study procedures. Exclusion criteria include having known brain metastases, using therapeutic coumadin for a history of pulmonary emboli and deep vein thrombosis, having active, uncontrolled bacterial, viral, or fungal infections, and having serious medical risk factors involving any of the major organ systems.",
    "The sample is a clinical trial for rheumatoid arthritis, with a combination of phase 1 and phase 2. The trial involves the drugs ocrelizumab and placebo. The eligibility criteria include having moderate to severe RA for at least 6 months, a positive serum rheumatoid factor, current treatment with RA on an outpatient basis, treatment failure with one DMARD or biologic, current treatment with methotrexate for at least 12 weeks, and use of highly effective contraception. The exclusion criteria include having other rheumatic autoimmune disease or inflammatory joint disease, concurrent treatment with any DMARD or anti-TNF-alfa or other biologic therapy, treatment with any other investigational drug within 4 weeks of screening, previous treatment with certain therapies or agents, history of severe allergic or anaphylactic reactions to humanized monoclonal antibodies, known active bacterial, viral or fungal infections, history of active tuberculosis and primary or secondary immunodeficiency, history of concomitant diseases such as cardiovascular disease, nervous system, pulmonary disease, renal, hepatic, endocrine or gastrointestinal disorders, and pregnancy or lactation.",
    "The sample is a clinical trial for patients with persistent or recurrent ovarian epithelial, primary peritoneal, or fallopian tube cancer. The trial is in phase 1/phase 2 and involves the use of the drug docetaxel. The trial requires patients to have received 1 prior platinum-based chemotherapy regimen containing carboplatin, cisplatin, or other organoplatinum compound. Patients must also meet a number of eligibility criteria, including having measurable disease, a Zubrod performance status of 0-2, and various blood count and organ function requirements. The trial excludes patients with certain medical conditions, such as active bleeding or pathologic conditions that carry a high risk of bleeding, and those with a history of allergic reactions to certain compounds. The trial also requires patients to undergo an MRI scan and prohibits concurrent use of other anticancer therapies or investigational agents.",
    "The sample is a clinical trial for patients with non-small-cell lung carcinoma that is unresectable and locally advanced or metastatic. The trial is in phase 1/phase 2 and the drug being tested is patupilone. The eligibility criteria include prior treatment with a platinum-containing regimen, age \u226518 years, performance status of 0-1 on the WHO scale, life expectancy of \u22653 months, and adequate hematologic parameters. Patients with brain metastases are eligible if they are neurologically stable and have at least one bidimensionally measurable intracranial lesion of minimum diameter 2 cm. Patients with brain metastases must show evidence of residual disease or progression of disease since prior radiological or surgical therapy. Patients with brain metastases who have extracranial metastases in more than two organs are excluded. The trial has other protocol-dependent inclusion/exclusion criteria that may apply.",
    "The sample is a clinical trial for pre-hypertension, with a phase 1/phase 2 design. The trial includes a list of diseases and their corresponding ICD-10 codes, as well as a list of drugs being tested. The eligibility criteria for the trial includes individuals who are over 18 years old with pre-hypertensive or borderline blood pressures, and have at least one additional risk factor for cardiovascular disease. Exclusion criteria include patients with a history of cardiac, cerebral or other vascular events within the previous 6 months, background therapy with a beta blocker or ACE inhibitor therapy, known or suspected intolerance to beta blockers or ACE inhibitors, angiotensin receptor blocker therapy, or diabetes. Pregnant or lactating women, and women of child-bearing age who are not using an acceptable form of contraception are also excluded from this study.",
    "The sample is a record of a clinical trial with a phase 1/phase 2 designation. The trial is focused on the disease of allergic asthma and includes a list of associated ICD-10 codes. The trial involves the use of three drugs: qge031, omalizumab, and placebo. The eligibility criteria for the trial includes adult patients between the ages of 18 and 65 who have a positive skin prick test to one or more common airborne allergens, airway hyperresponsiveness, and an early asthmatic response. Patients must also meet certain weight and IgE requirements for omalizumab. Exclusion criteria include pregnant or nursing women, smokers, and patients with poorly controlled asthma or who have had an asthma exacerbation within the past year. Other inclusion/exclusion criteria may also apply.",
    "The sample is a clinical trial with a combination of phase 1 and phase 2. The trial is for patients with intracranial glioblastoma multiforme or gliosarcoma, who have evidence of tumor progression by MRI or CT scan within the past 14 days and are on a stable steroid dose for at least 5 days. Patients who underwent prior therapy that included interstitial brachytherapy or stereotactic radiosurgery must have confirmation of true progressive disease. The trial allows treatment for any number of prior relapses, defined as disease progression after initial therapy. Patients must meet certain eligibility criteria, including having a Karnofsky performance status of 60-100%, certain blood counts, and no significant medical illnesses that would preclude study treatment. Patients must also not have any other active cancer, HIV disease, or allergies to certain compounds. The trial involves the use of several drugs, including sorafenib tosylate, erlotinib hydrochloride, tipifarnib, and temsirolimus. Patients must not have received these drugs before and must meet other criteria specific to each drug. The trial also has certain exclusion criteria, such as concurrent use of certain medications and concurrent prophylactic filgrastim.",
    "The sample is a clinical trial for breast cancer patients in the phase 1/phase 2 stage. The trial is testing the effectiveness of the drugs docetaxel, epirubicin, and bevacizumab. The eligibility criteria for the trial include having confirmed metastatic breast adenocarcinoma, no HER2 overexpression or gene amplification, and no previous therapy for metastatic breast cancer. Patients must also be between the ages of 18-75 and have measurable disease as defined by the presence of at least one measurable lesion. Additionally, patients must have a performance status (WHO) of 0-2 and adequate liver, renal, and bone marrow function. Exclusion criteria include active infection, brain metastases, significant cardiac disease, history of stroke, and other invasive malignancy except nonmelanoma skin cancer. Pregnant or lactating women are also excluded from the trial.",
    "The sample is a clinical trial for small cell lung cancer patients in phase 1/phase 2. The trial includes patients with extensive stage or recurrent lung small cell carcinoma. The trial involves the use of drugs such as carboplatin, cisplatin, etoposide, and sunitinib malate. The eligibility criteria include having measurable disease, no prior chemotherapy for small cell lung cancer, completed radiation therapy at least one week before the trial, and a Common Toxicity Criteria (CTC) performance status of 0-1 for phase IB and 0-2 for phase II. Patients with certain medical conditions such as ongoing cardiac dysrhythmias, atrial fibrillation, or QTc interval >= 500 msec are not eligible. The trial also has specific requirements for blood counts, liver and kidney function, and coagulation parameters.",
    "The sample is a clinical trial for lung cancer patients in phase 1/phase 2. The trial involves the drugs rad001 and docetaxel. The eligibility criteria include having histologically confirmed non-small cell lung cancer, an ECOG Performance Status of 0, 1, or 2, and a life expectancy greater than 12 weeks. Patients must also have adequate bone marrow, renal and hepatic function, and completed all prior therapy at least 3 weeks prior to registration. Exclusion criteria include chronic treatment with systemic steroids or other immunosuppressive agents, uncontrolled brain or leptomeningeal metastases, and a known history of HIV seropositivity. Final eligibility for the trial is determined by the health professionals conducting the trial.",
    "The sample is a clinical trial for patients with Richter's transformation, leukemia, or relapsed/refractory B-cell chronic lymphocytic leukemia. The trial is in phase 1/phase 2 and involves the use of oxaliplatin, fludarabine, cytarabine, rituximab, and pegfilgrastim. The eligibility criteria include confirmation of the disease, age of 18 or older, performance status of 0-2, adequate renal and hepatic function, and agreement to use contraception. Exclusion criteria include untreated or uncontrolled life-threatening infection, intolerance to the drugs, pregnancy or lactation, recent chemotherapy or radiation therapy, and medical conditions that may interfere with the study.",
    "The sample is a record from a clinical trial table that includes information about the trial's phase, diseases being studied, associated ICD-10 codes, drugs being tested, and eligibility criteria for participants. In this particular sample, the trial is a combination of phase 1 and phase 2, and it is focused on studying esophagus cancer. The trial is testing the effectiveness of three drugs - oxaliplatin, docetaxel, and capecitabine. The eligibility criteria for participants include having adenocarcinoma or squamous cell carcinoma of the esophagus or G/E junction, being a surgical candidate, having no previous treatment for esophageal cancer, having measurable or evaluable disease, being able to perform daily activities with minimal assistance, having adequate bone marrow, liver, and kidney function, and providing written informed consent. There are also exclusion criteria, such as having tumor location in the proximal esophagus, having metastatic disease or locally advanced cancer, having moderate to severe peripheral neuropathy, having serious pre-existing medical illnesses, having significant heart disease, being treated for an invasive cancer within the previous 5 years, being pregnant or breastfeeding, or being under 18 years of age. The study center will determine if a participant meets all of the criteria, and if they do not qualify, the study personnel will explain the reasons.",
    "The sample is a clinical trial for patients with B- or T-cell non-Hodgkin's lymphoma (NHL) who have relapsed or refractory disease. The trial is in phase 1/phase 2 and the patients must have received 1-3 prior therapeutic regimens. The trial is testing the effectiveness of bortezomib and gemcitabine hydrochloride as a treatment for NHL. The eligibility criteria include specific disease characteristics, patient characteristics, and prior concurrent therapy. Patients must meet certain requirements for blood counts, liver and kidney function, and heart health. They must not have certain medical conditions or be pregnant or nursing. Prior to the trial, patients must not have received bortezomib or gemcitabine hydrochloride, and they cannot receive other systemic cytotoxic chemotherapy or investigational agents during the trial.",
    "The sample is a clinical trial for patients with chronic lymphocytic leukemia in need of treatment. The trial is a combination of bendamustine, rituximab, and lenalidomide. The trial is in phase 1/phase 2. The eligibility criteria include being 18 years or older, having a confirmed diagnosis of CLL, having a life expectancy of more than 12 weeks, and having relapsed or refractory disease after at least one but no more than three prior regimens. The exclusion criteria include having previously been treated with more than three prior regimens for CLL, having known central nervous system involvement of CLL, and having other severe concurrent diseases that could interfere with the patient's ability to participate in the study.",
    "The sample is a clinical trial for kidney diseases and kidney transplantation, with a focus on patients who have received a kidney transplant. The trial is in phase 1/phase 2 and involves several drugs, including daclizumab, mycophenolate mofetil, prednisone, tacrolimus, ganciclovir, valganciclovir, and trimethoprim and sulfamethoxazole. The eligibility criteria include being the primary recipient of a kidney transplant, meeting site-specific transplant criteria, having a Panel Reactive Antibody (PRA) of 20% or less, and being willing to use acceptable forms of contraception. Exclusion criteria include previous treatment with steroids within 6 months prior to transplantation, receiving an organ from an HLA identical donor or a non-heart-beating donor, and currently receiving an investigational pharmacologic or biologic agent.",
    "The sample is a clinical trial for patients with non-small-cell lung carcinoma. The trial is in phase 1/phase 2 and includes patients with Stage IIIB or Stage IV disease or recurrent metastatic disease. Patients must have had disease progression or relapse following failure of platinum-based chemotherapy. The trial involves two drugs, chr-2797 (tosedostat) and erlotinib. The eligibility criteria include various medical and laboratory requirements, as well as the absence of certain medical conditions and prior treatments. Patients must also be willing to use contraception or be abstinent during the treatment period and for 3 months after discontinuation of treatment. The trial has exclusion criteria, including certain medical conditions, prior treatments, and allergies to study medication.",
    "The sample is a record from a clinical trial database. It includes information about the phase of the trial, which is a combination of phase 1 and phase 2. The trial is focused on treating multiple myeloma, a type of cancer. The record lists the icd-10 codes associated with the disease, as well as the drugs being used in the trial, which are ixazomib, lenalidomide, and dexamethasone. The record also includes the eligibility criteria for patients to participate in the trial, such as being 18 years or older, having measurable disease, and having an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2. The record also lists exclusion criteria, such as having peripheral neuropathy greater than or equal to Grade 2, being pregnant or lactating, and having a serious medical or psychiatric illness that could interfere with treatment.",
    "The sample is a clinical trial for a drug called ro5024048, which is being tested on individuals with chronic hepatitis C infection. The trial is in phase 1/phase 2 and includes both healthy volunteers and individuals with hepatitis C virus. The trial requires participants to meet certain eligibility criteria, such as being between the ages of 18 and 65, having a certain genotype of hepatitis C, and having a certain level of serum HCV RNA. Participants must also have a BMI between 18 and 36, be able to abstain from alcohol and limit caffeine consumption, and be willing to comply with study restrictions. The trial also has exclusion criteria, such as a positive test for HAV, HBV, or HIV, a history of certain medical conditions, and abnormal hematological or biochemical parameters. Participants must be willing to give written informed consent and effectively communicate with the investigators and testing center personnel.",
    "The sample is a clinical trial with a combination of phase 1 and phase 2. The trial is focused on male and female breast cancer patients with stage IIIB, IIIC, or IV disease. The trial involves the use of two drugs, vorinostat and paclitaxel. The eligibility criteria include having histologically or cytologically confirmed adenocarcinoma of the breast, accessible disease for biopsy, and consent to serial biopsy. Patients must also have at least one measurable indicator lesion, ECOG performance status of <=1, and meet certain laboratory values. Exclusion criteria include recent chemotherapy or radiotherapy, use of other investigational agents, and uncontrolled intercurrent illness.",
    "The sample is a record of a clinical trial with a phase 1/phase 2 designation. The trial is focused on the disease Friedreich ataxia, which is caused by homozygosity for the GAA repeat expansion in intron 1 of the FXN gene. The trial is testing the drug resveratrol. The eligibility criteria for the trial include being an adult with Friedreich ataxia and having a functional stage on the Ataxia subscale of the FARS of 1 or higher. Exclusion criteria include being pregnant or lactating, having active arrhythmias or significant cardiac insufficiency, using idebenone, Coenzyme Q or vitamin E within 30 days prior to enrollment, and using amiodarone or other medications which may have clinically significant drug interactions that cannot be safely monitored.",
    "The sample is a clinical trial for phase 1/phase 2 of a drug called tipifarnib. The trial is for patients with newly diagnosed non-disseminated intrinsic diffuse brainstem glioma. The eligibility criteria include a Karnofsky performance scale (KPS) or Lansky performance score of at least 50, no prior chemo or radiation therapy, and certain blood count and liver function requirements. Patients must not have any significant medical illnesses that cannot be controlled with appropriate therapy or any disease that will obscure toxicity or dangerously alter drug metabolism. Patients with disseminated intrinsic diffuse brainstem glioma, taking enzyme-inducing anticonvulsant drugs, known allergy to certain imidazoles, receiving any other anticancer or experimental drug therapy, or with uncontrolled infection are excluded from the trial.",
    "The sample is a clinical trial for patients with hormone refractory prostate cancer that has progressed after at least two prior hormonal manipulations. The trial is in phase 1/phase 2 and involves the drugs docetaxel and imatinib mesylate. The eligibility criteria include being at least 18 years old, having a histologically documented diagnosis of adenocarcinoma of the prostate gland, and having PSA levels of at least 5 ng/ml. Patients must have recovered from previous therapies and have adequate end organ function. Exclusion criteria include having received other investigational agents within 28 days of the trial, having severe and/or uncontrolled medical disease, and having a known diagnosis of HIV infection.",
    "The sample is a clinical trial with a combination of phase 1 and phase 2. The trial is focused on hypertension and renal transplant patients. The trial involves the use of two drugs, placebo and allopurinol. The eligibility criteria for the trial include males or females aged 6 to 18 years who are renal transplant recipients taking cyclosporin, with a weight greater than 20kg, and with SBP or DBP greater than 95th percentile for age, gender, and height. Exclusion criteria include severe or poorly controlled hypertension, taking certain medications, laboratory abnormalities, history of heart disease, pregnancy or lactation, and non-compliance with study procedures.",
    "The sample is a clinical trial for a combination of drugs (cetuximab, oxaliplatin, capecitabine, and diphenhydramine hydrochloride) for the treatment of rectal and colorectal cancer. The trial is in phase 1/phase 2 and the eligibility criteria include having histologically-confirmed adenocarcinoma of the rectum, being at least 18 years old, having a Karnofsky performance status of at least 70, and meeting certain blood count and liver function requirements. Patients with metastatic or stage IV disease, a history of treatment with cetuximab or other therapy targeting EGFR, or certain other medical conditions are excluded from the trial. Women of child-bearing potential must have a negative pregnancy test and use adequate contraception throughout the treatment.",
    "The sample is a clinical trial for patients with anaplastic or poorly differentiated variant thyroid carcinoma. The trial is in phase 1/phase 2 and the patients must have original/diagnostic tumor blocks available to confirm histopathology and for tumor microvessel density immunohistochemistry. The trial involves the use of drugs such as cisplatin, doxorubicin hydrochloride, and fosbretabulin disodium. The eligibility criteria include age 18 and over, ECOG 0-2 performance status, and a life expectancy of at least 12 weeks. Patients must also meet certain hematopoietic, hepatic, renal, and cardiovascular requirements. Prior concurrent therapy is not allowed, and patients must not have certain medical conditions or take certain medications known to prolong the QTc interval.",
    "The sample is a record of a clinical trial with a phase 1/phase 2 designation. The trial is focused on breakthrough nausea and vomiting and unspecified adult solid tumors. The trial involves the use of fosaprepitant dimeglumine and systemic chemotherapy drugs. The eligibility criteria for the trial include a diagnosis of cancer, scheduled to receive inpatient chemotherapy containing at least moderately emetogenic agents, and scheduled to receive 5-HT3 receptor antagonist antiemetic on the day of chemotherapy. The patient must also have self-reported at least mild nausea or moderate nausea, or have had at least one episode of emesis since receiving chemotherapy. The patient must not have a history of chronic nausea and/or vomiting, anticipatory nausea and/or vomiting, or emesis within 24 hours before chemotherapy, and must not have symptomatic brain metastases. The patient must be able to understand English, not be pregnant or nursing, have a negative pregnancy test, and have no clinical evidence of current or impending bowel obstruction. Prior chemotherapy is allowed, but aprepitant as prophylaxis or rescue treatment during the current course of chemotherapy is not allowed, and the patient is not scheduled to receive a dopamine antagonist after chemotherapy.",
    "The sample is a clinical trial for patients with stage IV pancreatic cancer that is unresectable. The trial is in phase 1/phase 2 and involves the drugs erlotinib hydrochloride and gemcitabine hydrochloride. The eligibility criteria include having measurable and/or nonmeasurable disease, a Zubrod performance status of 0-1, and meeting various laboratory values. Patients must not have endocrine or neuroendocrine tumors, lymphoma of the pancreas, or ampullary cancer, and must not have macroscopic residual disease post-resection as the only site of disease. They must also not have clinically significant ascites or known brain metastases. Other exclusion criteria include having a history of allergic reaction to compounds of similar chemical or biological composition to anti-IGF-1R recombinant monoclonal antibody IMC-A12, active acute or chronic infections requiring antibiotics, significant ongoing cardiac problems, and plans to receive concurrent chemotherapy, hormonal therapy, radiotherapy, immunotherapy, or any other type of therapy for treatment of cancer. Patients must also not have received prior chemotherapy, hormonal therapy, immunotherapy, or chemoradiotherapy for advanced or locally advanced pancreatic cancer, including drugs that target either EGFR or IGFR, and must not have received prior gemcitabine hydrochloride or chimerized or murine monoclonal antibody therapy. Concurrent CYP3A4 inducers or inhibitors are also not allowed, but concurrent prophylactic low-dose coumadin or low molecular weight heparin is allowed provided coagulation criteria are met. Full-dose anticoagulation is allowed provided coagulation criteria are met and are under strict control and monitoring.",
    "The sample is a clinical trial for ovarian cancer patients in phase 1/phase 2. The trial includes patients with advanced ovarian or primary peritoneal carcinoma who have measurable disease at least 2 cm in diameter and have been treated and progressed following chemotherapy which includes platinum and paclitaxel. The trial drugs are cc-5013 and topotecan. The eligibility criteria include being over 18 years old, having an ECOG performance status of 0 or 1, and meeting certain laboratory and medical condition requirements. The trial excludes patients with prior history of malignancy (except basal cell or squamous cell carcinoma or carcinoma in situ of the breast) unless the subject has been free of disease for > 1 year, known brain or leptomeningeal disease, and concurrent use of any other anti-cancer agents.",
    "The sample is a clinical trial for chronic plaque type psoriasis, with a combination of phase 1 and phase 2. The trial involves testing the effectiveness of various drugs, including ciclosporin, betamethasone, and calcipotriol, on the disease. The trial has specific inclusion and exclusion criteria, such as excluding subjects with erythrodermic psoriasis or acute virus infections. Sexually active females of childbearing potential must use contraception or be surgically sterile. The trial also excludes subjects who have received certain treatments or medications in the past few weeks or months.",
    "The sample is a clinical trial for patients with intracranial malignant glioma or recurrent or progressive benign or malignant meningioma. The trial is in phase 1/phase 2 and the drug being tested is erlotinib hydrochloride. The eligibility criteria include having measurable or evaluable disease, a performance status of Karnofsky 60-100%, and meeting certain medical requirements such as having a WBC of at least 3,000/mm^3 and a platelet count of at least 100,000/mm^3. Patients must also not have any other serious concurrent medical illness or other malignancy within the past 3 years except nonmelanoma skin cancer or carcinoma in situ of the cervix. They must not be pregnant or nursing and must use effective barrier contraception during and for 12 weeks after study participation if they are fertile. The trial also has various exclusion criteria, such as having prior chemotherapy for stable GBM or concurrent combination antiretroviral therapy for HIV-positive patients.",
    "The sample is a record from a clinical trial table that includes information about the trial's phase, diseases being studied, icd-10 codes associated with those diseases, drugs being used, and eligibility criteria for participants. In this particular sample, the trial is in phase 1/phase 2 and is focused on studying multiple myeloma. The icd-10 codes associated with this disease are listed as \"C90.01\", \"C90.02\", and \"C90.00\". The drugs being used in the trial are cci-779 and bortezomib. The eligibility criteria for participants include being 18 years or older, having received prior therapy for myeloma and having relapsed and/or relapsed/refractory multiple myeloma, having certain levels of monoclonal protein or light chain in the serum or urine, having an ECOG Performance Status of 0, 1 or 2, and meeting certain laboratory values as outlined in the protocol. There are also exclusion criteria listed, such as uncontrolled infection, recent chemotherapy or biologic therapy, pregnancy or nursing, and serious medical or psychiatric illness likely to interfere with participation in the trial.",
    "The sample is a record of a clinical trial with a phase 1/phase 2 designation. The trial is focused on non-Hodgkin's lymphoma and includes a list of ICD-10 codes for the disease. The trial involves the use of bortezomib, chop, and rituximab drugs. The eligibility criteria for the trial include a confirmed diagnosis of diffuse large B cell or mantle cell Non-Hodgkin's Lymphoma, no prior anti-cancer therapy for lymphoma, measurable disease, and specific blood count and organ function requirements. The exclusion criteria include known central nervous system involvement by lymphoma, HIV disease, pregnancy or nursing, recent major surgery, and known peripheral neuropathy.",
    "The sample is a record from a clinical trial table that includes information about the phase of the trial, diseases being studied, icd-10 codes of the diseases, drugs being tested, and eligibility criteria for participants. In this particular sample, the trial is in phase 1/phase 2 and is studying the effectiveness of imatinib mesylate in treating recurrent melanoma, stage iii melanoma, stage iv melanoma, and unspecified adult solid tumor. The eligibility criteria include having measurable disease, a performance status of ECOG 0-1, and meeting various medical requirements such as having no history of stroke, uncontrolled hypertension, or significant traumatic injury within the past 28 days. Participants must also not be pregnant or nursing, and must use effective contraception during and for at least 3 months after study participation.",
    "The sample is a record from a clinical trial table that includes information about the phase of the trial, diseases being studied, icd-10 codes of the diseases, drugs being tested, and eligibility criteria for study subjects. In this particular sample, the trial is in phase 1/phase 2 and is focused on cystic fibrosis. The icd-10 codes associated with the disease are listed, as well as the names of the drugs being tested. The eligibility criteria for study subjects are also provided, including requirements such as a confirmed diagnosis of CF, a history of chronic infection with P.aeruginosa, and the ability to comply with study medication use and procedures. The exclusion criteria are also listed, which include factors such as recent use of investigational drugs, hospitalization for respiratory-related illness, and history of alcohol or drug abuse.",
    "The sample is a record from a clinical trial table that includes information about the trial phase, diseases being studied, ICD-10 codes associated with those diseases, drugs being tested, and eligibility criteria for participants. In this particular sample, the trial is a phase 1/phase 2 trial for patients with multiple myeloma who have not responded to previous treatments. The trial is testing the effectiveness of two drugs, obatoclax mesylate and bortezomib. The eligibility criteria include specific requirements related to the patient's medical history, disease progression, and current health status. The criteria also exclude patients with certain medical conditions or who are taking certain medications.",
    "The sample is a clinical trial for the treatment of Fanconi Anemia and severe aplastic anemia. The trial is in phase 1/phase 2 and involves the use of the drug fludarabine. The eligibility criteria include a diagnosis of Fanconi Anemia or other DNA breakage/chromosomal instability syndromes, severe aplastic anemia, availability of an HLA matched or mismatched family member or unrelated donor, and certain health requirements such as life expectancy greater than 6 weeks and a Karnofsky score of 70% or more. Exclusion criteria include symptomatic cardiac disease, severe infection, severe personality disorder or mental illness, and HIV positivity. Patients with laboratory abnormalities may be included at the investigator's discretion after approval by the CCGT Protocol Review Committee and the FDA Reviewer.",
    "The sample is a clinical trial for kidney transplantation, with a phase 1/phase 2 designation. The trial is looking at the use of c1 esterase inhibitor and placebos as potential therapies. The eligibility criteria include having end-stage renal disease, being between the ages of 18-65, having a high level of HLA sensitization, and having a donor-specific antibody/cross match + non-HLA identical donor at the time of transplant. Exclusion criteria include being pregnant or lactating, having certain infections or medical conditions, and having received certain vaccines or investigational agents within a certain timeframe. The trial requires informed consent from the subject/parent/guardian.",
    "The sample is a clinical trial for a drug called PCI-32765 and ofatumumab for patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), prolymphocytic leukemia (PLL), or Richter's transformation arising out of CLL/SLL. The trial is in phase 1/phase 2 and the table includes information on the diseases being treated, the icd-10 codes of the diseases, the drugs being used, and the eligibility criteria for patients to participate in the trial. The eligibility criteria include factors such as previous treatments, organ and marrow function, and exclusion criteria such as significant cardiovascular disease or active systemic infection. The sample also includes the inclusion and exclusion criteria for the trial.",
    "The sample is a clinical trial for rheumatoid arthritis, with a combination of phase 1 and phase 2. The trial involves testing the effectiveness of a drug called he3286, and the eligibility criteria include being between 18-75 years old, having stable or active disease on a stable dose of methotrexate for at least 30 days prior to Day 1, having normal thyroid stimulating hormone (TSH) levels, and not having experienced renal or liver disease or acute cardiac disease within 6 months prior to screening. The trial also has exclusion criteria, such as having a history of clinically significant cardiovascular disease or active tuberculosis. The sample includes a list of diseases and their corresponding icd-10 codes, as well as the eligibility criteria for the trial.",
    "The sample is a clinical trial for chronic hepatitis C, in which the phase is a combination of phase 1 and phase 2. The trial involves testing the drugs daclatasvir and placebo on patients who are chronically infected with hepatitis C virus genotype 1 and have not received treatment before or have not responded to previous treatment. Patients who are co-infected with HIV or hepatitis B virus are excluded from the trial. The trial also has specific inclusion and exclusion criteria, such as a minimum BMI requirement and exclusion of patients with significant acute or chronic medical illnesses. The icd-10 codes for the disease are also included in the table.",
    "The sample is a record from a clinical trial table that includes information about the trial's phase, diseases being studied, icd-10 codes of the diseases, drugs being tested, and eligibility criteria for participants. In this particular sample, the trial is in phase 1/phase 2 and is focused on Crohn's Disease. The icd-10 codes associated with the disease are listed, as well as the specific drugs being tested. The eligibility criteria for participants are also listed, including age range, disease severity, and exclusion criteria such as previous use of certain medications or a history of certain medical conditions.",
    "The sample is a clinical trial for breast cancer patients with HER-2 positive and ER positive or PR positive (HR+) metastatic or resistant locally advanced breast cancer. The trial is in phase 1/phase 2 and the drug being tested is auy922. The eligibility criteria include being 18 years or older, having certain laboratory values within normal limits, having a negative pregnancy test, having at least one measurable lesion, and having a World Health Organization (WHO) Performance Status of less than 1. Exclusion criteria include unresolved diarrhea, pregnancy or lactation, impaired cardiac function, HIV positive status, known hypersensitivity to any of the study drugs or their excipients, and participation in another clinical study within 30 days before first study treatment.",
    "The sample is a record of a clinical trial with a combination of phase 1 and phase 2. The trial is focused on rheumatoid arthritis, and the icd-10 codes associated with the disease are listed. The trial involves the use of two drugs, ask8007 and placebo. The eligibility criteria for the trial are also listed, including the requirement that participants meet the American Rheumatism Association's criteria for the classification of RA and have been treated with an adequate dose of either MTX, leflunomide, or sulfasalazine for at least 4 months prior to baseline. The exclusion criteria are also listed, including recent treatment with investigational drugs or TNF\u03b1-blockers, and the presence of certain medical illnesses that could put the patient at risk.",
    "The sample is a clinical trial for patients with hematological malignancies who have undergone either ablative or non-myeloablative allogeneic stem cell transplantation. The trial is in phase 1/phase 2 and the drugs being tested are rituximab and 375 mg/m2 rrituximab. The eligibility criteria include being 18 years or older, having a performance status of 0-2, and having a life expectancy of over 100 days. Patients must have received transplantation from donors who are identical at 6 HLA loci, or mismatched at no more than 1 locus. Patients who have undergone a non-myeloablative stem cell transplant must have > 80% donor hematopoiesis within 30 days of study enrollment. Patients with CLL are eligible if there is no more than 20% residual leukemia in the bone marrow at the time of study entry. The exclusion criteria include evidence of relapsed or residual malignancy within 30 days of trial entry, highly aggressive B cell malignancy, evidence of any active uncontrolled infection, evidence of ongoing gastrointestinal or hepatic acute GVHD, or evidence of greater than ongoing Stage I cutaneous acute GVHD, among others.",
    "The sample is a record of a clinical trial with a phase 1/phase 2 designation. The trial is focused on kidney diseases and the associated ICD-10 codes. The drugs being tested are yspsl and placebo. The eligibility criteria for the trial include patients undergoing primary cadaver renal transplants, while exclusion criteria include patients with planned transplants from non-heart beating donors, donors < 6 years of age, or donors who have received investigational therapies to reduce the impact of ischemia/reperfusion injury, DGF, or other donor-related immune events. Patients planned to receive a living donor kidney or an ABO-incompatible donor kidney are also excluded.",
    "The sample is a clinical trial for non-small-cell lung carcinoma and carcinoma, non-small cell lung. The trial is in phase 1/phase 2 and involves the drugs entinostat, sndx-275, and erlotinib. The eligibility criteria include having confirmed NSCLC of stage IIIb or IV, having received at least 1 but no more than 2 prior chemotherapy or chemoradiotherapy regimens for advanced NSCLC, having at least 1 measurable lesion by conventional or spiral CT scan, having an ECOG performance score of 0, 1, or 2 and life expectancy of at least 6 months, and meeting various other medical criteria. The exclusion criteria include having prior stem cell transplant, clinical evidence of CNS involvement, prior treatment with an HDAC inhibitor or an EGFR inhibitor, and various other medical conditions. Patients must also be willing to use accepted and effective methods of contraception during the study and for 3 months after the last dose of SNDX-275.",
    "The sample is a clinical trial for breast cancer patients in phase 1/phase 2. The trial includes patients who are at least 18 years old and have a histological diagnosis of localized breast cancer with a primary tumor over 2 cm on its longest diameter. The patients must also have measurable disease with a primary lesion >2 cm by RECIST v1.1 criteria and be HER 2 negative. The trial involves the use of drugs such as bibf + paclitaxel and paclitaxel. The eligibility criteria include adequate hematologic, renal, and hepatic function, as well as premenopausal women being under effective birth control. The exclusion criteria include metastatic or non-surgical breast cancer, HER-2 positive breast cancer, and male patients. The trial also excludes patients with concurrent serious medical conditions and those who are unable to comply with the study and follow-up procedures.",
    "The sample is a clinical trial for patients with type 2 diabetes and incipient or overt diabetic nephropathy. The trial is in phase 1/phase 2 and the drug being tested is aliskiren. The eligibility criteria include having a BMI within the range of 20 and 32, a GFR of at least 40 ml/min, and being on stable hypoglycemic medications for at least 8 weeks prior to the trial. Patients must also be willing and medically able to discontinue certain medications for the duration of the study. Exclusion criteria include severe hypertension, kidney disease not caused by diabetes or hypertension, and a history of malignancy within the past five years. Other protocol-defined inclusion/exclusion criteria may also apply.",
    "The sample is a clinical trial for pancreatic cancer patients in phase 1/phase 2. The trial is testing the effectiveness of gemcitabine hydrochloride as a treatment option. The eligibility criteria for patients include having histologically or cytologically confirmed adenocarcinoma of the pancreas, completely resected disease, and no grossly positive surgical margins. Patients must also have an ECOG performance status of 0-1, be not pregnant or nursing, and have no known CNS disease. Other criteria include having certain blood counts and levels within normal ranges, no postoperative complications, and no history of major psychiatric disorder or other chronic medical illness that contraindicates the use of the study drugs. Patients must not have had prior chemotherapy or radiotherapy for pancreatic cancer, no prior systemic or investigational therapy for pancreatic cancer, and no major surgical procedure (except for resection of pancreatic cancer) or open biopsy within the past 28 days. The trial does not allow concurrent newly prescribed nonsteroidal anti-inflammatory drugs (NSAIDs), but concurrent chronic-dose NSAIDs for analgesia are allowed.",
    "The sample is a record from a clinical trial table that includes information about the trial phase, diseases being studied, corresponding ICD-10 codes, drugs being tested, and eligibility criteria for participants. In this particular sample, the trial is a combination of phase 1 and phase 2, and is focused on metastatic breast cancer. The drugs being tested are lapatinib and docetaxel. The eligibility criteria include age, performance status, HER positivity, prior treatment history, cardiac function, and adequate organ function. There are also exclusion criteria, such as certain medical conditions, prior treatments, and pregnancy.",
    "The sample is a clinical trial for a drug called Velcade, which is being tested on patients with peripheral T-cell lymphomas and non-Hodgkin lymphoma. The trial is in phase 1/phase 2 and has specific eligibility criteria for patients to be included, such as having a confirmed diagnosis of PTCLs or NK/T cell lymphomas (excluding ALK-positive anaplastic large cell T-cell lymphomas), being under the age of 65, and having measurable lesions. The trial also has exclusion criteria, such as having any other malignancies within the past 5 years (except for basal cell skin cancer or carcinoma in situ of the cervix) and serious comorbid diseases. Any waiver of these criteria must be approved by the investigator and sponsor on a case-by-case basis.",
    "The sample is a clinical trial for the treatment of multiple myeloma, a type of cancer. The trial is in phase 1/phase 2 and involves the use of drugs such as lenalidomide, bortezomib, dexamethasone, and doxil. The eligibility criteria for participants include being at least 18 years old, having measurable disease, completing necessary baseline studies, and having a left ventricular ejection fraction greater than or equal to 50 percent. Exclusion criteria include having grade 2 or higher peripheral neuropathy, renal insufficiency, evidence of bleeding or platelet refractory, and other medical conditions that place the subject at unacceptable risk. Participants must also not have received any other investigational drugs within 14 days of enrollment and must not be pregnant or breastfeeding.",
    "The sample is a clinical trial for lung cancer patients in phase 1/phase 2. The trial includes patients with non-small-cell lung cancer and other related diseases. The trial involves the use of drugs such as abt-751, pemetrexed, and placebo. The eligibility criteria for the trial include having only one prior anti-tumor treatment regimen, measurable disease by RECIST criteria, and an ECOG performance score of 0-2. The trial also has exclusion criteria such as allergy to sulfa medications, previous treatment with ABT-751 or pemetrexed, and significant systemic disease that would adversely affect participation.",
    "The sample is a clinical trial for patients with metastatic breast cancer who have received at least two prior chemotherapy regimens. The trial is in phase 1/phase 2 and involves the drugs hydroxychloroquine and ixabepilone. The eligibility criteria include having measurable disease according to RECIST criteria, being anthracycline-resistant and taxane-resistant, and having a known hormone receptor status. Patients must also meet certain patient characteristics, such as having an ECOG performance status of 0-2 and no serious uncontrolled medical disorder or active infection. Prior concurrent therapy is also taken into consideration.",
    "The sample is a clinical trial for non-Hodgkin's lymphoma patients in phase 1/phase 2. The trial involves the use of rituximab, dhap, tec, and autologous stem cell transplantation as drugs. The eligibility criteria include being between 18-65 years old, having first relapse or primary refractory disease of aggressive Non-Hodgkin's lymphoma stage I-IV, and having pretreatment with systemic therapy. The exclusion criteria include having a second neoplasia in history or existing, CNS-involvement by lymphoma, respiratory partial- or global insufficiency, cardiac insufficiency, severe neurological or psychiatric disease, pregnancy, HIV positivity, active virus hepatitis, bacterial infection, and no follow-up procedures ensured.",
    "The sample is a clinical trial with a combination of drugs, paclitaxel, carboplatin, and vorinostat, for patients with stage IIIA, IIIB, or IV non-small cell lung cancer. The trial is in phase 1/phase 2 and the eligibility criteria include having no prior chemotherapy for advanced or metastatic disease, measurable disease, and an ECOG performance status of 0 or 1. Patients must also meet certain laboratory values and have a life expectancy of greater than 12 weeks. Exclusion criteria include prior therapy with paclitaxel, uncontrolled intercurrent illness, and pregnancy.",
    "The sample is a clinical trial with a combination of phase 1 and phase 2. The trial is focused on heart failure and asymptomatic systolic dysfunction. The trial involves the use of nesiritide and placebo drugs. The eligibility criteria for the trial include having an ejection fraction of less than 45%, no clinical signs or symptoms of congestive heart failure, ability to walk a minimal distance of more than 450 meters on a 6-minute walk, and being on stable doses of an angiotensin converting enzyme (ACE) inhibitor for two weeks prior to the active study date. The exclusion criteria include having a recent myocardial infarction, unstable angina, significant valvular stenosis, hypertrophic, restrictive or obstructive cardiomyopathy, and other medical conditions.",
    "The sample is a clinical trial for patients with rectal cancer in phase 1/phase 2. The trial involves the drug capecitabine and has a list of inclusion and exclusion criteria. Inclusion criteria include having clinical stage T4 or recurrent adenocarcinoma of the rectum, confirmed histology, no distant metastatic disease, a performance status of 70% or greater, and meeting certain medical requirements. Exclusion criteria include prior radiotherapy to the pelvis, pregnancy or lactation, recent treatment for other carcinomas, uncontrolled intercurrent illness, major surgery within 4 weeks, and other serious uncontrolled medical conditions. Patients must also sign an informed consent form indicating their awareness of the investigational nature of the study and that participation is voluntary.",
    "The sample is a record of a clinical trial with a phase 1/phase 2 designation. The trial is focused on treating soft tissue sarcoma, including locally advanced or metastatic, unresectable disease. The trial involves the use of two drugs, amg 655 and doxorubicin. The eligibility criteria for the trial include having a confirmed diagnosis of soft tissue sarcoma, measurable disease according to modified RECIST, an ECOG performance status of 0 or 1, and adequate hematological, renal, hepatic, and coagulation function. The exclusion criteria include prior treatment with anthracyclines and uncontrolled cardiovascular disease.",
    "The sample is a clinical trial for patients with acute lymphoblastic leukemia. The trial is in phase 1/phase 2 and involves the drug clofarabine. The eligibility criteria include having received therapy with at least 1 but not more than 3 prior different induction regimens and having been deemed to have relapse or refractory disease. Patients must also have adequate renal and hepatic functions, be at least 16 years old, and have an ECOG PS of 0-2. Female patients of childbearing potential must have a negative serum pregnancy test within 2 weeks prior to enrollment, and both male and female patients must use an effective contraceptive method during the study and for a minimum of 6 months after study treatment. The exclusion criteria include current concomitant chemotherapy, radiation therapy, or immunotherapy other than as specified in the protocol, lack of bone marrow or blood involvement by leukemia, and any other severe concurrent disease or history of serious organ dysfunction or disease involving the heart, kidney, liver, or other organ system that may place the patient at undue risk to undergo treatment.",
    "The sample is a clinical trial for metastatic colorectal cancer patients who have received one prior line of chemotherapy. The trial is in phase 1/phase 2 and involves the drugs tivantinib, placebo, cetuximab, and irinotecan. The eligibility criteria include having measurable disease, expressing the wild-type form of the gene KRAS, having an ECOG performance status of 0 or 1, and meeting certain bone marrow, liver, and renal function requirements. Participants must also agree to use double-barrier contraceptive measures or avoid intercourse during the study and for 90 days after the last investigational drug dose received. Exclusion criteria include prior therapy with an Epidermal Growth Factor Receptor (EGFR) inhibitor, history of malignancy other than CRC, and certain cardiac diseases. Participants must be fully informed about the study and sign an Independent Ethics Committee (IEC) or Institutional Review Board (IRB)-approved informed consent form (ICF) before participating.",
    "The sample is a clinical trial for pancreatic cancer patients in phase 1/phase 2. The trial involves the drugs gefitinib and gemcitabine. The eligibility criteria include being diagnosed with pancreatic cancer, having a tumor volume less than 500 cc, being between the ages of 18 and 75, having an ECOG performance status of 1 or less, having a life expectancy of more than 12 weeks, and being willing to practice reliable methods of birth control if a woman of child-bearing potential. Exclusion criteria include having received previous radiotherapy or chemotherapy for malignant disease, having other co-existing malignancies or malignancies diagnosed within the last 5 years (with the exception of basal cell carcinoma or cervical cancer in situ), having evidence of severe or uncontrolled systemic disease, having certain blood counts or liver function tests outside of normal range, having active dermatoses, using certain medications, or having a severe hypersensitivity to ZD1839 or any of its excipients.",
    "The sample is a clinical trial for a drug called pt-523 for injection, aimed at treating non-small-cell lung carcinoma in patients who have failed standard first and second line chemotherapy regimens or are intolerant to them. The trial is in phase 1/phase 2 and the eligibility criteria include being over 18 years old, having confirmed NSCLC which is stage III or stage IV, or recurrent disease, and having adequate organ function and bone marrow reserve. Patients must also have a performance status of 0-2 on the ECOG scale and use appropriate contraceptive methods. The trial excludes patients who have received nitrosoureas or mitomycin-C within 6 weeks or other chemotherapy or radiation therapy within 3 weeks before study entry, as well as those with uncontrolled intercurrent illness, symptomatic or uncontrolled brain metastases, or uncontrolled pleural effusions. Patients must provide signed informed consent to participate in the trial.",
    "This is a sample from a table that contains information about clinical trials. The trial is in phase 1/phase 2 and is focused on chronic lymphocytic leukemia. The icd-10 codes associated with the disease are C91.11, C91.12, and C91.10. The drugs being used in the trial are gleevec and chlorambucil. The eligibility criteria for the trial include having B-cell chronic lymphocytic leukemia, having received at least one prior chemotherapy regimen, having a white blood cell count greater than 25 x 10^9/L, and having adequate renal and hepatic function. The exclusion criteria include having documented prolymphocytic leukemia, having active cardiovascular disease, having an intercurrent illness or medical condition that would make it unsafe to administer ribavirin, and having received any previous therapy for CLL within 28 days prior to study entry.",
    "The sample is a clinical trial for patients with high-risk myelodysplastic syndrome or acute myelogenous leukemia. The trial is in phase 1/phase 2 and the drug being tested is mgcd0103. The eligibility criteria include having a certain level of BM blasts, a certain ECOG performance status, being at least 18 years old, and meeting certain laboratory requirements. Patients with other active cancers, uncontrolled illnesses, or serious medical conditions are excluded. Patients must also be able to read, understand, and sign a written informed consent. The trial has both inclusion and exclusion criteria, and patients who meet the criteria will be enrolled in the study.",
    "The sample is a record of a clinical trial with a phase 1/phase 2 designation. The trial is focused on colorectal cancer and includes a list of ICD-10 codes for the disease. The trial involves the use of three drugs: bevacizumab, oxaliplatin, and capecitabine. The eligibility criteria for the trial include patients between the ages of 20-74 with histologically confirmed colorectal cancer that has not been previously treated with chemotherapy for metastatic disease. Patients must also have at least one measurable lesion according to RECIST. The exclusion criteria include evidence of clinically detectable ascites, recent major surgical procedures or biopsies, bleeding diathesis or coagulopathy, serious wounds or fractures, and the use of certain medications known to predispose to gastrointestinal ulceration.",
    "The sample is a record of a clinical trial with a combination of phase 1 and phase 2. The trial is focused on treating prostatic neoplasms using the drug samarium sm-153 lexidronam and docetaxel. The eligibility criteria for the trial include having histological evidence of adenocarcinoma of the prostate, progressive castrate metastatic disease, and evidence of at least 3 bone metastases on bone scan. Patients must also meet certain lab requirements and have a life expectancy of at least 12 weeks. Exclusion criteria include having small cell carcinoma, clinically significant cardiac disease, and participating in another research study or clinical trial protocol within 30 days of the baseline visit.",
    "The sample is a record from a clinical trial table. It includes information about the phase of the trial, which can be either phase 1 or phase 2, a list of diseases, their corresponding ICD-10 codes, and a list of drugs used in the trial. The eligibility criteria for the trial are also included, which specify the requirements for participants to be included or excluded from the trial. These criteria include factors such as ethnicity, performance status, tumor type, and medical history. The sample also includes exclusion criteria, which specify conditions that would prevent a participant from being included in the trial.",
    "The sample is a record of a clinical trial with a phase 1/phase 2 designation. The trial is focused on the disease \"essential tremor\" and the associated ICD-10 code is \"G25.0\". The trial involves two drugs, \"levetiracetam\" and \"placebo\". The eligibility criteria for the trial include having a history of tremor for 5 or more years and having no other neurological problems. The exclusion criteria include having a prior stroke or other neurological disease, psychiatric problems, a history of renal disease, and being pregnant.",
    "The sample is a clinical trial for patients with colorectal cancer that has spread and cannot be cured by surgery or radiotherapy. The trial is for patients who have received at least one prior chemotherapy regimen and have had disease progression or intolerable toxicity during or within 3 months of receiving a cetuximab-containing regimen. The trial involves the drug irinotecan hydrochloride and requires patients to meet a number of eligibility criteria, including having a KRAS wild-type tumor, measurable disease, and an ECOG performance status of 0-1. The trial also excludes patients with certain medical conditions or prior treatments, and requires patients to undergo various tests and screenings.",
    "The sample is a record of a clinical trial that is in phase 1/phase 2. The trial is focused on arthritis and rheumatoid arthritis, with a list of corresponding icd-10 codes. The drugs being tested are cdp 6038 sc and methotrexate. The eligibility criteria for the trial include having RA for more than 6 months on stable methotrexate, having a maximum of 9 swollen and tender joints (28 joint count), and a minimum screening CRP of 0.5mg/L. The exclusion criteria include previous participation or treatment with defined agents and durations, presence of certain medical conditions, pregnancy, positive tests/signs of possible latent/active tuberculosis, positive HIV, and drug addiction or alcohol abuse.",
    "The sample is a clinical trial for relapsing multiple sclerosis, in which the phase is a combination of phase 1 and phase 2. The trial involves the use of drugs such as cdp323 and placebo. The eligibility criteria for the trial include being between the ages of 18-65, having a relapsing form of MS with at least one clinical relapse in the 24 months before screening, having a screening EDSS score of 0-6.5, being fully immunocompetent, and female subjects of childbearing potential must agree to practice contraception methods. The exclusion criteria include any conditions that could interfere with the contrast-enhanced MRI, any clinically significant disease state or findings other than MS, any clinically significant deviation from the pre-defined ranges for laboratory tests, and concomitant treatment with MS disease modifying drugs.",
    "The sample is a clinical trial for a drug called ta-7284 and its placebo, conducted on patients with type 2 diabetes mellitus. The trial is a combination of phase 1 and phase 2. The table contains information about the diseases, icd-10 codes, drugs, and eligibility criteria for the trial. The eligibility criteria include factors such as stable diabetes, specific BMI and blood glucose levels, and blood pressure within a certain range. Patients who have not been administered anti-diabetic medication within 2 weeks prior to dosing are eligible. The exclusion criteria include patients with type 1 diabetes mellitus or secondary diabetic mellitus, history of diabetic complications, and treatment with certain medications within 3 months prior to informed consent. Patients with significant complications or serum creatinine levels above the upper limit of the normal range are also excluded.",
    "The sample is a clinical trial for patients with multiple myeloma in phase 1/phase 2. The trial includes patients who have been previously diagnosed with multiple myeloma and have received at least one but less than four lines of therapy. The patients must currently require further treatment due to relapse from CR or PD. The trial also includes patients who have been previously treated with bortezomib and had a duration of response of more than 6 months from the completion of therapy. Patients must be over 18 years old and willing and able to comply with the protocol requirements. Female patients of child-bearing potential and male patients with female partners of child-bearing potential must agree to use 2 simultaneous methods of contraception. Patients must have measurable disease and a Karnofsky performance status of at least 80%. Patients must have a life-expectancy of more than 3 months and meet certain laboratory values within 14 days before study drug administration. Patients with prior severe allergic reactions to bortezomib, romidepsin, boron, or mannitol, neuropathy of grade 3 or higher, or certain cardiac risk factors will be excluded from the study. Pregnant female patients will also be excluded.",
    "The sample is a record from a clinical trial table that includes information about the phase of the trial, diseases being studied, icd-10 codes of the diseases, drugs being tested, and eligibility criteria for participants. In this particular sample, the trial is in phase 1/phase 2 and is focused on non-small cell lung cancer. The drug being tested is irinotecan. The eligibility criteria include being 18 years or older, having received prior chemotherapy for advanced non-small cell lung cancer, displaying high ISG15, having a life expectancy of at least 12 weeks, and having an ECOG/Zubrod performance status of 0-2. Adequate bone marrow, hepatic, and renal function are also required. Exclusion criteria include symptomatic brain metastases, pregnancy or nursing, concurrent chemotherapy or radiation therapy, severe medical problems, and previous hypersensitivity reaction to camptothecins.",
    "The sample is a record from a clinical trial table that includes information about the phase of the trial, the disease being studied (in this case, metastatic melanoma), the ICD-10 codes associated with the disease, the drug being tested (raf265), and the eligibility criteria for participants. The eligibility criteria include requirements such as a confirmed diagnosis of melanoma, measurable disease, a certain performance status, and no concurrent anticancer or investigational therapy for at least 4 weeks prior to enrollment. The exclusion criteria include factors such as significant cardiac disease or other significant medical/psychiatric disease, a history of primary central nervous system tumor or brain metastases, and previous therapy with certain molecularly targeted agents.",
    "The sample is a clinical trial for HIV infections in phase 1/phase 2. The trial is testing the effectiveness of two drugs, tenofovir df and tenofovir alafenamide. The eligibility criteria for participants include having HIV-1 RNA levels greater than or equal to 30,000 copies/mL, a CD4 count greater than or equal to 200 cells/mm3, and adequate hematologic function. Participants must also have a serum creatinine level less than 1.5 mg/dl, hepatic transaminases less than or equal to 2.5 times the upper limit of normal, and a total bilirubin less than or equal to 1.5 mg/dL. Additionally, participants must have a serum amylase less than or equal to 1.5 times the upper limit of normal, serum phosphate greater than or equal to 2.2 mg/dL, and not be pregnant. Exclusion criteria include prior treatment with antiretroviral therapy, immunization within 30 days of study entry, a new AIDS defining condition within 30 days of study entry, and receiving nephrotoxic agents, probenecid, chemotherapeutic agents, corticosteroids, or interleukin-2.",
    "The sample is a clinical trial for prostate cancer patients who have not responded to hormone therapy. The trial is a combination of phase 1 and phase 2. The trial involves the use of drugs such as abiraterone acetate and dexamethasone. The eligibility criteria for the trial include having histologically documented adenocarcinoma of the prostate, evidence of progressive prostate cancer, and an ECOG performance status score of 0 or 1. Exclusion criteria include having central nervous system disease or brain metastases, active autoimmune disease, and having had major surgery or significant traumatic injury within 4 weeks of the start of the study.",
    "The sample is a record of a clinical trial for pancreatic cancer treatment. The trial is in phase 1/phase 2 and involves the use of four drugs: gemcitabine, capecitabine, erlotinib, and bevacizumab. The eligibility criteria for patients include having histologically or cytologically confirmed adenocarcinoma of the pancreas, locally advanced or metastatic disease, and not being amenable to curative resection. Patients must also meet certain age, performance status, and life expectancy requirements, as well as have specific hematopoietic, hepatic, renal, and cardiovascular health. Patients cannot be pregnant or breastfeeding, and must not have any other active malignancy except non-melanoma skin cancer and cervical cancer in-situ. Additionally, patients must not have had previous chemotherapy, radiotherapy, or other investigational drug treatment for metastatic disease, and must not be on full dose anti-coagulation or ongoing treatment with aspirin or other medications known to predispose to gastrointestinal ulceration.",
    "The sample is a clinical trial for small cell lung cancer patients who have progressed after only one prior platinum-containing chemotherapy regimen. The trial is in phase 1/phase 2 and the drugs being tested are at-101 and topotecan. The eligibility criteria include confirmed SCLC, measurable disease, ECOG performance status 0-1, adequate hematologic, liver and renal function, and ability to swallow oral medication. Exclusion criteria include more than one prior chemotherapy regimen, prior chemotherapy regimen containing irinotecan, active secondary malignancy, unstable or progressive brain metastases, and uncontrolled concurrent illness.",
    "The sample is a record from a clinical trial table that includes information about the trial's phase, diseases being studied, icd-10 codes of those diseases, drugs being tested, and eligibility criteria for participants. In this particular sample, the trial is in phase 1/phase 2 and is focused on non-small-cell lung cancer. The drugs being tested are vorinostat and erlotinib, and the eligibility criteria include having failed at least one prior treatment for NSCLC, being at least 4 weeks from any chemotherapy or surgeries, and having normal lab results. The sample also includes exclusion criteria, such as prior treatment with vorinostat or erlotinib, active infections, and pregnancy.",
    "The sample is a clinical trial for patients with stage IV non-small cell lung cancer that has spread and cannot be surgically removed. The trial is in phase 1/phase 2 and involves the use of a drug called paclitaxel albumin-stabilized nanoparticle formulation. The trial is looking to determine the safety and effectiveness of the drug in treating this type of cancer. The eligibility criteria for the trial include having measurable disease documented radiographically, no evidence of active brain metastases or leptomeningeal involvement, and meeting certain hematopoietic, hepatic, renal, and other health requirements. Patients must also not have any concurrent active malignancy, pre-existing peripheral neuropathy grade 1 or greater, or other concurrent clinically significant illness. Prior chemotherapy for metastatic disease is not allowed, and patients must not be concurrently enrolled in another clinical trial involving investigational drugs or procedures.",
    "The sample is a clinical trial for non-small cell lung cancer patients in phase 1/phase 2. The trial is testing the effectiveness of the drugs docetaxel and pemetrexed. The eligibility criteria include having inoperable stage IIIB-IV NSCLC, being previously untreated with docetaxel and pemetrexed, and having measurable disease according to RECIST criteria. Patients must also have a WHO performance status of 0-2, a life expectancy of at least 12 weeks, and meet certain laboratory values. Exclusion criteria include having other co-existing malignancies, severe uncontrolled concomitant disease, unresolved chronic toxicity from previous anticancer therapy, unstable central nervous system metastases, malnutrition, performance status of 4, psychiatric illness or social situation that would preclude study compliance, and being pregnant or lactating.",
    "The sample is a clinical trial for patients with acute myeloid leukemia. The trial is in phase 1/phase 2 and the patients must meet certain eligibility criteria to participate. These criteria include having primary refractory AML, relapsed AML, and not having received a high-dose cytarabine containing regimen within 3 months prior to registration. The trial involves the use of cytarabine and lovastatin as drugs. The sample also includes exclusion criteria, such as having other serious illnesses or a currently active second malignancy.",
    "The sample is a clinical trial with a phase 1/phase 2 designation, focused on small cell lung cancer and small cell lung carcinoma. The trial includes a list of icd-10 codes for the diseases being studied, as well as a list of drugs being used in the trial. The eligibility criteria for the trial include being at least 18 years old, having a documented diagnosis of small cell lung cancer or other non-hematological malignancy, having received prior chemotherapy treatment, and meeting certain medical criteria related to bone marrow, renal, and hepatic function. The trial also includes exclusion criteria, such as a history of bleeding or active immune thrombocytopenic purpura, and a requirement for archived diagnostic tissue for assessment of Bcl-2 family protein expression.",
    "The sample is a clinical trial for major depressive disorder, with a phase 1/phase 2 designation. The trial involves the drugs alks 5461 and placebo. The eligibility criteria include being between 18 and 65 years old, meeting DSM-IV-TR criteria for MDD, and having an inadequate/partial response to a stable dose of an SSRI or SNRI. Exclusion criteria include having certain Axis I or II diagnoses, experiencing psychotic symptoms, using certain medications or supplements, having received electroconvulsive therapy during the current MDD episode, and having a history of intolerance or hypersensitivity to buprenorphine or opioid antagonists/quinine. The trial also includes specific scoring criteria for depressive symptom severity and suicide risk.",
    "The sample is a clinical trial for patients with various hematologic diseases, including myelodysplastic and myeloproliferative disorders, acute myelogenous leukemia, acute lymphoblastic leukemia, chronic myelogenous leukemia, multiple myeloma, plasma cell dyscrasia, lymphoproliferative disorders, and other non-malignant hematologic diseases. The trial is in phase 1/phase 2 and involves the use of drugs such as campath, busulfan, fludarabine, and fk-506. The eligibility criteria include a diagnosis of one of the specified diseases, a performance status of 0-2 on the Zubrod scale, and various other medical conditions such as a certain ejection fraction, AST/ALT and bilirubin levels, and lung function. Patients must also have a healthy donor available for donation and be able to understand and sign consent. Exclusion criteria include pregnancy, HIV positivity, uncontrolled infections, and various other medical conditions.",
    "The sample is a clinical trial for cystic fibrosis patients in phase 1/phase 2. The trial is testing the effectiveness of two drugs, oligog cf-5/20 and saline. The eligibility criteria for participants include being 18 years or older, having a confirmed diagnosis of cystic fibrosis, and having a positive microbiological finding of Pseudomonas aeruginosa in expectorated sputum or cough swab documented within 24 months prior to screening. Participants must also have an FEV1 between 35%-80% of the predicted normal value and no clinical or laboratory findings suggestive of significant pulmonary illness, other than CF, which in the opinion of the investigator would preclude participation in the study. The trial has exclusion criteria such as changes in underlying therapy, pulmonary exacerbation within 28 days of screening, and current malignant disease.",
    "The sample is a clinical trial for patients with acute myeloid leukemia or acute promyelocytic leukemia. The trial is in phase 1/phase 2 and involves the drugs clofarabine and cytarabine. The eligibility criteria include having an ECOG performance status of 0-2, understanding the potential risks and benefits of the study, and providing valid informed consent. Patients must also have a negative pregnancy test (if female), use effective contraception, and meet certain laboratory values. Exclusion criteria include having a systemic infection, being pregnant or lactating, having a concurrent disease that would compromise safety or compliance, and having a history of serious organ dysfunction. The trial does not allow concomitant cytotoxic or investigational therapy, and the use of certain medications is to be avoided.",
    "The sample is a clinical trial for the treatment of chronic hepatitis C. The trial is in phase 1/phase 2 and the diseases being studied are limited to chronic hepatitis C. The icd-10 codes associated with the disease are listed. The drugs being tested are bilb 1941 zw and a placebo. The eligibility criteria for the trial are listed, including age, HCV infection, genotype, liver biopsy results, and RNA load. The exclusion criteria are also listed, including other causes of liver disease, decompensated liver disease, HIV or HBs antigen positivity, alcohol or drug abuse, concurrent medical illness or disease, and laboratory abnormalities. Patients must also be willing to abstain from alcohol during the trial period.",
    "The sample is a record from a clinical trial database. It includes information about the phase of the trial, which is a combination of phase 1 and phase 2. The diseases being studied are small cell lung cancer and carcinoma, small cell, both of which are represented by ICD-10 codes. The drugs being tested are pemetrexed and cisplatin. The eligibility criteria for the trial are listed under inclusion and exclusion criteria, which include factors such as measurable disease, performance status, age, prior treatment history, and organ function.",
    "The sample is a clinical trial for patients with non-small-cell lung carcinoma in phase 1/phase 2. The trial involves the use of cisplatinum and docetaxel drugs. The eligibility criteria include patients with a confirmed diagnosis of NSCLC, aged between 18 and 75 years, with a life expectancy of at least 12 weeks, and an ECOG performance status of 0, 1, or 2. Patients must also meet certain laboratory and lung function test requirements. Exclusion criteria include patients with small cell lung cancer, stage IIIB NSCLC, pregnant or lactating women, and those with prior systemic chemotherapy, immunotherapy, or biological therapy. Patients with certain medical conditions or illnesses are also excluded.",
    "The sample is a clinical trial for patients with multiple myeloma that is progressing or has relapsed after at least two different anti-myeloma treatments. The trial is divided into two phases, phase 1 and phase 2. The patients must be at least 18 years old and able to adhere to the study visit schedule and other protocol requirements. They must have sufficient bone marrow function and a performance status score of 0, 1, or 2. The trial requires patients to discontinue all anti-myeloma drug or non-drug therapy prior to the first dose of study drug. The trial also requires patients to have normal cardiac function and prior thromboembolic event with adequate anticoagulation. The trial has a list of inclusion and exclusion criteria that patients must meet to participate.",
    "The sample is a clinical trial for patients with hepatocellular carcinoma, a type of liver cancer. The trial is in phase 1/phase 2 and includes patients with a history of cirrhosis or chronic hepatitis B or C infection. The trial is testing the drug denspm. Patients must meet certain eligibility criteria, including having measurable disease and meeting certain laboratory values. Patients who have received certain types of therapy within a certain timeframe or who have certain medical conditions are excluded from the trial. Female patients of childbearing potential must use effective contraception and all patients must provide written informed consent.",
    "The sample is a clinical trial for a drug called Proellex, which is being tested on healthy adult females between the ages of 18 and 50 who have excessive menstrual bleeding, menstrual pain, uterine fibroids, or endometriosis. The trial is in phase 1/phase 2 and the eligibility criteria include having a normal menstrual cycle, agreeing not to attempt to become pregnant, and being willing to discontinue hormonal contraceptives and use double barrier contraceptive techniques. The exclusion criteria include being post-menopausal, pregnant, or lactating, having abnormal liver enzymes or liver disease, having a history of PCOS, and using certain medications or drugs. The trial will last for 7 months and participants must be available for all treatment and follow-up visits.",
    "The sample is a record of a clinical trial with a phase 1/phase 2 designation. The trial is focused on the disease uveitis, which is associated with vision loss. The icd-10 codes associated with the disease are listed as \"H44.133\", \"H44.131\", \"H44.132\", and \"H44.139\". The drug being tested is apremilast. The eligibility criteria for the trial include having failed to respond to prednisone and at least one other systemic immunosuppressive medication, or being unable to tolerate such medications due to side effects. Exclusion criteria include having a serious concomitant illness that could interfere with participation, previous or current use of an alkylating agent, use of CYP3A4 inhibitors during the trial, and TNF blocker use within the 8 weeks prior to enrollment.",
    "The sample is a table with information about clinical trials for prostate cancer. It includes the phase of the trial (phase I, II, or III), a list of diseases, a list of ICD-10 codes for those diseases, a list of drug names, and eligibility criteria for the trial. The eligibility criteria include inclusion and exclusion criteria for different types of prostate cancer, such as non-metastatic CRPC, metastatic CRPC (treatment-naive), and metastatic CRPC (chemotherapy-naive, post-abiraterone). The criteria specify requirements such as PSA levels, ongoing androgen depletion therapy, ECOG performance status, and life expectancy, as well as exclusion criteria such as prior treatment with certain drugs, concurrent treatment with medications known to have seizure potential, and evidence of severe or uncontrolled systemic disease or HIV infection.",
    "The sample is a record from a clinical trial table that includes information about the phase of the trial, the disease being studied (in this case, mesothelioma), the ICD-10 codes associated with the disease, the drugs being used in the trial (carboplatin, bevacizumab, and pemetrexed), and the eligibility criteria for patients to participate in the trial. The eligibility criteria include requirements for the patient's diagnosis, performance status, renal and hepatic function, bone marrow function, and ability to take certain medications. The sample also includes exclusion criteria, such as a history of certain medical conditions or recent surgeries, and laboratory values that must be met for a patient to be eligible for the trial.",
    "The sample is a clinical trial for patients with non-small cell lung cancer in phase 1/phase 2. The trial is testing the effectiveness of the drug erlotinib hcl. The eligibility criteria include having confirmed NSCLC, having received at least one chemotherapy regimen for advanced or metastatic NSCLC, and having an ECOG performance status of 0, 1, or 2. Patients must also be at least 18 years old, have recovered from prior anti-cancer therapy, and have measurable disease on CT and at least one detectable lesion on FDG-PET scan and/or FLT-PET scan. Patients must be able to comply with the study and follow-up procedures, including all specified imaging studies, and be able to take oral medication. Exclusion criteria include prior treatment with an investigational or marketed agent for the purpose of inhibiting epidermal growth factor receptor (EGFR), chemotherapy, radiotherapy, or investigational treatment within 14 days or within 5 half-lives of the active molecules in the chemotherapy or investigational treatment, whichever is longer, prior to study entry or from which patients have not yet recovered, and any unstable systemic disease.",
    "The sample is a record from a clinical trial table that includes information about the trial's phase, diseases being studied, icd-10 codes of the diseases, drugs being used, and eligibility criteria for participants. In this particular sample, the trial is a combination of phase 1 and phase 2, and is focused on prostate cancer. The icd-10 codes associated with the disease are listed, as well as the drugs being used in the trial (tak-700, docetaxel, and prednisone). The eligibility criteria for participants are also listed, including requirements such as a confirmed diagnosis of prostate adenocarcinoma, radiograph-documented metastatic disease, and an estimated life expectancy of 6 months or more. The sample also includes exclusion criteria, such as known hypersensitivity to the drugs being used, prior therapy with investigational compounds or radiation therapy for prostate cancer within 30 days prior to the trial, and uncontrolled cardiovascular conditions.",
    "The sample is a record from a clinical trial table that includes information about the trial's phase, diseases being studied, icd-10 codes of those diseases, drugs being used, and eligibility criteria for participants. In this particular sample, the trial is in phase 1/phase 2 and is studying metastatic or relapsed locally advanced breast cancer that is HER2-positive by FISH. The drugs being used are bevacizumab and herceptin. The eligibility criteria include various requirements such as bidimensionally measurable disease, normal left ventricular ejection fraction, and no prior chemotherapy for metastatic disease. There are also exclusion criteria such as more than 3 different metastatic sites and clinically significant cardiovascular disease.",
    "The sample is a record of a clinical trial with a phase 1/phase 2 designation. The trial is focused on the disease glioblastoma multiforme, which is identified by a list of ICD-10 codes. The drug being tested is aee788. The record includes the eligibility criteria for the trial, including requirements for confirmed GBM diagnosis, adequate hematologic, hepatic and renal function, age over 18, Karnofsky performance status score of at least 70%, and a life expectancy of at least 12 weeks. The record also lists exclusion criteria, including peripheral neuropathy greater than grade 1, diarrhea greater than grade 1, gastrointestinal dysfunction, compromised cardiac function, and concurrent severe and/or uncontrolled medical conditions.",
    "The sample is a clinical trial for patients with symptomatic multiple myeloma requiring treatment. The trial is in phase 1/phase 2 and the drug being tested is busulfan. The eligibility criteria include being approved for single or tandem autologous transplant, being over 65 years of age or diagnosed with renal insufficiency, having adequate pulmonary function, having an ECHO or MUGA performed within 60 days prior to registration, and having evaluable myeloma marker for response. Patients must also be able to receive full doses of DT-PACE, in the opinion of the treating investigator, with the exception of cisplatin. Exclusion criteria include having serum transaminases or direct bilirubin levels above a certain threshold, being HIV positive or having active Hepatitis B or C infection, having a prior malignancy in which life expectancy is more likely to be determined by the prior malignancy than the myeloma, and being pregnant or nursing.",
    "The sample is a record of a clinical trial with a combination of phase 1 and phase 2. The trial is focused on the treatment of osteoarthritis, and the icd-10 codes associated with the disease are listed. The drug being tested is normal saline. The eligibility criteria for the trial are also listed, including inclusion criteria such as having painful osteoarthritis in the study knee and being able to walk without assistive devices, and exclusion criteria such as having chronic pain conditions other than knee osteoarthritis or having had surgery to the study knee within 24 weeks.",
    "The sample is a clinical trial for a drug called tmc278la, which is being tested on individuals with HIV infections. The trial is a combination of phase 1 and phase 2. The eligibility criteria for the trial include being between the ages of 18 and 50, having a BMI between 16 and 35, and not having any significant health problems. Participants must also be willing to undergo HIV testing and use contraception if sexually active. Exclusion criteria include having a significant medical illness, being pregnant or lactating, and having a history of severe drug allergy. The trial is being conducted in the UK and participants must be registered with a GP.",
    "The sample is a record from a clinical trial table that includes information about the trial's phase, diseases being studied, icd-10 codes of the diseases, drugs being used, and eligibility criteria for participants. In this particular sample, the trial is in phase 1/phase 2 and is studying mantle cell lymphoma. The icd-10 codes associated with the disease are listed, as well as the drugs being used in the trial. The eligibility criteria for participants are also listed, including age, disease classification, previous treatments, bone marrow function, performance status, and other medical conditions. Exclusion criteria are also listed, such as prior treatment with certain medications, abnormal liver or renal function, and pregnancy or breastfeeding.",
    "The sample is a clinical trial for a drug called ino-8875 and a placebo, for the treatment of ocular hypertension and primary open-angle glaucoma. The trial is in phase 1/phase 2 and involves patients between the ages of 18 and 75 with a mean intraocular pressure of \u226524 and \u226434 mm Hg. The trial has inclusion criteria such as the diagnosis of ocular hypertension or primary open-angle glaucoma, and exclusion criteria such as no significant visual field loss, cup-to-disc ratio \u22650.8, central corneal thickness <500 \u00b5m or >600 \u00b5m, history of adult asthma or chronic obstructive pulmonary disease, and any recent or chronic medical condition that might obfuscate the subject's study data. The diseases are listed as glaucoma and ocular hypertension, and the icd-10 codes for these diseases are also provided.",
    "The sample is a clinical trial for a drug called hyaluronan, which is being tested on patients who have undergone unilateral ACL reconstruction surgery within six months of injury. The trial is in phase 1/phase 2 and is focused on treating anterior cruciate ligament injury and osteoarthritis. The table includes information on the diseases being treated, the icd-10 codes associated with those diseases, the drugs being used, and the eligibility criteria for participants. The eligibility criteria include age restrictions, willingness to participate in follow-up, and exclusion criteria such as pregnancy, previous allergic reactions to hyaluronan, and history of drug abuse.",
    "The sample is a clinical trial table that contains information about the phases of the trial, diseases being studied, ICD-10 codes of the diseases, drugs being tested, and eligibility criteria for the trial. The phase of the trial is either phase I, phase II, or phase III. The diseases being studied include leukemia, leukemia myeloid, leukemia myelogenous chronic, bcr-abl positive, Philadelphia chromosome, and hematologic diseases. The ICD-10 codes associated with these diseases are also listed. The drug being tested is radotinib. The eligibility criteria for the trial are listed separately for phase I and phase II and include factors such as age, performance status, laboratory values, and medical history. The exclusion criteria are also listed and include factors such as CNS infiltration, impaired cardiac function, severe GI disease, and use of certain medications.",
    "The sample is a clinical trial for patients with relapsed or refractory multiple myeloma. The trial is in phase 1/phase 2 and the patients must meet certain eligibility criteria to be enrolled. The criteria include having measurable levels of myeloma paraprotein in serum or urine, having a certain Eastern Cooperative Oncology Group (ECOG) performance status score, and having a life expectancy of more than 3 months. The trial also has exclusion criteria, such as having a serious medical condition or laboratory abnormality, being pregnant or lactating, or having a history of certain malignancies. The trial involves the use of the drug Revlimid and patients must not have received more than 3 previous anti-myeloma regimens.",
    "The sample is a clinical trial for a drug called ibi-20089/lucentis, which is being tested for the treatment of age-related macular degeneration and choroidal neovascularization. The trial is in phase 1/phase 2 and the table includes information on the diseases being treated, the icd-10 codes associated with those diseases, and the eligibility criteria for participants. The inclusion criteria include being 55 years or older, having a diagnosis of active, subfoveal choroidal neovascular membranes due to age-related macular degeneration, and having visual acuity from 20/25 to 20/400 in the study eye. The exclusion criteria include having received corticosteroids in the past 30 days, having a history of uncontrolled glaucoma, having had ocular surgery in the past 90 days, and having a history of allergy to corticosteroids. The sample also includes other exclusion criteria related to medical and psychological conditions that could jeopardize the safety of the patient or affect the validity of the study results.",
    "The sample is a clinical trial for HIV infection, with a phase 1/phase 2 designation. The trial is testing the drug panobinostat and has eligibility criteria for participants, including being over 18 years old, having documented HIV-1 infection, and having a CD4+ T-cell count above 500/mm3. There are also exclusion criteria, such as having a history of malignancy or transplantation, or having laboratory values outside of normal limits. Women who are pregnant or breastfeeding, or who are of childbearing potential and unwilling or unable to use contraception, are also excluded. The trial requires informed consent and the use of barrier contraception during sexual intercourse for the entire study period.",
    "The sample is a clinical trial with a combination of phase 1 and phase 2. The trial is focused on treating multiple diseases including hermansky-pudlak syndrome (HPS), pulmonary fibrosis, oculocutaneous albinism, platelet storage pool deficiency, and metabolic disease. The trial involves the use of drugs such as losartan, zileuton, n-acetylcysteine, pravastatin, and erythromycin. The eligibility criteria for participants include having a molecular diagnosis of HPS-1 or HPS-4, being between 18-70 years of age, having severe pulmonary fibrosis, and being available to come to the NIH Clinical Center for admission every 3 months. The exclusion criteria include having interstitial lung disease other than HPS, being pregnant or lactating, having a history of ethanol abuse or recreational drug use in the past two years, having chronic use of high-dose steroids, and having any severe medical complications. Women of child-bearing age must have an effective method of birth control. The trial requires informed consent from participants.",
    "The sample is a record from a clinical trial table that includes information about the trial phase, diseases being studied, corresponding ICD-10 codes, drugs being tested, and eligibility criteria for participants. In this particular sample, the trial is in phase 1/phase 2 and is studying the effectiveness of capecitabine, epirubicin, amg 102, cisplatin, and placebo in treating unresectable locally advanced or metastatic gastric or esophagogastric junction adenocarcinoma. The eligibility criteria for participants include having a confirmed diagnosis of the specified cancers, a performance status of 0 or 1, and being at least 18 years old. There are also exclusion criteria, such as having received previous systemic therapy for the specified cancers or having clinically significant upper gastro-intestinal bleeding within 30 days prior to enrollment.",
    "The sample is a clinical trial for patients with prostate cancer in phase 1/phase 2. The trial involves the use of drugs such as docetaxel, prednisone, and vatalanib. The eligibility criteria include having histologically documented adenocarcinoma of the prostate, progressive, systemic (metastatic) disease despite castrate levels of testosterone due to orchiectomy or luteinizing-hormone releasing hormone (LHRH) agonist, and meeting certain criteria for measurable or nonmeasurable disease with PSA levels. Patients must also meet certain patient characteristics such as having a Karnofsky performance status \u2265 60%, life expectancy > 12 weeks, and no pre-existing grade 3 or 4 clinical peripheral neuropathy. Prior concurrent therapy is also taken into consideration.",
    "The sample is a record of a clinical trial that is in phase 1/phase 2. The trial is focused on kidney transplantation and the associated diseases, which are listed as \"kidney transplantation\" in the record. The icd-10 codes for these diseases are also provided. The trial involves the use of two drugs, aeb071 and mycophenolic acid. The eligibility criteria for the trial are listed under \"Inclusion criteria\" and \"Exclusion criteria\". Inclusion criteria include patients of any race who are 18 years or older and have received a kidney transplant from a deceased or living donor. The graft must be functional within 36 hours of transplantation. Exclusion criteria include patients who require medication prohibited by the protocol, patients infected with hepatitis B or C or HIV, patients with a history of cancer, patients with severe systemic infections, and patients with heart diseases associated with an increased risk for arrhythmias. Other protocol-defined inclusion/exclusion criteria may also apply.",
    "The sample is a record from a clinical trial table that includes information about the trial phase, diseases being studied, corresponding ICD-10 codes, drugs being tested, and eligibility criteria for participants. In this particular sample, the trial is in phase 1/phase 2 and is studying metastatic colorectal cancer, colon cancer, colorectal cancer, and rectal cancer. The ICD-10 codes associated with these diseases are also listed. The drugs being tested are placebo, amg 655, modified folfox6, and bevacizumab. The eligibility criteria for participants include having confirmed metastatic adenocarcinoma of the colon or rectum, being at least 18 years old, having adequate hematologic, renal, hepatic, and coagulation function, and not having certain medical conditions or recent surgeries.",
    "The sample is a clinical trial for patients with acute myeloid leukemia (AML) or high risk myelodysplastic disorders (MDS). The trial is in phase 1/phase 2 and the patients must be aged 15 to 60 years, or older than 60 if deemed fit to receive intensive chemotherapy by the treating physician. The patients must not have received any prior chemotherapy (except hydrea) for AML or MDS. The trial involves the drugs idarubicin, sorafenib, and ara-c. The eligibility criteria include a diagnosis of AML or high risk MDS, certain serum biochemical values, ability to take oral medication, and understanding and providing signed informed consent. The exclusion criteria include certain medical conditions, nursing women, women of childbearing potential who are not willing to maintain adequate contraception, and patients with certain cardiac diseases or infections.",
    "The sample is a clinical trial for pancreatic cancer and pancreatic ductal adenocarcinoma patients who have not received prior therapy. The trial is in phase 1/phase 2 and involves the use of bevacizumab, 5-fluorouracil, oxaliplatin, and gemcitabine. The eligibility criteria include having a life expectancy of at least 4 months, being over 18 years old, and having certain blood counts and liver function tests within normal limits. Exclusion criteria include having certain medical conditions or recent surgeries, being pregnant or lactating, and having certain heart or bleeding disorders. The trial aims to evaluate the safety and efficacy of the drugs in treating the disease.",
    "The sample is a clinical trial for patients with advanced, histologically-confirmed solid tumors that are refractory to standard therapy or for which no standard therapy exists. The trial is in phase 1/phase 2 and the treatment being tested is camptothecin (cpt) conjugated to a linear, cyclodextrin-based polymer. The eligibility criteria include having measurable or evaluable disease, not having received prior chemotherapy or radiation for at least 4 weeks prior to the first dose of the study drug, and having acceptable organ and marrow function. Exclusion criteria include being pregnant or nursing, having had chemotherapy or radiotherapy within 4 weeks prior to the first dose of the study drug, and having a history of congestive heart failure requiring medical therapy. The trial also has specific criteria for brain metastases, ECOG performance status, and life expectancy.",
    "The sample is a list of clinical trial phases, diseases, ICD-10 codes, drugs, and eligibility criteria. The phase of the trial can be either phase I, phase II, or phase III. The diseases listed include various types of lymphoma, and the ICD-10 codes are provided for each disease. The drugs listed include vorinostat, ifosfamide, carboplatin, and etoposide. The eligibility criteria include having relapsed or primary refractory lymphoid malignancy, having measurable disease, having a bone marrow aspirate and biopsy within 28 days of enrollment, and having a SWOG performance status of 0, 1, or 2, among other requirements. There are also exclusion criteria, such as being HIV positive, having other prior malignancies, or having a history of impaired cardiac status.",
    "The sample is a clinical trial for non-small cell lung cancer patients in phase 1/phase 2. The trial involves the use of three drugs, tlk286, carboplatin, and paclitaxel. The trial has specific eligibility criteria, including being 18 years or older, having histologically confirmed NSCLC, having stage IV or IIIB disease, having measurable disease by RECIST, having an ECOG status of 0-1, and having adequate liver, renal, and bone marrow function. The trial also has exclusion criteria, such as having prior chemotherapy, immunotherapy, or biologic therapy for metastatic NSCLC, having a history of bone marrow transplantation or stem cell support, and being pregnant or lactating.",
    "The sample is a record from a clinical trial table that includes information about the trial's phase, diseases being studied, icd-10 codes of the diseases, drugs being used, and eligibility criteria for patients. In this particular sample, the trial is in phase 1/phase 2 and is studying liver carcinoma. The icd-10 codes associated with the disease are listed as \"C22.0\", \"D01.5\", and \"C22.7\". The drugs being used in the trial are \"ave1642\", \"sorafenib\", and \"erlotinib\". The eligibility criteria for patients are listed under inclusion and exclusion criteria, which include factors such as organ function, performance status, and prior exposure to certain compounds. The sample also includes a disclaimer that the information provided is not exhaustive and may not include all relevant considerations for a patient's participation in the trial.",
    "The sample is a clinical trial for a combination of drugs, pemetrexed and cisplatin, for the treatment of non-small cell lung cancer and malignant mesothelioma. The trial is divided into two phases, phase 1 and phase 2. The inclusion criteria for phase 1 participants include having a diagnosis of non-squamous NSCLC, malignant mesothelioma, or advanced/metastatic solid tumors, and being deemed appropriate for the combination of pemetrexed and cisplatin. Phase 2 participants must have a histological diagnosis of NSCLC other than predominantly squamous cell histology, be eligible for a first line of palliative treatment with a platinum doublet, and have archived or fresh tumor tissue. Both phase 1 and phase 2 participants must have a performance status \u22641 on the ECOG scale, adequate organ function, and meet other eligibility criteria. Exclusion criteria include serious preexisting medical conditions, CNS metastases, current active infection, known allergy to the drugs, and other factors. The sample also includes detailed eligibility criteria for both phases.",
    "The sample is a record from a clinical trial table that includes information about the phase of the trial, the disease being studied (in this case, metastatic colorectal cancer), the ICD-10 codes associated with the disease, the drugs being tested (pimasertib, placebo, and folfiri), and the eligibility criteria for participants. The eligibility criteria include requirements such as confirmation of K-Ras mutated colon/rectum cancer, evidence of measurable metastatic disease, and exclusion criteria such as bone marrow impairment, renal impairment, and history of CNS metastases. The sample also includes information about exclusion criteria such as pregnancy or nursing, retinal degenerative disease, and legal incapacity.",
    "The sample is a record from a clinical trial table that includes information about the trial's phase, diseases being studied, icd-10 codes of those diseases, drugs being tested, and eligibility criteria for participants. In this particular sample, the trial is in phase 1/phase 2 and is studying psoriasis and psoriasis vulgaris. The icd-10 codes associated with these diseases are listed. The drugs being tested are hat1 topical solution and calcipotriol. The eligibility criteria for participants are also listed, including age range, previous treatments, medical history, and other factors that may affect the course of psoriasis during the study period.",
    "The sample is a clinical trial for patients with non-small cell lung cancer in phases I and II. The trial includes patients with locally advanced stage IIIA or IIIB disease that is considered unresectable and requires radiotherapy. The trial involves the use of three drugs: bortezomib, paclitaxel, and carboplatin. The eligibility criteria include various medical conditions such as performance status, blood count, liver function, and heart disease. Patients who are pregnant or nursing, have uncontrolled infections, or have had prior radiation therapy or systemic chemotherapy for NSCLC are not eligible for the trial. The trial also has contraindications for pregnant or nursing women, men or women of childbearing potential or their sexual partners who are unwilling to employ adequate contraception, and patients with severe underlying diseases.",
    "The sample is a clinical trial for patients with Philadelphia chromosome positive adult precursor acute lymphoblastic leukemia or recurrent adult acute lymphoblastic leukemia. The trial is in phase 1/phase 2 and involves the drugs entinostat and imatinib mesylate. The eligibility criteria include confirmation of BCR-ABL1 in leukemia cells, prior treatment with tyrosine kinase inhibitors, ECOG performance status of 0, 1 or 2, and various laboratory values within normal limits. Patients who have undergone stem cell transplantation are eligible if they meet certain criteria. Female patients of childbearing age must have a negative pregnancy test and agree to use contraception. Patients may not be receiving any other investigational agents and must not have received previous treatment with entinostat or other HDAC inhibitors. Patients with active CNS leukemia or uncontrolled intercurrent illness are excluded from the study. Pregnant women and HIV-positive patients on combination antiretroviral therapy are also ineligible.",
    "The sample is a record of a clinical trial that is in phase 1/phase 2. The trial is focused on the disease systemic sclerosis, which is associated with a list of icd-10 codes. The trial is testing the effectiveness of two drugs, rapamycin and methotrexate, on patients who meet certain eligibility criteria. These criteria include satisfying the American College of Rheumatology classification criteria for systemic sclerosis, having skin thickening proximal to the elbows and/or knees, and having cutaneous involvement for less than 5 years from the onset of the first non-Raynaud's manifestation. The sample also lists exclusion criteria, such as severe intractable malabsorption and chronic debilitation from any underlying disease. Patients who have been off putative disease modifying therapies for one month prior to entry are also excluded from the trial.",
    "The sample is a record from a clinical trial table that includes information about the phase of the trial, diseases being studied, icd-10 codes of the diseases, drugs being used, and eligibility criteria for participants. In this particular sample, the trial is in phase 1/phase 2 and is studying malignant pleural mesothelioma and solid tumors. The icd-10 codes for the diseases are listed as C45.9, C45.0, C45.1, C45.2, and C45.7. The drugs being used are pemetrexed, cisplatin, and cbp501, as well as pemetrexed and cisplatin. The eligibility criteria include having a confirmed diagnosis of the disease, measurable disease according to the modified Response Evaluation Criteria in Solid Tumors, being at least 18 years old, having an ECOG Performance Status of 0-2, and having adequate organ function. There are also exclusion criteria, such as having an ongoing or active infection, previous history of another malignancy within 5 years of study entry, and presence of CNS metastases.",
    "The sample is a record from a clinical trial table that includes information about the phase of the trial, diseases being studied, icd-10 codes of the diseases, drugs being used, and eligibility criteria for participants. In this particular sample, the trial is for acute lymphoblastic leukemia and is in phase 1/phase 2. The drugs being used are bortezomib, dexamethasone, peg-asparaginase, doxorubicin, cytarabine, methotrexate, vincristine, and triple it therapy. The eligibility criteria include age restrictions, diagnosis requirements, performance level, prior therapy, reproductive function, and exclusion criteria such as drug allergies, renal and liver/pancreatic function, cardiac function, and infection.",
    "The sample is a clinical trial with a combination of phase 1 and phase 2. The trial is focused on treating mucositis and head and neck cancer using drugs such as placebo, palifermin, and cisplatin. The trial has eligibility criteria for the participants, including having a newly diagnosed histologically confirmed squamous cell carcinoma and being scheduled to receive adjuvant concurrent chemoradiation treatment within 12 weeks of surgery. The trial also has exclusion criteria, such as having tumors of the lips, paranasal sinuses, salivary glands, or unknown primary tumors, and having a history of pancreatitis or prior radiotherapy or chemotherapy.",
    "The sample is a clinical trial for patients with bladder cancer in phase 1/phase 2. The trial is looking at the effectiveness of paclitaxel, nanoparticle albumin-bound as a treatment for recurrent bladder cancer that is refractory to standard intravesical therapy. The eligibility criteria include having a diagnosis of transitional cell carcinoma of the urinary bladder, being over 18 years old, having a performance status of ECOG 0,1, and having no more than grade 1 peripheral neuropathy. Patients must also have adequate hematologic and hepatic function, and women of childbearing potential must have a negative pregnancy test and use effective contraception. Exclusion criteria include prior systemic docetaxel or paclitaxel therapy, concurrent treatment with any chemotherapeutic agent, and history of neuropathy of any cause.",
    "The sample is a clinical trial for pancreatic cancer patients who are deemed unresectable due to local involvement of vessels or organs. The trial is a combination of phase 1 and phase 2. The trial involves the use of three drugs: oxaliplatin, 5fu, and folfox 6. The eligibility criteria include having a clear clinical diagnosis of localized pancreatic cancer, no prior chemotherapy or abdominal radiation therapy, Eastern Cooperative Oncology Group (ECOG) Performance Status 0-1, clinically measurable or evaluable disease, life expectancy of at least 12 weeks, adequate bone marrow reserve, adequate renal function, adequate biliary function, age over 18 years, signed informed consent, no known allergy to one of the study drugs, and no prior malignancy within the last 5 years. The exclusion criteria include active or uncontrolled infection, presence of metastatic disease, inadequate organ function, pregnancy, serious concomitant systemic disorder, and use of any investigational agent within a month of treatment.",
    "The sample is a record of a clinical trial with a phase 1/phase 2 designation. The trial is focused on squamous cell cancer and includes a list of ICD-10 codes associated with the disease. The trial involves several drugs, including cilengitide, cetuximab, 5-fluorouracil, and cisplatin. The eligibility criteria for the trial include a confirmed diagnosis of SCCHN, at least one measurable lesion, and a Karnofsky performance status of greater than or equal to 70 or an ECOG PS of 0-1 at trial entry. Exclusion criteria include prior systemic chemotherapy, surgery or irradiation within 4 weeks before trial entry, nasopharyngeal carcinoma, documented or symptomatic brain or leptomeningeal metastasis, and previous treatment with epidermal growth factor receptor (EGFR) targeting therapy or signal transduction inhibitors.",
    "The sample is a clinical trial with a combination of phase 1 and phase 2. The trial is focused on treating metastatic or inoperable breast cancer, colon cancer, or melanoma using a drug called pd-0325901. The trial requires patients to meet certain eligibility criteria, such as being over 18 years old, having adequate renal, liver, and bone marrow function, and having a measurable lesion that has not been irradiated. Patients must also not have any ongoing radiation therapy or radio-cytotoxic therapy within the prior 4 weeks, no immunotherapy, biologic therapy, hormonal, or molecular targeted therapy within the prior 2 weeks, and no untreated brain metastases. The trial also has exclusion criteria, such as no parathyroid disorder or history of malignancy associated hypercalcemia, no concurrent serious infection or life-threatening illness unrelated to the tumor, and no history of any cancer other than the present condition unless in complete remission and off all therapy for that disease for a minimum of 3 years.",
    "The sample is a clinical trial for non-small cell lung cancer patients in phase 1/phase 2. The trial is testing the effectiveness of carboplatin, paclitaxel, and medi-575 drugs. The trial has specific eligibility criteria, including having inoperable Stage IIIB or Stage IV non-small cell lung cancer, an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1, and a life expectancy of at least 3 months. Participants must also have adequate hematologic and organ function and be suitable candidates for therapy with carboplatin/paclitaxel. The trial has exclusion criteria, including concurrent enrollment in another clinical study, previous monoclonal antibody (mAb) treatment specifically directed against platelet-derived growth factor (PDGF) or PDGF receptors, and history of serious allergy or reaction to any component of the MEDI-575 formulation. Participants must also not have any physical, social, or psychiatric condition which would prevent effective cooperation or participation in the study.",
    "The sample is a record of a clinical trial with a phase 1/phase 2 designation. The trial is focused on treating metastatic breast cancer using a combination of drugs including ct-p6, herceptin, and paclitaxel. The trial has eligibility criteria for inclusion and exclusion. Inclusion criteria include being a female with Her 2 over-expression and ECOG 0 or 1. Exclusion criteria include having current clinical or radiographic evidence of CNS metastases, current known infection, or being a pregnant or nursing mother. The icd-10 codes associated with the disease are also listed.",
    "The sample is a clinical trial for patients with head and neck cancer who have not responded to previous treatment. The trial is in phase 1/phase 2 and involves the use of three drugs: carboplatin, cetuximab, and rad001. The eligibility criteria include having measurable disease, being diagnosed with squamous cell carcinoma of the head and neck, and having a performance status of 0-2. Patients must also have adequate bone marrow, liver, and renal function, and a life expectancy of at least 4 months. Exclusion criteria include having uncontrolled brain or leptomeningeal metastases, receiving anticancer therapies within 4 weeks of the start of the study, and having a known hypersensitivity to the drugs being used. Patients must also not have any severe or uncontrolled medical conditions that could affect their participation in the study.",
    "The sample is a clinical trial for patients with locally advanced, inoperable or metastatic pancreatic adenocarcinoma. The trial is in phase 1/phase 2 and the drug being tested is a combination of bay86-9766 and gemcitabine. The eligibility criteria include having at least one measurable lesion, a certain performance status, and normal cardiac function. Exclusion criteria include a history of cardiac disease, active infections, and previous systemic therapy for pancreatic cancer or other malignancies. The sample also includes a list of diseases (pancreatic neoplasms), their corresponding ICD-10 codes, and the eligibility criteria for the trial.",
    "The sample is a clinical trial for Friedreich's Ataxia, a genetic disease affecting the nervous system. The trial is in Phase 1/Phase 2 and involves testing the effectiveness of the drug deferiprone compared to a placebo. The trial has specific inclusion and exclusion criteria, including a confirmed diagnosis of FRDA, a FARS score between 20 and 85, and no exposure to certain antioxidants for at least one month prior to the study. The trial also excludes individuals with iron deficiency, abnormal ALT levels, or a history of malignancy or drug abuse. Participants must provide written informed consent and adhere to study restrictions and appointments.",
    "The sample is a record of a clinical trial with a phase 1/phase 2 designation. The trial is focused on lung cancer and the icd-10 codes associated with it. The drug being tested is called ipi-504. The eligibility criteria for the trial include having a confirmed diagnosis of Stage IIIb or Stage IV NSCLC, having measurable disease by RECIST criteria, and not having received treatment for NSCLC with any approved or investigational product within a certain timeframe. The exclusion criteria include inadequate hematologic, renal, or hepatic function, and previous treatment with 17-AAG, DMAG, or other known Hsp90 inhibitor.",
    "The sample is a clinical trial for patients with HER-2-overexpressing breast cancer and radiographic evidence of metastatic disease. The trial is in phase 1/phase 2 and involves the drugs trastuzumab and rad001. The eligibility criteria include having a history of trastuzumab resistance, a performance status of 0-2, and meeting certain medical requirements such as having a certain level of blood counts and not having uncontrolled illnesses. Patients must also have measurable disease and cannot be receiving any other investigational agents. The trial has exclusion criteria such as having uncontrolled intercurrent illness, prior treatment with investigational drugs, and a history of noncompliance to medical regimens. Patients must sign an informed consent document and must be willing and able to comply with the protocol.",
    "The sample is a record from a clinical trial table that includes information about the trial phase, diseases being studied, ICD-10 codes associated with the diseases, drugs being tested, and eligibility criteria for participants. In this particular sample, the trial is in phase 1/phase 2 and is focused on advanced metastatic gastric cancer and recurrent gastric cancer. The ICD-10 codes associated with these diseases are listed. The drug being tested is paclitaxel. The eligibility criteria for participants include having a proper bone marrow, kidney, and liver function, and not having any remarkable dysfunction of the heart and lungs. Patients with blood tumors, uncontrolled infectious diseases, neurologic disorders, metastasis to CNS or ileus, or who have received bone marrow transplant are excluded from the trial. Patients with a medical history of atrial or ventricular arrhythmia, congestive heart failure, or who have received medical treatment for myocardial infarction within 6 months are also excluded.",
    "The sample is a record from a clinical trial table that includes information about the trial's phase, diseases being studied, associated ICD-10 codes, drugs being tested, and eligibility criteria for participants. In this particular sample, the trial is in phase 1/phase 2 and is focused on cardiovascular diseases, dilated cardiomyopathy, heart diseases, and congestive heart failure. The trial is testing the effectiveness of allopurinol and dobutamine as treatments. The eligibility criteria for participants include having a diagnosis of idiopathic cardiomyopathy, being in NYHA Class I-II heart failure, having stable heart failure medication for at least 1 month prior to study entry, and being able to lie flat for 45 minutes. There are also exclusion criteria, such as a history of poorly controlled hypertension, acute gout, or a contraindication to MRI.",
    "The sample is a record from a clinical trial table that includes information about the phase of the trial, diseases being studied, icd-10 codes of the diseases, drugs being used, and eligibility criteria for participants. In this particular sample, the trial is in phase 1/phase 2 and is studying prostate cancer. The icd-10 codes associated with the disease are listed, as well as the drugs being used in the trial (docetaxel and gemcitabine). The eligibility criteria for participants are also listed, including requirements such as a certain stage of the disease, PSA levels, and satisfactory liver and kidney function. The sample also includes exclusion criteria, such as previous treatment with certain medications or radiation therapy.",
    "The sample is a clinical trial for a drug called rituximab (anti-cd20) for the treatment of Sjogren's syndrome. The trial is in phase 1/phase 2 and the eligibility criteria include having stimulated whole saliva secretion of at least 0.15 ml/min, being over 18 years old, having primary Sjogren's syndrome according to the revised European-U.S. criteria, and having positive autoantibodies (IgM-Rf > 10 and SS-A and/or SS-B). Exclusion criteria include having any other connective tissue disease, having received certain treatments within a certain time frame, having certain abnormal lab values, and having certain medical conditions that would make participation in the study too risky. Participants must also use a reliable method of contraception during the study and provide written informed consent.",
    "The sample is a clinical trial with a combination of phase 1 and phase 2. The trial is focused on treating prostate cancer, including recurrent, stage I, III, and IV prostate cancer. The trial involves the use of three drugs: sunitinib malate, docetaxel, and prednisone. The eligibility criteria for the trial include having a histological diagnosis of adenocarcinoma of the prostate, being at least 18 years old, having metastatic prostate cancer that is unresponsive or refractory to hormone therapy, and having adequate hepatic and renal function. The trial also has exclusion criteria, such as not having received chemotherapy or biologic therapy within 28 days prior to the start of therapy, not having ongoing problems with bowel obstruction or short bowel syndrome, and not having a known severe and/or uncontrolled concurrent medical disease. The trial requires informed consent from all participants.",
    "The sample is a clinical trial for Crohn's disease, with a phase 1/phase 2 designation. The trial includes patients with colonic or ileocolonic CD who have been diagnosed for at least 3 months and have active CD, defined as a Crohn's Disease Activity Index (CDAI) of greater than 200 but less than 320 at the time of entry into the study. Patients must be over 18 years old and receiving stable doses of certain medications for a specified period of time prior to enrollment. The trial has both inclusion and exclusion criteria, with patients with only small bowel CD, fistulizing CD, or gastroduodenal CD without colonic involvement being excluded, as well as patients with known ulcerative colitis or who are expected to require surgery within 30 days for complications of CD. Patients with severe cardiac, pulmonary, or renal disease, a history of malignancy other than resected basal cell carcinoma of the skin, or who have participated in another clinical research study in the past 8 weeks are also excluded. Pregnant patients are not eligible for the trial.",
    "The sample is a clinical trial for patients with non-small cell lung cancer in phase 1/phase 2. The trial includes patients who are 70 years or older with either stage IIIB disease with malignant pleural effusion or stage IV disease. Patients must have measurable disease and an Eastern Cooperative Oncology Group (ECOG) performance status of either 0 or 1. Patients must also meet certain criteria for renal, hepatic, and bone marrow function, and must be able to take dexamethasone, folic acid, and vitamin B-12 supplementation. Patients must not have certain exclusion criteria, such as lung carcinoma of squamous cell histology or any histology in close proximity to a major vessel, with or without cavitation, or a history of hemoptysis, hematemesis, coagulopathy, or thrombosis. The trial requires patients to sign informed consent and comply with study and/or follow-up procedures.",
    "The sample is a clinical trial for patients with chronic lymphocytic leukemia or lymphoplasmocytic lymphoma. The trial is in phase 1/phase 2 and involves a combination of drugs including busulfan, cyclophosphamide, cyclosporine, fludarabine phosphate, methotrexate, and mycophenolate mofetil. The eligibility criteria include having poor prognostic features and low probability of successful autografting, as well as meeting certain disease characteristics such as having a clonal CDR III rearrangement detected by polymerase chain reaction. Patients must also meet certain patient characteristics such as having normal cardiac function and no serious localized or systemic infections. Prior concurrent therapy is not specified.",
    "The sample is a record of a clinical trial with a phase 1/phase 2 designation. The trial is focused on prostate cancer, specifically castration-resistant prostate cancer (CRPC). The trial is testing the drug MDV3100. The eligibility criteria for the trial include having confirmed adenocarcinoma of the prostate, ongoing androgen deprivation therapy, and progressive disease after prior androgen deprivation therapy. The exclusion criteria include having metastases in the brain, a history of another malignancy within the previous 5 years, and evidence of serious drug hypersensitivity.",
    "The sample is a clinical trial for the treatment of acute myeloid leukemia. The trial is in phase 1/phase 2 and involves the use of voreloxin injection and cytarabine. The eligibility criteria for the trial include having relapsed or refractory AML, being treated with one to three induction/reinduction AML regimens, having at least 10% blasts by BM biopsy or aspirate, and having an ECOG Performance Status score of 0 or 1. There are also several exclusion criteria, such as having a history of myocardial infarction or cerebrovascular accident/transient ischemic attack within the 3 months before treatment with vosaroxin, and having any other medical, psychological, or social condition that contraindicates participation in the clinical study. Women who are pregnant or breastfeeding, or of childbearing potential, are also excluded from the trial.",
    "The sample is a clinical trial for the treatment of b-cell chronic lymphocytic leukemia and small lymphocytic lymphoma. The trial is in phase 1/phase 2 and involves the drug pci-32765. The eligibility criteria include age requirements, confirmed diagnosis of the disease, and specific response to previous treatments. Exclusion criteria include prior malignancy, recent therapy, and certain medical conditions. Participants must be willing and able to participate in all required evaluations and procedures.",
    "The sample is a clinical trial with a phase 1/phase 2 design, focused on patients with metastatic infiltrating carcinoma of the breast. The trial aims to test the efficacy of a combination of drugs, including cyclophosphamide, doxorubicin hydrochloride, fludarabine phosphate, paclitaxel, and mesna. The trial also includes eligibility criteria, such as a Karnofsky performance status of greater than or equal to 70%, normal urinalysis, and a corrected carbon monoxide diffusing capacity (DLCO) greater than 50%. The trial excludes patients with autoimmune diseases, active inflammatory bowel disease, clinically significant cardiomyopathy, and brain metastases, among other conditions. The trial also includes exclusion criteria specific to vaccinia administration, such as a history of seizures, encephalitis, or multiple sclerosis, and allergy or complications with past vaccinia vaccination.",
    "The sample is a clinical trial for breast cancer patients who have Her-2 positive and ER-negative or ER-low breast cancer that has not spread to other parts of the body. The trial is in phase 1/phase 2 and the drug being tested is trastuzumab (herceptin\u00ae). The eligibility criteria include having had a core biopsy or incisional biopsy of the breast cancer but not yet having definitive breast surgery, not having a BRCA mutation found on genetic testing, and not having received any treatment for their breast cancer, including chemotherapy, hormonal therapy, or trastuzumab.",
    "The sample is a record from a clinical trial table that includes information about the trial's phase, diseases being studied, icd-10 codes associated with those diseases, drugs being used, and eligibility criteria for participants. In this particular sample, the trial is in phase 1/phase 2 and is focused on infertility in females. The icd-10 codes associated with the disease include N97.9, N97.0, N97.1, N97.2, N97.8, and Z31.81. The drugs being used in the trial are g-csf and saline. The eligibility criteria for participants include having endometrial growth of less than 7 mm and being unresponsive to standard treatment for invitro fertilization and embryo transfer. Exclusion criteria include having sickle cell disease, renal insufficiency, upper respiratory infection or pneumonia, chronic neutropenia, or a known past or present malignancy.",
    "The sample is a clinical trial with a combination of two drugs, ji-101 and everolimus, for patients with advanced solid tumors that are refractory to standard therapy or for whom no standard therapy is available. The trial is in phase 1/phase 2 and includes patients with various types of cancer, including neuroendocrine, ovarian, and colon cancer. The eligibility criteria include being at least 18 years old, having at least one measurable tumor, and having normal organ and marrow function. Exclusion criteria include having a history of drug or alcohol abuse within the past two years, being pregnant or breastfeeding, and having a history of significant retinopathy or any progressive eye disease that could lead to severe loss of visual acuity or visual field loss during the study period.",
    "The sample is a record from a clinical trial database. It includes information about the phase of the trial, which is a combination of phase 1 and phase 2. The trial is focused on the treatment of chronic hepatitis C, and the icd-10 codes associated with the disease are listed. The trial involves two drugs, bms-791325 and placebo. The eligibility criteria for the trial are also listed, including requirements for HCV genotype, viral load, and BMI, as well as exclusion criteria such as co-infection with HIV or HBV.",
    "The sample is a record from a clinical trial table that includes information about the phase of the trial, the disease being studied (in this case, prostate cancer), the ICD-10 codes associated with the disease, the drug being tested (he3235), and the eligibility criteria for participants. The eligibility criteria include requirements such as age, disease progression, and performance status, as well as exclusion criteria such as active infections or significant cardiovascular, hepatic, respiratory, or renal abnormalities. The sample also notes that additional criteria may apply to expansion cohorts.",
    "The sample is a table that contains information about a clinical trial for the treatment of renal cell carcinoma. The table includes the phase of the trial (phase 1/phase 2), a list of diseases (in this case, only renal cell carcinoma), a list of ICD-10 codes for the disease, a list of drugs being tested (a combination of temsirolimus and sunitinib), and eligibility criteria for the trial. The eligibility criteria include inclusion and exclusion criteria for both the dose escalation phase and the expanded cohort phase of the trial. The criteria specify requirements for the subject's medical history, prior treatments, and measurable lesions.",
    "The sample is a record of a clinical trial with a phase 1/phase 2 designation. The trial is focused on treating patients with intracranial glioblastoma multiforme or gliosarcoma using the drugs enzastaurin and temozolomide. The eligibility criteria for the trial include having a confirmed diagnosis of the specified diseases, having undergone biopsy or resection no more than 5 weeks prior to treatment, and having adequate organ function demonstrated by lab tests. The exclusion criteria include being unable to swallow tablets, being unable to discontinue use of certain antiepileptic drugs, having an active infection, having a significant medical illness that cannot be controlled with therapy, or concurrent therapy with an anticoagulant.",
    "The sample is a clinical trial with a combination of vincristine sulfate liposome injection and rituximab for patients with non-Hodgkin's lymphoma, including diffuse large B-cell lymphoma and mantle cell lymphoma. The trial is in phase 1/phase 2 and includes patients who have had one or more prior chemotherapy regimens and measurable disease in at least one site. The eligibility criteria include confirmation of CD20 expression on lymphoma cells, Eastern Cooperative Oncology Group (ECOG) \u22642, and total bilirubin and serum creatinine \u22642 times the ULN. Exclusion criteria include previous malignancies with less than a 5-year complete remission interval, history of or active CNS-lymphoma, and allergy to vincristine or other vinca alkaloids.",
    "The sample is a clinical trial for patients with relapsed CD20-positive B-cell non-Hodgkin's lymphoma. The trial is in phase 1/phase 2 and involves a list of drugs including y zevalin, in zevalin, rituxan, bcnu, vp -16, ara-c, melphalan, and g-csf. The eligibility criteria include being chemosensitive, having no prior anti-cancer therapy within three weeks, and having acceptable hematologic status. Patients must also have a prestudy performance status of 0, 1, or 2 according to the World Health Organization and be between the ages of 18 and 65. Exclusion criteria include impaired bone marrow reserve, prior radioimmunotherapy, and presence of central nervous system lymphoma.",
    "The sample is a clinical trial for patients with melanoma that involves treatment with Normothermic Isolated Limb Infusion (ILI) of melphalan. The trial is in phase 1/phase 2 and the disease being studied is neoplasms. The icd-10 codes associated with the disease are C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, and C17.2. The drugs being used in the trial are ADH-1 and melphalan. The eligibility criteria for the trial include signed written informed consent, measurable disease, and adequate performance status and organ function. Exclusion criteria include a history of tumors that have shown clinically significant evidence of active bleeding within 12 weeks before study entry and uncontrolled congestive heart failure, coronary artery disease, or life-threatening arrhythmias.",
    "The sample is a record from a clinical trial table that includes information about the trial phase, diseases being studied, corresponding ICD-10 codes, drugs being tested, and eligibility criteria. In this particular sample, the trial is in phase 1/phase 2 and is focused on chronic myelogenous leukemia and Philadelphia chromosome positive acute lymphoblastic leukemia. The drug being tested is dasatinib. The eligibility criteria include subjects who completed a previous study and are deemed suitable for continuation, as well as exclusion criteria such as pregnancy or breastfeeding, unwillingness to undergo transplantation, and previous intolerance to dasatinib.",
    "The sample is a clinical trial for patients with previously untreated aggressive non-Hodgkin's Lymphoma. The trial is in phase 1/phase 2 and the diseases being studied are lymphoma and non-Hodgkin's lymphoma. The icd-10 codes associated with these diseases are listed as [\"S33.110S\", \"S33.111S\", \"S33.120S\", \"S33.121S\", \"S33.130S\", \"S33.131S\", \"S33.140S\"]. The drugs being tested are cyclophosphamide, doxorubicin, vincristine, and prednisone. The eligibility criteria for the trial include having measurable or evaluable disease, being 18 years or older, and having no evidence of grade 3 or more neurosensory or neuromotor dysfunction. Patients with inadequate bone marrow and organ function, CNS involvement by Lymphoma, uncontrolled intercurrent disease, active infection or fever, and those who are pregnant or breastfeeding are excluded from the trial.",
    "The sample is a clinical trial for breast cancer patients in phase 1/phase 2. The trial is testing the effectiveness of two drugs, ptk787 and trastuzumab, on patients with measurable, unresectable, locally recurrent, or metastatic breast cancer. Patients must have HER2 gene amplification by FISH and cannot have received prior cytotoxic chemotherapy or trastuzumab for locally recurrent or metastatic disease. The trial has specific inclusion and exclusion criteria, including limitations on the number of metastatic sites and no history of CNS disease or other forms of cancer therapy within 21 days prior to being registered for protocol therapy. Patients must also meet certain health requirements, such as having controlled blood pressure and no impairment of gastrointestinal function that may significantly alter the absorption of PTK787.",
    "The sample is a clinical trial for patients with metastatic or locally recurrent adenocarcinoma of the colon or rectum that is not amenable to potentially curative surgical resection. The trial is in phase 1/phase 2 and involves the drugs zd1839 and oxaliplatin. The eligibility criteria include having failed prior therapy with fluorouracil, leucovorin calcium, and irinotecan, having at least one measurable lesion, and meeting certain patient characteristics such as being at least 18 years old and having a life expectancy of at least 3 months. The trial also has various exclusion criteria, such as having peripheral neuropathy greater than grade 1 or other concurrent uncontrolled illness that would preclude study. The sample includes detailed information on the disease characteristics, patient characteristics, and prior concurrent therapy.",
    "The sample is a clinical trial for neonatal seizures, with a phase 1/phase 2 designation. The trial is looking at the effectiveness of the drug bumetanide in treating seizures in newborns. The inclusion criteria for the trial include a gestational age of 37-43 weeks, an APGAR score of less than 5 at 5 minutes, and other clinical indicators of seizures. The trial also requires written informed consent from the parent or guardian and EEG monitoring within the first 48 hours of birth. Exclusion criteria include suspected or confirmed brain malformations, inborn errors of metabolism, genetic syndromes, or major congenital malformations, as well as other medical conditions such as anuria/renal failure or severe electrolyte depletion.",
    "The sample is a phase 2 clinical trial for patients with estrogen receptor-positive breast cancer, recurrent breast cancer, stage iiib breast cancer, stage iiic breast cancer, or stage iv breast cancer. The trial involves the drugs fulvestrant and tipifarnib. The eligibility criteria include having postmenopausal ER- and/or PR-positive disease, measurable disease, and an ECOG performance status of 0-2. Patients must also have leukocytes, absolute neutrophil count, and platelets within certain ranges, and must not have had certain prior treatments or have certain medical conditions. The trial has exclusion criteria as well.",
    "The sample is a phase 2 trial for the treatment of hepatitis C infection. The trial includes patients with quantifiable serum levels of HCV-specific RNA in excess of 100,000 IU/mL, chronic HCV status, HCV genotype 1 infection and IL28B genotype of C/T or T/T, and liver biopsy results within 3 years prior to screening indicating the absence of cirrhosis. The trial also includes patients with a body mass index (BMI) between 18 and 38 kg/m2 and laboratory variables within acceptable ranges. Patients of childbearing potential must agree to use 2 forms of contraception from Screening until 24 weeks after completion of treatment with RBV. The trial excludes patients with a history of clinically significant gastrointestinal, renal, hepatic, neurologic, hematologic, endocrine, oncologic, pulmonary, immunologic, psychiatric, or cardiovascular disease, females who are pregnant or breastfeeding, males with partners who are pregnant or are planning to become pregnant, HCV genotype other than genotype 1 and an IL28B genotype of C/C, seropositive for HIV-1 or HIV-2 or hepatitis B virus (HBV) surface antigen (HBsAg), use of any investigational agent within 3 months prior to dosing, evidence of cirrhosis on a previous liver biopsy, evidence of decompensated liver disease, recipient of an organ transplant, evidence of hepatocellular carcinoma, evidence of ongoing alcohol or substance abuse, poorly-controlled diabetes mellitus, congestive heart failure or unstable cardiopulmonary condition, renal disease, or hemoglobinopathy (sickle cell anemia or thalassemia), history of seizure disorder, history of severe psychiatric illness, including severe depression, history of suicidal ideation, suicidal attempts, related hospitalizations, bipolar disorder, or psychosis requiring medication, concurrent medical condition or laboratory abnormality that would constitute a contra-indication for interferon use, history of unstable thyroid disease that would preclude administration of interferon-based therapy, medical condition that requires use of systemic corticosteroids, received warfarin or other anticoagulants during the 21 days immediately prior to Screening, or is expected to require warfarin or other anticoagulants during the study, one or more additional known primary or secondary causes of liver disease, other than hepatitis C, any other concurrent medical condition likely to preclude compliance with the schedule of evaluations, or likely to confound the efficacy or safety observations, 12-lead ECG showing the following: Corrected QTc interval \u2265 450 msec (Bazett's correction), QRS > 120 msec, clinically significant abnormalities, severe retinopathy or other significant ophthalmological disorder, use of any herbal supplements within 28 days prior to dosing, and the use of CYP3A inducers or inhibitors for at least 2 weeks prior to initiation of treatment through Week 6.",
    "The sample is a phase 2 clinical trial for patients with multiple myeloma and lymphoma who are candidates for high dose chemotherapy and autologous hematopoietic stem cell transplant. The trial involves the use of the drugs palonosetron, aprepitant, and dexamethasone to manage nausea and vomiting associated with the treatment. The eligibility criteria include factors such as age, performance status, bone marrow function, renal function, pulmonary function, hepatic function, and informed consent. Exclusion criteria include factors such as active infections, previous malignancies, uncontrolled medical problems, and hypersensitivity to certain medications. The trial also involves completing an anti-emesis assessment questionnaire.",
    "The sample is a phase 2 clinical trial for the treatment of multiple myeloma. The trial includes patients who have relapsed or refractory myeloma and have previously been treated with lenalidomide and thalidomide as single agents or in combination with dexamethasone, but not in combination with each other. The eligibility criteria include measurable disease, certain laboratory parameters, and a Karnofsky performance status of at least 70%. Patients must also be registered into the mandatory RevAssist\u00ae and S.T.E.P.S.\u00ae programs and meet certain requirements for birth control. Exclusion criteria include certain medical problems, prior history of other malignancies, and known hypersensitivity to the study drugs.",
    "This sample is a phase 2 clinical trial for the treatment of multiple myeloma. The trial is testing the drug lbh589 and the eligibility criteria includes being an adult over 18 years old, having a diagnosis of symptomatic multiple myeloma, having received at least two prior lines of therapy and being refractory to the most recent line of therapy, having previously been treated with bortezomib or lenalidomide, having an Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) of 2 or less, and having adequate laboratory values. The exclusion criteria includes prior therapy with a histone deacetylase inhibitor (HDAC), impaired cardiac function or clinically significant cardiac diseases, impairment of gastrointestinal function (GI) function or GI disease that may significantly alter the absorption of LBH589, unresolved diarrhea > Common Terminology Criteria for Adverse Events (CTCAE) grade 1, concomitant use of certain medications, having received chemotherapy, radiation therapy or any investigational drugs, bortezomib or other immunomodulatory therapy or immunotherapy \u2264 3 weeks prior to starting study drug or who have not recovered from side effects of such therapy, having received steroids \u2264 2 weeks prior to starting study treatment or who have not recovered from side effects of such therapy, having received high-dose corticosteroids as the only component of their most recent line of therapy, having undergone major surgery \u2264 4 weeks prior to starting study drug or who have not recovered from side effects of such therapy, and being pregnant or breast feeding or women of childbearing potential not using an effective method of birth control. Other protocol-defined inclusion/exclusion criteria may also apply.",
    "The sample is a phase 2 clinical trial for patients with various types of squamous cell carcinoma of the head and neck, including recurrent, metastatic, and stage III/IV disease. The trial is testing the drug saracatinib as a potential treatment option. Patients must meet certain eligibility criteria, such as having measurable disease, a Karnofsky performance status of at least 60%, and certain blood counts within normal limits. Patients with brain metastases, certain allergies, or other medical conditions may be excluded from the trial. The trial also prohibits the use of certain drugs during the study period.",
    "The sample is a phase 2 clinical trial for patients with renal transplant. The trial is testing the effectiveness of two drugs, telmisartan and losartan, in reducing blood pressure in patients with stable renal function and no acute rejection episodes in the last six months. The trial has specific inclusion and exclusion criteria, including age over 18, stable immunosuppressive therapy, and legal capacity. Patients with certain medical conditions, such as heart failure or severe hepatic disease, are excluded from the trial. The trial also excludes pregnant women or women of child-bearing potential without following a scientifically accepted form of contraception, and patients with specific contraindications or history of hypersensitivity to the study drugs.",
    "The sample is for a phase 2 trial and includes a list of diseases such as postmenopause, hypertension, and pre-hypertension, along with their corresponding ICD-10 codes. The trial also involves the use of drugs such as drospirenone/17\u00df-estradiol and medroxyprogesterone acetate/conjugated equine. The eligibility criteria for the trial includes postmenopausal women between the ages of 45-65 with prehypertension, while the exclusion criteria includes those who have undergone hormone therapy with estrogen/progestin.",
    "The sample is a phase 2 clinical trial for Hodgkin's disease. The trial is testing the effectiveness of the drug combination of g-csf plus plerixafor. The eligibility criteria for the trial include having a diagnosis of HD eligible for autologous transplantation, having no more than 3 prior regimens of chemotherapy, and having recovered from all acute toxic effects of prior chemotherapy. Other criteria include having a certain level of white blood cells, polymorphonuclear cells, and platelets, as well as meeting certain requirements for serum creatinine, SGOT, SGPT, and total bilirubin levels. Patients must also have a certain level of left ventricle ejection fraction and forced expiratory volume of the lung. Exclusion criteria include having a co-morbid condition that puts the patient at high risk for treatment complications, having failed previous collections, and having a residual acute medical condition resulting from prior chemotherapy. Patients who previously received experimental therapy within 4 weeks of enrolling in this study or who are currently enrolled in another experimental study during the mobilization period are also excluded.",
    "The sample is a phase 2 clinical trial for the treatment of B-cell chronic lymphocytic leukemia and prolymphocytic leukemia. The trial involves the drug alvocidib and has eligibility criteria that include confirmed diagnosis of the disease, requiring therapy, having received prior chemotherapy, and meeting certain health criteria such as performance status and normal levels of bilirubin and creatinine. The trial excludes patients with other concurrent chemotherapy, chronic corticosteroids, or hormonal therapy.",
    "The sample is a record of a clinical trial with a phase 2 designation. The trial is focused on the disease of irritable colon, which is identified by a list of ICD-10 codes. The drug being tested is called gw876008. The eligibility criteria for the trial includes having irritable bowel syndrome, but excludes subjects who have taken any medication for the treatment of irritable bowel syndrome within 6 months prior to the start of the study. The criteria are divided into inclusion and exclusion criteria.",
    "The sample is a record of a clinical trial with a phase 2 designation. The trial is focused on the treatment of multiple myeloma, a type of cancer. The trial involves the use of two drugs, bortezomib and pegylated liposomal doxorubicin. The eligibility criteria for the trial include a confirmed diagnosis of multiple myeloma, prior treatment with bortezomib, and a sustained reduction in M-Protein. The trial also has exclusion criteria, such as patients with a history of allergic reactions to certain compounds or those with poorly controlled medical conditions.",
    "The sample is a phase 2 clinical trial for men aged 18 or older with hormone refractory prostate cancer. The trial requires patients to have evidence of disease progression despite adequate anti-androgen therapy and have received either one or two previous chemotherapy regimens, one of which must have included docetaxel. Patients must also have an ECOG performance status of 0-2 and adequate bone marrow, renal, and hepatic function. The trial involves the drug vinflunine and has a list of inclusion and exclusion criteria that patients must meet. Patients must be able to comprehend the nature of the study and provide written informed consent.",
    "The sample is a phase 2 clinical trial for osteoarthritis of the knee. The trial involves the drugs gefapixant and a sugar pill. The eligibility criteria include having clinical and radiographic evidence of chronic knee osteoarthritis, an average NPRS score of >=5 and <=9 over a 4-7 day washout period of previous osteoarthritis medications, being ambulatory, and providing written informed consent. Women of childbearing potential must not be pregnant during the study and must use two forms of birth control, while men and their female partners must also use two forms of birth control.",
    "The sample is a phase 2 clinical trial for the treatment of painful bladder syndrome and related symptoms. The trial is focused on participants who are 18 years or older and have been experiencing bladder pain, frequency, and urgency for at least 6 months. The trial involves the use of two drugs, dimethyl sulfoxide and ic cocktail, and requires participants to meet certain eligibility criteria, such as having a score of 8 or greater on the painful bladder syndrome symptom index and not having a urinary tract infection. The trial also has a list of exclusion criteria, such as a history of certain medical conditions or drug use, and requires participants to use a medically acceptable method of birth control throughout the study period.",
    "The sample is a clinical trial for HIV-infected individuals with lipoatrophy in at least two areas of their body. The trial is in phase 2/phase 3 and involves the drugs NucleomaxX and NucleomaxX placebo. The eligibility criteria include having a stable ART regimen containing zidovudine or stavudine for at least 12 consecutive weeks prior to study entry, a viral load of 5,000 copies/ml or less within 45 days prior to study entry, and not planning to add or change current vitamin supplementation. Exclusion criteria include having a life expectancy of less than 12 months, currently enrolled in or planning to enroll in an ART interruption study, and having certain abnormal laboratory values. Participants must also be willing to use acceptable forms of contraception.",
    "This sample is a phase 2 clinical trial for head and neck cancer. The trial includes patients who have undergone surgical resection and are eligible for post-operative radiation and cisplatin. Patients must have a tumoral biopsy stored in liquid nitrogen at the time of surgical resection. Patients receiving post-operative radiation associated with cisplatin, at least 60 Gy on tumor bed and/or cervical area, are included. Patients with small tumors located in the larynx are excluded. Patients with a previous history of cancer, except for skin basal cell carcinoma, are also excluded.",
    "The sample is a phase 2 clinical trial for patients with metastatic breast cancer, either HER2-positive or -negative. The trial is testing the effectiveness of sorafenib tosylate as a first- or second-line chemotherapy. The eligibility criteria include having measurable disease, having previously been treated with anthracycline- and/or taxane-containing regimens, and having no known brain metastases. Patients must also meet various health requirements, such as having normal blood counts and liver function, and not having any other uncontrolled illnesses. Additionally, patients must not be pregnant or nursing, and fertile patients must use effective contraception. The trial excludes patients with certain medical conditions or who are taking certain medications.",
    "The sample is a phase 2 clinical trial for patients with recurrent or persistent ovarian epithelial or primary peritoneal cancer. The trial requires patients to have received one prior platinum-based chemotherapy regimen for primary disease and have platinum-resistant or refractory disease. The trial also has eligibility criteria for patient characteristics such as age, performance status, and hematopoietic, hepatic, renal, and other health conditions. The trial involves the use of the drug pemetrexed disodium and has restrictions on prior and concurrent therapies. The schema definition of the table includes columns for phase, diseases, icd-10 codes, drugs, and eligibility criteria.",
    "The sample is a phase 2 clinical trial for patients with metastatic or advanced stage breast cancer. The trial is testing the drug STA-9090. The eligibility criteria include being at least 18 years old, having a confirmed diagnosis of breast cancer, having received prior treatment with at least one and no more than three lines of biologic and/or chemotherapy for metastatic breast cancer (excluding hormonal therapy), having measurable disease by RECIST 1.1, and having adequate hematologic, hepatic, and renal function. Patients with central nervous system metastases are permitted if treated and radiographically and clinically stable for at least 4 weeks prior to first dose of STA-9090. The exclusion criteria include having surgery, radiotherapy, or lesion ablative procedure to the only area of measurable disease, major surgery within 4 weeks prior to first dose of STA-9090, and poor peripheral venous access for study drug administration. Women who are pregnant or lactating are also excluded.",
    "The sample is a phase 2 trial for the treatment of diabetes mellitus and painful diabetic neuropathy. The trial involves the drug \"eaa-090\" and includes a list of diseases and their corresponding ICD-10 codes. The eligibility criteria for the trial includes having controlled diabetes mellitus and a diagnosis of painful diabetic distal symmetric sensory/motor polyneuropathy. Women of childbearing potential must have a negative pregnancy test result and there are certain exclusion criteria such as pregnancy, lactation, or history of multiple drug allergies.",
    "The sample is a phase 2 clinical trial for patients with stomach or esophageal cancer. The trial includes a list of diseases and their corresponding ICD-10 codes, a list of drugs including placebo, oxaliplatin, leucovorin, and 5-fluorouracil, and eligibility criteria for participants. The eligibility criteria include confirmation of adenocarcinoma of the esophagus, gastroesophageal junction, or stomach, metastatic or locally advanced, unresectable disease, signed informed consent, Eastern Cooperative Oncology Group Performance Status of 0-1, adequate renal, hematological, and hepatic function, measurable or non-measurable disease, and life expectancy of greater than or equal to 3 months. Exclusion criteria include prior first-line systemic therapy for advanced/unresectable and/or metastatic disease, previous or concurrent malignancy except for basal or squamous cell skin cancer and/or in situ carcinoma of the cervix, or other solid tumors treated curatively and without evidence of recurrence for at least 3 years prior to study entry, and other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or study drug administration.",
    "The sample is a phase 2 clinical trial for breast cancer patients with confirmed stage IV cancer and HER2-positive status. The trial is testing the effectiveness of the drugs docetaxel and vinorelbine. The eligibility criteria include various disease and patient characteristics such as age, sex, performance status, and hematopoietic, hepatic, renal, and cardiovascular health. Prior concurrent therapies are also specified, including chemotherapy, endocrine therapy, radiotherapy, and surgery. The sample provides detailed information on the eligibility criteria for patients to participate in the trial.",
    "The sample is a phase 2 clinical trial for gastroesophageal reflux disease (GERD). The trial includes subjects between the ages of 18 and 70 who have a history of GERD symptoms and have been on proton pump inhibitor (PPI) therapy for at least 8 weeks prior to the screening visit. The trial aims to test the efficacy of different doses of ssp-002358 in combination with PPI compared to a placebo in treating GERD symptoms. The eligibility criteria include having persistent symptoms of regurgitation for 3 or more days over the past week with or without heartburn while on PPI therapy, and having at least some improvement to the symptom of heartburn while on PPI therapy. The exclusion criteria include subjects with dyspepsia symptoms that are more predominant than their GERD symptoms, prior endoscopic anti-reflux procedure or major GI surgery, and presence of severe and clinically uncontrolled cardiovascular, liver, lung or neurologic disease, cancer or AIDS.",
    "The sample is a phase 2 clinical trial for patients with colorectal cancer and metastatic cancer. The trial involves the use of two drugs, capecitabine and oxaliplatin. The eligibility criteria include having a diagnosis of hepatic metastases secondary to colorectal cancer, resectable hepatic metastases, and measurable disease. Patients must also meet certain age, performance status, and hematopoietic, hepatic, renal, and cardiovascular requirements. Prior concurrent therapy is also taken into consideration. The sample includes a detailed list of eligibility criteria for patients to participate in the trial.",
    "The sample is a record of a clinical trial in phase 2, which involves the study of the effects of different drugs on patients with thromboembolism and heart valve prosthesis. The trial includes a list of icd-10 codes for the diseases being studied. The drugs being tested include dabigatran etexilate low dose, warfarin 5mg, dabigatran etexilate intermediate dose, warfarin 1mg, dabigatran etexilate high dose, and warfarin 3mg. The eligibility criteria for the trial include completing a previous study, having a continuing need for anticoagulation, and not having uncontrolled hypertension, severe renal impairment, active liver disease, or an increased risk of bleeding.",
    "The sample is a phase 2 clinical trial for the treatment of glioblastoma multiforme and primary brain tumors using the drugs temozolomide and bevacizumab. The trial has specific eligibility criteria, including a diagnosis of supratentorial glioblastoma by biopsy, patients aged 70 or older, and a KPS score between 30 and 70. Exclusion criteria include previous treatment with surgical resection, RT or chemotherapy to the tumor, and various medical conditions such as congestive cardiac failure and coagulation disorder. The trial requires patients to be enrolled at least 14 days after stereotactic biopsy and 28 days after surgical biopsy, and a CT or brain MRI must be performed within 4 weeks before treatment to rule out hemorrhage. Patients must also be included in the health social security system, undergo medical assessment prior to inclusion, and provide informed consent.",
    "The sample is a phase 2 trial for the treatment of type 2 diabetes. The trial includes participants who are between the ages of 18-70 and have a body mass index between 23-45 kg/m^2. The trial involves the use of various drugs, including placebo, ertugliflozin, sitagliptin, and metformin. The eligibility criteria for the trial includes having stable doses of background medicines for diabetes management, while exclusion criteria includes having type 1 diabetes, heart attack or stroke in the last 6 months, uncontrolled blood pressure, and significant kidney disease. The diseases being studied are limited to diabetes mellitus, type 2, and the icd-10 codes associated with the disease are provided.",
    "The sample is a phase 2 clinical trial for relapsing-remitting multiple sclerosis. The trial includes patients between the ages of 18 and 45 who have had at least 2 exacerbations within the preceding 12 months, with MRI activity expressed by at least one gadolinium-enhanced lesion. Patients must also have a significant disability at inclusion, with an EDSS score between 2.5 and 5.5. The trial excludes patients who are pregnant or breastfeeding, those using an insufficiently effective contraceptive method, those undergoing general immunosuppressive therapy using cyclophosphamide, mitoxantrone, or total lymphoid irradiation, those who have been treated with azathioprine during the 3 months preceding the study, those who have had a clinical relapse or intensive corticosteroid treatment within the 30 days preceding inclusion, and those with associated diseases such as psychiatric disorders or a history of heart disease.",
    "The sample is a phase 2 clinical trial for the treatment of akathisia, drug-induced movement disorders caused by antipsychotic agents. The trial involves the use of preladenant, placebo, anticholinergic agents or propanolol, and haloperidol as drugs. The eligibility criteria include participants or guardians willing to give written informed consent, participants with acute psychoses with a PANSS score of at least 60, participants initiating haloperidol for the treatment of an acute psychotic episode at a dose of at least 7.5 mg per day, and inpatient participants who have developed akathisia as a result of haloperidol at >=5 mg per day for the treatment of acute psychosis. The exclusion criteria include participants who have previously received this compound, participants who are currently participating in another clinical study or have participated in a clinical study within 30 days, and female participants who are pregnant or nursing.",
    "This sample is a phase 2 clinical trial for patients with recurrent or stage IV breast cancer. The trial is testing the effectiveness of the drug bortezomib. Patients must meet certain eligibility criteria, including having measurable lesions and no bone metastases. They must also have normal levels of various blood tests and no other concurrent illnesses or treatments. Prior chemotherapy and hormonal therapy are allowed, but patients cannot have had more than one prior chemotherapy regimen for metastatic disease. The trial is only open to female patients with a negative pregnancy test and effective contraception.",
    "The sample is a phase 2 clinical trial for chronic myelogenous leukemia, bcr-abl1 positive. The trial includes patients who have been diagnosed with CML within the last 180 days and have not received prior treatment for CML, except for hydroxyurea and/or anagrelide. Patients must have Zubrod performance status 0-2 and meet certain eligibility criteria, including normal serum bilirubin and SGOT/AST or SGPT/ALT levels, and no major surgery within 28 days before registration. Patients must also not have a history of significant bleeding disorder unrelated to cancer and must be informed of the investigational nature of the study and give written informed consent. The trial requires submission of bone marrow and peripheral blood specimens for cytogenetic and FISH analysis.",
    "The sample is a phase 2 trial that involves patients with two specific diseases, namely pulmonary hypertension and left ventricular dysfunction. The trial includes a list of icd-10 codes for each disease. The drugs being tested in the trial are riociguat and placebo. The eligibility criteria for the trial include male and female patients with symptomatic pulmonary hypertension due to left ventricular systolic dysfunction despite optimized heart failure therapy. Patients with types of pulmonary hypertension other than group 2.1 of Dana Point Classification are excluded from the trial.",
    "The sample is a phase 2 clinical trial for breast cancer patients who have either stage III disease not amenable to curative therapy or stage IV disease. The trial is testing the effectiveness of the drug capecitabine. The eligibility criteria include having received prior anthracycline and taxane therapy, having completed any prior radiotherapy and hormonal therapy, having adequate hematologic, coagulation, hepatic and renal function, and not having certain medical conditions such as cirrhosis or uncontrolled intercurrent illness. The exclusion criteria include having a concurrent active malignancy, known sensitivity to capecitabine or 5-fluorouracil, and having experienced certain medical events within a certain time frame. The trial requires participants to use adequate contraception during the study period and for 12 weeks after the last dose of study medication. Participants who are pregnant or lactating are excluded from the trial.",
    "This sample is a record of a clinical trial for a drug treatment for patients who have received a primary renal graft from a deceased or living donor and require basiliximab induction therapy. The trial is in phase 2 and the diseases being studied are related to renal transplantation. The icd-10 codes for these diseases are listed. The drugs being tested in the trial are simulect\u00ae, neoral\u00ae, certican\u00ae, myfortic\u00ae, and corticosteroids. The eligibility criteria for the trial are listed, including inclusion criteria such as a cold ischemia time of less than 30 hours and exclusion criteria such as previous organ transplantation, positive anti-HLA antibodies, and receiving a graft from an expanded criteria donor. The sample also notes that other protocol-defined inclusion/exclusion criteria may apply.",
    "The sample is a phase 2 clinical trial for patients with type II diabetes mellitus. The trial is testing the effectiveness of the drug GFT505 80mg compared to a placebo. The eligibility criteria include being a male or post-menopausal female with a stable hormonal replacement therapy, having a body mass index between 27 and 45 kg/m\u00b2, being drug-naive for type 2 diabetes mellitus, having an HbA1c level between 7.0% and 9.5%, and being Anti-GAD negative for patients under 40 years old. Exclusion criteria include having type I diabetes mellitus, high blood pressure, taking lipid-lowering drugs such as fibrates, having a fasting plasma glucose level of 240 mg/dL or higher, and having triglycerides levels of 400 mg/dL or higher.",
    "The sample is a phase 2 clinical trial for the treatment of metastasized or locally inoperable soft tissue sarcoma using the drug pemetrexed. The trial includes patients who have previously undergone cytostatic treatment with adriamycin and/or an ifosfamide containing chemotherapeutic substance. The trial has a list of inclusion and exclusion criteria, including two-dimensionally measurable/evaluable tumor parameters, adequate bone marrow and kidney function, and patient consent. Patients with severe impairment in hepatic function, active infection, or previous treatment with pemetrexed are excluded from the trial. The trial also excludes patients with symptomatic CNS-metastases, gravidity or lactation, and those who are participating in another trial at the same time.",
    "The sample is a phase 2 clinical trial for patients with unexplained anemia. The trial is testing the effectiveness of iron sucrose as a treatment for anemia in patients who are 65 years or older, have a hemoglobin concentration between 9.0 and 11.5 g/dL (women) or between 9.0 and 12.7 g/dL (men), and have a serum ferritin level between 20 and 200 ng/mL. Patients must be able to walk without assistance and provide written informed consent. Exclusion criteria include recent blood transfusions or use of erythropoiesis stimulating agents, intravenous iron infusions, and certain medical conditions such as unstable angina or uncontrolled hypertension. Patients who have recently started oral iron supplementation or have had at least a one gram/dL improvement in hemoglobin since starting oral iron supplementation are also excluded.",
    "The sample is a phase 2 clinical trial for chronic primary insomnia. The trial involves testing the effectiveness of a drug called act-078573, which comes in oral capsules at 25 and 100 mg, as well as a matching placebo. The trial includes elderly subjects over the age of 64 who have been diagnosed with primary insomnia. The inclusion criteria require that subjects have no history of any sleep disorder or any DSM-IV axis I disorder other than primary insomnia. Exclusion criteria include sleep apnea, restless legs syndrome, daytime napping of more than 1 hour per day, important caffeine consumption, heavy tobacco use, alcohol or drug abuse within 2 years prior to the screening visit, and unwillingness to refrain from drugs, over-the-counter or herbal medication having an effect on sleep or behavior. The icd-10 codes associated with chronic primary insomnia are also listed.",
    "The sample is a record of a clinical trial in phase 2 for the treatment of rheumatoid arthritis. The trial involves the use of a drug called scio-469 and a placebo. The eligibility criteria for the trial include patients with active rheumatoid arthritis who are not receiving hepatotoxic disease-modifying anti-rheumatic drugs (DMARDs) and patients taking hydroxychloroquine (Plaquenil) must be on a stable or consistent dose prior to entering the study. The exclusion criteria include patients who have used Enbrel, Remicade, Kineret, Humira, or an experimental biologic agent within the past 3 months, patients with elevated liver enzymes within the past 6 months, medical history of Tuberculosis, cancer, multiple sclerosis, neuropathy or encephalopathy, HIV positive, abnormal electrocardiogram, and chronic or acute infection.",
    "The sample is a phase 2 clinical trial for patients with migraine headaches. The trial includes patients between the ages of 18 to 65 years who have been diagnosed with migraine headache with or without aura for at least 6 months and have had at least 3 migraine attacks in the last 3 month period. Patients who have been pain-free for at least 48 hours since the end of their last migraine attack and have not taken any acute migraine or pain medication within 48 hours prior to dosing are eligible for the trial. The trial involves the use of two drugs, staccato loxapine and staccato placebo. Patients who are in good general health and meet the eligibility criteria are required to provide written informed consent on an IRB approved form prior to the initiation of any study procedures. The trial has a set of inclusion and exclusion criteria that must be met by the patients.",
    "The sample is a phase 2 clinical trial for the treatment of migraines with or without aura. The trial is testing the effectiveness of the drugs tonabersat and placebo. The eligibility criteria for the trial include having a history of migraine for at least one year, experiencing between four and 14 migraine headache days per month, and meeting the diagnostic criteria of the International Classification of Headache Disorders. Women of childbearing potential must be using a reliable form of contraception for at least three months prior to enrollment and have a negative pregnancy test at screening. Exclusion criteria include patients with a diagnosis of migraine at age 50 or older, frequent non-migraine headaches, and failure to respond to more than two adequately dosed migraine prophylactic medications. Patients taking certain medications or with certain medical conditions are also excluded.",
    "The sample is a phase 2 clinical trial for the treatment of amyotrophic lateral sclerosis. The trial includes patients who have been diagnosed with definite or probable ALS within the past 3 years and have a slow vital capacity test equal to or greater than 70% of the predicted value. Patients must also have a stable dose of riluzole for at least 8 weeks prior to screening. The trial excludes patients who use invasive or non-invasive ventilation, have undergone gastrostomy, have any clinically significant or unstable medical condition, or are participating in any other clinical trial within 12 weeks prior to screening. The trial involves the use of 40 mg glatiramer acetate and placebo as drugs. The eligibility criteria for the trial are listed in detail.",
    "This sample is a phase 2 clinical trial for patients with chronic hepatitis C infection. The trial is testing the effectiveness of pegylated interferon and ribavirin as a treatment for the disease. The eligibility criteria for the trial include having genotype 1 of the virus, no history of liver cirrhosis, and no co-infection with HIV or hepatitis B. Patients must also have normal laboratory parameters and no history of intravenous drug or alcohol abuse. Exclusion criteria include prior treatment for hepatitis C, a history of malignancy within the last 5 years, and serious concomitant medical disorders. Female patients and female partners of male patients must agree to use two effective methods of birth control during the study and for 6 months after the end of treatment.",
    "The sample is a phase 2 clinical trial for prostate cancer. The eligibility criteria include having a rising PSA value after local therapy, prior definitive therapy for prostate cancer, and no metastatic disease. Patients must also have a KPS of >70%, normal liver function tests, and a HgA1c <6%. Exclusion criteria include the presence of another active malignancy, diabetes mellitus, and evidence of local-only recurrence of prostate cancer. The trial is testing the effectiveness of nordihydroguaiaretic acid (ndga) as a treatment for prostate cancer.",
    "The sample is a phase 2 clinical trial for asthma. The eligibility criteria include being an outpatient, being at least 12 years old (or 18 years old in certain countries), having a diagnosis of asthma as defined by the National Institutes of Health, having a best FEV1 of 40%-85% of the predicted normal value during the morning screening period or a best FEV1 of 40%-90% of the predicted normal value during the evening screening period, and using a non-corticosteroid controller or short-acting beta2-agonist bronchodilators alone for at least 3 months preceding the study. Exclusion criteria include a history of life-threatening asthma, respiratory infection, asthma exacerbation requiring oral corticosteroids within 3 months of the study, and concurrent diseases/abnormalities that would put the safety of the subject at risk or affect the efficacy or safety analysis. The study involves the use of two drugs, gw685698x and placebo, and requires subjects to commit to consistent and correct use of an acceptable method of birth control if they are of childbearing potential.",
    "This sample is for a phase 2 clinical trial for patients with metastatic gastroesophageal cancer. The trial is testing the effectiveness of lapatinib and lapatinib plus capecitabine as treatments. The eligibility criteria include having confirmed adenocarcinoma of the stomach, measurable disease, and at least one prior chemotherapy for metastatic disease with progression during or no later than 6 months after last administration of chemotherapy. Patients must also have Her2 overexpression measured by FISH, be willing to allow for biomarker analyses on their tumor tissue, and meet certain health criteria. Exclusion criteria include previous non curatively treated malignant disease other than the current gastroesophageal cancer with a disease-free survival of less than 5 years, history of significant neurological or psychiatric disorders, and active Hepatitis B or C or history of an HIV infection.",
    "The sample is a phase 2 clinical trial for the treatment of gastric cancer. The trial involves the use of four drugs: docetaxel, oxaliplatin, folinic acid, and 5-fu. The eligibility criteria for the trial include having histologically confirmed adenocarcinoma of the gastroesophageal junction or gastric adenocarcinoma, being at least 18 years old, having expected operability, and having adequate hematological, renal, cardiac, and hepatic function. Exclusion criteria include prior chemotherapy or radiotherapy for the adenocarcinoma, distant metastasis or local relapse, known hypersensitivity to the drugs used in the trial, severe comorbidity or acute infections, and pregnancy or breastfeeding.",
    "The sample is a phase 2 clinical trial for the treatment of schizophrenia. The trial is testing the effectiveness of the drugs ave1625 and placebo on outpatients who have been diagnosed with schizophrenia and are currently being treated with olanzapine, risperidone/paliperidone, quetiapine or aripiprazole monotherapy for at least 2 months. The trial has inclusion and exclusion criteria, which are listed in the sample. The investigator will also evaluate whether there are any other reasons why a patient may not be able to participate in the trial.",
    "The sample is a record of a clinical trial with a phase 2 designation. The trial is focused on non-Hodgkin's lymphoma and includes a list of ICD-10 codes for the disease. The trial involves the use of two drugs, pegfilgrastim and pegfilgrastim. The eligibility criteria for the trial include a histologically proven mantle cell lymphoma or diffuse large B-cell non-Hodgkin's lymphoma, measurable and/or evaluable disease, and previously untreated patients. The exclusion criteria include Burkitt's or B-lymphoblastic lymphoma, central nervous system involvement, active infection requiring treatment with systemic anti-infectives within 72 hours of chemotherapy, prior malignancy within the last 5 years, T-cell lymphoma or history of indolent lymphoma, prior bone marrow or stem cell transplantation, and known sensitivity to E. coli derived drug products.",
    "The sample is a phase 2 clinical trial for the treatment of hepatocellular carcinoma, a type of liver cancer. The trial involves the use of the drugs sorafenib and zoledronic acid. The eligibility criteria for the trial include being at least 18 years old, having confirmed hepatocellular carcinoma, having an expected survival time of at least 12 weeks, and meeting various medical criteria such as having a certain level of platelets and hemoglobin. The exclusion criteria include having certain medical conditions or receiving certain treatments that could interfere with the trial.",
    "The sample is a phase 2 clinical trial for patients with various types of bile duct and gallbladder cancers. The trial is testing the effectiveness of two drugs, erlotinib hydrochloride and sorafenib tosylate. The eligibility criteria include having confirmed cancer, no prior systemic treatment, and certain health requirements such as a Zubrod performance status of 0-1 and normal blood counts. Patients must also be able to swallow and tolerate oral medications. The trial excludes patients with certain medical conditions such as uncontrolled hypertension or bleeding diathesis. Patients must not have received certain types of prior treatment and must not plan to receive concurrent chemotherapy, hormonal therapy, radiotherapy, immunotherapy, or any other therapy, including herbal or alternative medications for treatment of cancer.",
    "The sample is a record of a clinical trial with a phase 2 designation. The trial is focused on the treatment of malignant glioma, a type of brain cancer. The trial includes a list of ICD-10 codes for the diseases being studied. The drugs being tested are cdx-110 with gm-csf and temozolomide. The eligibility criteria for the trial are listed, including requirements for newly diagnosed de novo GBM with documented EGFRvIII expression in tumor tissue and gross total resection followed by conventional chemoradiation therapy without progression of disease. The exclusion criteria are also listed, including the presence of diffuse leptomeningeal disease or gliomatosis cerebri, systemic corticosteroid therapy, prior stereotactic radiosurgery, and known allergies or hypersensitivity to certain products.",
    "This sample is from a phase 2 clinical trial for infertility. The trial is testing the effectiveness of a drug called Org 36286 compared to a placebo. The eligibility criteria for participants include having a desire to conceive, experiencing oligomenorrhea (cycle length of 41 days or more) or amenorrhea (no menstrual cycle for more than 6 months), having a BMI between 18 and 32 kg/m^2, and having normal levels of serum FSH, prolactin, and thyroid stimulating hormone. Exclusion criteria include having tumors of the ovary, breast, uterus, pituitary or hypothalamus, being pregnant or lactating, having undiagnosed vaginal bleeding, having ovarian cysts or enlarged ovaries not related to polycystic ovarian disease (PCOD), and having any clinically relevant abnormal laboratory value.",
    "The sample is a phase 2 clinical trial for liver cirrhosis and biliary diseases. The trial involves the use of two drugs, placebo and obeticholic acid (oca). The eligibility criteria for participants include being postmenopausal, surgically sterile, or using effective contraception. Participants must also have a history of increased alkaline phosphatase levels, positive antimitochondrial antibody titer, or liver biopsy consistent with PBC. Exclusion criteria include the use of certain drugs, high levels of bilirubin or liver enzymes, and a history of hepatic decompensation or other liver diseases. Pregnant individuals are also excluded from the trial.",
    "The sample is a phase 2 clinical trial for the treatment of atopic dermatitis using the drug apremilast. The eligibility criteria for the trial include having a moderate to very severe disease severity, a baseline EASI score of 11 or higher, and being a candidate for or previously on systemic therapy. The exclusion criteria include a history of active mycobacterial infection, major bacterial infections resulting in hospitalization, and clinically significant abnormalities on chest X-ray or 12-lead ECG. Additionally, individuals with congenital or acquired immunodeficiency, hepatitis B or C, HIV infection, or a history of certain types of skin cancer are excluded. Systemic corticosteroid-dependent asthma and active infections of any type at the time of enrollment are also exclusion criteria.",
    "The sample is a phase 2 clinical trial for patients with diffuse large B-cell non-Hodgkin's lymphoma that has relapsed or is refractory after at least one prior chemotherapy regimen. The trial is testing the effectiveness of the drugs cytarabine and liposomal cytarabine. The eligibility criteria include having CD20-positive disease, bidimensionally measurable disease, less than 25% bone marrow involvement by lymphoma, and no transformed lymphoma from indolent to aggressive. Patients must also meet certain age, performance status, and hematopoietic, hepatic, and renal function requirements. Prior concurrent therapy is also taken into consideration.",
    "The sample is a phase 2 clinical trial for the treatment of small cell lung cancer and carcinoma. The trial involves the drug vinflunine and the eligibility criteria include having measurable or evaluable disease, being able to perform daily activities with minimal assistance, and having adequate hematological, liver, and kidney function. Exclusion criteria include CNS involvement, serious active infection or underlying medical condition, and significant history of uncontrolled cardiac disease. Participants must give written informed consent prior to entry.",
    "The sample is a phase 2 clinical trial for patients with extensive stage small cell lung cancer. The trial is testing the effectiveness of the drug bortezomib. Patients must have received a prior platinum-based chemotherapy regimen and meet certain criteria. Brain and/or leptomeningeal metastases are allowed under certain conditions. Patients must be at least 18 years old with a Zubrod performance status of 0-1. They must also meet certain hematopoietic, renal, and other health criteria. Patients cannot be pregnant or nursing and must use effective contraception if fertile. They cannot have symptomatic sensory neuropathy greater than grade 1 or any other malignancy within the past 5 years except for certain adequately treated cancers. The trial has specific requirements for prior concurrent therapy, including chemotherapy, endocrine therapy, radiotherapy, and surgery.",
    "The sample is a phase 2 clinical trial for patients with metastatic breast cancer who have HER2 gene amplification and have previously received 1-2 cytotoxic chemotherapy regimens. The trial is testing the investigational drug CP-724,714, which is a HER2 inhibitor. The eligibility criteria include limited visceral disease burden and disease-related symptoms, presence of at least one measurable target lesion, and adequate bone marrow, renal, liver, and cardiac function. Exclusion criteria include prior treatment with trastuzumab or other HER2-targeting agents, cumulative dose >450 mg/m2 of doxorubicin or doxorubicin equivalents, and concurrent treatment with certain medications. Patients must be willing and able to comply with scheduled visits, therapy plan, laboratory tests, and blood sampling for pharmacokinetic analyses.",
    "The sample is a phase 2 clinical trial for aggressive non-Hodgkin's lymphoma, including various subtypes. The trial is open to patients between the ages of 18 and 70 who meet specific eligibility criteria, including having measurable disease and meeting certain health requirements. The trial involves a combination of drugs, including the CHOP regimen, cyclophosphamide, doxorubicin hydrochloride, gemcitabine hydrochloride, prednisone, and vincristine sulfate. Patients cannot have had prior treatment for NHL or other concurrent anticancer therapy. The trial does not allow concurrent monoclonal antibodies and does not involve prior or concurrent radiotherapy.",
    "The sample is a phase 2 clinical trial for postmenopausal breast cancer patients with locally advanced or locally recurrent tumors that cannot be surgically removed or have measurable and/or assessable disease, including isolated bone metastasis. The trial involves the use of bevacizumab, anastrozole, and fulvestrant drugs. The eligibility criteria include being a female patient aged 18 years or older with documentation of estrogen and/or progesterone receptor positivity, no prior chemotherapy or hormone therapy for metastatic or inoperable breast cancer, and adequate bone marrow, renal, and liver function. The trial also has exclusion criteria, such as no metastatic disease to the central nervous system, no history of myocardial infarction or stroke in the last 6 months, and no significant psychiatric disorders. The study center will determine if the patient meets all the criteria, and if they do, they will explain the trial in detail and answer any questions the patient may have.",
    "This sample is a phase 2 clinical trial for the treatment of osteoporosis. The trial is looking at the effectiveness of the drug odanacatib compared to a placebo. The eligibility criteria for participants include being postmenopausal for at least 5 years, having a bone mineral density T-score of -2.0 or less, and having suitable spinal anatomy for dual-energy x-ray absorptiometry (DXA). Participants must also be in good general health and agree not to use any medications to treat osteoporosis during the study. Exclusion criteria include a history of prior osteoporotic fracture, past treatment with certain medications that affect bone, and significant clinical or laboratory abnormalities.",
    "The sample is a phase 2 clinical trial for the treatment of cystic fibrosis. The trial is open to males and females between the ages of 3 months and 18 years who have been diagnosed with cystic fibrosis according to the 1997 CF Consensus Conference criteria. Participants must have documented sweat chloride levels of at least 60 mEq/L, abnormal nasal transepithelial potential difference test, or two well-characterized, disease-causing genetic mutations in the CF transmembrane conductance regulator (CFTR) gene and one or more clinical features consistent with CF. They must also have a documented new onset of positive lower respiratory tract culture for PA within 30 days of study entry. The trial drug being tested is aztreonam for inhalation solution (azli). Participants must meet certain inclusion criteria, such as having a forced expiratory volume in 1 second (FEV1) of at least 80% predicted at screening visit and being clinically stable with no evidence of significant respiratory symptoms. They must also meet certain exclusion criteria, such as having a history of lung transplantation or hypersensitivity to monobactam antibiotics. Participants and/or parent/guardian must be able to give written informed consent prior to any study related procedure.",
    "The sample is a phase 2 clinical trial for the treatment of osteoporosis. The trial is focused on children between the ages of 5 and 15 who weigh at least 20 kg and have a history of multiple fractures. The trial involves the use of the drug alendronate and eligibility criteria include a diagnosis of osteoporosis by DXA, a bone mineral density (BMD) score of at least 2 standard deviations below the normal mean for age, and parental consent (and patient assent after age 12 years) to participate in the study. Exclusion criteria include a history of severe gastritis or reflux, abnormalities of the esophagus, marked kyphoscoliosis, hypersensitivity to bisphosphonates, and various other medical conditions.",
    "The sample is a phase 2 clinical trial for the treatment of allergic rhinitis. The trial includes patients with a clinical history of intermittent allergic rhinitis with seasonal onset and positive skin prick test to ragweed allergen within twelve months of screening. The trial excludes patients who have used any medication used to treat allergy, have a history of acute or chronic bronchospastic disease, or have nasal conditions such as nasal septal perforations, nasal polyps, sinus disease, or chronic nasal obstruction. The trial involves the use of several drugs, including qav680 + cetirizine placebo, qav680 + cetirizine, cetirizine + qav680 placebo, and qav680 placebo + cetirizine placebo. The eligibility criteria for the trial are defined by the protocol.",
    "The sample is a record from a clinical trial table that includes information about the phase of the trial, the diseases being studied, the corresponding ICD-10 codes, the drugs being used, and the eligibility criteria for patients to participate in the trial. In this particular sample, the trial is in phase 2/phase 3 and is studying three types of cancer: extrahepatic bile duct cancer, gallbladder cancer, and liver cancer. The drugs being used are cisplatin, gemcitabine hydrochloride, and oxaliplatin. The eligibility criteria include a diagnosis of cancer of the biliary tract, unresectable disease, amenable to radiotherapy, and no visceral metastases by imaging, among other requirements. Prior concurrent therapy is also listed as a factor in eligibility.",
    "The sample is a phase 2 clinical trial for ovarian neoplasm, which is a type of ovarian cancer. The trial is testing two drugs, both of which are PARP inhibitors called ku-0059436 (azd2281). The eligibility criteria for the trial include having advanced ovarian cancer with positive BRCA1 or BRCA2 status, having failed at least one prior chemotherapy, having no curative standard therapy available according to the investigator's opinion, and having measurable disease. The exclusion criteria include having brain metastases, having received treatment for the disease less than 28 days ago, and being considered a poor medical risk due to a serious uncontrolled disorder.",
    "The sample is a phase 2 clinical trial for patients with ovarian epithelial, fallopian tube, or primary peritoneal cavity cancer that has recurred or is refractory. Patients must have previously received at least one platinum-based chemotherapeutic regimen for management of primary disease. The trial is testing the drug temsirolimus. Patients must meet certain eligibility criteria, including having measurable disease, meeting certain blood count and liver function requirements, and not having certain prior treatments or conditions. The trial allows for concurrent low molecular weight heparin and hormone replacement therapy, but not prophylactic filgrastim or certain protective reagents.",
    "The sample is a phase 2 clinical trial for patients with papillary renal cell carcinoma, a type of kidney cancer. The trial is testing the effectiveness of sunitinib malate as a treatment for locally advanced or metastatic disease. The eligibility criteria include having measurable disease, an ECOG performance status of 0-1, and meeting certain laboratory test requirements. Patients must not have certain medical conditions or be taking certain medications. The trial also has exclusion criteria, such as having certain medical conditions or being unable to comply with the study procedures. Prior treatment with specific medications or participation in other clinical trials is not allowed.",
    "This sample is a phase 2 clinical trial for patients with breast or lung cancer who will receive docetaxel therapy as per protocol. The trial is testing the effectiveness of dexamethasone as a treatment option. The inclusion criteria for the trial include being aged 65 or older, having a performance status ECOG 0-2, and having adequate kidney and liver functions. The exclusion criteria include having received an investigational drug within 4 weeks of registration, having prior or concurrent malignancies, having a serious medical or psychiatric illness that would prevent informed consent, having a life expectancy of less than 3 months, and having an active uncontrolled bacterial, viral, or fungal infection. The diseases are listed as breast cancer and lung cancer, and the corresponding ICD-10 codes are also provided.",
    "The sample is a phase 2 trial for patients with atrial flutter who are scheduled for curative catheter ablation. The trial includes patients who have a ventricular rate of less than 100 beats per minute at enrollment and are in sinus rhythm at randomization. The trial excludes patients with a QTc (Fridericia, QTcF) greater than 450 ms measured in sinus rhythm at randomization, serum potassium below 3.8 or above 5.0 mmol/L, plasma potassium below 3.6 or above 5.0 mmol/L, and QRS duration greater than 120 ms at randomization. The trial is testing the drug azd1305. The diseases being studied are limited to atrial flutter and the corresponding ICD-10 codes are ['I48.3', 'I48.4', 'I48.92'].",
    "The sample is a phase 2 clinical trial for the treatment of relapsing remitting multiple sclerosis. The trial involves the use of two drugs, pleneva tm bgc20-0134 and placebo. The eligibility criteria for the trial include a diagnosis of relapsing MS according to the revised 2005 McDonald criteria, disease activity defined by at least one MS attack within the last year or the presence of active lesions on historical scans, a minimum total of 9 T2 lesions reported on a recent MRI obtained within 1 month prior to the screening visit, and a baseline EDSS score of 0 - 5.5. Patients who have refused to be treated with approved disease modifying therapies available for MS or for whom such treatments have proved to be intolerable are also eligible. Exclusion criteria include having experienced an MS relapse or received systemic corticosteroids or adrenocorticotropic hormone (ACTH) in the previous 1 month, having a secondary progressive (SPMS), progressive relapsing (PRMS), or primary progressive MS (PPMS), and having received certain agents to treat MS within specific timeframes.",
    "The sample is a phase 2 clinical trial for patients with metastatic melanoma with a BRAF mutation. The trial is testing the drug ro5185426. The eligibility criteria include being an adult patient over 18 years old, having brain metastases for which surgical resection is not an option, having failed at least one previous treatment for brain metastases, requiring corticosteroids for symptom control, and having an Eastern Cooperative Oncology Group (ECOG) performance status of 0-2. The exclusion criteria include increasing corticosteroid dose during the 7 days prior to study entry, previous malignancy within the past 2 years (except for basal or squamous cell carcinoma of the skin or carcinoma in-situ of the cervix), concurrent administration of any anticancer therapies other than those administered in the study, and clinically significant cardiovascular disease or event within the 6 months prior to the first dose of study drug. The diseases being studied are malignant melanoma and the icd-10 codes associated with the disease are listed as well.",
    "This is a sample of a clinical trial for a drug called migalastat hcl, which is being tested for the treatment of Fabry disease. The trial is in phase 2 and is looking for male participants between the ages of 18 and 65 who have been diagnosed with Fabry disease and have a stable dose level of agalsidase, another drug used to treat the disease. Participants must also have a body mass index between 18-35 kg per meter squared and an estimated creatinine clearance greater than or equal to 50 milliliters (mL)/minute. They must agree to use medically accepted methods of contraception during the study and for 30 days after study completion and be willing and able to provide written informed consent. Exclusion criteria include a history of allergy or sensitivity to the study drug or other iminosugars, and any intercurrent illness or condition that might preclude the participant from fulfilling the protocol requirements or suggest an unacceptable risk by participating in the study.",
    "The sample is a phase 2 clinical trial for patients with squamous metastatic non-small cell lung cancer. The trial is testing the effectiveness of the drugs ombrabulin and placebo. The eligibility criteria for the trial include having measurable disease, an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1, and not having received prior chemotherapy, immunotherapy, or targeted therapy for lung cancer disease. Exclusion criteria include having a history of brain metastases, uncontrolled spinal cord compression, or carcinomatous meningitis, and having any severe acute or chronic medical condition that could impair the ability to participate in the study or interfere with interpretation of study results. Additionally, pregnant or breastfeeding women, patients with inadequate organ function, and those with pre-existing peripheral neuropathy or hearing impairment are excluded. The sample also includes a list of diseases, icd-10 codes, and eligibility criteria.",
    "The sample is a phase 2 clinical trial for diabetic nephropathy and chronic kidney disease. The trial involves the use of drugs such as zemplar (paricalcitol) capsules and a placebo. The eligibility criteria include being at least 20 years old, having Type 2 Diabetes Mellitus, and having received a stable dose of ACEi and/or ARB for at least three months prior to the screening phase. Participants must also have an estimated glomerular filtration rate (GFR) between 15-90 mL/min/1.73m2, a urinary albumin to creatinine ratio (UACR) between 100 and 3000 mg/g, and a corrected serum calcium level <= 9.8 mg/dL, among other criteria. Exclusion criteria include a history of drug or alcohol abuse within six months prior to the screening phase and being known to be human immunodeficiency virus (HIV) positive.",
    "The sample is a phase 2 clinical trial for the treatment of advanced or metastatic adenocarcinoma of the stomach using the drug sorafenib. The trial includes patients with at least one measurable lesion larger than 10mm in diameter by spiral CT scan and an ECOG performance scale of 2 or less. Patients must also have adequate hepatic, renal, heart, and hematologic functions. The trial excludes pregnant or lactating women, patients with concurrent cancer or a history of other malignancies, neuropathy, brain, or leptomeningeal involvement, uncontrolled significant comorbid conditions, and previous radiotherapy. The diseases being studied are limited to gastric cancer, and the icd-10 codes associated with the disease are listed as well. The eligibility criteria for the trial are also provided.",
    "The sample is a phase 2 clinical trial for patients with advanced melanoma. The trial is testing the effectiveness of paclitaxel, carboplatin, and temozolomide as treatment options. Patients must have measurable disease, a life expectancy of at least 12 weeks, and a Zubrod performance status of 0-2. They must also have adequate bone marrow, hepatic, and renal function, and must not have received any other concurrent chemotherapy or radiation during the trial. Patients with brain metastases are eligible if they have been appropriately treated and are asymptomatic. Pregnant women or nursing mothers are not eligible, and patients with severe medical problems that would interfere with the therapy are also not eligible.",
    "The sample is a phase 2 trial for patients with melanoma of cutaneous or unknown origin, excluding ocular primary and mucosal primary. Patients must have Stage IV disease and undergo a CT or MRI of the brain within 42 days prior to registration that is negative for brain metastases. Patients must have measurable disease and Zubrod performance status of 0-1. They must not have received any prior systemic therapy for Stage IV disease except for noncytotoxic biologic agents. Patients may have had prior adjuvant immunotherapy with biological response modifiers. Adjuvant therapy containing cytotoxic agents is allowed if completed >= 180 days prior to registration. Patients may have received prior radiation therapy. They must meet certain laboratory criteria and not have a history of allergic reaction attributed to compounds of similar chemical or biologic composition to RO4929097. Patients must be able to swallow tablets and not have malabsorption syndrome or other condition that would interfere with intestinal absorption of the agent. They must not be taking strong inducers or strong inhibitors of CYP3A4 at the time of registration. Patients must not be known to be serologically positive for Hepatitis A, B, or C, or have a history of liver disease, other forms of hepatitis, or cirrhosis. They must have an ECG within 28 days prior to registration and not have symptomatic congestive heart failure or unstable angina pectoris. Women of childbearing potential must have a negative pregnancy test within 14 days prior to registration and must not be nursing. All patients must be informed of the investigational nature of this study and must sign and give written informed consent in accordance with institutional and federal guidelines.",
    "The sample is a phase 2 clinical trial that includes patients with various types of cancer, including brain tumors, leukemia, lymphoma, and myelodysplastic syndromes. The trial aims to test the effectiveness of cyproheptadine hydrochloride and megestrol acetate in treating cachexia, a condition characterized by weight loss and muscle wasting commonly seen in cancer patients. The eligibility criteria include having a documented history of weight loss, being between 2 and 21 years old, and having a predicted life expectancy of at least eight weeks. Patients who have taken certain medications or have certain medical conditions are excluded from the trial. The trial also collects information on the diseases and icd-10 codes of the patients, as well as the eligibility criteria and drugs used in the trial.",
    "The sample is a phase 2 clinical trial for the treatment of migraine disorders using a drug called GW274150. The trial is looking for participants who have been suffering from migraine for at least one year, are able to distinguish migraine headache attacks from other types of headaches, and have had at least 3 migraine headache attacks but less than 15 days with headache per month in each of the three months prior to the screening visit. Participants must also have no clinically significant abnormalities identified on medical or laboratory evaluation and must provide written informed consent prior to entry into the study. The trial has a list of exclusion criteria, including a history of alcohol, substance or drug abuse within the last year, uncontrolled hypertension, and a history of drug or other allergy which, in the opinion of the doctor, makes the subject unsuitable for participation in the study. The trial is not open to pregnant or nursing women, and participants must not have participated in another clinical study or investigational drug trial within the previous 3 months or be planning to participate in another drug or device study at any time during this study.",
    "The sample is a phase 2 clinical trial for the treatment of metastatic breast cancer in patients who have previously received HER2-directed therapy. The trial is testing the effectiveness of the drug trastuzumab emtansine (kadcyla). The eligibility criteria include having HER2-positive metastatic breast cancer, having received 1-3 chemotherapy regimens for MBC, and meeting certain blood and organ function requirements. The exclusion criteria include recent treatment for breast cancer, a history of significant cardiac disease, and prior cumulative doxorubicin dose exceeding 360 mg/m^2 or the equivalent.",
    "The sample is a phase 2 clinical trial for patients with mild-to-moderate uncomplicated essential hypertension. The trial includes both untreated patients and those currently taking antihypertensive therapy. The trial involves the use of drugs such as lcz696, valsartan, ahu377, and placebo. The eligibility criteria include age between 18 and 75 years, specific blood pressure readings, and exclusion criteria such as severe hypertension, history of angioedema, and secondary forms of hypertension. The trial also excludes patients with a history of certain cardiovascular diseases and interventions.",
    "The sample is a phase 2 clinical trial for patients with mantle cell lymphoma. The trial is testing the drug everolimus. Patients must have stable disease after first- or second-line chemotherapy and meet certain eligibility criteria, including having a WHO performance status of 0-2, a life expectancy of at least 3 months, and meeting certain blood count and organ function requirements. Patients must not have any other serious illnesses or HIV infection, and must not be pregnant or nursing. Patients must have complied with their previous drug prescription and recovered from all prior therapy. The trial excludes patients who have had organ transplantation or prior therapy with mTOR inhibitors. The sample includes detailed eligibility criteria for the trial.",
    "The sample is a phase 2 clinical trial for patients with pancreatic cancer that is locally advanced or metastatic and cannot be treated with surgery or other locally directed therapies. The trial involves the use of a combination of chemotherapy drugs, including placebo and caprelsa (vandetanib). The eligibility criteria include being at least 18 years old, having a confirmed diagnosis of pancreatic ductal adenocarcinoma or undifferentiated carcinoma of the pancreas, having measurable disease as shown by CT scan, and having a performance status of 0, 1, or 2. Exclusion criteria include having certain laboratory results outside of normal ranges, having certain medical or psychiatric conditions, having intracerebral metastases or meningeal carcinomatosis, having undergone major surgery within 4 weeks, and having certain cardiovascular events or conditions. Patients must also provide informed written consent to participate in the trial.",
    "The sample is a phase 2 clinical trial for the treatment of type 2 diabetes. The trial is looking at the effectiveness of the drugs placebo and srt2104. The eligibility criteria for participants include being between the ages of 18-65, having a stable metformin monotherapy for at least 3 months prior to screening, having a HbA1c level between 6.5%-9.5%, and having a BMI between 22-38 kg/m^2. Exclusion criteria include having any major illness in the 3 months prior to study entry, having renal or liver impairment, having a positive test for HIV antibody, and having a history of sensitivity to any of the study medications.",
    "The sample is a record of a clinical trial with a phase 2 designation. The trial is focused on the disease asthma, with a list of associated ICD-10 codes. The trial involves the use of three drugs: indacaterol, placebo, and mometasone furoate. The eligibility criteria for the trial are listed, including requirements for patients' asthma diagnosis, treatment history, lung function, and ACQ-5 score. The exclusion criteria are also listed, including restrictions on smoking history and other chronic respiratory conditions. The sample concludes by noting that additional inclusion/exclusion criteria may apply.",
    "The sample is a record of a clinical trial with a phase 2 designation. The trial is focused on diabetes, specifically type 2 diabetes, and involves two drugs, ex1000 and biphasic human insulin. The trial has a list of inclusion and exclusion criteria, including a requirement that participants have had type 2 diabetes for at least 12 months and a BMI less than or equal to 40.0 kg/m2. The trial also has a list of icd-10 codes associated with the diseases being studied.",
    "This sample is for a phase 2 clinical trial for the treatment of restless legs syndrome. The trial includes patients with moderate to severe idiopathic RLS whose symptoms occur predominantly in the evening and interfere with sleep onset or maintenance. The trial excludes patients with any secondary RLS, those who require treatment for daytime RLS symptoms, and those with symptomatic neuropathies. The trial will test the effectiveness of several doses of pregabalin compared to a placebo.",
    "The sample is a clinical trial for type 2 diabetes, in which the participants are divided into two groups: one receiving the drug dapagliflozin and the other receiving a placebo. The trial is in phase 2/phase 3 and the eligibility criteria include having inadequate glycemic control, receiving insulin and metformin and/or a thiazolidinedione, having a body mass index of 45.0 kg/m2 or less, and having a serum creatinine level below a certain threshold. The exclusion criteria include having type 1 diabetes, elevated levels of certain enzymes, symptoms of severely uncontrolled diabetes, and various other medical conditions.",
    "The sample is a phase 2 clinical trial for patients with clear cell kidney cancer. The trial is testing the effectiveness of the drugs everolimus and imatinib mesylate. Patients must meet certain eligibility criteria, including having received at least one prior systemic therapy for metastatic or unresectable renal cell carcinoma, having an Eastern Cooperative Oncology Group (ECOG) performance status of 0-2, and meeting specific laboratory values. Patients must also not have certain medical conditions or prior treatments, and must not be taking certain medications concurrently. The sample includes detailed disease and patient characteristics, as well as prior concurrent therapy information.",
    "The sample is a phase 2 clinical trial for patients with follicular lymphoma. The trial is testing the effectiveness of the drugs bortezomib and rituximab in treating the disease. The eligibility criteria for the trial include having a diagnosis of follicular B-cell lymphoma, having measurable lymph node masses, and meeting certain laboratory value requirements. Patients must also have resolved toxic effects from previous treatments and have a minimum life expectancy of 3 months. Exclusion criteria include having any other type of lymphoma, previous treatment with Velcade, and concurrent treatment with another investigational agent. Patients must provide informed consent before participating in the trial.",
    "This sample is for a phase 2 clinical trial for post-menopausal osteoporosis. The trial is testing the effectiveness of three drugs - ibandronate, risedronate, and alendronate. The eligibility criteria for the trial include being a female who is at least 5 years post-menopausal but under 85 years old, having a BMD T-score of less than or equal to 2.5 or a T-score less than or equal to -1 with a low trauma fracture, being ambulatory, and being able and willing to participate in the study and provide written informed consent. There are also several exclusion criteria, such as having evidence of a clinically significant organic disease, having a BMI less than 18 or greater than 35, and having a history of cancer within the past 5 years excluding skin cancer non melanomas. The sample also includes a list of icd-10 codes for the disease and a detailed list of inclusion and exclusion criteria.",
    "The sample is a phase 2 clinical trial for patients with stable plaque-type psoriasis. The trial includes patients between 18 and 75 years of age with psoriasis plaques located on the trunk and/or extremities. The trial requires comparable psoriasis plaques with at least \"2\" in each score for scaling, erythema, and induration. Patients must have enough psoriatic surface area to define 8 clearly distinguishable test areas of at least 1 cm\u00b2 plaque size. Patients must be willing and able to comply with the requirements of the clinical study protocol, including adhering to concomitant therapy prohibitions of the test areas and avoiding intense UV exposure of the test areas during the study. Patients must also provide written informed consent to participate in the study and agree to use one of the specified contraceptive methods for the duration of the study if they are of childbearing potential. Exclusion criteria include conditions that may interfere with the study assessments or sonographic measurements of the skin, known adverse reactions or hypersensitivity to any ingredient of the test products, unwillingness to avoid induction of heavy sweating or swimming, bathing, or wetting of the designated test areas between visits, and medical conditions that may put the patient at a general risk and therefore would prevent participation in the clinical trial.",
    "The sample is a phase 2 clinical trial for breast cancer patients who have previously undergone treatment with a bevacizumab-containing regimen in the adjuvant or first-line metastatic setting. The trial aims to evaluate the effectiveness of gemcitabine, sorafenib, and capecitabine compared to a placebo. The eligibility criteria include having histologically or cytologically confirmed adenocarcinoma of the breast, measurable or evaluable locally advanced or metastatic disease, age \u226518 years, and an ECOG Performance Status of 0 or 1. Patients must have discontinued chemotherapy at least 3 weeks prior to randomization and no more than one prior chemotherapy regimen for locally advanced or metastatic disease. The exclusion criteria include patients with breast cancer over-expressing human epidermal growth factor receptor 2 (HER-2), active brain metastases, and prior use of gemcitabine/capecitabine or sorafenib. Patients must be able to swallow and retain oral medication, have adequate bone marrow, liver, and renal function, and be willing to use adequate contraception. The trial also has other exclusion criteria related to medical, psychological, or social conditions that may interfere with the patient's participation in the study or evaluation of the study results.",
    "The sample is a record of a clinical trial with a phase 2 designation. The trial is focused on smoking cessation as the disease being studied. The icd-10 codes associated with the disease are listed as well. The trial involves two drugs, surinabant (sr147778) and placebo. The eligibility criteria for the trial are also listed, including inclusion criteria such as patients over legal age who smoke at least 10 cigarettes per day, and exclusion criteria such as patients with a limited level of motivation or those who have suffered from a major cardiovascular event within the past 6 months. The investigator will also evaluate whether there are any other reasons why a patient may not be able to participate in the trial.",
    "The sample is a phase 2 clinical trial for rheumatoid arthritis. The trial includes patients who have been diagnosed with rheumatoid arthritis for at least 6 months and have at least 8 tender and 8 swollen joints. The patients must have been on methotrexate treatment for 6 months and have a stable dose of at least 10mg/wk for at least 8 weeks. They must also have negative TB screening. The trial excludes patients who have used other disease-modifying anti-rheumatic drugs (DMARDs) other than Methotrexate MTX, previous use of more than 1 anti-TNF (tumor necrosis factor) agent, previous use of cytotoxics, p38 MAPkinase inhibitor, anti-CD4 antibody, receipt of live vaccine within 1 month of study drug, serious infection in previous 2 months or history of chronic or recurrent infectious disease or history of opportunistic infection, and other clinically significant disease of other organ system. The drugs being tested are rwj-445380 100 mg, rwj-445380 200 mg, rwj-445380 300 mg, and placebo.",
    "The sample is a record of a clinical trial with a phase 2 designation. The trial is focused on breast cancer and includes a list of ICD-10 codes associated with the disease. The trial is testing the effectiveness of second-line chemotherapy and trastuzumab (Herceptin) for patients with metastatic breast cancer who have HER2 overexpression and have experienced disease progression during or after previous first-line chemotherapy and Herceptin treatment. The eligibility criteria for the trial include being a female patient over 18 years of age, having metastatic breast cancer, and being scheduled to receive second-line chemotherapy. The exclusion criteria include concurrent immunotherapy or hormonal therapy, previous use of anthracyclines as part of first-line chemotherapy or planned second-line chemotherapy, cardiac toxicity during previous treatment, and a history of other malignancy within the last 5 years.",
    "The sample is a phase 2 clinical trial that involves patients with metastases, neoplasm, carcinoma, non-small-cell lung, and brain neoplasms. The trial uses the drug temozolomide and has a set of inclusion and exclusion criteria. Inclusion criteria include histologic confirmation of non-small-cell lung cancer, stable systemic disease, and adequate hematologic, renal, and liver function. Exclusion criteria include patients eligible for surgery of the brain, any previous chemotherapy for the brain metastasis, and inability to take oral medication. The trial also requires negative urine pregnancy test and non-use of adequate contraceptive techniques.",
    "The sample is a phase 2 clinical trial for renal transplantation. The trial involves testing multiple drugs, including sotrastaurin and mycophenolic acid, in combination with tacrolimus and standard of care medications. The eligibility criteria for the trial include being a recipient of a first or second kidney transplant from a deceased, living unrelated, or non-HLA identical living related donor, having a kidney with a cold ischemia time of less than 30 hours, and receiving a kidney from a donor between the ages of 10 and 65. Exclusion criteria include being a multi-organ transplant recipient, receiving an organ from a non-heart beating donor, having a previous kidney allograft that was functional for less than three years, and being treated with drugs that are strong inducers or inhibitors of CYP3A4 at screening and cannot discontinue this treatment. Other protocol-defined inclusion/exclusion criteria may also apply.",
    "The sample is a phase 2 clinical trial for the treatment of Ewing's sarcoma family of tumors of the bone or soft tissues. The trial includes patients who are newly diagnosed with the disease and have no CNS involvement. Patients with metastatic disease are also eligible, as long as the lesions are discontinuous from the primary tumor and do not share a body cavity with it. The trial involves the use of multiple drugs, including celecoxib, cyclophosphamide, doxorubicin hydrochloride, etoposide, ifosfamide, vinblastine sulfate, vincristine sulfate, mesna, and filgrastim. The eligibility criteria include age (50 and under), performance status, life expectancy, hematopoietic, hepatic, renal, cardiovascular, and other factors. Patients must not have any allergy to sulfa or aspirin hypersensitivity, and must not have any other prior cancer, including nonmelanoma skin cancer. The trial excludes patients who have had prior chemotherapy, radiotherapy, or bone marrow or stem cell transplantation.",
    "The sample is a record of a clinical trial with a phase 2 designation. The trial is focused on metastatic breast cancer and includes a list of ICD-10 codes associated with the disease. The trial involves the use of two drugs, liposomal doxorubicin and myocet/paclitaxel. The eligibility criteria for the trial include being a woman over 18 years old with histologically proven metastatic breast cancer, no prior chemotherapy in the advanced situation, an ECOG score of 2 or less, adequate bone marrow reserve, and a left ventricular ejection fraction (LVEF) of 50 or higher. The trial also has a list of exclusion criteria, including previous high dose therapy with stem cell support, prior adjuvant treatment with a cumulative anthracycline dose of 600 mg/m\u00b2 Epirubicin, 300 mg/m\u00b2 Doxorubicin, 80 mg/m\u00b2 Mitoxantrone, concomitant hormon- or chemotherapy or radiation therapy, Her2/neu overexpression, and pregnancy or breast feeding.",
    "The sample is a phase 2 clinical trial for patients with malignant melanoma that has progressed to stage IV and is not amenable to surgery. The trial is testing the effectiveness of three drugs: carboplatin, paclitaxel albumin-stabilized nanoparticle formulation, and temozolomide. The eligibility criteria include having a confirmed diagnosis of malignant melanoma, measurable disease, and an ECOG performance status of 0-1. Patients must also meet various medical criteria, such as having a life expectancy of at least 4 months, certain blood counts, and no active infections. Patients with certain medical conditions, such as poorly controlled high blood pressure or serious cardiac arrhythmia, are not eligible for the trial. Additionally, patients must not have had prior treatment with certain drugs or radiation therapy within a certain timeframe.",
    "The sample is a phase 2 clinical trial for non-small-cell lung cancer using the drug ispinesib. The trial has eligibility criteria for inclusion and exclusion. Inclusion criteria include having received only one prior platinum-based chemotherapy regimen and having adequate blood counts. Exclusion criteria include having received more than one chemotherapy regimen in the past, having less than adequate liver and kidney function, being pregnant, having any unstable pre-existing major medical condition or history of other cancers, and having received an investigational drug, chemotherapy, radiation treatment, or surgery within 28 days prior to entering the study. The icd-10 codes for the disease are also provided.",
    "The sample is a record of a clinical trial in phase 2, which involves testing drugs for the treatment of various diseases such as deep vein thrombosis, atrial fibrillation, venous thromboembolism, and pulmonary embolism. The trial involves the use of drugs such as odiparcil, warfarin, and coumadin. The eligibility criteria for the trial include being a woman who is unable to have children and undergoing a total knee replacement. However, there are exclusion criteria such as allergies to X-ray dye, warfarin, or coumadin, previous VTE or DVT, being on anticoagulation therapy, renal impairment, and participation in any clinical trial in the past 30 days. The icd-10 codes for the diseases are also provided.",
    "The sample is a phase 2 clinical trial for patients with recurrent ovarian, fallopian tube, or primary peritoneal cancer. The trial is testing the effectiveness of topotecan hydrochloride as a treatment option. Patients must have received only one prior platinum-based chemotherapy regimen and have platinum-sensitive disease. They must also meet certain eligibility criteria, including having measurable disease and a target lesion not previously irradiated. Patients must also have a performance status of GOG 0-2 and meet certain hematopoietic, hepatic, renal, and other criteria. Prior concurrent therapy is also taken into consideration.",
    "The sample is a phase 2 clinical trial for breast cancer. The trial is looking for patients with invasive breast cancer that is stage II-III and resectable. Patients must have a primary tumor estimated to be at least 3 cm and/or palpable axillary nodes greater than 1 cm for whom neoadjuvant chemotherapy is appropriate. Hormone receptor status is not specified. Patients must have an ECOG performance status of 0-1, absolute granulocyte count greater than 2,000/mm^3, and a platelet count greater than 100,000/mm^3. They must also have serum bilirubin less than 1.5 times the upper limit of normal (ULN) and serum creatinine less than 1.5 times ULN. Patients must not be pregnant or nursing, and must have a negative pregnancy test. Fertile patients must use effective contraception during and for 3 months after completion of study therapy. Patients must not have allergies to sulfa medication, aspirin, or other nonsteroidal anti-inflammatory drugs (NSAIDs). They must not have any uncontrolled concurrent illness that might jeopardize their ability to receive the chemotherapy program outlined in the protocol. Patients must not have had prior chemotherapy or radiation therapy for ipsilateral breast cancer, and must not be concurrently participating in another therapeutic clinical trial. The trial will use a combination of capecitabine, celecoxib, cyclophosphamide, docetaxel, and doxorubicin hydrochloride as the study therapy.",
    "The sample is a phase 2 clinical trial for patients with persistent or recurrent epithelial ovarian, primary peritoneal, or fallopian tube carcinoma. The trial requires patients to have had at least one prior platinum-based chemotherapy regimen for the management of their primary disease and be considered platinum refractory or resistant. Patients may have had no more than three prior treatment regimens for their epithelial ovarian, primary peritoneal or fallopian tube carcinoma. The trial requires patients to have measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria and an Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2. Patients must have adequate bone marrow and organ function and a life expectancy greater than three months. The trial also requires participants to have signed an approved informed consent and have archival tissue available from their original tumor debulking surgery for assessment of BRCA1 protein expression. Patients with borderline ovarian tumors, ovarian germ cell tumors, ovarian sex-cord stromal tumors, or other non-epithelial ovarian tumors are not eligible. Patients receiving any other investigational agents, patients who have received radiation therapy to more than 25% of the bone marrow, and patients who have previously received SJG-136 or related compounds are also not eligible. Patients with uncontrolled intercurrent illness or prior malignancy (other than cervical carcinoma in situ, ductal carcinoma in situ of the breast, or non-melanoma skin cancer) are also not eligible. Patients may not have baseline organ dysfunction or symptoms that qualify as grade 2 or higher by the CTEP Common Toxicity Criteria for Adverse Effects (CTCAE) v4.0.",
    "The sample is a phase 2 clinical trial for the treatment of melanoma. The trial is testing the drugs ym155 and docetaxel. The eligibility criteria for the trial include having histologically or cytologically confirmed Stage III (unresectable) or Stage IV melanoma, no prior systemic treatment or cytotoxic chemotherapy for advanced melanoma, and an Eastern Cooperative Oncology Group (ECOG) performance status of </= 1. The trial also requires subjects to have a life expectancy of > 12 weeks and at least one measurable target lesion according to Response Evaluation Criteria in Solid Tumors ({RECIST} version 1.1). Exclusion criteria include major surgery within 21 days of the baseline visit, presence or history of brain metastases, and hypersensitivity to docetaxel or polysorbate 80.",
    "The sample is a phase 2 clinical trial for breast cancer patients. The trial is evaluating the effectiveness of the drug docetaxel on patients with T2 or T3 tumors that are non-metastasized and non-inflammatory. The patients must have a clinically or radiologically measurable lesion greater than 2 cm and must have receptors RE+ and/or RP+. The trial is only open to menopausal patients aged 60 years or older with satisfactory hematological, hepatic, and renal functions. Patients must also meet a number of other eligibility criteria and cannot have certain exclusion criteria. The trial requires patients to be followed throughout the study and their consent must be obtained.",
    "The sample is a phase 2 clinical trial for patients with aggressive diffuse large B-cell lymphoma that is CD20-positive. The trial involves a combination of drugs including carboplatin, cyclophosphamide, doxorubicin hydrochloride, etoposide, ifosfamide, prednisone, and vincristine sulfate. Patients must meet certain eligibility criteria, including having measurable disease that is PET avid, being between the ages of 18 and 64, and having a Karnofsky performance status of 10-70% or a lactate dehydrogenase level greater than 200 U/L or stage III or IV disease. Patients must also meet certain hematopoietic, hepatic, renal, cardiovascular, and other criteria. Patients cannot have had prior biologic therapy, chemotherapy, radiotherapy, or surgery for malignancy. Prior steroid use is allowed if it was received no more than 1 week of therapy.",
    "The sample is a phase 2 clinical trial for patients with HIV infections and tuberculosis. The trial is testing the effectiveness of a drug called \"haart containing nevirapine\". The eligibility criteria for the trial include being HIV positive, aged between 18-60 years, having a CD4+ cell count of less than 200 cells/mm3 at the time of diagnosed TB, and using treatment with rifampin base therapy for at least 2 weeks but no longer than 4 weeks duration. The trial also has exclusion criteria, such as having laboratory variables outside of the normal range, current use of steroid and other immunosuppressive agents, and chronic active liver disease. The trial requires patients to provide written informed consent and to remain in follow-up for the protocol defined period.",
    "The sample is a phase 2 clinical trial for complicated intra-abdominal infection. The trial includes patients who are 18 to 90 years old and have evidence of intraperitoneal infection, such as cholecystitis, diverticular disease, or intraabdominal abscess. The patients must require surgical intervention within 24 hours of the first dose of study drug. The trial includes two drugs, cxa-101/tazobactam and metronidazole, and meropenem plus saline placebo. The eligibility criteria include various medical conditions and exclusions, such as pregnancy, abdominal wall abscess, and hepatic disease. The trial aims to evaluate the safety and efficacy of the study drugs in treating complicated intra-abdominal infection.",
    "The sample is a phase 2 clinical trial for patients with non-small cell lung cancer that has spread to other parts of the body. The trial is testing the effectiveness of two drugs, erlotinib and gemcitabine. The eligibility criteria for the trial include being an adult patient over 18 years old, having advanced or metastatic non-small cell lung cancer that cannot be surgically removed, and not having received previous systemic chemotherapy, radiation therapy, or immunotherapy. Patients with an Eastern Cooperative Oncology Group (ECOG) score of 2 or higher are also eligible. The exclusion criteria include having received prior systemic anti-tumor therapy with human epidermal growth factor receptor 1 (HER1/EGFR) inhibitors, having active non-controlled systemic disease, and having any other malignancies within the past 5 years, except for adequately treated cancer in situ of cervix or basal or squamous cell skin cancer.",
    "The sample is a phase 2 clinical trial for patients with type 2 diabetes mellitus. The trial includes patients who are currently being treated with metformin alone or metformin plus one other antidiabetic drug. The patients must have a glycosylated haemoglobin (HbA1c) level between 7.0% - 10.0% and a body mass index (BMI) of less than or equal to 45 kg/m2. Patients who have had a myocardial infarction (MI), stroke or transient ischaemic attack (TIA) within 6 months prior to informed consent, have impaired hepatic or renal function, or have had gastric bypass surgery are excluded from the trial. Patients who have been treated with glitazones, glucagon like peptide-1 (GLP-1) analogues/mimetics, antiobesity agents, or insulin within 3 months of informed consent are also excluded. Additionally, patients who are currently being treated with systemic steroids or have had a change in dosage of thyroid hormones, have a history of alcohol or drug abuse within 3 months of informed consent, or have participated in another trial with an investigational drug within 2 months prior to informed consent are excluded. Pre-menopausal women who are nursing, pregnant or not practicing an acceptable method of birth control are also excluded from the trial. The trial includes the use of linagliptin low dose, placebo, and linagliptin medium dose as drugs.",
    "The sample is a phase 2 clinical trial for patients with metastatic or locally advanced soft tissue sarcoma that is incurable by standard therapies. The trial is testing the effectiveness of the drug perifosine. The eligibility criteria include having a confirmed diagnosis of one of several types of sarcoma, excluding certain other types of cancer, having at least one measurable site of disease, and meeting certain medical and health criteria. Patients must not have had prior systemic chemotherapy for metastatic or locally advanced disease, and must not be receiving any other concurrent anticancer therapy or investigational agents. The sample includes detailed information on the patient characteristics and prior concurrent therapy allowed in the trial.",
    "The sample is a phase 2 clinical trial for metastatic colorectal cancer. The trial is testing the effectiveness of the drug combination of capecitabine and cetuximab. The eligibility criteria for the trial include having metastatic colorectal cancer, being at least 18 years old, having adequate organ function, and having measurable disease per RECIST criteria. In addition, participants must meet at least two of the following criteria: age over 65, ECOG PS 1 or 2, serum albumin less than or equal to 3.5g/dL, prior radiation therapy to the abdomen or pelvis, or stopping first-line combination systemic chemotherapy less than 6 weeks ago. The exclusion criteria include having tumors classified as KRAS mutation, prior therapy with cetuximab or other agents that target EGFR, known sensitivity to cetuximab or 5-FU, and uncontrolled medical illnesses. Participants with bowel disease associated with chronic diarrhea, major surgery within 28 days, or known uncontrolled CNS metastases are also excluded from the trial.",
    "The sample is a phase 2 clinical trial for patients with advanced non-small cell lung cancer who are not eligible for curative treatment. The trial includes patients with measurable disease and up to two prior cytotoxic regimens in the metastatic setting. Patients with uncontrolled brain metastases or leptomeningeal disease are not eligible. The trial requires patients to have an ECOG performance status of 0-2 and meet certain laboratory criteria. Patients must be willing to use adequate contraception and undergo pre-treatment and post-treatment biopsies. Patients with significant psychiatric illness or other concurrent investigational therapy are not eligible. The trial does not allow for other concurrent palliative radiotherapy.",
    "The sample is a phase 2 clinical trial for breast cancer patients with HER-2/neu overexpression. The trial involves the use of the drugs Herceptin and GM-CSF. The eligibility criteria include confirmation of invasive breast cancer, measurable stage IV disease, and progression after previous Herceptin-containing regimens. Patients must also have a Zubrod performance status of 0 or 1 and adequate hematological, renal, and liver function. Exclusion criteria include active brain metastasis, no measurable disease, more than two previous Herceptin-containing regimens, HIV positivity, chronic active hepatitis or cirrhosis, symptomatic pulmonary disease, and recent use of certain medications.",
    "The sample is a phase 2 clinical trial for patients with transfusion-dependent beta-thalassemia and cardiovascular diseases. The trial involves the use of two drugs, deferoxamine and deferiprone (l1), and has specific eligibility criteria for participants, including a left ventricular ejection fraction by MRI less than or equal to 56% by balanced steady-state free precession (SSFP) or 63% by spoiled gradient recalled echo (SPGR), and currently being on treatment with subcutaneous or intravenous DFO. The trial also has exclusion criteria, such as having a pacemaker or severe congestive heart failure, and requires participants to be willing and able to chelate 7 days per week 12-24 hours per day. Women who are pregnant or breastfeeding are not eligible to participate, and women of child-bearing potential must use a highly effective method of contraception.",
    "The sample is a phase 2 clinical trial for patients with renal cell carcinoma. The trial involves the use of two drugs, erlotinib hydrochloride and sirolimus. The eligibility criteria include a histological diagnosis of renal cell carcinoma, age of 18 or older, Eastern Cooperative Oncology Group (ECOG) Performance status of 2 or better, and failure or intolerance to previous treatment with Sutent\u00ae and/or Nexavar\u00ae. The trial also requires measurable disease by CT scan or MRI and certain baseline levels of hemoglobin, platelets, and absolute neutrophil count. Exclusion criteria include previous treatment with certain drugs, untreated metastasis to the central nervous system, and other serious medical conditions.",
    "The sample is a phase 2 clinical trial for patients with prostate cancer that has progressed while on standard hormonal management. The trial involves the use of two drugs, mitoxantrone hydrochloride and prednisone. Eligibility criteria include confirmed prostate cancer with regional or distant metastases, a prostate-specific antigen level greater than 5 ng/mL, and adequate hematologic, hepatic, renal, and cardiac function. Patients must also have no significant cardiac disease, no brain metastases, and no other serious medical illness. Fertile patients must use effective contraception during and for 2 months after completion of study treatment. Prior concurrent therapy includes no prior chemotherapy and more than 28 days since prior biologic therapy. Prior prostatectomy and/or orchiectomy are allowed.",
    "The sample is a phase 2 clinical trial for pancreatic cancer patients. The eligibility criteria include being between 18 and 75 years old, having a microscopic diagnosis of pancreatic cancer, and having a Karnofsky Performance status of over 50%. Prior radiotherapy is allowed, but prior chemotherapy is not, except for fluorouracil given concurrently as a radiosensitizer. Patients must have normal organ function and pain and biliary obstruction should be controlled for at least two weeks. Females of childbearing potential must have a negative pregnancy test. Exclusion criteria include contraindication to chemotherapy, uncontrolled CNS disease, and uncontrolled nausea and vomiting. Patients with a history of hypersensitivity to the study drugs, pregnant or lactating women, and those who have participated in a clinical trial with any investigational drug used with curative intent within 30 days prior to study entry are also excluded.",
    "The sample is a phase 2 clinical trial for asthma. The eligibility criteria include being healthy apart from asthma, being between the ages of 5 and 12, having a diagnosis of asthma for at least 6 months, and being on stable asthma therapy for at least 4 weeks prior to screening. The trial will test the effectiveness of two drugs, fluticasone furoate and fluticasone furoate/vilanterol. The inclusion criteria also require the ability to use a demonstration inhaler and a weight of at least 20 kilograms. The exclusion criteria include a history of life-threatening asthma, recent respiratory infections, abnormal ECG readings, and sensitivity to the ingredients in the inhaler. The trial will require the subject and parent/guardian to comply with protocol requirements and record diary information throughout the study.",
    "The sample is a phase 2 clinical trial for breast cancer patients. The eligibility criteria include being a female aged 65 or older, having a histological diagnosis of early breast cancer, and being recommended for (neo) adjuvant chemotherapy. Patients with triple negative breast cancer, HER-2 positive breast cancer, or \"Luminal B\" cancers are eligible if they meet certain criteria. Patients must also have a WHO performance status of 1 or less, adequate organ function, and no previous exposure to chemotherapy in this neoadjuvant or adjuvant setting. Additionally, patients must not have any serious cardiac illness or medical conditions that may interfere with planned treatment. The trial also includes a caregiver selection criteria, where the primary caregiver must be identified by the participating patient, be at least 18 years old, aware of the patient's cancer diagnosis, and be French speaking. Both the patient and caregiver must give their written informed consent to participate in the study.",
    "The sample is a phase 2 clinical trial for patients with adenocarcinoma of the prostate, recurrent prostate cancer, stage iib prostate cancer, stage iii prostate cancer, or stage iv prostate cancer. The trial is testing the drug perifosine. The eligibility criteria include having a rising PSA level following local curative therapy, no evidence of metastatic disease, and meeting certain medical requirements such as leukocyte count and platelet count. Patients must also agree to use contraception and sign a consent form. Exclusion criteria include prior cytotoxic chemotherapy, receiving other investigational agents, and having certain medical conditions such as uncontrolled illness or psychiatric illness.",
    "The sample is a record of a clinical trial in phase 2 for the treatment of hepatitis C infection. The trial involves the use of two drugs, bms-790052 and bms-650032. The eligibility criteria for the trial include having chronic HCV genotype 1 infection and a viral load of at least 100,000 IU/mL. However, individuals with liver cirrhosis, evidence of HCC, or co-infection with hepatitis B virus or HIV are excluded from the trial. The sample also includes the ICD-10 code for hepatitis C infection, which is B17.0.",
    "The sample is a phase 2 clinical trial for the treatment of cystic fibrosis. The trial involves administering ciprofloxacin (cipro inhale, bayq3939) and placebo to subjects with documented diagnosis of cystic fibrosis and chronic colonization with P. aeruginosa. The eligibility criteria include age, diagnosis, colonization, pulmonary function, stable regimen of standard CF treatment, and ability to understand and follow instructions. Exclusion criteria include medical disorders or conditions that would impair the subject's ability to participate or complete the study, febrile illness, exposure to investigational drugs, and history of allergic reaction to fluoroquinolones or other quinolones. The trial aims to evaluate the efficacy of ciprofloxacin in treating pulmonary exacerbation in subjects with cystic fibrosis.",
    "The sample is a phase 2 trial for chronic obstructive pulmonary disease (COPD) with a list of ICD-10 codes for the disease. The trial involves the use of drugs such as carmoterol and salmeterol, as well as a placebo. The eligibility criteria for the trial include being a male or non-pregnant female between the ages of 40-75 with a smoking history of at least 15 pack-years and a clinical diagnosis of COPD. The patient must also meet certain requirements after a FEV1 albuterol reversibility test. Exclusion criteria include a history of asthma, blood eosinophil count over 500/microliters, and uncontrolled cardiovascular or other diseases. The patient must not have taken certain medications prior to screening and must not have received a live-attenuated virus vaccination within two weeks prior to screening. The patient must also not be pregnant or lactating, mentally or legally incapacitated, or potentially non-compliant.",
    "The sample is a phase 2 clinical trial for patients with unresectable or metastatic urothelial cancer, specifically excluding transitional cell histologies. The trial involves the use of cisplatin, ifosfamide, and paclitaxel as drugs. The eligibility criteria include being 18 years or older, having a Karnofsky performance status of 60-100%, and meeting certain hematopoietic, hepatic, renal, and cardiovascular requirements. Patients cannot have any other concurrent malignancy except basal cell skin cancer and cannot have received prior systemic chemotherapy. The trial also specifies certain requirements for prior biologic therapy, endocrine therapy, radiotherapy, and surgery. The diseases being studied in this trial are bladder cancer and urethral cancer, and the icd-10 codes associated with these diseases are listed as well.",
    "The sample is a clinical trial for esophageal cancer and adenocarcinoma patients in phase 2/phase 3. The trial involves the use of nimotuzumab, cisplatin, and fluorouracil drugs. The eligibility criteria include being over 18 years old, having histological proof of SCC or esophageal adenocarcinoma, having a life expectancy of over 6 months, and having inoperable superior, medial, or distal third esophageal cancer. Other criteria include having a performance status of 0, 1, or 2, adequate body functions, and adequate calorie ingestion. Exclusion criteria include previous or planned treatment of esophageal carcinoma with surgery, radiotherapy, chemotherapy, or antineoplastic biological therapy, presence of active infection, and pregnancy or lactation.",
    "The sample is a phase 2 trial for asthma patients. The trial includes a list of icd-10 codes for asthma and a list of drugs, including a placebo and various doses of olodaterol. The eligibility criteria include being between the ages of 18 and 70, having a current diagnosis and documented history of asthma, and having a prebronchodilator Forced Expiratory Volume in one second (FEV1) between 60% and 90% predicted. Patients must also have stable asthma treatment for at least 6 weeks prior to screening. Exclusion criteria include having a significant disease other than asthma, frequent seasonal exacerbations of asthma, recent upper respiratory tract infection, and recent use of oral or other systemic corticosteroids. Patients undergoing allergen desensitization therapy are also excluded unless they are on an established maintenance regimen.",
    "The sample is a phase 2 clinical trial for the treatment of endometrial cancer using the drug ridaforolimus. The trial is open to individuals who are at least 18 years old and have histologically confirmed endometrial cancer with documented progression within the last 3 months. Participants must have at least one measurable lesion that can be accurately measured and meet certain criteria for renal and hepatic function, bone marrow function, and life expectancy. The trial has both inclusion and exclusion criteria, including exclusion of individuals who are pregnant or lactating, have brain metastases, or have had more than 2 prior regimens of cytotoxic chemotherapy or enzyme inhibitor therapy. Participants must also be able to understand and give written informed consent.",
    "The sample is a phase 2 clinical trial for non-small cell lung cancer. The trial includes patients with stage IIIB or IV disease, who have not received prior treatment and have no brain metastases. The patients must have measurable disease and an ECOG PS score of 0-1. The trial drugs include oxaliplatin, gemcitabine, and bevacizumab. The eligibility criteria include exclusion criteria such as a history of gross hemoptysis or deep vein thromboses or pulmonary embolus within 1 year.",
    "The sample is a phase 2 clinical trial for breast cancer patients who have undergone complete surgical removal of the cancer. The trial involves three different treatment regimens, including Tamoxifen, Adriamycin plus cyclophosphamide, and Adriamycin plus cyclophosphamide followed by Taxol. Patients must have an ECOG performance status of 0 or 1 and meet certain organ function criteria. They must also have recovered from prior surgery and radiation therapy and not have any other malignancies or serious underlying medical conditions. The trial has both inclusion and exclusion criteria, and patients must provide informed consent to participate.",
    "The sample is a phase 2 clinical trial for breast cancer patients. The trial is testing the effectiveness of the drug sorafenib on patients with metastatic or locally advanced disease who have residual measurable disease after maximal response to endocrine therapy or no response to endocrine therapy or progressive non-visceral disease on endocrine therapy. The trial is only open to female patients who are at least 18 years old and have histologically proven carcinoma of the breast with estrogen receptor and/or progesterone positive disease. Patients must also have an Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-2 and adequate organ function. The eligibility criteria include various other requirements, such as having a tumor block from either the primary or metastatic site, not having rapidly progressive disease on endocrine therapy, and not having any other coexisting malignancies except for basal cell carcinoma or cervical carcinoma in situ. The exclusion criteria include various factors such as prior use of anti-angiogenic agents, known brain metastasis, and pregnancy.",
    "The sample is a phase 2 clinical trial for breast cancer patients. The trial is testing the effectiveness of carboplatin and docetaxel drugs. The eligibility criteria include having clinical stage II or III breast cancer with no evidence of distant metastases, being at least 18 years old, having a performance status of ECOG 0-1, and meeting certain hematopoietic, hepatic, renal, and other health requirements. Patients must not have had prior surgical resection or other therapy for invasive breast cancer, and must not have certain medical conditions or allergies. Fertile patients must use effective contraception during and for 30 days after study treatment.",
    "The sample is a record of a clinical trial with a phase 2 designation. The trial is focused on the disease of aneurysmal subarachnoid hemorrhage, which is identified in the \"diseases\" field. The \"icdcodes\" field lists the ICD-10 codes associated with the disease. The trial involves the use of two drugs, tiopronin and placebo, which are listed in the \"drugs\" field. The \"criteria\" field outlines the eligibility criteria for the trial, including requirements for admission to a recruiting center, ability to initiate study drug treatment within 96 hours of aSAH onset, and ability to provide informed or surrogate consent. The exclusion criteria are also listed, which include hypersensitivity to penicillamine, certain levels of creatinine, platelet count, and white blood cell count, as well as a history of liver failure, pregnancy, and certain other medical conditions. Patients who are unable to comply with the protocol are also excluded.",
    "The sample is a phase 2 clinical trial for fibromyalgia. The trial includes patients who meet the American College of Rheumatology criteria for fibromyalgia and are over 18 years old. The trial involves taking either xyrem (sodium oxybate) oral solution or a placebo. Patients must discontinue all prescription medication taken for fibromyalgia until the study is completed and use only acetaminophen or over-the-counter non-steroidal anti-inflammatory drugs as rescue pain medications. Patients must also forego ingestion of alcohol for the duration of the study and use a medically accepted method of birth control if they are fertile females. The trial has exclusion criteria, including having other rheumatic diseases, uncontrolled medical conditions, recent substance abuse, and abnormal clinical laboratory results.",
    "The sample is a phase 2 clinical trial for patients with endometrial cancer. The trial is open to patients with stage III or IV cancer or recurrent endometrial carcinoma that cannot be cured by radiation therapy or surgery alone. Patients must have measurable disease and have discontinued platinum-based therapy at least 3 weeks prior to entry on the study. The trial is also open to patients who have received an unlimited amount of prior therapy. Patients must have adequate organ function and a Zubrod Performance Status of 0, 1, or 2. Patients must have signed an approved informed consent and have recovered from effects of recent surgery or radiotherapy. The trial excludes patients previously treated with gemcitabine, patients with a concomitant malignancy other than non-melanoma skin cancer, patients with papillary serous or clear cell carcinoma of the endometrium, or patients with malignant mixed mullerian tumor of the uterus. Patients with a prior malignancy who have been disease-free for less than 5 years, patients with concomitant medical illness such as serious uncontrolled infection, uncontrolled angina or serious peripheral neuropathy, patients with renal dysfunction, chronic or acute kidney disease, or renal failure, patients whose circumstances will not permit study completion or adequate follow-up, patients who have no measurable disease, and patients with a life expectancy of less than 3 months are also excluded from the trial.",
    "The sample is a phase 2 clinical trial for obesity and related metabolic diseases. The trial involves testing the effectiveness of a drug called R256918 compared to a placebo. The eligibility criteria for participants include being obese or overweight, having controlled hypertension and/or treated or untreated dyslipidemia, having a stable weight, and being able to swallow the drug capsule. Exclusion criteria include a history of certain medical conditions, prior exposure or known contraindication or hypersensitivity to R256918, and pregnancy or nursing. The trial also has a list of ICD-10 codes for the diseases being studied.",
    "The sample is a phase 2 clinical trial for rheumatoid arthritis. The trial includes patients who are between 18-75 years old and meet the diagnostic criteria for rheumatoid arthritis. Patients must have at least 6 swollen and tender joints, and either a Westergren ESR of >=28 mm/hour or a CRP level above the upper limit of normal for the central reference laboratory. Patients must have been treated with weekly oral or parenteral methotrexate for at least 6 months prior to baseline, and the dose must have been stable for at least 2 months. Patients must also meet other inclusion and exclusion criteria, such as negative pregnancy test for female patients of childbearing potential and not taking certain medications. The trial will evaluate the efficacy and safety of the drug cf101 compared to placebo.",
    "The sample is a phase 2 clinical trial for patients with multiple myeloma. The trial includes patients who have undergone high dose melphalan therapy and peripheral blood stem cell or bone marrow rescue. The trial aims to evaluate the effectiveness of a combination therapy of clarithromycin, thalidomide, and dexamethasone. The eligibility criteria include having a platelet count of over 50,000 cells/mm^3 and an absolute granulocyte count of over 1500 cells/mm^3 for 5 calendar days after recovery from high dose, starting therapy between 30 to 120 days after transplant, and willingness to comply with the FDA-mandated S.T.E.P.S. program. The exclusion criteria include having a Karnofsky score less than 70, a left ventricular ejection fraction less than 45%, and a history of deep venous thrombus, arterial occlusions, or pulmonary emboli. Patients who are pregnant or lactating, have untreated systemic infection, or have a history of seizures are also excluded from the trial.",
    "The sample is a phase 2 clinical trial for patients with HER2-positive breast cancer, recurrent breast cancer, or stage IV breast cancer. The trial involves the drug ixabepilone and has specific eligibility criteria, including measurable disease, adequate organ and marrow function, and a life expectancy of greater than 6 months. Patients must also have a performance status of 2 or less and cannot be receiving concurrent hormonal therapy, chemotherapy, or radiation treatments. The trial has exclusion criteria, including patients with leptomeningeal carcinomatosis, grade 3 or 4 allergic reactions to similar compounds, and uncontrolled intercurrent illness. The effects of the drug on the developing human fetus are unknown, so women of child-bearing potential and men must agree to use adequate contraception. Patients will be registered by contacting and faxing the completed eligibility checklist and all pages of the consent form to the Quality Assurance Office of Clinical Trials (QACT) at the Dana-Farber Cancer Institute.",
    "The sample is a phase 2 clinical trial for patients with carotid stenosis. The trial involves the use of two drugs, fasudil hydrochloride and a placebo oral tablet. The eligibility criteria for the trial include patients with at least 70% carotid stenosis who are scheduled to undergo elective carotid endarterectomy, aged 18 years or older, and with agreement from the operating surgeon. Exclusion criteria include pregnancy, scheduled surgery less than 14 days after randomization, elevated ALT or GGT levels, high creatinine levels, prior intolerance to statins, and reluctance to add or change dosage of statin therapy during the study. The diseases are listed as 'carotid stenosis' and the icd-10 codes associated with the disease are also provided.",
    "The sample is a phase 2 clinical trial for patients with recurrent ovarian, fallopian tube, or primary peritoneal carcinoma. The trial involves the use of three drugs - gemcitabine, oxaliplatin, and bevacizumab. The eligibility criteria include having measurable disease, a platinum-free interval of at least 6 months, and an Eastern Cooperative Oncology Group score of 0 or 1. Patients must also have adequate bone marrow, renal, neurologic, and liver function, and normal blood coagulation parameters. Exclusion criteria include recent chemotherapy, participation in other experimental drug studies, and a history of bleeding disorder or coagulopathy. Patients with other invasive malignancies, serious cardiovascular disease, or central nervous system disease are also excluded. Pregnant or lactating patients are not eligible for the trial.",
    "The sample is a phase 2 clinical trial for patients with end-stage renal disease who are undergoing maintenance hemodialysis. The trial is testing the effectiveness of soluble ferric pyrophosphate in liquid bicarbonate, a placebo of conventional liquid bicarbonate, an erythrocyte stimulating agent (ESA), and intravenous (IV) iron. The eligibility criteria include being male or female over 18 years old, having a mean hemoglobin level between 9.5 and 12.0 g/dL during screening, and having a mean ferritin level between 200 and 1000 \u00b5g/L during screening. The trial has several exclusion criteria, including having a catheter for dialysis, having an infection of the vascular access to be used at the time of randomization, and having a known cause of anemia other than anemia attributable to renal disease.",
    "The sample is a record of a clinical trial that is in phase 2/phase 3. The trial is focused on the treatment of generalized anxiety disorder in women between the ages of 18-65. The trial involves the use of three drugs: pexacerfont, escitalopram, and placebo. The eligibility criteria for the trial include meeting the DSM-IV TR criteria for GAD and having either moderate or severe symptoms. The exclusion criteria include being male and having a history of inadequate response to three or more adequate trials of any selective Serotonin reuptake inhibitors (SSRIs) for GAD within the last three years.",
    "The sample is a phase 2 clinical trial for liver cancer. The trial is testing the effectiveness of chemotherapy and embolization therapy for patients with unresectable hepatocellular carcinoma. The eligibility criteria include having confirmed liver cancer, being in Child's class A or B with liver-predominant and asymptomatic extrahepatic disease, and having an Eastern Cooperative Oncology Group (ECOG) performance status of 0-2. Patients must also meet certain laboratory values and cannot have had certain surgeries or treatments within a certain timeframe. The sample includes a detailed list of the eligibility criteria for the trial.",
    "The sample is a phase 2 clinical trial for the treatment of glaucoma and ocular hypertension. The trial involves the use of various bimatoprost ophthalmic solutions. The eligibility criteria for the trial include having ocular hypertension or glaucoma in both eyes and requiring IOP-lowering therapy in each eye. The exclusion criteria include having uncontrolled systemic disease or a known allergy or hypersensitivity to bimatoprost. The diseases and their corresponding ICD-10 codes are also listed in the sample.",
    "The sample is a phase 2 clinical trial for ovarian cancer. The trial includes patients who are in their second or later complete remission, or have untreated or refractory relapse. The trial requires patients to be between the ages of 18 and 70 and have no evidence of small bowel obstruction. Patients must also have adequate renal, hepatic, and pulmonary function, as well as adequate cardiac function. The trial excludes patients with unresolved grade 3 or greater non-hematologic toxicity from previous therapy, active Central Nervous System disease, and uncontrolled infection, among other criteria. The trial involves the use of multiple drugs, including bevacizumab, carboplatin, docetaxel, gemcitabine, and melphalan.",
    "The sample is a record of a clinical trial in phase 2 for the treatment of rheumatoid arthritis using the drug rituximab. The trial includes patients with active rheumatoid arthritis who are also using methotrexate. The inclusion criteria specify the requirements for patients to be eligible for the trial, while the exclusion criteria specify the conditions that would prevent a patient from participating in the trial. The icd-10 codes associated with the disease are also provided.",
    "The sample is a record from a clinical trial table. It is a phase 2 trial for patients with type 2 diabetes mellitus who have suboptimal glucose control. The trial includes a list of diseases and their corresponding ICD-10 codes, a list of drugs including mk0893, metformin, placebo to mk0893, and placebo to metformin, and eligibility criteria for inclusion and exclusion. The inclusion criteria require patients to not be on AHA therapy or to be on monotherapy or low-dose combination therapy. The exclusion criteria include patients with a history of type 1 diabetes mellitus, patients taking insulin or thiazolidinedione, and patients with a contraindication to metformin.",
    "This sample is a phase 2 clinical trial for obsessive-compulsive disorder. The trial includes patients with a confirmed diagnosis of OCD, symptoms lasting at least 1 year, and moderate to severe symptoms. Patients must have failed an adequate trial of an SSRI and agree to use reliable birth control if female. Exclusion criteria include a primary diagnosis of a psychotic disorder, substance abuse or dependence, unstable medical condition, prior exposure to N-Acetylcysteine, prior psychosurgery, pregnancy or breastfeeding, elevated liver function tests, evidence of active liver disease, seizure disorder, and active suicidal ideation. The trial will test the effectiveness of N-Acetylcysteine compared to a placebo.",
    "The sample is a phase 2 clinical trial for previously untreated non-cutaneous peripheral T-cell lymphoma, including human T-cell lymphotropic virus type 1 (HTLV-1) related T-cell lymphoma, and natural killer (NK)-cell lymphoma. The trial involves the use of a combination of drugs including velcade, doxorubicin, prednisone, cyclophosphamide, vindesine, and bleomycin. The eligibility criteria for the trial include being between the ages of 18 to 65 years, having a life expectancy of more than 3 months, and providing written informed consent. Exclusion criteria include having B-cell lymphoma or other subtypes of T-cell lymphoma, any previous therapy for lymphoma except for short-term corticosteroids before inclusion, and inability to tolerate the ACVBP regimen according to the investigator's judgement. The trial also excludes patients with positive serology for HIV, poor renal or liver function, poor bone marrow reserve, peripheral neuropathy, any central nervous system (CNS) disease, or any serious active disease or comorbidity according to the investigator's decision. Additionally, patients with any history of cancer during the last 5 years with the exception of non-melanoma skin tumours or stage 0 (in situ) cervical carcinoma are excluded. The trial also excludes patients with known hypersensitivity to bortezomib, boron or mannitol, contraindication to any cytotoxic drug contained in chemotherapy regimen, pregnant or lactating women or women of childbearing potential not willing to use an adequate method of birth control, men not agreeing to take adequate contraceptive precautions during the study, treatment with investigational drug within 30 days before planned first cycle of chemotherapy and during the study, and adult patient under tutelage.",
    "The sample is a record of a clinical trial with a phase 2 designation. The trial is focused on treating complicated skin and skin structure infections caused by gram-positive pathogens using the drug oritavancin. The trial has a list of diseases and their corresponding ICD-10 codes, including staphylococcal skin infections, wounds and injuries, abscess, cellulitis, and streptococcal infections. The eligibility criteria for the trial include being 18 years or older, not being below normal body weight or morbidly obese, and not having received antibiotics for more than 24 hours within the last 3 days. The exclusion criteria include having a condition that would prevent performing protocol safety and efficacy assessments, having an infection involving deep tissues or unlikely to be caused by gram-positive bacteria, and having a prior allergic reaction to glycopeptides.",
    "The sample is a phase 2 clinical trial for patients with advanced ovarian carcinoma, fallopian tube carcinoma, or primary peritoneal cancer of serous type with recurrent disease who responded to 2nd, 3rd or 4th line chemotherapy. The trial is testing the effectiveness of the drug bibf1120 compared to a placebo. The eligibility criteria include factors such as age, treatment-free interval, recovery from previous therapy, hepatic and renal function, and written informed consent. Exclusion criteria include serious illness or concomitant non-oncological disease, major injuries or surgery within the past 4 weeks, hypersensitivity to bibf1120, significant cardiovascular diseases, and other documented malignancy. The trial aims to determine the safety and efficacy of bibf1120 in treating advanced ovarian carcinoma.",
    "The sample is a phase 2 clinical trial for the treatment of venous thromboembolism. The trial involves the use of drugs such as xarelto and (lmw) heparin + vitamin k antagonist. The eligibility criteria for the trial include having confirmed acute symptomatic DVT without concomitant symptomatic PE, written informed consent, and meeting certain exclusion criteria such as having legal lower age limitations, thrombectomy, insertion of a caval filter, or use of a fibrinolytic agent to treat the current episode of DVT, and more. The trial also requires participants to have a life expectancy of at least 3 months and not have any contraindications listed in the labeling of certain drugs. Additionally, participants cannot have systemic treatment with azole compounds or other strong CYP3A4 inhibitors within 4 days prior to randomization and during the study.",
    "The sample is a phase 2 clinical trial for attention-deficit/hyperactivity disorder (ADHD). The trial includes patients between 18 and 55 years old who have a current DSM-IV diagnosis of ADHD of inattentive or combined subtype. Females of child-bearing potential must use acceptable methods of birth control during the study and for 1 month post-therapy. Patients with a history of neurological disorder, psychotic disorder, bipolar disorder, post-traumatic stress disorder, ongoing depression, sensitivity or allergy to methylphenidate, glaucoma, previous history of narrowing or blockage of the GI tract, sleep disorder, cardiovascular disorder, moderate or severe persistent asthma, or substance abuse or dependence not in sustained full remission for at least one year according to DSM-IV are excluded from the trial. The trial includes the drugs mk0249, Concerta (methylphenidate), and placebo. The icd-10 codes for the diseases are F90.2, F90.8, F90.9, F90.0, and F90.1.",
    "The sample is a phase 2 clinical trial for patients with recurrent or persistent ovarian epithelial, fallopian tube, or primary peritoneal cavity carcinoma. The trial requires patients to have measurable disease and at least one \"target lesion\" to assess response. Patients must have had one prior platinum-based chemotherapeutic regimen for management of primary disease containing carboplatin, cisplatin, or another organoplatinum compound. Patients are allowed, but not required to receive, two additional cytotoxic regimens for management of recurrent or persistent disease with no more than one non-platinum, non-taxane regimen. Patients must meet certain criteria related to their platelet count, ANC count, hemoglobin, creatinine, AST and ALT levels, CPK levels, bilirubin or direct bilirubin levels, alkaline phosphatase levels, neuropathy, and pregnancy status. Patients must also have recovered from recent surgery, radiotherapy, or chemotherapy and must not have had prior therapy with docetaxel and/or trabectedin.",
    "The sample is a record of a clinical trial with a phase 2/phase 3 designation. The trial is focused on the treatment of idiopathic pulmonary fibrosis, a disease with the ICD-10 code J84.112. The trial involves the use of the drugs bosentan and placebo. The eligibility criteria for the trial include being over 18 years old, having a proven diagnosis of IPF within the last 3 years, having a six-minute walk test distance of at least 150 meters but less than 500 meters, and not having certain medical conditions or taking certain medications. The sample also includes a list of exclusion criteria, which includes conditions such as severe concomitant illness, severe restrictive or obstructive lung disease, and recent pulmonary or upper respiratory track infection.",
    "The sample is a phase 2 clinical trial for the treatment of metastatic pancreatic cancer. The trial involves the use of simtuzumab, gemcitabine, and a placebo to match simtuzumab. The eligibility criteria include a diagnosis of metastatic pancreatic cancer within the past 6 weeks, measurable disease per RECIST, an ECOG Performance Status of 0 or 1, and adequate hepatic, hematologic, and renal functions. Exclusion criteria include a history of clinically significant disorders other than metastatic cancer of the pancreas, pancreatic islet neoplasms, major surgery within 4 weeks of randomization, biliary obstruction requiring external drainage, brain metastases, unstable cardiovascular function within the last 6 months of screening, clinically active liver disease, known HIV infection, uncontrolled hypertension at screening, history or presence of any form of cancer other than pancreatic cancer within the 3 years prior to enrollment, prior or concurrent anti-tumor therapy, uncontrolled systemic fungal, bacterial, or viral infection, and participation in an investigational drug or device trial with therapeutic intent within 30 days prior to the study.",
    "The sample is a record from a clinical trial table. It is a phase 2 trial for metastatic breast cancer. The trial includes patients who have been diagnosed with metastatic breast cancer and are to be treated with capecitabine at study entry. The trial also requires patients to have lymphopenia, a performance status ECOG of 0, 1, 2, or 3, and a life expectancy of at least 6 months. Patients must also have adequate bone marrow, hepatic, and renal function. The trial has inclusion and exclusion criteria, which are listed in the sample. The inclusion criteria include being a female aged over 18 years, having a histologic diagnosis of metastatic breast cancer, and being covered by medical insurance. The exclusion criteria include having a prior history of other malignancies, uncontrolled hypertension, and any history of severe auto-immune disease.",
    "The sample is a phase 2 trial for patients with coronary artery disease. The trial involves the drugs via-2291 and placebo. The eligibility criteria include having suffered from an ST elevation myocardial infarction, non-ST elevation MI, or unstable angina 21 days prior to study randomization, having documented coronary artery disease, and being a female patient of non-childbearing potential. The exclusion criteria include renal insufficiency, cirrhosis, uncontrolled diabetes mellitus, congestive heart failure, previous coronary artery bypass graft surgery, planned additional cardiac intervention, recurrence of ST elevation MI, non-ST elevation MI, or unstable angina less than 18 days prior to randomization, current atrial fibrillation, atrial flutter, or frequent premature ventricular contractions, and acetaminophen use in any form in the 7 days before enrollment.",
    "The sample is a phase 2 trial for the treatment of various types of adult acute myeloid leukemia. The trial includes patients who have not received any anti-leukemic therapy (except for hydroxyurea) between diagnosis and study registration. Patients must have a bone marrow or peripheral blood diagnosis within 28 days prior to study registration. The trial also requires cytogenetic analysis and pretreatment bone marrow and peripheral blood specimens for correlative studies. Patients with a history of antecedent MDS are eligible if prior treatment did not include intensive chemotherapy. The trial has various inclusion and exclusion criteria, including performance status, bilirubin, SGOT, SPGT, serum creatinine, left ventricular ejection fraction, and reproductive potential. Patients must also provide signed written informed consent and undergo a bone marrow examination on day 8 of the first induction cycle. The trial excludes patients with a diagnosis of another malignancy, myeloid blast crisis of chronic myelogenous leukemia, prior systemic chemotherapy for AML (except for hydroxyurea), and prior treatment with AML induction-type chemotherapy, GO, HDAC inhibitors, or high dose chemotherapy with hematopoietic stem cell support. The trial also excludes patients with known hypersensitivity to hydroxyurea, GO, or vorinostat, clinical evidence suggestive of CNS involvement with leukemia, prior positive test for HIV, breastfeeding, and uncontrolled systemic fungal, bacterial, viral, or other infection.",
    "The sample is a phase 2 clinical trial for patients with kidney cancer that has spread or cannot be surgically removed. The trial is testing the effectiveness of two drugs, gemcitabine hydrochloride and imatinib mesylate. The eligibility criteria include having confirmed renal cell carcinoma, measurable disease, and no known curative therapy. Patients must also meet certain medical criteria, such as having a certain performance status and blood counts, and not having certain medical conditions. Prior to the trial, patients must have recovered from previous therapies and cannot have had more than three prior treatment regimens. Concurrent use of certain medications is also not allowed. The sample includes detailed information on the disease characteristics, patient characteristics, and prior concurrent therapy.",
    "The sample is a phase 2 clinical trial for the treatment of hepatitis C. The trial is looking at the effectiveness of two drugs, miravirsen and saline, in patients who have not previously been treated with interferon-alpha based therapies and have genotype 1 of the disease. The trial has a list of inclusion and exclusion criteria, including BMI, HCV RNA levels, liver biopsy results, and various laboratory tests. Patients with other liver diseases, decompensated liver disease, hepatocellular carcinoma, or other clinically significant medical diagnoses are excluded from the trial. Additionally, patients who have participated in an investigational drug study within 30 days or 5 half-lives prior to the start of study medication are also excluded.",
    "The sample is a phase 2 clinical trial for patients with invasive ER/PR and HER2/neu-negative breast carcinoma. The trial involves the use of drugs such as paclitaxel, 5-fluorouracil, epirubicin, cyclophosphamide, and rad001. The eligibility criteria include having intact primary tumors, being at least 18 years old, having stage IIA to IIIC non-inflammatory breast cancer, and having a Karnofsky performance scale of 70% or higher. Patients must also have clinically measurable disease and adequate bone marrow, liver, and renal function. Exclusion criteria include a history of other invasive malignancies, prior exposure to mTOR inhibitors, and chronic treatment with systemic steroids or another immunosuppressive agent. Patients must sign an informed consent indicating that they are aware of the investigational nature of the study.",
    "The sample is a phase 2 clinical trial for the treatment of type 2 diabetes mellitus. The trial involves the use of drugs such as mk-0893, metformin, and placebos. The eligibility criteria for the trial include having type 2 diabetes, not currently being on antihyperglycemic agents, having a BMI between 20 and 40 kg/m2, and being either a postmenopausal woman or a surgically sterilized woman. The exclusion criteria include having type 1 diabetes, a history of ketoacidosis or unstable diabetic complications, recent treatment with certain medications, and various other medical conditions.",
    "This sample is a phase 2 clinical trial for kidney cancer. The trial is looking for patients with locally recurrent or metastatic renal cell carcinoma that cannot be removed through surgery. Patients must have progressive disease, either through the appearance of new lesions or a 20% increase in the sum of the longest diameters of the target lesions. Patients must also meet certain disease characteristics, such as having no prior or concurrent brain metastases. The trial is testing the drug atrasentan hydrochloride. Patients must meet certain eligibility criteria, such as being 18 years or older, having an ECOG performance status of 0-2, and meeting certain hematopoietic, hepatic, renal, cardiovascular, and pulmonary requirements. Patients must not have had prior chemotherapy or concurrent radiotherapy for palliation or any other indication. Prior bisphosphonates are allowed.",
    "The sample is a phase 2 clinical trial for psoriasis. The trial is looking for male or female participants over the age of 18 who have a clinical diagnosis of stable plaque type psoriasis and have two target plaques of similar severity. The plaques must be between 5 cm2 and 100 cm2 and located bilaterally on the arms or on the trunk with a minimum distance of 10 cm between them. The overall target plaque severity score must be between 2-4 (mild to moderate) with no more than a 1 point difference in the scores of the two target plaques. Participants must be willing and able to apply the study drug as directed, comply with study instructions, and commit to all follow-up visits. Exclusion criteria include any dermatological conditions or physical conditions that could interfere with clinical evaluations or might expose the patient to an unacceptable risk by study participation, any underlying disease(s) or other dermatological conditions that require the use of exclusionary topical or systemic therapy, and known sensitivity to any of the components of the study medication. Females of childbearing potential are excluded unless they are post-menopausal or surgically sterile. Participants must also meet certain washout periods for exclusionary therapies and cannot have AIDS or AIDS-related illness. Concurrent participation in another drug or device research study or use of certain medications is also excluded.",
    "The sample is a phase 2 clinical trial for patients with metastatic breast cancer. The trial requires patients to have bidimensionally measurable disease in the lungs, lymph nodes, liver, or abdomen. Patients must have failed or progressed on prior therapy or relapsed less than 12 months after therapy discontinuation. The eligibility criteria also include specific requirements for age, sex, performance status, life expectancy, hematopoietic, hepatic, renal, and cardiovascular function. Patients must not have any other serious illnesses or active infections and must not be pregnant or nursing. The trial allows for one prior regimen of hormonal therapy and no more than two prior chemotherapy regimens for metastatic disease. Patients must not be receiving any other concurrent anticancer or investigational therapy and must not be participating in another therapeutic clinical trial.",
    "The sample is a phase 2 clinical trial for the treatment of relapsing-remitting multiple sclerosis. The trial involves the use of the drugs natalizumab and placebo. The eligibility criteria for participants include a diagnosis of MS, being between the ages of 18 and 55, having a baseline EDSS score between 0.0 and 5.0, and having been treated with GA for at least 12 months prior to randomization. Exclusion criteria include progressive forms of MS, recent MS relapse, significant infectious illness, and significant disease that would prevent the administration of the drugs being tested. The diseases are listed as 'multiple sclerosis, relapsing-remitting' and the icd-10 codes associated with the disease are also provided.",
    "The sample is a phase 2 clinical trial for the treatment of herpes zoster and postherpetic neuralgia using the drug pregabalin. The trial has specific eligibility criteria, including having an acute outbreak of herpes zoster with unilateral skin rash and pain, having pain present for more than 3 days but less than 42 days after onset of the herpes zoster skin rash, and having an average score of at least 40 mm on the visual analog scale of the SF-McGill Pain Questionnaire. There are also exclusion criteria, such as having serious medical or psychological conditions that would compromise participation in the study, being pregnant or lactating, or having a history of illicit drug or alcohol abuse within the last year.",
    "The sample is a phase 2 clinical trial for patients with locally advanced colorectal cancer. The trial involves a combination of drugs including capecitabine, fluorouracil, irinotecan hydrochloride, leucovorin calcium, and oxaliplatin. The eligibility criteria include having a confirmed primary adenocarcinoma of the rectum, locally advanced disease, measurable disease, and available tumor tissue for molecular profiling. Patients must also meet certain age, performance status, and medical criteria, and cannot have had prior chemotherapy or pelvic radiotherapy. The trial does not specify any biologic or endocrine therapy, and excludes patients with other serious medical illnesses or unanticipated severe reactions to study drugs.",
    "This sample is for a phase 2 clinical trial for Alzheimer's disease. The trial is testing the effectiveness of a drug called ly2062430 compared to a placebo. The eligibility criteria for the trial include being at least 50 years old, having mild to moderate Alzheimer's disease or being a healthy volunteer, being fluent in English, and having a reliable study partner. Patients with Alzheimer's disease must have been on stable therapy for at least 2 months prior to starting the study drug. Exclusion criteria include a history of serious infectious disease affecting the brain, head trauma, cancer, drug or alcohol abuse in the past 5 years, serious or uncontrolled health problems or laboratory tests, multiple or severe drug allergies, and prior participation in an active immunization study.",
    "The sample is a record of a clinical trial in phase 2 for the treatment of heparin-induced thrombocytopenia. The trial involves the use of two drugs, fondaparinux and warfarin. The eligibility criteria for the trial include having a high risk for HIT based on the \"Four Ts score\" of 6 or more, and meeting certain exclusion criteria such as having pulmonary emboli or arterial thrombosis at the time of enrollment, having a platelet count less than 50, or being allergic to fondaparinux. The sample also includes a list of icd-10 codes associated with the disease.",
    "The sample is a phase 2 clinical trial for patients with non-small-cell lung carcinoma. The trial is testing the drug bibw 2992 and is looking for patients with activating mutations in the EGFR-receptor. Patients must have already undergone first-line cytotoxic chemotherapy or have recurrent disease after prior neoadjuvant or adjuvant chemotherapy. Inclusion criteria also include having at least one measurable tumor lesion, being 18 years or older, having a life expectancy of at least three months, and having an ECOG performance score of 0, 1, or 2. Exclusion criteria include having more than one prior cytotoxic chemotherapy treatment regimen, recent chemotherapy or hormone therapy, brain metastases, significant gastrointestinal disorders, other life-threatening illnesses or organ system dysfunction, other malignancies diagnosed within the past five years, and more.",
    "The sample is a phase 2 clinical trial for Tourette Syndrome. The eligibility criteria include being a male or female patient between the ages of 6-17, having a diagnosis of Tourette's Disorder with a Total Tic Score of at least 22 at baseline, having at least 1 tic per day, and having a body weight of at least 20 kg. Exclusion criteria include having a positive pregnancy test, clinically significant renal disease or abnormal lab results, a history of schizophrenia or any psychotic disorder, and having received certain medical treatments within a certain timeframe prior to the trial. The trial will test the effectiveness of pramipexole immediate release (ir) compared to a placebo.",
    "The sample is a phase 2 clinical trial for patients with advanced metastatic or unresectable epithelial ovarian cancer, primary peritoneal cancer, or fallopian tube cancer that is relapsed and resistant or refractory to prior platinum-based standard care systemic regimen. The trial involves the drug birinapant (tl32711) and has eligibility criteria such as measurable disease, adequate renal and hepatic function, and a life expectancy greater than 3 months. The trial also has exclusion criteria such as a known or suspected diagnosis of human immunodeficiency virus or chronic active hepatitis B or C, impaired cardiac function, and a recent history of autoimmune disease or inflammatory diseases. The study will be recruiting women from all racial/ethnic groups who meet the eligibility criteria.",
    "The sample is a phase 2 clinical trial for patients with metastatic adenocarcinoma of the colon or rectum. The trial is testing the drug saracatinib and the eligibility criteria includes having received only one prior chemotherapy regimen for metastatic colorectal cancer, having measurable disease, and having an ECOG performance status of 0-2. Patients must also meet certain laboratory values and agree to use adequate contraception during the study. Exclusion criteria include having received chemotherapy or radiotherapy within 4 weeks prior to study registration, having uncontrolled intercurrent illness, and having known brain metastases. Pregnant women and patients with a history of another primary malignancy within the last 5 years (with the exception of non-melanoma skin cancer and carcinoma in situ of uterine cervix) are also excluded.",
    "The sample is a record of a clinical trial with a phase 2 designation. The trial is focused on non-small cell lung cancer and involves the use of drugs such as bevacizumab, cisplatin, and docetaxel. The eligibility criteria for the trial include being an adult patient over the age of 18 with stage IIIb or IV non-small cell lung cancer who has not received chemotherapy before. The exclusion criteria include having received previous treatment for non-small cell lung cancer, having had a previous malignant tumor within the last 5 years (with the exception of basal cell skin cancer or preinvasive cervical cancer), having undergone a major surgical procedure or open biopsy within 28 days prior to the start of the study, and having received recent or current chronic treatment with aspirin (> 325 mg/day).",
    "The sample is a phase 2 clinical trial for patients with breast cancer, colorectal cancer, or non-small-cell lung carcinoma. The trial involves the use of three drugs, mk0683, vorinostat, and suberoylanilide hydroxamic acid (saha), administered twice daily for 14 days followed by 7 days of rest for a total of 10 cycles. The eligibility criteria include being 18 years or older with a confirmed diagnosis of one of the three cancers, having relapsed or refractory disease following at least one chemotherapeutic treatment regimen, having a measurable PET assessable lesion, and having adequate blood, liver, bone marrow, and kidney functions. Exclusion criteria include prior treatment with histone deacetylase (HDAC) inhibitor, treatment with investigational agents within the last 30 days, active infection or recent IV antibiotic, antiviral, or antifungal medication, HIV, hepatitis B or hepatitis C infection, pregnancy or lactation, and allergy to any component of the study drug.",
    "The sample is a phase 2 clinical trial for Alzheimer's disease and dementia. The trial involves the use of two drugs, nic5-15 and placebo. The eligibility criteria for the trial include meeting the NINCDS/ADRDA criteria for probable AD, having an MMSE score between 12-27, and being on a stable dose of a cholinesterase inhibitor or an NMDA antagonist for at least 12 weeks. The patient must also have home monitoring available for medication supervision, a caregiver available to accompany them to all visits, and be fluent in English or Spanish. They must be medically stable and able to swallow oral medications. Exclusion criteria include a history of diabetes mellitus, active hepatic or renal disease, cardiac disease, use of another investigational drug within the past two months, and major mental illness. The use of certain medications, such as oral hypoglycemic agents and drugs with significant anticholinergic or antihistaminic properties, is also excluded.",
    "The sample is a phase 2 clinical trial for the treatment of type 2 diabetes mellitus. The trial involves the drugs azd1656 and placebo. The eligibility criteria include women of non-childbearing potential, provision of informed consent, and T2DM patients with HbA1c levels between 7.5% and 10% who are either treatment-naive or treated with one or two oral anti-hyperglycemic agents. Exclusion criteria include a history of cardiovascular, renal, hepatic, or hematological disease, as well as participation in another clinical trial or intake of another investigational drug within the last 30 days.",
    "The sample is a phase 2 clinical trial for Parkinson's disease. The trial includes patients with a diagnosis of idiopathic Parkinson's disease, Hoehn and Yahr stage 2.0 to 4.0, who have drug-induced dyskinesias and are over 40 years old. The trial will test the effectiveness of sildenafil and placebo drugs. The eligibility criteria include a willingness and ability to comply with the study requirements and give informed consent. The exclusion criteria include atypical parkinsonian syndrome due to drugs, metabolic disorders, encephalitis, or degenerative diseases, history of stereotaxic brain surgery, clinical history of dementia, major psychiatric disorder, major depression, schizophrenia, alcoholism or substance dependence within previous 12 months, major hematological, renal, or hepatic abnormalities, coronary artery disease, stroke within the last 6 months, abnormal EKG consistent with cardiac ischemia, treatment with nitrates, malignant hypertension, history of priapism, retinitis pigmentosa, positive pregnancy test, bleeding disorder, active peptic ulcer disease associated with bleeding, unwillingness to use adequate contraceptive methods if of childbearing potential, and medical or psychological condition or social circumstances that would impair their ability to participate in the study. Patients who have used Viagra or any experimental drugs within 30 days of the screening visit are also excluded.",
    "The sample is a record of a clinical trial with a phase 2 designation. The trial is focused on treating non-Hodgkin's lymphoma using a combination of drugs called cdop plus rituximab. The eligibility criteria for the trial include being 65 years or older, having a diagnosis of non-Hodgkin's lymphoma, being previously untreated, having an ECOG score of 0-2, having adequate renal and hepatic functions, having a cardiac ejection fraction of at least 50% by MUGA, and signing an informed consent form. The exclusion criteria include having CNS involvement by lymphoma, being hypersensitive to the study drugs, having an active infection, having prior treatment with monoclonal antibodies for cancer, and having a history of cardiac disease with New York Heart Association Class II or greater or clinical evidence of congestive heart failure.",
    "The sample is a phase 2 clinical trial for patients with solid tumor malignancy who have failed at least one biologic or cytotoxic regimen or are unable to receive standard treatment due to performance status. The trial is specifically for patients with ascites, which is confirmed through paracentesis or CT scan within one month prior to enrollment. The drug being tested is sunitinib. The eligibility criteria include having a life expectancy of more than 3 months, negative urine pregnancy test for females, and agreement to use birth control. The exclusion criteria include a history of congestive heart failure, creatinine levels above 2.0, pregnancy or nursing, ALT levels above 2.5 times the upper limit of normal, blood pressure above 160/90, gastrointestinal or intra-abdominal hemorrhage within the last 6 months, history of QTc above 450 milliseconds, and brain metastasis.",
    "The sample is a phase 2 clinical trial for patients with relapsed and/or refractory acute promyelocytic leukemia. The trial is testing the drug tamibarotene. Patients must meet certain eligibility criteria, including having a confirmed diagnosis of APL and having failed therapy with ATRA and ATO. Patients must also have adequate organ function and an estimated life expectancy of at least 12 weeks. Patients who have extramedullary leukemia, impaired cardiac function, uncontrolled infections, or other severe concurrent diseases will be excluded from the study. Additionally, patients who are pregnant or lactating, have a history of myelodysplastic syndromes, or have a history of another primary malignancy that has been actively treated in the last 24 months will also be excluded.",
    "The sample is a phase 2 clinical trial for rheumatoid arthritis. The trial includes patients with active RA of functional classes I, II or III according to the criteria of American Rheumatism Association for RA. The patients must have received weekly doses of MTX (10-25 mg/week) for a minimum of 3 months prior to Day 1 dosing, and who have received a stable MTX dose of 10-25 mg/week without any change in route or change in folic acid supplementation for at least 6 weeks prior to Day 1 dosing. Patients may receive up to 10 mg/day of oral prednisolone or steroid equivalent. The trial has certain exclusion criteria, such as patients with RA of functional classes IV according to the criteria of American Rheumatism Association for RA, and patients who have received certain treatments within a specified washout period. The drugs used in the trial include sc12267 (4sc-101), placebo, methotrexate, and folic acid.",
    "The sample is a phase 2 clinical trial for patients with recurrent or persistent uterine carcinosarcoma. The trial requires patients to have measurable disease and at least one \"target lesion\" to assess response. Patients must have had one prior chemotherapeutic regimen for management of carcinosarcoma. Patients are allowed to receive one additional cytotoxic regimen for management of recurrent or persistent disease. The trial has inclusion and exclusion criteria, including requirements for blood counts, liver function, and neuropathy. Patients must have signed an approved informed consent and authorization permitting release of personal health information. The trial excludes patients with other invasive malignancies, signs or symptoms of bowel dysfunction or obstruction, and other severe concurrent diseases.",
    "The sample is a phase 2 trial for patients with soft tissue sarcoma who have failed \u22642 prior regimens including adjuvant therapy, or \u22641 prior regimen for metastatic/unresectable disease, and for whom treatment with doxorubicin is considered medically acceptable. The trial involves the use of two drugs, palifosfamide tris and doxorubicin. The eligibility criteria include age \u226518 years, histological or cytological documentation of sarcoma, measurable disease as per RECIST criteria, ECOG Performance Status of 0 or 1, anthracyclin na\u00efve, life expectancy of \u226512 weeks, and adequate bone marrow, liver, and renal function. The exclusion criteria include several medical conditions and prior or concomitant use of certain therapies and medications. Written informed consent must be obtained from potential subjects prior to the conduct of any study-specific procedures.",
    "The sample is a phase 2 clinical trial for patients with stage IV colorectal cancer with unresectable liver metastases. The trial involves the use of cetuximab and irinotecan drugs. The eligibility criteria include having a confirmed diagnosis of colorectal cancer, being refractory to 5-FU/oxaliplatin and/or 5-FU/irinotecan, having at least one measurable liver metastasis, having liver only or liver dominant disease, having an ECOG performance status of \u2264 2, having a life expectancy of > 3 months, being at least 18 years old, and meeting several other medical criteria. The exclusion criteria include having CNS metastases, contraindications to irinotecan therapy, active bacterial, viral or fungal infection, pregnancy or breastfeeding, allergy to contrast media, presence of another concurrent malignancy, and several other medical conditions.",
    "The sample is a phase 2 clinical trial for patients with advanced or metastatic colorectal cancer who are scheduled to receive first- or second-line therapy for their disease. The trial is testing the effectiveness of a combination of three drugs: fluorouracil, irinotecan hydrochloride, and leucovorin calcium. The eligibility criteria include confirmation of colorectal cancer, certain patient characteristics such as performance status and blood counts, and no contraindications to atropine. Patients must also not have certain conditions or prior treatments, and must have recovered from any prior anticancer therapy. The trial does not allow for any other concurrent anticancer therapy.",
    "The sample is a phase 2 clinical trial for patients with non-small cell lung cancer. The trial is testing the effectiveness of the drugs cisplatin and pemetrexed disodium in combination with surgery for patients with stage IB, II, IIIA, or IIIB (T4, N0-1) disease. Patients must have measurable and resectable disease, be eligible for curative surgery, and have no malignant pleural effusion. Eligibility criteria include age 18 and over, ECOG 0-1 performance status, adequate hematopoietic, hepatic, renal, and pulmonary function, and no other concurrent serious or uncontrolled disorder that would preclude study participation. Prior concurrent therapy is also restricted.",
    "The sample is a phase 2 clinical trial for patients with gastrointestinal stromal tumor. The trial involves the drug imatinib mesylate and has eligibility criteria that include having limited or generalized progression on imatinib, a confirmed diagnosis of Kit-expressing advanced GIST, measurable disease by CT, and an ECOG performance status of 0-2. Patients must also meet certain laboratory values and have recovered from prior therapies. The trial has exclusion criteria that include significant concurrent medical disease other than cancer and a history of second cancer, except for certain types.",
    "The sample is a phase 2 clinical trial for patients with soft tissue or bony sarcoma. The trial is testing the effectiveness of cetuximab, a drug that targets the EGFR pathway. Patients must meet certain eligibility criteria, such as having a pathologic diagnosis of sarcoma, being at least 16 years old, and having received at least one systemic chemotherapy treatment. Patients must also not have any exclusion criteria, such as active or uncontrolled infection or prior therapy that targets the EGFR pathway. The trial aims to assess the safety and efficacy of cetuximab in treating sarcoma.",
    "The sample is a phase 2 clinical trial for the treatment of multiple myeloma using the drug azacitidine. The trial includes patients who have been diagnosed with multiple myeloma according to IMWG criteria, are over 17 years old, and have received 2-4 prior lines of therapy. Patients must have failed to respond to the most recent anti-MM therapy or have demonstrably progressive disease. They must also have a life expectancy of at least 3 months and meet certain haematological and biochemical values. Patients must provide written informed consent and agree to use adequate contraceptive measures if indicated. The trial excludes patients with MGUS or indolent/smouldering MM, known or suspected hypersensitivity to AZA or mannitol, significant cardiac or pulmonary disease, active infections or other illnesses that preclude chemotherapy administration or patient compliance, active viral infection with known HIV or viral hepatitis type B or C, and pregnant or lactating women.",
    "This sample is a phase 2 clinical trial for the treatment of asthma. The trial is testing the effectiveness of the drug L-arginine compared to a placebo. The eligibility criteria for participants include having moderate to severe persistent asthma, being stable on the same asthma medications for at least one month, and having a negative pregnancy test if the participant is a woman of child-bearing age. Exclusion criteria include being under 18 years of age, having a baseline Forced Expiratory Volume in 1 second (FEV1) less than 40% predicted, having a known or suspected allergy to L-arginine, being pregnant, nursing, or actively trying to achieve pregnancy, being a current smoker, or having a history of smoking more than 15 pack-years. The diseases listed in the sample are only related to asthma, and the icd-10 codes provided are specific codes related to asthma.",
    "The sample is a phase 2 clinical trial for epilepsy. The trial is testing the effectiveness of a drug called YKP3089 compared to a placebo. The eligibility criteria for participants include being between the ages of 18-60, having a diagnosis and history of epilepsy, and being on 0-2 concomitant antiepileptic drugs. Participants must also have a reproducible IPS-induced photo-paroxysmal response (PPR) on EEG of at least 3 points on a frequency assessment scale in at least one eye condition. Exclusion criteria include a history of non-epileptic seizures, pregnancy or lactation, and any clinically significant laboratory abnormality or psychiatric illness that would interfere with participation in the study.",
    "The sample is a phase 2 clinical trial for the treatment of dry eye syndrome and dry eye using thymosin beta 4 and a placebo. The trial includes patients who have given written consent, have a history of dry eye in both eyes, and have used or desire to use an artificial tear substitute for dry eye symptoms within the past 6 months. Patients must also have a corneal fluorescein staining score of \u2265 2 in any corneal surface segment in at least one eye at Visit 1. Exclusion criteria include contraindications to the study drug, known allergy or sensitivity to the study drug or its components, anterior blepharitis, an ongoing ocular infection or active ocular inflammation, use of contact lenses within 1 week before Visit 1 or during the course of the study, previous LASIK surgery within 12 months prior to Visit 1, current use of any topical ophthalmic prescription or over-the-counter (OTC) solutions, artificial tears, gels, or scrubs that cannot be discontinued for the duration of the trial, past or present evidence of malignancy, and more.",
    "The sample is a phase 2 clinical trial for hypertension in children and adolescents aged 6 to under 18 years old. The trial includes patients who have a seated systolic blood pressure (SBP) equal to or greater than the 95th percentile based on age, height, and gender. The trial involves the use of the drug telmisartan and a placebo. The eligibility criteria include the ability to provide written informed consent, the ability to swallow whole tablets, and the absence of certain medical conditions such as stroke, solid organ transplantation, and clinically significant neurological or psychiatric conditions. The exclusion criteria include the use of certain medications, such as angiotensin II receptor antagonists and ACE inhibitors, and the presence of certain medical conditions, such as hereditary fructose intolerance and symptoms characteristic of angioedema during treatment with ACE inhibitors or angiotensin II receptor antagonists.",
    "The sample is a phase 2 clinical trial for metastatic colorectal cancer. The trial includes patients with histologically verified adenocarcinoma in colon or rectum, aged over 18, and who have progressed after chemotherapy regimens containing fluoropyrimidines, oxaliplatin, and irinotecan. Patients must also have a KRAS mutation in primary tumor or metastasis, measurable disease according to RECIST, and an ECOG performance status of 0, 1, or 2. Adequate function of liver, kidneys, and bone marrow is required, as well as specific blood counts and biochemistry measurements. Patients must also provide blood samples and paraffin-embedded tissue for translational research. Exclusion criteria include other concurrent diseases, other malignant disease within 5 years prior to study enrollment, and other experimental treatment within 30 days prior to treatment start. Pregnant or breastfeeding women are also excluded, as well as patients with clinical or radiological signs of CNS metastases, planned radiation of target lesions, or concurrent vaccination against yellow fever.",
    "The sample is a phase 2 clinical trial for asthma. The trial is looking for participants who are at least 12 years old, have had asthma for at least 6 months, and have a forced expiratory volume in 1 second (FEV1) between 50-80% of predicted value, and reversibility greater than or equal to 15% following 180 mcg albuterol. Participants must also be on a stable low dose of inhaled corticosteroids, be non-smokers with a smoking history of less than or equal to 10-pack years, and be otherwise healthy. The trial has inclusion and exclusion criteria, and participants must provide written informed consent. The trial is testing the effectiveness of albuterol spiromax\u00ae and proair\u00ae hfa.",
    "The sample is a phase 2 clinical trial for locally advanced adenocarcinoma of the female breast, specifically targeting patients with TNM Stage T3-4, N0-3 M0. The trial is testing the effectiveness of the drug capecitabine. The eligibility criteria include being 18 years or older, having negative pregnancy test results, and having a performance status of 0-1. The trial also has exclusion criteria, such as having HER2 positive breast cancer, being pregnant or lactating, and having a life expectancy of less than 3 months. The trial requires initial laboratory data, including granulocytes, platelet count, and calculated creatinine clearance. The sample also includes a list of diseases (breast cancer) and their corresponding ICD-10 codes.",
    "The sample is a phase 2 clinical trial for the treatment of psoriasis. The trial is looking for participants who have a clinical diagnosis of stable mild-to-moderate plaque-type psoriasis involving 2-35% of total body surface area (BSA) excluding face, scalp, and genitals. The trial requires participants to apply study medication as directed, comply with study instructions, and commit to attending all study visits. Women of childbearing potential must agree to use contraception for the entire study period. The trial has exclusion criteria, including any dermatological conditions that could interfere with clinical evaluations, concurrent or recent use of certain topical or systemic medications without a sufficient washout period, significant confounding conditions as assessed by study doctor, participation in any other trial of an investigational drug within 30 days or participation in a research study concurrent with this study, use of lithium- or hydroxychloroquine-containing products (e.g., Plaquenil), use of a beta-blocking medication (e.g., propranolol) if the dose has not been stabilized for at least 3 months, and pregnancy or lactation.",
    "The sample is a phase 2 clinical trial for patients with rheumatoid arthritis. The trial requires patients to have been receiving weekly doses of methotrexate for at least 180 days and have a stable dose of at least 15 mg without any change in route or folic acid supplementation for at least 30 days. Patients must have active RA, defined as the presence of swollen and tender joints and a CRP level above the upper limit of normal. Patients may receive up to 10 mg per day of oral prednisone or steroid equivalent, NSAID therapy, hydroxychloroquine, chloroquine, minocycline, sulfasalazine, and doxycycline, as long as the dose has been stable for at least 30 days. Females of childbearing potential must use adequate contraception during the study. Patients must be in good health and able to understand the nature of the study and comply with the requirements. Exclusion criteria include a history of substance abuse, drug addiction, or alcoholism, recent treatment for malignancy, and laboratory abnormalities. Patients must also abstain from alcohol during the study and not use CYP3A4 inhibitors or inducers within 3 days of randomization until the end of the study.",
    "The sample is a phase 2 clinical trial for attention deficit disorder with hyperactivity. The trial involves the use of two drugs, spd503 (guanfacine hcl) and placebo. The eligibility criteria for the trial include having a primary diagnosis of ADHD, a minimum baseline visit ADHD-RS-IV score of 24, and a baseline CGI-S score of at least 4. The subject must also be male or non-pregnant female and agree to comply with any applicable contraceptive requirements. Additionally, the subject must weigh more than 55 lbs and not be morbidly overweight. The exclusion criteria include having a comorbid psychiatric diagnosis (except ODD) with significant symptoms, a history of seizure disorder, any specific cardiac condition or family history of significant cardiac condition, and being pregnant, lactating, or within six months post-partum.",
    "The sample is a phase 2 clinical trial for Parkinson's disease. The eligibility criteria include patients diagnosed with Parkinson's disease at stage I to III, aged 20 years or older, both male and female, with limited prior exposure to low or moderate doses of L-dopa or dopamine agonists. Exclusion criteria include patients with serious physical signs and symptoms other than those of Parkinson's disease, symptomatic postural hypotension, serious psychiatric symptoms, and those who have been treated with certain drugs. Female patients who are pregnant or lactating, who may be pregnant, or who plan for pregnancy during the study or within 30 days after the last dose of the study drug are also excluded. Patients who have received surgical treatment for Parkinson's disease in the past or have been treated with any other investigational drug within 12 weeks prior to the treatment phase are also ineligible.",
    "The sample is a record of a clinical trial in phase 2 for the treatment of ischemic stroke. The trial involves testing the effectiveness of three drugs - placebo, sa4503 low, and sa4503 high. The eligibility criteria for the trial include being 18 years or older, having experienced a stroke between 48 to 72 hours before randomization, and having a total score of 4 or more on the NIHSS or 2 or more on the upper or lower extremity motor scores of the NIHSS. Patients with transient ischemic attack, stroke in progression, unstable cardiac, hepatic, or renal disease, or other major medical disorder are excluded from the trial. The icd-10 codes of the diseases associated with the trial are also listed.",
    "The sample is a phase 2 trial for patients with stable coronary artery disease. The trial involves the use of two drugs, ticagrelor and clopidogrel. The eligibility criteria for the trial include having undergone a Percutaneous Coronary Intervention or having had a previous documented acute coronary syndrome more than 3 months prior to randomization, as well as being treated with ASA. The exclusion criteria include having had an ACS, transient ischemic attack, or stroke within the 3 months prior to randomization, having a known concurrent disease of stroke or TIA with atrial fibrillation, or being treated with blood clotting agents that cannot be stopped.",
    "The sample is a phase 2 clinical trial for non-small cell lung cancer. The trial involves the use of the drugs pemetrexed, cisplatin, and bevacizumab. The eligibility criteria for participants include having a histological or cytological diagnosis of nonsquamous Stage IIIB or Stage IV NSCLC that is not amenable to curative therapy, an Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1, and adequate organ function. Exclusion criteria include having received prior systemic anticancer therapy for lung cancer, serious cardiac conditions, a second primary malignancy that is clinically detectable, and known central nervous system (CNS) disease, among others. Participants must sign an Informed Consent Document (ICD) to participate in the trial.",
    "The sample is a clinical trial with a phase 2/phase 3 design, focused on HIV infections. The trial includes patients who are HIV-1 infected adults with a CD4 count greater than 250 cells/mm3, not currently receiving HIV antiretroviral therapy for more than 6 months or are na\u00efve, and have a viral load greater than 3000 RNA copies/mL. The trial excludes patients with prior retinal eye disease, CD4 count less than 250 cells/\u00b5L, renal failure, active malignancy, corticosteroid therapy, and patients who are either under 18 or over 65 years old. The trial involves the use of chloroquine phosphate and placebo as drugs. The icd-10 code for the disease is 'Z21'.",
    "The sample is a record from a clinical trial table that includes information about the phase of the trial, diseases being studied, corresponding ICD-10 codes, drugs being tested, and eligibility criteria for participants. In this particular sample, the trial is in phase 2/phase 3 and is studying the effects of tonapofylline and placebo on patients with renal insufficiency and congestive heart failure. The eligibility criteria for participants include having a previous diagnosis of heart failure and requiring hospitalization for acute decompensated heart failure with clinical evidence of volume overload. There are also exclusion criteria listed, such as a history of allergic reactions to xanthine-containing substances, stroke, or myocardial infarction, among others.",
    "The sample is a phase 2 clinical trial for breast cancer patients with locally advanced or stage IV disease. The trial is looking for patients who are HER2/neu positive and have measurable or evaluable disease. Patients must also be postmenopausal, have a good performance status, and meet certain medical criteria such as having a bilirubin level less than 1.5 times the upper limit of normal. The trial is testing the drug exemestane and patients cannot have received prior treatment with this drug or trastuzumab. The eligibility criteria are quite detailed and include information on the patient's age, sex, menopausal status, and other medical history.",
    "The sample is a phase 2 clinical trial for patients with chronic lymphocytic leukemia, leukemia, or small lymphocytic lymphoma who have achieved a partial or complete response with residual disease by MRD flow cytometry following chemotherapy or chemoimmunotherapy. The trial involves the use of rituximab and alemtuzumab drugs. The eligibility criteria include being at least 18 years old, having an ECOG performance status of 2 or less, and meeting certain serum level requirements. Patients must also provide informed consent and agree to use an effective form of birth control. Exclusion criteria include a history of anaphylaxis following exposure to certain antibodies, active Hepatitis B, previous treatment with alemtuzumab plus rituximab, pregnancy or nursing, history of HIV infection, active uncontrolled infection, less than 6 months from the completion of prior chemotherapy or chemoimmunotherapy, and symptomatic CNS disease.",
    "The sample is a phase 2 clinical trial for the treatment of nodular basal cell carcinoma using the drug vismodegib. The eligibility criteria include having a confirmed new nodular BCC at a specific anatomical site, willingness to delay excision of the tumor site, and having adequate hematopoietic capacity and hepatic function. Women of childbearing potential must agree to use two forms of birth control during the study and for 7 months after discontinuation of the drug. Men with female partners of childbearing potential must use a male condom and advise their partners to use an additional form of birth control during the study and for 2 months after discontinuation of the drug. Exclusion criteria include prior treatment with vismodegib, inability or unwillingness to swallow capsules, pregnancy or lactation, and uncontrolled medical illness.",
    "The sample is a phase 2 clinical trial for non-small cell lung carcinoma. The trial involves the use of the drugs motexafin gadolinium and pemetrexed. The eligibility criteria for the trial include being 18 years or older, having stage IIIb, metastatic, or recurrent NSCLC and having received one prior platinum-based chemotherapy regimen. The patient must also have an ECOG performance status score of 0 or 1. The exclusion criteria include laboratory values indicating inadequate function of bone marrow, liver, or kidneys, symptomatic or uncontrolled brain metastases, evidence of meningeal metastasis, having more than one prior regimen (not counting adjuvant or neo-adjuvant cytotoxic chemotherapy if completed more than 12 months prior to the regimen), and having a medical condition that would increase risk if treated with motexafin gadolinium or impair ability to complete study procedures and assessments.",
    "The sample is a phase 2 clinical trial for patients with ovarian cancer, fallopian tube cancer, or primary peritoneal cavity cancer who have relapsed after and/or are refractory to platinum- and taxane-based chemotherapy. The trial is testing the effectiveness of imatinib mesylate as a treatment option. Patients must meet certain eligibility criteria, including having measurable disease outside of prior radiation field, availability of a sentinel lesion that is adequate for core biopsy, and meeting certain hematopoietic, hepatic, renal, and cardiovascular requirements. Patients must also have recovered from prior anticancer therapy and not have any concurrent alternative or complementary therapies or over-the-counter agents unless approved by the principal investigator.",
    "The sample is a phase 2 clinical trial for rheumatoid arthritis. The trial includes patients who are 18 to 65 years old and have a documented history of RA. The patients must have at least 6 swollen joint counts and 6 tender/painful joint counts, and meet at least two of the three following criteria: Rheumatoid Factor positive or Anti CCP positive, CRP \u22651.2 times upper limit of normal reference range or ESR >28 mm/hr, and morning stiffness lasting >45 min for at least last 4 weeks. The patients must also have DAS-28 CRP values \u2265 4.5 at screening and have been on stable (15 mg to 25 mg) or maximum tolerated dose of MTX for at least 12 weeks prior to screening. The trial has various inclusion and exclusion criteria, including laboratory criteria and medical history. The patients must provide written informed consent to participate in the study.",
    "The sample is a phase 2 clinical trial for bladder cancer. The eligibility criteria include having a histologic/cytologic diagnosis of urothelial carcinoma, having received four to six cycles of standard first-line chemotherapy for locally recurrent or metastatic disease and achieving stable disease, partial response, or complete response to this chemotherapy. Patients must be registered within one month of scans demonstrating stable disease or better and no more than 42 days after receiving the last standard chemotherapy dose. Exclusion criteria include major surgery within four weeks of starting the study treatment, NCI CTCAE grade 3 hemorrhage or higher within four weeks of starting the study treatment, and history of or known spinal cord compression, or carcinomatous meningitis, or evidence of symptomatic brain or leptomeningeal disease on screening CT or MRI scan. Pregnant or breastfeeding patients are also excluded.",
    "The sample is a phase 2 clinical trial for HIV-1 infected adults aged 18 or older. The trial is testing the efficacy of the drugs gsk2248761 and etravirine in treating HIV-1 infection with NNRTI resistance-associated mutations. The eligibility criteria include having a screening plasma HIV-1 RNA greater than or equal to 400copies/mL, having received or currently receiving antiretroviral therapy for HIV-1 infection, and having NNRTI resistance by screening genotype. Exclusion criteria include having pre-existing physical or mental conditions that may interfere with compliance or safety, having certain cardiac diseases or allergies to the study drugs, and having certain laboratory abnormalities or abnormal electrocardiograph findings. The trial also excludes those who have received certain treatments or immunizations within a certain timeframe prior to screening.",
    "The sample is a phase 2 clinical trial for the treatment of chronic hepatitis C infection with genotype 1. The trial involves the use of four drugs - abt-450, abt-072, ribavirin, and ritonavir. The eligibility criteria for the trial include being a treatment-naive male or female between the ages of 18 and 65, having a liver biopsy within 3 years with histology consistent with HCV-induced liver damage, and having no evidence of cirrhosis or liver pathology due to any cause other than chronic HCV. The trial also has exclusion criteria, such as having a history of cardiac disease, using strong enzyme inducers or inhibitors within 1 month of dosing, and having abnormal laboratory tests.",
    "The sample is a phase 2 trial for patients with chronic pain due to diabetic peripheral neuropathy and neuralgia. The trial involves two drugs, epicept np-1 (4% amitriptyline/ 2% ketamine) topical cream and a placebo cream. The trial also includes a list of diseases and their corresponding icd-10 codes. The eligibility criteria for the trial includes adult patients with chronic pain due to diabetic peripheral neuropathy of at least 6 months duration and an average daily pain score of > 4 during the baseline week. The exclusion criteria includes clinically significant intercurrent illness that could interfere with the efficacy or safety assessments in the study.",
    "The sample is a phase 2 clinical trial for patients with advanced or metastatic diffuse or mediastinal large B-cell lymphoma that is incurable by standard therapies, relapsed or refractory. The trial involves the drug sunitinib malate and has eligibility criteria including bidimensionally measurable disease, prior chemotherapy regimens, no known brain metastases, and various medical conditions that would preclude study participation. Patients must also meet certain medical requirements such as having an ECOG performance status of 0-1, normal LVEF, and no uncontrolled hypertension. The trial excludes patients with certain medical conditions or who have received certain prior treatments.",
    "The sample is a phase 2 clinical trial for the treatment of hepatitis C. The trial includes patients with chronic HCV genotype 1 viral infection who have previously not responded to PEG and RBV treatment for at least 12 weeks. The trial involves the use of drugs such as alisporivir, peginterferon alfa-2a, ribavirin, and placebo. The eligibility criteria include having HCV RNA levels of at least 1,000 IU/ml and not having received any anti-HCV drug within 3 months prior to screening. Women of child-bearing potential must be using highly effective contraception. Other protocol-defined inclusion/exclusion criteria may also apply.",
    "This is a sample from a table that contains information about clinical trials. The trial is in phase 2 and is focused on prostate cancer. The table includes a list of diseases and their corresponding ICD-10 codes, a list of drugs being used in the trial, and eligibility criteria for participants. The inclusion criteria include having a histologically documented evidence of prostate cancer, a PSA increase over baseline of >25% or 5ng/ml, and a serum total testosterone less than or equal to 50ng/ml. The exclusion criteria include prior therapy with ketoconazole or corticosteroids for HRPC, major surgery or radiation therapy within 4 weeks, and thromboembolism in the past 6 months.",
    "The sample is a phase 2 clinical trial for the treatment of idiopathic Parkinson's disease. The trial includes patients between the ages of 30 and 80 who have been diagnosed with Parkinson's disease and are in Hoehn and Yahr Stage 1-3 in an \"on\" state. Patients must require levodopa-containing medication at least 4 times during the waking day and experience motor fluctuations with a minimum of 2 hours of average daily \"off\" time per waking day. The trial includes the drugs cvt-301, placebo, sinemet (carbidopa/levodopa), and cvt-301. The eligibility criteria include exclusion criteria such as pregnant or lactating females, previous surgery for PD, history of psychotic symptoms requiring treatment, or suicide ideation or attempt within the last year, adequate lung function as measured by spirometry, and any significant condition, severe concurrent disease, abnormality or finding that would make patients unsuitable or may compromise patient safety.",
    "The sample is a phase 2 clinical trial for rectal cancer. The trial involves preoperative induction chemotherapy in combination with bevacizumab followed by combined radiochemotherapy with capecitabine. The eligibility criteria include being between the ages of 18-80, having histologic confirmation of rectal adenocarcinoma stage cT3 or cT4, and having no former chemotherapy, radiotherapy of the pelvic, or former tumor resection of a rectal carcinoma. Other criteria include having adequate bone marrow reserve, renal function, and liver function, and having a life expectancy of at least 3 months. Exclusion criteria include having rectal carcinoma stage cT3 (> 5mm from the mesorectal fascia), other malignant tumors within the last 5 years, and general contraindication or known hypersensitivity against Bevacizumab, Capecitabine, and Oxaliplatin. Patients with spinal cord compression or metastases in the central nervous system, pregnant or breastfeeding women, and patients with malabsorption syndrome or difficulties in swallowing are also excluded.",
    "The sample is a record of a clinical trial with a phase 2 designation. The trial is focused on the disease of seasonal allergic rhinitis, which is identified by the ICD-10 code J30.2. The trial involves several drugs, including bepotastine besilate formulation, fluticasone propionate, bepotastine besilate-fluticasone propionate, and a placebo comparator. The eligibility criteria for the trial include being at least 12 years old and having a history of Mountain Cedar pollen allergy. The exclusion criteria include having an active nasal infection or abnormality that could affect subject safety or symptom assessments.",
    "The sample is a record of a clinical trial in phase 2, focused on Parkinson's disease. The trial includes patients who have been experiencing L-dopa induced dyskinesia for at least 3 months and have been on L-dopa treatment for at least 3 years, with a minimum of 1 month of stability. The trial involves the drugs afq056 and placebo. The eligibility criteria include being a non-smoker and not having a history of severe allergy to food or drugs, very low or high body weight, or prior surgery for Parkinson's Disease. Other protocol-defined inclusion/exclusion criteria may also apply.",
    "The sample is a phase 2 clinical trial for the treatment of neurogenic detrusor overactivity. The trial is open to male and female patients between the ages of 2 and 15 who have documented detrusor overactivity associated with a known neurological condition, confirmed by urodynamics at baseline, and who are using clean intermittent catheterization and participating in a bowel program on a regular basis. The patients must be able to swallow the study medication and complete the bladder diary and follow the study procedures. There are several exclusion criteria, including treatment with drugs known to significantly affect the urinary bladder and urinary bladder outlet function, clinically significant anatomical abnormalities or acquired disorders of the urinary tract, and previous reconstructive surgery of the bladder or bladder outlet. Female adolescents of child-bearing potential must be using an acceptable method of contraception and pregnant or nursing females are excluded from the trial.",
    "The sample is a phase 2 clinical trial for patients with myelodysplastic syndrome. The trial includes patients with low or intermediate-1 risk features according to IPSS and requiring at least 4 units of red blood cells within the last 8 weeks prior to screening visit or presenting with neutropenia (<1 Gpt/l neutrophils), or patients with intermediate-2 or high-risk IPSS refractory or intolerant to 5-Azacytidine. CMML patients of dysplastic phenotype (WBC < 13 Gpt/l) may be included in both arms according to IPSS. CMML patients showing proliferative phenotype (WBC >=13 Gpt/l) will be included in the high-risk arm. Patients must not be eligible for an immediate allogeneic HSCT or conventional chemotherapy and all previous MDS specific therapies (except supportive approaches like transfusions or antibiotics) must have been discontinued at least 4 weeks prior to study enrollment. The trial drug is temsirolimus. The eligibility criteria include age >18 years, ability to understand the consequences of participating in the trial, and not having any disorders or other circumstances which keep them from giving written informed consent. The exclusion criteria include known hypersensitivity to temsirolimus, sirolimus or any components of the infusion solution, any condition which places the subject at unacceptable risk if he/she were to participate in the study or confounds the ability to interpret data from the study, known positive for HIV or any other uncontrolled infection, presence of any other malignancy being not in complete remission for at least 3 years, necessity of therapeutic anticoagulation (excluding low dose ASS), participation in another clinical trial within the last 4 weeks, pregnant or breastfeeding females, and patients with a history of chronic drug abuse or another illness which does not allow the patient to assess the nature and/or possible consequences of the study.",
    "The sample is a phase 2 clinical trial for asthma. The eligibility criteria include being between 18 and 55 years old, having a documented history of bronchial asthma, and currently being treated only with prn short-acting inhaled \u03b22-agonist therapy. The trial also requires participants to have a sensitivity to methacholine and a positive wheal and/or flare reaction to at least one allergen on skin prick testing. Exclusion criteria include past or present diseases other than asthma, respiratory tract infection or exacerbation of asthma within 4 weeks prior to the first dose of study drug, and administration of oral or injectable steroids within 5 weeks of the screening visit. The trial also requires participants to be able to understand and comply with the study procedures and other protocol requirements.",
    "The sample is a phase 2 clinical trial for the treatment of diabetic macular edema. The trial includes patients with type 1 or type 2 diabetes mellitus who have center involvement in at least one eye. The trial will withhold laser photocoagulation in the study eye for at least 3 months after randomization. Patients with uncontrolled systemic or ocular diseases, a history of intraocular surgery in the study eye within the past 6 months, or conditions that require chronic concomitant therapy with systemic or topical ocular corticosteroids are excluded from the trial. The trial will also apply other protocol-defined inclusion/exclusion criteria. The trial will test the efficacy of three drugs: ranibizumab 0.3 mg, ranibizumab 0.5 mg, and sham injection.",
    "The sample is a phase 2 clinical trial for the drug ramelteon, which is being tested for its effectiveness in treating Delayed Sleep Phase Syndrome. The trial is looking for female participants who are sexually active and willing to use contraception throughout the study. Participants must have a diagnosis of Delayed Sleep Phase Syndrome and a habitual sleep time that is more than 3 hours later than their desired sleep time. They must also have had self-reported insomnia and difficulty falling asleep. The trial has a list of inclusion and exclusion criteria, including being in good health, having a body mass index between 18 and 34 kg/m2, and not having used pharmacological sleep aids for more than 4 times/week during the 3 months prior to initial screening. The trial is looking to exclude participants who have a known hypersensitivity to ramelteon or related compounds, have participated in any other investigational study and/or taken any investigational drug within 30 days or 5 half-lives prior to the first dose of study medication, or have flown across greater than 3 time zones within the past 3 months prior to administration of study medication. The trial is also looking to exclude participants who have a history of alcohol or drug abuse, have a current, clinically significant neurological or other disease, have a probable current diagnosis of another circadian rhythm disorder or a sleep disorder other than Delayed Sleep Phase Syndrome that is the primary cause of insomnia, or have a history of seizures, sleep apnea, restless leg syndrome, chronic obstructive pulmonary disease, fibromyalgia, or a positive test result for the aforementioned ailments on the screening Polysomnography, schizophrenia, bipolar disorder, mental retardation, or cognitive disorder. The trial is also looking to exclude participants who smoke more than 3 cigarettes per day or use tobacco products during nightly awakenings, routinely consume caffeine including coffee, tea and/or other caffeine-containing beverages or food averaging more than 600 mg of caffeine per day, or have used any central nervous system drug or other medications, including those used to treat psychiatric disorders, known to affect sleep/wake function within 1 week whichever is longer prior to the administration of single blind study drug. The trial is also looking to exclude participants who have any clinically important abnormal finding as determined by a medical history, physical examination, Electrocardiogram, or clinical laboratory tests as determined by the investigator, have a positive hepatitis panel including anti- Hepatitis A Virus, hepatitis B surface antigen or anti- hepatitis C virus, or have any additional condition(s) that in the investigator's opinion would affect sleep/wake function, prohibit the subject from completing the study, or not be in the best interest of the subject. The trial is also looking to exclude individuals with a habitual sleep time later than 4:00 am.",
    "The sample is a phase 2 clinical trial for breast cancer patients with locally advanced or metastatic human epidermal growth factor receptor 2 positive (HER2/neu+) breast cancer who have progressed after treatment with chemotherapy including a taxane and trastuzumab. The trial is testing the effectiveness of apricoxib + lapatinib + capecitabine and placebo + lapatinib + capecitabine drugs. The eligibility criteria include having measurable disease by RECIST, an ECOG PS of 0,1, or 2, and left ventricular ejection fraction greater than or equal to 50%. The exclusion criteria include having a history of MI, stroke, ventricular arrhythmia, or symptomatic conduction abnormality, concurrent severe or uncontrolled medical disease, symptomatic central nervous system metastases, and being pregnant or nursing.",
    "The sample is a phase 2 clinical trial for non-squamous non-small cell lung cancer. The trial is testing the effectiveness of the drugs paclitaxel/carboplatin and bavituximab. The eligibility criteria include being over 18 years old with a life expectancy of at least 3 months, having stage IIIB or stage IV non-squamous NSCLC that has not been previously treated with systemic chemotherapy, having measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST, Version 1.1), and having adequate hematologic, renal, and hepatic function. There are also several exclusion criteria, such as having a history of bleeding diathesis or coagulopathy, having cavitary tumors or tumors abutting large blood vessels, and having symptomatic or clinically active brain metastases.",
    "The sample is a phase 2 clinical trial for the treatment of relapsed multiple myeloma. The trial requires eligible subjects to have had one previous autologous hematopoietic stem cell transplant (HSCT) at least one year prior to the planned autologous HSCT in this study. The trial involves the use of two drugs, iv busulfan and bortezomib. The eligibility criteria include age between 18 to 75 years, Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-2, negative pregnancy test for women of child-bearing potential, and ability to provide written informed consent. The exclusion criteria include prior treatment history of allogeneic HSCT, prior treatment history of more than one autologous HSCT or high-dose chemotherapy with stem cell rescue, and presence of a t(4;14) or p53 gene deletion. Other exclusion criteria include known allergy to boron or any components of bortezomib, left ventricular ejection fraction (LVEF) < 45%, uncontrolled arrhythmia or symptomatic cardiac disease, and current or history of drug and/or alcohol abuse.",
    "The sample is a phase 2 clinical trial for non-squamous, non-small cell lung cancer using the drugs bevacizumab and erlotinib. The trial includes patients with wet stage IIIB-IV or recurrent disease, with a performance status of 0-1 and no significant hemoptysis. Prior radiation is allowed if more than 15 days have passed, but no prior treatment for metastatic disease is allowed. The eligibility criteria include a histological or cytological diagnosis of non-squamous, non-small cell lung cancer, and exclusion criteria include a history of hemoptysis, current treatment with full-dose warfarin, and performance status of 2-4. The trial also has general medical exclusions, such as inability to comply with study procedures, and bevacizumab-specific exclusions, such as inadequately controlled hypertension and history of myocardial infarction or unstable angina within 6 months prior to study enrollment. Patients with proteinuria at screening or known hypersensitivity to any component of bevacizumab are also excluded. Effective means of contraception must be used by subjects of child-bearing potential.",
    "The sample is a phase 2 clinical trial for breast cancer patients with metastatic (Stage IV) disease. The trial is testing the drug CI-1033 and the eligibility criteria includes having no more than 2 prior cytotoxic chemotherapy regimens for metastatic disease, having at least one measurable target lesion, and having an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. Patients must also have adequate liver, renal, or bone marrow function and be capable of giving written informed consent. Exclusion criteria includes prior exposure to CI-1033 or other agents that target the erbB receptor family, recent cytotoxic chemotherapy, immunotherapy, or hormone therapy, and untreated brain metastases.",
    "The sample is a phase 2 clinical trial for colorectal cancer. The trial includes patients with histologically confirmed invasive adenocarcinoma of the rectum, with the distal border of the tumor within 8 cm from the anal verge. Patients with tumors fixed to adjacent structures on digital exam, positive perirectal nodes on ERUS examination, or histologic evidence of metastatic invasion of inguinal lymph nodes are not eligible. Patients with certain medical conditions or histories are also not allowed on the study. The trial involves the use of two drugs, capecitabine and oxaliplatin. Eligibility criteria include specific laboratory values and prior malignancy treatment. Patients of reproductive potential must agree to use an effective method of birth control during the trial.",
    "The sample is a phase 2 clinical trial for patients with metastatic pancreatic cancer. The trial is testing the effectiveness of two drugs, rhumab-vegf and docetaxel. Patients must meet certain eligibility criteria, including having a confirmed diagnosis of adenocarcinoma of the pancreas, measurable disease outside of the pancreas, and having received only one prior gemcitabine-containing regimen for metastatic disease. Patients must also meet certain patient characteristics, such as being 18 years or older and having a performance status of ECOG 0-1. The trial excludes patients with brain metastases, significant medical conditions, or psychiatric conditions that would preclude study participation. The trial also has specific requirements for prior concurrent therapy, such as no concurrent prophylactic granulocyte or platelet growth factors and no other concurrent experimental drug study participation.",
    "The sample is a phase 2 clinical trial for the treatment of vulvar vestibulitis. The trial includes women who have dyspareunia as their primary complaint and have a current sexual partner. The trial excludes postmenopausal women, those with pure vaginismus, generalized vulvodynia, pudendal neuralgia, pregnant or breastfeeding women, those less than 2 months post-delivery, those with a diagnosis of dermatologic condition on biopsy, positive fungal culture, currently on treatment for vvs, and those with a history of lidocaine treatment for vvs. The trial will test the effectiveness of 5% topical lidocaine ointment compared to a placebo cream.",
    "This sample is a record of a clinical trial in phase 2 for the treatment of non-Hodgkin lymphoma. The trial is testing the effectiveness of chemotherapy and radioimmunotherapy. The eligibility criteria for participants include having a confirmed diagnosis of follicular lymphoma, grades 1, 2, or 3, no prior chemotherapy or monoclonal antibody therapy, bulky or symptomatic disease at stage II-IV, and a performance status of 0-2. The exclusion criteria include impaired bone marrow reserve, presence of CNS lymphoma, and serious nonmalignant disease or active infection.",
    "The sample is a phase 2 clinical trial for patients with myelodysplastic syndromes and thrombocytopenia. The trial involves the drug lenalidomide, which is taken orally for at least 4 cycles. The eligibility criteria include a diagnosis of MDS based on the WHO classification, low or intermediate-1 risk category MDS using the IPSS, an ECOG performance status of 0-2, and being at least 18 years old. Exclusion criteria include prior exposure to more than 3 cycles of lenalidomide, exposure to lenalidomide within the last 30 days, prior history of leukemia or aplastic anemia, and other medical conditions such as uncontrolled hypertension or recent myocardial infarction. The sample also includes a list of icd-10 codes for the diseases and a list of exclusion criteria.",
    "The sample is a phase 2 clinical trial for breast cancer patients with unresectable, locally recurrent, or metastatic disease. The trial involves the use of gemcitabine and vinorelbine drugs. The eligibility criteria include having a histological or cytological diagnosis of breast carcinoma, presence of measurable lesions, no prior chemotherapy for metastatic or locoregionally recurrent disease, and completion of prior radiotherapy at least 30 days before study entry. Exclusion criteria include having received treatment with an investigational drug within the last 30 days, concurrent administration of other tumor therapy, active infection, pregnancy or breastfeeding, and serious concomitant disorders that would compromise the safety of the patient or their ability to complete the study.",
    "The sample is a phase 2 clinical trial for chronic low back pain. The trial includes patients with low back pain and recurrent low back pain, and the icd-10 codes for the diseases include M54.50, M54.51, M54.59, G47.13, J01.41, K11.22, K12.0, N96, F33.8, and G03.2. The trial involves the use of several drugs, including jnj-42160443 3 mg, jnj-42160443 1 mg, jnj-42160443 6 mg/3mg, jnj-42160443 10 mg, and matching placebo. The eligibility criteria for the trial include a diagnosis of chronic low back pain, and exclusion criteria include pain with radiation to the extremity and with neurologic signs, history of brain injury or epilepsy, and any new or unresolved neurologic deficits within 6 months before screening.",
    "The sample is a phase 2 clinical trial for the treatment of psoriasis. The trial is looking for male or female participants aged 18 to 80 years who have a diagnosis of clinically confirmed, stable plaque-type psoriasis for at least 6 months involving at least 10% of their body surface area and a baseline PASI score of at least 10. The trial is testing the effectiveness of the drug SRT2104 compared to a placebo. Participants must be willing to use reliable contraception if they are female and of child-bearing potential. The trial has a list of exclusion criteria, including recent treatment with certain therapies, active infections, abnormal chest x-rays, and liver or renal impairment. Participants must also be willing and able to comply with the protocol for the duration of the study.",
    "The sample is a clinical trial for breast cancer patients in phase 2/phase 3. The trial involves the use of two drugs, capecitabine and vinorelbine tartrate. The eligibility criteria include having metastatic breast cancer, prior treatment with taxanes, and no CNS metastases. Patients must also meet certain age, sex, and performance status requirements, as well as have certain hematopoietic, hepatic, renal, and cardiovascular levels within normal ranges. Patients must not be pregnant or nursing, and must not have any pre-existing grade 2 or greater neurotoxicity. Prior concurrent therapy is allowed for hormonal therapy, but not for biologic therapy or radiotherapy. Patients must not have any other concurrent investigational treatment.",
    "The sample is a phase 2 clinical trial for the treatment of gastroparesis in patients with type 1 or type 2 diabetes mellitus. The trial involves the use of drugs such as 5% dextrose in water and tzp-101. The eligibility criteria include having a confirmed diagnosis of gastroparesis, a minimum 3-month history of relevant symptoms, and a mean Gastroparesis Cardinal Symptom Index (GCSI) Score of \u2265 2.66. Exclusion criteria include having acute severe gastroenteritis, a gastric pacemaker, or a history of eating disorders. The trial also has requirements for stable medication dosages, HbA1c levels, BMI, and body weight. Female participants must be post-menopausal, surgically sterile, or using an adequate method of birth control. The trial excludes participants who are pregnant or breastfeeding.",
    "The sample is a phase 2 clinical trial for pancreatic cancer. The trial is looking for patients who have confirmed carcinoma in the pancreas and are deemed resectable or borderline resectable. Patients must have an expected life expectancy of at least 12 weeks and a Zubrod performance status of less than 2. They must also have adequate organ function and be free of other active systemic malignancy, ongoing infection, or any other serious uncontrolled, concomitant systemic disorders or psychiatric condition that would interfere with the safe delivery of protocol therapy. Patients must not have used any investigational agent in the month before enrollment into the study. The trial is excluding patients with neuroendocrine tumors or preexisting peripheral neuropathy greater than grade 2. Pregnant or nursing women are ineligible, and patients of reproductive potential must agree to use an effective contraceptive method during participation in this trial and for 6 months after the trial.",
    "The sample is a phase 2 clinical trial for patients with metastatic adenocarcinoma of the breast. The drug being tested is capecitabine. Patients must have measurable disease and meet certain eligibility criteria, including having an Eastern Cooperative Oncology Group (ECOG) performance status of 0-2, certain blood counts, and no significant history of noncompliance to medical regimens. Patients must not have received previous capecitabine and no other concurrent therapies intended to treat the primary condition including chemotherapy, biologic agents, or immunotherapy. The trial also excludes patients with certain medical conditions, such as liver disease or uncontrolled seizures. The trial allows concurrent use of bisphosphonates and megestrol acetate suspension as an appetite stimulant.",
    "The sample is a phase 2 clinical trial for kidney transplantation. The trial involves the use of rituximab and standard care as treatments. The eligibility criteria for the trial include being over 18 years old, receiving a single organ renal transplant from a living donor, and having a positive T-cell and/or B-cell crossmatch by complement dependent cytotoxicity (CDC) and/or positive flow cytometry crossmatch with confirmed donor-specific antibodies on solid-phase assay at screening. Exclusion criteria include having a primary renal transplant lost from acute rejection less than six months prior to randomisation, being a woman of childbearing potential with a positive serum or urine pregnancy test or nursing mothers, having a history of malignancy (other than non melanoma skin cancer that has been totally excised with no recurrence for two years), having known contraindications to treatment with rituximab, and having disorders or conditions that may interfere with the ability to comply with study procedures and/or requirements. Additional exclusion criteria at Day -2 before transplantation include having a positive T- and/or B-cell CDC crossmatch at Day -2.",
    "The sample is a phase 2 clinical trial for Duchenne muscular dystrophy and Becker muscular dystrophy. The trial is testing the effectiveness of two drugs, ataluren and chronic corticosteroid therapy, on patients with a specific mutation in the dystrophin gene who are unable to walk independently for at least one year. The trial has specific inclusion and exclusion criteria, including adequate liver, kidney, and adrenal function, ability to comply with study procedures, and written informed consent. Exclusion criteria include recent use of certain medications, ongoing immunosuppressive therapy, and ongoing participation in other clinical trials. The trial will also assess the safety of the drugs and any potential adverse effects.",
    "The sample is a phase 2 clinical trial for breast cancer. The trial includes postmenopausal women with biopsy-confirmed primary breast cancer and estrogen receptor-positive tumors who are fit for surgery within one month. The trial excludes women who have previously received anti-hormonal therapy, radiotherapy, or chemotherapy for the primary tumor. The trial involves the use of two drugs, fulvestrant and anastrazole. The diseases are listed as breast cancer, and the icd-10 codes associated with the disease are also provided. The eligibility criteria for the trial are listed under inclusion and exclusion criteria. Written informed consent is required to participate in the study.",
    "The sample is a record of a clinical trial with a phase 2 designation. The trial is focused on bladder cancer and includes a list of ICD-10 codes for related diseases. The trial involves the use of three drugs: cisplatin, gemcitabine, and bevacizumab. The eligibility criteria for the trial are listed, including requirements for measurable disease, no prior organ allograft, and no evidence of bleeding diathesis or coagulopathy. The exclusion criteria are also listed, including no history of serious, non-healing wound, ulcer or bone fracture, and no prior history of malignancy in the past 5 years with the exception of basal cell and squamous cell carcinoma of the skin. The sample provides a detailed description of the inclusion and exclusion criteria for the trial.",
    "The sample is a phase 2 clinical trial for rectal cancer. The trial is testing the efficacy of the \"ixo regimen\" drug. The eligibility criteria for the trial include having pathologically confirmed rectal adenocarcinoma, being categorized as having resectable locally advanced cancer, and having an ECOG performance status equal to or less than 1. Patients must also be between the ages of 18 and 80 and have adequate haematological, liver, and renal function. Exclusion criteria include having a diagnosis of metastatic disease, a clear indication of involvement of pelvic wall(s), or peritoneal carcinomatosis. Patients must not have previously undergone treatment for this disease or prior chemotherapy for colorectal cancer. They must also not have a history of ulcerative colitis or Crohn's disease, or be pregnant or lactating.",
    "The sample is a phase 2 clinical trial for the treatment of psoriasis. The trial compares the effectiveness of cyclosporine A versus mycophenolate mofetil. The eligibility criteria for the trial include having moderate-to-severe psoriasis with a PASI score of 10 or higher, providing written informed consent, and effective birth control for female patients. Exclusion criteria include having psoriasis arthritis, psoriasis palmo-plantaris, erythrodermic psoriasis, drug-induced psoriasis, pregnancy, previous treatment with cyclosporine A or mycophenolate mofetil, reduced liver or kidney function, high blood pressure, severe viral or bacterial infection, recent vaccinations, innate or acquired immunodeficiency, severe neurologic or psychiatric symptoms, participation in other trials, or other reasons voiced by the treating physician.",
    "The sample is a phase 2 clinical trial for patients with metastatic adenocarcinoma of the prostate, recurrent prostate cancer, or stage IV prostate cancer. The trial is testing the drug Tanespimycin. The eligibility criteria include having received at least one prior chemotherapy regimen for metastatic disease, having no known brain metastases requiring active therapy, and having a performance status of ECOG 0-2. Patients must also meet various medical and laboratory requirements, such as having a creatinine clearance of at least 60 mL/min and a platelet count of at least 100,000/mm^3. The trial excludes patients with certain medical conditions or who are taking certain medications.",
    "The sample is a record of a clinical trial in phase 2 that focuses on the treatment of the common cold. The trial includes a list of diseases and their corresponding ICD-10 codes, a list of drugs being tested, and the eligibility criteria for participants. The inclusion criteria for participants include having symptoms of the common cold for no more than 120 hours, self-rating congestion of at least moderate severity, and suffering from at least four symptoms of the common cold or flu.",
    "The sample is a phase 2 clinical trial for various types of lymphoma, including follicular lymphoma, small lymphocytic lymphoma, marginal zone lymphoma, lymphoplasmacytic lymphoma, diffuse large b cell lymphoma, mantle cell lymphoma, and Burkitt's lymphoma. The trial is testing the drug imexon. The eligibility criteria include having a confirmed diagnosis of one of the eligible lymphomas, having relapsed or refractory disease to at least one prior treatment regimen, having at least one measurable target lesion, having an ECOG performance status of 0-2, and meeting various laboratory value requirements. The exclusion criteria include having certain medical conditions, being pregnant or lactating, and not meeting the eligibility criteria.",
    "The sample is a phase 2 clinical trial for the treatment of acute myeloid leukemia and myelodysplastic syndromes. The trial is testing the drug vosaroxin on patients who are at least 60 years old and have not received previous treatment for their condition. Patients must have at least 20% blasts in their bone marrow biopsy or aspirate and an ECOG performance status of 0, 1, or 2. They must also have adequate cardiac, renal, and liver function. Patients with uncontrolled DIC, active central nervous system involvement by AML, or requiring hemodialysis or peritoneal dialysis are excluded from the trial. Patients with some prior history of heart attack or stroke (depending on how long ago the event occurred) are also excluded. The diseases and their corresponding ICD-10 codes are listed in the table along with the eligibility criteria.",
    "The sample is a phase 2 clinical trial for non-small cell lung cancer (NSCLC) patients with advanced stages IIIB or IV. The trial is testing the effectiveness of a combination of drugs, including osi-906, erlotinib, and placebo. Patients must have a confirmed EGFR mutation and meet certain eligibility criteria, such as having measurable disease according to RECIST, an ECOG performance status of 0-1, and adequate hematopoietic, hepatic, and renal function. Patients must also meet certain exclusion criteria, such as having a history of poorly controlled gastrointestinal disorders or significant cardiovascular disease. The trial requires patients to provide written informed consent and prohibits participation in any other interventional clinical study or treatment with investigational drugs during the course of the study.",
    "The sample is a phase 2 clinical trial for head and neck cancer patients. The trial is testing the effectiveness of the drug combination of panitumumab and paclitaxel. The eligibility criteria for the trial includes being over 18 years old, having confirmed SCCHN, and having at least one measurable lesion of a certain size. The trial also requires participants to have certain levels of hemoglobin, platelets, and kidney function. Exclusion criteria include having central nervous system metastases, interstitial lung disease, or a history of certain cancers. Participants must also not be pregnant or breastfeeding and must be willing to use adequate contraceptive precautions during the study.",
    "The sample is a phase 2 clinical trial for the treatment of rheumatoid arthritis. The trial includes patients who have had RA for at least 6 months and have been treated with and tolerated MTX for at least 6 months prior to screening. The trial involves the use of various drugs, including a placebo, ustekinumab, and CNTO 1959, in combination with MTX. The eligibility criteria include having active RA, defined as persistent disease activity with both swollen and tender joints, and a serum C-reactive protein (CRP) level of at least 0.80 mg/dL at screening. Patients must also meet other inclusion criteria, such as having a diagnosis of RA according to the revised 1987 criteria of the American Rheumatism Association and being positive for either anti-cyclic citrullinated peptide antibody or rheumatoid factor in serum at screening. The exclusion criteria include having other inflammatory diseases, current signs or symptoms of severe, progressive, or uncontrolled health conditions, a history of malignancy, and known allergies or hypersensitivity to the drugs being used in the trial.",
    "The sample is a phase 2 clinical trial for pancreatic cancer. The eligibility criteria include having histologically confirmed pancreatic carcinoma that is inoperable or metastatic, with a measurable lesion by physical examination, CT scan, or MRI. Patients must also have no known brain metastases and meet certain age, performance status, and life expectancy requirements. Additionally, patients must meet specific hematopoietic, hepatic, renal, cardiovascular, and pulmonary function criteria, and cannot have certain medical problems or be pregnant or nursing. Prior concurrent therapy is also restricted. The trial will test the effectiveness of cisplatin and gemcitabine hydrochloride as treatment options.",
    "The sample is a phase 2 clinical trial for the treatment of partial and catamenial epilepsy using the drug ganaxolone. The eligibility criteria include a diagnosis of epilepsy with partial-onset seizures, a documented seizure frequency of at least 3 per 4 weeks, and stable treatment with up to 3 FDA-approved antiepileptic drugs for at least 1 month prior to screening. The trial excludes individuals with certain medical conditions, a history of drug or alcohol abuse, and those who are currently breastfeeding. Participants must also be willing to keep a seizure and medication diary throughout the study and withhold grapefruit and grapefruit juice from their diet for the duration of the trial.",
    "The sample is a phase 2 clinical trial for pancreatic cancer. The trial is for patients with confirmed pancreatic adenocarcinoma that is either recurrent, unresectable, or metastatic. Patients must have at least one measurable lesion that is at least 20mm by conventional techniques or 10mm by spiral CT scan. Patients must not have any known brain metastases. The trial has eligibility criteria for patient characteristics such as age, performance status, life expectancy, hematopoietic, hepatic, renal, cardiovascular, pulmonary, and other factors. Patients must not be pregnant or nursing, have ongoing or active infections, or have psychiatric illness or social situations that would preclude study compliance. The trial has prior concurrent therapy restrictions for biologic therapy, chemotherapy, endocrine therapy, radiotherapy, surgery, and other investigational agents. Patients must not have concurrent combination antiretroviral therapy for HIV-positive patients. The trial uses gemcitabine hydrochloride and triapine as drugs.",
    "The sample is a phase 2 clinical trial for patients with myelodysplastic syndrome. The trial involves the use of azacitidine and oral vorinostat as treatment. The eligibility criteria include having myelodysplastic syndrome with an IPSS score of 1.5 or higher, absence of response to at least 6 cycles of azacitidine single agent, and adequate organ function. Patients must also be at least 18 years old, have an ECOG performance status of \u2264 2, and not be refractory to platelet transfusions. Exclusion criteria include prior treatment with an HDAC inhibitor, severe infection or uncontrolled severe condition, and active cancer. Women who are pregnant or breastfeeding are also excluded.",
    "The sample is a phase 2 clinical trial for patients with advanced cancer and refractory cancer pain. The trial is testing the effectiveness of the drug lenalidomide. The eligibility criteria include having a pain intensity score of 5 or greater, being able to adhere to the study visit schedule, and having certain laboratory test results within the past 14 days. Females of childbearing potential must have a negative pregnancy test and agree to use two forms of birth control. Exclusion criteria include any serious medical condition or laboratory abnormality that would prevent the subject from signing the informed consent form, pregnancy or breastfeeding, and any prior use of lenalidomide.",
    "The sample is a phase 2 clinical trial for the treatment of Major Depressive Disorder using the drug radafaxine. The trial is looking for patients who have been diagnosed with MDD and have had a depressive episode lasting between 12 weeks and 24 months. Patients must be able to read and write and provide signed consent. Female patients must be practicing an acceptable method of birth control. Patients with other psychiatric disorders that would affect their response to treatment, those who have not responded to two or more courses of antidepressant therapy, those currently abusing drugs or alcohol, those not receiving psychotherapy, those who have received electroconvulsive therapy within 6 months prior to screening, and pregnant or lactating patients are excluded from the trial.",
    "The sample is a phase 2 clinical trial for the treatment of stomach neoplasms using the drug oxaliplatin. The trial includes patients with histologically proven gastric or gastro-esophageal junction adenocarcinoma who have measurable disease and have not undergone resection or metastasis. The trial also has specific eligibility criteria, including a certain performance status, laboratory values, and imaging evaluations. Patients with certain medical conditions or who have undergone certain treatments are excluded from the trial.",
    "The sample is a phase 2 clinical trial for attention-deficit/hyperactivity disorder (ADHD). The trial includes a list of icd-10 codes for the disease and a list of drugs, including abt-089 and placebo. The eligibility criteria for the trial include meeting diagnostic criteria for ADHD, being in good health, and being able to keep required appointments for clinic visits and tests. Exclusion criteria include having a history of serious medical problems or significant allergic reactions to any drug, requiring ongoing treatment with any psychiatric medication, and planning to begin any type of behavioral or psychotherapy for treatment of ADHD. Female subjects of child-bearing potential must have a negative urine pregnancy test at screening and baseline and agree to comply with applicable contraceptive requirements, while male subjects must agree to comply with applicable contraceptive requirements.",
    "The sample is a phase 2 clinical trial for the treatment of multiple sclerosis. The trial involves the use of drugs such as teriflunomide, interferon-\u03b2, and a placebo for teriflunomide. The eligibility criteria for the trial include having a definite diagnosis of MS according to McDonald's criteria, having a relapsing clinical course, and having an Expanded Disability Status Scale (EDSS) less than or equal to 5.5. The patient must also have been on a stable dose of IFN-\u03b2 for at least 26 weeks prior to the screening visit and must not have had an MS relapse in the preceding 60 days. Exclusion criteria include having other chronic diseases of the immune system, liver function impairment, or chronic pancreatic disease, being pregnant or nursing, having a history of alcohol or drug abuse, and having used certain immunosuppressant agents before enrollment. The sample also includes a disclaimer that the information provided is not intended to contain all considerations relevant to a patient's potential participation in the clinical trial.",
    "The sample is a phase 2 clinical trial for patients with multiple myeloma who have relapsed after at least one line of therapy, including high dose therapy with autologous stem cell transplantation and chemotherapy. The trial includes the drugs velcade, thalidomide, adriamycin, and dexamethasone. The eligibility criteria include measurable disease, age under 75, performance status of ECOG 2 or less, expected survival of more than 6 months, and informed consent. Exclusion criteria include known hypersensitivity to thalidomide or dexamethasone, previous velcade therapy, sepsis, pregnancy, kidney or liver dysfunction, and other medical conditions.",
    "The sample is a record from a clinical trial table that includes information about the phase of the trial, the disease being studied (in this case, type 2 diabetes mellitus), the ICD-10 codes associated with the disease, the drugs being used in the trial (alogliptin and glimepiride), and the eligibility criteria for participants. The eligibility criteria include requirements such as having taken a sulfonylurea for at least 4 weeks prior to the observation period, having a glycosylated hemoglobin (HbA1c) level between 7.0% and 10.0%, and receiving specific diet and exercise therapies during the observation period. The exclusion criteria include having taken other diabetic medications besides glimepiride within 12 weeks before the treatment period.",
    "The sample is a phase 2 clinical trial for the treatment of eosinophilic esophagitis. The trial involves the use of the drugs fluticasone and placebo. The eligibility criteria for the trial include having more than 20 eosinophils per high-powered field on biopsies from the mid esophagus and abnormal dysphagia questionnaire results. Exclusion criteria include having a clinical evidence of infectious process potentially contributing to dysphagia, previous steroid treatment for Eosinophilic Esophagitis, intolerance to steroid therapy in the past, and other causes of dysphagia identified at endoscopy. The trial does not allow participants who have had dilatation of the esophagus at the time of index endoscopy or who have received systemic or topical steroid therapy for any reason over the past 3 months.",
    "The sample is a phase 2 clinical trial for the treatment of major depressive disorder and psychotic disorders using the drug \"org 34517\". The trial has specific eligibility criteria, including a diagnosis of severe depressive episode with psychotic features, a certain score on the PANSS and HAMD scales, and being on a stable dose of usual treatment consisting of an anti-depressant, antipsychotic, mood stabilizer, or any combination of these three drug classes. There are also exclusion criteria, such as having any other psychiatric diagnosis except MDD, being at significant risk of committing suicide, or having clinically unstable or uncontrollable renal, hepatic, respiratory, haematological, cardiovascular, or cerebrovascular disease. The trial requires participants to provide voluntary written informed consent and be willing to be hospitalized for at least 11 days from screening onwards.",
    "The sample is a phase 2 clinical trial for multiple myeloma, a type of cancer. The trial involves the drug velcade and is for previously untreated newly diagnosed patients with MM (stage II-III) who are under the age of 65 and have an Eastern Cooperative Oncology Group Performance Status of 0-1. The trial has a list of eligibility criteria, including adequate liver and renal function, platelet count, and hemoglobin levels. The trial also has a list of exclusion criteria, including a history of allergic reactions, peripheral neuropathy, uncontrolled or severe cardiovascular disease, and pregnancy or breastfeeding.",
    "The sample is a phase 2 clinical trial for patients with biliary cancer. The trial includes patients with confirmed adenocarcinoma of the intrahepatic or extrahepatic biliary tract, including cholangiocarcinoma, gallbladder cancer, and ampullary cancer. Patients who have previously received and failed one of the three drugs (gemcitabine, Xeloda, or docetaxel) are eligible for the trial. Measurable disease is required, and patients must be ineligible for other high priority national or institutional studies. Prior radiation and surgery are allowed, with a waiting period of 3 weeks since surgery or last chemotherapy and 4 weeks since RT. Patients must have a life expectancy of more than 3 months, be at least 18 years old, have a performance status of 0-2, and be able to tolerate oral chemotherapeutic medications. Patients must also be willing to use effective contraception while on treatment and for a reasonable period thereafter. The trial has various inclusion and exclusion criteria, including laboratory tests and informed consent. Patients with a history of severe hypersensitivity reaction to docetaxel or other drugs formulated with polysorbate 80, prior malignancy in the last 5 years (excluding certain types), serious medical or psychiatric illness preventing informed consent or intensive treatment, CNS metastases, compromised immune systems, currently active inflammatory bowel disease, or active infection with non-A hepatitis virus (Hepatitis B and C) are excluded from the trial.",
    "The sample is a phase 2 clinical trial for patients with advanced or metastatic non-small cell lung cancer. The trial is testing the effectiveness of the drug dasatinib. The eligibility criteria include having a documented diagnosis of NSCLC, a performance status of 0-2, and adequate organ function. Patients must also be able to take oral medication and agree to discontinue St. Johns Wort while receiving dasatinib therapy. Women of childbearing potential must have a negative pregnancy test and agree to use contraception throughout treatment and for at least 4 weeks after study drug is stopped. Exclusion criteria include prior dasatinib therapy, concurrent medical conditions that may increase the risk of toxicity, and certain medications that are generally accepted to have a risk of causing Torsades de Pointes. Patients with significant bleeding disorders unrelated to cancer and those on systemic anticoagulation at risk of bleeding related to tumor biopsy are also excluded.",
    "The sample is a phase 2 clinical trial for patients with non-small cell lung cancer that is locally advanced or metastatic and cannot be surgically removed. The trial is testing the effectiveness of two drug combinations, erlotinib with sorafenib and erlotinib with placebo. The eligibility criteria include having at least one measurable lesion, having failed one or two prior chemotherapy regimens, and having an ECOG performance status of 0-2. Patients must also meet certain laboratory values and have completed radiation therapy at least 28 days prior to the start of the study treatment. Exclusion criteria include a history of certain neoplasms, pregnancy or lactation, and certain cardiac diseases. The trial is designed to evaluate the safety and efficacy of the drug combinations in treating non-small cell lung cancer.",
    "The sample is a phase 2 clinical trial for the treatment of uterine leiomyoma, also known as fibroids. The trial involves the use of ulipristal acetate and a placebo. The eligibility criteria for the trial include being a female between the ages of 25 and 50, having a history of uterine leiomyoma causing symptoms of bleeding, pressure, or pain, having uterine leiomyoma of at least 2 cm size, being in good health, having menstrual cycles of 24-35 days, and using mechanical sterilization or abstinence methods of contraception for the duration of the study. Exclusion criteria include significant abnormalities in the history, physical or laboratory examination, pregnancy, lactation, use of certain medications, and previous participation in the study. The trial aims to evaluate the effects of the treatment in the target population for clinical trials.",
    "This sample is for a phase 2 clinical trial for psoriasis. The trial is testing the drug ruxolitinib. The eligibility criteria for the trial includes having psoriatic lesions of a certain size, but excludes those with lesions on specific areas of the body or with certain types of psoriasis. The icd-10 codes for psoriasis are also included in the table.",
    "The sample is a phase 2 trial for peripheral neuropathic pain. The study includes male and female subjects between the ages of 18-80 who have been diagnosed with peripheral neuropathic pain and have a baseline pain intensity score averaging \u2265 4 during the three days prior to study start. The study also includes a list of inclusion and exclusion criteria, such as having a negative pregnancy test for female subjects and refraining from excessive use of medications that may interfere with efficacy or safety assessments. The study will test the efficacy and safety of the drugs sb681323 and placebo.",
    "The sample is a phase 2 trial for various childhood lymphomas and leukemia. The diseases included are childhood Burkitt lymphoma, childhood diffuse large cell lymphoma, childhood immunoblastic large cell lymphoma, stage I-IV childhood large cell lymphoma, and stage I-IV childhood small noncleaved cell lymphoma, as well as untreated childhood acute lymphoblastic leukemia. The trial involves the use of drugs such as doxorubicin hydrochloride, cyclophosphamide, methotrexate, rasburicase, leucovorin calcium, prednisone, methylprednisolone, cytarabine, etoposide, vincristine sulfate, and hydrocortisone sodium succinate. The eligibility criteria for the trial include a diagnosis of mature B-lineage (CD20-positive) leukemia or lymphoma, with specific subtypes, and meeting certain FAB prognostic groups. Other criteria include known hepatitis B status, not being pregnant or nursing, and no prior malignancies treated with systemic chemotherapy with alkylator or anthracycline therapy.",
    "The sample is a phase 2 clinical trial for the treatment of head and neck cancer using the drug celecoxib. The eligibility criteria include having histologically confirmed thyroid carcinoma, assessable disease, and progressive disease within the past year. Patients must also meet certain age, performance status, and life expectancy requirements, as well as have certain hematopoietic, hepatic, renal, cardiovascular, and gastrointestinal health. Prior concurrent therapy is also taken into consideration. The sample provides a detailed list of patient characteristics and prior concurrent therapy that are allowed or not allowed for participation in the trial.",
    "The sample is a phase 2 clinical trial for acute myeloid leukemia. The trial includes patients who have relapsed after their first remission and have confirmed FLT-3 activating mutation positive status. The trial involves the use of three drugs: cep-701, high-dose cytarabine, and mitozantrone, etoposide, cytarabine (combination chemotherapy). The eligibility criteria include confirmation of AML, age 18 or older, ability to understand and comply with study restrictions, and no comorbid conditions that would limit life expectancy to less than 3 months. The exclusion criteria include various medical conditions and previous treatment with a FLT-3 inhibitor.",
    "This sample is a phase 2 clinical trial for the treatment of mantle cell lymphoma. The trial is testing the effectiveness of rituximab, also known as mabthera or rituxan, in combination with first line chemotherapy. The trial is open to patients with previously untreated disease at stage II, III, and IV who require therapy. The eligibility criteria include a histologically-proven diagnosis of mantle cell lymphoma and exclusion criteria include known hypersensitivity to rituximab or serious disorders that may interfere with chemotherapy dosing. Patients with stage I disease are not eligible for the trial. The diseases and their corresponding ICD-10 codes are also listed in the table.",
    "This sample is a phase 2 clinical trial for breast cancer patients with relapsed or recurrent brain metastasis progression after brain radiotherapy. The trial is testing the effectiveness of liposomal doxorubicin as a treatment option. The eligibility criteria include having histologically or cytologically proved breast cancer, measurable brain disease, prior chemotherapy or hormone therapy for metastatic breast cancer, and a performance status of ECOG 0, 1, or 2. Exclusion criteria include prior liposomal doxorubicin treatment, concurrent chemotherapy, radiotherapy, hormonal therapy, or other investigational drugs, and serious concomitant illnesses that might be aggravated by the study medication. Women who are pregnant or breastfeeding or of child-bearing potential unless using a reliable and appropriate contraceptive method are also excluded.",
    "The sample is a phase 2 clinical trial for the treatment of prostate cancer using the drug E7389. The trial is open to male patients with histologically proven adenocarcinoma of the prostate that has progressed despite castration or maintenance of castrate-level testosterone. Patients must also fulfill other inclusion criteria such as having no prior chemotherapy or having failed no more than one previous chemotherapeutic regimen with tubulin binding agents. Exclusion criteria include patients who have received chemotherapy, radiation, or experimental therapy within 4 weeks of starting E7389 treatment, patients with brain or subdural metastases, and patients with other significant diseases or disorders that would exclude them from the study. The eligibility criteria are detailed in the sample, including age, performance status, life expectancy, and adequate renal and liver function. Patients must also be willing and able to complete the Visual Analog Scale and comply with the study protocol for the duration of the study. Written informed consent is required prior to any study-specific screening procedures, with the understanding that the patient may withdraw consent at any time without prejudice.",
    "The sample is a phase 2 clinical trial for rheumatoid arthritis. The trial includes patients who are between the ages of 18 and 75 and meet the American College of Rheumatology criteria for RA. Patients must have at least 6 swollen and tender joints and either an ESR of 28 mm/hour or higher or a CRP level above the upper limit of normal. Patients must also have an elevated PBMC A3AR expression level and be taking a stable dose of NSAIDs or oral corticosteroids. Female patients of childbearing potential must have a negative pregnancy test and use two methods of contraception throughout the trial. Patients must not have received certain medications for a specified washout period prior to the trial and must not have previously failed to respond to methotrexate or any anti-rheumatic biological agent. The trial will compare the drug cf101 to a placebo control.",
    "The sample is a phase 2 clinical trial for the treatment of sarcoma, a type of cancer. The trial involves the use of the drug bortezomib and has specific eligibility criteria for patients to participate. These criteria include having a confirmed diagnosis of sarcoma with soft tissue metastasis or locally recurrent disease, having at least one measurable lesion, and having disease progression within the past 3 months. Patients must also meet certain age, performance status, and medical criteria, such as having no prior or active known brain metastases and no ongoing or active infection. The trial excludes patients with certain medical conditions or prior treatments, such as prior chemotherapy in the adjuvant or neoadjuvant setting or ongoing use of commercial anticancer agents or therapies.",
    "The sample is a phase 2 clinical trial for patients with metastatic (stage IV) 'triple receptor-negative' breast cancer. The trial is testing the effectiveness of the drug Tarceva. The eligibility criteria include having a confirmed diagnosis of 'triple receptor-negative' breast cancer, having measurable disease that is resistant to taxanes and anthracyclines, and not having prior exposure to an EGFR inhibitor or antibody. Patients must also have adequate bone marrow, liver, and renal function, and a negative pregnancy test if applicable. Women of childbearing potential must use contraception during the study. Patients with uncompensated congestive cardiac failure, a myocardial infarction in the previous 12 months, central nervous system metastases, an organ allograft, or a serious concurrent infection or illness are not eligible.",
    "The sample is a phase 2 trial for non-small cell lung cancer using the drug gefitinib. The eligibility criteria include being over 18 years old, having advanced or metastatic adenocarcinoma of the lung, being chemonaive, having at least one measurable lesion, having adequate hematologic, renal, and liver function, and being willing to comply with scheduled visits and procedures. Exclusion criteria include having symptomatic brain metastasis, having had major surgery within 3 weeks prior to enrollment, having a past medical history of interstitial lung disease, and being pregnant or breastfeeding.",
    "The sample is a phase 2 clinical trial for prostate cancer patients who have previously undergone surgery or radiation therapy. The trial is testing the effectiveness of the drug lapatinib ditosylate in treating hormone-sensitive prostate cancer that has shown biochemical progression. Patients must meet certain eligibility criteria, including having no evidence of metastatic disease, a certain level of testosterone, and a certain level of PSA. They must also have a normal range of various blood tests and cardiac function, and not be taking certain medications or have certain medical conditions. The trial is not open to patients with other malignancies within the past 5 years, except for non-melanoma skin cancer treated with curative intent.",
    "This sample is a phase 2 clinical trial for patients with multi-vessel coronary artery disease who are scheduled for coronary artery bypass surgery. The trial is testing the drug 6R-BH4. The eligibility criteria include exclusion criteria such as inability to provide informed consent, pregnancy or lactation, heart failure requiring diuretic therapy, recent acute coronary event, emergency CABG, newly diagnosed diabetes mellitus, body weight over 130kg, impaired renal function, elevated liver function tests, pacemakers or metallic implants not compatible with MRI scanning, receiving experimental medications or participating in another study, terminally ill subjects, known hypersensitivity to 6R-BH4, and concomitant treatment with methotrexate, levodopa, PDE-3 or PDE-5 inhibitors.",
    "This sample is a phase 2 clinical trial for patients with recurrent or metastatic colorectal cancer that has been previously resected within 12 weeks of study entry. The trial is testing the effectiveness of the drug thalidomide. The eligibility criteria include being 18 years or older, having a certain level of hematopoietic, hepatic, renal, and cardiovascular health, not being pregnant or nursing, and having no history of severe hypothyroidism, seizures, or other medical problems that would preclude surgery. Patients must also have had at least 4 weeks since prior biologic, chemotherapy, or radiotherapy treatments. The trial does not allow concurrent sedating drugs, recreational drugs, or alcohol, or antiseizure medications.",
    "This sample is for a phase 2 clinical trial for breast neoplasms. The trial is testing the effectiveness of two drugs, ku-0059436 (azd2281) (parp inhibitor), for patients with advanced breast cancer who have positive BRCA1 or BRCA2 status and have failed at least one prior chemotherapy. The trial is looking for patients who have no curative standard therapy available and have measurable disease. Patients with brain metastases, who have received treatment for the disease within the last 28 days, or who are considered a poor medical risk due to a serious uncontrolled disorder are excluded from the trial. The icd-10 codes for the diseases being studied are also provided.",
    "The sample is a phase 2 trial for various types of lymphoma and Waldenstr\u00f6m macroglobulinemia. The trial involves the use of drugs such as prednisone, cyclophosphamide, doxorubicin, and vincristine. The eligibility criteria include having a confirmed diagnosis of diffuse large cell lymphoma, being in stage I or II, having at least one measurable disease parameter, and meeting certain medical requirements such as having a certain level of neutrophils and platelets. Patients with certain risk factors such as age over 60 or bulky disease are also eligible. Exclusion criteria include prior chemotherapy or radiation therapy for other malignancies, pregnancy or breastfeeding, and known HIV infection.",
    "The sample is a record of a clinical trial with a phase 2/phase 3 designation. The trial is focused on HIV infections and the associated diseases and icd-10 codes. The drugs being tested include a combination of nrtis, nnrtis, and pis. The eligibility criteria for participants include being HIV infected, not having previously received HAART or anti-HIV drugs for less than 56 consecutive days after birth, and being willing to use acceptable methods of contraception. Exclusion criteria include having grade 3 or 4 clinical or laboratory toxicity, active opportunistic infection or serious bacterial infection, and pancreas, nervous system, blood, liver, or kidney problems that make it impossible to take study medications. Participants cannot be taking any medication that cannot be combined with the study medications in first-line therapy, cannot have received therapy for cancer, and cannot be pregnant or breastfeeding.",
    "The sample is a phase 2 clinical trial for patients with myelodysplastic syndrome. The trial is open to newly diagnosed patients aged 21 to 65 who meet certain criteria, including having acceptable cardiac, lung, renal, and liver function, and a performance status of ECOG 2 or HCT-specific Comorbidity Index < 3. Patients with certain co-morbidities or active infections are excluded from the trial. The trial involves the use of the drug decitabine and explores the possibility of allogeneic HCT as part of a curative treatment plan.",
    "This sample is a phase 2 clinical trial for HIV infections. The trial is testing the effectiveness of the drugs palifermin and palifermin placebo. The eligibility criteria for participants include being HIV infected, receiving potent ART for at least 6 months prior to study entry, having a CD4 count of 200 cells/mm3 or less within 30 days prior to study entry, having a documented current, persistent viral load less than or equal to 200 copies/ml for at least 6 months prior to study entry, and being willing to use acceptable forms of contraception for the duration of the study. Exclusion criteria include having active pancreatitis, recent use of certain medications or treatments, allergy or sensitivity to any component of palifermin, current drug or alcohol use that may interfere with study participation, serious illness or recent surgery that requires systemic treatment or hospitalization, active cancer, HIV-1 RNA levels >200 copies/mL within 6 months prior to study entry, and being pregnant or breastfeeding.",
    "The sample is a phase 2 clinical trial for the treatment of schizophrenia. The trial includes patients with a clinical diagnosis of schizophrenia who are able to remain hospitalized for at least the first 4 weeks of the study and need hospitalization due to worsening of their condition. The trial excludes patients with type 1 or 2 diabetes, previous use of clozapine, or serious medical illness other than schizophrenia. The trial involves the use of four drugs: sca-136 (200 mg), sca-136 (400 mg), olanzapine (15 mg), and placebo. The diseases included in the trial are only schizophrenia, and the icd-10 codes associated with the disease are listed as well.",
    "The sample is a phase 2 clinical trial for the treatment of endometrial cancer using the drugs carboplatin and docetaxel. The trial is for patients with advanced or recurrent disease, with specific eligibility criteria including confirmed histological diagnosis, failed local therapy or considered incurable with local therapy, measurable or evaluable disease, and a performance status of Gynecology Oncology Group (GOG) 0-1. Patients must also meet certain laboratory criteria, such as having a normal bilirubin level and a creatinine level of \u2264 1.5 mg/dL. Exclusion criteria include known hypersensitivity to docetaxel or polysorbate 80, severe infection, and prior chemotherapy or radiotherapy.",
    "The sample is a phase 2 clinical trial for the treatment of various types of melanoma that have progressed after one prior systemic treatment. The trial involves the use of three drugs - carboplatin, paclitaxel, and sorafenib tosylate. The eligibility criteria for the trial include having histologically proven uveal melanoma, measurable disease, and a Zubrod performance status of 0-1. Patients must also meet various laboratory and medical criteria, such as having no active bleeding or uncontrolled hypertension. The trial excludes patients who have had prior treatment with sorafenib or any other agents targeting raf kinase or vascular endothelial growth factor (VEGF) or VEGF receptor, as well as those with conditions affecting their ability to take oral medication or requiring IV alimentation.",
    "The sample is a phase 2 clinical trial for patients with B-cell non-Hodgkin's lymphoma, Burkitt or Burkitt-like lymphomas, and primary effusion lymphomas who have failed or relapsed after at least one prior chemotherapy treatment. The trial involves the use of pegylated liposomal doxorubicin (doxil) and rituximab. The eligibility criteria include being seropositive for HIV, having measurable or evaluable tumor, being over 18 years of age, having a Karnofsky performance status greater than 50%, and meeting certain hematologic and cardiac criteria. Patients with CNS involvement are eligible provided that systemic lymphomatous disease is also present. The trial excludes patients with certain medical conditions, prior exposure to certain medications, and pregnant or nursing mothers.",
    "This is a sample of a clinical trial for phase 2, focused on ovarian cancer. The trial is looking for patients who have received at least two prior cytotoxic chemotherapy regimens, including at least one platinum-containing regimen, and have recurrent or persistent disease that is not amenable to curative treatment with surgery and/or radiotherapy. Patients must have measurable disease according to Response Evaluation Criteria In Solid Tumors (RECIST) and/or a serum cancer antigen 125 (CA-125) level that is rising. They must also have an estrogen receptor-positive tumor, a Gynecologic Oncology Group (GOG) performance status of 0-3, and meet certain blood count and liver function criteria. Patients must not be pregnant or nursing, and must use effective contraception. They must have recovered from the effects of prior surgery, radiotherapy, and/or chemoradiotherapy, and must not have a history of bleeding or documented sensitivity to active or inactive excipients of fulvestrant. Patients must not be on concurrent hormone replacement therapy or prior long-term anticoagulation therapy other than anti-platelet therapy.",
    "The sample is a phase 2 clinical trial for participants infected with human immunodeficiency virus 1 (HIV-1) who are on their first-line treatment with highly active antiretroviral therapy (HAART). The trial aims to test the efficacy and safety of a new drug regimen consisting of darunavir, ritonavir, and two nucleoside reverse transcriptase inhibitors (NRTIs). The eligibility criteria include having a plasma HIV-1 ribonucleic acid (RNA) less than 50 cp/ml for at least 24 weeks before screening, a CD4 count more than 100/mm3 at the start of HAART and more than 200/mm3 at screening, and being healthy on the basis of physical examination, medical history, vital signs, clinical laboratory tests, and 12-lead electrocardiogram performed at screening. The exclusion criteria include a history of coronary heart disease, uncontrolled hypertension, peripheral vascular disease, and/or cerebrovascular disease, history of virological failure on highly active antiretroviral therapy, and current significant tobacco use, active drug or alcohol use or dependence.",
    "The sample is a phase 2 clinical trial for narcolepsy patients. The trial is testing the drug \"gsk189254\". The inclusion criteria for the trial include having a body mass index between 18-32 kg/m2, being able to withdraw from medication for daytime sleepiness, and agreeing to refrain from driving or operating heavy machinery for the duration of the study. The exclusion criteria include having a history of major psychiatric disorder or depression, significant head trauma in the previous 12 months, participation in a clinical trial in the previous 3 months, significant and recent history of drug or alcohol abuse, and being pregnant or breastfeeding. The icd-10 codes for narcolepsy are also provided.",
    "The sample is a phase 2 clinical trial for the treatment of primary insomnia. The trial is for male and female outpatients between the ages of 18 and 65 who have been diagnosed with primary insomnia according to DSM-IV-TR criteria. The trial involves the use of two drugs, gr205171 and gw597599. The eligibility criteria include having a self-reported sleep history of less than 6 hours of total sleep time, at least 30 minutes of sleep onset latency, and at least 3 awakenings per night in at least 3 nights per week. The trial also requires two screening polysomnography tests with specific criteria for total sleep time, latency to persistent sleep, and wake after sleep onset. The trial has a list of exclusion criteria, including any clinically significant psychiatric disorder other than primary insomnia, symptoms consistent with any primary sleep disorder other than primary insomnia, and a history of alcohol, narcotic, benzodiazepine, or other substance abuse or dependence within the past 12 months. Women of childbearing potential must commit to consistent and correct use of an acceptable method of birth control.",
    "The sample is a phase 2 clinical trial for patients with Parkinson's disease who are experiencing dyskinesias and are being treated with L-Dopa. The trial includes patients who have been on a stable anti-parkinsonian treatment regimen for at least four weeks. The trial excludes patients who have undergone surgical treatment for PD, have had cancer within the past 5 years (other than localized skin cancer and prostate cancer that has been effectively treated), have advanced, severe or unstable disease (other than PD) or evidence of dementia that may interfere with the study outcome evaluations. The trial may have other protocol-defined inclusion/exclusion criteria. The table includes columns for the phase of the trial, diseases being studied, icd-10 codes of the diseases, drugs being used, and eligibility criteria.",
    "The sample is a phase 2 clinical trial for patients with stage III or IV, recurrent or refractory, indolent B cell non-Hodgkin's lymphoma. The trial requires patients to have relapsed after prior chemotherapy and have at least one lymph node or visceral lesion that is at least 2 cm in diameter. Patients must be 18 years or older, have an ECOG performance status of 0-2, and a lymphocyte count less than 5,000/mm3. They must not be pregnant or nursing, and fertile patients must use effective contraception. Patients must not have an active infection, be HIV positive, have hepatitis B or C, or have any concurrent life-threatening condition. Prior to the trial, patients must not have received monoclonal antibody therapy for lymphoma, and they must not be receiving any other concurrent corticosteroids and/or epinephrine (unless anaphylactic shock). The trial drug is dexamethasone.",
    "The sample is a record of a clinical trial with a phase 2 designation. The trial is focused on prostate cancer and the icd-10 codes associated with it. The trial involves the use of two drugs, vandetanib and placebo. The eligibility criteria for the trial include a diagnosis of prostate cancer, a PSA level of 5 ng/mL or higher, recent completion of first hormone treatment, and a screening PSA level of 1.0 ng/mL or lower. The exclusion criteria include the presence of bone or soft tissue metastases and significant cardiovascular disease.",
    "The sample is a phase 2 clinical trial for alcoholism and alcohol abuse. The trial is looking at the effectiveness of quetiapine fumarate as a treatment for alcohol dependence. The eligibility criteria include being between the ages of 18 and 65, having a DSM-IV diagnosis of current alcohol dependence, reporting \"very heavy\" drinking at least 40% of the days during a 60-day period, seeking treatment for alcohol dependence, and being able to provide written informed consent. The trial also requires participants to have stable residence, reasonable transportation arrangements, and no plans to move within the next 3 months. Exclusion criteria are not specified in the sample.",
    "The sample is a phase 2 clinical trial for patients with gastrointestinal stromal tumors. The trial is testing the effectiveness of the drug nilotinib. The eligibility criteria include having confirmed GIST, measurable disease, and having received and progressed on imatinib and sunitinib. Patients must also meet certain organ and marrow function requirements and agree to use contraception during the study. Exclusion criteria include receiving other investigational agents, having impaired cardiac function, and having severe or uncontrolled concurrent medical disease. Patients with a history of noncompliance to medical regimens or inability or unwillingness to return for scheduled visits, patients who are pregnant or breastfeeding, and patients unwilling or unable to comply with the requirements for the protocol are also excluded.",
    "The sample is a phase 2 clinical trial for patients with recurrent bladder cancer or transitional cell carcinoma of the bladder. The trial is testing the effectiveness of the drug sunitinib malate. The eligibility criteria include having previously received BCG therapy, having certain blood counts and liver function within normal ranges, and not having certain medical conditions or taking certain medications. Patients must also agree to use contraception during the study. Exclusion criteria include having received certain types of prior treatment, having certain medical conditions, or being pregnant or breastfeeding.",
    "The sample is a record of a clinical trial with a phase 2 designation. The trial is focused on the disease asthma, with a list of associated ICD-10 codes. The trial involves two drugs, oc000459 and placebo. The eligibility criteria for the trial include being a non-smoker, having mild to moderate asthma for at least 12 months, and having a history of asthma symptoms increasing in response to external allergens. In addition, participants must test positive on a skin prick test to an allergen associated with their asthma. Exclusion criteria include recent use of inhaled or local corticosteroids and recent use of prescribed or over-the-counter medication.",
    "The sample is a record from a clinical trial table that includes information about the trial's phase, diseases being studied, ICD-10 codes associated with those diseases, drugs being used, and eligibility criteria for participants. In this particular sample, the trial is in phase 2 and is studying breast neoplasms. The ICD-10 codes associated with the disease include C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, and D48.60. The drugs being used in the trial are oxaliplatin and vinorelbine. The eligibility criteria for participants include having metastatic, histologically or cytologically proven breast cancer, at least one bi-dimensionally measurable lesion, and previous treatment with chemotherapy as first line for metastatic disease. There are also exclusion criteria, such as having symptomatic peripheral neuropathy or being pregnant or breastfeeding.",
    "The sample is a phase 2 clinical trial for patients with hormone-refractory prostate cancer who have failed 1st-line docetaxel-containing regimen. The trial is testing the effectiveness of the drugs mitoxantrone and GM-CSF. The eligibility criteria include being over 18 years old, having histologically-confirmed adenocarcinoma of the prostate, having a minimum prostate-specific antigen (PSA) level of >5 mg/dL and rising, and having a Karnofsky Performance Status (KPS) >60%. The trial also has exclusion criteria, such as having a concomitant second malignancy other than non-melanoma skin cancer, any concomitant serious infection, and noncompliance with study procedures.",
    "The sample is a clinical trial with a phase 2/phase 3 design, focused on treating patients with colorectal carcinoma and liver metastases. The trial involves the use of drugs such as folfox6 and bevacizumab, and the eligibility criteria include having confirmed adenocarcinoma of the colon or rectum, measurable CT evidence of liver metastases, and an ECOG performance status of 0-1. Exclusion criteria include evidence of ascites, cirrhosis, portal hypertension, and previous radiotherapy to the upper abdomen. The trial aims to assess the efficacy of the drugs in treating the specified conditions.",
    "The sample is a phase 2 clinical trial for asthma. The eligibility criteria include being between 18 and 65 years old, having a documented history of bronchial asthma, and currently being treated only with intermittent short-acting beta-2 agonist therapy. The trial also requires participants to have a best FEV1 of 60%-85% of the predicted normal value during the screening period. Exclusion criteria include a positive test for Hepatitis B or Hepatitis C antibody, current or chronic history of liver disease, and a positive pre-study drug/alcohol screen. The trial involves testing the effectiveness of several different doses of the drug gw870086, as well as a placebo. The sample includes a list of diseases and their corresponding icd-10 codes, as well as the eligibility criteria for the trial.",
    "The sample is a phase 2 clinical trial for patients with documented HIV-1 infection. The trial requires patients to have been on a current HAART regimen for at least 12 weeks and have an HIV-1 plasma viral load above 500 HIV-1 RNA copies/mL. The trial involves the use of the drugs etravirine and ritonavir, and darunavir. Patients must meet certain inclusion criteria, such as having no more than 2 previous virologic failures while on PI-containing HAART regimens and demonstrating phenotypic sensitivity to both etravirine and darunavir based on resistance testing at screening. Patients must also meet certain exclusion criteria, such as having a life expectancy of less than 6 months or any active clinically significant disease that would compromise their safety or the outcome of the trial.",
    "This sample is for a phase 2 clinical trial for relapsing multiple sclerosis. The trial includes the drug atacicept and a placebo matched to atacicept. The eligibility criteria for the trial includes a diagnosis of RMS as per McDonald criteria, 2005, and excludes patients with primary progressive MS, secondary progressive MS without superimposed relapses, relevant cardiac, hepatic and renal diseases, pretreatment with immunosuppressants and immunomodulating drugs, clinical significant abnormalities in blood cell counts and immunoglobulin levels, and clinical significant acute or chronic infections. Other protocol-defined inclusion and exclusion criteria may also apply.",
    "The sample is a phase 2 clinical trial for patients with rheumatoid arthritis and chronic anemia. The trial is testing the effectiveness of the drug epoetin alfa. The inclusion criteria require patients to have signed an informed consent, be postmenopausal, surgically sterile, or practicing an effective method of birth control, and not be breastfeeding during the study period. The exclusion criteria include uncontrolled hypertension, anticipated surgery requiring transfusion, thromboembolic events, uncontrolled psychiatric disease, and enrollment in another clinical trial during the study. The diseases being studied are anemia and rheumatoid arthritis, and the icd-10 codes associated with these diseases are listed.",
    "The sample is a phase 2 clinical trial for the treatment of allergic rhinitis. The trial includes patients aged 18-65 with a clinical history of intermittent allergic rhinitis with seasonal onset and offset of nasal allergy symptoms during each of the last two grass pollen allergy seasons. The patients must have a positive skin prick test to dactylis glomerata and a negative control. FEV1 measured by spirometry must be \u226580% of their predicted value at screening. The trial includes the drugs qaw039, montelukast, and placebo. The eligibility criteria include a TNSS score \u22656 on at least one assessment during the 2h EEC challenge at Screening. The exclusion criteria include the use of other investigational drugs, pregnancy or nursing, and women of child-bearing potential who are not using effective methods of contraception during dosing of study treatment.",
    "The sample is a phase 2 clinical trial for prostate cancer. The eligibility criteria include having histologically confirmed prostate cancer with a PSA level less than 10.0 ng/mL, T1c-T2a disease, and a Gleason sum of 6 or 7 (secondary pattern 4 only). Patients with low-risk disease must also meet additional criteria. The trial also requires patients to have measurable disease on MRI of at least 0.2 cc and to be eligible for active surveillance according to the criteria set out by the National Institute for Health and Clinical Excellence. Patients must also meet certain patient characteristics, such as having ALT and AST \u2264 2 times the upper limit of normal (ULN) and being able to swallow and retain oral medication. The trial excludes patients with a history of another malignancy within five years that could affect the diagnosis of prostate cancer, a history or current evidence of drug or alcohol abuse within the last 12 months that might confound the results of the study or pose additional risk to the patient, and a known hypersensitivity to any 5\u03b1-reductase inhibitor or to any drug chemically related to dutasteride. The trial also excludes patients with unstable serious co-existing medical condition(s) and those who have undergone certain prior concurrent therapies.",
    "The sample is a phase 2 clinical trial for patients with acute myeloid leukemia (AML) who have achieved a first morphologic complete remission. The trial includes patients with preceding myelodysplastic syndrome (MDS) or treatment-related AML, but excludes patients with acute leukemia following blast transformation of prior chronic myeloid leukemia (CML) or other myeloproliferative disease. The trial involves the use of drugs such as busulfan, fludarabine phosphate, methotrexate, and tacrolimus. The eligibility criteria include various medical conditions, performance status, and laboratory values. The trial requires the identification of a hematopoietic cell donor who must be an HLA-identical sibling or a matched unrelated donor with high resolution molecular typing at specific loci. The donor must also be healthy and meet institutional standards for stem cell donation. Syngeneic donors are not eligible.",
    "The sample is a phase 2 clinical trial for the treatment of hepatocellular carcinoma. The trial involves the use of arsenic trioxide as a drug. The eligibility criteria for the trial include having a histologic diagnosis of HCC or cholangiocarcinoma that is locally advanced but cannot be treated adequately by radiotherapy or surgery, or metastatic disease or an AFB > 20 w/CT scan consistent with HCC. Other criteria include having a life expectancy of more than 12 weeks, normal renal function, and normal serum electrolytes. Exclusion criteria include being pregnant or lactating, having a history of prior malignancy within the prior five years, and having uncontrolled metastatic disease of the central nervous system.",
    "The sample is a phase 2 clinical trial for the treatment of scleroderma, a disease that affects the skin. The trial is testing the drug imatinib mesylate. The eligibility criteria for the trial include having diffuse skin involvement and active disease as measured by worsening skin score and/or increased ESR. Exclusion criteria include past exposure to Gleevec, certain abnormal labs, and the use of certain drugs that could interact with imatinib mesylate. The trial also excludes individuals with serious comorbidities that may impair their ability to complete the study, as well as those with liver disease or high levels of creatinine. Additionally, the trial excludes individuals who consume more than three alcoholic drinks per week.",
    "The sample is a phase 2 clinical trial for metastatic breast cancer patients. The trial is testing the drug erlotinib and the eligibility criteria includes having a tumor block available, less than or equal to 1 prior chemotherapy for metastatic or locally unresectable disease, and prior treatment with anthracycline and taxane chemotherapy. Patients must also have measurable disease on CT or PET scan or physical exam, be ER-negative, PR-negative and HER2-neu-negative, and have an ECOG performance status of 0-2. Exclusion criteria includes having pleural effusions or blastic bone lesions as the only manifestations of the current metastatic breast cancer, other primary malignancies within 5 years, and symptomatic or untreated brain metastases.",
    "The sample is a phase 2 clinical trial for the treatment of severe sepsis and septic shock using the drugs azd9773 and placebo. The trial is open to Japanese adults who have a first episode of sepsis during their hospitalization and objective evidence of infection that requires parenteral antibiotics. Participants must also have at least 2 of 4 SIRS criteria in the 24 hours before organ dysfunction, which must include either fever or elevated white blood cells. Additionally, participants must have cardiovascular or respiratory dysfunction. There are several exclusion criteria, including immunocompromising comorbidities or concomitant medications, concomitant diseases, and medication and allergy disqualifications. The trial requires participants to meet specific eligibility criteria and excludes those who do not meet the criteria or have certain medical conditions or allergies.",
    "The sample is a phase 2 clinical trial for rheumatoid arthritis. The trial involves testing the effectiveness of a p38 inhibitor drug compared to a placebo. The trial has eligibility criteria for patients, including being over 18 years old and currently receiving outpatient treatment for RA. Patients must also use reliable contraception if they are of child-bearing potential. Exclusion criteria include recent major surgery, other autoimmune or inflammatory joint diseases, recent treatment with methotrexate, and concurrent use of other RA medications.",
    "The sample is a clinical trial that is in phase 2/phase 3 and focuses on cardiovascular disease, aging, endothelial dysfunction, and physical activity. The trial involves the drug alt-711 and has a list of inclusion and exclusion criteria. The inclusion criteria include healthy sedentary elderly individuals who are 65 years or older. The exclusion criteria include individuals with cardiovascular or cerebrovascular disease, changes on ECG indicating cardiomyopathy or ischemia, diabetes mellitus, hypercholesterolemia, BMI greater than 33 kg/m2, and intensive exercise greater than 1 hour a week.",
    "The sample is a phase 2 clinical trial for patients with advanced non-small cell lung cancer. The trial includes patients with confirmed diagnosis of locally advanced and/or metastatic NSCLC, who have bidimensionally measurable lesions or unidimensionally evaluable lesions, and are at least 18 years old. The trial also includes patients who have received prior chemotherapy (including taxanes) for advanced NSCLC, have an Eastern Cooperative Oncology Group (ECOG) performance status of 0-2, and a life expectancy of more than 12 weeks. Patients with active infections, abnormal liver and bone marrow function, and abnormal blood counts are excluded from the trial. The trial also excludes patients with untreated brain metastases, concurrent radiotherapy, and other concurrent cancer treatment-related investigational agent. Patients with treated brain metastases must be neurologically stable. The trial requires patients to provide written informed consent and use an adequate method of contraception if they are women of childbearing potential.",
    "The sample is a record of a clinical trial in phase 2 for the treatment of open-angle glaucoma. The trial involves the use of a drug called anecortave acetate sterile suspension, 30 mg/ml. The eligibility criteria for the trial include a diagnosis of open-angle glaucoma, while exclusion criteria include pseudoexfoliation and pigment dispersion component. Other protocol-defined inclusion and exclusion criteria may also apply. The sample also includes a list of icd-10 codes associated with the disease.",
    "The sample is a phase 2 clinical trial for locally advanced or metastatic colorectal cancer. The trial involves a combination of drugs including oxaliplatin, 5-fluorouracil, leucovorin, bevacizumab, irinotecan, and cetuximab. The eligibility criteria include confirmation of the disease, measurable or evaluable disease, ECOG performance status \u2264 2, age between 18 and 72 years, progression after 1st line therapy with FOLFOX/AVASTIN, adequate liver, renal, and bone marrow function, ability to understand the nature of the study, and written informed consent. Exclusion criteria include a history of serious cardiac disease, myocardial infarction or stroke within 6 months, clinically significant peripheral vascular disease, and other conditions that may preclude study compliance.",
    "The sample is a record of a clinical trial with a phase 2 designation. The trial is focused on Alzheimer's disease and the table includes a list of relevant ICD-10 codes. The trial involves testing several drugs, including chf 5074 at different dosages and a placebo. The eligibility criteria for the trial are also listed, including requirements for a diagnosis of amnestic or non-amnestic Mild Cognitive Impairment, a Mini-Mental State Examination score higher than 24 at screening, and an MRI scan of the brain at screening with fluid-attenuation inversion recovery (FLAIR) and T2*-weighted gradient-recalled-echo (GRE) sequences. The exclusion criteria are also listed, including a diagnosis of Alzheimer's disease, any medical condition that could explain the patient's cognitive deficits, and a history of stroke. Additionally, there are restrictions on the use of certain medications and psychoactive drugs.",
    "The sample is a phase 2 clinical trial for patients with refractory nasopharyngeal carcinoma. The trial is testing the effectiveness of the drugs ifosfamide and doxorubicin. The eligibility criteria for the trial include having a histological diagnosis of NPC, being over 18 years old, having measurable metastatic or recurrent disease, and having received one prior chemotherapy regimen for metastatic or recurrent NPC which relapsed or became refractory before entry. Other criteria include having a certain level of white blood cells, platelets, and creatinine, as well as having a certain ejection fraction and no recent history of heart issues. Patients must also have a random blood glucose level below 250 mg and sign an informed consent form. Exclusion criteria include having received more than one prior chemotherapy regimen, having certain levels of white blood cells, platelets, creatinine, or bilirubin, having an ECOG PS score greater than 3, and having a history of myocardial infarction within the last 6 months.",
    "The sample is a phase 2 clinical trial for patients with chronic obstructive pulmonary disease. The trial involves the use of drugs such as salmeterol xinafoate and serevent\u00ae diskus\u00ae as well as placebos. The eligibility criteria include patients who are current or ex-smokers with a smoking history of more than 10 pack-years, and who are able to perform technically acceptable pulmonary function tests. Exclusion criteria include patients with significant diseases other than COPD, recent history of myocardial infarction, and patients with malignancy for which the patient has undergone resection, radiation therapy or chemotherapy within the last five years. The trial also has specific criteria for patients who have undergone thoracotomy with pulmonary resection, and patients who have completed a pulmonary rehabilitation program in the six weeks prior to the Screening Visit.",
    "The sample is a phase 2 clinical trial for the treatment of metastatic breast cancer using the drug bortezomib. The eligibility criteria include having confirmed adenocarcinoma of the breast with at least one measurable lesion, having previously received one chemotherapy regimen for metastatic disease, and having no known brain metastases. Patients must also meet certain age, sex, and health requirements, and must not have any ongoing infections or psychiatric illnesses that would preclude study participation. Prior concurrent therapies are allowed, but patients must have recovered from them before starting the trial.",
    "The sample is a phase 2 clinical trial for the treatment of acute promyelocytic leukemia (APL) using a combination of arsenic trioxide, idarubicin, and tretinoin. The trial is open to patients with confirmed APL diagnosis through either conventional cytogenetics or fluorescence in situ hybridization (FISH) or positive PML-RAR\u03b1 transcript by reverse transcriptase-polymerase chain reaction (RT-PCR) assay. Patients with CNS involvement by APL are also eligible. The trial has specific eligibility criteria for patient characteristics, including Karnofsky performance status, creatinine levels, bilirubin levels, alkaline phosphatase levels, AST and ALT levels, LVEF, QTc, and pregnancy status. Patients must not have active serious infections, other concurrent active malignancy requiring immediate therapy, clinically significant cardiac disease, pulmonary disease, or other serious or life-threatening condition deemed unacceptable by the principal investigator. Prior treatment for APL is not allowed.",
    "The sample is a phase 2 clinical trial for patients with advanced stage III or IV melanoma originating from mucosal, acral-lentiginous, or chronic sun-damaged skin. The trial is testing the drug Sutent (sunitinib) and requires patients to have an aberration of the KIT gene or KIT receptor on in-vitro testing of their tumor tissue. Patients must also have evidence of measurable disease by RECIST criteria and meet certain eligibility criteria, including adequate organ function and an ECOG performance status of 0 or 1. Exclusion criteria include recent major surgery or radiation therapy, active brain metastases, and ongoing treatment with therapeutic doses of warfarin. The trial aims to enroll patients with a life expectancy of at least 3 months.",
    "The sample is a phase 2 clinical trial for HIV-infected individuals with cognitive impairment. The trial is testing the effectiveness of minocycline and placebo (tetracycline) drugs. The eligibility criteria include being on a stable ART regimen for at least 16 consecutive weeks, having a Karnofsky performance score of 60 or higher, and being able to sit and stand for at least 2 hours and swallow medications with an 8-ounce glass of water. Exclusion criteria include having current cancers, severe premorbid psychiatric illness, and active symptomatic AIDS-defining opportunistic infection within 45 days prior to study entry. The trial also requires participants to undergo neuropsychological tests and lumbar punctures.",
    "The sample is a record of a clinical trial in phase 2 for Parkinson's disease. The trial includes patients who have been diagnosed with early-stage idiopathic PD within the 2 years prior to screening and are not currently receiving any PD treatment. The trial excludes female patients of child-bearing potential, patients with a history of neurosurgical procedures for PD, and patients with a history of severe psychiatric illness. The trial involves the use of two drugs, pym50028 and placebo. The sample also includes the ICD-10 code for Parkinson's disease, which is G20.",
    "The sample is a record of a clinical trial with a phase 2 designation. The trial is focused on treating highly-malignant non-Hodgkins-Lymphoma, mantle-cell lymphoma or follicular lymphoma 3\u00b0 with CNS relapse (meningeal or/and intraparenchymal) with or without systemic lymphoma manifestations. The treatment involves combined systemic and intrathecal chemotherapy followed by hd-asct. The record includes a list of inclusion and exclusion criteria for the trial participants. The inclusion criteria include factors such as ECOG performance score \u22642, no active infection, and adequate renal function. The exclusion criteria include factors such as newly diagnosed NHL with primary CNS involvement, immunosuppression, and pregnancy or breastfeeding.",
    "The sample is a clinical trial for a drug called vr506 and a placebo for the treatment of asthma. The trial is in phase 2/phase 3 and the eligibility criteria include having a documented clinical history of asthma for at least 6 months, being between the ages of 12 and 65, having mild or moderate asthma, and being able to use the new inhaler and eDiary correctly. Exclusion criteria include having a history of lung cancer, HIV infection, or drug/alcohol abuse, as well as having any clinically significant abnormalities or findings that may compromise subject safety. The trial also requires subjects to comply with study procedures, including blood sampling, and to be available for all study visits.",
    "The sample is a phase 2 clinical trial for patients with recurrent or persistent endometrial adenocarcinoma that is refractory to curative therapy or established treatments. The trial involves the drug pemetrexed and has a list of inclusion and exclusion criteria. The diseases being studied include neoplasms, neoplasms by site, urogenital neoplasms, genital neoplasms, female, uterine neoplasms, endometrial neoplasms, cancer of endometrium, endometrial cancer, cancer of the endometrium, and neoplasms, endometrial. The icd-10 codes associated with these diseases are also listed.",
    "The sample is a phase 2 clinical trial for patients diagnosed with advanced or metastatic colorectal cancer. The trial is testing the drug enzastaurin hcl. The eligibility criteria for the trial include being able to visit the doctor's office every 28 days for at least 6 months and being able to swallow tablets. Women who are pregnant or breastfeeding and those with a history of significant heart disease or other medical problems are excluded from the trial. The diseases being studied are limited to colonic neoplasms, and the icd-10 codes associated with these diseases are listed.",
    "The sample is a phase 2 clinical trial for overweight and obese individuals. The trial involves the use of drugs such as pramlintide acetate and metreleptin, as well as placebo treatments. The eligibility criteria include being between 18 and 65 years old, having a stable body weight, and not having been treated with certain medications in the past 3 months. The trial also requires participants to be comfortable with having repeated telephone contacts with a lifestyle counselor. Exclusion criteria include having a medical history or physical characteristics suggestive of genetic or syndromatic obesity, currently being enrolled in a weight loss program, and having received certain medications or treatments in the past 2 months.",
    "The sample is a phase 2 clinical trial for asthma. The trial is looking for participants who have been diagnosed with asthma for at least 6 months and have a best AM pre-bronchodilator FEV1 of 60% to 85% of predicted normal value at Screening. The trial requires participants to have demonstrated reversibility of disease by at least 12% and 200mL increase in FEV1. Participants must have been prescribed a non-corticosteroid controller at least 3 months preceding Visit 1, and/or a short-acting beta 2 agonist, without the use of inhaled corticosteroids in the 4 weeks prior to Visit 1. The trial is looking for both male and eligible female participants (females of child-bearing potential must use acceptable method of birth control). The trial requires participants to be able to replace their current short-acting Beta-2-agonist with albuterol/salbutamol aerosol inhaler for the duration of the study and to be judged capable of withholding albuterol/salbutamol for at least 4 hours prior to study visits. The trial has a list of exclusion criteria, including a history of life-threatening asthma, severe asthma exacerbation, respiratory infection, concurrent respiratory disease, current smoker or smoking history of 10 pack years or more, and other clinically significant, uncontrolled condition or disease which would pose a safety risk to the patient, or confound interpretation of study results. The trial also excludes participants with drug allergy to any Beta-2-agonist, sympathomimetic drug, intranasal, inhaled or systemic corticosteroid therapy, known or suspected sensitivity to the constituents of the Novel DPI (ie lactose), history of severe milk protein allergy, administration of prescription or over-the-counter medication that would significantly affect the course of asthma, or interact with the study drug, any infirmity, disability or disease of a child or family member likely to impair compliance, alcohol or substance abuse history, viral hepatitis B surface antigen or Hepatitis C antibody, known HIV-positive history, and affiliation with investigator or site staff.",
    "The sample is a phase 2 clinical trial for patients with early-stage breast cancer that is HER2 positive. The trial is testing the effectiveness of a combination of drugs including cyclophosphamide, doxorubicin hydrochloride, lapatinib ditosylate, and paclitaxel. The eligibility criteria include having undergone mastectomy or lumpectomy with axillary node or sentinel node dissection within the past 84 days, having no active hepatic or biliary disease, and meeting certain patient characteristics such as having an ECOG performance status of 0-2 and being able to complete questionnaires by themselves or with assistance. Prior concurrent therapy is also restricted.",
    "The sample is a record of a clinical trial in phase 2, focused on the disease of asthma. The icd-10 codes associated with the disease are listed, along with a list of drugs being tested, including a placebo and two different doses of a drug called r940343. The eligibility criteria for the trial are also listed, including requirements for a clinical history of asthma and the ability to perform spirometry, as well as exclusion criteria such as the presence of chronic obstructive pulmonary disease or bronchiectasis, and upper or lower respiratory infections.",
    "The sample is a record of a clinical trial in phase 2 for the treatment of breast cancer using the drug fulvestrant. The trial is open to postmenopausal women who have confirmed invasive breast cancer and evidence of hormone sensitivity. Participants must be willing to undergo biopsies and have not received previous treatment for breast cancer. However, those with severe concurrent conditions that would preclude surgery or jeopardize compliance with the study, as well as those with a history of hypersensitivity to castor oil or bleeding disorders, are excluded from the trial. The diseases and their corresponding ICD-10 codes are also listed in the record.",
    "The sample is a phase 2 clinical trial for type 2 diabetes mellitus. The trial involves the use of two drugs, vi-0521 and placebo. The eligibility criteria for the trial include informed consent, having type 2 diabetes, having a BMI between 27-42, and following a specified diet/exercise and/or diabetes medications. The exclusion criteria include having high blood pressure, recent stroke/MI/unstable cardiovascular disease, clinically significant renal, hepatic, or psychiatric disease, unstable thyroid disease or replacement therapy, nephrolithiasis, obesity of known genetic or endocrine origin, participation in a formal weight loss program or lifestyle intervention, history of glaucoma, pregnancy or breastfeeding, alcohol abuse, eating disorder, and excluded medications.",
    "The sample is a record of a clinical trial in phase 2 for the treatment of chronic obstructive pulmonary disease (COPD). The trial involves the use of drugs such as formoterol, salmeterol, and placebo. The eligibility criteria for the trial include a clinical diagnosis of COPD according to GOLD guidelines, a smoking history equivalent to 10 or more packs per year, and documented use of a short-acting inhaled bronchodilator. Exclusion criteria include a history or current diagnosis of asthma, recent COPD exacerbation requiring hospitalization or treatment with antibiotics or systemic steroids, and a history or current diagnosis of atopic diseases such as allergic rhinitis or eczema before the age of 40.",
    "This sample is a phase 2 clinical trial for the treatment of gastrointestinal stromal tumor. The trial is testing the drug imatinib mesylate. The eligibility criteria for participants include having a confirmed diagnosis of malignant gastrointestinal stromal tumor, having a potentially resectable primary or recurrent disease, and having at least one measurable lesion. Participants must also meet certain medical criteria, such as having a performance status of Zubrod 0-2 and meeting certain blood count and liver function requirements. Additionally, participants must not have any uncontrolled chronic diseases or active infections, and must not be pregnant or nursing. The trial requires participants to abstain from certain medications and therapies for a period of time before and during the trial.",
    "The sample is a phase 2 clinical trial for patients with carcinoma of unknown primary. The trial includes eligibility criteria such as confirmed histological diagnosis, absence of primary site revealed by diagnostic tests, measurable disease, and specific patient characteristics such as age, performance status, and life expectancy. The trial also includes a list of drugs, gemcitabine hydrochloride and irinotecan hydrochloride, and a list of diseases and their corresponding icd-10 codes. The eligibility criteria also specify that patients must be willing to provide blood and tissue samples. The sample also includes prior concurrent therapy restrictions for biologic agents, chemotherapy, radiotherapy, and surgery.",
    "The sample is a phase 2 clinical trial for patients with primary peritoneal cavity cancer or recurrent ovarian epithelial cancer. The trial involves the use of imatinib mesylate as a drug. The eligibility criteria include having at least one measurable target lesion, having received at least one prior platinum-based chemotherapy regimen, and having a performance status of GOG 0-2 (if patient has received one prior treatment regimen) or GOG 0-1 (if patient has received two prior treatment regimens). Patients must also meet various medical criteria, such as having certain blood counts and no signs of bowel dysfunction. Additionally, patients must not be pregnant or nursing, and fertile patients must use effective barrier contraception during and for 3 months after study participation. The trial excludes patients with certain medical conditions or who have received certain prior treatments.",
    "The sample is a phase 2 clinical trial for the treatment of Parkinson's disease using the drug exenatide. The trial is looking for patients with moderate severity Parkinson's disease, aged between 45-70 years, with disease onset after age 40 years and disease duration of more than 5 years. Patients must be on oral L-dopa treatment and have a UPDRS motor off medication score of more than 15. They must also be L-dopa responsive, defined as having more than 33% improvement in UPDRS motor off medication score following L-dopa challenge. Patients must be able to give informed consent and comply with the trial protocol. Exclusion criteria include other causes of parkinsonism, concurrent dementia or severe depression, and ongoing treatment with certain medications. Females who are pregnant or breastfeeding or of childbearing potential are also excluded.",
    "The sample is a phase 2 clinical trial for the treatment of amyotrophic lateral sclerosis. The trial involves the use of pioglitazone and placebo drugs. The eligibility criteria include having possible, probable, or definite ALS according to the revised El Escorial World Federation of Neurology criteria, disease duration of more than 6 months and less than 3 years, best-sitting FVC between 50% and 95% of predicted normal, continuous treatment with 100 mg riluzole daily for at least one month, onset of progression weakness within 36 months prior to the study, and being capable of thoroughly understanding all information given and giving full informed consent according to GCP. The exclusion criteria include previous participation in another clinical study within the preceding three months, tracheotomy or assisted ventilation of any type during the preceding three months, gastrostomy, any medical condition known to have an association with motor neuron dysfunction which might confound or obscure the diagnosis of ALS, presence of any concomitant life-threatening disease or impairment likely to interfere with functional assessment, confirmed hepatic insufficiency or abnormal liver function, renal insufficiency, evidence of major psychiatric disorder or clinically evident dementia precluding evaluation of symptoms, known hypersensitivity to any component of the study drugs, likely to be not cooperative or comply with the trial requirements, other antidiabetics, heart failure or heart failure in the patient's history, history of macular oedema, treatment with thiazolidinediones within 3 months prior to screening, known or suspected history of alcohol and/or drug abuse, and treatment with gemfibrozil within 3 months prior to screening.",
    "The sample is a clinical trial for lupus nephritis, a disease affecting the kidneys in patients with systemic lupus erythematosus. The trial is in phase 2/phase 3 and involves the drugs atacicept, mycophenolate mofetil, placebo, and corticosteroids. The eligibility criteria for the trial include a diagnosis of SLE satisfying at least 4 out of the 11 American College of Rheumatology criteria, and a renal biopsy consistent with active ISN/PRS class III or IV lupus nephritis. Exclusion criteria include a low estimated glomerular filtration rate, severe or progressive central nervous system SLE, recent treatment with certain drugs, and prior treatment with certain B cell modulating agents.",
    "The sample is a phase 2 clinical trial for the treatment of obesity. The trial includes subjects who are between 18 to 65 years of age, have a body mass index (BMI) of 30 kg/m2 or higher, and are non-smokers. The trial also includes subjects with obesity and dyslipidemia and/or controlled hypertension, with a BMI of 27 kg/m2 or higher. The trial involves the use of various drugs, including zonisamide sr and bupropion sr, in different dosages and combinations. The eligibility criteria for the trial include various medical and lifestyle factors, such as normal blood pressure, stable medical regimen, and no history of drug abuse or dependence. The trial also includes exclusion criteria, such as a history of seizures or hypersensitivity to certain medications. Women of child-bearing potential must use acceptable contraception throughout the study period and for 30 days after discontinuation of study drug.",
    "The sample is a phase 2 clinical trial for patients with non-small-cell lung carcinoma. The trial is testing the effectiveness of the drugs bibw2992 and bibw2992 + paclitaxel in treating the disease. The eligibility criteria for the trial include having a confirmed diagnosis of NSCLC stage IIIB/IV adeno- or bronchoalveolar carcinoma, having a specific mutation in the EGFR or HER2-neu-receptor, and having not received more than 3 lines of chemotherapy. Patients must also have a measurable tumor lesion and a life expectancy of at least 3 months. Exclusion criteria include having more than 3 prior cytotoxic chemotherapy treatments, recent acute gastrointestinal disorders, and other life-threatening illnesses or organ system dysfunctions. Patients must also be willing to use contraception during the trial if they are of childbearing potential.",
    "The sample is a phase 2 clinical trial for patients with advanced or metastatic breast cancer that is not amenable to surgery or radiation therapy with curative intent. The trial is testing the drug Tanespimycin. The eligibility criteria include having confirmed primary adenocarcinoma of the breast, at least one measurable lesion, and progressive disease following hormonal therapy or treatment with both an anthracycline and a taxane. Patients must have discontinued previous cytotoxic chemotherapy at least 4 weeks before study entry and all acute toxicity of prior therapy must be resolved. Patients must also meet certain medical criteria, such as having a life expectancy of at least 3 months and an ECOG performance status of 0-2. Exclusion criteria include current treatment with any other anti-neoplastic agent, radiation therapy within 2 weeks of enrollment, and known brain or leptomeningeal metastatic disease requiring active therapy. Patients with certain medical conditions or laboratory abnormalities that may increase the risk associated with study participation or study drug administration are also excluded.",
    "The sample is a phase 2 clinical trial for patients with type 2 diabetes mellitus. The trial includes a list of icd-10 codes for the disease and a list of drugs, including a placebo and ro4876904. The eligibility criteria for the trial includes adult patients between the ages of 18-75 who have been diagnosed with type 2 diabetes for at least one month before screening. Patients must be drug-naive or pretreated with the maximum tolerated dose of metformin and have a BMI between 25-45kg/m2. Patients with type 1 diabetes or who have taken any anti-hyperglycemic medication other than metformin or a weight-lowering drug in the last three months are excluded from the trial.",
    "The sample is a phase 2 clinical trial for the treatment of seasonal allergic rhinitis. The trial includes subjects with a history of atopy and evidence of atopy, defined as a positive skin prick test to grass pollen allergen. The trial includes male and female subjects aged between 18 and 60 years, with a body mass index within the range of 18 to 32 kg/m2. The trial excludes subjects who have been treated with intranasal corticosteroids within 28 days prior to the first dose, have a history of asthma with treatment with inhaled or systemic corticosteroids within 6 months of the first dose, have a history of COPD, have had any exposure to human monoclonal or polyclonal antibodies, have had any allergy immunotherapy within 3 years prior to screening, have had any prior grass pollen allergy immunotherapy, or have FEV1 < 70% of predicted at screening or baseline. Other protocol-defined inclusion/exclusion criteria may also apply.",
    "The sample is a phase 2 clinical trial for patients with recurrent or metastatic squamous cell carcinoma of the head and neck. The trial includes patients who have had a maximum of one prior chemotherapy regimen for recurrent or metastatic disease. Patients must have measurable disease and a life expectancy of greater than 12 weeks. The trial also includes eligibility criteria related to laboratory values, performance status, and exclusion criteria related to concomitant use of medications. The trial drug is ispinesib. The eligibility criteria include a list of diseases and icd-10 codes, and the inclusion and exclusion criteria are described in detail.",
    "The sample is a phase 2 trial for the treatment of skin infections caused by bacteria such as staphylococcal and streptococcal infections. The trial involves the use of drugs such as radezolid and linezolid. The eligibility criteria for the trial include patients who are at least 18 years old, have uSSSI, and have acceptable clinical diagnoses of skin infections such as abscess, folliculitis, and cellulitis. Patients must also have 2 or more local signs and symptoms of infection, and a sample for microbiologic culture must be obtained from the primary infection site at the screening visit. Patients who have certain exclusion criteria such as chronic or underlying skin conditions, fungal infections, or significant peripheral vascular disease are not eligible for the trial.",
    "The sample is a record of a clinical trial with a phase 2 designation. The trial is focused on treating metastatic breast cancer using the drugs gemcitabine and gemcitabine. The trial has eligibility criteria for inclusion and exclusion, including having received prior chemotherapy for metastatic breast cancer with anthracycline and taxane regimen, having at least one measurable region, and having adequate organ function. Exclusion criteria include having interstitial pneumonia or pulmonary fibrosis, inflammatory carcinoma, brain metastasis with symptom, severe complications such as cardiac infarction, infection, drug hypersensitivity, or diabetes, and having undergone chemotherapy, radiotherapy, hormonal/immunotherapy, or surgery within a certain timeframe. The diseases are listed as metastatic breast cancer, and the icd-10 codes associated with the disease are also provided.",
    "The sample is a phase 2 clinical trial for infertility in females. The trial involves the use of two drugs, degarelix mid-luteal and placebo. The eligibility criteria include being a pre-menopausal female between the ages of 18-35 with regular menstrual cycles and a BMI between 18 and 29 kg/m2. Participants must also be willing to donate retrieved oocytes and use contraception during the study period. Exclusion criteria include abnormal karyotype, clinically significant systemic disease, endocrine or metabolic abnormalities, polycystic ovarian syndrome, and previous participation in the study.",
    "This sample is from a clinical trial in phase 2, focused on the disease of hyperlipidemia. The trial is testing the drug ezetimibe as a potential treatment. The eligibility criteria for participants include being between the ages of 18 and 75, currently taking a statin or low dose statin, having stable lipid lowering therapy, and having fasting triglycerides below 400 mg/dL. Exclusion criteria include having severe heart failure or a recent heart attack or stroke, uncontrolled cardiac arrhythmia, and uncontrolled hypertension.",
    "The sample is a phase 2 clinical trial for the treatment of asthma, specifically mild asthma. The trial involves the drug GSK256066 and has a list of inclusion and exclusion criteria for participants. Inclusion criteria include having a documented history of bronchial asthma, a pre-bronchodilator FEV1 greater than 75% of predicted, and a positive reaction to at least one allergen. Exclusion criteria include a history of cardiovascular disease, clinically significant abnormalities in safety laboratory analysis, and a positive test for hepatitis C antibody or hepatitis B surface antigen. The sample also includes a list of diseases and their corresponding ICD-10 codes.",
    "The sample is a phase 2 clinical trial for patients with relapsed acute myelocytic leukemia. The trial is testing the effectiveness of cladribine, a drug used to treat leukemia. The eligibility criteria include having a remission duration of at least 6 months after first complete remission or at least 3 months after second or higher complete remission, being at least 18 years old, having a life expectancy of at least three months, having an Eastern Cooperative Oncology Group (ECOG) score of 0-2, and providing written informed consent. Exclusion criteria include prior therapy of AML with cladribine, severe uncontrolled infection, cardiac insufficiency grade III or IV, severe renal or hepatic insufficiency, other severe organ impairment, HIV infection, intolerance to study drugs, pregnancy or breastfeeding, and any other malignant disease that may affect the course of AML.",
    "The sample is a phase 2 clinical trial for the treatment of sleep initiation and maintenance disorders. The trial involves the use of drugs such as zolpidem tartrate, sodium oxybate, and matching placebos. The eligibility criteria for the trial include being an outpatient between the ages of 18-75, experiencing insomnia for at least six months, and meeting diagnostic criteria for Chronic Insomnia according to International Classification of Sleep Disorders (ICSD) criteria. Exclusion criteria include having any clinically significant, uncontrolled medical or psychiatric conditions, a probable diagnosis of a current sleep disorder other than Chronic Insomnia, and a history of alcohol or drug abuse. Women must be surgically sterile, 2 years post-menopausal, or using a medically accepted method of birth control. The trial requires regular clinic visits and compliance with study restrictions.",
    "The sample is a phase 2 clinical trial for the treatment of osteoarthritis in the knee. The trial includes male and female participants with a body weight between 40 and 120 kilograms and a body mass index between 19-35 kilograms per square meter. The inclusion criteria require participants to have a diagnosis of osteoarthritis of the knee according to the American College of Rheumatology criteria, with a Kellgren and Lawrence grade of I, II, III or IV, and a mean score of at least 4 on the 24-hour average pain score. The trial involves the use of the drug LY2828360 and a placebo. The eligibility criteria include exclusion of participants with allergies to LY2828360, abnormality in the 12-lead electrocardiogram, recent or current history of cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, hematological, or neurological disorders, and a history of or symptoms suggestive of sleep apnea. The trial also excludes participants with autoimmune disorders, active malignancy of any type, or a history of malignancy, and women who are pregnant or lactating.",
    "The sample is a phase 2 clinical trial for the treatment of Waldenstrom's macroglobulinemia, a type of cancer. The trial involves the use of three drugs - bortezomib, dexamethasone, and rituximab. The eligibility criteria for the trial include a clinicopathological diagnosis of Waldenstrom's macroglobulinemia, no previous therapy for the disease, measurable disease, and a Karnofsky performance status of greater than 60. The trial also has exclusion criteria, such as previous therapy for the disease, serious medical or psychiatric illness likely to interfere with participation in the study, and pregnancy or breastfeeding.",
    "The sample is a phase 2 clinical trial for patients with stage I-IVB squamous cell carcinoma of the nasopharynx who have been treated with primary radiotherapy. The trial is testing the effectiveness of cisplatin and fluorouracil as treatments for head and neck cancer, oral complications of radiation therapy, and radiation toxicity. The eligibility criteria include age 18 and over, Zubrod performance status of 0-1, and no evidence of distant metastasis. Patients must also meet certain hematopoietic, renal, and other health criteria. Prior concurrent therapy is limited, and patients must not have had prior head and neck surgery to the primary tumor or lymph nodes except for incisional or excisional biopsies.",
    "The sample is a phase 2 clinical trial for patients with non-small cell lung cancer that has recurred or progressed. The trial is testing the effectiveness of the drug eribulin mesylate. Patients must have previously received platinum-based therapy and a taxane. They must also have measurable disease and meet certain criteria for platelet count, bilirubin levels, and other health factors. Patients cannot have certain illnesses or be taking other investigational agents. The trial has both inclusion and exclusion criteria.",
    "The sample is a phase 2 clinical trial for the treatment of migraine. The trial is looking at the effectiveness of nasal carbon dioxide and placebo in reducing the frequency of migraine attacks. The eligibility criteria for participants include being between the ages of 18-65, having a diagnosis of migraine with or without aura, and experiencing 2-8 migraine attacks per month in the 3 months prior to the trial. Exclusion criteria include having more than 15 headache days per month, being pregnant or breastfeeding, and having a history of alcohol or drug abuse within the past 2 years. The trial will last for 56 days and participants must commit to using an acceptable method of birth control if they are of childbearing potential.",
    "The sample is a phase 2 clinical trial for non-small cell lung cancer. The trial includes patients who have confirmed NSCLC, except for squamous cell carcinoma or predominantly squamous. The patients must have disease that is not curable by standard methods. Prior adjuvant systemic chemotherapy, immunotherapy, or biological therapy is allowed, except for prior use of bevacizumab. The patients must have recovered from the acute toxic effects of the treatment as determined by the treating physician prior to study registration. The trial also includes eligibility criteria related to prior radiation therapy, disease status, ECOG performance status, age, and adequate organ function. The trial has exclusion criteria related to intrathoracic lung carcinoma of squamous cell histology, pregnancy, hypertension, congestive heart failure, stroke, bleeding diathesis, coagulopathy, and other medical conditions. The trial also has exclusion criteria related to prior malignancy, major surgical procedure, serious active infection, and life expectancy.",
    "The sample is a phase 2 clinical trial for ulcerative colitis. The trial includes patients who have confirmed and active ulcerative colitis with a partial Mayo Score of 1-7 and disease involvement extending proximal to the rectum. The patients may be receiving conventional therapies for UC as defined by the protocol. The trial involves the use of vedolizumab and placebo drugs. The eligibility criteria include being a male or non-pregnant, non-lactating female who is voluntarily able to give informed consent and agrees to use two effective forms of contraception from screening to the end of the study. The exclusion criteria include patients who require UC surgical intervention or for whom surgical intervention is anticipated during the study, patients who fail to meet laboratory values as specified in the protocol, and patients with low-grade dysplasia, high-grade dysplasia, dysplasia-associated lesion or mass, or colorectal cancer. The trial also excludes patients who have received certain medications or treatments within a specified time frame, have certain medical conditions, or have a history of certain diseases or conditions.",
    "The sample is a record from a clinical trial table that includes information about the trial's phase, diseases being studied, icd-10 codes associated with those diseases, drugs being tested, and eligibility criteria for participants. In this particular sample, the trial is in phase 2/phase 3 and is focused on deep venous thrombosis. The icd-10 codes associated with this disease are listed, as well as the drugs being tested (desirudin and heparin). The eligibility criteria for participants are also listed, including inclusion criteria such as being scheduled for elective cardiac or thoracic surgery and being over 18 years old, and exclusion criteria such as having a history of DVT/PE, requiring anticoagulation during the post-op period, or having a history of HIT.",
    "The sample is a record of a clinical trial with a phase 2 designation. The trial is focused on prostate cancer and involves a list of drugs including etoposide, mitoxantrone hydrochloride, prednisone, and vinorelbine tartrate. The eligibility criteria for the trial include having a confirmed diagnosis of adenocarcinoma of the prostate, having received docetaxel as first-line chemotherapy, and having received at least one prior regimen of hormone therapy. Patients must also have a pain level of greater than 2 on the Visual Analog Scale or be taking level 2 analgesics. There are additional patient characteristics that must be met, such as having certain blood counts and liver function tests within normal limits. The sample also includes information on prior concurrent therapy and the time frame in which it must have been completed before participating in the trial.",
    "The sample is a phase 2 clinical trial for patients with lung cancer, specifically those with Stage IIIb (with malignant pleural or pericardial effusion), Stage IV, or recurrent NSCLC who have demonstrated ALK mutation. The trial is testing the drug ipi-504. The eligibility criteria include measurable disease by RECIST criteria, 18 years of age or older, life expectancy of at least 3 months, ECOG performance status of 0-2, and completion of baseline studies within 30 days of first study dose. Exclusion criteria include treatment for NSCLC with any approved or investigational product within 2 weeks of Cycle 1, Dose 1 for any small molecule therapy; within 4 weeks of Cycle 1, Dose 1 for any biologic or any conventional chemotherapy, concurrent radiation therapy, and use of a medication or food that is clinically relevant CYP3A inhibitor or inducer within 2 weeks prior to Cycle 1, Dose 1.",
    "The sample is a phase 2 clinical trial for pancreatic cancer. The eligibility criteria include being over 18 years old, having a documented ECOG/Zubrod performance status of 0 or 1, having a specific stage of adenocarcinoma of the head of the pancreas, having undergone a potentially curative gross total resection by pancreaticoduodenectomy within 56 days prior to beginning treatment, having stable or increasing weight, and having adequate bone marrow, hepatic and renal function. The patient must also have a baseline diagnostic CT scan of the chest and CT scan with IV contrast (or MRI) of abdomen/pelvis within 30 days prior to registration to exclude metastatic disease. The patient must not have certain types of pancreatic cancer, be pregnant or lactating, have received prior systemic chemotherapy or radiotherapy for pancreatic cancer, or have a preexisting psychiatric condition. The patient must provide written consent and authorization to allow the use and disclosure of their protected health information.",
    "The sample is a phase 2 clinical trial for osteoarthritis. The trial includes male and female participants of any race between the ages of 18 and 75 years who have knee pain due to osteoarthritis. The trial excludes pregnant participants, those who have participated in a clinical trial for an investigational drug and/or agent within 30 days prior to baseline, and those with a history of malignancy, convulsions, chronic infections, or arthroscopy of the worst knee within the past year. The trial involves the use of oxycodone, placebo, and pf-000592379 as drugs. The icd-10 codes associated with the disease are [\"M15.4\", \"M15.0\", \"M16.9\", \"M17.9\", \"M19.011\", \"M19.012\", \"M19.019\"].",
    "The sample is a phase 2 clinical trial for non-small cell lung cancer. The trial includes patients with advanced NSCLC, except squamous cell carcinoma, and requires measurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST). Patients must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1, and adequate hematologic, hepatic, renal, and coagulation function. Patients with known Central Nervous System metastases, prior cetuximab or bevacizumab therapy, prior systemic chemotherapy or radiation therapy for lung cancer, or any concurrent malignancy other than basal cell skin cancer or carcinoma in situ of the cervix are excluded. Patients with an ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements are also excluded. The trial requires patients to use an accepted and effective method of contraception if a woman of childbearing potential or if a male and sexually active. The trial also has exclusion criteria related to concurrent treatment with other anti-cancer therapy, history of thrombotic or hemorrhagic disorders, uncontrolled hypertension, treatment with certain medications, and pre-existing neuropathy.",
    "The sample is a phase 2 clinical trial for patients with both hepatitis B virus and HIV infections. The trial is testing the effectiveness of the drug emtricitabine. The eligibility criteria include being between the ages of 18 and 70, having a documented HIV infection with detectable HIV-1 RNA, and having a HBV DNA count greater than 106 copies/ml with a positive HBsAg for more than 6 months. Patients who have acquired the HBV infection less than 6 months ago may also be eligible if they meet certain criteria. Exclusion criteria include having other causes of chronic liver disease, being pregnant or lactating, and having any condition that may interfere with compliance or outcome of the study.",
    "The sample is a phase 2 clinical trial for breast cancer patients. The trial involves the use of zoledronic acid as a treatment. The eligibility criteria include being a woman over 18 years old with stage I, II, or III breast cancer, having completed adjuvant chemotherapy if recommended, having a positive bone marrow aspirate, having adequate renal and liver function, and being able to understand and sign informed consent. Concomitant hormonal and radiation therapy are allowed, and patients who have had surgery following neoadjuvant chemotherapy or hormonal therapy are also eligible. Exclusion criteria include a history of allergy to bisphosphonates, renal insufficiency, Karnofsky Performance status less than 90%, any significant medical condition that might interfere with treatment, and pregnancy. Women participating in the trial are not allowed to receive other bisphosphonate therapy during the study period.",
    "The sample is a record of a clinical trial with a phase 2 designation. The trial is focused on irritable bowel syndrome and includes a list of associated ICD-10 codes. The trial involves the use of two drugs, dronabinol and placebo. The eligibility criteria for the trial include being between the ages of 18-75, having positive IBS symptoms according to Rome III criteria, and having a baseline geometric center at 24 and 48 hours that meets certain criteria. The exclusion criteria include patients with significant depression or anxiety, although patients on stable doses of SSRIs or low doses of tricyclic antidepressants may still be eligible.",
    "The sample is a phase 2 clinical trial for the treatment of mild Alzheimer's disease and amnestic mild cognitive impairment. The trial involves the use of two drugs, aqw051 and placebo. The eligibility criteria for the trial include having a recent structural brain scan that shows no underlying disease, daily contact with a primary caregiver/partner, and meeting the diagnostic criteria for either amnestic mild cognitive impairment or mild Alzheimer's Disease. Exclusion criteria include a history of certain medical conditions, institutionalization, and use of certain medications. Other protocol-defined inclusion/exclusion criteria may also apply.",
    "The sample is a phase 2 clinical trial that involves patients with newly diagnosed brain metastases that can be treated with stereotactic radiosurgery. The trial aims to evaluate the effectiveness of sunitinib malate in treating patients with 1-3 brain metastases. The eligibility criteria include having a confirmed carcinoma, a Karnofsky performance status of 70-100%, and a life expectancy of more than 6 weeks. Patients must also meet certain medical criteria, such as having a platelet count of at least 100,000/mm^3 and a serum creatinine level of no more than 2.5 mg/dL. Patients must not have had prior sunitinib malate or cranial external beam radiotherapy, and must not be concurrently participating in another clinical trial or taking certain medications. The trial allows concurrent use of stable doses of steroids and systemic therapy for stable systemic disease.",
    "The sample is a phase 2 clinical trial for gastrointestinal stromal tumor. The trial is testing the drug regorafenib on patients who have previously failed conventional tyrosine kinase inhibitors, imatinib and sunitinib. The eligibility criteria include being at least 18 years old, having measurable disease per RECIST 1.1, having an ECOG Performance Status of 0 or 1, and having adequate organ and marrow function. Exclusion criteria include having had radiotherapy within 4 weeks prior to study entry, having symptomatic or uncontrolled brain or central nervous system metastases, and having a history of bleeding diathesis. The trial also requires patients to use effective means of birth control throughout the duration of the study and for at least 3 months after completion of study drug.",
    "The sample is a phase 2 clinical trial for patients with leukemia or lymphoma. The trial involves the use of two drugs, forodesine hydrochloride sterile solution and forodesine hydrochloride capsules. The eligibility criteria include having an unequivocal histologic diagnosis of precursor T-lymphoblastic leukemia/lymphoma, failure to respond to or relapse after two or more treatment regimens, a performance status of 2 by Eastern Cooperative Oncology Group criteria, being 18 years of age or older, having a life expectancy of at least three months, and having adequate liver function. Exclusion criteria include having known HIV or HTLV-1 infection, active hepatitis B or C infection, clinical evidence of active central nervous system leukemia, and concurrent treatment with other antileukemia agents. Patients must also be willing and able to use an adequate method of contraception to avoid pregnancy for the duration of the study.",
    "The sample is a clinical trial for patients with stage IIIB or IV non-small cell lung cancer. The trial is in phase 2/phase 3 and involves the use of the drugs vorinostat, paclitaxel, carboplatin, and placebo. The eligibility criteria include being at least 18 years old, having no prior systemic treatment for lung cancer except for adjuvant therapy at least 12 months prior, having adequate bone marrow, kidney, and liver function, and having an ECOG performance status of 0 or 1. Patients must also agree to use birth control during the study, and women able to have children must have a negative pregnancy test. Exclusion criteria include prior treatment with investigational agents less than 4 weeks before study enrollment, pregnancy or nursing, HIV positivity, Hepatitis A, B, or C, inability to take study medication by mouth, untreated brain cancer, and eligibility for treatment with bevacizumab if it is available.",
    "The sample is a phase 2 clinical trial for the treatment of schizophrenia. The trial includes patients who are 18 to 60 years old and meet the DSM-IV criteria for schizophrenia. The patients must have a PANSS score between 80 and 120 and have been diagnosed with schizophrenia for at least one year. The trial includes a placebo group as well as groups receiving cariprazine and risperidone. The eligibility criteria include exclusion of patients with abnormalities on physical examination or abnormal vital signs, electrocardiogram, or clinical laboratory values, and those experiencing their first episode of psychosis.",
    "The sample is a phase 2 clinical trial for patients with colorectal liver metastases. The trial includes patients with confirmed hepatic colorectal metastasis and radiological evidence of measurable liver metastasis. Patients must have unresectable colorectal liver metastases, as determined by a surgeon with expertise in hepatic surgery. The trial involves the use of 5-fluorouracil, bevacizumab, leucovorin, and oxaliplatin. The eligibility criteria include performance status, adequate bone marrow, renal and hepatic function, negative pregnancy test, and effective contraception. Patients must also have recovered from any prior surgery, radiotherapy, or other antineoplastic therapy. Exclusion criteria include surgically resectable colorectal liver metastases, evidence of unresectable extrahepatic disease, CNS metastases, and previous treatment with bevacizumab. Patients with preexisting chronic hepatic disease, known hypersensitivity to any of the components of the drugs, and autoimmune disease including HIV are also excluded.",
    "The sample is a phase 2 trial for graft versus host disease. The trial is open to patients who are candidates for unrelated donor hematopoietic stem cell transplant for hematologic conditions, either malignant or non-malignant. The donor can be unrelated marrow, blood or cord blood. Patients with progressive or poorly controlled malignancies for which the likelihood of durable disease control is less than 25% are not eligible. Patients must be receiving a recognized reduced intensity transplant as determined by the University of Michigan Blood and Marrow Transplantation Program. Patients age 50 or older are eligible based on age. Patients may be less than 50 years old if they are eligible for a reduced intensity conditioning regimen based on disease type or if comorbidities preclude a full-intensity transplant. Patients must have adequate venous access by either peripheral vein or central line so that ECP can be performed. Patients must be expected to tolerate the fluid shifts associated with ECP. The trial has several exclusion criteria, including not being a candidate for a reduced intensity transplant conditioning regimen, having a suitable related donor available for transplant, having a Karnofsky or Lansky performance status of less than 50% at the time of admission for HSCT, having evidence of HIV infection or other opportunistic infection, having active bacterial, fungal or viral infection not responding to treatment, having any medical or psychological conditions that would keep the patient from complying with the protocol and/or would markedly increase the morbidity and mortality from the procedure, being pregnant, and having a T-cell depleted allograft.",
    "The sample is a record from a clinical trial table that includes information about the trial's phase, diseases being studied, icd-10 codes associated with those diseases, drugs being used, and eligibility criteria for participants. In this particular sample, the trial is in phase 2 and is studying various types of cancer, including colon cancer, colorectal cancer, and rectal cancer. The drug being used is folfiri, and the eligibility criteria include having a diagnosis of metastatic adenocarcinoma of the colon or rectum, having failed first-line treatment with certain chemotherapy drugs, and having adequate hematologic, renal, hepatic, and metabolic function. There are also exclusion criteria, such as recent radiotherapy or unresolved toxicity from prior anti-cancer therapy.",
    "The sample is a phase 2 clinical trial for bladder and urethral cancer patients. The trial involves the use of drugs such as carboplatin, cisplatin, gemcitabine hydrochloride, and paclitaxel. The eligibility criteria include having histologically confirmed primary or recurrent invasive carcinoma of the urothelium, measurable or nonmeasurable disease, evidence of tumor invasion of the muscularis, and no extrapelvic metastases. Patients must also meet certain age, performance status, and hematopoietic, hepatic, renal, gastrointestinal, and other health criteria. Prior concurrent therapy is also taken into consideration.",
    "The sample is a record of a clinical trial in phase 2 for the treatment of metastatic colorectal cancer. The trial involves the drug \"rad001\" and the eligibility criteria include having measurable disease, being refractory to at least 2 chemo/biologic regimens, and having an ECOG score of 0-2. The exclusion criteria include having CNS disease, having received chemotherapy or radiotherapy within the last 4 weeks, and having an active bleeding diathesis. The diseases being studied are limited to colorectal cancer and are identified by a list of ICD-10 codes.",
    "The sample is a phase 2 clinical trial for pancreatic cancer using the drug dasatinib. The eligibility criteria for patients include having histologically confirmed stage IV pancreatic cancer, a Karnofsky performance status of 60-100%, and a life expectancy of at least 3 months. Patients must also meet certain laboratory values and not have any other malignancies or medical conditions that may increase the risk of toxicity. Prior to the trial, patients cannot have received prior chemotherapy or irradiation to the planned field. Additionally, patients must not be taking certain medications that may prolong the QT interval or directly and durably inhibit platelet function. The trial also prohibits the use of certain concurrent medications, anticoagulants, IV bisphosphonates, and Hypericum perforatum (St. Johns wort).",
    "The sample is a phase 2 clinical trial for patients with epithelial ovarian cancer, peritoneal serous cancer, or fallopian tube cancer. The trial involves the use of the drugs Avastin and Docetaxel. The eligibility criteria include having measurable or evaluable disease, having received up to three prior chemotherapy regimens, and having a negative pregnancy test. Exclusion criteria include prior treatment with Docetaxel or Avastin, peripheral neuropathy grade 2 or higher, and a history of severe hypersensitivity reaction to Docetaxel, Avastin, or other drugs formulated with polysorbate. Patients must also be willing to use effective contraception while on treatment and for 3 months following the completion of treatment.",
    "The sample is a phase 2 clinical trial for epilepsy. The study is looking for reliable and willing participants between the ages of 12 and 18 who have been diagnosed with partial-onset seizures with or without secondarily generalized seizures. The participants must have had at least one seizure in the four weeks prior to the study despite being on a stable regimen of 1 to 3 antiepileptic drugs. The study also requires participants to have a negative pregnancy test and to commit to using a medically acceptable method of birth control. Participants must have an IQ of 70 or higher and be able to perform cognitive tests appropriately. The study excludes participants with certain types of epilepsy, a history of pseudo-seizures, or unstable psychiatric diagnoses. Participants must provide written informed consent and have not previously participated in a clinical trial involving perampanel.",
    "The sample is a phase 2 trial for the treatment of glaucoma and ocular hypertension. The trial includes two diseases with their corresponding icd-10 codes. The drugs being tested are bimatoprost eye drops and a placebo. The eligibility criteria for the trial include having chronic glaucoma or ocular hypertension with controlled IOP on Xalatan. The exclusion criteria include having uncontrolled medical conditions or a known hypersensitivity to the study medications.",
    "The sample is a phase 2 clinical trial for patients with anorexia, weight loss, and cachexia. The trial involves the drug Haelan and has specific inclusion and exclusion criteria. Inclusion criteria include anorexia, weight loss, normal cognition, written informed consent, advanced solid tumor, perceived weight loss as a problem, and ability to maintain oral food intake. Exclusion criteria include evidence of ascites, receiving supplementary tube feedings or parenteral nutrition, known mechanical obstruction of the alimentary tract, or intractable vomiting, recent changes in medication, allergy to soy, positive pregnancy test, refusal to practice accepted methods of contraception, weight less than 80 lb, inability to tolerate oral intake of Haelan, and diagnosis of breast cancer. The diseases in the sample are anorexia, weight loss, and cachexia, and the corresponding ICD-10 codes are provided.",
    "The sample is a phase 2 trial that focuses on high blood pressure, metabolic syndrome, insulin resistance, and endothelial dysfunction. The trial involves the use of drugs such as aliskiren, amlodipine, placebo aliskiren, and placebo amlodipine. The eligibility criteria for the trial include being an adult aged 18 to 55 years, having a sitting diastolic blood pressure of at least 80 mm Hg and/or sitting systolic blood pressure of at least 130, having metabolic syndrome as defined by the Adult Treatment Panel III criteria, and having hypertension and impaired glucose tolerance or impaired fasting glucose. Other criteria include abnormal PET and euglycemic clamp results, a BMI of less than 40, and not being a smoker. Exclusion criteria include cardiovascular abnormalities, significant autonomic dysfunction, severe bronchospastic disease, and being pregnant or breastfeeding. African Americans are also not eligible for the study.",
    "The sample is for a phase 2 clinical trial and the disease being studied is \"healthy\". The trial is testing the effectiveness of various combinations of the drugs estetrol, desogestrel, and progesterone. The eligibility criteria for participants include being between 18 and 40 years old, having a body mass index between 18 and 30 kg/m2, being in good physical and mental health, and having both ovaries visible on ultrasound. Participants must also be willing to use a barrier method of contraception during the study period. Exclusion criteria include pregnancy, lactation, a history of breast cancer, and certain medical conditions such as hypertension and liver function disturbances. Participants must also not have used certain medications within a certain timeframe before the study. The sample includes both inclusion and exclusion criteria.",
    "The sample is a phase 2 clinical trial for patients with previously untreated Stage III, IV, or bulky Stage II diffuse large B-cell non-Hodgkin's lymphoma which is positive for CD20. The trial involves the use of cyclophosphamide, doxorubicin hydrochloride, vincristine sulfate, and prednisone. The eligibility criteria include various medical tests and assessments, such as a CT scan, bone marrow aspirate and biopsy, and serum LDH measurement. Patients must also meet certain health requirements, such as having a Zubrod performance status of 0-2 and a cardiac ejection fraction of at least 45%. Additionally, patients must not have a history of certain medical conditions or hypersensitivity reactions to certain products. The trial does not allow for patients who are pregnant or nursing. Patients must provide written informed consent and the treating institution must have institutional review board approval.",
    "The sample is a phase 2 clinical trial for patients with colorectal cancer and metastases. The trial involves the use of drugs such as cetuximab, bevacizumab, leucovorin, oxaliplatin, and fluorouracil. The eligibility criteria for the trial include having technically resectable liver metastases, being a medically suitable candidate for major liver resection, and having no metastatic disease outside the liver. Exclusion criteria include abnormal liver function, renal insufficiency, and peripheral neuropathy. Patients who have previously been treated with FOLFOX or cetuximab within the past 12 months are also excluded.",
    "The sample is a phase 2 clinical trial for non-small cell lung cancer. The trial includes patients with locally advanced tumors that are not suitable for surgery and have not received any cytostatic or immunological pre-treatment. Patients must be over 70 years old and have at least one measurable lesion that was not previously irradiated. They must also have an ECOG Performance Status of 0-1 and a life expectancy of more than 3 months. Adequate bone marrow, liver, and renal function are required, as well as the use of effective birth control for fertile men. Patients must provide signed written informed consent. Exclusion criteria include uncontrolled metastasis in the CNS, acute, heavy uncontrolled infection, and any other serious concomitant disease or medical condition that could interfere with participating in the study. Patients with a history of other active malignancy in the past 5 years (with the exception of carcinoma in situ of the cervix, non melanomatous skin cancers or local prostate carcinoma that was surgically treated successfully) are also excluded. Participation in another clinical trial with any investigational drug at the same time or within 30 days prior to registration is not allowed. Psychological, familial, social or geographical situations limiting the compliance with the study requirements are also exclusion criteria. The drugs being tested in this trial are erlotinib, vinorelbine, and carboplatin.",
    "The sample is a record of a clinical trial with a phase 2 designation. The trial is focused on non-Hodgkin's lymphoma and involves the use of two drugs, pro95780 and rituximab. The eligibility criteria for the trial include a signed informed consent form, a diagnosis of follicular, CD20-positive B-cell NHL, measurable disease, and a life expectancy of more than 3 months. Exclusion criteria include prior radiotherapy to certain lesions, concurrent systemic corticosteroid therapy, and a history of central nervous system disease. The sample also includes a list of ICD-10 codes for the disease and a detailed description of the inclusion and exclusion criteria for the trial.",
    "The sample is a phase 2 clinical trial for the treatment of opioid-induced constipation. The trial includes patients who have a history of constipation after starting opioid therapy and have used a stable daily regimen of opioids for at least 2 weeks prior to the screening visit. The patients must also have a self-reported OIC of approximately 3 spontaneous bowel movements (SBMs) per week or less for each week over at least the previous two week period. The trial will test the effectiveness of the drugs td-1211 and placebo. Patients will be required to stop all laxatives and other bowel regimens except for bisacodyl/enema treatment allowed per protocol throughout the OIC confirmation, treatment, and follow-up periods. Patients who have participated in a clinical trial of an investigational drug or medical device within 30 days prior to screening or have any condition that may affect drug absorption will be excluded from the trial.",
    "The sample is a phase 2 clinical trial for acute sinusitis. The trial includes patients who are at least 18 years old in Russia, Ukraine, and Germany, and at least 12 years old in all other countries. The trial involves the use of three different drugs, including a placebo nasal spray. The eligibility criteria include informed consent, outpatient status, uncomplicated acute rhinosinusitis diagnosis, ability and willingness to comply with study procedures and restrictions, and literacy. Exclusion criteria include a history of acute rhinosinusitis within 12 weeks prior to the current episode, current or a history of other sinonasal conditions, significant concomitant medical conditions, and use of certain medications. Female subjects must commit to the consistent and correct use of an acceptable method of birth control and should not be enrolled if they plan to become pregnant during the time of study participation. The trial also excludes subjects with positive pregnancy tests or who are breastfeeding, and those with affiliation with the investigational site or current tobacco use.",
    "The sample is a phase 2 clinical trial for Alzheimer's disease. The trial includes patients who are at least 50 years old and have been treated with donepezil for at least 3 months prior to screening. The trial has inclusion and exclusion criteria, including the patient having probable AD consistent with NINCDS-ADRDA criteria and not having evidence of any clinically significant neurodegenerative disease or other serious neurological disorders other than AD. The trial also includes a list of drugs, including lu ae58054 and placebo, and a list of diseases and their corresponding ICD-10 codes. The eligibility criteria for the trial are listed in detail, including the patient's ability to read and understand the informed consent form, having a knowledgeable and reliable caregiver, and signing the informed consent form. The exclusion criteria include having a disease or taking medication that could interfere with the assessments of safety, tolerability, or efficacy, and being unlikely to comply with the clinical study protocol or being unsuitable for any reason.",
    "The sample is a phase 2 trial for patients with recurrent endometrial adenocarcinoma, papillary serous or mixed mullerian tumor, or recurrent ovarian or primary peritoneal cancers. The patients must have measurable disease or disease felt to be reproducibly measurable on CT scan, chest x-ray and/or tumor marker elevations. The trial includes patients with specific histologic ovarian or uterine epithelial cell types and excludes patients with impairment of hepatic, renal or hematologic function, chronic or active hepatitis, severe or uncontrolled medical disease, dementia or altered mental status, severe hypersensitivity to Taxotere\u00ae, Topotecan\u00ae, or other drugs formulated with polysorbate 80, and women who are pregnant or breast-feeding. The patients must meet certain eligibility criteria, including age \u2265 18 years, ECOG performance status of \u2264 2, and peripheral neuropathy must be \u2264 grade 1. The trial also requires patients to have received no antineoplastic treatment for at least 4 weeks and not have received more than two previous chemotherapy regimens. The patients must be alert, oriented, and have signed an informed consent in accordance with institutional policies and be aware of the investigational nature of the study. Women of childbearing potential must be willing to consent to using effective contraception while on treatment and for at least 3 months thereafter. The trial involves the use of topotecan and taxotere as drugs.",
    "The sample is a phase 2 clinical trial for psoriasis vulgaris. The trial includes patients of any race or ethnicity, both male and female, who are 18 years or older and have all skin types. Females of childbearing potential must have a negative pregnancy test and agree to use a highly effective method of birth control during the study. The trial aims to test the effectiveness of three drugs: leo 90100, calcipotriol, and betamethasone. The eligibility criteria include being able to communicate with the investigator and understand and comply with the requirements of the study. Exclusion criteria include recent treatment with certain biological therapies or other therapies with a possible effect on psoriasis vulgaris, as well as certain skin conditions and other medical conditions. Females who are pregnant, wishing to become pregnant during the study, or are breast-feeding are also excluded.",
    "The sample is a phase 2 clinical trial for the treatment of lower urinary tract symptoms and prostatic hyperplasia. The trial involves the use of tamsulosin hydrochloride, solifenacin succinate, and a placebo. The eligibility criteria for male patients include having LUTS associated with BPH diagnosed for more than 3 months, an IPSS score greater than 13, voiding and storage symptoms, and a maximum flow rate of more than 4 mL/s and less than 15 mL/s. Exclusion criteria include a post void residual volume greater than 200 mL and symptomatic urinary tract infection.",
    "The sample is a phase 2 clinical trial for patients with primary CNS non-Hodgkin's lymphoma. The trial is testing the effectiveness of the drugs methylprednisolone and temozolomide. The eligibility criteria include having measurable disease, being 18 years or older, having a Karnofsky performance status of 60-100%, and having a life expectancy of more than 8 weeks. Patients must also meet certain hematopoietic, hepatic, and renal requirements, and cannot have any other malignancy within the past 3 years except nonmelanoma skin cancer or carcinoma in situ of the cervix. Additionally, patients cannot have uncontrolled significant medical illness, active infection, active HIV infection, or concurrent disease that would dangerously alter drug metabolism or obscure toxicity. Prior concurrent therapy is also taken into consideration.",
    "The sample is a phase 2 clinical trial for the treatment of multiple myeloma, a type of cancer. The trial is for patients who have not received any previous treatment and are eligible for induction therapy followed by high dose treatment supported by autologous stem cell transplantation. The trial excludes patients with severe uncontrolled infections, other active malignancies, severe heart or lung disease, poorly controlled diabetes, haemolytic anaemia, idiopathic thrombocytopenic purpura, terminal illness, planned allogenic transplantation within 6 months, chemotherapy before inclusion, pregnancy or breastfeeding, inadequate contraceptive precautions, psychiatric disease, abuse of alcohol or narcotics, or any other disorder that might compromise the patient's ability to give informed consent.",
    "The sample is a phase 2 trial for coronary disease. The trial involves the use of three drugs: otamixaban (xrp0673), unfractionated heparin, and eptifibatide. The eligibility criteria for the trial include experiencing ischemic discomfort at rest for at least 10 minutes within 24 hours of randomization, meeting ECG criteria for non-ST elevation ACS or having cardiac enzyme elevation, and not having ST elevation Myocardial Infarction (STEMI). The trial also requires planned coronary angiography followed by a Percutaneous Coronary Intervention (PCI) on Day 1 to Day 3. The exclusion criteria include inability to undergo coronary angiography or PCI by Day 3, prior PCI within 30 days, acute STEMI, cardiogenic shock, anticoagulant treatment for more than 24 hours prior to randomization, prior treatment with fondaparinux since ACS onset, requirement for oral anticoagulant (OAC) prior to Day 30, and creatinine clearance less than 30 ml/min.",
    "The sample is a record of a clinical trial in phase 2, focused on major depressive disorder. The trial involves the drug quetiapine fumarate (seroquel) and includes a list of icd-10 codes for the disease. The eligibility criteria for the trial include being between the ages of 18 and 65, having no prior use of atypical antipsychotics, and having a diagnosis of major depressive disorder. The exclusion criteria include a history of bipolar disorder or psychotic major depression disorder, and no use of fluvoxamine. The sample also includes specific details on the inclusion and exclusion criteria for the trial.",
    "The sample is a phase 2 clinical trial for the treatment of multiple myeloma using the drug bortezomib. The trial includes participants who have previously been diagnosed with multiple myeloma and have measurable disease. Participants must have previously tolerated bortezomib and had a complete or partial response to the therapy. The trial also includes eligibility criteria such as life expectancy, previous treatments, and medical history. Exclusion criteria include uncontrolled or severe cardiovascular disease, poorly controlled medical or psychiatric illness, and pregnancy or breastfeeding for female participants.",
    "The sample is a phase 2 clinical trial for the treatment of metastatic breast cancer using the drugs dexamethasone and trabectedin. The trial includes participants with measurable disease and an Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) of 0 or 1 who have not been previously exposed to trabectedin. Participants must also meet certain eligibility criteria, such as having a serum creatinine level less than or equal to 1.5 milligram per deciliter (mg/dl) and not having completed previous therapy within a certain timeframe. Exclusion criteria include known leptomeningeal disease and other serious illnesses. The table includes information on the phase of the trial, the diseases being treated, the icd-10 codes of those diseases, the drugs being used, and the eligibility criteria.",
    "The sample is a record of a clinical trial with a phase 2 designation. The trial is focused on prostate cancer and the icd-10 codes associated with it. The drug being tested is panobinostat. The record includes the eligibility criteria for the trial, including the requirement for patients to have confirmed adenocarcinoma of the prostate and evidence of disease progression. Patients must also be willing to use contraception throughout the study and for 12 weeks after completion. The record also lists exclusion criteria, such as a history of CNS disease or impaired cardiac function. Other protocol-defined inclusion/exclusion criteria may also apply.",
    "The sample is a phase 2 clinical trial for the treatment of adenocarcinoma of the esophagus using a combination of drugs including docetaxel, floxuridine, leucovorin, and oxaliplatin. The trial is for patients with stage II or III disease that is resectable and previously untreated. Patients must meet certain eligibility criteria, including having WBC, absolute neutrophil count, and platelet count within certain ranges, and not having any other malignancy within the past 5 years. Patients must also not have any concurrent medical or psychiatric problems that would preclude study treatment and must not have contraindications to paclitaxel. Prior chemotherapy or radiotherapy to the esophagus is not allowed, and patients must not have oral cryotherapy on day 1 of each course.",
    "The sample is a clinical trial for phase 2/phase 3 of lymphoma treatment. The trial is looking for patients with diffuse large B-cell or peripheral T-cell non-Hodgkin's lymphoma who have not received prior treatment and do not have cerebral or meningeal involvement. Patients must have at least one measurable target lesion and meet certain criteria for age, performance status, life expectancy, hematopoietic, hepatic, renal, cardiovascular, and other factors. Patients must also not have a history of concurrent severe disease or other malignancies, and must not be participating in another investigational drug study or taking other concurrent antineoplastic agents. The trial does not specify any particular biologic, chemotherapy, endocrine therapy, radiotherapy, or surgery treatments.",
    "The sample is a phase 2 clinical trial for patients with various types of salivary gland carcinomas that express EGFR and/or erbB2. The patients must have recurrent and/or metastatic disease that is not amenable to surgery or curative radiotherapy. They must also have measurable disease and meet certain eligibility criteria, including having a life expectancy of greater than 12 weeks, a certain performance status, and normal blood counts and organ function. Patients who have had prior treatment with EGFR or erbB2 targeting therapies or who have other active malignancies are excluded. The trial involves treatment with the drug lapatinib ditosylate and requires patients to undergo tumor biopsies before and during treatment.",
    "The sample is a phase 2 clinical trial for patients with relapsed or refractory multiple myeloma and plasma cell neoplasm. The trial is testing the effectiveness of lenalidomide as a treatment option. The eligibility criteria include measurable levels of myeloma paraprotein in serum or urine, ECOG performance status of 0-2, and certain laboratory values within normal limits. Patients must not have any serious medical conditions or psychiatric illnesses that would put them at risk, and must not have any known hypersensitivity to thalidomide or lenalidomide. Prior concurrent therapy is limited to no more than 3 prior treatment regimens for MM, and certain time intervals must have passed since prior treatments. No concurrent anticancer agents or treatments or investigational agents are allowed, and no concurrent thalidomide or radiotherapy.",
    "The sample is a phase 2 clinical trial for the treatment of psoriasis vulgaris. The trial is looking for participants who are 18 years or older, of any race or ethnicity, and have been diagnosed with psoriasis vulgaris for at least 6 months. The trial is testing the effectiveness of a drug called LEO 90100. Participants must meet certain eligibility criteria, such as having a certain extent of psoriasis on their body and scalp, having a normal HPA axis function, and not having received certain treatments within a certain time period prior to the trial. Participants must also agree to use a highly effective method of contraception during the trial if they are of child-bearing potential. There are also exclusion criteria, such as having certain medical conditions or being pregnant or breastfeeding.",
    "The sample is a phase 2 clinical trial for patients with Parkinson's disease who have a good response to levodopa. The trial aims to evaluate the efficacy and safety of perampanel compared to a placebo. The eligibility criteria include a clinical diagnosis of idiopathic Parkinson's disease, Hoehn and Yahr Stage II to IV, treatment with monotherapy of levodopa plus an aromatic acid decarboxylase inhibitor, age over 30 years, and women who are incapable of bearing children or who are practicing effective contraception. The exclusion criteria include inability or unwillingness to undergo SPECT or other study procedures, pregnant or lactating women, atypical or drug-induced PD, current treatment with dopamine agonists, MAO or COMT inhibitors, anticholinergics, and patients with a past or present history of psychotic symptoms requiring antipsychotic treatment.",
    "The sample is a phase 2 clinical trial for non-Hodgkin's lymphoma and mantle cell lymphoma patients who have had prior therapy. The trial is testing the effectiveness of bendamustine hydrochloride as a treatment option. The eligibility criteria include having confirmed indolent B cell Non-Hodgkin's lymphoma or mantle cell lymphoma, not having received treatment for at least 4 weeks (or 12 weeks for antibody therapy) after prior therapy, being between the ages of 20 and 75, having a performance status of 0 or 1, and having adequately maintained organ functions. Exclusion criteria include having infections, serious complications, serious heart failure, serious digestive symptoms, being positive for HBV, HCV or HIC, receiving other investigational drugs within 3 months before registration, having allogenic bone-marrow transplant, being pregnant or lactating, not agreeing to contraception, or being judged as unsuitable for inclusion by the investigator.",
    "The sample is a phase 2 clinical trial for the treatment of alcohol use disorder. The trial includes patients between the ages of 18 and 70 who have been diagnosed with alcohol dependence according to DSM-IV criteria. The patients must have consumed a minimum of 48 standard alcoholic drinks in a consecutive 30-day period over the 90-day period prior to starting pharmacotherapy. The trial involves the use of acamprosate and placebo drugs. The eligibility criteria include being able to speak, understand, and print in English, and giving written informed consent. The exclusion criteria include subjects with evidence of substance dependence other than alcohol or nicotine dependence, psychosis or dementia, and those who are pregnant or lactating. The trial also includes inclusion and exclusion criteria for the post-detoxification rehabilitative treatment phase.",
    "The sample is a phase 2 clinical trial for major depressive disorder. The trial includes patients who have a history of inadequate response to at least one antidepressant and meet diagnostic criteria for recurrent MDD without psychotic features. The trial involves the use of two drugs, placebo and ketamine. The eligibility criteria include being medically stable, having an IDS-C30 total score of at least 40, and being willing to be admitted to the clinic on each dosing day. The exclusion criteria include uncontrolled hypertension, allergies or intolerance to ketamine or its excipients, and inability to communicate with the study staff.",
    "The sample is a record of a clinical trial for non-small cell lung cancer in phase 2. The trial involves the use of three drugs - carboplatin, paclitaxel, and sunitinib. The eligibility criteria for the trial include having histologically proven NSCLC, being in stage IIIB or IV, and having no prior therapy for NSCLC. The exclusion criteria include previous treatment with systemic chemotherapy for lung cancer, history of or known brain metastases, and serious acute or chronic illness or recent history of significant cardiac abnormality. The sample also includes a list of icd-10 codes for the disease and the eligibility and exclusion criteria for the trial.",
    "The sample is a phase 2 clinical trial for patients with gastric adenocarcinoma. The trial includes patients with specific stages of the disease and certain eligibility criteria, such as acceptable hematological, renal, hepatic, pulmonary, and cardiac function. Patients with other types of gastric cancer, brain or bone metastases, peritoneal involvement, serious underlying medical conditions, or previous or current malignancies (with some exceptions) are excluded. The trial involves the use of docetaxel, cisplatin, and fluorouracil drugs. The sample also includes a list of icd-10 codes for the disease.",
    "The sample is a record of a clinical trial with a phase 2 designation. The trial is focused on non-small cell lung cancer and includes a list of ICD-10 codes associated with the disease. The trial is testing the effectiveness of two drugs, gemcitabine and cisplatin. The eligibility criteria for the trial include having inoperable non-small cell lung cancer at stage III, adequate hematological parameters, and adequate lung function reserve. The exclusion criteria include having received previous chemotherapy and thoracic radiation for non-small cell lung cancer, as well as having distant metastases.",
    "The sample is a phase 2 clinical trial for patients with incurable esophageal or gastric carcinoma. The trial involves the use of the drugs taxotere, cisplatin, and irinotecan. The eligibility criteria include having measurable disease, being 18 years or older, having an ECOG performance status of 0 or 1, and having adequate bone marrow and renal function. Patients with a history of severe hypersensitivity to the drugs used in the trial or with other active malignancies are excluded. The trial also has exclusion criteria for patients who have received prior chemotherapy or pelvic radiation therapy, have uncontrolled serious medical or psychiatric illness, or have clinically apparent central nervous system metastases or carcinomatous meningitis.",
    "The sample is a phase 2 clinical trial for patients with inoperable locally-advanced metastatic adenocarcinoma of the stomach, gastro-oesophageal junction or distal oesophagus. The trial is testing the drug aslan001. Patients must have received 1 or more prior chemotherapy for the treatment of adenocarcinoma of the stomach, gastro-oesophageal junction or distal oesophagus with metastatic disease. Patients with measurable and non-measurable disease per modified RECIST guidelines are eligible. Patients must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 and adequate organ and haematological function. Patients unable to swallow oral medications, with persistent gastric outlet obstruction, complete dysphagia or feeding jejunostomy, who underwent radiotherapy to the gastric remnant \u2264 14 days prior to enrolment, with total gastrectomy, with uncontrolled, clinically significant symptomatic cardiovascular diseases within 6 months prior to enrolment, with ongoing or clinically significant active infection, or who are pregnant or breast-feeding are excluded.",
    "The sample is a phase 2 trial for coronary disease. The trial involves the use of the drug \"ins50589 intravenous infusion\". The eligibility criteria for the trial include being scheduled for primary CABG by median sternotomy involving cardiopulmonary bypass and being willing to receive allogeneic blood product transfusions during and after surgery. The exclusion criteria include having had previous cardiac surgery or median sternotomy, having a tendency for bleeding or family history of bleeding, having an abnormally low platelet count, or having received certain anticoagulant or antiplatelet medications within a specified time period prior to the scheduled CABG surgery.",
    "The sample is a record of a clinical trial with a phase 2 designation. The trial is focused on treating lung neoplasms, which are identified by a list of ICD-10 codes. The trial involves the use of several drugs, including pemetrexed, gemcitabine, and carboplatin. The eligibility criteria for the trial include having non-small cell lung cancer that has relapsed after initial treatment with surgery and chemotherapy, having good kidney, liver, and bone marrow function, and being fully active or able to carry out light work. The exclusion criteria include having received pemetrexed or gemcitabine in the past for lung cancer, currently receiving another treatment for relapsed lung cancer, or having had chemotherapy or certain other therapies for relapsed lung cancer in the past. Additionally, participants must be able to take corticosteroid drugs, folic acid pills, and Vitamin B12 injections as required for the study, and must be able to stop taking aspirin or other drugs that control inflammation for certain periods of time during the study. Participants with heart problems that are not controlled with medication or who have had a heart attack in the last 6 months are also excluded from the trial.",
    "The sample is a phase 2 clinical trial for the treatment of chronic hepatitis C. The trial includes adult patients between the ages of 18 and 70 who have been diagnosed with genotype 1 or 4 hepatitis C for over 6 months and have not received any previous treatment. The trial involves the use of two drugs, ro5024048 and a combination of ribavirin and peginterferon alfa-2a. The eligibility criteria include a negative pregnancy test for female patients of childbearing age and male patients with female partners of childbearing age, who must use two forms of contraception during treatment and following the last dose of ribavirin. The exclusion criteria include pregnancy or breastfeeding, previous interferon or ribavirin based therapy, systemic antiviral therapy with established or perceived activity against HCV, and history or evidence of medical condition associated with chronic liver disease other than HCV.",
    "The sample is a phase 2 trial for patients with myelodysplastic syndrome, leukemia, or Chronic Myelomonocytic Leukemia (CMML). The trial allows for prior biologic therapies, targeted therapies, or single agent chemotherapy, but not prior intensive chemotherapy or high-dose ara-C (> 1g/m2). Patients must have been off chemotherapy for 2 weeks prior to entering the study and recovered from the toxic effects of that therapy, unless there is evidence of rapidly progressive disease. Hydroxyurea is permitted for control of counts prior to treatment. Procrit and GCSF are allowed before therapy. Patients must have a performance score of 0-2 (Eastern Cooperative Oncology Group (ECOG)) and adequate organ function. Patients must also sign informed consent. Nursing and pregnant females are excluded from the trial, and patients of childbearing potential should practice effective methods of contraception. Patients with active and uncontrolled infections or uncontrolled intercurrent illness are also excluded. Prior clofarabine treatment is also an exclusion criterion.",
    "The sample is a phase 2 clinical trial for chronic myeloid leukemia. The trial is testing the effectiveness of imatinib and dasatinib drugs on patients who have not responded well to imatinib monotherapy. The eligibility criteria include being 18 years or older, having a suboptimal response to imatinib, and not having previous diagnoses of accelerated phase or blast crisis CML. Exclusion criteria include uncontrolled or significant cardiovascular disease, history of significant bleeding disorder unrelated to CML, concurrent malignancies, intolerance of imatinib, prior treatment with imatinib at a dose higher than 400 mg, and prior stem cell transplantation and/or high-dose chemotherapy for CML.",
    "The sample is a phase 2 clinical trial for non-small cell lung cancer. The trial is testing the effectiveness of the drugs Tarceva, Carboplatin, and Paclitaxel. The trial has specific eligibility criteria, including age, performance status, and positive EGFR pathway markers. The trial also has exclusion criteria, such as concurrent anticancer therapy, other active malignancy, and uncontrolled brain metastases. The trial requires tumor tissue block or fine needle aspirate for participation.",
    "The sample is a phase 2 clinical trial for patients with metastatic melanoma. The table includes information on the diseases, icd-10 codes, drugs, and eligibility criteria for the trial. The inclusion criteria include having confirmed malignant eye melanoma with documented metastatic disease, at least one measurable lesion, and adequate liver, renal, and bone marrow function. Patients must also have an ECOG performance status of 0-2 and be at least 13 years old. The exclusion criteria include prior treatment with taxanes, symptomatic brain metastasis, current active infections requiring anti-infectious treatment, and unstable or serious concurrent medical conditions. Patients must not have had major surgery within the past 14 days and must not receive any concurrent chemotherapy, radiotherapy, or immunotherapy while on the study.",
    "The sample is a phase 2 clinical trial for patients with lymphoma who have relapsed after a prior autologous bone marrow transplantation. The trial requires patients to have received at least one course of chemotherapy after the relapse and achieved a complete or partial response with the largest residual tumor dimension being less than or equal to 2 cm. Patients must also have an HLA-identical donor available and meet certain criteria for age, performance status, life expectancy, hematopoietic, hepatic, renal, cardiovascular, pulmonary, and other health factors. The trial involves the use of fludarabine phosphate, melphalan, methotrexate, and tacrolimus as drugs. The eligibility criteria for the trial are listed in detail under \"criteria\".",
    "This sample is a phase 2 clinical trial for the treatment of cutaneous t-cell lymphoma and adult t-cell leukemia-lymphoma. The trial involves the drug panobinostat (lbh589) and has specific eligibility criteria for patients to participate. Inclusion criteria include biopsy-confirmed MF or SS stages IB-IVA2, patients with SS with bone marrow involvement, patients with transformed CTCL, and patients with cytologically or histopathologically confirmed lymphoma. Exclusion criteria include patients with a history of primary CNS tumors, any history or presence of brain metastases, and patients with unresolved diarrhea > CTCAE grade 1. Patients must have received at least two systemic therapy regimens and have had disease progression on or following their most recent treatment regimen. The trial requires patients to be at least 20 years old and have an ECOG Performance Status of \u2264 2. Written informed consent is required prior to any study specific screening procedures.",
    "The sample is a clinical trial for tobacco dependence, with a phase 2/phase 3 designation. The trial is looking at the effectiveness of the drugs s-adenosyl-l-methionine and s-adenosyl-l-methionine in helping individuals quit smoking. The eligibility criteria include being at least 18 years old, having smoked more than 10 cigarettes per day for at least 6 months, being willing to make a quit attempt, and being in good health as determined by the physician investigator. There are also exclusion criteria, such as having clinically significant levels of depression or a history of certain medical conditions. Participants must not be using other treatments for tobacco dependence or other investigational drugs at the time of enrollment. They must also not have a known allergy to SAMe.",
    "The sample is a phase 2 clinical trial for the treatment of prostate cancer. The trial involves the use of two drugs, abiraterone acetate and prednisone. The eligibility criteria for the trial include having a confirmed diagnosis of adenocarcinoma of the prostate, having undergone prior chemotherapy with docetaxel, having documented PSA progression, and ongoing androgen deprivation. Exclusion criteria include having an active or uncontrolled autoimmune disease, serious or uncontrolled non-malignant disease, uncontrolled hypertension, low hemoglobin levels, and abnormal liver function.",
    "The sample is a record of a clinical trial in phase 2, focused on pulmonary disease, chronic obstructive. The trial involves the use of the drug glycopyrrolate, as well as a comparator drug. The eligibility criteria for the trial include being over 40 years old with COPD, and not currently taking more than double or triple therapy. Exclusion criteria include being pregnant or lactating, experiencing a COPD exacerbation requiring hospitalization or systemic steroids/antibiotics, and having other diseases that could impact the feasibility or safety of the trial. The icd-10 codes associated with the disease are also listed.",
    "The sample is a phase 2 clinical trial for patients with relapsed or refractory acute myeloid leukemia or acute lymphoblastic leukemia. Patients with Philadelphia chromosome-positive (Ph+) ALL refractory to BCR/ABL inhibitors and those who have relapsed after prior autologous or allogenic stem cell transplant are eligible. The drug being tested is panobinostat. The eligibility criteria include various disease and patient characteristics such as ECOG performance status, serum albumin, AST and ALT levels, bilirubin levels, creatinine levels, potassium and phosphorous levels, and cardiac function. Patients must also not have uncontrolled hypertension, unresolved diarrhea, impaired gastrointestinal function or disease, or other concurrent severe and/or uncontrolled medical conditions. Prior concurrent therapy is also taken into consideration.",
    "The sample is a phase 2 trial for patients with stable moderate to severe plaque-type psoriasis involving at least 5% of their body surface area. The trial includes patients with a history of plaque psoriasis for at least 6 months prior to screening, aged between 18 and 75, and who meet certain eligibility criteria. The trial excludes patients with primary guttate, erythrodermic, or pustular psoriasis, as well as those who have failed to improve significantly with systemic treatments such as cyclosporine or methotrexate. Patients who have experienced treatment failure with a TNF-blocking agent are also excluded. The trial requires patients to wash out of all current psoriasis treatments (systemic, topical, and phototherapy) except emollients and shampoos prior to beginning trial medication. Patients taking certain medications known to elevate liver enzymes are excluded, as are those with clinically significant abnormal baseline hematology, blood chemistry, or urinalysis. Patients with any clinically significant psychiatric illness or history of cardiovascular, renal, neurologic, liver, immunologic, or endocrine dysfunction are also excluded. The trial further excludes patients with any history of heart failure, recent history of myocardial infarction, or any arrhythmia requiring drug therapy. Patients with any active immunodeficiency or active infection, or any serious infection in the past 3 months prior to screening are excluded. Patients with a history of drug or alcohol abuse within the past 2 years, active drug or alcohol abuse, or those who consume more than three alcoholic drinks per day are also excluded. Finally, patients who have taken an investigational drug within one month or six half-lives prior to screening, or who have been treated with any investigational antibody or other biological agent within the past 3 months are excluded.",
    "The sample is a phase 2 clinical trial for non-small cell lung cancer. The trial includes patients who are over 18 years old and have either metastatic cancer or locally advanced cancer with malignant effusion. Patients must have at least one measurable lesion and an ECOG performance status of 0-2. They must also have adequate hematologic, renal, and liver function. Patients who have had prior systemic therapy for NSCLC or have tumor harboring EGFR mutation are excluded from the trial. The trial involves the use of paclitaxel/carboplatin/gefitinib or paclitaxel/carboplatin as treatment. The eligibility criteria and exclusion criteria are listed in detail.",
    "The sample is a phase 2 clinical trial for patients with various types of transitional cell carcinoma, including bladder, urethra, ureter, and renal pelvis. The trial is testing the effectiveness of the drug bortezomib as a treatment option for patients who have received only one prior systemic chemotherapy regimen for advanced or metastatic disease. Patients must have completed radiotherapy or chemotherapy at least 4 weeks prior to registration and have measurable disease. They must also meet various eligibility criteria, including having a performance status of 2 or less, no active brain metastases, and no prior treatment with PS-341 or other proteasome inhibitors. Pregnant and nursing women are not eligible for the trial.",
    "The sample is a phase 2 clinical trial for patients with Cushing's disease, a condition caused by a pituitary tumor that produces too much cortisol. The trial is testing the effectiveness of rosiglitazone maleate in controlling the disease. Eligible patients must have a clinically demonstrable ACTH-secreting pituitary tumor, elevated cortisol levels, and lack of suppression of serum cortisol. Patients with evidence of optic nerve or chiasm compression on post-operative MRI must have a normal visual field evaluation. Patients with hypopituitarism are allowed to participate. Patients must not be pregnant or nursing, have no significant renal, hematologic, or hepatic abnormalities, and no prior or concurrent medical condition that may interfere with the study. Prior concurrent therapy is also restricted.",
    "The sample is a phase 2 clinical trial for patients with moderate persistent asthma who are symptomatic despite their current maintenance treatment with medium doses of inhaled corticosteroids. The trial involves the use of tiotropium 2.5 \u00b5g b.i.d, placebo, and tiotropium 5 \u00b5g q.d. as drugs. The eligibility criteria include patients aged 18-75 years with at least a 3-month history of asthma, a diagnosis of moderate persistent asthma, and a pre-bronchodilator FEV1 above 60% predicted and below 90% of predicted normal. Patients must also be able to use the Respimat\u00ae inhaler correctly and perform all trial-related procedures. Exclusion criteria include patients with significant diseases other than asthma, recent history of myocardial infarction or hospitalization for cardiac failure, lung diseases other than asthma, known active tuberculosis, malignancy, and significant alcohol or drug abuse within the past two years. Pregnant or nursing women and women of childbearing potential not using a highly effective method of birth control are also excluded. Patients who have been treated with certain medications within four weeks prior to Visit 1 or during the screening period are also excluded.",
    "The sample is a phase 2 clinical trial for head and neck squamous cell carcinoma. The trial includes patients who have not received palliative chemotherapy in the past 6 months and have at least one measurable lesion. Patients must also meet certain eligibility criteria, such as having adequate laboratory results and being 18 years or older. However, there are also exclusion criteria, such as being pregnant or lactating, having grade 2 or more peripheral neuropathy, or having a severe medical condition. The trial will test the effectiveness of two drugs, docetaxel+cddp and docetaxel+s-1.",
    "The sample is a phase 2 clinical trial for Hodgkin's lymphoma. The trial includes patients with a confirmed diagnosis of Hodgkin's lymphoma who have not received prior therapy for the disease. The trial also has specific eligibility criteria, including age range, stage of disease, and no prior chemotherapy or radiation. The trial involves a combination of drugs, including prednisone, vinblastine, doxorubicin, and gemcitabine. The trial's inclusion criteria also require patients to sign informed consent and agree to provide personal data and tissue samples to the GHSG. The exclusion criteria include various medical conditions and circumstances that may make protocol treatment or long-term follow-up impossible.",
    "The sample is a record from a clinical trial table that includes information about the phase of the trial (phase 2/phase 3), the disease being studied (cerebrovascular accident), the ICD-10 codes associated with the disease, the drug being tested (ono-2506), and the eligibility criteria for participants. The eligibility criteria include requirements such as a clinical diagnosis of acute cortical ischemic stroke, a measurable focal neurological deficit for at least 60 minutes, and a pre-stroke mRS scale score of 0 or 1. The exclusion criteria include factors such as a body weight over 125 kg, evidence of non-ischemic mechanisms on CT or MRI, and severe coexisting or terminal systemic disease.",
    "This sample is from a clinical trial with a phase 2 designation. The trial is focused on the disease postherpetic neuralgia, which is associated with the icd-10 code B02.22. The drug being tested is called spm 927. The eligibility criteria for the trial includes having postherpetic neuralgia as an inclusion criteria, and not benefiting from long term treatment as an exclusion criteria.",
    "The sample is a phase 2 clinical trial for patients with metastatic adenocarcinoma of the pancreas. The trial is testing the effectiveness of a combination of erlotinib hydrochloride and gemcitabine hydrochloride drugs. The eligibility criteria include having confirmed adenocarcinoma of the pancreas, no islet cell, acinar cell, or cystadenocarcinomas, and no locally advanced disease. Patients must have an ECOG performance status of 0-1, a life expectancy of at least 3 months, and meet certain laboratory values. Patients must not have had prior cytotoxic chemotherapy for metastatic disease or prior anti-EGFR antibody therapy. The trial also has other exclusion criteria, such as no concurrent immunotherapy or radiotherapy.",
    "The sample is a phase 2 clinical trial for patients with metastatic prostate cancer and bone metastasis. The trial is testing the drug paricalcitol and the eligibility criteria includes confirmed advanced adenocarcinoma of the prostate, androgen refractory disease, secondary hyperparathyroidism, and normal levels of various blood markers. Patients must also have had prior therapy with hormonal agents and no more than one prior taxane-containing chemotherapy regimen for metastatic disease. Patients with underlying metabolic bone disease or vitamin D deficiency, history of hypercalcemia, or concurrent uncontrolled illness or co-morbid condition that would interfere with study compliance are excluded from the trial. Concurrent chemotherapy or hormonal therapy, concurrent investigational or commercial agents for the malignancy, and concurrent ergocalciferol supplementation are also exclusion criteria.",
    "The sample is a phase 2 trial for osteoporosis, with a list of diseases and corresponding icd-10 codes, as well as a list of drugs. The eligibility criteria for inclusion in the trial include being an ambulatory female aged <80 years at screening and >5 years postmenopausal, having a T-score consistent with osteoporosis, having suitable vertebrae for BMD measurement, and being willing and able to comply with the requirements of the protocol. Exclusion criteria include having a T-score less than or equal to -4.0, having >1 prevalent vertebral fracture, having a history of non-vertebral osteoporosis related/fragility fracture after age 40, having significant spine deformity, having a BMI \u226533kg/m2, having other bone metabolic diseases, having a history of major upper gastrointestinal disease, having active or history of malabsorption, having past or current history of liver disease or known hepatic or biliary abnormalities, having active disease or history of rheumatoid arthritis, having a history of or active nephrolithiasis, being at increased risk of osteosarcoma, having malignant disease diagnosed within the previous 5 years, having any clinically relevant biological abnormality found and/or volunteered at screening, having presence of certain surgical and medical conditions within six months prior to screening, having a Glomerular filtration rate (GFR) <35 mL/min, having a marked baseline prolongation of QT/QTc interval, having a history of risk factors for Torsades de Pointes, having liver chemistries exceeding 2-fold the upper limit of the laboratory-specified reference range, having abnormal serum calcium, having PTH (intact or whole) outside the normal range, having creatine phosphokinase (CPK) outside the normal range, having alkaline phosphatase outside of the normal range, receiving thyroid hormone replacement therapy with certain TSH levels, having vitamin D deficiency, having previous treatment with certain drugs affecting bone metabolism, having certain contraindications to therapy with calcium or vitamin D, being pregnant, having certain interfering medications, having administration of any investigational drug within 90 days preceding the first dose of the study drug, having history or current evidence of drug or alcohol abuse within the previous 12 months, having inability to swallow a tablet whole, having current therapy with certain medications, having history of hip surgery resulting in a metal implant on either the left or right side that would cause an artefact on a QCT scan, and having certain contraindications to therapy with teriparatide according to locally approved datasheet.",
    "The sample is a phase 2 clinical trial for the treatment of multiple sclerosis. The trial is testing the effectiveness of a drug called abt-874, which is a human monoclonal antibody against il-12, compared to a placebo. The trial is looking for participants who are between the ages of 18 and 55, have had an active relapse within the past 12 months, and have been off Copaxone or interferon therapy for at least two months prior to screening. Participants must also be able to walk at least 65 feet with or without assistance and be willing to learn to self-administer weekly injections or have a designee who will administer the study medication. Female participants must use contraceptives while on the study drug. There are several exclusion criteria, including primary progressive multiple sclerosis, recent immunosuppressive therapy, recent systemic corticosteroid therapy, and participation in any clinical study within three months prior to the screening visit. The sample also includes a list of exclusionary laboratory values and other medical conditions that would make a participant unsuitable for the trial.",
    "The sample is a phase 2 trial for the treatment of mild, stable allergic asthma. The trial includes patients with a history of episodic wheeze and shortness of breath, with a baseline FEV1 of at least 70% of the predicted value. The trial involves the use of two drugs, memp1972a and placebo. The eligibility criteria include a positive skin prick test to common standard aeroallergens extracts, positive allergen-induced early and late airway response, and documented PC20 value for prediction of the starting allergen concentration at screening. The exclusion criteria include a worsening of asthma within 6 weeks preceding Visit 1, acute respiratory infection within 6 weeks preceding Visit 2, and any ongoing chronic infection. Other exclusion criteria include a history of recurrent bacterial infection, lung disease other than mild allergic asthma, history or symptoms of cardiovascular disease, significant neurologic disease, significant hepatic or renal impairment, evidence of an active or suspected cancer or history of treatment for cancer, and history or symptoms of clinically significant autoimmune disease. The sample also includes exclusion criteria related to medication use, pregnancy or lactation, and history of drug or alcohol abuse.",
    "The sample is a phase 2 clinical trial for patients with AL amyloidosis, a type of plasma cell neoplasm. The trial is testing the effectiveness of the drug melphalan in treating the disease. The eligibility criteria include having confirmed AL amyloidosis, having received prior high-dose chemotherapy, and having shown significant improvement in organ function after the prior treatment. Patients must also meet certain age, performance status, and life expectancy requirements, and must not have certain other medical conditions. The exclusion criteria include having myelodysplastic syndromes or abnormal bone marrow cytogenetics, being pregnant or nursing, having HIV, or having any other concurrent malignancy except treated skin cancer.",
    "The sample is a record of a clinical trial with a phase 2 designation. The trial is focused on rheumatoid arthritis and includes a list of ICD-10 codes associated with the disease. The trial involves the use of several drugs, including etoricoxib, placebo, and diclofenac. The eligibility criteria for the trial include a diagnosis of rheumatoid arthritis for at least 6 months and the use of nonsteroidal anti-inflammatory drugs to treat symptoms. Patients must stop taking these medications to participate in the trial but can continue taking other anti-rheumatic medications if they have been stable for a certain period of time. Patients with medical conditions that could interfere with the evaluation of the study medication are not allowed to participate.",
    "The sample is a phase 2 clinical trial for acute pain. The trial involves patients who are scheduled for elective primary unilateral first metatarsal bunionectomy surgery. The patients must be able to provide written informed consent, communicate clearly with the Investigator and staff, and have a negative urine drug screen for drugs of abuse. The trial also has inclusion and exclusion criteria, such as age, body weight, and medical history. The patients will be randomly assigned to receive either the drug cr845 or a placebo. The trial aims to evaluate the efficacy and safety of the drug in managing acute pain.",
    "The sample is a record of a clinical trial in phase 2 for the treatment of primary insomnia. The trial involves the use of two drugs, mk-6096 and a dose-matched placebo to mk-6096. The eligibility criteria for participants include being willing to stay overnight at a sleep laboratory for 6 separate nights, having a regular bedtime between 9 PM and 12 AM, being able to read and complete questionnaires and diaries, and refraining from napping during the study. Exclusion criteria include being pregnant or planning to become pregnant, having a history of neurological or cardiovascular disorders, difficulty sleeping due to a medical condition, and having participated in a study with an investigational compound or device within the last 30 days.",
    "The sample is a phase 2 trial for patients with small cell lung cancer that has progressed or recurred after receiving a standard first-time regimen containing either cisplatin or carboplatin. Patients must have measurable disease per RECIST criteria and have been previously treated with exactly one regimen that included cisplatin or carboplatin. The trial involves the drug sorafenib tosylate. The eligibility criteria include various medical conditions, such as serum creatinine, bilirubin, alkaline phosphatase, SGOT or SGPT, PTT and either PT or INR, ANC, platelet count, Zubrod performance status, and brain and/or leptomeningeal metastases. Patients must not have any evidence of bleeding diathesis and must be able to swallow and/or receive enteral medications via gastrostomy feeding tube. The effects of BAY 43-9006 on the developing human fetus at the recommended therapeutic dose are unknown, so patients must not be pregnant or nursing. Patients must not have a significant history of cardiac disease, and no other prior malignancy is allowed except for certain types of cancer. All patients must be informed of the investigational nature of this study and must sign and give written informed consent.",
    "The sample is a phase 2 clinical trial for patients with metastatic colorectal cancer. The trial is testing the effectiveness of irinotecan hydrochloride as a treatment option. The eligibility criteria include having a confirmed diagnosis of colorectal adenocarcinoma, wild type KRAS, measurable disease, and having previously been treated with oxaliplatin and fluorpyrimidines with or without bevacizumab, and irinotecan hydrochloride alone or in combination with fluorpyrimidines with or without bevacizumab. Patients must also meet certain patient characteristics such as having a WHO performance status of 0-2, ANC \u2265 1,500/mm\u00b3, and no significant cardiovascular disease. The trial has certain exclusion criteria such as having a history of interstitial pneumonitis, pulmonary fibrosis, or active inflammatory bowel disease. Prior concurrent therapy is also taken into consideration.",
    "The sample is a phase 2 clinical trial for the treatment of squamous cell carcinoma. The trial involves the use of two drugs, docetaxel and cddp. The eligibility criteria for the trial include confirmation of NSCLC, resectable or unresectable stage II or IIIa or IIIb NSCLC, and measurable disease. Patients must also have a Karnofsky Status greater than 70, adequate hematological function, and adequate renal and hepatic functions. Exclusion criteria include evidence of brain metastases or other distant metastasis equivalent to stage IV disease, history of prior malignancies, and other serious concomitant illness or medical condition. Prior chemotherapy or immunotherapy for NSCLC, prior surgery or radiotherapy for NSCLC, and concurrent treatment with other experimental drugs, unapproved medical procedures or other anticancer therapy are also exclusion criteria. Pregnant or lactating patients and patients with reproductive potential not implementing adequate contraceptive measurements are also excluded.",
    "The sample is a phase 2 clinical trial for patients with adenocarcinoma of the stomach or gastroesophageal junction. The trial includes patients with metastatic or locally advanced disease, measurable disease, and no known brain metastases. Patients must also meet certain eligibility criteria, including having a performance status of 0-2 and a life expectancy of more than 3 months. The trial involves the use of the drug saracatinib and has a list of exclusion criteria, such as no history of allergic reactions to similar compounds and no concurrent cardiac dysfunction. Prior chemotherapy is allowed if it was administered as part of initial curative intent therapy. The trial has a list of other criteria that patients must meet to be eligible and exclusion criteria that would limit compliance with study requirements.",
    "The sample is a phase 2 clinical trial for patients with locally advanced or metastatic breast cancer that is HER2-positive. The trial is testing the effectiveness of a combination of three drugs: trastuzumab emtansine (kadcyla), trastuzumab, and docetaxel. The eligibility criteria include having no prior chemotherapy for metastatic breast cancer, measurable disease, and being at least 18 years old. Exclusion criteria include a history of chemotherapy for metastatic breast cancer, current peripheral neuropathy of Grade \u2265 3, and current pregnancy or lactation. The trial also has various other exclusion criteria related to medical history and current health status.",
    "The sample is a phase 2 clinical trial for patients with type 2 diabetes mellitus. The trial includes patients between the ages of 20 and 70 who are currently being treated for diabetes with diet and exercise or with metformin. Patients must have a BMI between 25 and 40 and an HbA1c level between 6.5% and 10.5%. The trial involves the use of three drugs: ormd-0801 dose #1, ormd-0801 dose #2, and placebo. The eligibility criteria include various medical and lifestyle factors, such as no tobacco or nicotine use within 10 weeks prior to screening and no history of drug or alcohol abuse within the last year. The trial also has exclusion criteria, such as a history of T1DM or a fasting plasma glucose level above 260 mg/dL at the end of the washout/stabilization/run-in periods. The Principal Investigator has discretion to exclude patients based on any condition or factor deemed unsuitable for enrollment.",
    "The sample is a record of a clinical trial with a phase 2 designation. The trial is focused on prostate cancer and the ICD-10 codes associated with it. The drug being tested is dexamethasone. The eligibility criteria for the trial include having histologically confirmed adenocarcinoma of the prostate, being scheduled for radical prostatectomy, and meeting certain patient characteristics such as age and hematopoietic, hepatic, and renal health. The trial excludes patients with small cell carcinoma of the prostate, a history of diabetes mellitus requiring pharmacotherapy, and prior nephrectomy, prostatic surgery, cryotherapy, or transurethral resection of the prostate. The sample also includes information on prior concurrent therapy, which is not specified for biologic or chemotherapy, but requires more than 5 years since prior antiestrogens, antiandrogens, luteinizing hormone-releasing hormone agonists, estrogen, or progestational agents for endocrine therapy, and no prior radiotherapy.",
    "The sample is a phase 2 clinical trial for small cell lung cancer. The trial includes patients who have been histologically or cytologically diagnosed with extensive disease and measurable disease, with a WHO performance status of 0-2 and normal baseline cardiac function. Patients must be 18 years or older and have not received prior systemic chemotherapy for small cell lung cancer. Adequate organ function, including bone marrow, kidney, and liver, is required, and patients must not have a history of interstitial lung disease or pulmonary fibrosis. Patients must not have a history of prior malignancy unless they have been disease-free for greater than 5 years, or the tumor was a non-melanoma skin cancer or in-situ carcinoma of the cervix. Patients who are pregnant or breastfeeding are excluded, and patients of child-bearing potential must agree to use an appropriate method of contraception. The trial requires written informed consent before randomization. Exclusion criteria include pre-existing peripheral neuropathy greater than Grade 1, uncontrolled or severe cardiovascular disease, and any psychological, familial, sociological, or geographical condition that could potentially hamper compliance with the study protocol and follow-up schedule. The trial will test the efficacy of the drugs amrubicin, cisplatin, and etoposide.",
    "The sample is a phase 2 clinical trial for Crohn's disease. The trial includes patients with confirmed colitis, ileitis, or ileocolitis, who have been receiving stable doses of medication for Crohn's disease. The trial also has inclusion and exclusion criteria, such as a baseline Crohn's Disease Activity Index (CDAI) of 250-400, no evidence of bowel obstruction or history of extensive bowel resection, and no recent treatment with experimental therapeutics. The trial involves the use of the drugs semapimod and placebo. The diseases and their corresponding ICD-10 codes are also listed.",
    "The sample is a phase 2 clinical trial for patients with locally advanced or distant metastatic cholangiocarcinoma or gallbladder carcinoma. The trial involves the use of the drug sorafenib tosylate. The eligibility criteria include having a confirmed diagnosis of cholangiocarcinoma or gallbladder carcinoma, having measurable disease, not having received prior therapy for unresectable or metastatic disease, and meeting various medical requirements such as having a Zubrod performance status of 0-1 and having total serum bilirubin =< 3 x the institutional upper limit of normal. Patients must also not have any evidence of bleeding diathesis, clinically significant cardiac disease that is not well controlled by medication, uncontrolled hypertension, or known brain metastases. Women/men of reproductive potential must agree to use an adequate contraception prior to study entry and for the duration of protocol treatment. The trial requires patients to have no plans to receive concurrent chemotherapy, hormonal therapy, radiotherapy, immunotherapy or any other type of therapy for treatment of cancer while on this protocol. The trial also requires patients to be informed of the investigational nature of this study and must sign and give written informed consent in accordance with institutional and federal guidelines.",
    "The sample is a phase 2 clinical trial for asthma. The trial includes patients with a documented history of bronchial asthma who are currently being treated only with intermittent short-acting beta-agonist therapy by inhalation. The trial aims to test the efficacy of fluticasone furoate, ff/vilanterol (vi; gw642444m), and placebo drugs. The eligibility criteria include a body mass index within the range of 18.5-35.0 kilograms/metre2 (kg/m2), pre-bronchodilator FEV1 >70% of predicted at screening, and methacholine challenge PC20 < 8 mg/mL at screening. The exclusion criteria include a current or chronic history of liver disease, respiratory tract infection and/or exacerbation of asthma within 4 weeks prior to the first dose of study medication, and history of life-threatening asthma.",
    "The sample is a record of a clinical trial with a phase 2 designation. The trial is focused on the disease of asthma and includes a list of ICD-10 codes associated with the disease. The trial involves the use of two drugs, arformoterol and levalbuterol. The eligibility criteria for the trial includes age, weight, and a history of physician-diagnosed asthma for a certain duration. The exclusion criteria includes factors such as pregnancy, hospitalization for asthma within the past year, and a history of certain medical conditions.",
    "The sample is a clinical trial for a drug called Truvada, which is being tested for its effectiveness in treating patients with hepatitis B and HIV infections. The trial is in phase 2/phase 3 and the eligibility criteria include having a Karnofsky score above 80%, stable ARV treatment for at least 4 months, CD4 count above 200 per mm3, and ARN VIH below 10000 copies per ml. Patients must also have chronic hepatitis B with positive antigenaemia HBe and negative antiHBe, and positive DNA HBV before or under tenofovir treatment. Exclusion criteria include having HIV 2 infection, hepatitis C or D, opportunistic infection, alcohol consumption more than 50g/d, cirrhosis, pregnancy or plan of pregnancy, breastfeeding, immunosuppressive or modulating of the immune response treatment, and other Hepatitis B treatments than tenofovir, lamivudine or emtricitabine since 6 months. The sample also includes a list of diseases and their corresponding ICD-10 codes.",
    "The sample is a phase 2 clinical trial for patients with epithelial ovarian cancer or primary peritoneal carcinoma. The trial involves the use of two drugs, bevacizumab and abraxane. The eligibility criteria include having measurable disease by CT or MRI, having at least one \"target lesion\" to assess response, having an ECOG performance status of 0 or 1, being at least 18 years old, and having adequate hematologic and hepatic function. Exclusion criteria include having previously received bevacizumab, having a history of other invasive malignancy, and having a life expectancy of less than 12 weeks. The trial also has specific criteria for blood pressure, heart conditions, and other medical conditions.",
    "The sample is a phase 2 clinical trial for patients with ovarian, primary peritoneal, or fallopian tube cancer. The trial is testing the effectiveness of the drug irinotecan in patients who have relapsed within 6 months after completing front-line chemotherapy or had a best response of increasing disease during this front-line regimen. Patients must have unidimensionally measurable disease and meet certain eligibility criteria related to their disease characteristics and patient characteristics. Prior concurrent therapy is also taken into consideration. The sample includes a detailed list of eligibility criteria for patients to participate in the trial.",
    "The sample is a phase 2 clinical trial for patients with advanced hepatocellular carcinoma (HCC), which is unresectable or metastatic. The trial involves the use of sorafenib (nexavar, bay43-9006) plus doxorubicin or doxorubicin/placebo. The eligibility criteria include having a life expectancy of at least 12 weeks, having at least one tumor lesion that can be accurately measured according to Response Evaluation Criteria in Solid Tumors (RECIST), and having an Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2. The exclusion criteria include having a previous or concurrent cancer that is distinct in primary site or histology from HCC, history of cardiac disease, serious myocardial dysfunction, active, clinically serious infections, known history of Human Immunodeficiency Virus (HIV) infection, known Central Nervous System (CNS) tumors including metastatic brain disease, and clinically significant gastrointestinal bleeding within 30 days prior to study entry.",
    "The sample is a phase 2 clinical trial for metastatic breast cancer. The trial includes patients who are over 18 years old, have ER negative and PR negative cancer, and have experienced disease progression despite previous treatments. Patients must have evaluable disease and symptoms, and a performance status of 0, 1, or 2. They must also have had a mammogram within the past year. Exclusion criteria include uncontrolled hypercalcemia or congestive heart failure, central nervous system metastasis, and a performance status greater than 2. The trial involves the use of fluoxymesterone 10 mg and anastrozole 1 mg.",
    "The sample is a phase 2 trial for the treatment of type 2 diabetes. The trial includes subjects who are insulin na\u00efve and have been diagnosed clinically with type 2 diabetes for at least 3 months. The subjects must have been treated with one or two oral anti-diabetic drugs for at least 2 months at a stable maximally tolerated dose or at least half maximally allowed dose according to the summary of product characteristics. The trial also requires the subjects to have an HbA1c level between 7.0-11.0% and a body mass index (BMI) between 23-42 kg/m^2. The trial excludes subjects with metformin contraindication, thiazolidinedione (TZD) treatment within the previous three months, or any systemic treatment with products that could interfere with glucose or lipid metabolism. Additionally, subjects with clinically significant, active diseases of the gastrointestinal, pulmonary, neurological, genitourinary, or hematological system (except for conditions associated with type 2 diabetes) are excluded from the trial.",
    "The sample is a phase 2 trial for the treatment of open-angle glaucoma and ocular hypertension. The trial involves the drug brinzolamide/timolol and includes a list of diseases and their corresponding icd-10 codes. The eligibility criteria for the trial includes adults of any race and sex who have been diagnosed with open-angle glaucoma, with or without pseudoexfoliation or pigment dispersion component. The exclusion criteria includes individuals under the age of 18.",
    "The sample is a phase 2 clinical trial for patients with coronary heart disease. The trial includes patients with other CHD risk factors who are being treated for dyslipidemia and are clinically stable. The trial involves the drugs dalcetrapib (ro4607381) and placebo. The eligibility criteria for the trial include being an adult patient between 18-75 years of age, having CHD, and being treated appropriately for dyslipidemia. The exclusion criteria include previous exposure to any cholesteryl ester transfer protein (CETP) inhibitor or vaccine, recent clinically significant coronary events, transient ischemic attacks or cerebrovascular accident, severe anemia, uncontrolled hypertension, and poorly controlled diabetes.",
    "The sample is a phase 2 clinical trial for major depressive disorder. The trial involves the use of drugs such as ly2216684, placebo, and escitalopram. The eligibility criteria for participants include meeting the criteria for major depressive disorder without psychotic features, having a certain level of education and understanding, being reliable and able to keep appointments, and not having any additional ongoing psychiatric conditions other than major depression or dysthymia. Exclusion criteria include having a history of bipolar disorder, psychotic disorder, or factitious disorder, being at high risk for harming themselves or others, having a serious medical illness, and having any diagnosed medical condition that could be exacerbated by treatment with LY2216684.",
    "The sample is a phase 2 clinical trial for the treatment of prostate cancer and prostatic neoplasm. The trial involves the drug abiraterone acetate in combination with prednisone. The eligibility criteria include being a male over 18 years of age with adenocarcinoma of the prostate, currently receiving continuous treatment with Gonadotropin-releasing hormone (GnRH) monotherapy for at least 6 months before or have undergone surgical removal of the testicles, and having a serum testosterone level of less than 50 ng/dL. The trial also has exclusion criteria, such as having prior or current evidence of local disease progression or metastatic disease, receiving chemotherapy for treatment of castrate-resistant prostate cancer, and having partners of childbearing potential who are not willing to use a method of birth control.",
    "The sample is a phase 2 clinical trial for the treatment of primary testicular CD20-positive diffuse large B-cell non-Hodgkin's lymphoma. The trial involves the use of rituximab, chop, and intrathecal methotrexate drugs. The eligibility criteria include being 18 years or older, having an ECOG performance status of 0-2, having untreated lymphoma, having measurable or evaluable disease, having adequate bone marrow reserve, having a cardiac ejection fraction of at least 50%, not having received previous therapy with monoclonal antibody anti-CD20, not having any psychiatric illness that precludes understanding the trial concepts or signing informed consent, and not having any other major life-threatening illnesses that may preclude chemotherapy. The exclusion criteria include having impaired renal or liver function, being HIV positive, and having had an evolutive malignancy within 5 years with the exception of localized non-melanomatous skin cancer.",
    "The sample is a phase 2 clinical trial for non-squamous non-small cell lung cancer. The trial includes patients who are 18 years or older with locally advanced metastatic or recurrent NSCLC and at least one measurable tumor lesion. The trial excludes patients who have received prior chemotherapy or treatment with another systemic anti-cancer agent, have evidence of CNS metastases, have a history of grade 2 or higher hemoptysis, have evidence of tumor invading or abutting major blood vessels, have had malignancies other than NSCLC within 5 years prior to randomization, have clinically significant cardiovascular disease, or are currently or recently using aspirin or full dose anticoagulants or thrombolytic agents for therapeutic purposes. The trial will test the effectiveness of bevacizumab [avastin] and carboplatin-based chemotherapy.",
    "The sample is a phase 2 clinical trial for the treatment of keratoconjunctivitis sicca, a condition that causes dryness and inflammation of the eyes. The trial involves the use of two drugs, cf101 and placebo, and has specific eligibility criteria for participants, including a diagnosis of moderate-to-severe KCS, stable use of unpreserved artificial tears, and no use of topical ocular treatments except for the artificial tears. The trial also has exclusion criteria, such as the presence of certain medical conditions or use of certain medications. Participants must be willing to use two methods of contraception if they are of child-bearing potential. The trial aims to evaluate the safety and efficacy of the drugs in treating KCS.",
    "The sample is a record of a clinical trial with a phase 2 designation. The trial is focused on colorectal cancer and includes a list of ICD-10 codes for the disease. The trial involves the use of four drugs: bevacizumab (Avastin), eloxatin, capecitabine (Xeloda), and erlotinib (Tarceva). The eligibility criteria for the trial include being an adult patient over 18 years of age with adenocarcinoma of the colon or rectum and at least one measurable lesion. Exclusion criteria include previous treatment with Avastin or Tarceva, previous systemic treatment for advanced or metastatic disease, and adjuvant treatment for non-metastatic disease in the past 6 months.",
    "This sample is a record of a clinical trial in phase 2 for the treatment of cystic fibrosis. The trial involves the use of the drugs ivacaftor and placebo. The eligibility criteria for the trial include having a confirmed diagnosis of CF, having the G551D-CFTR mutation in at least one allele, and having FEV1 greater than 90% of predicted normal for age, gender, and height. The exclusion criteria include ongoing participation in another therapeutic clinical study or prior participation in an investigational drug study within the 30 days prior to screening, and use of inhaled hypertonic saline treatment within 2 weeks of the Period 1, Day 1 visit. The icd-10 codes associated with the disease are also provided.",
    "The sample is a phase 2 clinical trial for non-squamous non-small cell lung cancer. The trial is investigating the effectiveness of a combination of drugs including pemetrexed, cisplatin, folic acid, vitamin b12, and dexamethasone. The eligibility criteria for the trial include having confirmed non-small cell lung cancer, being in stage IIIAN2 disease, having a potentially resectable tumor, having good performance status, having no prior therapy for lung cancer, having measurable disease, having a life expectancy of at least 6 months, having functioning organs, and signing informed consent. Women must be surgically sterile, postmenopausal, or compliant with a medically approved contraceptive regimen, and men must be surgically sterile or compliant with a contraceptive regimen. Exclusion criteria include receiving or having received an investigational drug or device within the last 30 days, having a serious concomitant systemic disorder, having a serious cardiac condition, receiving concurrent administration of any other anticancer therapy, and being unable or unwilling to take Pemetrexed supplementation/premedication.",
    "The sample is a phase 2 trial for the treatment of overactive bladder. The trial includes patients with various urologic diseases and urinary bladder symptoms. The trial involves the use of three drugs: mirabegron, solifenacin succinate, and placebo. The eligibility criteria for the trial include having symptoms of overactive bladder for at least 3 months, experiencing a certain frequency of micturition, and not having certain medical conditions or taking certain medications. The trial also has exclusion criteria, such as having a urinary tract infection or clinically significant cardiovascular or cerebrovascular diseases.",
    "The sample is a phase 2 clinical trial for asthma in male and pre-menarchial female subjects aged 5-11 years. The trial involves the use of fluticasone furoate and a matching placebo as drugs. The eligibility criteria include a diagnosis of asthma at least 6 months prior to screening, being controlled on existing asthma treatment, and being in good health with no other significant medical conditions. The trial also requires subjects to be taking a stable regimen of a short-acting beta-agonist inhaler and to weigh at least 15 kg. The trial has exclusion criteria, including subjects who have changed their asthma medication within 4 weeks of screening or have received certain asthma therapies within 4 weeks of screening. The trial also excludes subjects with any medical condition or circumstance making them unsuitable for participation, such as a history of life-threatening asthma or clinically relevant abnormality identified on the screening medical assessment. The trial requires a signed and dated written informed consent from at least one parent/guardian and accompanying informed assent from the subject prior to admission to the study.",
    "The sample is a phase 2 clinical trial for patients with unresectable, metastatic adenocarcinoma of the esophagus, gastroesophageal junction, or gastric cardia. The trial is testing the effectiveness of a combination of drugs including bortezomib, carboplatin, and paclitaxel. The eligibility criteria include having at least one measurable lesion, a performance status of ECOG 0-2, and meeting certain hematopoietic, hepatic, renal, and other health requirements. Patients must not have had prior chemotherapy or radiotherapy for recurrent or metastatic disease, and must not have certain chronic diseases or allergies to the drugs being tested. The trial also specifies certain timeframes for prior surgeries and procedures.",
    "The sample is a record of a clinical trial in phase 2, focused on the disease \"status epilepticus\". The trial includes patients who are at least 18 years old and have been diagnosed with any type of status epilepticus by a medical examiner. Women between the ages of 18 and 50 must confirm that they are not pregnant. The trial will use the drug \"levetiracetam (add-on)\" and has specific inclusion and exclusion criteria, such as not having a known allergy to the drug and not taking more than 2000mg/day. The sample also includes the ICD-10 codes associated with the disease.",
    "The sample is a phase 2 clinical trial for the treatment of sarcoma, a type of cancer. The trial involves the use of erlotinib hydrochloride as a drug. The eligibility criteria for the trial include having a confirmed malignant peripheral nerve sheath tumor, malignant schwannoma, or neurofibrosarcoma with measurable disease and no known current CNS metastases. Patients must also meet certain age and performance status requirements, have adequate hematopoietic, hepatic, renal, and ophthalmic function, and not have any gastrointestinal or other active disorders. Patients must not be pregnant or nursing, and fertile patients must use effective contraception. Patients must not have had any other malignancy within the past 5 years except for certain types of skin cancer or adequately treated stage I or II cancer currently in complete remission. Patients must also meet certain prior concurrent therapy requirements, including not having received any investigational drugs for this malignancy within the past 28 days and not having had any concurrent antiretroviral therapy for HIV-positive patients.",
    "The sample is a phase 2 clinical trial for patients with Stage IIIA or IIIB non-small cell lung cancer. The trial involves the use of induction and consolidation carboplatin and paclitaxel as treatment. The eligibility criteria include having measurable disease, positive mediastinal lymph nodes, a Zubrod performance status of 0-1, and meeting certain laboratory values. Patients must also be evaluated and accepted by thoracic surgery, medical oncology, and radiation oncology, and be a potential surgical candidate prior to the initiation of therapy. Exclusion criteria include having small cell lung cancer, distant metastatic disease, or bronchioalveolar carcinoma with lobar or multilobar involvement, among others. Patients must sign a study-specific informed consent prior to study entry.",
    "The sample is a phase 2 clinical trial for patients with advanced stage IV or unresectable stage III melanoma. The trial involves the use of drugs such as temozolomide, velban, cisplatin, interleukin-2, and thalidomide. The eligibility criteria include having measurable or evaluable sites of disease, being between 18 and 65 years old with an expected survival greater than 8 weeks, having normal blood counts and no impairment of renal or hepatic function, and having no significant intercurrent illness. Exclusion criteria include having brain and/or bone metastases only, significant cardiac or pulmonary illness, symptomatic effusions, and a history of deep vein thrombi or pulmonary embolism.",
    "This sample is for a phase 2 clinical trial for the treatment of chronic lymphocytic leukemia. The trial is testing the drugs rituximab and chlorambucil. The eligibility criteria for the trial include being an adult patient over 60 years of age, having CD20+ CLL, and not having received previous treatment for CLL. The trial also requires a performance status of 0-1 on the ECOG scale. The exclusion criteria include having co-morbid conditions requiring long-term use of systemic corticosteroids, a history of severe cardiac disease, and transformation to aggressive B-cell malignancy.",
    "The sample is a phase 2 clinical trial for the treatment of glioma, glioblastoma multiforme, and anaplastic astrocytoma. The trial involves the use of the drug ls11 (talaporfin sodium) and is intended for patients who are undergoing planned tumor resection and meet certain eligibility criteria. These criteria include having a right-sided, supratentorial frontal or temporal lobe tumor, right-hand dominance, a Karnofsky Performance Status score of over 70, and an estimated life expectancy of over 12 weeks. Patients must also have completed any prior antineoplastic therapy at least 4 weeks prior to surgery and be recovered from acute side effects. Exclusion criteria include having tumors less than 2 cm in diameter, inadequate organ function, concurrent participation in another clinical trial involving experimental treatment, and any concurrent diseases or conditions that could compromise compliance with the trial's objectives and procedures. Patients who are fertile must agree to use an effective method of contraception during participation in the study, and patients with a known sensitivity to porphyrin-type drugs or a known history of porphyria are also excluded.",
    "The sample is a phase 2 clinical trial for the treatment of persistent pulmonary hypertension and respiratory failure. The trial involves the use of intravenous sildenafil and has specific eligibility criteria for participants, including being at least 35 weeks gestation, having moderate hypoxemic respiratory failure, and not having any structural heart disease or lethal congenital anomaly. There are also exclusion criteria, such as prior or immediate need for iNO or ECMO, congenital heart disease, and active seizures. The trial requires signed informed consent from a legally acceptable guardian and prohibits the use of certain concurrent medications.",
    "The sample is a phase 2 clinical trial for patients with metastatic breast cancer. The trial involves the drug lapatinib and has eligibility criteria that include having previously used an anti-estrogen or aromatase inhibitor and having had a partial response or stable disease for at least 24 weeks before disease progression. Patients must also have adequate hematologic, hepatic, and renal function, and an estimated life expectancy of at least 6 months. Exclusion criteria include having received an investigational agent within the prior four weeks, having uncontrolled brain metastases or leptomeningeal disease, and having a serious illness or condition.",
    "The sample is a phase 2 clinical trial for the treatment of metastatic breast cancer using the drugs gemcitabine and cisplatin. The eligibility criteria include being a female between the ages of 18 and 75, having been diagnosed with metastatic breast cancer, having the ability to visit a medical site during treatment and follow-up, and signing an informed consent form. Exclusion criteria include being pregnant or breastfeeding, having laboratory parameters outside of the study's requirements, having a serious concomitant or acute infectious disease, and having used experimental medications within the last month. The diseases are listed as 'breast cancer' and the icd-10 codes associated with the disease are also provided.",
    "The sample is a record of a clinical trial in phase 2, which is focused on the treatment of biliary tract cancer. The trial involves the use of two drugs, gemcitabine and cisplatin. The eligibility criteria for the trial include having a histological or cytological diagnosis of biliary tract cancer, having at least one measurable lesion, being chemotherapy-na\u00efve, having an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1, and having an estimated life expectancy of no less than 3 months. The exclusion criteria include having radiological or clinical evidence of pulmonary fibrosis or interstitial pneumonia.",
    "The sample is a phase 2 clinical trial for patients with Type 2 Diabetes Mellitus who are treated with a stable dose of basal insulin with or without concomitant metformin and/or sulfonylurea. The trial involves testing the effectiveness of four different drugs, including a placebo, on patients with a glycosylated hemoglobin A1c level between >7.0% and \u226410%. The trial has specific inclusion and exclusion criteria, including age, BMI, and medical history. Patients with poorly controlled hyperglycemia, frequent hypoglycemic events, recent MI, stroke, or TIA, impaired hepatic or renal function, gastric surgery, cancer within the last 5 years, blood dyscrasias, treatment with other anti-diabetics, anti-obesity medications, steroids or thyroid hormones, participation in another trial with an investigational drug, pre-menopausal women on insufficient birth control, and alcohol or drug abuse are excluded from the trial.",
    "The sample is a record of a clinical trial with a phase 2 designation. The trial is focused on Crohn's disease, with the ICD-10 codes for the disease listed. The trial involves the use of drugs, including cp-690,550 and a placebo. The eligibility criteria for the trial are also listed, including age requirements, duration of Crohn's disease, and a specific Crohn's Disease Activity Index score range. The exclusion criteria are also listed, including current use of certain medications and evidence of certain disorders.",
    "The sample is a record of a clinical trial with a phase 2 designation. The trial is focused on pancreatic cancer and the icd-10 code associated with it is C25.3. The trial involves the use of drugs such as gemcitabine, erlotinib, and oxaliplatin. The eligibility criteria for the trial include having histologically confirmed pancreatic cancer, measurable disease, an ECOG Performance Status of 0-2, and adequate liver, kidney, and bone marrow function. Exclusion criteria include chronic diarrheic syndrome, uncontrolled brain metastases after radiation, liver infiltration over 50%, and peripheral neuropathy \u2265 2. Additionally, the trial excludes individuals with a second primary malignancy within the past 5 years, except non-melanomas skin cancer or in situ carcinoma of the cervix, those with active uncontrolled infection, and those with active cardiac disease. Women who are pregnant or lactating are also excluded from the trial.",
    "The sample is a phase 2 clinical trial for the treatment of lymphoma using a combination of drugs including cyclophosphamide, doxorubicin, prednisone, and vincristine. The eligibility criteria for the trial include a confirmed diagnosis of Waldenstrom's macroglobulinemia, measurable disease, impaired bone marrow function, and certain blood counts within a specific range. Patients must also have a certain performance status and be symptomatic with clinically significant anemia, bulky lymphadenopathy, or symptoms attributable to hyperviscosity. Patients with a history of heart disease are allowed only if certain criteria are met. There are also exclusion criteria, such as prior treatment for Waldenstrom's macroglobulinemia, prior anti-CD20 therapy, and active heart disease.",
    "The sample is a phase 2 clinical trial for patients with malignant mesothelioma, a type of cancer that affects the lining of the lungs, abdomen, or heart. The trial is testing the effectiveness of the drug dasatinib in treating the disease. Patients must have confirmed malignant mesothelioma and meet certain eligibility criteria, including having measurable disease and not being amenable to curative surgery. They must also have received prior treatment with one and only one systemic chemotherapy regimen that included pemetrexed disodium. Patients with symptomatic pleural effusions are not eligible unless they undergo a therapeutic thoracentesis. The trial also has specific patient characteristics that must be met, such as having an ECOG performance status of 0-1 and not having significant cardiac disease. Prior concurrent therapy is also restricted, such as at least 4 weeks since prior pemetrexed disodium-containing chemotherapy and at least 4 weeks since prior major surgery.",
    "The sample is for a phase 2 clinical trial for Alzheimer's disease. The trial includes the drugs lecozotan sr and donepezil. The eligibility criteria for the trial include a diagnosis of probable Alzheimer's disease according to the NINCDS-ADRDA criteria and the ability to give informed consent. Patients' caregivers must also consent to participate in the study. Exclusion criteria include the use of medications for cognitive enhancement within 3 months of baseline and significant neurologic disease other than Alzheimer's disease that may affect cognition. The icd-10 codes for the disease are also provided.",
    "The sample is a phase 2 trial for the treatment of diabetic gastroparesis. The trial includes patients between the ages of 18 and 80 with type 1 or type 2 diabetes mellitus and a history of gastroparesis symptoms for at least 3 months. The trial requires documented delayed gastric emptying and rules out upper gastrointestinal obstruction by endoscopy or barium scan. Patients must have stable concomitant medications for at least 2 weeks leading up to the screening visit and must maintain them during the study. Females of child-bearing potential must have a negative serum pregnancy test and use an acceptable form of contraception throughout the study. The trial excludes patients who have had gastrectomy, bariatric surgery, fundoplication, or vagotomy/pyloroplasty, or who have had endoscopic pyloric injections of botulinum toxin within 6 months prior to the screening visit or during the study. Patients with NG, PEG, or PEJ feeding tubes or inpatient hospitalization for gastroparesis within 2 weeks prior to the screening visit, or who have required parenteral nutrition for treatment of gastroparesis within 2 months prior to the screening visit, are also excluded. Patients with an active gastric pacemaker within 3 months prior to the screening visit are also excluded. The trial includes the drugs 10 mg tzp-102 and placebo.",
    "This sample is a phase 2 clinical trial for lung cancer. The trial is looking at the effectiveness of the drug sorafenib in treating patients with stage IIIB or stage IV cancer that is incompletely resected or unresectable. The eligibility criteria include being over 18 years old, having a life expectancy of more than 12 weeks, having biopsy-proven BAC or adenocarcinoma, and being willing to provide smoking status. The exclusion criteria include having an O2 saturation level below 88% on room air, being pregnant or nursing, having had surgery or radiation therapy within 4 weeks of starting the study, having a major heart condition within 6 months of starting therapy, and taking certain concomitant medications that are prohibited.",
    "The sample is a record from a clinical trial table that includes information about the trial's phase, diseases being studied, associated ICD-10 codes, drugs being used, and eligibility criteria for participants. In this particular sample, the trial is in phase 2 and is studying gastric cancer. The associated ICD-10 codes for the disease are listed, as well as the drugs being used in the trial. The eligibility criteria for participants are also listed, including requirements such as age, measurable disease, performance status, and adequate bone marrow reserves. The exclusion criteria are also listed, including patients who are receiving concurrent therapy, have brain or leptomeningeal metastases, or have major systemic diseases.",
    "The sample is a phase 2 clinical trial for the treatment of prostate cancer using a drug called tak-700. The trial is open to male patients who are 18 years or older and have a confirmed diagnosis of prostate adenocarcinoma without radiographic evidence of metastasis but with a rising PSA during or following the patient's most recent antineoplastic therapy despite castrate concentrations of testosterone. The patients must also meet certain eligibility criteria, including having a baseline PSA greater than or equal to 2 ng/mL and PSA doubling time less than or equal to 8 months, or a baseline PSA greater than or equal to 8 ng/mL if PSA doubling time is greater than 8 months. The trial has exclusion criteria, including known hypersensitivity to TAK-700 or related compounds, prior therapy with aminoglutethimide or ketoconazole, and current bladder neck outlet obstruction caused by prostate cancer, among others. The patients must also meet certain screening laboratory values as specified in the protocol. The trial requires voluntary written consent from the patients.",
    "The sample is a phase 2 clinical trial for individuals with a history of physician-diagnosed and treated asthma for at least 3 months, who have presented with an acute exacerbation of asthma at the emergency department. The trial aims to test the effectiveness of MN-221, a drug that is being compared to a placebo and other dose groups. The eligibility criteria include having a FEV1 (forced expiratory volume in one second) of 55% or less within 10 minutes of completing the treatment provided at the ED, having no clinical or electrocardiographic signs of ischemic heart disease, and signing the informed consent. The exclusion criteria include having a current or prior diagnosis of COPD or other chronic lung disease, presence of pneumonia or other respiratory dysfunction, history or presence of tachyarrhythmias, and significant cardiac, renal, hepatic, endocrine, metabolic, neurologic or other systemic disease. The sample also includes a list of diseases, icd-10 codes, and drugs being tested.",
    "The sample is a record from a clinical trial table that includes information about the trial's phase, diseases being studied, associated ICD-10 codes, drugs being tested, and eligibility criteria for participants. In this particular sample, the trial is in phase 2 and is studying postherpetic neuralgia and pain. The associated ICD-10 codes for the diseases being studied are also listed. The drug being tested is a transdermal patch containing bupivacaine, and the eligibility criteria for participants include having pain in the thoracic or lumbar regions for at least 90 days after crusting of Herpes Zoster lesions, being over 21 years old, having intact skin over the painful area, and having a BMI no higher than 35 kg/m2. There are also exclusion criteria listed, such as having active HZ lesions or any immunosuppressed condition, recent use of certain pain medications, and participation in another clinical trial within 30 days of the screening visit.",
    "The sample is a phase 2 clinical trial for the treatment of bipolar disorder, bipolar depression, and depression. The trial involves the use of ziprasidone (geodon) and placebo drugs. The eligibility criteria for the trial include a diagnosis of bipolar disorder type II or unipolar major depressive disorder, meeting DSM-IV criteria for a major depressive episode, and presence of 2 or 3 DSM-IV manic criteria. Other baseline psychotropic drugs are allowed to be continued unchanged, but if antidepressant use has been initiated in the previous 2 months or was thought to be contributing to the depressive mixed state, then antidepressant medications would be discontinued 4 weeks before starting the study. The trial is open to sexually active females of reproductive potential who are using adequate contraception and are non-pregnant/non-lactating.",
    "The sample is a record of a clinical trial with a phase 2 designation. The trial is focused on two diseases, hemostasis and oral contraceptive, and includes a list of corresponding ICD-10 codes. The trial involves testing three different types of oral contraceptives: a 91-day levonorgestrel oral contraceptive, a 28-day levonorgestrel oral contraceptive, and a 28-day desogestrel oral contraceptive. The eligibility criteria for participants include being premenopausal, non-pregnant, non-lactating women between the ages of 18 and 40 with a BMI between 18 and 30 kg/m\u00b2 and a regular menstrual cycle. The exclusion criteria include any condition that contraindicates the use of combination oral contraceptives, a history of or active deep vein thrombosis, pulmonary embolism, or arterial thromboembolic disease within one year of screening, and any known genetic component for thrombophilia. Other criteria may also be dictated by the FDA-approved protocol.",
    "The sample is a record of a clinical trial with a phase 2 designation. The trial is focused on treating two types of cancer, specifically renal cell carcinoma. The trial involves the use of several drugs, including recombinant interleukin-21 and sunitinib. The eligibility criteria for the trial include having stage IV renal cell carcinoma that is incurable through surgery, having a good performance status, and having a life expectancy of at least 3 months. Exclusion criteria include having received prior systemic therapy for metastatic disease, having received radiotherapy within the last 4 weeks prior to treatment, having received any investigational drug within 3 months of starting treatment, and having a history of any other active malignancy within five years prior to enrollment.",
    "The sample is a phase 2 clinical trial for patients with metastatic prostate cancer who have previously been treated with ketoconazole for castration-resistant prostate cancer. The trial is testing the effectiveness of abiraterone acetate as a treatment option. The eligibility criteria include confirmation of adenocarcinoma of the prostate, evidence of progression on ketoconazole or grades 3/4 toxicities on ketoconazole, ongoing gonadal androgen deprivation therapy, and a testosterone level of less than 50 ng/dL. Patients must also have a life expectancy of more than 12 weeks and meet certain health criteria such as controlled blood pressure and serum potassium levels. Exclusion criteria include prior radiation therapy completed less than 4 weeks prior to enrollment, prior chemotherapy for castration-resistant prostate cancer, and serious intercurrent infections or uncontrolled medical illnesses.",
    "The sample is a phase 2 clinical trial for the treatment of glaucoma and ocular hypertension. The trial involves testing the effectiveness of three different drugs, including 0.25% ar-12286 / 0.004% travoprost and 0.5% ar-12286, 0.004% travoprost, on patients who meet certain eligibility criteria. These criteria include being 18 years or older, having a diagnosis of open angle glaucoma or ocular hypertension, and having unmedicated intraocular pressure of at least 24 mm Hg at two eligibility visits. Patients must also have corrected visual acuity of +1.0 logMAR or better by ETDRS in each eye and be willing to give informed consent and follow study instructions. Exclusion criteria include a history of certain ocular conditions, hypersensitivity to the drugs being tested, and certain systemic diseases. Women of childbearing potential must have a negative pregnancy test and not intend to become pregnant during the study.",
    "The sample is a phase 2 clinical trial for chronic lymphocytic leukemia using the drug alemtuzumab. The eligibility criteria include having CLL requiring treatment, being refractory to a previous fludarabine-containing regimen or having 17p deletion, being at least 18 years old, having a performance status of 0, 1 or 2, and having recovered from previous chemotherapy and/or immunotherapy. Exclusion criteria include having received more than five different prior therapeutic regimens, having major organ dysfunction, having active infection, having involvement of the central nervous system, being known to be positive for HIV, having previously been treated with alemtuzumab, and having received autologous or allogeneic SCT within the past six months. The sample also includes additional criteria for exclusion such as having a history of drug or alcohol abuse that might lead to inability to comply with the protocol.",
    "The sample is a phase 2 clinical trial for the treatment of acute lymphoblastic leukemia and lymphoblastic lymphoma using asparaginase erwinia chrysanthemi. The trial is open to patients between the ages of 1 and 30 who have been diagnosed with either of the two diseases and are currently undergoing asparaginase treatment. To be eligible, patients must have had a Grade 2 or higher hypersensitivity reaction to native or pegylated E. coli asparaginase or Calaspargase pegol, and must have at least two weeks of native E. coli asparaginase treatment or one remaining dose of either Pegaspargase or Calaspargase pegol. Patients must also have normal levels of amylase and lipase, and a direct bilirubin less than or equal to Grade 2. Patients who are 18 years or older must provide signed informed consent, while parents must provide consent for patients younger than 18 years old. There are no exclusion criteria listed.",
    "The sample is a phase 2 clinical trial for kidney cancer patients. The trial is testing the drug everolimus. The eligibility criteria for the trial include having advanced (metastatic) RCC with clear cell, papillary or chromophobe histology, and at least one measurable metastatic site that has not been previously irradiated. Patients must also be deemed surgical candidates for cytoreductive nephrectomy by the urologist and have adequate bone marrow, liver, and renal function. Exclusion criteria include CNS or leptomeningeal metastases, severe and/or uncontrolled medical conditions, and prior systemic anticancer therapies. Patients must also not have a history of HIV seropositivity or hepatitis C seropositivity, and must not be pregnant or breastfeeding.",
    "The sample is a phase 2 clinical trial for the treatment of chronic moderate to severe plaque psoriasis. The trial involves the use of drugs such as tofacitinib and placebo. The eligibility criteria for the trial includes being an adult over 18 years of age, having a diagnosis of chronic moderate to severe plaque psoriasis for at least 12 months, being in generally good health, and being on a stable dose of non-prohibited medications. Exclusion criteria includes having serious underlying diseases such as viral disorders or skin conditions that would interfere with skin biopsies or evaluation of psoriasis, conditions that could interfere with drug absorption after oral administration, and a history of malignancy or auto-immune disease. The use of oral or injected corticosteroids is also prohibited.",
    "The sample is a phase 2 clinical trial for patients with type 2 diabetes mellitus. The trial is testing the effectiveness of ranolazine compared to a placebo. The eligibility criteria include having a stable non-insulin antidiabetic therapy, a BMI between 25 and 40 kg/m^2, and an HbA1c level between 7 and 11%. Participants must also be willing to maintain a complete and accurate Subject Activity Log and use effective contraception if female and of child-bearing potential. Exclusion criteria include having type 1 diabetes mellitus, a history of insulin therapy, or clinically significant complications of diabetes. Other exclusion criteria include recent cardiovascular events, inadequately controlled hypertension, recent hospitalization or major surgery, and recent use of weight loss medication.",
    "The sample is a phase 2 clinical trial for patients with either stage I, II, or IIIa non-small cell lung cancer or stage I or II head and neck squamous cell carcinoma who have undergone complete surgical resection or definitive local treatment. The trial involves taking the drug celecoxib daily and undergoing bronchoscopy and endobronchial biopsy for biomarker studies. Participants must meet certain eligibility criteria, such as having a smoking history of at least 10 pack years, having no evidence of residual cancer, and having a performance status of <= 2 (Zubrod). They must also not have certain contraindications, such as active pulmonary infections or a history of ulcers requiring prophylactic H2 blockers. Exclusion criteria include a history of radiation therapy to the chest, systemic chemotherapy, and pregnancy or breastfeeding.",
    "The sample is a phase 2 clinical trial for the treatment of type 2 diabetes mellitus. The trial involves the use of drugs such as amg 151 and metformin, as well as a placebo. The eligibility criteria for the trial include being between the ages of 18 and 75, having a diagnosis of type 2 diabetes mellitus, and having HbA1c levels between 7.5% and 11.0%. In addition, participants must have a BMI between 25 and 45 kg/m2 and have been treated with metformin monotherapy for at least 3 months prior to randomization. Exclusion criteria include a history of type 1 diabetes, significant weight gain or loss, and the use of any weight loss medication within 60 days of randomization. Participants must also not have used any oral or injectable anti-hyperglycemic medication (other than metformin) within 3 months prior to randomization.",
    "The sample is a phase 2 clinical trial for patients with metastatic or recurrent head and neck cancer who have experienced progression after receiving cisplatin, cetuximab, and taxanes. The trial is testing the effectiveness of the drug cabazitaxel. The eligibility criteria include having at least one measurable lesion on CT-scan, adequate hematologic, renal, and hepatic function, and a life expectancy of at least 3 months. Patients must also be willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures. Exclusion criteria include active concurrent malignancy, severe and/or uncontrolled medical disease, and hypersensitivity to cabazitaxel or other taxanes. Patients must have recovered from previous toxicity of chemotherapy and must not have toxicity grade > 1. The trial prohibits concurrent or planned treatment with strong inhibitors or strong inducers of cytochrome P450 3A4/5.",
    "The sample is a record of a clinical trial that is in phase 2/phase 3. The trial is focused on the disease of dry eye and the icd-10 codes associated with it. The drug being tested is carboxymethylcellulose sodium and glycerin. The eligibility criteria for the trial includes having mild, moderate, or severe dry eye symptoms and currently using eye drops, as well as having reduced tear stability or production. There are no exclusion criteria listed for this particular sample.",
    "This is a sample from a table that contains information about clinical trials. The trial is in phase 2 and is focused on chronic lymphocytic leukemia. The trial involves the use of two drugs, abt-263 and rituximab. The eligibility criteria for the trial include being previously untreated for the disease, having an ECOG performance status of 0 or 1, having a life expectancy of more than 6 months, and being willing and capable of being accessible for follow-up until study termination or death. There are also exclusion criteria, such as having a history of other malignancies within 2 years prior to study entry, prior treatment with rituximab or ABT-263, and having clinically significant cardiovascular disease.",
    "The sample is a phase 2 clinical trial for the drug \"neu-p11\" to treat primary insomnia. The trial is looking for male or female participants aged 18-80 who meet specific criteria, including having a reported subjective sleep latency of at least 30 minutes on at least three nights per week for at least one month and subjective WASO of at least 45 minutes per night on at least 3 nights per week for at least one month. Participants must also not have been using benzodiazepine (BZD) and non-BZD hypnotics or melatoninergic drugs for the past 2 weeks or more prior to screening, and have not been using psychotropic treatments for the past 3 months or more prior to screening. The trial also has exclusion criteria, such as subjects suffering from insomnia secondary to other causes according to the sleep history questionnaire and use of psychotropic treatments for the past 3 months and during the study. Participants will be admitted into a sleep lab and will continue to the double-blind treatment phase if polysomnography (PSG) results meet specific criteria.",
    "The sample is a record of a clinical trial in phase 2, focused on the disease of dyspepsia. The trial includes the drug z-338 and has a list of eligibility criteria for participants. The criteria include having a positive diagnosis of functional dyspepsia via RomeII criteria and experiencing three or more moderate symptoms of gastrointestinal score. Participants must also have no history of functional dyspepsia and pass a clinical assessment, physical examination, and laboratory testing without evidence of relevant abnormality. Other inclusion and exclusion criteria may also apply.",
    "The sample is a phase 2 clinical trial for patients with hepatocellular carcinoma. The trial involves the use of oxaliplatin, fluorouracil, and leucovorin as treatment options. The eligibility criteria include having confirmed hepatocellular carcinoma, measurable disease by CT scan, not having received previous palliative systemic chemotherapy for metastatic disease, and having adequate organ and marrow function. Exclusion criteria include allergies to platinum compounds or other study drugs, active gastrointestinal bleeding or hematologic malignancy, previous liver transplantation, and receiving any other anti-cancer therapy. The trial is not suitable for pregnant or lactating women or those with serious illnesses or medical conditions. The information provided is not exhaustive and other considerations may be relevant for potential participants.",
    "The sample is a phase 2 clinical trial for patients with non ST-elevation myocardial infarction. The trial is testing the effectiveness of the drugs ro4905417 and placebo. The eligibility criteria include being an adult between the ages of 18 and 75, having a BMI of 40 kg/m2 or less, and not having had a STEMI or certain other medical conditions or procedures within a certain time frame. Women of childbearing potential must be using two acceptable methods of contraception. Exclusion criteria include bleeding disorders, inadequately controlled severe hypertension, and uncontrolled diabetes mellitus.",
    "The sample is a phase 2 clinical trial for the treatment of subarachnoid hemorrhage, cerebral vasospasm, and rupture of intracranial aneurysm. The trial involves the use of drugs such as placebo and sildenafil citrate in varying dosages. The eligibility criteria for the trial include being between 20 and 80 years old, having confirmed subarachnoid hemorrhage with specific criteria, having an aneurysm detected through imaging, and undergoing surgery within 72 hours of the event. Exclusion criteria include refusal to participate, hemodynamic instability, previous cardiac ischemic disease, and hypersensitivity to sildenafil.",
    "The sample is a phase 2 clinical trial for the treatment of sarcoma, a type of cancer. The trial is testing the effectiveness of the drug ifosfamide on patients with high-risk osteosarcoma, which includes those with recurrent disease, refractory to conventional therapy, newly diagnosed metastatic disease with multiple bone lesions or \u2265 4 pulmonary nodules, or unresectable primary tumor. Patients must have measurable disease by technetium Tc 99m diphosphonate bone scan and be refractory to all standard therapies or highly unlikely to respond to conventional treatment. They must also have a Karnofsky performance status of 60-100%, a life expectancy of more than 8 weeks, and meet certain blood count and kidney function criteria. Patients who are pregnant or nursing, have had prior radiotherapy to the site of currently active disease, or are enrolled in another protocol are excluded from the trial.",
    "The sample is a phase 2 clinical trial for chronic obstructive pulmonary disease (COPD) patients. The trial involves administering various drugs, including carmoterol and salmeterol, as well as a placebo. The eligibility criteria for the trial include being between the ages of 40-75, having a smoking history of at least 15 pack-years, and meeting certain FEV1 requirements. Patients with a history of asthma, allergic rhinitis, or atopy, as well as those with certain other medical conditions, are excluded from the trial. The trial also excludes pregnant or lactating females, those with mental or legal incapacitation, and those who have participated in another investigational study within 30 days prior to screening.",
    "The sample is a phase 2 clinical trial for the treatment of rheumatoid arthritis. The trial includes patients who have been diagnosed with rheumatoid arthritis for at least 4 months and have had an inadequate response to methotrexate treatment. The trial medication, CNTO 136, is being tested against a placebo and methotrexate. Patients must have active rheumatoid arthritis with at least 6 swollen and 6 tender joints, and either anti-cyclic citrullinated peptide antibody-positive or rheumatoid factor positive at screening. They must also have a C-reactive protein level greater than or equal to 1.0 mg/dL and agree to use contraception during the trial. Patients with certain medical conditions or who have received certain treatments within a certain timeframe are excluded from the trial.",
    "The sample is a phase 2 clinical trial for advanced epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer. The trial is testing the drug iniparib and has specific eligibility criteria for participants, including confirmed BRCA1 or BRCA2 status, at least one previous regimen with platinum/taxane combination therapy, and measurable lesions. The trial also has exclusion criteria, such as normal clinical laboratory values, any anti-cancer therapy within 21 days prior to study start, and active viral infections. The sample includes both inclusion and exclusion criteria for potential participants.",
    "The sample is a phase 2 clinical trial for chronic hepatitis C. The trial includes patients who have never been treated for Hepatitis C Viral (HCV) infection and have no clinically significant lab abnormalities. The trial also requires patients to have a certain amount of HCV Ribonucleic acid (RNA) in their blood and have undergone a liver biopsy or \"Fibroscan\" test within the past 3 years. Patients with liver cirrhosis or decompensated liver disease, any evidence of significant liver disease in addition to Hepatitis C, or who are infected with Human Immunodeficiency Virus (HIV) or Hepatitis B are excluded from the trial. Women who are pregnant, planning to be pregnant, or breastfeeding, or the partner of a woman who is pregnant or breastfeeding are also excluded. The trial involves the use of several drugs, including telaprevir, peg-ifn-alfa-2a, peg-ifn-alfa-2b, ribavirin (rbv) tablet, and ribavirin (rbv) capsule.",
    "The sample is a record of a clinical trial with a phase 2 designation. The trial is focused on chronic hepatitis C infection and hepatitis C virus, with a list of associated ICD-10 codes. The trial is testing the effectiveness of four drugs: abt-450, abt-333, ribavirin, and ritonavir. The eligibility criteria for participants include being treatment naive or a partial responder to previous treatment with peginterferon and ribavirin, having a body mass index between 18 and 35 kg/m^2, and being between the ages of 18 and 65. Females must be postmenopausal for at least 2 years or surgically sterile. Exclusion criteria include cirrhosis or extensive bridging fibrosis, history of cardiac disease, positive screen for certain drugs or alcohol, abnormal laboratory results, significant sensitivity to any drug, positive hepatitis B surface antigen or anti-human immunodeficiency virus antibody, and use of strong cytochrome P450 3A (CYP3A), cytochrome P450 2C8 (CYP2C8), and organic anion transporting polypeptide 1B1 (OATP1B1) enzyme inducers or inhibitors within 1 month of dosing.",
    "The sample is a phase 2 clinical trial for the treatment of hepatocellular carcinoma and fibrolamellar hepatocellular carcinoma using the drug Sutent. The trial has specific eligibility criteria, including the availability of tumor tissue for analysis, a WHO performance status of 2 or less, and adequate organ function. There are also exclusion criteria, such as hypersensitivity to Sutent and a history of brain metastases. The sample includes a list of diseases and their corresponding ICD-10 codes, as well as the eligibility criteria for the trial.",
    "The sample is a phase 2 clinical trial for patients with rheumatoid arthritis. The trial is testing the effectiveness of fostamatinib disodium (r935788) compared to a placebo. Patients must have had active RA for at least 12 months prior to the start of the trial and must have failed biologic therapy with an inhibitor of TNF, rituximab, abatacept, or anakinra. Patients may receive stable doses of certain medications, including methotrexate, but must not have changed their dose for at least 30 days prior to the start of the trial. Female patients of childbearing potential must use a reliable method of birth control during the trial. Patients must be in good health and must not have a history of certain illnesses or medical conditions. Patients with a history of substance abuse, drug addiction, or alcoholism are also excluded from the trial.",
    "The sample is a phase 2 clinical trial for patients with unresectable stage 3 or 4 melanoma. The trial is testing the effectiveness of two drugs, docetaxel and azd6244, compared to docetaxel and a placebo. The eligibility criteria include being at least 16 years old, having a wt BRAF status for their melanoma, having at least one measurable lesion, and having a life expectancy of at least 12 weeks. The trial also has exclusion criteria, such as having any unresolved toxicity from prior anti-cancer therapy greater than CTCAE grade 2, being pregnant or breastfeeding, and having clinically significant and uncontrolled major medical conditions.",
    "The sample is a phase 2 clinical trial for participants with primary hypercholesterolemia. The trial includes participants who are receiving a lipid-lowering treatment other than atorvastatin or not at a stable dose of atorvastatin 10 mg, 20 mg, or 40 mg for at least 6 weeks prior to the screening period, or drug-naive participants likely to have low-density lipoprotein cholesterol (LDL-C) \u2265 100 mg/dL (\u2265 2.59 mmol/L) at the end of the 6-week run-in treatment period on atorvastatin therapy. Alternatively, participants with primary hypercholesterolemia treated with atorvastatin at a stable dose of 10 mg, 20 mg, or 40 mg for at least 6 weeks prior to the screening period and likely to have LDL-C \u2265 100 mg/dL (\u2265 2.59 mmol/L) at the screening visit are also included. The trial excludes participants with LDL-C < 100 mg/dL (< 2.59 mmol/L), those not previously instructed on a cholesterol-lowering diet, participants with type 1 diabetes, participants with type 2 diabetes treated with insulin, participants with type 2 diabetes and with a glycated hemoglobin (HbA1c) \u2265 8.5% at the screening visit, and pregnant or breastfeeding women. The trial also excludes women of childbearing potential with no effective contraceptive method. The eligibility criteria for the trial are provided in detail.",
    "The sample is a record of a clinical trial with a phase 2 designation. The trial is focused on diabetic nephropathies, which are identified by a list of ICD-10 codes. The trial involves two drugs, pf-00489791 and placebo. The eligibility criteria for the trial include being 18 years or older, having a clinical diagnosis of type 2 diabetes with stages 3a, 3b or 4 CKD, and evidence of persistent, overt albuminuria. The exclusion criteria include having CKD resulting from type 1 diabetes or non-diabetic CKD, poorly controlled diabetes mellitus, and being on combination ACE inhibitor/ARB therapy.",
    "The sample is a phase 2 clinical trial for patients with chronic hepatitis C who have failed to respond to previous treatment with peginterferon and ribavirin. The trial is testing the effectiveness of nitazoxanide and ribavirin compared to a placebo. The eligibility criteria include having chronic hepatitis C genotype 1 and meeting certain health requirements, while exclusion criteria include pregnancy, liver disease from other causes, and certain medical conditions. The sample includes a list of diseases, ICD-10 codes, drugs, and eligibility criteria for the trial.",
    "The sample is a phase 2 clinical trial for breast cancer patients who are candidates for adjuvant chemotherapy and Trastuzumab. The trial is looking for female patients between the ages of 18 and 65 with histologically proven stage I, II or III adenocarcinoma of the breast and HER-2 positive breast cancer. The trial is testing the effectiveness of the drug paclitaxel. The eligibility criteria include adequate bone marrow, kidney, and hepatic function, as well as a negative pregnancy test and adequate cardiac function. Exclusion criteria include prior HER-2 targeted therapy, metastatic disease, uncontrolled intercurrent illness, and active cardiac disease. The trial requires patients to sign informed consent and undergo baseline mammogram, bone scan, CT chest and abdomen within 60 days of registration.",
    "The sample is a record of a clinical trial with a phase 2 designation. The trial is focused on two types of cancer: ovarian carcinoma and breast cancer. The diseases are identified by their respective ICD-10 codes. The trial is testing the effectiveness of a drug called azd2281. The eligibility criteria for participants are listed, including the requirement of a confirmed diagnosis of high grade serous and/or undifferentiated carcinoma of the ovary, fallopian tube, or peritoneum, or a negative advanced adenocarcinoma of the breast for estrogen, progesterone, and HER2. Participants must also have a performance status of no more than 2. There are also exclusion criteria listed, such as not having undergone chemotherapy, radiotherapy, endocrine or immunotherapy within 4 weeks prior to entry, and not having had major surgery within 4 weeks of entering the study.",
    "The sample is a phase 2 clinical trial for patients with lower limb amputation stumps and moderate-to-severe pain. The trial involves the use of strontium chloride hexahydrate and a placebo drug. The eligibility criteria include being an outpatient aged 18 years and above, having written informed consent, and meeting certain pain intensity requirements. Exclusion criteria include recent use of potent opioids, dissatisfaction with prosthesis comfort, pregnancy or breastfeeding, and documented or suspected alcohol or drug abuse.",
    "The sample is a phase 2 clinical trial for the treatment of anemia. The trial includes patients who have been admitted to the ICU due to a blunt multi-system traumatic injury and have sustained a leg or pelvic fracture. The patients must be between the ages of 18 and 55 and have a hemoglobin level of 12g/dL or less at the time of study entry. The trial involves the use of two drugs, Procrit and placebo. The eligibility criteria include various medical and demographic factors, such as Glasgow Coma Scale score, ability to function independently, and literacy in the patient's native language. The exclusion criteria include factors such as acute burns, traumatic brain injury, and chronic renal failure on dialysis. The trial also excludes patients who have received experimental drugs or medical devices within 30 days prior to the planned start of treatment.",
    "The sample is a phase 2 clinical trial for breast cancer patients who have undergone surgery within the past 60 days. The trial includes patients with invasive adenocarcinoma of the breast or inflammatory breast cancer, with axillary lymph node dissection. Patients must have HER2/neu positive or negative tumors and be either chemotherapy na\u00efve or have received prior chemotherapy more than 5 years ago. Patients who are to receive trastuzumab must have normal cardiac function. The trial has inclusion and exclusion criteria, including adequate bone marrow, liver, and renal function, and patients of childbearing potential must use an effective method of contraception. The trial does not permit concurrent treatment with any other anti-cancer therapy and excludes patients with significant psychiatric disorders, active, uncontrolled infection, or any other diseases or conditions that contraindicate the use of an investigational drug.",
    "The sample is a phase 2 clinical trial for patients with advanced colorectal cancer or adenocarcinoma of the colon or rectum. The trial involves the use of drugs such as abt-869, bevacizumab, oxaliplatin, folinic acid, and fluorouracil. The eligibility criteria include being 18 years or older, having received one prior chemotherapy regimen containing irinotecan or a fluoropyrimidine for locally recurrent or metastatic colon or rectal cancer, and having measurable disease by RECIST criteria. Exclusion criteria include having received more than one prior therapy in the metastatic setting, having received cytotoxic chemotherapy within 21 days prior to Study Day 1, and having a history of hypersensitivity to certain drugs.",
    "The sample is a phase 2 clinical trial for chronic low back pain. The trial is testing the effectiveness of naproxen, placebo, and pf-04383119 (rn624) drugs. The trial is open to both male and female participants of any race who are over 18 years old and have a BMI of 39 kg/m2 or less. The participants must have been experiencing chronic low back pain for at least 3 months and require regular use of analgesic medication. The primary location of the low back pain must be between the 12th thoracic vertebra and the lower gluteal folds, with or without radiation into the posterior thigh. The participants must have a score of at least 4 for Low Back Pain Intensity (NRS) while on current treatment at Screening, and complete at least 4 daily pain diaries during the 5 days prior to Randomization, with an average Low Back Pain Intensity (NRS) score of at least 4. There are also exclusion criteria, such as back pain due to visceral disorder or recent major trauma, history of lumbosacral radiculopathy, spinal stenosis associated with neurological impairment, or neurogenic claudication, among others.",
    "The sample is a phase 2 clinical trial for the treatment of atopic dermatitis. The trial involves the use of drugs such as jnj-39758979 (in 100mg and 300mg doses) and a placebo. The eligibility criteria for the trial include a diagnosis of atopic dermatitis based on specific criteria, childhood onset of the disease, moderate severity of the condition, and a certain level of itching. Patients with certain medical conditions or who have used certain medications within a certain timeframe are excluded from the trial. The trial aims to assess the effectiveness of the drugs in treating atopic dermatitis.",
    "The sample is a phase 2 clinical trial for patients with stage IV malignant melanoma that has spread to the central nervous system and is unresectable. The trial is testing the effectiveness of the drug temozolomide. Patients must meet certain eligibility criteria, including having no evidence of metastatic disease outside of the CNS, a Karnofsky performance status of 70-100%, and certain hematopoietic, hepatic, and renal levels within normal ranges. Patients must also not have any concurrent uncontrolled infections or other malignancies within the past 5 years, and must not have any prior allergy or intolerance to dacarbazine or hypersensitivity to temozolomide or any of its components. Prior biologic and immunotherapy must have been completed more than 4 weeks prior to the trial, and prior chemotherapy must have been completed more than 4 weeks prior (6 weeks for mitomycin or nitrosoureas) and the patient must have recovered. Concurrent steroids are allowed if the dose has been stable for at least 7 days prior to CNS imaging. Prior radiotherapy must have been completed more than 4 weeks prior, and patients must not have had prior radiotherapy to more than 15% of the bone marrow or to the head and neck area, or prior radiosurgery.",
    "The sample is a record from a table that contains information about clinical trials. The record includes the phase of the trial, which is a combination of phase 2 and phase 3. The diseases being studied are type 2 diabetes and dyslipidemia, and their corresponding ICD-10 codes are listed. The drugs being tested are fenofibrate, metformin, and placebo. The eligibility criteria for the trial are also provided, including inclusion criteria for patients with type 2 diabetes and dyslipidemia, and exclusion criteria for patients with type 1 diabetes.",
    "The sample is a phase 2 clinical trial for esophageal cancer. The trial is looking for patients with stage I-III squamous cell carcinoma or adenocarcinoma of the esophagus and gastro-esophageal junction. The trial is testing the effectiveness of cisplatin, fluorouracil, hydroxyurea, and leucovorin calcium as treatments. Patients must meet certain eligibility criteria, including having measurable disease, a certain level of white blood cells, granulocyte count, and platelet count, and no serious cardiovascular disease or prior or concurrent malignancy within the past 5 years. Patients must not have had prior chemotherapy, radiotherapy, or surgery.",
    "The sample is a phase 2 clinical trial for the treatment of malignant mesothelioma, a type of cancer. The trial involves the drug trabectedin and has eligibility criteria for patients, including confirmation of the disease, measurable lesions, and certain health parameters such as blood counts and liver function. Patients must also not have certain medical conditions or be pregnant or nursing. Prior treatments are also taken into consideration, with restrictions on prior chemotherapy and radiotherapy. The trial does not allow concurrent treatment for other neoplastic diseases or experimental anticancer medication.",
    "The sample is a phase 2 clinical trial for patients with chronic kidney disease and anemia. The trial is testing the drug FG-4592. The inclusion criteria for the trial include being between the ages of 18 and 75, having chronic kidney disease but not receiving dialysis, and having a body weight between 45 and 140 kg. The exclusion criteria include having a clinically significant infection or evidence of an underlying infection, having certain viruses or chronic liver disease, having congestive heart failure or recent heart issues, having a history of certain diseases or disorders, and having a history of alcohol or drug abuse.",
    "The sample is a phase 2 clinical trial for non-small cell lung cancer. The trial involves the use of two drugs, paclitaxel (genexol\u00ae) and paclitaxel loaded polymeric micelle (genexol-pm\u00ae). The eligibility criteria for the trial include having locally advanced, metastatic or recurrent NSCLC, having at least one measurable lesion, not having received previous palliative chemotherapy, being 18 years or older, having an ECOG PS score of 0-2, having a life expectancy of at least 3 months, and having adequate hematologic, hepatic, renal, and bone marrow function. The trial also has exclusion criteria, such as not having received prior chemotherapy for NSCLC, having peripheral neuropathy \u2265 grade 2, having clinically significant cardiac disease, having an active infection or other serious medical illness, having a contraindication to any drug contained in the chemotherapy regimen, and being pregnant or lactating.",
    "The sample is a phase 2 clinical trial for patients with previously untreated diffuse large B-cell lymphoma. The trial involves the use of bendamustine and rituximab drugs. The eligibility criteria include being over 65 years old, having stage II-IV disease, measurable disease, and an ECOG performance status of 0-3. Patients must also have a life expectancy of at least 3 months and meet certain laboratory criteria. Exclusion criteria include central nervous system involvement by lymphoma, history of previous allergic reactions to compounds of similar biological or chemical composition as rituximab or bendamustine, and other active malignancies. The trial requires patients to sign an institutional review board (IRB) approved informed consent document.",
    "The sample is a phase 2 clinical trial for the treatment of overactive bladder. The trial involves the use of drugs such as vibegron and tolterodine er, as well as placebo medications. The eligibility criteria for participants include having a clinical history of overactive bladder for at least 3 months, being able to read and complete questionnaires without assistance, and having no significant medical abnormalities. Exclusion criteria include pregnancy or breastfeeding, certain medical conditions, and recent surgeries. Participants must also agree to use birth control if of reproductive potential.",
    "The sample is a record from a clinical trial table that includes information about the trial's phase, diseases being studied, icd-10 codes of the diseases, drugs being tested, and eligibility criteria for participants. In this particular sample, the trial is in phase 2/phase 3 and is focused on Huntington's disease. The icd-10 code for Huntington's disease is 'G10'. The drugs being tested are minocycline and a matching placebo. The eligibility criteria for participants include being 18 years or older, having clinical features of HD and a confirmatory family history of HD, being able to walk independently and perform daily activities, and being able to take medication by mouth. Exclusion criteria include a history of hypersensitivity or intolerance to minocycline or any tetracycline, vestibular disease, underlying hematologic, hepatic or renal disease, and systemic lupus erythematosus (SLE).",
    "The sample is a phase 2 clinical trial for patients with metastatic melanoma. The trial is testing the effectiveness of the drugs paclitaxel, carboplatin, and everolimus. The eligibility criteria include having confirmed metastatic melanoma that is not amenable to resection, measurable disease, and an ECOG Performance Status of 0 or 1. Patients must also have adequate hematological, renal, and hepatic function, and be able to understand and give written informed consent. Exclusion criteria include previous treatment with certain drugs, receiving anticancer therapies within a certain timeframe, and having certain medical conditions or diseases. The trial is investigating the safety and efficacy of the drugs in treating metastatic melanoma.",
    "The sample is a phase 2 clinical trial for patients with chronic hepatitis C, genotype 1 or 4, who are between 18 and 65 years old. The trial has two cohorts: one for treatment-na\u00efve patients and one for prior null responders to treatment with approved doses of pegylated interferon plus ribavirin. Patients must have liver biopsy confirming cirrhosis and compensated cirrhosis (Child-Pugh A). The trial excludes pregnant or lactating women or male partners of pregnant women, patients with decompensated liver disease, patients who discontinued previous pegylated interferon plus ribavirin treatment due to reasons other than null response, and patients with a history of clinically significant cardiovascular or cerebrovascular disease. The trial will test the efficacy of a combination of drugs including ro5024048, danoprevir, peginterferon alfa-2a [pegasys], ribavirin, and ritonavir.",
    "The sample is a phase 2 trial for breast cancer patients with a palpable tumor size of at least 2 cm. The trial requires patients to have stages of disease in which adjuvant chemotherapy would be considered. Patients must also have a Karnofsky Performance status index of at least 80%, normal cardiac function, and meet certain laboratory requirements. Exclusion criteria include evidence of distant metastasis, prior chemotherapy or radiation therapy for breast cancer, pre-existing motor or sensory neuropathy of a severity greater than or equal to grade 2, and concurrent treatment with certain medications. Patients must also not have any other serious illness or medical condition. The trial requires a complete staging work-up within 3 months prior to registration and patients must be available and compliant for treatment and follow-up.",
    "The sample is a phase 2 clinical trial for patients with unresectable esophageal cancer, including the gastroesophageal junction. The trial is testing the effectiveness of the drug combination of docetaxel and cisplatin. The eligibility criteria include confirmed esophageal cancer, meeting certain staging criteria, and having a performance status of WHO 0-1. Patients must also meet certain hematopoietic, hepatic, renal, cardiovascular, and immunologic criteria, and cannot have certain medical conditions or prior treatments. The trial does not allow concurrent experimental drugs.",
    "The sample is a phase 2 clinical trial for patients with non-small cell lung cancer. The trial is testing the effectiveness of the drugs cisplatin, docetaxel, and etoposide. The eligibility criteria include having a confirmed diagnosis of non-small cell lung cancer, meeting certain tumor involvement criteria, having no more than one parenchymal lesion in the same or both lungs, and having no involvement of certain lymph node groups. Patients must also meet certain patient characteristics criteria, such as having a Zubrod performance status of 0-2 and no evidence of distant metastatic disease. Prior concurrent therapy is not allowed, except for prior exploratory thoracotomy for diagnosis or staging purposes.",
    "The sample is a record from a clinical trial table that includes information about the trial's phase, diseases being studied, associated ICD-10 codes, drugs being tested, and eligibility criteria for participants. In this particular sample, the trial is in phase 2 and is focused on studying diabetes mellitus type 2 and metabolic syndrome x. The associated ICD-10 codes for these diseases are also listed. The drug being tested is nc-503 (eprodisate disodium). The eligibility criteria for participants include being 30 years or older, having a diagnosis of type 2 diabetes mellitus, and having a stable therapeutic dose of either metformin, a sulfonylurea agent, or a combination of both for at least three months prior to the screening visit. Participants must also have a HbA1C level between 7.0-10.0%, central obesity, and at least one of the following metabolic syndrome characteristics: reduced HDL cholesterol, hypertriglyceridemia, or hypertension. Exclusion criteria include having received insulin, thiazolidinediones, or non-thiazolidinedione hypoglycemic agents other than metformin or sulfonylurea agents within three months prior to screening, having significant heart disease or stroke within the last six months, and having an increased red blood cell turn-over or thalassemia or anemia, among others.",
    "The sample is a phase 2 clinical trial for patients with asthma. The trial includes a list of diseases and their corresponding icd-10 codes, as well as a list of drugs that will be used in the trial. The eligibility criteria for the trial include patients between the ages of 18 and 70 with a history of asthma diagnosed by a physician at least 3 months prior to the trial. Patients must have a pre-bronchodilator FEV1 between 60% and 90% predicted at the start of the trial and must have shown an increase in FEV1 after taking salbutamol. Patients must have been taking inhaled corticosteroids for at least 12 weeks prior to screening and must be symptomatic. Exclusion criteria include patients with significant diseases other than asthma, recent hospitalization for asthma, and certain medical conditions such as thyrotoxicosis and myocardial infarction.",
    "The sample is a phase 2 clinical trial for patients with prostate neoplasms. The trial requires patients to have a histologically proven adenocarcinoma of the prostate, an Eastern Cooperative Oncology Group (ECOG) performance status of <=2, and serum testosterone levels <50ng/ml. Patients must also be on ongoing gonadal androgen deprivation therapy with luteinizing hormone-releasing hormone (LHRH) analogues or orchiectomy. The trial is for patients who have had progression of disease despite androgen ablation, with either documented osseous or soft tissue metastatic disease progression or by prostate specific antigen (PSA) criteria progression. Patients must have a PSA level of at least 5 ng/ml which has risen on at least 2 successive occasions, at least 2 weeks apart. The trial requires the presence of metastatic bone disease and the discontinuation of diethylstilbestrol or steroids treatment for >=4 weeks and for antiandrogens >6 weeks. Patients who are receiving an antiandrogen as part of primary androgen ablation must demonstrate disease progression following discontinuation of antiandrogen. Patients must have adequate adrenal function and laboratory values within protocol-defined parameters. Patients must not have evidence of chronic or acute disseminated intravascular coagulation or bleeding tendency and no angina at rest. Patients must agree to protocol-defined use of effective contraception. The exclusion criteria include histologic variants other than adenocarcinoma in the primary tumor, abnormal liver function, therapy with other hormonal therapy, active infection or intercurrent illness that are not controlled, unstable angina, myocardial infarction within the previous 6 months, or use of ongoing maintenance therapy for life-threatening ventricular arrhythmia, uncontrolled hypertension, New York Heart Association (NYHA) Class III or IV congestive heart failure, prior radiation therapy completed <4 weeks or single fraction of palliative radiotherapy within 14 days prior to first dose of study drug, any currently active second malignancy, other than non-melanoma skin cancer, active psychiatric illnesses/social situations that would limit compliance with protocol requirements, active or uncontrolled autoimmune disease that may require corticosteroid therapy during study, severely compromised immunological state, including being positive for the human immunodeficiency virus (HIV), acute or chronic hepatitis B or C, initiation of bisphosphonate therapy within 4 weeks prior to first dose of study drug, long QT syndrome or bundle branch block or hemiblock or other history of life-threatening arrhythmia (unless the patient has been effectively treated for it and is considered stable), known brain metastasis, history of pituitary or adrenal dysfunction, history of gastrointestinal disorders (medical disorders or extensive surgery) which may interfere with the absorption of the study drug, prior therapy with abiraterone acetate, any acute toxicities due to prior chemotherapy and/or radiotherapy that have not resolved to a NCI CTCAE (version 3) grade of <=1, and any condition or situation which, in the investigator's opinion, may put the patient at significant risk, may confound the study results, or may interfere significantly with the patient's participation in the study.",
    "The sample is a record of a clinical trial in phase 2, which involves patients with heart failure and chronic obstructive pulmonary disease. The trial is testing the effectiveness of bisoprolol compared to a placebo. The eligibility criteria for the trial include symptomatic NYHA II or III chronic heart failure, left ventricular systolic dysfunction, and moderate or severe chronic obstructive pulmonary disease. The exclusion criteria include beta-blocker contraindications, recent coronary percutaneous intervention or coronary artery bypass graft surgery, and serious concurrent systemic disease, such as malignancy, resulting in likely reduced life expectancy. The sample also includes the list of icd-10 codes for the diseases and the eligibility criteria for the trial.",
    "The sample is a phase 2 clinical trial for the treatment of non-Hodgkin's lymphoma, specifically diffuse large B cell lymphoma. The trial involves the use of three drugs: gm-csf, chop, and rituximab. The eligibility criteria for the trial include a confirmed diagnosis of the disease, no prior anti-cancer therapy, measurable disease, and a performance status of 0-2. Exclusion criteria include concurrent illnesses, prior exposure to Hepatitis B, and pregnancy or nursing. The trial is designed to evaluate the safety and efficacy of the drug combination in treating the disease.",
    "The sample is a phase 2 clinical trial for patients with adenocarcinoma of the pancreas, including those with recurrent, stage II, III, or IV pancreatic cancer. The trial is testing the effectiveness of the drug temsirolimus. Patients must meet certain eligibility criteria, including having radiographic evidence of disease, no known brain metastases, and a performance status of ECOG 0-2. They must also have normal blood counts, liver and kidney function, and cholesterol and triglyceride levels, and cannot have any other concurrent uncontrolled illness or ongoing infection. Patients cannot have received prior chemotherapy for metastatic pancreatic cancer, and must have evidence of recurrent disease or disease progression. They cannot be receiving any other concurrent anticancer therapy or investigational or commercial agents or therapies for the malignancy.",
    "The sample is a phase 2 clinical trial for patients with metastatic or locally recurrent squamous cell carcinoma of the head and neck. The trial involves the use of two drugs, pemetrexed and bevacizumab. The eligibility criteria include having measurable disease, an ECOG performance status of 0-1, and meeting certain laboratory values. Exclusion criteria include prior chemotherapy or biologic therapy for recurrent/metastatic head and neck cancer, prior use of pemetrexed, bevacizumab, or other antiangiogenesis agents, and certain medical conditions that would preclude full compliance with the study. The trial also has specific requirements for the time period between prior surgery or radiation therapy and enrollment in the study.",
    "The sample is a phase 2 clinical trial for breast cancer patients. The trial involves the use of drugs such as bevacizumab, docetaxel, and trastuzumab. The eligibility criteria for the trial include having a histologically or cytologically proven adenocarcinoma of the breast at first diagnosis, stage IV disease with at least one measurable lesion according to the RECIST criteria, HER2/neu positive, and a life expectancy of at least 24 weeks. The trial excludes patients who have had prior chemotherapy for metastatic breast cancer, prior treatment with bevacizumab or other anti-VEGF therapy, and those with current or prior history of brain or leptomeningeal metastases. The trial also has other exclusion criteria related to cardiovascular disease, gastrointestinal conditions, bleeding diathesis, and coagulopathy.",
    "The sample is a phase 2 clinical trial for patients with multiple myeloma. The trial is testing the effectiveness of the drug velcade\u2122 in treating relapsed or progressive multiple myeloma after at least one line of prior therapy. The eligibility criteria include having measurable disease, a performance status of <= 2, adequate platelet and neutrophil counts, and adequate renal and hepatic function. Patients must also not be pregnant or nursing, and must have signed an informed consent form. Exclusion criteria include recent chemotherapy or radiotherapy, previous bortezomib therapy, significant neurotoxicity, and various other medical conditions.",
    "The sample is a phase 2 clinical trial for the treatment of metastatic colorectal cancer. The trial involves the use of three drugs, tivozanib, bevacizumab, and mfolfox6. The eligibility criteria for the trial include having a documented diagnosis of metastatic colorectal cancer, having one measurable lesion per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1, and having an Eastern Cooperative Oncology Group (ECOG) status of 0 or 1. Exclusion criteria include having any prior Vascular Endothelial Growth Factor (VEGF)-directed therapy or any other agent or investigational agent targeting the VEGF pathway, having primary Central Nervous System (CNS) malignancies or CNS metastases, and having various hematologic and serum chemistry abnormalities. Other exclusion criteria include having significant cardiovascular disease, significant thromboembolic or vascular disorders within 6 months prior to administration of first dose of study drug, and having an active peptic ulcer disease, inflammatory bowel disease, ulcerative colitis, or other gastrointestinal condition with increased risk of perforation. The sample also includes other exclusion criteria related to history of significant gastrointestinal toxicity, active second primary malignancy, and various other medical conditions.",
    "The sample is a phase 2 clinical trial for psoriasis-type and plaque-type psoriasis. The trial is testing the effectiveness of the drug apremilast. The eligibility criteria include being over 18 years old, having a documented history of psoriasis for at least 6 months, and having a Static Physician Global Assessment (sPGA) score of at least 3 and a Body surface area (BSA) \u2265 10% at screening. Participants must also meet certain laboratory criteria and agree to use contraception methods if they are of childbearing potential. Exclusion criteria include having a history of certain diseases or conditions, being pregnant or lactating, and having used certain therapies within a certain timeframe.",
    "The sample is a phase 2 clinical trial for attention-deficit/hyperactivity disorder (ADHD). The trial includes subjects who have voluntarily signed an informed consent form, meet diagnostic criteria for ADHD, are generally in good health, weigh at least 37 pounds, and can swallow pills. Female subjects of child-bearing potential must have a negative urine pregnancy test and agree to comply with applicable contraceptive requirements. The trial excludes subjects with a current or past diagnosis of bipolar disorder, psychosis, autism, Asperger syndrome, pervasive developmental disorder, tics, Tourette syndrome, mental retardation, seizure disorder or traumatic brain injury, as well as those with a history of significant allergic reaction to any drug, planning to begin any type of behavioral or psychotherapy for treatment of ADHD, or requiring ongoing treatment with any psychiatric medication. The trial will test the effectiveness of the drugs abt-089 and placebo.",
    "The sample is a phase 2 clinical trial for neuropathy in diabetic patients. The trial includes patients who are 18 years or older, have stable glycemic control for 3 months, and have documented medical diagnosis of Type 1 or 2 diabetes. The trial also requires patients to have DPN (diabetic peripheral neuropathy) with specific symptoms and a baseline 24-hour average daily pain intensity score >4.0. Patients must not have other chronic pain conditions not associated with DPN and must not have other causes of neuropathy or lower extremity pain. The trial includes a list of exclusion criteria, such as impaired renal function, uncontrolled hypertension, and history of clinically significant drug or alcohol abuse. The trial includes a list of drugs, including placebo and pregabalin, and eligibility criteria for female subjects.",
    "The sample is a clinical trial for the treatment of esophageal cancer in phase 2/phase 3. The trial is looking for patients with localized, nonmetastatic disease that is not suitable for surgery. The patients must meet certain criteria, including having a confirmed diagnosis of esophageal cancer, having a WHO performance status of 0-1, and meeting certain blood count and organ function requirements. Patients must not have had any prior treatment for invasive esophageal carcinoma or gastroesophageal junction carcinoma, and must not have any other prior treatment that would compromise the ability to deliver definitive mediastinal chemoradiotherapy or compromise survival. The trial will use the drugs capecitabine and cisplatin, and patients will be evaluated based on their response to the treatment.",
    "The sample is a phase 2 clinical trial for patients with recurrent melanoma, stage III melanoma, or stage IV melanoma. The trial involves the drug Tanespimycin and has a list of eligibility criteria that patients must meet in order to participate. These criteria include having measurable disease, being free of brain or epidural metastases, having a Karnofsky performance status of 60-100%, and meeting certain blood count and liver function requirements. Patients must also not have any uncontrolled illnesses or ongoing infections, and must not be taking certain medications or herbal remedies. The trial does not allow for concurrent treatment with other anticancer therapies or investigational agents.",
    "The sample is a phase 2 trial for the treatment of opioid-induced constipation (OIC). The trial includes patients who are 18 years or older and receiving a stable opioid regimen, with documented OIC and willingness to stop all laxatives and other bowel regimens. The trial excludes patients with a life expectancy of less than 6 months, active substance abuse, fecal incontinence, irritable bowel syndrome, inflammatory bowel disease, or other active medical disorders associated with diarrhea or intermittent loose stools or constipation, pregnant or breastfeeding women, and those who have received an investigational medication within 30 days of screening or have a history or presence of specific cardiac, neurologic, endocrine, and/or psychiatric conditions. The trial will test the efficacy of two drugs, placebo and NKTR-118.",
    "The sample is a phase 2 clinical trial for asthma. The trial includes patients between the ages of 18 and 65 who have been diagnosed with asthma according to GINA guidelines and have a pre-bronchodilator forced expiratory volume in one second (FEV1) of less than or equal to 85% of their predicted normal value. The trial also requires patients to have an ACQ score of greater than or equal to 1.5. The trial excludes patients with a history of life-threatening asthma, recent treatment with medication for allergic airway disease, or a history of chronic pulmonary disease other than asthma. Pregnant or lactating women are also excluded from the trial. The trial will test the effectiveness of the experimental drug setipiprant compared to a placebo.",
    "The sample is a record of a clinical trial in phase 2 for the treatment of multiple sclerosis. The trial includes a list of diseases and their corresponding ICD-10 codes, as well as a list of drugs being tested, including a placebo and a drug called bms 188667 (abatacept). The eligibility criteria for the trial are also listed, including requirements for patients to have relapsing-remitting MS, at least one exacerbation in the preceding 2 years, and at least one MRI lesion. There are also exclusion criteria, such as patients with progressive MS, those currently being treated with an immunomodulatory therapy, and those who have previously been treated with an approved MS drug where treatment was discontinued for lack of efficacy. Additionally, patients with active bacterial or viral infections are also excluded from the trial.",
    "The sample is a phase 2 clinical trial for the treatment of gastroparesis in patients with type I or II diabetes mellitus. The trial involves the use of the drug GSK962040 in various dosages, as well as a placebo. The eligibility criteria include having a gastric half-time of emptying greater than the upper limit of normal, a history of relevant symptoms of gastroparesis, and a BMI between 18 and 35 kg/m2. Patients must also have stable dosages of any concomitant medications for at least 3 weeks, except for routine adjustments in daily insulin treatments. Exclusion criteria include acute severe gastroenteritis, a gastric pacemaker, chronic parenteral feeding, pronounced dehydration, recent history of poor control of diabetes, and a history of eating disorders.",
    "The sample is a phase 2 clinical trial for patients with non-Hodgkin's lymphoma or multiple myeloma who are eligible for autologous transplantation. The trial involves the use of the drug combination of g-csf and plerixafor. The eligibility criteria include having no more than 3 prior chemotherapy regimens, being recovered from all acute toxic effects of prior chemotherapy, having a certain level of white blood cells, polymorphonuclear cells, and platelets, and meeting certain requirements for kidney and liver function, heart function, and lung function. Patients with brain metastases or certain medical conditions are excluded from the trial. Women of childbearing potential must agree to use contraception. Patients who deteriorate between enrollment and transplant may be removed from the study.",
    "The sample is a clinical trial for pancreatic cancer patients in phase 2/phase 3. The trial involves the use of five drugs: fluorouracil, gemcitabine hydrochloride, irinotecan hydrochloride, leucovorin calcium, and oxaliplatin. The eligibility criteria for patients include being between the ages of 18 and 75, having a confirmed diagnosis of adenocarcinoma of the pancreas, having measurable disease in an area not previously irradiated, and meeting various medical requirements such as having a certain level of platelets and not having any other serious medical disorders. Patients cannot have had prior chemotherapy or radiotherapy, and cannot be participating in another clinical trial using therapeutic experimental agents.",
    "The sample is a phase 2 clinical trial for patients with non-small cell lung cancer who have undergone complete surgical resection within the past 2 months. The trial is testing the effectiveness of cisplatin-based adjuvant chemotherapy with the drugs cisplatin and docetaxel. Eligibility criteria include a Karnofsky performance status of at least 70%, certain blood counts and liver function tests within normal limits, and no history of severe hypersensitivity reaction to docetaxel or other drugs formulated with polysorbate 80. Patients must not have had prior chemotherapy or radiation therapy for NSCLC, and must not be currently taking prophylactic filgrastim or pegfilgrastim. Fertile patients must use effective contraception during and for 3 months after completion of study treatment.",
    "The sample is a phase 2 clinical trial for the treatment of depression and major depressive disorder in children and adolescents between the ages of 7 and 17. The trial is testing the effectiveness of desvenlafaxine succinate sustained-release tablets (dvs sr) as an antidepressant. The eligibility criteria include meeting the Diagnostic and Statistic Manual of Mental Disorders, Fourth Edition, Text Revision criteria for major depressive disorder, having a Children's Depression Rating Scale --Revised (CDRS-R) score greater than 40, and having symptoms of depression for at least 1 month before screening. Exclusion criteria include a history of suicide attempt or gesture, current substance abuse or dependence, and certain psychiatric disorders.",
    "The sample is a phase 2 clinical trial for patients with non-small cell lung cancer who have a positive mutational status for the KRAS, NRAS, BRAF, or MEK1 gene. The trial is testing the effectiveness of the drugs gsk1120212 and docetaxel. The eligibility criteria include being at least 18 years old, having measurable disease, and a performance status score of 0 or 1. Exclusion criteria include a history of another malignancy, certain medical disorders, and recent anti-cancer therapy. Women of childbearing potential must have a negative pregnancy test and agree to use effective contraception. The trial is also excluding patients with certain cardiovascular risks and infections.",
    "The sample is a phase 2 clinical trial for asthma patients. The trial includes patients aged 18-65 who have been diagnosed with asthma at least 6 months prior to screening and are already being treated with a dose of BDP or equivalent up to 2000 \u00b5g/day. The trial aims to test the effectiveness of different forms of the drug clenil\u00ae modulite\u00ae administered via aerochamber plus\u2122, volumatic\u2122 spacer, or charcoal block. The trial has a list of inclusion and exclusion criteria, including FEV1 \u2265 60% of predicted for the patient's normal value at screening and randomisation, no treatment with oral or parenteral corticosteroids in the previous 8 weeks (12 weeks for parenteral depot corticosteroids) before screening visit, and no exacerbation of asthma symptoms or hospitalization due to asthma exacerbation within the previous one month before screening until randomisation. The trial also excludes patients with a diagnosis of COPD, significant medical history and/or treatments for cardiac, renal, neurological, hepatic, endocrine diseases, or any laboratory abnormality indicative of a significant underlying condition, that may interfere with patient's safety, compliance, or study evaluations, according to the Investigator's opinion. The patients cannot participate in another clinical study at the same time as the present study.",
    "The sample is a phase 2 clinical trial for high-risk adenocarcinoma of the prostate. The trial includes patients with bone metastases to both axial and appendicular skeleton, or visceral disease. Patients with brain metastasis must have a negative brain CT or MRI. The eligibility criteria include age over 18, Zubrod performance status of 0-2, and no other prior malignancy within the past 5 years except adequately treated basal cell or squamous cell skin cancer or adequately treated stage I or II cancer currently in complete remission. The trial excludes patients with untreated spinal cord compression, active hypercoagulability, active coronary artery disease requiring antianginal therapy, active thrombophlebitis, history of pulmonary embolus, and other concurrent chemotherapy or bisphosphonates. The trial allows prior androgen-blockade therapy and neoadjuvant hormonal therapy, but not prior cytotoxic chemotherapy or concurrent biologic therapy, radiotherapy, or bisphosphonates.",
    "The sample is a record of a clinical trial with a phase 2 designation. The trial is focused on the disease ulcerative colitis, which is identified by a list of ICD-10 codes. The trial involves two drugs, krp203 and a placebo matching krp203. The eligibility criteria for the trial are listed, including requirements for active disease and inadequate response to 5-ASA therapy. Exclusion criteria are also listed, including recent treatment for UC, significant medical illness or lab abnormalities, and other medical conditions that could compromise the subject's health.",
    "The sample is a phase 2 clinical trial for patients with follicular lymphoma. The trial involves the use of two drugs, 90y ibritumomab tiuxetan and rituximab. The eligibility criteria include having a confirmed diagnosis of CD20+ve follicular lymphoma grades I to IIIa, experiencing symptoms requiring treatment, having an ECOG performance status less than or equal to 2, and an anticipated survival of at least 6 months. Patients must also meet certain laboratory criteria and have given informed consent. Exclusion criteria include having certain medical conditions, prior malignancy, or being pregnant or breastfeeding.",
    "The sample is a record from a clinical trial table that includes information about the trial's phase, diseases being studied, icd-10 codes of those diseases, drugs being used, and eligibility criteria for participants. In this particular sample, the trial is in phase 2 and is studying breast neoplasms. The icd-10 codes associated with the disease are listed, as well as the drugs being used in the trial (ave1642 and fulvestrant). The eligibility criteria for participants are also listed, including requirements for post-menopausal women, positive hormone receptor status, and measurable disease as per RECIST definition. The exclusion criteria are also listed, including prior exposure to certain drugs and evidence of hormonosensitivity. The information provided is not intended to be a comprehensive list of all considerations relevant to a patient's potential participation in the trial.",
    "The sample is a phase 2 clinical trial for major depressive disorder. The trial includes male and female outpatients between the ages of 18 and 65 who currently meet the DSM-IV-TR criteria for moderate to severe MDD and have had a major depressive episode lasting between 8 weeks and 24 months. The trial is for patients who have not responded adequately to antidepressant therapy. The trial includes both a placebo and cariprazine as drugs. The eligibility criteria include various inclusion and exclusion criteria, such as not having a principal diagnosis of an axis I disorder other than MDD, not being pregnant or planning to become pregnant, and not having a history of certain mental disorders or being considered a suicide risk.",
    "This sample is a phase 2 trial for smoking cessation. The trial includes participants who are healthy smokers, smoking at least 10 cigarettes daily for at least one year prior to inclusion, and smoking within 30 minutes of waking up. Female participants of child-bearing potential are required to use a medically acceptable means of birth control. The trial excludes participants who are pregnant, lactating, or intending to become pregnant, those who have used NRT, bupropion, or varenicline, or have a history of a quit attempt later than 3 months before the screening visit. Participants who have been treated with an investigational product, other than those described in the protocol, between 1 month preceding the first treatment visit and the last treatment visit of the study, or who have prior regular use of any of the investigational products are also excluded.",
    "The sample is a phase 2 clinical trial for patients with diffuse large B-cell lymphoma who have relapsed after initial treatment or failed to achieve initial remission. The trial requires patients to have received 2 cycles of second-line therapy and have a positive FDG-PET scan. Patients must also have a matched related or unrelated donor available and meet various eligibility criteria, including age, performance status, and organ function. The trial involves a combination of drugs, including rituximab, carmustine, etoposide, and cyclophosphamide, among others. The trial also has exclusion criteria, such as prior chemotherapy within 2 weeks of the initiation of protocol therapy and active infection requiring antibiotics. Donors must also meet certain eligibility criteria, including being in good health and having no contra-indication to donation.",
    "The sample is a phase 2 clinical trial that involves patients with lymphoma, including Hodgkin's and non-Hodgkin's lymphoma, as well as hematology and oncology. The trial uses three drugs, namely pegfilgrastim 12 mg, filgrastim, and pegfilgrastim 6 mg. The eligibility criteria for the trial include patients who are suitable for an autologous PBPC transplant and have not undergone a previous bone marrow or PBPC transplant. The icd-10 codes associated with the diseases in the trial are also provided.",
    "The sample is a record from a clinical trial table that includes information about the trial's phase, diseases being studied, ICD-10 codes associated with those diseases, drugs being used, and eligibility criteria for participants. In this particular sample, the trial is in phase 2 and is studying non-Hodgkin's lymphoma. The trial is only open to patients who have previously undergone BEAC or BEAM autologous SCT with PBSC rescue for any stage aggressive B-cell NHL, including transformed indolent NHL or mantle cell lymphoma according to REAL classification. The patient must also have an ECOG performance status of 0-1, previously documented CD20 +NHL, be over 18 years old, and be 30-100 days from autologous peripheral blood stem cell transplant. There are also various laboratory values that must be met, and patients must have a negative serum pregnancy test within 7 days prior to trial registration. There are also exclusion criteria, such as a history of hypersensitivity to study drugs, active infection, or a history of other malignancy within the last 5 years.",
    "The sample is a phase 2 clinical trial for patients with cirrhosis of the liver caused by the Hepatitis C virus. The trial is testing the effectiveness of three different drugs, including a placebo. The eligibility criteria for the trial include being between the ages of 40 and 70, having a positive HCV antibody test, and having a fibrosis score of 2, 3, or 4. Patients must also have failed previous treatment with interferon and ribavirin. Women who are of childbearing potential must have a negative pregnancy test and agree to use an acceptable form of contraception. Patients with certain medical conditions or taking certain medications are excluded from the trial. The trial aims to determine the safety and efficacy of the drugs in treating cirrhosis of the liver caused by HCV.",
    "The sample is a phase 2 clinical trial for patients with locally advanced unresectable or metastatic pancreatic ductal adenocarcinoma. The trial is testing the effectiveness of the drugs gemzar (gemcitabine) and th-302. The eligibility criteria include being at least 18 years old, having measurable disease by RECIST 1.1 criteria, and having an ECOG performance status of 0 or 1. The trial excludes patients with certain medical conditions, such as severe chronic obstructive or other pulmonary disease with hypoxemia, and those who have exhibited allergic reactions to a structural compound, biological agent, or formulation similar to TH-302.",
    "The sample is a phase 2 clinical trial for patients with renal impairment and a history or presence of gout. The trial is testing the effectiveness of febuxostat and placebo in reducing serum urate levels. The eligibility criteria include having a serum urate greater than 7 mg/dL and a serum creatinine greater than or equal to 1.5 mg at Day -21, an estimated Glomerular Filtration Rate (eGFR) of 15 or greater, or less than or equal to 50 mL/min, and meeting the American Rheumatism Association criteria for the diagnosis of gout. Exclusion criteria include having secondary hyperuricemia, tophaceous gout, a history of xanthinuria, and other medical conditions.",
    "The sample is a phase 2 clinical trial for patients with advanced pancreatic cancer that has progressed on gemcitabine or a gemcitabine-containing combination. Patients must have received no more than two prior regimens for metastatic disease. The trial is testing the drug px-12. The eligibility criteria include a confirmed diagnosis of advanced pancreatic cancer, a Karnofsky Performance Status of at least 70%, adequate organ function, and measurable disease by CT scan per RECIST criteria. Exclusion criteria include active infection requiring antibiotics, serious concomitant systemic disorder, active pulmonary disease or evidence of interstitial pneumonitis or pulmonary fibrosis, significant central nervous system or psychiatric disorder, known or suspected brain metastases that have not received adequate therapy, major surgery within 4 weeks of study entry, chemotherapy/investigational drugs within 3 weeks of study entry, and inability to tolerate prophylactic coumadin.",
    "The sample is a phase 2 clinical trial for patients with testicular or extragonadal germ cell cancer that has not responded to previous treatments. The trial is testing the effectiveness of arsenic trioxide as a potential treatment. Patients must meet certain eligibility criteria, including having measurable disease or elevated levels of beta-HCG or AFP. Patients must also meet certain patient characteristics, such as being male and having a Zubrod performance status of 0-2. Prior concurrent therapy is also taken into consideration. The trial is looking to enroll patients who have not received cytotoxic agents in the past 28 days and have not been treated with experimental agents in the past 28 days. Patients must also not be taking any drugs known to prolong the QT interval.",
    "The sample is a phase 2 clinical trial for the treatment of gastric cancer, gastric adenocarcinoma, and esophageal cancer. The trial involves the use of four drugs: irinotecan, cisplatin, floxuridine, and capecitabine. The eligibility criteria for the trial include being an untreated patient with histologically documented gastric/GEJ adenocarcinoma, having a clinical American Joint Committee on Cancer (AJCC) stage grouping IB-IV (Mo) by CT scan and laparoscopy/endoscopic ultrasound, having an Eastern Cooperative Oncology Group (ECOG) performance status of 0-2, and having preserved liver and renal function. Patients must also not have any severe concurrent disease, such as cardiac condition not responding to medication, myocardial infarction within the last 12 months, active infection or uncontrolled pulmonary disease, or any other disease which in judgment of the investigator would make the patient inappropriate for entry into this study. Patients who signed written informed consent are also eligible.",
    "The sample is a record of a clinical trial with a phase 2 designation. The trial is focused on two diseases, type 2 diabetes and hypogonadism, and includes a list of corresponding ICD-10 codes. The trial is testing the effectiveness of a drug called Androgel (testosterone gel). The eligibility criteria for participants include being able to read and write, being male, between the ages of 30-80, and having a diagnosis of type 2 diabetes and hypogonadism or low testosterone. The exclusion criteria include being on insulin monotherapy, having used testosterone therapy within the last 6 months, having male breast cancer, a history of prostate cancer, or a history of clinically significant sleep apnea.",
    "The sample is a record from a clinical trial table that includes information about the trial's phase, diseases being studied, icd-10 codes of the diseases, drugs being used, and eligibility criteria. In this particular sample, the trial is in phase 2 and is studying breast neoplasms. The icd-10 codes associated with the disease are listed, as well as the drugs being used in the trial. The eligibility criteria for the trial are also listed, including inclusion criteria such as having a histologically proven breast adenocarcinoma and acquired resistance to letrozole, and exclusion criteria such as having rapidly progressive disease in major organs or previous treatment with an EGFR and/or HER-2 inhibiting drug.",
    "This sample is for a phase 2 clinical trial for Alzheimer's disease. The trial is testing the effectiveness of simvastatin compared to a placebo. The inclusion criteria for the trial are individuals between the ages of 35 and 69 with a parent who has Alzheimer's disease. The exclusion criteria include current use of cholesterol-lowering medication, active liver disease, history of adverse reaction to statins, contraindication to lumbar puncture, elevated lab values, use of medications known to interact with statins, history of dementia, currently pregnant or planning to become pregnant, use of large quantities of grapefruit juice, current involvement in another investigational drug study, contraindications to MRI, and ethical contraindication to placebo for persons with high vascular risk.",
    "This is a sample from a clinical trial table. The trial is in phase 2 and is focused on myelodysplastic syndromes (MDS). The table includes a list of diseases, icd-10 codes, drugs, and eligibility criteria. The eligibility criteria include age, previous treatments, laboratory values, and other medical conditions. Patients with up to and including 30% blasts (FAB RAEB-T) will be eligible to enroll. The trial excludes patients with certain medical conditions, such as uncontrolled coagulopathy or abnormal thyroid function. Women who are pregnant or breastfeeding or women of childbearing potential (WOCBP) not willing to use a double barrier method of contraception during the study and 3 months after the end of treatment are also excluded. Male patients whose sexual partners are WOCBP not using a double method of contraception during the study and 3 months after the end of treatment are also excluded.",
    "The sample is a phase 2 clinical trial for patients with type 2 diabetes mellitus. The trial involves the use of three drugs: int131 besylate, pioglitazone hcl, and placebo. The eligibility criteria for the trial include a diagnosis of type 2 diabetes and being on either sulfonylurea monotherapy or sulfonylurea plus metformin combination therapy for at least 3 months at a stable dose. The patients must be between 30 and 75 years of age, have an HbA1c level between 7.5% and 10%, and a fasting plasma glucose level below 240 mg/dL at screening. The exclusion criteria include a history of type 1 diabetes, diabetic ketoacidosis, NYHA Class III or IV cardiac status, treatment with any non-PPAR antidiabetic agent other than metformin or permitted sulfonylureas within 3 months prior to screening, treatment with rosiglitazone, pioglitazone, or any PPAR investigational antidiabetic agent within 6 months prior to screening, body mass index over 45 kg/m2, fasting triglycerides over 500 mg/dL, uncontrolled hypertension, and presence of diabetic complications that would complicate the subject's participation in the study.",
    "The sample is a phase 2 clinical trial for non-small cell lung cancer. The trial includes patients with Stage IIIb with pleural/pericardial effusion or Stage IV NSCLC who have progressed after one prior systemic chemotherapeutic regimen for locally advanced or metastatic NSCLC. Patients must have measurable disease and an ECOG performance status of 0-1. The trial excludes patients who have received prior chemotherapy regimen containing docetaxel, have active secondary malignancy, or have uncontrolled concurrent illness. The trial also requires patients to have recovered from toxicities related to prior therapy. The trial will test the efficacy of at-101 and docetaxel compared to placebo and docetaxel.",
    "The sample is a record of a clinical trial in phase 2 for the treatment of chemotherapy-induced nausea and vomiting. The trial involves the drug carbamazepine and the eligibility criteria include being over 18 years old, starting moderate or highly emetogenic chemotherapy containing cisplatin, doxorubicin or epirubicin in higher doses than 60mg/m2, 50mg/m2 and 50mg/m2 respectively, and signing an informed consent form. The exclusion criteria include previous chemotherapy, low emetogenic antiemetic potential, and disagreement or refusal to sign the consent form. The diseases being treated are not specified, but the icd-10 codes for the disease are listed as D61.810.",
    "The sample is a phase 2 clinical trial for the treatment of Autism Spectrum Disorders using the drug arbaclofen. The eligibility criteria include a stable pharmacological treatment regimen for at least 4 weeks prior to screening, continuous participation in non-pharmacologic interventions for 2 months prior to screening, and being seizure-free for 6 months if currently receiving antiepileptics or 3 years if not. Exclusion criteria include any condition that may interfere with the study or endanger the subject's well-being, plans to initiate or change interventions during the study, recent use of another investigational drug, and inability to take oral medications. The diseases being studied are limited to Autism Spectrum Disorders and the corresponding ICD-10 code is Z16.12.",
    "The sample is a record of a clinical trial with a phase 2 designation. The trial is focused on psoriatic arthritis, with the ICD-10 code L40.52. The trial involves the use of four drugs: amg 827 140, placebo, amg 827 280, and amg 827 210. The eligibility criteria for the trial include having a diagnosis of psoriatic arthritis for at least 6 months, having at least 3 tender and 3 swollen joints, and not having certain medical conditions or laboratory abnormalities. Exclusion criteria include having an active infection or history of infections, being pregnant or breastfeeding, and having used certain medications or therapies within a certain timeframe. The sample includes detailed inclusion and exclusion criteria for the trial.",
    "The sample is a phase 2 clinical trial for patients with Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) who have measurable or assessable disease and have received prior therapies including chemotherapy, radiation, autologous stem cell transplant, or Rituximab. The trial aims to evaluate the safety and efficacy of the drug Rituximab. The eligibility criteria include a definitive diagnosis of CLL or SLL, active or symptomatic disease, age over 18 years, adequate bone marrow, liver, and renal function, and a life expectancy of greater than 12 weeks. The exclusion criteria include severe autoimmune hemolytic anemia, CNS involvement, severe lymphoma-related symptoms, and active second malignancy in the last 5 years. Patients must have recovered from prior therapies and be willing to sign a written informed consent document.",
    "The sample is a phase 2 clinical trial for patients with multiple myeloma, non-Hodgkin's lymphoma, or Hodgkin's disease. The trial is testing the drug TG-0054 and the eligibility criteria includes being between 18 and 75 years old, having a confirmed pathology diagnosis of one of the specified diseases, and being a potential candidate for autologous stem cell transplantation. Other criteria include having a certain white blood cell count, platelet count, and serum creatinine level, as well as meeting certain performance status requirements. Exclusion criteria include having received radiation therapy to the pelvis, having a history of other cancer within the past 5 years (excluding the specified diseases), and being pregnant or breastfeeding.",
    "The sample is a phase 2 clinical trial for patients with unresectable/metastatic renal cell carcinoma. The trial involves two drugs, sorafenib escalated dose and sorafenib standard dose. The eligibility criteria include being at least 18 years old, having a Karnofsky Performance Status of 50% or greater, and having adequate bone marrow, liver, and renal function. Women of childbearing potential must have a negative pregnancy test and agree to use adequate contraception. Exclusion criteria include prior systemic anticancer treatment for metastatic disease, prior treatment with bevacizumab, sunitinib, or sorafenib, and active malignancy other than RCC within 5 years of enrollment. The trial also excludes patients with certain medical conditions such as uncontrolled hypertension, serious non-healing wounds, and pregnancy or lactation.",
    "The sample is a phase 2 clinical trial for dry eye disease. The trial includes patients who are at least 18 years old and have a reported history of dry eye and a history of using or desiring to use eye drops for dry eye. The trial excludes patients with ongoing ocular infections or inflammation, planned ocular or lid surgeries, corrected visual acuity greater than or equal to +0.7, uncontrolled systemic disease, pregnancy or planning a pregnancy, allergies or sensitivities to the test article or its components, and those who are currently enrolled in an investigational drug or device study or have used an investigational drug or device within 45 days of Visit 1. The trial requires patients to follow instructions and participate in all study assessments and visits. The drugs being tested are mim-d3 ophthalmic solution and placebo ophthalmic solution.",
    "The sample is a phase 2 trial for asthma treatment. The eligibility criteria include being between 18 and 65 years old, having a diagnosis of asthma for at least 6 months, and having been treated with inhaled and oral corticosteroids for at least 3 months. Participants must also have a certain level of lung function and have had a documented increase in lung function after using inhaled Salbutamol. Long-acting \u03b2-agonists are mandatory. Women of childbearing potential must have a negative pregnancy test and agree to use contraception. Exclusion criteria include allergies to Budesonide, pregnancy or nursing, recent respiratory infections or hospitalizations, and other chronic lung diseases. Participants must not have a history of medication noncompliance or significant medical illness that would put them at risk.",
    "The sample is a phase 2 clinical trial for the treatment of oral mucositis. The trial involves administering at least 5000 centigray (cGy) radiation therapy to at least 2 of 14 pre-defined areas in the oral cavity. The trial will test the effectiveness of celecoxib and placebo drugs. The eligibility criteria include patients who are willing and able to provide written informed consent, women of childbearing potential who agree to use a medically accepted form of contraception during the course of the study, and patients without known hypersensitivity to celecoxib or other COX-2 inhibitors. The exclusion criteria include patients with a history of gastric, esophageal, pyloric channel or duodenal ulcer disease or gastrointestinal bleeding, patients with severe hepatic impairment, patients with advanced renal disease, patients with a significant bleeding disorder, patients under the age of 18 or over the age of 75, women who are pregnant or nursing, and patients with a history of thromboembolic events including myocardial infarction, pulmonary embolism, deep venous thrombosis, transient ischemic attack and ischemic cerebrovascular accident (stroke).",
    "The sample is a phase 2 clinical trial for patients with fallopian tube cancer, ovarian cancer, or primary peritoneal cavity cancer. The trial involves the use of two drugs, 7-hydroxystaurosporine and topotecan hydrochloride. The eligibility criteria include having confirmed cancer, measurable disease outside of prior radiotherapy field, no more than 2 prior chemotherapy regimens, and no known brain metastases. Patients must also meet certain age, performance status, and life expectancy requirements, as well as have certain hematopoietic, hepatic, renal, cardiovascular, and pulmonary health. Patients must not be pregnant or nursing, have ongoing or active infections, or have psychiatric illness or social situations that would preclude study compliance. Prior concurrent therapy is also taken into consideration.",
    "The sample is a phase 2 clinical trial for non-small cell lung cancer. The trial is testing the effectiveness of a combination of drugs, including carboplatin, gemcitabine hydrochloride, and thalidomide. The eligibility criteria for the trial include having stage II or IIIA disease, measurable disease, and a Karnofsky performance status of 70-100%. Exclusion criteria include being pregnant or nursing, having a positive pregnancy test, and having other serious medical illnesses that would preclude study participation. The trial also excludes patients who have had prior systemic chemotherapy or radiotherapy for non-small cell lung cancer, as well as those who are concurrently participating in another clinical study.",
    "The sample is a record of a clinical trial with a phase 2 designation and the disease being studied is epilepsy. The ICD-10 codes associated with the disease are listed as well. The drug being tested is lacosamide. The eligibility criteria for the trial are listed under inclusion and exclusion criteria, which include completing a previous study and being expected to benefit from participation. However, if the subject meets the withdrawal criteria for the previous study or is experiencing a serious adverse event, they will be excluded from participating in this trial.",
    "The sample is a phase 2 clinical trial for patients with chronic obstructive pulmonary disease. The trial involves the use of two drugs, bea 2180 br and tiotropium, and has eligibility criteria that include having moderate to severe airway obstruction, being a smoker or ex-smoker with a history of more than 10 pack years, and being at least 40 years old. Patients with any other significant disease or a history of asthma or allergic rhinitis will be excluded from the trial. The icd-10 codes for the disease are also provided.",
    "The sample is a phase 2 clinical trial for the treatment of glioblastoma multiforme, a type of brain cancer. The trial involves the use of two drugs, bevacizumab and metronomic temozolomide. The eligibility criteria for the trial include having a confirmed diagnosis of WHO grade IV primary malignant glioma, a Karnofsky Performance Status (KPS) of at least 60%, evidence of measurable primary CNS neoplasm on contrast-enhanced MRI, and no evidence of CNS hemorrhage on baseline MRI or CT scans. Exclusion criteria include a life expectancy of less than 8 weeks, pregnancy or breastfeeding, progression to metronomic temozolomide, and inadequately controlled hypertension.",
    "The sample is a phase 2 clinical trial that involves patients with major depressive disorder and chronic hepatitis C. The trial is testing the effectiveness of escitalopram and placebo in combination with peginterferon alfa2a and ribavirin treatment. The eligibility criteria include being between the ages of 18-65, having signed informed consent, and not having hepatic cirrhosis or carcinoma. Exclusion criteria include having comorbid severe medical conditions, baseline mental disorders that require antidepressants, and contraindications of escitalopram. The trial also requires patients to be able to understand and fill out written questionnaires.",
    "The sample is a phase 2 clinical trial for patients with Langerhans cell histiocytosis (LCH), a rare disease that affects multiple organs. The trial is for patients who have already undergone standard LCH-directed therapies and have progressive disease. The trial involves reduced-intensity hematopoietic cell transplantation (RI-HCT) using either a related or unrelated donor or unrelated umbilical cord blood (UCB). The eligibility criteria include confirmation of LCH, poor-risk disease, availability of a donor or UCB, and adequate hepatic, renal, cardiac, and pulmonary function. The exclusion criteria include congestive heart failure, pulmonary failure, liver sclerosis, active life-threatening infection, pregnancy or nursing, and concurrent chemotherapy agents.",
    "The sample is a phase 2 clinical trial for patients with metastatic colorectal cancer who are scheduled to receive one of several chemotherapy regimens. The trial is testing the effectiveness of a combination of drugs including aprepitant, dexamethasone, fluorouracil, irinotecan hydrochloride, leucovorin calcium, and oxaliplatin, as well as palonosetron hydrochloride to prevent nausea and vomiting. The eligibility criteria include having a diagnosis of colorectal cancer, no emesis or chronic nausea, and meeting certain patient characteristics such as having a life expectancy of more than 4 months and being able to swallow tablets and capsules. Prior concurrent therapy is also taken into account.",
    "The sample is a phase 2 trial that focuses on two diseases, insulin resistance and abdominal obesity. The trial includes a list of icd-10 codes for each disease. The trial involves two drugs, gft505 80mg and placebo. The eligibility criteria for the trial include a waist circumference of at least 94cm, a body mass index of no more than 45kg/m2, and a Homeostasis Model Assessment of Insulin Resistance (HOMA-IR) greater than 3. The exclusion criteria include high blood pressure, diabetes mellitus 1 or 2, a history of bariatric surgery, treatment with a lipid-decreasing medication, and high levels of fasting plasma triglycerides or plasma Low Density Lipoprotein Cholesterol (LDL-c).",
    "This sample is for a phase 2 clinical trial for the treatment of chronic myelogenous leukemia using the drug danusertib. The eligibility criteria include a confirmed diagnosis of the disease, relapse after prior therapy, and certain medical and laboratory requirements. Patients must not have significant cardiovascular disease or have had a major thromboembolic event within the past 6 months. They must also not be receiving any other concurrent anticancer treatment or participating in another treatment clinical trial.",
    "The sample is a phase 2 clinical trial for patients with liver cancer. The trial is testing the effectiveness of two drugs, doxorubicin hydrochloride and sunitinib malate, in treating the disease. The eligibility criteria for patients include having 1-4 lesions in the liver, measurable disease by CT scan or MRI, and a tumor burden that involves less than 50% of the liver. Patients must also meet certain patient characteristics, such as having an ECOG performance status of 0-2 and a life expectancy of at least 12 weeks. Prior concurrent therapy is allowed, but patients cannot have had prior antiangiogenesis therapy or liver transplantation. The trial is also excluding patients with certain medical conditions, such as active congestive heart failure or uncontrolled angina.",
    "The sample is a phase 2 clinical trial for squamous cell carcinoma of the head and neck. The trial includes patients who are 18 years or older, have documented SCCHN, and have local-regional and/or metastatic disease that cannot be treated with surgery or radiotherapy. The trial also requires patients to have a life expectancy of at least 3 months, an ECOG performance status of 0-2, and adequate bone marrow function. The trial excludes patients with severe or uncontrolled systemic disease, a history of arrhythmia, or a history of QTc prolongation. Patients who are pregnant or breastfeeding, have received investigational agents within 30 days prior to commencing study treatment, or have had major surgery within 4 weeks are also excluded.",
    "The sample is a phase 2 clinical trial for patients with germ cell tumors that have relapsed or are refractory and have metastasized. The trial is testing the effectiveness of the drug sunitinib malate. Patients must meet certain eligibility criteria, including having measurable disease and meeting certain medical and laboratory requirements. Patients cannot have received prior sunitinib malate treatment or be receiving other anticancer therapies during the trial. Palliative radiotherapy to metastatic lesions is allowed. The trial also allows for concurrent participation in supportive care or non-treatment trials.",
    "The sample is a phase 2 clinical trial for patients with recurrent glioblastoma, a type of malignant brain tumor. The trial is testing the effectiveness of the drug panobinostat. The eligibility criteria include being at least 18 years old, having a confirmed diagnosis of grade 4 malignant glioma, being a candidate for surgical resection of the tumor, and meeting certain medical criteria such as having a certain level of hemoglobin and platelets in the blood. Patients who have previously received certain types of cancer treatments or have certain medical conditions are excluded from the trial. Women of childbearing potential must use double contraception methods during the trial and for three months after treatment ends. Male patients whose sexual partners are women of childbearing potential must also use double contraception methods during the trial and for three months after treatment ends.",
    "This sample is for a phase 2 clinical trial for the treatment of stomach neoplasms using the drug edotecarin. The trial is for patients with locally advanced or metastatic disease that is non-amenable to surgery and chemo-radiation with curative intent. Patients must have had progression or recurrence after a fluoropyrimidine-containing regimen at any time for primary metastatic disease or within 6 months of last dose of adjuvant therapy. They must also have at least 1 measurable lesion and have discontinued all previous therapies at least 4 weeks before study entry. Patients must meet certain baseline tests and have an ECOG performance status of 0, 1 or 2. They must also be willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures. Patients who have had prior treatment with another topoisomerase I inhibitor, more than 1 prior chemotherapy regimen for advanced disease, or previous high-dose chemotherapy requiring hematopoietic stem cell rescue are excluded from the trial. Other exclusion criteria include ongoing cardiac dysrhythmias of NCI CTC grade >=2, active infection, pregnancy or breast-feeding, and other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or study drug administration or may interfere with the interpretation of study results.",
    "The sample is a phase 2 clinical trial for women with metastatic or locally advanced metastatic HER2/neu negative breast cancer. The trial is testing the effectiveness of non-pegylated liposomal doxorubicin and docetaxel as a treatment. The eligibility criteria include having completed previous chemotherapy more than 12 months before inclusion, normal LVEF, and normal haematological, hepatic and renal parameters. Exclusion criteria include previous chemotherapy for metastatic disease, poorly controlled hypertension, and symptomatic or progressive brain metastases. The trial requires signed written informed consent and regular medical follow-up.",
    "The sample is a phase 2 trial for the treatment of chronic postoperative neuropathic pain using lidocaine 5% medicated plaster and placebo topical plaster. The trial includes male and female subjects over 18 years of age with intact skin in the area of topical treatment and suffering from moderate to severe chronic daily postoperative neuropathic pain for the past 6 to 24 months. The trial also includes a list of diseases and their corresponding icd-10 codes, as well as eligibility criteria for inclusion and exclusion. The inclusion criteria include specific symptoms such as allodynia and dysesthesia, while the exclusion criteria include contraindications to the treatment, history of alcohol or drug abuse, and severe renal, hepatic, or heart disorders. The trial also excludes patients with other severe pain that could confound the assessment or self-evaluation of the localized postoperative neuropathic pain.",
    "The sample is a phase 2 clinical trial for patients with type 2 diabetes mellitus. The trial involves the drugs Xoma 052 and a placebo. The eligibility criteria for the trial include having a disease duration of at least 6 months, a stable regimen of metformin monotherapy for at least 12 weeks prior to the trial, and willingness to maintain a stable diet and exercise regime throughout the study. Exclusion criteria include uncontrolled hypertension, history of malignancy within 5 years, and advanced stage heart failure. Female subjects who are pregnant or planning to become pregnant are also excluded. Other protocol-defined inclusion/exclusion criteria may apply.",
    "The sample is a phase 2 clinical trial for patients with Hodgkin's disease who have relapsed after radiation therapy or are previously untreated with stage II bulky, III, and IV who are eligible for ABVD. The trial involves the use of rituximab, adriamycin, bleomycin, vinblastine, and dacarbazine (dtic) drugs. The eligibility criteria include having a histologically proven diagnosis of Hodgkin's disease, bidimensionally measurable disease, being older than 16 years of age, having adequate bone marrow reserve, and having a left ventricular ejection fraction (LVEF) of at least 50% by multigated acquisition (MUGA) scan or echocardiogram. The exclusion criteria include being HIV positive, pregnant women and women of childbearing age who are not practicing adequate contraception, prior chemotherapy, and severe pulmonary disease including Chronic obstructive pulmonary disease (COPD) and asthma.",
    "The sample is a record of a clinical trial with a phase 2 designation. The trial is focused on non-Hodgkin's lymphoma and the icd-10 codes associated with it. The drug being tested is ibritumomab tiuxetan (zevalin) + rituximab. The eligibility criteria for the trial include having biopsy-proven non-Hodgkin's lymphoma of follicular grade 1, 2, or 3, meeting FLIPI criteria for intermediate or high risk, and having no prior chemotherapy, radiotherapy, or immunotherapy for lymphoma. Patients may not have known HIV infection and must not be Hepatitis B Surface Antigen positive. The exclusion criteria include not being pregnant or breastfeeding, having documented CNS disease, and having received G-CSF or GM-CSF within 2 weeks prior.",
    "The sample is a phase 2 clinical trial for non-small cell lung cancer. The trial includes patients with stage IIIB or IV NSCLC, who have measurable disease and an ECOG performance status of 0-1. Patients with asymptomatic brain metastasis are also eligible if they have completed radiotherapy/radiosurgery at least 2 weeks prior to enrollment. The trial excludes patients with a history of prior cetuximab or other therapy that specifically and directly targets the EGFR pathway, prior severe reaction to a monoclonal antibody, or prior erythropoietin treatment. Women of childbearing potential must be using an adequate method of contraception to avoid pregnancy throughout the study. The trial requires physical and laboratory test findings to ensure adequate hematologic, hepatic, and renal function. The trial also prohibits prisoners or subjects who are compulsorily detained for treatment of either a psychiatric or physical illness from enrolling.",
    "The sample is a phase 2 clinical trial for the treatment of gout, hyperuricemia, arthritis, and joint disease. The trial involves the use of the drugs ulodesine and placebo. The eligibility criteria include being between the ages of 18 and 70, having a baseline sUA level of at least 6.0 mg/dL after at least 2 weeks of treatment on a stable 300 mg dose of allopurinol, and having a documented diagnosis of gout according to the American Rheumatism Association. Participants must also be willing and able to take colchicine or naproxen as prophylaxis for gout flares and meet certain requirements for contraception. Exclusion criteria include being unable to tolerate the treatment, having certain medical conditions, or having a history of drug abuse.",
    "The sample is a phase 2 clinical trial for asthma. The trial includes subjects who are at least 12 years old and have a documented diagnosis of asthma for at least 6 months prior to the study start. The trial involves the use of two drugs, levalbuterol hfa mdi followed by racemic albuterol hfa mdi and racemic albuterol followed by levalbuterol hfa mdi. The eligibility criteria include being in good health with the exception of reversible airways disease, having a chest X-ray, and being able to complete diary cards and medical event calendars reliably. Exclusion criteria include pregnancy or lactation, participation in another clinical trial, and a history of hospitalization for asthma within 4 weeks prior to study start.",
    "The sample is a phase 2 trial for patients with osteoarthritis in both knees. The trial is testing the effectiveness of ketoprofen, an NSAID, in reducing moderate pain in the most involved knee. Patients who completed a previous study or discontinued due to lack of efficacy are eligible, as well as those who have used an oral NSAID on at least three days per week for the last three months. Patients must also demonstrate x-ray evidence of osteoarthritis in the most involved knee during the last six months. Exclusion criteria include patients currently receiving physical therapy to either knee, having a history of allergy or hypersensitivity to ketoprofen, naproxen, or acetaminophen, or having a medical condition that would compromise their ability to complete the required assessments and visits. Patients who have received intra-articular injections or arthroscopy of the most involved knee during three months before screening visit, have a large bulging effusion, or have inflammation of the most involved knee that could be related to gout, pseudogout-induced synovitis, or infection are also excluded. Patients with a history of partial or total knee replacement in either knee, or a history of gout, pseudo-gout induced synovitis, or infection of the more severe knee are also excluded.",
    "The sample is a phase 2 clinical trial for macular degeneration. The trial involves the use of pazopanib eye drops and has specific eligibility criteria for subjects to be enrolled. The criteria include having consented to participate, being 50 years or older, having a specific type of macular degeneration in one eye, and meeting certain visual acuity and lesion area requirements. There are also exclusion criteria, such as having other eye diseases or certain medical conditions, that would prevent enrollment in the trial. The sample includes a detailed list of inclusion and exclusion criteria for the trial.",
    "The sample is a phase 2 clinical trial for patients with locally advanced, inflammatory, or early stage, unilateral, and histologically confirmed invasive breast cancer. The trial is specifically for patients with HER2-positive tumors, confirmed by central testing using immunohistochemistry (IHC) and in situ hybridization (ISH) methods. The drug being tested is trastuzumab emtansine, and patients must be willing to receive anthracycline-based chemotherapy or have received doxorubicin/cyclophosphamide (AC) OR 5-fluorouracil (FU)/epirubicin/ cyclophosphamide (FEC) in a similar dose and schedule as described in the protocol as part of neoadjuvant or adjuvant treatment. The eligibility criteria include being an adult patient \u2265 18 years of age, having an ECOG performance status of 0 or 1, and having adequate hematologic, biochemistry, and cardiac assessments. The exclusion criteria include having stage IV or bilateral breast cancer, being pregnant or breastfeeding, having a history of other malignancy within the previous 5 years (except contralateral breast cancer and ductal carcinoma in situ (DCIS)/lobular carcinoma in situ (LCIS), appropriately treated carcinoma in situ of the cervix, non-melanoma skin carcinoma, Stage I uterine cancer, or other cancers with outcome similar to those mentioned above), and having active cardiac history.",
    "The sample is a record of a clinical trial with a phase 2 designation. The trial is focused on the treatment of peripheral T-cell lymphoma using the drug alemtuzumab. The eligibility criteria for the trial include a diagnosis of one of several specific types of T-cell lymphoma, being newly diagnosed and between the ages of 15-65, and having a complete workup for baseline evaluation. Exclusion criteria include a known hypersensitivity to the drug, prior antilymphoma treatment, poor performance status, and various medical conditions that would preclude aggressive chemotherapy. Pregnant or lactating women are also excluded. The sample includes both inclusion and exclusion criteria in a detailed format.",
    "The sample is a phase 2 clinical trial for patients infected with HIV-1 type B or CRF02 and presenting with clinical lipohypertrophy. The trial is testing the effectiveness of the drug combination raltegravir-maraviroc. The eligibility criteria include being at least 18 years old, having received antiretroviral therapy for at least 5 years, having stable treatment for at least 6 months, having an undetectable plasma viral load, having an R5 tropic virus, and never having been treated with raltegravir or maraviroc. The trial also requires efficient contraception for women and free and informed written consent. Exclusion criteria include having X4, X4/5 or undetermined tropism of the HIV virus, chronic viral hepatitis B or C, and other medical conditions.",
    "The sample is a phase 2 clinical trial for patients with myelodysplastic syndrome. The trial requires patients to have a HLA-identical sibling or unrelated donor, and a target graft size of 2 to 10 x 106 CD34+ cells/kg BW recipient or at least 2 x 108 nucleated cells /kg BW. Patients must be between the ages of 18 and 60, have a Karnofsky Index of over 80%, and provide written informed consent. Exclusion criteria include previous allogeneic transplantation, severe concomitant illnesses, and known hypersensitivity to treosulfan and/or fludarabine.",
    "The sample is a phase 2 clinical trial for patients with or without documented coronary artery disease and dyslipidemia. The trial involves the use of two drugs, rvx000222 and placebo rvx000222. The eligibility criteria include being male or female and at least 18 years old, having a certain level of HDL-C, and taking statin therapy for at least 30 days prior to screening. Exclusion criteria include having clinically significant heart disease, uncontrolled hypertension, evidence of renal impairment, and a history of drug or alcohol abuse within the last 12 months. The trial also has various other criteria that must be met or avoided, and persons directly involved in the execution of the protocol are excluded.",
    "The sample is a phase 2 clinical trial for HIV infections. The trial is testing the effectiveness of the drugs tenofovir and abacavir on HIV-1 infected individuals who have not received any prior antiretroviral therapy. The eligibility criteria include having a CD4+ cell count greater than 200 cells/mm3, an HIV-1 RNA level greater than 5000 copies/mL, and meeting certain laboratory values. Exclusion criteria include having NRTI or NNRTI-associated resistance mutations, being pregnant or breastfeeding, having active drug or alcohol use, and having a serious illness requiring systemic treatment or hospitalization. Participants must also be at least 18 years old and willing to give written informed consent.",
    "The sample is a record of a clinical trial in phase 2 for the treatment of overactive bladder and urinary incontinence. The trial involves the use of a placebo drug and has specific eligibility criteria for participants, including being between 18-85 years old, having been diagnosed with overactive bladder at least 6 months ago, and being willing to record bladder function information in a diary. There are also exclusion criteria, such as not currently using catheterization to control incontinence and not having used botulinum toxin type A or any other botulinum toxin previously for any condition.",
    "The sample is a phase 2 clinical trial for the treatment of urothelial carcinoma and bladder cancer using the drug sunitinib. The trial includes patients who have previously undergone platin-based neoadjuvant chemotherapy and radical cystectomy revealing pT3NxM0 or pTanyN+M0. Patients must have an ECOG performance status of 0-1 and no evidence of metastases within 4 weeks of registration. The trial also has exclusion criteria, including prior antiangiogenic therapy and prior pelvic radiation for bladder cancer. The diseases are listed with their corresponding ICD-10 codes, and the eligibility criteria are provided for both inclusion and exclusion.",
    "The sample is a record of a clinical trial with a phase 2 designation. The trial is focused on the disease of type 2 diabetes mellitus and includes a list of associated ICD-10 codes. The trial involves testing several drugs, including a placebo and various doses of pf-04937319 and sitagliptin. The eligibility criteria for the trial include patients with type 2 diabetes who are on metformin and are between the ages of 18-55, regardless of gender. The exclusion criteria include patients with type 1 diabetes, those who are medically unstable, and those with unacceptable clinical laboratory test results at screening.",
    "The sample is a record of a clinical trial with a phase 2 designation. The trial is focused on the treatment of chronic hepatitis C and involves a list of drugs including copegus, pegasys, ro5024048, danoprevir, and ritonavir. The trial also has a list of diseases and their corresponding ICD-10 codes. The eligibility criteria for the trial are listed under inclusion and exclusion criteria, which include age, genotype, previous treatment failure, and absence of certain co-infections or liver diseases.",
    "The sample is a phase 2 clinical trial for the treatment of schizophrenia. The trial includes patients between the ages of 18 and 55 who are experiencing an acute exacerbation of psychosis and have a history of at least three months exposure to one or more antipsychotic therapies. The trial excludes pregnant or breastfeeding women, patients with concurrent dementia, delirium, mental retardation, epilepsy, drug-induced psychosis, or history of significant brain trauma, patients with schizoaffective disorder, bipolar disorder, acute mania, or major depression with psychotic features, patients considered to be an imminent danger to themselves or others, patients with hematological, renal, hepatic, endocrinological, neurological, or cardiovascular disease or substance abuse, and patients judged by the Investigator to be inappropriate for the study. The trial will test the effectiveness of three drugs: iti-007, placebo, and risperidone.",
    "The sample is a phase 2 clinical trial for locally advanced or metastatic breast cancer patients who have previously undergone at least two but no more than seven chemotherapy treatments. The trial requires patients to have received prior therapies including a taxane, an anthracycline, and capecitabine, as well as trastuzumab and lapatinib for patients whose tumors are positive for the human epidermal growth factor receptor 2 (HER2). Patients must also have a confirmed breast cancer tumor expressing GPNMB. The trial excludes patients with ongoing neuropathy or other chemotherapy or radiation-related toxicities that are moderate or worse in severity, known brain metastases, significant cardiovascular disease, or any other underlying medical condition that would make the administration of study treatment hazardous or obscure the interpretation of side effects.",
    "The sample is a phase 2 clinical trial for patients with malignant pleural mesothelioma. The trial is testing the effectiveness of pazopanib hydrochloride as a treatment. The eligibility criteria include having measurable disease, an ECOG performance status of 0-2, and a life expectancy of at least 12 weeks. Patients must also meet certain medical criteria, such as having certain blood counts and liver function tests within normal limits. Patients cannot have certain medical conditions, such as uncontrolled blood pressure or a history of certain cardiovascular illnesses. Patients must also not be pregnant or nursing and must use effective contraception if fertile. The trial excludes patients who have had more than one prior systemic therapy for malignant pleural mesothelioma or who have had major surgery within the past 4 weeks. The trial also excludes patients who are taking certain medications or who have certain medical conditions that could limit their ability to comply with the study requirements.",
    "The sample is a record of a clinical trial with a phase 2 designation. The trial is focused on the disease asthma, with a list of ICD-10 codes associated with the disease. The trial involves the use of multiple drugs, including amg 853 and a placebo. The eligibility criteria for the trial includes being between the ages of 18 and 65, having a percent of predicted FEV1 between 50% and 80%, and ongoing asthma symptoms with an ACQ score of at least 1.5 points. Exclusion criteria includes a history of chronic obstructive pulmonary disease or other chronic pulmonary condition, uncontrolled systemic disease, and a respiratory infection within 4 weeks of the screening visit.",
    "The sample is a record of a clinical trial with a phase 2 designation. The trial is focused on the disease asthma, and the associated ICD-10 codes are listed. The trial involves the use of three drugs: indacaterol, placebo, and salmeterol. The eligibility criteria for the trial are also listed, including both inclusion and exclusion criteria. Inclusion criteria include being a Japanese asthmatic patient between the ages of 18 and 75. Exclusion criteria include recent hospitalization or emergency room treatment for an acute asthma attack, tobacco use within the past 6 months, a history of malignancy (with the exception of localized basal cell carcinoma of the skin), and pregnancy or nursing. The sample also notes that there are other protocol-defined inclusion/exclusion criteria that apply to the study.",
    "The sample is a phase 2 clinical trial for chronic hepatitis C. The trial includes patients who have never received treatment with an interferon alfa product or an interferon alfa combination product, have HCV genotype 2 or 3, and have compensated liver disease. The trial excludes patients with decompensated liver disease, pregnant or lactating females, history of any other medical disease or condition that would make the subject unsuitable for the study, and current drug or alcohol addiction. The trial uses two drugs, albuferon and ribavirin, and the eligibility criteria include specific minimum criteria for white blood cell count, absolute neutrophil count, platelets, and hemoglobin.",
    "This sample is for a phase 2 clinical trial for small cell lung cancer. The trial is testing the drug gefitinib. The eligibility criteria for the trial include providing written informed consent, having confirmed relapsed or refractory SCLCr, being 18 years or older with a life expectancy of more than 2 months. The exclusion criteria include having clinically active interstitial lung disease or any other co-existing malignancies diagnosed within the last 5 years, except for basal cell carcinoma or cervical cancer in situ.",
    "The sample is a phase 2 trial for colorectal cancer. The trial includes patients with metastatic or inoperable locally advanced colorectal cancer who have at least one measurable target lesion. The trial excludes patients who have previously received systemic therapy for advanced or metastatic disease or have previously been treated with bevacizumab. The trial involves the use of capecitabine, oxaliplatin, and bevacizumab as drugs. The diseases are listed as 'colorectal cancer' and the icd-10 codes associated with the disease are also provided.",
    "The sample is a phase 2 clinical trial for HIV infections. The trial includes adult patients who are 18 years or older and have virologic failure with a viral load of more than 1000 RNA copies/mL. The patients must have been on the same stable HAART for more than 4 weeks and must be Fuzeon-naive. The trial excludes patients with HIV-2 coinfection, active opportunistic infection in the 4 weeks prior to screening, cirrhosis, or severe liver or renal disease. The trial will test the efficacy of enfuvirtide (Fuzeon) in combination with optimized background ARV therapy.",
    "The sample is a phase 2 clinical trial for the treatment of pulmonary hypertension using the drug Gleevec. The trial is open to male and female patients between the ages of 8-18 who have been diagnosed with idiopathic pulmonary arterial hypertension and have a functional classification of WHO class III-IV. The trial has specific inclusion and exclusion criteria, including stable IPAH medications for at least 3 months prior to the baseline visit, negative pregnancy tests for sexually active female patients of childbearing potential, and no pre-existing lung disease or congenital heart disease. The trial also excludes patients with certain medical conditions or allergies, and those who have participated in other treatment studies within 3 months prior to dosing.",
    "The sample is a record of a clinical trial with a phase 2 designation. The trial is focused on Parkinson's disease and the drug being tested is E2007. The record includes a list of inclusion and exclusion criteria for patients who are eligible to participate in the trial. The criteria cover a range of factors including medical history, current health status, and medication use. Patients who have completed a previous study and meet the entry criteria are eligible to participate. However, pregnant or lactating women, patients with serious adverse events related to the study drug, and patients with certain medical conditions or cognitive impairments are excluded from the trial. The record also includes a list of diseases and their corresponding ICD-10 codes.",
    "The sample is a phase 2 clinical trial that involves patients with sinusitis and cystic fibrosis. The trial is testing the effectiveness of the drug Pulmozyme (dornase alfa) compared to a placebo. The eligibility criteria for the trial include a clinical and laboratory diagnosis of cystic fibrosis, age greater than or equal to 5 years, forced expiratory volume in 1 second (FEV1) greater than or equal to 40% predicted, and sinus surgery within one week of enrollment. The exclusion criteria include pregnancy and intolerance of orally inhaled Pulmozyme (dornase alfa). The icd-10 codes for the diseases are also provided.",
    "The sample is a phase 2 clinical trial for patients with adenocarcinoma of the gastroesophageal junction or gastric cancer. The trial is testing the effectiveness of a combination of drugs including cisplatin, fluorouracil, and leucovorin calcium. The eligibility criteria include having confirmed histologically adenocarcinoma of the stomach or gastroesophageal junction, being in stage IB, II, or III disease according to TNM classification or type I, II, or III disease according to Siewert classification, having no gastric scirrhous carcinoma, having measurable disease according to RECIST V1.1, and being considered operable with curative intent. Patients must also meet certain patient characteristics such as having a WHO performance status of 0-2, a polynuclear neutrophil count of at least 1,500/mm\u00b3, and no recent weight loss exceeding 15%. Prior concurrent therapy is not allowed, and patients must not have had prior chemotherapy or radiotherapy for gastric cancer or any other concurrent anticancer treatment, immunotherapy, or hormone therapy.",
    "The sample is a phase 2 clinical trial for the treatment of polycythemia vera, a disease characterized by an overproduction of red blood cells. The trial is testing the drug dasatinib and has specific eligibility criteria for patients to participate. These criteria include being over 18 years old, having a certain performance status, and having previously received limited therapies. Patients must also have adequate organ function and be able to take oral medication. Women of childbearing potential must have a negative pregnancy test and agree to use contraception during the study. The trial has exclusion criteria, such as patients with certain cardiac problems or bleeding disorders. The sample includes a detailed list of inclusion and exclusion criteria for the trial.",
    "The sample is a phase 2 clinical trial for patients with non-small-cell lung carcinoma. The trial is testing the effectiveness of the drugs docetaxel and cisplatin. The eligibility criteria include having a confirmed diagnosis of NSCLC, being between the ages of 18 and 75, having a life expectancy of at least 12 weeks, and meeting certain laboratory and lung function requirements. Patients must also not have certain medical conditions or be taking certain medications. The exclusion criteria include having small cell lung cancer, being pregnant or lactating, and having prior treatment for NSCLC. The sample includes both inclusion and exclusion criteria for the trial.",
    "The sample is a phase 2 clinical trial for rheumatoid arthritis. The trial includes patients who are 18 to 75 years old and have had active RA for at least 6 months. The patients must have at least 6 swollen joints and 6 tender joints based on a 28 joint count. They must also be on stable doses and regimen of allowed RA medications and currently receiving at least 10 mg of methotrexate a week. The trial excludes patients with certain conditions such as Felty's syndrome, psoriatic arthritis, gout, or auto-immune rheumatic disease. Patients who have had certain surgical procedures within 30 days of screening or likely to need joint or tendon surgery or other surgical procedure during the study are also excluded. The trial also excludes patients who have had previous treatment with any biologic response modifying agent for RA within 90 days or 5 half-lives, whichever is greater, prior to screening, or previous treatment with rituximab at any time. Patients who use corticosteroid therapy equivalent to an average daily dose of >10 mg of prednisone are also excluded. The trial requires patients to comply with the protocol and study procedures and excludes patients who have any other significant illness or condition that may adversely affect their participation in the study.",
    "The sample is a phase 2 clinical trial for patients with ovarian cancer. The trial is testing the effectiveness of the drugs docetaxel and carboplatin. The eligibility criteria include having confirmed epithelial ovarian cancer, peritoneal serous cancer, or tubal carcinoma, having received only one prior chemotherapy regimen, and having measurable or evaluable disease. Patients must also have an Eastern Cooperative Oncology Group (ECOG) performance status of less than 2, be over 18 years old, and meet certain blood count and liver function requirements. Exclusion criteria include prior treatment with Taxotere, concurrent immunotherapy or hormonal therapy, and serious concurrent medical or psychiatric illness.",
    "The sample is a phase 2 clinical trial for advanced breast cancer. The trial is testing the effectiveness of goserelin acetate, a drug used to treat breast cancer. The trial is open to pre-menopausal women aged 18 years or over with histologically/cytologically-confirmed estrogen receptor positive (ER +ve) breast cancer. Participants must have a World Health Organization (WHO) performance status of 0, 1, or 2 and provide written informed consent. Exclusion criteria include treatment with tamoxifen or other hormonal therapies as early breast cancer (EBC) adjuvant in the previous 24 weeks, received radiotherapy within the past 4 weeks, history of systemic malignancy other than breast cancer within the previous 3 years, and estimated survival less than 24 weeks. The icd-10 codes associated with the disease are also provided.",
    "The sample is a phase 2 clinical trial for the treatment of cutaneous t-cell lymphoma using the drug romidepsin. The eligibility criteria for the trial include being 18 years or older, having a confirmed diagnosis of CTCL, and having failed previous therapies. Patients with certain cardiac abnormalities or other medical conditions are excluded from the trial. Women of childbearing potential must use effective contraception during the study and for at least one month after receiving the last dose of romidepsin. The use of certain medications, including CYP3A4 inhibitors, is also prohibited during the trial.",
    "The sample is a phase 2 clinical trial for patients with peripheral T-cell lymphoma. The trial is for patients who have not received prior treatment, except for radiation or a single cycle of CHOP. Patients must have at least one measurable site of disease and an ECOG performance status of 0 to 2. The trial includes a list of drugs, including denileukin diftitox, cyclophosphamide, doxorubicin, vincristine, and prednisone. The eligibility criteria include various medical conditions, such as adequate bone marrow reserve, liver function, and renal function. Patients with certain medical conditions, such as Mycosis Fungoides or Sezary Syndrome, active Hepatitis B or Hepatitis C infection, or known HIV infection, are excluded from the trial. The trial also excludes patients with preexisting severe cardiovascular disease, ongoing antineoplastic chemotherapy, radiation, hormonal or immunotherapy, or investigational medications within the past 30 days, and patients with deep vein thrombosis within 3 months.",
    "The sample is a phase 2 clinical trial for patients aged 16 and above with chronic myelogenous leukemia (CML) in either chronic, accelerated, or blast phase. The trial includes patients who are refractory or resistant to prior imatinib mesylate therapy, or have failed to achieve at least a complete hematologic or cytogenetic response to treatment. Patients with accelerated or blast phase may be newly diagnosed and previously untreated or previously treated with imatinib mesylate. The trial involves the use of homoharringtonine and imatinib mesylate drugs. The eligibility criteria include meeting specific disease criteria, having completed all previous anti-leukemic therapy for at least 2 weeks, and having fully recovered from side effects of a previous therapy. Patients must also have a certain level of bilirubin, alanine aminotransferase, and creatinine, and an Eastern Cooperative Oncology Group (ECOG) performance status of 0-2. Patients must be able to comply with the requirements of the entire study and provide written informed consent prior to any study-related procedure. The exclusion criteria include having NYHA Class III or IV heart disease, active ischemia, or any other uncontrolled cardiac condition, myocardial infarction in the previous 12 weeks, other intercurrent illness which would preclude study conduct and assessment, being pregnant or lactating, and having any medical or psychiatric condition which may compromise the ability to give written informed consent or to comply with the study protocol.",
    "The sample is a phase 2 clinical trial for the treatment of tardive dyskinesia. The trial is looking for subjects who have been diagnosed with schizophrenia, schizoaffective disorder, mood disorder, or gastrointestinal disorder and have been diagnosed with neuroleptic-induced tardive dyskinesia for at least 3 months prior to screening. The trial is testing the effectiveness of the drugs nbi-98854 and placebo. The eligibility criteria include having a stable dose of antipsychotic medication for at least 30 days before the study, having stable doses of concurrent medications and conditions being treated, and having a negative urine drug screen and alcohol breath test. The exclusion criteria include having an active clinically significant unstable medical condition, a history of substance dependence or abuse, a known history of neuroleptic malignant syndrome, and receiving any excluded concomitant medication.",
    "The sample is a phase 2 trial that involves patients with various thromboembolic diseases and who are undergoing unilateral total hip arthroplasty. The trial is testing the effectiveness of three drugs: du-176b 15mg, du-176b 30mg, and enoxaparin sodium 20 mg. The eligibility criteria for the trial include being between 20-84 years old and not having risks of hemorrhage or thromboembolic risks. Exclusion criteria include being pregnant or wanting to become pregnant, weighing less than 40 kg, and having risks of hemorrhage or thromboembolic risks.",
    "The sample is a phase 2 clinical trial for patients with hematologic or oncologic diagnoses without morphological evidence of disease, in which allogeneic HSCT (hematopoietic stem cell transplantation) is thought to be beneficial. The trial requires patients to have a related donor who is a two or more allele mismatch at the HLA-A, B, C, DR loci, and adequate organ function. The trial also requires patients to have a performance status of over 80% (TJU Karnofsky) and a Hematopoietic Comorbidity Index (HCT-CI) score of less than 5 points. Patients must be willing to use contraception if they have childbearing potential and able to give informed consent. Exclusion criteria include a performance status of less than 80% (TJU Karnofsky), an HCT-CI score of more than 5 points, HIV positivity, active involvement of the central nervous system with malignancy, psychiatric disorder that would preclude patients from signing an informed consent, pregnancy, life expectancy of less than 6 months for reasons other than their underlying hematologic/oncologic disorder, recent receipt of alemtuzumab or horse or rabbit anti-thymocyte globulin, inability to receive cyclophosphamide, and evidence of another malignancy.",
    "The sample is a phase 2 clinical trial for patients with biopsy-proven stage I/II non-small cell lung cancer who are candidates for surgical resection. The trial is testing the drug Tarceva (erlotinib). The eligibility criteria include having acceptable cardiac, breathing, kidney, liver, and bone marrow functions, being 18 years or older, and women of child-bearing potential must be taking adequate contraceptive precautions. The exclusion criteria include not being able to be on any other anti-cancer treatment during the study, having prior treatment with any EGFR inhibitor, having prior treatment with chemotherapy or radiation for this disease, having other active cancers, having tumors with a mixed histology of small cell and non-small cell carcinoma as well as patients with pulmonary carcinoid tumors, having gastro-intestinal abnormalities, including active peptic ulcer or inflammatory bowel disease, having hypersensitivity to compounds similar in chemical composition to Tarceva, having active infection or serious underlying medical conditions which would impair protocol treatment.",
    "The sample is a phase 2 clinical trial for patients with esophageal carcinoma. The trial involves the use of cetuximab and chemotherapy (docetaxel, cisplatin, 5-fluorouracil). The eligibility criteria include being over 18 and under 70 years old, having a Karnofsky performance status of over 70%, having a life expectancy of more than 3 months, and having a histologically confirmed diagnosis of squamous cell carcinoma or adenocarcinoma of the oesophagus or the gastroesophageal junction. The patients must have a T1N1M0 or T2-4; any N; M0 stage of the disease. The trial also requires the presence of a unidimensionally measurable and/or assessable lesion, adequate renal and liver function, and adequate nutritional status. The exclusion criteria include prior thoracic radiotherapy and/or systemic chemotherapy and/or oesophageal surgery, multiple carcinoma of the oesophagus, and diagnosis of any other cancer in the previous 5 years with the exception of appropriately treated carcinoma in situ of the uterine cervix and/or basal cell carcinoma of the skin.",
    "The sample is a phase 2 clinical trial for chronic prostatitis and pelvic pain. The trial involves the drug thalidomide and has specific eligibility criteria for male subjects aged 18 and older who have had symptoms of CP/CPPS for at least 3 months and are refractory to other therapies. The trial also requires a minimum score of 15 on the CPSI and written informed consent from male subjects. Additionally, male subjects must be willing and able to comply with the FDA-mandated S.T.E.P.S. program, which includes contraceptive measures and warnings about the hazards of taking thalidomide and exposing a fetus to the drug. The trial has exclusion criteria for subjects with certain medical conditions or who are not willing to comply with the S.T.E.P.S. program.",
    "The sample is a clinical trial for a drug called indacaterol maleate, which is being tested for the treatment of pulmonary disease, chronic obstructive (COPD) and other obstructive lung diseases. The trial is in phase 2/phase 3 and involves patients aged 40-75 years with a smoking history of at least 10 pack years and symptoms such as cough, sputum production, and shortness of breath. The trial has inclusion criteria such as FEV1 less than 65% of the predicted normal value and at least 0.75 L, and pre-bronchodilator FEV1/FVC less than 70%. Exclusion criteria include a history of asthma or COPD diagnosis before the age of 40, hospitalization for COPD exacerbation within the previous 6 weeks, and use of long-term oxygen therapy. Other protocol-defined inclusion/exclusion criteria may also apply.",
    "The sample is a phase 2 clinical trial for prostate cancer. The trial includes patients who have undergone radical prostatectomy within the last 2 months and have a predicted risk of PSA relapse by 5 years. The trial also requires low levels of circulating prostate cancer cells in the blood, detected by PCR amplification of PSA mRNA 6 weeks post-prostatectomy. The trial excludes patients with pre-operative serum PSA level >20ng/ml, clinical evidence of metastases, prior treatment with either ADT or bisphosphonate therapy, current active dental problems, recent or planned dental or jaw surgery, and other protocol-defined inclusion/exclusion criteria may apply. The trial will test the effectiveness of zoledronic acid and docetaxel as treatments for prostate cancer.",
    "The sample is a phase 2 clinical trial for allergic asthma. The trial includes the drug omalizumab and a placebo. The eligibility criteria for the trial include being between the ages of 18 to 65 years, having a normal chest X-ray within 2 years of screening, and meeting the criteria for the diagnosis of allergic asthma. Exclusion criteria include having a history of drug or alcohol abuse, being pregnant or lactating, and having significant medical illness other than asthma. The trial also excludes individuals who have taken other investigational drugs within 30 days or 5 half-lives prior to the screening visit, whichever is longer.",
    "This is a sample from a clinical trial table that includes information about the phase of the trial, diseases being studied, icd-10 codes of the diseases, drugs being used, and eligibility criteria for participants. In this particular sample, the trial is in phase 2 and is studying metastatic breast cancer. The icd-10 codes associated with this disease are listed, as well as the drugs being used in the trial (gemcitabine and paclitaxel). The eligibility criteria for participants are also listed, including requirements such as having a measurable lesion and a performance status of 0 or 1 on the Eastern Cooperative Oncology Group (ECOG) Scale. There are also exclusion criteria listed, such as prior chemotherapy for unresectable, locally advanced breast cancer or metastatic disease, and concurrent administration of any other tumor therapy.",
    "The sample is a phase 2 clinical trial for two types of lung cancer, non-small cell and small cell. The trial is testing the effectiveness of the drugs enzastaurin and placebo in treating brain metastases of lung cancer. The eligibility criteria for participants include having received whole brain radiotherapy within a certain timeframe, being over 18 years old, and having adequate organ function. Exclusion criteria include being unable to swallow tablets, taking certain anti-epileptic drugs, and having had any systemic anti-cancer treatment within the last 2 weeks prior to enrollment. The diseases and their corresponding ICD-10 codes are also listed.",
    "The sample is a record of a clinical trial with a phase 2 designation. The trial is focused on treating partial epilepsy, and the icd-10 codes associated with the disease are listed. The trial involves two drugs, ykp3089 and placebo. The eligibility criteria for the trial are also listed, including a diagnosis of treatment-resistant partial epilepsy, a history of epilepsy for at least 2 years, and a minimum number of seizures per month. The exclusion criteria are also listed, including a history of alcoholism or drug addiction, recent status epilepticus, and current major depressive episode.",
    "The sample is a phase 2 clinical trial for lung cancer patients who have not received prior chemotherapy or hormonal therapy. The trial is testing the effectiveness of the drugs erlotinib and bevacizumab. The eligibility criteria include having non-small cell lung cancer at stage III b with a pleural effusion or stage IV, with histology that is not squamous cell. Participants must also have measurable disease according to RECIST and an ECOG Performance Status of 2. They must not have received prior treatment with an epidermal growth factor receptor (EGFR) inhibitor or antiangiogenic agent, or any investigational agent within 30 days prior to being registered for protocol therapy. Participants must be over 18 years old, willing to use an effective method of contraception, and able to comply with study and/or follow-up procedures. Exclusion criteria include evidence of bleeding diathesis or coagulopathy, central nervous system involvement or brain metastases, major surgical procedure or significant traumatic injury within 28 days prior to registration, and other active malignancy.",
    "The sample is a phase 2 clinical trial for the treatment of type 2 diabetes mellitus. The trial includes subjects who have been diagnosed with T2DM for at least 6 months and have stable hypertension or dyslipidemia on therapy. The trial requires subjects to have HbA1c levels between 7.0% and 9.5% and be on monotherapy with metformin at a maximum tolerated dose of at least 1000 mg for at least 2 months prior to dosing. The trial also requires subjects to have a fasting plasma glucose level less than 13.3 mmol/L at screening and be between 20 and 70 years of age. The trial excludes subjects who require insulin therapy or use of combination oral antidiabetic medications or use of monotherapy other than metformin within the 3 months prior to screening, have renal impairment, or have any concurrent serious illness that may interfere with a subject completing the study. The trial also excludes subjects who have a positive pre-study Hepatitis B surface antigen, or positive Hepatitis C result within 3 months of screening, or have a positive pre-study drug screen.",
    "The sample is a phase 2 trial that focuses on aging, obesity, insulin resistance, and hypogonadism. The trial uses a topical testosterone gel of 10 g/day as the drug. The eligibility criteria for the trial includes men over 60 years of age with a total testosterone level below 300 ng/dL, waist circumference over 102 cm, and fasting insulin level over 18 U/L. The exclusion criteria includes various medical conditions such as uncontrolled hypothyroidism, diabetes, and sleep apnea requiring CPAP. The trial also excludes individuals who have used anabolic agents or cytokine therapy in the past 12 months.",
    "The sample is a phase 2 trial that includes healthy participants who are between 21 and 45 years old and have a normal weight and body mass index. The trial involves the drug sr141716 (rimonabant) and focuses on two diseases: healthy and alcohol drinking. The eligibility criteria include being certified as healthy, having normal vital signs, and having laboratory results within the normal range. Participants must also provide written informed consent and agree to abstain from illicit drugs and grapefruit juice consumption during the study. Exclusion criteria include a history of significant medical conditions or psychiatric disorders, frequent headaches or migraines, and a positive reaction to certain tests.",
    "This sample is a phase 2 clinical trial for non-small cell lung cancer. The trial is testing the effectiveness of pazopanib plus paclitaxel as a first-line therapy for patients with Stage IIIB or Stage IV NSCLC who have not received any prior systemic therapy. Patients must have an ECOG performance status of 0-2 and must not be eligible for doublet therapy as first-line therapy. The inclusion criteria also specify that patients must have a confirmed diagnosis of NSCLC and must not have received prior systemic first-line therapy for Stage IIIB/IV NSCLC with chemotherapy or any other biologic therapy. The exclusion criteria state that patients who are appropriate for doublet therapy as first-line therapy are not eligible for the trial.",
    "The sample is a phase 2 clinical trial for patients with stage IV or recurrent adenocarcinoma of the breast. The trial is testing the effectiveness of the drugs docetaxel and erlotinib hydrochloride. Patients must have measurable disease and not have had disease recurrence within 1 year of receiving prior adjuvant docetaxel. Hormone receptor status is not specified. Patients must be 18 years or older, male or female, and have a performance status of ECOG 0-2 or Karnofsky 60-100%. Patients must have a life expectancy of more than 6 months and meet certain hematopoietic, hepatic, renal, and cardiovascular criteria. Patients must not be pregnant or nursing, have no ongoing or active infection, and have no other concurrent uncontrolled medical condition that would preclude study participation. Prior trastuzumab (Herceptin) and hormonal therapy are allowed, but no prior chemotherapy for recurrent or metastatic disease. Patients must not have had a severe hypersensitivity reaction to docetaxel or drugs formulated with polysorbate 80, and must have no other malignancy within the past 10 years except inactive nonmelanoma skin cancer, carcinoma in situ of the cervix, carcinoma in situ of the breast, or bilateral breast cancer. Patients must not have peripheral neuropathy greater than grade 1, no other concurrent investigational agents, and no psychiatric illness or social situation that would preclude study compliance.",
    "The sample is a clinical trial for a drug called pioglitazone to treat endometriosis. The trial is in phase 2/phase 3 and the eligibility criteria include being a healthy woman between the ages of 18-45 with regular cycles and pelvic pain for at least 3 months. Participants must also have no prior use of hormonal therapy, no history of liver disease, and be scheduled for surgery to confirm the diagnosis of endometriosis. Exclusion criteria include major psychiatric conditions, liver dysfunction, pre-existing malignancy, and known pregnancy. The trial requires consent to participate and enrollment into the data analysis portion if endometriosis is diagnosed from surgical specimen.",
    "The sample is a phase 2 clinical trial for new-onset type 1 diabetes mellitus. The trial involves administering antithymocyte globulin or a placebo to participants who meet certain eligibility criteria. These criteria include being diagnosed with type 1 diabetes within 100 days of enrollment, testing positive for one or more autoantibodies, having a certain level of C-peptide, and having evidence of prior Epstein-Barr virus infection. There are also exclusion criteria, such as having certain infections or diseases, using certain medications, or being pregnant. The purpose of the trial is to evaluate the effectiveness and safety of the treatment.",
    "The sample is a phase 2 trial for pulmonary disease, chronic obstructive. The icd-10 codes for the disease are J44.9, J44.1, and J44.0. The trial involves the drugs salmeterol, tiotropium, and gsk233705. The eligibility criteria for the trial include being a non-childbearing female or postmenopausal, having a history of COPD as defined by ATS/ERS criteria, having moderate COPD that is responsive to ipratropium and salbutamol, and being a current or ex-smoker. The exclusion criteria include having unstable COPD, taking more than 1000 mcg of inhaled steroids per day, and not being able to take B-blockers.",
    "The sample is a phase 2 clinical trial for patients with chronic obstructive pulmonary disease. The trial involves the use of two drugs, bea 2180 br and tiotropium, and has eligibility criteria that include having moderate to severe airway obstruction, being a smoker or ex-smoker with a history of more than 10 pack years, and being at least 40 years old. Patients with any other significant disease or a history of asthma or allergic rhinitis will be excluded from the trial. The trial also requires patients to have an increase in FEV1 of at least 12% from baseline after inhalation of 80 ?g Atrovent MDI.",
    "The sample is a phase 2 clinical trial for depression and psychotic disorders. The trial involves the use of the drugs org 34517 and placebo. The eligibility criteria include having a severe depressive episode with psychotic features, being between 18 and 75 years old, and being willing to be hospitalized for at least 11 days. Exclusion criteria include having any other current psychiatric diagnosis, being at significant risk of committing suicide, and having any clinically unstable or uncontrollable disease that would put the patient at risk.",
    "The sample is a record of a clinical trial for multiple myeloma patients in phase 2. The trial involves the use of two drugs, bortezomib and dexamethasone. The eligibility criteria for the trial include having previously been diagnosed with multiple myeloma and requiring second or third line therapy due to disease progression or relapse. Patients must also have measurable disease, a Karnofsky performance status of at least 60%, and a life expectancy of more than 3 months. Exclusion criteria include prior therapy with bortezomib, severe allergic reactions to the drug, and neuropathy greater than grade 2 with pain. The sample also includes a list of diseases, icd-10 codes, and inclusion and exclusion criteria.",
    "The sample is a phase 2 clinical trial for the treatment of type 2 diabetes mellitus. The trial includes subjects who have not taken any anti-diabetic medication in the past 3 months or have been newly diagnosed and treated with diet and exercise for at least 6 weeks. The trial will test the efficacy and safety of the drugs \"gsk189075\" and \"placebo\". The eligibility criteria include having a documented diagnosis of T2DM and HbA1c levels between 7.0% and 9.5%, being 18 to 70 years old, and having a negative urine pregnancy test. The exclusion criteria include having a history of Type 1 diabetes mellitus, recent history or presence of clinically significant acute cardiovascular disease, significant renal disease, and any concurrent condition or any clinically significant abnormality identified on the screening physical examination, laboratory tests, ECG, including pulmonary, neurological or inflammatory diseases. The trial also has specific criteria for female participants, including the use of contraception methods and having a signed and dated written consent.",
    "The sample is a clinical trial for a drug that is being tested for the treatment of type 2 diabetes. The trial is in phase 2/phase 3 and involves the use of three drugs: rivoglitazone, pioglitazone, and placebo. The trial is looking for male or female patients between the ages of 18 and 75 who have type 2 diabetes and a HbA1c level between 7.5% and 10.5%. The trial has certain exclusion criteria, such as patients who are currently on insulin therapy or have a history of ketoacidosis or therapy with certain drugs. The trial's eligibility criteria are listed in detail under inclusion and exclusion criteria.",
    "The sample is a phase 2 clinical trial for patients with chronic obstructive pulmonary disease (COPD) who are being admitted to the hospital to treat an exacerbation of their condition. The trial includes inclusion criteria such as being 40 years of age or older, having normal prothrombin time and activated partial thromboplastin time, and certain exclusion criteria such as having certain diseases like asthma, left heart failure, or lung cancer, taking certain medications like Plavix or Warfarin, and having exacerbations that are too severe. Women who are pregnant or breastfeeding are also excluded. The trial involves open-label drugs and a placebo comparator with 0.9% sodium chloride and odsh. The eligibility criteria are designed to ensure that the trial participants are suitable for the study and that the results are reliable.",
    "The sample is a phase 2 clinical trial for patients diagnosed with idiopathic pulmonary fibrosis. The trial involves the use of the drugs pirfenidone and placebo. The eligibility criteria include being between 18-75 years old, having a resting state PaO2\u226550mg, FVC%\u226545% normal predicted value and DLCO\u226530% normal predicted value, and being clinically or multidisciplinarily diagnosed with idiopathic pulmonary fibrosis. Exclusion criteria include being allergic to pirfenidone, having dyspnea symptoms relieved in the past 6 months, being in an acute exacerbation phase, having malignant tumors or hemorrhagic diseases, having serious underlying pulmonary or heart disease, liver or kidney disease, having taken certain medications in the past 3 months, being pregnant or lactating, having participated in other clinical trials in the past month, or being assessed as inappropriate to participate by the investigator.",
    "The sample is a phase 2 clinical trial for rectal cancer. The trial includes patients between the ages of 18 and 80 who have bioptically confirmed adenocarcinoma of the rectum in operable T3-T4NxM0 status. Patients must not have had previous chemotherapy, radiotherapy of pelvis or abdomen, or tumor resection of a rectum carcinoma. The trial requires patients to have a WHO performance status of 0-2, adequate bone marrow reserve, adequate hepatic function, and adequate renal function. Women of childbearing potential must have a negative pregnancy test and be willing to use approved contraceptives during and at least 3 months after the study. Patients must have a life expectancy of at least 3 months and sign an informed consent before recruitment. Exclusion criteria include former radiotherapy of pelvis or abdomen, former chemotherapy, any other kind of malign tumor in the last 5 years, general contraindication or known hypersensitivity against Cetuximab and/or Capecitabine, and non-malign disease with contraindication with radiotherapy or chemotherapy with Cetuximab and Capecitabine or a resection of the rectum. Patients who are pregnant or breastfeeding, have florid serious infections, legally limited contractual capability, evidence of neurological or psychiatric disease that will constrict the patient's compliance, or evidence of lacking cooperation are also excluded.",
    "The sample is a phase 2 clinical trial for patients aged 4-75 with chronic myelogenous leukemia (CML) treatable by allogeneic hematopoietic stem cell transplant. The trial requires patients to have demonstrated refractoriness/resistance to STI571 and have an Eastern Cooperative Oncology Group (ECOG) performance status of 0-2. Patients must also have a human leukocyte antigen (HLA) matched sibling donor at the HLA-A, B, and DR loci or an unrelated hematopoietic stem cell donor matched using high resolution typing for class II human leukocyte antigen (HLA-DR beta-1, 3, 4, 5 and DQ beta-1) and matched with intermediate to high resolution molecular typing at class I human leukocyte antigen (HLA-A, B, and C) loci. The trial excludes patients who have received another investigational drug within 30 days, fertile men unwilling to use contraceptive techniques during and for 24 months following treatment, females who are pregnant or fertile women unwilling to use contraceptive techniques for two months prior to entering the study and for 24 months following treatment, patients with active bacterial or fungal infections unresponsive to medical therapy, patients with organ dysfunction including cardiac ejection fraction of less than 35% or pulmonary status with a diffusing capacity of the lung for carbon monoxide(DLCO) of less than 40% and/or receiving supplemental oxygen, patients with a history of non-compliance to medical regimens or who are considered potentially unreliable, patients with a history of any prior bone marrow or peripheral blood stem cell transplantation, patients with any other serious, uncontrolled, concomitant medical condition, and HIV positive patients. The eligibility criteria for donors are also included in the sample.",
    "The sample is a record from a clinical trial table. It includes information about the phase of the trial, which is phase 2, and the disease being studied, which is dry eye syndrome. The icd-10 codes associated with the disease are also listed. The drugs being tested are \"pro-148 ophthalmic solution\" and \"active comparator: systane \u00ae ophthalmic solution\". The eligibility criteria for the trial are listed, including inclusion criteria such as having a diagnosis of mild-to-moderate dry eye syndrome and being 18 years of age or older, and exclusion criteria such as having a history of active stage of any other concomitant ocular disease or taking any medication that could interfere with the study's results. The record also includes discontinuation criteria, which could result in a patient being removed from the study before completion.",
    "The sample is a phase 2 clinical trial for small cell lung carcinoma. The trial is looking for participants who have been histologically or cytologically diagnosed with SCLC and have distant metastases. Participants must have at least one measurable lesion and a WHO performance status of 0 to 1. They must not have received previous SCLC-related chemotherapy, surgery, or radiotherapy (except for brain metastasis). Participants must also have adequate function of major organs and systems, including the nervous and cardiovascular systems. Exclusion criteria include superior vena cava syndrome or obstruction of any vital structure, untreated malignant hypercalcemia, pleural effusion as the only manifestation of disease, extensive disease amenable to radiation therapy, symptomatic brain metastases requiring whole brain irradiation, and any concomitant malignancy excepting non-melanoma skin cancer or carcinoma in situ of the cervix. The drug being tested in this trial is sagopilone (bay86-5302, zk 219477).",
    "The sample is a phase 2 clinical trial that involves patients with carotid artery diseases and atherosclerosis. The trial is testing the effectiveness of the drug valsartan compared to a placebo. The eligibility criteria for the trial include having a certain thickness of the carotid artery, being within a certain age range, and being able to take certain medications. Exclusion criteria include recent use of certain medications, certain medical conditions, and inability to give informed consent. The trial will involve follow-up blood drawing and MR imaging.",
    "The sample is a phase 2 clinical trial for the treatment of Major Depressive Disorder (MDD) using the drug radafaxine. The trial includes patients who have been diagnosed with MDD and have had a current depressive episode lasting between 12 weeks and 24 months. Patients must be able to read and write at a sufficient level to provide a signed consent and if female, must be practicing an acceptable method of birth control. Patients with other psychiatric disorders that would affect their response to treatment, those who have not responded to two or more adequate courses of antidepressant therapy, those currently abusing illicit drugs or alcohol, those not currently receiving psychotherapy, those who have received electroconvulsive therapy within 6 months prior to screening, and those who are pregnant or lactating are excluded from the trial.",
    "The sample is a phase 2 clinical trial for patients with relapsed or refractory systemic Anaplastic Large Cell Lymphoma (ALCL) or mature T-cell lymphoma. The trial is testing the drug ucn-01 (7-hydroxystaurosporine). Patients must have evaluable or measurable disease and confirmed histology by the Laboratory of Pathology, National Cancer Institute (NCI). They must also have a Performance Status Eastern Cooperative Oncology Group (ECOG) less than or equal to 2, be 7 years or older, and meet certain criteria for creatinine, bilirubin, AST, ANC, and platelet levels. Patients must provide signed informed consent, not be pregnant or nursing, and be HIV negative. They must also be willing to use contraception and continue for at least 8 weeks following the last treatment. Patients should not have received systemic cytotoxic chemotherapy within 3 weeks of study entry and must have recovered from the toxic effects of prior therapy to a grade less than or equal to 1. They should not have a history of diabetes mellitus requiring insulin treatment, symptomatic pulmonary disease, or evidence of symptomatic cardiac disease. Patients may not be concurrently receiving any other investigational agents. They must not be a candidate for potentially curative (i.e. transplant) treatment at the time of study entry or have a window of opportunity to receive UCN-01 before a transplant. If, having considered a transplant, they refuse it, decide against it, or decide to wait, they would be eligible for this study.",
    "The sample is a phase 2 clinical trial for the treatment of metastatic colorectal cancer using the drugs folfox4 (oxaliplatin) and cetuximab. The trial requires patients to have a confirmed diagnosis of adenocarcinoma of the colon or rectum, and at least one measurable lesion that is not within an irradiated area. Patients must also have a Karnofsky performance status of greater than 80 and meet certain blood count and liver function criteria. Patients with brain metastasis, previous chemotherapy for metastatic disease, or a history of inflammatory bowel disease are excluded from the trial. Other exclusion criteria include pre-existing neuropathy, known grade 3 or 4 allergic reaction to any of the treatment components, and inadequate contraception for patients of childbearing or procreational potential.",
    "The sample is a phase 2 clinical trial for pancreatic cancer. The eligibility criteria include having clinically staged I-III, pathologically confirmed adenocarcinoma of the pancreas that is either resectable or borderline resectable. Patients must not have received prior therapy for pancreatic cancer and must be at least 18 years old. Adequate organ function is also required. Exclusion criteria include pregnancy or lactation, comorbid conditions with a life expectancy of less than 6 months, and other malignancies diagnosed within the past 5 years (excluding in situ cancers and invasive nonmelanomatous skin cancers). The drug being tested is capecitabine.",
    "The sample is a phase 2 clinical trial for allergic asthma. The trial includes patients who have had symptoms of asthma for the last 6 months and have a documented allergy to a common aeroallergen. The patients must also have an unmedicated FEV1 of at least 70% of the predicted normal value and a positive Methacholine inhalation challenge. The trial involves the use of the drugs roflumilast and placebo. The eligibility criteria include being an outpatient, having a negative pregnancy test, and being able to provide written informed consent. The exclusion criteria include having a neuropsychiatric condition, impairment of hepatic function, and recent use of certain medications. The trial aims to evaluate the safety and efficacy of the drugs in treating allergic asthma.",
    "The sample is a phase 2 clinical trial for uterine cancer. The trial is testing the effectiveness of a combination of drugs called paclitaxel and carboplatin. The eligibility criteria for the trial include having a specific type and stage of uterine cancer, having undergone certain surgical procedures, and meeting certain organ function and performance status requirements. Patients must also be at least 19 years old and have signed informed consent. Exclusion criteria include having a history of certain types of cancer, receiving past pelvic radiotherapy, and having a known hypersensitivity to the drugs being tested.",
    "The sample is a phase 2 clinical trial for bladder cancer. The trial is looking for patients with operable primary muscle invasive bladder cancer that is T2-T4a, NX or N0, M0 (stage II or III) and who have an adequate functioning bladder. Patients must have undergone a prior transurethral resection of the bladder tumor within the past 8 weeks and must not have evidence of tumor-related hydronephrosis or distant metastases or histologically or cytologically confirmed lymph node metastases. Patients with involvement of the prostatic urethra with transitional cell cancer that was visibly completely resected are allowed, but there should be no evidence of stromal invasion of the prostate. The trial is open to patients of any age with a Zubrod performance status of 0-1 and a life expectancy that is not specified. Patients must meet certain hematopoietic, hepatic, and renal criteria, and must not be pregnant or nursing. Fertile patients must use effective contraception. Patients must not have had any other malignancy within the past 5 years except nonmelanoma skin cancer, stage T1a prostate cancer, or carcinoma in situ of the cervix. Patients must be able to tolerate systemic chemotherapy with pelvic radiotherapy and radical cystectomy. The trial excludes patients who have had prior systemic chemotherapy, pelvic radiotherapy, or concurrent drugs that have potential nephrotoxicity or ototoxicity (e.g., aminoglycosides).",
    "The sample is a phase 2 clinical trial for patients aged 2 to 45 years with acute myeloid leukemia (AML) who have either experienced primary induction failure or have relapsed AML with low disease burden. The trial involves the use of drugs such as allopurinol, fludarabine, cyclophosphamide, levetiracetam, and busulfan. The eligibility criteria include acceptable organ function, a Karnofsky Performance Status of at least 70%, and the absence of active infections or HIV infection. Women of childbearing potential must agree to use adequate contraception during treatment. Patients with prior central nervous system (CNS) involvement are eligible provided that it has been treated and is in remission. The exclusion criteria include active infection, HIV infection, pregnancy or breastfeeding, and known hypersensitivity to any of the study agents.",
    "The sample is a phase 2 clinical trial for patients with local regional carcinoma of the thoracic esophagus or gastroesophageal junction. The trial involves the use of 5-fluorouracil and oxaliplatin drugs. The eligibility criteria include having T1N1 or T2-3 with any N (M1a only), normal liver, kidney, and bone marrow functions, performance status 0 or 1, and being medically fit for surgery. Patients must also be between 18 and 76 years old, have no known allergy to the study drugs, and have not received prior therapy for this cancer. Exclusion criteria include having T1N0, T4, or M1b cancer, significant comorbid conditions, more than grade 1 neuropathy, and being unable to comprehend or comply with the study requirements.",
    "The sample is a clinical trial for phase 2/phase 3 of a drug treatment for metastatic non-small cell lung cancer. The trial is for previously untreated patients with an ECOG performance status of 0-1 and normal liver function tests. The drug being tested is chemotherapy +/- disulfiram. The eligibility criteria include being over 18, willingness to abstain from alcohol, not being pregnant, and having no psychiatric history.",
    "The sample is a record of a clinical trial in phase 2, which is focused on the treatment of Huntington's disease and chorea. The trial involves the use of two drugs, atomoxetine and a matching placebo. The eligibility criteria for the trial include a confirmed diagnosis of Huntington's disease, age between 18 and 65, and mild HD with complaints of poor attention. The exclusion criteria include a history of ADHD symptoms, diagnosis of certain mental disorders, current use of MAOI medication, pregnancy, uncontrolled hypertension, tachycardia, cardiovascular or cerebrovascular disease, history of loss of consciousness, and any other neurological disorder or insult other than Huntington disease.",
    "The sample is a phase 2 clinical trial for patients with cutaneous T-cell lymphoma (CTCL) including its variants, such as mycosis fungoides and S\u00e9zary syndrome. The trial is testing the effectiveness of the drugs bexarotene and gemcitabine hydrochloride. Patients must have developed progressive disease after receiving or have been refractory to at least 1 course of prior standard, systemic, skin-directed therapy. The eligibility criteria include various medical and psychiatric conditions, and patients must not have any other malignancy within the past 5 years except curatively treated basal or squamous cell skin cancer, cervical epithelial neoplasm CIN1, or carcinoma in situ. Prior concurrent therapy is also specified in the criteria.",
    "The sample is a record of a clinical trial that is in phase 2/phase 3 and is focused on treating multiple sclerosis. The trial involves the drug colecalciferol and has specific eligibility criteria for participants, including having a certain level of disability due to multiple sclerosis and having used the drug Betaferon for at least one month with a positive MxA-response. There are also exclusion criteria, such as having hypercalcaemia, kidney stones, uncontrolled hypertension, hypothyreosis, peanut allergy, severe depression, sarcoidosis, or using other IMD than interferon-beta.",
    "The sample is a phase 2 clinical trial for the treatment of type 2 diabetes mellitus. The trial includes subjects who are 18 to 70 years old and have a documented diagnosis of T2DM with an HbA1c level of \u22657.0% and \u22649.5%. The trial also includes subjects who are treatment-na\u00efve and have not taken insulin or any oral or injectable anti-diabetic medication in the past 3 months. The trial involves the use of two drugs, gsk189075 and pioglitazone. The eligibility criteria include various medical and non-medical factors such as BMI, blood pressure, and contraception use. The exclusion criteria include various medical conditions and medications that may affect the interpretation of efficacy and safety data. The trial also excludes subjects who are pregnant or lactating, have a history of alcohol or substance abuse, or have participated in any study with an investigational or marketed drug in the 3 months prior to screening.",
    "The sample is a phase 2 clinical trial for patients with stage IV adenocarcinoma of the breast, including male breast cancer, recurrent breast cancer, and stage IV breast cancer. The trial involves the drug vorinostat and has eligibility criteria such as measurable disease, prior adjuvant therapy, and a life expectancy of greater than 6 months. Exclusion criteria include uncontrolled intercurrent illness and pregnancy. The trial also requires patients to have histologically or cytologically confirmed stage IV adenocarcinoma of the breast and measurable disease. The trial is not open to patients who have had chemotherapy or radiotherapy within 4 weeks prior to entering the study or those who have not recovered from adverse events due to agents administered more than 4 weeks earlier.",
    "The sample is a phase 2 clinical trial for the treatment of acute coronary syndrome. The trial involves the drug TAK-442 and a placebo. The eligibility criteria include being hospitalized for acute coronary syndrome, having certain ischemic risk factors, and not having certain exclusion criteria such as severe hypertension or a bleeding disorder. Females of childbearing potential who are sexually active must agree to use adequate contraception. The trial also has a list of excluded medications and requires subjects to not take any disallowed medication during the trial.",
    "The sample is a phase 2 clinical trial for infertility and in vitro fertilization. The trial involves the use of drugs such as Org 36286, Puregon\u00ae, Orgalutran\u00ae, and Pregnyl\u00ae. The eligibility criteria for the trial include having a BMI between 18 and 29 kg/m^2, a normal menstrual cycle length of 24-35 days, and having ejaculatory sperm. However, individuals with a history of endocrine abnormalities such as polycystic ovary syndrome (PCOS), treated hyperprolactinemia, or evidence of ovarian dysfunction are excluded from the trial. Other exclusion criteria include having more than three unsuccessful cycles of COH for IVF, having any clinically relevant abnormal laboratory value, and having any ovarian or abdominal abnormality interfering with ultrasound examination. The trial also excludes individuals with contraindications for the use of gonadotropins, epilepsy, diabetes, cardiovascular, gastro-intestinal, hepatic, renal, pulmonary, or abdominal disease, history or presence of alcohol or drug abuse within 12 months prior to signing informed consent, hypersensitivity to Orgalutran\u00ae or any of its components, administration of investigational drugs within three months prior to screening, and use of hormonal preparations within one month prior to the start of Org 36286 with the exception of thyroid medication.",
    "The sample is a phase 2 clinical trial for patients with uterine leiomyosarcoma that is advanced, persistent, or recurrent. The trial is testing the effectiveness of the drugs docetaxel and gemcitabine hydrochloride. Patients must meet certain eligibility criteria, including having measurable disease and being ineligible for higher priority GOG protocols. Patients must also meet certain patient characteristics, such as having a performance status of GOG 0-2 and no neuropathy greater than grade 1. Prior concurrent therapy is also specified, including no prior cytotoxic chemotherapy for the malignancy and recovered from prior surgery.",
    "The sample is a phase 2 clinical trial for patients with metastatic melanoma. The trial includes patients with stage IV or unresectable stage III disease, with measurable disease, and without known brain metastases. Patients must have an ECOG performance status of 0-2 or Karnofsky PS 60-100%, and a life expectancy of more than 12 weeks. They must also meet various laboratory criteria, including WBC, ANC, platelet count, hemoglobin, total bilirubin, AST, ALT, creatinine, and proteinuria levels. Patients must not be pregnant or nursing, and must use effective contraception if fertile. They must also not have a history of allergic reactions to compounds of similar chemical or biologic composition to AZD0530, and must not have poorly controlled hypertension or intercurrent cardiac dysfunction. Patients must not have had any other malignancy within the past 5 years, except definitively treated, localized, nonmelanoma skin cancer or low-grade cervical neoplasm. They must have had at least 4 weeks since prior and no more than one prior treatment regimen for advanced disease, and must not have had prior kinase inhibitor with activity against Src kinases for metastatic melanoma. Patients must not be on concurrent combination antiretroviral therapy for HIV-positive patients, and must not be on concurrent prohibited cytochrome P450 3A4 (CYP3A4)-active agents or substances. They must not be on other concurrent investigational agents or commercial therapies. The drug being tested is saracatinib.",
    "The sample is a phase 2 trial for patients with anaplastic or recurrent thyroid cancer. The trial involves the use of the drug sorafenib tosylate. Patients must meet certain eligibility criteria, including having measurable or evaluable disease, no symptomatic bulky disease, and no known brain metastases. They must also have a certain performance status, life expectancy, and blood counts within normal ranges. Patients must not have certain medical conditions or be taking certain medications. The trial is only open to patients with anaplastic thyroid cancer that is not amenable to definitive curative surgery or radiotherapy.",
    "The sample is a phase 2 trial for hepatocellular carcinoma, a type of liver cancer. The trial includes patients who are over 18 years old, have an ECOG performance status of 0-2, and have unresectable and/or metastatic HCC that has been confirmed through histological or cytological testing. Patients must also have measurable disease according to RECIST criteria and have completed any previous local therapy more than 6 weeks prior to the trial. Additionally, patients must meet a number of other eligibility criteria related to liver function, blood counts, and other medical conditions. Patients with certain medical conditions or who have received certain types of prior treatment are excluded from the trial. The trial involves the use of two drugs, sorafenib and tegafur/uracil, and the eligibility criteria are designed to ensure patient safety and the validity of the trial results.",
    "The sample is a phase 2 clinical trial for the treatment of migraine headaches. The trial includes patients who have been diagnosed with migraine for at least a year and experience 2-10 migraine headaches per month. The patients must be willing to arrive at the investigator's center within 1 hour of migraine pain onset and must be able to abstain from taking medications not allowed by the protocol. The trial also requires patients to undergo a comprehensive urine toxicology screen for both licit and illicit drugs. The trial excludes patients with unstable or uncontrolled significant metabolic, hepatic, renal, hematological, pulmonary, gastrointestinal, urological, neurological (except migraine headaches), or psychiatric disorders. Patients with severe or acute cardiovascular or cerebrovascular disease, uncontrolled hypertension, or basilar or hemiplegic migraines are also excluded. Additionally, patients with a history of hypersensitivity, allergies, or nonresponse to valproic acid or who have taken VPA or other AED in the 30 days prior to screening are excluded. Patients with newly started or changed the dose of either feverfew or magnesium (above 200 mg, the amount in common daily supplements) within 3 months prior to screening are also excluded.",
    "The sample is a phase 2 clinical trial for the treatment of benign prostatic hyperplasia. The trial involves the use of botulinum toxin type A and normal saline as drugs. The eligibility criteria for the trial include clinical enlargement of the prostate gland and a body weight of at least 50 kg or 110 lbs. The exclusion criteria include a history of chronic prostatitis, urinary tract infections, bladder stones, previous prostate surgery, bladder cancer or prostate cancer, and previous or current usage of botulinum toxin therapy for any urological or non-urological condition. The trial requires participants to meet the inclusion criteria and not meet any of the exclusion criteria.",
    "The sample is a phase 2 clinical trial for patients with primary malignant glioma, specifically glioblastoma multiforme or gliosarcoma. The trial is testing the effectiveness of the drugs Avastin, Temozolomide, and Irinotecan. The eligibility criteria include having a confirmed diagnosis of the disease, being over 18 years old, having no prior radiotherapy or chemotherapy for a brain tumor, and meeting certain health requirements such as a Karnofsky score of at least 60 percent and normal blood counts. The trial also has exclusion criteria, such as pregnancy or breast feeding, recent participation in an experimental drug study, and certain medical conditions. The trial is approved by the Institutional Review Board and requires signed informed consent from participants.",
    "The sample is a phase 2 clinical trial for patients with metastatic breast cancer. The trial is testing the effectiveness of the drugs ixabepilone and ixabepilone. The eligibility criteria include female patients aged 18 to 75 years who have previously undergone chemotherapy in the adjuvant or neo-adjuvant setting, have a diagnosis of HER-2 negative metastatic breast adenocarcinoma, have an Eastern Cooperative Oncology Group performance status of 0 or 1, and have a life expectancy of at least 12 weeks. The trial also requires patients to have measurable disease by the Response Criteria in Solid Tumors (RECIST) method and laboratory values within specified ranges. Exclusion criteria include patients with CTC grade 2 or greater neuropathy at baseline, any history or evidence of brain and/or leptomeningeal metastasis, clinically significant cardiac disease, and psychiatric disorders or other conditions rendering the subject incapable of complying with the requirements of the protocol. The trial also excludes patients with any concurrent active malignancy other than non-melanoma skin cancer or in situ carcinoma of the cervix, prior severe HSR to agents containing Cremophor EL, women who are pregnant or breastfeeding, and women with a positive pregnancy test on enrolment or prior to study therapy. No other concomitant chemotherapy, endocrine therapy, immunotherapy, radiation therapy (except for palliative radiotherapy for bone metastases), or investigational treatments are allowed during the subject's participation in the study.",
    "The sample is a record of a clinical trial with a phase 2 designation. The trial is focused on the disease of secondary hypogonadism, which is associated with a list of ICD-10 codes. The trial involves the use of two drugs, 25 mg Androxal and Testim 1%, and has specific eligibility criteria for participants. Inclusion criteria include healthy adult males between 21 and 60 years of age who have been diagnosed with AIHH and have been treated with a topical testosterone replacement therapy for at least 6 months but no more than 2 years. Exclusion criteria include a history of infertility due to primary hypogonadism, testicular failure, Kallmann's syndrome, or any other infertility condition, as well as clinically significant medical conditions that render the subjects infertile or marginally fertile other than AIHH. Men with a history of, known, or suspected prostate disease not ruled out by a prostate biopsy, or a prostate-specific antigen (PSA) >3.6 or clinical suspicion of current prostate disease, and men with a hematocrit in excess of 50% or hemoglobin >17 g/dl are also excluded.",
    "The sample is a phase 2 clinical trial for the treatment of chronic obstructive pulmonary disease (COPD) using the drugs ph-797804 and placebo. The trial is for male and female subjects between the ages of 40 and 80 who have been diagnosed with moderate to severe COPD for at least 6 months and meet the criteria for Stage II-III disease. Subjects must have a smoking history of at least 10 pack-years and be current smokers or ex-smokers that gave up more than 6 months ago. They must also have been treated with a LABA/ICS combination for at least 1 month prior to screening. The trial has inclusion and exclusion criteria, which are listed in the sample.",
    "The sample is a phase 2 clinical trial for breast neoplasms, with the drug docetaxel being tested. The eligibility criteria include being a female patient with a histologically or cytologically documented breast adenocarcinoma, having received a prior neoadjuvant or adjuvant Taxotere-based chemotherapy regimen, and having a Her2/neu negative tumor. Patients must also have an ECOG performance status of 0 to 2, normal cardiac function, and at least one measurable lesion according to RECIST guidelines. Exclusion criteria include prior therapy for advanced or recurrent disease, previous cumulative exposure to epirubicin or doxorubicin, and symptomatic brain metastases or clinically diagnosed leptomeningeal metastases. Patients must also not have other serious illnesses or medical conditions, be pregnant or lactating, or have a history of hypersensitivity to docetaxel, epirubicin, or doxorubicin.",
    "The sample is a phase 2 clinical trial for pancreatic neoplasms, with the drug tnp-470 being tested. The eligibility criteria include having locally advanced disease with no radiographic evidence of metastatic disease, no prior chemotherapy or irradiation, and a baseline Karnofsky performance status of at least 60. Patients must also have adequate bone marrow reserve, estimated life expectancy of at least 12 weeks, and be at least 18 years old. Female patients must have had childbearing potential terminated or attenuated by an approved contraceptive method. Patients cannot have hepatic or peritoneal metastases detected by ultrasound, CT scan, or laparotomy prior to chemoradiation. Before receiving external beam irradiation, patients should be able to maintain adequate oral nutrition and be free of significant nausea and vomiting. Patients must have bilateral renal function and no fever or evidence of infection or other coexisting medical condition that would preclude protocol therapy. Patients must sign an informed consent form.",
    "The sample is a phase 2 clinical trial for patients with mantle cell lymphoma. The trial is for newly diagnosed, previously untreated disease and requires confirmation of positivity for certain phenotypes by immunohistochemistry or flow cytometry. Patients must have measurable disease and adequate tumor tissue from the original diagnostic specimen available. They must also have a Zubrod performance status of 0-2 and cannot be pregnant or nursing. Patients cannot have peripheral neuropathy \u2265 grade 2, hypersensitivity to certain drugs, or any other prior malignancy except for adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, adequately treated stage I or II cancer for which the patient is currently in complete remission, or any other cancer for which the patient has been disease-free for the past 5 years. Patients cannot have had prior chemotherapy, radiotherapy, or antibody therapy for lymphoma and must have gone more than 14 days since prior investigational drugs.",
    "The sample is a phase 2 clinical trial for non-small-cell lung cancer. The trial involves the use of docetaxel plus bavituximab or placebo as a treatment. The eligibility criteria include being over 18 years old with a life expectancy of at least 3 months, having confirmed stage IIIB or stage IV non-squamous non-small-cell lung cancer that has progressed after one chemotherapy regimen, having measurable disease, and having an Eastern Cooperative Oncology Group (ECOG) Performance Status of \u2264 2. The exclusion criteria include having squamous, small cell, or mixed histology, a known history of bleeding diathesis or coagulopathy, and ongoing therapy with oral or parenteral anticoagulants, among others.",
    "The sample is a phase 2 clinical trial for uterine papillary serous carcinoma (UPSC) with no visible residual disease. The trial requires surgical staging to include total abdominal hysterectomy, bilateral salpingo-oophorectomy, peritoneal washings, and lymph node samplings. Patients must be over 18 years old, have an ECOG performance status of less than 2, and provide written voluntary informed consent. The trial excludes patients with impairment of hepatic, renal or hematologic function, severe or uncontrolled concurrent medical disease, prior chemotherapy or radiotherapy for pelvic malignancy, and dementia or altered mental status that would prohibit the giving and understanding of informed consent at the time of study entry. The trial involves the use of carboplatin and paclitaxel and pelvic radiation therapy or carboplatin and paclitaxel and radiation therapy.",
    "The sample is a phase 2 clinical trial for Crohn's disease. The table includes information on the diseases being studied, the icd-10 codes associated with those diseases, the drugs being used in the trial, and the eligibility criteria for participants. The inclusion criteria include being between 18 and 70 years old, having a confirmed diagnosis of Crohn's disease, and having undergone surgery for ileal or ileo-colonic Crohn's disease with ileo-colonic anastomosis. The exclusion criteria include having short bowel syndrome, previous long-term therapy with ciprofloxacin, and serious secondary illnesses that would make the patient unsuitable for the study. Participants must also use appropriate contraceptive methods and be able to start oral nutrition and medication intake within 14 days after surgery.",
    "The sample is a phase 2 clinical trial for patients with transfusional iron overload due to hereditary anemias such as sickle cell disease, \u03b2-thalassemia, and Diamond-Blackfan anemia, or acquired anemias such as Myelodysplastic Syndrome and other forms of bone marrow failure. The patients must be transfusion-dependent and require chronic treatment with deferoxamine, deferasirox, and/or deferiprone. The trial requires patients to discontinue all existing iron chelation therapies throughout the study period. The inclusion criteria include a serum ferritin greater than 500 ng/mL at screening, baseline liver iron concentration and cardiac MRI T2* per protocol requirements, and a mean of the previous three pre-transfusion hemoglobin concentrations greater than or equal to 7.5 g/dL. The exclusion criteria include evidence of clinically relevant oral, cardiovascular, gastrointestinal, hepatic, renal, endocrine, pulmonary, neurologic, psychiatric, immunologic, bone marrow, or skin disorder as determined by the investigator, and use of any investigational agent within the 30 days prior to the baseline testing.",
    "The sample is a phase 2 clinical trial for non-Hodgkin lymphoma and diffuse large B-cell lymphoma. The trial involves the use of rituximab and cytarabine drugs. The eligibility criteria for the trial include having a primary cerebral or oculocerebral NHL not previously treated with chemotherapy or radiotherapy, being diagnosed with diffuse large cell CD20+ lymphoma, being between the ages of 18 and 60 years, having a measurable target to evaluate response, and having a life expectancy of at least 3 months. Exclusion criteria include having CD20- lymphoma, a history of indolent lymphoma, contraindication for one of the products used in polychemotherapy, known hypersensitivity to mouse antibodies, absence of measurable target to evaluate response, and other medical conditions such as severe renal insufficiency, severe immunosuppression, and pregnancy.",
    "The sample is a phase 2 clinical trial for the treatment of multiple myeloma. The eligibility criteria include being at least 18 years old, having relapsed and refractory disease, measurable levels of myeloma paraprotein in serum or urine, and an Eastern Cooperative Oncology Group (ECOG) performance status score of 0, 1, or 2. Exclusion criteria include pregnancy or lactation, laboratory abnormalities, prior history of malignancies other than multiple myeloma, and prior use of CC-5013. The drug being tested is cc-5013. The sample also includes a list of icd-10 codes associated with multiple myeloma.",
    "The sample is a record from a clinical trial table. It is a phase 2 trial for the treatment of chronic hepatitis C infection. The table includes information on the diseases being treated, the ICD-10 codes associated with those diseases, the drugs being used in the trial, and the eligibility criteria for participants. The inclusion criteria include being female and practicing specific forms of birth control, having chronic HCV infection, and being treatment naive or having previous pegylated interferon/ribavirin treatment experience. The exclusion criteria include having a positive test result for Hepatitis B surface antigen or anti-Human Immunodeficiency virus antibody, prior therapy with direct acting antiviral agents for the treatment of HCV, and any current or past clinical evidence of cirrhosis.",
    "The sample is a phase 2 clinical trial for a vaccine to prevent HIV infection. The trial is looking for healthy adults who are at high risk of acquiring HIV and have not previously received an investigational vaccine. The trial excludes individuals who are in a monogamous relationship with an HIV-negative partner for more than a year, have a history of anaphylaxis or allergy to vaccine components, have received immune globulin or blood-derived products within three months before injection, have previously been vaccinated with a live or inactivated virus vaccine within a certain timeframe, have a known history of immunodeficiency or malignancy, have a contraindication to intramuscular injection, are pregnant or breastfeeding, have active drug or alcohol abuse or dependence, or have a condition that might endanger their health or interfere with the evaluation of the study objectives.",
    "The sample is a record of a clinical trial for a drug called GEn, which is being tested for its effectiveness in treating postherpetic neuralgia (PHN). The trial is in phase 2 and the sample includes information on the diseases being studied, the icd-10 codes associated with those diseases, the drugs being tested (including different dosages of GEn and a placebo), and the eligibility criteria for participants. The inclusion criteria include being 18 years or older, having a documented medical diagnosis of PHN with pain present for at least three months, and providing written informed consent. The exclusion criteria include having other chronic pain conditions not associated with PHN, impaired renal function, uncontrolled hypertension, and a history of drug or alcohol abuse. The sample also includes detailed information on the eligibility criteria, including specific medical conditions that would exclude a participant from the trial.",
    "The sample is a record of a clinical trial with a phase 2 designation. The trial is focused on the treatment of anemia and HIV. The diseases are listed as 'anemia' and 'HIV', while the ICD-10 codes associated with these diseases are also provided. The drug being tested is 'epoetin alfa'. The eligibility criteria for the trial are listed under 'Inclusion Criteria' and 'Exclusion Criteria'. The inclusion criteria include being HIV positive and on a stable antiretroviral regimen for at least four weeks prior to enrollment, having a hemoglobin level below 12.0 g/dL, and not having undergone cancer therapy within 12 months prior to enrollment. The exclusion criteria include having a history of acute, symptomatic opportunistic infection or other acute AIDS defining illness within six months of enrollment, having a history of any primary hematologic disease, having anemia attributable to factors other than HIV infection, having Hepatitis C virus (HCV) co-infection, and having uncontrolled or severe cardiovascular disease including recent myocardial infarction, hypertension, or congestive heart failure.",
    "The sample is a phase 2 trial for Parkinson's disease and other related neurodegenerative diseases. The trial includes participants who are at least 30 years old and have a moderate to severe diagnosis of idiopathic Parkinson's disease. The participants must have been on a regimen of L-Dopa and/or a dopamine agonist. The trial excludes participants who experienced a serious adverse event in a previous study, have any form of drug-induced or atypical parkinsonism, cognitive impairment, or psychosis, are taking tolcapone, or are participating in any other clinical study. The trial is testing the effectiveness of preladenant and other Parkinson's disease treatments.",
    "The sample is a phase 2 clinical trial for the treatment of head and neck cancer using the drug irinotecan hydrochloride. The eligibility criteria for the trial include having histologically confirmed medullary thyroid cancer, measurable disease by CT scan, and adequate lab functions. Exclusion criteria include having other severe or uncontrolled systemic disease, being pregnant or nursing, and having an illness that would preclude study participation.",
    "The sample is for a phase 2 clinical trial for rheumatoid arthritis. The icd-10 codes for the disease are listed as M06.9, M05.9, M06.08, M06.00, M06.011, M06.012, and M06.019. The drug being tested is abatacept. The eligibility criteria for the trial includes all subjects who have completed the short term portion of IM101-101.",
    "The sample is a phase 2 clinical trial for kidney transplantation. The trial is testing the effectiveness of three drugs - aeb071, certican, and neoral. The eligibility criteria for the trial includes male and female patients who are 18 years or older and have received their first kidney transplant from a deceased or living not related donor. Patients who require medication prohibited in the study, have heart disease, are HIV, Hepatitis B or Hepatitis C positive, have high immunological risks, or have a history of cancer are excluded from the trial. Other inclusion/exclusion criteria may also apply as defined by the protocol.",
    "The sample is a phase 2 clinical trial for patients with B-cell chronic lymphocytic leukemia who have relapsed or are refractory to first-line therapy. The trial is testing the effectiveness of fludarabine phosphate as a treatment. The eligibility criteria include specific disease characteristics, patient characteristics, and prior concurrent therapy. Patients must meet certain requirements related to their age, performance status, life expectancy, hematopoietic, hepatic, renal, immunologic, and other health factors. They must also not have any active secondary malignancy or concurrent severe diseases or mental disorders. Prior concurrent therapy is also taken into consideration. The sample provides a detailed list of the eligibility criteria that patients must meet to participate in the trial.",
    "The sample is a phase 2 clinical trial for patients with renal cell carcinoma. The trial is testing the effectiveness of a combination of drugs, including ec17 (folate-fitc), interleukin-2, and interferon-alpha. The eligibility criteria for the trial include having a confirmed diagnosis of renal cell carcinoma, having relapsed or Stage IV disease that is medically or surgically unresectable and has progressed after systemic therapy, having measurable/evaluable metastatic disease sites that have not previously received radiotherapy, and having at least one tumor lesion that displays uptake of 99mTc-EC20. Patients must also be over 18 years old, have an ECOG score less than or equal to 2, and have adequate hematologic, renal, and hepatic function. Exclusion criteria include having a history of severe hypersensitivity, medical conditions that preclude the use of IL-2 or IFN-\u03b1, being pregnant or breastfeeding, currently undergoing chemotherapy or immunosuppressant therapy, and having any concomitant malignancy except for basal cell or squamous cell carcinoma of the skin. Patients must also not have radiographically documented evidence of current brain metastases, a history of stem cell transplant, immunodeficiency, and/or a medical or psychiatric illness that would prevent adequate compliance with study therapy or evaluation of the endpoints.",
    "The sample is a phase 2 clinical trial for heart failure. The trial includes patients between the ages of 18 and 85 who have a negative pregnancy test (if applicable) and weigh less than or equal to 100 kg. Patients must have a documented LV Ejection Fraction of less than or equal to 35% within 6 months prior to screening or at hospitalization. Patients must also have stabilized within 48 hours from hospitalization and not require continuous iv drug treatments. The trial includes the drugs istaroxime and placebo. The eligibility criteria include various medical conditions and laboratory values that would make the patient unsuitable for evaluation in the study.",
    "The sample is a phase 2 clinical trial that involves patients with a history of cardiac ischemia related chest discomfort. The trial aims to test the effectiveness of the drugs vorapaxar, placebo, aspirin, and clopidogrel in treating atherosclerosis, myocardial ischemia, and myocardial infarction. The eligibility criteria for participants include having positive biomarkers or ECG changes, being willing to give informed consent, and adhering to dosing and visit schedules. Exclusion criteria include pregnancy or nursing, serious illness, hypersensitivity to investigational products, and history of bleeding diathesis or hemorrhagic stroke. The trial also excludes patients with severe hypertension, impaired renal function, or hepatic disease, and those receiving certain types of concurrent or anticipated treatments.",
    "The sample is a phase 2 clinical trial for patients with pancreatic adenocarcinoma that has progressed after first-line therapy. The trial is testing the effectiveness of the drug sunitinib malate. The eligibility criteria include having received prior therapy with gemcitabine, having no brain metastases, and having measurable disease. Patients must also meet certain health requirements, such as having well-controlled hypertension and no significant cardiac disease. The trial excludes patients who are pregnant or breastfeeding, have a history of significant bleeding events, or have a currently active second malignancy. The trial requires patients to have certain blood counts and liver function tests within normal ranges.",
    "The sample is a phase 2 clinical trial for non-small cell lung cancer. The trial includes patients who have not received previous therapy for NSCLC and have unresectable locally advanced stage IIIA/IIIB NSCLC. The trial involves the use of drugs such as docetaxel, gemcitabine, and carboplatin. The eligibility criteria include age over 18, bidimensionally measurable disease, performance status of 0-2, absence of pleural effusion, adequate liver, renal, and bone marrow function, and a life expectancy of more than 3 months. Exclusion criteria include active infection, significant cardiac disease, malnutrition, performance status of 3-4, sensor or motor neuropathy greater than grade I, second primary malignancy (except for non-melanoma skin cancer), psychiatric illness or social situation that would preclude study compliance, and pregnancy or lactation.",
    "The sample is a record of a clinical trial with a phase 2 designation. The trial is focused on the treatment of pain and includes a list of icd-10 codes related to pain. The trial involves two drugs, matrix transdermal fentanyl/chadd drug delivery system and a placebo patch. The eligibility criteria for the trial include being between the ages of 18 and 70, having moderate to severe non-malignant chronic pain, being opioid-tolerant, and currently taking a dose of 50 mcg/hr transdermal fentanyl for at least 2 weeks. Patients must also be experiencing 1 to 4 episodes of target breakthrough pain per day. Exclusion criteria include having active cancer, a history of substance abuse or disorder, and being pregnant or breastfeeding.",
    "The sample is a record of a clinical trial in phase 2 for the treatment of prostate cancer using the drug triptorelin (decapeptyl\u00ae). The trial is looking for patients with locally advanced or metastatic prostate cancer who are scheduled to receive hormonal deprivation therapy and have a life expectancy of more than 9 months. The inclusion criteria also require documented testosterone levels of \u2265 125 ng/dl measured within the previous 6 months. The exclusion criteria include a history of hypersensitivity to the Investigational Medicinal Product or drugs with a similar chemical structure, previous use of certain medications within the last year, concomitant anti-coagulation treatment, orchidectomy, or known spinal medullar compression.",
    "The sample is a phase 2 clinical trial for ovarian neoplasms. The trial includes patients between the ages of 20 and 75 with histologically confirmed epithelial ovarian cancer, primary peritoneal carcinoma, or tubal cancer at stage 3 or 4. The patients must also meet certain blood count and liver function criteria, have adequate compliance and geographical closeness for follow-up, and have a GOG performance status of 0-2. The trial excludes patients with a history of chemotherapy or radiotherapy on the abdomen/pelvis area, pleural/pericardial effusion, ascites causing respiratory difficulties, history of other cancers within 5 years, history of unapproved therapy within 30 days before enrollment, and other serious diseases that could threaten the safety of participants or impair their ability to complete the participation.",
    "The sample is a phase 2 clinical trial for non-small cell lung cancer patients with locally or advanced metastatic disease. The trial is testing the effectiveness of the drugs docetaxel and ly2181308. The eligibility criteria include having measurable disease, an ECOG performance status of 0 to 1, adequate bone marrow reserve and organ functioning, and not being pregnant or breastfeeding. The trial also requires participants to make available any existing tumor tissue from the primary biopsy. Exclusion criteria include having serious concomitant systemic disorders, a second primary malignancy, or documented central nervous system or brain metastasis at the time of study entry. Participants must also not have a pre-existing neuropathy equivalent to a CTCAE code greater than or equal to 2.",
    "The sample is a phase 2 clinical trial for the treatment of opioid-induced constipation. The trial involves the use of two drugs, alks 37 and placebo. The eligibility criteria include being at least 18 years old, having a BMI between 19 and 35 kg/m2, receiving prescribed opioid medication for chronic non-cancer pain, meeting the criteria for OIC, and agreeing to use an acceptable method of contraception during the study. Exclusion criteria include pregnancy or breastfeeding, significant medical conditions other than the pain condition, treatment with opioid therapy for cancer-related pain or addiction, any gastrointestinal disorder other than OIC, and recent participation in a clinical trial of a pharmacological agent.",
    "The sample is a phase 2 clinical trial for patients with a history of migraine with aura. The trial includes patients between the ages of 18-65 who experience at least one aura per month and meet the diagnostic criteria of the International Classification of Headache Disorders. The trial involves the use of the drugs tonabersat and placebo. The eligibility criteria include the use of reliable contraception for women of childbearing potential, no overuse of acute migraine treatments, and no use of certain medications for migraine prophylaxis. Exclusion criteria include significant cerebrovascular or cardiovascular disease, major depressive disorder or schizophrenia, renal or hepatic dysfunction, substance abuse, and other clinically significant conditions.",
    "The sample is a phase 2 clinical trial for the treatment of psoriasis using a drug called wbi-1001. The trial is looking for patients with stable plaque psoriasis for at least 6 months, representing a maximum of 10% of BSA with a minimum of 1% BSA excluding the face, groin, scalp, and genital regions, and with a minimum of one target plaque that is at least 2 x 2 cm in size at Day 0. Patients must also have a PGA of 2 to 4 at Day 0 and be in good general health without any disease state or physical condition that might impair the evaluation of plaque psoriasis. Women of childbearing potential must have a negative serum beta-human chorionic gonadotrophin (b-hCG) pregnancy test before randomization. Patients must be willing and able to comply with the protocol and likely to attend all study visits and provide written, informed consent prior to the initiation of any study-related procedures. The sample also includes exclusion criteria such as spontaneously improving or rapidly deteriorating plaque psoriasis, any other skin diseases that might interfere with the clinical assessment of plaque psoriasis and/or put the patient at risk, and other concomitant, serious illness or medical condition that could put the patient at risk during the study.",
    "The sample is a record of a clinical trial with a phase 2 designation. The trial is focused on the disease asthma, with a list of associated ICD-10 codes. The trial involves testing several drugs, including fp mdpi, fs mdpi, advair diskus, and albuterol. The eligibility criteria for the trial include a diagnosis of asthma, a certain level of lung function, and a demonstrated ability to respond to albuterol. There are also several exclusion criteria, including a history of life-threatening asthma, recent respiratory infections, and recent use of certain medications.",
    "The sample is a record of a clinical trial in phase 2 for the treatment of transitional cell carcinoma. The trial involves the use of the drugs gemcitabine and cisplatin. The eligibility criteria for the trial include having an ECOG performance status of 0-2, an estimated GFR greater than 60, high grade TCC on initial biopsy, clinical stage T1-T3, Nx, Mx based on the AJCC Classification system, TCC confined to the ureter or renal pelvis, and grade II neuropathy or less. The exclusion criteria include having any other malignancy over the previous five years with a risk of relapse that exceeds 30%, a history of previous cystectomy, evidence of metastatic disease, and a history of pelvic irradiation or prior chemotherapy. The icd-10 codes associated with the disease are also provided.",
    "The sample is a phase 2 trial for an oral contraceptive. The trial includes healthy female volunteers aged 18-35 years (smokers up to 30 years) who are willing to use non-hormonal methods of contraception during the study. The volunteers must have confirmed ovulation during the cycle before treatment and have normal routine blood values. Exclusion criteria include contraindications for the use of oral contraceptives, pregnancy, lactation, simultaneous participation in another clinical study, and considerable overweight. The trial involves the use of two drugs, sh t04769g and ethinyl estradiol / dienogest (sh d00659 af). The icd-10 codes associated with the disease are T38.4X1A, T38.4X1D, T38.4X1S, T38.4X2A, T38.4X2D, T38.4X2S, and T38.4X3A.",
    "The sample is a phase 2 clinical trial for patients with colorectal cancer that is inoperable, locally advanced, or metastatic and not amenable to curative therapy. The trial involves the use of the drugs s-1, irinotecan, and bevacizumab. The eligibility criteria include having measurable or assessable disease, no previous treatment, being at least 20 years old, having a life expectancy of at least 3 months, and having adequate function of major organs. Exclusion criteria include serious drug hypersensitivity, active double cancer, active infections, and other serious complications. Patients must also be able to take capsules orally and provide voluntary written informed consent.",
    "The sample is a phase 2 clinical trial for patients with documented HIV-1 infection. The trial is testing the effectiveness of the drug tmc114 (darunavir) / ritonavir. The eligibility criteria include having a CD4+ cell count above 100 cells/\u00b5l, signing the informed consent form, and being able to comply with the protocol requirements. Exclusion criteria include having a currently active AIDS defining illness, previous or current use of antiretroviral drugs, and having certain resistance-associated mutations. Female patients of childbearing potential must use effective non-hormonal birth control methods or be willing to continue practicing these methods for at least 30 days after the end of the treatment period. Any active clinically significant disease or findings during screening that are expected to compromise the patient's safety or outcome in the trial are also exclusion criteria.",
    "The sample is a phase 2 clinical trial for postmenopausal osteoporosis. The trial includes healthy postmenopausal women between the ages of 45 and 80 who have been diagnosed with osteoporosis. The trial excludes women who are using estrogen or hormone replacement therapy, bisphosphonates, strontium ranelate, denosumab, parathyroid analogues, or other bone metabolic agents. Women with medical conditions that might alter bone metabolism or any known clinically significant disease affecting calcium metabolism or history of metabolic disorders including Paget's disease, osteogenesis imperfecta, or osteomalacia are also excluded. Additionally, women with impairment of thyroid function are excluded from the trial. The trial will test the effectiveness of PTH analog, placebo, and Forsteo (teriparatide) as potential treatments for postmenopausal osteoporosis.",
    "The sample is a phase 2 clinical trial for the treatment of acute lymphoblastic leukemia in patients who are 55 years or older and have the Philadelphia chromosome or BCR-ABL positive acute lymphoblastic leukemia. The drug being tested is dasatinib. The eligibility criteria include not having been previously treated except with corticosteroids or single dose vincristine, having or not having documented CNS involvement, and having molecular evaluation for BCR-ABL done. The exclusion criteria include having ECOG status > 2, having been previously treated with Tyrosine Kinase Inhibitors, having QTc > 470 ms, having heart insufficiency NYHA grade III/IV, LEVF < 50% and or RF < 30%, having active secondary malignancy, having active bacterial, viral or fungal infection, known infection with HIV, Hepatitis B (except post vaccinal profile) or C, treatment with any other investigational agent or participating in another trial within 30 days prior to entering this study, having inadequate hepatic functions defined as ASAT or ALAT > 2,5 times the institutional upper limit of normal and total bilirubin > 2 fold the institutional upper limit unless considered to be due to organ involvement by the leukemia, and having concurrent severe diseases which exclude the administration of therapy.",
    "The sample is a phase 2 clinical trial for early-stage, operable breast cancer patients who are scheduled to receive adjuvant or neoadjuvant systemic chemotherapy. The trial is testing the effectiveness of the drug triptorelin in reducing the risk of premature ovarian failure in premenopausal women under the age of 45 who have not had a history of premature ovarian failure. The trial has specific inclusion and exclusion criteria, including hormone receptor status, age, menopausal status, performance status, and prior concurrent therapy. The trial also has a list of diseases and their corresponding ICD-10 codes, as well as eligibility criteria for patients to participate in the trial.",
    "The sample is a phase 2 trial for subjects with type 2 diabetes who have not previously been treated with insulin or have had short-term insulin treatment within the last 3 months. The trial involves treatment with one or two oral anti-diabetic drugs, such as metformin, sulfonylurea, or alpha-glucosidase inhibitors, and the inclusion criteria require a stable maximum tolerated dose or at least half the maximum allowed dose. The subjects must have an HbA1c level between 7.0% and 11.0% and a BMI between 25.0 and 37.0 kg/m^2. The trial excludes subjects with contraindications to metformin, recent treatment with thiazolidinedione, or any systemic treatment that could interfere with glucose or lipid metabolism. Additionally, subjects with clinically significant active diseases of the gastrointestinal, pulmonary, neurological, genitourinary, or hematological system are excluded.",
    "The sample is a phase 2 clinical trial for patients with Waldenstrom's macroglobulinemia, a type of cancer. The trial is testing the effectiveness of simvastatin, a drug used to lower cholesterol levels, in treating the disease. The eligibility criteria for the trial include being 18 years or older, having a clinicopathological diagnosis of Waldenstrom's macroglobulinemia, having measurable disease, and having a slowly progressing disease that does not require therapy for at least 3-6 months and does not meet consensus panel criteria for initiation of therapy. Patients must also have an ECOG performance status of 0 or 1 and adequate organ function. Patients who have had chemotherapy or radiotherapy within 4 weeks prior to entering the study, those who have not recovered from adverse events due to agents administered more than four weeks earlier, and those who have taken any Statin in the past are excluded. Other exclusion criteria include taking cyclosporin, danazol, or gemfibrozil, having a prior history of rhabdomyolysis, having uncontrolled intercurrent illness, being pregnant or breastfeeding, being HIV-positive, taking verapamil, having active or history of liver disease, and consuming more than three alcoholic beverages per day.",
    "The sample is a phase 2 clinical trial for Huntington's disease. The eligibility criteria include having a CAG repeat number of at least 36, a Total Functional Capacity between 6 and 13, cognitive impairment as demonstrated by a MoCA score of at least 12, and being at least 25 years old. Patients must also have a study partner who spends at least two hours a day with them and is willing to provide accurate information about the patient. Exclusion criteria include having an allergy to the drug being tested, having other known primary neurodegenerative disorders associated with dementia, and having clinically significant uncontrolled medical or psychiatric illness. Pregnant or lactating females are also excluded.",
    "The sample is a phase 2 clinical trial for the treatment of schizophrenia. The trial includes adult patients between the ages of 18 and 65 who have been diagnosed with schizophrenia and are experiencing an acute exacerbation within the prior 8 weeks. The trial involves the use of drugs such as bitopertin and olanzapine, as well as a placebo. The eligibility criteria include a diagnosis of schizophrenia, surgical sterilization or post-menopausal status for female patients, and exclusion criteria include current psychiatric diagnosis other than schizophrenia, recent alcohol or substance abuse, and previous treatment with certain medications. The trial aims to evaluate the effectiveness of the drugs in treating schizophrenia.",
    "The sample is a phase 2 clinical trial for patients with esophageal cancer. The trial involves the use of drugs such as erlotinib, 5-fluorouracil, leucovorin, and oxaliplatin. The eligibility criteria include having histologically confirmed esophageal carcinoma, surgically unresectable or metastatic disease, and no prior chemotherapy except for neoadjuvant treatment. Patients must also have a life expectancy of more than 12 weeks, measurable disease, and meet certain laboratory values. Exclusion criteria include the presence of a Kras mutation, lack of expression of EGFR, and prior treatment with EGFR-inhibiting agents, chemotherapy, or radiotherapy for esophagogastric carcinomas. Patients must not have uncontrolled intercurrent illness or current New York Heart Association Class III or IV heart disease. Pregnant or breastfeeding women are also excluded from the trial.",
    "The sample is a phase 2 trial for a drug called \"sch 486757\" and a placebo for the treatment of a dry cough lasting more than 6 months. The trial is open to both male and female subjects aged 18 to under 65 years old who have been evaluated for gastroesophageal reflux disease and postnasal drip, as well as asthma, and have not responded to treatment. The trial has exclusion criteria for subjects with certain medical conditions, allergies to multiple classes of medications, and a history of smoking. The trial also excludes subjects who are currently taking certain medications or have taken them within a certain period of time.",
    "This sample is for a phase 2 clinical trial for breast cancer. The trial is looking at the effectiveness of two drugs, capecitabine (xeloda\u00ae) and docetaxel (taxotere\u00ae), for women over 18 years old who have locally advanced or metastatic breast cancer and have demonstrated resistance to anthracycline. The trial requires participants to have at least one target lesion and to have undergone at least two regimens of chemotherapy for advanced/metastatic disease. The inclusion and exclusion criteria are listed in detail. The diseases are specified as breast cancer and the icd-10 codes associated with the disease are also provided.",
    "The sample is a phase 2 clinical trial for cervical cancer. The eligibility criteria include having carcinoma of the uterine cervix, being at International Federation of Gynecology and Obstetrics (FIGO) Stage I to IVA, having no evidence of metastatic disease outside of the pelvis (except to the para-aortic nodes), having a Karnofsky Performance Status of >= 60, being at least 18 years old, and having adequate bone marrow and renal function. Patients with certain medical conditions or prior surgeries are excluded. The trial involves the use of cisplatin as a treatment.",
    "The sample is a phase 2 clinical trial for hypertension and concurrent obesity. The trial includes subjects of non-childbearing potential who are 18 years or older and have mild to moderate essential hypertension. The inclusion criteria require a mean seated systolic blood pressure (msSBP) of at least 130 mmHg and less than 180 mmHg for untreated subjects, and a msSBP of less than or equal to 160 mmHg at screening and less than 180 mmHg at the end of the washout period for pre-treated subjects. The trial also requires a waist circumference of at least 102 cm for men and at least 88 cm for women. The exclusion criteria include a history of angioedema, hypersensitivity to the drugs being tested, severe hypertension, type 1 or type 2 diabetes mellitus, dyslipidemia requiring pharmacological therapy with a fibrate or nicotinic acid, and concomitant use of certain medications.",
    "The sample is a phase 2 clinical trial for non-squamous non-small cell lung cancer. The trial involves the use of four drugs: ro5083945, cisplatin, gemcitabine, and pemetrexed. The eligibility criteria for the trial include being an adult patient over 18 years of age with advanced, metastatic, or recurrent non-small cell lung cancer, having at least one measurable disease lesion as per RECIST criteria, confirmed presence of EGFR in tumor tissue, ECOG performance status of 0-1, and adequate hematological, renal, and liver function. Exclusion criteria include prior chemotherapy or treatment with another systemic anti-cancer agent, recent radiotherapy, symptomatic or active CNS metastases, poorly controlled hypertension, and requirement for steroids over 40 mg prednisolone.",
    "The sample is a phase 2 clinical trial for patients with metastatic adenocarcinoma of the prostate that is unresponsive to androgen-deprivation therapy. The trial is testing the drug ispinesib. The eligibility criteria include having received only one prior taxane-containing chemotherapy regimen for metastatic disease, evidence of disease progression, and a pre-study PSA level of over 5 ng/mL. Patients must also have measurable or evaluable disease, and meet various other medical criteria such as having a Zubrod performance status of 0-2 and no ongoing or active infections. The trial excludes patients with brain metastases, peripheral neuropathy of grade 2 or higher, ongoing or active infections, and other uncontrolled illnesses. Patients must also not have had any other malignancy within the past 5 years except for adequately treated basal cell or squamous cell skin cancer or adequately treated stage I or II cancer in complete remission. The trial has various other exclusion criteria related to prior treatments and concurrent medications. Patients must not be receiving any other concurrent anticancer therapy or combination antiretroviral therapy for HIV-positive patients. Concurrent enrollment on SWOG-9205 (central prostate cancer serum repository protocol) is allowed.",
    "The sample is a record of a clinical trial with a phase 2 designation. The trial is focused on the treatment of melanoma and skin neoplasms using the drug axitinib [ag-013736]. The trial includes patients with histologically documented melanoma with metastases who have had no more than one prior systemic therapy for metastatic disease. Patients with a history of hemoptysis or brain metastases are excluded from the trial. The sample also includes a list of icd-10 codes associated with the diseases being studied.",
    "This sample is for a phase 2 clinical trial that focuses on gastrointestinal stromal tumors and soft tissue sarcomas. The trial is testing the effectiveness of a drug called azd2171. The eligibility criteria for the trial includes having a confirmed diagnosis of GIST that is resistant or intolerant to imatinib mesylate, or having metastatic STS that is refractory to standard therapies or for which no standard therapy exists. Patients with poorly controlled diabetes or high blood pressure are excluded from the trial.",
    "The sample is a phase 2 clinical trial for Alzheimer's disease. The trial includes patients between the ages of 55-90 who have been diagnosed with probable Alzheimer's disease and have a history of progressive cognitive deterioration. The patients must also have brain imaging consistent with Alzheimer's disease and a Mini-mental state examination score between 12-21. They must be treated with donepezil, rivastigmine or galantamine and have at least a mild level of behavioral symptoms. The trial has exclusion criteria, including other types of dementias, myocardial infarction within the past 2 years, malignancy within the past 5 years, and a history of alcoholism or drug abuse within 5 years. Patients who reside in a skilled nursing facility or are not able to swallow capsules are also excluded. The trial also has specific criteria for blood pressure, ECG, laboratory tests, physical examination, and orthostatic hypotension. The patients must not have abnormal findings in these areas. The trial also excludes patients who have participated in a drug study within 60 days or have previously received AD immunotherapy treatment. The patients must be able to complete the computerized cognitive training.",
    "The sample is a phase 2 clinical trial for non-small-cell lung cancer. The trial involves the drugs pemetrexed and cisplatin. The eligibility criteria for the trial include a diagnosis of non-small-cell carcinoma of the lung, locally advanced or metastatic disease, and the possibility of curative surgery. Patients must also have at least one measurable lesion and adequate pulmonary function for surgical resection. Exclusion criteria include active infection, pregnancy or breastfeeding, serious concomitant illness, previous diagnosis of malignant disease, and recent treatment with a drug not approved for any indication.",
    "The sample is a record of a clinical trial with a phase 2 designation. The trial is focused on treating various types of cancer, including peritoneal cancer, ovarian cancer, neoplasms, and fallopian tube cancer. The trial uses a drug called gw786034. The eligibility criteria for the trial include having a confirmed diagnosis of one of the specified types of cancer and having received one prior platinum-based chemotherapy regimen. The exclusion criteria include having had any surgery, chemotherapy, hormonal therapy, biologic, immunotherapy, or radiotherapy within the last 28 days and having poorly controlled hypertension or currently taking warfarin. The sample also includes a list of icd-10 codes associated with the diseases being treated.",
    "The sample is for a phase 2 clinical trial that focuses on the disease of menopause. The icd-10 codes associated with the disease are listed as \"E28.310\" and \"E28.319\". The trial involves the use of two drugs, \"esterified estrogens 1.25 mg and methyltestosterone 2.5 mg\" and \"esterified estrogens 1.25 mg\". The eligibility criteria for the trial includes non-hysterectomized women between the ages of 35 and 65 who are experiencing symptoms of estrogen and/or androgen deficiency that are not currently controlled by estrogen therapy.",
    "The sample is a phase 2 clinical trial for patients with renal cell carcinoma. The trial is testing the effectiveness of two drugs, pazopanib and sunitinib, on locally advanced or metastatic renal cell carcinoma. The eligibility criteria include a diagnosis of renal cell carcinoma with clear-cell component histology, no prior systemic therapy for advanced or metastatic RCC, measurable disease by CT or MRI, Karnofsky performance scale status of >=70, age >=18 years, and adequate organ system function. Exclusion criteria include pregnancy or lactation, history or clinical evidence of central nervous system metastases, clinically significant gastrointestinal abnormalities, presence of uncontrolled infection, prolongation of corrected QT interval, history of certain cardiovascular conditions, poorly controlled hypertension, and ongoing toxicity from prior anti-cancer therapy. The trial requires written informed consent and adherence to certain contraceptive measures for female participants.",
    "The sample is a phase 2 clinical trial for patients with recurrent or metastatic soft tissue sarcoma or ovarian cancer. The trial involves the use of the drug dolastatin 10. The eligibility criteria include having measurable disease, being 18 years or older, having a good performance status, and meeting certain laboratory values. Patients must not have any uncontrolled infections or a history of malignancy within the past 5 years, except for certain types of cancer. Patients must not have received more than one prior chemotherapy regimen in the adjuvant setting and must have recovered from prior surgery. The trial requires patients to use effective contraception during and for 3 months after the study if they are fertile.",
    "The sample is a phase 2 clinical trial for patients with stage IV breast cancer that has spread to other parts of the body. The trial is testing the effectiveness of two drugs, abi-007 (abraxane) and bevacizumab, in treating the disease. The eligibility criteria for the trial include having confirmed adenocarcinoma of the breast, measurable disease, and an Eastern Cooperative Oncology Group (ECOG) performance status of 0-2. Patients must not be candidates for Herceptin therapy and must have recovered from any prior chemotherapy. Exclusion criteria include inadequate control of hypertension, history of myocardial infarction or unstable angina, and current or recent participation in an experimental drug study. The trial requires informed consent and patients must meet certain blood count and chemistry level requirements.",
    "The sample is a phase 2 clinical trial for patients with peripheral artery disease and intermittent claudication. The trial involves testing the effectiveness of three different drugs, including a placebo. The eligibility criteria include having a stable claudication symptom, being between 40 and 80 years old, having a BMI between 18.0 and 30.0 kg/m2, and being able to perform certain physical tests. Exclusion criteria include having critical leg ischemia, poorly controlled hypertension, or a recent history of alcoholism or drug abuse. The trial does not allow patients who have previously been treated with CK-2017357 or gene therapy.",
    "The sample is a phase 2 clinical trial for patients with metastatic colorectal cancer. The trial involves the use of four drugs - bevacizumab, irinotecan, oxaliplatin, and 5-fluorouracil/leucovorin. The eligibility criteria for the trial include confirmation of colorectal adenocarcinoma, unresectable and measurable metastatic disease, age between 18 and 75 years, ECOG Performance Status less than 2, life expectancy of more than 3 months, and adequate hematological and liver function. The exclusion criteria include prior palliative chemotherapy, bowel obstruction, history of inflammatory enteropathy, and presence or history of CNS metastasis, among others.",
    "The sample is a record of a clinical trial with a phase 2 designation. The trial is focused on treating advanced non-small cell lung cancer using the drugs pf-00299804. The trial requires patients to have previously undergone and failed at least one chemotherapy and erlotinib treatment, and no more than two chemotherapy regimens overall. Patients must also have measurable disease, an ECOG performance status of 0-2, and tissue available for KRAS/EGFR testing. Exclusion criteria include recent chemotherapy, radiotherapy, or use of biological or investigational agents within 4 weeks of baseline disease assessment, as well as a lack of tolerance for erlotinib therapy.",
    "The sample is a phase 2 clinical trial for advanced or metastatic breast cancer. The trial is for postmenopausal females with amenorrhoea > 12 months and an intact uterus, with FSH levels within postmenopausal range or have undergone a bilateral oophorectomy, and ER &/or PR positive. The trial involves the use of gefitinib and fulvestrant drugs. The eligibility criteria include measurable disease according to RECIST and/or non-measurable bone disease, life expectancy of at least 12 weeks, and World Health Organisation (WHO) performance status (PS) of 0 to 1. The exclusion criteria include males, life-threatening metastatic visceral disease, evidence of clinically active interstitial lung disease, ER and PR negative, treatment with LHRH analogues < 3 months prior to enrolment, patients who have restarted menses or do not have FSH levels within the postmenopausal range, treatment with strontium - 90 (or other radio pharmaceutical) within the previous 3 months, treatment with hormonotherapy and/or chemotherapy for advanced disease, extensive radiotherapy to measurable lesions within the last 4 weeks, currently receiving oestrogen replacement therapy, treatment with a non-approved or experimental drug within 4 weeks before enrolment, and certain medical conditions such as absolute neutrophil count (ANC) less than 1.5 x 109/litre (L) or platelets less than 100 x 109/L, and history of bleeding diathesis or long term or present anticoagulant therapy.",
    "This sample is for a phase 2 clinical trial for the treatment of depression using the drug \"naltrexone sr 32 mg/ bupropion sr 360 mg daily\". The trial is looking for female and male subjects between the ages of 18 and 65 with a body mass index (BMI) greater than or equal to 27 and less than or equal to 43kg/m2 who also meet the criteria for major depression. The trial requires subjects to be able to comply with all required study procedures and schedule, speak and read English, and give written informed consent. Exclusion criteria include obesity of known endocrine origin, serious medical conditions, history of drug or alcohol abuse or dependence, use of excluded concomitant medications, history of surgical or device intervention for obesity, history or predisposition to seizures, pregnancy or breastfeeding, planned surgical procedures that can impact the study, use of investigational drugs, devices or procedures within 30 days prior to screening, participation in any previous clinical trial conducted by Orexigen Therapeutics, and any condition which in the opinion of the investigator makes the subject unsuitable for inclusion in the study.",
    "The sample is a phase 2 clinical trial for the treatment of psoriasis using the drug bicillin l-a. The trial is looking for male or female participants between the ages of 18 and 50 who have chronic plaque type psoriasis that is unresponsive to topical treatments and extensive enough to consider systemic therapy. The inclusion criteria also require participants to be in good general health, with the exception of their skin disease, and to have had no systemic prescription medication to control psoriasis within the past 30 days. The exclusion criteria include various forms of psoriasis, as well as other medical conditions and histories that may affect the safety or efficacy of the treatment. The eligibility criteria are listed in detail, including specific age ranges, medical histories, and other factors that may affect participation in the trial.",
    "The sample is a phase 2 clinical trial for patients with stage IV cutaneous melanoma. The trial is testing the effectiveness of the drug lapatinib. The eligibility criteria include having no more than two oncogenic somatic ERBB4 mutations, not having received certain types of therapy for at least 4 weeks prior to starting the medication, having normal organ and marrow function, and having a life expectancy of greater than 3 months. Women of childbearing potential must have a negative pregnancy test and practice effective birth control while receiving treatment. The trial is open to both men and women of all races and ethnic groups.",
    "The sample is a phase 2 clinical trial for various types of lymphoma and leukemia. The trial is testing the effectiveness of the drug lenalidomide on patients who have relapsed or progressed after allogeneic hematopoietic cell transplantation (HCT) and are not responding to immunosuppressive medications. The trial includes patients with certain blood count levels, liver and kidney function, and who are willing to use birth control methods. Patients with certain medical conditions or who are pregnant or breastfeeding are excluded from the trial. The trial also excludes patients with resistance to prior use of lenalidomide, concurrent use of other anti-cancer agents or treatments, and active grades III or IV acute graft-versus-host disease (GVHD).",
    "The sample is a phase 2 clinical trial for the treatment of cutaneous t-cell lymphoma. The trial includes patients with stages IB, IIA, IIB, III, or IVA who have not received any prior systemic therapies. The drug being tested is vorinostat. The eligibility criteria include confirmation of diagnosis by histologic examination, anticipated life expectancy greater than 6 months, and certain laboratory values within normal limits. Exclusion criteria include the presence of extracutaneous visceral CTCL involvement, concomitant use of any anti-cancer therapy or immune modifier, and poorly controlled diabetes mellitus. Women of childbearing potential must have a negative pregnancy test and use adequate contraception throughout the study and for a period of at least 3 months after the study.",
    "The sample is a phase 2 clinical trial for patients with stage IV or unresectable stage III non-ocular malignant melanoma who have not undergone prior chemotherapy for the treatment of melanoma. The trial is testing the drug cp-4055 (elacyt). The trial has inclusion criteria such as measurable disease, performance status 0-2, age 18 years or more, life expectancy of more than 3 months, and adequate hematological and biological functions. Exclusion criteria include known brain metastases, diagnosis of ocular malignant melanoma, prior immunotherapy and/or chemotherapy for the treatment of melanoma, and drug and/or alcohol abuse. The trial also has other exclusion criteria such as pregnancy, breastfeeding, and absence of adequate contraception for both male and female fertile patients.",
    "The sample is a record of a clinical trial in phase 2, focused on the disease of renal transplantation. The icd-10 codes associated with this disease are listed. The trial involves the use of three drugs: campath 1h\u00ae, rituximab, and mycophenolate mofetil. The eligibility criteria for the trial are also listed, including inclusion criteria for renal transplant recipients and exclusion criteria for recipients of HLA-identical living-donor renal transplants, multi-organ transplant, and known hypersensitivity to the drugs being used in the trial.",
    "The sample is a phase 2 clinical trial for the treatment of chronic hepatitis C. The trial includes patients with genotype 1 infection who are either treatment-naive or null-responders to previous treatment with pegylated interferon and ribavirin. The trial excludes patients with liver cirrhosis, significant liver disease with any cause other than HCV, positive hepatitis B surface antigen and anti-human immunodeficiency virus antibody, positive screen for drugs and alcohol, significant sensitivity to any drug, use of contraindicated or prohibited medications within 1 month of dosing, and abnormal laboratory tests. The trial involves the use of five drugs: abt-450, abt-333, abt-267, ribavirin, and ritonavir. The diseases included in the trial are chronic hepatitis C, hepatitis C (HCV), and hepatitis C genotype 1, and their corresponding ICD-10 codes are listed in the table.",
    "The sample is a phase 2 clinical trial for small cell lung cancer. The trial includes patients with extensive stage disease, metastatic disease outside the chest, contralateral supraclavicular nodes or contralateral hilar nodes that cannot be included in a single radiation port, or cytologically confirmed malignant pleural effusion. Patients must have previously untreated disease or stable disease, partial response, or complete response \u2264 4 weeks after completion of one course (four 3-week courses) of standard platinum-based chemotherapy. Patients must also meet various eligibility criteria, including having an ECOG performance status of 0-2, life expectancy \u2265 12 weeks, and meeting certain laboratory values. Patients must not have certain medical conditions or take certain medications. The trial allows for prior nonthoracic palliative radiotherapy and concurrent bisphosphonates for treatment of lytic metastatic bone disease at the discretion of the treating physician, but does not allow for concurrent prophylactic granulocyte colony-stimulating factor, products that stimulate thrombopoiesis, or St. John's wort. No other concurrent chemotherapy, immunotherapy, hormonal therapy, or radiotherapy is allowed.",
    "The sample is a phase 2 clinical trial for patients with primary adenocarcinoma of the thoracic esophagus or gastroesophageal junction. The trial is testing the effectiveness of the drugs fluorouracil and oxaliplatin. The eligibility criteria include having clinical stage II or III disease, measurable or non-measurable disease, and meeting certain hematopoietic, hepatic, renal, cardiovascular, and pulmonary requirements. Patients must not have had prior chemotherapy or radiotherapy for esophageal cancer, and must not have had a myocardial infarction or cerebrovascular event within the past 6 months. The trial is not open to patients who have had prior surgical resection or attempted surgical resection of esophageal cancer.",
    "The sample is a record of a clinical trial in phase 2 for the treatment of overactive bladder. The trial involves the use of two drugs, ym178 and placebo. The eligibility criteria for the trial include patients over 20 years of age who suffer from overactive bladder, while pregnant and breastfeeding women and patients with clinically significant abnormal conditions are excluded from the trial. The diseases are listed as 'urinary bladder, overactive' and the corresponding ICD-10 code is 'N32.81'.",
    "The sample is a phase 2 clinical trial for newly diagnosed adenocarcinoma of the esophagus or gastroesophageal junction. The trial includes patients with specific tumor stages and extension into the cardia, and who are considered surgically resectable. Patients must have an ECOG performance status of 0-1 and meet certain blood and organ function criteria. Fertile patients must use effective contraception and patients with a history of a curatively treated malignancy must have been disease-free for at least 2 years with a survival prognosis of over 5 years. Exclusion criteria include pregnancy or breastfeeding, prior severe infusion reaction to a monoclonal antibody, prior therapy targeting the epidermal growth factor receptor pathway, hypertension, uncontrolled diabetes, and recent heart or cerebrovascular events.",
    "The sample is a phase 2 clinical trial for sepsis and disseminated intravascular coagulation. The trial involves the use of two drugs, art-123 and placebo. The eligibility criteria for the trial includes having an infection or suspected infection resulting in sepsis and DIC, and not having any known conditions that could confound the diagnosis of DIC due to sepsis or increase the risk of bleeding. Additionally, subjects must be over 18 years of age and not have any known medical conditions associated with a hypercoagulable state or severe liver disease. History of solid organ, bone marrow or stem cell transplantation, and renal failure are also exclusion criteria.",
    "The sample is a phase 2 clinical trial for patients with Burkitt's lymphoma or B-cell lymphoma unclassified. The trial is for newly diagnosed patients with any stage of the disease. Patients must meet certain criteria for disease risk and have measurable or nonmeasurable disease. Patients must also have a Karnofsky performance status of 40-100%, be not pregnant or nursing, and have negative pregnancy test. Patients with active hepatitis B infection are eligible provided they receive concurrent dual antiviral therapy. The trial involves a combination of drugs including cyclophosphamide, cytarabine, doxorubicin hydrochloride, etoposide, ifosfamide, leucovorin calcium, liposomal cytarabine, methotrexate, therapeutic hydrocortisone, and vincristine sulfate. Prior concurrent therapy is limited to seven consecutive days of steroids alone or in combination with a non-CHOP regimen necessary for patient stabilization or one course of CHOP or fractionated CHOP with or without rituximab. Patients must not have had epoetin alfa or filgrastim within 24 hours of study chemotherapy and no concurrent zidovudine.",
    "The sample is a phase 2 clinical trial for adult acute myeloid leukemia and myelodysplastic syndromes. The trial includes patients who have relapsed or resistant AML, untreated AML, or MDS. Patients must meet certain eligibility criteria, including age, performance status, and normal levels of bilirubin, AST/ALT, and creatinine. Patients must also have no active CNS metastasis or symptomatic leukostasis. The trial involves the drug cediranib maleate and patients must not have any significant ECG abnormalities or history of allergic reactions to similar compounds. The trial excludes patients with certain concurrent illnesses or medications. The trial requires patients to have had no more than 3 prior courses of induction chemotherapy and no concurrent CYP interactive medications or investigational agents. Prior and concurrent hydroxyurea is allowed to control peripheral blast count.",
    "The sample is a phase 2 clinical trial for patients with metastatic adenocarcinoma of the colon or rectum who have failed previous chemotherapy treatments. The trial is testing the effectiveness of gemcitabine and capecitabine as a treatment option. The eligibility criteria include having measurable disease, a certain performance status, and meeting certain laboratory values. Patients must also have received at least two prior chemotherapy regimens for advanced disease. The exclusion criteria include having a history of malignancy other than colon or rectal cancer, brain metastasis, recent myocardial infarction, or other medical conditions that would prevent compliance with the study protocol.",
    "The sample is a phase 2 clinical trial for patients with relapsed or refractory classical Hodgkin's lymphoma. The trial is testing the drug entinostat. The eligibility criteria include having confirmed relapsed or refractory Hodgkin's lymphoma, having measurable disease, and having a performance status of 0 or 1. Exclusion criteria include having another active cancer, being pregnant or lactating, and having certain medical conditions that could interfere with the study procedures. Patients must also be able to read, understand, and sign a written informed consent.",
    "The sample is a phase 2 clinical trial for patients with metastatic renal cell carcinoma. The trial is evaluating the effectiveness of four drugs - temsirolimus, bevacizumab, sunitinib, and interferon alpha-2a. The eligibility criteria for the trial include being male or female and over 18 years of age, having histological or cytological evidence of metastatic renal cell carcinoma (except for papillary type), having no prior systemic treatment for metastatic renal cancer, having no brain metastases, having an E.C.O.G performance status of 2 or less, having at least one measurable lesion using the RECIST criteria, and having normal blood tests and renal and liver functions. The exclusion criteria include having pure papillary renal cell carcinoma, having prior systemic treatment for metastatic renal cancer, having a history of other malignancies, having evidence of brain metastasis, having significant cardiovascular disease or uncontrolled hypertension, having hepatic affection, having undergone major surgical procedure or open biopsy, having uncontrolled hypercalcemia or hypercholesterolemia, being under anti-vitamin K therapy or strong CYP3A4 inhibitors, having severe neuropsychiatric disorder, being included in another clinical trial, and being pregnant or lactating.",
    "The sample is a phase 2 clinical trial for the treatment of metastatic colorectal cancer. The trial involves the use of two drugs, vandetanib and the folfox regimen (oxaliplatin, fluorouracil, and folinic acid). The eligibility criteria for the trial include having progression on or following treatment for metastatic colorectal cancer, having failed therapy with an irinotecan and fluoropyrimidine containing regimen, having a World Health Organisation (WHO) performance status of 0-2, and a life expectancy of more than 12 weeks. The exclusion criteria include previous treatment with small molecule tyrosine kinase inhibitors of VEGFR or EGFR, previous adjuvant therapy with irinotecan within 12 months of randomisation, and more than one prior course of chemotherapy for treatment of metastatic colorectal cancer.",
    "The sample is a phase 2 clinical trial for individuals with impaired glucose tolerance who are on diet and exercise therapy and are unlikely to conceive. The trial involves the use of sitagliptin, with both 25 mg and 50 mg doses, as well as placebos for each dose. The trial has specific glycemic parameters that participants must meet. The inclusion criteria also includes having a Hemoglobin A1c (Japan Diabetes Society value) of less than 6.1%, a fasting plasma glucose level of less than 126 mg/dL, and a 2-hour plasma glucose level in a 75g oral glucose tolerance test between 140 mg/dL and 200 mg/dL. The exclusion criteria includes a history of diabetes mellitus, a disease or condition that affects glucose tolerance, and previous treatment with a drug to prevent diabetes or any antihyperglycemic drug.",
    "The sample is a record of a clinical trial with a phase 2 designation. The trial is focused on the disease hepatitis C and includes a list of ICD-10 codes associated with the disease. The trial involves two drugs, lcq908 and placebo. The eligibility criteria for the trial includes written informed consent, subjects between the ages of 18 and 65 with hepatitis C infections, no prior therapy or inadequate response to therapy for hepatitis C, and a weight of at least 50 kg and body mass index (BMI) within 18 - 35 kg/m2. The exclusion criteria includes the use of other investigational drugs within at least 30 days of enrollment and women of child-bearing potential. Other protocol-defined inclusion/exclusion criteria also apply.",
    "The sample is a phase 2 clinical trial for patients with pulmonary hypertension. The trial is testing the effectiveness of simvastatin, aspirin, and placebo as treatments. The eligibility criteria for the trial include having a mean pulmonary artery pressure greater than 25 mm Hg at rest with a pulmonary capillary wedge pressure less than 16 mm Hg, a diagnosis of PAH that is idiopathic, familial, or associated with certain conditions, and the ability to perform six-minute walk testing without limitations in musculoskeletal function or coordination. Exclusion criteria include having PAH related to other etiologies, sickle cell disease, clinically significant untreated sleep apnea, left-sided valvular disease, and hospitalization or acute illness. Other exclusion criteria include kidney failure, initiation of PAH therapy within 3 months of study entry, allergy or hypersensitivity to aspirin or simvastatin, and current treatment with statin therapy. Participants must also be willing to avoid non-steroidal, anti-inflammatory medications for 6 months following study entry.",
    "The sample is for a phase 2 trial and focuses on the disease \"Friedreich's Ataxia\". The ICD-10 code for this disease is \"G11.11\". The trial involves testing three drugs: \"alpha-tocopherolquinone (a0001)\", \"alpha-tocopherolquinone (a0001)\", and \"placebo\". The eligibility criteria for the trial include having genetically confirmed Friedreich's Ataxia and impaired glucose tolerance measured by Oral GTT. The exclusion criteria include having overt diabetes mellitus and clinically significant cardiovascular disease.",
    "The sample is a phase 2 clinical trial for patients with melanoma. The trial is testing the effectiveness of the drugs imatinib and interferon. The eligibility criteria for the trial include having had the primary tumor and regional lymph nodes removed, being diagnosed with AJCC stage IIB to IIIC melanoma, having a documented c-kit mutation, having an ECOG performance status of 0 or 1, being 18 years or older, and meeting certain medical criteria such as having a creatinine level below 1.5 times the upper limit of normal and platelets above 100,000 ul. There are also exclusion criteria, such as having severe or uncontrolled medical disease, being pregnant or nursing, or having received chemotherapy within 4 weeks prior to study entry.",
    "The sample is a phase 2 clinical trial for the treatment of migraines. The trial includes patients with a history of migraines lasting between 4-72 hours, occurring more than once a month, and with an age of onset prior to 50 years old. Patients must be able to distinguish migraine attacks from other types of headaches and have consistent migraine headaches of at least 2 moderate to severe intensity attacks in each of the last 3 months. Patients must also have less than 15 days of headache per month in the 3 months prior to screening. The trial includes both male and female patients aged 18-65 with no clinically significant abnormalities identified on medical or laboratory evaluation. Exclusion criteria include a history of basilar or hemiplegic migraines, no relief from triptan migraine treatment, and regular use of certain medications. The trial will test the effectiveness of rimegepant, placebo, and sumatriptan as treatments for migraines.",
    "The sample is a phase 2 clinical trial for patients with non-small cell lung cancer who have had no more than 2 prior lines of therapy, with the latest being single-agent erlotinib. The trial involves the drugs sorafenib and erlotinib. The eligibility criteria include having a measurable lesion, a performance status of 0, 1, or 2, and meeting certain laboratory values. Patients must also have experienced a clinical benefit from prior therapy with erlotinib for a period of 8 weeks. Exclusion criteria include a history of neoplasm other than the entry diagnosis, significant cardiac disease, and untreated brain metastases. Patients must be able to understand the nature of the study, give written informed consent, and comply with study requirements. Effective contraception must be used to prevent pregnancy during treatment and for a minimum of 90 days thereafter.",
    "The sample is a phase 2 clinical trial for the treatment of ovarian cancer, fallopian tube cancer, and primary peritoneal cancer. The trial involves the use of drugs such as amg 386, paclitaxel, and amg 386 placebo. The eligibility criteria include having histologically or cytologically documented cancer, radiographically documented progression, and no more than 3 previous regimens of anti-cancer therapy. The trial also requires adequate organ and hematological function, as evidenced by laboratory studies, and a GOG Performance Status of 0 or 1. There are exclusion criteria such as ongoing small bowel dysfunction, history of arterial or venous thrombosis, and concurrent or prior anticoagulation therapy.",
    "The sample is a record of a clinical trial in phase 2 for the treatment of postmenopausal osteoporosis. The trial involves the use of two drugs, bazedoxifene and placebo. The eligibility criteria for the trial include being postmenopausal and diagnosed with osteoporosis based on bone mineral density and/or vertebral fracture. The exclusion criteria include having diseases that may induce secondary osteoporosis or osteopenia and affect bone metabolism. The icd-10 codes associated with the disease are also provided.",
    "The sample is a phase 2 clinical trial for patients with type 2 diabetes mellitus. The trial includes the drugs actos, placebo, and aleglitazar. The eligibility criteria include being an adult between 18-75 years old, having been diagnosed with type 2 diabetes for at least one month, and having an HbA1c level between 7.0-10.0% at the pre-randomisation visit. Patients cannot have type 1 diabetes, cannot have been treated with insulin, a thiazolidinedione, or a dual PPAR agonist, and cannot have clinically significant cardiovascular disease or CHF NYHA 3-4.",
    "The sample is a record of a clinical trial that is in phase 2/phase 3 and is focused on the disease of arthritis, rheumatoid. The icd-10 codes associated with the disease are listed as well. The trial involves the drugs ce-224,535 and placebo. The eligibility criteria for the trial include having active rheumatoid arthritis and an incomplete response to methotrexate, while exclusion criteria include not being on biologic therapies and having no recent infections.",
    "This is a sample of a clinical trial for phase 2, focused on non-small cell lung cancer. The trial is testing the effectiveness of the drug erlotinib. The eligibility criteria for participants include having a histological or cytological diagnosis of inoperable, locally advanced, recurrent or metastatic NSCLC, being chemo-na\u00efve, having measurable disease according to the RECIST criteria, having an ECOG performance status of 0-3, having a life expectancy of at least 12 weeks, being able to take oral medication, having serum calcium within normal ranges, and being at least 18 years old. Exclusion criteria include prior systemic antitumor therapy, any unstable systemic disease that contraindicates the use of the study drug, any other malignancies within 5 years (except for adequately treated carcinoma in situ of the cervix or basal or squamous cell skin cancer), nursing mothers or pregnant women, hypersensitivity to Tarceva or co-formulants, and patients with brain metastasis or spinal cord compression that has not yet been definitively treated with surgery and/or radiation.",
    "The sample is a record of a clinical trial with a phase 2 designation. The trial is focused on Crohn's disease, with the ICD-10 codes for the disease listed. The drug being tested is interferon beta-1a. The eligibility criteria for the trial include patients who have previously gone into remission using corticosteroids within 4 weeks before the study. Patients who have received any other treatment for the maintenance of remission of Crohn's disease are excluded from the trial.",
    "The sample is a phase 2 clinical trial for patients with breast cancer and HER-2 overexpression. The trial is focused on patients with at least one measurable brain metastasis who are deemed best suited for whole brain radiotherapy by the investigator. The inclusion criteria include being an adult patient over 18 years of age, having a performance status (WHO) of 2 or less, and a life expectancy of at least 3 months. The exclusion criteria include the presence of neoplastic meningitis, any prior radiotherapy to the brain, and previous neoplasms other than breast carcinoma within 5 years of enrollment. The trial is testing the effectiveness of trastuzumab (herceptin) as a treatment option.",
    "The sample is a phase 2 clinical trial for the treatment of metastatic clear cell renal cell cancer. The trial involves a combination of gemcitabine, capecitabine, and bevacizumab. The eligibility criteria include having measurable disease, being 18 years or older, having an ECOG performance status of 0-1, and having normal organ function. Patients must not have had prior treatment with pyrimidine analogs or VEGF binding agents, and must not be receiving any other investigational or therapeutic agents. Exclusion criteria include having had chemotherapy or radiotherapy within 4 weeks prior to entering the study, having a serious nonhealing wound or bone fracture, and being pregnant. Patients with known brain metastases or HIV-positive patients receiving combination anti-retroviral therapy are also excluded from the study.",
    "The sample is a record of a clinical trial with a phase 2 designation. The trial is focused on the treatment of relapsing-remitting multiple sclerosis. The trial involves the use of interferon beta 1b (betaseron, bay86-5046) as the drug being tested. The eligibility criteria for the trial include a signed and dated statement of informed consent, completion of Protocol 307000A, negative serum pregnancy test results, and agreement to adequate contraception for female patients. Exclusion criteria include pregnancy or lactation, history of alcohol or drug abuse, inability to administer subcutaneous injections either by self or by caregiver, medical, psychiatric or other conditions that compromise the patient's ability to give informed consent, to understand the patient information, to comply with the study protocol, or to complete the study, and any significant change in the patient's medical condition after enrollment in Study 307000A which would have led to his/her exclusion from participation in that study. The icd-10 codes associated with the disease being studied are also included in the record.",
    "The sample is a record of a clinical trial for a drug called bn83495 in phase 2. The trial is focused on treating endometrial cancer in postmenopausal or ovariectomised female patients over 18 years of age who have been diagnosed with ER positive endometrial carcinoma in the primary tumor or metastatic disease. The patients must have received one line of chemotherapy prior to enrollment in the adjuvant or in the metastatic setting and progressed after this line of chemotherapy. The trial has inclusion and exclusion criteria, which are listed in the sample. The diseases are listed as 'endometrial cancer', and the icd-10 codes are listed as [\"['N85.00', 'N85.01', 'N85.02', 'N99.85']\"].",
    "The sample is a record of a clinical trial that is in phase 2/phase 3. The trial is focused on three different diseases: chronic myelogenous leukemia, malignant melanoma, and renal cell carcinoma. The diseases are identified by their corresponding ICD-10 codes. The trial is testing two drugs: pegylated interferon alfa-2a and recombinant interferon alfa 2a. The eligibility criteria for participants are listed, including requirements for previous participation in related trials and confirmed response to treatment. There are also exclusion criteria, such as pregnancy or refusal to use adequate contraception.",
    "The sample is a phase 2 clinical trial for the treatment of clostridium difficile infection. The trial includes patients who meet the case definition of CDI and have been treated with metronidazole or vancomycin. The trial involves the use of two drugs, miya-bm fine granules (cbm588) and placebo fine granules (without cbm588). The eligibility criteria include being an adult between the ages of 18-80, having no other known etiology of diarrhea, and not having certain medical conditions or taking certain medications. The trial also includes exclusion criteria such as having a history of acute pancreatitis or chronic intestinal disease, being unable to complete a daily study diary, or having a known allergy to any component of the drugs being used.",
    "The sample is a phase 2 clinical trial for non-small cell lung cancer. The trial includes patients who have measurable, evaluable disease outside of a radiation port and an ECOG performance status of 0-2. Patients must have adequate hematologic function and have received one prior chemotherapy regimen, with disease progression or recurrence within 6 months of the last dose of chemotherapy in the first regimen. Patients must also have at least a 2-week recovery from prior therapy toxicity and sign informed consent. Exclusion criteria include prior Iressa or other EGFR inhibiting agents, prior docetaxel therapy, and any unresolved chronic toxicity greater than CTC grade 2 from previous anticancer therapy. Other exclusion criteria include incomplete healing from previous oncologic or other major surgery, concomitant use of certain medications, and evidence of severe or uncontrolled systemic disease. Patients who are pregnant or breastfeeding, have uncontrolled seizure disorder, active neurological disease, or Grade >= 2 neuropathy, or have received any investigational agent(s) within 30 days of study entry are also excluded. The trial includes a list of drugs, including zd1839 and docetaxel, and a list of icd-10 codes of diseases. The eligibility criteria are also provided.",
    "The sample is a record of a clinical trial with a phase 2/phase 3 designation, focused on breast neoplasm. The trial involves the use of two different drug combinations, paclitaxel weekly in combination with capecitabine and docetaxel every 3 weeks in combination with capecitabine. The eligibility criteria for the trial include having morphologically proven breast carcinoma, measurable and/or evaluable disease, age 18 years or older, ECOG Performance Status 0-2, and adequate cardiac, hematological, renal, and hepatic functions. Exclusion criteria include having a recurrence-free interval of less than one year if previous adjuvant or neoadjuvant regimen contained a taxane, having a neoplasm other than breast carcinoma, pregnancy or lactation, known brain metastases, preexisting motor or sensory neuropathy \u2265 grade 2, severe hepatic or renal impairment, history of known dihydropyrimidine dehydrogenase (DPD) deficiency, active infection or other serious underlying medical condition, and dementia or significantly altered mental status that would prohibit the understanding and giving of informed consent.",
    "The sample is a phase 2 clinical trial for advanced/metastatic non-small cell lung cancer. The trial involves the use of drugs such as ixabepilone, paclitaxel, and carboplatin. The eligibility criteria for the trial include having histologically confirmed non-small cell lung cancer, measurable disease, and a Karnofsky performance status of 70-100. Exclusion criteria include uncontrolled brain metastases, peripheral neuropathy greater than Grade 1, and any prior antineoplastic systemic regimens.",
    "This is a sample of a clinical trial for phase 2, focused on the disease of leukemia. The trial is looking at the effectiveness of two drugs, hydroxychloroquine and imatinib mesylate, in treating chronic myeloid leukemia in chronic phase. Patients must have been treated with imatinib mesylate for at least one year and achieved at least major cytogenetic response. They must also meet certain patient characteristics, such as having a certain level of neutrophil and platelet counts, and not having impaired cardiac function or other severe medical conditions. Patients must not be pregnant or nursing, and fertile patients must use effective contraception during and after the study. Prior concurrent therapy is also taken into consideration.",
    "The sample is a phase 2 trial for pulmonary disease, chronic obstructive. The trial includes a list of icd-10 codes for the disease and a list of drugs, including gw642444m, gw642444h, and placebo. The eligibility criteria for the trial include being male or female over 40 years old, having a history of COPD, being a smoker or ex-smoker, and having a body weight of at least 50 kg with a BMI between 18-32 kg/m2. Exclusion criteria include a history of significant disease, a primary asthma diagnosis, alpha-1 antitrypsin deficiency as the underlying cause of COPD, recent respiratory tract infection, poorly controlled COPD, blood potassium level below 3.5mmol/L, short-term or long-term oxygen therapy, recent participation in another trial, history of drug or alcohol abuse, known allergies, recent blood donation, and ECG abnormalities.",
    "The sample is a phase 2 clinical trial for cervical cancer patients who meet certain criteria. The trial involves the use of two drugs, isotretinoin and paclitaxel. The eligibility criteria include having histologically and/or cytologically confirmed cervical cancer, measurable disease, and not being amenable to chemoradiotherapy or surgery. Patients must also meet certain age, performance status, and hematopoietic, hepatic, and renal function requirements. They must not be pregnant or nursing, have no active infections, and must not have any medical conditions that would preclude study compliance. The trial excludes patients who have had prior interferon or other concurrent immunotherapy, concurrent hormonal therapy for cancer, concurrent radiotherapy, or concurrent surgery for cancer. Patients must have recovered from prior radiotherapy and surgery. They must not have had prior retinoids or other concurrent anticancer therapy or experimental agents.",
    "The sample is a phase 2 clinical trial for patients with newly diagnosed stage Ia-IIb resectable non-small cell lung cancer who will be undergoing definitive surgery. The trial involves treatment with the drug pioglitazone for a minimum of 2 weeks and a maximum of 6 weeks prior to surgery. The eligibility criteria include being an adult patient with an ECOG performance score of less than or equal to 2, normal organ and marrow function, and the capacity and willingness to sign a written informed consent. The exclusion criteria include being pregnant or lactating, undergoing chemotherapy, treatment with biologic agents, or radiation therapy, having congestive heart failure or moderate edema, being treated with insulin or any pharmacologic therapy for diabetes mellitus, taking gemfibrozil or rifampin, and having uncontrolled intercurrent illness.",
    "The sample is a record of a clinical trial with a phase 2 designation, focused on the treatment of multiple myeloma. The trial involves the use of drugs such as bortezomib, dexamethasone, and pd 0332991. The eligibility criteria for the trial include a diagnosis of symptomatic multiple myeloma, measurable disease after at least one previous treatment, and a life expectancy of more than three months. Exclusion criteria include a history of allogeneic stem cell transplant, prior radiation therapy to more than 25% of the bone marrow, and significant blood level changes while on previous bortezomib therapy.",
    "The sample is a phase 2 clinical trial for pancreatic cancer. The eligibility criteria include having non-metastatic, unresectable disease, being 18 years or older, having a Karnofsky performance status greater than or equal to 70, and meeting certain bone marrow, renal, and hepatic function requirements. Patients must also sign a study-specific consent form. Exclusion criteria include having a history of prior metastatic cancer, significant infection, uncontrolled cardiac disease, prior therapy targeting the estimated EGFR pathway, and prior severe infusion reaction to a monoclonal antibody. Patients must not have had prior radiotherapy to the abdomen or organ allograft. Patients taking certain medications must discontinue them prior to starting capecitabine.",
    "The sample is a phase 2 clinical trial for patients with high risk uterine leiomyosarcoma or uterine neoplasm. The trial involves the use of gemcitabine, docetaxel, and doxorubicin drugs. The eligibility criteria include being 18 years or older, having undergone surgical resection of cancer no longer than 12 weeks ago, having no evidence of residual disease, and meeting certain health requirements such as having adequate liver function and no more than grade 1 neuropathy. Exclusion criteria include having other invasive malignancies, prior therapy with the drugs being used in the trial, and cardiac ejection fraction below 50%.",
    "The sample is a phase 2 trial for patients with pain and discomfort during scaling and root planning due to periodontitis. The trial includes patients diagnosed with periodontitis marginalis adulta progressiva lenta and rapid in the hygiene phase, where depurations are repeated within a short timeframe. The patients must be between 18 and 80 years old, able to speak, read and understand Danish, and able to give oral and written consent. Exclusion criteria include known allergy to bupivacaine or other local anaesthetics of the amide type, other gingival infections such as lichen planus, pregnancy, and breastfeeding. The trial will test the effectiveness of bupivacaine lozenge and lidocaine-adrenalin injection as treatments for the pain and discomfort experienced during scaling and root planning.",
    "The sample is a record of a clinical trial with a phase 2 designation. The trial is focused on breast cancer and the associated ICD-10 codes. The drugs being tested are trastuzumab and taxane (docetaxel or paclitaxel). The eligibility criteria for the trial include having at least 10 months of Herceptin treatment for HER2-positive early breast cancer, having metastatic breast cancer at least 12 months after discontinuation of Herceptin, and having measurable disease. The exclusion criteria include having previous chemotherapy for metastatic breast cancer, brain metastases, or invasive malignancy other than metastatic breast cancer.",
    "The sample is a phase 2 clinical trial for patients with locally advanced or metastatic breast cancer that cannot be treated with surgery or radiation with curative intent. The trial is testing the drug edotecarin. The trial includes patients who have received any chemotherapy regimen in the past and have evidence of tumor resistance to the last chemotherapy. Patients must have measurable disease and adequate bone marrow, liver, and renal function. They must also provide informed consent and be willing and able to comply with scheduled visits, treatment plan, and study procedures. Exclusion criteria include having received more than 2 prior chemotherapy regimens for metastatic disease, having received another drug of the same class as the investigational drug, being enrolled in another clinical intervention study, being pregnant or breastfeeding, having had a cardiac or thrombotic event in the last 12 months, or having brain metastases.",
    "The sample is a phase 2 clinical trial for patients with stage IIIB or IV non-small cell lung cancer with pleural effusion or radiographically measurable disease. The trial is testing the effectiveness of the drug tamibarotene compared to a placebo. The eligibility criteria include being at least 18 years old, having a life expectancy of at least 12 weeks, and having adequate bone marrow, liver, and kidney function. Participants must also be able to swallow tablets and understand and sign a written informed consent document. Female participants of childbearing potential must agree to use two effective methods of contraception, and male participants must agree to use an effective method of contraception. The trial has exclusion criteria, including having received chemotherapy or antibody therapy, having a coagulopathy or bleeding disorder, and having a serious medical or psychiatric illness that could interfere with treatment.",
    "The sample is a record from a clinical trial table. It is a phase 2 trial for the treatment of gastroesophageal reflux disease. The record includes the list of diseases, icd-10 codes, drugs, and eligibility criteria for the trial. The inclusion criteria include patients with a history of GERD symptoms, between the ages of 18-70, who develop GERD symptoms following ingestion of a refluxogenic meal, and are able to take a stable Proton Pump Inhibitor regimen for the duration of the study. The exclusion criteria include pregnant or lactating women and those who are allergic to pumosetrag or formulation excipients.",
    "This sample is for a phase 2 clinical trial for the treatment of chronic myeloid leukemia. The trial is testing the drug omacetaxine mepesuccinate. The eligibility criteria includes patients who are 18 years or older, have Philadelphia chromosome positive chronic myelogenous leukemia in either chronic, accelerated, or blast phase, have the T315I BCR-ABL gene mutation, and have failed prior imatinib therapy. Patients with certain heart conditions or recent myocardial infarction are excluded from the trial.",
    "The sample is a phase 2 clinical trial for HIV-1 and HIV infections. The trial is testing the effectiveness of the drugs TMC114 and ritonavir on participants who are failing their current antiretroviral therapy. The eligibility criteria include having a stable CD4+ percentage, being able to swallow the medications, and using safe and effective birth control if sexually active. Exclusion criteria include having any currently active AIDS defining illness, being pregnant or breastfeeding, and having any Grade 3 or 4 toxicity. The trial is divided into two parts based on body weight, and the use of the non-nucleoside analogue reverse transcriptase inhibitor efavirenz is not allowed in Part 1 but is allowed in Part 2.",
    "The sample is a phase 2 clinical trial for attention-deficit/hyperactivity disorder (ADHD) using the drugs td-9855 and placebo. The trial includes subjects who meet the DSM-IV-TR criteria for current ADHD subtypes and have a total score of 24 or greater on the Adult Attention-Deficit/Hyperactivity Disorder Clinical Diagnostic Scale (ACDS V1.2) at both the screening and baseline visits. Subjects must also have a CGI-S score of at least 4 (moderate) at both visits. Women of childbearing potential must have a negative pregnancy test and use a highly effective method of birth control during the study and for at least 1 month after completion of study drug dosing. Exclusion criteria include any current psychiatric disorder other than ADHD, a diagnosis of ADHD NOS, any diagnosis of lifetime bipolar disorder or psychotic disorder, a current diagnosis of any severe comorbid Axis II disorder, and any history of mental retardation, organic mental disorders due to general medical condition or pervasive developmental disorder as defined by DSM-IV-TR.",
    "The sample is a phase 2 clinical trial for obsessive compulsive disorder. The trial includes patients who meet certain inclusion criteria such as having a Y-BOCS total score of at least 20 and having OCD symptoms for at least one year. Patients with bipolar disorder, schizophrenia, or psychotic disorder, severe or uncontrolled organic diseases, neurological disorder, and women of childbearing potential who are not using effective contraception are excluded from the trial. The trial involves the use of two drugs, agomelatine a and placebo. The diseases are listed as \"obsessive compulsive disorder\" and the corresponding ICD-10 codes are listed as \"F42.8\", \"F42.9\", and \"F60.5\".",
    "The sample is a phase 2 clinical trial for non-Hodgkin's lymphoma. The trial involves the use of drugs such as bortezomib, rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone. The eligibility criteria for the trial include confirmation of histologically confirmed primary mediastinal large B-cell lymphoma, previously untreated patients (with the exception of limited radiotherapy or steroids for SVC syndrome), age over 18, and measurable disease. Exclusion criteria include platelet count of less than 100,000/uL, absolute neutrophil count of less than 1500/uL, calculated or measured creatinine clearance of less than 30 mL/minute, Grade 2 peripheral neuropathy, recent myocardial infarction, New York Hospital Association (NYHA) Class III or IV heart failure, uncontrolled angina, severe uncontrolled ventricular arrhythmias, electrocardiographic evidence of acute ischemia or active conduction system abnormalities, hypersensitivity to bortezomib, boron or mannitol, pregnancy or breastfeeding, receipt of other investigational drugs within 14 days before enrollment, serious medical or psychiatric illness likely to interfere with participation in this clinical study, and a cardiac ejection fraction of less than 50% by echocardiogram or MUGA scan.",
    "The sample is a record from a clinical trial table that includes information about the trial's phase, diseases being studied, icd-10 codes of those diseases, drugs being tested, and eligibility criteria for participants. In this particular sample, the trial is in phase 2 and is studying ovarian neoplasms. The icd-10 codes associated with the disease are listed, as well as the drug being tested, which is aflibercept. The eligibility criteria for participants are also listed, including requirements for symptomatic malignant ascites resulting from advanced ovarian epithelial cancer and platinum-resistant disease. There are also exclusion criteria listed, such as prior treatment with a VEGF or VEGF receptor inhibitor and uncontrolled hypertension.",
    "The sample is a phase 2 trial for the treatment of active seropositive rheumatoid arthritis. The trial includes patients who have been on a stable dose of methotrexate for at least 12 weeks, with or without a history of anti-TNF use. The trial excludes patients who have previously used rituximab or other B cell depleting agents, have significant health problems other than rheumatoid arthritis, or have clinically significant laboratory abnormalities. The trial involves the use of drugs such as tru-015, methylprednisolone, and prednisone. The diseases being studied are arthritis, rheumatoid, and the icd-10 codes associated with these diseases are listed as well.",
    "The sample is a phase 2 trial for the treatment of post herpetic neuralgia, PHN, neuropathy, and nerve pain. The trial involves the use of epicept-np-1 cream, gabapentin capsules, and a placebo. The eligibility criteria for the trial include adult patients who have been experiencing pain for at least 3 months following the onset of a herpes zoster rash. Patients with clinically significant intercurrent illnesses that could interfere with the efficacy or safety assessments are excluded from the trial. The icd-10 codes for the diseases being treated are also provided.",
    "This sample is for a phase 2 clinical trial for advanced cancer patients using the drug cetuximab. The eligibility criteria include having measurable or evaluable disease, adequate recovery from previous therapy or intervention, and not being pregnant or unwilling to use contraception. Exclusion criteria include having symptomatic brain metastasis, a history of certain heart conditions, and being currently enrolled in another clinical trial or having received an investigational drug or device within the past 21 days. The sample also includes a list of icd-10 codes for the diseases being studied.",
    "The sample is a phase 2 clinical trial for the treatment of medulloblastoma, a type of brain tumor. The trial includes patients with standard-risk disease and no residual tumor greater than 1.5 cm^2 after surgery. The trial involves the use of drugs such as cisplatin, cyclophosphamide, etoposide, lomustine, and vincristine. The eligibility criteria include histologically confirmed medulloblastoma, no tumor in the spinal or cerebral subarachnoid space by MRI or CSF, and no failure to perform staging studies preoperatively or postoperatively. Pregnant females and patients with prior radiotherapy and anti-tumor chemotherapy other than corticosteroids are not eligible. The trial requires patients to begin radiotherapy on the study within 28 days after surgery.",
    "The sample is a phase 2 clinical trial for head and neck cancer. The trial is looking for patients with newly diagnosed and resectable squamous cell carcinoma of the hypopharynx or base of the tongue. The disease must be staged as either stage III that is T2-3 N0-1 M0 or stage IV that is T2-3 N2-3 M0. Patients must have measurable or evaluable disease other than pleural effusion, ascites, or disease documented by indirect evidence. The trial is closed to patients with cancer of the base of the tongue as of 11/15/1998. Patients must meet certain eligibility criteria, including age, performance status, hematopoietic, hepatic, renal, and other factors. Patients must not have had prior therapy. The trial will involve induction chemotherapy, cisplatin, and fluorouracil.",
    "The sample is a phase 2 clinical trial for metastatic cutaneous melanoma that has been previously treated with a BRAF inhibitor. The trial is testing the drug GSK1120212 and requires subjects to have a positive BRAF mutation and radiographically measurable tumor. Inclusion criteria also include adequate organ system function and blood cell counts, ability to carry out daily life activities without significant difficulty, and use of acceptable methods of contraception for sexually active subjects. Exclusion criteria include previous treatment with a MEK inhibitor, uncontrolled glaucoma, brain metastasis unless previously treated, significant unresolved side effects from previous anti-cancer therapy, and pregnancy or breastfeeding.",
    "The sample is a phase 2 clinical trial for asthma. The trial includes patients who have been diagnosed with asthma by a physician at least 1 year prior to study enrollment and have poorly-controlled asthma at study enrollment. The patients must be non-smokers or have a limited lifetime history of smoking, have a body mass index between 30-60, and respond to a methacholine challenge test with PC20 of <16 mg/ml. They must also be on a stable dose of inhaled corticosteroid for at least 4 weeks prior to study entry and have an FEV1 >60% predicted. The trial has both inclusion and exclusion criteria, including no systemic steroids within the past 4 weeks, no lung pathology other than asthma, and no other significant non-pulmonary co-morbidities. The patients must not have a B-type natriuretic peptide (BNP) >400 pg/mL, be pregnant or lactating, currently taking certain medications, or have certain medical conditions. The trial also excludes patients who have had an asthma exacerbation within the past 4 weeks or are undergoing evaluation for sleep apnea. Women of childbearing potential using oral contraceptives who are not willing to use a second method of contraception during the study are also excluded.",
    "The sample is a phase 2 clinical trial for patients primarily diagnosed with post-traumatic stress disorder (PTSD) who experienced a motor vehicle accident with severe or potential severe physical injury more than 3 months ago but less than 12 months ago. The trial is testing the effectiveness of paroxetine as a treatment for PTSD. The eligibility criteria include being aged 20 and <65, having a combined score of the CAPS-SX standard B, C, and D over 50, and being able to give written informed consent. Exclusion criteria include having a DSM-IV-TR Axis I disorder other than PTSD, receiving disability payments due to PTSD or other psychiatric diseases, and being pregnant, lactating, or of childbearing potential and likely to become pregnant. The trial also excludes patients with a history or complication of manic psychosis, convulsive disorder, cognitive disorder, serious cerebral organic disorder, or cancer or malignant tumor. The trial requires patients to undergo an fMRI procedure and excludes those who are unable or unwilling to do so. The sample includes patients who meet the inclusion criteria and do not meet any of the exclusion criteria.",
    "The sample is a clinical trial for a drug called ads-5102, which is being tested for its effectiveness in treating dyskinesia in patients with Parkinson's disease. The trial is in phase 2/phase 3 and the table includes information on the diseases being treated, the icd-10 codes associated with those diseases, the drugs being used, and the eligibility criteria for participants. The inclusion criteria include having a diagnosis of Parkinson's disease, experiencing troublesome dyskinesia following levodopa dosing, and being able to complete a standardized PD home diary. The exclusion criteria include a history of neurosurgical intervention related to Parkinson's disease, cognitive impairment, and treatment with an investigational drug or device within 30 days prior to screening.",
    "The sample is a record of a clinical trial with a phase 2 designation. The trial is focused on prostate cancer and the associated diseases are listed as well as the corresponding ICD-10 codes. The drugs being tested are capecitabine and docetaxel. The eligibility criteria for patients to participate in the trial are also listed, including clinical stage, PSA levels, biopsy Gleason's sum, and other medical conditions that would exclude them from participation.",
    "The sample is a record of a clinical trial in phase 2 for Alzheimer's disease. The trial involves the drugs azd3480 and donepezil. The eligibility criteria for the trial include the provision of informed consent from the patient and caregiver, a clinical prognosis of probable Alzheimer's disease, and the patient must have a caregiver visiting them at least three times weekly. The exclusion criteria include significant neurologic disease or dementia other than Alzheimer's disease, major depressive disorder, other major psychiatric disorder, use of acetylcholinesterase inhibitor or memantine for treatment of Alzheimer's disease within 8 weeks prior to enrollment, and impaired vision and/or hearing making cognitive testing difficult. The icd-10 codes associated with the disease are also provided.",
    "The sample is a phase 2 trial for the treatment of tumors. The trial is testing the drug azd2171, which is a vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor. The eligibility criteria for the trial require that the patient has a confirmed advanced solid tumor that is refractory to standard therapies or for which no standard therapy exists. The patient must not have received prior treatment with a VEGF inhibitor and must not have poorly controlled hypertension. The diseases are listed as 'tumors' and the icd-10 codes associated with the disease are provided as [\"['E88.3', 'R97.8', 'C49.A0', 'C49.A1', 'C49.A2', 'C49.A5', 'C49.A3']\"].",
    "The sample is a phase 2 clinical trial for the treatment of glioblastoma multiforme, a type of brain cancer. The trial includes patients who have already undergone surgery, radiation therapy, and one previous regimen of systemic chemotherapy. The trial is testing the effectiveness of two drugs, cilengitide 500 mg and cilengitide 2000 mg. The eligibility criteria include having measurable disease, a Karnofsky Performance Score of at least 70%, and no prior radiation therapy greater than 66 Gray. The trial also requires archived tumor tissue specimens for central pathology review and exploratory analysis of angiogenic markers. The exclusion criteria include prior antiangiogenic therapy, placement of Gliadel wafer at surgery for recurrence, and legal incapacity or limited legal capacity.",
    "The sample is a phase 2 clinical trial for patients with cutaneous T-cell lymphoma. The trial is testing the effectiveness of the drug bexarotene. The eligibility criteria include having confirmed cutaneous T-cell lymphoma at stage IB, IIA, IIB, III, or IV, and having measurable or assessable disease. Patients must also meet certain age and performance status requirements, have certain levels of hematopoietic, hepatic, renal, and cardiovascular health, and meet other medical criteria. Patients cannot have certain concurrent therapies or medical conditions. The trial is not testing any other biologic therapies, chemotherapy, or systemic corticosteroids. Patients must not have had certain systemic doses of vitamin A or any other retinoid class drug within the past 30 days, and must not be participating in any other investigational drug study.",
    "The sample is a phase 2 clinical trial for patients aged 2 to 30 years with acute lymphoblastic leukemia or lymphoblastic lymphoma. The trial includes patients who have not responded to standard induction therapy or have relapsed after standard curative therapies. Patients with CNS positive disease and Philadelphia chromosome-positive (Ph + ALL) are also eligible, provided they are not imatinib resistant or intolerant. The trial involves the use of bortezomib, vorinostat, dexamethasone, methotrexate, and imatinib mesylate drugs. The eligibility criteria include acceptable organ function, recovery from non-hematologic toxic effects of all prior therapy, and adequate contraception for women of childbearing potential. The exclusion criteria include pregnancy or lactation, known hypersensitivity to the drugs used in the trial, inability to swallow capsules, and serious concomitant medical or psychiatric disorders.",
    "The sample is a phase 2 clinical trial for chronic constipation. The trial includes patients who are 18 years or older, meet colonoscopy requirements, and have weekly bowel movement frequency requirements. Patients must also report one or more symptoms of constipation and have completed study requirements with no clinically-significant findings. Patients who are fluent in English are eligible for the trial. Exclusion criteria include patients who report loose or watery stools, meet criteria for IBS, or cannot take prohibited medications per protocol. Patients with medical diagnoses, medical conditions, or family history that would not make them a good candidate for the study or limit their ability to complete the clinical study are also excluded. The trial involves the use of linaclotide acetate and a matching placebo.",
    "The sample is a phase 2 clinical trial that involves patients with acute pharyngitis and pain. The trial is testing the effectiveness of ambroxol spray and placebo spray as treatments for sore throat. The eligibility criteria include having sore throat due to acute pharyngitis, a score of 6 or greater on a pain intensity numerical rating scale, and willingness to remain at the study center for one hour following the first dose of study medication and return one to three days later. The exclusion criteria include known allergy to ambroxol, drug dependence and/or alcohol abuse, use of certain medications within a certain time frame, and any medical or psychiatric condition that could increase the risks associated with participation in the study.",
    "The sample is a phase 2 clinical trial for patients with high grade glioma (WHO grade 3-4) that is progressive or recurrent following radiation therapy with or without chemotherapy. Patients with previous low grade glioma who progressed after radiotherapy and chemotherapy and are biopsied and found to have a high grade glioma are also eligible. The trial involves the use of the drugs ritonavir and lopinavir. The eligibility criteria include having recovered from toxicity of prior therapy, a minimum interval since last drug therapy, a Karnofsky performance status of at least 60%, normal hematologic, renal, and liver function, and the ability to provide written informed consent. Exclusion criteria include serious concurrent infection or medical illness, pregnancy or breastfeeding, HIV positive status, prior therapy with HIV protease inhibitors, concurrent therapy with hepatic enzyme inducing anticonvulsant, and the use of medication contraindicated for concomitant use with lopinavir/ritonavir.",
    "The sample is a phase 2 clinical trial for lung cancer patients who have progressed during or after prior first line chemotherapy. The trial is testing the drug sunitinib. The eligibility criteria includes having histologic or cytologic confirmed SCLC, clinically diagnosed ED-SCLC, and resolution of all acute toxic effects of prior therapy or surgical procedure to grade \u2264 1 (except alopecia). Patients must also have a performance status of 0, 1, or 2 on the ECOG criteria, at least one uni-dimensionally measurable lesion meeting Response Evaluation Criteria in Solid Tumors, and an estimated life expectancy of at least 12 weeks. Patients must have adequate organ function for chemotherapy, adequate cardiac function, and normal thyroid function. Exclusion criteria includes diagnosis of any second malignancy within the past 3 years, ongoing treatment with therapeutic doses of coumarin derivatives, uncontrolled brain metastases, spinal cord compression, carcinomatous meningitis, or leptomeningeal disease, and other severe acute or chronic medical or psychiatric condition, or laboratory abnormality that may increase the risk associated with study participation or study drug administration.",
    "The sample is a phase 2 clinical trial for ovarian cancer. The trial includes participants who are females aged 18 or older with a histologic diagnosis of ovarian, primary peritoneal, or fallopian tube carcinoma, Stage Ib- IV, with either optimal or suboptimal residual disease following initial surgery. The trial also includes participants with measurable and non-measurable disease, and those who have met the pre-entry requirements specified including serologic measurement of CA-125 as a baseline for subsequent determination of response using Rustin criteria. The trial excludes participants with a current diagnosis of epithelial ovarian tumor of low malignant potential, germ cell tumors, sex cord-stromal tumors, carcinosarcomas, mixed mullerian tumors or carcinosarcomas, metastatic carcinomas from other sites to the ovary and low malignant potential tumors including so called micropapillary serous carcinomas. Participants who have received prior radiotherapy to any portion of the abdominal cavity or pelvis, any prior anticancer chemotherapy or biologic therapy for any malignancy, or those with synchronous primary endometrial cancer, or a past history of primary endometrial cancer, are also excluded. The trial has various eligibility criteria including adequate bone marrow function, renal function, urine protein/creatinine reaction, neurologic function, hepatic function, and blood coagulation parameters. The trial also has exclusion criteria including serious, non-healing wound, ulcer, or bone fracture, active bleeding or pathologic conditions that carry high risk of bleeding, clinically significant cardiovascular disease, clinically significant proteinuria, and any medical condition that in the judgment of the investigator would jeopardize any participant safety or the study drug evaluation for efficacy and safety.",
    "The sample is a phase 2 clinical trial for Alzheimer's disease. The trial includes subjects between the ages of 50 and 75 who have been diagnosed with Alzheimer's disease and have a MMSE score of 20 to 26. The trial also requires subjects to have a caregiver and to have given informed written consent and approval of the Local Ethical Committee. The trial excludes subjects who have used other drugs that can modify the course of the disease or symptomatic cognitive treatments in the 3 months prior to study enrollment, have a modified Hachinski Ischemic Score \u2265 4, are unable to undergo neuropsychological evaluation, have significant liver, thyroid, or hematological dysfunctions, have a history of depression unresponsive to medication or past medical history of suicidal ideation, have severe cardiac disease, epilepsy, or concomitant use of hypnotic, anxiolytic, antidepressant, antipsychotic, anticholinergic, or known allergic reactions against IFNs or other components of the applied drug.",
    "The sample is a record from a clinical trial table that includes information about the trial's phase, diseases being studied, associated ICD-10 codes, drugs being tested, and eligibility criteria for participants. In this particular trial, the phase is a combination of phase 2 and phase 3, and the diseases being studied are gastroesophageal reflux and asthma. The associated ICD-10 codes for these diseases are also listed. The drugs being tested are lansoprazole and placebo. The eligibility criteria for participants include both inclusion and exclusion criteria, such as having chronic cough consistent with bronchoreactivity and gastroesophageal reflux as inclusion criteria, and severe asthmatics who have been hospitalized within the last 6 months or who have required oral steroid use within the last 4 weeks as exclusion criteria.",
    "The sample is a phase 2 clinical trial for hypertension. The trial includes patients with mild to moderate essential hypertension who are either untreated or currently taking antihypertensive therapy. Patients must be willing and able to undergo ambulatory blood pressure monitoring for a 24-hour period at the beginning and end of the 8-week treatment. The trial involves the use of the drugs lcz696 and placebo. The eligibility criteria include patients giving written informed consent, being able to communicate and comply with all study requirements, and demonstrating good medication compliance. Exclusion criteria include patients with severe hypertension, history of angioedema, pregnant or nursing women, and those with a history of secondary form of hypertension, among others. Other protocol-defined inclusion/exclusion criteria may also apply.",
    "The sample is a phase 2 clinical trial for patients with malignant melanoma. The trial involves the use of the drugs bosentan and placebo. The eligibility criteria include being 18 years or older, having stage IV measurable disease as defined by RECIST criteria, and having not received prior therapy with DTIC. Patients with certain medical conditions or who have received certain treatments are excluded from the trial. The trial requires patients to provide written informed consent and to return to the study center for follow-up.",
    "The sample is a phase 2 clinical trial for patients with locally advanced unresectable biliary tract or gallbladder adenocarcinoma. Patients with resected biliary tract or gallbladder adenocarcinoma who have residual tumor left are also eligible. The trial involves the use of capecitabine, oxaliplatin, and bevacizumab drugs. The eligibility criteria include being 18 years or older, having an ECOG performance status of 0-2, and having a life expectancy of more than 12 weeks. The trial also has exclusion criteria, such as prior chemotherapy or radiation therapy for biliary tract or gallbladder cancer, peripheral neuropathy of grade 2 or greater, and known brain metastases or carcinomatous meningitis.",
    "The sample is a phase 2 clinical trial for non-small cell lung cancer patients who meet certain staging criteria and are deemed surgical candidates. The trial involves the drugs carboplatin, paclitaxel, and zactima. The eligibility criteria include various patient characteristics such as performance status, blood counts, and organ function, as well as exclusion criteria such as prior lung cancer, certain cardiac events, and uncontrolled hypertension. Prior concurrent therapy is also specified, including a minimum time since major surgery and no prior use of the study drugs or certain other medications.",
    "The sample is a phase 2 clinical trial for the treatment of psoriasis. The trial is testing the effectiveness of the drugs cp-690,550 and placebo. The eligibility criteria for participants include having been diagnosed with plaque psoriasis for at least 6 months, having plaque psoriasis covering at least 15% of their total body, and being a candidate for phototherapy or systemic treatment of psoriasis. Participants must also be willing and able to comply with scheduled visits, treatment plan, and other study procedures. Exclusion criteria include having non-plaque forms of psoriasis or drug-induced psoriasis, being unable to discontinue systemic therapies and/or topical therapies for the treatment of psoriasis, participating in another trial using an investigational agent or procedure, and being pregnant or breastfeeding or considering becoming pregnant.",
    "The sample is a phase 2 clinical trial for active rheumatoid arthritis. The trial includes patients who meet the American College of Rheumatology's criteria for classification of rheumatoid arthritis for at least 6 months prior to screening, have at least 5 swollen and 5 tender joints, and have either a C-reactive protein level of at least 10 mg/L or an erythrocyte sedimentation rate of at least 28 mm/h. Patients must also be seropositive for rheumatoid factor or anti-cyclic citrullinated peptide and be receiving a stable dose of methotrexate. Exclusion criteria include any significant health problems other than rheumatoid arthritis, clinically significant laboratory abnormalities, and prior use of B cell-depleting therapy. The trial involves the use of the drug sbi-087 and a placebo.",
    "The sample is a record of a clinical trial that is in phase 2/phase 3 and is focused on the disease of venous thromboembolism. The trial includes patients who are at least 18 years old and have been admitted to San Francisco General Hospital for injury with at least one risk factor for VTE. The risk factors include age \u2265 40 years, pelvic fracture, lower extremity fracture, spinal cord injury, shock or head injury, major operative procedure, mechanical ventilation > 3 days, and venous injury. The trial excludes prisoners, pregnant patients, patients who are anticipated to have a < 5 day length of stay as determined by the admitting trauma surgeon, and patients who decline to participate in the study. The trial involves the drug fondaparinux sodium.",
    "The sample is a phase 2 trial for treating major cutaneous abscess, cellulitis, and erysipelas. The trial involves the drug \"tr701 fa\" and the eligibility criteria include patients who are 18 years or older, have a suspected or documented gram-positive infection, and have cellulitis/erysipelas or major cutaneous abscesses. Exclusion criteria include postsurgical or open wound infections, severe sepsis or septic shock, uncomplicated skin and skin structure infections, infections associated with a prosthetic device, and known bacteremia or osteomyelitis at the time of screening.",
    "The sample is a phase 2 clinical trial for patients with advanced, recurrent, or metastatic adenoid cystic carcinoma of the head and neck, as well as other salivary gland cancers. The trial involves the use of two drugs, bortezomib and doxorubicin hydrochloride, and has a list of eligibility criteria that patients must meet in order to participate. These criteria include having measurable disease, a certain performance status, and normal levels of various blood tests. Patients must also not have stable disease for at least 9 months prior to the study, and must not have a history of certain medical conditions or allergies. The trial excludes patients who have had certain types of chemotherapy or radiation therapy within a certain timeframe, as well as those with other concurrent anticancer therapies or agents.",
    "The sample is a phase 2 clinical trial for patients with follicular lymphoma, grade 1, 2 or 3a. The trial involves the use of lenalidomide and r-chop drugs. The eligibility criteria include having at least one sign requiring treatment, being aged between 18 and 70 years, having a WHO performance status of 0, 1 or 2, and having a life expectancy of at least 90 days. The trial also has exclusion criteria, such as having a serious active disease or co-morbid medical condition, being pregnant or lactating, and having a prior history of malignancies other than lymphoma. The trial requires patients to sign an informed consent form and to agree not to share the study drug with another person.",
    "The sample is a phase 2 clinical trial for patients with pancreatic adenocarcinoma. The trial includes patients with locally advanced disease that is considered to be \"borderline\" surgically resectable. Patients with metastatic disease or grossly resectable disease on presentation are ineligible. The trial involves the use of gemcitabine, oxaliplatin, and erlotinib. Patients must have measurable disease prior to starting the study. Patients must also fulfill the required initial laboratory data and have an ECOG/Zubrod performance status of 0-2. Patients must be able to read and understand English or have a certified translator present. Patients who are pregnant, planning to become pregnant, or lactating should not participate in the study. Women of childbearing potential must have a negative pregnancy test. Men and women of childbearing potential must be willing to consent to using effective contraception while on treatment and for at least 3 months thereafter. Patients must sign, date, and give written consent in accordance with institutional and federal guidelines. Patients with known brain metastases, prior surgery for their pancreatic carcinoma, prior chemotherapy, radiotherapy, chemoradiotherapy, surgery, immunotherapy, or hormonal therapy for pancreatic cancer, prior erlotinib or other therapies that target EGFR, significant history of uncontrolled cardiac disease, significant history of interstitial lung disease, significant history of peripheral neuropathy, temperature >101.30 F or active infection, or known HIV infection are ineligible for the study.",
    "The sample is a phase 2 clinical trial for the treatment of systemic lupus erythematosus and lupus. The trial involves the use of pravastatin, aspirin, ramipril, and vitamins B6, B12, and folate. The eligibility criteria for the trial include having SLE as defined by the 1997 American College of Rheumatology criteria and using acceptable methods of contraception. Exclusion criteria include participation in another experimental protocol for ASVD prevention, heavy alcohol consumption, aspirin intolerance, certain medications, peptic ulcer disease, history of an intracranial bleed or brain tumor, bleeding diathesis, history of allergy or sensitivity to ACE inhibitors, uncontrolled high blood pressure, creatinine levels above 2.0 mg/dl, renal artery stenosis, pregnancy or breastfeeding, abnormal liver function tests, and history of a muscle disease or baseline CPK levels above 500U/L or 2 X upper limit of normal.",
    "The sample is a record from a clinical trial table that includes information about the trial's phase, diseases being studied, icd-10 codes of the diseases, drugs being used, and eligibility criteria for participants. In this particular record, the trial is in phase 2 and is studying non-Hodgkin's lymphoma. The icd-10 codes associated with the disease are listed, as well as the drugs being used in the trial. The eligibility criteria for participants are also listed, including age, prior chemotherapy treatment, and performance status. Additionally, there are exclusion criteria listed, such as certain medical conditions or prior exposure to certain drugs.",
    "The sample is a phase 2 clinical trial for Parkinson's disease. The trial includes patients who are non-childbearing and over the age of 30 with a diagnosis of PD according to the UK PDS Brain Bank diagnostic criteria. Patients must also have predictable signs of end-of-dose deterioration despite \"optimal\" levodopa/carbidopa or levodopa/benserazide therapy. The trial includes a list of exclusion criteria such as non-idiopathic parkinsonism, a history of abuse of alcohol, drugs or medications within the last 2 years, and a clinically relevant ECG abnormality. The trial also includes a list of inclusion criteria such as being treated with a stable regimen of 3 to 8 doses per day of standard-release levodopa/carbidopa 100/25 mg or levodopa/benserazide 100/25 mg for at least 1 week prior to randomisation.",
    "The sample is a phase 2 clinical trial for the treatment of Follicular Lymphoma. The trial involves the use of drugs such as ofatumumab, cyclophosphamide, doxorubicin, vincristine, and prednisolone or prednisone. The eligibility criteria for the trial include being diagnosed with Follicular Lymphoma, being 18 years or older, and not having received previous treatment for the disease. Exclusion criteria include having other diseases or participating in other clinical studies. Women who are pregnant or breastfeeding or who are of childbearing potential and not willing to use contraception are also excluded.",
    "The sample is a phase 2 clinical trial for gastric cancer. The trial is testing the drug \"abi-007\" on patients who have previously received a regimen containing fluoropyrimidine analogs and have developed disease progression or recurrence. The trial has specific inclusion criteria, such as confirmation of gastric adenocarcinoma, age between 20-74, and at least one measurable lesion by RECIST criteria. There are also exclusion criteria, such as a history of Taxans use, another active malignancy, pre-existing peripheral neuropathy of Grade 2, 3, or 4, and chronic treatment with steroids. The icd-10 codes for the diseases being studied are listed as well.",
    "The sample is a phase 2 clinical trial for patients with COPD (chronic obstructive pulmonary disease) and chronic bronchitis. The trial is testing the effectiveness of a drug called bio-11006 inhalation solution compared to a placebo. The trial is looking for male or female outpatients who are 45 years or older, have active COPD with chronic bronchitis, and have a 20-pack year history of smoking. The trial has specific inclusion and exclusion criteria, such as not having been treated with oral prednisone or changed inhaled corticosteroid dose or long acting bronchodilator dose during the 6 weeks before enrollment. The trial is looking to enroll patients who have not had a change in smoking status during the previous 6 months.",
    "The sample is a phase 2 clinical trial for Crohn's disease. The eligibility criteria include being between the ages of 12 and 75, having a history of Crohn's disease for at least 1 year, and having moderately severe symptoms as defined by a Crohn's Disease Activity Index score of >220 and <400. The trial also requires that subjects have normal thyroid function, meet certain laboratory test criteria, and be able to adhere to the study visit schedule and other protocol requirements. Exclusion criteria include pregnancy or lactation, a history of cardiac disease, ulcerative colitis, and certain other medical conditions. The trial involves the use of the drug cc-5013 and requires subjects to have unchanged treatment for Crohn's disease for a certain period of time prior to randomization.",
    "The sample is a phase 2 clinical trial for asthma. The eligibility criteria include having a body mass index within a certain range, being a non-smoker, having a documented history of bronchial asthma, and having a pre-bronchodilator FEV1 greater than 70% of predicted at screening. The trial also requires participants to abstain from certain medications and treatments. The exclusion criteria include having liver disease, being hypertensive, having a respiratory tract infection or exacerbation of asthma within 4 weeks prior to the first dose of study medication, and having participated in a study with a new molecular entity during the previous 3 months or in 4 or more clinical studies in the previous 12 months.",
    "The sample is a phase 2 clinical trial for breast cancer. The trial includes patients between the ages of 18 and 75 with confirmed breast adenocarcinoma and no prior anthracycline-based chemotherapy for advanced breast cancer. The trial also requires patients to have adequate bone marrow function and measurable disease. The trial excludes patients who are pregnant or nursing, have a history of congestive heart failure or serious arrhythmia, or have other invasive malignancies. Patients with brain metastases without prior radiation therapy are also excluded. The trial requires written informed consent from all participants.",
    "The sample is a phase 2 trial that involves patients with venous thromboembolism, deep vein thrombosis, and those undergoing unilateral total knee arthroplasty. The trial uses the drug du-176b and a placebo. The eligibility criteria for the trial include patients who are undergoing unilateral total knee arthroplasty and exclude those with risks of hemorrhage, thromboembolic risks, weight less than 40 kg, pregnant, suspect pregnancy, or subjects who want to become pregnant. The icd-10 codes for the diseases are also provided.",
    "The sample is a phase 2 clinical trial for the treatment of chronic hepatitis C. The trial involves the use of drugs such as ribavirin, pegylated interferon alfa 2a, placebo, and telaprevir. The eligibility criteria for the trial include having Hepatitis C virus Genotype 1 with detectable plasma hepatitis C virus RNA, being infected with Hepatitis C virus for more than 6 months, and being seronegative for hepatitis B surface antigen and human immunodeficiency virus 1 and 2. In addition, female subjects must have a negative pregnancy test at all visits before the first dose and must agree to use 2 methods of contraception, including 1 barrier method, during and for 24 weeks after the completion of the study (unless the subject is a female of documented non-child-bearing potential). The exclusion criteria include having received any approved or investigational drug or drug regimen for the treatment of hepatitis C, any medical contraindications to Peg-IFN-alfa-2a or Ribavirin therapy, and any other cause of significant liver disease in addition to hepatitis C.",
    "The sample is a record of a clinical trial in phase 2, focused on the disease of hyperlipidemia. The trial includes a list of icd-10 codes associated with the disease, as well as a list of drugs being tested, which are rosuvastatin and atorvastatin. The eligibility criteria for the trial are also listed, including age, the presence of hyperlipidemia, and urinary protein. The exclusion criteria include previous treatment with rosuvastatin, statin intolerance, severe hypertension, and diabetes.",
    "The sample is a record of a clinical trial in phase 2 for the treatment of type 2 diabetes mellitus. The trial involves the use of the drugs alogliptin and voglibose. The eligibility criteria for the trial include having completed the phase 2 dose-ranging study and not having clinical manifestations of hepatic or renal impairment. The diseases are listed as 'type 2 diabetes mellitus' and the icd-10 codes associated with the disease are also provided.",
    "The sample is a record of a clinical trial with a phase 2 designation. The trial is focused on the disease of interstitial cystitis, which is identified by its ICD-10 codes of N30.10 and N30.11. The drug being tested is called lidocaine releasing intravesical system - liris\u00ae, and the eligibility criteria for participants include being a woman over the age of 18, having a diagnosis of interstitial cystitis, being able to complete questionnaires and a diary, and being able to comply with the visit schedule. Exclusion criteria include being pregnant or lactating, having anatomical features that would prevent the safe use of the investigational product, having a history or presence of any condition that would make it difficult to evaluate symptoms, and not having completed the blinded study.",
    "The sample is a phase 2 clinical trial for patients with HIV infections, hepatitis C, and liver disease. The trial involves the use of two drugs, peginterferon alfa-2a and ribavirin, and has eligibility criteria for each step of the trial. The inclusion criteria for step 1 include being HIV infected, having stable antiretroviral therapy, having a low HIV viral load, and having chronic liver disease consistent with chronic viral hepatitis. The exclusion criteria for steps 1 and 3 include having received HCV treatment within 4 weeks of study entry, having decompensated liver disease, and having a history of major organ transplantation with an existing functional graft. The sample also includes a list of diseases, icd-10 codes, and eligibility criteria for each step of the trial.",
    "The sample is a phase 2 clinical trial for patients with advanced stage or recurrent cervical or uterine cancer. The trial involves the use of bevacizumab and paclitaxel drugs. The eligibility criteria include having measurable disease, adequate bone marrow, renal and hepatic function, and a performance grade of 0 or 1. Patients who have progressed through or recurred within 3 months of treatment with a taxane agent administered on a weekly basis, or who have previously been treated with bevacizumab or other anti-angiogenic agents, are excluded. The trial also has several other exclusion criteria, including inadequate control of hypertension, history of myocardial infarction or unstable angina within 6 months prior to study enrollment, and known hypersensitivity to any component of bevacizumab.",
    "The sample is a phase 2 clinical trial for patients with various types of lung cancer, including adenocarcinoma and adenosquamous carcinoma. The trial is testing the effectiveness of a combination of drugs, including carboplatin, erlotinib, erlotinib hydrochloride, and paclitaxel. Patients must meet certain eligibility criteria, such as having a histologic documentation of lung cancer, being chemotherapy na\u00efve, and having no prior exposure to treatments targeting the human epidermal growth factor receptor (HER) family axis. Additionally, patients must have certain laboratory values within normal limits and must not have certain medical conditions, such as uncontrolled central nervous system metastases or active gastrointestinal disease. The trial is designed to measure the effectiveness of the drug combination in treating measurable disease, which is defined as at least one lesion that can be accurately measured in at least one dimension.",
    "The sample is a phase 2 clinical trial for the treatment of B-cell chronic lymphocytic leukemia and other stages of the disease. The trial involves the use of the drug fludarabine phosphate. Patients must meet certain eligibility criteria, including having a specific diagnosis of B-cell CLL, an absolute lymphocytosis of over 5,000/\u03bcL, and a predominant B-cell monoclonal population sharing a B-cell marker with the CD5 antigen. Patients must also be in the intermediate- or high-risk categories of the modified three-stage Rai staging system and have evidence of active disease. Other criteria include no prior therapy for CLL, a negative Coomb's test, and a performance status of 0-2. Pregnant or nursing women and patients with HIV are not eligible for the trial.",
    "The sample is a phase 2 trial for the treatment of polycystic ovary syndrome. The trial includes women with PCOS who have 8 or fewer menstrual periods per year, elevated serum total testosterone, and elevated LDL cholesterol. The trial excludes women who are currently pregnant or breastfeeding, using oral contraceptives or progestins, insulin sensitizing medications, have thyroid disease, hyperprolactinemia, active liver disease, type 1 or type 2 diabetes. The trial will test the effectiveness of lipitor and placebo as potential treatments for PCOS.",
    "The sample is a phase 2 clinical trial for the treatment of squamous cell neoplasms. The trial involves the use of drugs such as gefitinib and cisplatin. The eligibility criteria for the trial include having stage III or IVA squamous cell carcinoma of the head and neck, no prior surgery or chemotherapy/biological therapy/radiation therapy, measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST), and a life expectancy of more than 12 weeks. The exclusion criteria include having cancers of the nasal space, oral cavity and larynx, certain lung diseases, abnormal blood chemistry, uncontrolled respiratory, cardiac, hepatic, or renal disease, or coexisting malignancies.",
    "The sample is a phase 2 clinical trial for acute heart failure. The trial involves the use of drugs such as cinaciguat and placebo. The eligibility criteria for the trial include being male or non-pregnant, non-lactating female aged 18 years or older, or postmenopausal women aged 55 years or older. The subjects must have been diagnosed with CHF at least three months prior to enrollment and must have experienced worsening of dyspnea and clinical evidence of volume overload leading to hospitalization at the time of entry into the study. The exclusion criteria include acute de-novo heart failure, acute myocardial infarction, valvular heart disease requiring surgical intervention, primary hypertrophic cardiomyopathy, acute inflammatory heart disease, and unstable angina requiring angiography.",
    "The sample is a phase 2 clinical trial for breast cancer patients who are estrogen receptor positive and human epidermal growth factor receptor 2 (HER-2) negative. The trial involves the use of drugs such as ridaforolimus, dalotuzumab, and exemestane. The eligibility criteria include having a confirmed diagnosis of breast cancer that is metastatic or locally advanced, being post-menopausal, having a life expectancy of at least 3 months, and having received at least one line of endocrine therapy for metastatic disease. Exclusion criteria include receiving any other systemic tumor therapy, having poorly controlled diabetes, and having a known history of active Hepatitis B or C.",
    "The sample is a clinical trial with a phase 2/phase 3 designation, focused on Alzheimer's disease and using the drug talsaclidine. The eligibility criteria for participants include having completed a preceding talsaclidine trial within the last four weeks with adequate compliance, being able to understand and provide written informed consent, having a caregiver willing to provide trial-related information, and meeting certain physical and medical requirements. Exclusion criteria include certain medical conditions, drug-related adverse events, and insufficient compliance. The trial also excludes patients using certain medications and undergoing certain therapies.",
    "The sample is a phase 2 clinical trial for sickle cell disease, specifically for patients with Hb SS or Hb S-B0 Thalassemia. The trial is testing the effectiveness of a drug called HQK-1001 compared to a placebo. The eligibility criteria include having experienced at least one episode of SCD pain crisis, acute chest syndrome, other acute SCD complications, or leg ulcers in the 12 months prior to screening, not being treated with Hydroxyurea, and having a baseline Hb F level obtained within 14 days prior to randomization. Exclusion criteria include having a serious concurrent illness that would limit ability to complete or comply with the study requirements, being currently pregnant or breastfeeding, and having a known infection with HIV-1 or hepatitis B or C.",
    "The sample is a record from a clinical trial table that includes information about the trial phase, diseases being studied, corresponding ICD-10 codes, drugs being used, and eligibility criteria for participants. In this particular sample, the trial is in phase 2 and is focused on eosinophilic esophagitis. The ICD-10 code associated with this disease is K20.0. The drug being used in the trial is Flovent. The eligibility criteria for participants include having a peak eosinophil density of at least 24 per high power field in the esophagus, undergoing an allergy evaluation, and having undergone a minimum of 3 months of elimination diet without detectable resolution. Exclusion criteria include a history of poor tolerance to Fluticasone Propionate, inability to cooperate with the use of MDI, pregnancy, recent use of systemic corticosteroids, and comorbid eosinophilic disorders.",
    "The sample is a phase 2 clinical trial for hormone refractory prostate cancer. The trial includes patients who are male and over 18 years old with confirmed adenocarcinoma of the prostate that has metastasized. The trial aims to test the effectiveness of at-101, prednisone and docetaxel and placebo, prednisone and docetaxel drugs. The eligibility criteria include various medical conditions and restrictions, such as progression of disease despite androgen deprivation, serum testosterone level \u2264 50 ng/dL, and ECOG performance status \u2264 2. The exclusion criteria include prior chemotherapy for HRPC, concurrent anti-androgen hormonal therapy for HRPC, and known history of or clinical evidence of central nervous system (CNS) metastases or leptomeningeal carcinomatosis.",
    "The sample is a phase 2 clinical trial for cervical cancer. The trial includes patients who have measurable disease on clinical exam or by RECIST criteria, have a Karnofsky performance status greater than 60%, and have received one prior platinum-based systemic chemotherapy regimen for advanced disease. Patients with serious medical or psychiatric illness likely to interfere with participation in the study, ongoing or active infection, or a history of active secondary cancer within the last 5 years (except for superficial basal cell skin cancers) are excluded. The trial involves the use of two drugs, velcade (bortezomib) and irinotecan. The eligibility criteria include age greater than 18, adequate hematopoietic function, adequate renal and hepatic function, and a negative pregnancy test for women of child-bearing potential. The trial also requires voluntary written informed consent before performance of any study-related procedure not part of normal medical care, with the understanding that consent may be withdrawn by the subject at any time without prejudice to future medical care.",
    "The sample is a phase 2 clinical trial for patients with irresectable, metastatic or recurrent adenocarcinoma of the stomach or gastroesophageal junction. The trial involves the use of docetaxel, oxaliplatin, and capecitabine as treatment. The eligibility criteria include having measurable disease according to RECIST, ECOG Performance Status \u2264 2, and adequate bone marrow, hepatic and renal function. Patients must also have had prior surgery more than 28 days ago and negative pregnancy test in women with childbearing potential. Exclusion criteria include prior cytotoxic chemotherapy or radiotherapy, peripheral neuropathy \u2265 grade 2, and clinically significant concomitant diseases. The trial aims to evaluate the safety and efficacy of the treatment regimen.",
    "The sample is a phase 2 clinical trial for patients with type 2 diabetes and a stable dose of metformin. The trial is testing the effectiveness of the drugs placebo and exenatide in reducing HbA1c levels in patients with a BMI between 27 and 40 kg/m2. Patients must also have a history of stable body weight and stable medication for high blood pressure and lipid-lowering agents. Exclusion criteria include a history of certain medical conditions, recent use of certain medications, and participation in weight loss programs.",
    "The sample is a record from a clinical trial table that includes information about the phase of the trial, diseases being studied, icd-10 codes of the diseases, drugs being tested, and eligibility criteria for participants. In this particular sample, the trial is in phase 2/phase 3 and is focused on systemic lupus erythematosus. The icd-10 codes associated with the disease are listed, as well as the drugs being tested. The eligibility criteria for participants are also listed, including the requirement that they meet at least 4 of the 11 classification criteria for systemic lupus erythematosus and have had a renal biopsy indicating active proliferative lupus glomerulonephritis within the past 12 months. There are also exclusion criteria listed, such as a rise in serum creatinine within 1 month prior to the screening visit and having received treatment with cyclophosphamide within 3 months of randomization.",
    "The sample is a phase 2 clinical trial for patients with adenocarcinoma of the pancreas, specifically those with unresectable or locally advanced disease. The trial involves the use of three drugs - oxaliplatin, fluorouracil, and gemcitabine hydrochloride. The eligibility criteria for the trial include confirmation of the disease through histology or cytology, absence of cystadenocarcinoma or neuroendocrine tumors, no evidence of distant metastases, and a performance status of ECOG 0-1. Patients must also meet certain laboratory values and not have any significant infections or medical conditions that would preclude study participation. Additionally, patients must not have had prior biologic or chemotherapy, concurrent biologic or immunotherapy, or concurrent radiotherapy. The trial requires patients to maintain adequate oral nutrition and have no significant nausea or vomiting. The trial also has a minimum of 21 days since prior laparotomy.",
    "The sample is a phase 2 trial for postherpetic neuralgia, a condition where pain persists for at least 3 months after the healing of herpes zoster rash. The trial involves the use of drugs such as adl5747, placebo, and pregabalin. The eligibility criteria include having a diagnosis of PHN, an average daily pain score of at least 4 on the numeric pain rating scale, and being willing to comply with protocol requirements. Participants must also meet certain exclusion criteria, such as having a history of seizures or an active malignancy. The trial aims to evaluate the effectiveness of the drugs in treating PHN.",
    "The sample is a phase 2 clinical trial for postmenopausal osteoporosis. The trial includes a list of icd-10 codes for the disease and a list of drugs being tested, including different doses of abaloparatide transdermal and injection, as well as a placebo. The eligibility criteria for the trial include being a postmenopausal woman under 85 years old with a BMD T-score of -2.5 or lower in the spine or hip, or -2.0 or lower with a previous fracture within 5 years. Normal physical exam, vital signs, ECG, and medical history are also required, as well as normal laboratory tests for calcium, Vitamin D, PTH, serum phosphorus, and alkaline phosphatase. Exclusion criteria include a BMD T-score of -5.0 or lower, history of bone disorders other than postmenopausal osteoporosis, significantly impaired renal function, and history of any cancer.",
    "The sample is a clinical trial for a drug called memantine, which is being tested for its effectiveness in treating cognitive dysfunction in patients with multiple sclerosis. The trial is in phase 2/phase 3 and includes patients with relapsing-remitting, secondary progressive, and primary progressive forms of MS who are between the ages of 18 and 65. The trial also has a list of inclusion and exclusion criteria, such as a history of major depression or pregnancy, that determine whether a patient is eligible to participate. The diseases being studied include multiple sclerosis and cognition disorders, and the icd-10 codes associated with these diseases are also listed.",
    "The sample is a phase 2 clinical trial for the treatment of systemic lupus erythematosus. The trial includes patients who have an established diagnosis of SLE and meet certain criteria, such as having a positive test for antinuclear antibody and a clinical SLEDAI-2K score of at least 6 points. The trial also has exclusion criteria, such as patients who have received certain treatments within a certain time frame or have certain medical conditions. The trial will test the effectiveness of the drug lupuzor compared to a placebo.",
    "The sample is a record of a clinical trial with a phase 2 designation. The trial is focused on treating acute myelogenous leukemia and chemotherapy-induced nausea and vomiting. The diseases are listed along with their corresponding ICD-10 codes. The trial involves the use of two drugs, ondansetron and palonosetron. The eligibility criteria for the trial are listed, including age requirements and the need for patients to sign an informed consent form. The exclusion criteria are also listed, including restrictions on patients with certain levels of nausea or emesis, known hypersensitivity to the study drug, or ongoing emesis due to any organic etiology.",
    "The sample is a phase 2 clinical trial for the treatment of hepatitis C. The trial includes a list of diseases and their corresponding ICD-10 codes, a list of drugs including a placebo, and eligibility criteria for participants. The inclusion criteria includes being treatment naive, having a HCV RNA level greater than 100,000 IU/mL, having genotype 1, and having a diagnosis of chronic HCV infection for at least 6 months. The exclusion criteria includes having evidence of acute or chronic infection with HIV or HBV, exposure to an investigational anti-HCV agent within the previous three months, having severe or decompensated liver disease, and having liver disease unrelated to HCV infection.",
    "The sample is a phase 2 clinical trial for previously untreated patients with classical Hodgkin Lymphoma. The trial includes patients with confirmed CD30+ HL and stage IA, IIA, IIIA disease without bulky disease. Patients must have an Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-1, a life expectancy of more than 6 months, and be between the ages of 18-70. The trial requires periodic blood sampling, study-related assessments, and management of toxicity at the treating institution. Females of childbearing potential must have a negative pregnancy test result within three days of enrollment and all patients must agree to use effective contraceptive methods during the course of the study and for 6 months following the end of full treatment. The trial also has exclusion criteria, including peripheral neuropathy > Grade 1, a histologic diagnosis different from Hodgkin Lymphoma, compressive symptoms, previous treatment with any anti-CD30 antibody, known HIV positive status, known hepatitis B surface antigen-positive, or known or suspected active hepatitis C infection, signs or symptoms of progressive multifocal leukoencephalopathy (PML), and known cerebral/meningeal disease.",
    "The sample is a phase 2 clinical trial for the treatment of Clostridium difficile infection and diarrhea. The trial involves administering drugs such as cb-183,315, placebo, and vancomycin to eligible participants who have established non-severe or severe CDI with a positive stool test for toxin A and/or B within 72 hours prior to the first dose of study drug. The eligibility criteria include being at least 18 years old, providing informed consent, and meeting certain medical requirements such as not being pregnant or lactating, having no major gastrointestinal surgery within 3 months of enrollment, and not having a history of inflammatory bowel disease. The exclusion criteria include having received certain types of antibacterial therapy, having a known positive stool culture for other enteropathogens, and having a life expectancy of less than 6 weeks. Participants with severe CDI have additional exclusion criteria such as being unable to tolerate oral medications due to persistent vomiting and having a white blood cell count greater than 30,000/mm\u02c43.",
    "The sample is a phase 2 clinical trial for the treatment of complex regional pain syndrome, type I. The trial involves the use of lenalidomide and placebo drugs. The eligibility criteria include being at least 18 years old, having a diagnosis of CRPS Type 1 for at least a year, and having a CRPS pain intensity score of at least 4 on an 11-point scale. The trial also requires measurable sural, median sensory, median motor, and peroneal motor nerves at the screening nerve conduction study. Participants must be able to adhere to the study visit schedule and other protocol requirements. Women of childbearing potential must agree to practice complete abstinence from heterosexual intercourse or use two methods of contraception. Exclusion criteria include a history of DVT or stroke in the past 5 years, peripheral neuropathies, and current signs or symptoms of severe, progressive, or uncontrolled diseases. Prior treatment with lenalidomide or thalidomide is also an exclusion criterion.",
    "The sample is a record of a clinical trial with a phase 2 designation. The trial is focused on the treatment of pain and includes a list of icd-10 codes for the diseases being studied. The drugs being tested are azd1386, naproxen, and placebo. The eligibility criteria for the trial are listed, including inclusion criteria such as patients scheduled for surgical removal of one partial or complete impacted mandibular third molar and provision of signed informed consent. Exclusion criteria are also listed, such as a history of somatic disease/condition that may interfere with the study objectives, clinically significant illness or trauma within the 2 weeks prior to the administration of the investigational product, a family history of short QT syndrome or sudden cardiac death amongst first degree relatives, and a body temperature above 37.5\u00b0C at Visit 2 before the start of surgical procedures.",
    "The sample is a phase 2 clinical trial for patients with coronary artery disease who are undergoing elective PCI (percutaneous coronary intervention) with or without stenting. The trial is testing the effectiveness of varespladib (a-002) compared to a placebo. The eligibility criteria for the trial include being 18 years or older, not having had a recent ST elevation MI or troponin elevation, not having certain heart conditions or liver or kidney diseases, and not being on certain medications. Patients must also be able to provide consent to participate in the trial.",
    "The sample is a phase 2 clinical trial for patients with chronic myeloid leukemia in blast crisis or acute myeloid leukemia. The trial is testing the effectiveness of imatinib mesylate and clag drugs. The eligibility criteria include being at least 18 years old, having a diagnosis of AML or CML blast crisis, and having an ECOG performance status of 0 or 1. Patients must also sign a written informed consent and agree to employ an effective barrier method of birth control throughout the duration of the trial and for 3 months following study medication discontinuation. The exclusion criteria include abnormal kidney or liver functions, systemic active infection, Grade III/IV cardiac problems, chronic liver disease, HIV infection, history of other curatively untreated malignancy, and history of allergic reaction to compounds of similar chemical or biologic composition to Gleevec or any component of the CLAG regimen.",
    "The sample is a phase 2 clinical trial for patients with stage II-III head and neck cancer. The trial involves the use of two different drug combinations, 5-fluorouracil and hydroxyurea with bevacizumab, and 5-fluorouracil and hydroxyurea. Patients must have a confirmed diagnosis of head and neck carcinoma and have not received prior chemotherapy or radiotherapy for a malignancy of the head and neck. The trial has specific inclusion and exclusion criteria, including normal organ and bone marrow function, ECOG performance status of 0-2, and no history of certain medical conditions. Pregnant women and HIV-positive patients receiving combination anti-retroviral therapy are excluded from the trial.",
    "The sample is a phase 2 clinical trial for patients with acute myeloid leukemia, chronic myelomonocytic leukemia, or myelodysplastic syndrome. The trial is testing the effectiveness of the drug decitabine. The eligibility criteria include being over 18 years old, having a certain level of bone marrow blasts, and having failed therapy with azacitidine. Patients must also have a performance status of 0-2 and adequate liver and kidney function. Exclusion criteria include pregnancy, previous or concurrent malignancy, uncontrolled illness, and previous treatment with decitabine. Patients must also not have active infections or autoimmune hemolytic anemia or immune thrombocytopenia. The trial requires patients to comply with treatment and monitoring requirements.",
    "The sample is a phase 2 clinical trial for patients with metastatic colorectal adenocarcinoma. The trial is testing the effectiveness of a combination of three drugs: ixabepilone, fluoropyrimidine, and irinotecan. The eligibility criteria include having received prior treatment for metastatic disease with at least one regimen of irinotecan in combination with a fluoropyrimidine or two regimens comprising fluoropyrimidine-based first-line therapy and irinotecan-based second-line therapy. Patients must also have disease progression during or within 4 months of treatment with irinotecan, at least one bidimensionally measurable lesion, and no known CNS metastases. Other eligibility criteria include being 18 years or older, having an ECOG performance status of 0-1, and having a life expectancy of at least 12 weeks. Patients must also meet certain hematopoietic, hepatic, renal, and cardiovascular criteria, and must not have certain medical conditions or prior severe hypersensitivity reactions to agents containing Cremophor EL. Prior concurrent therapy is also restricted.",
    "The sample is a phase 2 trial for the treatment of cachexia. The trial includes patients with Stage 2, 3 or 4 non-small cell lung cancer, Stage 2, 3 or 4 colorectal cancer, non-hodgkin's lymphoma, chronic lymphocytic leukemia, or Stage 3 or 4 breast cancer who have experienced greater than or equal to 2% weight loss from the highest patient reported weight in the 6 months prior to screening. The trial drugs include gtx-024 and placebo. The eligibility criteria include having a life expectancy of >6 months, being clinically confirmed as postmenopausal for females and over 45 years of age for males, and having an ECOG score \u22641. Exclusion criteria include a history of active/uncontrolled congestive heart failure, chronic hepatitis, hepatic cirrhosis, or HIV infection, uncontrolled hypertension, positive screen for Hepatitis B or HIV, currently taking certain medications, and more.",
    "The sample is a phase 2 clinical trial for patients with recurrent glioblastoma. The trial is testing the drug bibf1120. The eligibility criteria include having a histologically verified primary GBM and failure after radiotherapy and TMZ, having received prior treatments more than 4 weeks ago, having an ECOG performance status of 0-1, being over 18 years old, having normal creatinine levels or a clearance of at least 60 mL/min, and using contraception if fertile. Exclusion criteria include prior treatment with BIBF 1120 or any other VEGFR inhibitor, recent therapy with chemo, hormone, radio, or immunotherapy, and various medical conditions that may increase the risk associated with study participation or study drug administration.",
    "The sample is a phase 2 clinical trial for locally advanced T3/T4 rectal carcinoma with or without nodal involvement requiring surgery of the primary tumor. The trial is testing the effectiveness of the drugs capecitabine and oxaliplatin. The eligibility criteria include having a confirmed diagnosis of the disease, a performance status of 0-2, and adequate laboratory values. Exclusion criteria include evidence of distant metastases, previous chemotherapy or immunotherapy for colorectal cancer, and pre-existing conditions that would deter radiotherapy. The sample also includes a list of icd-10 codes for the disease and a detailed list of inclusion and exclusion criteria.",
    "The sample is a phase 2 trial for the treatment of type 2 diabetes mellitus. The trial involves testing the effectiveness of four drugs, including placebo, pioglitazone, and ccx140-b. The eligibility criteria for participants include having a body mass index between 25 and 45 kg/m2, being on a stable dose of metformin for at least 8 weeks prior to randomization, and having a hemoglobin A1c (HbA1c) level between 6.5% and 10.0%. Exclusion criteria include having type 1 diabetes mellitus, receiving insulin treatment within 12 weeks of randomization, and having a history of drug-induced myopathy or cancer within the past 5 years.",
    "The sample is a phase 2 clinical trial for non-small cell lung cancer patients with either stage IIIB disease with malignant pericardial or malignant pleural effusions or stage IV disease. The trial involves the use of cisplatin and docetaxel drugs. The eligibility criteria include having measurable disease, being 18 years or older, having an ECOG performance status of 0-1, and having a life expectancy of at least 12 weeks. Patients must also meet certain hematopoietic, hepatic, renal, and immunologic requirements, and cannot have any other primary malignancy within the past 5 years except for adequately treated nonmelanoma skin cancer or carcinoma in situ of the cervix. Prior concurrent therapy is also restricted.",
    "The sample is a record of a clinical trial with a phase 2 designation. The trial is focused on prostate cancer and includes a list of ICD-10 codes associated with the disease. The trial is testing the effectiveness of a drug called sagopilone (zk 219477) in combination with prednisone. The eligibility criteria for the trial include having confirmed metastatic prostate cancer, a serum testosterone level less than 50 ng/mL, and disease progression despite anti-androgen therapy. The trial also has exclusion criteria, such as previous cytotoxic chemotherapy for prostate cancer and active infection. Additional criteria may be determined during the screening visit.",
    "The sample is a phase 2 clinical trial for women between the ages of 40 and 75 who are postmenopausal and experiencing symptoms of vulvovaginal atrophy, painful intercourse, and dyspareunia. The trial is testing the effectiveness of estradiol versus a placebo in treating these symptoms. The eligibility criteria include having a BMI less than or equal to 34 kg/m2, being in good health, and abstaining from using products containing estrogen throughout the study. Exclusion criteria include a history of thrombosis, coronary artery or cerebrovascular disease, liver or kidney dysfunction, and various other medical conditions. Participants must also be willing to abstain from sexual activity and vaginal douching within 24 hours prior to screening and visit 3 vaginal pH measurements.",
    "The sample is a phase 2 trial for patients with stable moderate to severe plaque-type psoriasis involving at least 10% of their body surface area. The trial involves the use of two drugs, BIRT 2584 XX and placebo. The eligibility criteria include being between the ages of 18 and 75, having a minimum disease severity score, and being a candidate for systemic psoriasis treatment or phototherapy. Exclusion criteria include having certain types of psoriasis, using certain medications, having active liver disease, and having a history of drug or alcohol abuse within the past two years. Patients must also be willing to avoid excess sun exposure during the trial duration.",
    "The sample is a phase 2 clinical trial for the treatment of malignant mesothelioma, a type of cancer affecting the lining of the lungs. The trial involves the use of two drugs, bortezomib and cisplatin, and has specific eligibility criteria for patients to participate. Patients must have confirmed pleural malignant mesothelioma and meet certain criteria, such as having measurable or evaluable disease and a WHO performance status of 0-1. They must also have no clinical evidence of brain or leptomeningeal metastases and meet various other medical and health criteria. Prior to participating in the trial, patients must not have received systemic chemotherapy for mesothelioma and must not be taking any other concurrent antineoplastic agents except for medications that may have antineoplastic activity but are taken for other reasons.",
    "The sample is a phase 2 clinical trial for chronic hepatitis C. The trial includes participants between the ages of 18 and 60 with a documented genotype 1 chronic hepatitis C and consistent liver biopsy results. The participants must also meet certain weight requirements and agree to use contraception during the study period. The trial involves the use of four drugs: boceprevir (sch 503034), peginterferon-alfa 2b (pegintron), ribavirin, and ribavirin (low-dose). The eligibility criteria include various medical and psychiatric conditions that would exclude participants from the trial. The trial also excludes participants who are pregnant or nursing, have a history of malignancy within the past 5 years, or have participated in any other clinical trial within 30 days of screening. The sample includes both inclusion and exclusion criteria for the trial.",
    "The sample is a phase 2 clinical trial for non-small-cell lung cancer. The trial involves the use of oxaliplatin and docetaxel as drugs. The eligibility criteria include having measurable disease, being at least 18 years old, having an ECOG performance score of 0, 1, or 2, and meeting certain blood count and liver function requirements. Patients must also have recovered from any prior surgery or radiation therapy and be able to provide informed consent. Exclusion criteria include having an active infection, active central nervous system metastasis, prior chemotherapy for lung cancer, and certain medical conditions or illnesses that may interfere with the study.",
    "The sample is a record of a clinical trial in phase 2. The trial is focused on two diseases, Asperger's Disorder and Pervasive Developmental Disorder, and their corresponding ICD-10 code is F84.5. The drug being tested is aripiprazole. The eligibility criteria for the trial include having a mental age of 18 months, being diagnosed with either Asperger's Disorder or Pervasive Developmental Disorder, being in good overall health, and not having taken any psychotropic medication for at least 2 weeks. The exclusion criteria include having a weight less than 15kg, having previously taken aripiprazole, having an active seizure disorder, having a significant medical condition, having a history of neuroleptic malignant syndrome, and being a female with a positive Beta human chorionic gonadotropin (HCG) pregnancy test.",
    "The sample is a phase 2 clinical trial for HIV infection and gastrointestinal symptoms. The trial is testing the effectiveness of a placebo drug. The eligibility criteria include being 18 years or older, having stable HIV infection, and having certain laboratory parameters within the last 30 days. Patients with documented GI symptoms are also eligible. Females of childbearing potential must be practicing an effective method of contraception and agree to use birth control while on the protocol. Exclusion criteria include active opportunistic infection, recent antibiotic or probiotic therapy, and known history of allergic reactions to any of the investigational products or their ingredients. The trial aims to determine the safety and efficacy of the placebo drug in treating HIV infection and gastrointestinal symptoms.",
    "The sample is a record of a clinical trial with a phase 2/phase 3 designation. The trial is focused on the disease of allergic rhinoconjunctivitis, which is associated with a list of icd-10 codes. The trial involves two drugs, avanz phleum pratense and placebo. The eligibility criteria for the trial include a history of grass pollen allergy, positive skin prick test to grass, and positive Immunoglobulin E test to grass. The exclusion criteria include other allergies overlapping the grass pollen season and severe asthma with a Forced expiratory volume in 1 second (FEV1) below 70% after adequate treatment.",
    "This sample is a phase 2 clinical trial for patients with Stage IIIB or Stage IV non-small cell lung cancer with malignant pleural effusion or metastatic disease. The trial is testing the effectiveness of a combination of drugs including fosbretabulin, carboplatin, paclitaxel, and bevacizumab. The eligibility criteria include having measurable disease on CT scan, an Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1, adequate blood counts, liver and kidney function, and the ability to provide written informed consent. Exclusion criteria include certain types of cancer, bleeding disorders, cardiac disorders, uncontrolled high blood pressure, active infection, and known hypersensitivity to certain drugs. Additional inclusion and exclusion criteria can be discussed with an investigator.",
    "The sample is a phase 2 clinical trial for patients with chronic graft-versus-host disease following allogeneic hematopoietic stem cell transplantation. The trial is testing the effectiveness of the drug lenalidomide in treating the disease. The eligibility criteria include having failed a trial of steroids and calcineurin inhibitors, having a certain level of blood counts and heart and lung function, and not having any uncontrolled infections or evidence of malignancy. Patients must also be able to provide written informed consent and be at least 18 years old. Women of childbearing potential must have a negative pregnancy test and agree to use two forms of birth control during the study. The exclusion criteria include having any serious medical condition or psychiatric illness that would prevent the subject from signing the informed consent form, being pregnant or lactating, having any condition that places the subject at unacceptable risk, and having used any other experimental drug or therapy within 28 days of baseline.",
    "The sample is a phase 2 clinical trial for the treatment of stroke. The trial involves endovascular repair of ruptured or unruptured brain aneurysms using various techniques. The trial has eligibility criteria including a diagnosis of a suitable aneurysm for repair, absence of ongoing ischemic symptoms, and normal or abnormal but not clinically significant physical examination findings. Exclusion criteria include life-threatening allergic reactions to medication, chronic renal disease, and previous serious traumatic brain injury. The trial involves the use of two drugs, NA-1 and placebo. The sample includes detailed inclusion and exclusion criteria for the trial.",
    "The sample is a phase 2 clinical trial for men with benign prostate hypertrophy requiring surgical treatment. The trial involves the use of two drugs, vardenafil (levitra, bay38-9456) and placebo. The eligibility criteria for the trial include being a man with benign prostate hypertrophy requiring surgical treatment, being up to 80 years old, having documented, dated, written informed consent, and having an anesthesiologist's agreement to swallow one tablet one hour prior to surgery. Exclusion criteria include having any unstable medical, psychiatric, or substance abuse disorder, a history of previous prostatectomy, being suspected of having prostate cancer, having a hereditary degenerative retinal disorder, having a history of previous Non-arteric Anterior Ischemic Optic Neuropathy (NAION) episode or unilateral vision impairment, having any cardiovascular condition, having a history of myocardial infarction, stroke or life-threatening arrhythmia within the prior 6 months, having uncontrolled atrial fibrillation/flutter at screening, having severe chronic or acute liver disease, having chronic hematological disease which may lead to priapism, having a bleeding disorder, having significant active peptic ulceration, having resting hypotension, having a history of positive test for Hepatitis B surface antigen or Hepatitis C, having symptomatic postural hypotension within 6 months of Visit 1, not tolerating the initial dose of study medication well, taking nitrates or nitric oxide donors, taking androgens or anti-androgens, taking potent inhibitors of cytochrome P4503A4, having received any investigational drug within 30 days of Visit 1, using alpha-blockers during two days prior to first dosing of study medication and after ablation of prostate, using inhibitors of 5-alpha reductase after ablation of prostate, having serum creatinine clearance <30.0 mL/min, having elevation of Aspartate aminotransferase (AST) and/or Alanine aminotransferase (ALT) >3 times the upper limit of normal, having known hypersensitivity to Vardenafil, being illiterate or unable to understand subject diaries, and being non-compliant with the study visit schedule.",
    "The sample is a record from a clinical trial table that includes information about the trial's phase, diseases being studied, ICD-10 codes associated with those diseases, drugs being used, and eligibility criteria for participants. In this particular sample, the trial is in phase 2 and is studying the treatment of peritoneal cancer, ovarian cancer, neoplasms, and fallopian tube cancer. The drugs being used are topotecan and gemcitabine. The eligibility criteria include having had one prior platinum-based chemotherapy regimen, a treatment-free interval of greater than 6 months following response to platinum, and an ECOG performance status of 0, 1, or 2. There are also exclusion criteria, such as being pregnant or lactating, having received more than one primary chemotherapy regimen, and having active uncontrolled infection requiring antibiotics.",
    "The sample is a phase 2 clinical trial for adult T-cell leukemia-lymphoma. The trial includes subjects who have tested positive for serum anti-human T-cell lymphotropic virus type I antibody and have been diagnosed with peripheral lymphoid tumor of T-cell origin. The trial also includes subjects who have never been treated for adult T-cell leukemia-lymphoma and have presented with enlarged lymph nodes, tumor nodules in extranodal organs, abnormal lymphocytes in peripheral blood or cutaneous lesions. The trial requires subjects to have a performance status of 0 to 2 and be negative for HBs antigen and anti-HCV antibody. The trial excludes subjects who are scheduled for transplant therapy, have had a myocardial infarction within 12 months before study enrollment, have been positive for anti-HIV antibody, have active multiple cancer, have a history of allergic reactions to therapeutic antibodies, require emergency radiotherapy for treating the symptoms caused by bulky masses, or are pregnant, lactating or of childbearing potential, or who are planning to have children.",
    "The sample is a phase 2 clinical trial for patients with metastatic colorectal cancer. The trial involves a combination of drugs including 5-fu, folfox regimen, placebo, bevacizumab [avastin], leucovorin, and onartuzumab [metmab]. The eligibility criteria include being an adult patient with confirmed adenocarcinoma of the colon or rectum, having an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1, and having measurable disease by RECIST criteria. Exclusion criteria include prior systemic or radiation therapy for metastatic colorectal cancer, adjuvant chemotherapy for colorectal cancer within 12 months prior to diagnosis of metastatic disease, and other active cancers or history of treatment for invasive cancer within the last 5 years, except for non-melanoma skin cancer.",
    "The sample is a phase 2 clinical trial for the treatment of allergic rhinitis. The eligibility criteria include having a history of persistent allergic rhinitis for at least 2 years, a positive allergen skin test, a mean score of at least 6 for the baseline Total Nasal Symptom Score, normal screening laboratory values, and being between the ages of 18 and 70. The subject must also be able to read and understand German well enough to answer questions in the TNSS and Mini Rhinoconjunctivitis Quality of Life Questionnaire. Female subjects must meet certain contraceptive requirements or be surgically sterile or postmenopausal. Exclusion criteria include non-allergic rhinitis, recent nasal surgery, upper respiratory or sinus infection, and use of certain medications. The trial aims to test the efficacy of the drugs wf10 and nacl solution.",
    "The sample is a phase 2 clinical trial for patients with esophageal cancer or gastroesophageal junction tumors. The trial is testing the effectiveness of erlotinib hydrochloride as a treatment option. Patients must have biopsy-proven primary squamous cell carcinoma or adenocarcinoma of the esophagus or GE junction, with stage I-IVA disease determined by CT scan or MRI of the chest and abdomen. Patients must also meet certain eligibility criteria, including having an ECOG performance status of 0-2, a life expectancy of more than 4 months, and no prior chemotherapy or radiotherapy for this tumor. The trial excludes patients with certain medical conditions or allergies to erlotinib or any of its excipients. Prior concurrent therapy is also not allowed.",
    "The sample is a phase 2 clinical trial for patients with locally advanced adenocarcinoma of the esophagus or gastroesophageal junction who have received potentially curative chemotherapy, radiotherapy, and/or surgery within the past 1-3 months and have no evidence of residual tumor or metastatic disease. The trial is testing the drug gefitinib. The eligibility criteria include age 18 and over, ECOG performance status of 0-2, life expectancy of at least 12 weeks, and various hematopoietic, hepatic, renal, and cardiovascular requirements. Patients must not be pregnant or nursing, must have negative pregnancy test, and must use effective contraception if fertile. They must also be able to swallow the study drug and have no other malignancy within the past 5 years except adequately treated basal cell or squamous cell skin cancer or noninvasive carcinoma. Prior concurrent therapy is specified for chemotherapy, radiotherapy, and surgery, and patients must not have received prior gefitinib or concurrent CYP3A4 inducing agents or antacids 4 hours before or after study drug administration.",
    "The sample is a phase 2 clinical trial for the treatment of interstitial cystitis, painful bladder syndrome, and pain. The trial involves the use of oxycodone naloxone prolonged release tablets and placebo tablets. The eligibility criteria for the trial include having a history of severe pain due to Bladder Pain Syndrome (BPS) for at least 6 months, insufficient treatment of pain due to BPS, and not having received opioid-containing medication in the last 6 months. The exclusion criteria include being pregnant or lactating, having a contraindication or hypersensitivity to the study medication or its ingredients, having certain medical conditions that may place the subject at risk upon exposure to the study medication, and having abnormal levels of certain laboratory tests.",
    "The sample is a phase 2 clinical trial for patients with myelofibrosis, essential thrombocythemia related myelofibrosis, and polycythemia vera related myelofibrosis requiring therapy. Patients who have previously been treated and relapsed or refractory, or newly diagnosed with intermediate or high risk according to Lille scoring system are eligible. Patients must have signed informed consent for both the bevacizumab protocol and for the mandatory biomarker MDP-RC 107 protocol to be eligible to participate. Patients must have been off any IM-directed therapy for 2 weeks prior to entering this study and have recovered from the toxic effects of that therapy. There are various inclusion and exclusion criteria, including age, serum bilirubin levels, serum glutamic-pyruvic transaminase levels, serum creatinine levels, and LVEF. Women of childbearing potential must have a negative serum or urine pregnancy test prior to bevacizumab treatment and should be advised to avoid becoming pregnant. Men must be advised to not father a child while receiving treatment with bevacizumab. Both women of childbearing potential and men must practice effective methods of contraception.",
    "The sample is a record from a clinical trial table. It is a phase 2 trial for the treatment of type 2 diabetes. The trial involves testing the effectiveness of different doses of a drug called \"den\" compared to a placebo. The trial has eligibility criteria for participants, including having type 2 diabetes and not taking any other medication for it. There are also exclusion criteria, such as having any underlying or significant active disease that would prevent the subject from safely participating in the trial. The sample includes the list of diseases, icd-10 codes, drugs, and eligibility criteria for the trial.",
    "The sample is a phase 2 trial for the treatment of melanoma. The trial includes patients with mucosal melanoma, recurrent melanoma, and stage IV melanoma. The trial involves the use of two drugs, temsirolimus and selumetinib. The eligibility criteria include having a histologic diagnosis of unresectable stage IV melanoma, being BRAF V600E mutation positive, and having at least 4 weeks since any previous treatment. Other criteria include having a life expectancy of at least 3 months, an ECOG performance status of 0 or 1, and meeting certain laboratory values. Exclusion criteria include having any prior malignancy except for certain types, active infection, pregnancy or nursing, and prior treatment with certain drugs.",
    "The sample is a phase 2 clinical trial for the treatment of primary open angle glaucoma and ocular hypertension. The trial involves the use of drugs such as pf-03187207 and latanoprost 0.005%, as well as their respective vehicles. The trial has specific eligibility criteria, including a minimum age of 20 and a diagnosis of primary open-angle glaucoma or ocular hypertension. There are also exclusion criteria, such as a history of acute angle closure or contraindications to the treatment.",
    "The sample is a phase 2 clinical trial for the treatment of moderate to severe Major Depressive Disorder (MDD) using citalopram and pipamperone or citalopram. The trial includes male and female patients between the ages of 18-65 who have been diagnosed with MDD and have a Clinical Global Impression-Severity Scale (CGI-S) rating of at least four and a minimum Hamilton Depression Scale (HAM-D) 17 items total score of 18 at screen and baseline. The trial also includes a list of inclusion and exclusion criteria, such as no recent ingestion of antidepressants or psychotropic medication, no history of cardiac dysrhythmia, and no significant physical illness that would interfere with trial assessments. The trial will use the Mini International Neuropsychiatric Interview (MINI) version 5.0.0 to confirm diagnosis.",
    "The sample is a phase 2 clinical trial for the treatment of breast cancer. The trial includes patients with Stage IV breast cancer who have received no more than one prior chemotherapeutic regimen in the metastatic setting. The trial drug is a combination of lapatinib and nab-paclitaxel. The eligibility criteria include confirmation of ErbB2 amplification, normal organ and marrow function, and a life expectancy of at least 6 months. Patients with stable central nervous system metastases and liver metastases or stable chronic liver disease are also eligible. The trial excludes patients with prior treatment with lapatinib, concurrent anticancer or concomitant radiotherapy treatment, and concurrent treatment with prohibited medications. The trial also excludes patients with unresolved or unstable, serious toxicity from prior administration of another investigational drug and/or of prior cancer treatment.",
    "The sample is a phase 2 clinical trial for the treatment of hepatitis C. The trial involves the use of drugs such as telaprevir, ribavirin, and pegylated interferon alfa 2a, as well as a matching placebo. The eligibility criteria for the trial include being between 18 and 70 years old, having detectable plasma hepatitis C virus (HCV) ribonucleic acid (RNA) greater than or equal to (>=) 10,000 international units per milliliter (IU/mL), having chronic hepatitis C (genotype 1) and having already received at least one prior course of pegylated interferon alfa 2a with ribavirin. Participants cannot also be infected with Human Immunodeficiency Virus or hepatitis B, must be judged to be in general good health and able to receive Pegasys\u00ae and Copegus\u00ae, and must not have had drug or alcohol abuse in the last year. Additionally, participants must agree to use two effective methods of birth control during the study and for 6 months after stopping the study medication. Exclusion criteria include participation in any clinical trial of a HCV protease inhibitor of any duration, prior response to therapy and failure to achieve SVR which was due to treatment non-compliance, any other cause of significant liver disease in addition to hepatitis C, diagnosed or suspected hepatocellular carcinoma, history of or current evidence of decompensated liver disease, and participation in any clinical trial of an investigational drug within 90 days before drug administration or participation in more than 2 drug studies in the last 12 months (exclusive of the current study).",
    "The sample is a phase 2 clinical trial for patients with chronic hepatitis C virus (HCV) genotype 1 or 4. The trial includes patients with a viral load of at least 100,000 IU/mL and who have not been previously exposed to interferon, pegIFN\u03b1, or RBV. Patients must also have had a liver biopsy demonstrating absence of cirrhosis obtained \u226424 months prior to randomization. The trial includes patients with a body mass index of 18 to 35 kg/m^2. The trial excludes patients who are positive for hepatitis B or HIV-1/HIV-2 antibody at screening, have evidence of a medical condition associated with chronic liver disease other than HCV, or have evidence of decompensated cirrhosis based on radiologic criteria or biopsy. The trial includes the drugs daclatasvir, peg-interferon alfa-2a, ribavirin, and a placebo.",
    "The sample is a phase 2 clinical trial for osteoarthritis. The trial is looking at the effectiveness of the drug lacosamide in treating the symptoms of osteoarthritis in the knee. The inclusion criteria for the trial require that the subject has symptomatic osteoarthritis of the knee diagnosed using clinical and radiographic evidence, as well as ACR criteria, with symptom duration of at least 6 months. The subject must also require a therapeutic dose of an NSAID, COX-2 NSAID, and/or paracetamol/acetaminophen for osteoarthritis pain of the index knee and has taken that medication at least 5 days per week for the last 4 weeks prior to the screening visit. The exclusion criteria include not being able to withdraw NSAIDs, COX-2 NSAIDs and/or paracetamol, taking analgesics other than NSAIDs COX-2 NSAIDs and/or paracetamol, and planning to begin or stop treatment with glucosamine and/or chondroitin during the trial.",
    "The sample is a phase 2 clinical trial for the treatment of type 2 diabetes mellitus. The trial involves the use of drugs such as ac-201 and placebo. The eligibility criteria for the trial include having a diagnosis of type 2 diabetes mellitus for at least 6 months, being on a stable regimen of oral anti-diabetic medications for at least 3 months, and having a HbA1c level between 7.5% and 10%. Exclusion criteria include a history of type 1 diabetes, pregnancy or lactation, and a history of severe hypoglycemic episodes within 6 months of screening. The trial also requires participants to maintain a stable diet and exercise regimen throughout the study.",
    "The sample is a phase 2 clinical trial for patients with hormone refractory prostate cancer. The trial involves the drug patupilone and has a list of inclusion and exclusion criteria. Inclusion criteria include having a histological or cytological diagnosis of adenocarcinoma of the prostate, metastatic or locally recurrent disease, documented evidence of PSA progression, and an ECOG performance status of 0, 1 or 2. Patients must have received prior docetaxel based chemotherapy and be hormone refractory. Prior external beam radiation is permitted, but patients with known brain metastases should be excluded. Exclusion criteria include a history of other invasive cancer, serious intercurrent illness, and peripheral neuropathy > grade 1.",
    "The sample is a phase 2 clinical trial for patients with recurrent or stage IV melanoma. The trial involves the use of carboplatin and paclitaxel drugs. The eligibility criteria include having confirmed melanoma, measurable disease, and no invasion of adjacent organs or major blood vessels. Patients must also meet certain health requirements such as having a certain level of blood counts and no history of certain medical conditions. Patients must not have had certain prior treatments or be taking certain medications during the trial. The trial also has restrictions on concurrent treatments and experimental drugs.",
    "The sample is a phase 2 clinical trial for patients with primary peritoneal carcinoma or recurrent ovarian carcinoma that is resistant to platinum-based chemotherapy. The trial is testing the effectiveness of a drug called cositecan. Patients must meet certain eligibility criteria, including having at least one measurable lesion and a target lesion to assess response, and having a performance status of GOG 0-2. They must also have certain blood counts and liver and kidney function within normal limits, and cannot have had certain medical conditions or treatments within a certain timeframe. Patients must also use effective contraception if they are fertile. The trial is not open to patients who are eligible for a higher priority study or other phase II cytotoxic study for platinum-resistant disease.",
    "The sample is a record of a clinical trial with a phase 2 designation. The trial is focused on lung cancer and includes a list of ICD-10 codes for the disease. The trial involves the use of several drugs, including enzastaurin, pemetrexed, cisplatin, and placebo. The eligibility criteria for participants include a diagnosis of advanced non-small cell lung cancer, no prior systemic therapies or pleurodesis with chemotherapy for this disease, a good performance status, and signing an informed consent document. Exclusion criteria include recent myocardial infarction, inability to swallow tablets, taking certain medications for seizure activity, inability to interrupt aspirin and/or other anti-inflammatory agents, and unwillingness or inability to take vitamin supplementation or medications to prevent side effects.",
    "The sample is a phase 2 clinical trial for breast cancer. The trial includes patients with clinical T1c-T3, N0-1, M0 breast cancer, who have been diagnosed within the last 62 days and have a life expectancy of at least 10 years. The trial also requires patients to have adequate bone marrow, renal, and liver function, as well as a negative bone scan and serum pregnancy test. Patients must discontinue hormone replacement therapy before entering the trial and use adequate contraceptive methods. The trial excludes male breast cancer patients, those under 21 years of age, and those with certain skin conditions or advanced stages of the disease. Patients who have had prior therapy for breast cancer or anthracycline for any malignancy, or who have had non-breast malignancy within the last 5 years, are also excluded. Patients with non-malignant diseases that would preclude follow-up, recent heart attack, or heart failure are also excluded. Patients with psychiatric disorders or conditions that would preclude provision of informed consent are also excluded. The trial uses pegylated liposomal doxorubicin (doxil) as the drug being tested.",
    "The sample is a phase 2 clinical trial for attention deficit hyperactivity disorder. The trial includes male and non-pregnant, non-lactating females between the ages of 18-50 who are using an acceptable method of birth control or are surgically sterile. Participants must be fluent in the language of the investigator and able to discontinue the use of any psychotropic medications for the treatment of ADHD symptoms at screening. They must also meet strict operational criteria for adult ADHD according to the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV-TRTM) and have a Clinical Global Impression ADHD score of 4 or higher at screening. The trial has exclusion criteria, including any clinically significant concurrent medical condition, abnormal laboratory findings, history of liver disease, seizure disorder, and positive test results for HIV or hepatitis. Participants must not be pregnant, have QTc values >450 msec, or have a confirmed positive result in the alcohol/drug screen test for alcohol, illegal or non-prescribed drugs at screening (except marijuana/ tetrahydrocannabinol [THC]). They must also not have a current or lifetime history of bipolar and psychotic disorders, current major depression disorder, obsessive-compulsive disorder, post-traumatic stress disorder, generalized anxiety disorder, panic disorder, and eating disorder (also if treated but not currently symptomatic). Additionally, they must not have a current comorbid dysthymia or social anxiety disorder that is currently treated with psychotropic medication or a current untreated social anxiety disorder that may interfere with the assessment of ADHD in the investigator's opinion. Finally, they must not present an imminent risk of self-harm or harm to others, have any history of a significant suicide attempt, or possess a current risk of attempting suicide, in the investigator's opinion, based on clinical interview and responses provided on the Beck Scale for Suicidal Ideation (BSS). The trial will not include participants who have a history of jailing or imprisonment in the past 6 months due to worsening of symptoms of ADHD.",
    "The sample is a record of a clinical trial with a phase 2 designation. The trial is focused on treating restless legs syndrome. The diseases column lists only one disease, which is restless legs syndrome. The icdcodes column lists the ICD-10 code for restless legs syndrome, which is G25.81. The drugs column lists two drugs, asp8825 and placebo. The eligibility criteria for the trial are listed in the criteria column, with inclusion criteria including a diagnosis of RLS, a history of RLS symptoms, and documented symptoms during a baseline study period. Exclusion criteria include the presence of a sleep disorder that may affect the assessment of RLS, a history of RLS symptom augmentation or end-of-dose rebound with previous dopamine agonist treatment, and the presence of a neurologic disease or movement disorder.",
    "The sample is a phase 2 clinical trial for attention-deficit/hyperactivity disorder. The trial includes patients between the ages of 18 and 60 who meet the criteria for ADHD and are in generally good health. Patients must also be fluent in English and use contraceptive methods during the study. However, patients with certain mental health conditions, a history of substance or alcohol abuse, or a positive urine drug screen are excluded from the trial. The trial involves the use of two drugs, abt-089 and placebo, and has specific eligibility criteria for patients to participate.",
    "The sample is a phase 2 clinical trial for patients with relapsed or recurrent colorectal cancer that has progressed on at least first-line therapy. The trial involves the use of drugs such as irinotecan, capecitabine, folfox, capeox/xelox, and folfiri. The eligibility criteria include being older than 18 years of age, having measurable disease on a CT or MRI study, and having an Eastern Cooperative Oncology Group (ECOG) performance status of <=2 and a minimum life expectancy of \u22654 months. Exclusion criteria include a history of another malignancy, known treated or untreated leptomeningeal metastasis, and clinically significant hepatitis at Screening, among others.",
    "The sample is a record of a clinical trial with a phase 2 designation. The trial is focused on the disease of osteoporosis and includes a list of ICD-10 codes associated with the disease. The trial involves testing several drugs, including 100 mg amg 162, 60 mg amg 162, 14 mg amg 162, and a placebo. The eligibility criteria for the trial include being an ambulatory postmenopausal woman with specific BMD values at the lumbar spine, femoral neck, and total hip. The exclusion criteria include recent use of certain treatments and a history of hypocalcemia or severe vertebral fractures.",
    "The sample is a phase 2 clinical trial for patients with iron overload, as a result of various diseases such as breast cancer, leukemia, lymphoma, and others. The trial is testing the effectiveness of the drug deferasirox in reducing iron levels in the body. The eligibility criteria include having a confirmed diagnosis of iron overload, having undergone prior allogeneic hematopoietic stem cell transplantation, and meeting certain medical requirements such as adequate renal function and no evidence of disease relapse. Patients must also meet certain exclusion criteria, such as being pregnant or having uncontrolled infections. The trial requires patients to give written informed consent and to follow certain guidelines for contraception and medication use.",
    "The sample is a phase 2 clinical trial for Crohn's disease using the drug STA-5326. The eligibility criteria include being between the ages of 18 and 75, having a definitive diagnosis of Crohn's disease, and having a CDAI score between 220 and 450. There are also specific requirements for the use of certain medications and the absence of certain medical conditions. The exclusion criteria include having any clinically significant disease, being pregnant or breastfeeding, and having a history of drug or alcohol dependency. The trial also excludes individuals who have had certain surgeries or have certain gastrointestinal conditions. Prior medication use is also taken into consideration for eligibility.",
    "The sample is a phase 2 clinical trial for pancreatic cancer. The eligibility criteria include having cytologic or histologic proof of adenocarcinoma of the pancreatic head or uncinate process, being potentially resectable with no extra pancreatic disease, no evidence of tumor extension to the celiac axis or SMA, and no evidence of occlusion of the SMV or SMPV confluence. Patients cannot have known hepatic or peritoneal metastases and must have adequate renal and bone marrow function. There is no upper age restriction, but patients must have a Karnofsky performance status greater than 70. Pregnant women and patients with tumors in the body or tail of the pancreas, unstable angina or congestive heart failure, central nervous system or brain metastases, inability to comply with study and/or follow-up procedures, or under 18 years of age are excluded.",
    "The sample is a record of a clinical trial with a phase 2/phase 3 designation. The trial is focused on cytomegalovirus infections and the icd-10 code associated with it is P35.1. The drug being tested is valganciclovir [valcyte]. The eligibility criteria for the trial includes patients between 3 months and 16 years of age who have undergone their first solid organ transplant and are able to tolerate oral medication. Females of childbearing potential must agree to use contraception throughout the study and for 90 days after discontinuing the study drug. Patients who are at risk of developing CMV disease are eligible for the trial, except for those who are D-R- for CMV. Exclusion criteria include patients who have previously participated in the study, those who are participating in another clinical trial (except with the approval of the Sponsor), those with severe, uncontrolled diarrhea (more than 5 watery stools per day), and pregnant or lactating females.",
    "The sample is a phase 2 clinical trial for patients with unresectable stage III or stage IV colorectal cancer. The trial involves the use of drugs such as gemcitabine, avastin, 5fu/folinic acid, and oxaliplatin. The eligibility criteria include having no prior chemotherapy, immunotherapy, or hormonal treatment for metastatic disease, and having recovered from any prior radiation therapy. Patients with CNS metastasis or certain cardiac conditions are excluded from the trial. The trial requires patients to meet certain inclusion criteria, such as having a histological or cytological diagnosis of colon or rectum cancer, and having a urine dipstick for proteinuria of less than 1+. The trial also has exclusion criteria, such as having tumors that demonstrate free perforation or invasive procedures within a certain timeframe.",
    "The sample is a phase 2 clinical trial for patients with dementia associated with Parkinson's disease or dementia with Lewy bodies. The trial involves the use of memantine and placebo drugs. The eligibility criteria include a diagnosis of Parkinson's disease or dementia with Lewy bodies, mild-to-moderate or moderate dementia, written informed consent, ability and willingness to comply with study procedures, and a reliable caregiver. Exclusion criteria include other brain diseases causing dementia, mental retardation, terminal illness with life expectancy shorter than 6 months, recent major changes in health status, known epilepsy or previous convulsive seizure, major depression, severe dementia, moderate to severe renal impairment, moderate or severe heart or pulmonary disease, moderate to severe hepatic impairment, women of childbearing potential, lactating, laboratory values exceeding normal limits, and known allergies to the investigational product.",
    "The sample is a phase 2 clinical trial for patients with metastatic adenocarcinoma or carcinoma of the pancreas that is not amenable to resection with curative intent. The trial involves the use of two drugs, bortezomib and carboplatin. The eligibility criteria include having measurable disease, having received only one prior systemic regimen for metastatic disease, and having recovered from all associated toxicities. Patients must also have an ECOG performance status of <=1, certain blood counts and liver function tests within normal limits, and no significant history of cardiac disease. Patients with brain metastases or current neurotoxicity are excluded, as are pregnant women and HIV-positive patients on combination antiretroviral therapy. The trial requires patients to use adequate contraception and to sign a written informed consent document.",
    "The sample is a phase 2 clinical trial for ovarian cancer. The trial is testing the drug BSI-201 and the eligibility criteria includes being at least 18 years old, having a histological diagnosis of epithelial ovarian carcinoma, fallopian tube cancer, or primary peritoneal carcinoma, and having completed only one previous course of chemotherapy which contained a platinum therapy, with resistance to that regimen. The trial also requires measurable disease, adequate organ function, and a negative pregnancy test for women of childbearing potential. The exclusion criteria includes concurrent invasive malignancy, lesions identifiable only by PET, prior treatment with PARP inhibitors, and major medical conditions that might affect study participation.",
    "The sample is a phase 2 clinical trial for non-small cell lung cancer. The trial is testing the effectiveness of a combination of drugs including cisplatin, etoposide, and irinotecan hydrochloride. The eligibility criteria for patients include having stage IIIA (N2) or IIIB disease, at least one measurable lesion, and no known brain metastasis. Patients must also meet certain health requirements such as having an ECOG performance status of 0-2 and no serious, uncontrolled systemic intercurrent illness. Patients cannot have had prior chemotherapy or radiotherapy for NSCLC and cannot be receiving any other concurrent systemic chemotherapy, investigational drug, or radiotherapy.",
    "The sample is a phase 2 clinical trial for breast cancer. The trial is looking at the effectiveness of a combination of drugs, including docetaxel, liposomal doxorubicin, and cyclophosphamide. The eligibility criteria for the trial include having stage II or III breast adenocarcinoma, being female, being HER2 negative, being over 18 years old, having an ECOG score of less than 1, and having proper organic function. Patients must also be available for treatment and follow-up and must be treated at the investigator or co-investigator site. Exclusion criteria include having previously received treatment for breast cancer, having stages IIIb, IIIc, or IV breast cancer, and having certain other medical conditions.",
    "The sample is a phase 2 clinical trial for metastatic colorectal cancer. The trial involves the drugs azd6244 and capecitabine. The eligibility criteria for the trial include having failed one or two previous chemotherapeutic regimens that included oxaliplatin and/or irinotecan, having a World Health Organisation (WHO) performance status of 0-2, and a life expectancy of more than 12 weeks. Exclusion criteria include previous therapy with EGFR inhibitor, MEK inhibitor or capecitabine, recent surgery, unhealed surgical incision, severe concomitant condition, nausea and vomiting, chronic gastrointestinal disease, or significant bowel resection that would preclude adequate absorption.",
    "The sample is a phase 2 clinical trial for the treatment of locally advanced, metastatic, or recurrent epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer. The trial involves the use of two drugs, mm-121 and paclitaxel, and requires patients to have received at least one prior platinum-based chemotherapy regimen and be platinum-resistant or refractory. Patients must also be eligible for weekly paclitaxel and have adequate liver and kidney function. The trial has inclusion and exclusion criteria, which are listed in detail. The diseases are listed along with their corresponding ICD-10 codes.",
    "The sample is a phase 2 clinical trial for psoriatic arthritis. The trial includes patients who meet the classification criteria for psoriatic arthritis for at least 3 months and have failed prior therapy with disease-modifying antirheumatic drugs. The trial also requires patients to have disease activity as defined by a tender joint count of \u22653, swollen joint count of \u22653, and clinically detectable synovitis at screening and Day 01 (prior to infusion). Patients must also have active psoriasis with a qualifying target lesion \u22652 cm in diameter and be able to undergo magnetic resonance imaging. Women of childbearing potential must use appropriate birth control. The trial has exclusion criteria, including recent history of clinically significant drug or alcohol abuse, current symptoms of severe, progressive, or uncontrolled renal, hepatic, hematologic, pulmonary, cardiac, neurologic, ophthalmologic, or cerebral disease, and cancer within the last 5 years. Participants must also be willing to undergo screening to evaluate the presence of cancer. Long-term period participants must have met eligibility criteria for short-term period and completed short-term (24-week) period of the study.",
    "This sample is for a phase 2 clinical trial for colorectal cancer. The eligibility criteria include a confirmed diagnosis of adenocarcinoma of the rectum, located up to 12 cm from the anal verge with no extension of malignant disease into the anal canal, and clinically determined to be stage T3 or T4, N0-N2, and M0 tumor. Patients must have a Zubrod performance status of 0-2, ANC \u2265 1,800/mm\u00b3, platelet count \u2265 100,000/mm\u00b3, hemoglobin \u2265 8.0 g/dL, AST < 2.5 times upper limit of normal (ULN), alkaline phosphatase < 2.5 times ULN, bilirubin \u2264 1.5 times ULN, creatinine clearance > 50 mL/min, and not be pregnant or nursing. Exclusion criteria include severe, active comorbidity, prior allergic reaction to oxaliplatin or capecitabine, lack of physical integrity of the gastrointestinal tract, prior systemic chemotherapy for colorectal cancer, and participation in any investigational drug study within 28 days of study enrollment.",
    "The sample is a phase 2 clinical trial for patients with metastatic or locally recurrent squamous cell carcinoma of the head and neck. The trial is testing the effectiveness of the drugs Abraxane and Cetuximab. The eligibility criteria include having confirmed carcinoma of the head and neck region, being considered incurable by means of locoregional therapy, having measurable or non-measurable disease, and having adequate bone marrow and hepatic function. Patients must not have prior therapy with Abraxane, any evidence of active or uncontrolled infection, recent myocardial infection, unstable angina, or life-threatening arrhythmia. Patients with baseline grade 3 peripheral neuropathy or known brain metastasis are also not eligible.",
    "The sample is a record from a clinical trial table that includes information about the phase of the trial, diseases being studied, icd-10 codes of the diseases, drugs being tested, and eligibility criteria for participants. In this particular sample, the trial is in phase 2/phase 3 and is studying type 2 diabetes mellitus. The icd-10 codes associated with the disease are listed, as well as the drugs being tested. The eligibility criteria for participants are also listed, including common criteria for all participants and specific criteria for those completing the core phase 2/3 metformin add-on study. Exclusion criteria are also listed, including clinical manifestations of hepatic or renal impairment, serious cardiac disease, cerebrovascular disorder, or serious pancreatic or hematological disease.",
    "The sample is a phase 2 clinical trial for patients with non-Hodgkin lymphoma, Hodgkin disease, or other specified types of lymphoma. The trial involves the use of two drugs, G-CSF and plerixafor, and eligibility criteria include having a histological diagnosis of the specified types of lymphoma, being eligible for autologous transplantation, having a history of relapse following initial treatment with an anthracycline-containing regimen or having disease that is refractory or progresses during initial therapy with an anthracycline-containing regimen, and meeting various other medical criteria. The trial also has exclusion criteria, such as having a second active malignancy, uncontrolled central nervous system involvement by lymphoma, and various other medical conditions.",
    "The sample is a phase 2 clinical trial for patients with leukemia or lymphoma. The trial involves a list of drugs including cyclophosphamide, cyclosporine, fludarabine phosphate, methotrexate, mycophenolate mofetil, and tacrolimus. The eligibility criteria include a diagnosis of chronic lymphocytic leukemia or non-Hodgkin's lymphoma, availability of a 6/6 human leukocyte antigen (HLA) A, B, and DR identical sibling donor, and being a nonmyeloablative transplantation candidate. Patients must also meet certain age and health requirements, such as having a life expectancy of at least 6 months and no clinically significant effusions or ascites that would preclude administration of methotrexate. Prior concurrent therapy is allowed in some cases, but patients must not have any other active malignancy except basal cell skin cancer or recent history of drug or alcohol abuse.",
    "This is a sample from a clinical trial table that includes information about the phase, diseases, icd-10 codes, drugs, and eligibility criteria. In this particular sample, the phase is phase 2 and the disease being studied is prostate cancer. The icd-10 codes associated with the disease are listed as well. The drugs being tested are metformin hydrochloride, docetaxel, and prednisone. The eligibility criteria for the trial are also listed, including age, life expectancy, performance status, and various medical conditions that may exclude patients from participating in the trial.",
    "The sample is a phase 2 clinical trial for endometrial cancer. The trial is looking for patients with histologically confirmed primary endometrial carcinoma that meets certain criteria, such as stage III or IV disease or recurrent disease that is considered incurable. The trial requires patients to have measurable disease and meet certain patient characteristics, such as a GOG performance status of 0-2 and certain blood counts. Patients cannot have a history of severe hypersensitivity reaction to doxorubicin hydrochloride liposome or any other invasive malignancy within the past 5 years except nonmelanoma skin cancer. Additionally, patients cannot have certain cardiac diseases, such as myocardial infarction within the past 6 months or NYHA class II-IV heart failure. Prior to the trial, patients cannot have received chemotherapy or any cancer therapy that would contraindicate study treatment, and they cannot be receiving any concurrent investigational agents. The trial will be testing the efficacy of carboplatin and pegylated liposomal doxorubicin hydrochloride as treatment options.",
    "The sample is a phase 2 clinical trial for a drug called bol-303259-x and latanoprost to treat open angle glaucoma or ocular hypertension. The trial requires subjects to have a mean/median intraocular pressure (IOP) of at least 22 mmHg in one eye and a maximum of 32 mmHg in both eyes. Subjects must also have a best-corrected visual acuity of +0.7 logMAR units or better in either eye. Exclusion criteria include hypersensitivity or contraindications to the study drugs, known contraindications to nitric oxide treatment, and various eye conditions such as advanced glaucoma, corneal disease, and narrow angles. Subjects who require other treatments that affect IOP during the study period are also excluded.",
    "The sample is a phase 2 clinical trial for the treatment of rheumatoid arthritis. The trial includes patients who are 18 years or older and have been diagnosed with rheumatoid arthritis. The drug being tested is mtx. The eligibility criteria for the trial includes exclusion of pregnant females and any other clinically significant disease or disorder that may put the subject at risk. The diseases are listed as 'rheumatoid arthritis (ra)' and the icd-10 codes associated with the disease are also provided.",
    "This is a sample from a clinical trial table that includes information about a phase 2 trial for HIV infections. The trial is looking for asymptomatic HIV-1-infected individuals who have not been on ART for at least 16 weeks and have documented prior non-suppressive ART or ART resistance. The trial requires participants to have >2,500 copies/mL of HIV-1 RNA at screening and a stable CD4 cell count while off ART and >250 cells/mL at screening. The inclusion criteria also require participants to have no clinically significant findings on screening evaluations. The exclusion criteria include having a current or recent opportunistic infection that is not being controlled by medication, any condition that could compromise subject safety or adherence to the protocol, and a documented positive test for hepatitis B surface antigen or having received any antiviral therapy for hepatitis C <6 weeks prior to study drug administration.",
    "The sample is a phase 2 clinical trial for the treatment of triple negative locally advanced non-resectable breast cancer and metastatic breast cancer. The trial involves the use of two drugs, ixabepilone and ixabepilone + cetuximab. The eligibility criteria for the trial includes female subjects with triple negative breast cancer who have undergone prior anthracycline-based chemotherapy. The exclusion criteria includes tumors that are FISH positive or IHC 3+, neuropathy greater than grade 1, and prior systemic therapy for metastatic disease.",
    "The sample is a phase 2 clinical trial for the treatment of multiple myeloma, a type of cancer. The trial involves the use of two drugs, lenalidomide and dexamethasone, and has specific eligibility criteria for participants. Inclusion criteria include being over 18 years old, having a prior or current diagnosis of Durie-Salmon Stage II or III multiple myeloma with disease progression after at least 2 cycles of systemic anti-myeloma treatment or relapse with progressive disease after treatment, and having measurable levels of myeloma paraprotein in serum or urine. Exclusion criteria include serious medical conditions, laboratory abnormalities, or psychiatric illness that would prevent participation, pregnancy or lactation, certain laboratory abnormalities, significant active cardiac disease within the previous 6 months, prior history of malignancies other than multiple myeloma, and known hypersensitivity to thalidomide or dexamethasone, among others.",
    "The sample is a record of a clinical trial with a phase 2 designation. The trial is focused on treating patients with cystic fibrosis, infection, and pseudomonas aeruginosa using the drug amitriptyline. The eligibility criteria for the trial include patients who are older than 18 years but younger than 50 years, have no secondary discrimination, are pulmonal colonized with bacteria, and do not have signs of pulmonary exacerbation. The trial also has exclusion criteria, such as patients who are poor metabolizers for amitriptyline, have glaucoma, seizures, heart insufficiency, or depression, have signs of acute pulmonary illness, have received intravenous antibiotic treatment in the last 4 weeks, are involved in another study, or are pregnant. The trial requires lung function measurement and a full course of therapy without any restrictions.",
    "The sample is a phase 2 trial for the treatment of detrusor muscle hyperactivity. The trial involves the use of a placebo drug and has specific eligibility criteria for participants, including being willing and able to perform clean intermittent catheterisation, having an inadequate response to anticholinergic medication, and being naive to botulinum toxin injections. Participants must also have a minimum of 2 incontinences per day. Exclusion criteria include significant baseline renal and/or urinary tract pathology and previous treatment with any endovesical pharmacology agent, including detrusor botulinum toxin injection.",
    "The sample is a record from a clinical trial table that includes information about the phase of the trial (phase 2/phase 3), the disease being studied (systemic lupus erythematosus), the ICD-10 codes associated with the disease, the drugs being tested (rituximab, placebo, prednisone, acetaminophen, and diphenhydramine), and the eligibility criteria for participants. The inclusion criteria include a diagnosis of SLE, active disease at screening, stable use of one immunosuppressive drug, use of an antimalarial drug, and reliable contraception for subjects of reproductive potential. The exclusion criteria include unstable patients with thrombocytopenia, active moderate to severe glomerulonephritis, and various other medical conditions that would preclude participation.",
    "The sample is a phase 2 clinical trial for the treatment of urinary tract infection. The trial involves the use of two drugs, lactin-v and placebo, and has a list of inclusion and exclusion criteria for participants. Inclusion criteria include being a pre-menopausal woman aged 18-40 years, having current symptomatic uncomplicated cystitis, and agreeing to return for the Randomization Visit. Exclusion criteria include having complicated cystitis or uncomplicated pyelonephritis, being pregnant or within two months of last pregnancy, and having drug or alcohol abuse within the past two years. The trial aims to evaluate the effectiveness of lactin-v in treating urinary tract infections.",
    "The sample is a phase 2 clinical trial for the treatment of melanoma. The trial includes patients with confirmed malignant melanoma and at least one measurable index brain metastasis that has not been previously irradiated, or two measurable lesions visible on contrast magnetic resonance. The trial involves the use of the drug ipilimumab, along with various corticosteroids, for eligible participants. The trial also has specific inclusion and exclusion criteria, including a requirement for a certain level of laboratory test results and an Eastern Cooperative Oncology Group performance status of 0 or 1. Women of childbearing potential must use adequate contraception throughout the study. The trial excludes patients with a history of carcinomatous meningitis, prior stereotactic or highly conformal radiotherapy, and documented history of autoimmune disease.",
    "The sample is a phase 2 trial for the treatment of human immunodeficiency virus infection. The trial involves the use of two drugs, gsk1349572 and placebo. The eligibility criteria include being male or female between the ages of 18 and 65, having a CD4+ cell count of at least 100 cells/mm3, and having documented HIV-1 infection with a screening plasma HIV-1 RNA of at least 5000 copies/mL. Exclusion criteria include a positive pre-study drug screen, participation in a clinical trial within the past 30 days, and a history of sensitivity to any of the study medications. The trial also has specific criteria for female subjects, including being of non-childbearing potential or postmenopausal, and using contraception methods listed in the protocol.",
    "The sample is a phase 2 clinical trial for bladder cancer. The trial is testing the effectiveness of two drugs, oxaliplatin and taxotere, on patients with advanced muscle invasive bladder cancer who have had one prior therapy for advanced disease. The eligibility criteria include having measurable disease, an ECOG performance score of 0 or 1, and being between the ages of 18 and 70. Patients must also have no CNS metastases, no peripheral neuropathy greater than grade 1, and no other serious concomitant illness. They must have fully recovered from any prior therapy and have signed informed consent. Additionally, patients must meet certain laboratory values, such as ANC >1500/mm3 or WBC > 3000/mm3, platelets >100,000/mm3, and creatinine <1.8mg/dL. They must also have no active congestive heart failure, uncontrolled angina, or myocardial infarction within the past 6 months. Patients with metastatic cancer of the urothelial tract (TCC, Adenocarcinoma) are eligible, but those with prior exposure to oxaliplatin or cytotoxics or radiation within 4 weeks prior to enrolling on the protocol are not eligible. PT/PTT must be normal.",
    "The sample is a phase 2 clinical trial for the treatment of recurrent or persistent epithelial ovarian or primary peritoneal carcinoma using the drug enzastaurin. The trial includes participants with measurable disease and at least one \"target lesion\" to assess response. Participants must have had one prior platinum-based chemotherapeutic regimen for management of primary disease containing carboplatin, cisplatin, or another organoplatinum compound. Hormonal therapy directed at the malignant tumor must be discontinued at least one week prior to registration. Any other prior therapy directed at the malignant tumor, including immunologic agents, must be discontinued at least four weeks prior to registration. Participants must not be eligible for a higher priority GOG protocol, if one exists. The trial has inclusion and exclusion criteria, including negative serum pregnancy test for participants of child-bearing potential and practicing an effective form of contraception during and for 3 months after discontinuation of study treatment. Participants with previous enzastaurin treatment, previous radiation to more than 25% of marrow-bearing areas, other invasive malignancies, and serious concomitant systemic disorders are excluded from the trial.",
    "The sample is a phase 2 clinical trial for patients with advanced or metastatic breast cancer who have failed prior anthracycline/taxane based chemotherapy. The trial is testing the effectiveness of the drug oxaliplatin. The eligibility criteria include having measurable disease, no brain metastases, and meeting certain medical requirements such as having a certain level of blood counts and liver function. Patients must also meet certain age and gender requirements and have a life expectancy of at least 3 months. The trial excludes patients who have had certain prior treatments or have certain medical conditions. The sample includes detailed information on the patient characteristics, disease characteristics, and prior concurrent therapy.",
    "The sample is a phase 2 clinical trial for the treatment of rheumatoid arthritis. The trial is testing the effectiveness of the drug clazakizumab compared to a placebo. The eligibility criteria for participants include a diagnosis of active rheumatoid arthritis, inadequate response to tumor necrosis factor inhibitors, and a minimum dose of 15 mg per week of Methotrexate for at least 12 weeks. Participants must also have a minimum of 6 swollen and 6 tender joints on a 66/68 joint count and elevated high-sensitivity CRP and/or ESR. Exclusion criteria include active serious infection, history of or active tuberculosis, and elevated liver function tests.",
    "The sample is a phase 2 clinical trial for the treatment of rheumatoid arthritis. The trial is testing the drug sb-681323 and the eligibility criteria includes a diagnosis of RA according to specific criteria, stable use of certain RA medications, and a BMI range of 18.5-35.0 kg/m2. Inclusion criteria also includes the use of defined contraceptive methods for females of child-bearing potential, informed consent, and abstaining from alcohol during the trial. Exclusion criteria includes non-responsiveness to biological RA treatment, positive alcohol screen, history of liver disease, active tuberculosis, and other significant diseases that may place the subject at risk.",
    "The sample is a phase 2 clinical trial for major depressive disorder. The trial involves the use of esketamine and a placebo. The eligibility criteria include being medically stable, having a diagnosis of major depressive disorder without psychotic features, and having an inadequate response to at least one antidepressant. Women must not be pregnant and must be using a highly effective method of birth control during the study. Men must use a double barrier method of birth control and not donate sperm during the study. The exclusion criteria include having certain medical conditions, such as uncontrolled hypertension or HIV, and having certain psychiatric disorders, such as bipolar disorder or borderline personality disorder. The trial also excludes individuals who have had major surgery within 4 weeks before screening or who are planning to have surgery during the study.",
    "The sample is a phase 2 clinical trial that involves patients between the ages of 6-17 who have been diagnosed with any malignancy that required CNS treatment such as surgery and/or irradiation and/or intrathecal chemotherapy. The patients must be off treatment and cancer-free for at least 6 months and have a proficiency in English. The trial aims to investigate the effects of Adderall-XR\u00ae and Concerta\u00ae on patients with depression, neurotoxicity, and unspecified childhood solid tumor. The trial has a list of inclusion and exclusion criteria that patients must meet to participate. The inclusion criteria include age, diagnosis, cancer-free status, and proficiency in English. The exclusion criteria include IQ level, ADHD diagnosis, current medication use, blindness, glaucoma, family history of motor and phonic tics or Tourette's syndrome, uncontrolled seizures, taking a monoamine oxidase (MAO) inhibitor, and a history of cardiovascular disease, uncontrolled hypertension or hyperthyroidism.",
    "The sample is a record of a clinical trial with a phase 2 designation. The trial is focused on the treatment of myeloid leukemia using the drug as1411. The eligibility criteria for the trial includes patients who have primary refractory or relapsed AML, confirmed diagnosis of AML, and are at least 18 years old. The exclusion criteria includes patients with acute promyelocytic leukemia, patients in blast crisis stage of chronic myeloid leukemia, and patients who have received high-dose cytarabine in the last 6 months. Additionally, patients who have received more than three previous induction cycles or treatment regimens are also excluded. The diseases and their corresponding ICD-10 codes are also listed in the sample.",
    "The sample is a clinical trial for smoking cessation that is in phase 2/phase 3. The trial is focused on individuals who smoke an average of at least 10 cigarettes per day and are willing to take either Chantix or Zyban. The trial is open to Duke employees and their dependents who are enrolled in a Duke Health Plan and intend to remain employed at Duke for the next six months. The trial has a list of inclusion and exclusion criteria that participants must meet. The inclusion criteria include being between 18-65 years old and expressing a desire to quit smoking within the next 30 days. The exclusion criteria include having certain medical conditions, such as hypertension, coronary heart disease, or active ulcers, as well as having a history of certain psychiatric conditions or adverse reactions to smoking cessation aids.",
    "The sample is a phase 2 clinical trial for non-small cell lung cancer. The trial includes patients who are at least 18 years old and have confirmed diagnosis of non-small cell lung cancer. The participants must have radiological evidence of disease progression following the most recent prior treatment and have an Eastern Cooperative Oncology Group (ECOG) performance status of 0-1. The trial involves the use of drugs such as ec145, ec145 + docetaxel, docetaxel, and ec20. The eligibility criteria include adequate organ function, recovery from prior cytotoxic-therapy-associated acute toxicities, and no prior therapy with docetaxel, vinorelbine, or vinca-containing compounds. The exclusion criteria include serious cardiac illness, anti-folate therapy such as methotrexate for rheumatoid arthritis, and active infections such as hepatitis or HIV carriers.",
    "The sample is a phase 2 clinical trial for patients with leukemia, specifically MDS (Low, Int-1 by IPSS, or hypocellular), aplastic anemia, or T-LGL. The trial involves the use of the drug alemtuzumab. The eligibility criteria include having adequate organ function, an ECOG performance status of < or = 3, and an indication for therapy for their disease such as transfusion dependence or morbidity associated with their cytopenia(s) such as bleeding, severe fatigue, or frequent/multiple infections (eg. neutropenia). Patients must have been off of cytotoxic, immunosuppressive, or targeted therapy (except hydroxyurea) for at least 2 weeks prior to entering this study, and have recovered from the toxic effects of that therapy to grade 1 or less. Women of child-bearing potential and men must agree to use adequate contraception prior to study entry and for the duration of study participation. The exclusion criteria include pregnant women, known HIV infection, known Hepatitis B or Hepatitis C infection, uncontrolled intercurrent illness, and patients with documented hypersensitivity to alemtuzumab.",
    "The sample is a phase 2 clinical trial for atopic dermatitis. The trial is testing the effectiveness of four different ointments, including an2728 ointment, 2%, an2898 ointment, 1%, an2898 ointment vehicle, and an2728 ointment vehicle. The trial is looking for participants who have a clinical diagnosis of atopic dermatitis that has been stable for at least one month, have a total body surface area of atopic dermatitis involvement of no more than 35%, and have two comparable target lesions. Participants must be willing and able to apply the study medications as directed, comply with study instructions, and attend all visits. Females of childbearing potential must use at least one highly effective method of birth control, and males with partners of childbearing potential should inform them of their participation in the study and use highly effective methods of birth control during the study. Exclusion criteria include concurrent or recent use of certain medications or phototherapy, active or potentially recurrent dermatologic conditions other than atopic dermatitis in the target lesion area, significant confounding conditions, history or evidence of allergies requiring acute or chronic treatment, participation in any other trial of an investigational drug or device within 30 days, and pregnancy or lactation.",
    "The sample is a phase 2 clinical trial for asthma. The eligibility criteria include being 12 years or older, having a diagnosis of asthma as defined by the National Institutes of Health, and having a best forced expiratory volume in one second (FEV1) of 40%-85% of the predicted normal value. The trial also requires subjects to be on a short-acting \u03b22-agonist alone or a non-corticosteroid maintenance medication for at least 3 months preceding the screening visit. The exclusion criteria include having a history of life-threatening asthma, any asthma exacerbation requiring oral corticosteroids within 3 months of the screening visit, and having any clinically significant disease that could put the safety of the subject at risk through participation. The trial also excludes subjects who have used tobacco products within the past year and those who have participated in any investigational drug study within the 30 days preceding the screening visit or plan to participate in another investigational drug study during the trial period.",
    "The sample is a phase 2 clinical trial for the treatment of tardive dyskinesia, a movement disorder. The trial is for males and females aged 18 to 65 years who have moderate or severe symptoms of tardive dyskinesia and a clinical diagnosis of schizophrenia or schizoaffective disorder. Participants must be receiving a stable dose of antipsychotic medication for at least 30 days and have stable psychiatric status. They must also have a body mass index (BMI) of 18 to 38 kg/m^2 and be in good general health. The trial has inclusion and exclusion criteria, which are listed in detail.",
    "The sample is a phase 2 clinical trial for the treatment of squamous cell carcinoma of the head and neck. The trial involves the use of lapatinib oral tablets and a placebo. The eligibility criteria include having a confirmed diagnosis of SCCHN, being at stage III, IVA or IVB, and willing to have a tumor biopsy taken. The subjects must also have adequate haematological, renal and hepatic function, and an Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2. Exclusion criteria include having received prior systemic chemotherapy given with curative intent, prior or concurrent treatment with tyrosine kinase inhibitors, and having known history of uncontrolled or symptomatic angina, arrhythmias, or congestive heart failure. The trial is expected to last for at least 6 months.",
    "The sample is a phase 2 clinical trial for various types of cancer, including lung cancer, malignant mesothelioma, pancreatic cancer, and sarcoma. The trial is testing the effectiveness of a drug called l-alanosine. The eligibility criteria for patients include having a confirmed malignancy of one of the specified types, being chemotherapy na\u00efve or having had no more than a certain number of prior cytotoxic treatment regimens, and having measurable disease. Patients must also meet certain age, performance status, and hematopoietic, hepatic, renal, and other health criteria. Prior concurrent therapy is also taken into consideration.",
    "The sample is a phase 2 clinical trial for rheumatoid arthritis. The trial includes patients between the ages of 18 and 80 who have been diagnosed with RA for at least 3 months and are receiving outpatient treatment. The patients must have failed treatment with at least one DMARD, but not anti-TNF or other biologic therapy, and must have had an inadequate response to methotrexate, having taken and tolerated it for at least 12 weeks with a stable dose for at least 4 weeks. The trial excludes patients with other rheumatic autoimmune diseases or significant systemic involvement secondary to RA, a history of or current inflammatory joint disease other than RA, or other systemic autoimmune disorders. Patients who have had bone/joint surgery within 12 weeks of the study or prior use of anti-TNF or other biologic therapy, an anti-alpha 4 integrin, or any cell-depleting therapies are also excluded.",
    "The sample is a phase 2 clinical trial for children and young adults between the ages of 6 months and 21 years who have been diagnosed with either a hematologic malignancy or an inherited metabolic disease. The trial involves a cord blood transplant using one or two available 4, 5, or 6/6 antigen matching unrelated UCB units that will deliver a cell dose between 3.0-5.0 x 107cells/kg. The units must be HLA-matched minimally at 4 of 6 HLA-A and B and DRB1 loci with the subject. The trial requires that subjects have adequate function of other organ systems, including creatinine, hepatic transaminases, bilirubin, cardiac function, and pulmonary function. Female subjects capable of reproduction must agree to use an effective oral or IM contraceptive method during the course of the study and 2 months following the last administration of study drug. The trial has exclusion criteria, including subjects with an uncontrolled infection at the time of cytoreduction, pregnant or breastfeeding subjects, subjects who are known to be seropositive for HIV or HTLV-1, and subjects who have received treatment with an investigational agent within 30 days of anticipated administration of the first dose of study drug.",
    "The sample is a phase 2 clinical trial for kidney diseases. The trial involves the use of two drugs, namely lanthanum carbonate and placebo. The trial has a list of inclusion and exclusion criteria that participants must meet to be eligible for the trial. The inclusion criteria include being under a physician's care for chronic kidney disease for more than two months, having a screening estimated GFR of 15-59 mL/1.73 m2, and having a serum phosphorus level of at least 4.7 mg/d following washout. The exclusion criteria include not being able to receive treatment with cinacalcet HCI or compounds containing phosphate, aluminum, calcium, or magnesium, having rapidly progressing glomerulonephritis, having cirrhosis or other clinically significant liver diseases, and having past or present uncontrolled peptic ulcer, Crohn's disease, malignancy, or recent GI bleed.",
    "The sample is a phase 2 clinical trial for attention deficit hyperactivity disorder (ADHD). The trial includes patients who have been diagnosed with ADHD despite treatment with a stimulant by their primary care provider and have not responded well to the treatment. The patients must have an IQ greater than 70 and be in school. The trial involves testing the effectiveness of aripiprazole compared to a sugar pill. Patients and their guardians must be able to understand the protocol and attend weekly visits. There are several exclusion criteria, including the presence of other psychiatric disorders, drug abuse, pregnancy or breastfeeding, and abnormal cardiac function. Patients taking prohibited concomitant medication during phase 1 or phase 2 of the trial are also excluded.",
    "The sample is a phase 2 clinical trial for rheumatoid arthritis. The trial includes patients with a diagnosis of RA (class I to III) who have been on a stable dose of methotrexate for at least 12 weeks. The trial excludes pregnant or breastfeeding patients and those with abnormal screening laboratory test values considered to be clinically significant. The trial will test the efficacy of three drugs, including ak106-001616 and an active comparator. The diseases are listed as 'rheumatoid arthritis' and the icd-10 codes associated with the disease are also provided.",
    "The sample is a record from a clinical trial table that includes information about the trial's phase, diseases being studied, associated ICD-10 codes, drugs being tested, and eligibility criteria for participants. In this particular sample, the trial is in phase 2/phase 3 and is focused on studying allergy. The associated ICD-10 codes for the disease are listed, as well as the drugs being tested, which include a salbutamol inhaler, budesonide/formoterol inhaler, prednisone tablet, desloratadine tablet, and budesonide nasal spray. The eligibility criteria for participants are also listed, including requirements such as a clinical history of house dust mite induced persistent mild to moderate asthma, a positive specific serum IgE test to Dermatophagoides, and willingness to comply with the trial protocol regimen for asthma and/or rhinoconjunctivitis medication. There are also exclusion criteria listed, such as having a mental condition rendering the subject unable to understand the nature of the trial or evidence of an uncooperative attitude.",
    "The sample is a phase 2 clinical trial for the treatment of breast neoplasm. The trial involves the use of drugs such as doxorubicin, cyclophosphamide, paclitaxel, trastuzumab, and pld, cyclophosphamide, trastuzumab, paclitaxel. The eligibility criteria for the trial include having operable, node-positive or high-risk node-negative HER2-positive breast carcinoma, being of female gender and at least 18 years of age, having complete resection of the primary tumor and axillary lymph nodes, having adequate postoperative bone marrow function, renal function, and liver function, and being free of any clinically relevant disease that would interfere with the study. Exclusion criteria include having clinical or radiological evidence of metastatic disease, prior radiotherapy, chemotherapy or biotherapy for the currently diagnosed breast cancer prior to randomization, and serious cardiac illness.",
    "The sample is a phase 2 clinical trial that focuses on the treatment of iron deficiency anemia and kidney disease. The trial involves the use of two drugs, ferumoxytol and iron sucrose, and has a set of inclusion and exclusion criteria for participants. Inclusion criteria include being over 18 years old, having a low estimated glomerular filtration rate or a diagnosis of chronic kidney disease, and having low levels of hemoglobin and transferrin saturation. Exclusion criteria include having a history of allergy to IV iron, being pregnant or breastfeeding, and having other causes of anemia besides iron deficiency. The trial aims to evaluate the safety and efficacy of the drugs in treating the targeted diseases.",
    "The sample is a phase 2 clinical trial for the treatment of steatohepatitis. The trial includes patients with a definite diagnosis of NASH who are not suffering from significant concomitant medical illness and are taking stable doses of anti-diabetic agents. Patients with cirrhosis or serum ALT levels above 300 U/L are excluded from the trial. The trial also excludes patients who are using drugs associated with steatohepatitis or certain anti-NASH agents such as Vitamin E, Omega-3-acid ethyl esters, or thiazolidinediones. Patients who are using non-stable doses of certain anti-NASH agents such as statins, fibrates, or probiotics are also excluded. Other liver diseases are also excluded from the trial.",
    "The sample is a phase 2 clinical trial for the treatment of schizophrenia. The trial includes subjects who have been diagnosed with schizophrenia according to DSM IV/DSM IV TR criteria and are capable of providing informed consent. The subjects must be between the ages of 18 and 60, of any race, and have been treated with one of the following second generation antipsychotics for the previous two months: risperidone, olanzapine, quetiapine, ziprasidone, or aripiprazole, with no change in dose in the last month. Alternatively, they may have been treated with injectable depot antipsychotics (fluphenazine or haloperidol decanoate) with no change in the last 3 months. The trial also includes eligibility criteria related to symptom and cognitive performance. Exclusion criteria include current treatment with oral conventional antipsychotics or clozapine, recent alcohol or substance abuse or dependence, significant head injury/trauma, and various medical conditions that could pose a risk to the patient or confound the results of the study. Women who are pregnant or breastfeeding or who are of child-bearing potential and not using appropriate methods of birth control are also excluded, as are subjects who have participated in a clinical trial of investigational medication within the last 60 days.",
    "The sample is a phase 2 clinical trial for patients with histologically proven gastric adenocarcinoma, including adenocarcinoma of the gastro-oesophageal junction. The trial includes patients with metastatic or locally recurrent disease who have not received prior palliative chemotherapy. The trial involves the use of drugs such as docetaxel, oxaliplatin, 5-fluorouracil, and capecitabine. The eligibility criteria include a Karnofsky index of more than 70, hematology within 7 days before randomization, and measurable and/or evaluable metastatic disease. The exclusion criteria include any prior palliative chemotherapy and neurosensory symptoms of grade 2 or higher.",
    "The sample is a phase 2 clinical trial for patients with colorectal cancer. The trial includes patients who have had progression on or intolerance of all standard therapies and are over 18 years old with an ECOG performance status of 0-2. Patients must also have no brain metastases or a history of previously treated brain metastases and have adequate hepatic, bone marrow, and renal function. The trial involves the use of two drugs, temozolomide and abt-888. The eligibility criteria include various medical conditions and factors such as age, pregnancy status, and understanding of the protocol. The exclusion criteria include active severe infections, cardiovascular disease problems, and other severe concurrent diseases.",
    "The sample is a phase 2 clinical trial for the treatment of exudative age-related macular degeneration. The trial involves the use of two drugs, esba1008 solution and aflibercept. The eligibility criteria for the trial include a diagnosis of wet age-related macular degeneration, a specified best-corrected visual acuity, and the ability to make required study visits and follow instructions. There are also several exclusion criteria, such as any active ocular or periocular infection, any approved or investigational treatment for exudative AMD other than vitamin supplements, and any concurrent intraocular condition that could require medical or surgical intervention during the course of the study. Women of childbearing potential must be using adequate birth control or not planning to become pregnant.",
    "The sample is a record of a clinical trial in phase 2, focused on treating painful diabetic neuropathy. The trial involves testing the effectiveness of drugs such as agn 203818 and a placebo capsule. The eligibility criteria for participants include a diagnosis of diabetic peripheral neuropathy and moderate to severe neuropathic pain, while exclusion criteria include any other uncontrolled disease and pregnancy or nursing. The sample also includes a list of icd-10 codes associated with the disease.",
    "The sample is a phase 2 clinical trial for the treatment of dyskinesias, Parkinson's disease, movement disorders, and parkinsonian disorders using the drugs afq056 and placebo. The trial includes patients between the ages of 30 and 80 who have a clinical diagnosis of Parkinson's disease and a score of at least 2 on UPDRS items 32 and 33. Patients must have experienced dyskinesias for at least 3 months prior to baseline and have been on a stable treatment regimen with L-dopa and other anti-parkinsonian treatment for 4 weeks prior to baseline. Patients must also demonstrate the capacity to complete accurate diary ratings and have a primary caregiver willing to assess their condition throughout the study. Exclusion criteria include atypical/secondary forms of Parkinson's disease, history of surgical treatment for PD, evidence of dementia, and treatment with certain prohibited medications.",
    "The sample is a phase 2 clinical trial for patients aged 12 months to 21 years with recurrent or refractory sarcoma tumors, including rhabdomyosarcoma, nonrhabdomyosarcomatous soft tissue sarcoma, and Ewing's sarcoma. The trial requires measurable disease by imaging studies and excludes patients with significant metastatic liver disease. Patients must meet various performance and blood count criteria, and cannot have concurrent CYP3A4 inhibitors or active uncontrolled infections. The trial also has restrictions on prior treatments and concurrent medications. Patients must use effective contraception during and for 2 months after study participation if fertile. The trial allows concurrent steroids and radiotherapy to localized painful lesions, provided at least 1 measurable lesion is not irradiated.",
    "The sample is a phase 2 clinical trial for breast cancer patients with HER2-overexpression that is unresectable or metastatic. The trial is testing the effectiveness of lapatinib and bevacizumab drugs. The eligibility criteria include being a female over 18 years old, having adequate hepatic, renal, and cardiac function, and having an ECOG score of 0-1 with a life expectancy of at least 12 weeks. The exclusion criteria include pregnancy, unstable or symptomatic CNS metastases, and a history of significant vascular disease or myocardial infarction. The trial requires signed informed consent and subjects must be able to swallow oral medication.",
    "The sample is a phase 2 clinical trial for the treatment of hypercholesterolemia. The trial involves administering the drug ISIS 301012 or a placebo to eligible participants. The eligibility criteria include having a BMI between 25 and 32 kg/m^2, fasting stable LDL-cholesterol levels of at least 130 mg/dL, and triglycerides below 400 mg/dL. Female participants must not be of childbearing potential. Exclusion criteria include having certain diseases or conditions, testing positive for hepatitis B, C, or HIV, having high blood pressure, taking certain medications, and having a history of alcohol or drug abuse. The trial also excludes individuals who have donated blood or smoked excessively.",
    "The sample is a phase 2 trial for patients with incurable unresectable stage III or IV melanoma with V600-mutant BRAF disease who have progressed after therapy on selective BRAF inhibitor. The trial includes patients with measurable disease and who have received prior therapy and progressed following a selective BRAF inhibitor. Patients must have completed prior therapy a minimum of 4 weeks previously and all treatment-related toxicity must have resolved to grade 2 or less. Patients cannot receive chemotherapy after the BRAF inhibitor treatment and prior to enrollment on this protocol. Up to two prior immunotherapy regimens for advanced disease are allowed and one may be given between BRAF inhibitor therapy and this trial. The eligibility criteria include various medical tests and requirements such as life expectancy of greater than or equal to 3 months, Eastern Cooperative Oncology Group (ECOG) performance status \u22641, and various blood tests. Patients must not have received chemotherapy in the time between the failure of BRAF inhibitor and the enrollment onto the present trial.",
    "This sample is for a phase 2 clinical trial for the treatment of knee osteoarthritis. The trial includes patients with mild to moderate knee osteoarthritis confirmed by radiographic technique. The trial excludes patients with secondary knee osteoarthritis, other diseases that could cause knee pain, any disease or intervention that would impact knee pain or mobility, and drugs that potentially act on the bone or cartilage component of the knee joint. The trial involves the use of a drug called pg-530742, as well as a placebo and different doses of the drug.",
    "The sample is a record from a clinical trial table. It is a phase 2 trial for the treatment of cystic fibrosis using the drug ptc124. The eligibility criteria for patients to participate in the trial are listed, including completion of a previous study, specific lung function requirements, and willingness to comply with study procedures. Exclusion criteria are also listed, such as ongoing acute illness and abnormal laboratory values. The record includes information on diseases, icd-10 codes, and drugs related to the trial.",
    "The sample is a phase 2 trial for patients with primary soft tissue sarcoma of the upper or lower extremities. The trial is testing the effectiveness of chemotherapy as a treatment option. Patients must have had an incisional or core biopsy within the past 8 weeks and must not have any histopathological diagnosis of certain types of sarcoma. The tumor must be surgically resectable and limb-preservation surgery alone would not provide adequate local control. Patients must not have sarcoma of the hand, foot, head, neck, or intra-abdominal or retroperitoneal region or body wall, and no sarcoma \u2265 32 cm in any direction. Patients must also not have any lymph node or distant metastases. The eligibility criteria also include certain patient characteristics such as Zubrod performance status, blood counts, liver and kidney function, and no severe, active co-morbidity. Prior concurrent therapy is also taken into consideration.",
    "The sample is a record of a clinical trial that is in phase 2/phase 3 and is focused on the disease of hypertension. The trial includes a list of icd-10 codes for the disease and a list of drugs being tested, which are irbesartan and atenolol. The eligibility criteria for participants include being at least 18 years old, having a seated blood pressure diastolic between 90-115 mm Hg, and having a left ventricular mass above a certain threshold. There are also exclusion criteria, such as having significant cardiac or renal disease, drug or alcohol abuse, and uncontrolled diabetes mellitus. The sample includes both inclusion and exclusion criteria for potential participants.",
    "The sample is a phase 2 clinical trial for chronic hepatitis B. The trial includes patients who have tested positive for HBsAg for at least 6 months or HBsAg positive for more than 3 months and positive for immunoglobulin G antibody against hepatitis B core antigen. The patients must be between 18 and 69 years old, HBeAg positive, and have HBV DNA levels of at least 10^8 copies/mL. The trial involves the use of tenofovir df, ftc, and placebo drugs. The eligibility criteria include various medical conditions such as calculated creatinine clearance, hemoglobin levels, and neutrophils levels. The exclusion criteria include pregnant women, individuals with decompensated liver disease, and those who have received interferon therapy within 6 months of the screening visit.",
    "The sample is a phase 2 clinical trial for patients with symptomatic stage I or II and III myeloma who have completed standard first-line non-melphalan containing induction treatment. The trial aims to evaluate the efficacy of various drug combinations, including vinorelbine, g-csf, and plerixafor, in consolidating the treatment with high-dose chemotherapy with melphalan and autologous stem cell support. The trial has inclusion criteria such as achieving at least a partial response after induction chemotherapy, being aged 18-70 years with an ECOG < 2, and having given voluntary written informed consent. Exclusion criteria include having previously received melphalan or extensive radiotherapy to the bone marrow, being not fit for autologous stem cell transplantation, and having other serious medical conditions that could potentially interfere with the completion of treatment. The sample also includes eligibility criteria for platelet count, ANC, corrected serum calcium, AST, ALT, total bilirubin, creatinine clearance, and negative pregnancy test for women of childbearing potential.",
    "The sample is a phase 2 clinical trial for cancer patients with BRAF mutation positive melanoma or colorectal cancer. The trial involves the use of two drugs, gsk2118436 and gsk1120212, and requires patients to meet certain eligibility criteria, such as being able to give written informed consent, having measurable disease according to RECIST version 1.1, and having an Eastern Cooperative Oncology Group Performance Status of 0 or 1. The trial also has a list of exclusion criteria, such as currently receiving cancer therapy, having a history of retinal vein occlusion or glaucoma, and being pregnant or lactating. The trial aims to assess the safety and efficacy of the drugs in treating cancer.",
    "The sample is a record of a clinical trial in phase 2 for the treatment of primary open angle glaucoma. The trial involves the use of two drugs, t2345 and prostaglandin. The eligibility criteria for the trial includes untreated bilateral newly diagnosed patients with primary open angle glaucoma, while exclusion criteria includes any ocular hypertension other than chronic open angle glaucoma. The sample also includes a list of icd-10 codes associated with the disease.",
    "The sample is a record of a clinical trial with a phase 2 designation. The trial is focused on treating chronic lymphocytic leukemia, and the table includes a list of diseases, icd-10 codes, and drugs associated with the trial. The eligibility criteria for patients to participate in the trial are also listed, including requirements for diagnosis, previous treatment, disease stage, performance status, and organ function. Patients cannot receive concurrent chemotherapy, radiotherapy, or immunotherapy, and must not have untreated or uncontrolled life-threatening infection. The sample also includes exclusion criteria, which in this case is none.",
    "This is a sample from a clinical trial table that includes information about a phase 2 trial. The trial is focused on pulmonary disease, chronic obstructive, and the icd-10 codes associated with it. The trial involves two drugs, one being a placebo, and the eligibility criteria includes a signed informed consent, being 40 years or older, having a COPD diagnosis, and having a 10 pack-year history or greater of cigarette smoking. The exclusion criteria includes having other significant respiratory disorders besides COPD, having a BMI greater than 35, having cancer, and having allergies or hypersensitivity to anticholinergics or inhaler excipients.",
    "The sample is a phase 2 clinical trial for patients with metastatic nasopharyngeal carcinoma (NPC) who have failed previous treatments. The trial is testing the effectiveness of the drug celecoxib. The eligibility criteria include having confirmed NPC, measurable disease, and meeting certain patient characteristics such as ECOG performance status and no active CNS metastases. Prior concurrent therapy is also taken into consideration. The sample includes a detailed list of patient characteristics and exclusion criteria.",
    "This sample is for a phase 2 clinical trial focused on the disease of obesity. The trial involves the use of two drugs, exenatide and placebo. The eligibility criteria for participants include having a Body Mass Index (BMI) of 30kg/m^2 or higher, and not having participated in this study or any other study using exenatide or GLP-1 analogs before. Participants must also not have participated in any interventional medical, surgical, or pharmaceutical study within 30 days of the study start. Additionally, participants must not have a diagnosis of diabetes mellitus (other than gestational diabetes) or have used anti-diabetic medications for more than 3 months. Other exclusion criteria include having a history of chronic use of drugs that directly affect gastrointestinal motility, having had bariatric surgery, or having had an organ transplant.",
    "The sample is a phase 2 clinical trial for liver cancer patients who have either refractory or recurrent disease and have failed prior first-line or second-line treatment. Metastatic disease is allowed, but hepatocellular carcinoma is not. Patients must have measurable disease and elevated serum alpha-fetoprotein levels. They must also meet certain patient characteristics such as having a performance status of 50-100%, a life expectancy of more than 8 weeks, and normal metabolic parameters. Patients must not be pregnant or nursing and must not have severe uncontrolled infection or enterocolitis. Prior concurrent therapy is also specified, including no chemotherapy within 3 weeks prior to study entry and no prior use of irinotecan.",
    "The sample is a phase 2 clinical trial for the treatment of multiple myeloma using the drug carfilzomib. The trial includes subjects who have measurable disease and have been responsive to standard first-line therapy, but have relapsed and/or refractory or progressive disease after at least one, but no more than three, prior therapeutic treatments or regimens for multiple myeloma. The trial also includes demographic and laboratory criteria, such as adequate hepatic function and platelet count, and ethical criteria, such as written informed consent and the use of dual methods of contraception for female subjects of child-bearing potential. The trial excludes subjects with certain diseases or conditions, such as non-secretory multiple myeloma or significant neuropathy, and those who have previously been treated with carfilzomib.",
    "The sample is a phase 2 clinical trial for the treatment of metastatic pancreatic cancer. The trial includes patients who are 18 years or older, have measurable or evaluable disease that is histologically confirmed, and have a Karnofsky performance status of at least 60. Patients must have failed 1st-line gemcitabine treatment for metastatic pancreatic cancer, and an alternate chemotherapeutic agent is acceptable as 1st-line therapy if the patient is intolerant to or ineligible to receive gemcitabine. Patients must have recovered or been at a new stable baseline from any related toxicities for at least 2 weeks since the completion of previous chemotherapy. Exclusion criteria include having more than 1 prior chemotherapy regimen for metastatic disease, evidence of central nervous system metastases (unless stable for more than 3 months) or history of uncontrolled seizures, ongoing or prior radiation therapy administered as a second-line treatment, other active malignancy except basal or squamous carcinoma of the skin, inability to swallow food or any condition of the upper GI tract that precludes administration of oral medications, and inadequate renal, hepatic, and bone marrow function demonstrated by clinical observations and/or laboratory assessments. The trial includes the drugs capecitabine, ruxolitinib, and placebo.",
    "The sample is a phase 2 clinical trial that involves patients with colorectal neoplasms, breast neoplasms, non-small-cell lung carcinoma, and pancreatic neoplasms. The trial is testing the drug ci-1040. The eligibility criteria include confirmation of the cancer diagnosis, limited prior chemotherapy, availability of tumor tissue, adequate organ function, and ability to swallow capsules. Exclusion criteria include unstable medical condition, recent chemotherapy, serious infection, other tumor types, and poor performance status.",
    "The sample is a phase 2 clinical trial that involves patients with impaired glucose tolerance and abdominal obesity. The trial is testing the effectiveness of two drugs, gft505 80mg and placebo. The eligibility criteria for the trial include having a waist circumference of at least 94cm for males and 80cm for females, fasting plasma glucose levels between 110 and 126 mg/dl, and 2-hour glycaemia at OGTT of at least 140 mg/dL. Exclusion criteria include having a BMI of 40 kg/m\u00b2 or higher, blood pressure above 160/95 mmHg, known type I or type II diabetes mellitus, HbA1c levels above 7%, and fasting TG levels above 400mg/dl and LDL-C levels above 220mg/dl.",
    "The sample is a record from a clinical trial table that includes information about the trial's phase, diseases being studied, icd-10 codes of the diseases, drugs being used, and eligibility criteria for patients. In this particular sample, the trial is in phase 2/phase 3 and is studying non-small cell lung cancer. The drugs being used are carboplatin, cediranib maleate, and paclitaxel. The eligibility criteria include specific disease characteristics, patient characteristics, and prior concurrent therapy. The criteria specify that patients must have histologically or cytologically confirmed non-small cell lung cancer, measurable disease, and meet certain performance and health status requirements. Additionally, patients must not have certain medical conditions or have received certain prior treatments.",
    "The sample is a phase 2 clinical trial for patients with recurrent or metastatic squamous cell carcinoma of the head and neck. The trial is testing the effectiveness of a combination of drugs including docetaxel, capecitabine, and premedication. The eligibility criteria include having measurable disease, not being able to undergo surgery or salvage chemoradiation, and having negative pregnancy test. Patients must have fully recovered from any prior radiation therapy and cannot have relapsed within 6 months of completing a combined modality curative treatment that included a fluoropyrimidine or taxanes. Exclusion criteria include having brain metastases, major neurological disease, prior chemotherapy regimen for recurrent/metastatic disease, and hypersensitivity to certain drugs. Patients must not be receiving certain medications and must have fully recovered from any prior surgery. Other exclusion criteria include having serious uncontrolled medical conditions, peripheral neuropathy > grade 1, and daily consumption of alcohol. Patients must not have a prior history of malignancy in the last 5 years, excluding in situ carcinoma of the cervix or adequately treated basal or squamous cell carcinoma of the skin or Gleason Grade < VII organ confined prostate cancer. Current breastfeeding is also an exclusion criterion.",
    "The sample is a record from a clinical trial table that includes information about the trial phase, diseases being studied, corresponding ICD-10 codes, drugs being tested, and eligibility criteria for participants. In this particular sample, the trial is in phase 2 and is focused on metastatic breast cancer. The ICD-10 codes associated with the disease are listed, as well as the drugs being tested. The eligibility criteria for participants are also provided, including requirements for prior antiestrogen therapy, postmenopausal status, and fasting serum glucose levels. Exclusion criteria are also listed, such as a history of poorly controlled diabetes or prior chemotherapy regimens.",
    "The sample is a clinical trial for a drug treatment for chronic sinusitis and nasal polyps. The trial is in phase 2/phase 3 and the table includes information on the diseases, icd-10 codes, drugs, and eligibility criteria. The eligibility criteria include requirements such as a confirmed diagnosis of chronic sinusitis, previous surgery, and recurrent sinus obstruction due to polyposis. Patients must also be able to tolerate the use of Nasonex topical intranasal steroid spray and the implant procedure. There are also exclusion criteria, such as recent surgery or evidence of disease that could compromise survival or follow-up assessments. The trial is also excluding patients with certain ocular conditions.",
    "The sample is a phase 2 clinical trial for patients with localized pancreatic cancer that has not spread to other parts of the body. The trial is testing the effectiveness of the drug gemcitabine in treating the cancer. Patients must meet certain eligibility criteria, including having a resectable or unresectable tumor based on specific criteria, having a certain performance status, and not having any other significant medical conditions. Patients must also not have received prior treatment for pancreatic cancer and must not have had any major surgical procedures within the past 28 days. The trial is looking to enroll patients who have not received chemotherapy for any other type of cancer within the past 5 years.",
    "The sample is a phase 2 clinical trial for the treatment of multiple myeloma, a type of cancer. The trial involves the drug clofarabine and has eligibility criteria that include having measurable levels of monoclonal protein in serum or urine, having had at least one prior therapy for multiple myeloma with documented evidence of progression on the most recent treatment, and having acceptable organ and marrow function. The trial also has exclusion criteria, such as not being able to comply with study requirements or having a history of other malignancy except for certain types of skin or breast cancer. Women of childbearing potential must agree to use adequate contraception during the study.",
    "The sample is a clinical trial for acute myeloid leukemia, in phase 2/phase 3. The trial includes patients between the ages of 18-60 who have been newly diagnosed with AML, excluding acute promyelocytic leukemia. The trial involves the use of drugs such as cytarabine, idarubicin, etoposide, all-trans retinoic acid, and pegfilgrastim. The eligibility criteria include written informed consent, molecular and cytogenetical diagnostics, and exclusion criteria such as bleeding independent of AML, uncontrollable infection, and severe neurological or psychiatric disorders. The trial also excludes patients with insufficiency of the kidneys, liver, severe obstructive or restrictive ventilation disorder, heart failure, and those with a performance status WHO > 2 or pregnancy.",
    "The sample is a phase 2 clinical trial for the treatment of painful diabetic neuropathy. The trial is looking for male participants over 18 years of age or post-menopausal females over 60 years of age who have had painful diabetic neuropathy for over 6 months and are either pain treatment naive or have had inadequate relief from their current pain medication. Participants must have stable diabetes and have scored over 2 points on the Michigan Neuropathy Screening Instrument. Inclusion criteria also include having measurable pain perception and having stopped current pain medication at least 14 days prior to the baseline visit. Exclusion criteria include being pregnant or lactating, having a documented neuropathy of any cause other than those mentioned in the inclusion criteria, having other neurological diseases, being on pain treatment with strong opioids, having a current medication of lipid lowering agents other than statins, having a BMI over 40 kg/m2, having had surgery within the previous 2 months, having concurrent serious neurological disease, having a recent history or current evidence of alcohol or drug abuse, having concurrent unstable disease involving any system, having participated in any other investigational drug or therapy study within the previous 3 months, and having a lack of ability or willingness to give informed consent.",
    "The sample is a phase 2 clinical trial for the treatment of type 2 diabetes. The trial includes patients between the ages of 18 and 70 who have a body mass index between 22.5 and 45.5 kg/m2 and are on stable doses of background medicines for diabetes management. The trial involves the use of various doses of a drug called pf-04991532 and sitagliptin 100 mg, as well as a placebo. The trial has inclusion criteria and exclusion criteria, with patients who have type 1 diabetes, heart attack or stroke in the past 6 months, uncontrolled blood pressure, or significant kidney disease being excluded. The diseases and icd-10 codes associated with the trial are limited to diabetes mellitus, type 2.",
    "This sample is for a phase 2 clinical trial for rheumatoid arthritis. The trial includes the drugs cetrorelix and placebo. The eligibility criteria for the trial includes being an adult over 18 years old, having moderate to severe disease activity, and using a reliable method of contraception for sexually active female patients. The exclusion criteria includes being pregnant or breastfeeding, and taking biologic therapy or prednisolone over 7.5mg. The icd-10 codes for the disease are also provided.",
    "The sample is a phase 2 clinical trial for HIV-1 infection. The trial includes a list of inclusion and exclusion criteria for participants, such as having no evidence of exclusionary resistance mutations, being ARV drug-na\u00efve, having certain laboratory values within a certain range, and refraining from participating in a conception process. The trial also includes a list of drugs being tested, including efv/ftc/tdf, calcium carbonate, vitamin d3, and placebos for calcium carbonate and vitamin d3. The diseases being studied are only HIV-1 infection, and the icd-10 codes associated with it are listed.",
    "The sample is a phase 2 clinical trial for the treatment of type 2 diabetes. The trial involves the use of multiple drugs, including exenatide once weekly and exenatide once monthly suspension. The eligibility criteria for participants include being at least 18 years old, having a diagnosis of type 2 diabetes mellitus, and having a HbA1c level between 7.1% and 11.0%. Participants must have been treated with diet and exercise alone or with a stable regimen of metformin, pioglitazone, or a combination of both for at least 2 months prior to the study start. Exclusion criteria include having a history of medullary thyroid carcinoma or multiple endocrine neoplasia, active cardiovascular disease within 3 months of study start, and underlying hepatic or renal disease. Participants must not have received any investigational drug within 30 days prior to study start and must not be treated with certain excluded medications, including any exposure to exenatide, liraglutide, or any GLP-1 receptor agonist.",
    "The sample is a phase 2 clinical trial for patients with metastatic colorectal cancer. The trial involves the use of drugs such as cetuximab, irinotecan, oxaliplatin, and uft. The eligibility criteria for the trial include having histologically confirmed adenocarcinoma of the colon or rectum, not having a mutation of K-ras, having inoperable metastatic or locoregional disease, and not having received previous chemotherapy for established metastatic disease. Other criteria include having measurable or evaluable disease, meeting certain bone marrow, hepatobiliary, and renal function requirements, having an ECOG performance status of 0-1, and being considered fit and able to undergo all possible treatments. Exclusion criteria include having a K-ras mutation, having concurrent uncontrolled medical illness or other previous or current malignant disease likely to interfere with protocol treatments or comparisons, and having partial or complete bowel obstruction.",
    "The sample is a phase 2 clinical trial for newly diagnosed patients with Acute Lymphoblastic Leukemia. The trial includes patients with precursor-B ALL, precursor-T ALL, and Philadelphia chromosome positive ALL. The trial involves a combination of drugs including cyclophosphamide, cytarabine, dexamethasone, doxorubicin hydrochloride, imatinib mesylate, methotrexate, methylprednisolone, pegaspargase, and vincristine sulfate. The eligibility criteria include being between 18 to 60 years of age, having an Eastern Cooperative Oncology Group (ECOG) performance status < 2, and having adequate renal and hepatic function. Patients must also be willing to use adequate contraception to avoid pregnancy for the duration of study participation. The exclusion criteria include having mature B (Burkitt's) ALL, having an active malignancy other than ALL within the past 5 years, having severe pulmonary, renal, or hepatic disease not related to ALL, and having cardiac dysfunction. Patients who have had chemotherapy or radiotherapy for ALL prior to entering the study will also be excluded.",
    "The sample is a phase 2 clinical trial for patients with mantle cell lymphoma. The trial is testing the effectiveness of a combination of drugs including cyclophosphamide, doxorubicin, vincristine, prednisone, dexamethasone, and il-2. The eligibility criteria for the trial include having histologically confirmed mantle cell lymphoma, being at stage II, III, or IV of the disease, and not having symptomatic brain metastasis. Patients must also meet certain age, performance status, and hematopoietic, hepatic, renal, and immunologic criteria. They must not be pregnant or nursing, and must use effective contraception if they are fertile. Patients must not have received other concurrent immunotherapy, chemotherapy, radiotherapy, or immunosuppressive therapy.",
    "The sample is a phase 2 clinical trial for Parkinson's disease. The eligibility criteria include being an outpatient, being at least 35 years old, having a diagnosis of Parkinson's syndrome with at least two of the three key symptoms, having a disease duration of less than 3 years, having a Modified Hoehn and Yahr stage of 2.5 or less, being optimized on monotherapy by levodopa or a dopamine agonist, being generally healthy and ambulatory, and giving informed written consent. Exclusion criteria include having indications of forms of parkinsonism other than PD, severe resting tremor, treatment with certain medications, having dementia or uncontrolled depression, being a female of childbearing potential, and having any clinically significant or unstable medical disorder that could interfere with participation in the trial.",
    "The sample is a phase 2 clinical trial for patients with persistent or recurrent endometrial adenocarcinoma who are refractory to curative or standard therapy. The trial is testing the effectiveness of the drug pemetrexed disodium. The eligibility criteria include having received one prior chemotherapy regimen for endometrial cancer, having measurable disease, and meeting certain hematopoietic, hepatic, renal, and other health requirements. Patients must also have recovered from prior treatments and not be eligible for a higher priority GOG protocol. The sample includes detailed patient and disease characteristics, as well as prior concurrent therapy information.",
    "The sample is a phase 2 clinical trial for type 2 diabetes. The trial involves the use of drugs such as rivoglitazone hcl, pioglitazone hcl, and placebo. The eligibility criteria for the trial include having type 2 diabetes with HbA1c levels between 6.5% and 10.0%, and FPG levels between 126 mg/dL and 270 mg/dL. However, individuals with a history of type 1 diabetes, ketoacidosis, current insulin therapy, C-peptide levels below 0.5ng/mL, impaired hepatic function, NYHA Class II-IV cardiac status, hospitalization for CHF, or EF<40%, and uncontrolled hypertension are excluded from the trial. The icd-10 codes for the disease are also provided.",
    "The sample is a record of a clinical trial in phase 2, focused on essential hypertension. The trial includes a list of ICD-10 codes for the disease and a list of drugs being tested, including lcz696, amlodipine, and hydrochlorothiazide (hctz). The eligibility criteria for the trial are also listed, including requirements for patients who have previously completed a related protocol and are able to comply with the study requirements. The exclusion criteria are also listed, including patients who did not complete the previous protocol or who are deemed unable to comply with the current protocol.",
    "The sample is a phase 2 clinical trial for mild cognitive impairment and Alzheimer's disease. The trial involves the use of regular insulin and a placebo. The eligibility criteria include being 55 years or older, having good physical health, and having memory impairment with a diagnosis of MCI or AD. Participants on stable doses of Memantine or cholinesterase inhibitors are also eligible. Exclusion criteria include chronic sinus problems/allergies with chronic use of nasal decongestants or antihistamines, significant neurologic disease that might affect cognition (other than AD), significant medical illness or organ failure, preexisting diabetes or current or previous use of hypoglycemic agents or insulin, clinically significant elevations in liver function tests, cholesterol, or triglycerides, major psychiatric disorders, and chronic use of certain types of medications.",
    "The sample is a phase 2 clinical trial that involves patients with chronic kidney disease, hypertension, and hyperkalemia. The trial is testing the effectiveness of the drugs patiromer, losartan, and spironolactone. The eligibility criteria for the trial include being between the ages of 30 and 80, having type 2 diabetes mellitus, and having an estimated glomerular filtration rate (eGFR) of 15-<60 mL/min/1.73m2. Participants must also have a urine albumin/creatinine ratio (ACR) of at least 30 mg/g and be receiving an ACEI and/or ARB for at least 28 days prior to screening. Exclusion criteria include having type 1 diabetes mellitus, a confirmed SBP > 180 mmHg or DBP > 110 mmHg, and a history of alcoholism or drug/chemical abuse within 1 year.",
    "The sample is a record of a clinical trial in phase 2, focused on the disease of multiple sclerosis. The icd-10 codes associated with the disease are \"G35\" and \"C81.18\". The trial involves the use of a drug called \"ono-4641\" and a placebo. The eligibility criteria for the trial include being an adult between the ages of 18-55 with a definite diagnosis of relapsing-remitting multiple sclerosis. Exclusion criteria include having a different type of multiple sclerosis, a history of malignancy, clinically significant chronic disease of the immune system, inability to undergo Gd-enhanced MRI scans, and a diagnosis of diabetes mellitus (type I or type II).",
    "The sample is a phase 2 clinical trial for the treatment of idiopathic pulmonary fibrosis. The trial involves the use of two drugs, qax576 and placebo. The eligibility criteria for the trial include a confirmed diagnosis of IPF based on clinical definition and diagnostic HRCT or surgical lung biopsy, as well as a 6-minute walk test distance of at least 50 meters at screening. Exclusion criteria include smoking within the past 3 months and lung residual volume greater than 120% predicted at screening.",
    "The sample is a phase 2 clinical trial for hypertension. The trial includes patients who have a stable systolic blood pressure between 140 mmHg and 190 mmHg and are on three or more antihypertensive medications, including a diuretic. The drug being tested is clonidine. The eligibility criteria include a diagnosis of hypertension and the ability to understand the risks. The exclusion criteria include allergies to clonidine, being pregnant or breastfeeding, and having certain medical conditions such as unstable ischemic heart disease or renal disease. Patients who have participated in an investigational drug study within 30 days of enrollment or have taken certain prohibited medications are also excluded.",
    "The sample is a record of a clinical trial in phase 2, focused on the disease of prostatic hyperplasia. The trial includes a list of icd-10 codes for the disease, as well as a list of drugs being tested, including tamsulosin and uk-369,003. The eligibility criteria for the trial include male subjects aged 40 years and above with documented LUTS and an IPSS score of 13 or higher, as well as a clinical diagnosis of BPH. The trial also has exclusion criteria, such as urinary tract infection and primary neurological conditions affecting bladder function.",
    "The sample is a phase 2 clinical trial for patients with neurofibromatosis type 1 and extensive plexiform and/or paraspinal neurofibromas that are producing pain, causing progressive neurologic deficit, or significant neurologic consequences with continuous tumor growth. The trial includes patients who meet certain diagnostic criteria for NF1 and have measurable disease. Patients with symptomatic neurofibroma, in whom surgery is not feasible, who refuse surgery or are not good surgical candidates due to high risk of damage to vital structures or spinal cord injury are also eligible. The trial involves the use of the drug cediranib maleate. The eligibility criteria include various medical conditions and laboratory values, as well as exclusion criteria such as concurrent medication that may markedly affect renal function, concurrent CYP interactive medications, and concurrent use of drugs or biologics with proarrhythmic potential.",
    "The sample is a phase 2 trial that involves patients with two specific diseases, namely pulmonary hypertension and left ventricular dysfunction. The trial includes two drugs, riociguat and placebo, and has eligibility criteria for patients to be included or excluded from the trial. The inclusion criteria require patients to have symptomatic pulmonary hypertension due to left ventricular systolic dysfunction despite standard heart failure therapy, while the exclusion criteria exclude patients with types of pulmonary hypertension other than group 2.1 of Dana Point Classification. The diseases are represented by their names and ICD-10 codes, while the drugs are represented by their names.",
    "The sample is a phase 2 clinical trial for patients with either esophageal or gastric cancer. The trial is testing the effectiveness of the drugs docetaxel and oxaliplatin. The eligibility criteria include having histologically confirmed gastric or gastroesophageal junction adenocarcinoma that is locally advanced unresectable or metastatic, measurable disease, and a SWOG performance status of 0-1. Patients must also meet certain hematopoietic, hepatic, renal, cardiovascular, and other criteria. Prior concurrent therapy is not allowed, and patients must not have any serious non-healing wounds, unresolved bacterial infections, or other active malignancies within the past 3 years.",
    "The sample is a phase 2 clinical trial for the treatment of hypercholesterolemia. The trial involves the use of the drugs alirocumab and placebo. The eligibility criteria for participants include meeting the World Health Organization criteria for heFH, being on a stable statin dose for at least 6 weeks before screening, having serum LDL-C levels \u2265 100 mg/dL at screening, and being willing to follow a specific diet plan. Exclusion criteria include having homozygous FH, using certain medications or nutraceuticals that may alter lipid levels, having disorders known to influence lipid levels, and having fasting serum TG >350 mg/dL at screening. The trial also requires a negative pregnancy test for women of childbearing potential.",
    "The sample is a phase 2 clinical trial for the treatment of schizophrenia. The trial includes patients with a diagnosis of schizophrenia as defined in the DSM-IV-TR and confirmed by the SCID. Patients must be non-pregnant females who agree to use acceptable birth control, considered moderately ill in the opinion of the investigator, and willing to participate in a minimum of 3 weeks of inpatient hospitalization. Patients must have a 1-year history of schizophrenia prior to entering the study and must have experienced an exacerbation of illness within the 2 weeks prior to entering the study. The trial includes the drugs risperidone, placebo, and ly2140023. The eligibility criteria include exclusion criteria such as participation in any clinical trial with any pharmacological treatment intervention for which they received a study-related medication in the 6 months prior to visit 1, treatment with clozapine at doses greater than 200 mg daily within 12 months prior to entering the study, or patients who are currently suicidal.",
    "The sample is a phase 2 clinical trial for arthritis, specifically rheumatoid arthritis. The trial involves the use of drugs such as cp-195,543, celecoxib, and methotrexate. The eligibility criteria for the trial include a diagnosis of RA based on the American college of Rheumatology 1987 revised criteria, active disease at screening, and a stable dose of methotrexate between 10-25 mg/week oral or parenteral. Exclusion criteria include a diagnosis of any other inflammatory or secondary, noninflammatory arthritis that would interfere with disease activity assessments, and a history of hypersensitivity or allergic reactions to certain medications.",
    "The sample is a phase 2 clinical trial for acute myeloid leukemia. The trial includes patients who have been diagnosed with AML and have had prior exposure to leukemogenic chemotherapy or radiotherapy, or have been diagnosed with MDS for at least 3 months prior to study entry. The trial also includes patients who are 18 years or older, have an ECOG performance status of 2 or less, and have not received prior induction chemotherapy for AML. The trial requires participants to use effective contraception and have a negative pregnancy test if they are fertile and sexually active. Participants must also have adequate renal and hepatic function, and be able to participate fully in all aspects of the trial. The trial excludes patients with FAB M3 AML, clinically active CNS leukemia, known HIV positivity, active hepatitis B or C, or other active liver disease. Patients who have had major surgery or radiation therapy within 4 weeks prior to study entry, or prior cytotoxic chemotherapy within 4 weeks prior to study entry (unless they have rapidly rising blast count) are also excluded. Additionally, patients with persistent chronic non-hematologic toxicity from prior chemotherapy, serious concomitant illness, women who are pregnant or lactating, or those with a history of clinically significant allergic reactions attributed to compounds similar to amonafide or cytarabine are excluded. Finally, patients who have been previously enrolled in the trial or have any other known condition or behavior that would make them a poor candidate for the trial are also excluded.",
    "The sample is a phase 2 clinical trial for the treatment of major depressive disorder. The trial includes patients who meet the criteria for MDD without psychotic features as defined by DSMIV, based on clinical assessment and confirmed by Structural Clinical Interview for DSM-IV Axis I Disorder-Clinical Version (SCID-I) plus the MDD Specifiers included in the Research Version of SCID-I. Patients must have a HAM-D (17-item) score of \u2265 22 at Screening (Visit 1) and > 20 at Baseline (Visit 2), and a minimum CGI-S score of \u2265 4 at Screening (Visit 1) and at Baseline (Visit 2) to be included in the trial. Patients who have failed to respond to adequate dose and duration (12 weeks) of treatment with clomipramine and one SSRI, or with two or more SSRIs, or have > 20% HAM-D (17-item) improvement (decrease) from Screening (Visit 1) at Baseline (Visit 2), or have uncorrected hypothyroidism or hyperthyroidism are excluded from the trial. The trial involves the use of various drugs, including sertraline/[s,s]-reboxetine, sertraline, and [s,s]-reboxetine monotherapy, as well as a placebo. The trial is focused on the treatment of depressive disorder, major, and the icd-10 codes associated with the disease include \"['F33.0', 'F33.1', 'F33.9', 'F32.0', 'F32.1', 'F32.9', 'F33.40']\".",
    "The sample is a phase 2 clinical trial for patients with head and neck cancer. The trial includes patients who are incurable due to unresectable local or distant disease and are not potentially curable by radiation therapy. The patients must have a histologic diagnosis of certain malignancies originating from salivary tissue and an ECOG performance status of less than 3. They must also have at least uni-dimensionally measurable disease and adequate organ function. The trial involves the use of two drugs, capecitabine and oxaliplatin. The eligibility criteria include various medical tests and measurements, as well as the ability to tolerate and swallow tablets or undergo GI tube insertion. The exclusion criteria include previous cytotoxic chemotherapy for metastatic salivary gland cancer and any form of anti-neoplastic therapy other than XELOX while participating in the study. Pregnant and breastfeeding women are not eligible, and patients with significant active illness are also excluded.",
    "The sample is a phase 2 clinical trial for the treatment of hepatitis C and hepatitis. The trial involves the use of three drugs: merimepodib, peg-interferon-alpha 2a (pegasys\u00ae), and ribavirin (copegus\u00ae). The eligibility criteria for the trial include having been diagnosed with hepatitis C, having been treated with pegylated interferon and ribavirin for at least 12 weeks but not having received more than one course of this combination therapy, being a \"non-responder\" to this treatment, and not having used illegal drugs or had significant alcohol use within the last year. Women who can have children must be willing to use two effective methods of birth control during the study and for 6 months after the last dose of the medication, and men must have a female partner who is not pregnant and both must be willing to use birth control during the study and for 6 months after the last dose of the medication.",
    "The sample is a phase 2 clinical trial for non-small cell lung cancer. The trial is testing the effectiveness of the drugs carboplatin and paclitaxel in treating the disease. The eligibility criteria for patients include having confirmed NSCLC, being in stage IIIA or selected stage IIIB disease, having measurable disease, and being suitable for radiotherapy. Patients must also meet certain patient characteristics, such as having an ECOG performance status of 0-1 and no history of allergic reactions to certain compounds. Prior concurrent therapy is not allowed, including chemotherapy or radiotherapy for NSCLC, taxanes or platinum drugs, and other investigational agents or anticancer therapy.",
    "The sample is a phase 2 clinical trial for Alzheimer's disease. The trial includes subjects between the ages of 55 and 90 who meet the NINCDS/ADRDA criteria for probable AD and have a Mini-Mental Status Examination (MMSE) score of 10 to 24. The trial involves the use of drugs such as abt-384, donepezil, and placebo. The eligibility criteria include having a reliable caregiver, being in generally good health, and having sufficient language and cognitive skills to complete the procedures. Exclusion criteria include a history of drug or alcohol abuse, uncontrolled medical or psychiatric illness, and unsuitability for receiving ABT-384 or donepezil.",
    "The sample is a phase 2 clinical trial for the treatment of diabetic macular edema. The trial is testing the effectiveness of the drug danazol on patients with Type 1 or 2 diabetes mellitus. The eligibility criteria include having a best corrected visual acuity score of at least 20/320 and no worse than 20/32, having a definite retinal thickening due to diabetic macular edema, and having a HbA1c level less than or equal to 10%. Patients must also meet several other inclusion criteria, such as having stable diabetic and metabolic control and not having any major changes in diabetic or lipid reducing medications for 3 months prior to the start of the study. The trial has several exclusion criteria, such as having a history of systemic androgens, progesterone or corticosteroids, or having significant hepatic or renal disease. The study eye must also meet certain inclusion and exclusion criteria, such as not having substantial cataract that is likely to interfere with ocular measurements or evaluations during the study.",
    "The sample is a phase 2 clinical trial for the treatment of chronic hepatitis C. The trial includes patients between the ages of 18 and 65 who have never received treatment for chronic hepatitis C. The patients must have a liver biopsy within the last 3 years without evidence of cirrhosis and must have HCV genotype 1 with HCV RNA levels greater than 10,000 IU/mL at screening. The trial involves the use of four drugs: sovaprevir, ach-3102, rbv, and placebo. The eligibility criteria include various medical and lifestyle factors, such as BMI, pregnancy, and drug use. The trial also requires patients to be willing to use effective contraception during the dosing period and for six months after the last dose of ribavirin. The trial has exclusion criteria, such as a history of severe or uncontrolled psychiatric disease, malignancy, major organ transplantation, and ongoing alcohol abuse.",
    "The sample is a phase 2 clinical trial for ovarian cancer. The trial includes patients with stage III or IV epithelial ovarian carcinoma who have not received previous chemotherapy or radiation therapy. Patients must have undergone cytoreductive surgery with specific results, including no residual tumor nodule larger than 3cm and no residual tumor involvement of the bowel. Patients must also have measurable or evaluable disease, an ECOG performance status of 0 or 1, and meet certain blood count and liver function criteria. Women of childbearing potential must have a negative pregnancy test and agree to use contraception during the study and for at least 3 months after the last administration of study drug. The trial excludes patients with certain medical conditions, including active cardiac disease, CNS metastases, uncontrolled hypertension, and bleeding events within 4 weeks of starting treatment. Patients must be able to understand the nature of the study and give written informed consent. The trial involves the use of sorafenib, paclitaxel, and carboplatin.",
    "The sample is a record from a clinical trial table that includes information about the phase of the trial, the disease being studied (in this case, atrial flutter), the corresponding ICD-10 codes, the drug being tested (vernakalant injection 20 mg/ml), and the eligibility criteria for participants. The phase of the trial is listed as phase 2/phase 3, indicating that it is in the later stages of testing. The inclusion criteria specify that participants must be 18 years or older, have an atrial arrhythmia with dysrhythmic symptoms lasting between 3 hours and 45 days, and have adequate anticoagulant therapy. The exclusion criteria include having a QRS > 0.14 s or uncorrected QT > 0.440 seconds on a 12-lead ECG, participating in another drug study or having received an investigational drug within 30 days prior to enrollment, having serious diseases/illnesses that could interfere with the study or compromise patient safety, and having received certain IV antiarrhythmic drugs within 24 hours prior to dosing.",
    "The sample is a clinical trial with a phase 2 designation. The trial is focused on sickle cell disease and pulmonary hypertension, with a list of corresponding ICD-10 codes. The trial involves the use of sildenafil and a placebo. The eligibility criteria for the trial include age, diagnosis of sickle cell disease, and provision of informed consent. The trial also has exclusion criteria, such as current pregnancy or lactation, certain medical conditions, and the use of certain medications. The trial involves a 16-week, double-blind phase and requires completion of scheduled assessments.",
    "The sample is a phase 2 clinical trial for patients with recurrent uterine sarcoma or uterine carcinosarcoma. The trial involves the drug temsirolimus and has specific eligibility criteria, including confirmation of the disease, measurable disease, and only one prior systemic treatment. Patients must also meet certain laboratory values and have an ECOG performance status of 0-1. Exclusion criteria include prior therapy with temsirolimus or another mTOR inhibitor, untreated central nervous system metastases, and pregnancy or lactation. The trial requires availability of tissue samples or blocks for tumor studies and willingness to donate blood for correlative marker studies.",
    "The sample is a phase 2 clinical trial for patients with gastrointestinal cancer. The trial is testing the effectiveness of a combination of two drugs, capecitabine and oxaliplatin. The eligibility criteria for the trial include having histologically or cytologically confirmed adenocarcinoma of the small bowel or ampulla of Vater that is either unresectable or metastatic, having measurable disease, and meeting certain health requirements such as having adequate bone marrow and renal function. Patients must also not have had prior exposure to platinum therapy or received chemotherapy within 4 weeks prior to entering the study. The trial has exclusion criteria such as having known brain metastases or uncontrolled intercurrent illness.",
    "The sample is a record from a clinical trial table that includes information about the trial's phase, diseases being studied, icd-10 codes associated with those diseases, drugs being used, and eligibility criteria for participants. In this particular sample, the trial is in phase 2/phase 3 and is focused on lung cancer. The icd-10 codes associated with the disease are listed, as well as the drugs being used in the trial. The eligibility criteria for participants are also listed, including disease characteristics, patient characteristics, and prior concurrent therapy. The criteria specify that patients must have histologically or cytologically confirmed stage I-III non-small cell lung cancer that is inoperable or that the patient refuses surgery, and that the disease can be encompassed within the radical radiotherapy treatment volume. Additionally, patients must meet certain performance status, life expectancy, hematopoietic, hepatic, renal, cardiovascular, and pulmonary criteria, and must not have certain prior concurrent therapies or medical conditions.",
    "The sample is a record from a clinical trial table. It is a phase 2 trial for the treatment of radiotherapy-induced nausea and vomiting (RINV). The table includes information on the diseases being treated, the ICD-10 codes associated with those diseases, the drugs being used, and the eligibility criteria for patients to participate in the trial. The eligibility criteria include conditions such as having a histologically verified malignant tumor, receiving radiotherapy alone, and having a performance status of Eastern Cooperative Oncology Group (ECOG) of 0 to 2. The exclusion criteria include conditions such as having nausea and/or emesis, having primary or metastasized brain tumors, and taking drugs that affect the evaluation of nausea or emesis.",
    "The sample is a phase 2 clinical trial for the treatment of induced panic attack. The trial includes subjects who meet DSM-IV criteria for panic disorder, with or without agoraphobia, and have had at least one panic attack per week in each of the four weeks prior to the start of treatment. The trial also includes male or female subjects who are English-speaking between 18 and 55 years of age, and who are medically healthy without a clinically significant unstable medical condition such as asthma, coronary artery disease, renal insufficiency, etc. The trial excludes subjects who have met DSM-IV criteria for substance abuse or dependence within six months of study entry, subjects with a baseline Acute Panic Inventory score of 41 or higher on the test day, and subjects who are taking benzodiazepines, SSRIs, or medication that is effective for the prevention or treatment of the patient's panic disorder. The trial also excludes subjects who are clinically depressed, have received an investigational drug within 30 days prior to test day, have epilepsy or other convulsive disorders, have a history of allergy or intolerance to benzodiazepines or related drugs, test positive for alcohol or have a positive urine drug screen for illicit or disallowed drugs, are breastfeeding or have a positive pregnancy test, or have any other disease or condition that in the investigator's opinion, would present undue risk to the subject or may confound the interpretation of study results.",
    "The sample is a phase 2 clinical trial for patients with bladder cancer, transitional cell cancer of the renal pelvis and ureter, and urethral cancer. The trial is testing the effectiveness of the drug sunitinib malate. Eligible patients must have confirmed transitional cell carcinoma of the urinary tract that is unresectable, locally recurrent, locally advanced, or metastatic. They must also be ineligible for cisplatin-based chemotherapy due to creatinine clearance levels. Patients must have measurable or nonmeasurable disease according to RECIST criteria and meet certain patient characteristics, such as having an ECOG performance status of 0-1 and a life expectancy of more than 12 weeks. They must also not have certain medical conditions or laboratory abnormalities that would make them inappropriate for the study. Prior concurrent therapy is also taken into consideration.",
    "This is a sample from a table that contains information about clinical trials. The sample describes a phase 2 trial for the treatment of postherpetic neuralgia. The trial includes eligibility criteria for participants, such as being 18 years or older, having a documented medical diagnosis of PHN with pain present for at least 3 months from the healing of a herpes zoster rash, and having a baseline 24-hour average pain intensity score of at least 4.0 based on an 11-point PI-NRS. The trial also includes exclusion criteria, such as having other chronic pain conditions not associated with PHN, impaired renal function, or a history of clinically significant drug or alcohol abuse. The sample also includes information about the drugs being tested, including the names and dosages of the drugs, as well as the diseases being treated and their corresponding ICD-10 codes.",
    "The sample is a phase 2 clinical trial for infertility and ovulation induction. The trial involves the use of drugs such as r-hlh + r-hfsh, r-hfsh, recombinant human choriogonadotropin (r-hcg), and gnrh antagonist. The eligibility criteria for the trial include premenopausal women aged 35 to 42 years who want to become pregnant, have FSH baseline plasma levels less than or equal to 10 IU/L, have regular spontaneous menstrual cycles lasting 25-35 days, and have infertility that is susceptible to treatment with IVF/ICSI. The trial also has exclusion criteria, such as subjects with known positivity for HIV or Hepatitis-B/Hepatitis-C virus, and those with drug dependence or history of drug or alcohol abuse in the previous 5 years.",
    "The sample is a phase 2 clinical trial for non-small cell lung cancer. The trial involves two drugs, erlotinib and docetaxel, and the eligibility criteria include having histologically proven NSCLC, wild type or unknown EGFR mutational status, and stage IV disease with cytologic or histologic documentation. Patients must also have at least one measurable target lesion, normal hepatic and renal function, and a life expectancy of more than 12 weeks. Exclusion criteria include previous treatment with an anti-EGFR agent or docetaxel, uncontrolled arterial hypertension, and pregnancy or breastfeeding.",
    "The sample is a phase 2 clinical trial for patients with advanced or metastatic non-small cell lung cancer that cannot be cured with surgery, radiation, or combination thereof. The trial is testing the effectiveness of the drug sunitinib. The eligibility criteria include having no more than 2 prior chemotherapy treatments, evidence of measurable disease by radiographic technique, being 18 years or older, having an ECOG performance status of 0 or 1, and adequate organ function. The exclusion criteria include having had major surgery or radiation therapy within 4 weeks, severe hemorrhage within 4 weeks, previous treatment with anti-angiogenesis agents, diagnosis of a second malignancy within the last 5 years, history of or known brain metastases, spinal cord compression, or carcinomatous meningitis, known HIV, serious acute or chronic illness, current treatment on another clinical trial, and being pregnant or breastfeeding.",
    "The sample is a phase 2 clinical trial for breast cancer patients who are either treatment-na\u00efve with newly diagnosed her2neu non-overexpressing metastatic breast cancer or HER2/neu-negative patients with metastasis diagnosed 6 or more months after completing primary systemic treatment. The trial involves the use of drugs such as avastin, gemcitabine, and abraxane. The eligibility criteria include being 18 years or older, having measurable or evaluable disease, having an Eastern Cooperative Oncology Group (ECOG) score of 0-1, and having laboratory parameters within certain ranges. Exclusion criteria include previous treatment with gemcitabine, history of gastrointestinal bleeding in the previous 3 months, and presence of central nervous system or brain metastases. Participants with serious medical or psychiatric illness that would render chemotherapy unsafe are also ineligible.",
    "The sample is a phase 2 trial for chronic obstructive pulmonary disease (COPD) and involves the use of two drugs, aclidinium/formoterol 400/12\u03bcg and formoterol. The trial has eligibility criteria for inclusion, such as a history of at least 10 pack-years of cigarette smoking and a diagnosis of stable moderate to severe COPD. Exclusion criteria include recent hospitalization for an acute COPD exacerbation and clinically significant respiratory or cardiovascular conditions. The sample also includes a list of disease names and their corresponding ICD-10 codes.",
    "The sample is a phase 2 clinical trial for chronic hepatitis C. The trial includes patients with histologically confirmed chronic hepatitis C, HCV RNA in serum >600 IU/ml, elevated ALT, HCV genotypes 1, 2, 3 or 4, failure to respond to a prior treatment with a pegylated interferon alpha + ribavirin, and HOMA score > 2.00. The trial also has inclusion and exclusion criteria, including documentation of adequate contraception for sexually active female patients of childbearing potential, and acceptable methods of contraception for sexually active male patients. The trial involves the use of pioglitazone, interferon alfa-2a, and ribavirin. The sample includes a list of diseases and their corresponding icd-10 codes, as well as eligibility criteria for the trial.",
    "The sample is a record of a clinical trial with a phase 2 designation. The trial is focused on the treatment of bladder neoplasms, which are identified by a list of ICD-10 codes. The drug being tested is apaziquone. The eligibility criteria for the trial are listed, including requirements for patients with high-risk superficial bladder cancer, normal bimanual examination, absence of upper urinary tract tumor, and a performance status of 0-2. Exclusion criteria are also listed, including patients with muscle-invasive disease, prior intravesical treatment within the last 3 months, and existing urinary tract infection or recurrent severe bacterial cystitis. Women who are pregnant or lactating are also excluded.",
    "The sample is a phase 2 clinical trial for non-alcoholic steatohepatitis. The trial involves testing the effectiveness of two drugs, silymarin 700 mg and silymarin 420 mg, on patients who meet certain eligibility criteria. These criteria include being at least 18 years old, having a liver biopsy demonstrating features consistent with NASH without cirrhosis, and agreeing to adhere to alcohol consumption guidelines. The trial also has exclusion criteria, such as having a BMI over 45 kg/m2, evidence of poorly-controlled diabetes, or a history of immunologically mediated disease. Patients who meet the eligibility criteria and do not meet the exclusion criteria will be enrolled in the trial.",
    "The sample is a phase 2 clinical trial for patients with metastatic or recurrent colorectal cancer that cannot be surgically removed. The trial is testing the effectiveness of the drug capecitabine. The eligibility criteria include having measurable disease, no known brain metastases, and meeting certain age, performance status, and hematopoietic, hepatic, renal, and other health requirements. Patients must not be pregnant or nursing, must use effective contraception, and must not have HIV or a seizure disorder. Patients must not have had prior chemotherapy for advanced cancer, but prior adjuvant chemotherapy is allowed if recurrence occurred more than 1 year after the last treatment. Other prior concurrent therapies are not specified. Patients must not have taken sorivudine or brivudine within the past 4 weeks and must not take these drugs during the trial.",
    "The sample is a record of a clinical trial with a phase 2 designation. The trial is focused on treating locally advanced or metastatic non-small cell lung cancer (NSCLC) of nonsquamous histology that is not amenable to curative therapy. The trial involves the use of drugs such as pemetrexed and erlotinib. The eligibility criteria for the trial include a histological or cytological diagnosis of NSCLC, failure of previous treatment with one prior platinum-based chemotherapy regimen, good performance status, and adequate bone marrow reserve, renal and hepatic functions. The exclusion criteria include serious concomitant systemic disease, inability to take oral medication, inability or unwillingness to take vitamin supplementation and corticosteroids, pregnancy/breastfeeding, and treatment with certain medicines that prevent blood from clotting.",
    "This sample is a phase 2 clinical trial for the treatment of head and neck cancer using the drug capecitabine. The eligibility criteria include having histologically confirmed squamous cell carcinoma of the head and neck, having undergone curative surgical resection, radiotherapy, and/or chemotherapy at least 1 month but no more than 4 years ago, and having no evidence of active disease. Patients must also meet certain performance status, life expectancy, hematopoietic, hepatic, renal, cardiovascular, gastrointestinal, and other criteria. Prior concurrent therapy is allowed under certain conditions. The sample provides a detailed list of the eligibility criteria for patients to participate in the clinical trial.",
    "This is a sample entry from a clinical trial table. The trial is in phase 2 and is focused on treating recurrent small cell lung cancer. The trial is looking at the effectiveness of the drug imatinib mesylate. The eligibility criteria for participants include having only received one prior treatment regimen, having a certain level of performance status, and meeting certain medical requirements such as having no uncontrolled CNS metastasis and having a platelet count of at least 100,000/mm^3. The sample also includes a list of icd-10 codes associated with the disease.",
    "The sample is a phase 2 clinical trial for psoriasis vulgaris. The table includes information on the diseases, icd-10 codes, drugs, and eligibility criteria for the trial. The inclusion criteria require participants to be 18 years or older, able to communicate with the investigator, and have a negative pregnancy test for females of childbearing potential. The exclusion criteria include recent treatment with certain therapies, skin conditions that may confound the evaluation of psoriasis vulgaris, and known or suspected disorders of calcium metabolism or severe renal or hepatic disorders. Participants cannot be pregnant, wishing to become pregnant during the study, or breastfeeding.",
    "The sample is a phase 2 clinical trial for acute coronary syndrome. The trial includes patients who have experienced symptoms suggestive of ACS lasting at least 10 minutes at rest within 7 days of randomization and have a diagnosis of ST-elevation myocardial infarction or non-ST elevation myocardial infarction/unstable angina with at least 1 protocol-defined high risk feature. The trial excludes patients with active bleeding or high risk of bleeding or intracranial hemorrhage, those who require continued anticoagulant therapy, those with significantly impaired renal or hepatic function, and those with severe concomitant diseases such as cardiogenic shock or refractory ventricular arrhythmias. The trial involves the use of rivaroxaban/placebo and rivaroxaban as drugs.",
    "The sample is a phase 2 clinical trial for non-small cell lung cancer. The trial is testing the effectiveness of a drug called bavituximab in combination with paclitaxel and carboplatin. The trial is open to adults over the age of 18 with a life expectancy of at least 3 months who have histologically or cytologically confirmed non-small cell lung cancer at stage IIIB (with pleural effusion), stage IV, or recurrence. Participants must have measurable disease on cross-sectional imaging and meet certain hematologic, renal, and hepatic function criteria. There are also exclusion criteria, such as a history of bleeding diathesis or coagulopathy, prior chemotherapy or radiotherapy to an area of measurable disease, and uncontrolled intercurrent disease. The trial is not open to individuals with symptomatic or clinically active CNS disease or metastatic lesions.",
    "The sample is a phase 2 clinical trial for patients with various types of bladder and urethral cancers that have progressed to a regional or metastatic stage. The trial involves the use of the drug sorafenib tosylate. Patients must have measurable disease and have only received one prior systemic chemotherapy for metastatic disease. They must also meet various eligibility criteria, including having an ECOG performance status of 0 or 1, no history of severe cardiovascular disease, and meeting certain laboratory values. Patients with a history of prior malignancy are eligible if they have been disease-free for at least 5 years. Women of childbearing potential must use contraception and not be pregnant or breastfeeding.",
    "The sample is a phase 2 trial for patients with adult giant cell glioblastoma, adult glioblastoma, adult gliosarcoma, or recurrent adult brain tumor. The trial involves the use of the drugs vorinostat and bortezomib. The eligibility criteria include having evidence of tumor progression by MRI or CT scan, bidimensionally measurable or evaluable disease, and an ECOG performance status of 0-2. Patients must also meet various laboratory and medical criteria, not have any uncontrolled infections or known hypersensitivity to the drugs, and not have any other active malignancy within the past 3 years except nonmelanoma skin cancer or carcinoma in situ of the cervix. The trial excludes patients with certain medical conditions or who are taking certain medications.",
    "The sample is a phase 2 clinical trial for Alzheimer's disease and cognitive impairment. The trial involves testing the effectiveness of three drugs - sodium oligo-mannurarate 600mg, sodium oligo-mannurarate 900mg, and placebo. The eligibility criteria for participants include being primarily educated, meeting the criteria for probable Alzheimer's disease according to the National Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer's Disease and Related Disorders Association, having a minimum mean-square error score between 10 and 24, and having a Hachinski ischemia scale score of less than 4. Participants must also have a stable accompanying person who can help them throughout the trial. Exclusion criteria include having been in other clinical trials within 30 days before the start of this trial, being pregnant or lactating, having dementia caused by other diseases, having previous nervous system diseases, having abnormal laboratory results, having uncontrolled hypertension, having unstable or serious diseases of the heart, lung, liver, kidney, or blood, having visual or auditory handicap, having significant focal lesions revealed by electronic computer X-ray tomography or magnetic resonance imaging in the year before enrollment, having alcohol or drug abuse, being psychotic, being in drug therapy for Alzheimer's disease that cannot be stopped, being in treatment of heparin, Polysaccharide sulfate, mannose ester 3 weeks before the recruitment, or being considered by the investigator as unable to finish the trial for any reason. Relatives or employees of the investigators, staff of the investigate centers, contract research organization, and sponsor are also excluded from participating in the trial.",
    "The sample is a phase 2 clinical trial for Parkinson's disease. The trial is testing the effectiveness of a drug called biib014 compared to a placebo. The eligibility criteria for participants include having a diagnosis of idiopathic PD according to UK Parkinson's Disease Society Brain Bank Clinical Diagnostic Criteria, being Hoehn & Yahr Stage II to IV when OFF, and being on a stable dose of L-3,4-dihydroxyphenylalanine (L-DOPA)/carbidopa or L-DOPA/benserazide for at least 4 weeks prior to enrollment. Participants must not be receiving any other PD medications except for L-DOPA and certain allowed dopamine agonists. Some participants must demonstrate a definite end of L-DOPA dose wearing off and must be able to keep accurate patient diaries of PD activity. There are also several exclusion criteria, including a Mini Mental State Examination (MMSE) score <26, history or clinical features consistent with an atypical parkinsonian syndrome, any significant non-Parkinson's central nervous system disorder, any significant AXIS I psychiatric disease from the Diagnostic and Statistical Manual of Mental Disorders (DSM), any previous surgical intervention for Parkinson's Disease, history of certain malignancies, history of severe allergic anaphylactic reactions to any drug, clinically significant baseline electrocardiogram (ECG), orthostatic hypotension, and HbA1c >7.0%.",
    "The sample is a phase 2 clinical trial for the treatment of moderate to severe interstitial cystitis. The trial includes male and female adults who are at least 18 years old and have a mean pain intensity score above a pre-defined level. The trial excludes individuals who have had interstitial cystitis symptoms for less than 6 months, a history of recurrent urinary tract infections or genitourinary cancer, a history of hepatitis B, C or HIV, and those who have used certain drugs given into the bladder up to 1 month prior to study entry. The trial will test the effectiveness of two drugs, pf-04383119 and placebo.",
    "The sample is a record of a clinical trial that is in phase 2/phase 3 and focuses on nicotine dependence. The trial includes a list of icd-10 codes for the disease and a drug called \"extended treatment\". The eligibility criteria for the trial includes being between the ages of 14-18, smoking at least 10 cigarettes per day, and having made at least one quit attempt in the previous 6 months. The exclusion criteria includes having a current DSM-IV disorder, daily or heavy use of drugs, a positive pregnancy test, currently taking certain medications, and currently receiving treatment for substance abuse, depression, or anxiety.",
    "The sample is a record of a clinical trial with a phase 2 designation. The trial is focused on treating urothelial cancer, which includes cancer of the bladder, renal pelvis, ureter, or urethra. The trial is testing the drug azd4877 and has specific eligibility criteria for participants, including having stage IV urothelial cancer that cannot be treated with curative surgery or radiotherapy, having had a maximum of two prior chemotherapeutic regimens, and being ambulatory and capable of self-care for more than 50% of waking hours. The sample also includes exclusion criteria, such as inadequate bone marrow reserve, impaired liver or renal function, and recent treatment with investigational or standard anti-cancer agents.",
    "The sample is a phase 2 clinical trial for a drug called dlbs1033 and a placebo, conducted on healthy male individuals aged between 18-55 years with a normal physical examination and a body mass index between 18-25 kg/square metres. The trial has inclusion and exclusion criteria, which are listed in the \"criteria\" column. The diseases column lists \"healthy\" as the disease being studied, and the icdcodes column lists two ICD-10 codes, \"Z76.3\" and \"Z76.2\".",
    "The sample is a record from a clinical trial table that includes information about the trial's phase, diseases being studied, ICD-10 codes associated with those diseases, drugs being used, and eligibility criteria for participants. In this particular sample, the trial is in phase 2 and is studying malignant pleural effusion and non-small cell lung cancer. The ICD-10 codes associated with these diseases are listed. The drug being used in the trial is zoledronic acid. The eligibility criteria for participants include having histologically documented non-small cell lung cancer, pleural effusion cytologically proven to be malignant, and having 0 or 1 prior chemotherapy regimens for non-small cell lung cancer. Other criteria include performance status, estimated life expectancy, and signed informed consent. There are also exclusion criteria, such as being pregnant or lactating, having concurrent medical or psychiatric illness, or having recent dental or jaw surgery.",
    "The sample is a phase 2 clinical trial for patients with atrial fibrillation. The trial is testing the effectiveness of a drug called vernakalant (oral) compared to a placebo. The eligibility criteria for the trial include being between 18 and 85 years old, having symptomatic AF that has been sustained for greater than 72 hours and less than 6 months duration and is clinically indicated for cardioversion, having adequate anticoagulant therapy for cardioversion, and being haemodynamically stable. Exclusion criteria include having known prolonged QT syndrome, having clinically significant moderate or severe aortic valvular stenosis, having Class III or Class IV congestive heart failure, and having any other surgical or medical condition that might warrant exclusion or be contraindicated for safety reasons. The trial also requires participants to comprehend and sign a written informed consent form and to be able to communicate well with the Investigator and comply with the requirements of the entire study.",
    "The sample is a phase 2 clinical trial for patients with primary myelofibrosis or post ET/PV MF. The trial is testing the drug IPI-926. Patients must be at least 18 years old, have confirmed PMF or post ET/PV MF, and have intermediate-1, intermediate-2, or high risk disease according to the IWG prognostic scoring system. Patients with low risk disease must have symptomatic splenomegaly. Patients must also have an ECOG performance of 0-2 and a life expectancy of at least 3 months. Exclusion criteria include prior treatment with any inhibitor of the hedgehog pathway, inadequate hepatic or renal function, and significant co-morbid conditions or diseases. Women of child-bearing potential must have a negative pregnancy test and all sexually active patients must agree to use adequate methods of birth control throughout the study.",
    "The sample is a phase 2 clinical trial for the treatment of type 2 diabetes mellitus. The trial includes subjects between the ages of 30 and 64 who have been diagnosed with type 2 diabetes and are taking stable metformin. The trial also has specific eligibility criteria, including adequate renal function, no history of liver or cardiovascular disease, and a BMI between 24 and 40 kg/m^2. Female subjects must be of non-childbearing potential, and male subjects with female partners of child-bearing potential must agree to use contraception. The trial excludes subjects with certain medical histories, including liver disease, pancreatitis, and gastrointestinal disease, as well as those with certain diagnostic assessments, such as abnormal ECG readings and positive test results for hepatitis B or C, HIV, or drug/alcohol use.",
    "The sample is a phase 2 clinical trial for patients with recurrent or metastatic squamous cell carcinoma of the head and neck. The trial includes patients who have had one prior chemotherapy regimen and have completed treatment at least 4 weeks prior to study entry. Patients must not have been previously treated with irinotecan or bortezomib and must not be receiving radiation treatment. The trial also includes eligibility criteria related to disease confirmation, measurable disease, ECOG performance status, peripheral neuropathy, blood counts, liver and kidney function, and prior invasive malignancy. Women who are pregnant or breastfeeding are excluded from the trial, and all females of childbearing potential must have a negative pregnancy test prior to enrollment. Patients with known brain metastases or a history of allergic reactions to PS-341 or similar compounds are also excluded. The trial involves the use of bortezomib and irinotecan hydrochloride as treatment options.",
    "The sample is a phase 2 clinical trial that focuses on patients with type 2 diabetes and presumed non-alcoholic fatty liver disease (NAFLD). The trial involves the use of two drugs, int-747 and placebo. The eligibility criteria for the trial include specific glucose and liver enzyme levels, as well as exclusion criteria for certain medications. The sample also includes a list of disease names and corresponding ICD-10 codes.",
    "The sample is a phase 2 clinical trial for the treatment of chronic atopic dermatitis using a drug called wbi-1001. The trial is looking for patients who have been diagnosed with chronic atopic dermatitis for at least 6 months and have a minimum of 5% and a maximum of 20% BSA. Patients must also have IGA scores of 2-4 at Day 0 and must be willing to comply with the protocol and attend all visits. The trial has a list of inclusion and exclusion criteria, including no pregnancy or lactation, no other skin diseases that might interfere with clinical assessment, and no history of neurological/psychiatric disorders. Patients must also not have received any systemic immunomodulatory therapies or phototherapy within a certain timeframe prior to the baseline visit. The trial is looking for patients who are willing to provide written informed consent prior to entering study procedures.",
    "The sample is a phase 2 clinical trial for the treatment of graft-versus-host disease. The trial is focused on patients with chronic GvHD that is corticosteroid refractory, dependent or intolerant. The trial drug being tested is methoxsalen. The eligibility criteria for the trial include having documented skin disease classical for chronic GvHD, being at least 100 days post transplantation, and weighing at least 40 kg. Women of childbearing potential must agree to use a reliable method of birth control for the duration of the study. The exclusion criteria include active gastrointestinal bleeding, previous treatment with ECP, and being pregnant or lactating.",
    "The sample is a phase 2 clinical trial for the treatment of stable plaque-type psoriasis. The trial involves the use of topical therapy with three different drugs, including a placebo. The eligibility criteria include having psoriasis affecting 2% to 10% of the body surface area, a moderate severity level, and agreeing to follow dosing instructions and complete required clinic visits. Exclusion criteria include being pregnant or nursing, recent use of certain medications or treatments, and having certain medical conditions or histories.",
    "The sample is a phase 2 clinical trial for patients with squamous cell carcinoma or oral cancer. The trial is testing the effectiveness of a combination of drugs including docetaxel, cisplatin, and 5-fluorouracil. The eligibility criteria for the trial include having stage 3 or 4 disease without evidence of distant metastases, being at least 18 years old, having a WHO performance status of 2 or less, and not having any active alcohol addiction. The trial also has exclusion criteria such as previous treatment with radiotherapy or chemotherapy, concurrent treatment with any other anti-cancer therapy, and participation in an investigational trial within 30 days of study entry. The final eligibility for the trial is determined by the health professionals conducting the trial.",
    "The sample is a phase 2 clinical trial for the treatment of systemic sclerosis using the drug paquinimod. The trial includes patients who are at least 18 years old and have a clinical diagnosis of SSc according to ACR criteria. Patients must also have progressive SSc and meet certain criteria related to skin thickness progression rate and mRSS score. The trial excludes patients with severe SSc manifestations, ongoing infections, or other significant medical conditions that could confound the study results or put the patient at risk. The study drug is ABR-215757.",
    "The sample is a phase 2 clinical trial for smoking cessation. The eligibility criteria include being between 18 and 65 years old, having a history of smoking at least 10 cigarettes per day for at least 1 year, indicating a plan to quit smoking within the next 3 months, and having a CO measurement of \u2265 10 ppm at screening and baseline. Female subjects must have been postmenopausal for the previous 6 months or be surgically sterile, or must have a negative pregnancy test and use one of the acceptable methods of birth control for the duration of the study. The exclusion criteria include having attempted to quit smoking using FDA-approved smoking cessation products for longer than 1 week in the past 3 months, having been enrolled in another structured smoking cessation program in the last 30 days, having been in another smoking cessation trial in the past 6 months, and having a history of certain medical conditions or taking certain medications.",
    "The sample is a phase 2 clinical trial for patients with metastatic gastric adenocarcinoma or gastroesophageal junction cancer. The trial involves the use of two drugs, docetaxel and vandetanib. The eligibility criteria include having measurable disease, an ECOG performance status of 0-1, and various laboratory values within normal ranges. Exclusion criteria include uncontrolled systemic disease, uncontrolled infection, and certain cardiac conditions. Patients must have recovered from prior therapy and not have received prior docetaxel treatment. The trial also has restrictions on concurrent medication and participation in other experimental drug studies.",
    "The sample is a record of a clinical trial with a phase 2 designation. The trial is focused on the treatment of chronic hepatitis C. The trial includes a list of ICD-10 codes for the disease, as well as a list of drugs being tested, including sofosbuvir, gs-0938, rbv, and placebos to match the two drugs. The eligibility criteria for the trial include being a naive patient to all HCV antiviral treatment, having chronic HCV-infection, and being otherwise healthy. The exclusion criteria include having a positive test for HBsAg, anti-HBc IgM Ab, or anti-HIV Ab, having a history of any other clinically significant chronic liver disease, or having a medical history that the investigator considers unsuitable for the study.",
    "The sample is a record of a clinical trial with a phase 2 designation. The trial is focused on treating malignant pleural mesothelioma, a type of cancer affecting the lining of the lungs. The trial involves the use of three drugs: morab-009 (amatuximab), pemetrexed, and cisplatin. The eligibility criteria for participants include having a confirmed diagnosis of malignant pleural mesothelioma, measurable disease at screening, a KPS score of at least 70%, and a life expectancy of at least 3 months. Exclusion criteria include having a sarcomatous type of mesothelioma, prior systemic therapy or radiotherapy for MPM, confirmed presence of CNS tumor involvement, and evidence of other active malignancy requiring treatment.",
    "The sample is a phase 2 clinical trial for locally advanced or metastatic breast cancer patients who are resistant to aromatase inhibitors therapy. The trial involves the drugs enzastaurin, placebo, and fulvestrant. The eligibility criteria include being a female with postmenopausal status, having a performance status of 0, 1, or 2 on the Eastern Cooperative Oncology Group (ECOG) scale, having adequate organ function, and having an estimated life expectancy of at least 24 weeks. The trial also has exclusion criteria, such as having prior treatment with fulvestrant or enzastaurin, being unable to discontinue use of anticoagulants, having hypercalcemia, and having a serious cardiac condition.",
    "This is a sample from a clinical trial table that includes information about the phase of the trial, the disease being studied (in this case, Parkinson's disease), the ICD-10 codes associated with the disease, the drug being tested (fipamezole), and the eligibility criteria for participants. The eligibility criteria include requirements such as having idiopathic Parkinson's disease, experiencing peak-dose dyskinesia for at least 25% of the waking day, and being on stable Parkinson's medication for at least one month prior to randomization. The exclusion criteria include factors such as the use of certain medications or supplements, and recent intake of an investigational drug.",
    "The sample is a phase 2 clinical trial for patients with colorectal cancer. The trial is testing the effectiveness of the drugs capecitabine (xeloda) and bevacizumab. The eligibility criteria include having stage IV colon cancer with at least one measurable lesion, no prior chemotherapy for metastatic colorectal cancer, and meeting certain laboratory values. Exclusion criteria include prior chemotherapy for metastatic colorectal cancer, prior treatment with an anti-angiogenic agent, and presence of neuropathy > grade 2. Patients must also be able to comply with the study protocol and follow-up procedures.",
    "The sample is a phase 2 clinical trial for patients with metastatic or unresectable locally recurrent clear cell renal carcinoma. The trial involves the use of the drug pazopanib and has specific eligibility criteria, including having only received one previous targeted agent therapy with either sunitinib or bevacizumab and having an ECOG performance status of 0 or 1. The trial also has exclusion criteria, such as previous treatment with more than one targeted agent or concurrent cancer therapy. The sample includes a detailed list of inclusion and exclusion criteria for the trial.",
    "The sample is a phase 2 clinical trial for chronic obstructive pulmonary disease (COPD). The trial is looking for male and female subjects between the ages of 40 and 80 with a documented diagnosis of mild, moderate, or severe COPD according to Global Initiative for Chronic Obstructive Lung Disease (GOLD) criteria and a history of smoking. The subjects must have a post-bronchodilator 40% \u2264 FEV1 \u2264 80% of predicted normal and post-bronchodilator FEV1/FVC < 70%. They must also have signed an informed consent form prior to the initiation of any study-related procedure. The trial is testing the effectiveness of indacaterol 300\u03bcg compared to a placebo. The inclusion criteria also require subjects to demonstrate a plethysmographic functional residual capacity >120% predicted normal. Exclusion criteria include no COPD exacerbations within 6 weeks prior to dosing, no concomitant lung disease such as asthma, no requirement for long term oxygen treatment or history of lung reduction surgery, no medical conditions that would interfere with the performance of spirometry or clinical exercise testing, and any other medical condition that in the opinion of the investigator may cause the patient to be unsuitable for completion of the study or place the patient at potential risk from participating in the study e.g. uncontrolled hypertension or unstable ischemic heart disease. Other protocol-defined inclusion/exclusion criteria may apply.",
    "The sample is a phase 2 clinical trial for the treatment of restless legs syndrome. The trial includes individuals aged 18-70 with a history of primary RLS for at least 6 months prior to screening. The trial involves the use of the drugs ipx159 and placebo. The eligibility criteria include being able to understand and sign an informed consent form, having a BMI between 18.5-32, and agreeing to use a medically acceptable method of contraception throughout the study. Exclusion criteria include a history of HIV, hepatitis B or C, and the use of certain medications or herbal supplements. The trial requires participants to comply with the protocol and attend all scheduled clinic visits and telephone calls.",
    "The sample is a record of a clinical trial with a phase 2 designation. The trial is focused on the disease melanoma, which is identified in the 'diseases' field. The 'icdcodes' field lists the ICD-10 codes associated with melanoma. The 'drugs' field lists the names of drugs being used in the trial, including ipilimumab. The 'criteria' field outlines the eligibility criteria for patients to participate in the trial, which includes having previously treated, therapy-refractory or -intolerant, Stage III or Stage IV melanoma.",
    "The sample is a phase 2 clinical trial for esophageal cancer. The trial is looking at the effectiveness of 5-fu, cisplatin, and taxotere as treatments. The eligibility criteria for participants include having histologically confirmed esophageal cancer, measurable non-metastatic disease, and no previous cancer therapy. Participants must also have a life expectancy of more than 3 months, be over 18 years old, and have a WHO status of 2 or less. Exclusion criteria include being pregnant or nursing, having certain medical conditions, and having a history of malignant disease within the last 5 years. The trial requires signed informed consent from participants.",
    "The sample is a phase 2 clinical trial for the treatment of metastatic adenocarcinoma of the prostate using the drug docetaxel. The eligibility criteria include having received at least 12 weeks of treatment with docetaxel or a similar drug, demonstrating hormone-resistance, and having an elevated PSA level. Patients must also meet certain patient characteristics, such as having a WHO performance status of 0-2 and no serious underlying medical conditions. Prior concurrent therapy is also taken into consideration. The sample provides detailed information on the disease characteristics, patient characteristics, and prior concurrent therapy requirements for participation in the trial.",
    "The sample is a phase 2 clinical trial for obsessive-compulsive disorder. The trial is testing the effectiveness of ketamine as a treatment option. The eligibility criteria for participants include being between the ages of 18 and 65, having a Y-BOCS score greater than 24, having treatment-refractory OCD, and being medically and neurologically healthy. Participants must also have stable doses of all psychiatric medications for at least a month prior to treatment. Exclusion criteria include a history of substance dependence, recent suicidal ideation or attempt, pregnancy, and hypersensitivity to ketamine.",
    "The sample is a phase 2 clinical trial for patients with metastatic colorectal cancer. The trial involves the drugs mk-0646 and placebo. The eligibility criteria include having measurable disease by RECIST criteria, adequate hepatic, renal, and bone marrow function, and a negative pregnancy test. Exclusion criteria include prior systemic chemotherapy for metastatic colorectal cancer, uncontrolled central nervous system metastases or carcinomatous meningitis, and inadequately controlled hypertension. Patients must also have an Eastern Cooperative Oncology Group (ECOG) performance status of 2 or less and a life expectancy of at least 12 weeks. The trial does not allow pregnant or lactating women, and both men and women of childbearing potential must use effective birth control measures during the course of the study.",
    "The sample is a phase 2 clinical trial for patients with locally advanced and unresectable adenocarcinoma of the pancreas. The trial involves the use of gemcitabine, amg 479, and placebo drugs. The eligibility criteria include having confirmed adenocarcinoma of the pancreas, measurable or non-measurable disease, an ECOG score of 0 or 1, and adequate organ function. Exclusion criteria include early or metastatic disease, non-adenocarcinoma types of cancer, external biliary drain, and previous treatment with certain types of therapies for pancreatic cancer.",
    "The sample is a phase 2 clinical trial for patients with congestive heart failure and edema. The trial is testing the drug OPC-41061 (tolvaptan) and the eligibility criteria includes patients who have taken furosemide at a certain dosage for 3 days, have stable body weight, and are between the ages of 20 and 80. Exclusion criteria includes patients with unstable heart failure, implanted ventricular assist device, and various other diseases or complications. The trial is being conducted on patients who are hospitalized or can be hospitalized for the study period.",
    "The sample is a phase 2 clinical trial for patients with metastatic transitional cell cancer of the urothelium or bladder. The trial is testing the effectiveness of pazopanib hydrochloride, and the eligibility criteria include having measurable disease, a performance status of 0-2, and a life expectancy of at least 12 weeks. Patients must also meet various medical criteria, such as having normal bilirubin and creatinine levels, and not having any uncontrolled illnesses or conditions that would limit compliance with the study therapy. Patients must not have any other active second malignancy other than non-melanoma skin cancer, and must not have had prior experimental treatment for metastatic disease. The trial also has various exclusion criteria, such as not having a history of allergic reactions to compounds of similar chemical or biological composition to pazopanib hydrochloride, and not having concurrent medications that are associated with a risk of QTc prolongation and/or Torsades de Pointes.",
    "This sample is for a phase 2 clinical trial for the treatment of leukemia using the drugs azacytidine and gm-csf. The trial is open to patients with low- or intermediate-1-risk MDS according to the International Prognostic Scoring System (IPSS) classification who are over 18 years old and have not previously been treated with azacytidine or decitabine. The eligibility criteria include signed informed consent, and the exclusion criteria include any previous adverse reaction to GM-CSF, prior treatment with azacytidine or decitabine, and unresolved diarrhea. The diseases being treated are listed as 'leukemia', and the icd-10 codes associated with the disease are also provided.",
    "The sample is a phase 2 clinical trial for the treatment of non-Hodgkin's lymphoma and marginal zone lymphoma using the drug gemcitabine. The trial includes patients who are at least 18 years old and have a confirmed diagnosis of marginal zone B-cell lymphoma, with measurable lesions and laboratory values within certain ranges. Patients with other malignancies within the past 5 years, serious comorbid diseases, or who are pregnant or breastfeeding are excluded from the trial. The trial requires informed consent from all participants.",
    "The sample is a phase 2 clinical trial for the treatment of follicular lymphoma. The trial is testing the drug enzastaurin. The eligibility criteria for participants include having a confirmed diagnosis of Grade 1 or 2 follicular lymphoma, being in Ann Arbor Stage III or IV, and being chemo-naive or having relapsed disease after receiving only one prior chemotherapy regimen. Participants must not require cytoreductive therapy for at least 3 months from the first dose of study treatment. Exclusion criteria include being unable to swallow tablets, receiving concurrent administration of any other antitumor therapy, being pregnant or breastfeeding, and having a serious concomitant systemic disorder.",
    "The sample is a phase 2 clinical trial for the treatment of renal cell carcinoma, a type of kidney cancer. The trial is testing the effectiveness of the drug sunitinib malate (sutent) on patients who have not undergone nephrectomy and are candidates for surgical treatment. The eligibility criteria include having a locally confined tumor \u2264 7 cm, being 18 years or older, having an ECOG performance status of 0 or 1, and meeting certain organ function requirements. The trial also has exclusion criteria, such as prior therapy for RCC, abnormal ECG, evidence of metastatic RCC, and pregnancy or breastfeeding. The sample includes a detailed list of inclusion and exclusion criteria for the trial.",
    "This sample is a phase 2 clinical trial for pediatric patients with acute lymphoblastic leukemia. The trial is testing the effectiveness of the drug clofarabine on patients who have relapsed or are refractory to at least two other drugs. The eligibility criteria include confirmation of the disease through histology, normal cardiac, hepatic, and renal function, an ECOG performance status of 0-2, and a life expectancy of more than 3 months. Exclusion criteria include patients who have not recovered from prior therapy, those who have undergone stem cell transplantation within the last 3 months, those with central nervous involvement or uncontrolled infection, and those who have used clofarabine before or are allergic to fludarabine or cladribine.",
    "The sample is a phase 2 clinical trial for Alzheimer's disease. The trial is designed to enroll individuals who meet specific eligibility criteria and do not have any medical conditions or medications that could affect cognitive testing or increase the risk of treatment. The inclusion criteria include meeting the NINDS/ADRDA criteria for probable AD, having a Mini Mental State Examination score between 10 and 24, being fluent in English or Spanish, and having a modified Hachinski score equal to or less than 4, among others. The exclusion criteria include having a history of active peptic ulcer disease, clinically significant cardiac arrhythmia, or epilepsy, among others. The trial also excludes the use of certain medications, such as cholinesterase inhibitors and anti-Parkinsonian medications, within a certain timeframe prior to screening. The trial allows the use of certain medications, such as estrogen and memantine, if the dose has been stable for 3 months prior to screening. The trial encourages women and members of minority groups to volunteer.",
    "The sample is a record of a clinical trial with a phase 2 designation. The trial is focused on the disease of arthritis, specifically rheumatoid arthritis. The icd-10 codes associated with the disease are listed. The trial involves the use of several drugs, including a placebo and a drug called cp-690,550. The eligibility criteria for the trial are also listed, including the requirement that subjects have failed a previous treatment with at least one DMARD due to lack of efficacy or toxicity. The exclusion criteria include current therapy with any DMARD.",
    "The sample is a phase 2 clinical trial for the treatment of panic disorder. The trial is testing the efficacy of two doses of a drug called org 25935 compared to a placebo. The trial is open to both male and female participants between the ages of 18 and 65 who have been diagnosed with panic disorder, with or without agoraphobia. Participants must have a Clinical Global Impressions (CGI)-Severity score at Screening of >= 4 and <= 6. Participants must not be taking any psychotropic medications or be willing to discontinue these medications prior to the first CBT session. Anti-depressant and anxiolytic medications are acceptable only if they are stabilized for at least 8 weeks prior to Screening. Participants must be able to complete all scheduled assessment and treatment visits and be willing to comply with the requirements of the study protocol. There are several exclusion criteria, including a diagnosis of a primary Axis I disorder other than panic disorder, a Screening Montgomery-Asberg Depression Rating Scale (MADRS) score of >= 35 (severe depression), any history of bipolar disorder, psychotic disorder, or obsessive compulsive disorder, a diagnosis of post traumatic stress disorder, eating disorder, or substance abuse or dependence (excluding nicotine) within the past six months, and significant personality dysfunction that could interfere with trial participation. Participants with known borderline or avoidant personality disorder are excluded. Participants must also not be at imminent risk of self-harm or harm to others, in the investigator's opinion based on clinical interview and responses provided on the Columbia Suicide Severity Rating Scale (C-SSRS). There are also several medical exclusion criteria, including uncontrolled, unstable clinically significant medical conditions, clinically relevant visual disturbance, and clinically significant abnormal laboratory, vital sign, physical examination, or electrocardiogram (ECG) findings at Screening that may interfere with the interpretation of safety or efficacy assessments in the opinion of the investigator. Females must have a negative serum pregnancy test (at Screening) and not plan to become pregnant during the course of the trial. Participants must not have a history of sensitivity/idiosyncrasy to glutamatergic drugs or chemically related compounds or excipients which may be employed in the trial or to any other unknown drug used in the past. Participants must not be receiving concurrent psychotherapy for the treatment of panic disorder or have received a prior adequate trial of CBT for panic disorder. Participants must not have been exposed to an investigational drug within 6 months prior to Screening.",
    "The sample is a record of a clinical trial with a phase 2 designation. The trial is focused on patients with type 2 diabetes and includes a list of specific ICD-10 codes related to the disease. The trial involves the use of three drugs, including a comparator placebo and pioglitazone. The eligibility criteria for the trial include patients between the ages of 18 and 70 who have not been able to control their blood glucose levels and have not taken any antihyperglycemic medicine for three months. The exclusion criteria include patients taking certain medications, those with liver or kidney disease, poorly controlled high blood pressure, heart disease, or certain blood disorders, and those with abnormal laboratory results from a blood test.",
    "The sample is a phase 2 clinical trial for patients with primary peritoneal carcinoma or recurrent ovarian carcinoma. The trial involves the use of the drug sorafenib tosylate. The eligibility criteria include having received one prior platinum-based chemotherapeutic regimen for primary disease, having measurable or evaluable disease, and meeting various medical requirements such as having a certain performance status, blood counts, and organ function. Patients must also not have certain medical conditions or be taking certain medications. The trial does not allow for concurrent use of other investigational or commercial agents or therapies for the malignancy.",
    "The sample is a phase 2 clinical trial for patients with advanced unresectable hepatocellular carcinoma. The trial is testing the effectiveness of the drugs tac-101 and placebo. The eligibility criteria include having discontinued from first line treatment with sorafenib monotherapy for any reason at least 14 days prior to planned randomization, having recovered from any significant sorafenib-related treatment toxicities prior to randomization, having at least 1 target lesion that is viable and can be accurately measured according to RECIST, having an ECOG score of 0, 1, or 2, and having adequate organ function. Exclusion criteria include having a history of DVT, PE, myocardial infarction, CVA, transitory ischemic attack, or any other significant TE during the last 3 years, having clinically significant symptoms of hepatic encephalopathy or known brain metastasis, and having received a previous systemic therapy (including investigational agents) other than sorafenib for treatment of HCC.",
    "The sample is a phase 2 clinical trial for patients with M\u00fcllerian carcinomas, including primary epithelial ovarian, primary peritoneal, or fallopian tube cancer. The trial is testing the effectiveness of carboplatin, gm-csf (sargramostim), and interferon gamma as treatment options. The eligibility criteria include having had a response to platinum-based chemotherapy and a chemotherapy treatment-free interval of at least 6 months, measurable disease, no prior immunotherapy, and adequate hematological, renal, and hepatic function. Exclusion criteria include pregnancy or lactation, brain metastases, and history of hypersensitivity to platinum agents.",
    "The sample is a phase 2 clinical trial for patients with metastatic hormone refractory prostate cancer. The trial involves the use of the drugs dexamethasone and doxorubicin. The eligibility criteria include having symptoms related to the disease, measurable disease or PSA levels, adequate organ function, and a left ventricular ejection fraction of at least 50%. Patients must also have failed to respond to discontinuation of anti-androgens and have an expected survival of at least 4 months. Exclusion criteria include previous chemotherapy, uncontrolled intercurrent illness, and a history of cardiac disease with New York Heart Class II or greater. Patients must be willing to use adequate contraceptive methods during treatment and for 3 months after completing treatment.",
    "The sample is a phase 2 clinical trial for patients with ovarian cancer who have relapsed within 6 months after primary therapy with platin and taxan. The trial requires patients to have an ECOG score of 0-2, be at least 18 years old, and meet certain blood count requirements. The trial involves the use of the drugs topotecan and topotecan. The eligibility criteria include a written informed consent, while the exclusion criteria include earlier topotecan therapy, simultaneous or planned radiotherapy, and secondary malignancy. The diseases are specified as ovarian cancer, and the icd-10 codes associated with the disease are listed as well.",
    "The sample is a phase 2 trial for chronic cough. The trial includes the drugs gefapixant and placebo. The eligibility criteria for the trial includes having a history of cough for more than 8 weeks, a normal chest radiograph, and either having idiopathic cough or treatment-resistant cough. The exclusion criteria includes being a current smoker, having given up smoking within the past 6 months, having a pack-year smoking history of more than 20, being treated with an ACE-inhibitor, or having a FEV1/FVC ratio of less than 60%.",
    "The sample is a record from a clinical trial table that includes information about the trial's phase, diseases being studied, icd-10 codes of the diseases, drugs being tested, and eligibility criteria for participants. In this particular sample, the trial is in phase 2 and is studying the effects of injections of incobotulinum toxin a and placebo on patients with Parkinson's disease and amyotrophic lateral sclerosis who have troublesome sialorrhea (excessive drooling). The eligibility criteria include specific age ranges, diagnosis criteria, and a minimum score on the FOIS scale for swallowing function. Exclusion criteria include current use of Coumadin, significant medical illness, history of myasthenia gravis or Lambert-Eaton Syndrome, ongoing substance abuse, history of unreliable follow-up, past use of Xeomin\u00ae or other botulinum toxin preparations, and cognitive impairment.",
    "The sample is a record of a clinical trial in phase 2 for the treatment of non-small-cell lung carcinoma. The trial involves two drugs, pf-3512676 and erlotinib, and includes a list of eligibility criteria for participants. Inclusion criteria include having advanced, EGFR-positive NSCLC, a measurable disease, and an ECOG Performance Status of 0, 1, or 2. Exclusion criteria include having known CNS metastasis or pre-existing autoimmune or antibody mediated disease. The icd-10 codes associated with the disease are also listed.",
    "The sample is a phase 2 clinical trial for the treatment of moderate to severe ulcerative colitis. The trial includes patients who have never been medically treated for ulcerative colitis, as well as those who are refractory or intolerant to other therapies. The trial involves the use of a drug called Natura alpha, which is being compared to a placebo. The eligibility criteria include having active mucosal disease, a rectal bleeding sub score of at least 1, and a physician's global assessment sub score of at least 2. Patients must also have adequate cardiac, renal, and hepatic function, and be able to adhere to the study visit schedule and other protocol requirements. Exclusion criteria include a history of colonic or rectal surgery, pregnancy or breastfeeding, and a diagnosis of diabetes, heart failure, or any other unstable medical condition.",
    "The sample is a phase 2 clinical trial for the treatment of chronic plaque psoriasis. The trial involves the use of drugs such as mometasone furoate, nortriptyline hcl, and a placebo. The eligibility criteria for the trial include being between 18 and 70 years of age, having stable plaques in an area sufficient for six treatment fields, and not having certain medical conditions such as cardiac disease or mania. The trial also has exclusion criteria such as a history of drug or alcohol abuse, pregnancy or lactation, and being institutionalized due to legal or regulatory order. The sample includes a detailed list of inclusion and exclusion criteria for the trial.",
    "The sample is a phase 2 clinical trial that focuses on herniorrhaphy and postoperative pain related to inguinal hernia. The trial involves the use of two drugs, bupivacaine collagen sponge and placebo collagen sponge. The eligibility criteria for the trial include being a man over 18 years old with a BMI between 19 and 40 kg/m2, and having a planned unilateral inguinal herniorrhaphy to be performed under general anesthesia. Exclusion criteria include known hypersensitivity to certain substances, scheduled bilateral herniorrhaphy, recent major surgery, cardiac arrhythmias or AV conduction disorders, and use of certain medications.",
    "This sample is a phase 2 clinical trial for postmenopausal women with low bone mineral density, specifically osteopenia or osteoporosis. The trial is testing the effectiveness of the drugs bps804 and placebo. The eligibility criteria include having a T score or equivalent BMD absolute value for the lumbar spine between -2.0 and -3.5, a BMI between 18 and 35kg/m2, and a 25-(OH) vitamin D serum level of \u2265 15ng/ml. Exclusion criteria include having certain bone diseases, a history of osteoporotic fractures, and regularly using certain medications affecting bone metabolism. The trial will also exclude subjects with certain diseases or abnormalities of the spine or hip that would prevent proper acquisition of a lumbar spine DXA or femur DXA.",
    "This sample is for a phase 2 clinical trial for breast cancer. The trial includes postmenopausal women with hormone receptor-positive early breast cancer who have a positive Disseminated Tumour Cell immunocytochemical result from bone marrow aspiration prior to randomisation. The trial excludes women with inflammatory and/or metastatic breast cancer, current or previous malignancy within the previous 5 years (other than breast cancer or adequately treated non-melanoma skin cancer or in-situ cervical cancer), and a history of bleeding diathesis. The trial will test the effectiveness of fulvestrant and anastrozole as potential treatments for breast cancer.",
    "The sample is a phase 2 clinical trial for the treatment of breast cancer. The trial includes patients with stage IV invasive breast cancer who have measurable disease and are 3+ positive for HER2 overexpression. The patients must not have received prior chemotherapy or trastuzumab therapy for metastatic breast cancer, but may have received prior chemotherapy and/or hormonal therapy for early stage breast cancer. The trial involves the use of gemcitabine and trastuzumab as drugs. The eligibility criteria and exclusion criteria are also provided.",
    "The sample is a phase 2 clinical trial for non-small cell lung cancer. The trial includes patients with advanced histologically or cytologically confirmed NSCLC, measurable or non-measurable disease, and treated brain metastases with no evidence of progression or hemorrhage after treatment. The trial also includes patients with prior treatment for CNS disease as deemed appropriate by the treating physician, ECOG performance status 0 or 1, and ability and willingness to comply with study and follow-up procedures. The trial excludes patients with prior systemic chemotherapy for metastatic disease, active malignancy other than lung cancer, current, recent, or planned participation in another experimental drug study, and prior treatment with anti-VEGF agent or agents targeting similar pathways as sunitinib. The trial also excludes patients with inadequate organ function, known evidence of disseminated intravascular coagulopathy, active infection or fever > 38.5\u00b0C within 3 days prior to Day 1 of Cycle 1, and any other medical condition(s) deemed by the clinician to be likely to interfere with a patient's ability to provide informed consent, cooperate, or participate in the study, or to interfere with the interpretation of the results.",
    "This is a sample of a clinical trial for phase 2, focused on breast cancer. The trial includes patients who have been previously treated with both an anthracycline and a taxane, but have not received more than two prior chemotherapy treatment programs. Patients must have stopped any antitumoral hormonal treatment before enrolling in the study and must have a negative pregnancy blood test if menstruating or capable of becoming pregnant. The trial involves the use of three drugs: enzastaurin, placebo, and capecitabine. Patients must follow certain inclusion and exclusion criteria, such as not being able to follow the study procedures, receiving another treatment for their cancer, having received another experimental drug in the last 4 weeks, having had serious heart disease within the last 6 months, or being pregnant or breastfeeding.",
    "The sample is a phase 2 clinical trial for patients with intracranial malignant glioma, including glioblastoma multiforme, anaplastic astrocytoma, anaplastic oligodendroglioma, and anaplastic mixed oligoastrocytoma. Patients must have evidence of tumor progression by MRI or CT scan and have failed prior radiation therapy. They must also meet certain eligibility criteria, including being over 18 years old, having a Karnofsky performance status of over 60, and having adequate bone marrow, liver, and renal function. Patients must not have any significant medical illnesses that cannot be controlled with appropriate therapy or active infections requiring IV antibiotics. Women of childbearing potential must have a negative pregnancy test and agree to use adequate contraceptive methods during and for 2 months after treatment with Talampanel. Patients with significant active cardiac, hepatic, renal, or psychiatric diseases, concurrent use of other standard chemotherapeutics or investigative agents, or known active, life-threatening malignancy are ineligible.",
    "The sample is a clinical trial for phase 2/phase 3 that involves patients with colorectal cancer and liver metastases, who are also undergoing chemotherapy. The trial includes a list of ICD-10 codes for the diseases, a list of drug names, and eligibility criteria for the patients. The eligibility criteria include having histologically proven adenocarcinoma of the colon or rectum without previous resection, hepatic unresectable metastases, and not optimally resectable metastases. The patients must also have a WHO performance status of 0-1 and a life expectancy of equal or more than 3 months. Adjuvant chemotherapy is allowed, except for oxaliplatin and irinotecan based combination. The exclusion criteria are not specified in the sample.",
    "The sample is a phase 2 clinical trial for the treatment of metastatic breast cancer. The trial is testing the effectiveness of cetuximab and cisplatin, as well as cisplatin alone, in patients who have not received more than one prior chemotherapy treatment for their metastatic breast cancer. The trial is only open to patients who have been diagnosed with estrogen receptor and progesterone receptor negative breast cancer, and have HER2 expression less than 3+. The trial has specific inclusion and exclusion criteria, including no prior use of platinum agents or mitomycin, and no history of brain metastases.",
    "The sample is a phase 2 clinical trial for major depressive disorder. The trial includes a list of icd-10 codes for the disease and a list of drugs being tested, including azd7268, escitalopram, placebo capsules, and placebo tablets. The eligibility criteria for the trial include a documented primary clinical diagnosis meeting DSM-IV criteria for major depressive disorder, and exclusion criteria include patients with a secondary DSM-IV Axis I disorder other than GAD or social anxiety disorder, patients with a diagnosis of DSM-IV Axis II disorder that has a major impact on their current psychiatric status, and patients whose current episode of depression started less than 4 weeks before enrollment.",
    "The sample is a phase 2 trial for patients with myelodysplastic syndromes, chronic myelomonocytic leukemia, or acute myeloid leukemia in complete remission. The trial involves the use of drugs such as clofarabine, cytarabine, and thymoglobulin. The eligibility criteria include being 18 years or older, having an ECOG performance status of <=2, and having a suitable donor. The donor must be healthy and meet certain criteria, such as being an adequate HLA match and having no significant cardiopulmonary, renal, endocrine, or hepatic disease. The trial has exclusion criteria, such as having active systemic infection or severe concurrent disease.",
    "The sample is a phase 2 clinical trial for Crohn's disease. The trial includes patients who have been diagnosed with Crohn's disease for at least 3 months and have confirmed the disease through endoscopic or imaging examination. The patients must have moderately active Crohn's disease at baseline, defined as a CDAI score between 220 and 450, and have not responded to prior treatment with corticosteroids or immunosuppressants. The trial includes both an experimental drug called ain457 and a placebo. The eligibility criteria include age between 18 and 75 years old, a stable dose of certain medications, and exclusion criteria such as a positive PPD tuberculin skin test or QuantiFeron test, active pulmonary disease, and multiple bowel surgeries. Other protocol-defined inclusion/exclusion criteria may also apply.",
    "The sample is a phase 2 clinical trial for the treatment of moderate to severe endometriosis. The trial includes premenopausal women who have been diagnosed with endometriosis within the past 10 years and have experienced pelvic pain, menstrual pain, or dyspareunia with a score of at least 4 on the numerical rating scale. The trial involves active treatment with a high or low dose of bgs649 or a placebo treatment to blind the study. Patients must not plan to become pregnant within one year after the screening visit and must be willing to use two effective methods of non-hormonal, barrier birth control for the duration of the study or be surgically sterile. The trial has several exclusion criteria, including the use of certain medications and medical conditions that may interfere with the study.",
    "The sample is a phase 2 clinical trial for individuals diagnosed with type 2 diabetes. The trial is testing the effectiveness of two drugs, EGT0001442 and placebo, in treating the disease. The eligibility criteria include being over 18 years old, having a BMI of 45 kg/m2 or less, and having an HbA1c level between 7 and 10%. Participants must also have a stable dose and regimen of any anti-diabetic, anti-hypertensive, or lipid modifying medications they are taking. Exclusion criteria include having certain medical conditions, such as kidney stones or abnormal liver function, and not being able to comply with the study's scheduled visits.",
    "This sample is for a phase 2 clinical trial that focuses on diabetes complications and fatty liver. The trial is testing the effectiveness of the drug exenatide on patients with type 2 diabetes who are on stable doses of sulfonylurea and/or metformin, have a body mass index greater than 35 kg/m2, and have a presumed diagnosis of non-alcoholic fatty liver disease (NAFLD) based on an ALT level greater than 1.5 times the upper limit of the reference range, no evidence of other causes of liver disease, and ultrasound findings compatible with fatty liver. The trial has a list of exclusion criteria, including clinical signs of cirrhosis, liver disease, current use of alcohol, and pregnancy or lactation. The trial also has a list of inclusion criteria, including age between 18 and 70 years old and willingness to avoid alcohol during the course of the study.",
    "The sample is a phase 2 clinical trial for non-small cell lung cancer using the drugs paclitaxel and cisplatin. The trial has specific eligibility criteria, including confirmation of the cancer diagnosis, age above 18, and a certain range of ECOG, neutrophil count, hemoglobin, AST and ALT levels, bilirubin levels, and creatinine levels. Women of childbearing potential must have a negative pregnancy test. Exclusion criteria include previous cytotoxic chemotherapy or radiotherapy, systematic brain metastasis, allergic reactions to the drugs or their ingredients, pregnancy or nursing, uncontrolled illness, HIV positivity, and previous splenectomy.",
    "The sample is a phase 2 clinical trial for rheumatoid arthritis. The trial includes patients who meet the ACR criteria for RA and have active RA, characterized by at least 6 out of 66 swollen joints and 6 out of 68 tender joints, and at least 2 of the following: a serum C-reactive protein level greater than the upper limit of normal, an erythrocyte sedimentation rate >= 28 mm per hour, or morning stiffness > 45 minutes. Patients must also be seropositive for rheumatoid factor and on MTX (10 to 25 mg weekly) for at least 6 months receiving a stable dose for 42 days before randomization and no anticipated change in MTX dose while on study. The trial includes low-dose corticosteroids and NSAIDs at study entry and must have been stable for at least 28 days before randomization. All other disease modifying non-biologic anti-rheumatic drugs (DMARDs) must have been discontinued at least 28 days prior to randomization except for leflunomide (discontinued at least 60 days before randomization). The trial also includes screening laboratory values such as Hemoglobin \u2265 8.5 g/dL, White blood cell (WBC) \u2265 3000/mm\u00b3, Neutrophils \u2265 1.5x10(9)/L, Platelets \u2265 125x10(9)/L, Serum creatinine < 2 mg/dL, Aspartate aminotransferase (AST) \u2264 2xULN, and Alanine aminotransferase (ALT) \u2264 2xULN. Women must be postmenopausal (> 12 months without menses) or surgically sterile or using effective contraception for at least 4 weeks prior to the anticipated Visit 2 date and agree to continue contraception for the duration of their participation in the study. Sexually active male subjects must use a barrier method of contraception during the course of the study. The trial has exclusion criteria such as prior treatment with B cell depleting therapy, any other monoclonal antibody or immunoglobulin-based fusion proteins \u2264 8 weeks prior to randomization, any other experimental treatment \u2264 4 weeks prior to randomization, primary or secondary immunodeficiency, any other autoimmune disease other than RA (except concurrent Sjogren's syndrome or hypothyroidism), complications of RA including active rheumatoid vasculitis, bed bound or wheelchair bound, clinically significant pulmonary fibrosis, Felty's syndrome, any history of malignancy, excluding adequately treated and cured basal or squamous cell carcinoma of the skin, or cervical carcinoma in situ, active major psychiatric disease, evidence of acute or chronic infection, clinically significant cardiac disease requiring medication, unstable angina, myocardial infarction within 6 months of randomization, or congestive heart failure, arrhythmia requiring active therapy, with the exception of clinically insignificant extrasystoles, or minor conduction abnormalities, history of cerebrovascular disease requiring medication/treatment, concomitant anticoagulation therapy or a known bleeding disorder, seizure disorder requiring active therapy, known drug or alcohol abuse, and pregnant or nursing.",
    "The sample is a phase 2 clinical trial for type 2 diabetes. The trial involves the use of the drugs incb013739, metformin, and a placebo comparator matching incb013739. The eligibility criteria include having an established diagnosis of type 2 diabetes and a stable dose of metformin for more than 8 weeks. Exclusion criteria include subjects with Addison's disease or Cushing's Syndrome, type 1 diabetes mellitus or secondary forms of diabetes, uncontrolled thyroid disease, and a history of renal impairment.",
    "The sample is a phase 2 clinical trial for the treatment of prostate cancer using the drug docetaxel. The eligibility criteria include having a confirmed diagnosis of prostate adenocarcinoma, previous non-response or progression with chemotherapy (excluding Taxotere\u00ae), castration levels of testosterone, and a performance status of 0-2. The patient must also meet certain laboratory requirements for hematology, hepatic function, and renal function. Exclusion criteria include recent chemotherapy or anti-androgen therapy, participation in another clinical trial with an investigational drug within 30 days prior to study screening, and other serious illnesses or medical conditions that would prevent the patient from being managed according to the protocol.",
    "The sample is a phase 2 clinical trial that involves patients with various diseases such as thrombosis, cancer, and pulmonary embolism. The trial is testing the effectiveness of the drug apixaban compared to a placebo. The eligibility criteria for the trial include patients who have received first or second-line chemotherapy for certain types of cancer and are able to begin study medication within 6 weeks of starting chemotherapy. Patients with a history of deep vein thrombosis or pulmonary embolism, active bleeding, or metastatic brain cancer are excluded from the trial. Other exclusion criteria include uncontrolled hypertension, coagulopathy, and certain liver and kidney function abnormalities.",
    "The sample is a phase 2 clinical trial for prostate cancer. The trial includes patients with adenocarcinoma of the prostate who have castration-resistant disease despite ongoing chemical or surgical castration. The trial also includes patients with radiographic evidence of metastatic disease who have had prior treatment with docetaxel and have progressed by RECIST or PSA or are intolerant of treatment. The trial excludes patients with small cell carcinoma of the prostate, those who have received treatment within 2 weeks with approved, investigational, or small molecule, and those who have received treatment within 4 weeks with biologic or external beam radiation. The trial also excludes patients with ANC <1,500 cells m3, platelets <100,000 mm3, hemoglobin <9.0g/dL, AST/ALT >2.5 ULN, serum creatinine >3.0mg/dL, active keratitis or keratoconjunctivitis, previous treatment with 17-AAG, DMAG, or any other HSP-90 inhibitor, and baseline Qtc >450 mses. The drug being tested in the trial is ipi-504.",
    "The sample is a phase 2 trial for the treatment of primary open angle glaucoma and ocular hypertension. The trial involves the drug dorzolamide-timolol-brimonidine. The eligibility criteria for the trial includes adult subjects of any race and gender with open-angle glaucoma or ocular hypertension and a visual acuity of 20/40 to 20/80 or better. The exclusion criteria includes any clinically relevant ophthalmic or systemic conditions. The diseases are listed along with their corresponding ICD-10 codes.",
    "The sample is a phase 2 clinical trial for the treatment of leukemia. The trial is looking for patients with morphologically confirmed acute myeloid leukemia or secondary AML. Patients must have received prior remission induction chemotherapy and have a genotypically HLA-identical sibling donor available. Patients must also meet certain age and performance status criteria. The trial is testing the effectiveness of cyclosporine, fludarabine, and mycophenolate mofetil. The eligibility criteria include various medical and personal factors, such as negative pregnancy test, HIV negative, and no other malignancy within the past 2 years. The sample also includes information on prior concurrent therapy, such as no prior allogeneic hematopoietic stem cell transplantation.",
    "This sample is for a phase 2 clinical trial for the treatment of mild to moderate allergic asthma. The trial is testing the effectiveness of two drugs, tpi-1020 and budesonide. The eligibility criteria include being between 18 and 65 years old, having a smoking history of more than 5 pack/years but less than 25 pack/years, and currently smoking at least 5 cigarettes per day. In addition, the participant must have mild to moderate, stable, allergic asthma as defined by American Thoracic Society criteria and be currently receiving only inhaled short-acting bronchodilator treatment for asthma. The exclusion criteria include a history or symptoms of significant autoimmune, hematological, or neurological disease, a history of serious adverse reaction or hypersensitivity to corticosteroids, and use of oral/parenteral/inhaled corticosteroids within the last 28 days or injectable depot corticosteroids within the last 6 weeks.",
    "The sample is a record of a clinical trial with a phase 2 designation. The trial is focused on the disease asthma and includes a list of ICD-10 codes associated with the disease. The trial involves the use of three drugs: jnj 40929837, placebo, and montelukast. The eligibility criteria for the trial include being generally healthy, having mild atopic asthma, and having a positive response to a bronchial allergen challenge. Females who are post-menopausal, surgically sterilized, or practicing a highly effective method of birth control are eligible to participate. Exclusion criteria include recent respiratory tract infections, HIV or Hepatitis B or C positive status, recent use of investigational drugs or medical devices, and current or recent tobacco use. The sample also includes additional exclusion criteria related to abnormal physical examination, vital signs, or electrocardiogram results.",
    "The sample is a phase 2 clinical trial for the treatment of malignant mesothelioma, a type of cancer that affects the lining of the lungs, abdomen, or heart. The trial involves the use of three drugs - bevacizumab, cisplatin, and pemetrexed - and has specific eligibility criteria for patients to participate. Patients must have histologically proven malignant mesothelioma that is not amenable to curative surgery or radiotherapy, and must not have a currently active second malignancy or uncontrolled intercurrent illness. The trial also has exclusion criteria, such as a history of allergic reactions to the study medications or inability to interrupt aspirin or other non-steroidal medication for a 5 day period. The trial is designed to evaluate the safety and efficacy of the drug combination in treating malignant mesothelioma.",
    "The sample is a phase 2 clinical trial for the treatment of atopic dermatitis. The trial involves testing several drugs, including gw870086 2.0%, gw870086 0.2%, fp 0.05%, and placebo. The eligibility criteria for the trial include having a diagnosis of atopic dermatitis, being between 18 and 65 years old, having a BMI within the range of 19.0 - 29.0 kg/m2, and having body surface area (BSA) disease involvement of >5%. Exclusion criteria include having any systemic disorder or active skin disease, having atopic dermatitis restricted to the face, feet, or hands only, and having a history of sensitivity to heparin or heparin-induced thrombocytopenia. The sample also includes a detailed list of inclusion and exclusion criteria for the trial.",
    "The sample is a phase 2 clinical trial for patients with stage IIIB or IV non-small cell lung cancer. The trial is testing the drug bortezomid (velcade\u00ae). The eligibility criteria include having no prior chemotherapy or systemic anti-tumour therapy, measurable disease as defined by RECIST criteria, an ECOG performance status of 0-2, and a life expectancy of at least 12 weeks. Patients must also meet certain health requirements, such as having a granulocyte count > 1.5 x 109/L and a platelet count > 100 x 109/L. The trial excludes patients with certain medical conditions or who are nursing mothers. Patients must provide written informed consent to participate in the study.",
    "The sample is a phase 2 clinical trial for smoking cessation. The trial includes individuals between the ages of 18 and 65 who have smoked cigarettes daily for the past 6 months and are currently smoking more than 10 cigarettes per day. The trial involves the use of the drug methylphenidate and a placebo. The eligibility criteria include being able to participate fully in all aspects of the study, having provided informed consent, and not having clinically significant levels of current depression or a lifetime diagnosis of bipolar disorder, schizophrenia, or dementia. Exclusion criteria include current use of any tobacco treatment program, recent use of an investigational drug, alcohol or drug abuse or dependence within the past year, pregnancy or lactation, and a history of major cardiovascular events or specific medical conditions where the use of methylphenidate is contraindicated.",
    "The sample is a phase 2 clinical trial for breast cancer and its effects, including cognitive/functional effects, depression, malnutrition, and psychosocial effects. The trial involves the use of the drugs ac regimen, cyclophosphamide, and doxorubicin hydrochloride. The eligibility criteria include having histologically confirmed invasive adenocarcinoma of the breast, being postmenopausal, and meeting various medical requirements such as having normal blood counts and no serious comorbid conditions. Participants must also have undergone prior surgery that included axillary lymph node or sentinel node dissection and have negative margins. The trial excludes individuals with certain medical conditions or other cancers within the past 5 years, as well as those with familial, geographical, social, or psychological conditions that would preclude study participation.",
    "The sample is a record of a clinical trial with a phase 2 designation, focused on bladder cancer. The trial includes patients who are 18 years or older and have been newly diagnosed with muscle-invasive transitional cell bladder cancer. The patients must be eligible for neoadjuvant chemotherapy and radical cystectomy with curative intent. The trial has inclusion and exclusion criteria, including the requirement that patients have histopathologically confirmed transitional cell carcinoma and tumor tissue that has been confirmed to express hCG-\u03b2 by a central laboratory. Patients who have previously undergone systemic chemotherapy or radiation for bladder cancer are not eligible for the trial. Additionally, patients with certain medical conditions or infections are excluded from the trial.",
    "The sample is a phase 2 clinical trial for the treatment of melanoma (skin cancer) using the drug Tanespimycin. The trial requires patients to have confirmed metastatic melanoma with measurable disease progression at two time points separated by at least 6 months. Patients must also meet certain eligibility criteria, including being 18 years or older, having a performance status of ECOG 0-1, and having a life expectancy of more than 3 months. Patients must also meet certain hematopoietic, hepatic, renal, and cardiovascular requirements, and cannot have certain other illnesses or conditions. Prior concurrent therapy is also restricted. The trial is designed to evaluate the safety and efficacy of Tanespimycin in treating melanoma.",
    "The sample is a phase 2 clinical trial for the treatment of impetigo, a skin infection. The trial is testing the effectiveness of a topical minocycline foam called fxfm244. The eligibility criteria for the trial include patients with a clinical diagnosis of pure impetigo, impetigo contagiosa, or uncomplicated blistering impetigo, who are 2 years of age or older and in general good health. Patients must have no less than two lesions and no more than seven lesions, each with an area of 0.5x0.5cm. Patients must not have any medical conditions that could interfere with study participation and must be willing and able to comply with all requirements of the protocol. Exclusion criteria include the presence of skin diseases at or near the investigational area, immunosuppressed state or other serious systemic disease, signs and/or symptoms of systemic infection, and use of other drugs that could confound the evaluation of the effect of the study drugs. Pregnant or lactating women are also excluded from the trial.",
    "The sample is a phase 2 trial for knee pain. The trial includes patients who have chronic prosthetic knee joint pain for more than 3 months and have a pain rating of 6 or greater on a 10 point Numerical Pain Rating scale. The trial involves the use of botulinum toxin a and normal saline as drugs. The eligibility criteria include being 18 years or older, providing written informed consent, and having a negative urine pregnancy test (for females of childbearing potential). Exclusion criteria include having a medical condition that may put the subject at increased risk with exposure to BOTOX, known allergy or sensitivity to any of the components in the study medication, and history of recent or ongoing alcohol or drug abuse.",
    "The sample is a record of a clinical trial with a phase 2 designation. The trial is focused on patients with type 2 diabetes mellitus who have been previously treated with no more than one drug. The trial includes a list of diseases and their corresponding ICD-10 codes, as well as a list of drugs being tested, including placebos and linagliptin. The eligibility criteria for the trial include a specific range of glycosylated haemoglobin A1 (HbA1c) levels and exclude patients with recent myocardial infarction, stroke, or TIA, impaired hepatic function, renal insufficiency, and recent treatment with certain drugs.",
    "This is a sample from a clinical trial table that includes information about the trial's phase, diseases being studied, icd-10 codes of those diseases, drugs being used, and eligibility criteria for participants. In this particular sample, the trial is in phase 2 and is studying recurrent non-small cell lung cancer. The icd-10 codes associated with this disease are listed, as well as the drugs being used in the trial (triapine and gemcitabine hydrochloride). The eligibility criteria for participants are also listed, including requirements such as having failed one prior cytotoxic chemotherapy regimen, having an ECOG performance status of 0 or 1, and having completed any radiation therapy or prior chemotherapy at least 3 weeks prior to registration. There are also exclusions, such as pregnant women and patients with active second malignancies or uncontrolled intercurrent illness.",
    "The sample is a record of a clinical trial with a phase 2 designation. The trial is focused on treating malignant glioma, a type of brain tumor. The trial is testing the drug enzastaurin. The eligibility criteria for the trial include being at least 18 years old, having a recurrent brain tumor diagnosed by MRI or CT scan, and being able to swallow the LY317615 tablets. The exclusion criteria include being pregnant or breastfeeding if you are a woman, and having significant heart, liver, kidney, or psychiatric disease as determined by your doctor.",
    "The sample is a phase 2 clinical trial for the treatment of multiple myeloma and plasma cell neoplasm. The trial involves the use of drugs such as cyclophosphamide, dexamethasone, and lenalidomide. The eligibility criteria for the trial include a diagnosis of multiple myeloma, measurable or evaluable disease, and certain patient characteristics such as ECOG performance status, ANC, platelet count, and creatinine levels. Prior concurrent therapy is also taken into consideration. The sample includes detailed information on the disease characteristics, patient characteristics, and prior concurrent therapy.",
    "The sample is a phase 2 clinical trial for patients with rheumatoid arthritis. The trial includes patients between the ages of 18 and 75 who have been diagnosed with rheumatoid arthritis for at least 6 months and have failed at least one DMARD due to lack of efficacy or tolerability. The trial also requires patients to meet certain RA activity criteria, such as having documentation of swollen or tender joints or elevated CRP or ESR levels. Patients must provide written informed consent and meet other inclusion criteria, while also not meeting any of the exclusion criteria, such as having a history of vasculitis or recent drug or alcohol abuse. The trial involves testing the effectiveness of three drugs, including a placebo, and requires patients to comply with the protocol and attend multiple visits.",
    "The sample is a phase 2 clinical trial for patients with chronic anemia who are at least 65 years old and have a life expectancy of more than 6 months. The trial is testing the effectiveness of the drug Epoetin alfa. The trial includes patients who are community dwelling and have a Short Physical Performance Summary Score of 4-10 at screening and baseline, as well as a Mini Mental State Examination score of at least 24. Patients with active cancer or a history of venous thromboembolytic disease are excluded from the trial, as well as those who have previously been treated with Epoetin alfa or any form of erythropoietin recently.",
    "The sample is a phase 2 clinical trial for the treatment of pancreatic ductal adenocarcinoma. The trial includes patients who are 18 years or older, have confirmed locally advanced, unresectable, and/or metastatic pancreatic ductal adenocarcinoma, and have experienced cancer progression after treatment with one gemcitabine and one fluoropyrimidine-containing chemotherapy regimen. The trial drug being tested is inno-206. The eligibility criteria include measurable tumor lesions, ECOG performance status 0-1, life expectancy of at least 8 weeks, and the ability to provide informed consent and comply with trial procedures. Women must not be able to become pregnant for the duration of the study and must have a negative pregnancy test at the screening visit. The exclusion criteria include prior exposure to > 3 cycles or 225 mg/m2 of doxorubicin or Doxil\u00ae, palliative surgery and/or radiation treatment less than 4 weeks prior to randomization, and exposure to any investigational agent within 30 days of randomization. Other exclusion criteria include laboratory values outside of normal ranges, clinically evident congestive heart failure, history or signs of active coronary artery disease, and any condition that is unstable and could jeopardize the subject's participation in the study.",
    "The sample is a phase 2 trial for Burkitt lymphoma, non-Hodgkin's lymphoma, and atypical Burkitt lymphoma. The trial involves the use of drugs such as rituximab, cyclophosphamide, doxorubicin, vincristine, methotrexate, leucovorin, ifosfamide, etoposide, cytarabine, and mesna. The eligibility criteria for the trial include having a histologically documented Burkitt or atypical Burkitt according to World Health Organization criteria, measurable or evaluable disease, and being over 18 years old. Exclusion criteria include previous chemotherapy or radiation therapy, uncontrolled bacterial, fungal, or viral infection, and serious comorbid disease. All males and females with reproductive potential must consent to use an effective form of contraception while on the study.",
    "The sample is a phase 2 clinical trial for Parkinson's disease. The trial is looking at the effectiveness of topiramate as a treatment for patients with stable levodopa-induced dyskinesias that are moderately to completely disabling. The trial has specific inclusion and exclusion criteria, such as a diagnosis of idiopathic PD, stable anti-parkinsonian medication for at least one month prior to enrollment, and no history of certain medical conditions or drug use. The trial is not open to pregnant women or individuals with cognitive impairment.",
    "The sample is a phase 2 clinical trial for patients with acute coronary syndrome. The trial involves the use of two drugs, via-2291 and placebo. The eligibility criteria for the trial include recent documentation of an ACS event, carotid or ascending aorta artery plaque inflammation, and receiving concomitant statin therapy for at least 4 weeks. Exclusion criteria include renal insufficiency, cirrhosis, uncontrolled diabetes, heart failure, recent CABG surgery, use of certain medications, and allergies to contrast agents. The trial does not allow for patients with planned additional cardiac intervention or certain heart conditions.",
    "The sample is a record of a clinical trial in phase 2, focused on HIV infections. The trial involves the use of two drugs, rosiglitazone and placebo, and includes a list of eligibility criteria for participants. Inclusion criteria include having lipoatrophy, using thymidine sparing ARV for at least 24 weeks, and having used prior thymidine NRTIs for at least 12 months. Exclusion criteria include having diabetes, heart failure, liver disease, or undergoing hormonal therapies.",
    "The sample is a phase 2 clinical trial for patients aged 20 years or older with permanent atrial fibrillation and a resting ventricular heart rate of at least 80 bpm at screening. The trial is testing the effectiveness of dronedarone (sr33589) compared to a placebo. The eligibility criteria include exclusion of patients with unstable angina pectoris, history of torsades de pointes, prolonged QT corrected interval, third degree atrioventricular block, congestive heart failure of New York Heart Association classification class IV or recent unstable NYHA class III, treatment with other class I or III anti-arrhythmic drugs, and clinically relevant haematologic, hepatic, gastro-intestinal, renal, pulmonary, endocrinologic or psychiatric disease. Hypokalemia and hypomagnesemia must be corrected before randomization. The sample includes the disease name of atrial fibrillation and the corresponding ICD-10 codes.",
    "The sample is a phase 2 clinical trial for rheumatoid arthritis. The trial includes patients who have been diagnosed with rheumatoid arthritis and have been receiving methotrexate for at least 6 months with a stable weekly dose between 10 and 25 mg for at least 8 consecutive weeks prior to study entry. The trial excludes patients who have taken certain drugs within a specific timeframe, including leflunomide, infliximab, etanercept, adalimumab, abatacept, or other biological therapies (except rituximab) within 12 weeks prior to the first dose of study medication, rituximab within 12 months prior to the first dose of study medication, and disease-modifying anti-rheumatic drugs (DMARDs) or other anti-rheumatic therapies not specified above within 12 weeks prior to the first dose of study medication. Additionally, patients who have been treated with any investigational medication within 12 weeks prior to the first dose of study medication are also excluded. The trial will involve the use of two drugs, incb018424 and placebo.",
    "The sample is a record of a clinical trial in phase 2 for the treatment of breast cancer. The trial is focused on pre-menopausal women who have undergone radical surgery and have histological/cytologically-confirmed ER +ve breast cancer. The trial involves the use of two drugs, goserelin acetate, and the eligibility criteria include a WHO performance status of 0, 1, or 2. The exclusion criteria include evidence of metastatic disease, previous bilateral oophorectomy or radiotherapy to the ovaries, previous chemotherapy, breast surgery completed over 12 weeks before starting trial treatment, and previous neo-adjuvant/adjuvant hormonal breast cancer therapy. The icd-10 codes associated with the disease are also included in the record.",
    "The sample is for a phase 2 clinical trial for the treatment of prostate cancer using the drug metformin. The eligibility criteria for patients include having histologically confirmed adenocarcinoma of the prostate that is locally advanced or metastatic with no curative therapy possible. Patients must also have PSA progression, defined as an increase in PSA of at least 25% (and an absolute increase of at least 2 ng/mL) over nadir value on hormonal therapy measured on 3 successive occasions at least 1 week apart. Patients must have a PSA doubling time of at least 55 days (if used to define progression, must not be older than 6 months), PSA less than 114 ng/mL, and testosterone level less than or equal to 1.7 nmol/L (less than or equal to 50 ng/dL) after at least 1 hormonal treatment (orchiectomy or luteinizing hormone-releasing hormone [LHRH] agonist). Patients who have not undergone surgical castration must continue LHRH agonist therapy during study treatment. Patients must also meet certain patient characteristics, such as having a WHO performance status of 0-1, hemoglobin of at least 90 g/L, and no serious underlying medical condition that would impair the ability of the patient to participate in the trial. Prior concurrent therapy is also specified, including at least 6 weeks since prior antiandrogen therapy and without withdrawal response, at least 30 days since prior treatment in another clinical trial, and no prior chemotherapy, radioisotopes, small molecules, or immunotherapy for prostate cancer.",
    "This sample is for a phase 2 clinical trial for sepsis. The trial is testing the effectiveness of a drug called intravenous gr270773- phospholipid emulsion. The eligibility criteria for the trial include receiving parenteral antibiotic therapy for a suspected or confirmed Gram-negative infection, having at least one new hypoperfusion abnormality or at least one new onset organ failure resulting from the current septic episode, and being available and able to receive the first dose of study medication no more than 12 hours after the confirmation of a new hypoperfusion abnormality or new onset organ failure and within 36 hours after the initiation of new parenteral antibacterial therapy for the suspected or confirmed Gram-negative infection believed to be responsible for this episode of sepsis. There are also exclusion criteria, such as having neutropenia, known active hemolytic disease, or a history of allergic reaction to certain components of the drug. The sample also includes a list of diseases and their corresponding icd-10 codes.",
    "The sample is a phase 2 clinical trial for metastatic breast adenocarcinoma. The trial is testing the effectiveness of the drugs vinorelbine and lapatinib on patients who have previously undergone treatment with an anthracycline and a taxane, as well as trastuzumab for locally advanced or metastatic disease. Patients must have measurable disease and meet certain eligibility criteria, including being HER2 positive, having a performance status of 0-2, and having adequate liver, renal, and bone marrow function. Patients with brain metastases must have received prior radiation therapy and cannot have progressive brain metastases. Patients must also provide written informed consent. Exclusion criteria include being unable to take oral medication, having an active infection, a history of significant cardiac disease, other invasive malignancies, psychiatric illness, or being pregnant or lactating.",
    "The sample is a phase 2 clinical trial for patients with myelodysplastic syndrome. The trial is investigating the effectiveness of the drug LBH589. The eligibility criteria include having intermediate-1 risk MDS or transfusion dependent low risk MDS, being at least 18 years old, and having certain laboratory criteria within normal limits. Patients must also have a negative pregnancy test and agree to use contraception during sexual contact. Exclusion criteria include prior treatment with an HDAC inhibitor, impaired cardiac function, and certain medications or medical conditions. The trial aims to determine the safety and efficacy of LBH589 in treating MDS.",
    "The sample is a phase 2 clinical trial for the treatment of obesity. The trial includes volunteers who weigh at least 50 kg and have a BMI between 30 and 50 kg/m2. The trial allows for participants with type 2 diabetes mellitus. The trial excludes participants who have used weight loss agents in the past month, have a current clinically significant eating disorder, or have type 1 diabetes mellitus. The trial will test the effectiveness of the drug beloranib compared to a placebo.",
    "The sample is a record of a clinical trial in phase 2 for the treatment of myelodysplastic syndrome. The trial involves the drug dn-101 (calcitriol) and the eligibility criteria include a diagnosis of low or intermediate-1 risk MDS, dependence on monthly blood transfusions, no history of cancer within the last 5 years (except for cured skin cancer), no heart attack or stroke within the last 6 months, and no kidney stones within the last 5 years. The icd-10 codes associated with the disease are also provided.",
    "The sample is a phase 2 clinical trial for the treatment of uterine leiomyosarcoma using the drug trabectedin. The trial is for patients with advanced, persistent, or recurrent disease who have documented disease progression and meet certain eligibility criteria. The eligibility criteria include having a confirmed histological diagnosis of uterine leiomyosarcoma, measurable disease, and a GOG performance status of 0-2. Patients must also meet certain laboratory values and have no active infections or neuropathy. Prior to enrollment, patients must have recovered from prior surgery, radiotherapy, or other therapy and must not have received prior cytotoxic chemotherapy or biologic therapy for uterine sarcoma. The trial excludes patients with prior trabectedin treatment or radiotherapy within the past 5 years to any portion of the abdominal cavity or pelvis other than for treatment of uterine sarcoma. Hormonal therapy for the malignancy is allowed if it was stopped at least 1 week prior to enrollment. Patients must be willing and able to have a central venous catheter and must not be receiving concurrent amifostine or other protective agents.",
    "The sample is a phase 2 clinical trial for patients with pulmonary arterial hypertension. The trial includes patients who are 18 years or older and have been diagnosed with PAH according to specific subgroups of the Venice Classification Group 1. The trial drug being tested is tezosentan. The eligibility criteria include having a modified NYHA functional class II-III and documented hemodynamic diagnosis of PAH by right heart catheterization. Exclusion criteria include patients with PAH in Venice Classification Groups 2-5, hypotensive patients, patients with body weight less than 50 kg, and patients with clinically significant chronic renal insufficiency. The trial also excludes patients who have received any investigational drugs within 28 days of Baseline and those with a known hypersensitivity to any of the excipients of the drug formulation. Females who are lactating or pregnant or not using a reliable method of birth control are also excluded. The trial has a total of 14 exclusion criteria.",
    "The sample is a phase 2 clinical trial for esophageal cancer. The trial is testing the effectiveness of cisplatin, fluorouracil, and iressa drugs. The eligibility criteria include having histologically or cytologically confirmed squamous cell carcinoma, adenocarcinoma, or large cell undifferentiated cancer of the esophagus or gastroesophageal junction with T3, N1, or M1a disease only. Patients must have no evidence of distant hematogenous tumor metastases or malignant pleural effusions. They must also have a performance status of ECOG 0-1 and meet certain hematopoietic, hepatic, renal, cardiovascular, and pulmonary criteria. Patients must not be pregnant or nursing, must use effective contraception if fertile, and must have no evidence of severe or uncontrolled systemic disease, no other uncontrolled malignancy, no active infection, and no known severe hypersensitivity to gefitinib or any of its excipients. Patients must not have had prior immunotherapy, chemotherapy, or radiotherapy for this cancer, and must have recovered from any prior oncologic or other major surgery. They must not have had prior surgical resection for this cancer or concurrent ophthalmic surgery, and must not have had prior photodynamic therapy for this cancer. Patients must not have taken phenytoin, carbamazepine, barbiturates, rifampin, phenobarbital, or Hypericum perforatum (St. John's wort) within 30 days prior to the trial.",
    "The sample is a phase 2 clinical trial for lupus erythematosus, systemic and lupus. The trial includes a list of icd-10 codes for the diseases, as well as a list of drugs including medi-545 and placebo. The eligibility criteria for the trial includes being at least 18 years old, meeting certain classification criteria for SLE, having positive ANA test results, and having at least one system with a score of A or two systems with a score of B on the BILAG index or a SELENA-SLEDAI score of 6 or higher. The trial also includes exclusion criteria such as having received MEDI-545 within 120 days prior to screening, having a history of allergy or reaction to any component of the study drug formulation, and having received certain medications within 28 days before randomization. The trial lasts for 168 days and participants must be willing to forego other forms of experimental treatment during the study.",
    "The sample is a clinical trial in phase 2 for the treatment of Generalized Anxiety Disorder (GAD) using the drug paroxetine and a placebo. The trial includes patients who have been diagnosed with GAD according to DSM-IV criteria and have given written informed consent. Patients with certain conditions such as Major Depressive Episode, Panic Disorder, and substance abuse are excluded from the trial. Women who are pregnant or lactating, or who plan to become pregnant within 30 days after the completion of the final dose, are also excluded. The trial aims to evaluate the effectiveness of paroxetine in treating GAD.",
    "The sample is a record of a clinical trial in phase 2 for the treatment of relapsing-remitting multiple sclerosis (RRMS). The trial includes the use of two drugs, ain457 and placebo. The eligibility criteria for the trial are not specified in the sample. However, the icd-10 codes for the diseases associated with the trial are listed as G35, G93.81, K74.1, Q85.1, G12.21, G12.23, and M34.0.",
    "The sample is a phase 2 clinical trial for patients with recurrent ovarian or primary peritoneal cancer. The trial requires patients to have received one prior platinum-based chemotherapy regimen containing carboplatin. Patients must have measurable disease and a treatment-free interval without clinical evidence of progressive disease for more than 6 months after response to a prior platinum-based regimen. Patients must also meet certain eligibility criteria related to age, performance status, hematopoietic, hepatic, renal, cardiovascular, neurologic, and other factors. The trial excludes patients with certain prior concurrent therapies and invasive malignancies within the past 5 years. The trial involves the use of the drug carboplatin and requires patients to meet certain criteria related to their disease characteristics and patient characteristics.",
    "The sample is a phase 2 clinical trial for chronic lymphocytic leukemia. The trial involves the drugs ofatumumab and lenalidomide. The eligibility criteria include confirmed diagnosis of CLL, prior therapy with rituximab, age over 18, life expectancy greater than 12 months, normal organ function, adequate bone marrow function, and willingness to sign a consent form. Female participants of childbearing potential must have a negative pregnancy test and commit to using two forms of birth control. Exclusion criteria include recent chemotherapy or radiotherapy, use of other investigational or anti-cancer agents, allergic reactions to the drugs, uncontrolled illness, pregnancy, and prior treatment with lenalidomide. Patients will also be screened for hepatitis B.",
    "The sample is a phase 2 trial for diabetes mellitus type 2. The trial includes patients between the ages of 18-70 who are currently taking metformin alone or in combination with one other oral agent. The trial will test the effectiveness of several drugs, including a placebo, pf-04937319 at 10mg, 50mg, and 100mg doses, and glimepiride. The trial has specific inclusion and exclusion criteria, such as excluding subjects with recent cardiovascular events or evidence of diabetic complications.",
    "The sample is a record from a clinical trial table that includes information about the phase of the trial, the disease being studied (in this case, type 2 diabetes mellitus), the corresponding ICD-10 codes, the drugs being tested (alogliptin and metformin), and the eligibility criteria for participants. The eligibility criteria include requirements such as having a stable dose of metformin for at least 12 weeks prior to the trial, having a certain level of glycosylated hemoglobin (HbA1c), and not having a history or symptoms of lactic acidosis. The sample is from a phase 2/phase 3 trial.",
    "The sample is a record from a clinical trial table that includes information about the trial's phase, diseases being studied, ICD-10 codes associated with those diseases, drugs being tested, and eligibility criteria for participants. In this particular sample, the trial is in phase 2 and is studying overactive bladder. The ICD-10 code associated with this disease is N32.81. The trial is testing three drugs: tarafenacin 0.2 mg, placebo, and tarafenacin 0.4 mg. The eligibility criteria for participants include being between the ages of 20 and 80, having experienced symptoms of overactive bladder for at least 6 months, and meeting certain criteria related to frequency and urgency of urination. There are also several exclusion criteria, including having certain medical conditions or contraindications to antimuscarinic drugs.",
    "The sample is a phase 2 clinical trial for patients with multiple myeloma and renal insufficiency. The trial is testing the effectiveness of the drug carfilzomib in patients who have relapsed or have progressive disease after receiving at least two prior treatment regimens. The eligibility criteria include having measurable disease, a life expectancy of more than three months, and meeting certain laboratory values. Exclusion criteria include recent chemotherapy or radiation therapy, glucocorticoid therapy, and certain medical conditions. Female subjects of child-bearing potential must have a negative pregnancy test and agree to use dual methods of contraception during and for 3 months following the last dose of the drug. The trial is looking to enroll patients who have not previously received carfilzomib treatment.",
    "The sample is a phase 2 clinical trial for the treatment of Rett syndrome, a neurological disorder. The trial involves the drugs epi-743 and placebo, and the eligibility criteria include a confirmed diagnosis of Rett syndrome with disease stage 1-2, abnormality of at least two disease biomarker levels, confirmed MeCP2 mutation, and the ability to consent and comply with protocol requirements. Exclusion criteria include any condition that could compromise the subject's safety or adherence to treatment with EPI-743, clinically significant allergies or hypersensitivity to EPI-743 or vitamin E, lack of confirmation of MeCP2 mutation, and other medical conditions such as hepatic or renal insufficiency.",
    "The sample is a phase 2 clinical trial for patients with confirmed Stage IIIB/ IV non-small cell lung cancer who have relapsed after treatment with 1 or 2 prior chemotherapy regimens, including at least 1 platinum-based treatment. The trial is testing the effectiveness of the drugs pralatrexate and erlotinib. The eligibility criteria include having an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1, adequate blood, liver and kidney function, and having received specific doses of folic acid and vitamin B12. Patients must also be accessible for repeat dosing and follow-up, and must give written informed consent. Exclusion criteria include having an active concurrent primary malignancy (except non-melanoma skin cancer or in situ carcinoma of the cervix), use of investigational drugs, biologics, or devices within 4 weeks prior to randomization, and previous exposure to pralatrexate or erlotinib.",
    "The sample is a phase 2 clinical trial for the treatment of head and neck cancer and squamous cell carcinoma. The trial involves the use of two drugs, cisplatin and panitumumab. The eligibility criteria for the trial include having a confirmed diagnosis of Stage III or IVa-b squamous cell carcinoma of the oral cavity, oropharynx, hypopharynx or larynx, having an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1, being at least 18 years of age, having adequate kidney, liver and blood cell function, and having measurable disease. Exclusion criteria include having cancer of the nasopharynx, sinus, salivary gland or skin, having a history of another cancer (other than head and neck) unless treated with curative intent and with no evidence of disease for more than 3 years, having previous treatment with anti-endothelial growth factor receptor (EGFr) antibody therapy or EGFr inhibitors, having previous treatment for head and neck cancer with chemotherapy, surgery or radiotherapy, having clinically significant cardiovascular disease, chronic obstructive pulmonary disease resulting in hospitalization within 6 months of study screening, having a history or evidence of interstitial lung disease, and having had major surgery within 28 days of screening.",
    "This sample is a phase 2 clinical trial for patients with squamous cell carcinoma of the head and neck who have stage III or IV disease without evidence of distant metastases. The trial is testing the effectiveness of the drug docetaxel. The eligibility criteria include having measurable disease, an ECOG performance status of 0-1, and meeting certain laboratory values. Patients must not have a history of certain medical conditions, including heart disease, stroke, or HIV positivity. They must also not have received prior chemotherapy or radiotherapy, or be receiving any other concurrent anticancer therapy.",
    "The sample is a phase 2 clinical trial for hypertension. The trial includes patients between the ages of 30 and 80 with a mean seated systolic blood pressure between 150 and 179 mmHg and a mean seated diastolic blood pressure below 110 mmHg at two consecutive qualifying visits. The trial also requires patients to have a mean daytime ambulatory systolic blood pressure between 140 and 179 mmHg and a mean daytime diastolic blood pressure below 110 mmHg. Patients must have a usual daytime schedule and cannot be night shift workers. Women of child-bearing potential and male subjects must use two reliable forms of contraception if sexually active, or female subjects must be postmenopausal for at least one year. Exclusion criteria include serious disorders that may limit the ability to evaluate the efficacy or safety of the drug, a history of myocardial infarction, angina, coronary angioplasty, bypass surgery, or New York Heart Association class II-IV heart failure within the last six months, a history of cerebrovascular accident or transient ischemic attack within the last year, and diabetes mellitus (type I and type II).",
    "The sample is a phase 2 clinical trial for lung cancer. The eligibility criteria include having operable stage IIIB non-small cell lung cancer, no prior or concurrent metastatic disease, and meeting certain medical requirements such as normal bilirubin levels and a creatinine clearance of at least 60 mL/min. Patients must also meet certain age and performance status requirements, and cannot have certain medical conditions or be pregnant or nursing. The trial involves the use of the drug taxotere/cisplatin and patients cannot have had prior radiotherapy to the chest or other concurrent experimental drugs.",
    "The sample is a phase 2 clinical trial for patients with advanced or metastatic colorectal cancer who have failed prior fluorouracil-, oxaliplatin- and irinotecan-containing regimens. The trial requires patients to have mutant-type k-ras status (mutation in codon 12, 13, or 61) on tumor material and measurable disease according to RECIST criteria version 1.1. Patients must also meet certain patient characteristics such as having a WHO performance status of 0-2, normal levels of WBC, ANC, platelet count, hemoglobin, serum bilirubin, AST/ALT, creatinine clearance, magnesium, and calcium. Patients must not have a history of interstitial lung disease or clinically significant cardiovascular disease. They must also not have a history of toxicity during statin use and must not be using verapamil, amiodarone, or dronedarone. Prior concurrent therapy is also taken into consideration.",
    "The sample is a phase 2 clinical trial for patients with non-small cell lung cancer. The trial includes patients with unresectable stage III or stage IV disease who are at least 70 years old and have an ECOG performance status of 0-1. Patients who have had previous radiation therapy or systemic therapy are also eligible, provided certain criteria are met. The trial involves the drugs erlotinib and satraplatin. The eligibility criteria include adequate hematological, hepatic, and renal function, as well as specific exclusion criteria such as concurrent invasive malignancy requiring ongoing therapy and a history of cardiac disease.",
    "The sample is a phase 2 clinical trial for the treatment of severe congenital hemophilia A using the drug rituximab. The trial is looking for participants who have a documented historical inhibitor titer to factor VIII of at least 5 BU/mL and an inhibitor level greater than or equal to 5 BU/mL 5 to 14 days after initial factor VIII exposure during screening. The trial has a list of exclusion criteria, including known hypersensitivities or allergies to murine and/or humanized antibodies, currently participating in investigational hemophilia studies, HIV infected, any immunodeficiency disorder, liver disease, and more. The trial is not looking for participants who have previously received rituximab treatment or are currently undergoing immune tolerance therapy. The trial also has specific criteria for participants with a high responding inhibitor. Participants who routinely receive factor VIII concentrate for the treatment of both major and minor bleeding events or have received factor VIII concentrate in the 7 days prior to study entry are not eligible to participate.",
    "The sample is a phase 2 clinical trial for kidney transplantation. The trial involves administering a combination of drugs including alefacept, tacrolimus, basiliximab, mycophenolate mofetil, and corticosteroids to recipients of a de novo kidney transplant from a non-HLA identical related living donor, a non-related living donor, or a deceased donor. The trial has specific inclusion and exclusion criteria, such as the recipient having a screening estimated CD4+ T-cell count of at least 250 cells/\u00b5L and not receiving a kidney with an anticipated cold ischemia time of more than 30 hours.",
    "The sample is a phase 2 clinical trial for the treatment of myasthenia gravis, a disease affecting neuromuscular function. The trial involves the use of two drugs, eculizumab and placebo, and has specific eligibility criteria for participants, including a minimum QMG score and a positive serologic test for binding anti-acetylcholine receptor Abs. Exclusion criteria include a history of thymoma or other neoplasms of the thymus, pregnancy or lactation, and current or chronic use of plasmapheresis/plasma exchange. The trial aims to assess the efficacy and safety of the drugs in treating the disease.",
    "The sample is a phase 2 clinical trial for patients with relapsed/refractory multiple myeloma. The trial is testing the drug \"syb l-0501\". The eligibility criteria include having a diagnosis of multiple myeloma, measurable lesions, and meeting certain criteria for prior chemotherapy. Patients must also have adequately maintained organ functions and be expected to survive for at least 3 months. Exclusion criteria include having infections, serious complications, or medical history of serious cardiac disease. Patients who have received allogeneic stem cell transplants in the past or who are pregnant or lactating are also excluded. Patients must provide written consent to participate in the study.",
    "This sample is a phase 2 clinical trial for the treatment of colorectal and liver neoplasms. The trial involves a combination therapy of irinotecan with 5-fu, leucovorin plus bevacizumab in the neoadjuvant setting. The eligibility criteria for the trial include having an ECOG performance status of 0 or 1, and a histological documentation of adenocarcinoma of the colon or rectum. The exclusion criteria include having prior systemic anticancer therapy for mCRC, and prior hepatic surgery, chemoembolization, hepatic artery infusion, radiofrequency ablation or cryotherapy for liver metastases. The diseases are listed along with their corresponding ICD-10 codes, and the drugs used in the trial are also listed.",
    "The sample is a phase 2 clinical trial that involves patients with cancer and constipation. The trial is testing the effectiveness of different doses of the drug alvimopan compared to a placebo in treating opioid-induced constipation. The patients must be taking opioid therapy for continued intractable pain and experiencing less bowel movement frequency compared to before the opioid treatment. The inclusion criteria also require the patients to meet the protocol-definition of opioid-induced constipation. However, patients with gastrointestinal or pelvic disorders known to affect gastrointestinal functions or induce bowel transit disorder and ileus are excluded from the trial. Additionally, patients who have gastrointestinal dysfunction predominantly due to causes other than the use of opioids are also excluded.",
    "The sample is a phase 2 clinical trial for patients with non-small cell lung cancer. The trial is testing the effectiveness of three drugs - cisplatin, docetaxel, and pemetrexed disodium. The eligibility criteria include having a histologic or cytologic diagnosis of NSCLC and meeting specific staging criteria. Patients must also have a SWOG performance status of 0 or 1, certain blood counts, and normal liver and kidney function. They cannot have brain metastases or any other concurrent malignancy. Patients must not have had prior chemotherapy or radiotherapy for NSCLC and cannot participate in another therapeutic investigational study. They must also be willing and able to take certain medications and not have any serious medical illnesses.",
    "The sample is a phase 2 clinical trial for patients with metastatic breast cancer. The trial is testing the effectiveness of the drugs wx-671 and placebo as first-line, mono chemotherapy with capecitabine. The eligibility criteria include being a female aged 18 or older, having histological or cytological confirmed, non-inflammatory metastatic breast cancer, being HER2-negative, having a complete staging within 2 weeks prior to randomization, having an ECOG performance status of \u2264 2, and having normal organ and marrow function. Exclusion criteria include having undergone endocrine therapy, prior chemotherapy or biologic therapy for metastatic disease, major surgery within 4 weeks prior to the start of treatment, and other anti-cancer treatment within 2 weeks before the start of treatment. The trial also excludes patients with a history of brain metastasis, active seizure disorder or history of cerebrovascular accident, history of other malignancy within the last 3 years, active cardiac disease, and any unrelated illness or medical condition that might significantly affect patients' study participation.",
    "The sample is a phase 2 clinical trial for the treatment of epithelial ovarian cancer, primary peritoneal carcinoma, or fallopian tube cancer using voreloxin injection. The trial requires patients to have completed at least one Platinum Based Therapy (PBT) regimen and have evidence of platinum-resistant disease, relapse/progression within 6 months of the completion of PBT, or be intolerant to PBT. Patients with primary platinum-resistant disease are allowed to receive no more than one nonplatinum cytotoxic regimen and no more than one noncytotoxic regimen for the management of recurrent or persistent disease after the development of primary platinum-resistance. The trial also requires patients to have measurable disease per GOG-RECIST criteria and a GOG Performance Status of 0 or 1. There are various exclusion criteria, including recent radiotherapy, chemotherapy, and hormonal, cytokine, or targeted therapy, unresolved or impending bowel obstruction, and other active malignancies or other malignancies within the last 12 months except nonmelanoma skin cancer or cervical intraepithelial neoplasia. Patients with a history of active CNS metastases or any other medical, psychological, or social condition that would contraindicate their participation in the clinical study due to safety or compliance with clinical study procedures are also excluded.",
    "The sample is a phase 2 clinical trial for patients with myasthenia gravis, a neuromuscular disease. The trial includes patients between the ages of 18 and 80 who have a confirmed diagnosis of MG and have been stable for at least 4 weeks prior to the trial. The trial involves testing the effectiveness of three different drugs, including a placebo. Patients must meet certain inclusion criteria, such as having a BMI between 18.0 and 36.0 kg/m2 and being able to perform all elements of the QMG. Patients must also meet certain exclusion criteria, such as having a history of chronic degenerative, psychiatric, or neurologic disorder other than MG that can produce weakness or fatigue. The trial requires patients to refrain from IVIg treatments and cholinesterase-inhibitors for a certain period of time before each dose. Female patients must agree to use a double barrier during sexual intercourse, and male patients must agree to use a condom during sexual intercourse with female partners who are of reproductive potential.",
    "The sample is a phase 2 clinical trial for the treatment of migraine headaches. The trial includes individuals who are 18 years or older and have a well-documented history of migraine headaches with or without aura. The trial requires participants to have at least 2 (or 3, depending on the country) well-defined migraine headache attacks per month, with at least 24 hours of freedom from headaches and other symptoms of migraine between attacks. Participants must be able to distinguish migraine headache attacks from other types of common headaches. The trial excludes individuals with a known hypersensitivity to the drug being tested or to other carboxamide derivatives, suspected or confirmed medication-overuse headache, and more than 14 headache days per month in either of the 2 months prior to screening. The trial also excludes individuals with consistent or recurrent frequent headaches other than migraine headaches, and those who are unable to discontinue medications primarily used for migraine prophylaxis that have been commonly used for other indications. The trial requires participants to comply with all study requirements and be willing to provide written informed consent to participate in the study.",
    "The sample is a phase 2 clinical trial for breast cancer patients. The trial is testing the effectiveness of the drug docetaxel in treating stage IV breast cancer that is HER2-negative. The trial has eligibility criteria that include being a female over 18 years old, having a confirmed diagnosis of adenocarcinoma of the breast, having at least one measurable lesion according to the RECIST criteria, and having an ECOG performance status of 0-1. The trial also has exclusion criteria that include having prior chemotherapy for metastatic breast cancer, having concurrent therapy with any other non-protocol anti-cancer therapy, and having a history of a severe hypersensitivity reaction to Bevacizumab, Docetaxel, or other drugs formulated with polysorbate 80. The trial requires patients to provide written informed consent and meet certain laboratory values.",
    "The sample is a record from a clinical trial table. It is a phase 2 trial for diabetic peripheral neuropathy. The table includes a list of diseases, icd-10 codes, drugs, and eligibility criteria. The inclusion criteria include being 18 years or older, having a diagnosis of type-1 or type 2 non-insulin dependent diabetes mellitus, chronic bilateral pain due to diabetic neuropathy, pain for at least six months, and primary pain located in the feet. The exclusion criteria include symptoms of other painful conditions, presence of amputations other than toes, clinically significant psychiatric or other neurological disorder, use of certain medications, clinically important other diseases, pregnancy, history of alcohol or narcotic abuse within two years.",
    "The sample is a clinical trial that is in phase 2/phase 3 and focuses on patients with diabetes mellitus, heart failure, and coronary artery disease. The trial involves the use of the drugs telmisartan and bisoprolol, as well as a placebo. The eligibility criteria for the trial include being over 18 years old, having known diabetes mellitus for more than 6 months, and having an increased Nt-proBNP level above 125pg/ml. Exclusion criteria include having a life expectancy below 1 year due to a disease other than diabetes, suffering from chronic infection or malignant disease, being a woman of childbearing age without contraceptive, having a history of cardiac disease, being on systemic cortisone treatment, and being on chronic or acute hemodialysis, ultra filtration or peritoneal dialysis.",
    "The sample is a phase 2 clinical trial for the treatment of staphylococcal skin infection. The trial involves the use of two drugs, td-1792 and vancomycin. The eligibility criteria for the trial include patients with major abscess requiring surgical incision and drainage, infected burn, deep/extensive cellulitis, infected ulcer, or wound infections, who require at least 7 days of intravenous antibiotic treatment. Exclusion criteria include patients who have received more than 24 hours of antibiotic therapy, have moderate or severe liver disease, are severely neutropenic, have baseline QTc > 500 msec, congenital long QT syndrome, uncompensated heart failure, uncorrected abnormal K+ or Mg++ blood levels, or severe left ventricular hypertrophy.",
    "The sample is a phase 2 clinical trial for breast cancer patients with metastatic disease. The trial is testing the effectiveness of the drug docetaxel as a first-line chemotherapy treatment. The eligibility criteria include having histologically confirmed adenocarcinoma of the breast, measurable disease by CT scan or MRI, and meeting certain patient characteristics such as being female, over 70 years old, and having a certain performance status. The trial also has specific requirements for hematopoietic, hepatic, renal, and cardiovascular health, as well as other medical conditions and prior concurrent therapies. The trial does not allow concurrent trastuzumab therapy and has limitations on prior hormonal therapy and chemotherapy. The trial allows concurrent bisphosphonates for bone metastases, osteoporosis, or osteopenia, but no other concurrent anticancer or investigational drugs.",
    "The sample is a record of a clinical trial with a phase 2 designation. The trial is focused on breast cancer and includes a list of ICD-10 codes associated with the disease. The trial is testing the effectiveness of three drugs: gemcitabine, paclitaxel, and bevacizumab. The eligibility criteria for the trial includes being a female diagnosed with breast cancer that has spread to distant areas of the breast or organs, being able to measure the disease by specific medical parameters, having received breast cancer treatment in the early stage of the disease, being restricted in physically strenuous activity but able to carry out light work, and having adequate organ function as seen in blood test results. The exclusion criteria includes cancer that has spread to the brain, unstable heart problems, unstable high blood pressure, breast cancer treatment after the disease has considered to spread to other areas or organs, and being unable to agree with the requirements of the study.",
    "The sample is a phase 2 clinical trial for patients with metastatic renal cell carcinoma. The trial involves the use of the drug bevacizumab and requires patients to meet certain eligibility criteria, such as having measurable disease, adequate tumor tissue, and a Karnofsky Performance Status of at least 80%. Patients must also have adequate end organ function and appropriate contraception. Exclusion criteria include previous use of bevacizumab or IL-2, concomitant second malignancy, and significant co-morbid illness. The trial also has various other exclusion criteria related to medical history and current health status.",
    "The sample is a phase 2 trial for the treatment of hypercholesterolemia. The trial includes patients aged 18 to 75 years with primary hypercholesterolemia and an LDL-cholesterol level above 3.0 mmol/L. The trial involves the use of drugs such as ezetimibe and placebo, and eprotirome and ezetimibe. The eligibility criteria include following a specific diet and having no history of somatic or psychiatric conditions that may interfere with the study's objectives.",
    "The sample is a phase 2 clinical trial for patients with relapsed or refractory lymphoma. The trial includes patients with DLBCL stage II-IV or follicular lymphoma who have measurable disease and have failed 3 or more prior therapies. The trial drug is called MGCD0103. Patients must have at least one related symptom due to disease, an ECOG performance status of 0 or 1, and meet certain laboratory requirements. Exclusion criteria include patients with active cancer (excluding basal cell carcinoma or cervical intraepithelial neoplasia), pregnant or lactating women, uncontrolled intercurrent illness, and serious medical conditions that would interfere with participation in the study.",
    "The sample is a phase 2 clinical trial for patients with neurogenic detrusor overactivity due to spinal cord lesions. The trial is testing the effectiveness of a drug called saf312 compared to a placebo. The patients must be inadequately managed by antimuscarinic medication and have a cystometric bladder capacity of max. 400 mL. The inclusion criteria also specify that patients must not have chronic inflammation such as interstitial cystitis, bladder stones, hematuria of unknown origin, previous pelvic radiation therapy or previous or current malignant disease of the pelvic organs, or pelvic or genitourinary tract anomalies including surgery or bladder disease other than detrusor overactivity impacting on bladder function.",
    "The sample is a record from a clinical trial table that includes information about the trial's phase, diseases being studied, ICD-10 codes associated with those diseases, drugs being tested, and eligibility criteria for participants. In this particular sample, the trial is in phase 2 and is focused on knee osteoarthritis. The ICD-10 codes associated with the disease are listed, as well as the drugs being tested (sar113945 and placebo). The eligibility criteria for participants are also listed, including requirements for diagnosis, age, gender, and exclusion criteria such as the presence of other conditions or recent intra-articular injections. The information provided is not intended to be comprehensive and may not include all relevant considerations for potential participants.",
    "The sample is a phase 2 clinical trial for patients with non-small cell lung cancer who have failed at least one front-line metastatic NSCLC chemotherapy regimen. The trial requires patients to have a diagnosis of pathologically confirmed NSCLC by tumor biopsy and/or fine-needle aspiration, and a diagnosis of either stage IIIB, stage IV, or advanced, incurable NSCLC. Patients must also have uni-dimensionally measurable NSCLC, a Karnofsky performance status >/= 60 or ECOG performance status 0-2, and adequate hematologic, hepatic, and renal function. Patients must be >/= 18 years of age, have signed informed consent, and be considered legally capable of providing their own consent for participation in the study. The trial has exclusion criteria, including prior investigational therapy, chemotherapy, surgery, or radiotherapy within 4 weeks of initiating study drug, significant medical history or unstable medical condition, uncontrolled seizure disorder, active neurologic disease, or neuropathy >/= grade 2, and pregnancy or breastfeeding.",
    "The sample is a phase 2 clinical trial for the treatment of ankylosing spondylitis, a type of arthritis that affects the spine. The trial involves testing the effectiveness of the drugs sarilumab and placebo. The eligibility criteria for participants include a diagnosis of AS according to the New York modified criteria, having active AS for at least 3 months before screening, and meeting certain scores on the Bath Ankylosing Spondylitis Disease Activity Index and Total back pain score. Participants must also have had an adequate trial of at least 2 different Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) taken for at least 2 weeks in each case and, on a stable dose for \u22652 weeks or be intolerant to NSAIDs. Exclusion criteria include being under 18 or over 75 years old, having complete fusion of the spine, and having a past history of non-response to any anti-Tumor Necrosis Factors (TNFs) treatment or non-response to any other biological treatment for AS. The sample also includes information on stable doses of certain medications and restrictions on the use of corticosteroids and other drugs.",
    "The sample is a phase 2 clinical trial for the treatment of atopic dermatitis. The trial is open to both male and female participants who are 12 years of age or older and have mild to severe atopic dermatitis. The participants must have an Investigator Global Assessment rating of 2 through 4 and a Visual Analog Scale of Itch score at Baseline greater than or equal to 50 on a 100-point scale. The percentage of overall body surface area of involvement must be at least 2%. Women of childbearing potential are allowed to participate but must use at least one form of birth control. Exclusion criteria include the use of certain medications, the presence of certain medical conditions, and known allergies or sensitivities to the treatment being studied. Pregnant women and women who are breastfeeding are also excluded from the trial.",
    "The sample is a record of a clinical trial with a phase 2 designation, focused on the disease gastroparesis. The trial includes a list of ICD-10 codes for the disease, as well as a list of drugs being tested, including gsk962040 (50 mg), placebo, and gsk962040 (75 mg). The eligibility criteria for the trial are also listed, including age range, mechanical ventilation status, and nasogastric tube feeding intolerance. The sample also includes exclusion criteria, such as recent exposure to investigational products or sensitivity to study medications.",
    "This sample is for a phase 2 clinical trial for the treatment of metastatic breast cancer. The trial is testing the effectiveness of sagopilone (zk 219477) in patients who have previously received treatment with anthracyclines and taxanes for their breast cancer. The trial requires patients to have at least one measurable lesion by CT or MRI and to have experienced progression of their disease following previous therapy. Patients must not be pregnant and must meet additional criteria to be determined at the screening visit. Exclusion criteria include having received more than three previous chemotherapy regimens, more than one treatment with non-cytotoxic agents for breast cancer therapy, prior treatment with epothilones, and symptomatic brain metastases. Additional exclusion criteria will also be determined at the screening visit.",
    "The sample is a phase 2 clinical trial for non-small cell lung cancer. The trial includes patients who have not received any prior chemotherapy, molecular therapy, immunotherapy, biological therapy, or radiotherapy, except for palliative radiotherapy that was completed at least 4 weeks prior to study enrollment. Patients must have a histologic or cytologic diagnosis of non-small cell lung cancer (NSCLC) at Stage IIIB or IV, and must have 'never smoked' (defined as having smoked less than 100 cigarettes during their lifetime). Patients must also have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1. The trial excludes patients who are concurrently receiving any other tumor therapy, have other co-existing malignancies, are pregnant or breastfeeding, have serious concomitant disorders, or are unable or unwilling to take folic acid or vitamin B12 supplementation. The trial will test the effectiveness of the drugs pemetrexed, cisplatin, and gefitinib.",
    "The sample is a record of a clinical trial with a phase 2 designation. The trial is focused on treating patients with colorectal adenocarcinoma and liver metastases using perioperative chemotherapy. The eligibility criteria for the trial include having stage IV colorectal cancer isolated to the liver, one measurable lesion, and metastases that are completely resectable or amenable to ablation. Patients must also have a Karnofsky score of over 70 and adequate bone marrow, hepatic, and renal function. The exclusion criteria include having a primary tumor that is not controlled by locoregional treatments, previous chemotherapy for metastatic colorectal cancer, and underlying liver disease or Gilbert's disease. Patients who are pregnant or have another malignancy other than basal cell or squamous cell carcinoma of the skin within the preceding 5 years are also excluded. Additionally, patients cannot be using another investigational medication concurrently or within 4 months of enrollment.",
    "The sample is a phase 2 clinical trial for patients with colorectal cancer. The trial involves the use of two drugs, capecitabine and celecoxib, and has specific eligibility criteria for patients to participate. These criteria include having histologically confirmed rectal adenocarcinoma, being at a certain stage of the disease, and having no distant metastatic disease. Patients must also meet certain age and health requirements, such as having a certain performance status and no significant cardiac disease. The trial has specific prior concurrent therapy requirements, including no prior systemic anticancer chemotherapy and no prior radiotherapy to the pelvis. Patients must also not be taking certain medications or undergoing certain treatments during the trial.",
    "This sample is for a phase 2 clinical trial for breast cancer patients with HER2-positive, ER-positive and/or PR-positive disease. The trial is testing the drug Faslodex and the eligibility criteria includes being a postmenopausal female with a histologically or cytologically proven adenocarcinoma of the breast. Patients must have no prior chemotherapy, endocrine therapy, Herceptin, or other biologic or investigational therapy for metastatic breast cancer. The trial also requires certain laboratory values to be met and excludes patients with certain medical or psychiatric disorders, bleeding diathesis, and long-term anticoagulant therapy.",
    "The sample is a phase 2 clinical trial for asthma treatment. The trial includes patients between 6 and 11 years old who have had asthma for at least 6 months and are currently on maintenance treatment with inhaled corticosteroids. Patients must also be symptomatic and have a pre-bronchodilator FEV1 between 60% and 90% of predicted normal. The trial involves the use of tiotropium bromide inhaler and patients must be able to inhale from the inhaler correctly. The eligibility criteria also includes technical requirements for spirometric manoeuvres and the use of an electronic diary/peak flow meter. Patients with certain medical conditions or history are excluded from the trial.",
    "The sample is a phase 2 clinical trial for patients with colorectal cancer. The trial is testing the drug romidepsin and the eligibility criteria includes having locally advanced unresectable disease or distant metastatic disease, measurable disease, and having been previously treated with at least one but no more than two prior chemotherapy regimens. Patients must also meet certain patient characteristics such as being over 18 years old, having a Zubrod performance status of 0-1, and meeting certain hematopoietic, hepatic, renal, and cardiovascular requirements. Patients must not be pregnant or nursing, must use effective contraception if fertile, and must not have had any other malignancy within the past 5 years except for adequately treated basal cell or squamous cell skin cancer or carcinoma in situ of the cervix. The sample also includes information on prior concurrent therapy, including biologic therapy, chemotherapy, endocrine therapy, radiotherapy, and surgery, as well as other concurrent agents that are not allowed.",
    "The sample is a phase 2 clinical trial for the treatment of multiple myeloma, a type of cancer. The trial involves the use of three drugs - bortezomib, cyclophosphamide, and dexamethasone. The eligibility criteria for the trial include being at least 18 years old, having stage II-III multiple myeloma, and having relapsed or primary refractory disease after initial chemotherapy. Other criteria include having a certain level of neutrophil and platelet counts, being able to understand the requirements of the study, and using adequate contraception during therapy. Exclusion criteria include previous treatment with bortezomib, pre-existent polyneuropathy, and active uncontrolled infections.",
    "This sample is a phase 2 clinical trial for patients with metastatic or unresectable colorectal cancer. The trial is testing the effectiveness of the drug celecoxib in treating the disease. The eligibility criteria include having measurable disease, having progressed after at least one chemotherapy regimen, and having normal organ and marrow functions. Patients must also be at least 18 years old and have an ECOG performance status of 2 or less. Exclusion criteria include having had chemotherapy or radiotherapy within 4 weeks prior to the study, having known brain metastases, and having prior treatment with EGFR targeting therapies. Patients must also be off all other selective or non-selective COX-2 inhibitors for at least 2 weeks prior to study entry. The trial requires patients to provide written informed consent and to use adequate contraception during the study.",
    "The sample is a phase 2 clinical trial for breast cancer patients with CNS progression after radio-surgery and whole brain radiotherapy or whole brain radiotherapy alone. The trial is testing the effectiveness of the drug capecitabine (also known as Xeloda) on patients with at least one measurable lesion and an ECOG performance status of 0-2. The eligibility criteria include being a female patient over 18 years of age with no prior systemic treatment of brain metastases and no previous disease progression while on Xeloda treatment. However, patients with a previous history of cancer (other than curatively treated basal and squamous cell cancer of the skin or in situ cancer of the cervix) in the previous 5 years or clinically significant cardiovascular disease are excluded from the trial.",
    "The sample is a record from a clinical trial table that includes information about the trial's phase, diseases being studied, corresponding ICD-10 codes, drugs being used, and eligibility criteria. In this particular record, the trial is in phase 2 and is focused on studying lymphoma. The ICD-10 codes associated with the disease are listed, as well as the specific drug being used in the trial. The eligibility criteria for the trial are also included, which specify the types of lymphoma that qualify for the study and the exclusion criteria for patients who have received prior treatment with purine analogs or whose diagnostic/histologic subtype cannot be confirmed.",
    "The sample is a phase 2 clinical trial for patients with T lymphoid malignancy, including untreated and relapsed/refractory cases. The trial is testing the effectiveness of the drugs pentostatin and alemtuzumab. The eligibility criteria include being 18 years or older, having a diagnosis of T lymphoid malignancy, and meeting certain health requirements such as adequate kidney and liver function. Patients must also be willing to use contraception during the study. The trial excludes patients who are pregnant or lactating, known to be HIV+, or have an active and uncontrolled infection.",
    "The sample is a phase 2 clinical trial for patients with metastatic breast cancer. The trial is testing the effectiveness of the drug fulvestrant. The eligibility criteria include having received an aromatase inhibitor in the past, having measurable or nonmeasurable disease, and meeting certain patient characteristics such as being post-menopausal and having a certain level of blood counts. Patients must not have certain medical conditions or have received certain treatments in the past. The trial does not allow concurrent treatment with other anticancer therapies or participation in other clinical studies with investigational procedures or therapies.",
    "The sample is a phase 2 clinical trial for Alzheimer's disease. The eligibility criteria include being male or post-menopausal female, meeting the NINCDS-ADRDA criteria for Alzheimer's disease, having mild to moderate Alzheimer's disease as classified by a Mini Mental State Examination score of 16-26, being aged between 50 and 85 years, having a permanent caregiver, and providing full written informed consent. Exclusion criteria include having a history of or suffering from claustrophobia, having a history or presence of other neurological or medical conditions that may influence the outcome or analysis of the PET scan results, having a history of Type I or Type II diabetes mellitus, having a history or clinical/laboratory evidence of moderate congestive heart failure, having a history or clinical laboratory evidence of cerebrovascular disease, having a history or evidence of any other CNS disorder that could be interpreted as a cause of dementia, having significant peripheral oedema, having a history of major psychiatric illness such as schizophrenia or bipolar affective disorder, having systolic blood pressure >165 mmHg or diastolic blood pressure >95 mmHG whilst receiving optimal antihypertensive therapy according to local practice, having clinically significant anaemia, having renal dysfunction, having ALT, AST, total bilirubin, or alkaline phosphatase >2.5 times the upper limit of normal laboratory range, having fasting triglycerides >12mmol/L, having a history or presence of gastro-intestinal, hepatic or renal disease or other condition known to interfere with absorption, distribution, metabolism or excretion of drugs, having any clinically relevant abnormality, medical or psychiatric condition, which, in the opinion of the investigator, makes the subject unsuitable for inclusion in the study, having donated >/= ml of blood within the past 2 months, having used any other investigational agent within 30 days or 5 half-lives prior to the screening visit, having a history of alcohol abuse, or of drug abuse within the past 6 months, being unable to take study medication as prescribed throughout the study, having a history of non-compliance with prescribed medication, or risk of non-compliance with study medication or procedures, being an immediate family member or employee of the participating investigator or of any of the participating site staff, and showing any neurological abnormality by MRI, which in the opinion of the Principal Investigator would introduce additional risk factors, study procedures or effect endpoint data.",
    "The sample is a phase 2 clinical trial for patients with pulmonary arterial hypertension. The eligibility criteria include being 18 years or older, having a documented hemodynamic diagnosis of PAH, and being in NYHA functional class II-III. Patients must also have been on treatment with ERAs, PDE-5 inhibitors, or a combination of both for at least 3 months prior to the trial and have stable dosing for at least 28 days prior to the trial. Exclusion criteria include having PAH in Dana Point Classification Groups 2-5, having clinically significant liver or renal insufficiency, or having received certain medications within 28 days of the trial. Females who are pregnant or not using reliable birth control are also excluded. The drug being tested is act-050089.",
    "The sample is a phase 2 clinical trial for breast cancer. The trial includes patients with early stage breast cancer and no evidence of disease outside the breast or chest wall, except ipsilateral axillary lymph nodes. The trial excludes patients who have received prior chemotherapy, hormonal therapy, biologic therapy or radiation therapy for breast cancer, have undergone major surgery within 28 days of study entry, or have evidence of central nervous system (CNS) metastases. The trial will be conducted by health professionals who will determine the final eligibility of patients. The trial will test the effectiveness of the drugs docetaxel and capecitabine. The diseases are listed as 'breast cancer' and the icd-10 codes associated with the disease are also provided. The eligibility criteria for the trial are also listed, including both inclusion and exclusion criteria.",
    "The sample is a phase 2 clinical trial for patients with epithelial ovarian, fallopian or peritoneal carcinoma of certain histological types. The trial involves the drug temsirolimus and requires patients to have received first-line platinum based chemotherapy and have documented CA125 progression according to GCIC criteria. Patients must also meet certain eligibility criteria, including being 18 years or older, having no evidence of measurable or evaluable disease, and having adequate baseline hepatic function and blood counts. Patients must also have a negative pregnancy test and use effective contraception during the period of therapy. The trial has exclusion criteria, such as having other histological types, a history of certain medical conditions, or treatment with non-approved or investigational drugs within 30 days before Day 1 of trial treatment.",
    "The sample is a phase 2 clinical trial for advanced ovarian, primary peritoneal, or fallopian tube carcinoma. The trial involves the use of drugs such as placebo, gemcitabine, and pertuzumab. The eligibility criteria include having measurable or clinically detectable disease, being platinum-resistant or refractory, having a life expectancy of at least 12 weeks, and having an ECOG performance status of 0 or 1. The trial also requires the use of effective contraception for women of childbearing potential and certain clinical laboratory test results. Exclusion criteria include prior treatment with certain drugs, history of other malignancies within 5 years, and inability to comply with study and follow-up procedures.",
    "The sample is a phase 2 clinical trial for patients with chronic obstructive pulmonary disease. The trial involves testing the effectiveness of two drugs, bi 1744 cl/tiotropium bromide fixed dose combination and tiotropium bromide. The eligibility criteria for the trial include having a diagnosis of COPD, being a current or ex-smoker with a smoking history of more than 10 pack years, and being able to perform pulmonary function tests and maintain records during the study period. Exclusion criteria include having a significant disease other than COPD, abnormal baseline haematology, blood chemistry, or urinalysis, and a history of asthma or a total blood eosinophil count >= 600/mm3. Pregnant or nursing women and patients who have previously been randomized in this study or are currently participating in another study are also excluded.",
    "This sample is a phase 2 trial for the treatment of chronic obstructive pulmonary disease (COPD). The trial includes subjects who are 40 years or older, have an established clinical history of COPD, and are current or previous cigarette smokers with a history of at least 10 pack-years of cigarette smoking. The trial involves the use of drugs such as gsk961081, salmeterol, and placebo. The eligibility criteria include outpatient subjects who give their signed and dated informed consent to participate, and subjects with a measured post-salbutamol FEV1/FVC ratio of less than 0.70 at Visit 1 (Screening). The exclusion criteria include women who are pregnant or lactating, current diagnosis of asthma, and other significant respiratory disorders besides COPD. The trial also excludes subjects with any significant disease that would put them at risk through study participation, BMI greater than 35, pacemaker, significantly abnormal ECG, clinical lab finding (including Hepatitis B or C), cancer, allergy or hypersensitivity to beta adrenergic receptor-agonist, sympathomimetic, anticholinergic/anti-muscarinic receptor antagonist, or inhaler excipients, and diseases that would contra-indicate the use of anticholinergics.",
    "The sample is a phase 2 clinical trial for patients with moderate to severe cancer-related pain that requires the use of step-3 opioids. The trial includes patients with neoplasms and pain, and the icd-10 codes for these diseases are listed. The drugs being tested are methadone and morphine. The eligibility criteria include having a telephone, being between 18 and 70 years old, having a life expectancy of at least 3 months, and not having prior use of step-3 opioids. Patients must also provide informed consent and score 26 or higher on the Mini-Mental Status Exam. Exclusion criteria include nursing home patients, obvious cognitive dysfunction, and a true allergy or intolerance to opioids. Women who are pregnant or nursing, as well as patients with recent substance abuse history or major depression, will also be excluded.",
    "The sample is a phase 2 clinical trial for HIV-1 infection and HIV infections. The trial is testing the effectiveness of a drug called pro 140, which is a humanized monoclonal antibody to ccr5, compared to a placebo. The trial has eligibility criteria for participants, including being at least 18 years old, having a certain level of CD4+ lymphocyte cell count, and having not taken any antiretroviral therapy within 12 weeks of the early screening visit. The trial also has exclusion criteria, such as having a CXCR4 tropic virus or dual/mixed tropic virus, being pregnant or lactating, and having a history of active hepatitis within the previous 24 weeks.",
    "The sample is a phase 2 clinical trial for attention deficit disorder with hyperactivity. The trial includes the use of drugs such as lobeline sulfate, methylphenidate hcl, and placebo. The eligibility criteria for the trial includes a diagnosis of ADHD, healthy males or females aged 21 to 45 years, a body mass index between 18 and 30, and the ability and willingness to provide written consent and comply with study instructions. The trial also requires subjects to have no medical contraindications and to be non-smokers. Females must have a negative pregnancy test and use a medically accepted form of contraception. Exclusion criteria include unresolved/unstable psychiatric comorbidities, recent history of drug addiction and/or alcoholism, and current significant acute or chronic medical disease.",
    "The sample is a phase 2 clinical trial for gastrointestinal cancer. The trial includes patients with confirmed adenocarcinoma of the stomach, gastroesophageal junction or distal esophagus with metastatic disease. The trial involves the use of drugs such as amg 386 placebo, amg 386 10mg/kg, amg 386 3mg/kg, cisplatin, and capecitabine. The eligibility criteria include being 18 years or older, having an ECOG performance status of 0 or 1, and being able to swallow oral medication. The trial also has exclusion criteria such as having a history of arterial or deep venous thromboembolism within 12 months prior to randomization, ongoing or clinically significant active infection, and known hypersensitivity to bacterial proteins or any of the drugs required in the study.",
    "The sample is a phase 2 clinical trial for the treatment of chronic hepatitis C. The trial is looking for male and female participants between the ages of 18 and 70 who have not yet received treatment for their HCV infection. Participants must have a liver biopsy indicating the absence of cirrhosis, be infected with HCV genotype 1, and have an HCV RNA level greater than 10^4 IU/mL. They must also have a body mass index between 18 and 36 kg/m2 and agree to use two forms of contraception for the duration of the study and for 7 months after the last dose of study medication. Exclusion criteria include pregnancy, certain medical conditions such as autoimmune disease and poorly controlled diabetes, and current use of certain drugs such as amphetamines and opiates.",
    "The sample is a phase 2 clinical trial for Alzheimer's disease. The eligibility criteria include being male or female over the age of 50, having a diagnosis of probable Alzheimer's disease consistent with criteria from both the National Institute of Neurological and Communicable Disease and Stroke and Alzheimer's Disease and Related Disorders Association (NINCDS-ADRDA) and the Diagnostic and Statistical Manual of Mental Disorders (DSM IV), having a Mini-mental status exam score of 16-26 inclusive, and having a Rosen-Modified Hachinski Ischemia Score of less than or equal to 4. The exclusion criteria include having a diagnosis or history of other demential or neurodegenerative disorders, clinically significant cerebrovascular disease, specific findings on magnetic resonance imaging (MRI) such as cortical infarct, micro hemorrhage, multiple white matter lacunes, or extensive white matter abnormalities, a history of autoimmune disorders, or a history of allergic or anaphylactic reactions. The drugs being tested in this trial are a placebo.",
    "The sample is a phase 2 clinical trial for patients with metastatic colorectal cancer. The trial involves the use of cetuximab 5mg/ml as a treatment. The eligibility criteria include patients who are at least 70 years old, have a confirmed diagnosis of CRC, have non-resectable and/or non-operable metastatic colorectal carcinoma, have at least one lesion by two-dimensional measurement, and have a Karnofsky functional status of at least 80%. Patients must also have a life expectancy greater than 3 months and have not received chemotherapy for advanced or metastatic disease. The trial has exclusion criteria, including patients with documented or suspected cerebral and/or leptomeningeal metastases, chronic, concomitant systemic immunotherapy, chemotherapy, or hormonal treatment for cancer, and prior administration of monoclonal antibodies, EGFR signal transduction inhibitors or EGFR-targeted treatment. The trial also has other exclusion criteria related to medical and psychological disorders, lack of physical integrity of the upper gastrointestinal tract, and serious active infections. Patients who are catalogued as delicate or \"frail\" for compliance with certain criteria are also excluded.",
    "The sample is a phase 2 clinical trial for hormone refractory prostate cancer. The trial includes patients who are male with confirmed metastatic adenocarcinoma of the prostate with progressive disease, despite androgen deprivation. The trial involves the use of drugs such as sargramostim, docetaxel, and prednisone. The eligibility criteria include having a signed IRB-approved informed consent, fulfilling certain hormonal therapy criteria, having a serum testosterone level below 50 ng/dL, and having a Karnofsky Performance Status greater than 60. The trial also has exclusion criteria such as prior systemic chemotherapy for the treatment of HRPC, known HIV-positive status, and poorly controlled diabetes. Patients must agree to use effective contraceptive measures during study treatment and for a reasonable time thereafter. The trial involves self-administration or administration by a caregiver of sargramostim.",
    "The sample is a phase 2 clinical trial for patients with non-small cell lung cancer. The trial is testing the effectiveness of the drugs carboplatin and pemetrexed. The eligibility criteria include having confirmed non-small cell lung cancer, meeting certain stage criteria, having no known CNS metastases, and meeting various patient characteristic requirements such as age, performance status, and no history of certain medical conditions. Prior concurrent therapy is also taken into consideration. The sample includes a detailed list of eligibility criteria for both disease and patient characteristics, as well as prior concurrent therapy.",
    "The sample is a phase 2 clinical trial for the treatment of rheumatoid arthritis. The trial involves the use of the drugs amg 108 and placebo. The eligibility criteria for the trial include having active rheumatoid arthritis for at least 6 months, taking methotrexate for at least 12 weeks, and not having received any other DMARDs within 6 weeks of screening. Exclusion criteria include having a serious infection, class IV rheumatoid arthritis, and being pregnant or nursing. The trial also excludes individuals who have received commercial or experimental biologic therapies for the treatment of inflammatory disease, have a prior or current history of tuberculosis infection or exposure, have received live vaccines within 3 months, or have Felty's syndrome.",
    "The sample is a phase 2 clinical trial for patients with relapsing-remitting multiple sclerosis. The trial includes patients who have had at least two confirmed relapses within the last 24 months or at least one confirmed relapse within the last 12 months, or one confirmed relapse between 12 and 24 months prior to screening, and at least one documented T1 Gd-enhancing lesion on an MRI performed within 12 months prior to screening. Patients must have a disability equivalent to Expanded Disability Status Scale (EDSS) score of 0-5.0 at screening and be neurologically stable with no evidence of relapse for at least 30 days prior to the start of screening and during the screening phase. The trial includes female patients who are either post-menopausal, surgically incapable of bearing children, or practicing an acceptable method of birth control. Patients must provide signed informed consent before any trial-related activity is carried out. The trial has exclusion criteria, including patients with secondary progressive multiple sclerosis, primary progressive multiple sclerosis, or progressive relapsing multiple sclerosis, or neuromyelitis optica. Patients with a history of severe, clinically significant central nervous system trauma or a history or presence of myelopathy due to spinal cord compression by disk or vertebral disease are also excluded. Patients with significant concurrent, uncontrolled medical conditions are also excluded. The trial also has exclusion criteria for patients who have received certain treatments or therapies within a certain time frame.",
    "This is a sample entry from a clinical trial table. The trial is in phase 2 and is focused on treating malignant mesothelioma. The table includes a list of diseases and their corresponding ICD-10 codes, a list of drugs being used in the trial, and eligibility criteria for patients to participate in the trial. The eligibility criteria include disease characteristics such as confirmed malignant pleural mesothelioma and patient characteristics such as ECOG performance status, hemoglobin levels, and platelet counts. The sample also includes exclusion criteria such as symptomatic or known brain or leptomeningeal metastases, uncontrolled or severe cardiovascular disease, and serious medical or psychiatric illness that would interfere with study participation. Prior concurrent therapy is also listed, including no prior bortezomib and no prior extensive radiation therapy, systemic chemotherapy, or other antineoplastic therapy within 4 weeks before enrollment.",
    "The sample is a phase 2 clinical trial for low back pain. The trial is comparing the effectiveness of zoledronic acid versus a placebo. The trial has specific eligibility criteria for inclusion, such as being over 18 years old, having low back pain for more than 3 months, and having Modic type I or II change in lumbar magnetic resonance imaging. The trial also has exclusion criteria, such as premenopausal female patients with possibility of pregnancy, patients with calculated creatinine clearance of less than 40 ml/min, and patients with known hypersensitivity to zoledronic acid or other bisphosphonates or ingredients of the infusional product.",
    "The sample is a phase 2 clinical trial for ovarian neoplasms. The trial is testing the effectiveness of three drugs, azd2281 and liposomal doxorubicin, both of which are being used twice, on patients with advanced ovarian cancer who have positive BRCA1 or BRCA2 status and have experienced progressive or recurrent disease after platinum-based chemotherapy. The patients must also have measurable disease by RECIST. The trial has exclusion criteria, which include previous anthracycline treatment, brain metastases, less than 28 days since last treatment used to treat the disease, and being considered a poor medical risk due to a serious uncontrolled disorder.",
    "The sample is a phase 2 clinical trial for osteoarthritis of the knee. The trial involves testing multiple drugs, including pf-04191834 and naproxen, as well as placebos. The eligibility criteria for the trial include a confirmed diagnosis of osteoarthritis based on the American College of Rheumatology criteria, willingness to stop all current pain therapy for the duration of the study, and ability to complete a daily diary. Exclusion criteria include a BMI of >39 kg/m2, known allergy or hypersensitivity to naproxen, and any condition or medical history that might interfere with the subject's ability to complete the study visits and assessments. The icd-10 codes associated with the disease are also provided.",
    "The sample is a phase 2 clinical trial for patients with metastatic or recurrent adenocarcinoma of the colon. The trial includes patients who have received at least one prior chemotherapy regimen, with one of the prior regimens including irinotecan hydrochloride, fluorouracil, and leucovorin calcium or irinotecan hydrochloride and other fluoropyrimidine. The trial also includes patients who have not received prior oxaliplatin or gemcitabine hydrochloride. The trial aims to evaluate the efficacy and safety of gemcitabine hydrochloride and oxaliplatin as a treatment for colorectal cancer. The eligibility criteria include measurable disease, ECOG performance status 0-2, and various laboratory values within normal limits. Patients must not have any serious medical or psychiatric illness that would render chemotherapy unsafe, and must not be pregnant or nursing. The trial excludes patients with concurrent clinically evident malignancy except inactive nonmelanoma skin cancer, low-grade low-stage bladder carcinoma followed off therapy, or lobular neoplasia of the breast. Patients must have recovered from prior therapy and must not be receiving any other concurrent anticancer therapy including chemotherapy, radiotherapy, hormonal therapy, or immunotherapy.",
    "The sample is a phase 2 clinical trial for depression. The trial is looking at the effectiveness of several drugs, including duloxetine and escitalopram, as well as a placebo. The trial is open to men and women between the ages of 18 and 65, with a diagnosis of Major Depressive Disorder and a current depressive episode lasting between 8 weeks and 3 years. Patients must have had an inadequate response to 1-3 previous antidepressant treatments and have a 17-item Hamilton Depression Rating Scale (HAM-D17) total score of 18 or higher at screening and baseline. Patients who have failed Duloxetine and Escitalopram at an adequate dose and duration in their current episode or have had an inadequate response to more than three adequate trials of antidepressant treatments during the current depressive episode are excluded from the trial.",
    "The sample is a phase 2 clinical trial for patients with clear cell renal cell carcinoma. The trial is testing the effectiveness of the drug perifosine in treating the disease. The eligibility criteria include having measurable disease that is not curable by standard radiation therapy or surgery, experiencing disease progression while on sorafenib or sunitinib, and being off of sorafenib or sunitinib for at least 2 weeks prior to initiation of perifosine. Patients must also have a confirmed diagnosis of clear cell renal cell carcinoma and be at least 18 years old with an ECOG performance status of 0 or 1. The exclusion criteria include a history or clinical evidence of CNS disease, having had prior mTOR inhibitors, and having stopped sorafenib or sunitinib due to toxicity but only progressed off therapy.",
    "The sample is a phase 2 clinical trial for the treatment of chronic hepatitis C. The trial involves the use of two drugs, interferon-alpha lozenges and placebo lozenges. The eligibility criteria for the trial include having HCV genotype 1b, completing pegylated IFN-alpha and ribavirin therapy within 4 weeks, and having serum HCV RNA negative within 4 weeks of study entry. Exclusion criteria include having a Child-Pugh score of B or C, decompensated liver function, history of malignancy within the past 5 years, other causes of liver disease besides HCV infection, uncontrolled diabetes or hypertension, and unwillingness to use two forms of birth control during study treatment.",
    "The sample is a phase 2 trial for HIV infections. The trial includes individuals who are at least 18 years old, have a screening plasma HIV-1 RNA level of at least 5,000 copies/mL, and a CD4+ T-lymphocyte cell count of at least 300 cells/mm3. They must not have taken any anti-retroviral therapy within 12 weeks of the early screening visit and must have an exclusive CCR5-tropic virus as determined by the Trofile\u2122 Assay. Women of reproductive potential must have a negative pregnancy test and be non-lactating. The trial excludes individuals with CXCR4 tropic virus or dual/mixed tropic (R5X4) virus, pregnant or breastfeeding women, those with a history of active hepatitis within the previous 24 weeks, and those who have previously used any entry, attachment, CCR5 co-receptor or fusion inhibitor, experimental or approved.",
    "This sample is a phase 2 clinical trial for breast cancer patients who have been diagnosed with oestrogen receptor negative primary breast cancer, with tumour stage T2-3, N0-2, M0 and are eligible for surgery. The trial is testing the drug gefitinib. The inclusion criteria require patients to have a WHO performance score of 0-1 and histologically confirmed breast cancer. The exclusion criteria include prior anticancer therapy with gefitinib, epirubicin or cyclophosphamide, distant metastases or bilateral breast cancer, clinically active interstitial lung disease, other co-existing malignancies or malignancies diagnosed within the last 5 years (with the exception of basal cell carcinoma or cervical cancer in situ), and pregnancy or breastfeeding. The icd-10 codes associated with the disease are also provided.",
    "The sample is a phase 2 trial for patients with locally advanced or metastatic squamous cell carcinoma or adenocarcinoma histological subtypes of non-small-cell lung cancer (stage IIIB or IV). The trial involves the drugs axl1717 and docetaxel. The eligibility criteria include being at least 18 years old, having a confirmed diagnosis of the specified types of lung cancer, having previously received certain treatments depending on the histology, having a certain performance status, and meeting certain hematology and clinical chemistry values. Exclusion criteria include having mixed histology of squamous and non-squamous NSCLC, ongoing infection or major disease, and certain medical conditions. The trial also has specific criteria for measurable disease and excludes patients with certain types of cancer or hypersensitivity to the drugs being used.",
    "The sample is a phase 2 trial for the treatment of hyperlipidemia. The trial involves the drug ezetimibe and the eligibility criteria includes being between the ages of 18 and 75, having LDL-C levels between 100 and 190 mg/dL, having a Framingham risk score of 10% or less, and having fasting triglycerides below 400 mg/dL. The exclusion criteria includes having a history of coronary heart disease, NYHA II - IV heart failure, uncontrolled cardiac arrhythmia, and uncontrolled hypertension.",
    "The table contains information about clinical trials for various diseases, including chronic myelogenous leukemia, acute lymphoblastic leukemia, and non-Hodgkin lymphoma. The table includes the phase of the trial, a list of diseases, corresponding ICD-10 codes, a list of drugs, and eligibility criteria for patients and donors. The eligibility criteria include factors such as the patient's diagnosis, the presence of active infections or CNS disease, and the availability of a matched unrelated donor. The sample includes patients who meet the inclusion criteria and do not meet the exclusion criteria.",
    "The sample is a phase 2 clinical trial for patients with unresectable stage III non-small-cell lung carcinoma or lung neoplasms. The trial involves administering a single low dose of cyclophosphamide to eligible patients who have stable disease or clinical response after primary therapy of chemo-radiation treatment. The trial has specific inclusion and exclusion criteria, including confirmation of mediastinal involvement by biopsy, completion of primary therapy at least 4 weeks and no later than 6 months prior to study entry, and an Eastern Cooperative Oncology Group (ECOG) performance status of less than or equal to (<=) 1. Patients who have undergone lung cancer specific therapy prior to primary chemo-radiation therapy, received immunotherapy/systemic immunosuppressive drugs/investigational systemic drugs within 4 weeks prior to study entry, or have clinically significant hepatic, renal dysfunction or cardiac diseases are excluded from the trial.",
    "The sample is a phase 2 clinical trial for patients with recurrent uterine corpus carcinoma. The trial involves the use of the drug gefitinib and has a list of eligibility criteria that patients must meet in order to participate. These criteria include having received one prior chemotherapy regimen for endometrial carcinoma, having at least one measurable lesion, and having a tumor that is accessible for guided core needle or fine needle biopsy. Patients must also meet certain health requirements, such as having a performance status of GOG 0-2 and having certain blood counts within normal ranges. Additionally, patients must not have certain medical conditions or be taking certain medications that could interfere with the study.",
    "The sample is a phase 2 clinical trial for asthma and bronchoconstriction. The trial involves the use of two drugs, levalbuterol hfa mdi and racemic albuterol. The eligibility criteria include being between the ages of 6 to 11 years, having a documented diagnosis of asthma for at least 6 months, and being in good health except for their reversible airways disease. The trial also requires the subject's parent or legal guardian to be able to complete diary cards and medical event calendars reliably on a daily basis. Exclusion criteria include being pregnant or lactating, having participated in another clinical trial within 30 days of study start, and having a history of hospitalization for asthma within 4 weeks prior to study start.",
    "The sample is a clinical trial for patients with primary progressive multiple sclerosis. The trial is in phase 2/phase 3 and involves the use of rituximab and a placebo. The eligibility criteria include having a definitive diagnosis of PPMS, a disease duration of at least 1 year, and an EDSS score between 2.0 and 6.5 points. In addition, patients must have a score of at least 2.0 on the Functional Systems (FS) scale for the pyramidal system or gait that is due to lower extremity findings. Patients must also have at least one of the specified CSF specimen results and use reliable contraception during the study treatment and for 1 year following the last dose of study drug. Exclusion criteria include pregnancy or lactation, incompatibility with MRI, history of severe allergic or anaphylactic reactions to humanized or murine monoclonal antibodies, and known active bacterial, viral, fungal, mycobacterial, or other infection. Other exclusion criteria include history of cancer, alcohol or drug abuse within 6 months prior to screening, and significant cardiac or pulmonary disease.",
    "The sample is a phase 2 clinical trial for patients with stage IV melanoma cancer with biopsy proven metastases. The trial is testing the effectiveness of the drug combination of disulfiram and chelated zinc. The eligibility criteria include being 18 years or older, having an ECOG performance status of 0-2, having received and progressed after or not responded to at least one cycle of first line therapy, and having measurable disease by RECIST criteria. Patients with brain metastases are eligible if their brain disease has been treated with surgery or radiation. Exclusion criteria include participation in another clinical trial of a therapeutic drug during the past 30 days, addiction to alcohol or cocaine, and current use of certain medications. Women of child-bearing potential must use effective contraception and will have a pregnancy test before enrollment. Patients must be willing to refrain from ingestion of alcoholic beverages while on the study.",
    "The sample is a phase 2 clinical trial for the treatment of kidney neoplasms and kidney (renal cell) cancer using the drugs everolimus and bevacizumab. The trial has eligibility criteria that include having confirmed metastatic RCC, being at least 18 years old, having a certain ECOG performance status, and having no more than 2 prior systemic therapies. There are also exclusion criteria, such as inadequate organ function, active infection or fever, and certain medical conditions that may interfere with the study. The trial also has disease-specific exclusion criteria, such as RCC with predominantly sarcomatoid features and prior treatment with bevacizumab or any mTOR inhibitor. The criteria for bevacizumab and RAD001 (everolimus) are also listed separately.",
    "The sample is a phase 2 clinical trial for patients with non-operable and/or metastatic soft tissue sarcoma. The trial includes patients aged between 18 and 70 with measurable disease according to RECIST criteria and a performance status of 0-2 Eastern Cooperative Oncology Group (ECOG). The trial involves the use of two drugs, doxorubicin and trabectedin. The eligibility criteria include a signed informed consent form, adequate bone marrow function, normal cardiac function, and negative pregnancy test for women of childbearing potential. The exclusion criteria include previous chemotherapy or radiotherapy treatment, CNS metastases, significant cardiovascular or systemic diseases, uncontrolled infections, and participation in another clinical trial or use of any other investigational product. The trial also specifies the histological subtypes that can be included and excluded.",
    "The sample is a record of a clinical trial in phase 2 for the treatment of thyroid neoplasms. The trial is testing the drug ag-013736 on patients with radioiodine-refractory metastatic or unresectable locally-advanced thyroid cancer who have at least one measurable target lesion. The inclusion and exclusion criteria for the trial are also listed. The icd-10 codes associated with the disease are also provided.",
    "The sample is a phase 2 clinical trial for lung cancer patients with histologically proven bronchoalveolar carcinoma (BAC) that is unresectable Stage IIIB, IV, or recurrent. The trial requires evidence of multinodular lesions involving the lungs bilaterally or unilaterally, and at least one target lesion that has not undergone prior irradiation. Patients must meet certain eligibility criteria, including being between the ages of 18 and 75, having a performance status of ECOG 0-2, and having a life expectancy greater than 3 months. They must also meet certain hematopoietic, hepatic, renal, and cardiovascular requirements, and cannot have preexisting motor or other serious sensory neurotoxicity, active or prior second primary cancer except basal cell carcinoma of the skin or carcinoma in situ of the cervix, clinical evidence of uncontrolled infection, or be pregnant or nursing. The trial does not allow for prior chemotherapy, but does allow for prior radiotherapy as long as it has been at least 4 weeks since the treatment and the patient has at least one bidimensional lesion outside the irradiated fields. The trial is testing the drug paclitaxel.",
    "The sample is a phase 2 clinical trial for kidney cancer patients with unresectable or metastatic disease. The trial involves the use of two drugs, erlotinib hydrochloride and sunitinib malate. The eligibility criteria include having confirmed renal cell carcinoma with a component of clear cell or papillary carcinoma, measurable disease, and an Eastern Cooperative Oncology Group (ECOG) performance status of 0-2. Patients must also meet certain medical criteria, such as having normal liver and kidney function, no uncontrolled medical conditions, and no other active malignancy within the past 5 years. Prior concurrent therapy is also taken into account.",
    "The sample is a phase 2 clinical trial for the treatment of chronic genotype 1 hepatitis C virus (HCV) infection. The trial is testing the effectiveness of the drugs tmc435, psi-7977 (gs7977), and ribavirin. The trial is divided into two cohorts, with patients in both cohorts being null responders to PegIFN/ribavirin with at least one documented previous course of PegIFN/ribavirin therapy for at least 12 consecutive weeks. Patients in cohort 2 could also be HCV treatment-naive, meaning they have never received treatment with any approved or investigational drug for the treatment of HCV. The inclusion criteria include having a plasma HCV RNA of more than 10,000 IU/mL at screening, meeting the defined criterion for a null responder, and having had a liver biopsy within 3 years before screening or at any time in the past which showed Metavir F3 or F4 fibrosis. The exclusion criteria include having evidence of hepatic decompensation, any liver disease of non-HCV etiology, an infection/co-infection with non-genotype 1 HCV, a co-infection with Human immunodeficiency virus (HIV) type 1 or type 2 (HIV-1 or HIV-2), a co-infection with hepatitis B virus (hepatitis B surface antigen [HBsAg] positive), and a history of malignancy within 5 years of the screening visit. Patients must agree to use 2 forms of effective contraception throughout the study.",
    "The sample is a phase 2 clinical trial for patients with non-small cell lung cancer that cannot be treated with radical irradiation. The trial is testing the effectiveness of a combination of drugs including carboplatin, nitroglycerin, and paclitaxel. The eligibility criteria include having confirmed non-small cell lung cancer, a certain stage of the disease, and meeting specific patient characteristics such as having a certain performance status, blood counts, and no cardiac problems. Patients cannot have had prior chemotherapy or radiotherapy and cannot be taking certain medications concurrently. The trial is not open to pregnant or nursing patients and patients cannot be participating in another clinical trial at the same time.",
    "The sample is a phase 2 clinical trial for Parkinson's disease and movement disorder syndrome. The trial is testing the drug istradefylline (kw-6002). The inclusion criteria for the trial include having early Parkinson's disease by UKPDS criteria, mild to moderate difficulty with daily activities, and being either postmenopausal or willing to use adequate contraception if female. The exclusion criteria include being unable to discontinue current PD medication, exposure to Levodopa for more than 1 month, symptoms that may suggest a diagnosis other than Parkinson's disease, and medical conditions and/or abnormal laboratory findings which preclude participation, including cancer in the last 5 years, a history of drug abuse/dependence, abnormal cognitive status, a history of seizures, neuroleptic malignant syndrome, psychosis, or abnormal liver function tests.",
    "The sample is a phase 2 clinical trial for chronic obstructive pulmonary disease (COPD) in Japanese individuals aged 40 to 75 years old with a smoking history of at least 20 pack years. The trial includes the drugs indacaterol 150 \u03bcg, indacaterol 300 \u03bcg, and a placebo. The eligibility criteria for the trial include having moderate to severe COPD and not having a history of hospitalization for COPD exacerbation within the past 6 months, not using long-term oxygen therapy, not having a history of asthma, not having had a respiratory tract infection within the past month, and not having consistently very high or low blood sugar. Additionally, there are other protocol-defined inclusion/exclusion criteria applied to the study.",
    "The sample is a phase 2 clinical trial for Crohn's disease. The trial includes three drugs: d9421-c at 9mg and 15mg doses, and a placebo. The eligibility criteria include being between 18 and 65 years old, having a diagnosis of Crohn's disease, and not having an ileostomy or pouch and/or colostomy, previous gastric surgery, or a known or suspected systemic infection.",
    "The sample is a phase 2 clinical trial for patients with advanced non-clear cell renal cell carcinoma. The trial includes patients with locally recurrent disease or measurable metastatic disease. The eligibility criteria include having adequate organ and marrow function, measurable disease, and an Eastern Cooperative Oncology Group (ECOG) performance status of 0-2. Patients must have recovered from any effects of surgery and/or radiation therapy and be free of significant detectable infection. The trial excludes pregnant or lactating women, patients with prior malignancy (except for non-melanoma skin cancer, in situ carcinoma of any site, or other cancers for which the patient has been adequately treated and disease-free for 2 years), and patients with significant medical disease that would significantly increase the risk for participation in this trial.",
    "The sample is a phase 2 trial for the treatment of graft versus host disease. Patients with chronic GvHD following allogeneic HCT or donor lymphocyte infusion are eligible if they have extensive stage disease requiring systemic immunosuppressive therapy. Patients with limited stage disease are excluded. The eligibility criteria include having failed treatment with or experiencing progression after prior corticosteroids for extensive stage chronic GvHD. Patients with established chronic GvHD not improving or progressing on other immunosuppressive agents are also eligible if steroid refractoriness has been established previously. Patients must be at least 18 years old with a performance status of 0-3 and no active infection or HIV infection. Women and men of reproductive potential should agree to use an appropriate method of birth control throughout their participation in this study. Required initial laboratory values include calc. creatinine clearance \u2265 30 mL/min/1.73 m^2, ANC > 1000/\u03bcL, and platelets > 50,000/\u03bcL without transfusion.",
    "The sample is a phase 2 clinical trial for metastatic colorectal cancer. The trial involves the use of three drugs - oxaliplatin, capecitabine, and bevacizumab. The eligibility criteria for the trial include having histologically or cytologically confirmed adenocarcinoma of the colon or rectum, being in stage IV, having measurable disease that has not been irradiated, having a life expectancy of more than 3 months, being at least 70 years old, having a performance status of WHO \u2264 2, and meeting certain laboratory criteria. Exclusion criteria include having prior chemotherapy for metastatic disease, a history of thromboembolic disease or myocardial infraction within the last 6 months, peripheral neuropathy \u2265 grade 2, bowel obstruction or chronic diarrhea, psychiatric illness or social situation that would preclude study compliance, other concurrent uncontrolled illness, and other concurrent investigational agents.",
    "The sample is for a phase 2 clinical trial for rheumatoid arthritis. The icd-10 codes associated with the disease are listed. The drugs being tested are placebo, amg 719, and agm 719, with a placebo to amg 719 comparison. The eligibility criteria for participants include being at least 18 years old, diagnosed with rheumatoid arthritis for at least 24 weeks, receiving methotrexate, and having no recent history of substance or alcohol abuse.",
    "The sample is a record of a clinical trial that is in phase 2/phase 3. The trial is focused on treating depressive disorder, major using the drug sertraline. The trial has eligibility criteria for inclusion and exclusion. Inclusion criteria include having a diagnosis of depressive disorder, major and a HDRS score greater than 18. Exclusion criteria include having other axis I disorders, any axis II disorders, any serious/life-threatening axis III disorders, and neurological diseases such as stroke or dementia. The icd-10 codes associated with the disease are also listed.",
    "The sample is for a phase 2 clinical trial for the treatment of peripheral T-cell non-Hodgkin's lymphoma. The trial is open to patients who have been newly diagnosed, have relapsed, or have progressing disease after one prior treatment with a non-platinum based chemotherapy. The disease must be bulky stage II or stage III or IV. Patients with certain histologies are not eligible. The disease must be bidimensionally measurable and adequate samples from the original diagnostic specimen must be available. Patients must be 18 years or older with a Zubrod performance status of 0-2. They must have no clinical evidence of CNS involvement by lymphoma and meet certain hematopoietic, hepatic, renal, cardiovascular, and other criteria. Patients must not be pregnant or nursing, must have negative pregnancy test, and must use effective contraception if fertile. They must have no other malignancy within the past 5 years except adequately treated basal cell or squamous cell skin cancer or carcinoma in situ of the cervix. The trial has certain prior concurrent therapy requirements for biologic therapy, chemotherapy, endocrine therapy, radiotherapy, and surgery. No prior cytotoxic therapy for this cancer is allowed. Concurrent enrollment in SWOG-8819 or SWOG-8947 is allowed.",
    "The sample is a phase 2 clinical trial for patients with aggressive non-Hodgkin lymphoma, including various subtypes. The trial is testing the effectiveness of a combination of three drugs: gemcitabine hydrochloride, lenalidomide, and oxaliplatin. Patients must meet certain eligibility criteria, including having refractory or relapsed disease, having evaluable or measurable disease, and meeting certain patient characteristics such as having an ECOG performance status of 0-3 and no neurosensory or neuromotor dysfunction \u2265 grade 3. Patients must also not have certain medical conditions or prior treatments, and must be enrolled in the mandatory RevAssist\u00ae program. The trial allows for prior rituximab treatment but not prior gemcitabine hydrochloride, oxaliplatin, or lenalidomide treatment.",
    "The sample is a phase 2 clinical trial for the treatment of basal cell carcinoma, a type of skin cancer. The trial involves the drug lde225 and includes a list of inclusion and exclusion criteria for eligible patients. Inclusion criteria include having locally advanced or metastatic BCC and adequate bone marrow, liver, and renal function. Exclusion criteria include recent major surgery, inability to take oral drugs, concurrent medical conditions that may interfere with the study, neuromuscular disorders, concurrent treatment with other anti-neoplastic agents, recent participation in an experimental drug trial, pregnancy or nursing, and unwillingness or inability to comply with the protocol. The trial also includes a list of icd-10 codes for the disease.",
    "The sample is a phase 2 clinical trial for patients with recurrent intracranial glioblastoma multiforme (GBM) or those who were initially diagnosed with low-grade glioma and subsequently confirmed to have GBM. The trial requires patients to undergo a surgical procedure for tumor removal and have a Karnofsky performance status of 60-100%. Patients must also meet certain medical criteria, such as having a white blood count of at least 3,000/mm^3 and a platelet count of at least 100,000/mm^3. The trial involves the use of the drug cilengitide and patients must not have received prior cilengitide or other targeted antiangiogenic treatments. Patients must also not have any concurrent anticancer therapy or investigational agents. The trial has various exclusion criteria, such as having active infections or other significant uncontrolled medical illnesses that would preclude study participation.",
    "The sample is a record of a clinical trial in phase 2, focused on coronary heart disease. The trial includes the drugs dalcetrapib and placebo. The eligibility criteria for the trial include patients who have completed treatment on study NC19453, but exclude those with significant lymph node abnormalities at the end of the same study. The icd-10 codes associated with the disease are also provided.",
    "The sample is a phase 2 clinical trial for HIV infections. The trial involves testing the effectiveness of several drugs, including tipranavir (tpv) low dose, tipranavir (tpv) high dose, ritonavir low dose, ritonavir high dose, and saquinavir. The eligibility criteria for the trial include having clinical failure while on the current PI-containing regimen of indinavir, nelfinavir, or amprenavir, exposure of at least 6 months to the current PI therapy, and having at least two new nucleoside reverse transcriptase inhibitor (NRTI) options available. The trial also requires acceptable screening laboratory test values that indicate adequate baseline organ function, acceptable medical history, physical examination, ECG, and chest radiograph prior to entry into the treatment phase of the study, and the use of a barrier contraceptive method of birth control for at least 30 days prior to study drug administration, during the study, and 30 days after study completion. The exclusion criteria include treatment with more than one PI-containing regimen, clinically significant active or acute medical problems, prior exposure to tipranavir, saquinavir, or ritonavir, and history of clinically significant nervous system or muscle diseases, seizure disorder, or psychiatric disorder that might impair adherence to the protocol.",
    "The sample is a phase 2 clinical trial for the treatment of various types of acute myeloid leukemia (AML) using the drug vorinostat. The trial includes patients who have relapsed AML or untreated AML and are ineligible for potentially curative options such as stem cell transplantation. Patients must meet certain criteria, including age, performance status, and absence of certain medical conditions. The trial excludes patients with certain concurrent illnesses or treatments. The table includes information on the phase of the trial, the diseases being treated, the ICD-10 codes for those diseases, the drug being used, and the eligibility criteria for patients.",
    "The sample is a record of a clinical trial in phase 2 for the treatment of overactive bladder. The trial involves the drug YM178 and the comparator drug tolterodine. The eligibility criteria for the trial includes patients over 18 years old who have been suffering from overactive bladder for more than 3 months. Pregnant and breastfeeding women are excluded from the trial, as well as patients with any medical condition or need for co-medication that may interfere with the drugs being investigated. The sample also includes the disease name, the corresponding ICD-10 code, and the phase of the trial.",
    "The sample is a clinical trial with a combination of phase 2 and phase 3. The trial is focused on patients undergoing cardiac surgery with the use of cardiopulmonary bypass. The trial aims to identify the risk factors for postoperative acute kidney injury (AKI) in these patients. The trial includes patients who are over 18 years of age and have at least one risk factor for postoperative AKI. The trial excludes patients who have emergency operations, are pregnant or breastfeeding, have a renal allograft, have preoperative acute renal failure within 6 weeks, have pre-operative end-stage renal disease, or are on chronic moderate to high dose corticosteroid therapy. The trial involves the use of sodium bicarbonate and sodium chloride as drugs. The diseases included in the trial are cardiac surgery and cardiopulmonary bypass, and the corresponding ICD-10 codes are also provided.",
    "The sample is a phase 2 clinical trial for patients with non-small cell lung cancer that has recurred or progressed after prior treatment. The trial is testing the effectiveness of two drugs, gemcitabine hydrochloride and imatinib mesylate. Patients must meet certain eligibility criteria, including having measurable disease and a performance status of 0-1. They must also have received no more than one prior chemotherapy regimen in the recurrent or metastatic setting. The trial excludes patients with certain medical conditions, such as uncontrolled illness or chronic liver disease, and those who have had prior treatment with gemcitabine hydrochloride or imatinib mesylate for metastatic disease. Prior concurrent therapy is also restricted. The trial aims to evaluate the safety and efficacy of the drugs in treating non-small cell lung cancer.",
    "The sample is a record of a clinical trial with a phase 2 designation. The trial is focused on the disease glioblastoma multiforme, which is a type of brain cancer. The icd-10 codes associated with the disease are listed as L51.0, L51.8, and L51.9. The trial is testing the effectiveness of two drugs, bevacizumab (also known as Avastin) and fotemustine. The eligibility criteria for the trial are listed, including age, previous treatment history, and adequate organ function. There are also exclusion criteria listed, such as previous treatment with anti-angiogenic drugs and significant cardiovascular disease.",
    "The sample is a record of a clinical trial with a phase 2 designation. The trial is focused on primary open angle glaucoma and ocular hypertension, with a list of corresponding ICD-10 codes. The trial involves testing various doses of a drug called pf-04217329, as well as a vehicle and latanoprost 0.005%. The eligibility criteria for the trial include a diagnosis of primary open-angle glaucoma or ocular hypertension, and a qualifying intraocular pressure measurement. Exclusion criteria include a closed or barely open anterior chamber angle, a history of acute angle closure, and the anticipated need to initiate or modify medication that affects intraocular pressure during the study period.",
    "The sample is a record of a clinical trial in phase 2 for the treatment of cystic fibrosis. The trial involves the use of the drugs sitagliptin and placebo. The eligibility criteria for the trial include being 19 years or older, having cystic fibrosis-related diabetes with or without fasting hyperglycemia, and not using basal insulin therapy. Exclusion criteria include being under 19 years of age, having a creatinine clearance of less than 50 mL/min, having an active cystic fibrosis exacerbation, being pregnant, not using effective contraception if of child-bearing age, and having current or prior use of DPPIV inhibitor. The diseases associated with the trial are listed as 'cystic fibrosis' and the icd-10 codes associated with the disease are also provided.",
    "The sample is a phase 2 clinical trial for major depressive disorder. The trial includes patients with a body mass index less than or equal to 40 kg/m2 who have been treated with an adequate dose of SSRI/SNRI for at least 8 weeks and have a history of inadequate response to 1 or 2 adequate antidepressant treatments, including current treatment. Patients must also be physically healthy and meet certain exclusion criteria, such as not having certain axis I or II diagnoses, not experiencing hallucinations or delusions, and not having attempted suicide within the past 2 years. The trial involves the drugs alks 5461 and placebo, and additional inclusion/exclusion criteria may apply.",
    "This sample is a phase 2 clinical trial for patients with clear cell renal cell carcinoma, recurrent renal cell cancer, or stage IV renal cell cancer. The trial is testing the drug cediranib maleate. Patients must meet certain eligibility criteria, including having measurable disease, no known brain metastases, and a performance status of 0-2. They must also have normal levels of certain blood components, no history of certain medical conditions, and not be taking certain medications. Patients cannot have received prior therapy with vascular endothelial growth factor (VEGF) binding agents or VEGF receptor (VEGFR) tyrosine kinase inhibitors, and no more than one prior nonVEGF-directed systemic therapy for this disease. They cannot receive concurrent palliative or therapeutic radiation therapy or drugs or biologics with proarrhythmic potential.",
    "The sample is a record of a clinical trial with a phase 2 designation. The trial is focused on the disease adenocarcinoma, which is identified through histological testing. The trial includes a list of ICD-10 codes associated with the disease. The trial will test the effectiveness of two drugs, pemetrexed and gemcitabine. The eligibility criteria for the trial include being 18 years or older, having an ECOG Performance Status of 0-1, and being on a fixed analgesic regimen for pain control. The exclusion criteria include having received treatment with an unapproved drug within the last 30 days, being unable to stabilize pain and analgesics for 7 days prior to starting treatment, having received prior chemotherapy, and having high levels of bilirubin or AST/ALT.",
    "The sample is a phase 2 clinical trial for the treatment of lymphoma. The trial is looking for patients with stage III or IV indolent B-cell lymphoma, diffuse small cleaved cell lymphoma, follicular small cleaved cell lymphoma, follicular mixed cell lymphoma, or follicular large cell lymphoma, who have at least one lymph node or visceral lesion that is at least 2 cm in diameter. Patients must have a lymphocyte count less than 5,000/mm3 and an ECOG performance status of 0-2. They must also not have any active infections, concurrent life-threatening diseases, or be pregnant. Effective contraception is required for all fertile patients. The only exclusion criteria is that patients cannot have had prior therapy for lymphoma. The drug being tested is cyclophosphamide.",
    "The sample is a phase 2 clinical trial for metastatic breast cancer patients who have progressed from prior hormonal therapy. The trial is testing the effectiveness of the drugs lapatinib and metformin. The eligibility criteria include being a female patient with receptor positive disease, documented disease progression after first-line hormone therapy, and measurable or evaluable metastatic disease. Patients must also have adequate bone marrow, liver, and renal function, normal respiratory function, and a New York Hearth Association (NYHA) Classification of \u2264 2 with a baseline left ventricular ejection fraction (LVEF) of \u2265 50%. Exclusion criteria include previous or concomitant treatment with lapatinib and/or metformin, more than one line of prior hormone therapy for metastatic breast cancer, and more than two lines of prior chemotherapy for metastatic breast cancer. Patients with brain metastasis, osteosclerotic bone metastasis as unique disease site, and pathological tumor markers as unique sign of progressive disease are also excluded. Other exclusion criteria include serious, not solved or unstable toxicity from previous treatment, diabetes mellitus Type I and Type II, renal insufficiency, malabsorption syndrome or diseases that significantly may alter gastroenteric functions, and other serious illness or medical conditions judged by the investigator to be clinically significant that may adversely affect patient's participation in the trial or interfere with safety profile. Women who are pregnant or lactating are also excluded.",
    "The sample is a phase 2 clinical trial for patients with nasopharyngeal cancer. The trial includes patients with histologically confirmed WHO type I or II a/b NPC and clinically and/or radiologically documented disease. Patients must have a life expectancy of at least 12 weeks and an ECOG performance status of 0, 1, or 2. Previous therapy is allowed, but patients may not have had prior therapy for recurrent or metastatic disease. Laboratory requirements must be met within 7 days prior to registration. Patients must sign a consent form prior to randomization or registration. Exclusion criteria include a history of other malignancies, non-measurable disease only, pregnancy or lactation, known brain metastases, serious illness or medical condition, and prior anti-EGFR monoclonal antibody or tyrosine kinase inhibitors.",
    "This sample is a phase 2 clinical trial for patients with extensive-stage small cell lung cancer. The trial is testing the effectiveness of a combination of drugs, including cisplatin, etoposide, and sorafenib tosylate. The eligibility criteria include having a diagnosis of extensive-stage small cell lung cancer, no untreated brain metastases, and an ECOG performance status of 0-2. Patients must also meet certain medical criteria, such as having a hemoglobin level of at least 9.0 g/dL and a platelet count of at least 100,000/mm\u00b3. Additionally, patients must not have a history of certain cardiac diseases or other medical conditions that could impair their ability to participate in the trial. Prior chemotherapy is not allowed, but prior radiotherapy to the brain is allowed. Concurrent anti-coagulation treatment is also allowed.",
    "The sample is for a phase 2 clinical trial for the disease diabetes. The icd-10 codes associated with the disease are listed as \"E23.2\", \"N25.1\", \"P70.2\", \"O24.92\", \"Z83.3\", \"Z86.32\", and \"E10.65\". The drug being tested is vi-0521. The eligibility criteria for the trial include completing a previous qualifying trial, using adequate contraception if female and of child-bearing potential, providing written informed consent, being willing and able to comply with scheduled study visits, treatment plan, lab tests, and other study procedures, and being greater than 80% compliant in study medication use during the last three visits for DM-230. The exclusion criteria include having developed one or more morbidities during the DM-230 trial that would pose a safety concern.",
    "The sample is a phase 2 clinical trial for newly diagnosed, localized adenocarcinoma of the prostate. The trial is testing the drug everolimus and the eligibility criteria includes various disease characteristics such as clinical stage, Gleason score, and PSA levels, as well as patient characteristics such as performance status, blood counts, and liver and kidney function. Patients with certain medical conditions or who have received certain prior treatments are excluded from the trial. The trial is also testing for the efficacy of everolimus in patients who have not received prior radiotherapy or hormone therapy for prostate cancer.",
    "The sample is a phase 2 clinical trial for the treatment of cerebral infarction. The trial includes men and women over 18 years old who have had a cerebral infarction within the past year and have a stable nervous system for more than 24 hours. Participants must be confirmed to have a cerebral infarction lesion by brain CT or MRI. The trial involves the use of drugs such as vorapaxar, aspirin, and placebo. The eligibility criteria include giving informed consent, completing all study-related procedures, and adhering to dosing and visit schedules. Women of child-bearing potential must agree to use contraception while receiving the study drug. Exclusion criteria include pregnancy, nursing, serious complications, hypersensitivity to the study drug, and participation in another study within 30 days before obtaining consent. Participants with bleeding disorders, cerebral hemorrhage, severe hypertension, impaired renal function, or hepatic disease are also excluded. The trial aims to detect new ischemic events and improve the treatment of cerebral infarction.",
    "The sample is a phase 2 clinical trial for liver cancer patients who have previously been treated with sorafenib. The trial is testing the effectiveness of lenalidomide as a treatment option. The eligibility criteria include having confirmed HCC or triple phase CT consistent with HCC, having known cirrhosis and AFP > 200 ng/ml, and having discontinued all previous cancer therapy at least 4 weeks prior to treatment. Patients must also have radiologically assessable tumor and an ECOG performance status of 0-2. The trial also has exclusion criteria, such as any serious medical condition or laboratory abnormality that would prevent the subject from signing the informed consent form, and any prior use of lenalidomide.",
    "The sample is a phase 2 clinical trial for the treatment of inflammation and rheumatoid arthritis. The trial involves the use of two drugs, nnc0142-0002 and placebo, and has specific eligibility criteria for participants. Inclusion criteria include a diagnosis of RA meeting certain criteria, active RA with a high disease activity score, and concomitant treatment with methotrexate. Exclusion criteria include other chronic inflammatory autoimmune diseases, ongoing infections, and a body mass index outside of a certain range. The trial requires participants to be examined by Magnetic Resonance Imaging (MRI) and have failed no more than two non-biologic disease modifying antirheumatic drugs.",
    "The sample is a phase 2 clinical trial for non-small cell lung cancer. The trial involves the use of four drugs: enzastaurin, pemetrexed, docetaxel, and carboplatin. The eligibility criteria for the trial include having been diagnosed with non-small cell lung cancer, being able to visit the doctor's office weekly during the active treatment period, being willing and able to swallow capsules, meeting study requirements for entry labs and medical tests, and being willing to have blood and tissue samples taken for gene and protein testing. Exclusion criteria include having received radiation within 2 weeks of study enrollment, having previously received any anti-cancer drug therapy for non-small cell lung cancer, having an active infection or other serious condition, taking aspirin or aspirin-like medication regularly and not being able to stop taking them for a few days during each cycle of chemotherapy, and having recently lost a significant amount of weight.",
    "The sample is a phase 2 clinical trial for the treatment of migraines with or without aura. The trial includes patients between the ages of 18-65 who have a history of migraines for at least 1 year and experience an average of at least 4 migraine attacks per month. Patients must meet specific diagnostic criteria and have a maximum of 12 migraine headache days during the baseline period. The trial involves the use of the drugs tonabersat and placebo. Patients must meet certain inclusion criteria, such as providing written informed consent and using reliable contraception if they are women of childbearing potential. Patients who have certain medical conditions or are taking certain medications are excluded from the trial. The trial aims to evaluate the safety and efficacy of the treatment and ensure patient adherence to the protocol.",
    "The sample is a record of a clinical trial for the treatment of advanced gastric adenocarcinoma. The trial is in phase 2/phase 3 and involves the use of two drugs, s-1 + irinotecan and irinotecan. The eligibility criteria for the trial include having a confirmed diagnosis of inoperable advanced gastric adenocarcinoma or relapse gastric adenocarcinoma, being able to take medication orally, and having a confirmed PD status after first-line chemotherapy using S-1 alone, S-1 + Cisplatinum or S-1 + taxane, except S-1 + CPT-11. The trial also has exclusion criteria, such as having a history of hypersensitivity to fluoropyrimidines and CPT-11, being pregnant or lactating, and having gastrointestinal bleeding.",
    "The sample is a phase 2 clinical trial for breast cancer patients who have tumors that overexpress ErbB2. The trial involves the use of drugs such as lapatinib, paclitaxel, 5-fluorouracil (5-fu), epirubicin, and cyclophosphamide. The eligibility criteria include having signed informed consent forms, having a confirmed diagnosis of breast carcinoma with a clinical diagnosis of IBC, having either measurable or clinically evaluable skin disease, having an Eastern Cooperative Oncology Group (ECOG) performance status of 0 - 1, and being able to swallow and retain oral medication. The exclusion criteria include having received any prior chemotherapy, having prior therapy with an ErbB1 and/or ErbB2 inhibitor, and having a concurrent disease or condition that would make the woman inappropriate for study participation.",
    "The sample is a phase 2 clinical trial for newly diagnosed primary acute myeloid leukemia (AML) patients with at least 20% bone marrow blasts. The trial includes patients who meet the customary FAB criteria for AML, have a karyotypic abnormality characteristic of de novo AML, or have the unequivocal presence of megakaryoblasts. Isolated granulocytic sarcoma (myeloblastoma) is also allowed regardless of the results outlined above. The trial excludes patients with promyelocytic leukemia (FAB M3), documented myelodysplastic syndromes (preleukemia), juvenile myelomonocytic leukemia, Fanconi's anemia, Kostmann syndrome, Shwachman syndrome, or any other known bone marrow failure syndrome, and Down syndrome. The age range for eligible patients is 1 month to 21 years, with children under 1 month of age who have progressive disease also allowed. The trial also has specific eligibility criteria for performance status, life expectancy, hematopoietic, hepatic, renal, cardiovascular, pulmonary, and other factors. Prior concurrent therapy is also specified. The trial is conducted by the Children's Oncology Group (COG).",
    "The sample is a phase 2 clinical trial for the treatment of prostate cancer using abiraterone acetate and prednisolone. The trial includes patients with confirmed adenocarcinoma of the prostate, documented PSA progression, and prior chemotherapy with Docetaxel. Patients must also have ongoing androgen deprivation and an Eastern Cooperative Oncology Group Performance Status less than or equal to 2. Exclusion criteria include active or uncontrolled autoimmune disease, serious or uncontrolled non-malignant disease, uncontrolled hypertension, low hemoglobin levels, abnormal liver function tests, and recent surgery or local prostatic intervention.",
    "The sample is a phase 2 clinical trial for patients with high- or intermediate-grade malignant soft tissue sarcoma, as well as other types of cancer such as ovarian cancer and small intestine cancer. The trial is testing the effectiveness of two drugs, brostallicin and doxorubicin hydrochloride, and has specific eligibility criteria for patients to participate. Patients must have measurable disease, be at least 60 years old or 18 years old if not suitable for intensive combination chemotherapy treatments, have a WHO performance status of 0-1, and meet certain medical criteria such as normal cardiac function and no serious medical conditions that would preclude study participation. Patients cannot have had prior chemotherapy for advanced or metastatic disease and cannot be participating in any other concurrent clinical treatment trials.",
    "The sample is a phase 2 clinical trial for Crohn's disease. The trial is testing the effectiveness of growth hormone and corticosteroid drugs in treating moderate to severely active Crohn's disease in patients aged 5 years and above. The trial has specific inclusion and exclusion criteria, such as a diagnosis of Crohn's disease with ileo-colonic involvement, and exclusion of patients with active neoplasia or diabetes mellitus. The trial also allows for the continuation of stable doses of certain medications, such as AZA/6-MP, methotrexate, and/or mesalamine. The trial has a 52-week extension phase, during which patients must have a PCDAI score of less than 30 to be eligible.",
    "This sample is for a phase 2 clinical trial for patients with melanoma (skin cancer) that has spread to other parts of the body. The trial is testing the effectiveness of the drugs everolimus and temozolomide. Patients must have confirmed melanoma with measurable disease, but no untreated or unstable brain metastases within the past 3 months. Patients must also meet certain criteria related to their health status, such as having a certain level of blood counts and liver function, and not being pregnant or nursing. Patients must have recovered from any prior cancer treatments and cannot have certain medical conditions or be taking certain medications during the trial. The trial will also collect blood samples for research purposes.",
    "The sample is a phase 2 clinical trial for the treatment of vulvodynia and vulvar vestibulitis using the drug pregabalin. The trial is open to adult women aged 18 or older who have chronic vulvar discomfort or pain, characterized by burning, stinging, irritation or rawness of the female genitalia in cases in which there is no infection or skin disease of the vulva or vagina causing these symptoms. The trial requires participants to have a pain score of at least 40 on a 100mm VAS and to be practicing a reliable form of birth control. Exclusion criteria include various infections, pregnancy, breastfeeding, chronic neurologic disease, chronic renal insufficiency, inability to read and speak English, contraindication to pregabalin or history of prior use of pregablin, chronic narcotic or benzodiazepine use, chronic alcohol abuse, other chronic pain disorders, and chronic neuropathic pain or anything affecting sensation.",
    "The sample is a phase 2 clinical trial for the treatment of venous thromboembolism. The trial involves the use of the drugs tak-442 and enoxaparin. The eligibility criteria for the trial include being scheduled to undergo elective, unilateral, primary, total knee replacement, having laboratory tests within the reference range, and not having any conditions that would compromise subject safety or make it difficult to follow the protocol. Exclusion criteria include having a bleeding diathesis, a history of bleeding or ulcers, taking certain medications that may interfere with the study medication, and having certain medical conditions such as severe hypertension or renal dysfunction. The trial also excludes those who are currently participating in another investigational study or have participated in one within 30 days prior to screening.",
    "The sample is a record of a clinical trial in phase 2 for Alzheimer's disease. The trial involves testing three drugs - pf-04494700 in low and high doses, and a placebo comparator. The eligibility criteria for participants include a diagnosis of Alzheimer's disease for at least a year, a Mini Mental State Exam (MMSE) score between 12-26 at screening, and being on a stable dose of cholinesterase inhibitor and/or memantine for at least 2 months. The exclusion criteria include having a neurological or psychiatric illness that could contribute to dementia, living alone, and having poorly controlled high blood pressure.",
    "The sample is a phase 2 clinical trial for patients with metastatic melanoma. The trial involves the use of the drug bevacizumab and has two levels of treatment. Patients who have progressed on standard first-line treatment with dacarbazine are eligible for second-line treatment with bevacizumab. If they show objective clinical response, they may be included for first-line treatment with bevacizumab. Inclusion criteria include confirmed metastatic melanoma, WHO performance status 0-2, age over 18, ability to undergo outpatient treatment, and measurable disease according to RECIST criteria. Exclusion criteria include pregnancy or lactation, prior interferon alpha or IL-2 for metastatic disease, more than one prior chemotherapy regimen for metastatic disease, and various medical conditions such as coagulopathy, brain metastases, and uncontrolled hypertension. Patients must provide written informed consent before registration in the trial.",
    "The sample is a phase 2 clinical trial for the treatment of kidney cancer using the drug talabostat mesylate. The trial requires patients to have a confirmed diagnosis of metastatic renal cell carcinoma and to have progressed after receiving at least one multikinase inhibitor regimen. Patients must also meet certain eligibility criteria, including having a performance status of 0-2, not being pregnant or nursing, and having no active serious infections or other malignancies within the past 5 years. Prior concurrent therapy is allowed as long as the patient has recovered from it and there is no prior radiotherapy to more than 50% of the bone marrow. The sample also includes a list of icd-10 codes for the disease and eligibility criteria for patients.",
    "The sample is a phase 2 clinical trial that involves patients with painful bone metastases, breast carcinoma, non-small cell lung cancer, small cell lung cancer, or adenocarcinoma. The trial uses high intensity focused ultrasound (hifu) in combination with thermodox as the drug. The eligibility criteria include having a confirmed diagnosis of one of the mentioned cancers, having a bone metastasis in specific areas, and having failed at least one prior attempt or not being eligible for external beam radiation therapy (EBRT). The exclusion criteria include having a history of significant cardiac issues, brain metastases, and contraindications for MR imaging or known intolerance or allergy to MRI contrast agents.",
    "The sample is a phase 2 clinical trial for kidney cancer. The trial is for patients with locally advanced unresectable or metastatic disease that is histologically confirmed. The disease must be measurable by physical exam or imaging study, and certain types of disease, such as bone-only disease, are not considered measurable. Patients must be over 18 years old with an ECOG performance status of 0-2 and a life expectancy that is not specified. They must also meet certain hematopoietic, hepatic, renal, and gastrointestinal criteria, and cannot be pregnant or nursing. Patients must not have any mental incapacitation or psychiatric illness that would preclude giving informed consent, and cannot have any other active malignancy except nonmelanoma skin cancer. They must not have any other severe disease that would preclude study participation. Patients cannot have had prior chemotherapy or concurrent chemotherapy, and must meet certain criteria for prior concurrent therapy. The trial is looking at the effectiveness of gemcitabine hydrochloride and irinotecan hydrochloride as treatments for kidney cancer.",
    "The sample is a phase 2 clinical trial for the treatment of hepatocellular carcinoma, a type of liver cancer. The trial involves the use of the drugs sorafenib and gemcitabine. The eligibility criteria for the trial include being at least 18 years old, having confirmed advanced unresectable and/or metastatic HCC, having adequate bone marrow reserve and liver and renal function, and practicing adequate contraception during the study. Exclusion criteria include having certain medical conditions or undergoing certain therapies or medications. The trial aims to evaluate the effectiveness of the drugs in treating HCC.",
    "The sample is a phase 2 clinical trial for patients with stage IIIA or IIIB non-small-cell lung cancer. The trial involves the use of docetaxel and carboplatin as treatment options. The eligibility criteria include having measurable disease, no previous chemotherapy or radiation therapy, being over 18 years old, having a life expectancy of over 12 months, having an ECOG performance status of 0-1, and being medically fit for surgery at the time of enrollment. The trial also requires patients to have normal organ and marrow function, and to be willing to use adequate contraception during the study. The exclusion criteria include previous chemotherapy or radiation therapy, receiving any other investigational agents, having known metastatic disease, having a history of severe hypersensitivity reaction to docetaxel or other drugs, having peripheral neuropathy greater than grade 1, having uncontrolled concurrent illness, being pregnant, having experienced weight loss greater than 10% in the past 3 months before diagnosis, having hyperglycemia, or being HIV positive and receiving combination anti-retroviral therapy.",
    "The sample is a phase 2 trial that involves testing drugs for the treatment of bacterial infections and infections. The trial includes patients who are over 18 years old and have documented acute bacterial skin and skin structure infection. The trial excludes patients with uncomplicated skin and skin structure infection. The diseases are listed as \"bacterial infections\" and \"infection\" and their corresponding ICD-10 codes are also provided. The drugs being tested are \"bc-3781\" and \"vancomycin\". The eligibility criteria for the trial are also listed, including inclusion and exclusion criteria.",
    "The sample is a phase 2 clinical trial for the treatment of bipolar I disorder. The trial involves testing the effectiveness of different doses of eslicarbazepine acetate and a placebo. The eligibility criteria include being 18 years or older, having a documented diagnosis of bipolar I disorder, currently displaying an acute manic episode, and having a Young Mania Rating Scale (YMRS) total score of 20 or greater. Exclusion criteria include a history of schizophrenia or schizoaffective disorder, currently being treated with carbamazepine or oxcarbazepine, and pregnancy or nursing. The trial also includes a list of diseases, icd-10 codes, and drugs being tested.",
    "The sample is a record of a clinical trial with a phase 2 designation. The trial is focused on coronary heart disease and includes a list of ICD-10 codes associated with the disease. The trial involves the use of two drugs, placebo and dalcetrapib. The eligibility criteria for the trial include being an adult between the ages of 18 and 75, having CHD or CHD risk equivalent, and having a body weight of less than 125kg at visit 1. The exclusion criteria include recent clinically significant coronary events, history of statin-associated myopathy or intolerance to statin, history of malignancy (except for curatively treated basal cell or squamous cell cancer of the skin) during the 3 years prior to screening, and exposure to RO4607381 in the past 12 months.",
    "The sample is a phase 2 clinical trial for patients with systemic sclerosis, specifically diffuse or limited SSc, who have current areas of skin fibrosis due to SSc. The trial is testing the drug bosentan (tracleer) and has a list of inclusion and exclusion criteria for patient eligibility. Inclusion criteria include fulfilling ACR criteria, being postmenopausal or having a negative pre-treatment pregnancy test, and signing informed consent. Exclusion criteria include severe PAH or interstitial lung disease, skin fibrosis and digital ulcers due to conditions other than SSc, and treatment with certain drugs within a certain timeframe prior to study participation. Patients with conditions that prevent compliance with the protocol or adhering to therapy are also excluded.",
    "The sample is a phase 2 clinical trial for fibromyalgia. The trial includes patients who are 18 years or older and have a clinical diagnosis of fibromyalgia as defined by the 1990 American College of Rheumatology criteria. The patients must provide written informed consent to participate in the study and understand that they may withdraw their consent at any time without prejudice to their future medical care. The inclusion criteria also require patients to have a score of between 20mm and 90mm on the Visual Analog Scale for Pain (VAS-P) section of the SF-MPQ at screening and baseline visits. The exclusion criteria include uncontrolled hypertension, use of certain medications, clinically relevant depression, history of drug or substance abuse, and significant systemic, hepatic, cardiac or renal illness, among others. The trial also has requirements for contraception for women of childbearing potential and sexually active males whose partner is a woman of childbearing potential. The trial involves the use of drugs such as droxidopa, carbidopa, droxidopa/carbidopa, and placebo.",
    "The sample is a phase 2 clinical trial for patients with kidney cancer or renal cell carcinoma that has spread to the bones. The trial is testing the effectiveness of the drugs zoledronate and atorvastatin in treating bone metastases. The eligibility criteria include having confirmed renal cell carcinoma with evidence of bone metastases, controlled impending complications from skeletal metastases, and adequate physiologic reserves. Exclusion criteria include patients with poor dentition, history of other malignancies, overt psychosis or mental disability, and known hypersensitivity to the drugs being tested. Patients must sign an informed consent indicating that they are aware of the investigational nature of the study.",
    "The sample is a phase 2 clinical trial for chronic kidney disease. The inclusion criteria require participants to have been diagnosed with CKD, have an estimated glomerular filtration rate between 30-70 milliliter/minute/1.73 square meters, and have been taking an angiotensin converting enzyme (ACE) inhibitor and/or angiotensin II receptor blocker (ARB) for at least 3 months. Participants must also meet certain renal function criteria and have stable blood pressure medication use. Exclusion criteria include previous enrollment in the study or any other study investigating LY2623091, taking certain medications, and having a history of acute kidney injury or congestive heart failure. Participants must be willing to comply with study procedures and have venous access sufficient for blood sampling.",
    "The sample is a phase 2 clinical trial for the treatment of lymphoma, specifically large b-cell diffuse lymphoma and non-hodgkin lymphoma. The trial involves the use of several drugs including sgn-40, placebo, rituximab, etoposide, carboplatin, and ifosfamide. The eligibility criteria for the trial include having a confirmed diagnosis of de novo or transformed DLBCL or follicular grade 3b lymphoma, having received at least four cycles of first-line therapy with R-CHOP or equivalent, and having a measurable lesion that is greater than or equal to 1.5cm by radiographic imaging and by positive FDG-PET scan. The exclusion criteria include having leptomeningeal or central nervous system lymphoma, having received any therapy for relapsed or progressive disease except for local radiation, steroids, or rituximab, and having received a hematopoietic stem cell transplant.",
    "The sample is a phase 2 clinical trial for Crohn's disease. The trial includes patients between the ages of 18 and 80 who have been diagnosed with Crohn's disease for at least 6 months and have endoscopic and/or histopathological and/or radiological documentation consistent with Crohn's disease. The trial involves the use of two drugs, ldp-02 and placebo, and patients may have been receiving oral or topical 5-ASA compounds provided the dosage had been stable for at least the 14-day period before the screening visit. The trial has specific inclusion and exclusion criteria, including a CDAI score from 220 to 400 and the absence of certain medical conditions or use of certain medications. Patients must be able to attend all study visits and comply with study procedures.",
    "The sample is a phase 2 clinical trial for patients with advanced or metastatic colorectal cancer who have not responded to at least one prior therapy and have mutations in the PI3K gene in their tumor tissue. The trial is testing the effectiveness of the drug everolimus. Patients must meet certain eligibility criteria, including having a measurable lesion, normal blood counts and liver function, and no history of allergic reactions to compounds similar to everolimus. They must also be willing to undergo two sequential tumor biopsies and two sequential skin biopsies. Patients cannot have any concurrent anticancer therapy, including chemotherapy, hormonal therapy, immunotherapy, alternative therapy, or radiotherapy, and cannot receive live vaccinations during the trial.",
    "The sample is a record of a clinical trial with a phase 2 designation. The trial is focused on treating chronic lymphocytic leukemia. The trial involves the use of drugs such as ofatumumab and fludarabine, as well as eligibility criteria for patients to participate in the trial. The eligibility criteria include age, previous treatments, medical conditions, and other factors that may impact the patient's ability to participate in the trial. The sample also includes exclusion criteria, such as pregnancy or breastfeeding, and the use of adequate contraception for female patients.",
    "The sample is a phase 2 clinical trial for patients with CD20 positive, diffuse large B-cell non-Hodgkin's lymphoma who have relapsed after or not responded to at least one standard, upfront multi-agent chemotherapy. The trial involves the use of bortezomib, dexamethasone, ifosfamide, mesna, cisplatin, etoposide, and rituximab. The eligibility criteria include having measurable PET positive disease, being at stage II, III, or IV, having adequate liver and kidney function, adequate bone marrow reserves, an ECOG performance status of less than 2, and a life expectancy of at least 3 months. Patients must also be bortezomib-naive and provide voluntary written informed consent. Exclusion criteria include having \u2265 Grade 2 peripheral neuropathy, myocardial infarction within 6 months prior to enrollment, hypersensitivity to boron or mannitol, being pregnant or nursing, having received other investigational drugs or cytotoxic chemotherapy within 14 days of enrollment, and having serious medical or psychiatric illness likely to interfere with participation in the clinical study.",
    "The sample is a phase 2 clinical trial for the treatment of atopic dermatitis. The trial involves testing various doses of a drug called jnj-26113100, as well as a placebo. The eligibility criteria for participants include having atopic dermatitis involving at least 10% of their body surface area, being in good general health, and using contraception if necessary. Exclusion criteria include having certain medical conditions or using certain medications. The trial is designed to assess the safety and efficacy of the drug in treating atopic dermatitis.",
    "The sample is a phase 2 clinical trial for the treatment of myelodysplastic syndrome (MDS), a type of blood cancer. The trial involves the use of two drugs, lbh589 and epoetin alfa, and has specific eligibility criteria for patients to participate. Patients must have a lower risk MDS and be dependent on red blood cell transfusions. They must also not be responding to Erythropoietin stimulating agents (ESA) or have a low chance of responding. Additionally, patients must have normal cardiac, kidney, and liver function. There are also exclusion criteria, such as not being able to use ESA or any other investigational drug, having another malignancy that is not in remission for at least 1 year, having a platelet count less than 75 x 109/L, or having impaired cardiac function or clinically significant cardiac diseases.",
    "The sample is a phase 2 clinical trial for newly diagnosed primary CNS lymphoma. The trial is looking at the effectiveness of a combination of drugs including cytarabine, etoposide, leucovorin calcium, methotrexate, and temozolomide. The eligibility criteria for the trial includes having histologically confirmed primary CNS lymphoma, no evidence of systemic non-Hodgkin's lymphoma, and measurable contrast-enhancing disease by MRI of the brain and spine. Patients must also meet certain age, performance status, and hematopoietic, hepatic, renal, and other health criteria. Prior concurrent therapy is not specified, but concurrent steroids for the management of symptoms related to lymphoma are allowed.",
    "The sample is a phase 2 clinical trial for non-small cell lung cancer patients with measurable or evaluable disease. The trial involves the use of three drugs - bevacizumab, pemetrexed, and carboplatin. The eligibility criteria include being up and about, having adequate kidney, liver, and bone marrow function, and not having received prior treatment for the disease. In addition, patients must be able to give written informed consent and take folic acid, vitamin B12, and dexamethasone as described in the protocol. There are also several exclusion criteria, such as having stage IV or IIIB disease with pleural or pericardial effusions, being pregnant or lactating, having active infections, or having a recent history of blood in the sputum or vomitus. The study center will determine if patients meet all of the criteria, and if they do, study personnel will explain the trial in detail and answer any questions they may have.",
    "The sample is a phase 2 clinical trial for breast cancer patients with metastatic or recurrent disease. The trial involves the use of the drugs celecoxib and celecoxib, and the eligibility criteria include having at least 4 prior courses of chemotherapy resulting in stable disease, partial response, or complete response, as well as having measurable or evaluable disease. The trial also has specific patient characteristics, such as being female and having a performance status of CTC (ECOG) 0-2. Prior concurrent therapy is allowed for certain treatments, such as trastuzumab for biologic therapy and prior hormonal therapy for metastatic disease. However, concurrent therapy with celecoxib or other nonsteroidal anti-inflammatory drugs (NSAIDs) is not allowed.",
    "The sample is a phase 2 clinical trial for patients with advanced or recurrent adenocarcinoma of the colon or rectum. The trial includes patients with specific measurable lesions and excludes those with brain metastases, severe concurrent illnesses, or prior chemotherapy for advanced disease. The trial involves the use of four drugs: irinotecan hydrochloride, gefitinib, leucovorin calcium, and fluorouracil. Patients must meet a range of eligibility criteria, including having a granulocyte count of at least 1,500/mm^3, a platelet count of at least 100,000/mm^3, and no symptomatic congestive heart failure. The trial also excludes patients with a history of allergic reactions to compounds of similar chemical or biologic composition to gefitinib and those with psychiatric illness or social situations that would preclude study compliance.",
    "This sample is a phase 2 clinical trial for the treatment of major depression. The trial includes patients who have been diagnosed with major depression by a psychiatrist and have a HamD-17 score of at least 22. The trial excludes patients with psychotic depression, bipolar disorder, obsessive-compulsive disorder, anxiety disorder, personality disorder, drug or alcohol abuse, schizoaffective disorders, schizophrenia, and all DSM IV TR Axis-I disorders except depression. Patients who have been unsuccessfully treated with more than 2 antidepressant medications, are using psychotropic drugs, have an immediate risk of suicidal behavior, are pregnant, breastfeeding, or planning to become pregnant during the course of the study, or have a history of cardiovascular disease, upper or lower gastrointestinal ulceration, perforation and/or obstruction, inflammatory bowel disease, or any other heart disease are also excluded. The trial will test the effectiveness of the drugs cimicoxib and placebo.",
    "The sample is a phase 2 clinical trial for patients with recurrent prostate cancer. The trial includes patients who have undergone definitive local therapy for prostate cancer and are free of macrometastatic disease. The eligibility criteria include specific requirements for PSA levels, testosterone levels, and no measurable disease. Patients must also have an Eastern Cooperative Oncology Group (ECOG) performance status of 0-2 or a Karnofsky PS of 60-100%. The trial involves the use of pazopanib hydrochloride, leuprolide acetate, and goserelin acetate. Patients must meet a variety of medical criteria, including normal levels of bilirubin, AST, and ALT, and no history of allergic reactions to the study drugs. Patients must also not have any concurrent uncontrolled illness, HIV positivity, or conditions that impair the ability to swallow and retain pazopanib hydrochloride tablets. The trial excludes patients with certain medical conditions, including serious or nonhealing wounds, ulcers, or bone fractures, and those with a history of myocardial infarction or venous thrombosis within the past 6 months. Patients must also not be taking certain medications, including concurrent ketoconazole or cytochrome P450 2C9 (CYP2C9) substrates.",
    "The sample is a phase 2 trial for mantle cell lymphoma, a type of cancer. The trial includes patients who have not received prior chemotherapy, immunotherapy, or radiotherapy for mantle cell lymphoma. Patients must have measurable disease and an Eastern Cooperative Oncology Group (ECOG) performance status of 0-2. The trial also has various inclusion and exclusion criteria, including specific laboratory values and tests, as well as restrictions on prior malignancies and central nervous system involvement. The trial involves the use of five drugs: bortezomib, cyclophosphamide, doxorubicin hydrochloride, vincristine, and dexamethasone. The eligibility criteria for the trial are also listed in detail.",
    "The sample is a clinical trial for a drug to treat excessive daytime somnolence in patients with Parkinson's disease. The trial is in phase 2/phase 3 and involves the use of caffeine and a placebo. The eligibility criteria include a diagnosis of idiopathic PD and excessive daytime somnolence, while exclusion criteria include certain medical conditions and medication use. The trial also has specific criteria for pre-menopausal women and patients with dementia or depression. The antiparkinsonian medication cannot be changed during the study protocol.",
    "This is a phase 2 clinical trial for HIV-1 infection. The trial is testing the drug FTC/RPV/TDF. The eligibility criteria for participants include being on EFV/FTC/TDF for at least 3 months, having undetectable levels of HIV-1 RNA for at least 8 weeks prior to screening, and having no known resistance to any of the study agents. Participants must also meet certain health criteria, such as having normal ECG and liver function, and must agree to use highly effective contraception methods. Exclusion criteria include having a new AIDS-defining condition, being pregnant or breastfeeding, and having a history of certain medical conditions or treatments.",
    "The sample is a phase 2 clinical trial for patients aged 18 and above with relapsed or refractory epithelial ovarian, fallopian tube, or primary peritoneal cancer. The trial involves the drug vandetanib and requires patients to have measurable disease and a sentinel lesion adequate for core biopsy. Patients must also meet certain eligibility criteria, including having good end organ function, a performance status of Eastern Cooperative Oncology Group (ECOG) = 0, 1, or 2, and having received no more than 4 prior regimens for the treatment of ovarian cancer. Patients must have recovered from any toxicity related to prior cancer therapy to NCI grade 1, except for peripheral neuropathy, which must have recovered to grade 2 or better. Women of childbearing age and potential must agree to use adequate barrier contraception prior to study entry, during therapy, and for 3 months after completion of therapy. The trial has exclusion criteria, including evidence of severe or uncontrolled systemic disease, evidence of central nervous system (CNS) involvement, and history of cardiac disorders.",
    "The sample is a clinical trial for lupus erythematosus, systemic and lupus nephritis, in which the participants are divided into two groups: one receiving infliximab and the other receiving a placebo. The trial is in phase 2/phase 3 and the eligibility criteria include having SLE with biopsy-proven membranous glomerulonephritis, proteinuria greater than 3 g/day despite adequate therapy with ACE inhibitors and steroids, and meeting certain laboratory test results. Exclusion criteria include having active WHO class IV SLE nephritis, treatment with certain medications within a certain time frame, and having certain medical conditions or histories. The trial also requires participants to use adequate birth control measures and to have a negative tuberculin skin test or have received appropriate treatment for latent TB.",
    "The sample is a phase 2 clinical trial for patients with moderate to severe chronic obstructive pulmonary disease (COPD). The trial includes male and female adults aged 40 years or older who have signed an informed consent form. Patients must have a smoking history of at least 10 pack years and meet certain lung function criteria. The trial involves the use of three drugs: nva237, placebo, and tiotropium. The eligibility criteria include both inclusion and exclusion criteria, such as not being pregnant or nursing, not requiring daily oxygen therapy, and not having certain medical conditions. The trial also has other protocol-defined inclusion/exclusion criteria that may apply.",
    "The sample is a phase 2 clinical trial for the treatment of rheumatoid arthritis. The trial includes patients who have been diagnosed with rheumatoid arthritis for at least 4 months and are currently receiving outpatient treatment with methotrexate. The trial will test the efficacy of apremilast 30 mg, apremilast 20 mg, and placebo. Patients must have active disease despite current methotrexate treatment, as defined by swollen and tender joint counts and lab requirements. Participants will be required to maintain their stable dose of methotrexate throughout the study. The trial also includes eligibility criteria related to laboratory values, medical history, and contraception use. Exclusion criteria include major surgery within 8 weeks prior to screening, other rheumatic autoimmune diseases, and inadequate response to treatment with an anti-tumor necrosis factor agent. The trial also includes MRI assessments for some participants.",
    "This sample is for a phase 2 clinical trial for non-small cell lung cancer. The trial is testing the drug erlotinib. The eligibility criteria for participants include having unresectable locally advanced or metastatic NSCLC, being a non-smoker or having less than 5 pack-years smoking history, having adenocarcinoma histology, and having a performance status of 0-3. Participants must also have adequate liver, renal, and bone marrow function, and be able to take oral medication. A tissue sample for tumour mutational analysis is required. Exclusion criteria include having serious chronic skin conditions, active infection, significant cardiac disease, malnutrition, a performance status of 4, psychiatric illness or social situation that would preclude study compliance, and being pregnant or lactating.",
    "The sample is a clinical trial with a combination of phase 2 and phase 3. The trial is focused on two diseases, sarcoidosis and pulmonary arterial hypertension, and their corresponding ICD-10 codes. The trial involves the use of two drugs, bosentan and placebo. The eligibility criteria for the trial include patients with known sarcoidosis, age 18 or greater, documented pulmonary hypertension with a PA mean > 25 mm Hg, WHO class II or III, and a six-minute walk distance of between 100 to 500 meters. Patients on stable immunotherapy for their sarcoidosis are also eligible. Exclusion criteria include patients on pulmonary vasodilator drugs, severe airway obstruction, WHO class IV status, pregnant or breastfeeding patients, significant left ventricular dysfunction, cardiac index < 2.0 liters and/or right atrial pressure >15 mm Hg, significant liver dysfunction not due to sarcoidosis, severe other organ disease, and patients unable to perform the 6 minute walk study.",
    "The sample is a phase 2 clinical trial for asthma. The trial includes outpatient subjects who are 12 years of age or older, with a diagnosis of asthma as defined by the National Institutes of Health. The trial requires subjects to have a best FEV1 of 40%-90% of the predicted normal value during Visit 1 and demonstrated a \u2265 12% and \u2265200mL reversibility of FEV1 within approximately 30-minutes following 4 inhalations of albuterol/salbutamol inhalation aerosol. Subjects must have been using an inhaled corticosteroid for at least 8 weeks prior to Visit 1 and maintained on a stable dose of inhaled corticosteroids for four weeks prior to Visit 1. The trial also requires subjects to commit to consistent and correct use of an acceptable method of birth control if they are of childbearing potential. The trial has a list of exclusion criteria, including a history of life-threatening asthma, respiratory infection, asthma exacerbation, and concurrent diseases/abnormalities.",
    "The sample is a phase 2 clinical trial for the treatment of head and neck cancer using the drug fenretinide. The eligibility criteria include having histologically proven oral mucosal intraepithelial neoplasia stage II or III, with no myelodysplastic syndrome or retinopathies. Patients must not be currently undergoing biologic, chemotherapy, endocrine, or radiotherapy treatments, but prior surgical ablation of dysplastic sites is allowed. Patients must not be pregnant or nursing, and fertile patients must use effective contraception during the study and for at least 2 months after. There are no specific age or life expectancy requirements, and no specific hematopoietic, hepatic, or renal requirements.",
    "The sample is a phase 2 clinical trial for breast cancer patients. The trial includes patients who are 18 years or older, have infiltrating breast cancer, and have no evidence of metastatic disease except to the ipsilateral axillary lymph nodes. The primary tumor must be greater than or equal to 2 cm or with pathologically proven axillary nodal involvement. Patients with inflammatory breast cancer are also allowed. The trial involves the use of cyclophosphamide, docetaxel, doxorubicin, and nov 002 drugs. The eligibility criteria include normal cardiac ejection fraction, no prior history of myocardial infarction, congestive heart failure, symptomatic coronary artery disease, or cardiac arrhythmias, and an ECOG Performance Status of 0-1. The exclusion criteria include prior therapy of any modality for the treatment of breast cancer, any prior therapy with an anthracycline or a taxane for any other indication, HER-2 positive breast cancer, and women who are pregnant or lactating.",
    "The sample is a phase 2 clinical trial for the treatment of bipolar disorder using the drug lamotrigine. The trial is open to individuals between the ages of 10 and 20 who have been diagnosed with bipolar disorder and are able to swallow tablets. The trial has inclusion and exclusion criteria, including the exclusion of individuals with certain medical conditions or who are taking certain medications. The trial also includes an fMRI study, which has additional exclusion criteria such as body weight and contraindications for fMRI studies. Participants with an IQ of less than 70 are also likely to be excluded. The trial does not select participants based on sex, race, or ethnic group.",
    "The sample is a record of a clinical trial with a phase 2 designation. The trial is focused on Alzheimer's disease and involves the use of the drug abt-089 and a placebo. The trial has specific eligibility criteria, including a requirement for patients to have mild to moderate Alzheimer's disease, be receiving a stable dose of an acetylcholinesterase inhibitor, have a MMSE score between 12 and 26, and have a MHIS score of less than or equal to 4. Patients must also have a reliable caregiver who will support them and accompany them to each outpatient visit. There are also exclusion criteria, such as patients living in a nursing home or having a history of drug or alcohol abuse/dependence.",
    "This sample is a phase 2 clinical trial for the treatment of cystic fibrosis. The trial is testing the effectiveness of two drugs, mp-376 and placebo, on patients who are over 16 years old and have a confirmed diagnosis of cystic fibrosis. The patients must have had a positive sputum culture for P. aeruginosa within the past 18 months and be able to elicit a forced expiratory volume in 1 second (FEV1) of at least 25% but no more than 85% of predicted value at screening. They must have also received at least 3 courses of inhaled antimicrobials over the preceding 12 months and be clinically stable with no changes in health status within the last 30 days. The patients must be able to reproducibly produce sputum and perform spirometry. Exclusion criteria include the use of any nebulized or systemic antibiotics within 30 days prior to baseline, history of hypersensitivity to fluoroquinolones or intolerance with aerosol medication, evidence of acute upper within 10 days or lower respiratory infections within 30 days prior to dosing, and creatine clearance < 50mg/ml, aspartate transaminase (AST), alanine transaminase (ALT) or total bilirubin >/= 3 x upper limit of normal (ULN) at Screening.",
    "The sample is a phase 2 clinical trial for the treatment of acromegaly, a disease characterized by excessive growth hormone production. The trial is testing the drug pasireotide, and the eligibility criteria include having completed a previous study and achieved biochemical control with pasireotide, as well as not experiencing any adverse events or tolerability issues. Exclusion criteria include certain medical conditions and interventions during the previous study. Other inclusion and exclusion criteria may also apply. The diseases are listed as a single item, while the icd-10 codes, drugs, and criteria are listed as lists.",
    "The sample is a phase 2 clinical trial for the treatment of gastric cancer using the drugs capecitabine and oxaliplatin. The trial is open to patients with histologically confirmed primary adenocarcinoma of the stomach that is newly diagnosed and amenable to curative resection, with stage IB-III (T2-4) disease. Patients must have measurable or nonmeasurable disease and no distant metastasis or gastroesophageal junction tumors. They must also meet certain patient characteristics, including a Zubrod performance status of 0-1, certain blood counts and levels, and no evidence of ischemic heart disease or other medical conditions that would prevent treatment. Patients must not be pregnant or nursing and must use effective contraception if fertile. Prior therapy for this malignancy, including chemotherapy, surgery, immunotherapy, or radiotherapy, is not allowed. Patients must not have had prior coronary angioplasty or stenting and must not receive concurrent 2-dimensional or intensity-modulated radiotherapy. The eligibility criteria are listed in detail in the \"criteria\" column of the table.",
    "The sample is a phase 2 clinical trial for patients with myelodysplastic syndromes or myelomonocytic leukemia. The trial is testing the effectiveness of the drug sorafenib. The eligibility criteria include being 18 years or older, having a certain level of creatinine clearance, and having a certain ECOG performance status. Patients must not have received other investigational drugs for this disease within 14 days of enrollment and must not have undergone allogeneic stem cell transplant. Exclusion criteria include pregnancy or lactation, serious medical or psychiatric illness, and significant cardiac or vascular events within 6 months.",
    "The sample is a phase 2 clinical trial for kidney neoplasms, which is a type of cancer that affects the kidneys. The trial involves the use of two drugs, thalidomide and capecitabine, and has a list of eligibility criteria that participants must meet in order to be included in the trial. These criteria include being able to comprehend and sign an IRB approved Informed consent, willingness and ability to comply with the FDA-mandated S.T.E.P.S.\u00ae program, being male or female 18 years or older, having a pathologic diagnosis of renal cell carcinoma, having bi-dimensionally measurable disease, evidence of disease progression prior to start of treatment, and having failed prior immunotherapy or being unwilling/unable to receive prior immunotherapy. Additionally, participants must have adequate hematologic data, renal function, and liver function, as well as an ECOG performance status of 0-1. The exclusion criteria include having known brain metastases, peripheral neuropathy, being pregnant and/or lactating, and being unable to take a baby aspirin.",
    "The sample is a phase 2 clinical trial for patients with relapsing multiple sclerosis. The trial involves the drugs fty720 and placebo. The eligibility criteria include having at least two documented relapses in the previous 2 years or one documented relapse in the last year, having an Expanded Disability Status Scale (EDSS) score of 0-6, and being neurologically stable with no evidence of relapse within 30 days prior to randomization. Female patients must either be post-menopausal, surgically incapable of bearing children, or practicing an acceptable method of birth control. The exclusion criteria include having other chronic diseases of the immune system, malignancies, pulmonary or heart disease, being pregnant or nursing, and having diabetes mellitus.",
    "The sample is a phase 2 clinical trial for patients with various connective tissue neoplasms, including malignant fibrous histiocytoma, desmoid tumors, and sarcoma. The trial is testing the effectiveness of the drug sunitinib malate. The eligibility criteria include having confirmed connective tissue neoplasm, measurable disease, and no untreated brain metastases or symptomatic brain metastases. Patients must also meet certain health requirements, such as having an ECOG performance status of 0-2 and normal blood counts. Prior therapy is allowed, but patients cannot have previously received sunitinib malate. Concurrent use of other anticancer agents or treatment is not allowed.",
    "The sample is a phase 2 clinical trial for patients with overactive bladder and detrusor overactivity. The trial involves the use of two drugs, vardenafil hcl (levitra, bay38-9456) and placebo. The eligibility criteria include patients aged over 18 years, with specific urodynamic and micturition diary criteria, and who have signed a written informed consent form. The exclusion criteria include patients with certain medical conditions or who have been treated with certain drugs.",
    "The sample is a record from a clinical trial table that includes information about the phase of the trial (phase 2/phase 3), the disease being studied (multiple sclerosis), the ICD-10 codes associated with the disease (G35 and C81.18), the drug being tested (mycophenolate mofetil), and the eligibility criteria for participants. The inclusion criteria include being between the ages of 21-45, having clinically definite or laboratory-supported definite relapsing MS of less than or equal to two years in duration, and having had at least one exacerbation in the preceding two years. The exclusion criteria include having primary progressive, secondary progressive, or progressive relapsing MS, having used corticosteroids or plasma exchange within a certain timeframe, having certain medical conditions or cognitive impairments, and being pregnant or breastfeeding. Females of childbearing age who have not undergone sterilization must be willing to practice effective birth control.",
    "The sample is a record of a clinical trial with a phase 2 designation. The trial is focused on the disease of gout and includes a list of associated ICD-10 codes. The trial involves the use of the drugs febuxostat and has specific eligibility criteria for participants, including hyperuricemia, meeting American College of Rheumatology criteria for gout, and adequate renal function. The sample also includes exclusion criteria, such as a history of xanthinuria and active liver disease. The trial requires females of childbearing potential who are sexually active to use adequate contraception and cannot be pregnant or lactating throughout the study.",
    "The sample is a phase 2 clinical trial for diabetic foot. The trial is looking for healthy adult male subjects between the ages of 18 to 45 years old, with a weight not less than 50 kg and a normal BMI. The subjects must be willing and capable of providing written informed consent to participate in the study. They must also be free of significant diseases or clinically significant abnormal findings based on medical history, physical examination, laboratory evaluations, 12-lead ECG, Chest X-ray [PA view]. The trial requires the absence of disease markers of HIV 1 and 2, Hepatitis B and C and Syphilis. The subjects must have normal AST, ALT, alkaline phosphatase and bilirubin levels. The ECG must be normal for morphology and measurements, with QTcB or QTcF < 450 msec or QTc < 480 msec in subjects with Bundle Branch Block, based on an average from three ECGs obtained over a brief recording period. Male subjects with female partners of child-bearing potential must agree to use one of the contraception methods listed. The trial has exclusion criteria, including a history or presence of significant cardiovascular, pulmonary, hepatic, renal, hematological, gastro-intestinal, endocrine, immunologic, dermatologic, neurological, psychiatric disease, alcohol dependence, alcohol abuse during past one year, drug abuse, smoking of more than 5 cigarettes per day or consumption of other forms of tobacco containing products, asthma, urticaria or other allergic type reactions after taking aspirin or any other drug, ulceration or history of gastric and / or duodenal ulcer, jaundice in the past 6 months, bleeding disorder, allergy to the test drug or any drug chemically similar to the drug or to the excipients of the products under investigation, donation of 500 mL or more blood within 8 weeks prior to receiving the first dose of study drug, subjects who have participated in another clinical study in the past 3 months prior to commencement of this study, any difficulty in accessibility of forearm veins for cannulation or blood sampling, refusal to abstain from food for at least 10 h prior to drug administration and for at least 4 h post dose in each period, refusal to abstain from fluid for at least 1 h prior to and 1 h post each dose except 20 % glucose solution given after dosing, positive breath alcohol test result found on the day of check-in, positive urine test result for drug of abuse found on the day of check-in, history of difficulty in swallowing tablet, use of any concomitant medication [including over-the-counter products, vitamins etc.] for 14 days preceding the study drug administration, and use of drugs which induce or inhibit metabolizing enzymes within 30 days prior to receiving the first dose of study medication. The investigator must refer to the product data sheet for detailed information regarding warnings, precautions, contraindications, adverse events, and other significant data pertaining to the product being used in this study.",
    "This sample is for a phase 2 clinical trial for HIV infections. The trial is testing the effectiveness of two drugs, fosamprenavir and saquinavir, on patients who have not previously taken protease inhibitors and have a wild type genotype. The inclusion criteria for the trial include having a CD4 count greater than 200/mm3 and a viral load between 10,000 copies/ml and 750,000 copies/ml. Patients must also have signed informed consent. The exclusion criteria include pregnancy or breastfeeding, previous antiretroviral treatment, hyperlipidemic treatment, and evolutive disease.",
    "The sample is a phase 2 clinical trial for chronic hepatitis C. The trial is testing the effectiveness of several drugs, including gsk2336805, pegylated interferon alfa-2a, ribavirin, and a placebo. The eligibility criteria include having documented chronic genotype 1 or genotype 4 HCV infection, being naive to all HCV antiviral treatments, having a body mass index between 18 and 36 kg/m2, and having a non-cirrhotic fibrosis classification from a liver biopsy obtained within the past 3 years. Participants must also use two forms of effective contraception during treatment and for 24 weeks after treatment ends. Exclusion criteria include a positive test for hepatitis B surface antigen or anti-human immunodeficiency virus antibody, a history of any other clinically significant chronic liver disease, and a history of alcohol/drug abuse or dependence within 6 months of the study start.",
    "The sample is a phase 2 clinical trial for patients with metastatic or recurrent squamous cell carcinoma of the head and neck. The trial involves the use of drugs such as cisplatin, panitumumab, and docetaxel. The eligibility criteria include confirmation of the disease, measurable disease by CT scan, an ECOG performance score of 0 or 1, and adequate hematologic, renal, metabolic, hepatic, and thyroid function. Exclusion criteria include prior systemic treatment for the disease, CNS metastases, or nasopharyngeal carcinoma, history of interstitial lung disease, history of another primary cancer, and any co-morbid disease that would increase the risk of toxicity.",
    "The sample is a phase 2 clinical trial for the treatment of iron deficiency anemia. The trial is testing the effectiveness of two drugs, ferric carboxymaltose and iron dextran injection. The eligibility criteria for the trial include being a female over 18 years old with a history of heavy uterine bleeding within the past 6 months, having a central laboratory hemoglobin level of less than 12 g/dL, and having a ferritin level of less than or equal to 100 ng/mL or less than or equal to 300 when transferrin saturation is less than or equal to 30%. Exclusion criteria include having a known hypersensitivity reaction to the drugs being tested, having previously been randomized in a clinical study of ferric carboxymaltose, requiring dialysis for treatment of chronic kidney disease, having a history of primary hypophosphatemic disorder, and having any other medical condition or psychiatric disorder that may put the subject's disease management at risk or may result in the subject being unable to comply with study requirements.",
    "The sample is a phase 2 clinical trial for the treatment of type 1 diabetes mellitus using the drugs ly2605541 and insulin glargine. The trial is looking for participants who have had T1DM for at least 1 year and have been using insulin glargine for at least 6 months with a maximum daily dose of 1 unit per kilogram. Participants must also have a HbA1c of no greater than 10.5%, a BMI between 19 and 45 kg/m\u00b2, and be willing and capable of monitoring their own blood glucose and injecting insulin. Women of childbearing potential must test negative for pregnancy and agree to use reliable birth control. There are several exclusion criteria, including recent use of other diabetes medications, insulin pump use, and a history of severe hypoglycemia or hospitalizations due to poor glucose control.",
    "The sample is a phase 2 clinical trial for patients with recurrent skin cancer, squamous cell carcinoma of the skin, stage 0 or stage I chronic lymphocytic leukemia, or basalosquamous cell disease. The trial is testing the drug dasatinib. Patients must meet certain eligibility criteria, including having measurable disease, a certain performance status, and meeting certain laboratory values. Patients must also not have certain medical conditions or be taking certain medications. The trial is not allowing concurrent use of other investigational agents or combination antiretroviral therapy for HIV-positive patients.",
    "The sample is a phase 2 clinical trial for patients with locally advanced or metastatic non-small cell lung cancer. The trial is testing the effectiveness of two different drug combinations: gemcitabine plus pemetrexed and paclitaxel plus gemcitabine. The eligibility criteria for the trial include having no previous chemotherapy or radiotherapy, having a measurable lesion, and having a good performance status and overall health. Patients with certain medical conditions or previous malignancies are excluded from the trial. Written informed consent is required for participation.",
    "The sample is a phase 2 trial for patients with bone metastases from any primary solid tumor site who are scheduled to receive a single 8 Gy fraction of palliative radiotherapy considered to be moderately emetogenic. The trial is being conducted at the RRRP at Sunnybrook Odette Cancer Centre. The diseases being studied are nausea and vomiting, and the corresponding ICD-10 codes are listed. The drugs being used in the trial are aprepitant and granisetron. The eligibility criteria include not having nausea or vomiting 24 hours prior to radiation, not having received or being scheduled to receive cranial radiation or moderately or highly emetogenic cytotoxic therapy 7 days prior to, during, or after radiation, not receiving corticosteroids (except inhaled or topical), 5HT3 receptor antagonists or NK-1 antagonists or other antiemetic medication, not being allergic to study medications, having a KPS<40, not being pregnant or of childbearing potential and not using contraceptive measures.",
    "The sample is a phase 2 clinical trial for patients with metastatic breast cancer. The trial is testing the effectiveness of irinotecan hydrochloride, a chemotherapy drug. Patients must have confirmed adenocarcinoma of the breast and clinical manifestations of metastatic disease. They must also have measurable disease and not have bone metastases or other non-measurable disease. Patients must have received at least one prior trastuzumab-containing regimen if their tumor is HER2 positive. Patients must meet certain eligibility criteria, including having an ECOG performance status of 0-2 and a life expectancy of more than 3 months. They must also not have any serious concomitant medical conditions that would make it undesirable for them to participate in the trial or would jeopardize compliance with protocol treatment. Prior concurrent therapy is also specified.",
    "The sample is a phase 2 clinical trial for prostate cancer using the drug thalidomide. The eligibility criteria include having histologically confirmed adenocarcinoma of the prostate meeting certain criteria for high-risk disease, no clinical evidence of CNS metastases, and no metastatic disease as demonstrated by radiological exam within 8 weeks of study entry. Patients must also meet certain patient characteristics such as having an ECOG performance status of 0-1 and no pre-existing peripheral neuropathy > grade 1. Prior concurrent therapy includes no prior radiotherapy to the prostate or pelvis, no prior chemotherapy or hormonal therapy for prostate cancer, and no parenteral antibiotics within the past 7 days.",
    "The sample is a phase 2 clinical trial for the treatment of type 2 diabetes mellitus. The trial includes a list of diseases and their corresponding ICD-10 codes, a list of drugs being tested, and eligibility criteria for participants. The inclusion criteria require participants to have type 2 diabetes mellitus, be between 18 and 70 years old, have a BMI between 20 and 43 kg/m^2, and not be on antihyperglycemic agent medication or have inadequate glycemic control. The exclusion criteria include a history of type 1 diabetes mellitus or ketoacidosis, recent weight loss program or medication, insulin therapy within the past 14 weeks, active liver disease, congestive heart failure, recent coronary heart disease symptoms, recent acute coronary syndrome, coronary artery intervention, stroke or transient ischemic neurological disorder, history of malignancy, or clinically important hematological disorder.",
    "The sample is a phase 2 clinical trial that involves patients with alcohol use disorders and bipolar disorder. The trial aims to test the effectiveness of zonisamide and placebo drugs in reducing or stopping drinking. The eligibility criteria include being between 18-65 years old, having a diagnosis of bipolar disorder and a current alcohol use disorder, and being on a standard mood stabilizer medication. Exclusion criteria include having another major Axis I disorder, a history of drug abuse or dependence, serious neurological or endocrine disorders, and known adverse reactions to zonisamide or other severe adverse drug reactions. Patients currently undergoing ECT treatment or taking certain anticonvulsant medications will also be excluded. The trial requires patients to have at least 2 heavy drinking days per week and to be able to provide informed consent.",
    "The sample is a phase 2 clinical trial for the treatment of acquired immunodeficiency syndrome (AIDS) and HIV infections. The trial involves the use of four drugs: e/c/f/tdf, e/c/f/taf placebo, e/c/f/taf, and e/c/f/tdf placebo. The eligibility criteria for the trial include having a plasma HIV 1 RNA level of at least 5,000 copies/mL, not having used any approved or experimental anti-HIV drug before, having normal ECG and adequate renal and hematologic function, and meeting various other health requirements. The trial also has exclusion criteria, such as having a new AIDS-defining condition diagnosed within the 30 days prior to screening, being hepatitis B surface antigen positive, or having an implanted defibrillator or pacemaker.",
    "The sample is a phase 2 trial for patients with genetic lymphohematological diseases who are candidates for allogeneic transplantation and have a histocompatible sibling or related donor. The trial includes patients aged 0 to 21 years with diseases such as Hemaphagocytic lymphohistiocytosis (HLH), Thalassemia, and Wiskott-Aldrich Syndrome. The trial involves the use of drugs such as cyclophosphamide at different dose levels. The eligibility criteria include having adequate physical and vital organ function to tolerate the transplant procedure, as well as meeting certain cardiac, hepatic, renal, and pulmonary function requirements. Patients with certain conditions, such as Fanconi Anemia, are excluded from the trial.",
    "The sample is a record of a clinical trial with a phase 2 designation. The trial is focused on the disease of endometrial carcinoma, which is confirmed through histological testing. The icd-10 codes associated with the disease are listed. The drug being tested is fulvestrant. The eligibility criteria for the trial are listed, including requirements for postmenopausal status and hormone receptor positivity. There are also exclusion criteria listed, such as previous treatment with fulvestrant or endocrine therapy for the same disease. Additionally, any previous malignancies within the past 3 years, other than in situ carcinoma of the cervix, basal cell carcinoma, or squamous carcinoma of the skin, are grounds for exclusion from the trial.",
    "The sample is a phase 2 clinical trial for the treatment of psoriasis vulgaris. The trial involves the use of a gel containing pth (1-34) and a placebo gel. The eligibility criteria include being mentally competent, between the ages of 18 to 65, having a clinical diagnosis of stable plaque psoriasis for at least 3 months, and having a minimum of 2% affected BSA. The trial also requires the subject to have a Target Plaque with a minimum of 16 cm2 in area, an Overall Disease Severity Score of 2 or 3, and an induration score of 2 or 3. The subject must be willing and able to apply the assigned study medication as directed, comply with study instructions, and commit to all follow-up visits for the duration of the study. The exclusion criteria include being lactating or planning to become pregnant during the study, having non-plaque forms of psoriasis, using any psoriasis vaccine or participating in an investigational study of any psoriasis vaccine, and using any systemic immunomodulatory therapy known to affect psoriasis within a certain time frame prior to the start of treatment. The trial also excludes subjects who have used any photo-therapy, photo-chemotherapy, or systemic psoriasis therapy within 4 weeks prior to start of treatment, and those who have used topical anti-psoriatic therapy or emollients/moisturizers on areas to be treated within 2 weeks prior to start of treatment. The trial also excludes subjects who have used lithium or hydroxychloroquine within 4 weeks prior to start of treatment, and those who may be unreliable including subjects who engage in excessive alcohol intake or drug abuse.",
    "The sample is a phase 2 clinical trial for patients with salivary gland cancer who have undergone surgery to remove the tumor. The trial is testing the effectiveness of postoperative radiotherapy and panitumumab, a drug that targets the EGFR pathway. The eligibility criteria include having no distant metastasis, no prior chemotherapy or radiotherapy for head and neck cancer, and a performance status of 0-2. Patients must also have normal organ and marrow function, and be at least 18 years old. Pregnant or breastfeeding women are excluded from the trial. The trial has both inclusion and exclusion criteria, which are detailed in the sample.",
    "The sample is a phase 2 clinical trial that focuses on the treatment of various diseases such as herpes zoster, neuralgia, pain, HIV infections, and peripheral nervous system diseases. The trial involves the use of capsaicin dermal patch as a drug. The eligibility criteria for the trial include being in good health, having successfully completed a past trial of NGX-4010, and not having any adverse events that would contraindicate further treatment. Additionally, there are specific inclusion and exclusion criteria that must be met before enrollment in the study. The icd-10 codes of the diseases are also provided in the table.",
    "The sample is a phase 2 clinical trial for non-small cell lung cancer. The trial includes participants who have not received prior systemic chemotherapy and have measurable disease. The eligibility criteria include having an estimated life expectancy of at least 12 weeks, an ECOG performance status of 0, 1, or 2, and meeting certain hematologic and hepatic function evaluations. Exclusion criteria include having received prior systemic chemotherapy or radiation therapy, having cardiovascular diseases or related treatment, having a surgical procedure or serious nonhealing wound, and having a history of certain diseases or conditions that contraindicate the use of an investigational drug. The trial is not intended to contain all considerations relevant to a patient's potential participation.",
    "The sample is a phase 2 clinical trial for patients with pulmonary fibrosis. The trial includes a list of eligibility criteria, such as being over 40 years old, having a diagnosis of IPF within the last 5 years, and having a FVC greater than 50% of predicted value. The trial also has a list of exclusion criteria, such as having a history of myocardial infarction or unstable angina within the previous 6 months, having a bleeding or thrombotic risk, and having known hypersensitivity to lactose or any component of the study medication. The trial includes a list of drugs being tested, including low dose bibf1120 once daily, low dose bibf 1120 twice daily, intermediate dose bibf 1120 twice daily, high dose bibf 1120 twice daily, and placebo.",
    "This is a sample from a table that contains information about clinical trials. The trial is in phase 2 and is focused on HIV infections. The trial is looking at the effectiveness of two drugs, bms-663068 and ritonavir. The table also includes a list of eligibility criteria for participants, including having a certain level of HIV RNA and CD4+ lymphocytes, being between the ages of 18 and 35, and not currently being co-infected with HCV or HBV. There are also exclusion criteria, such as being pregnant or breastfeeding, having a history of drug allergy, or being a prisoner or involuntarily incarcerated.",
    "The sample is a phase 2 clinical trial for patients with urothelial or bladder cancer that has metastasized or recurred locally. The trial is for a drug called abi-007 (abraxane\u00ae). The eligibility criteria include being at least 18 years old, having measurable disease, and having an Eastern Cooperative Oncology Group (ECOG) performance status of 0-2. Patients must also have adequate organ and marrow function and a life expectancy of at least 12 weeks. Exclusion criteria include previous systemic chemotherapy for the current stage of disease, pre-existing neuropathy that is > grade 2, and known HIV positive status. Patients must sign an informed consent and agree to use effective contraception during the period of therapy if they have reproductive potential.",
    "The sample is a phase 2 clinical trial for attention deficit disorder with hyperactivity. The trial includes males and non-pregnant females aged 6-12 years who meet the DSM-IV-TR criteria for diagnosis of ADHD, combined or hyperactive-impulsive subtypes. Participants must have been on a stable regimen of stimulants for at least one month in the last six months and have shown adequate response to stimulants without unacceptable side effects. The trial excludes individuals with co-morbid psychiatric diagnosis such as psychosis, bipolar illness, severe OCD, severe depressive or anxiety disorder, history of seizure during the last 2 years, a tic disorder or Tourette's, clinically significant ECG or laboratory abnormalities at screening or baseline, taking clonidine or anticonvulsant drugs, and taking medications that affect blood pressure or heart rate. The drugs being tested are nrp104, adderall xr, and placebo.",
    "The sample is a phase 2 clinical trial for various types of gastrointestinal cancers, including anal cancer, colorectal cancer, and liver cancer. The trial is testing the effectiveness of a drug called palonosetron hydrochloride in reducing nausea and vomiting in patients undergoing radiation therapy to the abdomen. The eligibility criteria include having a diagnosis of primary gastrointestinal or retroperitoneal sarcoma, a performance status of 0-2, and no hypersensitivity to the drug being tested. Patients must also not have had certain medications or treatments within a certain timeframe prior to enrollment.",
    "The sample is a record of a clinical trial with a phase 2 designation. The trial is focused on the treatment of chronic hepatitis C, and the list of diseases includes only this condition. The icd-10 codes associated with the disease are also listed. The trial involves several drugs, including copegus, danoprevir, pegasys, and ritonavir. The eligibility criteria for the trial are also listed, including age, genotype, and HCV RNA levels. The exclusion criteria include patients with cirrhosis or other liver diseases, HIV infection, hepatocellular carcinoma, or severe cardiac disease.",
    "The sample is a phase 2 clinical trial for the treatment of acute myelogenous leukemia. The eligibility criteria include a diagnosis of AML, being older than or equal to 60 years, having an ECOG performance status of 0-2, and meeting at least one of several other factors. Patients must also provide written informed consent and be able to comply with study procedures and follow-up evaluations. Exclusion criteria include a diagnosis of acute promyelocytic leukemia, previous treatment with clofarabine, and inadequate renal or hepatic function. Patients must also not have received investigational products within 30 days before the first dose of study drug and must not have any concomitant serious disease or a history of severe organ dysfunction.",
    "The sample is a phase 2 clinical trial for bladder cancer. The eligibility criteria include former smokers with a history of Grade 1, 2, or 3 papillary TCC or CIS TCC, with a newly diagnosed or recurrent tumor within 6 months of accrual who are rendered disease-free by standard of care. Participants must have no evidence of disease and may have been previously treated with intravesical therapy. Other criteria include being over 18 years old, having adequate bone marrow function, and satisfactory renal and hepatic function. Exclusion criteria include prior chemotherapy or radiotherapy, significant medical or psychiatric conditions, TCC greater than or equal to T2 at most recent diagnosis, and involvement of the upper urinary tract prior to or at the time of initial tumor resection. Participants must also not have a positive pregnancy test, normal consumption of greater than 5 cups of green tea daily, or be taking certain medications.",
    "The sample is a phase 2 clinical trial for prostate cancer. The eligibility criteria include having histologically confirmed adenocarcinoma of the prostate, locally advanced disease with no metastatic disease, and high-risk characteristics such as a large, hard tumor on digital exam or aggressive-appearing cancer cells on biopsy. Patients must also have a prostate-specific antigen level greater than 10 ng/mL and a performance status of 0-1. Other eligibility criteria include meeting certain hematopoietic, hepatic, renal, cardiovascular, and pulmonary requirements, as well as not having any other significant medical conditions. Patients must not have received prior treatment for prostate cancer, and must not be participating in any other investigational studies. The treatment regimen includes the drugs bicalutamide, leuprolide acetate, and squalamine lactate.",
    "The sample is a phase 2 clinical trial for non-small cell lung cancer. The trial includes patients with measurable disease by RECIST, who have not received prior chemotherapy, radiation therapy to chest, immunotherapy, or biologic therapy. The trial also requires patients to have an ECOG performance status of 0-1 and be in stage IIIA or IIIB, non-resectable. The trial excludes patients with carcinoid tumor, small cell carcinoma of lung, any distant metastasis, history of another malignancy except cured basal cell carcinoma of skin and cured carcinoma in-situ of uterine cervix, any other morbidity or situation with contraindication for radiotherapy, pregnant or lactating women, women who have not taken a pregnancy test within 7 days before the first administration, and women and men of childbearing potential who have no willingness to employ adequate contraception. The trial involves the drugs endostar and paclitaxel/carboplatin.",
    "The sample is a phase 2 clinical trial for the treatment of primary hepatocellular carcinoma (HCC) using a combination of jx-594 and sorafenib. The trial is open to patients with histologically confirmed or clinically diagnosed HCC that is not surgically resectable for cure. Patients must have a Child Pugh score of A or B, a KPS score of at least 70, and meet various other eligibility criteria related to platelet count, bilirubin levels, liver function, kidney function, and tumor status. Patients who are pregnant or nursing, have significant immunodeficiency, or have certain contraindications to sorafenib are excluded from the trial. The trial also excludes patients with certain medical conditions or who are taking certain medications.",
    "The sample is a record of a clinical trial in phase 2, which is focused on the disease of cystitis interstitial. The icd-10 codes associated with this disease are N30.10 and N30.11. The drug being tested is AGN 203818. The eligibility criteria for the trial include a diagnosis of painful bladder syndrome/interstitial cystitis and moderate or severe bladder pain. The exclusion criteria include any other uncontrolled disease and pregnant or nursing females.",
    "The sample is a phase 2 clinical trial for the treatment of glaucoma, ocular hypertension, and ocular surface disease. The trial involves the use of two drugs, latanoprost and travatan z. The eligibility criteria include being at least 18 years old, having a documented diagnosis of the specified eye conditions, and agreeing to submit to a pregnancy test and use an acceptable method of contraception. Exclusion criteria include having a sensitivity or poor tolerance to the study medications, having any form of glaucoma other than the specified types, and having a history of significant ocular conditions that would contraindicate the use of the study medications. The trial aims to evaluate the safety and efficacy of the drugs in reducing intraocular pressure.",
    "The sample is a phase 2 trial for the treatment of hypercholesterolemia. The trial includes a list of diseases and their corresponding icd-10 codes, a list of drugs being tested, and eligibility criteria for participants. The inclusion criteria includes subjects with LDL-C levels between 100-220 mg/dL and triglycerides less than 350 mg/dL, or subjects not on current daily statin therapy with LDL-C levels between 110-220 mg/dL. The exclusion criteria includes subjects with acute significant cardiovascular disease or uncontrolled hypertension.",
    "This sample is for a phase 2 clinical trial for patients with progressive or recurrent stage IV non-small cell lung cancer. The trial includes patients with brain metastases on CT or MRI scan, and symptomatic cases must have had brain radiotherapy at least one month prior to registration. Patients without brain metastases must have at least one target lesion that is bidimensionally measurable and not previously irradiated. The trial also has eligibility criteria for patient characteristics such as age, performance status, life expectancy, hematopoietic, hepatic, renal, and other factors. Prior and concurrent therapy restrictions are also outlined in the criteria. The drug being tested in this trial is temozolomide.",
    "The sample is a phase 2 clinical trial for breast cancer patients with locally advanced or metastatic breast carcinoma. The trial is testing the drug TAS-108 and the eligibility criteria includes being a postmenopausal female with positive estrogen receptor and/or progesterone receptor status, having received and progressed after one or two prior systemic hormonal anti-tumor therapies, and having a predicted life expectancy of at least 12 weeks. The trial also requires measurable disease according to the Response Evaluation Criteria in Solid Tumors criteria, adequate liver and renal function, and recovery from previous anti-cancer treatment related toxicities. All previous investigational drugs must be stopped at least four weeks before commencement of treatment with TAS-108.",
    "The sample is a record of a clinical trial in phase 2 for the treatment of depressive disorder using bupropion hydrochloride. The trial has a list of inclusion and exclusion criteria that patients must meet in order to participate. The inclusion criteria include having a current episode of major depressive disorder for at least 8 weeks prior to the screening visit, giving written informed consent, and meeting certain rating scores. The exclusion criteria include a history of seizure disorder or brain injury, anorexia or bulimia nervosa, manic episode, schizophrenia or other psychotic disorder, substance abuse, pregnancy or lactation, suicidal tendencies, high blood pressure, and history or complication of cancer or malignant tumor. The trial also includes a list of disease names and ICD-10 codes associated with the disease being treated.",
    "The sample is a clinical trial for patients with major depressive disorder in phase 2/phase 3. The trial includes a list of diseases, icd-10 codes, drugs, and eligibility criteria. The eligibility criteria include patients who have a diagnosis of major depressive episode, have reported an inadequate response to 1 and no more than 1 adequate SSRI or SNRI treatment, have a 17-item Hamilton Rating Scale for Depression score \u2265 18, and have a Body Mass Index of approximately 18-40. The trial also includes exclusion criteria such as patients with unstable medical illness, evidence or history of significant neurological disorder, and patients who demonstrate less than 80% compliance of their antidepressant medication during the Screening Phase.",
    "This sample is for a phase 2 clinical trial for the treatment of acute myeloid leukemia (AML) using the drug Troxatyl\u2122 (troxacitabine). The eligibility criteria include having a confirmed diagnosis of AML in the second salvage setting, having received at least two previous courses of induction chemotherapy, and having adequate organ and immune function. Exclusion criteria include active central nervous system leukemic involvement, uncontrolled infection, and known or suspected intolerance or hypersensitivity to Troxatyl\u00ae. The sample also includes a list of disease names and ICD-10 codes, as well as the eligibility and exclusion criteria in detail.",
    "The sample is a phase 2 clinical trial for patients with metastatic or locally recurrent adenocarcinoma of the colon or rectum. The trial is testing the drug irofulven. The eligibility criteria include bidimensionally measurable disease, certain hematopoietic, hepatic, and renal levels, and no significant uncontrolled medical or psychiatric illness. Patients must not be pregnant or nursing, and must use effective contraception if fertile. They must also have no serious active infection or other active malignancy except nonmelanoma skin cancer or carcinoma in situ of the cervix unless adequately treated and less than 30% risk of relapse. The trial excludes patients who have had certain prior treatments, including certain chemotherapy and radiotherapy.",
    "The sample is a record of a clinical trial with a phase 2 designation. The trial is focused on non-small cell lung cancer and the ICD-10 codes associated with it. The drug being tested is ps-341 (velcade-drug). The eligibility criteria for the trial includes patients with confirmed NSCLC (squamous, adeno- and large cell anaplastic carcinoma) stage III B or Stage IV who have not undergone prior chemotherapy. Patients must also have adequate organ and marrow function. The exclusion criteria includes patients with untreated symptomatic brain metastasis and those with known HIV positivity.",
    "The sample is a phase 2 clinical trial for patients aged 18 and above with a histologically proven diagnosis of cancer of the ovary, fallopian tube, or peritoneum. The trial includes patients with peritoneal and/or nodes and/or visceral metastases and disease in progression under treatment or within 6 months after a first or second platinum-based line. The trial requires a period of 3 weeks between the last chemotherapy and inclusion. Patients must have measurable disease or cancer antigen assessable disease, an ECOG performance status of less than 2, and a life expectancy of at least 12 weeks. The trial excludes patients who have previously received weekly administration of paclitaxel chemotherapy, those involved in a trial within the last 30 days, those who have previously received a bone marrow autograft or irradiation of the abdomen within 5 years due to intensive chemotherapy, those with a prior diagnosis of malignancy, those with a history of ischemic cardiopathy, congestive heart failure, arrhythmia, hypertension, or significant valvulopathy, those with pre-existing motor or sensory neurologic pathology or symptoms, those with bone marrow, renal, or hepatic insufficiency, those with severe active infection or occlusive or sub-occlusive disease, those with a history of symptomatic brain metastases, fertile women not using adequate contraceptive methods, pregnant or breastfeeding women, and those with hypersensitivity to compounds chemically related to paclitaxel, topotecan, or carboplatin.",
    "The sample is a phase 2 clinical trial for the treatment of endometriosis. The trial includes premenopausal women aged 18-48 who have been diagnosed with endometriosis within the past ten years and have experienced symptoms for at least three months. Participants must also be sexually active or have endometriosis-related dyspareunia, have a regular menstrual cycle lasting from 24 to 36 days, and detectable ovulation during the baseline period. The trial involves the use of drugs such as proellex 25 mg, placebo, and proellex 50 mg. The eligibility criteria include various inclusion and exclusion criteria, such as not having had a menstrual period for six months or more, having a prior hysterectomy or bilateral oophorectomy, and having a diagnosis of osteopenia.",
    "The sample is a phase 2 clinical trial for asthma. The trial includes patients between the ages of 18 and 60 who have a history of episodic wheezing and a pre-bronchodilatory FEV1 of at least 70% of predicted normal. Patients must also show a positive allergen-induced early and late airway bronchoconstriction with a fall in FEV1 of at least 20% for the early response and at least 15% for the late response, as well as a positive skin prick test to common aeroallergens. Exclusion criteria include any clinically significant disease or disorder, any clinically relevant abnormal finding at screening examinations, smoking or having stopped smoking less than 12 months prior to the study start, worsening of asthma or respiratory infection within 6 weeks from visit 1, and allergen-specific immunotherapy within 6 months prior to visit 1. The trial will test the effectiveness of four drugs: azd5423, budesonide 200 microgram, and two placebos.",
    "The sample is a phase 2 clinical trial for bladder cancer. The trial is for patients with locally advanced or metastatic disease that is not amenable to surgery. The trial is testing the effectiveness of gemcitabine hydrochloride and irinotecan hydrochloride as treatments. The eligibility criteria include having histologically confirmed transitional cell carcinoma of the bladder, being over 18 years old with an ECOG performance status of 0-2, and meeting certain hematopoietic, hepatic, renal, and gastrointestinal requirements. Patients must not be pregnant or nursing, have no other active malignancy except nonmelanoma skin cancer, and have no mental incapacitation or psychiatric illness that would preclude giving informed consent. The sample also includes information on prior concurrent therapy, including restrictions on chemotherapy, radiotherapy, and biologic therapy.",
    "The sample is a record of a clinical trial with a phase 2 designation. The trial is focused on Alzheimer's disease and involves the use of a drug called hf0220. The eligibility criteria for participants include being over 55 years old, having a diagnosis of probable Alzheimer's disease, and having a Mini-Mental State Examination (MMSE) score of 12-24. Participants must also have a responsible carer who is capable of assisting with medication and attending assessments. Exclusion criteria include having other types of dementia, significant medical conditions, or taking certain medications. The sample also includes detailed instructions for recruitment and obtaining consent from participants and their carers.",
    "The sample is a phase 2 clinical trial for patients with metastatic cancer and peritoneal metastases with malignant ascites. The trial is testing the effectiveness of the drug mitomycin c. The eligibility criteria include a diagnosis of peritoneal metastases and malignant ascites, not being eligible for cytoreductive surgery, having undergone at least 1 prior paracentesis procedure, and meeting certain health requirements. The exclusion criteria include prior peritoneal chemotherapy and dense intraabdominal adhesions limiting laparoscopy.",
    "The sample is a phase 2 clinical trial for the treatment of multiple myeloma, a type of cancer. The trial is focused on patients with Mucinous glycoprotein 1 (MUC1)-expressing, slowly progressive asymptomatic multiple myeloma or MUC1-expressing stage II or III multiple myeloma with a treatment-free interval of at least 3 months following prior anti-tumor therapy. The trial requires patients to have MUC1-expressing myeloma cells in the bone marrow, be at least 18 years old, have a life expectancy of at least 6 months, and have an Eastern Cooperative Oncology Group (ECOG) performance status of less than or equal to (<=) 1 at study entry. The trial also has a list of inclusion and exclusion criteria that patients must meet. The drugs being tested in the trial are single low dose cyclophosphamide and multiple low dose cyclophosphamide.",
    "The sample is a phase 2 clinical trial for major depressive disorder. The trial includes patients aged 18 to 70 years who have a clinical diagnosis of major depressive disorder and a history of inadequate response to at least 3 antidepressants. The trial also requires women of child-bearing potential to have a negative pregnancy test and use a highly effective form of birth control for at least 3 months before enrollment. The trial excludes patients with a history of diagnosed bipolar disorder or schizophrenia, those who have had a suicide attempt within the last 6 months, and those who have received certain types of treatment within the 6 months prior to screening. The trial involves the use of the drugs azd6765 iv and placebo. The eligibility criteria and exclusion criteria are also provided.",
    "The sample is a phase 2 clinical trial for patients with metastatic breast carcinoma that is Human Epidermal Growth Factor Receptor 2 (HER2) overexpressing. The trial involves the use of pegylated liposomal doxorubicin, docetaxel, and trastuzumab as treatment options. The eligibility criteria include being a female aged 18 to 70 years-old, having no prior chemotherapy for metastatic breast cancer, having at least one measurable lesion according to RECIST criteria, and meeting various laboratory requirements. Exclusion criteria include having prior chemotherapy for metastatic disease, a history of prior malignancy in the last 10 years (other than non melanoma skin cancer or excised cervical carcinoma in situ), and other serious illnesses or medical conditions.",
    "The sample is a phase 2 clinical trial for the treatment of urothelial cancer, which includes bladder cancer, transitional cell cancer of the renal pelvis and ureter, and urethral cancer. The trial involves the use of two drugs, gemcitabine hydrochloride and paclitaxel. The eligibility criteria for the trial include having histologically confirmed urothelial cancer, being previously untreated with metastatic or locoregionally advanced disease, having measurable disease, and meeting certain patient characteristics such as age, performance status, and hematopoietic, hepatic, and renal function. Prior concurrent therapy is also specified in the eligibility criteria.",
    "The sample is a phase 2 clinical trial for moderately active ulcerative colitis. The trial includes patients who have had at least one previous flare-up of UC and are currently on stable doses of 5-aminosalicylic acid (5-ASA) for management of UC. The trial will test the efficacy of interferon-beta-1a, 44 microgram and interferon-beta-1a, 66 microgram against a placebo. The eligibility criteria include a diagnosis of UC documented by clinical, radiological and endoscopic or histological findings, proctosigmoidoscopic diagnosis, and a flare in disease activity considered moderate in accordance with the UCSS during the 14 days before initiation of study medication. The trial excludes patients who have had previous systemic treatment with interferons, immunosuppressive therapy, or other biological treatment in the 3 months before Study Day 1, and those with inadequate liver or renal function, histopathological findings of high-grade dysplasia or history of cancer, and other serious concurrent systemic disorders incompatible with the study.",
    "The sample is a phase 2 clinical trial for potentially resectable adenocarcinoma of the pancreas using gemcitabine and abraxane as the study drugs. The eligibility criteria include having no prior chemotherapy or radiation for pancreatic cancer, meeting certain blood count and chemistry levels, having an ECOG performance status of 0-1, and being willing to comply with study procedures. Exclusion criteria include having borderline resectable disease, active infections, known infections with HIV, hepatitis B, or hepatitis C, and serious medical risk factors involving major organ systems. Patients aged \u2265 80 are not excluded but should be thoroughly evaluated before enrollment. The sample includes detailed inclusion and exclusion criteria for the trial.",
    "The sample is a record of a clinical trial in phase 2, focused on the disease of irritable bowel syndrome. The icd-10 codes associated with the disease are listed as ['K58.2', 'K58.8', 'K58.0', 'K58.1', 'K58.9']. The trial involves two drugs, ym060 and placebo. The eligibility criteria for the trial are listed under \"Inclusion Criteria\" and \"Exclusion Criteria\". Patients must meet the Rome III Diagnostic Criteria and have experienced loose or watery stools within the last 3 months, as well as abdominal discomfort and/or pain during their non-menstrual period. Patients with a history of surgical resection of the stomach, small intestine or large intestine, or with a history or current diagnosis of inflammatory bowel disease, colitis ischemic, enteritis infectious, hyperthyroidism or hypothyroidism, malignant tumor, or drug or alcohol abuse within the past year are excluded from the trial. Additionally, patients who are currently participating in another clinical trial or who have participated in one within the past 12 weeks are also excluded.",
    "The sample is a phase 2 clinical trial for pancreatic ductal adenocarcinoma. The trial requires documented tissue diagnosis of the disease and eligibility for a Whipple's or distal pancreatectomy procedure. Participants must also have adequate organ function and meet certain blood count and albumin levels. They must be willing to comply with scheduled visits, treatment plans, laboratory tests, and other study procedures. The trial involves the drug GDC-0449 and has both inclusion and exclusion criteria. Women who are pregnant, plan to become pregnant, or are lactating are excluded from the trial.",
    "The sample is for a phase 2 clinical trial for the treatment of irritable bowel syndrome with diarrhea. The trial includes male and non-pregnant, non-lactating female subjects who have been diagnosed with IBS confirmed by the Rome III criteria. The subjects must meet certain IBS symptom scores during the diary eligibility period and must not have had adequate relief of IBS symptoms over the past 7 days on the first day of screening and on the day of randomization. The trial excludes subjects who have hard or lumpy stools, a history of inflammatory bowel disease, Type 1 or 2 diabetes, are pregnant or lactating, or have a history of HIV or hepatitis B or C. The trial will test the effectiveness of three different drugs, including a placebo and two different doses of mesalamine granules.",
    "The sample is for a phase 2 clinical trial for the treatment of psoriatic arthritis. The eligibility criteria include a diagnosis of psoriatic arthritis, active symptoms, and certain laboratory criteria. Participants must not have certain medical conditions or be pregnant or lactating. They must also not have received certain medications or treatments within a certain timeframe. The trial involves the use of the drug apremilast or a placebo. The criteria for inclusion and exclusion are detailed and specific.",
    "The sample is a phase 2 clinical trial for patients with metastatic or recurrent nasopharyngeal carcinoma that is not amenable to potentially curative surgery or radiotherapy. The trial is testing the effectiveness of the drugs gemcitabine and oxaliplatin. The eligibility criteria include having a measurable lesion, a performance status of 0-2, and adequate hematological, renal, and hepatic functions. Exclusion criteria include prior treatment with oxaliplatin or gemcitabine, persistent grade 2 or more sensory and/or motor neuropathy, and active or past history of central nervous system metastasis from the primary tumor. The trial is not open to patients who have used any investigational drug treatment in the month prior to inclusion, are pregnant, or are not exercising appropriate birth control during the course of the study.",
    "The sample is a phase 2 clinical trial for the treatment of Complex Regional Pain Syndrome (CRPS). The trial includes patients who are at least 18 years old and have been diagnosed with CRPS using International Association for the Study of Pain criteria for more than 6 months. The patients must have normal liver and kidney function, and a full blood count with a haematocrit level of over 38%. They must also be willing and able to give informed consent and complete study questionnaires. The trial involves the use of two drugs, placebo and ethosuximide, for suboptimal pain pharmacotherapy. Patients must be able to attend the research center according to the visit schedule. Women of child-bearing potential must be using a reliable form of contraception. Exclusion criteria include optimal response to opioids, antidepressants, anticonvulsants or anti-inflammatory medications, any history or indication of kidney or liver disease, any history of alcohol abuse, presence of diabetes, and participation in other clinical trials in the 30 days prior to enrollment.",
    "The sample is a phase 2 clinical trial for patients with type 2 diabetes. The trial includes patients who are either new to diabetes therapy or have been taking metformin for at least 3 months prior to screening. The trial involves testing the effectiveness of different doses of a drug called msdc-0602, as well as pioglitazone and a placebo. The trial also has a list of inclusion and exclusion criteria that patients must meet in order to participate. These criteria include age, BMI, medical history, and willingness to make multiple visits to the clinic.",
    "The sample is a phase 2 clinical trial for the treatment of hypercholesterolemia and hypertriglyceridemia. The trial involves the use of five different doses of a drug called gemcabene and a placebo. The eligibility criteria for the trial include being a man or a naturally or surgically menopausal woman between the ages of 18 and 80 with a baseline HDL-C level of less than 35 mg/dL. Exclusion criteria include various medical conditions such as uncontrolled hypertension, diabetes, renal dysfunction, and hepatic dysfunction, as well as recent major cardiovascular events.",
    "The sample is a record of a clinical trial with a phase 2 designation. The trial is focused on patients with type 2 diabetes mellitus and includes a list of specific icd-10 codes for the disease. The trial involves the use of several drugs, including linagliptin and glimepiride, as well as a placebo. The eligibility criteria for the trial include a specific range of HbA1c levels, age restrictions, and a minimum body mass index. The exclusion criteria include a history of cardiovascular disease, impaired liver or kidney function, recent treatment with certain medications, and recent insulin use.",
    "The sample is a phase 2 trial for HIV infected subjects with CC Chemokine Receptor5-tropic (R5-tropic) virus. The trial involves the use of two drugs, gw873140 and combivir. The eligibility criteria include having a screening lab result of plasma HIV-1 RNA greater than or equal to 10,000 copies/mL and CD4 cell count greater than or equal to 100 cells/mm3, being treatment-naive, and having no drug resistance mutations in HIV-1 Reverse Transcriptase. The trial also requires participants to practice safe sex using a proven double barrier method of contraception throughout the study. The exclusion criteria include having any CXC Receptor4-tropic (X4-tropic) virus, any drug resistance mutations in HIV-1 Reverse Transcriptase, and active Class C AIDS-defining illness. Pregnant or breastfeeding women are also excluded from the trial. Additional qualifying criteria may be determined by the physician.",
    "The sample is a record from a clinical trial table. It is a phase 2 trial for the treatment of renal cell carcinoma. The table includes information on the diseases being studied, the icd-10 codes associated with those diseases, the drugs being used in the trial, and the eligibility criteria for participants. The inclusion criteria include disease progression as defined by Response Evaluation Criteria in Solid Tumors criteria following documented stable disease or better after at least 8 weeks of sunitinib as first-line treatment, or two cycles of 4 weeks on and 2 weeks off treatment. Patients who have discontinued sunitinib treatment at any point due to toxicity are also eligible. The exclusion criteria include patients with unresolved chronic toxicity grade greater than 1 related to prior therapy with sunitinib.",
    "The sample is a phase 2 clinical trial for the treatment of hypercholesterolemia. The trial involves the use of drugs such as alirocumab and atorvastatin, as well as placebos for each drug. The eligibility criteria for participants include receiving a lipid-lowering treatment other than atorvastatin or not being at a stable dose of atorvastatin 10 mg for at least 6 weeks prior to screening, or being drug naive with primary hypercholesterolemia and likely to have low-density lipoprotein cholesterol (LDL-C) \u2265 100 mg/dL (\u2265 2.59 mmol/L) at the end of the 6-week run-in treatment period on atorvastatin therapy. Participants with primary hypercholesterolemia treated with a stable dose of atorvastatin 10 mg for at least 6 weeks prior to screening and likely to have LDL-C \u2265 100 mg/dL (\u2265 2.59 mmol/L) at the screening visit are also eligible. Exclusion criteria include having LDL-C < 100 mg/dL (< 2.59 mmol/L) at Week -1 (V1), not previously being instructed on a cholesterol-lowering diet, having type 1 diabetes, being treated with insulin for type 2 diabetes, having type 2 diabetes and an HbA1c \u2265 8.5% at screening visit, having triglycerides (TG) > 350 mg/dL (> 3.95 mmol/L) at screening visit, having a positive serum or urine pregnancy test in females of childbearing potential, being pregnant or breast-feeding, and being a woman of childbearing potential with no effective contraceptive method.",
    "The sample is a phase 2 clinical trial for the treatment of rheumatoid arthritis. The trial involves testing the effectiveness of a drug called mk-8457, along with methotrexate and a placebo. The eligibility criteria for participants include having a diagnosis of rheumatoid arthritis for at least 6 months, having a certain number of swollen and tender joints, and having evidence of synovitis on imaging. Participants must also have received methotrexate for at least 3 months prior to screening and failed treatment with 1 or 2 anti-tumor necrosis factor alpha therapies or been intolerant to them. Exclusion criteria include having other inflammatory diseases, a history of drug or alcohol abuse, and severe opportunistic infections within the 6 months prior to screening.",
    "The sample is a record of a clinical trial with a phase 2 designation. The trial is focused on the treatment of pain and includes a list of ICD-10 codes related to pain. The trial involves the use of three drugs: azd1940, naproxen, and placebo. The eligibility criteria for the trial include patients scheduled for surgical removal of one partial or complete impacted mandibular third molar, provision of signed informed consent, and healthy males or non-fertile females. The exclusion criteria include a history of somatic disease/condition that may interfere with the objectives of the study, as judged by the investigator, and a history of previous or ongoing psychiatric disease/condition.",
    "The sample is a record of a clinical trial in phase 2, focused on the disease of acute pain. The trial includes a list of icd-10 codes associated with the disease. The trial involves testing three drugs: sufentanil nanotab 20 mcg, sufentanil nanotab 30 mcg, and placebo nanotab. The eligibility criteria for the trial include patients scheduled for bunion surgery, while exclusion criteria include daily opioid use, drug or alcohol abuse, and pregnancy or breastfeeding.",
    "The sample is a record of a clinical trial for metastatic colorectal cancer. The trial is in phase 2/phase 3 and involves testing two drugs, cmab009 plus irinotecan and irinotecan-only, sequentially with cmab009. The eligibility criteria for the trial include having histologically confirmed metastatic colorectal adenocarcinoma, KRAS wild-type tumors, measurable lesions, and an ECOG performance status of 0 to 1. The exclusion criteria include previous irinotecan or anti-EGFR therapies, abnormal hematologic, liver, or renal function, and symptomatic central nervous system metastases. The diseases are listed as metastatic colorectal cancer, and the icd-10 codes associated with the disease are also provided.",
    "The sample is a phase 2 clinical trial for the treatment of breast neoplasm. The trial involves the use of drugs such as epirubicin, cyclophosphamide, docetaxel, and trastuzumab. The eligibility criteria for the trial include being a non-pregnant female over 18 years of age with non-inflammatory breast cancer stage IIA - IIIC or high risk node negative, documented ER/PgR receptor status, normal cardiac function, and adequate hematologic function. The patient must also be HER2 positive and have no evidence of metastatic disease. Exclusion criteria include having been treated with other investigational drugs within 30 days, having uncontrolled intercurrent disease or active infection, known sensitivity to e. coli-derived proteins or polysorbate 80, psychiatric illness or social situation that would limit study compliance, pre-existing peripheral neuropathy > Grade 1, cancer within 5 years of screening with the exception of surgically cured nonmelanomatous skin cancer; in-situ carcinoma of the cervix; or in-situ carcinoma of the breast, bilateral synchronous breast cancer, and being pregnant or breast feeding.",
    "The sample is a phase 2 clinical trial for individuals with a history or presence of gout and joint damage. The trial is testing the effectiveness of the drug febuxostat compared to a placebo. The eligibility criteria include having hyperuricemia, a history of no more than two gout flares, and being able to understand and comply with the protocol requirements. Exclusion criteria include having previously taken urate-lowering therapy, having secondary hyperuricemia, and having a significant medical condition that would interfere with the treatment or safety of the participant. The trial also includes a list of diseases and their corresponding icd-10 codes.",
    "The sample is a phase 2 clinical trial for the treatment of idiopathic restless legs syndrome. The trial includes subjects who are between 20 and 80 years old and have previously received treatment with either L-dopa or dopamine agonists and efficacy was observed in either of drugs. The trial has inclusion and exclusion criteria, which are listed in detail. The inclusion criteria include having a score of at least 15 on the IRLS sum score and RLS symptoms occurring twice or more a week. The exclusion criteria include having secondary RLS in association with renal impairment, sleep disorders, additional clinically relevant concomitant diseases or symptoms, other central nervous diseases, psychiatric conditions, serious cardiac dysfunction and/or arrhythmias, and more. The trial also has a list of drugs being used, which includes \"spm 962\".",
    "The sample is a phase 2 clinical trial for the treatment of knee osteoarthritis using the drug diclofenac and the supplement wobenzym. The trial includes patients with confirmed knee osteoarthritis and specific scores on the Lequesne Functional Index and WOMAC-A pain subscale. The trial also has exclusion criteria, including a history of knee trauma or joint surgery, use of certain medications, and known sensitivities to certain drugs. The diseases and their corresponding ICD-10 codes are listed as well.",
    "The sample is a phase 2 clinical trial for non-small cell lung cancer and brain neoplasms. The trial involves the use of bevacizumab, first-line chemotherapy agents, and second-line chemotherapy agents. The eligibility criteria for the trial include having confirmed NSCLC except for squamous cell carcinoma, treated brain metastases without evidence of progression or hemorrhage, and being appropriate for first- or second-line systemic therapy for advanced NSCLC. Other criteria include having an ECOG performance status of 0 or 1, being at least 18 years old, and using an accepted and effective method of contraception for sexually active participants. Exclusion criteria include having a recent brain biopsy or neurosurgical procedure, active malignancy other than lung cancer, and inadequate organ function.",
    "The sample is a phase 2 clinical trial for patients with metastatic colorectal cancer. The trial involves the drug STA-9090 and requires patients to have received at least one prior standard or investigational regimen for metastatic disease. The trial has inclusion criteria such as measurable disease, adequate hematologic and hepatic function, and a life expectancy of more than 3 months. Exclusion criteria include recent chemotherapy, primary brain tumors or active brain metastases, and uncontrolled intercurrent illness. The trial also requires patients to have a normal QTc interval on baseline ECG and to agree to use adequate contraception if of childbearing potential. The first 15 patients in the trial must have accessible tissue for biopsy.",
    "The sample is a phase 2 clinical trial for the treatment of obesity using the drug topiramate. The trial is looking for participants who have a BMI between 27 and 40, a waist circumference of at least 100 cm, and a blood lipid disorder. Participants must also be non-smokers and have a sedentary lifestyle. The trial has a list of exclusion criteria, including patients with endocrine disease or other physical causes of obesity, abnormal liver or renal function, history of schizophrenia or eating disorders, and other significant medical conditions. The trial is designed to test the efficacy of topiramate in treating obesity in eligible participants.",
    "The sample is a phase 2 clinical trial for the treatment of major depressive disorder. The trial is testing the effectiveness of the drug filorexant compared to a placebo. The eligibility criteria for participants include having a current diagnosis of recurrent major depressive disorder without psychotic features, with a current moderate or severe depressive episode, and having undergone an adequate trial of an antidepressant. Exclusion criteria include having a current primary psychiatric diagnosis other than major depression, a history of bipolar disorder or other psychotic disorder, and a history of electroconvulsive therapy or other treatments for depression. Participants must also not be pregnant or breastfeeding and must agree to use contraception if of reproductive potential.",
    "The sample is a phase 2 clinical trial for patients with non-small cell lung cancer that is not able to be treated surgically and who have failed 1 or 2 lines of chemotherapy. The trial is testing the drug crlx101. The eligibility criteria include being at least 18 years old, having measurable disease and evidence of progression on previous therapy, having an ECOG performance status of 0 or 1, and having adequate hepatic and renal function. Exclusion criteria include having CNS metastases, having more than 2 previous lines of chemotherapy for lung cancer, and having a history of cardiac arrhythmia requiring medical or electrical therapy. The trial is looking to enroll patients who are likely to live for at least 90 days.",
    "The sample is a clinical trial for the treatment of benign prostatic hyperplasia, a condition that causes lower urinary tract symptoms in males aged 45 years or older. The trial is in phase 2/phase 3 and involves the use of the drug tadalafil and a placebo. The eligibility criteria include having an International Prostate Symptom Score (IPSS) greater than or equal to 13, not using any approved or experimental treatments for benign prostatic hyperplasia or erectile dysfunction during the study, and not having taken certain medications for a specified duration of time prior to the study. The exclusion criteria include a history of urinary retention or lower urinary tract stones, bladder outlet obstruction, certain cardiac or neurological conditions, and nitrate use.",
    "The sample is a record of a clinical trial with a phase 2 designation. The trial is focused on the treatment of non-small cell lung cancer using the drug pd-0325901. The eligibility criteria for the trial include having histologically documented non-small cell lung cancer with metastases or locally advanced disease, adequate renal, liver, and bone marrow function, and an ECOG status of <=1. The trial also requires evidence of disease progression within 6 months of the most recent prior systemic anticancer therapy. The exclusion criteria include no ongoing radiation therapy or radio-cytotoxic therapy within the prior 4 weeks, no immunotherapy, biologic therapy, hormonal, or molecular targeted therapy within the prior 2 weeks, no concurrent serious infection or life-threatening illness unrelated to the tumor, no history of malignancy other than non-small cell lung cancer, no active seizure disorders or untreated brain metastases, and no parathyroid disorder or history of malignancy associated hypercalcemia.",
    "The sample is a phase 2 clinical trial for patients with atherosclerosis or coronary artery disease. The trial involves the use of the drugs rvx000222 and placebo. The eligibility criteria include being at least 18 years old, having documented coronary artery disease, and taking a stable dose of statin therapy for at least 30 days prior to enrollment. Exclusion criteria include being pregnant or lactating, having certain medical conditions or taking certain medications, and having a history of noncompliance with medical regimens. The trial requires signed informed consent from participants.",
    "The sample is a record of a clinical trial with a phase 2 designation. The trial is focused on two diseases, myocardial infarction and percutaneous coronary intervention, and includes a list of corresponding ICD-10 codes. The trial involves the use of two drugs, clopidogrel, and clopidogrel. The eligibility criteria for the trial include being between 18 and 75 years old, having an indication for the use of clopidogrel due to either spontaneous MI or PCI within the past 6 months, and being clinically stable and at least 4 weeks post-MI or PCI. The exclusion criteria include conditions that alter platelet function and conditions that increase bleeding risk.",
    "The sample is a phase 2 clinical trial for seasonal allergic rhinitis. The trial includes a list of icd-10 codes for the disease and a list of drugs, including bilastine, fexofenadine, cetirizine, and placebo. The eligibility criteria for the trial include having a history of seasonal allergic rhinitis and a positive skin prick or RAST test within the past 12 months. Exclusion criteria include having a clinically significant illness or disease, unstable asthma, or having participated in a clinical trial within 30 days prior to the screening visit.",
    "The sample is a record of a clinical trial with a phase 2 designation. The trial is focused on chronic kidney disease and includes a list of associated ICD-10 codes. The trial involves the use of several drugs, including sbr759 and sevelamer hcl. The eligibility criteria for the trial include being at least 18 years old (or 20 years old in Japan), having stable maintenance of hemodialysis three times per week, and having a serum phosphate level above 6.0 mg/dL prior to study treatment initiation. There are also several exclusion criteria, such as having a history of hemochromatosis or being treated with sevelamer HCl monotherapy or SBR759.",
    "The sample is a phase 2 clinical trial for the treatment of colorectal neoplasms. The trial involves the use of drugs such as regorafenib, oxaliplatin, folinic acid, and 5-fu (mfolfox6). The eligibility criteria for the trial include being at least 18 years old, having histological or cytological documentation of adenocarcinoma of the colon or rectum, being suitable to receive the mFOLFOX6 regimen as first-line metastatic treatment, having at least one measurable lesion as per RECIST version 1.1, having unresectable or unlikely becoming resectable metastatic disease, having an Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1, having a life expectancy of at least 3 months, and having adequate bone marrow, liver, and renal function. The exclusion criteria include having prior systemic anticancer therapy for metastatic colorectal cancer, prior treatment with antivascular endothelial growth factor (anti-VEGF) agents and any signal transduction inhibitors (STIs), uncontrolled hypertension, symptoms, signs, or history of brain metastases, any hemorrhage or bleeding event \u2265 Common Terminology Criteria for Adverse Events (CTCAE) Grade 3 within 4 weeks of start of study treatment, and sensory neuropathy (> CTCAE Grade 1), unresolved toxicity > CTCAE Grade 1 attributed to any prior therapy/procedure excluding alopecia.",
    "The sample is a phase 2 clinical trial for patients with high-risk primary gastrointestinal stromal tumor. The trial involves the use of imatinib mesylate as a treatment. The eligibility criteria include having a diagnosis of high-risk primary GIST, having undergone complete gross resection of a primary GIST within 70 days prior to registration, and having a histologic diagnosis of GIST confirmed by central pathology review. Patients must also meet certain health criteria, such as having a performance status of \u2264 2, and having normal levels of creatinine, WBC, platelets, total bilirubin, AST, and ALT. Patients must not have received post-operative chemotherapy, radiation therapy, or investigational treatment, and must not have had an active infection requiring antibiotics within 14 days prior to registration. Other exclusion criteria include having objective evidence of residual disease on the post-operative CT scan or MRI, being a breastfeeding female, having New York Heart Association class 3 or 4 cardiac disease, or taking full dose warfarin.",
    "The sample is a phase 2 clinical trial for the treatment of mild to moderate chronic plaque psoriasis. The trial includes patients with a target plaque of at least 9 sq. cm. The trial excludes patients with non-plaque form of psoriasis, current drug-induced psoriasis, or currently on systemic therapy or phototherapy for psoriasis. The trial involves the use of two different ointments, one containing cp-690,550 and the other containing a vehicle. The eligibility criteria for the trial are listed under inclusion and exclusion criteria.",
    "The sample is a phase 2 clinical trial for osteoarthritis. The trial is testing the effectiveness of ibuprofen and placebo in treating the disease. The trial is open to male and female patients aged 40 years or older who have primary osteoarthritis in a single knee joint, grade II/III based on the Kellgren and Lawrence classification system. Patients must have radiographic evidence consistent with osteoarthritis carried out within 6 months before screening. Patients must have pain that is currently not adequately controlled with a simple analgesic or an NSAID OR would necessitate treatment, but is not yet treated. Patients with other types of continuous pain that are more severe in intensity in comparison with the osteoarthritis target joint pain are excluded from the trial. Patients with osteoarthritis causing significant pain in any joint other than the identified knee, or contralateral knee (\u2265 20 mm pain) as confirmed by a separate VAS at visit 1 for any other painful joint concerned are also excluded. Female patients who are pregnant or breast-feeding are also excluded from the trial.",
    "The sample is a phase 2 clinical trial for the treatment of tardive dyskinesia in patients with schizophrenia or schizoaffective disorder. The trial involves the use of the drugs nbi-98854 and placebo. The eligibility criteria include having a clinical diagnosis of neuroleptic-induced tardive dyskinesia for at least 3 months prior to screening, receiving a stable dose of antipsychotic medication for a minimum of 30 days before study start, and having a negative urine drug screen and alcohol breath test at screening and study start. Exclusion criteria include having an active clinically significant unstable medical condition within 1 month prior to screening, a history of substance dependence or abuse within the 3 months before study start, and receiving medication for the treatment of tardive dyskinesia.",
    "The sample is a phase 2 trial for fracture healing. The eligibility criteria include males and females aged 55 to 95 years with a fresh unilateral low energy intertrochanteric or femoral neck fracture that can be repaired by internal fixation. The internal fixation must be performed no later than 7 days after injury for intertrochanteric or undisplaced femoral neck fractures and no later than 2 days after injury for displaced femoral neck fractures. The trial excludes individuals with severe symptomatic osteoarthritis of the lower extremity, inability to independently rise from an armchair or walk 200 meters before hip fracture, and concomitant injuries such as rib fractures, wrist fractures, or acute symptomatic vertebral fractures that severely impair the ability to rise from a chair. Other exclusion criteria include head injury, use of bone grafts or bone substitutes at the time of fracture fixation, major polytrauma or significant axial trauma, and history of metabolic or bone disease that may interfere with the interpretation of the results.",
    "The sample is a phase 2 clinical trial for patients with hormone refractory prostate cancer and bone metastases. The trial is testing the effectiveness of radium-223 dichloride (bay88-8223) as a treatment. The eligibility criteria include having confirmed adenocarcinoma of the prostate, being hormone refractory with evidence of progressive disease, having multifocal skeletal metastases confirmed by bone scintigraphy, and having bone pain with a score of at least 2 on BPI average pain. Other criteria include having a performance status of ECOG 0-2 or Karnofsky >/= 60%, a life expectancy of at least 3 months, and meeting certain laboratory requirements. Exclusion criteria include having received an investigational drug within 4 weeks before the administration of radium-223, having received chemo-, immunotherapy, or external radiotherapy within the last 4 weeks prior to entering the study, and having other clinically significant or symptomatic disease that might interfere with the assessment of bone pain.",
    "The sample is a record of a clinical trial with a phase 2 designation. The trial is focused on the treatment of colorectal neoplasms, which are listed in the \"diseases\" field. The corresponding ICD-10 codes for these diseases are listed in the \"icdcodes\" field. The trial involves the use of four drugs: sunitinib, mfolfox6, bevacizumab, and mfolfox6, which are listed in the \"drugs\" field. The eligibility criteria for the trial are listed in the \"criteria\" field, which includes both inclusion and exclusion criteria. The inclusion criteria require that patients have adenocarcinoma of the colon or rectum with locally advanced or metastatic disease, evidence of measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST), and an Eastern Cooperative Oncology Group (ECOG) score of 0 or 1. The exclusion criteria include previous treatment with Sutent, Avastin, or any other systemic therapy for locally advanced or metastatic colorectal cancer, less than 6 months since completion of adjuvant chemotherapy to documentation of recurrent disease, history of cardiac disease, and brain metastases.",
    "The sample is a phase 2 clinical trial for chronic obstructive pulmonary disease (COPD). The trial includes patients between the ages of 40 and 80 with a clinical history of COPD and airflow limitation that is not fully reversible. The patients must also have a measured post-bronchodilator FEV1/FVC ratio of less than or equal to 0.70 and a measured post-bronchodilator FEV1 of at least 750ml or 30% predicted and less than or equal to 80% of predicted normal values. The trial involves the use of multiple drugs, including pt005 mdi, formoterol fumarate 12 \u03bcg (foradil\u00ae aerolizer\u00ae), and formoterol fumarate 24 \u03bcg (foradil\u00ae aerolizer\u00ae). The eligibility criteria include signed written informed consent, acceptable contraceptive methods for females of childbearing potential, and a history of at least 10 pack-years of cigarette smoking for current/former smokers. The trial also has exclusion criteria, such as pregnancy or lactation, primary diagnosis of asthma, and active pulmonary diseases.",
    "The sample is a phase 2 clinical trial for patients with squamous cell carcinoma. The trial involves the use of two drugs, paclitaxel and carboplatin. The eligibility criteria include being an adult over 18 years old, having an ECOG performance status of 0, 1 or 2, having pathologically documented bulky T2, III and IV SCCHN (excluding M1 disease), and being medically fit for undergoing chemotherapy. Patients must also have measurable or evaluable disease and meet certain medical criteria, such as having an absolute neutrophil count of > 1000/uL and platelet count > 100,000/uL. Exclusion criteria include having a history of previous or current malignancy at other sites diagnosed within the last 5 years, having active infection, and having grade II or greater peripheral neuropathy.",
    "The sample is a record of a clinical trial with a phase 2 designation. The trial is focused on breast neoplasms, which is a list of diseases. The icd-10 codes associated with the diseases are also listed. The trial involves the use of four drugs: cp-751,871, exemestane, fulvestrant, and another dose of exemestane. The eligibility criteria for the trial include being a postmenopausal woman with a diagnosis of hormone receptor positive advanced breast cancer and having an HbA1c level below 5.7%. The exclusion criteria include having received previous treatment for advanced disease.",
    "The sample is a record of a clinical trial in phase 2, focused on the disease of type 1 diabetes mellitus. The trial includes a list of ICD-10 codes for the disease and a list of drugs being tested, including regular insulin and insulin lispro. The eligibility criteria for the trial include having had type 1 diabetes for 1-15 years and being on multiple daily injections or insulin pump in stable control with HbA1c <= 9.0%. The trial requires attendance at the clinic for 5 different days. Exclusion criteria include having a BMI > 32 kg/m2, evidence of gastroparesis or impaired renal function, or lipodystrophy.",
    "The sample is a phase 2 clinical trial for breast cancer. The trial includes patients who are adult females over the age of 18 with inflammatory breast cancer and HER2-positive tumors, and have a performance status of 0-2. The trial excludes patients with metastases, previous treatment with chemotherapy, radiation therapy or hormone therapy for a breast tumor, and clinically significant cardiovascular disease or a history of thrombotic disorders. The trial will test the effectiveness of standard chemotherapy, bevacizumab (avastin), and trastuzumab (herceptin) as treatments for breast cancer. The icd-10 codes associated with the disease are also provided.",
    "The sample is a clinical trial for a drug called vortioxetine and placebo for the treatment of Major Depressive Disorder. The trial is in phase 2/phase 3 and the disease being studied is depressive disorder, major. The icd-10 codes associated with the disease are F33.0, F33.1, F33.9, F32.0, F32.1, F32.9, and F33.40. The eligibility criteria for the trial include having a primary diagnosis of Major Depressive Disorder, a reported duration of the current major depressive episode of at least 3 months, and a Montgomery-\u00c5sberg Depression Rating Scale (MADRS) total score \u226526 at the Screening and Baseline Visits. Exclusion criteria include having any current psychiatric disorder other than Major Depressive Disorder, a current diagnosis or history of manic or hypomanic episode, schizophrenia or any other psychotic disorder, including major depression with psychotic features, and any DSM-IV-TR axis II disorder that might compromise the study. The trial also excludes participants who have received electroconvulsive, vagal nerve stimulation, or repetitive transcranial magnetic stimulation therapy within 6 months prior to the Screening Visit, are currently receiving formal cognitive or behavioral therapy, systematic psychotherapy, or plans to initiate such therapy during the study, and are at significant risk of suicide or have attempted suicide within 6 months prior to the Screening Visit.",
    "The sample is a phase 2 clinical trial for individuals with a history of seasonal allergic rhinitis. The trial involves testing the effectiveness of two drugs, gsk256066 and azelastine hydrochloride, on individuals who exhibit a moderate response to 1500 grass pollen grains/m3 after 2 hours in the Vienna Challenge Chamber. The trial has specific inclusion and exclusion criteria, including age, body mass index, smoking history, and medical history. Participants must also be willing to use contraception if they are of childbearing potential. The trial involves a variety of measurements and tests, and participants must be able to comply with the study procedures and restrictions.",
    "The sample is a record of a clinical trial with a phase 2 designation. The trial is focused on Alzheimer's disease and includes a list of ICD-10 codes associated with the disease. The trial involves the use of three drugs: ssr180711c, donepezil, and placebo. The eligibility criteria for the trial include being an outpatient with a mild diagnosis of Alzheimer's disease, and exclusion criteria include previous treatment with acetylcholinesterase inhibitors and/or memantine, medical conditions that may interfere with the study, history of epileptic seizures, lens opacity, and lack of a reliable caregiver. The information provided is not intended to be a comprehensive list of all considerations relevant to a patient's potential participation in the trial.",
    "The sample is a phase 2 clinical trial for the treatment of migraines. The trial includes patients between the ages of 18 and 65 who have a history of migraines lasting from 4 to 72 hours if untreated and have had 2 to 8 moderate or severe migraine attacks per month in the last 2 months. The trial excludes patients who are pregnant or planning to become pregnant in the next 6 months, cannot distinguish migraine attacks from tension type headaches, have migraines that are mild or resolve without medication in less than 2 hours, have more than 15 headache-days per month or have taken medication on more than 10 days per month in the last 3 months, have basilar type or hemiplegic migraine headaches, are more than 50 years old when migraines began, or have a history of cardiovascular disorder within the last 6 months. The trial will test the effectiveness of several doses of the drug mk3207 compared to a placebo.",
    "The sample is a phase 2 clinical trial for patients with non-Hodgkin's lymphoma that is exclusively localized in the central nervous system, cranial nerves, or eyes. The trial is testing the effectiveness of high dose methotrexate and high dose cytarabine as treatments. The eligibility criteria include having a histological or cytological diagnosis of non-Hodgkin's lymphoma, being untreated (except for steroids), having at least one measurable lesion, being between the ages of 18 and 75, having a performance status of less than 3, and having adequate bone marrow, renal, cardiac, and hepatic function. Patients must also not have any concurrent malignancies (except for certain exceptions), not be pregnant or lactating, and not be receiving any other experimental drugs. Informed consent must be obtained from the patient before registration.",
    "The sample is a phase 2 clinical trial for individuals with HIV-1 and hepatitis C co-infection. The trial involves the use of pioglitazone, peginterferon, and ribavirin as potential treatments. The eligibility criteria include being HIV infected, having no response to previous treatment with PEG-IFN alfa-2a or alfa-2b and ribavirin, having a CD4 count of at least 200 cells/mm3, and having certain laboratory values within a specified time frame. Participants must also be willing to use effective forms of contraception and give written informed consent. The trial has exclusion criteria, such as the presence of known causes of significant liver disease, evidence of decompensated liver disease, and history of HCV treatment within a certain time frame. Participants must also not have certain medical conditions or be taking certain medications.",
    "The sample is a phase 2 clinical trial for patients who are scheduled for total thyroidectomy and/or extensive neck dissections. The trial is focused on the treatment of hypocalcemia, which is defined as a corrected serum calcium level of less than 8.0mg/dL, and involves the use of teriparatide (forteo), calcium, and calcitriol. The trial has a list of inclusion and exclusion criteria, which include factors such as age, previous treatments, medical history, and pregnancy status. Patients who meet the inclusion criteria and do not meet any of the exclusion criteria are eligible to participate in the trial.",
    "The sample is a phase 2 clinical trial for the treatment of end stage renal disease, chronic kidney disease stage 5, and esrd. The trial involves the use of drugs such as azd1722 and placebo, and the eligibility criteria includes being between the ages of 18 and 80, having a body mass index between 18 and 45 kg/m2, and being on a stable dialysis treatment regimen for at least 2 months prior to the screening visit. Exclusion criteria includes currently taking diuretic medication, having a urine production of \u2265 200 ml/day, and having predialysis systolic BP >200 mmHg or diastolic BP >110 mmHg on two successive occasions during the 2-week run-in period.",
    "The sample is a record of a clinical trial with a phase 2/phase 3 designation. The trial is focused on treating multiple myeloma, CLL/SLL, non-Hodgkin's lymphoma, Waldenstroms, and mantle cell lymphoma. The trial involves the use of the drug fludarabine and has a set of inclusion and exclusion criteria for participants. Inclusion criteria include having stage II or III non-progressive disease multiple myeloma, being \u2264 70 years old, having an eligible and willing HLA matched related donor, and meeting certain health criteria such as having a minimum performance score of 70% and platelet count >130 x103 micro L. Exclusion criteria include being over 70 years old, having a performance status <70%, having uncontrolled infections or being HIV positive, and having a history of rapidly growing disease at diagnosis or at any progression or having MDS.",
    "The sample is a phase 2 clinical trial for the treatment of seasonal allergic rhinitis. The trial is testing the effectiveness of a drug called histamine on patients who have a clinical history of seasonal allergic rhinitis with seasonal nasal allergy symptoms during each of the last 2 ragweed allergy seasons. The trial has a list of inclusion and exclusion criteria that patients must meet in order to participate. The inclusion criteria include being willing and able to give signed informed consent, having a positive skin test to ragweed allergen within 12 months of screening, and having minimum qualifying symptom scores at the last visit of the Pre-Treatment EEC sessions. The exclusion criteria include having a history of more than mild asthma that requires the use of a daily inhaled or oral corticosteroid, leukotriene inhibitor, or cromolyn, having received immunotherapy within the last 2 years that has contained ragweed pollen extract, and having previously participated in a clinical trial with TOLAMBA or another ragweed-based immunotherapy.",
    "The sample is a phase 2 trial for patients with grade 1 or 2 essential hypertension. The trial includes patients with less than 3 risk factors, who are either naive to treatment or currently on monotherapy or one combination tablet, and have a systolic blood pressure between 140 and 169 mmHg. The trial excludes patients with atrial fibrillation or left or right VBBB, left ventricular hypertrophy, significant renal or hepatic disease, obesity over 30kg/m2, and diabetes mellitus. The trial uses the drug rostafuroxin and includes a list of disease names and icd-10 codes.",
    "The sample is a phase 2 clinical trial for patients with squamous cell carcinoma of the head and neck. The trial is testing the effectiveness of the drugs cisplatin and docetaxel. Patients must meet certain eligibility criteria, including having a confirmed diagnosis of the cancer and meeting specific pathological stage requirements. Patients must also meet certain health criteria, such as having a certain level of blood counts and no active cardiac or neurological disease. Patients cannot have had prior head and neck radiotherapy or certain types of prior therapy. The sample includes detailed information on the eligibility criteria for the trial.",
    "The sample is a phase 2 trial for rheumatoid arthritis. The trial includes patients with at least 4 swollen joints and 6 tender/painful joints, with elevated ESR or CRP levels. Patients must also have a documented history and current presence of positive rheumatoid factor or baseline radiographic erosion. They must have been receiving oral or subcutaneous/intramuscular methotrexate for at least 6 months prior to randomization. Patients with any other inflammatory disease in addition to RA, chronic pain disorders, or persistently abnormal liver function enzymes are excluded from the trial. The trial includes the drugs azd9056, etanercept, and placebo.",
    "The sample is a phase 2 clinical trial for pancreatic cancer. The eligibility criteria include having pathologically confirmed pancreatic adenocarcinoma, being at least 18 years old, having at least one measurable site of disease that has not been previously irradiated, and having documented tumor progression on gemcitabine or intolerance to gemcitabine. The trial also requires a minimum of two weeks since any major surgery, completion of radiation, or completion of all prior systemic anti-cancer therapy. Patients must have an ECOG performance status of 0-1 and a life expectancy of greater than 12 weeks. Adequate bone marrow and liver function are also required, as well as the ability to swallow tablets. Exclusion criteria include prior treatment with an investigational drug within the preceding 4 weeks, prior treatment with an inhibitor of mTOR, chronic treatment with systemic steroids or another immunosuppressive agent, and more than one prior chemotherapy treatment for metastatic disease. Other exclusion criteria include uncontrolled brain or leptomeningeal metastases, other malignancies within the past 3 years except for adequately treated carcinoma of the cervix or basal or squamous cell carcinomas of the skin, chronic renal insufficiency, other concurrent severe and/or uncontrolled medical disease which could compromise participation in the study, known history of HIV seropositivity, impairment of gastrointestinal function or gastrointestinal disease that may significantly alter the absorption of RAD001, active bleeding diathesis or an oral vitamin K antagonist medication, and women who are pregnant or breastfeeding.",
    "The sample is a phase 2 clinical trial for head and neck cancer patients. The trial involves the use of the drug amifostine and patients must meet certain eligibility criteria to participate. The criteria include being at least 18 years old, having a negative pregnancy test for women of reproductive potential, and agreeing to practice effective contraception during the trial. Patients must also have a Zubrod performance status of 0 or 1, adequate nutritional status, and a hemoglobin level of at least 10 g/dL. The trial excludes patients with certain medical conditions, prior malignancies within the past 5 years, and evidence of distant metastases.",
    "The sample is a record of a clinical trial with a phase 2 designation. The trial is focused on the disease melanoma, which is identified in the \"diseases\" field. The \"icdcodes\" field lists the ICD-10 codes associated with the disease. The trial is testing the drugs azd6244 and temozolomide, which are listed in the \"drugs\" field. The \"criteria\" field provides the eligibility criteria for the trial, including requirements for diagnosis, age, and previous treatments. The inclusion criteria specify that patients must have late stage malignant melanoma and be 18 years or older. Female patients must be post-menopausal or have a negative urine pregnancy test if pre-menopausal. The exclusion criteria specify that patients cannot have had previous radiotherapy or chemotherapy, except for palliative radiotherapy, and cannot have participated in another trial with an investigational product within the previous 30 days.",
    "The sample is a phase 2 clinical trial for patients with chronic anemia who are at least 65 years old and have a life expectancy of more than 6 months. The trial is testing the effectiveness of the drug Epoetin alfa. The trial includes patients who are community dwelling and have a Short Physical Performance Summary Score of 4-10 at screening and baseline, as well as a Mini Mental State Examination score of at least 24. Patients with active cancer, a positive stool guaiac test, a diagnosis of multiple myeloma and/or MGUS, a history of venous thromboembolytic disease, previous treatment with Epoetin alfa, Darbepoetin or any form of erythropoietin recently, or uncontrolled or severe cardiovascular disease are excluded from the trial. The diseases included in the trial are anemia, aged, and hemoglobins, and the corresponding ICD-10 codes are listed as well.",
    "The sample is a phase 2 clinical trial for the treatment of sarcoma. The trial involves the use of the drugs cisplatin and etoposide. The eligibility criteria for the trial include having a histologically confirmed Ewing's family tumor with evidence of a chromosomal translocation involving the EWS gene, metastases outside the lung or pleura, and at least one measurable lesion outside of a previously irradiated area. Patients must also have a WHO performance status of 0-2, meet certain hematopoietic, hepatic, renal, and cardiovascular requirements, and have no other severe medical illnesses or prior primary malignancies. Patients must not have received prior chemotherapy and must meet certain radiotherapy and surgery requirements. Fertile patients must use effective contraception.",
    "The sample is a phase 2 clinical trial for locally advanced squamous cell carcinoma of the head and neck. The trial includes patients with various primary sites and stages, as long as they are unresectable. Patients must have a Karnofsky performance status of 70% or better and no evidence of distant metastatic disease. They must also meet certain laboratory parameters for renal and bone marrow function. Patients with loco-regional recurrences from any site with no prior radiation therapy and not amenable for salvage surgery are eligible for study. The trial excludes patients with preexisting clinically significant neuropathy, poorly-controlled hypertension, angina, arrhythmias, or a history within the past 6 months of myocardial infarction or acute congestive heart failure. Pregnant or lactating females or females of child bearing potential not employing adequate contraception are also excluded.",
    "The sample is a phase 2 clinical trial for lung cancer patients. The trial is testing the effectiveness of the drug pemetrexed in treating patients with stage IV or selected stage IIIB (T4) disease that is incompletely resected or unresectable. Patients must have measurable or nonmeasurable disease documented by CT scan and cannot have known brain metastases. The trial also has eligibility criteria for patient characteristics, including specific laboratory parameters and a Zubrod score of 0-2. Patients must not have a history of allergic reaction to compounds of similar chemical or biological composition as pemetrexed disodium and must not have had more than 2 prior systemic therapies. The trial also has criteria for prior concurrent therapy, including a minimum of 28 days since prior systemic therapy and at least 28 days since prior radiotherapy and recovered. Patients must discontinue certain non-steroidal anti-inflammatory drugs (NSAIDs) at least 5 days before and for 2 days following pemetrexed treatment.",
    "The sample is a phase 2 clinical trial for patients with adenocarcinoma of the prostate and stage IV prostate cancer. The trial involves the use of three drugs: cediranib maleate, docetaxel, and prednisone. The eligibility criteria for the trial include having clinical/radiologic metastases with objective evidence of disease progression, rising PSA levels, and meeting certain disease measurement criteria. Patients must also have castrate levels of testosterone, normal bilirubin levels, and meet certain blood count and organ function criteria. Additionally, patients must not have certain medical conditions or be taking certain medications. The trial aims to evaluate the safety and efficacy of the drug combination in treating metastatic prostate cancer.",
    "This sample is for a phase 2 clinical trial with the disease being studied being \"healthy\". The trial is testing the effects of drugs such as risperidone, risperidone matched placebo, risperidone-matched placebo, and mifepristone-matched placebo. The eligibility criteria for participants include having a BMI between 18 and 23 kg/m2, being able to provide written informed consent, having normal clinical laboratory tests, having normal AST, ALT, and Tbili levels, having a medical and psychiatric history and physical examination without any significant findings that would interfere with participation, agreeing to use a barrier method of birth control for 28 days following the last dose of study medication, and having maintained a stable weight for at least 6 months prior to screening. Exclusion criteria include having a prior or current history of any psychiatric disorder, testing positive for any drug of abuse, participating in a clinical investigation of any drug, biological or other investigational therapy within 30 days prior to dosing, having a history of an allergic reaction to either mifepristone or risperidone, having any other clinically significant abnormality on screening laboratory tests, having a QTc Bazzett's \u2265 450 msec, having a history of or current major medical condition that would place the patient at undue risk, receiving any prescription or over-the-counter medications that could potentially affect appetite or weight, having any history of a movement disorder such as Tardive Dyskinesia or Parkinsonism, and having any personal or family history of Neuroleptic Malignant Syndrome.",
    "The sample is a phase 2 clinical trial for the treatment of recurrent or metastatic breast cancer. The trial involves the use of two drugs, su011248 and chemotherapy, and the eligibility criteria includes having negative status for estrogen receptor (ER), progestin receptor (PR) and HER2/neu receptor (HER2), having received prior treatment with an anthracycline and a taxane in the adjuvant or advanced disease setting, and having relapsed following adjuvant chemotherapy within 6 months of last treatment and/or received one or two chemotherapy regimens for advanced disease. The exclusion criteria includes having received more than two chemotherapy regimens for advanced disease and having uncontrolled/symptomatic spread of cancer to the brain. The diseases involved in the trial are breast neoplasms and the icd-10 codes associated with them are [\"C79.81\", \"D24.1\", \"D24.2\", \"D24.9\", \"D49.3\", \"C44.501\", \"D48.60\"].",
    "The sample is a record of a clinical trial with a phase 2 designation. The trial is focused on treating adenocarcinoma of the stomach or esophagogastric junction using the drug tesetaxel. The eligibility criteria for participants include having a confirmed diagnosis of the specified cancers, measurable disease, and having only received one prior regimen of treatment that included a fluoropyrimidine and/or a platinum analogue. Participants must also have documented disease progression within 4 months of the last dose of the prior regimen and meet certain health criteria. The exclusion criteria include having nonmeasurable disease, brain metastasis or leptomeningeal disease, and certain medical conditions. Participants must also not have had prior treatment with a taxane or other tubulin-targeted agent other than a vinca alkaloid and must not be taking medication that is a potent inhibitor or inducer of the CYP3A pathway or P-glycoprotein activity.",
    "The sample is a phase 2 clinical trial for patients with metastatic or recurrent breast cancer that cannot be treated with surgery or radiation. The trial is testing the drug temsirolimus. Patients must have measurable disease and either the primary or metastatic tumor must be positive for estrogen receptor, progesterone receptor, or human epidermal growth factor receptor. Patients must also meet certain eligibility criteria, such as having an Eastern Cooperative Oncology Group performance status of 0 or 1, and not having had prior exposure to rapamycin or any other mechanistic target of rapamycin inhibitor. Patients must also agree to use adequate contraception and have tissue available for correlative studies. There are also exclusion criteria, such as not receiving any other investigational agents or herbal preparations, and not having known hypersensitivity reactions to macrolide antibiotics.",
    "The sample is a phase 2 clinical trial for the treatment of type 2 diabetes mellitus. The trial includes patients who have been diagnosed with type 2 diabetes mellitus at least 4 months but not more than 12 years prior to screening. The patients must have a BMI between 25 to 48 kg/m2 (23 to 48 kg/m2 for India) and be currently treated with a stable dose of metformin, TZD, or metformin + TZD for at least 4 weeks (metformin) or 10 weeks (TZD) prior to screening. The patients must also have a fasting plasma glucose level between 118 - 220 mg/dL (6.6 - 12.2 mmol/L), inclusive; HbA1c level between 7.3% - 11.0%, inclusive; and a fasting plasma C peptide greater than 0.26 nmol/L at screening. Patients with type 1 diabetes mellitus or marked diabetic long-term complications are not eligible for the trial.",
    "The sample is a phase 2 clinical trial for patients with neuroendocrine tumors that have spread to the liver. The trial is testing the effectiveness of octreotide acetate as a treatment. Patients must have confirmed neuroendocrine tumors that are well-differentiated or moderately well-differentiated, and must have measurable disease. They must also meet certain symptomatic criteria, such as refractory carcinoid symptoms or evidence of radiographic progression. Patients must have a Karnofsky performance status of 50-100%, a life expectancy of at least 6 months, and must not be pregnant or nursing. They must also meet certain laboratory criteria, such as having a creatinine level of \u2264 1.5 mg/dL and a platelet count of \u2265 65,000/mm\u00b3. Prior surgery, chemotherapy, or locally ablative technique for the liver cancer is allowed, but prior radiotherapy to the upper abdomen that includes the liver in the treatment field is not allowed. Patients must not have participated in another clinical trial within the past 4 weeks, and must not have had any other specific anticancer treatment (other than octreotide acetate) during and for 3 months after completion of study therapy.",
    "The sample is a phase 2 clinical trial for recurrent or persistent endometrial cancer. The trial includes female subjects who are at least 18 years old and have provided written informed consent. The subjects must have had pathologic confirmation of their original endometrial carcinoma and at least one measurable lesion according to GOG-modified RECIST criteria. The trial involves the use of the drug topotecan and subjects must have received one prior chemotherapy regimen (excluding all topoisomerase I inhibitors). The trial also includes eligibility criteria related to prior non-cytotoxic therapy, radiotherapy, major surgery, ECOG Performance Status, probable life expectancy, and screening laboratory criteria. Exclusion criteria include pregnancy or lactation, more than one prior chemotherapy regimen, active uncontrolled infection, brain metastases, prior treatment with HYCAMTIN, history of an allergic reaction to compounds chemically-related to HYCAMTIN or its constituents, and receipt of any investigational agent within 30 days or five half-lives (whichever is longer) prior to study entry.",
    "The sample is a phase 2 clinical trial for patients between the ages of 12 and 17 with moderate persistent asthma. The trial involves the use of tiotropium bromide and a placebo. The eligibility criteria include having a history of asthma for at least 3 months, being on a stable medium dose of inhaled corticosteroids for at least 4 weeks, and having a pre-bronchodilator FEV1 above 60% and less than or equal to 90% of predicted normal. Patients must also be symptomatic and have an Asthma Control Questionnaire mean score of equal or above 1.5. Exclusion criteria include having a significant disease other than asthma, a history of heart disease, malignancy, or lung diseases other than asthma. Patients must be able to use the Respimat inhaler correctly and perform all trial-related procedures. Female patients must not be pregnant or nursing and must be using a highly effective method of birth control.",
    "This sample is for a phase 2 clinical trial for the treatment of eczema. The trial is looking at the effectiveness of three different drugs (las41003, las189962, and las189961) for patients with clinically diagnosed super-infected or impetiginized eczema. The eligibility criteria for the trial includes exclusion of patients with general signs of systemic infections, bacterial skin infections that cannot be treated with topical medication, and certain other diseases such as tuberculosis, psoriasis, and viral infections of the skin. Additionally, patients with eczema on certain areas of the body, such as the palms of the hands, soles of the feet, and face, are also excluded. The trial is looking to enroll patients who have not received any topical treatment with antibiotics, antimycotics, immunomodulators, and corticosteroid preparations within the last 2 weeks before treatment with the investigational medicinal product (IMP).",
    "The sample is a phase 2 trial for patients with type 2 diabetes mellitus. The trial includes patients who are currently being treated with diet and exercise therapy, or a combination of diet and exercise with metformin or sulfonylurea for at least 3 months prior to entering the trial. Patients must have had diabetes for at least 6 years and have an HbA1c value between 7% and 10%. Women must not be of child-bearing potential and male patients must use a reliable method of birth control during the study. The trial excludes patients who have used insulin or any antidiabetic agent other than metformin or sulfonylurea during the 3 months prior to entering the trial, have gastrointestinal disease that significantly impacts gastric emptying or motility, have had more than 1 episode of severe hypoglycemia within 6 months prior to entry into the study, have cardiac autonomic neuropathy, have cardiac disease with functional status that is New York Heart Association Class II, III, or IV or a history of myocardial infarction, unstable angina, or decompensated congestive heart failure in the past 6 months, have poorly controlled hypertension, have fed or fasting state hypertriglyceridemia, have obvious clinical signs or symptoms of liver disease, acute or chronic hepatitis, or repeated alanine transaminase (ALT) levels >2.5 times the upper limit of the reference range at screening, have evidence of a significant active, uncontrolled endocrine or autoimmune abnormality, have an active or untreated malignancy or have been in remission from a clinically significant malignancy for less than 5 years, or have a history of seizure disorder.",
    "The sample is a phase 2 clinical trial for the treatment of hepatitis C virus. The trial includes participants who are chronically infected with HCV genotype 2 or 3 and have not been previously exposed to interferon or ribavirin. The trial involves the use of drugs such as placebo, daclatasvir, pegylated interferon alfa-2a, and ribavirin. The eligibility criteria include a BMI of 18 to 35 kg/m^2, inclusive, and participants must be between 18 and 70 years of age. The trial excludes participants who have undergone liver transplant, have documented or suspected hepatocellular carcinoma, or have evidence of decompensated cirrhosis. Other exclusion criteria include a history of chronic hepatitis B virus, current or known history of cancer, and any gastrointestinal disease or surgical procedure that may impact the absorption of study drug. Participants must also be able to tolerate oral medication and have good venous access. The trial also excludes participants with severe psychiatric disease, chronic pulmonary disease, or clinically significant cardiac disease. Additionally, participants with preexisting ophthalmologic disorders considered clinically significant on eye, uncontrolled diabetes mellitus, or any known contraindication to pegylated interferon alfa-2a or ribavirin are excluded. Finally, participants who have been exposed to any HCV direct antiviral agent or investigational drug or placebo are also excluded.",
    "This sample is for a phase 2 clinical trial for the treatment of secondary hyperparathyroidism. The trial involves the use of two drugs, etelcalcetide and placebo. The eligibility criteria for the trial include having intact parathyroid hormone levels of at least 350 pg/mL, corrected calcium levels of at least 9.0 mg/dL, and adequate hemodialysis three times per week. The subject must also be in stable medical condition based on medical history, physical examination, and routine laboratory tests. Exclusion criteria include a history of ventricular dysrhythmias, angina pectoris, congestive heart failure, myocardial infarction, coronary angioplasty, or coronary artery bypass grafting within the past 6 months, treatment for seizure disorder, recent parathyroidectomy, and serum transaminases greater than two times the upper limit of normal at screening.",
    "The sample is a record of a clinical trial in phase 2 for the treatment of vulvodynia, a condition characterized by chronic pain in the vulva. The trial includes a list of diseases and their corresponding ICD-10 codes, a list of drugs being tested (lidocaine/diphenhydramine, lidocaine, and placebo), and eligibility criteria for patients to participate in the trial. The inclusion criteria require patients to have sought medical care for the condition and have menstrual cycles, while the exclusion criteria state that patients must not have any vaginal infections, must not be pregnant or nursing, and must not be receiving any other medicinal therapies or medications that could interfere with the study's outcome.",
    "The sample is a record of a clinical trial with a phase 2 designation. The trial is focused on the disease Diffuse Large B-Cell Lymphoma, and the ICD-10 codes associated with it. The trial is testing the effectiveness of two drugs, sar3419 and rituximab. The eligibility criteria for participants include having a histological diagnosis of DLBCL, having relapsed or being refractory after at least one standard treatment including rituximab, and having CD19 and CD20 positive disease. Exclusion criteria include not having a bi-dimensionally measurable lesion by CT scan and not meeting other relevant considerations for participation in the trial.",
    "The sample is a phase 2 clinical trial for patients with metastatic colorectal cancer. The trial involves the use of drugs such as capecitabine, irinotecan, oxaliplatin, and cetuximab. The eligibility criteria include having histologically confirmed metastatic colorectal cancer, EGF-receptor testing, no prior chemotherapy for colorectal cancer (except adjuvant chemotherapy with an interval of at least 6 months), and no prior therapy directed against the EGF-pathway. Patients must also have measurable disease, be between 18 and 75 years old, have a Karnofsky PS of at least 70%, and have a life expectancy of at least 3 months. Adequate bone marrow, liver, and renal function are also required. Exclusion criteria include concurrent treatment of colorectal cancer (except study medication), known contraindications against study medication, and participation in other studies during the 30 days before study entry.",
    "The sample is a phase 2 clinical trial for patients with chronic obstructive pulmonary disease. The trial is testing the effectiveness of various doses of salmeterol and a placebo using the HandiHaler and Diskus devices. The eligibility criteria include having a diagnosis of COPD, being a current or ex-smoker with a smoking history of more than 10 pack-years, and being able to perform pulmonary function tests. Exclusion criteria include having significant diseases other than COPD, recent history of myocardial infarction or heart failure, malignancy within the last five years, and significant alcohol or drug abuse within the past two years. Patients must also sign an informed consent consistent with International Conference on Harmonization Good Clinical Practice guidelines.",
    "The sample is a phase 2 clinical trial for patients aged 18 and above with congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency. The trial is testing the effectiveness of hydrocortisone modified release capsules as a treatment for CAH. The eligibility criteria include stable dosage of hydrocortisone, good general health, and negative pregnancy test for females of childbearing potential. Exclusion criteria include co-morbid conditions requiring medication that interferes with glucocorticoid metabolism, hepatic or renal disease, and participation in another clinical trial within the past 3 months.",
    "The sample is a record of a clinical trial with a phase 2 designation. The trial is focused on patients with hepatitis C infection, specifically those with genotype 1 and a viral load of at least 10*5* IU/mL at screening. The trial is looking at the effectiveness of several drugs, including bms-790052, peginterferon alfa-2b, and ribavirin, as well as a placebo. The eligibility criteria for the trial include being naive or nonresponsive to the current standard of care, but exclude patients with cirrhosis, hepatocellular carcinoma, or coinfection with hepatitis B virus, HIV-1 or HIV-2.",
    "The sample is a phase 2 clinical trial for patients with HIV infection and hypercholesterolemia. The trial is testing the effectiveness of pravastatin (drug) in reducing cholesterol levels in HIV-positive patients who are on antiretroviral therapy. The inclusion criteria for the trial include confirmed HIV-1 infection, age above 18 years, stable antiretroviral therapy, plasma HIV-RNA level of < 50 copies/mL for >= 3 months before randomization, and total cholesterol > = 5.5 mmol/L with LDL-cholesterol > = 3.4 mmol/L on fasting status after three months of standardized dietary advice. The exclusion criteria include current AIDS event or infectious disease, tumoral, inflammatory, muscle diseases, kidney or hepatic failure, psychiatric conditions, biological elevated muscular enzymes, chronic alcohol consumption, and pregnancy.",
    "The sample is a phase 2 clinical trial for patients with unresectable adenocarcinoma of the pancreas. The trial involves the use of three drugs - capecitabine, fluorouracil, and gemcitabine hydrochloride. The eligibility criteria include having no evidence of metastatic disease outside of the planned radiotherapy field, no history or known presence of CNS metastases, and an Eastern Cooperative Oncology Group (ECOG) performance status of 0-1. Patients must also meet certain laboratory values and not have any uncontrolled intercurrent illness or significant cardiovascular disease. Prior concurrent therapy is also restricted.",
    "The sample is a phase 2 clinical trial for breast cancer patients with bone metastases. The trial is testing the effectiveness of a drug called radium-223 chloride (bay88-8223). The eligibility criteria for the trial include being a post-menopausal female or surgically sterile, having histological or cytological evidence of primary breast cancer, having bone dominant disease with at least one non-irradiated bone metastasis, having progressed on endocrine therapy, and having been on bisphosphonate therapy for at least 3 months prior to treatment start. The trial also has exclusion criteria, such as having received an investigational drug within 4 weeks prior to the administration of Alpharadin, or having received chemotherapy, immunotherapy, or external beam radiation therapy within the last 4 weeks prior to administration of study drug. The trial is expected to last for 16 weeks and patients with any other serious illness or medical condition are excluded from the trial.",
    "The sample is a phase 2 clinical trial for patients with advanced, nonsquamous cell non-small cell lung cancer. The trial is testing the effectiveness of a combination of drugs including enzastaurin, pemetrexed, carboplatin, bevacizumab, and placebo. The eligibility criteria include having a confirmed diagnosis of advanced NSCLC, not having received prior systemic chemotherapy or targeted therapy for advanced NSCLC, having measurable disease, and adequate organ function with an estimated life expectancy of 12 weeks. Exclusion criteria include having known CNS disease, major surgery within 28 days, serious concomitant systemic disorder, serious cardiac condition, and having received treatment within the last 30 days with any drug that has not received regulatory approval for any indication at the time of study entry. Additionally, patients who have previously received treatment with enzastaurin, pemetrexed, or bevacizumab, are pregnant or breastfeeding, or unable to swallow tablets are also excluded from the trial.",
    "The sample is a record of a clinical trial with a phase 2 designation. The trial is focused on the treatment of growth hormone deficiency in adults. The diseases listed are limited to growth hormone deficiency. The icd-10 codes associated with the disease are also provided. The drugs being tested in the trial are tv-1106 and recombinant human growth hormone. The eligibility criteria for the trial are listed under inclusion criteria, which includes age range, confirmed diagnosis of GH deficiency, and prior treatment with rhGH. Exclusion criteria are also listed, which includes patients with active or chronic diseases that could confound results, history of malignancy, and other medical conditions.",
    "The sample is a phase 2 clinical trial for attention deficit hyperactivity disorder. The trial includes children between the ages of 6 and 17 who meet the Diagnostic & Statistical Manual of Mental Disorders criteria for a primary diagnosis of ADHD combined, predominately hyperactive impulsive type, or predominately inattentive type. The trial involves the use of two drugs, d-amphetamine transdermal system and a placebo patch. The eligibility criteria include factors such as age, gender, race, and intelligence quotient, as well as the ability to wear a patch for 9 hours and complete a PERMP assessment. The trial also has exclusion criteria, such as a history of substance abuse or dependence disorder, a tic disorder, or a family history of sudden cardiac death. The trial requires parental consent and written or verbal assent from the subject, and participants must be willing and able to comply with all protocol requirements.",
    "The sample is a phase 2 clinical trial for non-small cell lung cancer. The trial is testing the effectiveness of two drugs, belotaxel and belloxa. The eligibility criteria for the trial includes having stage IIIB/IV or relapsed NSCLC, being at least 18 years old, having at least one measurable lesion by RECIST (version 1.1), having an ECOG PS of 0, 1, or 2, and meeting certain hematologic and hepatic profile requirements. Patients must also have recovered from toxicities of previous treatment and provide written informed consent. Exclusion criteria includes having been previously treated with chemotherapy for NSCLC, having an active infection requiring antibiotics treatment, having a prior diagnosis of other malignancy except for certain types of skin cancer and carcinoma in situ of the uterine cervix, having peripheral neuropathy of grade 2 or higher, having uncontrolled hypertension or certain heart conditions, having entered other clinical trials within 4 weeks, and being pregnant or lactating or not willing to use a contraceptive measure if of childbearing age.",
    "The sample is a phase 2 clinical trial for patients with rheumatoid arthritis. The trial includes a list of inclusion and exclusion criteria for patients, such as age range, recent diagnosis of RA, and negative tuberculosis skin test reaction. The trial also includes a list of drugs being tested, including canakinumab (investigational), placebo, and methotrexate (mtx). The eligibility criteria also includes vital sign ranges, weight and BMI requirements, and contraception requirements for women of child-bearing potential. The exclusion criteria includes previous treatment with biological therapy or MTX, limited kidney function, and participation in any clinical investigation within 4 weeks prior to study start.",
    "The sample is a phase 2 clinical trial for rheumatoid arthritis. The trial includes patients who are either new to treatment or have stopped previous treatment due to intolerance or lack of efficacy. Patients must have a certain number of tender and swollen joints, as well as morning stiffness, and a confirmed C-Reactive Protein level. Patients must also have a non-poor Cytochrome P2D6 metabolizer status. Exclusion criteria include functional Rheumatoid Arthritis class IV, fever, infections with hepatitis B, C, or HIV, presence or history of cancer within the last 5 years, and manifest or latent tuberculosis. The sample is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.",
    "The sample is a phase 2 clinical trial for the treatment of diabetic neuropathy. The trial includes patients with a diagnosis of diabetes mellitus and diabetic neuropathy, who have been experiencing symptoms for at least six months. The trial will test the effectiveness of the drug abt-894 and duloxetine, as well as a placebo. The eligibility criteria include having a negative pregnancy test for female patients, and having an HgbA1c level of 9 or lower. Exclusion criteria include a history of seizures or major depressive episodes, as well as a history of myocardial infarction or uncontrolled hypertension. The trial will not include patients with a history of fibromyalgia or a functioning implanted medical device for the treatment of neuropathic pain.",
    "The sample is a phase 2 clinical trial for the treatment of major depressive disorder. The trial includes the use of drugs such as lu aa24530, duloxetine, and placebo. The eligibility criteria for the trial includes having a major depressive episode that has lasted at least 3 months and is moderate to severe. Exclusion criteria includes having any current psychiatric disorder other than MDD, a history of manic or hypomanic episode, schizophrenia or any other psychotic disorder, mental retardation, organic mental disorders, or mental disorders due to a general medical condition. Additionally, patients who have had two unsuccessful courses of antidepressant treatment, electroconvulsive therapy within 6 months prior to baseline, ongoing formal cognitive or behavioral therapy, or clinically significant unstable illness are excluded. Pregnant or breastfeeding patients are also excluded.",
    "The sample is a phase 2 clinical trial for chronic myelogenous leukemia. The trial is for patients who have failed to achieve or have lost an adequate response to imatinib mesylate (IM). Patients must be in complete or partial hematological remission, have an ECOG performance status of 2 or less, and have adequate liver and renal function. Patients must also be over 18 years old and have signed an informed consent form. Exclusion criteria include serious intercurrent medical illnesses, active infections requiring parenteral antibiotics, pregnancy or breastfeeding, taking steroids, prior bone marrow transplant, and known positivity for HIV.",
    "The sample is a phase 2 clinical trial for patients with aggressive non-Hodgkin's lymphoma who are candidates for initial chemotherapy treatment. The trial is testing the effectiveness of the drug palonosetron in preventing chemotherapy-induced nausea and vomiting. The eligibility criteria include being over 18 years old, having an ECOG performance status of 0-1, and being scheduled to receive a single intravenous dose of at least one moderately emetogenic agent on Day 1. Exclusion criteria include having received investigational drugs within 30 days before study entry, having a known hypersensitivity to 5HT3 receptor antagonists, and being pregnant or breastfeeding. The trial requires patients to complete a patient diary and to have acceptable hepatic and renal functions.",
    "This sample is for a phase 2 clinical trial for the treatment of multiple myeloma. The trial is testing the effectiveness of lenalidomide, pegylated liposomal doxorubicin (pld), and dexamethasone. The eligibility criteria include having measurable myeloma paraprotein levels in serum or urine, an Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-2, and adequate bone marrow and renal function. Patients must also be able to tolerate aspirin, low molecular weight heparin, or coumadin. Exclusion criteria include ongoing severe infection, life expectancy of less than 3 months, and prior chemotherapy for multiple myeloma. Females of childbearing potential must have a negative pregnancy test and agree to use two methods of birth control.",
    "The sample is a record from a clinical trial table that includes information about the trial's phase, diseases being studied, corresponding ICD-10 codes, drugs being tested, and eligibility criteria for participants. In this particular sample, the trial is in phase 2 and is studying the effects of various drugs on patients with coronary arteriosclerosis and acute coronary syndrome. The ICD-10 codes associated with these diseases are also listed. The drugs being tested include prasugrel 10 mg, clopidogrel, prasugrel placebo, prasugrel 60 mg, and clopidogrel placebo. The eligibility criteria for participants are also listed, including age requirements, exclusion criteria, and other medical conditions that may disqualify a participant from the trial.",
    "The sample is a phase 2 trial for the treatment of chronic obstructive pulmonary disease (COPD) using the drugs losmapimod and placebo. The trial includes male and female outpatients aged 40 years or older with a clinical history of COPD, a FEV1/FVC ratio of \u22640.70, FEV1 \u2264 80% of predicted normal, and 6MWD < 350m. Participants must also have a current or prior history of \u226510 pack-years of cigarette smoking and meet certain liver function and ECG criteria. Exclusion criteria include a current diagnosis of asthma, pregnancy or lactation, \u03b11-antitrypsin deficiency, lung resection, and other medical conditions.",
    "The sample is a record of a clinical trial with a phase 2 designation. The trial is focused on the disease of arthritis, specifically rheumatoid arthritis. The icd-10 codes associated with the disease are listed. The trial is testing the effectiveness of the drug cp-690,550, with multiple instances of the drug being used. The eligibility criteria for the trial are listed, including the requirement of having active rheumatoid arthritis and inadequate response to methotrexate. The exclusion criteria are also listed, including the exclusion of current therapy with any DMARD or biologic other than methotrexate.",
    "The sample is a phase 2 clinical trial for the treatment of multiple myeloma, a type of cancer. The trial involves the use of three drugs - bortezomib, lenalidomide, and dexamethasone. The eligibility criteria for the trial include a diagnosis of multiple myeloma, relapsed or relapsed and refractory disease after receiving between 1 and 3 prior regimens, negative pregnancy test, age 18 years or older, and a Karnofsky performance status of 60 or greater. There are also exclusion criteria, such as grade 2 or greater peripheral neuropathy, renal insufficiency, evidence of mucosal or internal bleeding, and prior malignancy within the last 3 years. The sample also includes a list of ICD-10 codes for multiple myeloma and the inclusion and exclusion criteria for the trial.",
    "The sample is a phase 2 clinical trial for the treatment of hepatitis C. The trial includes treatment-naive males and females between the ages of 18-65 with genotype 1 HCV infection. Females of childbearing age must have a negative pregnancy test and both males and females must use two forms of contraception during treatment and following the last dose of ribavirin. The trial excludes individuals with hepatitis B or HIV infection, pregnant or breastfeeding females or male partners of pregnant females, those who have previously undergone interferon or ribavirin-based therapy or investigational anti-HCV agent, and those with a history or evidence of medical condition associated with chronic liver disease other than HCV. The trial involves the use of sofosbuvir, placebo, peg, and rbv drugs.",
    "The sample is a phase 2 clinical trial for the treatment of postherpetic neuralgia. The trial includes patients who have experienced pain in the area affected by herpes zoster for at least 6 months after the skin rash has healed. The patients must have a pain score between 3 and 8 on the PI-NRS scale. The trial involves the use of two drugs, z160 and placebo. The eligibility criteria include being at least 18 years old, providing written informed consent, and being willing and able to comply with all study procedures. The exclusion criteria include having severe pain caused by diseases other than PHN, a history of seizure or stroke, and clinically significant conditions that may interfere with the study procedures or compromise the subject's safety.",
    "The sample is a clinical trial for the treatment of hepatitis C and liver fibrosis using the drugs ribavirin and ribavirin-placebo. The trial is in phase 2/phase 3 and includes patients over 18 years old with a hepatitis C virus infection who have not responded to previous antiviral treatment. The patients must have an active chronic hepatitis C and a Metavir fibrosis score of at least 2, as well as serum ALT levels above the upper limit of the laboratory on two occasions within 6 months before inclusion. The trial has inclusion and exclusion criteria, including a negative pregnancy test for women, no history of hepatic complications or severe seizures, and no regular alcohol consumption. Patients must also be willing to undergo a liver biopsy at the end of the study and provide written informed consent.",
    "The sample is a phase 2 clinical trial for patients with low or intermediate-1 IPSS risk category MDS (excluding 5q deletion) and red blood cell transfusion-dependent anemia. The trial is testing the effectiveness of lenalidomide and darbepoetin alfa as treatments. The eligibility criteria include being at least 18 years old, having an Eastern Cooperative Oncology Group (ECOG) performance status of 0-2, and meeting certain laboratory test result ranges. Patients must also be disease-free of prior malignancies for at least 2 years, except for certain exceptions. Females of childbearing potential must have a negative pregnancy test and agree to use two forms of birth control. The exclusion criteria include having any serious medical condition or laboratory abnormality that would prevent the subject from signing the informed consent form, being pregnant or breastfeeding, and having any condition that places the subject at unacceptable risk if they were to participate in the study.",
    "The sample is a phase 2 clinical trial for patients with advanced, recurrent, or metastatic colorectal adenocarcinoma. The trial requires patients to have measurable disease and to have progressed on at least one prior, but no more than two prior, fluorouracil and/or irinotecan containing treatment regimens for metastatic colorectal cancer. Patients must also have documented HER-2/neu overexpression by immunohistochemistry staining. The trial has various eligibility criteria related to patient characteristics, including age, performance status, hematopoietic, hepatic, renal, cardiovascular, and other factors. Prior concurrent therapy is also specified. The trial involves the use of drugs such as fluorouracil, leucovorin calcium, and oxaliplatin.",
    "The sample is a phase 2 clinical trial for patients with advanced, progressive adenocarcinoma of the lung. The trial requires participants to have previously received at least 2 cytotoxic containing chemotherapeutic regimens and have an Eastern Cooperative Oncology Group (ECOG) performance status of 0-2. Participants must also have radiographic evidence of measurable disease and ertafolide \"positive\" tumor, adequate bone marrow reserve, hepatic, and renal function, and a negative serum pregnancy test for women of childbearing potential. The trial has exclusion criteria, including serious comorbidities, history of carcinomatous peritonitis, and history of severe bowel obstruction. Participants with central nervous system (CNS) metastasis are eligible if they have been treated for the CNS metastasis and have been clinically stable for >4 weeks and do not require steroids or antiseizure medications. The trial requires participants to be off steroids and/or antiseizure medications for at least 14 days.",
    "The sample is a phase 2 clinical trial for patients who have had a stroke within the past 4 weeks to 12 months. The trial is testing the effectiveness of ropinirole, a drug used to treat Parkinson's disease, in combination with physical therapy compared to a placebo and physical therapy. The trial is looking for patients who are between the ages of 18 and 85, have no significant pre-stroke disability, and have not had another stroke in the previous 3 months. Patients must also have a Fugl-Meyer motor score of 23-83 out of 100 and a Functional Independence Measure (FIM) ambulation-subscore of 3 or more, and 50 foot walk takes longer than 15 seconds. Patients with significant daytime somnolence, advanced liver, kidney, cardiac, or pulmonary disease, orthostatic hypotension, or a terminal medical diagnosis consistent with survival < 1 year are excluded from the trial. Additionally, patients with coexistent major neurological or psychiatric disease, a history of significant alcohol or drug abuse in the prior 3 years, a coexistent disease characterized by an abnormality of CNS dopaminergic tone, current enrollment in another investigational study related to stroke or stroke recovery, or a contraindication to ropinirole prescription are also excluded.",
    "The sample is a record from a clinical trial table that includes information about the trial's phase, diseases being studied, icd-10 codes of those diseases, drugs being used, and eligibility criteria for participants. In this particular sample, the trial is in phase 2 and is studying lung cancer. The icd-10 codes associated with the disease are listed, as well as the drugs being used in the trial (topotecan and docetaxel). The eligibility criteria for participants are also listed, including requirements such as having relapsed or progressive disease, being at stage IIIB or IV, having no more than one prior chemotherapy regimen, and having adequate bone marrow, liver, and kidney function. The sample also includes exclusion criteria, such as prior treatment with topotecan or docetaxel, uncontrolled brain metastases, and moderate peripheral neuropathy. The study center will determine if a participant meets all of the criteria, and if they do not qualify, study personnel will explain the reasons.",
    "The sample is a phase 2 clinical trial for breast cancer patients who are not eligible for curative therapy. The trial allows patients with HER-2 positive disease and those who have relapsed or progressed after aromatase inhibitor therapy. Patients must have measurable disease according to RECIST criteria or other radiological exams. They must have received no more than one line of chemotherapy for advanced stage disease and must be estrogen receptor and/or progesterone receptor-positive. Patients must also meet certain patient characteristics such as having a WHO performance status of 0-2 and being postmenopausal. The trial excludes patients with certain medical conditions such as uncontrolled hypertension or serious cardiovascular disease. Prior concurrent therapy is also restricted. The trial involves the use of fulvestrant and selumetinib drugs and requires patients to adhere to proper staging, treatment, and follow-up.",
    "This is a sample of a clinical trial for phase 2, focused on non-small-cell lung cancer. The trial includes patients with Stage IV and Stage III squamous or adenocarcinoma carcinomas of the lung who have not received prior anticancer treatment for metastatic/advanced disease. Patients must also have adequate hematologic parameters, creatinine, and total bilirubin levels, as well as a performance status (ECOG) of 0-2 and a life expectancy of at least 3 months. Patients must sign written informed consent to participate in the study. Exclusion criteria include patients with non-squamous tumors who have no contradiction for administration of bevacizumab, active infection or malnutrition, known hypersensitivity reaction to any of the component of the treatment, concurrent or previous chronic systemic immune therapy, pregnancy or lactation period, known alcohol/drug abuse, legal incapacity or limited legal capacity, medical or psychological condition which in the opinion of the investigator would not permit the subject to complete the study or sign meaningful informed consent, a second primary tumor other than non-melanoma skin cancer or in situ cervical carcinoma, previous radiotherapy to the target lesions, and patients with severe cardiac dysfunction, unstable angina petrosis, or high risk of uncontrolled arrhythmia. The trial will involve treatment with gemcitabine, cisplatin, docetaxel, cisplatin, vinorelbine, and pemetrexate.",
    "The sample is a phase 2 clinical trial for patients with chronic obstructive pulmonary disease (COPD) or emphysema. The trial involves the use of sildenafil citrate and a placebo. The inclusion criteria for the trial include a clinical diagnosis of COPD or emphysema, a FEV1/FVC ratio of less than 70%, a FEV1 of less than 80%, and a stable medication regimen. The exclusion criteria include recent COPD exacerbation or hospitalization, heart disease, contraindication to sildenafil, unrelated lung disease, inability to walk or pedal on a stationary bike, pregnancy or breast-feeding, and pulmonary hypertension at rest.",
    "The sample is a record from a clinical trial table that includes information about the phase of the trial, diseases being studied, icd-10 codes associated with those diseases, drugs being tested, and eligibility criteria for participants. In this particular sample, the trial is in phase 2/phase 3 and is studying heart and liver transplantation as well as bone resorption. The icd-10 codes associated with these diseases are listed, as well as the drugs being tested (zoledronic acid and alendronate). The eligibility criteria for participants are also listed, including age range, exclusion criteria such as hyperparathyroidism and cancer, and other factors such as pregnancy or lactation.",
    "The sample is a phase 2 clinical trial for patients with stage IIIb or stage IV non-small cell lung cancer. The trial involves the use of drugs such as zd6474, carboplatin, and paclitaxel. The eligibility criteria include having an ECOG performance status of 0-1, having at least one site of measurable disease that is amenable to biopsy, and having adequate hepatic, renal, and bone marrow function. Exclusion criteria include having received prior chemotherapy for this disease type, having brain metastases, and having any concomitant uncontrolled medical or psychiatric disorders. Patients must also agree not to use herbal remedies or other over-the-counter biologics. The trial involves a tissue biopsy at study entry and again at week 3.",
    "The sample is a phase 2 clinical trial for asthma. The eligibility criteria include being an outpatient, being at least 12 years old (or 18 years old if local regulations or the regulatory status of study medication permit enrollment of adults only), having a diagnosis of asthma as defined by the National Institutes of Health, having a best AM FEV1 of 50% to 80% of the predicted value during Visit 1, demonstrating 12% and 200mL reversibility of FEV1 within 30 minutes following 200 to 400mcg of albuterol/salbutamol inhalation aerosol, using an inhaled corticosteroid for at least 3 months prior to Visit 1 and being maintained on a stable dose for four weeks prior to Visit 1, being able to replace short-acting beta2-agonists with albuterol/salbutamol inhalation aerosol at Visit 1 for use as-needed for the duration of the study, being able to comply with all the study requirements, and giving written informed consent to take part in the study. The exclusion criteria include having a history of life-threatening asthma, using certain asthma medications prior to Visit 1 for the required interval listed, having a respiratory tract infection or asthma exacerbation within a certain time frame prior to Visit 1, using any investigational drug within 30 days prior to Visit 1 or within ten half-lives of the prior investigational study, having certain concurrent diseases/abnormalities, having evidence of oropharyngeal candidiasis at Visit 1, having any adverse reaction including immediate or delayed hypersensitivity to any beta2-agonist, sympathomimetic drug, or any intranasal, inhaled, or systemic corticosteroid therapy, having a history of severe milk protein allergy, using or requiring use of immunosuppressive medications during the study, having any infirmity, disability, or geographical location which seems likely to impair compliance with any aspect of this study protocol or scheduled visits to the study center and compliance with study medication or procedures, having neurological or psychiatric disease or history of drug or alcohol abuse which would interfere with the subject's proper completion of the protocol requirements, having used tobacco products within the past one year or having historical use of >10 pack years, and being an immediate family member of the participating investigator, sub-investigator, study coordinator, or employee of the participating investigator.",
    "The sample is a phase 2 clinical trial for non-Hodgkin's lymphoma. The trial involves the use of the drug \"intravenous t900607-sodium\" and has a list of eligibility criteria that includes having received prior chemotherapy for NHL, being at least 18 years old, having measurable disease amenable to CT scanning, and having a Karnofsky performance status of at least 70%. The trial also has exclusion criteria, such as having severe concurrent disease or having received any investigational agent within 4 weeks of enrollment. The sample includes the icd-10 codes for the disease and a list of inclusion and exclusion criteria.",
    "The sample is a phase 2 clinical trial that involves testing the effectiveness of the drug orlistat versus a placebo in treating obesity-related comorbidities such as diabetes mellitus, hypertension, metabolic disease, obesity, and sleep apnea syndrome. The trial includes participants between the ages of 12 and 17 who have a body mass index above the 95th percentile and evidence of a quantifiable obesity-related comorbidity. The eligibility criteria also include good general health, a negative pregnancy test for sexually active females, and a self-identified race of all four grandparents as either all Caucasian or all African American. The exclusion criteria include the presence of certain medical conditions, recent use of anorexiant medications, and physical impairments that would prevent completion of the tests. The trial also includes a control group of healthy children and adolescents who meet specific inclusion and exclusion criteria.",
    "The sample is a phase 2 clinical trial for the treatment of amyotrophic lateral sclerosis (ALS) using a drug called ONO-2506PO. The trial is open to adult male and female patients over the age of 18 who have previously completed the ONO-2506POE014 study. The eligibility criteria include no significant medical history or presence of certain diseases that may pose a risk to the patient. The trial also involves the use of another drug called Riluzole.",
    "The sample is a phase 2 clinical trial for ovarian cancer, fallopian tube cancer, and peritoneal cancer. The trial involves the use of two drugs, topotecan and bevacizumab. The eligibility criteria for the trial include having received primary taxane and platinum-based chemotherapy and no more than one other chemotherapy regimen, having platinum-resistant disease, having measurable disease or elevated CA-125 levels, and having a performance status greater than or equal to 70%. Exclusion criteria include prior treatment with anti-angiogenesis agents, treatment with more than two cytotoxic regimens, evidence of other malignancy within three years of study enrollment, history of abdominal fistula, grade 4 bowel obstruction or gastrointestinal perforation, history of intra-abdominal abscess within six months prior to day 0, and being pregnant or lactating. The icd-10 codes for the diseases are also provided.",
    "The sample is a phase 2 clinical trial for the treatment of ovarian cancer, fallopian tube cancer, or primary peritoneal cancer using a drug called ly573636-sodium. The trial is open to individuals who are at least 18 years old and have received at least one but no more than 2 systemic treatment regimens containing platinum, and have platinum-resistant disease. The trial has inclusion and exclusion criteria, which are listed in the \"criteria\" column of the table. The \"diseases\" column lists the names of the diseases being targeted in the trial, while the \"icdcodes\" column lists the corresponding ICD-10 codes.",
    "The sample is a record of a clinical trial in phase 2, which involves studying the effects of the drugs mirabegron and placebo on patients with lower urinary tract symptoms and bladder outlet obstruction. The trial has eligibility criteria for men aged 45 years or older with documented bladder outlet obstruction, and exclusion criteria for those with a history of urinary retention or symptomatic and recurrent urinary tract infection. The diseases are listed along with their corresponding ICD-10 codes.",
    "The sample is a phase 2 clinical trial for ovarian cancer. The trial includes patients with stage IIIB/IV ovarian cancer who have previously failed chemotherapy with paclitaxel/carboplatin regimen and have been treatment-free for more than 6 months. The trial requires patients to have measurable disease, a life expectancy of more than 3 months, and be at least 18 years old with a performance status of 0-2. Patients must also have adequate bone marrow, liver, and renal function. The trial excludes pregnant or nursing patients, those with psychiatric illness or social situations that would preclude study compliance, other concurrent uncontrolled illness, other invasive malignancy within the past 5 years except nonmelanoma skin cancer, and other concurrent investigational agents. The trial will test the efficacy of docetaxel, carboplatin, docetaxel, and liposomal doxorubicin as treatment options.",
    "The sample is a phase 2 clinical trial for patients with stage IV malignant melanoma that cannot be surgically cured. The trial is testing the effectiveness of the drug thalidomide. Patients must have measurable or evaluable disease and no brain metastases. They must have received only one prior systemic therapy for metastatic disease. Patients must also meet certain eligibility criteria related to age, performance status, life expectancy, hematopoietic, hepatic, renal, and other factors. Prior concurrent therapy is also restricted. The trial is investigating the safety and efficacy of thalidomide in treating stage IV malignant melanoma.",
    "The sample is a phase 2 clinical trial for patients with hormone refractory prostate cancer that has spread to other parts of the body. The trial is testing the effectiveness of a drug called radium-223 dichloride (bay88-8223). The eligibility criteria include having a confirmed diagnosis of adenocarcinoma of the prostate, evidence of rising PSA levels, and multifocal skeletal metastases confirmed by bone scintigraphy within the last 6 weeks. Patients must also have a performance status of ECOG 0-2 and a life expectancy of at least 6 months. The trial excludes patients who have received an investigational drug within 4 weeks prior to the administration of radium-223, or have received chemo-, immunotherapy, or external radiotherapy within the last 4 weeks prior to administration of study drug, among other exclusion criteria.",
    "The sample is a phase 2 clinical trial for patients with Philadelphia chromosome-positive chronic myelogenous leukemia (CML) in chronic or accelerated phase. The trial is testing the effectiveness of the drug bortezomib. Patients must have failed prior treatment with imatinib mesylate or be intolerant, unable, or unwilling to receive it. They must also be ineligible for higher-priority or higher-efficacy regimens or protocols. The eligibility criteria include specific disease characteristics, such as the presence of certain levels of blasts, promyelocytes, and basophils, as well as progressive splenomegaly and clonal evolution. Patients must also meet certain patient characteristics, such as being 18 years or older and having an Eastern Cooperative Oncology Group (ECOG) performance status of 0-2. Prior concurrent therapy is limited to no more than 2 prior cytotoxic regimens in addition to imatinib mesylate and/or hydroxyurea. The sample includes detailed information on the eligibility criteria for the trial, including disease characteristics, patient characteristics, and prior concurrent therapy.",
    "The sample is a phase 2 clinical trial for sickle cell disease and vaso-occlusive crisis. The trial is testing the effectiveness of the drugs GMI-1070 and placebo. The eligibility criteria for the trial include being between the ages of 12 and 60, having a confirmed diagnosis of sickle cell disease, and being diagnosed with vaso-occlusive crisis at the time of enrollment. Exclusion criteria include having an infection, acute chest syndrome, atypical SCD pain, recent major surgery or hospitalization, and active use of illicit drugs or alcohol dependence. The trial requires documented and observed written informed consent and assent where applicable.",
    "The sample is a phase 2 clinical trial for the treatment of ovarian cancer using the drug glufosfamide. The trial is looking for patients who have confirmed epithelial ovarian cancer, peritoneal serous cancer, or carcinoma of the fallopian tube and have previously been treated with at least one platinum-based chemotherapy. Patients must also show evidence of resistance to their most recent platinum-containing regimen and have evidence of CA 125 progression. The trial has a list of inclusion and exclusion criteria that patients must meet in order to participate.",
    "The sample is a phase 2 clinical trial for patients with locally advanced or metastatic breast cancer that is HER2-overexpressing. The trial is testing the effectiveness of the drugs trastuzumab and pf03512676. The eligibility criteria include having achieved partial response, complete response, or stable disease while on trastuzumab or other therapies, having a certain performance status, and meeting certain laboratory values. Patients must not have unstable brain metastases or ongoing infections, and must not have a history of certain medical conditions. Prior concurrent therapies are also listed.",
    "The sample is a phase 2 clinical trial for the treatment of ovarian neoplasms. The trial involves the use of two drugs, pazopanib and a placebo comparator. The eligibility criteria for the trial include being at least 18 years old, having a confirmed diagnosis of stage II-IV epithelial ovarian, fallopian tube or primary peritoneal carcinoma, having undergone surgical debulking and at least five cycles of platinum-taxane doublet chemotherapy, and having no evidence of disease progression. Other criteria include having an Eastern Cooperative Oncology Group (ECOG) performance status of less than or equal to 2, being able to swallow and retain oral medication, and having adequate hematologic, hepatic, and renal system function. The exclusion criteria include having bulky disease or any residual disease that will need imminent second-line therapy, having clinically significant gastrointestinal abnormalities, and having a history of certain cardiovascular conditions within the past 6 months prior to randomization.",
    "The sample is a phase 2 trial for squamous cell carcinoma of the head and neck cancer. The trial includes patients who are at least 18 years old and have a confirmed diagnosis of R/M SCCHN. Patients must have a history of progressing disease on a first-line cytotoxic chemotherapy regimen for R/M SCCHN, such as 5-fluorouracil (FU) plus cisplatin, or taxanes. Patients must also have at least one radiographically documented lesion measurable according to response evaluation criteria in solid tumors (RECIST) 1.0. The trial excludes patients with a history of exposure to cetuximab or panitumumab or any other approved or investigational anti-epidermal growth factor receptor (EGFR) agents, undifferentiated nasopharyngeal carcinoma, or active malignancy other than SCCHN, non-metastatic basal cell or squamous cell carcinoma of the skin, or second primary SCCHN. Patients must also meet certain eligibility criteria, such as having an Eastern cooperative oncology group performance status (ECOG PS) of 0 or 1, and recovered from previous toxicities of prior cytotoxic regimen to common terminology criteria of adverse events (CTCAE) Grade 1 (with the exception of alopecia).",
    "The sample is a phase 2 clinical trial for pancreatic cancer patients who have failed one prior gemcitabine-based regimen. The trial includes patients with inoperable or advanced pancreatic cancer that is measurable by the Response Evaluation Criteria in Solid Tumors (RECIST) criteria. Patients must be at least 18 years old with an ECOG performance status of 0 or 1. The trial excludes patients with local or locally advanced pancreatic cancer, previous adjuvant radiotherapy for pancreatic cancer, and more than six months since last adjuvant chemotherapy. Patients must have recovered from all treatment-related toxicity prior to enrollment and must have documented evidence of disease progression following prior chemotherapy. The trial also excludes patients with other primary tumors within the last 5 years, evidence of spinal cord compression or current evidence of central nervous system (CNS) metastases, and inability to take oral medication. Pregnant or lactating females are also excluded. Men and women of childbearing potential must use effective means of contraception. Patients must not have received current or recent treatment with another investigational drug or participated in another investigational study. Patients with known hypersensitivity to any of the study drugs are also excluded.",
    "The sample is a phase 2 clinical trial for the disease phenylketonuria. The trial is testing the drug Kuvan. The eligibility criteria for participants include being between the ages of 10-45, weighing at least 75 pounds, and meeting group-specific criteria. Exclusion criteria include smoking, history of cardiovascular disease, hepatic impairment, anemia, unwillingness to discontinue certain dietary supplements, taking medications that interfere with selected endpoints, currently pregnant or breastfeeding, having a chronic illness or disorder, having taken any investigational drug within 3 months prior to the study, and being deemed unfit for the study by the investigator.",
    "The sample is a phase 2 clinical trial for the treatment of seasonal allergic rhinitis and asthma. The trial includes patients between the ages of 18 and 65 who have a positive skin prick test to Dactylis glomerata and a TNSS of > 5 at least once during the 2h-baseline ECC exposure. Patients must also have a pre-bronchodilator FEV1 equal or greater than 80% of predicted value and a BMI between 18 and 35. Patients with significant pulmonary disease or other medical conditions that may put them at risk or influence the results of the study are excluded. Patients must also not have any other nasal and sinusoidal diseases or conditions that may influence the study results. The trial includes a list of drugs and placebos that will be used, and patients must be able to comply with the requirements and procedures of the study protocol. Women who are pregnant or nursing or women of childbearing potential not using a highly effective method of birth control are also excluded.",
    "The sample is a record of a clinical trial with a phase 2 designation. The trial is focused on the disease of multiple sclerosis, which is identified by its ICD-10 codes of \"G35\" and \"C81.18\". The trial involves two drugs, fty720 and placebo. The eligibility criteria for the trial include patients aged 18-60 with a diagnosis of multiple sclerosis, but exclude patients with chronic immune system diseases other than MS, a history of malignancy, pulmonary or heart disease, and pregnant or nursing women. There may be additional inclusion/exclusion criteria defined by the protocol.",
    "The sample is a phase 2 clinical trial for hypertension. The trial is looking for patients over the age of 18 who have hypertension that is not adequately controlled despite treatment with the maximum tolerated dose of three antihypertensive agents. The trial is specifically looking for patients whose current antihypertensive treatment includes a thiazide diuretic and at least one of a beta-blocker, angiotensin converting enzyme inhibitor or angiotensin II receptor antagonist. The trial is testing the effectiveness of spironolactone as an additional antihypertensive treatment. The trial has inclusion and exclusion criteria, including serum creatinine and potassium levels, blood pressure levels, and pregnancy status.",
    "The sample is a phase 2 clinical trial for patients with breast cancer and metastasis. The trial involves the use of two drugs, paclitaxel and capecitabine. The eligibility criteria include being a female patient over 18 years old with histologically proven breast adenocarcinoma, HER2 negative receptors, and having previously received first or second line chemotherapy for metastatic disease. Patients must also have previously been treated with anthracycline and/or docetaxel in adjuvant and/or as first or second line therapy, have one or several evaluable metastatic lesion(s), and have at least one target lesion not previously irradiated. Patients must have also been previously treated with hormonotherapy in adjuvant or in metastatic line, and have an ECOG Performance status of less than 2. The exclusion criteria include patients previously treated with paclitaxel or capecitabine for metastatic breast cancer, patients with only local metastatic disease (with the exception of axillary lymph nodes), and patients with an active symptomatic brain metastasis. Other exclusion criteria include patients with a history of significant cardiovascular impairment, peripheric neuropathy grade \u2265 2, history of another malignancy within past 5 years, and patients with any medical or psychiatric condition that would preclude them from participating in the study. Patients who may not be regularly available due to geographical, social or family reasons, and patients with a known allergy to one or several of the study compounds are also excluded. Additionally, patients with a history of renal, hepatic or metabolic pathology that could preclude with metabolism or elimination of the study product, deficiencies of the upper intestinal tract, malabsorption syndrome, patients who are pregnant, breast-feeding or using inadequate contraception are also excluded.",
    "The sample is a phase 2 clinical trial for the treatment of plaque psoriasis. The trial includes patients of both sexes who are at least 18 years old and have a clinical diagnosis of plaque psoriasis with a body surface area of at least 10% and a PASI score of at least 10. The trial requires patients to have stable psoriasis for at least 6 months prior to randomization and to provide signed informed consent. Female patients of childbearing potential must use a medically accepted contraceptive method during the trial and for one month after the trial is finished. Patients must be in good general health and willing to comply with the trial procedures. Exclusion criteria include pregnancy or breastfeeding, known allergy to the product being tested, pustular forms of psoriasis, and other serious or progressive diseases that may interfere with treatment outcome. Patients must not have used certain treatments for psoriasis within a certain timeframe prior to the baseline visit and must not have certain medical conditions or laboratory abnormalities. Patients who have participated in another clinical trial within a certain timeframe or who are involved in the organization of the clinical investigation are also excluded.",
    "The sample is a phase 2 clinical trial for patients with acute leukemia who are scheduled to receive induction chemotherapy. The trial is testing the effectiveness of doxycycline hyclate in treating mucositis, a condition that causes inflammation and sores in the mouth and throat. The eligibility criteria include being over 18 years old, having the capacity to give written informed consent, and being able to attend follow-up visits. Exclusion criteria include allergies or intolerance to tetracyclines, acute or chronic renal insufficiency, contraindication for oral administration of drugs, and active septic processes. Patients who have received less than 10 doses of the assigned treatment, require ergot derivates, or receive photosensitive drugs during the study period are also excluded.",
    "The sample is a phase 2 clinical trial for patients with type 2 diabetes mellitus and albuminuria. The trial involves the use of the drugs bosentan and placebo. The eligibility criteria for the trial include having diabetes mellitus type 2 for more than 2 years and having albuminuria. Exclusion criteria include age over 80, recent myocardial infarction or unstable angina, congestive heart failure, changes in dosage of vasodilator drugs, being a fertile woman, impaired hepatic function, ongoing treatment with certain drugs, having any concomitant disease or condition that may interfere with the study protocol, being a participant in another ongoing study, and unwillingness to participate after receiving oral and written information.",
    "The sample is a phase 2 clinical trial for the treatment of restless legs syndrome. The trial includes patients who meet specific inclusion criteria, such as experiencing an urge to move their legs accompanied by uncomfortable sensations, and having a PLM index of at least 5 per hour in the worst affected leg. Patients who have taken certain medications or dietary supplements within 14 days before drug administration, have diabetes mellitus requiring insulin therapy, or have other sleep disorders are excluded from the trial. The trial involves the use of pramipexole 0.125 mg tablets and a placebo, and patients will be monitored for RLS symptoms and severity.",
    "The sample is a clinical trial for a drug called melatonin, which is being tested on women between the ages of 30 and 75 with breast cancer who are undergoing surgery at Herlev Hospital. The trial is in phase 2/phase 3 and also includes patients with depression. The table includes a list of diseases and their corresponding ICD-10 codes, as well as a list of drugs being used in the trial. The eligibility criteria for the trial are listed, including age, ASA score, and absence of depression. The exclusion criteria are also listed, which include various medical conditions and previous or current cancer. The trial is also excluding patients who are pregnant or breastfeeding, have a low MMSE score, or are predicted to have poor compliance.",
    "The sample is a phase 2 clinical trial for patients with inoperable adenocarcinoma of the pancreas. The trial includes patients who are at least 18 years old and have confirmed histologic or cytologic diagnosis. The trial excludes patients who have received any chemotherapeutic treatment for pancreatic adenocarcinoma before enrollment, have undergone major surgery within 4 weeks prior to enrollment, or have major cardiovascular disease. The trial involves the use of multiple drugs, including gemcitabine alone and endotag-1 and gemcitabine, and aims to evaluate their effectiveness in treating adenocarcinoma, metastasis, and pancreas neoplasms. The diseases are identified by their names and ICD-10 codes.",
    "The sample is a phase 2 clinical trial for patients with relapsed or refractory acute myeloid leukemia or chronic myeloid leukemia in myeloid blast crisis who have failed at least one previous tyrosine kinase inhibitor. The trial involves the use of three drugs: ly2181308 sodium, cytarabine, and idarubicin. The eligibility criteria include having discontinued all previous cancer therapies for at least 21 days for myelosuppressive agents or 14 days for non-myelosuppressive agents, having adequate organ function, and being at least 18 years old. Exclusion criteria include having received treatment with an unapproved drug within the last 30 days, having acute promyelocytic leukemia, having serious pre-existing medical conditions, and being pregnant or breastfeeding.",
    "The sample is a record of a clinical trial with a phase 2 designation. The trial is focused on the disease epilepsy, with a list of associated ICD-10 codes provided. The drug being tested is brivaracetam. The eligibility criteria for the trial are listed, including a clinical diagnosis of epilepsy, recent seizure activity, and stable dosing of 1-3 concomitant antiepileptic drugs. The exclusion criteria are also listed, including pregnancy or nursing, concomitant use of Levetiracetam, and a history of suicide attempt, among others.",
    "The sample is a phase 2 clinical trial for the treatment of type 2 diabetes mellitus. The trial involves the drugs mb07803 and placebo. The eligibility criteria include having a fasting plasma glucose level between 120-270 mg/dL and HbA1c measurements between 6.0-10%. Female participants must be surgically sterile or postmenopausal, or use an approved double-barrier method of birth control. The BMI of participants should be between 18.5-37 kg/m2, or up to 40 kg/m2 on a case-by-case basis. Exclusion criteria include type 1 diabetes mellitus, a history of diabetic ketoacidosis or ketosis-prone, use of thiazolidinediones, currently on more than two oral hypoglycemic agents, history of outpatient insulin use, and clinically significant history of cardiac disease within 6 months of informed consent.",
    "The sample is a phase 2 clinical trial for patients with recurrent small-cell lung cancer (SCLC) or lung cancer, small cell. The trial involves the use of oral hycamtin (topotecan) capsules and IV avastin (bevacizumab) as treatment. The eligibility criteria for the trial include a confirmed diagnosis of SCLC, first recurrence of SCLC after therapy with one prior chemotherapy regimen at initial diagnosis, ECOG performance status of </= 2, and adequate bone marrow reserve, hepatic, renal, and cardiovascular function. The exclusion criteria include uncontrolled emesis, active uncontrolled infection, GI conditions or drugs that could impact absorption of oral topotecan, and known hypersensitivity to any component of topotecan capsule or compounds chemically related to topotecan. The trial also excludes patients with a history of myocardial infarction, stroke, or TIA within 6 months, and those with concurrent chemotherapy, immunotherapy, or investigational therapy for the treatment of small cell lung cancer.",
    "The sample is a phase 2 clinical trial for patients with recurrent mantle cell lymphoma. The trial is testing the effectiveness of the drugs bortezomib and lenalidomide. The eligibility criteria include having a confirmed diagnosis of mantle cell lymphoma, having received prior therapy with at least one regimen, and having progressive or refractory disease. Patients must also meet certain medical criteria, such as having an Eastern Cooperative Oncology Group (ECOG) performance status of 0-2 and no known central nervous system involvement by lymphoma. Additionally, female patients of childbearing potential must have a negative pregnancy test and agree to use two forms of birth control. The trial is designed to evaluate the safety and efficacy of the drugs in this patient population.",
    "The sample is a phase 2 clinical trial for breast cancer patients with hormone receptor-positive tumors. The trial includes patients with stage I-III breast cancer, who have been diagnosed by core needle biopsy and have undergone sentinel lymph node biopsy. Patients must be postmenopausal or have had bilateral oophorectomy, and meet certain criteria for serum creatinine, bilirubin, potassium, calcium, magnesium, and liver function. They must also have an ECOG Performance Status of 0, 1, or 2, and a measurable disease. Patients with inflammatory breast cancer, metastatic breast cancer, inoperable disease, HER2-overexpressed breast cancer, prior chemotherapy or radiotherapy for the current breast cancer, prior hormonal therapy for the current breast cancer, prior surgical biopsy, lumpectomy, or mastectomy for the current breast cancer, or any concurrent condition that would jeopardize compliance with the protocol are excluded. Patients with clinically significant cardiac events, history of arrhythmia, previous history of QTc prolongation, congenital long QT syndrome, presence of left bundle branch block, or use of any concomitant medication that may cause QTc prolongation are also excluded. Patients with hypertension not controlled by medical therapy, previous or current malignancies of other histologies within the last 5 years (with the exception of cervical carcinoma in situ and adequately treated basal cell or squamous cell carcinoma of the skin), major surgery within 4 weeks, or receipt of any investigational agents within 30 days prior to commencing study treatment are also excluded.",
    "The sample is a record of a clinical trial with a phase 2 designation. The trial is focused on breast neoplasms, which are listed in the \"diseases\" field. The \"icdcodes\" field contains a list of ICD-10 codes associated with the disease. The trial is testing the effectiveness of three drugs - gemcitabine, paclitaxel, and docetaxel - which are listed in the \"drugs\" field. The \"criteria\" field contains the eligibility criteria for the trial, including inclusion and exclusion criteria. In this particular sample, the inclusion criteria include having advanced or metastatic breast cancer that can be measured by a physician or radiologic test, having had one chemotherapy treatment for advanced or metastatic disease, and having received any prior adjuvant chemotherapy at least 6 months prior to enrollment. The exclusion criteria include having only non-measurable disease, cancer that has spread to the brain, having received a taxane with metastatic disease, being pregnant, and having received prior gemcitabine.",
    "The sample is a record of a clinical trial with a phase 2 designation. The trial is focused on breast cancer and metastatic bone disease. The icd-10 codes associated with the diseases are listed. The trial involves the use of drugs including za, odanacatib, odanacatib matching placebo, and za matching placebo. The eligibility criteria for the trial are also listed, including inclusion criteria such as histologically or cytologically-confirmed breast cancer and documented skeletal metastases, and exclusion criteria such as current oral bisphosphonate therapy or a history of oral bisphosphonate use within 6 months of entry into the study.",
    "The sample is a phase 2 clinical trial for the treatment of psoriasis. The trial involves the use of an anti-IL-12 monoclonal antibody called abt-874 and a placebo. The trial is looking for participants who are 18 years or older, in good health, and have been diagnosed with psoriasis for at least 6 months with moderate to severe plaque psoriasis. Participants cannot have previously received systemic or biologic anti-IL-12 therapy, cannot be taking or require oral or injectable corticosteroids, and cannot be pregnant or breastfeeding. The trial has specific inclusion and exclusion criteria that must be met for participation.",
    "The sample is a phase 2 clinical trial for patients with non-small cell lung cancer that is in a resectable stage of IB-IIIA disease. The trial is testing the effectiveness of the drugs carboplatin and docetaxel. The eligibility criteria for patients include having confirmed non-small cell lung cancer, no CNS or brain metastases, and an ECOG performance status of 0-1. Patients must also meet certain medical criteria, such as having adequate pulmonary and cardiovascular function to tolerate surgical resection, and not having any serious systemic diseases or medical conditions. Patients cannot have had prior chemotherapy or VEGF inhibitor treatment, and cannot be participating in another experimental drug study. The trial is sponsored by Genentech and patients cannot be on concurrent full-dose anticoagulation or other concurrent chemotherapy, immunotherapy, radiotherapy, or investigational therapy for this cancer.",
    "This sample is a phase 2 clinical trial for patients with follicular lymphoma. The trial is testing the effectiveness of a combination of drugs including bortezomib, rituximab, fludarabine, mitoxantrone, and dexamethasone. The eligibility criteria for the trial include a diagnosis of grade 1-3 follicular lymphoma with persistent, relapsed, or refractory disease to at least one prior regimen, no prior bortezomib therapy, and various other medical and demographic requirements. The trial also has exclusion criteria, such as platelet count of less than 50,000 and absolute neutrophil count of less than 1000 within 14 days before enrollment, and serious medical or psychiatric illness likely to interfere with participation in the study.",
    "This sample is for a phase 2 clinical trial for macular degeneration. The trial is testing two different doses of a drug called brimonidine tartrate implant. The eligibility criteria for the trial include having geographic atrophy in both eyes due to age-related macular degeneration and having a visual acuity between 20/40 to 20/320. Exclusion criteria include having a known allergy to brimonidine, uncontrolled systemic disease or infection of the eye, recent eye surgery or injections in the eye, and being a female patient who is pregnant, nursing, or planning a pregnancy.",
    "The sample is a phase 2 clinical trial for Alzheimer's disease. The eligibility criteria include having a stable dose of an AChEI for at least 90 days prior to screening, having a Mini-Mental Status Examination (MMSE) total score of 12 to 24, and having a Cornell Scale for Depression in Dementia (CSDD) score \u2264 10 at screening. The trial also requires an identified, reliable caregiver to provide support and ensure compliance with the study medication and procedures. Exclusion criteria include having taken galantamine or memantine within 60 days prior to screening, having clinically significant abnormal laboratory values, and having a history of any significant neurologic disease other than Alzheimer's disease.",
    "The sample is a phase 2 clinical trial for patients with gastric or gastroesophageal junction adenocarcinoma. The trial is testing the effectiveness of the drug sunitinib in treating the disease. The eligibility criteria for the trial include having documented disease progression or recurrence after treatment with one prior chemotherapy regimen, evidence of measurable disease by radiographic technique, and adequate organ function. Exclusion criteria include clinically relevant ascites, severe weight loss, and a diagnosis of a second malignancy within the last 3 years. Patients with a history of brain metastases, spinal cord compression, or carcinomatous meningitis are also excluded. Additionally, patients who are currently on another clinical trial, pregnant, or breastfeeding are not eligible for the trial.",
    "The sample is a phase 2 trial for the treatment of acquired bleeding disorder and trauma. The trial involves the use of activated recombinant human factor vii and a placebo. The eligibility criteria for the trial include informed consent, injury due to blunt or penetrating trauma, receipt of 6 units of PRBC within 4 hours of admittance to the trauma center, and receipt of 8 units of PRBC upon administration of the trial drug. The exclusion criteria include prehospital cardiac arrest, cardiac arrest in the ER or OR, gunshot wound to the head, Glasgow Coma Scale below 8, base deficit of above 15 mEq/l or severe acidosis, and transfusion of 8 units or more of PRBC prior to arrival in the trauma center. The diseases involved in the trial are acquired bleeding disorder and trauma, and the icd-10 codes associated with these diseases are listed.",
    "The sample is a phase 2 clinical trial for bladder cancer and urinary bladder diseases. The trial involves the use of the drug combination gemcitabine and cisplatin plus sorafenib. The eligibility criteria for the trial include having measurable or evaluable urothelial cancer, confirmation of the disease by the Department of Pathology at MSKCC, a Karnofsky Performance Status (KPS) of at least 60%, adequate marrow function, serum creatinine levels below 2.0 mg/dl, and normal liver function. Patients must also be at least 18 years old, provide informed consent, and have a negative pregnancy test if they are women of childbearing potential. Exclusion criteria include prior treatment with systemic chemotherapy, participation in an experimental drug study within four weeks of the trial, and evidence of another active cancer.",
    "This sample is for a phase 2 clinical trial for chronic lymphocytic leukemia. The trial is testing the effectiveness of maintenance lenalidomide as a treatment option. The eligibility criteria for participants include having previously undergone induction treatment with bendamustine and rituximab, being 18 years or older, having an ECOG performance status of 2 or less, and having an absolute neutrophile count of more than 1,000 and a platelet count of more than 70,000. Exclusion criteria include having a serious medical condition that would prevent treatment with lenalidomide, evidence of tumor lysis syndrome, and any prior treatment with lenalidomide.",
    "The sample is a record of a clinical trial for the treatment of moderate to severe ulcerative colitis. The trial is in phase 2 and involves the use of two drugs, placebo and rhumab beta7. The eligibility criteria for the trial are listed, including the requirement of a diagnosis of moderate to severe ulcerative colitis and a disease duration of at least 12 weeks. Exclusion criteria are also listed, such as the presence of an ileostomy or colostomy, significant uncontrolled co-morbidities, and previous exposure to rhuMAb Beta7. The diseases are listed as 'ulcerative colitis' and the icd-10 codes associated with the disease are also provided.",
    "The sample is a phase 2 clinical trial for patients with refractory/relapsed indolent lymphomas, including extranodal marginal lymphoma of MALT type, nodal marginal zone B-cell lymphoma, and splenic marginal B-cell lymphoma. The trial involves the use of three drugs: zevalin, rituximab, and ^111 in ibritumomab tiuxetan. The eligibility criteria include no anti-cancer therapy for three weeks (six weeks if Rituximab, nitrosourea or Mitomycin C) prior to study initiation, previously treated patients with the specified histology, signed informed consent, age >/= 18 years, expected survival >/= 3 months, acceptable hematologic status, and more. The exclusion criteria include prior myeloablative therapies with autologous bone marrow transplantation, presence of hypocellular bone marrow, prior radioimmunotherapy, presence of Central Nervous System lymphoma, and more.",
    "The sample is a phase 2 clinical trial for patients with stage IIIB or IV non-small cell lung cancer who have failed first-line chemotherapy. The trial is testing the effectiveness of the drugs gemcitabine hydrochloride and oxaliplatin. Patients must meet certain eligibility criteria, including having at least one measurable lesion and an ECOG performance status of 0 or 1. They must also have no symptomatic brain metastases and meet certain medical and psychiatric requirements. Patients must have recovered from prior surgery and not have participated in another investigational drug study within the past 4 weeks. Concurrent immunotherapy is not allowed. The sample includes detailed disease and patient characteristics, as well as prior concurrent therapy information.",
    "The sample is a phase 2 clinical trial for the treatment of metastatic colorectal cancer or loco-regional recurrence or unresectable disease. The trial involves the use of 5-fluorouracil, leucovorin, oxaliplatin, and avastin drugs. The eligibility criteria include having histological proof of adenocarcinoma in primary colon or rectum tumor, being between the ages of 18 to 86 years, having at least one bi-dimensionally measurable disease with at least one diameter > or = 2 cm, and having a WHO/ECOG performance status < 3 (0, 1, or 2). Prior treatment with oxaliplatin, 5-FU, or leucovorin is permitted. The exclusion criteria include having peripheral sensory neuropathy > or = grade 3, serum bilirubin (total) > 3 X ULN, symptomatic or uncontrolled brain metastasis, metastases limited to bone, pleural effusion, or ascites, uncontrolled overt cardiac disease, uncontrolled hypercalcemia, uncontrolled infections, uncontrolled hypertension (>180/110), history of GI perforation, history of arterial thromboembolic events, history of congestive heart failure, taking warfarin (Coumadin), and being pregnant.",
    "The sample is a phase 2 clinical trial for patients with metastatic colorectal cancer. The trial involves the use of two drugs, lapatinib and capecitabine. The eligibility criteria include being over 18 years old, having confirmed locally advanced or metastatic adenocarcinoma of the colon or rectum, having had progression of disease on prior therapy with an oxaliplatin-containing or irinotecan-containing regimen, having proper radiographic documentation of measurable disease using RECIST criteria, having an ECOG performance status of 0 or 1, and meeting certain laboratory parameters. Exclusion criteria include having had more than one prior systemic chemotherapy for metastatic disease, being pregnant or breastfeeding, having active inflammatory bowel disease, significant bowel obstruction, or chronic diarrhea, having known HIV positivity or AIDS-related illness, having previous or concurrent malignancy except for certain types, having known CNS metastases, having prior therapy which specifically and directly targets the EGFR pathway, and having a significant history of uncontrolled cardiovascular disease.",
    "The sample is a record of a clinical trial with a phase 2 designation. The trial is focused on prostate cancer and includes a list of icd-10 codes associated with the disease. The trial involves the use of three drugs: zd6474 (vandetanib), bicalutamide, and placebo. The eligibility criteria for the trial are listed, including requirements for a confirmed diagnosis of adenocarcinoma of the prostate with evidence of metastases, and a rise in PSA. The exclusion criteria are also listed, including restrictions on recent anti-cancer therapy and certain cardiovascular conditions.",
    "The sample is a record of a clinical trial with a phase 2/phase 3 designation. The trial is focused on the disease of asthma and includes a list of ICD-10 codes associated with the disease. The drug being tested is indacaterol maleate. The eligibility criteria for the trial includes individuals between the ages of 12 and 75 with a diagnosis of persistent asthma who are currently being treated with a bronchodilator and a daily dose of at least 100 \u00b5g beclomethasone dipropionate or equivalent. The FEV1 (forced expiratory volume in one second) at Visit 1 must be at least 50% of the predicted normal value and the FEV1 reversibility must be at least 15%. Exclusion criteria include recent tobacco use, chronic obstructive pulmonary disease (COPD), seasonal allergies likely to worsen asthma during the study period, recent emergency room treatment or hospitalization for asthma, and recent respiratory tract infection. Other exclusion criteria may also apply.",
    "The sample is a phase 2 clinical trial for asthma. The trial is looking for male or female adults with mild to moderate persistent asthma, between the ages of 18 and 45. The trial requires participants to have a documented diagnosis of asthma at least 3 months prior to the start of the trial, and to be able to withhold short-acting bronchodilators for at least 4 hours prior to clinic visits. Participants must also have a baseline FEV1 greater than or equal to 50% of predicted normal. The trial excludes participants with any other significant illness or abnormality, a history of upper or lower respiratory tract infection within 2 weeks, or a history of acute or severe asthma attack requiring ICU admission or ventilatory support. The trial will test the effectiveness of several drugs, including map0010 low dose, map0010 high dose, budesonide inhalation suspension 0.25mg, and budesonide inhalation suspension 0.5mg.",
    "The sample is a phase 2 trial for smoking and smoking cessation. The trial includes participants who smoke more than 5 cigarettes per day and have a BMI within the range of 19-35 kg/m^2. Female participants of childbearing potential must be practicing a reliable method of contraception. The trial involves the use of nicotine lower dose, nicotine higher dose, and placebo drugs. The eligibility criteria include exclusion of pregnant women, participants with known or suspected intolerance or hypersensitivity to the study materials, and those who have participated in another clinical study or received an investigational drug within 30 days of the screening visit. Additionally, participants with recent history or current history of alcohol or other substance abuse are excluded.",
    "The sample is a record from a clinical trial table that includes information about the trial phase, diseases being studied, corresponding ICD-10 codes, drugs being tested, and eligibility criteria for participants. In this particular sample, the trial is in phase 2 and is focused on primary biliary cirrhosis. The ICD-10 code associated with this disease is K74.3. The trial is testing the effectiveness of several drugs, including ustekinumab and a placebo. The eligibility criteria for participants include having a proven or likely diagnosis of primary biliary cirrhosis, being on a stable dose of ursodeoxycholic acid for at least 6 months prior to the trial, having a screening alkaline phosphatase level above a certain threshold, and meeting other protocol-specified limits. There are also exclusion criteria, such as having a history of gastrointestinal bleeding or testing positive for surface antigen.",
    "The sample is a phase 2 clinical trial for patients with ovarian cancer or primary peritoneal carcinoma. The trial is testing the effectiveness of the drugs lapatinib and topotecan. Patients must have had debulking surgery and must have platinum-refractory and/or -resistant disease after first-line chemotherapy. They must also meet certain patient characteristics, such as having an ECOG performance status of 0-2 and no uncontrolled infection. Prior concurrent therapy is also taken into consideration, with certain medications and treatments being excluded. The eligibility criteria are quite extensive and include various medical tests and measurements.",
    "The sample is a phase 2 clinical trial for patients with non-small cell lung cancer or lung cancer, non-small cell. The trial involves the drug pazopanib and requires patients to meet certain eligibility criteria, such as being at least 21 years old with a life expectancy of at least 12 weeks, having a performance status of 0 or 1, and having a single measurable lesion that is scheduled for surgical resection. The trial also has exclusion criteria, such as having active malignancy or any unresolved or unstable serious toxicity from prior administration of another investigational drug. Patients must provide signed, written informed consent and be willing to comply with treatment and follow-up.",
    "The sample is a phase 2 clinical trial that involves patients with various diseases such as cardiac surgery, coronary artery bypass, aortic aneurysm, valve surgery, and kidney diseases. The trial aims to test the effectiveness of a drug called AP214 compared to a placebo. The eligibility criteria for the trial include patients who are at least 18 years old, not of childbearing potential, and undergoing specific types of surgeries or have stage III chronic kidney disease. The exclusion criteria include patients with certain medical conditions, history of organ transplant or cancer, and those who are currently abusing alcohol or substances. The trial requires patients to sign a trial-specific informed consent form and meet all the inclusion criteria while not meeting any of the exclusion criteria.",
    "The sample is for a phase 2 clinical trial for castrate-resistant metastatic prostate cancer. The trial includes patients who are at least 75 years old and have progressive disease despite previous therapy with docetaxel. Patients must meet certain eligibility criteria, including having a performance status of 0-1, ongoing androgen deprivation, and normal laboratory values. Patients must also have a life expectancy of at least 6 months and cannot have participated in an investigational trial within 30 days of starting treatment with cabazitaxel. The trial excludes patients with a history of severe hypersensitivity reaction to docetaxel, uncontrolled severe illness or medical condition, or clinically significant cardiac disease within 6 months. Patients with unresolved toxicities from previous chemotherapy or major surgery within 2 weeks prior to the start of the study are also excluded.",
    "The sample is a record from a clinical trial database and contains information about a completed trial. The trial was a phase 2 trial and focused on HIV infection. The trial tested the effectiveness of two drugs, tenofovir disoproxil fumarate and placebo. The eligibility criteria for the trial included being a healthy biologic male between the ages of 18-60, having a negative HIV-1 test, and meeting certain health requirements. The sample also includes a list of diseases and their corresponding ICD-10 codes, as well as the SMILES notation for the drugs. The criteria for inclusion and exclusion in the trial are also listed.",
    "The sample is a phase 2 clinical trial for the treatment of inflammation and Crohn's disease. The trial involves the use of the drugs naltrexone-hcl and placebo. The eligibility criteria for the trial include having endoscopic, histologic, or radiographic confirmed Crohn's Disease, a Crohn's Disease Activity Index (CDAI) of at least 220 at baseline, and stable doses of medications for Crohn's disease over the preceding 4-12 weeks. Exclusion criteria include having ostomies or ileorectal anastomosis from prior surgical colectomy, receiving infliximab or humira within a certain timeframe, requiring high doses of steroids, having short-bowel syndrome, abnormal liver enzymes, or a history of cancer in the past 5 years. Women of childbearing potential must use adequate contraception during the trial and for 3 months after completion.",
    "The sample is a phase 2 clinical trial for patients with metastatic breast cancer. The trial involves the use of three drugs: bevacizumab, sunitinib, and paclitaxel. The eligibility criteria for the trial include having a confirmed diagnosis of adenocarcinoma of the breast with locally recurrent or metastatic disease, being at least 18 years old, having adequate left ventricular function, and having an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. Exclusion criteria include having unknown or known HER2-positive status, having received prior chemotherapy for locally recurrent or metastatic disease, and having a life expectancy of less than 12 weeks. The trial also has a list of other exclusion criteria related to medical history, organ function, and other factors.",
    "The sample is a phase 2 clinical trial for patients with non-small cell lung cancer or metastatic cancer. The trial is testing the effectiveness of the drug pemetrexed disodium. The eligibility criteria include having evidence of brain metastases, recovered from prior surgery, and not having received certain types of treatments within a certain timeframe. Inclusion criteria include having a certain performance status, life expectancy, and blood counts. Exclusion criteria include having certain medical conditions or being pregnant/nursing.",
    "The sample is a phase 2 clinical trial for patients under 65 years old with various hematologic malignancies who require stem cell transplants but do not have a matched sibling donor. The trial includes patients with acute myelogenous leukemia, acute lymphocytic leukemia, chronic lymphocytic leukemia, chronic myelogenous leukemia, Hodgkin's disease, non-Hodgkin's lymphoma, aplastic anemia, multiple myeloma, and myelodysplastic syndrome. The trial involves the use of drugs such as busulfan, clofarabine, fludarabine, melphalan, carmustine, etoposide, and cytarabine. The eligibility criteria include having 6/6, 5/6, or 4/6 molecular matches from unrelated UCB donors, being HIV negative, and being able to give written consent. Patients who do not meet all of the inclusion criteria are excluded from the trial.",
    "The sample is a phase 2 clinical trial for smoking dependence and smoking. The trial includes two drugs, oral nicotine and placebo, and lists the icd-10 codes for the diseases being studied. The eligibility criteria for the trial includes being a current cigarette smoker who smokes more than 20 cigarettes per day for at least a year and being in good general health with no significant medical history abnormalities. The exclusion criteria includes any disease that may interfere with the study product and any medical condition that may jeopardize the safety of the subject or the validity of the study results.",
    "The sample is a phase 2 clinical trial for bipolar disorder. The trial includes patients who meet the criteria for bipolar disorder I or II as defined in DSM-IV-TR based on clinical assessment and confirmed by structured diagnostic interview (SCID-P). Patients must also be symptomatic on the Hamilton Depression Scale and the Young Mania Rating Scale, and free of medications or herbal/nutritional supplements with primarily central nervous system activity. The trial involves the use of the drug mcn36 (nutritional supplement) and a placebo. The eligibility criteria include various inclusion and exclusion criteria, such as no current or lifetime diagnosis of certain disorders, no alcohol or substance abuse in the previous six months, and no current use of any other medication or herbal/nutritional supplement with primarily central nervous system activity. Women who are pregnant or breastfeeding, or women of childbearing potential who are not using a medically accepted means of contraception when engaging in sexual intercourse are also excluded from the trial.",
    "The sample is a record from a clinical trial table that includes information about the trial's phase, diseases being studied, icd-10 codes of the diseases, drugs being tested, and eligibility criteria for participants. In this particular sample, the trial is in phase 2 and is studying prostate cancer. The icd-10 codes associated with the disease are listed, as well as the drugs being tested (abr-215050, tasquinimod, and placebo). The eligibility criteria for participants are also listed, including requirements such as a confirmed diagnosis of adenocarcinoma of the prostate, evidence of metastatic disease, and castrate levels of serum testosterone. The sample also includes exclusion criteria, such as prior cytotoxic chemotherapy within 3 years and known brain metastases.",
    "The sample is a phase 2 trial for patients with relapsed or refractory T-cell non-Hodgkin's lymphoma. The trial involves the use of two drugs, vorinostat and bortezomib. Patients must have had at least one prior systemic regimen and have measurable disease. They must also meet certain eligibility criteria, including having adequate bone marrow, liver, and renal function, and using effective contraception. Patients with certain medical conditions or taking certain medications are excluded from the trial. The trial also has exclusion criteria for patients with certain psychiatric or social situations that may limit compliance with the study medication and requirements.",
    "The sample is a phase 2 clinical trial for asthma. The trial is looking for male or female participants between the ages of 18 and 65 who have had symptoms of asthma for at least 2 years. Participants must have evidence of bronchial hyper-responsiveness or a documented hospital admission for asthma since the age of 18. They must also have had at least one asthma exacerbation suspected to have been caused by a respiratory virus in the last 24 months which required the use of oral steroids and/or additional treatment with antibiotics on one or more occasion. Participants must be taking regular inhaled corticosteroids and have a pre-bronchodilator FEV1 of at least 40% predicted at screening. They must also provide written informed consent and be motivated to complete all study visits. Females of childbearing potential must be using a medically acceptable adequate form of birth control and agree to maintain this usage throughout the duration of and four weeks post the Treatment Phase of the study.",
    "This sample is a record of a clinical trial with a phase 2 designation, focused on the treatment of metastatic breast cancer. The trial involves the use of drugs such as etoposide, ifosfamide, and topotecan hydrochloride. The eligibility criteria for participants include having confirmed metastatic breast cancer that has shown at least a partial response to a previous treatment regimen, with no more than three organs involved with metastatic disease. Participants must also meet certain age, sex, and health status requirements, and cannot have certain medical conditions or be pregnant or nursing. The trial excludes patients who have had more than two prior salvage regimens for metastatic disease or have previously received topotecan.",
    "The sample is a phase 2 clinical trial for the treatment of recurrent adult acute lymphoblastic leukemia. The trial includes patients who have failed to achieve complete remission with one prior regimen or are in their first relapse. The trial also allows patients with prior central nervous system leukemia, provided their cerebrospinal fluid is normal. Patients must have an ECOG performance status of 0-3, normal bilirubin and creatinine levels, and must test negative for HIV and pregnancy. Fertile patients must use effective contraception. Exclusion criteria include hepatitis B positivity, bacterial or fungal infection, active cytomegalovirus infection, known hypersensitivity to alemtuzumab or its components, and other malignancies within the past 5 years except for adequately treated basal cell skin cancer or cervical carcinoma. The trial will use a combination of drugs including asparaginase, methotrexate, dexamethasone, leucovorin calcium, mercaptopurine, and vincristine.",
    "The sample is a phase 2 clinical trial for patients with certain types of lung cancer. The trial is testing the effectiveness of the drug bortezomib. The eligibility criteria for the trial include having confirmed bronchoalveolar carcinoma or adenocarcinoma of the lung with BAC features, measurable disease, and a performance status of ECOG 0-2. Patients must also meet certain health requirements, such as having normal liver and kidney function, and not having any other uncontrolled illnesses. The trial excludes patients who have had prior bortezomib treatment or who are currently receiving other anticancer therapy.",
    "The sample is a record of a clinical trial with a phase 2 designation. The trial is focused on the treatment of non-small cell lung cancer using the drug combination of erlotinib and digoxin. The eligibility criteria for the trial include a diagnosis of non-small cell lung cancer, measurable or evaluable disease, and a primary tumor documented by histopathological analysis. Other criteria include having received only one prior chemotherapy regimen for advanced disease, a Zubrod performance status of 0-3, and normal levels of serum creatinine and CT scan results. Exclusion criteria include pregnancy or nursing, a history of certain cardiac conditions, hypersensitivity to the drugs being used, and abnormal levels of certain electrolytes.",
    "The sample is a phase 2 clinical trial for HER2-positive breast cancer patients with metastatic breast cancer who have progressed on trastuzumab-based therapy. The trial involves the use of pertuzumab and trastuzumab drugs. The eligibility criteria include being a female aged 18 or older, having received no more than three chemotherapy regimens prior to study entry, and having a left ventricular ejection fraction of at least 55%. Exclusion criteria include previous treatment with an anti-cancer vaccine or any targeted therapy other than trastuzumab, brain metastases, history of any cardiac adverse event related to trastuzumab therapy, and any other malignancy in the last 5 years, except for basal cell cancer or cancer in situ of the cervix. The diseases involved in the trial are limited to breast cancer, and the icd-10 codes associated with the disease are provided.",
    "The sample is a phase 2 clinical trial for patients diagnosed with chronic hepatitis C who have not responded to previous treatments. The trial involves the use of three drugs: debio 025, peg-ifn\u03b12a, and ribavirin. The eligibility criteria include being between 18 and 60 years old, having adequate liver function, and not having hepatitis B or HIV. Female participants must be surgically sterile, post-menopausal, or using two reliable contraceptive methods, and must have a negative pregnancy test. Exclusion criteria include recent use of antiviral medication, known intolerance to the drugs being used, and presence of any severe related disease.",
    "The sample is a phase 2 clinical trial for the treatment of bacterial pneumonia. The trial is open to male and female subjects who are 18 years or older and have been diagnosed with acute hospital-acquired pneumonia (HAP) or ventilator-associated pneumonia (VAP). The inclusion criteria include the presence of a new or evolving infiltrate on a chest x-ray, fever or leukocytosis, respiratory failure requiring mechanical ventilation, or other clinical signs and symptoms. The exclusion criteria include subjects with underlying conditions that would make it difficult to evaluate or complete the therapy, infection with resistant organisms, or contraindications or hypersensitivity to any of the test articles. The trial will test the efficacy of tigecycline and imipenem/cilastatin as treatments for bacterial pneumonia.",
    "The sample is a record of a clinical trial in phase 2, focused on the disease of knee replacement surgery. The trial includes a list of ICD-10 codes related to the disease, as well as a list of drugs being tested. The eligibility criteria for the trial are also listed, including inclusion criteria such as being scheduled for elective primary knee arthroplasty and having given written informed consent, and exclusion criteria such as having a documented history of previous VTE, being at increased risk of VTE, having active bleeding or any condition associated with increased risk of bleeding, and planning to have surgery on the contralateral knee at the same time or within 6 weeks after enrollment into the study.",
    "The sample is a phase 2 clinical trial for patients with chronic obstructive pulmonary disease (COPD) and pulmonary hypertension. The trial involves the use of the drug iloprost and a placebo. The eligibility criteria include being between 40 and 75 years old, having a clinical diagnosis of moderate to severe COPD, being a current or past smoker of at least 10 pack years, and having confirmed pulmonary hypertension by right heart catheterization. Exclusion criteria include having other causes of pulmonary hypertension besides COPD, having a BMI over 35 kg/m2, being pregnant or nursing, and having known hypersensitivity to iloprost or any of the excipients of the drug formulations.",
    "The sample is a phase 2 clinical trial for patients with aggressive B-cell non-Hodgkin's lymphoma, including diffuse large cell NHL, Burkitt's or Burkitt-like NHL, and primary mediastinal NHL. The patients must have relapsed or refractory disease and bidimensionally measurable disease. They must not be eligible for stem cell transplantation and have no active CNS involvement by lymphoma. The trial drug is belinostat. The eligibility criteria include various medical conditions, such as Zubrod performance status, absolute neutrophil count, platelet count, WBC, creatinine, EKG abnormalities, bilirubin, SGOT/SGPT, and cardiovascular disease. Patients must not have had major surgery within 28 days prior to study entry and must not be taking concurrent combination antiretroviral therapy for HIV-positive patients or medication that may cause Torsades de Pointes. They must not have clinical evidence of severe peripheral vascular disease, diabetic ulcers or venous stasis ulcers, or history of deep venous or arterial thrombosis within the past 3 months. Patients must not have known AIDS or HIV-associated complex, and must not be pregnant or nursing. Fertile patients must use effective contraception. They must not have had any other malignancy within the past 5 years except adequately treated basal cell or squamous cell skin cancer or in situ carcinoma of the cervix. Patients must have had no more than 5 prior chemotherapy regimens and at least 2 weeks since prior therapy and recovered.",
    "The sample is a record of a clinical trial with a phase 2 designation. The trial is focused on prostate cancer and the patients must have received primary definitive local therapy to the prostate, as well as being surgically or pharmacologically castrated at least 6 months prior to starting the study. The trial also requires patients to have had a previous trial of anti-androgen therapy and a rising PSA, with no evidence of distant metastatic disease. The patients must have an ECOG performance status of less than 2, be over 18 years of age, and have normal hepatic function. The trial has exclusion criteria, including patients with a history of any previous cytotoxic therapy or radionuclide therapy, patients receiving renal dialysis, and patients with significant pulmonary disease who have received chronic or pulse steroid therapy within the last 3 months prior to randomization. Patients who have known hypersensitivity to any of the AndroGel ingredients, including testosterone that is chemically synthesized from soy, are also excluded.",
    "The sample is a phase 2 clinical trial for rectal cancer. The trial is testing the effectiveness of the drugs capecitabine and bevacizumab. The eligibility criteria for participants include being between the ages of 18 and 80, having bioptically confirmed adenocarcinoma of the rectum in T3NxM0 status, and having no former chemotherapy, radiotherapy of pelvis or abdomen, and/or tumor resection of rectum carcinoma. Participants must also have a WHO performance status of 0-2, adequate bone marrow reserve, adequate hepatic function, adequate renal function, and the ability to intake pills. Women of childbearing potential must have a negative pregnancy test and be willing to use approved contraceptives during and at least 3 months after the study. Exclusion criteria include failure of one inclusion criteria, former radiotherapy of pelvis or abdomen, former chemotherapy, any other kind of malign tumor in the last 5 years, and any other kind of tumour in the last 5 years with exception of basal cell carcinoma of skin and cervix carcinoma in situ. Participants must also not have general contraindication or known hypersensitivity against Bevacizumab and/or Capecitabine, non-malign disease, florid, serious infections at the time of recruitment, peripheral neuropathy, legally limited contractual capability or evidence of neurological or psychiatric disease, evidence of lacking cooperation of the patient, major intervention within 28 days before recruitment, serious injuries, unhealed wounds or fractures, patients with spinal compressions or metastases in central nervous system, evidence of bleeding diathesis or coagulation dysfunction, actual intake of anticoagulant or thrombolytic agents, Aspirin > 325 mg/d or within 10 days before study start, actual or recent (within 10 days before recruitment) therapeutic therapy with fully-dosed anticoagulants, previous thromboembolic or hemorrhagic events within the last 6 months before recruitment, previous abdominal fistulas, GI perforation or intra-abdominal abscess within the last 6 months, treatment with other study medication within 28 days before recruitment, patients with malabsorption syndrome or difficulties swallowing, and pregnant or breast feeding women.",
    "The sample is a phase 2 clinical trial for patients with relapsed or refractory B cell lymphoma. The trial is testing the drug ps341 (bortezomib) and requires patients to have measurable disease, a Zubrod status of </= 3, and no anti-cancer treatment within the past 3 weeks. Patients must also meet certain health criteria, including ANC >= 1500/uL, Plt >/= 50,000, Bilirubin <2 mg/dL, SGPT <2.5xULN, creatinine <2. Patients with ANC>/1000, PLT>/30000 will be eligible if due to massive splenomegaly and/or BM involvement. Patients must be HIV negative and have no active CNS lymphoma or serious intercurrent illness, active infections, or cancer except basal cell carcinoma of the skin or in situ cervical carcinoma. Patients must not be eligible for treatment of a higher priority and must not be pregnant. Patients must be age > 16. The trial has certain exclusion criteria, including platelets <30x10(9)/L within 14 days before enrollment, ANC<1.0 x10(9)/L within 14 days before enrollment, and peripheral neuropathy >/= grade 3 within 14 days before enrollment.",
    "The sample is a phase 2 clinical trial for the treatment of endometrial cancer using the drug lenvatinib. The trial includes patients with confirmed diagnosis of endometrial carcinoma and radiographic evidence of disease progression after one prior systemic, platinum-based chemotherapy regimen. The trial also requires measurable disease meeting specific criteria, an ECOG performance status less than 2, and adequate controlled blood pressure, renal function, bone marrow, blood coagulation, and liver functions. Exclusion criteria include brain or leptomeningeal metastases, more than one prior systemic chemotherapy regimen for recurrent metastatic or primary unresectable endometrial carcinoma, and significant cardiovascular impairment. Females who are pregnant or breastfeeding are also excluded. The trial requires negative serum or urine pregnancy test for women of reproductive potential.",
    "The sample is a phase 2 clinical trial for constipation predominant irritable bowel syndrome. The trial includes the drug rdx5791 and has a list of inclusion and exclusion criteria. Inclusion criteria include meeting Rome III criteria for IBS-C, having a negative colonoscopy if any \"warning symptoms,\" and being compliant with IVRS. Exclusion criteria include having IBS-D, IBS-M, or un-subtyped IBS according to Rome III criteria, having a diagnosis or treatment of any clinically symptomatic biochemical or structural abnormality of the GI tract, using medications that affect stool consistency, and having any protocol-excluded or clinically significant medical or surgical history that could confound the study assessments or prevent completion of the study.",
    "The sample is a phase 2 clinical trial for the treatment of migraine and headache. The trial involves the use of two drugs, mk-6096 and placebo. The eligibility criteria for the trial include having a history of migraine with or without aura for more than a year and experiencing between 4 and 14 migraine days per month in the 3 months prior to the study. Participants must also be male, female not of reproductive potential, or female of reproductive potential who is not pregnant by pregnancy test and agrees to use acceptable contraception. Exclusion criteria include pregnancy, breast-feeding, or expecting to become pregnant, planning to donate egg or sperm during the study or within 90 days after last dose of study medication, and having basilar or hemiplegic migraine headache. Other exclusion criteria include having a history of narcolepsy, cataplexy, circadian rhythm disorder, parasomnia, sleep related breathing disorder, restless legs syndrome, periodic limb movement disorder, excessive daytime sleepiness or difficulty sleeping due to a medical condition, and having clinical, laboratory, or electrocardiogram (ECG) evidence of uncontrolled hypertension, uncontrolled diabetes, human immunodeficiency virus (HIV) disease, or significant pulmonary, renal, hepatic, endocrine, or other systemic disease. Participants must also not have had a myocardial infarction, unstable angina, coronary artery bypass surgery, or other revascularization procedure, stroke, or transient ischemic attack within 3 months of the study. Other exclusion criteria include having other confounding pain syndromes, psychiatric conditions such as uncontrolled major depression, dementia or significant neurological disorders other than migraine, and being at imminent risk of self-harm or harm to others. Participants must also not have had a history of malignancy \u22645 years prior to the study, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer, and must not have had a recent history or current evidence of drug or alcohol abuse or \"recreational use\" of illicit drugs or prescription medications. Other exclusion criteria include having donated blood products or having had phlebotomy of >300 ml within 8 weeks of the study, consuming 3 or more alcoholic drinks per day, having a body mass index >40 kg/m^2, and having a history of transmeridian travel or shift work within the past 2 weeks or anticipating needing to travel across >3 time zones at any time during the study.",
    "The sample is a clinical trial for phase 2 of a treatment for metastatic colorectal cancer. The trial involves the use of erlotinib and capecitabine drugs. The eligibility criteria for the trial include having a confirmed diagnosis of metastatic colorectal adenocarcinoma, being over 18 years old, having a performance status of over 60 on the Karnofsky scale, having an expected life expectancy of at least 12 weeks, and having measurable or evaluable disease. Exclusion criteria include prior chemotherapy or treatment with inhibitors of EGFR, being pregnant or lactating, having clinical signs of brain involvement or leptomeningeal disease, having serious illness or medical conditions, and being known to be HIV positive.",
    "The sample is a record of a clinical trial with a phase 2 designation. The trial is focused on the disease of anemia and includes a list of ICD-10 codes associated with the disease. The drug being tested is epoetin alfa. The eligibility criteria for the trial are listed, including inclusion criteria such as a clinical diagnosis of diabetes mellitus and a glomerular filtration rate between 15 and 90 mL/minute/1.73m2, and exclusion criteria such as poorly controlled high blood pressure and active malignancy.",
    "The sample is a phase 2 clinical trial for depression, with the goal of testing the effectiveness of the drug \"org 24448\" compared to a placebo. The trial includes male and female subjects between the ages of 21 and 70 who meet DSM-IV criteria for Major Depression without psychotic features. Subjects must have a history of at least one previous episode of depression and an initial score of greater than or equal to 32 on the Inventory of Depressive Symptoms, Clinician version (IDS-C) at Visit 1 and Visit 2. Subjects must not have greater than a 25% decrease in the IDS-C total scores during washout (between Visits 1 and 2). The trial has a list of inclusion and exclusion criteria, including the presence of psychotic features or a diagnosis of Schizophrenia or any other psychotic disorder or bipolar disorder, a history of DSM-IV drug or alcohol dependency or abuse within the preceding 3 months, and serious, unstable illnesses including hepatic, renal, gastroenterologic, respiratory, cardiovascular (including ischemic heart disease), endocrinologic, neurologic, immunologic, or hematologic disease. The trial also has additional inclusion and exclusion criteria for PET scans.",
    "The sample is a record of a clinical trial with a phase 2 designation. The trial is focused on the disease lupus erythematosus, systemic and includes a list of ICD-10 codes associated with the disease. The trial involves testing the effectiveness of several drugs, including a placebo and different doses of belimumab. The eligibility criteria for the trial are listed, including primary inclusion and exclusion criteria. The inclusion criteria require a clinical diagnosis of SLE, active SLE disease, a stable SLE treatment regimen, and a history of measurable autoantibodies. The exclusion criteria include recent use of non-FDA approved investigational agents, recent use of certain medications, active lupus nephritis, active CNS lupus, history of renal transplant, recent history of certain infections, hypogammaglobulinemia or immunoglobulin A deficiency, and HIV, Hepatitis B, or Hepatitis C.",
    "The sample is a phase 2 clinical trial for the treatment of attention deficit hyperactivity disorder (ADHD) using the drug modafinil. The trial includes patients between the ages of 18 and 65 who meet the full Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR) criteria for ADHD. Patients must also have a Hamilton Anxiety Scale (HAM-A) and a Hamilton Depression Scale (HAM-D) score less than 15, an AISRS total score of greater than 24, and a Clinical Global Impression of Severity of Illness (CGI-S) rating for ADHD of at least 4. Women of childbearing potential must use a medically accepted method of contraception. Patients with a history or current diagnosis of schizophrenia, bipolar or other psychotic disorders, or clinical assessment of suicide risk are excluded from the trial, as are patients with any current psychiatric comorbidity, including but not limited to depression or other mood disorder or anxiety disorder, that requires pharmacotherapy. Patients must also not have a current diagnosis of a clinically significant sleep disorder, be intellectually challenged, be satisfied with current ADHD medication and have no unacceptable medication side effects, have previously used modafinil, be using other prescription medications for ADHD with psychoactive properties, have had drug or alcohol abuse or dependence within the last 6 months, have used monoamine oxidase (MAO) inhibitors or selective serotonin reuptake inhibitors (SSRIs) within 2 weeks before the baseline visit, have used an investigational drug within 1 month before the baseline visit, be pregnant or lactating, have any clinically significant uncontrolled medical conditions, have a clinically significant deviation from normal in the physical examination, or have any disorder that may interfere with drug absorption, distribution, metabolism, or excretion.",
    "The sample is a phase 2 clinical trial for primary central nervous system lymphoma. The trial is looking at the effectiveness of two drugs, methotrexate and temozolomide, and methotrexate, procarbazine, vincristine, and cytarabine. The eligibility criteria for the trial include confirmation of the lymphoma through brain biopsy, CSF cytology, or vitrectomy, a KPS score of 40 or higher, absence of systemic disease, and certain blood and organ function levels. Patients must also be over 60 years old, have a negative HIV test, and provide informed consent. Exclusion criteria include previous cranial radiotherapy, prior chemotherapy for primary central nervous system lymphoma, presence of another cancer (except for basal cell carcinoma of the skin and cervical carcinoma in situ), systemic lymphoma outside the CNS, isolated ocular lymphoma, immunosuppressed patients, other uncontrolled or progressive disease compromising short-term survival, severe renal or hepatic disease, patients not legally covered by the French Social Security, and inability to swallow the medication.",
    "The sample is a phase 2 clinical trial for patients with metastatic or recurrent esophageal cancer. The trial is testing the effectiveness of the drugs pemetrexed and carboplatin. The eligibility criteria include having measurable disease, a performance status of 0-2, and adequate bone marrow, liver, and renal function. Patients must not have had prior chemotherapy treatment for metastatic esophageal cancer, and must not have received pemetrexed in the past. The trial also excludes patients with pre-existing neuropathy greater than or equal to grade 2, known active CNS metastases, and pregnant or nursing females.",
    "The sample is a phase 2 clinical trial for the treatment of recurrent glioblastoma, gliosarcoma, anaplastic astrocytoma, anaplastic oligodendroglioma, and anaplastic oligoastrocytoma using the drug bibf 1120. The trial has eligibility criteria for inclusion, such as having a confirmed diagnosis of the disease, demonstrating recurrent disease on MRI, and having measurable disease. Exclusion criteria include having received other investigational agents, having more than 2 prior relapses, and having a history of allergic reactions to compounds similar to bibf 1120. The trial also has criteria for normal organ and marrow function, as well as recovered toxic effects from prior therapy.",
    "The sample is a phase 2 clinical trial for patients with symptomatic multiple myeloma or light-chain amyloidosis that has been treated with at least one prior regimen. Patients must have received 1-3 treatment regimens, and measurable disease is required. Patients must have an ECOG performance status of 0, 1, or 2, and meet certain criteria for ANC, platelet count, creatinine, and pregnancy status. Patients must also be willing to abstain from donating blood during the study and for 28 days after discontinuation of study drug. Prior concurrent therapy must have been discontinued at least 2 weeks prior to study registration, and no other concurrent anti-myeloma therapy is allowed. Routine concurrent bisphosphonate therapy is allowed for patients with myeloma bone disease.",
    "The sample is a record from a clinical trial table that includes information about the trial's phase, diseases being studied, ICD-10 codes associated with those diseases, drugs being tested, and eligibility criteria for participants. In this particular sample, the trial is in phase 2 and is studying non-Hodgkin's lymphoma and multiple myeloma. The drug being tested is a combination of g-csf and plerixafor. The eligibility criteria include having a certain diagnosis, a limited number of prior chemotherapy regimens, specific blood counts and organ function, and no other medical conditions that would make the patient high risk for treatment complications. There are also exclusion criteria, such as having brain metastases or being pregnant, that would prevent a patient from participating in the trial.",
    "The sample is a phase 2 clinical trial for asthma. The trial includes subjects with a documented history of persistent asthma who are between 18 and 70 years old. The trial requires all subjects to be using an inhaled corticosteroid for at least 12 weeks prior to screening. The trial also requires subjects to demonstrate the presence of reversible airway disease during the screening visit. The trial includes a list of inclusion and exclusion criteria, such as no evidence of significant abnormality in the 12-lead ECG performed at screening and no history of life-threatening asthma within the last 5 years. The trial involves the use of several drugs, including ff(100mcg)/vilanterol(25mcg) am, ff(100mcg)/vilanterol(25mcg) pm, placebo am, and placebo pm. The trial also involves a list of diseases and icd-10 codes of diseases.",
    "The sample is a phase 2 clinical trial for patients with certain types of cancer who have not responded to standard treatments. The trial is testing the effectiveness of oral lapatinib tablets or placebo tablets. The eligibility criteria include being over 18 years old, having a confirmed diagnosis of certain types of cancer, having documented tumor progression after receiving all standard/approved chemotherapies, and having a negative serum pregnancy test if female of childbearing potential. The trial also requires certain organ function levels and excludes patients with certain medical conditions or who are pregnant or lactating. The sample includes a detailed list of inclusion and exclusion criteria.",
    "The sample is a phase 2 clinical trial that involves patients between the ages of 2 and 18 who have unintentionally lost more than 5% of their body weight due to cancer or cancer treatment, have a BMI below the 5th percentile, or have been diagnosed with cancer. The trial aims to test the effectiveness of cyproheptadine hydrochloride in improving appetite and weight gain in these patients. The trial has specific inclusion and exclusion criteria, such as not currently taking or having taken certain medications, not having certain medical conditions, and not being pregnant or lactating. The trial requires patients to have a predicted life expectancy of at least 6 months and to not be receiving concomitant cancer treatment during the 4-week intervention period.",
    "The sample is a phase 2 trial for patients with type 2 diabetes who have inadequate glycemic control on diet and exercise. The trial includes patients who have not been previously treated with antihyperglycemic medication or have been treated for less than 30 days since diagnosis and have received less than 3 consecutive doses or 7 non-consecutive doses in the last 30 days. The trial also includes patients with a C-peptide level greater than 1.0 ng/ml, a body mass index of 40 kg/m2 or less, and a serum creatinine level of less than 1.5 mg/dL for men or less than 1.4 mg/dL for women. Patients with overt proteinuria are excluded from the trial. Exclusion criteria include unstable renal disease, significant liver disease, recent cardiovascular events, and clinically significant anemia. The trial includes the drug dapagliflozin, metformin, and a placebo.",
    "The sample is a record of a clinical trial with a phase 2 designation. The trial is focused on the treatment of irritable colon, and the study includes a list of diseases and icd-10 codes associated with the condition. The drug being tested is talnetant. The eligibility criteria for the trial are listed, including requirements for self-assessments of IBS symptoms, a diagnosis of IBS consistent with the Rome II criteria, and normal results from a colonic procedure within 2 years of randomization. The sample also includes a list of permitted and prohibited medications for the trial.",
    "The sample is a phase 2 clinical trial for various types of cancer, including rhabdomyosarcoma, osteosarcoma, Ewing's sarcoma, synovial sarcoma, and Wilms' tumor. The trial is for patients who have refractory or recurrent disease with no known curative treatment options. The eligibility criteria include age \u2264 21 years at original diagnosis for some types of cancer, ECOG performance status 0-2, life expectancy \u2265 8 weeks, and no evidence of active graft-versus-host disease. The trial involves the use of the drug ixabepilone, and patients must meet various medical criteria to participate. The trial does not allow concurrent radiotherapy or other chemotherapy or immunomodulating agents.",
    "The sample is a phase 2 clinical trial for chronic obstructive pulmonary disease (COPD). The trial involves the use of three drugs: theophylline - adc4022, placebo, and budesonide. The eligibility criteria for the trial include having a confirmed diagnosis of COPD that has been symptomatic for at least 2 years, having moderate to severe COPD, being able to produce an adequate sputum specimen after induction, having a history of \u2265 10-pack years of cigarette smoking, and being able to provide written, informed consent to participate. Exclusion criteria include having experienced a respiratory tract infection and/or an exacerbation of COPD within 30 days, using systemic corticosteroids (oral or parenteral), having received long term oxygen therapy within 30 days, having a previous history or diagnosis of asthma, and having a chest x-ray within the past 12 months which is diagnostic of an active or clinically significant disease other than COPD. Other inclusion/exclusion criteria may also apply.",
    "The sample is a record of a clinical trial with a phase 2 designation. The trial is focused on liver cancer and includes a list of ICD-10 codes associated with the disease. The trial involves the use of two drugs, bevacizumab (avastin) and erlotinib (tarceva). The eligibility criteria for the trial include being an adult patient over the age of 18 with advanced or metastatic liver cancer and at least one measurable lesion that has not been previously treated with local therapy within 4 weeks of enrollment. The exclusion criteria include prior or concomitant systemic anti-cancer treatment for advanced disease, patients at high risk of variceal bleeding, clinically significant cardiovascular disease, and major surgery, open biopsy, or significant traumatic injury within 4 weeks of study start.",
    "The sample is a phase 2 clinical trial for patients with squamous cell carcinoma of the head and neck, including nasopharyngeal carcinoma of World Health Organization (WHO) Grade I. The trial is for patients with advanced disease that is incurable or metastatic, or for those with persistent or progressive disease following curative-intent radiation who are not candidates for surgical salvage due to incurability or morbidity. Patients must be platinum-refractory or platinum-ineligible, and have measurable disease based on response evaluation criteria in solid tumors (RECIST). They must also have an Easter Cooperative Oncology Group (ECOG) performance status of 0-2 and adequate hematologic reserve and organ function. Patients must be able to provide written, voluntary consent, use an effective contraceptive method if they have reproductive potential, and have a life expectancy of at least 12 weeks. Exclusion criteria include prior treatment blocking the epidermal growth factor receptor (EGFR) in the advanced disease setting, prior treatment blocking EGFR in the curative-intent setting if delivered in the previous 6 months, prior treatment with a drug blocking the mammalian target of rapamycin (mTOR), sensitivity to temsirolimus or erlotinib, uncontrolled metastatic disease of the central nervous system, radiotherapy or surgery within the 2 weeks before Cycle 1' Day 1, pregnancy or lactation, myocardial infarction or ischemia within the 6 months preceding study treatment, any co morbid condition that renders the patient at high risk from treatment complications, and history of prior malignancy within the prior five years, with the exception of non-melanoma carcinomas of the skin and carcinoma in situ of the cervix. The drugs being tested are erlotinib and temsirolimus.",
    "The sample is a phase 2 clinical trial for metastatic breast cancer patients with measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) criteria. The trial is testing the effectiveness of the drugs gemcitabine/carboplatin and iniparib. The eligibility criteria include being at least 18 years old, having 0-2 prior chemotherapy regimens in the metastatic setting, and having ER-negative, PR-negative, and HER-2 nonoverexpressing breast cancer. Patients must have completed prior chemotherapy at least 2 weeks prior to trial entry and recovered from toxicity of prior chemotherapy. Patients with central nervous system (CNS) metastases are eligible if they did not require steroids, whole brain radiation therapy (XRT), gamma/cyber knife, and brain metastases were clinically stable without symptomatic progression. Patients must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0-1 and adequate organ function. Patients must also have a tissue block (primary or metastatic) available for PARP and PG studies. Exclusion criteria include lesions identifiable only by positron emission tomography (PET), prior treatment with gemcitabine, carboplatin, cisplatin or iniparib, and major medical conditions that might have affected trial participation. Patients enrolled in another investigational device or drug trial, or receiving other investigational agents are also excluded. Concurrent radiation therapy is not permitted throughout the course of the trial.",
    "The sample is a record of a clinical trial with a phase 2 designation. The trial is focused on the disease of type 2 diabetes mellitus, and the icd-10 codes associated with the disease are listed. The trial involves several drugs, including alogliptin, voglibose, and a placebo. The eligibility criteria for the trial are also listed, including a specific range for glycosylated hemoglobin (HbA1c) values and a requirement for receiving a specific diet and exercise therapy for at least four weeks prior to the start of screening. The exclusion criteria include a restriction on the use of any antidiabetic drugs within the four weeks prior to the start of screening or during screening.",
    "The sample is a phase 2 trial for the treatment of essential tremor. The trial is testing the effectiveness of sodium oxybate as a treatment for moderate or severe classic essential tremor. The trial requires participants to abstain from caffeine and alcohol for at least 48 hours prior to certain days of the trial. The inclusion criteria for the trial includes a diagnosis of essential tremor and willingness to follow the dietary restrictions. The exclusion criteria includes any significant medical abnormalities or history of certain diseases, being on a sodium-restricted diet, and having a known history of sleep apnea.",
    "The sample is a phase 2 clinical trial for the treatment of schizophrenia. The trial includes patients who have been receiving monotherapy treatment for at least 3 months prior to study entry with one of 4 atypical antipsychotic medications. The patients must have evidence of prominent negative symptoms of schizophrenia and meet certain criteria as assessed by the clinician. The trial has inclusion and exclusion criteria, and patients must be willing to perform all study procedures and have given their informed consent. The trial excludes patients who are actively suicidal, pregnant or nursing, have had electroconvulsive therapy within 3 months of screening, or have certain serious or unstable illnesses.",
    "The sample is a phase 2 clinical trial for various types of lymphoma, including non-Hodgkin's lymphoma, large cell lymphoma, mantle cell lymphoma, follicular lymphoma, and diffuse large B-cell lymphoma. The trial is testing the effectiveness of two drugs, SyB L-0501 and rituximab, on patients who have relapsed or are refractory after 1 to 3 prior therapeutic treatments for diffuse large B-cell lymphoma. The eligibility criteria include having measurable lesions, being CD20-positive for lymphoma cells, and having a Performance Status of 0 to 1. Exclusion criteria include having serious infections or complications, a history of certain cancers, and having received certain medications within a certain timeframe.",
    "The sample is a phase 2 clinical trial for patients with colorectal cancer who have failed therapy with an oxaliplatin and fluoropyrimidine containing regimen. The trial involves the drugs vandetanib and folfiri. The eligibility criteria include confirmed colorectal cancer and progression on or following treatment for metastatic colorectal cancer or progression within 12 months of adjuvant chemotherapy for colorectal cancer. The exclusion criteria include previous treatment with certain small molecule tyrosine kinase inhibitors and more than one prior course of chemotherapy for treatment of metastatic colorectal cancer. The diseases are listed as 'colorectal cancer' and the icd-10 codes associated with the disease are also provided.",
    "The sample is a phase 2 clinical trial for patients with non-small cell lung cancer who have failed at least one front-line metastatic NSCLC chemotherapy regimen. The trial requires patients to have a diagnosis of pathologically confirmed NSCLC by tumor biopsy and/or fine-needle aspiration, and a diagnosis of either stage IIIB, stage IV, or advanced, incurable NSCLC. Patients must also have uni-dimensionally measurable NSCLC, a Karnofsky performance status >/= 60 or Eastern Cooperative Oncology Group (ECOG) performance status 0-2, and adequate hematologic, hepatic, and renal function. Patients must not have received prior investigational therapy, chemotherapy, surgery, or radiotherapy within 4 weeks of initiating study drug, and must not have undergone prior thoracic or abdominal surgery within 28 days of study entry, excluding prior diagnostic biopsy. The trial also has a list of exclusion criteria, including significant medical history or unstable medical condition, uncontrolled seizure disorder, active neurologic disease, or neuropathy >/= grade 2, and pregnancy or breastfeeding.",
    "The sample is a phase 2 clinical trial for the treatment of type 2 diabetes mellitus. The trial includes patients who have been diagnosed with type 2 diabetes mellitus for at least three months and have a concurrent type 2 diabetes mellitus therapy. The patients must have a HbA1c level between 7 and 10%, a body mass index between 20 and 40 kg/m\u00b2, and be between 18 and 75 years old. The trial excludes patients with metabolic diseases, significant cardiovascular and/or cerebrovascular disease, fasting serum triglycerides \u2265800mg/dL, and significant renal disease. The trial also excludes patients who are currently lactating, pregnant, or actively trying to become pregnant, have a history of pancreatitis within five years prior to randomization, have a documented history of chronic or advanced hepatobiliary disease, and have a history of alcohol or substance abuse within the past year. The trial requires patients to sign and date informed consent before any study-related procedures are performed.",
    "The sample is a record of a clinical trial with a phase 2 designation. The trial is focused on treating moderate to severe vasomotor symptoms in postmenopausal women. The diseases being studied are listed as \"moderate to severe vasomotor symptoms in postmenopausal women\" and the corresponding ICD-10 codes are listed as \"N95.0\" and \"N95.2\". The trial involves several drugs, including \"mk-6913\", \"17-\u03b2 estradiol\", \"placebo to mk-6913\", \"placebo to 17-\u03b2 estradiol\", and \"mk-6913 25 mg\". The eligibility criteria for the trial are also listed, including requirements such as being postmenopausal, having at least 50 moderate to very severe hot flash episodes per week, and not receiving hormone therapy. The exclusion criteria are also listed, including a history of cancer (except for certain skin cancers), undiagnosed vaginal bleeding or any uterine endometrial disorder, current or recent tobacco use, and HIV.",
    "The sample is a phase 2 clinical trial for Multicentric Castleman's Disease. The trial includes patients with measurable and symptomatic Multicentric Castleman's Disease, who have adequate organ function and an Eastern Cooperative Oncology Group performance status of 0, 1, or 2. The trial excludes patients who are Human Immunodeficiency Virus or Human Herpes Virus-8 positive, have skin lesions as the sole measurable manifestation of Multicentric Castleman's Disease, have a previous history of lymphoma, have malignancies (except for adequately treated basal cell or squamous cell carcinoma of the skin, carcinoma in situ of the cervix, or cancer other than lymphoma, from which the patient has been disease-free for 3 or more years), have concurrent medical conditions or diseases that may interfere with study participation, or have prior exposure to Interleukin-6 or Interleukin-6 receptor targeted therapies. The trial involves the use of siltuximab, placebo, and best supportive care (bsc) as drugs.",
    "The sample is a phase 2 clinical trial for patients with metastatic breast cancer who have tumors resistant to chemotherapy with certain agents or cannot be treated with them due to toxicity. The trial involves the drug E7070 and has a list of inclusion and exclusion criteria for patients. The criteria include factors such as age, performance status, and adequate organ function. Patients must also be willing to comply with the study protocol and give written informed consent. Exclusion criteria include factors such as recent chemotherapy or radiation therapy, untreated brain metastases, and significant medical conditions that would exclude the patient from the study.",
    "The sample is a phase 2 clinical trial for previously untreated BCR-ABL-positive acute lymphoblastic leukemia. The trial is open to individuals between the ages of 15 and 64 with a performance status between 0 and 3 according to ECOG criteria. Participants must also have adequate liver, kidney, and heart function, and provide written informed consent. Exclusion criteria include uncontrolled active infection, another severe and/or life-threatening disease, positive HIV or hepatitis B tests, another clinically active primary malignancy, pregnancy or lactation, and past history of renal failure. The trial involves a combination of drugs including imatinib, cyclophosphamide, daunorubicin, vincristine, prednisolone, methotrexate, cytarabine, and dexamethasone. The icd-10 codes associated with the disease are C91.01, C91.02, and C91.00.",
    "The sample is a phase 2 clinical trial for patients with advanced or metastatic colorectal cancer. The trial involves the use of the drug simvastatin and the eligibility criteria include a diagnosis of colorectal cancer, progressive disease in the past 3 months, and failure of prior oxaliplatin-, fluorouracil (5-FU)-, and irinotecan-containing regimens with the presence of a k-ras mutation within codon 12, 13, or 61. Patients must also have a WHO performance status of 0-2, adequate organ function, no history of toxicity during statin use, no other malignancy within the past 5 years, no history of severe pulmonary disease, and no clinically relevant coronary artery disease. Prior concurrent therapy is also taken into consideration.",
    "The sample is a phase 2 trial for the treatment of lymphoma. The trial includes patients with high risk indolent or intermediate B-cell lymphoma, small cleaved cell lymphoma, Waldenstrom's macroglobulinemia, follicular small cleaved cell or mixed cell, follicular large cell, diffuse immunoblastic, and mantle zone histology. Patients must have at least one lymph node or visceral lesion that is at least 2 cm in diameter. Eligible patients must not have received prior therapy for lymphoma and must meet certain patient characteristics such as having an ECOG performance status of 0-2 and not having any active infections or life-threatening medical conditions. Fertile patients must use effective contraception and pregnant patients are not eligible for the trial.",
    "The sample is a phase 2 clinical trial for breast cancer patients with unresected clinical stage T1c, T2, T3, or T4 lesions. The trial requires patients to have a confirmed diagnosis of infiltrating carcinoma of the breast and clinically measurable disease. Patients must also have a certain hormone receptor status and meet specific patient characteristics, such as being female and having a certain performance status. The trial excludes patients who have had prior chemotherapy, endocrine therapy, or radiotherapy for their current breast cancer. The trial also requires patients to meet certain hematopoietic, hepatic, and renal criteria. The drug being tested in the trial is docetaxel. The table includes columns for the phase of the trial, the diseases being studied, the ICD-10 codes associated with those diseases, the drugs being tested, and the eligibility criteria for the trial.",
    "The sample is a phase 2 clinical trial for patients with primary or recurrent biliary duct carcinoma from the proximal, middle, or distal bile ducts. The trial is evaluating the effectiveness of the drug fluorouracil in treating the disease. Patients must have measurable or evaluable disease that is considered resectable, with no distant metastases or non-contiguous liver metastases. They must also meet certain eligibility criteria, including being 18 years or older, having an ECOG performance status of 0-1, and meeting certain hematopoietic, hepatic, renal, and other health requirements. Patients cannot have had prior radiotherapy and must meet other prior concurrent therapy requirements.",
    "The sample is a phase 2 clinical trial for patients with hepatocellular carcinoma. The trial is testing the effectiveness of the drugs vandetanib and best supportive care in treating locally advanced or metastatic HCC. The eligibility criteria include having a histologically or clinically diagnosed HCC, being able to understand and provide informed consent, having a Karnofsky performance status of at least 70, and having a life expectancy of at least 2 months. Exclusion criteria include receiving concurrent anti-cancer therapy, prior systemic cytotoxic chemotherapy, and prior therapy targeting VEGF or EGF signalling pathways. The trial also has a list of other exclusion criteria related to medical history, laboratory results, and medication use.",
    "The sample is a phase 2 clinical trial for patients with advanced non-small cell lung cancer. The trial is testing the effectiveness of the drugs sorafenib and placebo. The eligibility criteria include having confirmed NSCLC that has progressed after at least 2 prior chemotherapy regimens, measurable or nonmeasurable disease, and meeting certain blood count and liver function requirements. Patients must also have recovered from prior therapy and use effective contraception if fertile. Exclusion criteria include prior brain or meningeal tumors, active second malignancy, serious cardiac conditions, and certain medications. Pregnant or nursing patients and those with serious active infections or medical conditions that would preclude study participation are also excluded.",
    "The sample is a phase 2 clinical trial for acute myeloid leukemia. The trial includes patients with newly diagnosed AML, except APL, and those with AML evolving from MDS or other hematologic diseases and AML after previous cytotoxic therapy or radiation. The trial requires bone marrow aspirate or biopsy to contain at least 20% blasts of all nucleated cells, except for AML FAB M6, where at least 30% of non-erythroid cells must be leukemic blasts. Patients must be at least 61 years old and provide informed consent to participate in the study. Male patients must use adequate barrier birth control measures during the course of the Sorafenib treatment and for at least 3 months after the last administration of Sorafenib. The exclusion criteria include central nervous system manifestation of AML, cardiac disease, chronically impaired renal function, chronic pulmonary disease with relevant hypoxia, inadequate liver function, total bilirubin greater than or equal to 1.5 x ULN, resting blood pressure consistently higher than systolic 160 mmHg and/or diastolic 95 mmHg, any severe concomitant condition which makes it undesirable for the patient to participate in the study or which could jeopardize compliance with the protocol, uncontrolled active infection, concurrent malignancies other than AML, previous treatment of AML except hydroxyurea and up to 2 days less than or equal to 100 mg/m\u00b2/d cytarabine, known HIV and/or hepatitis C infection, evidence or history of CNS disease, including primary or metastatic brain tumors, seizure disorders, thrombotic or embolic events such as cerebrovascular accident or pulmonary embolism within 1 year of study entry, evidence or history of severe non-leukemia associated bleeding diathesis or coagulopathy, history of organ allograft, concomitant treatment with kinase inhibitors, angiogenesis inhibitors and Myelotarg, patients with major surgery, open biopsy or significant traumatic injury within 4 weeks of start or first dose, serious, non-healing wound, ulcer or bone fracture, allergy to study medication or excipients in study medication, investigational drug therapy outside of this trial during or within 4 weeks of study entry, and patients who are not eligible for standard chemotherapy.",
    "The sample is a phase 2 clinical trial for osteoarthritis. The trial includes a list of icd-10 codes for the disease and a list of drugs, including naproxen, ce-224535, and placebo. The eligibility criteria for the trial include being a healthy adult between 18 and 75 years old with a diagnosis of knee OA according to the American College of Rheumatology (ACR) clinical/radiographic classification criteria. Women must be of non-childbearing potential and have a confirmed negative pregnancy test. Exclusion criteria include a history of other diseases involving the study joint and being pregnant or lactating.",
    "The sample is a phase 2 clinical trial for the treatment of Parkinson's disease and other related neurological disorders. The trial involves the use of the drug preladenant, along with other Parkinson's disease treatments and a placebo. The trial has specific eligibility criteria, including a diagnosis of moderate to severe idiopathic Parkinson's disease for at least 5 years, normal clinical laboratory tests, and exclusion of participants with drug-induced or atypical parkinsonism, cognitive impairment, major depression, or other medical conditions. The trial also excludes participants who are breastfeeding or participating in any other clinical study.",
    "The sample is a phase 2 clinical trial for the treatment of diabetic gastroparesis, a condition where the stomach takes too long to empty its contents. The trial involves the use of a drug called rm-131 and a placebo. The eligibility criteria for the trial include having type 1 or type 2 diabetes with HbA1c \u226411%, a history of symptoms suggestive of gastroparesis for at least 3 months, and delayed gastric emptying confirmed by abnormal gastric emptying breath test. Patients must also have stable concomitant medications and not have used certain medications for at least 2 weeks prior to the trial. Exclusion criteria include a history of certain surgeries, persistent daily vomiting, and certain medical conditions. Female patients must have negative pregnancy tests and use birth control throughout the trial.",
    "The sample is a phase 2 clinical trial for patients with type 2 diabetes mellitus or impaired glucose tolerance. The trial involves the use of canakinumab 150 mg and a placebo to canakinumab. The eligibility criteria include having a stable treatment with metformin, sulfonylurea, thiazolidinedione combination therapy, or at least two insulin injections a day with or without metformin. The patient must also have an HbA1c between 6.5% and 8% and be between the ages of 18-74. Exclusion criteria include having type 1 diabetes, active pulmonary disease, or a known presence or suspicion of active or recurrent bacterial, fungal, or viral infection at the time of enrollment.",
    "The sample is a phase 2 clinical trial for patients with chronic myelogenous leukemia. The trial involves the use of gleevec (imatinib) and valproic acid as drugs. The eligibility criteria include being 18 years or older, having a life expectancy of at least 12 weeks, having an ECOG performance status of 0-2, and having adequate hepatic and renal function. Patients must also have received at least 9 months of imatinib since the diagnosis of CML and be tolerating it without any grade 3 or greater toxicity. Pregnant women or nursing mothers are not eligible, and patients with severe medical problems or hypersensitivity to valproic acid are also excluded.",
    "The sample is a record from a clinical trial table that includes information about the phase of the trial, diseases being studied, corresponding ICD-10 codes, drugs being tested, and eligibility criteria for participants. In this particular sample, the trial is in phase 2/3 and is focused on type 2 diabetes mellitus. The drugs being tested are a combination of alogliptin and pioglitazone. The eligibility criteria include completing a previous phase of the study, being capable of understanding and complying with the protocol, and signing a written informed consent form. Exclusion criteria include clinical manifestations of hepatic or renal impairment and a history or symptoms of cardiac failure.",
    "The sample is a phase 2 clinical trial for patients with metastatic adenocarcinoma of the prostate who have progressed after at least one prior docetaxel-based chemotherapy regimen for metastatic disease. The trial is testing the effectiveness of a combination of drugs including carboplatin, rad 001, and prednisone. The eligibility criteria include various disease and patient characteristics such as confirmed castration, Zubrod performance status 0-1, and certain laboratory values within normal limits. Prior concurrent therapy is also specified, including no prior treatment with an mTOR inhibitor and no concurrent chronic, systemic treatment with corticosteroids or other immunosuppressive agents.",
    "The sample is a phase 2 clinical trial for the treatment of schizophrenia. The trial includes patients who have been hospitalized with acute or relapsing schizophrenia within 3 weeks of screening and have had a duration of illness of at least one year. The trial involves the use of drugs such as lurasidone and haloperidol, as well as a placebo. The eligibility criteria include having a primary diagnosis of schizophrenia, a BPRS score of at least 42 at baseline, and being able to remain off antipsychotic medication for a 4 day washout period. Exclusion criteria include having had psychiatric hospitalizations other than current hospitalizations within 1 month prior to screening, being considered treatment resistant, having substance abuse, having a prolactin level of > 200 ng/mL at baseline, and being pregnant.",
    "The sample is a phase 2 clinical trial for the treatment of type 2 diabetes. The trial includes patients with a historical diagnosis of type 2 diabetes who have not used anti-diabetic therapy for at least 8 weeks prior to screening, or those who are stable on at least 1500 mg per day of metformin as monotherapy for at least 8 weeks at screening. The trial involves the use of several drugs, including placebo, tak-875, sitagliptin, and combinations of tak-875 and sitagliptin. The eligibility criteria include age between 18 and 80 years, BMI between 23 and 45, and HbA1c level between 7.5% and 10.0% if on metformin and between 7.5% to 10.9% if treated with diet and exercise alone. The trial also includes exclusion criteria, such as a history of hypersensitivity or allergies to the drugs being tested, a history of drug or alcohol abuse, and certain medical conditions that may affect the outcome of the trial.",
    "The sample is a phase 2 clinical trial for breast cancer patients. The trial includes patients with locally advanced or primary breast cancers that are HER2 overexpressing. The eligibility criteria include being female, having a negative pregnancy test, having kidney and liver function tests within normal limits, having a performance status less than 2, and being at least 18 years old. Exclusion criteria include pregnancy, severe underlying chronic illness or disease, cardiomyopathy or baseline LVEF less than 50%, and taking any lapatinib-prohibited medication within 7 days of first dose of study medications. The trial will test the effectiveness of lapatinib, trastuzumab, and endocrine drugs.",
    "The sample is a phase 2 clinical trial for patients with Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, or mantle cell lymphoma who are considered appropriate candidates for hematopoietic stem cell transplant. The trial involves the use of leuprolide acetate depot (lad) 11.25 mg 3 month and a matched placebo. The eligibility criteria include being between the ages of 18-50 (if female) or 18-65 (if male), having a partial or complete response to chemotherapy (for multiple myeloma patients), and achieving a partial response to initial chemotherapy or first or second chemosensitive relapse (for Hodgkin's disease or non-Hodgkin's lymphoma patients). The exclusion criteria include having an uncontrolled life-threatening infection, previously receiving hematopoietic stem cell transplantation, and having medical or psychiatric conditions that would compromise the patient's ability to participate in the study.",
    "The sample is a phase 2 clinical trial for patients with HIV infections. The trial is testing the effectiveness of abacavir sulfate as a treatment option. The eligibility criteria for the trial include being HIV-positive, having been on an acceptable anti-HIV drug combination for 60 to 104 days before the study, having a viral load between 500 and 10,000 copies/ml, and being at least 13 years old. Patients must also agree to practice abstinence or use barrier methods of birth control during the study and for 3 months after. Exclusion criteria include having taken ABC before, having received anti-HIV therapy for more than 104 days in the past, having certain medical conditions or illnesses, taking drugs that affect the immune system or any experimental anti-HIV drugs, and being pregnant or breastfeeding.",
    "The sample is a phase 2 trial that involves patients with various diseases such as anemia, leukemia, lymphoma, lymphoproliferative disorder, multiple myeloma and plasma cell neoplasm, precancerous condition, and unspecified adult solid tumor, protocol specific. The trial requires patients to have a diagnosis of solid tumor or nonmyeloid hematologic malignancy, with no nonmelanomatous skin cancer, and a hemoglobin level of 10.5 g/dL or less. Patients must also have a ferritin level greater than 20 ng/mL and be planning to receive at least 12 weeks of anticancer chemotherapy. The trial excludes patients with anemia secondary to certain conditions such as cyanocobalamin or folic acid deficiency, gastrointestinal bleeding within the past 2 weeks, hemolysis, myelodysplastic syndromes, myeloproliferative disorders, or acute myeloid leukemia. Patients must also meet certain patient characteristics such as having an ECOG performance status of 0-2, a life expectancy of at least 6 months, and not being pregnant or nursing. The trial also has certain exclusion criteria such as uncontrolled hypertension, pulmonary emboli and/or deep vein thrombosis within the past 12 months, and a history of chronic hypercoagulable disorders. Prior concurrent therapy is also taken into consideration, and patients must have had more than 1 year since prior peripheral blood stem cell, bone marrow, or cord blood transplantation, more than 14 days since prior red blood cell transfusion, and more than 14 days since prior major surgery. Patients must also have had more than 10 weeks since prior darbepoetin alfa, epoetin alfa, or any investigational form of erythropoietin. The trial excludes patients who are planning to have stem cell transplantation within the next 4 months.",
    "The sample is a phase 2 clinical trial for patients with metastatic breast cancer. The trial involves the use of the drugs capecitabine, oxaliplatin, and trastuzumab. The eligibility criteria include a histologic or cytologic diagnosis of breast cancer with evidence of unresectable, locally recurrent, or metastatic disease, HER2 gene amplification by FISH, at least one measurable lesion, and a maximum of one prior chemotherapy regimen or trastuzumab-containing regimen. The exclusion criteria include no prior therapy with capecitabine or oxaliplatin, no prior therapy with other platinum compounds, and no other forms of cancer therapy within 21 days prior to beginning protocol therapy. Other exclusion criteria include no symptomatic brain metastasis, no evidence of serious concomitant systemic disorders incompatible with the study, and no peripheral neuropathy. Patients must not be treated with certain medications while on protocol therapy or within 28 days prior to beginning protocol therapy.",
    "The sample is a record of a clinical trial in phase 2, focused on the disease of pain. The trial includes a list of icd-10 codes related to the disease. The drugs being tested are '[s,s]-reboxetine + pregabalin' and 'pregabalin'. The eligibility criteria for the trial include patients who have had pain for more than 3 months after the healing of shingles skin rash and have a score of at least 40 mm on the pain visual analogue scale. Patients with significant renal and hepatic impairment, other severe pain that may impair self-assessment of the pain due to shingles, and clinically abnormal electrocardiogram are excluded from the trial.",
    "The sample is a record of a clinical trial with a phase 2 designation. The trial is focused on the treatment of chronic hepatitis C, and the list of diseases includes only this condition. The icd-10 codes associated with the disease are also listed. The trial involves several drugs, including copegus, pegasys, and ro4588161. The eligibility criteria for the trial are listed, including age range, genotype, and liver disease status. The exclusion criteria are also listed, including previous treatment for CHC and other medical conditions associated with chronic liver disease.",
    "The sample is a phase 2 clinical trial for relapsing-remitting multiple sclerosis. The trial is looking at the effectiveness of a placebo drug. The eligibility criteria for participants include having a confirmed diagnosis of relapsing-remitting MS according to McDonald criteria #1-4, with a baseline Expanded Disability Status Scale (EDSS) between 0.0 and 5.0, inclusive. Participants must have experienced at least 1 relapse within the 12 months prior to randomization, with a cranial magnetic resonance imaging (MRI) demonstrating lesion(s) consistent with MS, or show evidence of gadolinium-enhancing lesions of the brain on an MRI performed within the 6 weeks prior to randomization. There are also several exclusion criteria, including a diagnosis of primary progressive, secondary progressive, or progressive relapsing MS, a history of malignancy, and abnormal laboratory results based on investigator judgment.",
    "The sample is a record of a clinical trial with a phase 2 designation. The trial is focused on treating squamous cell carcinoma of the head and neck. The trial includes a list of ICD-10 codes for the diseases being treated, a list of drugs being used in the trial, and eligibility criteria for participants. The eligibility criteria include requirements such as the cancer being at a certain stage and being surgically resectable with curative intent. The exclusion criteria include factors such as having stage IVB squamous cell carcinoma, having used an investigational agent within the previous 30 days, and having uncontrolled cardiovascular disease.",
    "The sample is a record of a clinical trial in phase 2 for the treatment of bladder neoplasms using the drug gemcitabine. The trial has eligibility criteria for inclusion and exclusion. Inclusion criteria include having superficial bladder cancer and no prior chemotherapy. Exclusion criteria include having grade 3 tumors, papillary tumors invading connective tissue, and significant urologic disease that may interfere with intravesical therapy. The icd-10 codes associated with the disease are also provided.",
    "The sample is a phase 2 trial for the treatment of major depressive disorder. The trial includes the use of drugs such as cp-316,311, placebo, and sertraline. The eligibility criteria for the trial includes being an outpatient with DSM-IV major depressive disorder, while women of childbearing potential are excluded from the trial. The diseases are listed as 'depressive disorder, major' and the icd-10 codes associated with the disease are also provided.",
    "The sample is a phase 2 clinical trial for major depressive disorder. The trial includes the use of a vasopressin v1b receptor antagonist and a placebo. The eligibility criteria for the trial includes a diagnosis of major depressive disorder as defined by the DSM-IV-TR and the MINI criteria. Patients with certain exclusion criteria, such as alcohol or substance abuse, prior use of certain medications, or a current depressive episode with certain features, are not eligible for the trial. The sample provided includes the inclusion and exclusion criteria for the trial.",
    "The sample is a phase 2 clinical trial for Parkinson's disease. The trial includes patients between the ages of 30 and 75 who have been diagnosed with Parkinson's disease according to the UK PDS Brain Bank diagnostic criteria and are experiencing end-of-dose deterioration despite optimal levodopa/carbidopa or levodopa/benserazide therapy. The trial will test the efficacy of the drugs bia 9-1067, placebo, levodopa/carbidopa, and levodopa/benzerazide. The eligibility criteria include being of non-childbearing potential, having a modified Hoehn and Yahr stage of less than 5 in the off-state, and having a mean duration of OFF stage \u2265 1.5 h during waking hours. The exclusion criteria include having non-idiopathic parkinsonism, being treated with certain medications, having a history of abuse of alcohol, drugs or medications within the last 2 years, and having a clinically relevant ECG abnormality. The patients must be able and willing to give written informed consent.",
    "The sample is a phase 2 clinical trial for the treatment of schizophrenia. The trial includes patients who meet the diagnostic criteria for schizophrenia as defined in DSM-IV and have a PANSS total score of at least 70 at Screen and Baseline and a minimum score of 4 on at least 2 of the following: conceptual disorganization, hallucinatory behaviour, suspiciousness, or unusual thought content at the Screen and Baseline visits. Patients with a history of epilepsy or other seizure disorder, first episode of schizophrenia or other psychotic disorders, bipolar disorder, a history of substance dependence, or a medical or psychiatric disorder that would interfere with the accurate assessment of safety or efficacy are not eligible. The trial will test the efficacy and safety of two drugs, sb-773812 and olanzapine.",
    "The sample is a record of a clinical trial with a phase 2/phase 3 designation. The trial is focused on Parkinson's disease and includes a list of ICD-10 codes for the disease. The trial involves testing the effectiveness of three different drugs: cep-1347 10mg, cep1347 25mg, and cep-1347 50mg. The eligibility criteria for the trial are listed, including age, disease severity, and screening procedures for cancer. The exclusion criteria are also listed, including other medical or psychiatric conditions that may compromise participation in the study, history of seizures, and prior treatment with CEP-1347.",
    "The sample is a phase 2 clinical trial for a vaccine against cytomegalovirus infections. The trial is looking for mothers between the ages of 14 and 40 who have delivered a newborn infant within the previous 12 months and reside within the Birmingham metropolitan area or the Tuscaloosa county area. The inclusion criteria include being CMV seronegative, in good health, willing to participate in follow-up visits, and willing to use an effective means of contraception. The exclusion criteria include having a known immune disorder, chronic disease requiring medication, positive rapid test for HIV antibody, maternal sterilization procedure planned in the postpartum period, current use of steroids or other immunosuppressive medications, maternal drug or alcohol abuse, nursing their infants, participation in a clinical trial of another investigational vaccine or drug, history of anaphylaxis or serious vaccine reactions, previous receipt of CMV vaccine, and receipt of blood products within 3 months prior to study enrollment.",
    "The sample is a phase 2 clinical trial for patients with advanced non-small cell lung cancer. The trial is testing the drug erlotinib (also known as Tarceva) and the eligibility criteria includes being an adult patient over 18 years old with no previous chemotherapy, having a documented diagnosis of advanced non-small cell lung cancer, and having an Eastern Cooperative Oncology Group (ECOG) performance status of 0-2. The exclusion criteria includes previous therapy that acts on the Epidermal Growth Factor Receptor (EGFR) axis, clinical evidence of brain metastasis, any unstable systemic disease, inability to take oral medication, and any significant ophthalmological abnormality. The diseases are listed as non-small cell lung cancer and the icd-10 codes associated with the disease are also provided.",
    "The sample is a phase 2 clinical trial for psoriasis. The trial includes patients who have been diagnosed with stable plaque psoriasis for at least 6 months and have itchy psoriasis on both intended treatment areas. The trial aims to evaluate the effectiveness of cromoglicate and placebo in treating psoriasis. The eligibility criteria include being 18 years or older, having a clinical diagnosis of stable plaque psoriasis, and having disease severity graded as mild, moderate, or severe. The exclusion criteria include having received systemic treatment with biological therapies or all other therapies with a possible effect on psoriasis vulgaris within a certain time period prior to randomization, having any topical treatment of the treatment areas (except for emollients) within 2 weeks prior to randomization, and having a history of serious allergy, allergic skin rash, or sensitivity to any component of the investigational products or formulations being tested.",
    "The sample is a record of a clinical trial in phase 2, focused on the disease of acute heart failure. The trial includes a list of ICD-10 codes associated with the disease and a drug called acipimox. The eligibility criteria for the trial are listed, including inclusion criteria such as NYHA class III-IV and ejection fraction less than 35, and exclusion criteria such as age under 18 or over 85, allergies, renal failure, and recent myocardial infarction. The sample also includes exclusion criteria related to heart failure due to restrictive or hypertrophic cardiomyopathy or stenotic valvular heart disease, as well as exclusion criteria related to diabetes mellitus treated with insulin, peptic ulcer, and pregnancy.",
    "The sample is a phase 2 trial for patients with myelodysplastic syndromes or acute myelogenous leukemia. The trial involves the drug lenalidomide and has specific eligibility criteria, including being in complete hematological remission after allogeneic HSCT, having certain karyotype abnormalities, and meeting certain laboratory test result ranges. Females of childbearing potential must agree to use two reliable forms of contraception or practice complete abstinence during the study. There are also exclusion criteria, such as having a serious medical condition or a history of arterial or venous embolism or stroke.",
    "The sample is a phase 2 clinical trial for patients with non-small cell lung cancer. The trial is testing the effectiveness of erlotinib hydrochloride, a drug used to treat cancer. The eligibility criteria for patients include having confirmed NSCLC, being a lifelong nonsmoker, having a Zubrod performance status of 0-2, and meeting certain laboratory parameters. Patients must also not have any major medical conditions or psychological conditions that would preclude study treatment. The trial also has specific requirements for prior concurrent therapy and excludes patients who have received certain targeted therapies against the epidermal growth factor receptor or vascular endothelial growth factor axes.",
    "The sample is a phase 2 clinical trial for patients with advanced stages IIB/III/IV cutaneous T-cell lymphoma. The trial requires patients to have measurable or evaluable disease, and meet certain eligibility criteria such as age, performance status, and life expectancy. Patients must not have any contraindication to indwelling central venous catheter, no active infection including HIV, and no other medical condition that would preclude protocol compliance. The trial allows prior biological therapy and systemic chemotherapy, but patients with more than one prior regimen are analyzed separately. Prior skin irradiation and topical therapy are also allowed. The trial uses aminocamptothecin as the drug and includes a list of icd-10 codes of diseases. The eligibility criteria include disease characteristics and patient characteristics.",
    "The sample is a phase 2 clinical trial for breast cancer patients with ErbB2 (HER2/neu) overexpression. The trial includes patients with T2-4, N0-2 invasive breast cancer who have either measurable or evaluable disease. The trial involves the use of four drugs: trastuzumab, paclitaxel, fec75, and lapatinib. The eligibility criteria include having signed an informed consent form and a Patient Authorization Form, having adequate organ function, and being able to tolerate 8 cycles of preoperative chemotherapy. The trial also requires two mandatory core biopsies to obtain tissue for biologic expression profiling. The exclusion criteria include having received any prior chemotherapy, having malabsorption syndrome, having an active or uncontrolled infection, and being pregnant or breastfeeding.",
    "The sample is a phase 2 clinical trial for coronary artery disease, with the drug A-002 being tested. The trial is looking for men and women over 18 years of age who have stable CAD and are in a stable medical condition. The eligibility criteria include written informed consent, while the exclusion criteria include planned coronary artery bypass surgery, acute or chronic heart failure, hospitalization for acute coronary syndrome or STEMI, chronic inflammatory disease, recent infection or major surgery, and other medical conditions. Women who are pregnant or nursing, or intend to become pregnant during the study, are also excluded. The trial is being conducted at participating centers, and subjects must be able to comply with the requirements of the protocol.",
    "The sample is a phase 2 clinical trial for patients diagnosed with myeloproliferative neoplasms (MPN). The trial is testing the drug itacitinib. To be eligible for the trial, patients must have a confirmed diagnosis of primary myelofibrosis (PMF), post-polycythemia vera myelofibrosis (PPV-MF), or post-essential thrombocythemia myelofibrosis (PET-MF) through a bone marrow biopsy. They must also score at least 1 point on the Dynamic International Prognostic Scoring System (DIPSS) and have a peripheral blast count of less than 10%. Patients must discontinue all drugs used to treat their underlying MF disease no later than Day -14. They must have a hemoglobin value of at least 8.0g/dL and be willing to receive blood transfusions, have a platelet count of at least 50x10^9/L, and an absolute neutrophil count (ANC) of at least 1x10^9/L. Patients must also have a palpable spleen or history of splenectomy and active symptoms at the screening visit. Exclusion criteria include pregnancy or breastfeeding, impaired liver function, end-stage renal disease on dialysis, clinically significant concurrent infections requiring therapy, unstable cardiac function, and invasive malignancies over the previous 2 years except treated basal or squamous carcinomas of the skin, completely resected intraepithelial carcinoma of the cervix, and completely resected papillary thyroid and follicular thyroid cancers.",
    "The sample is a phase 2 clinical trial for prostate cancer. The trial includes patients with a histologic diagnosis of adenocarcinoma of the prostate and evidence of metastatic disease within 4 weeks of registration. Patients must meet certain criteria, including having a PSA level of at least 10 ng/mL and at least one lesion on bone scan or soft tissue metastases and/or visceral disease per CT scan. Patients must also show progressing prostate cancer as seen by one of the following: at least one new lesion on bone scan, increase in size or number of measurable disease lesions, or at least 2 rising PSA measurements at least two weeks apart. Patients must have a WHO performance status of 0-2 and peripheral neuropathy must be less than or equal to grade 1. There are also exclusion criteria, such as no prior cytotoxic chemotherapy and no known brain metastases.",
    "The sample is a record of a clinical trial in phase 2, which is testing the effectiveness of the drug \"domperidone\" in treating patients with Parkinson's disease and peripheral edema. The trial has specific eligibility criteria for patients to be included, such as having idiopathic PD and being on a stable medication regimen for at least one month. There are also exclusion criteria, such as pregnancy, diabetes mellitus, and alcohol abuse. The record includes the list of diseases and their corresponding ICD-10 codes, as well as the eligibility criteria for the trial.",
    "The sample is a record of a clinical trial in phase 2 for the treatment of constipation and chronic constipation. The trial involves the drug \"a3309\" and includes a list of ICD-10 codes for the diseases. The eligibility criteria for the trial are listed, including inclusion criteria such as meeting protocol specified criteria for constipation and successfully completing study requirements, and exclusion criteria such as having a medical history or condition that would not make the patient a good candidate for the study or needing medications prohibited by the protocol.",
    "The sample is a record of a clinical trial in phase 2, focused on the disease of asthma. The trial includes a list of icd-10 codes related to asthma. The drugs being tested include mometasone, montelukast, and an unspecified placebo. The eligibility criteria for the trial include having decreased breathing capacity that improves after taking a fast-acting asthma inhaler, having been treated with a fast-acting asthma inhaler within one month of the first study visit, and possibly being treated with a corticosteroid inhaler or an inhaler that combines a corticosteroid plus a bronchodilator. Exclusion criteria include hypersensitivity to inhaled beta-agonists, corticosteroids, leukotriene antagonists, or any of their components, and having required an oral corticosteroid rescue for worsening asthma during the screening period.",
    "The sample is a phase 2 clinical trial for patients with extensive stage small cell lung cancer or recurrent small cell lung cancer. The trial is testing the effectiveness of two drugs, topotecan hydrochloride and 7-hydroxystaurosporine, on patients who have received only first-line platinum-based chemotherapy and relapsed or progressed at least 3 months after completion of therapy. The trial has specific eligibility criteria, including measurable disease as defined by the Response Evaluation Criteria in Solid Tumours (RECIST), ECOG performance status =< 2 (Karnofsky >= 60%), and various blood and organ function requirements. Patients who have had prior therapy with a topoisomerase I inhibitor (topotecan or irinotecan) or other chemotherapy regimens other than first-line platinum-based chemotherapy will be excluded. The trial also has exclusion criteria, including uncontrolled intercurrent illness, pregnant women, and patients with immune deficiency.",
    "The sample is a phase 2 clinical trial for patients with urothelial carcinoma, specifically transitional cell carcinoma. The trial includes patients with metastatic or locally advanced unresectable disease who have received one prior chemotherapeutic regimen that included a platinum. Patients with certain types of other cancers or serious illnesses are excluded. The trial involves treatment with the drug paclitaxel and has specific eligibility criteria, including measurable disease according to RECIST criteria and an estimated life expectancy of more than 12 weeks. Patients must also have adequate organ function and be willing to use contraception if fertile.",
    "The sample is a phase 2 clinical trial for lung cancer patients who have previously undergone surgery or radiation and received adjuvant treatment or neoadjuvant with erlotinib or gefitinib for at least 3 months. The trial requires confirmation of EGFR sensitizing mutation in the primary or recurrent tumor and evaluation for the presence of the T790M mutation. Patients must have measurable disease by RECIST and meet certain eligibility criteria, including being over 21 years old and agreeing to use contraception during treatment. Exclusion criteria include prior progressive disease while receiving erlotinib or gefitinib therapy, pre-existing interstitial lung disease, and certain abnormal lab values. The trial is not open to pregnant or lactating women and patients who are medically unfit for erlotinib therapy.",
    "The sample is a phase 2 clinical trial for patients with metastatic or locally advanced breast cancer that cannot be cured with standard therapy. The trial involves the drugs custirsen sodium and docetaxel. The eligibility criteria include having measurable disease, no known CNS metastases, and meeting certain hematopoietic, hepatic, renal, cardiovascular, and immunologic requirements. Patients must also have recovered from prior chemotherapy and surgery, and not have any other serious medical conditions or illnesses that would preclude study participation. Prior trastuzumab therapy is allowed, but no other concurrent chemotherapy or investigational therapy is permitted.",
    "The sample is a phase 2 clinical trial that involves patients with hypertension and a confirmed solid tumor malignancy. The trial aims to test the effectiveness of lisinopril, losartan potassium, benazepril hydrochloride, and ramipril in treating hypertension in these patients. The trial has inclusion criteria such as having a systolic pressure > 130 OR a diastolic pressure > 80, not being on active chemotherapy or radiation therapy, and having a creatinine level < 2.5 and potassium level < ULN. The trial also has exclusion criteria such as being pregnant or nursing, unable to take oral medications, or currently taking an ACE-Inhibitor or ARB. Patients who meet the inclusion criteria and do not meet the exclusion criteria are eligible to participate in the study, including HIV positive patients.",
    "The sample is a phase 2 clinical trial for patients with type 2 diabetes. The trial is testing the effectiveness of a drug called ly2189265 compared to a placebo. The eligibility criteria for the trial include having type 2 diabetes and taking at least one oral diabetes medication for at least one month prior to screening. Participants must also have a glycosylated hemoglobin (HbA1c) value between 7% and 9.5%, a mean blood pressure between 90/60 mmHg and 140/90 mmHg, and a stable weight for three months prior to screening. Other criteria include having a BMI greater than or equal to 23 kg/m^2, being willing to wear an ambulatory blood pressure monitoring device for at least 24 hours on multiple occasions, and using a reliable method of birth control. Exclusion criteria include having a history of heart failure, chronic insulin therapy, or use of certain medications within a certain timeframe prior to screening.",
    "The sample is a phase 2 clinical trial for the treatment of metastatic renal cell carcinoma and kidney neoplasms. The trial involves the drugs zd6126 and placebo. The eligibility criteria for the trial include being newly diagnosed with metastatic renal cell carcinoma and being suitable for nephrectomy. Exclusion criteria include prior chemotherapy, biological therapy, or radiation therapy for renal cell carcinoma or any other cancer within the last 3 years, significant cardiac events within 3 months of entry, and any history of coronary angioplasty or myocardial infarction. The diseases are listed as \"carcinoma, renal cell\" and \"kidney neoplasms\" with corresponding ICD-10 codes.",
    "The sample is a phase 2 clinical trial for non-small cell lung cancer. The trial includes patients with unresectable locally advanced or metastatic non-squamous NSCLC who have not received previous chemotherapy or immunotherapy for advanced/metastatic NSCLC. The trial involves the use of multiple drugs including vinorelbine, cisplatin, bevacizumab, docetaxel, and gemcitabine. Patients must meet certain eligibility criteria, including having a performance status of 0-1, adequate bone marrow, liver, and renal function, and measurable disease. Patients must also not have active CNS disease and must be able to understand the nature of the study and give written informed consent. There are also exclusion criteria, such as pregnancy or lactation, active CNS disease, and concurrent treatment with other anti-cancer drugs.",
    "This sample is a phase 2 clinical trial for the treatment of renal cell carcinoma, a type of cancer that affects the kidneys and has spread to other parts of the body. The trial is testing the effectiveness of a drug called su011248 capsule. The eligibility criteria for the trial include having a confirmed diagnosis of renal cell carcinoma with clear cell histology and having metastases. The exclusion criteria include having received certain types of therapies for RCC, such as cellular therapy or molecular-targeting therapy.",
    "The sample is a phase 2 clinical trial for patients with HER2-positive metastatic breast cancer who are resistant to trastuzumab. The trial is testing the effectiveness of ridaforolimus and requires patients to meet certain eligibility criteria, such as having measurable disease, a certain performance status, and adequate cardiovascular, hematological, hepatic, and renal function. Patients must also not have received prior treatment with certain mTOR inhibitors and must have left ventricular ejection greater than or equal to 50%. The trial has exclusion criteria, such as inadequate recovery from prior surgery, known allergy to macrolide antibiotics, and concurrent treatment with medications that strongly induce or inhibit cytochrome P450. Patients must provide informed consent and comply with the protocol.",
    "The sample is a phase 2 clinical trial for the treatment of metastatic breast cancer using the drugs capecitabine and mitomycin c. The trial includes patients with histologically/cytologically confirmed breast cancer and at least one target lesion according to the RECIST criteria. Patients must be over 18 years old and have signed informed consent. Exclusion criteria include prior cytotoxic chemotherapy or active/passive immunotherapy for metastatic breast disease, prior usage of capecitabine or mitomycin as adjuvant or neoadjuvant treatment, life expectancy less than 3 months, not being ambulatory or having an ECOG performance status greater than 1, and insufficient hematological, renal, and hepatic functions. The trial also specifies criteria for target lesions and severe renal impairment.",
    "The sample is a phase 2 clinical trial for non-squamous non-small cell lung cancer. The trial includes patients with advanced Stage IIIb with pleural effusion or Stage IV. The patients must have an ECOG Performance Status of 0-1 and measurable disease per RECIST criteria. The trial excludes patients with squamous cell, small cell, or carcinoid lung cancer, CNS metastasis, pre-existing autoimmune or antibody mediated disease, and prior systemic treatment for NSCLC with chemo, immunotherapy, biologics, or investigation drugs. The trial involves two different drug combinations: paclitaxel + carboplatin + bevacizumab and carboplatin + paclitaxel + bevacizumab + pf-3512676.",
    "The sample is a phase 2 clinical trial for the treatment of fallopian tube cancer, ovarian cancer, and peritoneal cavity cancer. The trial involves the use of three drugs: cisplatin, liposomal doxorubicin, and paclitaxel. The eligibility criteria for the trial include having histologically confirmed stage III ovarian epithelial, fallopian tube, or primary peritoneal carcinoma, and having undergone staging exploratory laparotomy with tumor debulking within the past 70 days. Patients must also meet certain age, performance status, hematopoietic, hepatic, renal, cardiovascular, and other criteria. Patients must not have had prior chemotherapy or immunotherapy for ovarian cancer, and must not have any other concurrent antitumor treatment or antibiotics for infection of undetermined etiology.",
    "The sample is a record from a clinical trial table. It is a phase 2 trial for lymphoma. The trial includes a list of drugs, diseases, and icd-10 codes. The eligibility criteria for the trial are also listed, including inclusion and exclusion criteria. Patients must be less than 70 years old and have chemosensitive disease with less than 10% marrow involvement. Newly diagnosed patients are eligible for autologous transplant, while patients in relapse would receive a non-myeloablative transplant if a sibling donor is available. Otherwise, patients would undergo autologous transplant if the International Prognostic Index (IPI) is 0-1, or unrelated transplant if IPI is greater than 1. Exclusion criteria include HIV or HTLV seropositivity, pregnancy, low cardiac ejection fraction, active central nervous system involvement, and other medical or psychiatric illnesses.",
    "The sample is a phase 2 clinical trial for the treatment of eosinophilic esophagitis. The trial includes patients between the ages of 18 and 75 who have been diagnosed with EoE based on established diagnostic criteria. The trial will test the efficacy of several drugs, including low and high dose budesonide tablets and suspension, as well as a placebo. The eligibility criteria include having active symptomatic and histological EoE at baseline, and exclusion criteria include having other esophageal diseases or relevant gastrointestinal diseases, abnormal hepatic or renal function, a history of cancer within the last five years, and intolerance or hypersensitivity to the study drug. The trial also excludes patients who are pregnant or breastfeeding or who have undergone esophageal surgery or dilation procedures within the last 8 weeks prior to screening.",
    "The sample is a phase 2 clinical trial for various types of leukemia, lymphoma, myelodysplastic syndrome, and paroxysmal nocturnal hemoglobinuria. The trial involves the use of systematic chemotherapy and antibodies. The eligibility criteria include being between the ages of 2 and 21, having certain diagnoses or disease statuses, lacking a suitable HLA-identical sibling or matched unrelated donor, and meeting certain health criteria such as cardiac shortening fraction and creatinine clearance. Exclusion criteria include known allergy to murine products, lactating or pregnant females, and active central nervous system leukemia.",
    "The sample is a phase 2 clinical trial for small cell lung cancer. The trial includes patients with extensive-stage disease who have measurable or evaluable disease and an Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-1. Patients must also have adequate bone marrow function and normal organ function. The trial involves the use of the drugs irinotecan, carboplatin, and sunitinib. The eligibility criteria include resolution of all acute toxic effects of prior therapy or surgical procedures, informed consent, and agreement to use a form of birth control to prevent pregnancy during treatment. Exclusion criteria include pregnancy or breastfeeding, previous treatment with sunitinib, and ongoing cardiac dysrhythmias of National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) grade >=2.",
    "The sample is a phase 2 clinical trial for colorectal cancer. The trial includes patients who are 18 years or older and have carcinoma of the colon and/or rectum. The patients must have had disease progression during or within 6 months of their last dose of oxaliplatin containing first-line combination therapy for metastatic disease. The trial also requires patients to have an ECOG performance status of 0-1 and adequate hematological, renal, and liver function. The trial excludes patients who have had prior treatment with monoclonal antibody/small molecule against epidermal growth factor receptor (EGFR), prior treatment with irinotecan, radiotherapy within the last 4 weeks before the first dose of study drug (except for limited field palliative radiotherapy for bone pain relief), CNS metastasis, and a history of or active autoimmune disorders/conditions. The trial will use folfiri, ro5083945, and cetuximab as drugs.",
    "The sample is a phase 2 clinical trial for chronic hepatitis B. The trial is looking for participants who are between 18 and 69 years old and have been diagnosed with chronic HBV infection for at least 6 months. Participants must be currently treated with adefovir dipivoxil for at least 24 weeks but not more than 96 weeks, and have HBeAg positive or negative at screening. They must also have plasma HBV DNA of at least 1000 copies/mL at screening, irrespective of HBeAg status, and serum ALT less than 10 times the upper limit of normal (ULN). Participants must have a calculated creatinine clearance of at least 70 mL/min using the Cockcroft-Gault formula, hemoglobin at least 8 g/dL, and neutrophils at least 1,000 /mm3. They must be nucleoside naive except for lamivudine (>/= 12 weeks of therapy), negative for serum beta human chorionic gonadotropin, and compliant with adefovir dipivoxil. Participants must be willing and able to provide written informed consent. Exclusion criteria include pregnant women, women who are breastfeeding or who believe they may wish to become pregnant during the course of the study, and male or females of reproductive potential who are unwilling to use an effective method of contraceptive while enrolled in the study. For males, condoms should be used and for females, a barrier contraception method should be used. Other exclusion criteria include decompensated liver disease, prior use of tenofovir DF or entecavir, evidence of hepatocellular carcinoma (HCC), co-infection with HCV, HIV, or hepatitis delta virus (HDV), significant renal, cardiovascular, pulmonary, or neurological disease, received solid organ or bone marrow transplantation, currently receiving therapy with immunomodulators, investigational agents, nephrotoxic agents, or agents capable of modifying renal excretion, has proximal tubulopathy, and known hypersensitivity to the study drugs (tenofovir DF or emtricitabine/tenofovir DF), the metabolites (tenofovir or emtricitabine) or formulation excipients.",
    "The sample is a phase 2 clinical trial for the treatment of melanoma (skin cancer) using the drug everolimus. The trial is for patients with stage IV melanoma that is not curable with standard therapies. Patients must have measurable disease and meet certain eligibility criteria, including being at least 18 years old, having a performance status of ECOG 0-2, and having a life expectancy of at least 12 weeks. Patients must also meet certain hematopoietic, hepatic, renal, and other criteria, and must not have any other malignancy within the past 5 years except basal cell or squamous cell skin cancer treated with local resection only. Patients must not have received certain prior therapies, and must not be receiving concurrent chemotherapy, radiotherapy, or immunosuppressive therapy. The trial is designed to evaluate the safety and efficacy of everolimus in this patient population.",
    "The sample is a phase 2 clinical trial for the treatment of secondary hyperparathyroidism. The trial involves the drug etelcalcetide and has eligibility criteria such as intact PTH levels, corrected calcium levels, hemoglobin levels, and adequate hemodialysis. Exclusion criteria include a history of ventricular dysrhythmias, angina pectoris, congestive heart failure, myocardial infarction, coronary angioplasty, or coronary artery bypass grafting within the past 6 months, treatment for seizure disorder within the last 12 months, and postdialysis blood pressure levels. The trial requires written informed consent from the subjects.",
    "The sample is a phase 2 clinical trial for patients with recurrent or metastatic breast cancer. The trial includes patients with local regional recurrence, including axillary and/or chest wall involvement, and allows for brain metastases that have been treated with surgery or radiotherapy and have remained stable for at least 3 months. Patients must have estrogen receptor- or progesterone receptor-positive disease by standard immunohistochemical techniques. The trial also has specific eligibility criteria for patient characteristics, including age, sex, performance status, life expectancy, and absence of severe or uncontrolled systemic diseases. Prior concurrent therapy is also restricted, including no concurrent chemotherapy or radiotherapy and specific requirements for prior hormonal therapy.",
    "The sample is a phase 2 trial for patients with stomatitis who are enrolled in participating stomatogenic autologous or allogeneic PBSCT/BMT protocols. The trial involves the use of the drugs etanercept and placebo. The eligibility criteria include being a male or female oncology patient who is willing to participate in the study, able to understand and sign the protocol consent or assent, and aged 16 years or older. The exclusion criteria include being pregnant or lactating, unable to follow oral rinsing directions, intubation, chronic use of medications that may confound assessment of the inflammatory response, pre-existing oral infection or upper respiratory infection, and known hypersensitivity or allergic reaction to etanercept.",
    "The sample is a phase 2 clinical trial for the treatment of inflammation and rheumatoid arthritis. The trial involves two drugs, nnc 0151-0000-0000 and placebo, and includes a list of eligibility criteria for participants. Inclusion criteria include being between the ages of 18 and 65, having a diagnosis of rheumatoid arthritis for at least three months, and being on a stable dose of methotrexate for at least four weeks prior to the trial. Exclusion criteria include known or suspected allergies to the trial product or related products, and having a body mass index less than 18.0 or more than 38.0 kg/m2. The diseases are listed along with their corresponding ICD-10 codes.",
    "The sample is a phase 2 clinical trial for the treatment of peripheral neuropathy and neuropathic pain. The trial involves the use of drugs such as adl5859, duloxetine, and placebo. The eligibility criteria include being between 18 and 75 years old, having stable glycemic control for at least 3 months, and experiencing daily pain due to diabetic peripheral neuropathy for at least 3 months. Exclusion criteria include having pain conditions that cannot be distinguished from DPN, significant renal or hepatic disease, a history of seizure disorder, and use of certain medications. Participants must be willing and able to comply with the protocol requirements and provide written informed consent in English.",
    "The sample is a record of a clinical trial with a phase 2 designation. The trial is focused on eosinophilic esophagitis, a disease characterized by an excess of eosinophils in the esophagus. The trial includes a list of ICD-10 codes associated with the disease. The trial involves two drugs, budesonide plus prevacid and placebo plus prevacid. The eligibility criteria for the trial include histologic evidence of EE, ages 1 year and older, and the ability to continue the same diet that the patient was on at the time of EGD with biopsy. The exclusion criteria include adverse reaction or allergy to budesonide, pregnancy, chronic diseases requiring immunomodulatory therapy, use of swallowed topical corticosteroids for EE within the past 3 months, use of systemic steroids 2 months prior to study entry, upper gastrointestinal bleed within 4 months of study entry, chronic use of medications that predispose to upper gastrointestinal bleeding including non-steroidal anti-inflammatory medications or anticoagulants, evidence of adrenal suppression prior to study entry, evidence of concurrent eosinophilic gastritis, enteritis, colitis, or proctitis, and recent changes in asthma or allergic rhinitis therapy for 3 months.",
    "This sample is for a phase 2 clinical trial for the treatment of chronic hepatitis C virus infection using a drug called cts-1027. The eligibility criteria for the trial include having a history of unsuccessful HCV treatment, liver impairment, and normal levels of AFP, hemoglobin, platelet count, and white blood cell count. Patients must also be willing to use adequate contraception during the trial. Exclusion criteria include severe liver disease, hepatocellular carcinoma, HIV or HBV infection, pregnancy or lactation, renal impairment, pancreatitis, and use of certain drugs or illicit substances. Patients must not have received any investigational drug or device within 30 days of dosing or be scheduled to receive another investigational drug or device during the trial.",
    "The sample is a phase 2 clinical trial for patients with symptomatic multiple myeloma. The trial includes patients who have received conventional chemotherapy in their first line of treatment and are in their first relapse or refractory to the first line therapy. The trial requires patients to have measurable disease and a life expectancy of at least 3 months. Patients must also meet certain laboratory test results and performance status criteria. The trial involves the use of bendamustine, velcade, and dexamethasone as the treatment plan. Patients must adhere to the study visit schedule and other protocol requirements, and use effective contraceptive methods during and for 6 months after study treatment. The trial has exclusion criteria, including any serious medical condition, laboratory abnormality, or psychiatric illness that would prevent the subject from signing the informed consent form, and any comorbidity which places the subject at unacceptable risk if he/she were to participate in the study.",
    "The sample is a phase 2 clinical trial for asthma. The trial includes patients who have had a three-month history of reversible asthma, are between 18 and 65 years old, and have a stable inhaled corticosteroid dose for three months prior to screening. The trial also requires patients to have a diagnosis of asthma prior to 40 years old and an Asthma Control Questionnaire score of at least 1.5 at randomization. Patients must be non-smokers or ex-smokers with less than 10 pack years history and negative cotinine screen. The trial excludes patients with significant diseases other than asthma or allergic rhinitis, hepatic transaminases or total bilirubin greater than 1.5 ULN, hospitalization for asthma exacerbation or asthma-related intubation within 3 months, uncontrolled asthma on iCS + other controller, respiratory tract infection or exacerbation within 4 weeks, FEV1 less than 40%, more than 12 puffs rescue salbutamol on more than two consecutive days, or asthma exacerbation during the run-in period. Pregnant or nursing women and women of childbearing potential not using appropriate methods of birth control as defined by the study protocol are also excluded. The trial will test the effectiveness of bi671800, placebo, and montelukast as treatments for asthma.",
    "The sample is a phase 2 clinical trial for the treatment of multiple myeloma. The trial includes patients who are newly diagnosed with Salmon-Durie stage II or III MM, or stage I MM patients who display poor prognostic factors. The patients must have measurable disease and meet certain laboratory parameters. They must also be willing to comply with the requirements of RevAssist\u00ae and the S.T.E.P.S.\u00ae programs. The trial involves the use of four drugs: thalomid, lenalidomide, clarithromycin, and dexamethasone. The eligibility criteria include age over 18, Karnofsky performance status \u226570%, and life expectancy \u2265 3 months. The trial has exclusion criteria, such as patients with non-secretory MM, prior history of other malignancies, and active hepatitis B or hepatitis C infection.",
    "The sample is a phase 2 clinical trial for patients with metastatic melanoma. The trial includes patients with measurable disease who have had up to one prior cytotoxic regimen for metastatic disease. Patients must have recovered from the acute toxicities of prior treatment and have a life expectancy of greater than 3 months. The trial involves the use of two drugs, everolimus and imatinib, and patients must meet certain eligibility criteria, including having organ and marrow function within certain parameters and agreeing to use adequate contraception. Patients with known brain metastases or leptomeningeal disease are excluded from the trial, as are pregnant women and patients with uncontrolled intercurrent illness. The trial has both inclusion and exclusion criteria, and patients must understand and be willing to sign a written informed consent document.",
    "The sample is a phase 2 clinical trial for patients with mild or moderate dementia of the Alzheimer type. The trial involves the use of a drug called TRx0014 and a placebo. Patients must have a clinical diagnosis of dementia of the Alzheimer type and meet certain criteria, including having a competent carer who is willing to participate in the study. Patients must also be able to give written informed consent to participate. The trial has exclusion criteria, such as patients with a known sensitivity to TRx0014 or other anti-dementia drugs, and patients who are unlikely to comply with the trial visit schedule or medication. The trial aims to assess the safety and efficacy of TRx0014 in treating dementia of the Alzheimer type.",
    "The sample is a record of a clinical trial with a phase 2 designation. The trial is focused on the treatment of atrial fibrillation and stroke. The diseases and their corresponding ICD-10 codes are listed. The drugs being tested are dabigatran etexilate, and the eligibility criteria for participants are also listed. Inclusion criteria include a history of coronary artery disease, a diagnosis of paroxysmal, persistent, or permanent non-rheumatic atrial fibrillation, and an additional risk factor for stroke such as hypertension, diabetes, or congestive heart failure. Exclusion criteria include valvular heart disease, contraindication to anticoagulant therapy, severe renal impairment, uncontrolled hypertension, pregnancy or refusal to use contraception, recent malignancy or radiation therapy, and other conditions that may not allow safe participation in the study.",
    "The sample is a clinical trial for Parkinson's disease, with a combination of phase 2 and phase 3. The trial involves testing the efficacy and safety of various doses of a drug called tozadenant (syn115) in comparison to a placebo and levodopa. The trial includes a list of inclusion and exclusion criteria for participants, such as meeting the UK PD diagnostic criteria, having a good response to levodopa, and not having a history of hepatitis or cholangitis. The trial also requires participants to complete a Parkinson's disease diary and follow study instructions.",
    "The sample is a record of a clinical trial in phase 2 for the treatment of amyotrophic lateral sclerosis (ALS) using the drug thalidomide. The trial has eligibility criteria for inclusion and exclusion of patients, including a clinically proven diagnosis of ALS, a disease duration of less than or equal to 5 years, and an ALSFRS-R score equal to or greater than 30. Patients with known deep venous thrombosis or hypercoagulable state, as well as those with a forced vital capacity (FVC) less than 80%, will be excluded from the trial. The icd-10 code for ALS is also included in the record.",
    "The sample is a phase 2 clinical trial for previously untreated symptomatic classical C-GVHD (with prior allogeneic stem cell transplant) requiring systemic therapy. The trial is for patients who have at least 3 sites of organ involvement or individual organ score of at least 2, and are on agents for GVHD prophylaxis or have received therapy for acute GVHD prior to enrollment. Patients must be 18 years of age or older, have an ECOG performance status of 0-2, and be accessible for treatment and follow-up. The trial requires patients to be treated and followed at the participating center. Patients must be willing and able to complete the GVHD questionnaire. Patients who have been started on prednisone therapy for cGVHD but otherwise meet all of the eligibility criteria must be registered into this trial no later than 14 days from the start of prednisone therapy. Exclusion criteria include uncontrolled infection, recurrent malignancy, previous systemic therapy for C-GVHD, inability to tolerate prednisone or rituximab, usage of additional concurrent agents which could treat C-GVHD, administration of anticancer therapies or other investigational agents, sexually active males and females of childbearing potential unwilling to practice contraception during the study, women of childbearing potential with either a positive or no pregnancy test at baseline or lactating, patients with immune deficiency, and patients with active hepatitis B.",
    "The sample is a phase 2 clinical trial for a drug called afn-12520000. The trial is focused on treating skin and subcutaneous tissue bacterial infections, wound infections, cutaneous abscesses, burn infections, and cellulitis caused by staphylococci. The trial is open to patients between the ages of 18 and 70 who have failed previous treatment and meet specific eligibility criteria. The eligibility criteria include having a primary infected lesion with certain symptoms, signs of systemic inflammation or complicating factors, and a Gram stain or PCR result indicating an infection with Staphylococci. The trial has exclusion criteria, such as having certain chronic infections, being unable to tolerate an oral formulation of antibiotic, or having a known or suspected non-skin source of infection. The trial also has criteria for exclusion, such as being pregnant or breastfeeding, having a history of epilepsy or severe and frequent migraine headaches, or being an employee of the Investigator or study center with direct involvement in the proposed study.",
    "The sample is a phase 2 clinical trial for patients with systemic mastocytosis, including mast cell leukemia. The trial is testing the drug rad001 (everolimus). The eligibility criteria include being at least 18 years old, having adequate liver function, and having an Eastern Cooperative Oncology Group (ECOG) performance status of 2 or lower. Exclusion criteria include having received treatment with any conventional or investigational medicine for SM within the preceding 4 weeks, having chronic treatment with systemic steroids or another immunosuppressive agent, and having other concurrent severe and/or uncontrolled medical disease which could compromise participation in the study. Patients must also be willing to comply with the protocol and have signed informed consent.",
    "The sample is a phase 2 clinical trial for the treatment of cystic fibrosis. The trial involves the use of drugs such as ivacaftor and placebo. The eligibility criteria for the trial include having a confirmed diagnosis of cystic fibrosis with a G551D mutation, weighing at least 40 kg, and having a forced expiratory volume in 1 second (FEV1) of at least 40% of predicted normal for age, gender, and height. Participants must also be willing to remain on a stable medication regimen for the duration of the study and use at least 2 highly effective birth control methods during Part 1 and 1 highly effective birth control method during Part 2 of the study if they are not pregnant. Exclusion criteria include a history of any illness or condition that might confound the results of the study or pose an additional risk in administering study drug to the subject, ongoing acute respiratory infection, pulmonary exacerbation, or changes in therapy for pulmonary disease within 14 days of Day 1 of the study, and abnormal liver or renal function. Participants must not be pregnant or breastfeeding, and must not be participating in another therapeutic clinical trial or have prior participation in an investigational drug study without appropriate washout. Concomitant use of any inhibitors or inducers of cytochrome P450 3A4 (CYP3A4) is also not allowed.",
    "The sample is a record from a clinical trial table that includes information about the phase of the trial, diseases being studied, icd-10 codes of the diseases, drugs being tested, and eligibility criteria for participants. In this particular sample, the trial is in phase 2/phase 3 and is focused on low-grade B-cell lymphoma, excluding mantle cell lymphoma and histologic transformation to DLBCL. The drugs being tested are rituximab + standard chop and rituximab + bi-weekly chop. The eligibility criteria include factors such as age, lymphoma cell count, ECOG PS, and bidimensionally measurable disease. There are also exclusion criteria, such as CNS involvement, glaucoma, and liver cirrhosis.",
    "The sample is a phase 2 clinical trial for patients with stable symptoms of intermittent claudication of the lower extremities caused by chronic occlusive arterial disease from atherosclerosis etiology. The trial includes patients with an initial claudication distance of 30 to 250 meters at screening constant workload treadmill test and confirmation of underlying Peripheral Arterial Disease (PAD) at screening. The patients must have optimal cardiovascular risk prevention and appropriate management of PAD, including clopidogrel at the dose of 75mg per day, during the study period. The trial excludes patients who participated in investigational clinical trials in the last month prior to screening, pregnant or breast-feeding women or women without documented double birth control measures for at least 3 months prior to randomization, and patients treated by cilostazol within 3 months prior to screening. The trial also excludes patients with recent lower-extremity surgical or endovascular arterial reconstructions or sympathectomy, or recent deep venous thrombosis, and recent occurrence of acute myocardial infarction, unstable angina, coronary artery bypass graft, percutaneous coronary intervention, transient ischemic attack or stroke.",
    "The sample is a phase 2 clinical trial for castration-resistant prostate cancer. The trial is testing the effectiveness of two drugs, rad001 and bicalutamide, on patients with a baseline PSA of 2ns/mL or greater and testosterone levels of 50ng/mL or less. The trial has inclusion criteria such as being 18 years or older, having histologically documented prostate cancer, and having completed prior systemic anticancer therapy. Exclusion criteria include prior treatment with an mTOR inhibitor, uncontrolled brain or leptomeningeal metastases, and known hypersensitivity to RAD001 or other rapamycins. The trial also has specific eligibility criteria related to bone marrow and liver function, gastrointestinal function, and medical history.",
    "The sample is for a phase 2 clinical trial that focuses on patients with type 2 diabetes mellitus. The trial includes a list of icd-10 codes for the disease and a list of drugs, including gk activator and metformin. The eligibility criteria for the trial include being an adult between the ages of 30-75 with type 2 diabetes mellitus and having taken the maximum daily dose of metformin for at least 3 months prior to screening. Patients with type 1 diabetes mellitus or who have taken any other oral anti-hyperglycemic medication, other than metformin, in the last 3 months are excluded from the trial.",
    "The sample is a record of a clinical trial for a drug called tadalafil, which is being tested for its effectiveness in treating pulmonary hypertension in patients with biopsy-proven sarcoidosis. The trial is in phase 2/phase 3 and the eligibility criteria include specific medical conditions and test results, such as mean pulmonary artery pressure, pulmonary capillary wedge pressure, PVR values, forced vital capacity, and forced expiratory volume. Patients must also be on a stable sarcoidosis treatment regimen for three months prior to entry into the study and have a 6-minute walk distance between 150-450 meters. There are also exclusion criteria, such as severe systemic hypertension, severe systemic hypotension, and history of priapism. The sample includes a detailed list of inclusion and exclusion criteria for the trial.",
    "The sample is a phase 2 clinical trial for the treatment of growth hormone disorders and adult growth hormone deficiency. The trial involves the use of the drugs nnc126-0083 and placebo. The eligibility criteria include having been diagnosed with GH deficiency, being on GH replacement therapy for at least 3 months, having a BMI between 22.0 and 35.0 kg/m2, and being a fertile female who agrees to use appropriate contraceptive methods. Exclusion criteria include having malignant disease, heart insufficiency, or impaired liver or kidney function, among others.",
    "The sample is a phase 2 clinical trial for patients with metastatic pancreatic cancer. The trial is testing the effectiveness of a combination of gemcitabine and lapatinib. The eligibility criteria include having confirmed metastatic adenocarcinoma of the pancreas, no prior chemotherapy for pancreatic cancer, ECOG performance status 0-1, ability to swallow oral medications, age over 18, and adequate hematologic, hepatic, and renal function. Women of childbearing potential must use effective contraception and cannot be pregnant or lactating. Exclusion criteria include prior treatment with lapatinib or any EGFR targeting therapies, prior treatment with systemic chemotherapy for pancreatic cancer, clinical evidence of brain metastases or leptomeningeal disease, uncontrolled intercurrent illness, active cardiac disease, known hypersensitivity to drugs related to lapatinib, HIV-positive patients receiving combination anti-retroviral therapy, participation in any investigational study within 28 days prior to study enrollment, major surgery within the last 4 weeks, pregnant or lactating females, uncontrolled malabsorption syndrome, unresolved bowel obstruction, inadequate venous access, taking any medication on the prohibited medications list, and receiving any other investigational agents or concurrent anticancer therapy.",
    "The sample is a phase 2 clinical trial for breast cancer patients with stage IV disease and evidence of metastatic disease. The trial is testing the effectiveness of the drug gemcitabine. The eligibility criteria include having measurable disease, no active CNS metastases, and meeting certain patient characteristics such as being female and having a SWOG performance status of 0-2. Prior concurrent therapy is also taken into consideration, with restrictions on prior chemotherapy and hormonal therapy. Patients must also meet certain hematopoietic, hepatic, and renal requirements, and cannot have any serious systemic disorders or unresolved bacterial infections. The trial also has restrictions on concurrent medication and supplements.",
    "The sample is a phase 2 clinical trial for patients with relapsed/refractory multiple myeloma. The trial includes the drugs bortezomib, dexamethasone, and doxorubicin hcl liposome. The eligibility criteria include being at least 18 years old, having measurable disease by serum or urine, having received at least 1 prior treatment regimen, having an ECOG score of \u2264 2, and providing voluntary written informed consent. Exclusion criteria include having certain medical conditions or receiving other investigational drugs within 14 days before enrollment.",
    "The sample is a phase 2 clinical trial for the treatment of velo-cardio-facial syndrome and psychosis. The trial involves the use of two drugs, metyrosine and placebo. The eligibility criteria include a genetically confirmed diagnosis of VCFS, a DSM-IV TR diagnosis of schizophrenia, schizoaffective disorder, psychosis not otherwise specified (NOS), bipolar disorder, or mood disorder with psychotic features, and a total PANSS composite score >65. Exclusion criteria include evidence of acute suicidality, clinically significant cardiovascular, pulmonary, renal, hepatic, or gastrointestinal disorders, full scale IQ of less than 50, pregnancy, and not using a reliable means of contraception.",
    "The sample is a phase 2 clinical trial for the treatment of prostatic neoplasms. The trial involves the use of cetuximab and docetaxel drugs. The eligibility criteria for the trial include having histologic proof of prostatic adenocarcinoma without evidence of regional and/or distant metastasis, recent negative bone scan and MRI of abdomen and pelvis, being an appropriate surgical candidate for radical prostatectomy, having adequate bone marrow, hepatic, and renal function, and having no history of congestive heart failure or previous MI within the last 12 months. The exclusion criteria include previous or current hormonal treatment, chemotherapy, radiation therapy, immunotherapy, or other investigational status drug, inability to tolerate transrectal ultrasound, and having certain medical conditions such as uncontrolled cardiac, hepatic, renal, or neurologic/psychiatric disorder.",
    "The sample is a phase 2 clinical trial for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma. The trial is testing the drug pivanex. Patients must have relapsed or refractory disease after previous chemotherapy treatment and meet certain eligibility criteria, including adequate renal and liver function, bone marrow function, and a predicted life expectancy of at least 6 months. Patients must also have an Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2. Exclusion criteria include having more than three systemic treatment regimens for CLL/SLL, concurrent malignancy, pregnancy or lactation, known HIV-positive status, and any underlying medical conditions that would contraindicate therapy with the study treatment.",
    "The sample is a phase 2 clinical trial for patients with moderate to severe early rheumatoid arthritis who have not previously been treated with methotrexate or biologic disease modifying antirheumatic drugs. The trial involves three different drugs: tasocitinib plus methotrexate, tofacitinib plus placebo methotrexate, and placebo tofacitinib plus methotrexate. The eligibility criteria for the trial include being an adult patient with early rheumatoid arthritis, not being pregnant or lactating, not having renal or hepatic impairment or other severe or progressing disease, and not having a contraindication to magnetic resonance imaging with gadolinium contrast.",
    "The sample is a phase 2 clinical trial for patients with neoplastic meningitis or B cell lymphoma. The trial is testing the effectiveness of cytarabine liposome injection. The eligibility criteria include confirmation of the disease, a Karnofsky Performance Score of 60 or above, and adequate hematologic, renal, and liver function. Patients must also meet certain laboratory requirements and have no uncontrolled infections. Patients who have had prior CNS radiation or intrathecal methotrexate are eligible. The trial excludes patients who have received experimental chemotherapy or immunotherapy within four weeks prior to the study, as well as those receiving whole brain radiotherapy or craniospinal irradiation. Pregnant or lactating women are also excluded.",
    "The sample is a phase 2 clinical trial for HIV infection. The trial includes male and female participants between the ages of 2 and 18. Female participants must have a negative pregnancy test and agree to use a form of contraception during the study. The trial requires participants to have a plasma HIV-1 RNA level of at least 400 copies/mL and be able to construct an active NRTI backbone regimen consisting of 2 NRTIs. The trial excludes participants who have received amprenavir, have had an AIDS defining illness within 28 days of screening, are pregnant or lactating, have a malabsorption syndrome or other gastrointestinal dysfunction, have a serious medical condition that might compromise their safety, have certain medication allergies, or have received certain medications within 28 days prior to receiving study medication. The trial also requires informed consent from the parent or legal guardian of the participant.",
    "The sample is a phase 2 clinical trial for Parkinson's Disease. The trial includes patients who are outpatients and have been treated with L-dopa, experiencing OFF time and dyskinesias for at least three months. The trial excludes patients who have undergone surgical treatment for PD, have had cancer within the past 5 years (other than localized skin cancer and prostate cancer that has been effectively treated), and have advanced, severe or unstable disease (other than PD) that may interfere with the study outcome evaluations. The trial may also have other protocol-defined inclusion/exclusion criteria. The trial involves the use of two drugs, afq056 with l-dopa and placebo.",
    "This sample is a phase 2 clinical trial for patients with intraocular melanoma that has spread to other parts of the body. The trial is testing the effectiveness of the drug temozolomide. The eligibility criteria for patients include having confirmed uveal melanoma, measurable disease, and no curative surgical treatment options. Patients must also meet certain health requirements, such as having a certain level of hemoglobin and platelet count, and not having any uncontrolled active disease or clotting disorders. Patients cannot have had prior chemotherapy for metastatic disease and must not be receiving any other concurrent anticancer treatment.",
    "The sample is a phase 2 clinical trial for Parkinson's disease. The trial includes patients with idiopathic PD who have end-of-dose motor fluctuations and Hoehn and Yahr stage 2-4 during the on state. Patients must have an average of 3.0 hours of off time, with a minimum of 0.5 hours of off time on each day, as recorded in a PD home diary on 3 consecutive days before the decision of entry. Patients must be treated with 3-8 daily doses of levodopa/dopa decarboxylase inhibitor (DDCI) with entacapone or without entacapone, including daily use of soluble levodopa formulation, with a total daily levodopa dose in the range of 400-1400 mg. Patients must not have secondary or atypical parkinsonism, severe dyskinesias, currently active hallucinations, severe orthostatic hypotension, current dementia, problematic impulse control disorders, history of neuroleptic malignant syndrome, past or current treatment with deep brain stimulation or other surgical treatment for PD, narrow-angle glaucoma or pheochromocytoma, or any active malignant cancer. Patients must also demonstrate acceptable/appropriate use of the diary, despite adequate training, during the screening visit or other separate training sessions during the screening period.",
    "The sample is a phase 2 clinical trial for the treatment of intermittent claudication, a condition caused by peripheral artery disease. The trial involves the drug sapropterin dihydrochloride and has specific eligibility criteria for participants, including age range, diagnosis of PAD, and certain physical requirements. Participants must also discontinue certain medications and supplements for the duration of the study. The trial has exclusion criteria, such as recent surgeries or other medical conditions that could interfere with participation. Participants must provide written consent and comply with all study-related procedures.",
    "The sample is a record of a clinical trial for Crohn's disease, in phase 2. The trial involves the drug laquinimod and includes a list of inclusion and exclusion criteria for potential participants. The diseases and their corresponding ICD-10 codes are also listed.",
    "The sample is a phase 2 trial for patients with dialysis and anemia. The trial is testing the drug fg-4592. The eligibility criteria includes being between the ages of 18 and 80, receiving hemodialysis or peritoneal dialysis for end-stage renal disease for 2 weeks to 4 months, having a hemoglobin level below 10 g/dL, and having a body weight between 40 and 140 kg. Exclusion criteria includes having previously received erythropoiesis-stimulating agents, receiving IV iron within 4 weeks prior to randomization, having a positive test for HIV, hepatitis B surface antigen, or anti-hepatitis C virus antibody, having a history of chronic liver disease, having a clinically significant infection, having New York Heart Association Class III or IV congestive heart failure, having a history of cancer within the past 4 years, having a chronic inflammatory disease even if it is in remission, having a history of other blood disorders, having active hemolysis or diagnosis of hemolytic syndrome, having known bone marrow fibrosis, having uncontrolled or symptomatic secondary hyperparathyroidism, having a history of alcohol or drug abuse, having a history of allergy or sensitivity to oral or intravenous iron, having had a heart attack, deep vein thrombosis, or pulmonary embolism in the past 3 months, having a seizure disorder or receiving anti-epilepsy medication, and being pregnant or breast-feeding.",
    "The sample is a phase 2 clinical trial for HIV infection. The trial is testing the drug tmc125. The eligibility criteria for the trial include being 18 years or older, having documented HIV-1 infection, and having prior experience with NNRTIs with evidence of resistance to currently available NNRTIs. The trial also requires the subject to be sensitive to the 2 NRTIs to be used as underlying ART. The exclusion criteria include previous treatment with Protease Inhibitors, presence of any currently active AIDS defining illness except stable cutaneous Kaposi's Sarcoma and Wasting syndrome due to HIV infection, and current or past history of alcohol and/or drug use which, in the investigator's opinion, would compromise the subject's safety or compliance to the study protocol procedures.",
    "The sample is a record of a clinical trial in phase 2, focused on the disease of congestive heart failure. The trial includes patients with fluid overload despite standard treatment, and the drug being tested is extraneal. The eligibility criteria for the trial include exclusion of patients with reversible CHF or other conditions that would make peritoneal dialysis contraindicated. The icd-10 codes associated with the disease are also provided.",
    "The sample is a phase 2 clinical trial for patients with gastric cancer that is locally advanced, unresectable, or metastatic. The trial involves the use of two drugs, capecitabine and oxaliplatin. The eligibility criteria include having histologically or cytologically confirmed gastric cancer, measurable disease, and no known brain metastases. Patients must also meet certain patient characteristics such as having an ECOG performance status of 0-2 or Karnofsky PS 60-100%, and meeting certain laboratory values. Patients must not have any uncontrolled intercurrent illness and must not be receiving any other concurrent anticancer agents or therapies. Prior concurrent therapy must have been completed at least 4 weeks prior to the trial and patients must have recovered.",
    "This is a sample from a clinical trial table that includes information about the phase of the trial, diseases being studied, icd-10 codes of the diseases, drugs being tested, and eligibility criteria for participants. In this particular sample, the trial is in phase 2 and is studying benign prostatic hyperplasia. The icd-10 codes associated with this disease are N40.0 and N40.1. The drugs being tested are tadalafil and a placebo. The eligibility criteria for participants include being male and over 40 years old with lower urinary tract symptoms and a total International Prostate Symptom Score (IPSS) greater than or equal to 13 at Visit 1. Participants must also agree not to use any other approved or experimental medications for BPH-Lower Urinary Tract Symptoms during the study. Exclusion criteria include a history of certain medical conditions and procedures, such as pelvic surgical procedures on the urinary tract and neurologic diseases associated with neurogenic bladder.",
    "The sample is a phase 2 clinical trial for patients with stage III unresectable or AJCC stage IV cutaneous, mucosal, ocular, or unknown primary melanoma with measurable disease. The trial is testing the drug Depsipeptide. The eligibility criteria include having normal organ and marrow function, a negative pregnancy test, and a performance status of 0-2 on the ECOG scale. Exclusion criteria include prior chemotherapy, active CNS metastases, and a history of coronary atherosclerotic heart disease or myocardial infarction. Patients must also have a corrected QT (QTc) less than 500 msec and an LVEF greater than 40% by MUGA. The trial requires patients to switch from hydrochorthiazide to a potassium-sparing diuretic or another antihypertensive. The trial lasts at least 4 weeks after prior radiotherapy. Patients with cardiac hypertrophy may be enrolled but should be carefully monitored.",
    "The sample is a phase 2 clinical trial for the treatment of refractory partial onset seizures in pediatric subjects aged 4 to 16 years old. The trial is testing the drug levetiracetam and the eligibility criteria includes having a minimum of two partial onset seizures during the four weeks prior to enrollment, being on a stable regimen of one or a maximum of two other antiepileptic drugs for at least 2 weeks prior to enrollment, having an IQ of at least 70, and being fluent in English. Exclusion criteria includes not having had previous treatment with levetiracetam, receiving benzodiazepines on a routine or chronic basis and having a current psychiatric disorder other than mild to moderate attention deficit, behavior, or learning disorders.",
    "The sample is a phase 2 clinical trial for patients with unresectable AJCC Stage III/IV malignant melanoma. The trial involves the use of the drug cyclophosphamide. The eligibility criteria include being at least 18 years old, having a life expectancy of at least 4 months, having measurable disease, and meeting certain laboratory test values. Patients must also have a negative pregnancy test and use contraception if they are of childbearing potential. Exclusion criteria include having certain medical conditions, a history of certain diseases, and being pregnant or breastfeeding.",
    "The sample is a phase 2 clinical trial for the treatment of Restless Legs Syndrome. The trial includes patients who are 18 years or older and have been diagnosed with primary Restless Legs Syndrome using ICSD-2 criteria. The patients must have an urge to move their legs, usually accompanied by uncomfortable and unpleasant sensations in the legs, which worsen during periods of rest or inactivity. The trial involves the use of the drugs aplindore and placebo. The eligibility criteria include having an International Restless Leg Syndrome Study Group (IRLSSG) RLS rating scale score of more than 15 at screening, a PLMI of greater than 10 per hour of total sleep time (TST) determined by PSG during the adaptation night, and a body mass index (BMI) of less than or equal to 35 kg/m2. Patients must also be in good general health, have normal clinical laboratory values, and be off all prescription drug therapy or OTC medication they may be taking for RLS as well as any other psychotropic medication for at least 5 half lives prior to adaptation night and off any investigational drug for at least 30 days. The trial also includes exclusion criteria such as clinically significant unstable medical illness, evidence or history of clinically significant allergic, hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, or neurological disease, and history of non-Basal Cell cancer within 5 years of screening.",
    "The sample is a record of a clinical trial in phase 2 for the treatment of esophageal cancer using the drug paclitaxel. The trial includes patients with measurable disease who have previously undergone chemotherapy and are aged 20 years or older with an ECOG PS score of 0-1. Patients who have previously received therapy with Taxanes are excluded from the trial. The diseases are listed as esophageal cancer and the icd-10 codes associated with the disease are also provided. The eligibility criteria for the trial are listed under inclusion and exclusion criteria.",
    "The sample is a phase 2 clinical trial for mesothelioma and pleural mesothelioma. The trial involves the use of two drugs, pemetrexed and cisplatin. The eligibility criteria for the trial include having a histologically proven diagnosis of MPM stages I to III, a performance status of 0 to 2 on the ECOG performance status schedule, and no prior systemic chemotherapy. Patients must also have an estimated life expectancy of at least 12 weeks and adequate organ function. Female patients of childbearing potential must test negative for pregnancy at the time of enrollment and both male and female patients must agree to use a reliable method of birth control during and for 3 months following the last dose of radiation therapy. The exclusion criteria include having received treatment within the last 30 days with a drug that has not received regulatory approval for any indication at the time of study entry, pregnancy or breast-feeding, serious concomitant systemic disorders, and refusal to have any of the treatment in the protocol.",
    "The sample is a phase 2 clinical trial for patients with anemia and kidney disease. The trial is testing the effectiveness of the drugs akb-6548 and placebo. The eligibility criteria for the trial include being between 18 and 79 years old, having chronic kidney disease with an eGFR of less than 60 mL/min but not yet on dialysis, having a hemoglobin level of 10.5 g/dL or less, and meeting certain TSAT and ferritin levels. There are also several exclusion criteria, such as having a BMI over 42, having received a red blood cell transfusion within the past 12 weeks, or having certain liver or heart conditions.",
    "The sample is a record of a clinical trial in phase 2 for the treatment of painful diabetic neuropathy. The trial involves the use of two drugs, grt3938y and placebo. The eligibility criteria for the trial include having symmetrical painful diabetic peripheral neuropathy, while exclusion criteria include a history of hypersensitivity or allergy to opioids and acetaminophen, confounding painful conditions, significant vascular disease, history or risk of seizure, chronic disease that might affect drug absorption, distribution, metabolism, or excretion, being pregnant or breastfeeding, and evidence or history of alcohol, medication, or drug abuse.",
    "The sample is a phase 2 clinical trial for breast cancer patients with distant metastatic disease. The trial is testing the effectiveness of the drug docetaxel. The eligibility criteria include having histologically confirmed breast cancer, measurable disease, no known brain or CNS metastases, and meeting certain age, sex, and performance status requirements. Patients must also have certain hematopoietic, hepatic, and renal function levels, and cannot be pregnant or nursing. Prior concurrent therapies are not allowed, except for certain types of prior chemotherapy or hormonal therapy. Patients cannot have had more than one prior regimen for advanced, recurrent, or metastatic disease.",
    "The sample is a phase 2 clinical trial for the treatment of chronic obstructive pulmonary disease (COPD) using the drug glycopyrronium bromide. The trial is open to both male and female participants aged 40-75 who have a clinical diagnosis of moderate to severe COPD and a history of smoking. The trial has specific inclusion and exclusion criteria, including the ability to perform acceptable spirometry and a demonstrated response to ipratropium. Participants must also be willing and able to provide written informed consent. Exclusion criteria include recent hospitalization due to an exacerbation of airway disease, primary diagnosis of asthma, and regular use of daily oxygen therapy. The trial aims to evaluate the safety and efficacy of glycopyrronium bromide in treating COPD.",
    "The sample is a phase 2 clinical trial for the treatment of prostate cancer using the drug fulvestrant. The trial includes patients who are 18 years or older, have confirmed adenocarcinoma of the prostate, and are currently receiving LHRH agonists or have had an orchiectomy. Patients must have had a rise in PSA despite anti-androgen withdrawal and exhibit two consecutive rises in PSA after the last hormonal manipulation. The trial allows for up to one prior chemotherapy treatment and requires a minimum PSA level of 5mg/dL and a KPS score of greater than 80%. Patients must also have a life expectancy of greater than 6 months. Exclusion criteria include concomitant hormonal therapy other than an LHRH, noncompliance, and various medical conditions such as low platelet count, high INR, and liver dysfunction. Patients with a history of bleeding diathesis or long-term anticoagulant therapy are also excluded, as are those with a hypersensitivity to the drug fulvestrant or its inactive excipients.",
    "The sample is a phase 2 clinical trial for patients with unresectable stage III or stage IV melanoma. The trial is testing the effectiveness of the drug dasatinib. The eligibility criteria include having measurable disease, evidence of tumor growth or new lesions within the past 6 months, and meeting certain health requirements such as having a certain level of blood counts and no significant cardiovascular disease. Patients must also not have any other active malignancy within the past 3 years except for curatively treated stage I malignancies or resected skin carcinomas. Additionally, patients must not be pregnant or nursing, and must use effective contraception if fertile. The trial has various exclusion criteria, such as having uncontrolled intercurrent illness or having previously received certain types of therapies.",
    "The sample is a phase 2 clinical trial for patients with non-small cell lung cancer. The trial is testing the effectiveness of a combination of drugs including carboplatin, cediranib maleate, and gemcitabine hydrochloride. The eligibility criteria for patients include having confirmed NSCLC, measurable disease, and an ECOG performance status of 0-1. Patients must also meet certain medical criteria such as having a life expectancy of at least 12 weeks, normal blood counts, and no uncontrolled blood pressure. Patients with certain medical conditions or who have undergone certain treatments in the past may be excluded from the trial. The trial also has restrictions on concurrent medications and treatments.",
    "The sample is a phase 2 clinical trial for patients with prostate adenocarcinoma that has metastasized and is unresponsive to hormone therapy and mitoxantrone-based chemotherapy. The trial is testing the effectiveness of a combination of three drugs: estramustine, docetaxel, and carboplatin. The eligibility criteria include having a histological diagnosis of adenocarcinoma of the prostate, being over 18 years old, having received prior hormonal therapy and mitoxantrone therapy, and having a castrate level of testosterone. Patients must also have pain attributable to metastatic prostate cancer and meet certain laboratory and medical criteria. Exclusion criteria include a history of myocardial infarction or angina pectoris within one year of registration, a history of brain metastases, and ongoing therapy with certain drugs that may interfere with the study.",
    "The sample is a phase 2 clinical trial for psoriasis. The eligibility criteria include being between 18 and 65 years old, having severe plaque type psoriasis for at least 6 months with at least 15% affected total body surface area, meeting certain clinical laboratory criteria, having a psoriatic plaque of at least 2.5 cm in diameter, and being a candidate for photo/systemic therapy. Women of childbearing potential must have a negative pregnancy test and agree to use two forms of contraception throughout the trial. Exclusion criteria include any serious medical condition, pregnancy or lactation, use of certain medications, and history of certain diseases or conditions. The trial involves the drug cc10004.",
    "The sample is a record of a clinical trial with a phase 2 designation. The trial is focused on the disease of essential tremor, which is identified by NIH criteria and is causing significant functional activity limitation. The trial is open to patients who have failed or cannot tolerate alternative treatments for essential tremor, as well as treatment-naive patients who have considered but declined alternative treatment. The trial has a list of exclusion criteria, including patients who are adequately controlled without side effects on a current ET treatment, pregnant patients, patients with other medical conditions that may cause tremor, patients taking medications that might produce tremor or interfere with the evaluation of tremor, patients who must take medications that alter liver metabolism, patients with liver disease or coagulation disorders, patients with seizure disorders, patients with a history of allergy or hypersensitivity reaction to barbiturates or other related medications, and patients with significant general medical or clinical laboratory abnormalities. The trial is testing the effectiveness of a drug called t2000, which is listed multiple times in the record.",
    "The sample is a phase 2 clinical trial for the treatment of HCV infection. The eligibility criteria include being between 18 and 65 years old, having a body mass index between 19 and 32 kg/m2, and having chronic hepatitis C infection of any genotype. Subjects must have been previously treated with pegylated interferon (PEG) or interferon (INF) with or without ribavirin (RBV) and either did not achieve a sustained viral response or did not tolerate the therapy. The trial drugs are gs-9450 and gs-9450 placebo. The inclusion criteria also include meeting certain laboratory values and having a creatinine clearance of at least 70 mL/min. Females of child-bearing potential must have a negative pregnancy test and agree to use contraception during the study and for at least 30 days after the last dose of study drug. Males must also agree to use contraception during the study and for at least 3 months after the last dose of study drug. The exclusion criteria include pregnancy or breastfeeding, coinfection with hepatitis B virus or HIV, ongoing alcohol abuse, and recent therapy with certain medications.",
    "The sample is a phase 2 clinical trial for patients with advanced ovarian epithelial or primary peritoneal cancer. The trial includes patients who have been treated with only one prior platin-containing chemotherapy regimen and have platin-resistant disease. The trial also includes patients who relapse during or less than 6 months after completion of post-debulking chemotherapy, as well as \"platinum sensitive\" patients in second relapse after having been treated/rechallenged with their initial regimen upon first relapse. The trial excludes patients with CNS metastases, cardiac arrhythmia, cardiac failure, diabetes, peripheral neuropathy >= grade 2, baseline diarrhea (>= 4 stools/day), uncontrolled infection, and other concurrent uncontrolled serious medical conditions. The trial requires patients to have measurable or evaluable disease plus CA 125 >= 2 times post-treatment nadir. Patients must also have a negative pregnancy test, use effective contraception if fertile, and have recovered from all prior therapy. The trial involves the use of cisplatin, alvocidib, and cisplatin/flavopiridol.",
    "The sample is a phase 2 clinical trial for patients with relapsed or progressive multiple myeloma. The trial involves the use of drugs such as melphalan, velcade, thalidomide, and dexamethasone. The eligibility criteria include having measurable disease, a performance status of 2 or less, adequate platelet and ANC counts, and adequate renal and hepatic function. Patients must also not be pregnant or nursing, and must have signed an informed consent form. Exclusion criteria include recent chemotherapy or radiotherapy, significant neurotoxicity, and certain medical conditions such as heart failure or uncontrolled infections. Women of childbearing potential must have a negative pregnancy test and use an effective contraceptive method.",
    "The sample is a phase 2 clinical trial for patients with stage I-III invasive breast cancer who are awaiting surgery or neoadjuvant treatment. The trial is testing the effectiveness of the drug combination of vorinostat and tamoxifen. The eligibility criteria include having an ECOG performance status of 0, 1 or 2, adequate organ function, and discontinuing prior use of hormone contraception or replacement therapy at least 30 days prior to diagnostic biopsy. The exclusion criteria include prior or current treatment for the current breast cancer, current use of any other investigational drugs, and uncontrolled or active infection, congestive heart failure, cardiac arrhythmia, or psychiatric illness. The table also includes a list of diseases and their corresponding ICD-10 codes.",
    "The sample is a phase 2 clinical trial for contraception. The trial is looking for women between the ages of 18 and 35 who are in good general health, not at risk of pregnancy, have regular menstrual cycles, and have not used hormonal contraception recently. The trial will last for 5 complete menstrual cycles and participants must be willing to abstain from any use of hormonal contraception during this time. There are various exclusion criteria, including current participation in another trial, known hypersensitivity to the test substances, current pregnancy, desire to get pregnant before the end of the study, and abnormal thyroid status. Participants must also be able to give voluntary, written informed consent.",
    "The sample is a clinical trial for phase 2/phase 3 of treatment for anal cancer. The trial is looking for patients with histologically confirmed squamous cell anal carcinoma, with measurable disease, and who meet certain eligibility criteria. The eligibility criteria include age between 18 to 75, WHO performance status of 0-1, and certain hematopoietic, renal, and cardiovascular requirements. Patients must not have had prior treatment for anal cancer, and must not have any other prior malignancy except adequately treated basal cell skin cancer or carcinoma in situ of the cervix. The trial will use cisplatin, fluorouracil, and mitomycin c as drugs. The table also includes a list of diseases, icd-10 codes, and eligibility criteria.",
    "The sample is a phase 2 trial for patients with gastrointestinal stromal tumors. The trial requires patients to have a histologically proven diagnosis of primary, locally advanced and/or metastatic GIST for which complete or partial resection is planned by a MDACC sarcoma surgeon. Patients must also have immunohistochemical documentation of kit expression in the tumor using the DAKO A4502 or other acceptable antibody. In addition, patients must have at least one lesion greater than 1 cm that can be accurately measured in one dimension by plain radiograph, CT or magnetic resonance imaging (MRI). Patients must have normal organ and marrow function and a serum glucose < 200 mg/dl prior to PET scan. Patients must be able to lie flat and still for the PET scan. Patients may not have any uncontrolled medical or psychiatric conditions that would make the patient unable to tolerate therapy. Patients may not have any prior malignancy in the past 5 years other than non-melanoma skin cancer, cervical cancer in situ, or any other malignancy that is not currently clinically significant. Patients must have a Zubrod performance status of 0 - 3 and may not have metastases outside of the peritoneal cavity. Patients may not have had chemotherapy, radiotherapy, biological therapy or any investigational drugs 3 weeks prior to the study. Women should have a negative pregnancy test within 7 days of study opening and must agree to use an effective contraceptive method. Exclusion criteria include prior treatment using Gleevec, patients with Class III or Class IV New York Heart Association congestive heart failure, pregnant or nursing women, and patients taking therapeutic doses of Coumadin for anticoagulation. Coumadin may be taken but dose should be less than or equal to 1 mg po per day. Patients MAY take a low molecular weight heparin.",
    "The sample is a phase 2 clinical trial for the treatment of depressive disorder. The trial involves the use of two drugs, gsk372475 and paroxetine. The eligibility criteria for the trial include having a major depressive episode associated with Major Depressive Disorder, having symptoms of decreased energy, pleasure, and interest, and agreeing to use acceptable methods of birth control throughout the study (for female subjects). Exclusion criteria include having a current diagnosis of Panic Disorder or symptoms of generalized anxiety or panic attacks that could interfere with the trial, having symptoms of MDE better accounted for by another diagnosis, and having a diagnosis of panic disorder/attacks, generalised anxiety, borderline or antisocial personality disorder, dementia, anorexia nervosa/bulimia (within 6 months of screening), bipolar disorder, schizophrenia, or any other psychotic disorder(s). Other exclusion criteria include starting psychotherapy within 3 months prior to the screening, receiving electroconvulsive therapy or transcranial magnetic stimulation within 6 months prior to screening, receiving psychoactive drugs within 4 weeks of randomization, having a positive urine drug screen or positive blood alcohol, having suicidal risk or a previous suicide attempt or a family history of suicide attempt, having a positive pregnancy test, having a history of seizure disorder, myocardial infarction (< 1yr), or unstable medical condition, and failing to respond to an adequate course of pharmacotherapy of at least 2 different antidepressants.",
    "The sample is a phase 2 trial for the treatment of neuropathic pain. The trial is focused on patients with neuropathic pain due to painful diabetic polyneuropathy. The trial includes a list of drugs, including azd2423 and a placebo, and a list of inclusion and exclusion criteria. The inclusion criteria include patients aged 18 to 80 years who have provided a signed informed consent form. The exclusion criteria include patients with other pain that may confound assessment of neuropathic pain, a history of treatment failure with more than three adequate trials of medication for neuropathic pain, and central neuropathic pain conditions caused by Central Nervous System injury/disease, such as a stroke.",
    "The sample is a record of a clinical trial in phase 2, focused on the treatment of pain. The trial includes patients with neuropathic pain and allodynia after a peripheral nerve injury, with a minimum VAS score of 4. The trial excludes patients who cannot cooperate or understand Danish, fertile women, those with clinically significant abnormalities or diseases, drug and alcohol abusers, those with clinically abnormal ECG, hypersensitivity to any of the treatments, patients in treatment with certain medications, those who have previously been treated in a NS1209 study, and patients treated with an investigational drug. The trial involves the use of two drugs, ns1209 and lidocaine.",
    "The sample is a record from a clinical trial table that includes information about the trial phase, diseases being studied, corresponding ICD-10 codes, drugs being tested, and eligibility criteria for participants. In this particular sample, the trial is in phase 2 and is focused on Parkinson's disease. The ICD-10 code for Parkinson's disease is G20. The drugs being tested are xp21279 and carbidopa (experimental), sinemet (comparator), and placebos for both xp21279 and carbidopa and sinemet. The eligibility criteria for participants include having predictable motor fluctuations of the wearing off type, being on a stable QID or 5 times daily regimen of Sinemet or carbidopa-levodopa for at least 4 weeks prior to screening, and meeting certain exclusion criteria such as not having secondary or atypical Parkinsonism and not taking certain medications.",
    "The sample is a phase 2 clinical trial for patients with operable invasive mammary carcinoma, specifically those with measurable residual tumor at the primary site. The trial is testing the effectiveness of lapatinib ditosylate and letrozole as treatment options for patients who are HER2-positive by Herceptest (3+) or FISH and ER-positive and/or PR-positive by IHC. The trial has specific inclusion and exclusion criteria for patients, including being postmenopausal, having a certain ECOG performance status, and not having evidence of distant metastatic disease. The trial also has exclusion criteria for prior concurrent therapy, such as prior chemotherapy for primary breast cancer or concurrent treatment with an investigational agent.",
    "This sample is for a phase 2 clinical trial that focuses on the disease of diabetes mellitus. The trial includes a list of icd-10 codes associated with the disease. The drugs being tested in the trial are rosuvastatin and atorvastatin. The eligibility criteria for the trial include having hyperlipidemia, urinary protein, and diabetes. The exclusion criteria include having had previous rosuvastatin treatment within 6 months prior to Visit 1, statin intolerance, and severe hypertension.",
    "The sample is a phase 2 clinical trial for patients with peripheral T-cell lymphoma. The trial includes patients who have not received prior treatment except for radiation or a single cycle of CHOP chemotherapy. Patients must have at least one measurable site of disease and meet certain criteria for bone marrow, liver, and kidney function. Patients with certain medical conditions or allergies are excluded from the trial. The trial aims to evaluate the effectiveness of the drugs Ontak and CHOP chemotherapy in treating peripheral T-cell lymphoma.",
    "This sample is for a phase 2 clinical trial for patients with recurrent or persistent leiomyosarcoma of the uterus. The trial is testing the effectiveness of the drug sunitinib malate. Patients must have received at least one but no more than two prior cytotoxic regimens and must have measurable disease. They must also meet a number of other eligibility criteria, including having a GOG performance status of 0-2, normal blood counts and organ function, and no other invasive malignancies within the past 5 years. Patients must not have any significant EKG abnormalities, poorly controlled hypertension, or gastrointestinal tract disease that would prevent them from taking oral medication. They must also not have any other serious or nonhealing wounds or fractures, active infections, or other conditions that would impair their ability to swallow and retain the study drug. Patients must have recovered from prior surgery, chemotherapy, or radiotherapy and must not have received prior noncytotoxic chemotherapy for recurrent or persistent disease. They must also not be taking any concurrent proarrhythmic potential agents, therapeutic coumarin-derivative anticoagulants, or other protective agents. Finally, they must not be taking any other concurrent investigational agents or anticancer therapies.",
    "The sample is a phase 2 clinical trial for advanced hepatocellular carcinoma, a type of liver cancer. The trial is testing the effectiveness of a drug called apatinib. The eligibility criteria for participants include having confirmed advanced hepatocellular carcinoma, a life expectancy of more than 3 months, and no cirrhosis with child-pugh score A. Participants must also have at least one measurable lesion and adequate hepatic, renal, heart, and hematologic functions. Exclusion criteria include factors such as pregnancy or breastfeeding, history of second malignancies within 3 years, evidence of CNS metastasis, and abuse of alcohol or drugs. Participants must also be willing and able to comply with scheduled visits, treatment plans, laboratory tests, and other study procedures.",
    "The sample is a phase 2 clinical trial for patients with soft tissue sarcoma that has metastasized or is non-resectable. The trial is testing the effectiveness of the drugs adriamycin and trofosfamide. The eligibility criteria include having measurable tumors, no previous radiation therapy on the only measurable lesion, and no previous chemotherapy for metastatic disease. Patients must also be aged 60 years or older, have an ECOG status of 0-2, and meet certain blood and organ function requirements. Exclusion criteria include certain types of sarcoma and having had a secondary malignancy within the past 5 years, except for certain adequately treated conditions.",
    "The sample is a record from a clinical trial table that includes information about the phase of the trial, the disease being studied (in this case, diffuse large B-cell lymphoma), the ICD-10 codes associated with the disease, the drugs being tested (lenalidomide, gemcitabine, oxaliplatin, rituximab, and etoposide), and the eligibility criteria for participants. The eligibility criteria include requirements such as a histologically proven diagnosis of DLBCL, relapse or refractory status to previous chemotherapy treatments, measurable disease by CT/MRI, and an ECOG performance status of 0-2. The exclusion criteria include a diagnosis of lymphoma other than DLBCL, a history of malignancies other than DLBCL, eligibility for autologous stem cell transplant, and certain medical conditions such as HIV, HBV, HCV, and neuropathy grade 4.",
    "The sample is a record of a clinical trial in phase 2 for the treatment of bladder cancer. The trial involves the use of drugs such as cisplatin, doxorubicin hydrochloride, methotrexate, and vinblastine. The eligibility criteria for the trial include a confirmed diagnosis of invasive bladder cancer, as well as specific patient characteristics such as ECOG performance status, blood counts, liver and kidney function, and absence of certain medical conditions. Prior systemic chemotherapy is not allowed for participants in the trial. The record also includes the list of disease names and ICD-10 codes associated with bladder cancer.",
    "The sample is a phase 2 clinical trial for the treatment of acute myeloid leukemia, myelodysplastic syndrome, and chronic myeloid leukemia. The trial involves the use of drugs such as clofarabine, busulfan, fludarabine, thymoglobulin (atg), and filgrastim. The eligibility criteria include a diagnosis of the specified diseases, not having received intensive systemic chemotherapeutic drugs within 21 days prior to trial enrollment, being under the age of 60, having a related or unrelated donor who is HLA-matched or mismatched in 1 HLA, A, B, C, DR or DQ locus, and meeting various health requirements. The exclusion criteria include having effusion or ascites estimated to be >1L prior to drainage, being HIV-positive, having hepatitis C or HBsAg positive, having undergone a stem cell transplant after a myeloablative conditioning program, having active or prior Central Nervous System (CNS) leukemia, and having biphenotypic acute leukemia.",
    "The sample is a phase 2 clinical trial for patients with various types of melanoma that has spread and cannot be surgically removed. The trial is testing the effectiveness of a drug called vorinostat. The eligibility criteria include having confirmed melanoma, measurable disease, and no prior treatment or only one prior treatment for metastatic disease. Patients must also meet certain health requirements and agree to use contraception during the study. The trial excludes patients with certain medical conditions or who are pregnant or HIV-positive.",
    "The sample is a phase 2 trial for chronic obstructive pulmonary disease (COPD) with a list of ICD-10 codes associated with the disease. The trial involves several drugs, including aclidinium 200 \u03bcg / formoterol 12 \u03bcg, placebo, formoterol 12 \u03bcg, aclidinium 200 \u03bcg, and aclidinium 200 \u03bcg / formoterol 6 \u03bcg. The eligibility criteria for the trial include being an adult between 40 and 80 years old, having a clinical diagnosis of stable moderate to severe COPD, being a current or ex-cigarette smoker with a smoking history of at least 10 pack-years, and meeting certain FEV1 and FEV1/FVC measurements. The trial also has exclusion criteria, such as a history or current diagnosis of asthma or exercise-induced bronchospasm, clinically significant respiratory conditions, and signs of a COPD exacerbation or respiratory infection within the previous 6 weeks. Patients must also maintain regular day/night, waking/sleeping cycles to be eligible for the trial.",
    "The sample is a phase 2 clinical trial for the treatment of chronic obstructive pulmonary disease (COPD) using the drugs prochymal\u2122 and placebo. The trial is open to individuals between the ages of 40 and 80, of any race and gender, who have a diagnosis of moderate or severe COPD, a post-bronchodilator FEV1/FVC ratio of less than 0.7, and a post-bronchodilator FEV1 % predicted value between 30% and 70%. The trial has a list of inclusion and exclusion criteria, which includes factors such as smoking history, body mass, and medical conditions. The trial aims to evaluate the safety and efficacy of the drugs in treating COPD.",
    "The sample is a record of a clinical trial in phase 2, focused on the disease of hypertension. The trial includes a list of icd-10 codes related to hypertension, as well as a list of drugs being tested, including mk0736, mk0916, and a placebo. The eligibility criteria for the trial are also listed, including specific blood pressure ranges, exclusion criteria such as pre-menopausal women and patients taking more than two blood pressure medications, and other health conditions that would disqualify a patient from participating in the trial.",
    "The sample is a phase 2 clinical trial for patients with non-small cell lung cancer. The trial is testing the effectiveness of carboplatin and pemetrexed disodium as a treatment for inoperable stage IIIA and selected IIIB lung cancer. Patients must have histologically or cytologically documented NSCLC and meet certain eligibility criteria, including having measurable disease, an ECOG performance status of 0-1, and a negative PET scan for distant metastasis. Patients must also meet certain laboratory value requirements and have no active second malignancy or uncontrolled intercurrent illness. The trial is not open to HIV-positive patients receiving combination anti-retroviral therapy or those with a known history of hypersensitivity to carboplatin, pemetrexed, or a monoclonal antibody.",
    "The sample is a phase 2 clinical trial for patients with esophageal cancer. The trial is testing the effectiveness of the drugs cisplatin and irinotecan hydrochloride. The eligibility criteria include having histologically confirmed primary squamous cell carcinoma or adenocarcinoma of the thoracic esophagus or the gastroesophageal junction, with disease confined to the esophagus or peri-esophageal soft tissue, and T4, M0 disease. Patients must also have measurable or non-measurable disease by x-ray, CT scan and/or MRI, or physical examination within the past 4-6 weeks, and tumor specimens available. Other eligibility criteria include being 18 years or older, having a Zubrod performance status of 0-2, and meeting certain hematopoietic, hepatic, renal, and other health criteria. Patients must not have had prior chemotherapy or radiotherapy for esophageal cancer, and must not have had prior surgical resection or attempted surgical resection of esophageal cancer.",
    "The sample is a phase 2 clinical trial for patients with moderate to severe chronic obstructive pulmonary disease (COPD). The trial is testing the effectiveness of a drug called uk-432,097 compared to a placebo. The trial has specific inclusion criteria, such as patients having a smoking history of at least 10 pack-years and stable disease for at least 1 month prior to screening. There are also exclusion criteria, such as a history of respiratory failure or significant disease instability. The trial is designed to evaluate the safety and efficacy of the drug in treating COPD.",
    "The sample is a phase 2 clinical trial that involves patients with colorectal neoplasms and metastases. The trial includes the use of drugs such as zd6126, placebo, 5-fluorouracil, leucovorin, and oxaliplatin. The eligibility criteria for the trial include having metastatic colorectal carcinoma and being suitable for first-line treatment of metastatic disease. Exclusion criteria include having peripheral neuropathy greater than Grade 1, prior oxaliplatin treatment, prior pelvic or whole abdomen radiation, and any history of coronary angioplasty or myocardial infarction. The icd-10 codes for the diseases are also provided.",
    "The sample is a phase 2 clinical trial for chronic myelogenous leukemia. The trial involves the use of the drugs nilotinib and pegylated interferon 2a. The eligibility criteria include a performance status of 0-2, a diagnosis of CP CML within the last 3 months without previous TKI or interferon treatment, and adequate organic functions. Exclusion criteria include prior TKI or interferon treatment for CML, pregnancy, breast feeding, and other uncontrolled severe diseases. The trial also has specific criteria related to cardiac health, bleeding disorders, and other medical conditions.",
    "The sample is a phase 2 clinical trial for patients with non-Hodgkin's lymphoma or multiple myeloma who are eligible for autologous transplantation. The trial involves the use of the drug combination of g-csf and plerixafor. The eligibility criteria include having no more than 3 prior chemotherapy regimens, being recovered from all acute toxic effects of prior chemotherapy, having a certain level of white blood cells, polymorphonuclear cells, and platelets, and meeting certain requirements for kidney and liver function, heart function, and lung function. Patients with certain medical conditions or infections, or who have previously received experimental therapy, are excluded from the trial. Women of childbearing potential must agree to use contraception. Patients who deteriorate between enrollment and transplant may be removed from the study.",
    "The sample is a phase 2 clinical trial for the treatment of psoriasis vulgaris. The trial involves the use of the drug calcipotriol plus hydrocortisone (leo 80190) on patients with psoriasis vulgaris on the face and intertriginous areas. The eligibility criteria include having a clinical diagnosis of psoriasis vulgaris, an extent of psoriatic involvement on the face of at least 5 cm2, and a disease severity of the face and intertriginous areas graded as moderate, severe or very severe. Patients must also have a normal HPA axis function and albumin corrected serum calcium within reference range. Exclusion criteria include a history of active allergy, asthma, allergic skin rash, or sensitivity to any medication, systemic treatment with all other therapies than biologicals, and systemic use of biological treatments directed against or with a potential effect on psoriasis vulgaris within 12 weeks prior to Visit 1.",
    "The sample is a phase 2 clinical trial for patients with non-small cell lung cancer who have progressed while receiving treatment with a tyrosine kinase inhibitor targeting the EGFR pathway. The trial requires patients to have a suitable tissue sample available for EGFR mutational analysis and measurable disease as defined by RECIST criteria. Patients with asymptomatic brain metastasis are eligible if they have completed radiotherapy/radiosurgery at least 3 weeks prior to enrollment and are clinically stable. The trial also has inclusion and exclusion criteria related to age, pregnancy status, bone marrow, renal and hepatic function, and prior medical history. The drug being tested in the trial is cetuximab.",
    "The sample is a phase 2 clinical trial for osteoarthritis of the knee. The trial includes patients who have been diagnosed with OA of the knee, confirmed by X-ray, and have at least moderate or severe pain due to OA in one knee. The patients must have been on nonsteroidal anti-inflammatory drug (NSAID) for 28 days prior to the study start and willing to continue on NSAID throughout the study. The trial includes three drugs: arry-371797, p38 inhibitor; oral, oxycodone hydrochloride (hcl) extended release (er), opioid agonist; oral, and placebo; oral. The eligibility criteria include several key inclusion and exclusion criteria, such as no recent infection, no surgery on the index knee within the previous 6 months, and no prior parenteral tumor necrosis factor (TNF) inhibitor or anti-nerve growth factor (NGF) therapies.",
    "The sample is a phase 2 clinical trial for metastatic breast adenocarcinoma. The trial includes patients who have had at least one previous chemotherapy regimen for metastatic breast cancer and are between the ages of 18-75. The trial requires patients to have measurable disease, a performance status of 0-2, and adequate liver, renal, and bone marrow function. Patients with brain metastases must have received prior radiation therapy and cannot have progressive brain metastases. The trial excludes patients who are unable to take oral medication, have an active infection, a history of significant cardiac disease or stroke, are on anticoagulation therapy, have other invasive malignancies, or have psychiatric illness or social situations that would preclude study compliance. Pregnant or lactating women are also excluded.",
    "The sample is a record of a clinical trial with a phase 2 designation. The trial is focused on treating lung cancer, pulmonary complications, and radiation fibrosis. The trial involves the drug captopril and has specific eligibility criteria for patients, including age, performance status, hematopoietic, hepatic, renal, and cardiovascular health. Patients must also not be pregnant or nursing, have normal sodium and potassium levels, and not have any known hypersensitivity to ACE inhibitors. The trial allows for induction or concurrent chemotherapy and prior pulmonary lobectomy or segmentectomy, but not concurrent use of certain medications. The sample includes detailed disease and patient characteristics, as well as prior concurrent therapy information.",
    "The sample is a phase 2 clinical trial for the treatment of insomnia. The trial includes subjects between the ages of 18 and 65 who meet DSM IV diagnostic criteria for Primary Insomnia and report a time in bed between 6.5 and 9 hours. The trial involves the use of two drugs, zaleplon ap formulation and placebo capsule. The eligibility criteria include various sleep-related factors such as time to sleep onset, wake time after sleep, and total sleep time. The trial also has exclusion criteria such as participation in another drug clinical trial within 1 month prior to first screening diary day and use of any drug known to affect sleep or wake functions within 5 half lives of the drug or two weeks, whichever comes first. Females who are pregnant or nursing are also excluded from the trial.",
    "The sample is a phase 2 clinical trial for patients with end stage renal disease, chronic kidney disease, hyperphosphatemic kidney disease, and other related conditions. The trial is testing the effectiveness of the drug AMG 223 compared to a placebo in reducing serum phosphorus levels. The eligibility criteria for participants include being on maintenance hemodialysis for at least 3 months, having a certain level of serum phosphorus, and not having made any recent changes to their non-investigational phosphate binder medication. There are also exclusion criteria, such as a history of noncompliance with phosphate binder therapy or current use of certain medications. The trial requires participants to avoid intentional changes in their diet and to not be pregnant or breastfeeding.",
    "The sample is a phase 2 clinical trial for HIV infections. The trial involves several drugs, including emtricitabine/tenofovir disoproxil fumarate, tenofovir disoproxil fumarate, and tenofovir 1% vaginal gel, as well as their respective placebos. The eligibility criteria for the trial include being sexually active, agreeing to use effective contraception, and not having HIV or any adverse reactions to the study products or latex. Exclusion criteria include recent pregnancy or gynecologic procedures, certain medical conditions or abnormal laboratory values, and plans to relocate or travel away from the study site for an extended period. The trial aims to evaluate the safety and efficacy of the drugs in preventing HIV transmission.",
    "The sample is a phase 2 clinical trial for Crohn's disease and ulcerative colitis patients with mild or moderate anemia. The trial involves administering iron supplements and vitamin E to eligible participants who are over 18 years old and have been diagnosed with inflammatory bowel disease. The trial has certain exclusion criteria, such as not having bowel obstruction or short bowel syndrome, and not taking iron supplements or antioxidant vitamins and minerals.",
    "The sample is a record of a clinical trial that is in phase 2/phase 3. The trial is focused on the treatment of pain, analgesia, and inguinal hernia. The diseases are identified by their ICD-10 codes. The drug being tested is gabapentin. The eligibility criteria for the trial include having elective surgery with open unilateral inguinal herniorraphy, not currently being on gabapentin therapy, not being hypersensitive to gabapentin, not having a history of alcohol or drug abuse, and not being pregnant or nursing.",
    "The sample is a record of a clinical trial with a phase 2 designation. The trial is focused on the treatment of irritable bowel syndrome. The diseases column lists only one disease, which is irritable bowel syndrome. The icdcodes column lists a series of ICD-10 codes that correspond to the disease. The drugs column lists two drugs, eluxadoline and placebo, that are being tested in the trial. The criteria column lists the eligibility criteria for patients who can participate in the trial, including a diagnosis of IBS by Rome III criteria with a subtype of diarrhea, and exclusion criteria such as a history of inflammatory or immune-mediated gastrointestinal disorders, or a history of intestinal obstruction or other related conditions.",
    "The sample is a phase 2 clinical trial for the treatment of acute myeloid leukemia. The trial includes patients who have not received any prior cytotoxic chemotherapy for AML, with the exception of hydroxyurea. The patients must be between the ages of 18 and 60 and have an Eastern Cooperative Oncology Group (ECOG) performance status of 2 or less. The trial also requires that the patients have a serum creatinine level of 1.0 mg/dL or less, or an estimated glomerular filtration rate (GFR) of greater than 60 mL/min/1.73m^2. The patients must have a cardiac ejection fraction of at least 45% and be able to provide signed informed consent. The trial excludes patients with acute promyelocytic leukemia (APL) and any coexisting medical condition that may interfere with the study procedures or results. Nursing women, women of childbearing potential who are not willing to maintain adequate contraception, and patients with active and uncontrolled infections are also excluded from the trial.",
    "This is a sample from a clinical trial table that includes information about a phase 2 trial for the treatment of metastatic renal cell carcinoma. The table includes the phase of the trial, a list of diseases, a list of icd-10 codes for the diseases, a list of drugs being tested, and eligibility criteria for participants. The eligibility criteria include requirements such as a measurable disease, a certain level of performance status, and adequate organ function. The exclusion criteria include factors such as recent anti-cancer therapy, certain medical conditions, and pregnancy or breastfeeding.",
    "The sample is a phase 2 trial for patients with previously untreated stage III, IV, or bulky stage II diffuse large B-cell non-Hodgkin's lymphoma which is positive for CD20. The trial involves the use of cyclophosphamide, doxorubicin hydrochloride, vincristine sulfate, and prednisone. The eligibility criteria include having an age-adjusted International Prognostic Index score of 0 or 1, bidimensionally measurable disease, and a unilateral bone marrow aspirate and biopsy. Patients must not have clinical evidence of central nervous system involvement by lymphoma, a previous diagnosis of indolent lymphoma, or have received prior chemotherapy, radiation, or antibody therapy for lymphoma. The trial also has other exclusion criteria, such as patients known to be HIV positive or who have a history of solid organ transplantation. Patients must sign and give written informed consent in accordance with institutional and federal guidelines.",
    "The sample is a phase 2 clinical trial for patients with locally advanced or metastatic pancreatic cancer who have progressed after standard first-line therapy that included gemcitabine. The trial is testing the effectiveness of the drugs bortezomib and panobinostat. The eligibility criteria include having measurable disease on a CT scan, meeting certain laboratory criteria, having a performance status of \u2264 1, and being able to provide written consent. Exclusion criteria include having received more than one prior systemic treatment regimen for pancreatic cancer, having impaired cardiac function, and having serious concomitant medical or psychiatric disorders. The sample also includes a detailed list of inclusion and exclusion criteria.",
    "The sample is a phase 2 clinical trial for individuals with atherogenic dyslipidaemia and abdominal obesity. The trial involves the use of two drugs, gft505 80mg and placebo. The eligibility criteria for the trial include having a waist circumference of at least 102cm for males and 88cm for females, having atherogenic dyslipidaemia that is not controlled by lifestyle changes, and having specific levels of fasting triglycerides and HDL cholesterol. Exclusion criteria include having a BMI of 40 or higher, high blood pressure, and type I or type II diabetes mellitus.",
    "The sample is a phase 2 clinical trial for patients with lymphoblastic lymphoma or acute lymphoblastic leukemia. The trial includes patients who have refractory disease or relapsed disease, with or without extramedullary disease. Patients must have a Karnofsky performance status of 50-100% (for patients \u2265 16 years of age) OR Lansky PS 50-100% (for patients < 16 years of age) and a life expectancy of at least 8 weeks. The trial also has various eligibility criteria related to creatinine clearance, ALT levels, bilirubin levels, LVEF, and shortening fraction. Patients must not be pregnant or nursing, and must have recovered from prior therapy. The trial has exclusion criteria related to graft-versus-host disease, concurrent valproic acid, and concurrent coumadin/warfarin other than a short course administered in a prophylactic setting.",
    "The sample is a record of a clinical trial in phase 2 for the treatment of renal cell carcinoma. The trial involves the use of two drugs, cediranib and cediranib placebo. The eligibility criteria for the trial include confirmation of metastatic or recurrent renal cell carcinoma, while exclusion criteria include certain types of previous anti-cancer therapy for Renal Cell Carcinoma, patients with type I insulin-dependent diabetes or poorly-controlled type II insulin-independent diabetes, and patients with a history of poorly controlled high blood pressure. The diseases are listed as 'renal cell carcinoma', and the icd-10 codes associated with the disease are also provided.",
    "The sample is a phase 2 trial for the treatment of type 2 diabetes. The trial includes patients between the ages of 18 and 70 who have been diagnosed with type 2 diabetes and are on a stable dose of metformin monotherapy at randomization. The trial excludes patients with a history of type 1 diabetes, diabetic ketoacidosis, persistent hypoglycemia, alcoholism, drug abuse, significant renal impairment, diabetic retinopathy, diabetic gastroparesis, active liver disease, cirrhosis, symptomatic gallbladder disease, uncontrolled high blood pressure, and history or evidence of cardiovascular or pulmonary disease. The trial involves the use of drugs such as krp-104 qd, placebo, and metformin, and the eligibility criteria include laboratory and medical history clinical criteria.",
    "The sample is a phase 2 clinical trial for the treatment of acute schizophrenia and schizoaffective disorder. The trial involves the use of drugs such as rp5063, aripiprazole, and a placebo. The eligibility criteria for the trial include patients who have provided informed consent, meet the DSM-IV-TR criteria for schizophrenia or schizoaffective disorder, and have normal physical examination, laboratory, vital signs, and ECG. Patients with other primary psychiatric disorders such as delirium or bipolar I or II disorder are excluded from the trial. The diseases are listed along with their corresponding ICD-10 codes.",
    "The sample is a phase 2 clinical trial for psoriasis. The trial includes a list of diseases and their corresponding ICD-10 codes, as well as a list of drugs. The eligibility criteria for the trial are listed, including inclusion and exclusion criteria for each part of the trial. Inclusion criteria include having active plaque psoriasis covering at least 10% of the body surface area and a PASI score of at least 12 at screening and randomization, being a candidate for systemic therapy, and having a Static Physician's Global Assessment (sPGA) score of at least 3 at screening and randomization. Exclusion criteria include having pustular, erythrodermic, and/or guttate forms of psoriasis, having recently used any biologic agent/monoclonal antibody, having received systemic psoriasis therapy or phototherapy within the previous 4 weeks, having donated more than 500 mL of blood within the last month, having another serious disorder or illness, and more. The sample also includes specific exclusion criteria for parts B and C of the trial.",
    "The sample is a phase 2 clinical trial for patients with recurrent and/or metastatic head and neck squamous cell carcinoma that is not amenable to curative treatment with surgery and/or chemotherapy and/or radiation. The trial is testing the drug SU011248. The eligibility criteria include confirmation of recurrence by anatomopathology, at least one measurable lesion by MRI or CT-scan, failure or relapse after first line chemotherapy including a platinum or a taxane-based chemotherapy regimen, ECOG performance status 0-2, and an expected survival of at least 3 months. Patients must also have normal organ function, be over 18 years old, and be able to give written informed consent. The exclusion criteria include non-squamous head and neck cancer, nasopharynx cancer, brain metastases, more than two lines of chemotherapy for palliative treatment, and other uncontrolled illnesses.",
    "The sample is a phase 2 clinical trial for cardiovascular disease and bleeding. The trial involves the ingestion of omega n3 fatty acids (Lovaza\u00ae) and is open to males and females over 18 years old who are not on antiplatelet or anticoagulation therapy, or are on chronic therapy with warfarin or aspirin alone or combination therapy with clopidogrel and aspirin. The trial has inclusion and exclusion criteria, including stable medical therapy, no recent admissions for atrial fibrillation, and no planned procedures or changes in medical therapies over the 24-week duration of the study. All female subjects of childbearing potential must have a negative serum pregnancy test prior to randomization and not plan on getting pregnant for the duration of the study. The trial also has exclusion criteria, including any medical condition that would preclude ingestion of omega n3 fatty acids, liver dysfunction, chronic kidney disease, history of significant anemia, baseline PT>ULN, INR>1.3, and aPTT>ULN in subjects who are not on chronic warfarin therapy, history of thrombocytopenia or thrombocytosis, known bleeding diathesis and/or congenital hemostasis disorder and/or congenital platelet abnormalities, history of stroke in the past 12 months, history of peptic ulcer disease in the past year or gastrointestinal bleeding in the last 3 months, genitourinary bleeding in the last 3 months, HIV or other infectious diseases, allergy to iodine, fish, or other components of the study drug, alcohol or substance abuse, emotionally or psychiatrically unstable, use of any investigational drug or device within the past 30 days, and any terminal illness or illness that may cause mortality that could obscure the results of the test in any way for them to appear inaccurate.",
    "The sample is a phase 2 clinical trial for patients with chronic obstructive pulmonary disease (COPD). The trial includes a list of drugs, including aclidinium bromide and formoterol, as well as a placebo. The eligibility criteria include being aged 40 or older, having a clinical diagnosis of moderate to severe COPD, being a current or ex-cigarette smoker with a smoking history of at least 10 pack-years, and having a post-salbutamol FEV1/FVC ratio of less than 70%. The trial also has exclusion criteria, such as a history or current diagnosis of asthma, clinically significant respiratory conditions other than COPD, and clinically significant cardiovascular conditions. Patients who meet the inclusion criteria and do not meet the exclusion criteria are eligible to participate in the trial.",
    "The sample is a phase 2 clinical trial for the treatment of leukemia. The trial is for patients with newly diagnosed acute lymphoblastic leukemia (ALL) or acute mixed lineage leukemia who are positive for the Bcr-Abl transcript. The trial involves a combination of drugs including cytarabine, daunorubicin hydrochloride, etoposide, imatinib mesylate, leucovorin calcium, methotrexate, prednisolone, therapeutic hydrocortisone, and vincristine sulfate. Patients must meet certain eligibility criteria, including having bilirubin levels below 2 mg/dL, SGOT levels below 3 times the upper limit of normal, and creatinine levels below 2.0 mg/dL. Patients must also have an ejection fraction greater than 45% by MUGA scan and cannot be nursing. Fertile patients must use effective contraception and cannot have any known sensitivity to the study drugs. Additionally, patients cannot have any severe medical conditions that would prohibit their participation in the study and cannot have received any other investigational agents in the past 30 days.",
    "The sample is a phase 2 clinical trial for patients with multiple sclerosis and optic neuritis. The trial is testing the effectiveness of the drug minocycline. The eligibility criteria include being between 18 and 60 years old, having onset of optic neuritis within the previous 30 days, and intending to continue current multiple sclerosis therapy for at least 6 months. Exclusion criteria include having any other disease that could be responsible for optic neuritis, liver, renal, or bone marrow dysfunction, and prior use of certain drugs. Participants must also be willing to provide written informed consent.",
    "This sample is a record of a clinical trial for the treatment of colorectal cancer in phase 2/phase 3. The trial involves the use of drugs such as cediranib, bevacizumab, 5-fluorouracil, leucovorin, and oxaliplatin. The eligibility criteria for the trial include a clinical diagnosis of colon or rectal cancer and no prior systemic therapy for metastatic disease. However, patients who have received adjuvant/neoadjuvant oxaliplatin therapy must have done so more than 12 months prior to study entry, and those who have received adjuvant/neoadjuvant 5-FU must have done so more than 6 months prior to study entry. Patients who have previously been treated with a VEGF inhibitor, including bevacizumab and cediranib, or who have poorly controlled hypertension are excluded from the trial.",
    "The sample is a phase 2 clinical trial for patients with unresectable stage IV melanoma (skin cancer) that is measurable and confirmed histologically. The trial involves the use of the drug temozolomide and requires patients to meet certain eligibility criteria, including having a WHO performance status of 0-2, no CNS metastases, and no other primary tumors within the past 5 years. Patients must also have a paraffin block of primary tumor and/or metastatic tissue available for analysis of MGMT. The trial excludes patients with certain medical conditions, such as uncontrolled hypertension or serious non-healing wounds, and those who are pregnant or nursing. Prior concurrent therapy is also restricted.",
    "This sample is for a phase 2 clinical trial for patients with epithelial ovarian cancer who have previously received standard platinum therapy and showed recurrence within 3 months. The trial is testing the effectiveness of a combination of drugs, mk-1775 and carboplatin. The eligibility criteria include having measurable disease or elevated CA-125 levels, being willing to undergo blood sampling, having a life expectancy of at least 3 months, and meeting certain safety laboratory values. Exclusion criteria include having symptomatic cerebral or leptomeningeal metastases, having had more than 1 prior cytotoxic chemotherapy regimen, and having unresolved toxicities from previous chemotherapy. Patients must also agree to use a reliable contraceptive method throughout the study if they are fertile women.",
    "The sample is a phase 2 clinical trial for endometrial cancer. The trial includes patients with histologically confirmed endometrial cancer, excluding carcinosarcoma. Patients must have undergone hysterectomy and bilateral salpingo-oophorectomy within the past 56 days and have no evidence of metastatic extrauterine disease, gross or residual disease, or distant metastases. The trial also has specific eligibility criteria related to performance status, blood counts, liver and kidney function, and other medical conditions. The trial involves the use of carboplatin, cisplatin, and paclitaxel. The trial does not allow concurrent use of certain medications or prior therapy with anti-vascular endothelial growth factor compounds. The trial also has restrictions on prior surgeries and concurrent surgeries.",
    "The sample is a phase 2 clinical trial for patients with acute lymphoblastic leukemia. The trial is testing the drug dasatinib and has specific eligibility criteria for patients to be included in the trial. These criteria include being over 18 years old, having no prior treatment with anti-leukemic drugs (except for steroids for no more than 14 days), and having normal levels of certain serum markers. The trial also has exclusion criteria, such as having impaired cardiac function or other severe medical conditions that could pose safety risks. Patients must provide written informed consent before participating in the trial.",
    "This is a sample from a clinical trial table. The trial is in phase 2 and is focused on treating non-small cell lung cancer. The table includes a list of diseases, icd-10 codes, drugs, and eligibility criteria. The eligibility criteria include requirements such as a suspected or confirmed diagnosis of non-small cell lung cancer, being a surgical candidate, and having tumors of a certain size without evidence of nodal metastases. Other criteria include age, performance status, organ function, and no prior treatment for any malignancy. Exclusion criteria include previous or concomitant malignancy, prior dasatinib therapy, and certain cardiac symptoms or conditions. The sample also includes a list of medications that must be discontinued prior to starting dasatinib therapy.",
    "The sample is a record of a clinical trial in phase 2 for the treatment of head and neck cancer using a drug called tas-106. The trial has eligibility criteria for participants, including being 18 years or older, having confirmed head and neck carcinoma, and having received a prior platinum-based regimen with disease progression or recurrence. The trial also has exclusion criteria, such as having brain involvement or leptomeningeal disease, having grade 2 or higher peripheral neuropathy, and having a history of another malignancy. The diseases are listed as 'head and neck cancer', and the icd-10 codes associated with the disease are also provided.",
    "The sample is a phase 2 clinical trial for pancreatic cancer. The trial is looking for patients with histologically confirmed adenocarcinoma of the pancreas that is resectable, marginally resectable, or unresectable. The patients must have measurable disease and no known brain metastases or tumor metastatic to the peritoneum, liver, or other organs. The trial is also looking for patients with an ECOG performance status of 0-1, ANC \u22651,500/mm\u00b3, platelet count \u2265 100,000/mm\u00b3, AST and ALT \u2264 2.5 times upper limit of normal (ULN), creatinine < 1.5 times ULN, and bilirubin < 2.0 mg/dL (\u2264 10 mg/dL for patients with biliary obstruction by tumor). The patients must not have significant traumatic injury within the past 28 days, serious non-healing wounds, ulcers, or bone fractures, abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within the past 6 months, myocardial infarction, unstable angina, or cerebrovascular accident within the past 6 months, NYHA class II-IV congestive heart failure, or clinically significant peripheral vascular disease. The patients must have adequate oral intake of > 1500 calories/day and be able to maintain hydration OR have access for supplemental enteral feeding. The trial is not looking for patients who have had prior chemotherapy or radiotherapy for pancreatic cancer, concurrent major surgical procedures, treatment plan requiring treatment of > 50% of the liver at a dose > 30 Gy or > 50% of the total kidney volume at a dose > 18 Gy, concurrent combination antiretroviral therapy for HIV-positive patients, other concurrent investigational agents, or oral or parenteral anticoagulation unless patients is receiving a stable dose of anticoagulant.",
    "The sample is a phase 2 clinical trial for patients with metastatic breast cancer or neoplasms in the breast. The trial involves the drugs lapatinib and capecitabine and has a list of eligibility criteria that patients must meet to participate. These criteria include having documented progressive advanced or metastatic breast cancer, refractory breast cancer, and a history of prior treatments with taxane and anthracycline-containing regimens. Patients must also have archived tumor tissue available for biomarker assessment and meet certain hematologic, hepatic, and renal function requirements. The trial has exclusion criteria, such as pregnancy or lactation, unresolved or unstable serious toxicity from prior administration of another investigational drug, and active or uncontrolled infection.",
    "The sample is a phase 2 clinical trial for patients with pancreatic cancer that is locally advanced, unresectable, or metastatic. The trial is testing the effectiveness of the drug eribulin mesylate. The eligibility criteria include having measurable disease, having received up to one prior line of gemcitabine-based systemic therapy, and meeting certain health requirements such as leukocyte count and platelet count. Patients must also not have received chemotherapy or radiotherapy within the past four weeks and must not have any other active malignancies. The trial excludes pregnant women and HIV-positive patients on combination antiretroviral therapy.",
    "The sample is a phase 2 clinical trial for the treatment of postherpetic neuralgia. The trial includes patients between the ages of 18 and 80 who have persistent pain for more than 6 months from the appearance of herpes zoster rash that is not located on the face, above the scalp hairline, or in proximity to mucous membranes. The trial involves the use of two drugs, xpf-002 and placebo, and has a list of inclusion and exclusion criteria that patients must meet in order to participate. The inclusion criteria include having a diagnosis of PHN, persistent neuropathic pain that involves at least 1 dermatome and covering no more than 400 cm2, and a mean daily pain intensity score in the target area of greater than or equal to 4 on an 11-point Likert NRS for a minimum of 4 days during the single-blind, placebo run-in period. The exclusion criteria include having a systemic disease that would put the patient at additional risk or limit their ability to participate in the study, having a creatinine clearance less than 30 mL/min, and having a known history of human immunodeficiency virus, hepatitis C, or hepatitis B.",
    "The sample is a phase 2 clinical trial for potentially resectable esophageal cancer. The trial involves the use of carboplatin, celecoxib, and paclitaxel as drugs. The eligibility criteria include having histologically confirmed esophageal cancer of either squamous cell or adenocarcinoma type, no distant metastases, and a Karnofsky performance status of 80-100%. Patients must also meet certain medical requirements, such as having acceptable pulmonary function and no significant history of unstable cardiovascular disease. Patients must not have any serious underlying medical conditions that would preclude study therapy, and must not be pregnant or have uncontrolled diabetes mellitus or infection. The trial does not allow concurrent chronic NSAID use or other concurrent investigational agents. Concurrent low-dose aspirin is allowed for cardiovascular prophylaxis.",
    "This is a sample from a clinical trial table that includes information about the phase of the trial, diseases being studied, icd-10 codes of the diseases, drugs being used, and eligibility criteria for patients. In this particular sample, the trial is in phase 2 and is studying non-small-cell lung carcinoma. The icd-10 codes associated with this disease are listed as \"D02.20\", \"D02.21\", and \"D02.22\". The drug being used in the trial is rad001. The eligibility criteria for patients include having advanced (unresectable or metastatic) NSCLC, having a tissue sample of the metastatic or primary tumor available for pathology evaluation and molecular marker analyses, having received \u2264 2 chemotherapy regimens, and having documented evidence of tumor progression. There are also exclusion criteria listed, such as not being able to have concurrent therapy with agents used otherwise as anticancer therapy and not having uncontrolled brain or leptomeningeal metastases.",
    "The sample is a phase 2 clinical trial for ambulant female patients with metastatic breast cancer who have previously been treated with an anthracycline and a taxane. The trial aims to test the effectiveness of the drug e7070. The eligibility criteria include confirmed breast cancer with at least one measurable lesion, completion of all previous treatments at least 4 weeks prior to study entry, a Karnofsky performance status of at least 70%, and written informed consent. Exclusion criteria include previously receiving more than two chemotherapy regimens for metastatic breast cancer, primary diagnosis of inflammatory breast cancer, untreated brain metastases, and other medical conditions that may affect drug absorption or study compliance.",
    "The sample is a clinical trial for phase 2, involving patients with recurrent or persistent ovarian or primary peritoneal cancer. The trial requires patients to have measurable disease and have received one prior platinum-based chemotherapy regimen for primary disease. Patients who have not received prior paclitaxel may have received a second regimen that included paclitaxel. The treatment-free interval after prior platinum-based therapy must be less than 6 months, or the patient must have progressed during platinum-based therapy. Patients who are not eligible for a higher priority Gynecologic Oncology Group (GOG) protocol are also included. The trial excludes patients who have had prior therapy with pemetrexed, have a history of other invasive malignancies within the last five years, or have received radiation to more than 25% of marrow. The table also includes information on the diseases, icd-10 codes, drugs, and eligibility criteria.",
    "The sample is a phase 2 clinical trial for prostate cancer. The trial is looking for patients who have undergone radical prostatectomy within the past year and have no lymph node or distant metastases. The trial is testing the effectiveness of four drugs - bicalutamide, docetaxel, flutamide, and lhrh agonist. The eligibility criteria include specific disease characteristics, such as Gleason score and post-operative PSA nadir, as well as patient characteristics, such as Zubrod performance status and blood counts. Patients must not have any other invasive malignancy within the past 3 years except non-melanomatous skin cancer and must not have any active, severe co-morbidity. Prior concurrent therapy is also taken into consideration.",
    "The sample is a phase 2 clinical trial for osteoporosis. The trial is looking at the effectiveness of two drugs, placebo and dp001. The eligibility criteria for the trial includes being a postmenopausal female who has been amenorrheic for at least 5 years, having a body mass index between 18 and 35, being osteopenic, generally healthy, and providing informed consent. Exclusion criteria includes having a history or evidence of certain diseases, current or recent treatment with certain medications or investigational drug therapy, abnormal creatinine clearance, elevated urinary calcium levels, vitamin D deficiency, excessive dietary calcium or vitamin D intake, and current use of any illicit drug and/or history of alcohol abuse.",
    "The sample is a phase 2 clinical trial for rheumatoid arthritis. The trial includes subjects who are between 18-75 years old and have functional class I to III rheumatoid arthritis for at least 3 months prior to screening. The trial requires a minimum of 8 swollen joints and 8 tender/painful joints at screening, and a serum C-reactive protein (CRP) above 5 mg/L. The subjects must have been on methotrexate for at least 16 weeks and on a stable dose for at least 8 weeks prior to randomization. The trial also has various inclusion and exclusion criteria, such as negative results for HIV, hepatitis B, and hepatitis C, and not having received certain medications within a certain time frame. The trial requires written informed consent and compliance with the study protocol.",
    "The sample is a phase 2 clinical trial for chronic obstructive pulmonary disease (COPD). The trial is testing the effectiveness of the drugs rv568 and placebo. The eligibility criteria for the trial includes being between the ages of 40-75, having a COPD diagnosis, and conforming to the current severity classification for GOLD Stage II/III disease. Exclusion criteria includes having a history of life-threatening COPD, hospitalization for COPD in the previous 2 years, and having other respiratory disorders such as asthma or lung cancer. The sample also includes a detailed list of inclusion and exclusion criteria for the trial.",
    "The sample is a phase 2 clinical trial for the treatment of pulmonary hypertension. The trial includes subjects between the ages of 18 and 75 with symptomatic PAH, a 6-min walking distance of more than 150 m, a pulmonary vascular resistance >300 dyn*s*cm-5, and a mean pulmonary artery pressure \u2265 25 mmHg. The trial involves the use of riociguat (adempas, bay63-2521), placebo, and sildenafil. The eligibility criteria include stable pretreatment with sildenafil at a dose of 20 mg tid, and the use of other unspecified treatments for PAH such as oral anticoagulants, diuretics, digitalis, calcium channel blockers, or oxygen supplementation. The exclusion criteria include subjects with a medical disorder or condition that would impair their ability to participate or complete the study, substance abuse within the previous 180 days, and severe allergies or multiple drug allergies. The trial requires subjects to perform a valid 6MWD test, and excludes subjects with a relative difference of more than 15% between the eligibility- and the baseline 6MWD test. The trial also excludes subjects with all types of pulmonary hypertension except subtypes of Updated Clinical Classification of pulmonary hypertension (PH) (Dana Point 2008) Group I specified in the inclusion criteria.",
    "The sample is a phase 2 clinical trial for HIV infections. The trial involves testing the effectiveness of a drug called rdea806 at different dosages (400 mg, 1000 mg, 600 mg, and 800 mg) compared to a placebo. The eligibility criteria for participants include being male, aged between 18 and 65 years, having chronic HIV-1 infection with a viral load above 5000 HIV-1 RNA copies/ml, and having never received antiretroviral therapy or only having received a short course of treatment. Exclusion criteria include a history of alcohol or drug abuse, CD4 count below 350 cells/mm3, life expectancy of less than 6 months, and currently active AIDS-defining illness. The trial also excludes participants with acute hepatitis A or acute or chronic hepatitis B or C infection, and those with significant cardiac dysfunction.",
    "The sample is a phase 2 clinical trial for patients with ovarian, fallopian tube, or primary peritoneal carcinoma that has recurred or persisted after prior platinum-based chemotherapy. The trial is testing the effectiveness of paclitaxel albumin-stabilized nanoparticle formulation as a second regimen for patients who have not received prior paclitaxel-based chemotherapy. The eligibility criteria include having measurable disease, a target lesion, and a GOG performance status of 0-2, as well as meeting various medical and health requirements. Patients must not have received prior paclitaxel albumin-stabilized nanoparticle formulation or other cancer treatments that would preclude study therapy. The trial also allows for one additional prior noncytotoxic regimen for management of recurrent or persistent disease.",
    "This sample is for a phase 2 clinical trial for patients with recurrent non-small cell lung cancer. The trial is testing the drug cediranib maleate. The eligibility criteria include having received prior platinum-based chemotherapy, having measurable disease, and having a life expectancy of greater than 12 weeks. Patients must also meet certain health requirements, such as having a Karnofsky performance status of at least 50% and certain blood counts within normal limits. Patients with certain medical conditions or taking certain medications are excluded from the trial. Women of child-bearing potential must have a negative pregnancy test and agree to use contraception during the trial. Patients will be closely monitored for any adverse events.",
    "The sample is a phase 2 clinical trial for cancer patients with advanced, surgically unresectable colorectal cancer. The trial involves the use of bevacizumab and capecitabine in combination with oxaliplatin. The eligibility criteria include having measurable disease, an ECOG performance status of 0, 1, or 2, and an estimated life expectancy of at least 12 weeks. Patients must not have received prior therapy for metastatic disease and must have evidence of adequate organ function. Exclusion criteria include any systemic therapy administered for metastatic or locally recurrent disease, any histology other than adenocarcinoma of the colon or rectum, and serious concomitant medical conditions that would compromise the safety of the patient or their ability to complete the study.",
    "The sample is a phase 2 clinical trial for non-small cell lung cancer. The trial includes patients who are at least 70 years old and have a histologic or cytologic diagnosis of non-small cell lung cancer with at least one site of measurable disease. The trial also includes patients with Stage IIIB with pleural effusion or Stage IV disease. Patients must have adequate hepatic, renal, and marrow function, and an ECOG Performance Status of 0, 1, or 2 at the time of informed consent. Patients must also provide written, voluntary consent and use an acceptable contraceptive method if they have reproductive potential. The trial excludes patients with uncontrolled brain metastasis, symptomatic neuropathy, prior chemotherapy for advanced non-small cell lung cancer, and any serious or uncontrolled concomitant disorder that would compromise the patient's ability to complete the study. Patients with chronic liver disease, major surgery two weeks prior to study treatment, any significant history of non-compliance to medical regimens, or any condition requiring continuous administration of systemic corticosteroids are also excluded. The trial does not include patients who are on therapeutic anti-coagulation with warfarin.",
    "The sample is a phase 2 clinical trial for patients with metastatic prostate cancer and bone metastases. The trial is testing the drug tandutinib and has eligibility criteria including a castrate level of testosterone, evidence of progressive disease, and adequate organ and marrow function. Patients must have had one prior taxane-based regimen but no prior known PDGFR inhibitor therapy is permitted. The trial excludes patients with certain medical conditions, including chronic liver disease and uncontrolled intercurrent illness. The trial is only open to men and requires informed consent.",
    "The sample is a phase 2 trial for HIV infected, therapy-naive subjects. The trial includes two diseases, \"infection, human immunodeficiency virus i\" and \"HIV infection\", with corresponding ICD-10 codes of \"Z21\". The trial involves two drugs, \"gw873140\" and \"kaletra (lopinavir/ritonavir)\". The eligibility criteria for the trial include having a screening lab result of plasma HIV-1 RNA greater than or equal to 50,000 copies/mL and CD4 cell count greater than or equal to 100 cells/mm3, being treatment-naive, and having CC Chemokine Receptor5-tropic (R5-tropic) or CC Chemokine Receptor5/CXC Chemokine Receptor4-tropic (R5/X4-tropic) virus based on viral tropism test at screening visit. The trial also includes various exclusion criteria, such as no detection of CXC Receptor4-tropic (X4-tropic) virus only, no active Class C AIDS-defining illness, and no pregnant or breastfeeding women. Additional qualifying criteria will be determined by the physician.",
    "The sample is a phase 2 clinical trial for patients with epilepsy who have uncontrolled partial seizures despite being treated with at least three different anti-epileptic drugs for at least 2 years. The trial includes male and female patients between the ages of 18 and 70 who weigh at least 40 kg and have been diagnosed with epilepsy with partial-onset seizures with or without secondarily generalized seizures. The trial involves the use of the drugs e2007 (perampanel) and placebo. Patients must meet certain inclusion criteria, such as providing written informed consent, being reliable and willing to make themselves available for the study period, and having a negative serum beta-human chorionic gonadotropin (beta-hCG) at screening. Patients must also meet certain exclusion criteria, such as having participated in a study involving administration of an investigational compound within one month of screening, having a history of drug abuse, or having a history of alcohol abuse in the past 2 years. The eligibility criteria also include specific medical requirements, such as having a diagnosis of epilepsy with partial-onset seizures and having uncontrolled partial seizures despite being treated with at least three different anti-epileptic drugs. The trial involves a prospective baseline phase of 28 days, during which patients must have at least 3 seizures to be randomized. The trial also includes various medical tests and assessments to ensure patient safety and to evaluate the efficacy of the drugs.",
    "The sample is a phase 2 clinical trial for patients with mild asthma. The trial is testing the effectiveness of a drug called SB010 compared to a placebo. The eligibility criteria include being a male Caucasian aged between 18 and 60 years, having a clinical diagnosis of mild asthma for at least 6 months, and having a positive skin prick test to common aeroallergens. Exclusion criteria include having other clinically significant diseases, being on concomitant treatments, and having a history of interstitial lung or pulmonary thromboembolic disease. The trial involves various procedures and visits, and patients must be able to give informed consent and cooperate adequately.",
    "The sample is a record of a clinical trial with a phase 2 designation. The trial is focused on heart failure and includes a list of ICD-10 codes associated with the disease. The trial involves several drugs, including jnj-39588146 at varying dosages and a placebo. The eligibility criteria for the trial include a diagnosis of heart failure, postmenopausal status for women or surgical sterilization at least 6 months prior, and the willingness of males to use birth control for 3 months after the last dose of medication. Exclusion criteria include a history of heart-assist device or heart transplant, recent ischemic attack or heart attack, and lung disease or congenital heart failure.",
    "The sample is a record of a clinical trial with a phase 2 designation, focused on the disease of endometriosis. The trial includes a list of ICD-10 codes associated with the disease, as well as a list of drugs being tested, including placebo and leuprorelin acetate. The eligibility criteria for the trial are listed, including both inclusion and exclusion criteria. Inclusion criteria include participants who have completed a previous study, while exclusion criteria include participants who have experienced adverse events or are unable to comply with the protocol. The investigator may also exclude participants who show no efficacy or who experience low estrogen symptoms.",
    "This sample is for a phase 2 clinical trial for HIV infection. The trial is testing the effectiveness of raltegravir film-coated tablet, raltegravir chewable tablet, and other anti-retroviral therapy drugs. The eligibility criteria for participants include being HIV positive, having a weight of at least 7 kg, and having an HIV RNA level of at least 1000 copies/mL within 45 days before the study treatment. Participants of reproductive potential must agree to remain abstinent or use an acceptable method of birth control throughout the study. Exclusion criteria include being pregnant or breastfeeding, having a current diagnosis of acute or chronic hepatitis, having a history of malignancy, and using recreational or illicit drugs or having a recent history of drug or alcohol abuse or dependence.",
    "The sample is a clinical trial for a drug called plecanatide, which is being tested for the treatment of chronic idiopathic constipation. The trial is in phase 2/phase 3 and the eligibility criteria include being between the ages of 18-75, having a body mass index between 18-35 kg/m2, and meeting the modified Rome III criteria for functional chronic idiopathic constipation for at least 3 months with symptom onset for at least 6 months. Patients with manual maneuvers required for more than 25% of defecations will not be eligible for participation. The trial also requires patients to discontinue use of supplemental fiber, laxatives, prescription and nonprescription medications, herbal or dietary supplements intended to treat constipation during the screening, pre-treatment, treatment and 2-week post-treatment periods. Patients must also be willing to maintain a stable diet during the study. The exclusion criteria include loose stool or watery stool in the absence of any laxative or prohibited medicine for more than 25% of bowel movements during the 3 months prior to screening visit or during the 14 day treatment period, meeting the Rome III criteria for Irritable Bowel Syndrome (IBS-C), active peptic ulcer disease not adequately treated or not stable, history of cathartic colon, laxative, enema abuse, or ischemic colitis, fecal impaction within 3 months of screening, and having any diseases or conditions associated with constipation (GI or CNS), structural abnormality of the GI tract or gastric bypass surgery, pelvic floor dysfunction, pseudo-obstruction, active infectious gastritis, diverticulitis, anal fissures or any disease or condition that can affect GI motility or defecation or can be associated with abdominal pain. Major surgery within 60 days of screening is also an exclusion criterion.",
    "This sample is for a phase 2 clinical trial for the treatment of influenza. The trial is testing the effectiveness of nitazoxanide compared to a placebo. The eligibility criteria for participants include being between the ages of 18 and 65, having symptoms of influenza, and being diagnosed with influenza A or B in the local community within 48 hours of onset of illness. Exclusion criteria include severe illness requiring hospitalization, high risk of complications from influenza, pregnancy or breastfeeding, recent vaccination for influenza, recent treatment with antiviral medication or investigational drugs, known sensitivity to nitazoxanide, and other pre-existing chronic infections or illnesses that may increase the risk of participation in the study. Participants must be willing and able to comply with the requirements of the study protocol.",
    "The sample is a phase 2 clinical trial for patients with metastatic, hormone-receptor positive breast cancer that has progressed despite previous systemic hormonal therapy. The trial is testing the effectiveness of the drug naltrexone. Inclusion criteria include measurable disease as defined by solid tumor response criteria or non-measurable bone disease that is PET avid, Karnofsky performance status >70%, and adequate organ function. Exclusion criteria include brain metastases, pregnancy or lactation, use of certain opioid medications, uncontrolled pain with non-narcotic drugs, history of sensitivity to naltrexone, acute hepatitis or liver failure, and immunosuppressive therapy for patients with autoimmune diseases, organ transplant, or other indications. Women of childbearing potential must use an effective method of contraception during the study and for 3 months after the last dose of study drug. Patients must provide voluntary written informed consent before participating in any study-related procedures.",
    "The sample is a phase 2 clinical trial for the treatment of generalized anxiety disorder. The trial includes male and female subjects between the ages of 18 and 50 who are in good general health and have been diagnosed with GAD. The trial excludes subjects with a history of HIV, hepatitis B or hepatitis C, major depressive disorder, panic disorder, post-traumatic stress disorder, body dysmorphic disorder, eating disorder, or other disorders. Subjects with a history or presence of obsessive-compulsive disorder, any psychotic, bipolar or schizophrenic disorder, or antisocial personality or other severe disorder are also excluded. Additionally, subjects with refractory GAD, a history of seizures, or who have initiated psychotherapeutic intervention within 30 days are excluded. Current smokers or those who have smoked within the last 12 months, as well as those who have donated blood within the past 30 days or plan to donate during and within 30 days after study participation are also excluded. The trial involves the use of the drugs eszopiclone and placebo.",
    "The sample is a phase 2 clinical trial for patients with colorectal cancer and metastatic cancer. The trial involves the use of three drugs - fluorouracil, leucovorin calcium, and oxaliplatin. The eligibility criteria include confirmation of primary cancer of the colon or rectum, isolated hepatic metastases, and measurable disease. Patients must also meet certain patient characteristics such as having a WHO performance status of 0-1, a life expectancy of more than 3 months, and normal levels of various blood components. Exclusion criteria include severe cardiac disease, active or uncontrolled infection, and other concurrent serious disorders. Prior concurrent therapy is also considered in the eligibility criteria.",
    "This sample is for a phase 2 clinical trial for patients with moderate to severe chronic obstructive pulmonary disease (COPD). The trial includes the drugs tiotropium, salmeterol, fluticasone, ciclesonide low, ciclesonide high, and a placebo. The eligibility criteria include being a current or ex-smoker with a smoking history of more than 10 pack years, being 40 years of age or older, and having relatively stable COPD. Exclusion criteria include having other significant diseases that could affect the study results or pose a safety risk, taking other medications that could affect the study results, having hypersensitivity to the study medication, and having unstable COPD.",
    "The sample is a phase 2 clinical trial for patients with recurrent or persistent endometrial carcinoma. The trial is testing the effectiveness of the drug thalidomide. Patients must meet certain eligibility criteria, including having at least one measurable lesion, having received one prior chemotherapy regimen for endometrial carcinoma, and having no active infection requiring antibiotics. Patients must also have a certain performance status, blood counts within a certain range, and no other invasive malignancy within the past 5 years except non-melanoma skin cancer. Patients must not have prior thalidomide treatment or concurrent bisphosphonates. The trial is not open to patients who are eligible for higher priority GOG protocols.",
    "The sample is a phase 2 clinical trial for sickle cell disease. The trial is testing the effectiveness of nitric oxide and oxygen in treating acute pain crisis in patients with sickle cell disease. The eligibility criteria include having a documented diagnosis of Hemoglobin SS, Hemoglobin S\u00df0thal or Hemoglobin SC, being between the ages of 9 and 22, and having a pain score of at least 6 cm. Exclusion criteria include having more than 24 pain crises in the last 12 months, having received treatment for pain crisis within the last 12 hours, and having certain medical conditions such as acute or chronic cardiac dysfunction or acute priapism. Pregnant females and cigarette smokers are also excluded from the trial.",
    "The sample is a phase 2 clinical trial for chronic hepatitis C. The trial includes participants who are between the ages of 18 and 70 and have not been previously exposed to interferon, ribavirin, or other HCV-specific direct-acting antiviral drugs. The trial also requires participants to have chronic hepatitis C genotype 1a, 1b, 2, or 3 as documented by positive test results for anti-HCV antibody, HCV RNA, or a HCV genotype at least 6 months prior to screening. The trial has a list of exclusion criteria, including evidence of a medical condition associated with chronic liver disease other than HCV, history of variceal bleeding, hepatic encephalopathy, or ascites requiring management with diuretics or paracentesis, and history of cancer within 5 years prior to enrollment. The trial also has a list of other medical, psychiatric, and/or social reasons that may make a candidate inappropriate for participation in the study.",
    "The sample is a phase 2 clinical trial for non-small cell lung cancer patients who are either in stage IIIB or IV or have had a recurrence after primary surgery or radiotherapy. The trial is testing the effectiveness of the drugs bevacizumab and erlotinib. The eligibility criteria include confirmation of the cancer diagnosis, ECOG PS 0-1, measurable disease, certain blood counts, and liver function tests within normal limits, ability to swallow and absorb oral medication, and willingness to sign consent. Exclusion criteria include certain medical conditions, prior treatment with certain drugs, history of bleeding or clotting disorders, and recent surgeries or traumas. Pregnant or lactating women are also excluded.",
    "The sample is a phase 2 clinical trial for patients with stage IV pancreatic cancer. The trial involves the use of two drugs, sorafenib tosylate and gemcitabine hydrochloride. The eligibility criteria include having measurable disease, no prior chemotherapy for metastatic disease, and a life expectancy of greater than 3 months. Patients must also meet certain health requirements, such as having a certain level of leukocytes and platelets. Women of child-bearing potential and men must agree to use adequate contraception during the trial. Patients with certain medical conditions or taking certain medications are excluded from the trial.",
    "The sample is a phase 2 clinical trial for the treatment of moderate to severe plaque psoriasis. The trial involves the drugs peficitinib and placebo, and the eligibility criteria include having at least 10% of the body surface area affected by psoriasis for 6 months or longer, being a candidate for phototherapy and/or systemic therapy, and not having non-plaque or drug-induced psoriasis. Exclusion criteria include being on systemic psoriasis therapy within 56 days or 5 half-lives prior to the first dose of study drug, having a positive TB skin test within 3 months of screening or at screening, and having an abnormal chest x-ray.",
    "The sample is a phase 2 clinical trial for the treatment of renal cell carcinoma. The trial includes patients with a confirmed diagnosis of predominantly clear-cell histology renal cell carcinoma that is either metastatic or locally recurrent. Patients must have either no prior systemic therapy or have failed only one prior cytokine-based or bevacizumab-based therapy. The trial involves the use of two drugs, gw786034 and placebo. The eligibility criteria include having measurable disease, being at least 21 years old, having a negative pregnancy test, and using adequate contraception. Patients must also have an Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) of 0 or 1, adequate bone marrow, hepatic, and renal function, and be able to swallow and retain oral medications. Exclusion criteria include having received prior non-cytokine or non-bevacizumab therapies, chemotherapy for renal cell carcinoma, major surgery, radiotherapy, or immunotherapy within the last 28 days, and having any serious pre-existing medical, psychiatric, or other condition that could interfere with subject safety or obtaining informed consent.",
    "The sample is a phase 2 clinical trial for the treatment of pulmonary arterial hypertension. The trial includes patients who have been diagnosed with PAH according to the Dana Point 2008 Meeting criteria and have not responded well to one or more classes of PAH drugs. The patients must have a WHO Functional Class II or III performance and a 6MWD between 150 m and 450 m at screening. The trial involves the use of the drug nilotinib and a placebo to nilotinib. The eligibility criteria include various inclusion and exclusion criteria, such as pre-existing lung disease, chronic nitric oxide therapy, and uncontrolled systemic arterial hypertension. Other protocol-defined inclusion/exclusion criteria may also apply.",
    "The sample is a phase 2 clinical trial for HIV infections. The trial involves testing the effectiveness of tenofovir gel and a placebo (universal hec placebo) as potential treatments. The eligibility criteria for participants include being between the ages of 18-40, sexually active, HIV negative, and willing to adhere to study visits and procedures. Exclusion criteria include a history of adverse reaction to latex, plans to travel away from the study site for more than 30 consecutive days, and having any condition that would preclude provision of informed consent or make participation in the study unsafe.",
    "The sample is a phase 2 clinical trial for obesity. The trial includes a list of icd-10 codes for the disease and a list of drugs that will be used in the trial, including placebo, diazoxide, and metformin + diazoxide. The eligibility criteria for the trial include being male, between the ages of 25-50, having a BMI of 30-35 kg/m2, stable body weight for 3 months prior to the study, glucose levels less than or equal to 6.0 mmol/L, C-peptide levels greater than or equal to 1.0 nmol/L, and HbA1c levels less than or equal to 6.0%. Exclusion criteria include comorbidity, medication, serum creatinine levels greater than 120 micromol/L, liver enzymes greater than 2 times the upper limits of normal, gout, alcohol use greater than 2 alcoholic drinks a day, drug abuse, and cessation of smoking less than 6 months ago.",
    "The sample is a phase 2 clinical trial for patients with platinum-sensitive recurrence of epithelial ovarian cancer, primary peritoneal cancer, or fallopian tube cancer. The trial includes patients with various histologic subtypes and requires at least one measurable lesion according to RECIST criteria via CT or MRI scan. Patients must have received a platinum-containing regimen at initial diagnosis and have an ECOG performance status of 0, 1, or 2. The trial also has various eligibility criteria, including age, life expectancy, blood counts, liver function, and kidney function. Patients with certain medical conditions or prior treatments are excluded from the trial. The trial involves the use of two drugs, carboplatin and pemetrexed.",
    "The sample is a phase 2 clinical trial for infertility. The trial is testing the effectiveness of two drugs, fsh-gex(tm) and gonal-f(r), on female patients who require ICSI treatment. The eligibility criteria for the trial include having a certain level of follicle-stimulating hormone and anti-mullerian hormone concentration, a normal uterine cavity, and regular menstrual cycles. Patients who have had more than two unsuccessful previous assisted reproduction technology cycles, previous poor responders, or a history of certain medical conditions are excluded from the trial. The sample also includes a list of icd-10 codes for the disease and a list of inclusion and exclusion criteria.",
    "This sample is for a phase 2 clinical trial for the treatment of multiple myeloma. The trial is testing the drug cetuximab +/- dexamethasone. The eligibility criteria for the trial include having stage II or III multiple myeloma according to the Durie-criteria, measurable disease, and having relapsed or refractory disease after at least one line of treatment. Patients must also be at least 18 years old, have an ECOG performance status of 0-2, and have a life expectancy of more than 12 weeks. Exclusion criteria include having certain medical conditions, such as severe cardiovascular disease or insufficient bone marrow reserve, and having participated in another clinical trial or taken any investigational agent in the preceding 30 days. Patients must also provide written informed consent to participate in the trial.",
    "The sample is a phase 2 clinical trial for seasonal allergic rhinitis. The trial includes subjects who are healthy and have a history of seasonal allergic rhinitis. The trial also requires male subjects between the ages of 18 and 55 who exhibit a moderate response to 4-hour exposure to grass pollen in the challenge chamber. The trial has inclusion and exclusion criteria, including no structural nasal abnormalities or nasal polyps, no history of drug allergy, and no regular consumption of more than 21 units of alcohol per week. The trial also requires subjects to be compliant with protocol requirements and available to complete all study measurements.",
    "The sample is a phase 2 clinical trial for colorectal cancer. The trial includes patients with adenocarcinoma of the rectum originating at or below 12 cm from the anal verge without evidence of distant metastases. The trial drugs include capecitabine, irinotecan, oxaliplatin, folinic acid, and fluorouracil. The eligibility criteria include age over 18, potentially resectable en bloc based upon surgeon evaluation, clinical stages T3 or T4, and certain blood count and liver function requirements. Exclusion criteria include evidence of distant metastasis, prior radiation therapy to the pelvis, prior chemotherapy for malignancies, pregnancy or lactation, serious uncontrolled concurrent infections, and other serious uncontrolled medical conditions that might compromise study participation.",
    "The sample is a phase 2 clinical trial for patients with ovarian, fallopian tube, or primary peritoneal cavity cancer. The trial is testing the effectiveness of gemcitabine hydrochloride and topotecan hydrochloride drugs for patients with recurrent or persistent platinum-refractory disease. The eligibility criteria include having measurable or evaluable disease, being 18 years or older, having a performance status of GOG 0-3, and meeting certain hematopoietic, hepatic, renal, and other medical condition requirements. Prior concurrent therapy is allowed under certain conditions. The sample includes a detailed list of eligibility criteria for the trial.",
    "The sample is a phase 2 clinical trial for patients with locally advanced or metastatic unresectable pancreatic adenocarcinoma. The trial is testing the effectiveness of the drugs arq 197 and gemcitabine. The eligibility criteria include being at least 18 years old, having measurable disease, and a Karnofsky performance status of at least 70%. Patients of child-producing potential must agree to use contraception during the study and for 90 days after treatment. Exclusion criteria include having received prior therapy for pancreatic malignancy, central nervous system metastases, and significant co-morbid conditions that would impair study participation.",
    "The sample is a phase 2 clinical trial for patients with metastatic melanoma or skin cancer. The trial involves the use of cyclophosphamide and fludarabine phosphate drugs. The eligibility criteria include having measurable disease, being a non-responder to high dose interleukin-2 (IL-2) or having recurred, being positive for MART-1 by immunohistochemistry (IHC), having tumor infiltrating lymphocytes (TIL) cells not available for treatment on other Surgery Branch protocols, being over 18 years old, having a clinical performance status of Eastern Cooperative Oncology Group (ECOG) 0 or 1, having a life expectancy of greater than three months, and meeting certain hematology and chemistry requirements. Patients must also be willing to practice birth control for four months after receiving the preparative regimen and be human leukocyte antigens (HLA-A) 0201 positive. Exclusion criteria include being pregnant or breastfeeding, having active systemic infections or major medical illnesses, having any form of primary immunodeficiency, ongoing opportunistic infections, systemic steroid therapy, a history of severe immediate hypersensitivity reaction to any of the agents used in the study, a history of coronary revascularization or ischemic symptoms, and having a documented left ventricular ejection fraction (LVEF) less than or equal to 45 percent or a documented forced expiratory volume in 1 second (FEV1) less than or equal to 60 percent predicted.",
    "The sample is a phase 2 clinical trial for patients with stage III or IV squamous cell carcinoma of the oral cavity, oropharynx, larynx, hypopharynx, or nasopharynx. The trial involves planned definitive or adjuvant radiation with concurrent cisplatin and the use of fosaprepitant dimeglumine, cisplatin, palonosetron hydrochloride, and dexamethasone. The eligibility criteria include having a documented squamous cell carcinoma, a certain stage of disease, a good performance status, adequate organ function, and a predicted life expectancy of more than 12 weeks. Patients must also be willing to complete patient diaries and questionnaires and use an acceptable contraceptive method. Exclusion criteria include inability or unwillingness to comply with treatment, use of illicit drugs or ongoing alcohol use, vomiting within 24 hours prior to cisplatin infusion, and certain medical conditions.",
    "The sample is a phase 2 clinical trial for chronic plaque psoriasis. The trial is looking at the effectiveness of certolizumab pegol as a treatment option. The eligibility criteria for the trial includes adult men and women over 18 years old who have had stable chronic plaque psoriasis for at least 3 months and moderate to severe symptoms for at least 6 months. Participants must have a Psoriasis Area and Severity Index (PASI) score of 12 or higher and a Body Surface Area (BSA) of 10% or higher. They must also be candidates for systemic psoriasis therapy and/or phototherapy and/or photochemotherapy. Exclusion criteria includes having an erythrodermic, guttate, palmar or plantar, generalized pustular form of psoriasis, a history of chronic infection, recent serious or life-threatening infection, or any current sign or symptom that may indicate an infection. Other exclusion criteria includes having white blood cell counts less than 4000/mm^3 or more than 20000/mm^3, suspected or diagnosed demyelinating disease of the central nervous system, systemic lupus, non-respect of adequate wash out periods for treatments that might have an impact on the disease, any associated disease that could be impacted by the study treatment intake, and any other condition that would make the subject unsuitable for inclusion in the study.",
    "The sample is a record from a clinical trial table that includes information about the phase of the trial (phase 2/phase 3), the disease being studied (rheumatoid arthritis), the ICD-10 codes associated with the disease, the drug being tested (prednisone), and the eligibility criteria for participants. The inclusion criteria include meeting the American College of Rheumatology Criteria for Rheumatoid Arthritis, being between the ages of 18-80, having adequate renal function, and being willing to comply with the study protocol. The exclusion criteria include having an inflammatory arthritis other than RA, having a history of drug or alcohol abuse within the past 6 months, and having any disease or condition that contraindicates the use of an investigational drug or may affect the interpretation of the results.",
    "The sample is a phase 2 clinical trial for the treatment of large granular lymphocytic leukemia (LGL leukemia) using the drug cyclosporine. The trial has eligibility criteria that include a histologic or cytologic diagnosis of T-cell LGL leukemia, hemocytopenias, measurable or evaluable disease, a creatinine level of less than 2.0 mg/dl, and a life expectancy of greater than 3 months. Exclusion criteria include uncontrolled hypertension, pregnancy or nursing, underlying immunodeficiency, and serious intercurrent illnesses. All female patients must use adequate contraception during participation in the trial and for three months after completing therapy.",
    "The sample is a record of a clinical trial in phase 2 for the treatment of depression using a drug called azd6765. The trial includes patients who have been diagnosed with depression and have not responded well to previous antidepressant treatments. The trial excludes patients with other psychiatric disorders, those who are pregnant or lactating, and those with a current diagnosis of cancer. The diseases are listed as 'depression' and the icd-10 codes associated with it are [\"['F32.A', 'F53.0', 'P91.4', 'Z13.31', 'Z13.32']\"].",
    "The sample is a phase 2 clinical trial for patients with locally advanced or metastatic adenocarcinoma of the pancreas. The trial involves the use of gemcitabine and etoposide as drugs. The eligibility criteria include being 18 years or older, having unidimensional measurements obtainable using RECIST criteria, and having a Karnofsky Performance Scale of 50 or better. Patients must also meet certain hematologic and chemical parameters, have a life expectancy of at least eight weeks, and provide signed informed consent prior to study entry. Exclusion criteria include previous chemotherapy (with the exception of 5FU given as part of an adjuvant regimen), pregnancy or nursing, concurrent radiation therapy, and other active neoplasms or serious active infections or underlying medical conditions that would impair their ability to receive treatment as prescribed. The disease diagnostic criteria and staging involve a histologic or cytologic diagnosis of locally advanced or metastatic adenocarcinoma of the pancreas using standard pathologic criteria, and staging according to AJCC criteria.",
    "The sample is a phase 2 clinical trial for liver cancer. The trial is testing the effectiveness of the drugs epirubicin hydrochloride and thalidomide. The eligibility criteria for the trial include having a diagnosis of hepatocellular carcinoma that is locally unresectable or metastatic, having measurable disease, and not having clinically apparent CNS metastases or carcinomatous meningitis. Patients must also meet certain age, performance status, life expectancy, hematopoietic, hepatic, renal, and cardiovascular criteria. They must not be pregnant or nursing, must use effective contraception if fertile, and must be willing and able to participate in the System for Thalidomide Education and Prescribing Safety (STEPS) program. Patients must not have any uncontrolled serious medical or psychiatric illness or any other concurrent uncontrolled malignancy. The sample does not specify any prior biologic or endocrine therapy, radiotherapy, or surgery, but patients must not have had more than one prior chemotherapy regimen for hepatocellular carcinoma and must not have had prior chemoembolization to the liver.",
    "The sample is a phase 2 clinical trial for the treatment of schizophrenia. The trial is testing the effectiveness of the drug \"merck l-830982\" compared to a placebo. The trial is looking for male participants between the ages of 18 and 50 who meet the diagnostic criteria for schizophrenia or schizoaffective disorder and have been clinically stable on their current medication for at least 3 months. Participants must also be unemployed. Exclusion criteria include recent substance abuse, head trauma or neurological disorders, certain medical illnesses or medications, mental retardation, seizure disorder, and history of heart disease.",
    "The sample is a record of a clinical trial with a phase 2 designation, focused on bladder cancer. The trial includes a list of ICD-10 codes for the disease, as well as a list of drugs being tested (gemcitabine and cisplatin). The eligibility criteria for the trial are also listed, including requirements for patients to have measurable disease and specific stages of urothelial carcinoma. The exclusion criteria include prior or concomitant malignant diseases, a PSA level greater than 5.0 ng/mL, and concurrent administration of other tumor therapies.",
    "The sample is a phase 2 clinical trial for patients with metastatic clear cell renal cell carcinoma who are eligible for cytoreductive nephrectomy. The trial includes patients with measurable disease, an ECOG performance status of 1 or less, and certain blood count and liver function requirements. Patients must also meet certain exclusion criteria, such as not having received any systemic anticancer therapy or radiotherapy within 4 weeks prior to entering the study, not having a primary brain tumor or any brain metastases, and not having clinically significant cardiovascular disease. The trial involves the use of the drug sorafenib tosylate.",
    "The sample is a phase 2 clinical trial for patients with urothelial carcinoma, a type of bladder cancer. The trial involves the use of two drugs, docetaxel and asa404. The eligibility criteria for the trial include having histological or cytological proof of TCC, measurable disease according to RECIST, and having received only one prior chemotherapy regimen that included cisplatin, carboplatin, or gemcitabine. Patients must also be over 18 years old, willing to use contraception, and have no prior treatment with docetaxel. Exclusion criteria include no prior treatment with investigational or chemotherapeutic agents within 30 days prior to registration, no major surgery within 30 days prior to registration, and no history of certain medical conditions such as ventricular fibrillation or Torsades de Pointes.",
    "The sample is a phase 2 clinical trial for patients with mantle cell lymphoma. The trial involves the use of a combination of drugs, fludarabine, mitoxantrone, and rituximab. The eligibility criteria include having a pathologic diagnosis of Non-Hodgkin's Lymphoma of the mantle cell subtype, measurable or evaluable disease, and a Karnofsky performance status greater than or equal to 50%. Patients must also meet certain laboratory values and have no history of congestive heart failure or significant cardiac disease. Exclusion criteria include prior exposure to fludarabine or mitoxantrone, active infection, and presence of psychological or emotional disorders that would make valid informed consent impossible.",
    "The sample is a phase 2 clinical trial for the treatment of chronic myelogenous leukemia. The trial includes patients with various subtypes of the disease and uses the drug imatinib mesylate. The eligibility criteria include specific diagnostic criteria, performance status, and various medical parameters such as blood counts and organ function. Patients must not have received certain prior treatments and must not have certain medical conditions. The trial also prohibits the use of certain medications and herbal supplements.",
    "This sample is for a phase 2 clinical trial for pancreatic cancer. The eligibility criteria include having histologically confirmed adenocarcinoma of the pancreas, measurable disease, and no metastases. Patients must also have a performance status of ECOG 0-2, and meet certain hematopoietic, hepatic, renal, and other criteria. Patients cannot have had prior chemotherapy or radiotherapy for this disease. The trial will test the effectiveness of cisplatin, fluorouracil, and gemcitabine hydrochloride as treatment options.",
    "The sample is a phase 2 clinical trial for patients with urothelial carcinoma of the bladder or urethra, with T-stage ranging from T2 to T4a. The trial includes patients with radiographic N0 or N1 disease, but not those with metastatic disease. The trial allows mixed histologies as long as there is no component of small cell histology. Patients must be candidates for radical cystectomy with the goal of cure and have an ECOG performance status of 0 or 1. The trial involves the use of gemcitabine hydrochloride and cisplatin as drugs. The eligibility criteria include various laboratory values, adequate renal function, and negative pregnancy tests for women of child-bearing potential. The exclusion criteria include various medical conditions, prior radiation or chemotherapy for urothelial carcinoma, and pregnancy.",
    "The sample is a phase 2 clinical trial for osteoarthritis, a disease affecting the knee or hip. The trial involves the use of drugs such as cg100649 and celecoxib. The eligibility criteria include being at least 20 years old, having confirmed osteoarthritis, experiencing pain for at least 3 months, having normal blood pressure and heart rate, and meeting certain laboratory test requirements. Exclusion criteria include the use of certain medications, cognitive or psychiatric disorders, and various medical conditions. Participants must also agree to use double barrier contraception or provide proof of surgical sterility or post-menopause.",
    "The sample is a phase 2 clinical trial for rheumatoid arthritis. The trial includes patients who have active RA with five or more swollen joints, five or more tender joints, and a serum CRP \u22651.0 mg/dL. The patients must have received methotrexate for 12 weeks or longer and at a stable dose of 7.5 to 25 mg/week for at least 4 weeks prior to screening and willing to continue on this regimen for the duration of the study. The trial also includes patients who are taking oral steroids at a dose \u226410 mg/day of prednisone or prednisone equivalent and stable for at least 4 weeks prior to screening, and those taking non-steroidal anti-inflammatory drugs (NSAIDs) at a stable dose for at least 2 weeks prior to screening. Female subjects must have a negative pregnancy test unless they are surgically sterile or have been post-menopausal for at least one year. Women of childbearing potential must use a medically acceptable means of birth control and agree to continue its use during the study and for at least 12 weeks after the last dose of study drug. Sexually active men must agree to use a medically acceptable form of contraception during the study and continue its use for at least 3 months after the last dose of study drug. The trial excludes patients who have been treated with disease-modifying antirheumatic drugs (DMARDs), other than background methotrexate, or current or previous RA treatment with a biological agent, with the exception of biologics administered in a clinical study setting more than six months prior to screening (12 months for rituximab or other B cell depleting agents). The trial also excludes patients who have a history of any inflammatory rheumatological disorders other than RA, or a history of tuberculosis (TB) infection.",
    "The sample is a phase 2 clinical trial for patients with Burkitt's leukemia or Burkitt's or Burkitt-like lymphoma. The trial includes a list of diseases, icd-10 codes, drugs, and eligibility criteria. The eligibility criteria include age, hepatic and renal function, HIV status, pregnancy and nursing status, and prior concurrent therapy. The trial is for previously untreated patients except for hydroxyurea for leukocytosis, and CNS involvement is allowed. The patients must have confirmed Burkitt's leukemia or lymphoma with specific cytogenetic evidence and L3 morphology surface IgG expression. The trial also has specific requirements for patients with bone marrow involvement and requires enrollment in other clinical trials.",
    "The sample is a phase 2 clinical trial for obesity. The eligibility criteria include being a right-handed female between 18 and 45 years old with a BMI between 27 and 40 kg/m\u00b2, free from clinically significant illness or disease, and in good general health. The trial involves two drugs, naltrexone sr 32 mg/bupropion sr 360 mg/day and placebo. The exclusion criteria include a history of endocrine or genetic obesity, inability to participate in fMRI scanning sessions, and a history of certain illnesses or psychiatric disorders. The trial is sponsored by Orexigen Therapeutics and study personnel and their immediate families are excluded from participation.",
    "The sample is a phase 2 clinical trial for patients with malignant glioma, glioblastoma multiforme, anaplastic astrocytoma, oligo-astrocytoma, or gliosarcoma. The trial requires patients to have a confirmed diagnosis of the disease and have experienced progression or recurrence following radiotherapy. Patients must also be eligible for resection of the recurrent tumor and have a Karnofsky Performance Status greater than or equal to 60%. The trial excludes patients with concurrent malignancy, non-contiguous satellite lesions, known allergy to iodine, and those who are pregnant or breastfeeding. The eligibility criteria for the trial are detailed in the study protocol.",
    "The sample is a phase 2 clinical trial for rheumatoid arthritis. The trial includes patients who are at least 18 years old and have been diagnosed with RA according to ACR criteria. Patients must have at least 4 swollen joints and 6 tender joints at screening and baseline. They must also have a CRP level above the upper limit of normal at screening. Patients must have been on DMARD or DMARD combination for at least 3 months and be on a stable dose of DMARD(s) for at least 6 weeks prior to screening. The trial includes several inclusion and exclusion criteria, such as no history of major diseases, no history of drug or alcohol abuse, and no recent surgery. Patients must also be willing to comply with the requirements of the trial, including returning for follow-up visits on schedule. The trial includes several drugs, including crx-102, prednisolone, dipyridamole, and placebo. The eligibility criteria are quite strict, and patients must meet all of the criteria to participate in the trial.",
    "The sample is a phase 2 clinical trial for patients with thyroid cancer who are not eligible for surgery, external beam radiotherapy, or radioiodine. The trial is testing the effectiveness of the drug sunitinib. The eligibility criteria include having a life expectancy of at least 3 months, a Karnofsky performance status of at least 70%, and measurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST). Patients must not have more than one previous systemic treatment for cancer and must have discontinued radiation therapy at least 4 weeks before starting the study treatment. Patients with reproductive potential must use medically acceptable contraceptive methods. The exclusion criteria include prior treatment with sunitinib or other anti-angiogenic therapy, ongoing cardiac dysrhythmias of NCI CTCAE grade > 2, and other severe acute or chronic medical or psychiatric conditions that may increase the risk associated with study participation or study drug administration.",
    "The sample is a phase 2 clinical trial for seasonal allergic rhinitis. The trial involves testing various drug combinations, including a placebo, to alleviate symptoms. The eligibility criteria include being at least 12 years old, having a documented history of SAR, and being clinically symptomatic at the screening and baseline visits. Exclusion criteria include having certain medical conditions or dependencies on certain medications. Female subjects must have a negative pregnancy test and use birth control during the study. The trial requires regular electronic diary data transmission.",
    "The sample is a phase 2 clinical trial for primary effusion lymphoma (PEL) involving a body cavity, with Kaposi's sarcoma associated-herpesvirus. The trial allows for previously treated or untreated disease and HIV infection. The trial involves a combination of drugs including bortezomib, cyclophosphamide, doxorubicin hydrochloride, etoposide, ganciclovir, valganciclovir, and zidovudine. The eligibility criteria include age 18 and over, ECOG performance status 0-3 (ECOG 4 allowed if due to a mechanical effect of the PEL that can be corrected by effusion drainage resulting in improved performance status to ECOG 3 or better), and various medical criteria related to hematopoietic, hepatic, renal, cardiovascular, neurologic, and other conditions. The trial excludes patients with certain other malignancies requiring treatment, grade IV organ dysfunction unrelated to PEL, and certain infections requiring chronic systemic therapy. The trial also excludes patients with gastrointestinal bleeding within the past 6 months or pathological conditions that would confer a high risk for bleeding (for patients receiving bevacizumab during study treatment). The trial has various exclusion criteria related to concurrent therapies, including no live virus vaccines or bacterial vaccines during and for 3 months after completion of study treatment, no prior cumulative anthracycline dose > 450 mg/m^2 (unless cardiac ejection fraction normal), and no concurrent chronic daily aspirin \u2265 325 mg/day or nonsteroidal medication that interferes with platelet function (for patients receiving bevacizumab during study treatment). The trial also excludes patients with concurrent therapeutic anticoagulation (INR > 1.5) unless patient is on full-dose warfarin (for patients receiving bevacizumab during study treatment).",
    "The sample is a phase 2 clinical trial for Parkinson's disease. The trial includes patients who meet specific eligibility criteria, such as having a diagnosis of Parkinson's disease and being on a stable regimen of anti-Parkinson's drugs for at least four weeks before randomization. The trial also has exclusion criteria, such as patients who have a diagnosis of dementia or a mini-mental status examination score of 25 or less. The trial involves the use of drugs such as istradefylline and placebo, and patients are required to complete a 24-hour patient Parkinson's diary. Pregnant or lactating females are excluded from the trial.",
    "The sample is a phase 2 clinical trial for breast cancer. The trial includes patients who are female and over 18 years old, with primary HER2-negative operable breast cancer and a tumor size greater than 2cm. The trial drugs include bevacizumab (Avastin), docetaxel, and standard chemotherapy. The eligibility criteria include an ECOG performance status of 0-1, and exclusion criteria include previous treatment for breast cancer, metastatic disease, current or recent use of aspirin or full-dose anticoagulants, and clinically significant cardiovascular disease.",
    "This sample is for a phase 2 clinical trial for the treatment of acromegaly, a condition caused by excess growth hormone. The trial is testing the drugs octreotide and dg3173. The eligibility criteria include having a diagnosis of acromegaly of pituitary origin, age-adjusted IGF-1 concentrations \u22651.5 times the upper limit of normal range on two consecutive measurements in the 6 months prior to the first dosing day, and a random hGH level of \u22655 \u00b5g/L in the 6 months prior to or at screening. Exclusion criteria include previous specific treatment for acromegaly in the 6 months prior to screening, uncontrolled hypertension or orthostatic hypotension, and pregnancy or lactation. The sample also includes a list of diseases, icd-10 codes, and eligibility criteria.",
    "The sample is a phase 2 clinical trial for chronic hepatitis C infection. The trial includes patients who have had unsuccessful prior HCV treatment and have liver impairment. The trial is testing the effectiveness of two drugs, idn-6556 and placebo. The eligibility criteria for the trial include having chronic hepatitis C infection, liver impairment, and adequate hematologic parameters. The exclusion criteria include severe liver disease, hepatocellular carcinoma, HIV infection, co-infection with hepatitis B virus, renal impairment, pancreatitis, use of illicit or drugs of abuse, history of alcohol abuse, presence of clinically significant cardiac arrhythmias, and being pregnant or lactating if female.",
    "The sample is a phase 2 clinical trial for chronic obstructive pulmonary disease (COPD) with the drugs gw856553, placebo, and seretide. The trial is for male and female adults between the ages of 40 and 75 who have a history of smoking and have been diagnosed with COPD. The trial has a list of inclusion and exclusion criteria, including having a post-bronchodilator FEV1 to FVC ratio (FEV1:FVC) < 0.7, having a post-bronchodilator FEV1 \u2265 50% and < 80% of predicted normal for height, age and sex, and having a QTc <450 msec on baseline ECG or triplicate ECG averaged over a brief recording interval. The trial also has a list of diseases and icd-10 codes, as well as eligibility criteria for enrollment.",
    "The sample is a phase 2 clinical trial for diabetic neuropathic pain. The trial includes patients with type 1 or 2 diabetes mellitus and documented painful, symmetrical, sensorimotor polyneuropathy for at least 6 months. The trial will test the effectiveness of two drugs, bvt.115959 and placebo. Patients must either not be taking any analgesic medication or have been on stable analgesic medication for at least 4 weeks. Female patients who are fertile and of child-bearing potential are excluded from the trial, as well as patients with clinically significant or unstable hepatic, respiratory, renal, hematologic, cardiovascular or peripheral vascular disease, and painful conditions that may confound the evaluation of neuropathic pain.",
    "The sample is a phase 2 clinical trial for asthma. The trial includes patients who are 18 years or older, non-smokers or former smokers with a smoking history of \u2264 10 pack years, and have been diagnosed with asthma as defined by the National Institutes of Health. The patients must have a Best FEV1 of 50% to <80% of the predicted normal value and a post-albuterol FEV1/FVC ratio of >0.70 at Visit 1/1a. They must also have \u2265 12% and \u2265200mL reversibility of FEV1 and have been using FP/SAL 250/50mcg inhalation powder BID for at least 2 weeks just prior to Visit 1. The patients must be able to replace their current short-acting beta2-agonists with albuterol inhalation aerosol and must be able and willing to give written informed consent to take part in the study. The trial excludes patients with a history of life-threatening asthma, recent asthma exacerbation, concurrent respiratory disease, recent respiratory infection, liver disease, other concurrent diseases/abnormalities, oral candidiasis, drug allergy, milk protein allergy, immunosuppressive medications, administration of systemic, oral or depot corticosteroids within 12 weeks of Visit 1, OATP1B1 substrates within 4 weeks of Visit 1, Cytochrome P450 3A4 (CYP 3A4) Inhibitors, Cytochrome P450 3A4 (CYP 3A4) Inducers, Investigational Medications, compliance issues, and affiliation with Investigator's Site. The trial involves the use of several drugs, including fp/sal 250/50mcg bid, gsk2190915 200mg qd (am), gsk2190915 100mg qd (am), montelukast 10mg qd (pm), placebo tablets (2) (am), and placebo capsule (pm).",
    "This is a sample from a table that contains information about clinical trials. The trial is in phase 2 and is focused on treating multiple myeloma. The table includes a list of diseases, icd-10 codes, drugs, and eligibility criteria. The eligibility criteria include having a diagnosis of multiple myeloma, measurable disease, and progressive MM that has relapsed or is refractory. The patient must also meet certain laboratory test results and be disease-free of prior malignancies for 5 years. The patient must be registered into the mandatory RevAssist\u00ae program and willing to comply with the requirements. There are also exclusion criteria, such as having plasma cell dyscrasia with polyneuropathy, organomegaly, endocrinopathy, monoclonal protein and skin changes syndrome, or having undergone major surgery within 28 days prior enrollment. The sample also includes information on the required tests and treatments that the patient must undergo before and during the trial.",
    "This sample is for a phase 2 clinical trial focused on infertility. The trial is looking at the effects of omega 3 fats and folic acid on infertile men between the ages of 35 and 55 who are having difficulty timing relations with their partner's ovulation. The inclusion criteria for the trial include being an infertile man within the specified age range and expressing difficulty with timing relations. The exclusion criteria include having hypertension, heart disease, or other systemic diseases, consuming fatty fish more than twice per week, having marked semen abnormalities, using anticoagulants, and not being willing to abstain from taking PDE 5 inhibitors or other supplements during the study.",
    "The sample is a phase 2 clinical trial for patients with non-small cell lung cancer that has advanced or metastasized and cannot be cured. The trial involves the use of two drugs, cetuximab and pemetrexed. The eligibility criteria include having previously received one platinum-containing or taxane-containing chemotherapy regimen, having an ECOG performance status of 0-2, and having no more than two prior systemic anti-cancer therapies. Patients must also have measurable disease, adequate bone marrow and renal function, and signed an informed consent. Exclusion criteria include prior treatment with pemetrexed, active or uncontrolled infection, and pregnancy or breastfeeding. Patients must also be able to interrupt aspirin or other nonsteroidal anti-inflammatory agents for a 5-day period and take folic acid or vitamin B12 supplementation.",
    "The sample is a phase 2 clinical trial for Crohn's disease. The trial is looking at the effectiveness of 4-aminosalicylic acid and paser placebo granules as treatments. The eligibility criteria include being between the ages of 18-65, having a confirmed diagnosis of Crohn's disease involving predominantly the ileum and/or cecum, and having a Harvey Bradshaw Index of at least 7. Exclusion criteria include the use of certain medications within the previous few months, coexisting diagnoses, and allergies or sensitivities to salicylates. The trial requires written informed consent and adequate contraception for sexually active women of child-bearing age.",
    "The sample is a phase 2 clinical trial for patients with advanced hepatocellular carcinoma. The trial involves the use of two drugs, tac-101 and placebo. The eligibility criteria for the trial include having a confirmed diagnosis of HCC, being TACE na\u00efve or having received the most recent TACE procedure at least 120 days before signing ICF, having lesions in the liver that are confirmed nodular type with demonstrated substantial hypervascularity, and meeting certain organ function criteria. Patients will be excluded from participation if they have certain conditions such as extrahepatic metastasis of HCC, have received systemic chemotherapy or treatment with TAC-101, or have uncontrolled metabolic disorders or other nonmalignant organ or systemic diseases. The trial requires patients to comply with scheduled visits, treatment plans, laboratory tests, and other study procedures and to provide written informed consent prior to the implementation of any study assessment or procedures.",
    "The sample is a phase 2 clinical trial for patients with liver neoplasms or unresectable hepatocellular carcinoma. The trial is testing the effectiveness of the drug sunitinib (su011248). The eligibility criteria for the trial include a confirmed diagnosis of hepatocellular carcinoma, measurable disease by radiographic technique, and adequate organ function. Exclusion criteria include prior treatment with any systemic treatment for liver cancer, clinically relevant ascites, severe hemorrhage within 4 weeks of starting study treatment, diagnosis of a second malignancy within the last 3 years, history of or known brain metastases, spinal cord compression, or carcinomatous meningitis, known human immunodeficiency virus (HIV), serious acute or chronic illness, current treatment on another clinical trial, and pregnancy or breastfeeding.",
    "The sample is a phase 2 trial for patients with relapsed breast cancer or neoplasms in the breast. The trial involves the use of drugs such as lapatinib, capecitabine, docetaxel, and nab-paclitaxel. The eligibility criteria include having confirmed breast cancer, measurable lesions, documented amplification of the ErbB2 gene, and having relapsed breast cancer after trastuzumab-containing therapy. The trial also requires a baseline cardiac ejection fraction of at least 50%, adequate organ function, and an ECOG performance status of 0-2. Exclusion criteria include pregnancy or lactation, concurrent therapy for cancer, unresolved or unstable serious toxicity from prior cancer treatment, and concurrent treatment with an investigational agent.",
    "The sample is a phase 2 clinical trial for patients with advanced non-small cell lung cancer. The trial is testing the drug GW572016 (lapatinib) and requires patients to have had a maximum of one prior systemic therapy for NSCLC that ended at least 3 weeks prior to enrollment. Patients with certain histological subtypes of adenocarcinoma or who are never smokers are eligible. Patients must have measurable lesions according to RECIST and a life expectancy of at least 12 weeks. The trial has a list of inclusion and exclusion criteria, including adequate organ function and cardiac ejection fraction within the institutional range of normal. Patients must complete all screening assessments as outlined in the protocol. The trial excludes patients with concurrent cancer therapy, concurrent treatment with an investigational agent, or participation in another clinical trial. The trial also excludes patients with a known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs chemically related to GW572016.",
    "The sample is a phase 2 clinical trial for patients with either esophageal or gastric cancer. The trial involves the use of four drugs: matuzumab, epirubicin, cisplatin, and capecitabine. The eligibility criteria for the trial include confirmation of the cancer type, evidence of Epidermal Growth Factor Receptor (EGFR) expression, Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0-1, and at least one measurable lesion. Exclusion criteria include previous chemotherapy within the last 12 months, recent radiotherapy or major surgery, brain metastases, peripheral neuropathy or ototoxicity greater than or equal to Grade 2, and abnormal electrocardiogram (ECG). The diseases are represented as lists of disease names and their corresponding ICD-10 codes.",
    "The sample is a phase 2 clinical trial for the treatment of rheumatoid arthritis. The trial involves the use of a placebo drug and requires participants to meet certain eligibility criteria, such as having a diagnosis of active rheumatoid arthritis and being on a stable dose of Methotrexate. Participants must also have previously failed or been intolerant to treatment with at least one biologic tumor necrosis factor-alpha (TNF\u03b1) inhibitor therapy. The trial has exclusion criteria, such as having a systemic inflammatory condition other than rheumatoid arthritis or evidence of tuberculosis. All participants must provide written informed consent and women must not be at risk of becoming pregnant during the study.",
    "The sample is a phase 2 clinical trial for the treatment of glioblastoma multiforme, a type of brain cancer. The trial is testing the effectiveness of three drugs - talampanel, temozolomide (tmz) 75mg, and adjuvant tmz 200mg. The eligibility criteria for the trial include being 18 years or older, having histologically confirmed supratentorial Grade IV astrocytoma, not having received prior radiation therapy, chemotherapy, immunotherapy, or therapy with a biologic agent or hormonal therapy (glucocorticoid therapy is allowed), having recovered from the immediate post-operative period, and having a Karnofsky performance score of at least 60%. Patients with serious concurrent infection or medical illness, or those receiving concurrent chemotherapeutics or investigational agents are excluded from the trial.",
    "The sample is a phase 2 clinical trial for the treatment of multiple sclerosis. The trial includes patients who have been diagnosed with relapsing-remitting multiple sclerosis according to the revised McDonald Diagnostic Criteria for Multiple Sclerosis. The trial involves the use of four different drugs, including a placebo, and has specific inclusion and exclusion criteria for patients. Patients must provide informed consent before participating in the study. The trial also has additional criteria related to medical conditions and concomitant treatments that could affect patients' risk from participating in the study.",
    "The sample is a phase 2 clinical trial for non-small cell lung cancer and efficacy. The trial includes patients who have not received chemotherapy before and have adenocarcinoma or large-cell carcinoma at stage IIIB or IV. Patients must have at least one measurable lesion, an Eastern Cooperative Oncology Group performance status of 0 or 1, be at least 18 years old, and have adequate bone marrow reserve and organ function. Prior radiation therapy is allowed if completed at least 4 weeks before the study treatment and patients have fully recovered from its acute effects. Patients with peripheral neuropathy greater than National Cancer Institute Common Toxicity Criteria grade 1, progressive brain metastases, uncontrolled third-space fluid retention before study entry, or unable to interrupt aspirin and other nonsteroidal anti-inflammatory drugs or take folic acid, vitamin B12, or corticosteroids are excluded from the trial.",
    "The sample is a phase 2 clinical trial for the treatment of breast cancer using the drug eribulin mesylate. The trial is open to individuals who are 18 years or older and have locally recurrent or metastatic breast cancer with at least one measurable lesion. Participants must also have HER2 positive breast cancer, as determined by a score of 3 on immunohistochemistry (IHC) staining or gene amplification by fluorescence in situ hybridization (FISH). Other eligibility criteria include having an Eastern Cooperative Oncology Group (ECOG) performance status (PS) score of 0, 1 or 2, adequate renal, bone marrow, liver, and cardiac function, and having completed prior neoadjuvant or adjuvant chemotherapy at least 12 months prior to enrollment. Exclusion criteria include prior chemotherapy, biologic therapy, or investigational therapy for locally recurrent or metastatic HER2 breast cancer, a prior malignancy other than carcinoma in situ of the cervix or nonmelanoma skin cancer, and clinically significant cardiovascular impairment. The trial also excludes individuals with known central nervous system (CNS) disease, except for those with treated brain metastasis, and those with preexisting Grade 3 or 4 neuropathy.",
    "The sample is a phase 2 clinical trial that involves patients with bone metastases in men with hormone-refractory prostate cancer, bone metastases in subjects with advanced breast cancer, and bone metastases in subjects with advanced cancer or multiple myeloma. The trial requires patients to have radiographic evidence of one or more bone lesions or lytic lesion in myeloma and currently receiving IV bisphosphonates. The eligibility criteria include age above 18 years, confirmed solid tumor carcinomas (except lung) or multiple myeloma, Eastern Cooperative Oncology Group (ECOG) 0, 1 or 2, and urinary N-Telopeptide (uNTx) greater than 50 nM BCE/mM creatinine. The exclusion criteria include more than two prior skeletal related events (SRE), known brain metastases, prior history or current evidence of osteonecrosis/osteomyelitis of the jaw, active dental or jaw conditions which require oral surgery, non-healed dental/oral surgery, prior administration of AMG 162, evidence of impending fracture in weight-bearing bones, and pregnancy or breastfeeding. Subjects must be surgically sterile, postmenopausal, or must agree to use effective contraception during the study.",
    "This sample is for a phase 2 clinical trial for acute myeloid leukemia. The eligibility criteria include a diagnosis of AML according to WHO criteria, untreated relapse or refractory disease after a minimum of one standard induction therapy, age above 40 years, and adequate renal and hepatic functions. The patient must also be eligible for intensive chemotherapy and capable of understanding the clinical trial as an investigational approach. Exclusion criteria include prior allogeneic HCT, autologous transplantation within 100 days prior to start of study treatment, and any significant concurrent disease, illness, or psychiatric disorder that would compromise patient safety or compliance. The sample also includes a list of icd-10 codes for AML, the drug clofarabine, and detailed inclusion and exclusion criteria.",
    "The sample is a phase 2 clinical trial for the treatment of schizophrenia. The trial is testing the effectiveness of the drugs amg 747 and placebo. The eligibility criteria for participants include a diagnosis of schizophrenia, a certain score on the PANSS Marder Negative Symptom Factor Scale, and stable antipsychotic therapy for at least 8 weeks prior to screening. Exclusion criteria include current schizoaffective or bipolar disorder, substance abuse within the 8 weeks prior to screening, and positive urine drug test for substances of abuse.",
    "The sample is a phase 2 clinical trial for patients with refractory multiple myeloma. The trial involves the drug sorafenib tosylate and has a list of eligibility criteria that patients must meet in order to participate. These criteria include having measurable disease, relapsed or resistant disease, and a Zubrod Performance Status of 0-2. Patients must also have no significant neurotoxicity, no evidence of POEMS Syndrome, and no active infection requiring antibiotics. Additionally, patients must meet certain laboratory values and be able to take oral medication without crushing, dissolving, or chewing tablets. The trial has been approved by the institutional review board and patients must provide written informed consent to participate.",
    "The sample is a phase 2 clinical trial for patients with relapsed or refractory acute lymphoblastic leukemia. The trial is testing the effectiveness of the drug lenalidomide. The eligibility criteria include having a certain percentage of bone marrow or peripheral blood blasts, being over 18 years old, and not being a candidate for curative treatment regimens. In addition, patients must be registered in a restricted distribution program and willing to comply with its requirements. The trial also has exclusion criteria, such as prior therapy with lenalidomide, advanced malignant hepatic tumors, and uncontrolled psychiatric illness. Patients must adhere to the study visit schedule and other protocol requirements and must understand and voluntarily sign a written informed consent.",
    "The sample is a phase 2 clinical trial for patients with unresectable stage IV melanoma. The trial is testing the effectiveness of carboplatin and paclitaxel albumin-stabilized nanoparticle formulation as treatment options. Patients must have measurable disease and formalin-fixed, paraffin-embedded tumor tissue available for secreted protein acidic and rich in cysteine (SPARC) analysis pre-treatment. Brain metastases are allowed if previously treated with no progression for at least 3 months. Patients must meet certain eligibility criteria, including having an ECOG performance status of 0-2, a life expectancy of at least 3 months, and meeting certain blood count and liver function requirements. Patients must not be pregnant or nursing, and must use effective contraception during and for 1 month after completion of study therapy. Patients must not have uncontrolled intercurrent illness, peripheral neuropathy \u2265 grade 2, or any other malignancy within the past 5 years except basal cell or squamous cell carcinoma of the skin previously treated with local resection only or carcinoma in situ of the cervix. Prior concurrent therapy is also specified.",
    "The sample is a phase 2 clinical trial for the treatment of type 2 diabetes mellitus. The trial includes male and female subjects between the ages of 18 and 65 who have been diagnosed with type 2 diabetes by American Diabetes Association criteria for at least 3 months prior to screening. The subjects must have no significant known medical conditions other than T2DM that would affect the safety of the subject or the objectives of the study. The trial involves the use of the drugs gsk1292263, gsk1292263 matching placebo, and sitagliptin. The eligibility criteria include various medical and health-related factors such as BMI, fasting plasma glucose, HbA1c, and liver function tests. The exclusion criteria include factors such as positive drug/alcohol screen, smoking, significant renal disease, and history of regular alcohol consumption within 6 months. The trial also includes various restrictions on the use of certain medications, vitamins, and supplements.",
    "The sample is a phase 2 clinical trial for the treatment of non-small-cell lung carcinoma. The trial involves the use of three drugs, zd6474, paclitaxel, and carboplatin. The eligibility criteria for the trial include being 18 years or older, having locally advanced or metastatic NSCLC, and having no prior chemotherapy, biological therapy, or radiation therapy. In addition, participants must have one or more measurable lesions and a life expectancy of more than 12 weeks. Exclusion criteria include having brain metastases or spinal cord compression, currently active skin disease, history of significant hemoptysis, abnormal blood chemistry, cardiac abnormalities, recent significant cardiac event, and coexisting malignancies. Participants must also provide signed informed consent.",
    "The sample is a phase 2 clinical trial for the treatment of myelodysplastic syndromes. The trial is testing the drug lenalidomide and the eligibility criteria includes being over 18 years old, having an IPSS score of Int-2 or high with deletion 5q(31), and having a documented diagnosis of MDS that meets IPSS criteria for intermediate-2 or high-risk disease and has an associated del 5q[31]. The exclusion criteria includes being pregnant or lactating, having prior therapy with lenalidomide, having MDS with IPSS scores low or Int-1, having clinical neuropathy of greater than grade 2, having proliferative chronic myelomonocytic leukemia, receiving rHuEPO therapy within 28 days, and using androgens other than for treating hypogonadism.",
    "This sample is for a phase 2 clinical trial for the treatment of arthritis, specifically gouty arthritis. The trial is testing the effectiveness of the drug dexamethasone. The eligibility criteria for participants include having a pain score over 50 on a 0-100 VAS pain scale and experiencing an acute, confirmed gout flare for no longer than 3 days. Exclusion criteria include recent treatment with biological anti-tumor necrosis factor (anti-TNF), recent use of anti-inflammatory medication for acute gout, pregnancy or breastfeeding, history of severe allergy to food or drugs, history or risk of tuberculosis, and active infection. Other inclusion/exclusion criteria may also apply.",
    "The sample is a record of a clinical trial with a phase 2 designation. The trial is focused on bladder cancer and includes a list of ICD-10 codes associated with the disease. The trial involves the use of three drugs: gemcitabine, cisplatin, and gefitinib. The eligibility criteria for the trial include having histologically or cytologically-confirmed transitional cell carcinoma of the urothelium, locally advanced or metastatic disease, at least one measurable lesion as defined by RECIST, and being chemotherapy-naive. The exclusion criteria include previous chemotherapy or other systemic antitumour therapy, and other co-existing malignancies or malignancies diagnosed within the last 5 years with the exception of basal cell carcinoma, cervical cancer in situ or locally limited prostate cancer.",
    "The sample is a phase 2 clinical trial for systemic sclerosis, a disease affecting the skin and internal organs. The trial includes patients who meet specific eligibility criteria, such as having diffuse cutaneous involvement and a Modified Rodnan Skin Score of at least 15. The trial involves the use of two drugs, sar100842 and a placebo, and patients must not have taken certain medications or have certain medical conditions to be eligible. The criteria for inclusion and exclusion are listed in detail.",
    "The sample is a phase 2 clinical trial for kidney transplantation. The table includes information about the diseases, icd-10 codes, drugs, and eligibility criteria for the trial. The diseases listed are related to kidney transplantation and are identified by their icd-10 codes. The drugs being tested in the trial are cyclosporine and cp-690,550. The eligibility criteria for the trial include being a first-time kidney transplant recipient between the ages of 18 and 70, and not having received any non-kidney transplant.",
    "The sample is a phase 2 clinical trial for various types of cancer, including adenocarcinoma of the extrahepatic bile duct, adenocarcinoma of the gallbladder, and gastrointestinal cancer. The trial is testing the effectiveness of the drug bortezomib. The eligibility criteria for participants include having confirmed adenocarcinoma of the intrahepatic or extrahepatic bile duct or gallbladder, having at least one measurable lesion, and not being amenable to curative surgical resection. Participants must also meet certain health criteria, such as having a platelet count of at least 100,000/mm3 and no symptomatic congestive heart failure. The trial allows for prior chemotherapy as a radiosensitizer or as adjuvant therapy, but no more than two prior chemotherapy regimens for locally advanced or metastatic disease. Participants cannot be concurrently receiving other anticancer agents or therapies or other investigational agents.",
    "The sample is a phase 2 clinical trial for patients with either Waldenstrom's Macroglobulinemia or Multiple Myeloma who have been previously treated with 1-5 therapies. The trial involves the drug Enzastaurin. The eligibility criteria include being at least 18 years old, having certain laboratory values within normal ranges, having an expected survival of greater than 12 weeks, and being able to provide informed consent. Exclusion criteria include prior allogeneic hematopoietic stem cell transplant, uncontrolled infection, and being pregnant or breastfeeding. The trial also has specific criteria for patients with MM or WM.",
    "The sample is a phase 2 clinical trial for the treatment of acquired immunodeficiency syndrome (AIDS) and HIV infections. The trial involves the use of several drugs, including d/c/f/taf, drv, cobi, ftc/tdf, and their respective placebos. The eligibility criteria for the trial include being an adult (18 years or older), having a plasma HIV-1 RNA level of at least 5,000 copies/mL, and a CD4+ cell count of more than 50 cells/\u00b5L. Participants must also be treatment-naive, meaning they have not used any approved or experimental anti-HIV drug before. Other criteria include having normal ECG, adequate renal function, and normal thyroid-stimulating hormone (TSH) levels. Females of childbearing potential must have a negative serum pregnancy test and agree to use highly effective contraception methods throughout the study period. Exclusion criteria include having a new AIDS defining condition diagnosed within the 30 days prior to screening, hepatitis B surface antigen positivity, and ongoing malignancy other than cutaneous Kaposi's sarcoma (KS), basal cell carcinoma, or resected, non-invasive cutaneous squamous carcinoma.",
    "The sample is a record of a clinical trial with a phase 2 designation. The trial is focused on treating metastatic breast cancer using the drugs capecitabine and oxaliplatin. The diseases are listed as \"metastatic breast cancer\" and the corresponding ICD-10 codes are also provided. The eligibility criteria for the trial are listed under \"Inclusion Criteria\" and \"Exclusion Criteria\", which include factors such as preserved organ function, good performance status, and no active brain metastasis. The trial also specifies that participants should not have had prior treatment with capecitabine or oxaliplatin and should not be receiving concurrent therapy.",
    "The sample is a phase 2 clinical trial for the treatment of diabetic neuropathic pain. The trial includes patients who are between the ages of 18 and 75, have been diagnosed with painful distal symmetric diabetic polyneuropathy, and have experienced pain for at least 6 months. Patients must be willing to stop taking any analgesic medications before entering the study. The trial will test the effectiveness of the drug abt-894 compared to a placebo. The sample also includes a list of inclusion and exclusion criteria for the trial.",
    "The sample is a phase 2 clinical trial for patients with advanced or metastatic breast cancer that is estrogen and/or progesterone receptor positive. The trial is testing the effectiveness of the drugs lapatinib ditosylate and tamoxifen citrate. The eligibility criteria include having a confirmed diagnosis of breast cancer, having failed hormonal manipulation with tamoxifen, having at least one measurable lesion, and meeting certain medical and laboratory requirements. Patients who have had prior treatment with EGFR and/or Her-2 targeting therapies, current treatment with any other anti-neoplastic agent, or certain medical conditions are excluded from the trial.",
    "The sample is a phase 2 clinical trial for chronic kidney disease. The trial includes subjects who are at least 18 years old and have been in the care of a physician for CKD for more than 2 months, and are not expected to begin dialysis for at least 6 months. The trial involves the use of two drugs, namely lanthanum carbonate and placebo. The eligibility criteria include normal serum phosphate levels, endogenous 25-hydroxy Vitamin D levels above 20ng/mL, and an adequate protein diet. The exclusion criteria include acute renal failure, rapidly progressing glomerulonephritis, and clinically significant uncontrolled concurrent illness. The subjects must not have used another investigational medicinal product or taken part in a clinical trial within the last 30 days prior to enrollment.",
    "The sample is a phase 2 clinical trial for patients aged 18-65 with moderate to severe ankylosing spondylitis. The trial is testing the effectiveness of the drug abatacept. Patients must meet certain inclusion criteria, such as having a BASDAI score of >= 4 and back pain score of >= 4 despite concurrent NSAID therapy or prior treatment with TNFalpha inhibitors. Patients must also meet certain exclusion criteria, such as having a history of active or latent tuberculosis, other chronic inflammatory articular disease or systemic autoimmune disease, or significant uncontrolled concomitant diseases. The trial is also excluding patients who are currently participating in another clinical trial or who are incapable of giving legal informed consent.",
    "The sample is a phase 2 clinical trial for non-squamous non-small cell lung cancer. The trial includes patients with newly diagnosed or recurrent disease who meet certain staging criteria and have measurable disease. The trial involves the use of two different drug combinations: bevacizumab + erlotinib hydrochloride and gemcitabine hydrochloride + cisplatin or carboplatin. Eligibility criteria include specific patient characteristics such as WHO performance status, hemoglobin levels, and absence of brain metastases, as well as no prior chemotherapy for advanced disease and no concurrent use of certain drugs. The trial also requires patients to have no pre-existing conditions that would preclude swallowing and/or absorption of oral medication. Prior concurrent therapy is also specified in the eligibility criteria.",
    "The sample is a phase 2 clinical trial for patients with multiple myeloma, a type of cancer. The trial is testing the effectiveness of three drugs - topotecan, cyclophosphamide, and melphalan - on patients with intermediate or high tumor mass multiple myeloma with responsive or primary refractory disease, as well as patients with responsive or refractory relapse. The trial has certain eligibility criteria, such as a physiological age of 70 or younger, a Zubrod performance status of less than 3, and a life expectancy of greater than 12 weeks. Patients must also meet certain health requirements, such as having a left ventricular ejection fraction of 50% or greater, no uncontrolled arrhythmias or symptomatic cardiac disease, and no symptomatic pulmonary disease. Patients must also have a serum creatinine level of less than 1.5 mg/dL and a serum bilirubin level of less than 2 times the upper limit of normal. Patients must not have evidence of chronic or active hepatitis or cirrhosis, must not be pregnant, and must be able to sign informed consent. The trial has no active CNS disease exclusion criteria and requires a platelet count of greater than 100K.",
    "The sample is a phase 2 clinical trial for asthma. The trial is looking for participants who have been diagnosed with persistent asthma for at least 12 months and whose airway inflammation is likely to be eosinophilic. The participants should also be partially controlled or uncontrolled on ICS plus LABA therapy and on a stable dose of either Fluticasone/Salmeterol, Budesonide/Formoterol, Mometasone/Formoterol combination therapy for at least 1 month prior to screening. The trial is testing the effectiveness of several drugs, including dupilumab, placebo (for dupilumab), fluticasone/salmeterol combination therapy, fluticasone monotherapy, albuterol, and levalbuterol. The eligibility criteria include age, laboratory values, lung diseases, smoking history, participation in other studies, compliance, allergies, pregnancy, and recent history of parasitic infection or travel to a parasitic endemic area. The sample also includes exclusion criteria.",
    "The sample is a phase 2 clinical trial for the treatment of depression. The trial is testing the effectiveness of the drugs mk-8777 and placebo. The eligibility criteria for participants include being a non-pregnant, non-lactating female who is using an acceptable method of birth control or is not of child-bearing potential, having a diagnosis of current major depressive disorder with a score of at least 9 but not more than 20 on the Quick Inventory of Depression Symptomatology - Clinician Rated (QIDS-C), being anti-depressant na\u00efve, and smoking less than or equal to 10 cigarettes or equivalent daily. Exclusion criteria include having any current and primary Axis I disorder other than major depressive disorder, having a history of bipolar I or II disorder, dysthymia, psychotic depression, psychotic disorders, posttraumatic stress disorder, borderline personality disorder, obsessive-compulsive disorder, or eating disorder, having a current depressive episode longer than 2 years at screening, having a history of a significant suicide attempt or posing a current risk of attempting suicide, being known to be HIV positive or positive for hepatitis B surface antigen or hepatitis A antibodies or hepatitis C total antibodies, having any clinically significant concurrent medical condition, or having donated blood within 60 days prior to the anticipated first dose of trial medication.",
    "The sample is a phase 2 clinical trial for patients with non-small-cell lung carcinoma or lung neoplasms that cannot be cured with conventional therapy. The trial is testing the drug HKI-272. The inclusion criteria require a pathologic diagnosis of NSCLC, current stage IIIB or IV, progression following at least 12 weeks of treatment with Tarceva or Iressa (for Arms A and B only), ECOG performance status of 0, 1, or 2, tumor sample available and adequate for analysis, at least one measurable target lesion, adequate cardiac, kidney, and liver function, and adequate blood counts. The exclusion criteria include more than 3 prior cytotoxic chemotherapy treatments for relapsed or metastatic disease, significant cardiac disease or dysfunction, prior treatment with anthracyclines with cumulative dose of >400 mg/m^2, active central nervous system metastases, use of Tarceva or Iressa within 14 days of treatment day 1 (for Arms A and B only), major surgery, chemotherapy, radiotherapy, investigational drugs, or other cancer therapy within 3 weeks of treatment day 1, significant chronic or recent acute gastrointestinal disorder with diarrhea as a major symptom, inability or unwillingness to swallow HKI-272 capsules, and pregnant or breastfeeding women.",
    "The sample is a phase 2 clinical trial for patients with advanced pancreatic adenocarcinoma that is unresectable or metastatic. The trial involves the use of two drugs, rad001 and erlotinib, and has specific eligibility criteria that patients must meet in order to participate. These criteria include having received at least one prior chemotherapy regimen for unresectable/metastatic disease, having a measurable site of disease, and having adequate hematologic, hepatic, and renal parameters. Patients must also agree to use adequate contraception during the study and for 30 days after the end of treatment. There are also exclusion criteria, such as prior treatment with any investigational drug within the preceding 2 weeks and chronic treatment with systemic steroids or another immunosuppressive agent. The trial aims to evaluate the safety and efficacy of the drug combination in this patient population.",
    "The sample is a phase 2 clinical trial for patients with metastatic melanoma. The trial is testing the effectiveness of the drugs sorafenib and pegylated interferon \u03b1-2b as a first-line treatment for stage IV melanoma. The eligibility criteria include having measurable disease, being at least 18 years old, having an ECOG performance status of 0 or 1, and not having received any systemic treatment for stage IV disease. Patients must also have adequate hematological, renal, and liver functions, and a life expectancy of at least 6 months. Exclusion criteria include having ocular or mucosal melanoma, a history or evidence of brain metastasis, and various other medical conditions. Patients must understand and sign the informed consent.",
    "The sample is a phase 2 clinical trial for the treatment of cystic fibrosis. The trial involves two drugs, reduced glutathione sodium salt and 0.9% normal saline (control), and has eligibility criteria for patients including a confirmed diagnosis of CF, acceptable spirometric maneuvers, and FEV1 between 40% and 90% predicted. Patients must also be clinically stable and not have evidence of acute upper or lower respiratory tract infection or pulmonary exacerbation requiring antibiotics or corticosteroids within 4 weeks of screening. The trial has exclusion criteria including a history of allergy/hypersensitivity, concomitant inhaled thiol-containing medications, and clinically relevant diseases or medical conditions other than CF that would compromise patient safety or data quality.",
    "The sample is a phase 2 clinical trial for patients with metastatic pancreatic adenocarcinoma who have previously received gemcitabine-based therapy. The trial is testing the drug CO-1.01 and the eligibility criteria include having at least one measurable lesion, no radiological stable disease or better allowed at any time, and no hENT1 expression in primary or metastatic tumor sample. Patients must also have a Performance Status (ECOG) of 0 or 1, be at least 18 years old, and have adequate hematological and biological function with no residual gemcitabine-related toxicity. Exclusion criteria include stable disease, partial response or complete response to first line gemcitabine-based therapy, and concomitant treatment with prohibited medications. The trial requires written consent on an Institutional Review Board (IRB)-approved IC Form prior to any study-specific evaluation.",
    "The sample is a phase 2 trial for patients with coronary artery disease. The trial includes patients between the ages of 45 and 80 who have confirmed coronary artery disease and are at high risk due to factors such as elevated hsCRP, diabetes mellitus, history of carotid artery disease and/or peripheral artery disease, or thrombo-embolic transient ischemic attack or stroke. Patients must also be receiving low dose aspirin and/or clopidogrel and/or ticlopidine. The trial excludes patients with bleeding disorders, intracranial bleeding, significant hematological, hepatic or renal abnormalities, specific ST-segment changes, severe congestive heart failure, or uncontrolled cardiac arrhythmias.",
    "The sample is a phase 2 clinical trial for attention deficit hyperactivity disorder (ADHD). The trial includes patients who have been diagnosed with inattentive predominant ADHD per DSM-IV TR criteria and have a score of at least 2 on at least 6 of 9 items in the inattentive subscale of the CAARS-INV at baseline. The trial also includes patients who have a score of less than 2 on at least 4 of 9 items in the hyperactive/impulsivity subscale of the CAARS-INV at baseline. The trial excludes patients with a current DSM-IV Axis I psychiatric disorder other than ADHD, known or suspected drug abuse within the last 6 months prior to screening, and patients at imminent risk of suicide or of danger to themselves or others as judged by the investigator. The trial also excludes patients with a history of significant other major or unstable neurological, metabolic, hepatic, renal, hematological, pulmonary, cardiovascular (CV), gastrointestinal (GI), or urological disorder, or diagnosis of major depressive disorder. The trial includes the use of drugs affecting cognitive function within 4 weeks prior to Day 1. This includes use of any concomitant medications for treatment of ADHD. The trial also excludes patients with a BMI less than 15 or greater than 35, male weight less than 100 lbs, or female weight less than 80 lbs. The trial includes patients who are tobacco non-users as indicated by lack of tobacco use within the last 6 months prior to screening, and by negative urinary cotinine level of less than 50 ng/mL after quantification. The trial also includes patients who are women of child-bearing potential and male participants willing or able to use accepted methods of birth control. The trial excludes patients who have participated in another Central Nervous System (CNS)-related clinical trial in the last 3 months and any other clinical trial in last 30 days prior to screening, or participation in a previous TC-5619 clinical trial. The trial includes the use of drugs such as tc-5619-238 5mg, tc-5619-238 25mg, and placebo.",
    "The sample is a record of a clinical trial in phase 2, focused on the disease of acute respiratory infection. The trial includes a list of ICD-10 codes associated with the disease, as well as a list of drugs being tested, including mucinex and a placebo. The eligibility criteria for the trial are also listed, including symptoms of cough, thickened mucus, and chest congestion, as well as the ability to produce sputum and being a non-smoker. The exclusion criteria include being pregnant, a smoker, having a fever above 101\u00b0F, or having any chronic illness.",
    "The sample is a phase 2 clinical trial for the treatment of amyotrophic lateral sclerosis. The trial involves the use of drugs called kns-760704 and placebo. The eligibility criteria for the trial include patients with a diagnosis of familial or sporadic ALS, with symptom onset less than 24 months from randomization, and with upright VC greater than 65% of predicted for age, height, and gender. Patients with other neuromuscular weaknesses, without clinical evidence of upper motor neuron dysfunction, or with prior exposure to KNS-760704 or the R(+) enantiomer of pramipexole are excluded from the trial. Patients taking other investigational agents within 30 days of randomization or during the study are also excluded.",
    "The sample is a phase 2 clinical trial for patients with persistent asthma. The trial is testing the effectiveness of various doses of a drug called las100977, as well as a placebo and salbutamol, in improving lung function. The trial has specific inclusion and exclusion criteria, such as patients must be between 18-70 years old, have a clinical diagnosis of persistent asthma for at least 6 months, and have a screening FEV1 value of 60% < FEV1 \u2264 85% of the predicted normal value. Patients who are current or former smokers within the last 6 months, have been diagnosed with COPD, or have had recent respiratory tract infections are excluded from the trial. The trial also requires patients to be able to properly use a dry powder or pMDI inhaler device and perform acceptable spirometry.",
    "The sample is a phase 2 clinical trial for breast cancer. The trial includes patients with primary invasive breast cancer that expresses estrogen and/or progesterone receptors but is negative for HER2. The patients must have high-risk ER+ or PR+ breast cancer as defined by the protocol. The trial involves the use of four drugs: doxorubicin, cyclophosphamide, paclitaxel, and bevacizumab. The eligibility criteria include being 18 years or older, having a performance status of 0 or 1 by ECOG criteria, and having normal organ function. The exclusion criteria include prior cytotoxic chemotherapy or radiation for the current breast cancer, inflammatory breast cancer, HER2 positive disease, known metastatic disease, and other investigational agents within 4 weeks prior to the start of study treatment.",
    "The sample is a phase 2 clinical trial for breast cancer patients with metastatic or locally recurrent disease. The trial is testing the effectiveness of the drugs anastrozole and gefitinib. The eligibility criteria include confirmed breast cancer, failed prior tamoxifen therapy, and hormone receptor positivity. Patients must also be postmenopausal females with an ECOG performance status of 0-2 and no severe or uncontrolled systemic disease. Prior concurrent therapies are restricted, and patients must not have any unresolved chronic toxicity from prior anticancer therapy. The trial is also excluding patients with known hypersensitivity to anastrozole or gefitinib or any of their excipients.",
    "The sample is a record of a clinical trial with a phase 2 designation. The trial is focused on the disease \"levodopa induced dyskinesia\" and includes a list of associated ICD-10 codes. The trial involves the use of two drugs, \"levetiracetam\" and \"placebo\". The eligibility criteria for the trial are listed, including age range, disease severity, and willingness to adhere to the protocol. The exclusion criteria are also listed, including medical history, pregnancy or breastfeeding, and use of certain medications.",
    "The sample is a phase 2 clinical trial for smoking cessation. The trial includes male subjects between 18 and 55 years of age with a BMI between 18 and 30 and a minimum weight of 50 kg. The subjects must have smoked between 17 and 34 cigarettes per day for the past year and have not tried to quit smoking in the 3 months prior to screening. The trial requires subjects to be willing and able to quit for about 12 hours in each of three subsequent study periods. The trial also includes eligibility criteria and exclusion criteria, such as negative urine drug and alcohol screen, liver function test results not above 1.5 times the upper normal limit, and no participation in another clinical study within 60 days of screening. The trial also excludes subjects with active significant psychiatric or neurological disease or dependency other than cigarettes, known hypersensitivity to MAO inhibitors or any substance that is contained in the study formulations, and known allergy to plasters or NRT patches. The trial requires subjects to not be planning to father a child or donate sperm during the study and 3 months after the end of the study. The trial also excludes subjects with recent myocardial infarction, unstable or worsening angina pectoris, prince metal angina, severe arrhythmias, recent stroke, and creatinine clearance calculated according to the formula by Modification of Diet in Renal Disease (MDRD) of <80 mL/min.",
    "This is a sample from a table that contains information about a clinical trial. The trial is in phase 2 and is focused on the disease multiple sclerosis. The icd-10 codes associated with the disease are \"G35\" and \"C81.18\". The trial involves two drugs, memantine and placebo. The eligibility criteria for the trial include patients with MS who are between the ages of 18 and 60 and have all MS subtypes (RR, SP, PP, PR), as long as they are stable. Patients with severe cognitive impairment, defined as performing 1.5 standard deviations below a control group in 2 or more subtests, are also eligible. Patients with psychiatric diseases, depression, drug or alcohol abuse, benzodiazepine therapy, or other medical diseases are excluded from the trial.",
    "This sample is for a phase 2 clinical trial that focuses on colorectal neoplasms and metastases. The trial involves the drug irinotecan and has a list of inclusion and exclusion criteria. Inclusion criteria include having a histologically proven adenocarcinoma of the colon and rectum, no prior chemotherapy or only adjuvant chemotherapy and/or radiotherapy, advanced, metastatic or recurrent not amenable to curative local therapy, measurable lesion(s), ECOG performance status 0 to 2, normal marrow, hepatic and renal function, and provision of written informed consent. Exclusion criteria include having an active infection and/or severe comorbidity, and a known history of anaphylaxis of any origin.",
    "The sample is a phase 2 clinical trial for the treatment of schizophrenia. The trial includes the drugs azd2624, olanzapine, and a placebo. The eligibility criteria for the trial includes a diagnosis of schizophrenia and being a non-childbearing female. Exclusion criteria includes having any clinically relevant disease or abnormalities, not being in remission from alcohol or substance abuse, and being enrolled in another investigational study within the past 30 days. The icd-10 codes associated with schizophrenia are also included in the sample.",
    "The sample is a phase 2 clinical trial for patients with chronic obstructive pulmonary disease. The trial involves the use of two drugs, bea 2180 br and tiotropium. The eligibility criteria include patients who are current or ex-smokers with a smoking history of more than 10 pack years, have relatively stable, moderate to severe airway obstruction, and are able to perform technically acceptable pulmonary function tests. Patients with significant diseases other than COPD, abnormal baseline haematology, blood chemistry or urinalysis, recent history of myocardial infarction, unstable or life-threatening cardiac arrhythmia, hospitalized for heart failure within the past 3 years, malignancy for which the patient has undergone resection, radiation therapy or chemotherapy within the last five years, known symptomatic prostatic hyperplasia or bladder neck obstruction, known narrow-angle glaucoma, asthma or a history of asthma, history of life-threatening pulmonary obstruction, or a history of cystic fibrosis or clinically evident bronchiectasis, known active tuberculosis, and history of and/or active significant alcohol or drug abuse are excluded from the trial.",
    "The sample is a record from a table that contains information about clinical trials. It is a phase 2 trial for non-Hodgkin lymphoma, with a list of ICD-10 codes for the disease. The trial is testing the effectiveness of intravenous vitamin C as a treatment. The eligibility criteria for the trial include being over 18 years old, having aggressive or very aggressive NHL, having failed one or more therapies, not having progressed within 60 days of the last therapy, not having received an allogeneic stem cell transplant, and having no reasonable standard therapeutic options available. There are also additional criteria related to health status and pregnancy. The exclusion criteria include significant co-morbid disorders, significant psychiatric symptoms, smoking, excessive alcohol or drug use, enrollment in other experimental therapy, active infection, and recent chemotherapy or biological therapy.",
    "The sample is a record of a clinical trial with a phase 2 designation. The trial is focused on treating relapsed or refractory follicular Stage III or IV, Grade 1 and 2, cluster of differentiation 20 plus (CD20+) lymphoma using the drugs bortezomib and rituximab. The eligibility criteria for participants include having confirmed lymphoma that requires therapy, having undergone at least two previous cytostatic therapies, and meeting certain health requirements such as having a Karnofsky Status greater than or equal to 60 percent. Exclusion criteria include having had previous treatment with bortezomib within 6 months before enrollment, having a life expectancy of less than 3 months, and having peripheral neuropathy common terminology criteria for adverse events (CTCAE) grade greater than or equal to 2.",
    "The sample is a phase 2 clinical trial for the treatment of acute myeloid leukemia. The trial involves the use of drugs such as lintuzumab (sgn-33), low dose cytarabine, and placebo. The eligibility criteria for the trial include having untreated AML, at least 20% blasts in blood or marrow, and a minimum of 50% leukemic blasts that express CD33. Patients must have declined intensive chemotherapy for AML after being informed of the potential benefits and risks of available treatment options. Exclusion criteria include having other active systemic malignancies treated with chemotherapy within the last 12 months, significantly abnormal kidney or liver disease, and known human immunodeficiency virus (HIV).",
    "The sample is a record of a clinical trial with a phase 2 designation. The trial is focused on treating non-small cell lung cancer and carcinoma using the drugs pemetrexed and cisplatin. The trial has specific eligibility criteria, including a requirement for pathologic documentation of NSCLC, accessibility of the tumor for tissue sample collection, and a clinical stage of IB, II, or IIIA. Patients must also have an ECOG performance status of 0 or 1 and cannot have received prior systemic chemotherapy or radiation therapy for NSCLC. The trial also has exclusion criteria, such as patients with bronchoalveolar carcinoma or stage IIIA tumor involving the superior sulcus, pregnant or breastfeeding patients, and patients with a history or presence of other malignancy. Patients must also be willing to take folic acid or vitamin B12 supplementation.",
    "The sample is a phase 2 clinical trial for the treatment of esophageal cancer using the drug gefitinib. The trial includes patients with a histologically documented diagnosis of esophageal cancer that can be encompassed in a radiotherapy field, with celiac, perigastric, mediastinal or supraclavicular adenopathy. Patients must be between 70-85 years old and have a performance status of 0 to 2. They must also have a neutrophil count >1.5 x 10 to the 9th power/L and platelets > 100 x 10 to the 9th power/L, and meet certain hepatic and renal function criteria. Exclusion criteria include evidence of tracheoesophageal fistula or invasion into the trachea or major bronchi, prior invasive malignancy (except non-melanomatous skin cancer) unless disease-free for a minimum of 2 years, and prior systemic chemotherapy or radiation therapy for esophageal cancer.",
    "The sample is a phase 2 clinical trial for patients with metastatic or unresectable locally recurrent clear cell renal carcinoma. The trial is testing the effectiveness of the drugs bevacizumab and rad001. The eligibility criteria include having a previous nephrectomy, measurable disease, adequate liver, kidney, and bone marrow function, and an ECOG performance status of 0 or 1. Patients must not have received previous bevacizumab or treatment with m-TOR inhibitors. Exclusion criteria include a history of acute myocardial infarction, clinically significant cardiovascular disease, active brain or meningeal metastases, pregnancy or lactation, and a history of other invasive cancers. Patients must be able to understand the nature of the study and give written informed consent.",
    "The sample is a phase 2 trial for HIV infections and lipodystrophy. The trial includes patients with documented HIV-1 infection or plasma HIV-1 RNA levels above 2000 on two occasions. Female subjects who are 18 years or older and have central fat accumulation are eligible to participate. Patients must have a documented HIV RNA level of less than 50 copies/mL at screening and less than 400 copies/mL in the past 6 months. They must also be on current antiretroviral therapy with two nucleoside analogues and either a non-nucleoside analogue or an approved protease inhibitor. Patients on NNRTI+PI at study entry will be excluded. The trial also has exclusion criteria, including pregnancy, prior treatment history that would preclude the use of emtricitabine or abacavir as the nucleoside backbone during study treatment, and current use of metformin or thiazolidinediones. The trial will last for 48 weeks, and laboratory values at screening must meet certain criteria.",
    "The sample is a phase 2 clinical trial for patients with moderate to severe Chronic Obstructive Pulmonary Disease (COPD). The trial is testing the effectiveness of the drugs indacaterol/glycopyrrolate, indacaterol, and glycopyrrolate, as well as a placebo. The eligibility criteria include being a male or female adult aged 40 years or older, having a smoking history of at least 10 pack years, and having a post-bronchodilator Forced Expiratory Volume in one second (FEV1) between 30% and 80% of the predicted normal. Exclusion criteria include being pregnant or nursing, requiring long term oxygen therapy, having had a respiratory tract infection within 6 weeks of screening, and having a history of asthma or other conditions that may compromise patient safety or compliance.",
    "The sample is a phase 2 clinical trial for individuals aged 18-55 years with a diagnosis of chronic posttraumatic stress disorder (PTSD) and/or traumatic brain injury (TBI) lasting at least 3 months. The trial aims to test the effectiveness of treatment for cognitive symptoms using drugs such as methylphenidate hydrochloride, placebo capsule, and galantamine. The eligibility criteria include having clinically significant cognitive complaints, being interested in receiving treatment, and being capable of giving informed consent. Exclusion criteria include a history of certain medical conditions, substance abuse, and certain medications. The trial also requires discontinuation of concurrent cognitive therapy and a washout period for certain medications.",
    "The sample is a phase 2 clinical trial for rheumatoid arthritis. The trial includes patients who have at least 5 tender or painful joints on motion and at least 5 swollen joints, with a C-reactive protein concentration of at least 1.5 mg/dL. Patients must have been on methotrexate for at least 6 months at a stable dose of 7.5-25 mg/week for at least 12 weeks, and must continue taking it throughout the study. Patients must not have received treatment with DMARDs, other than background methotrexate, or any treatment with a cytotoxic agent, other than methotrexate, before screening. They must not have received intra-articular or parenteral corticosteroid injection within four weeks prior to screening, and must not regularly be using aspirin or any other anti-coagulant medication. Women of childbearing potential must use a medically acceptable means of birth control and agree to continue its use during the study and for at least 12 weeks after the last dose of study drug. Patients must not have any condition or circumstances which in the opinion of the Investigator may make a subject unlikely or unable to complete the study or comply with study procedures and requirements, or may pose a risk to the patient's safety.",
    "The sample is a phase 2 clinical trial for patients with relapsed or primary refractory lymphoid malignancy, multiple myeloma, or other transplant eligible diagnoses. The trial includes patients with various diseases and corresponding ICD-10 codes. The drugs used in the trial are bendamustine hydrochloride, dexamethasone, and etoposide. The eligibility criteria include having an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1, certain blood counts, and no prior failed PBSC collection due to inability to mobilize stem cells. Exclusion criteria include prior autologous or allogeneic transplantation, prior radioimmunotherapy within 12 weeks of registration, and concurrent use of other anti-cancer agents or experimental treatments.",
    "The sample is a record of a clinical trial with a phase 2 designation. The trial is focused on the disease multiple myeloma and includes a list of ICD-10 codes associated with the disease. The drug being tested is called pxd101. The eligibility criteria for the trial are listed, including requirements for age, performance status, liver and hematologic function, and estimated life expectancy. The sample also includes a list of exclusion criteria, such as prior treatment with certain drugs or significant cardiovascular disease.",
    "The sample is a phase 2 clinical trial for patients with malignant ascites, which is a condition where there is an abnormal accumulation of fluid in the abdomen due to cancer. The trial is testing the effectiveness of the drug bevacizumab in treating this condition. The eligibility criteria for the trial include having persistent or symptomatic ascites with positive cytology, being 18 years or older, having a life expectancy of 12 weeks or more, and having normal organ and marrow function. Exclusion criteria include having received bevacizumab within 60 days prior to study entry, current or recent administration of chemotherapy or radiation therapy, and having certain medical conditions such as uncontrolled hypertension or a history of myocardial infarction.",
    "This is a sample from a clinical trial table. The trial is in phase 2 and is focused on congestive heart failure. The table includes a list of diseases, icd-10 codes, drugs, and eligibility criteria. The inclusion criteria include being 18 years or older, having a history of chronic CHF, and having clinical evidence of volume overload. The exclusion criteria include pregnancy, low blood pressure, recent heart attack or stroke, and other major diseases that may interfere with safe participation in the study. The sample also includes a list of prohibited medications and a requirement for signed and dated informed consent.",
    "The sample is a phase 2 clinical trial for the treatment of adult-onset rheumatoid arthritis. The trial includes ambulatory males and females between the ages of 20 and 75 years who have been diagnosed with adult-onset RA for at least 6 months but not longer than 15 years prior to screening. Participants must have at least 6 swollen and 6 tender joints based on the 66/68 joint count and must be on a stable dose of methotrexate for at least 8 weeks prior to the treatment period. The trial includes the use of placebo, baricitinib, and methotrexate as drugs. The eligibility criteria include regular use of methotrexate, a stable dose of 6 to 16 mg/week, and a CRP measurement > 0.5 mg/dL or ESR > 28 mm/hr. The exclusion criteria include prior treatment with an oral Janus Kinase (JAK) inhibitor, a diagnosis of Felty's syndrome, and evidence of HIV or hepatitis C virus infection.",
    "The sample is a phase 2 clinical trial for patients with advanced primary non-small cell lung cancer. The trial is testing the effectiveness of the drugs paclitaxel and carboplatin. The eligibility criteria for the trial include being 18 years or older and having histologically or cytologically confirmed stage IIIB or stage IV lung cancer. Exclusion criteria include having received investigational or non-investigational agents to treat lung cancer, having received radiation therapy or major surgery within 4 weeks before randomization, having any grade 2 or greater neuropathy, and having a history of severe hypersensitivity reaction to products containing Cremophor EL. Additionally, patients with known brain or spinal cord metastases, history of other cancers within 5 years before randomization, known HIV, hepatitis-B or hepatitis-C infection, pregnant or breastfeeding women, and those previously treated with Mapatumumab are also excluded from the trial.",
    "The sample is a phase 2 clinical trial for chronic hepatitis C. The trial includes patients between the ages of 18 and 65 who have been diagnosed with chronic active HCV infection based on a liver biopsy within the past 3 years and have failed treatment with Interferon or Peg-Interferon and Ribavirin. The trial also requires patients to have HCV RNA in their blood at the screening visit of at least 600 copies/mL and to have compensated liver disease with specific hematologic, biochemical, and serologic criteria. Patients must also have fasting glucose levels between 70-140 mg/dl and ANA up to +1. The trial has various exclusion criteria, including subjects who have undergone surgery within the last 3 months, have a history of coagulopathy, or are HIV-positive. The trial also excludes women who are pregnant or breastfeeding and subjects who are unlikely to be compliant with the protocol.",
    "The sample is a phase 2 clinical trial for Parkinson's disease. The trial includes patients with idiopathic Parkinson's disease who meet the United Kingdom Parkinson's Disease Society Brain Bank diagnostic criteria and have a good response to levodopa. The patients must be between Hoehn & Yahr stage I to III when in an OFF medication state and may have symptoms of wearing OFF and/or levodopa induced dyskinesia. The trial excludes patients who are Young Onset Parkinson's Disease (YOPD) and/or genetically related, women of child-bearing potential, pregnant or lactating, patients with tumor growth and/or malignancy, patients with a past or present history of psychotic symptoms requiring anti-psychotic treatment, patients with active symptoms of major depression with suicidal ideation or suicide attempt, patients with previous brain surgery (including pallidotomy and deep brain stimulation), patients with significant cognitive impairment (Mini-Mental State Examination, MMSE < 24), and patients who do not sign the inform consent. The trial will test the effectiveness of g-csf and placebo drugs.",
    "The sample is a phase 2 clinical trial for breast cancer patients. The trial includes patients who are female and between the ages of 18-65. Patients must have histologically confirmed HER2-positive breast cancer with measurable lesions according to RECIST criteria. The trial is for patients with metastatic disease after first-line therapy or recurrent disease after (neo)adjuvant therapy with Herceptin and taxanes. Patients must have an ECOG performance status of 0-2. The trial excludes patients with uncontrolled CNS metastases, those receiving simultaneous treatment with sorivudine, those with a history of another malignancy within the last 5 years (except for cured basal cell carcinoma of the skin and cured carcinoma in-situ of the uterine cervix), and pregnant or lactating women. The drugs being tested in the trial are capecitabine [xeloda] and trastuzumab [herceptin].",
    "The sample is a record of a clinical trial with a phase 2 designation. The trial is focused on the disease of schizophrenia, with a list of corresponding ICD-10 codes. The trial involves the use of drugs such as pf-02545920, risperidone, and a placebo. The eligibility criteria for the trial include a diagnosis of schizophrenia with acute exacerbation of illness, with the exacerbation being less than 4 weeks prior to the initial evaluation. Exclusion criteria include evidence or history of clinically significant uncontrolled medical illness, current diagnosis of schizoaffective disorder, major depression, bipolar disorder, or obsessive-compulsive disorder, and meeting DSM-IV defined diagnostic criteria for psychoactive substance dependence or abuse.",
    "This is a sample from a clinical trial table that includes information about a phase 2 trial for breast cancer. The table includes columns for the phase of the trial, the diseases being studied, the ICD-10 codes associated with those diseases, the drugs being used, and the eligibility criteria for participants. In this particular sample, the trial is focused on invasive breast cancer that is resectable and measurable, with a primary breast mass greater than 2.0 cm. Participants must be planning to undergo surgical resection after neoadjuvant therapy and have an ECOG performance status of 0-1. There are also various exclusion criteria, such as intracranial disease, severe asthma or allergies, and unstable systemic disease. The drug being studied in this trial is everolimus.",
    "This sample is for a phase 2 clinical trial for the treatment of advanced prostate cancer using the drug dasatinib. The trial is open to males who are 18 years or older and have documented metastatic disease with rising PSA levels and castrate levels of testosterone. The inclusion criteria also require that the participants have proven advanced prostate cancer. However, individuals with symptomatic CNS metastasis or medical conditions that may increase the risk of toxicity are excluded from the trial. Additionally, those who have received prior or ongoing anti-cancer medical therapy or immunotherapy for prostate cancer other than primary androgen deprivation agents are also excluded. The participants must be able to take oral medication. The diseases are listed as 'prostate cancer' and the icd-10 codes associated with it are also provided.",
    "The sample is a phase 2 clinical trial for the treatment of complicated skin and skin structure infections caused by gram-positive bacteria. The trial is testing the effectiveness of two drugs, daptomycin and vancomycin. The eligibility criteria include being over 18 years old, having a creatinine clearance of at least 50 mL/min, and having at least three clinical signs and symptoms associated with the infection. The exclusion criteria include having certain types of infections, being allergic or intolerant to the study medications, and being unlikely to comply with study procedures.",
    "The sample is a phase 2 clinical trial for the treatment of type 2 diabetes. The trial involves the use of three drugs - ipragliflozin, metformin, and placebo. The eligibility criteria for the trial include having a diagnosis of type 2 diabetes, a HbA1c value between 6.8 and 9.5%, not currently taking anti-diabetic medication or willing to discontinue them during the study, being on a stable diet and exercise program, and using an acceptable form of contraception if female. The exclusion criteria include having type 1 diabetes, using insulin therapy, having certain abnormal lab values, having significant cardiovascular disease, having certain infections or illnesses, and having a history of drug or alcohol abuse/dependency.",
    "The sample is a phase 2 clinical trial for non-small cell lung cancer. The trial includes patients with stage IIIB or IV tumors of certain histological types. The trial drugs include erlotinib, bevacizumab, gemcitabine, and cisplatin. The eligibility criteria include various laboratory parameters, age, ECOG score, and adequate cardiac function. Patients must also have a measurable lesion according to RECIST criteria and provide informed consent. Exclusion criteria include previous chemotherapy within the last five years, pregnancy or lactation, and other co-existing malignancies. Patients with certain CNS disorders or psychiatric disabilities, clinically significant diseases, and uncontrolled hypertension are also excluded.",
    "The sample is a phase 2 clinical trial for patients with locoregionally advanced undifferentiated nasopharyngeal cancer. The trial involves the use of drugs such as amifostine trihydrate, carboplatin, cisplatin, and paclitaxel. The eligibility criteria include having confirmed UNPC, measurable target lesions, no evidence of distant metastases, and meeting certain hematopoietic, hepatic, renal, and cardiovascular requirements. Patients must also not have had prior chemotherapy or radiotherapy for UNPC, and must not have any other concurrent anticancer drugs. The trial does not allow concurrent immunotherapy, but does allow corticosteroids for antiemetic prophylaxis. Patients must also meet certain age, performance status, and life expectancy requirements, and must not have any other malignancy within the past 5 years except for adequately controlled carcinoma in situ of the cervix or basal cell or squamous cell skin cancer.",
    "The sample is a phase 2 clinical trial for patients with metastatic colorectal cancer. The trial is testing the drug everolimus (rad001) and requires patients to have sufficient and obtainable tumor tissue for biomarker analysis from original surgical resection. Patients must also have documented disease progression within 6 months of their most recent dose of chemotherapeutic regimens and at least one measurable lesion. In addition, patients must meet certain eligibility criteria such as adequate bone marrow, liver, and renal function, a life expectancy of more than 3 months, and a World Health Organization (WHO) performance status of 0, 1, or 2. Exclusion criteria include patients currently receiving anti-cancer agents or who have received them within 4 weeks prior to study entry, patients with a known hypersensitivity to everolimus or other rapamycins, and patients with untreated central nervous system (CNS) metastases or neurologically unstable CNS metastases. Other protocol-defined inclusion/exclusion criteria may also apply.",
    "This sample is for a phase 2 clinical trial for the treatment of myelodysplastic syndromes. The trial is looking for patients with low or intermediate-1 risk myelodysplastic syndromes who require transfusion of 2 units of red blood cells at least once a month and have high levels of endogenous epoetin alfa. Patients must also have an ECOG Performance Status of 0-2 and meet certain medical criteria. They must not be pregnant or nursing, and fertile patients must use effective contraception. The trial is testing the drug everolimus and patients must not have had chronic use of physiologic doses of a corticosteroid agent within 28 days of the first day of study drug. Patients must also not be receiving concurrent therapy with any cytotoxic drugs, steroids, or growth factors.",
    "This sample is for a phase 2 clinical trial for the treatment of asthma. The trial is looking at the effectiveness of several drugs, including chf 5188 pmdi, budesonide extrafine pmdi, and seretide(r) evohaler(r). The eligibility criteria for participants include having moderate or severe asthma that is partly controlled with ICS or ICS/LABA, and having an FEV1 between 60% and 90% of predicted normal value. Participants cannot have a diagnosis of COPD, a history or current evidence of significant cardiovascular disease, or uncontrolled concomitant disease.",
    "The sample is a record of a clinical trial with a phase 2 designation. The trial is focused on the disease of primary insomnia, which is identified by the ICD-10 code F51.01. The trial involves the use of the drug pd 0200390. The eligibility criteria for participants include a 3-month history of primary insomnia, specific sleep criteria, and normal daytime-awake, nighttime-sleep schedule. Exclusion criteria include comorbid psychiatric disease or disorders, breathing-related disorders, and use of certain medications or substances.",
    "This is a sample from a clinical trial table that includes information about a phase 2 trial for non-small-cell lung carcinoma. The table includes columns for the trial phase, diseases being studied, ICD-10 codes for those diseases, drugs being used, and eligibility criteria for participants. The eligibility criteria include requirements for disease stage, prior therapy, performance status, and laboratory values. The exclusion criteria include factors such as age, pregnancy or nursing, and uncontrolled illness. The sample also includes specific inclusion and exclusion criteria for the trial.",
    "The sample is a phase 2 clinical trial for non-small cell lung cancer. The trial includes patients between the ages of 18 and 75 who have confirmed non-small cell lung cancer and have failed first-line chemotherapy for advanced disease. The patients are scheduled for second-line therapy with Tarceva. The trial excludes patients with a rash of any etiology at study entry, a history of significant heart disease, any other malignancies (other than adequately treated squamous cell skin cancer or in situ cancer of the cervix), and a history of allergic reactions to tetracyclines. The table also includes a list of icd-10 codes for the disease and a list of drugs used in the trial.",
    "The sample is a phase 2 clinical trial for patients with squamous cell carcinoma of the head and neck. The trial involves the use of the drug cetuximab and has specific eligibility criteria for patients to participate. Inclusion criteria include being over 18 years old, having confirmed SCCHN that has relapsed or metastasized, having a life expectancy of at least 3 months, and meeting certain medical criteria such as adequate hematological and liver function. Exclusion criteria include being over 75 years old, having certain types of cancer, being unable to follow the treatment and evaluation schedule, and having certain medical conditions or therapies that may interfere with the study objectives. Patients must also provide written informed consent to participate in the trial.",
    "The sample is a phase 2 clinical trial for the treatment of dry eye. The trial involves testing the effectiveness of loteprednol etabonate ophthalmic suspension, 0.5% and a vehicle of loteprednol etabonate. The eligibility criteria for participants include being at least 18 years old, having a diagnosis of dry eye, and having a history of intermittent or regular artificial tear use within the past 3 months. Participants must also have a best corrected visual acuity (BCVA) of +0.7 or better and a fluorescein staining score of \u2265 1+ in at least one region in at least one eye. Exclusion criteria include having clinically significant blepharitis or Meibomian Gland Dysfunction (MGD), wearing contact lenses, and currently taking any topical ophthalmic prescription or over-the-counter solutions, artificial tears, gels or scrubs that cannot be discontinued for the duration of the study.",
    "The sample is a phase 2 clinical trial for patients with metastatic renal cell cancer. The trial requires patients to have undergone prior nephrectomy and to have failed at least one prior treatment for metastatic RCC. Patients must also have a Zubrod performance status of less than one and be willing to undergo allogeneic transplantation. The trial also requires patients to have a potential related donor for the transplantation. The eligibility criteria include age equal to or less than 65 years old, predominant conventional cell type, and stage IV RCC. Patients must also have adequate major organ functions and sign an informed consent. Exclusion criteria include prior history of allogeneic stem cell transplantation, multiple brain metastasis, and severely limited life expectancy due to concomitant illness.",
    "The sample is a phase 2 trial for the treatment of postherpetic neuralgia, a condition characterized by moderate to severe pain that persists for at least 3 months after the resolution of shingles. The trial includes patients who are 18-85 years old, have a BMI between 17 and 36, and have an average pain severity of at least 4 on a 0-10 scale over three days prior to the treatment visit. The trial involves the use of two drugs, atx08-001 and placebo, and patients must meet certain eligibility criteria, such as being able to provide written informed consent, having no other source of moderate-to-severe pain, and not actively abusing alcohol or drugs. Patients must also meet certain exclusion criteria, such as having a history of poorly controlled hyperthyroidism or hypothyroidism, having a known history of a positive HIV antibody test or known HIV infection, or having received an investigational medication within 30 days prior to the treatment visit.",
    "This sample is for a phase 2 clinical trial for patients with heart failure and renal impairment. The trial includes the use of two drugs, placebo and rolofylline. The eligibility criteria for the trial includes patients currently using furosemide with systolic blood pressure above 95 mm Hg. Patients with active infection, acute tubular necrosis, severe pulmonary disease, or any heart problems within the last two weeks are excluded from the trial. The diseases are listed as 'heart failure' and the icd-10 codes associated with the disease are also provided.",
    "The sample is a phase 2 clinical trial for patients with moderate to severe chronic obstructive pulmonary disease (COPD). The trial includes patients who are 40 years or older, have a smoking history of at least 10 pack years, and have a post-bronchodilator Forced Expiratory Volume in One Second (FEV1) equal or greater than 30% of the predicted normal value and less than 80% of the predicted normal value, and post-bronchodilator FEV1/FVC less than 0.7 at visit 2. The trial excludes patients requiring oxygen therapy on a daily basis for chronic hypoxemia, or who have been hospitalized for an exacerbation of their airways disease in the 6 weeks prior to visit 1 or during the screening period (up to visit 3). Other exclusion criteria include a history of asthma, long QT syndrome, untoward reactions to sympathomimetic amines or inhaled medication, and clinically relevant laboratory abnormalities or significant conditions that might compromise patient safety or compliance. The trial involves the use of drugs such as nva237 100 \u00b5g and nva237 200 \u00b5g, as well as a placebo. The eligibility criteria and exclusion criteria are clearly defined in the sample.",
    "The sample is a phase 2 clinical trial for patients with metastatic colorectal adenocarcinoma that is not curable by surgery or amenable to radiotherapy with curative intent. The trial involves the use of drugs such as fluorouracil, irinotecan hydrochloride, leucovorin calcium, and oxaliplatin. The eligibility criteria include having measurable disease, no known CNS metastases or carcinomatous meningitis, and meeting certain hematopoietic, hepatic, renal, cardiovascular, and pulmonary requirements. Patients must also not be pregnant or nursing, have no active or uncontrolled infection, and have no other concurrent serious illness. Prior concurrent therapy is also restricted.",
    "The sample is a phase 2 clinical trial for the treatment of esophageal cancer using the drug gefitinib. The trial is open to patients with histologically confirmed squamous cell or adenocarcinoma of the thoracic esophagus that is resectable and localized with or without metastases in local lymph nodes. The disease must be stage I-III and there should be no known distant metastases, cervical-esophageal tumors, or supraclavicular metastases. Patients must have an ECOG performance status of 0-2 and adequate bone marrow, hepatic, renal, and cardiovascular function. They must not have any significant clinical disorder or laboratory finding that would preclude study participation, and must not be pregnant or nursing. Patients must not have had prior therapy for this or any other malignancy, and must not be taking concurrent phenytoin, carbamazepine, barbiturates, rifampin, or Hypericum perforatum (St. John's wort). The trial allows concurrent stable-dose steroids, and patients must have recovered from any prior oncologic or other major surgery. The trial requires more than 30 days since prior nonapproved or investigational drug.",
    "The sample is a phase 2 clinical trial for Crohn's disease. The trial involves the use of two drugs, tu-100 and a matching placebo. The eligibility criteria include being between 18 to 75 years old, having a diagnosis of Crohn's disease for at least 3 months, and having a CDAI score of 220-300 at screening. Participants must also be able to orally ingest the study medication and provide written informed consent. Exclusion criteria include a history of any bowel condition that may interfere with the evaluation of the study drug, positive stool cultures, and current pregnancy or lactation. Additionally, participants must not have a history of alcohol or drug abuse within one year, and must not be currently using certain medications or herbal supplements. The study doctor will determine if a participant is suitable for the trial.",
    "The sample is a phase 2 clinical trial for patients aged 18 or older with recurrent, intracranial glioblastoma multiforme or gliosarcoma. Patients must have a Karnofsky Performance Status (KPS) score greater than 60 and a life expectancy of more than 8 weeks. They must have had prior external beam radiation and temozolomide chemotherapy, and must have recovered from the toxic effects of prior therapy. Patients must also have adequate bone marrow and renal function, and must have shown evidence of tumor progression by MRI scan. A subset of 15 patients may be enrolled prior to a planned surgical resection. Patients must not have any significant medical illnesses that cannot be controlled with appropriate therapy, and must not have a history of any other cancer unless in complete remission for at least 3 years. Patients on certain medications will not be eligible. The trial requires patients to sign an informed consent and authorization for the release of their protected health information.",
    "The sample is a phase 2 clinical trial for the treatment of cystic fibrosis. The trial involves the use of two drugs, l-arginine and l-arginine. The eligibility criteria for the trial include a diagnosis of cystic fibrosis, being 14 years of age or older, clinically stable, and having a FEV1 % predicted between 40% and 80%. The trial also has exclusion criteria, such as a positive respiratory culture for B. cepacia complex, use of systemic corticosteroids within 30 days of screening, and history of lung transplantation or currently on lung transplant list. The trial requires compliance with medication use, study visits, and study procedures.",
    "The sample is a phase 2 clinical trial for patients with type 2 diabetes mellitus who have been treated with a stable dose of metformin for at least 2 months. The trial includes patients with a BMI between 25 and 45 kg/m2 and HbA1c levels between 7% and 10%. The trial also has exclusion criteria, such as patients with diabetes other than type 2 diabetes mellitus, those who have been treated with oral anti-diabetic agents (other than metformin) or insulin during the 12 weeks before baseline visit, and those with a history of intolerance or hypersensitivity to sulfonylurea or sitagliptin. The trial will test the effectiveness of the drug jnj16269110 compared to a placebo and metformin.",
    "The sample is a phase 2 clinical trial for non-small cell lung cancer. The trial includes patients with various types of lung cancer, including adenocarcinoma, large cell, and squamous cell. Patients with stage IV disease or stage IIIB due to a malignant pleural effusion or supraclavicular node involvement are eligible. Patients with known CNS metastases who have received therapy and are neurologically stable and off steroids by the time of enrollment are also eligible. Patients must have measurable or non-measurable disease, and no prior systemic treatment for advanced NSCLC is permitted. The trial involves the use of the drugs docetaxel and bortezomib. The eligibility criteria include various medical conditions and laboratory values, such as granulocytes, platelets, serum creatinine, bilirubin, and AST.",
    "The sample is a phase 2 clinical trial for the treatment of rheumatoid arthritis. The trial involves the use of two drugs, MK-8457 100 mg and methotrexate, as well as a placebo. The eligibility criteria for participants include a diagnosis of rheumatoid arthritis for at least 6 months, the presence of at least 6 swollen and 6 tender joints, a C-reactive protein blood level of over 0.9 mg/dL, and a positive test for anti-citrullinated protein antibody or rheumatoid factor. Participants must also have been receiving a stable dose of methotrexate for at least 3 months prior to screening. Exclusion criteria include the presence of other inflammatory diseases, positive test results for hepatitis B or C or HIV, and recent drug or alcohol abuse. Females of childbearing potential must agree to use two forms of birth control.",
    "The sample is a phase 2 clinical trial for the treatment of paranoid schizophrenia. The trial involves testing the effectiveness of two drugs, mk0249 and a placebo, on patients who have been clinically stable on antipsychotic medication for at least 3 months. The trial has a list of inclusion and exclusion criteria that patients must meet in order to participate. The inclusion criteria include having a 6th grade reading level or better, being in good health, and having a total Positive and Negative Syndrome Scale (PANSS) score between 36 and 75. The exclusion criteria include having a major disease or disorder that may interfere with cognitive testing, a history of head trauma with loss of consciousness greater than 15 minutes, and a history of alcohol or drug dependence within the past year.",
    "The sample is a phase 2 clinical trial for patients with hepatocellular carcinoma who are not suitable for liver transplantation or resection. The trial is testing the effectiveness of the drug bevacizumab. The eligibility criteria include having confirmed HCC, being in Child-Pugh Stage A or B, having liver disease of any etiology, and having a life expectancy of more than 3 months. Patients must also meet certain hematology and biochemistry requirements, and women of childbearing potential must have a negative pregnancy test and use effective contraception. Exclusion criteria include extra hepatic tumor spread, complete portal vein thrombosis, and prior TACE or TAE. Patients with certain medical conditions or taking certain medications are also excluded.",
    "The sample is a phase 2 trial that focuses on treating ventilator-associated pneumonia, respiratory infection, and tracheobronchitis. The trial uses aerosolized vancomycin or gentamicin as the drug. The eligibility criteria for the trial include being on mechanical ventilation for more than 3 days, being at least 18 years old with a survival rate of more than 14 days, and having more than 2 ccs of tracheal secretions every 4 hours. The exclusion criteria include having an allergy to the drugs or being pregnant.",
    "The sample is a phase 2 clinical trial for patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal carcinoma. The trial involves the use of two drugs, Abraxane and Bevacizumab. The eligibility criteria include having measurable disease, having had one prior platinum-based chemotherapeutic regimen, and meeting certain organ and marrow function requirements. Exclusion criteria include having received chemotherapy or radiotherapy within 28 days prior to the study, having a history of other invasive malignancies within the last five years, and having known active liver disease or hepatitis. Patients who are pregnant or lactating, or who are HIV-positive, are also excluded from the study. The trial aims to assess the safety and efficacy of the two drugs in treating the specified cancers.",
    "The sample is a record from a clinical trial table that includes information about the trial's phase, diseases being studied, ICD-10 codes associated with those diseases, drugs being used in the trial, and eligibility criteria for participants. In this particular sample, the trial is in phase 2 and is studying non-small cell lung cancer stage IV. The drugs being used in the trial are iniparib, gemcitabine, and cisplatin. The eligibility criteria include having stage IV disease with no prior systemic therapy, having a confirmed diagnosis of squamous cell bronchogenic carcinoma or non-squamous cell carcinoma, having at least one measurable lesion according to the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1, and having an Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1, among other criteria. The sample also includes exclusion criteria, such as having a history of neoplasm other than the entry diagnosis, presence of active brain metastases, and known or suspected allergy/hypersensitivity to any agent given in the course of the trial.",
    "This sample is a record of a clinical trial in phase 2 for the treatment of thyroid cancer using the drug amg 706. The eligibility criteria for the trial include having locally advanced or metastatic thyroid cancer, measurable disease, and evidence of disease progression within 6 months before starting the study. Patients must also not be candidates for surgical resection, external beam radiotherapy, radioiodine therapy, or other local therapy. The sample also includes exclusion criteria such as having untreated or symptomatic brain metastases, prior malignancy, and unstable cardiac conditions. The diseases are listed as 'thyroid cancer' and the icd-10 codes associated with the disease are also provided.",
    "The sample is a phase 2 trial for individuals with both attention deficit disorder with hyperactivity and cocaine-related disorders. The trial is testing the effectiveness of the drug atomoxetine. The eligibility criteria for the trial includes meeting DSM-IV criteria for cocaine dependence and adult ADHD, describing cocaine as the primary drug of abuse, and not having certain psychiatric or physical disorders. Exclusion criteria includes having certain psychiatric or physical disorders, being pregnant or breastfeeding, and having a history of suicidal or homicidal behavior within 2 years prior to study entry.",
    "The sample is a phase 2 clinical trial for prostate cancer. The trial includes patients who have been histologically confirmed to have prostate adenocarcinoma and have a serum testosterone level above 180 ng/dl. Patients must also have a Karnofsky performance status of at least 70% and meet certain laboratory criteria for organ function. The trial allows for prior hormonal therapy, but only for a limited duration. Patients must be at least 18 years old and have signed an informed consent document. Exclusion criteria include significant cardiac or pulmonary disease, active infection, anticipated survival of less than 3 months, and inability or unwillingness to comply with the treatment protocol. Men of childbearing potential must use effective contraception while on treatment and for at least 6 months after completion of the treatment. Prior chemotherapy and certain concomitant medications are also prohibited.",
    "This sample is for a phase 2 clinical trial for the treatment of metastatic colorectal cancer using the drug su011248. The trial is looking for participants who have failed previous cancer therapies and have not been treated with certain tyrosine kinase inhibitors or VEGF inhibitors. The diseases are listed as 'colorectal neoplasms' and the corresponding ICD-10 codes are also provided. The eligibility criteria are listed under inclusion and exclusion criteria.",
    "The sample is a phase 2 clinical trial for non-small-cell lung cancer. The trial involves the use of two drugs, apatinib and placebo. The eligibility criteria for the trial include being between 18 and 70 years old, having confirmed advanced non-squamous and non-small cell lung cancer, having at least one measurable lesion that has not received radiotherapy, and having failed for 2 lines of chemotherapy including EGFR-TKI. Other criteria include having an ECOG performance scale of 0-1, a life expectancy of more than 3 months, and adequate hepatic, renal, heart, and hematologic functions. The trial also has exclusion criteria, such as having squamous cell carcinoma or small cell lung cancer, being pregnant or breastfeeding, and having intercurrence with certain medical conditions. The sample also includes a list of icd-10 codes for the diseases being studied.",
    "The sample is a phase 2 clinical trial for the treatment of colorectal cancer and familial adenomatous polyposis. The trial involves the use of the drugs celecoxib and eflornithine. The eligibility criteria include a diagnosis of FAP, willingness to abstain from NSAIDs, and having assessable colonic and/or rectal segments. Exclusion criteria include a history of hypersensitivity to COX-2 inhibitors, chronic use of NSAIDs, and significant medical or psychiatric problems. Participants must also be willing and able to sign informed consent. The trial involves a randomized control group and requires follow-up tests.",
    "The sample is a phase 2 clinical trial for the treatment of overactive bladder and urinary incontinence. The trial involves the use of two drugs, elb245 and tolterodine. The eligibility criteria for the trial include being at least 18 years old, having symptoms of OAB for at least 3 consecutive months, and not having received any medication for OAB in the 4 weeks prior to the study. Exclusion criteria include pregnancy, significant stress urinary incontinence, neurological diseases affecting bladder function, and a history of lower urinary tract surgery or pelvic irradiation. Participants must also provide written informed consent.",
    "The sample is a record of a clinical trial with a phase 2 designation. The trial is focused on two diseases, namely pulmonary hypertension and left ventricular dysfunction. The diseases are identified using ICD-10 codes. The trial involves the use of four drugs, including riociguat and a placebo. The eligibility criteria for the trial include male and female patients with symptomatic pulmonary hypertension due to left ventricular diastolic dysfunction. Patients with other types of pulmonary hypertension are excluded from the trial.",
    "The sample is a phase 2 clinical trial for the treatment of prostate cancer and adenocarcinoma of the prostate in patients with measurable or evaluable Stage I or II. The trial involves the use of the drugs docetaxel and prednisone. The eligibility criteria include having an Eastern Cooperative Oncology Group (ECOG) performance status of 0-2, adequate renal function, and a pre-study PSA within 28 days prior to start of therapy. Patients who have received prior radiotherapy are not eligible. The trial also has exclusion criteria, such as patients with measurable metastatic diseases, ongoing problems with bowel obstruction or short bowel syndrome, and a history of severe hypersensitivity reaction to docetaxel or other drugs formulated with polysorbate 80. Patients must also not have any medical life-threatening complications of their malignancies or a known severe and/or uncontrolled concurrent medical disease.",
    "The sample is a phase 2 clinical trial for patients with type 2 diabetes mellitus that is not adequately controlled by metformin. The trial involves the use of three drugs: lixisenatide (ave0010), liraglutide, and metformin. The eligibility criteria include having a diagnosis of type 2 diabetes mellitus for at least one year, having an HbA1c level between 6.5% and 9%, and not being under any administrative or legal supervision. The exclusion criteria include having a BMI outside of the range of 20-37 kg/m^2, having a history of certain medical conditions such as myocardial infarction or stroke, and having certain laboratory findings such as a creatinine clearance of less than 60 mL/min.",
    "The sample is a phase 2 clinical trial for allergic rhinoconjunctivitis. The trial includes patients who are male or female, aged 18 to 65 years, and have a clinical history of allergic rhinitis to birch pollen for at least the last 2 years. The trial also requires patients to have a birch pollen specific IgE result greater than 0.75 kU/L on a blood sample drawn at Visit 1, and a positive skin prick test to birch allergen(s) at Visit 1, with a wheal diameter of at least 4 mm. Patients with sensitization to certain allergens may also be included if sensitization is not clinically relevant. The trial excludes patients who are pregnant or lactating, have a negative pregnancy test at enrolment and are not willing to use a reliable and highly effective method of birth control, weigh less than 40 Kg, have diagnosed asthma, have PEF or FEV1 < 80% of predicted normal, have any acute or chronic disease that would affect the study objectives or subject safety, have autoimmune diseases or immune-defects, or have a history of other clinically significant diseases which might impact efficacy analysis. The trial uses a placebo drug and requires patients to attend required study visits.",
    "The sample is a phase 2 clinical trial for patients with stage III-IVB head and neck cancer, including unknown primary tumors, nasopharyngeal cancer, and bulky stage II lesions of the base of tongue or hypopharynx. The trial involves the use of docetaxel, cisplatin, and cetuximab as drugs. The eligibility criteria include having measurable disease, no prior chemotherapy or radiotherapy for head and neck cancer, and an ECOG PS of 0 or 1. Exclusion criteria include severe allergic reactions to docetaxel or similar compounds, uncontrolled intercurrent illness, and receiving any other investigational agents. The trial also requires confirmation of diagnosis of squamous cell or poorly differentiated carcinomas, or WHO types I-III of the nasopharynx, and meeting certain organ and marrow function criteria.",
    "The sample is a phase 2 clinical trial for patients with metastatic colorectal cancer that has spread to the liver. The trial involves the use of two drugs, capecitabine and oxaliplatin. The eligibility criteria include having measurable disease in the liver, no evidence of extrahepatic metastases or CNS metastases, and an ECOG performance status of 0-1. Patients must also meet certain laboratory values and have no serious concurrent illnesses. Prior therapy for advanced disease is allowed, but not prior oxaliplatin-based therapy. The trial allows for concurrent maintenance and palliative treatment during study chemotherapy, but not concurrent corticosteroids or other chemotherapy. The placement of a hepatic artery port for regional chemotherapy is also not allowed.",
    "The sample is a record of a clinical trial in phase 2 for the treatment of bipolar disorder using the drug memantine hcl. The trial is looking for patients who have a clinical diagnosis of bipolar I disorder and are currently experiencing a manic or mixed episode. Patients must be voluntarily hospitalized with a primary diagnosis of mania. The trial has exclusion criteria such as rapid cycling bipolar disorder, suicidal risk, first manic episode, ECT, clozapine or a depot neuroleptic in the past 3 months, substance dependence, known HIV infection, and co-morbid serious, uncontrolled systemic illness.",
    "The sample is a phase 2 clinical trial for the treatment of leukemia using cyclophosphamide, methotrexate, and prednisone. The eligibility criteria include having certain levels of CD3+, CD57+, or CD8+ cells, evidence of clonal T-cell receptor gene rearrangement, and certain blood levels of bilirubin, SGOT(AST), and creatinine. Patients must also have an ECOG performance status of 0-2, be at least 18 years old, and provide written informed consent. Exclusion criteria include prior therapy with oral MTX or oral Cy, previous or concurrent malignancies (except for certain types), pregnancy or breastfeeding for female patients, serious medical illness, or psychiatric conditions that would prevent informed consent. Patients must have had no response after at least 4 months of methotrexate treatment to be eligible for step 2 of the study.",
    "The sample is a phase 2 trial for hormone refractory prostate cancer. The trial includes patients with nodal or visceral metastases, PSA only disease, or bone involvement. The eligibility criteria include a signed informed consent, confirmed adenocarcinoma of the prostate, adequate bone marrow function, and an ECOG status of 0 or 1. The trial excludes patients who have received prior chemotherapy for prostate cancer, are receiving other hormonal therapy, have started bisphosphonate or denosumab therapy less than 28 days before the anticipated Week 1 visit, or are using supplements or complementary medicines/botanicals. The trial also excludes patients with major surgery or radiation therapy completed less than 4 weeks prior to screening, known HIV or hepatitis B or C, cerebral metastases, or evidence of symptomatic congestive heart failure, pulmonary embolus, vascular thrombosis, transient ischemic attack, cerebrovascular accident, unstable angina, myocardial infarction or active ischemia on ECG.",
    "The sample is a phase 2 clinical trial for patients with metastatic or recurrent breast cancer who cannot undergo surgery for curative purposes. The trial involves the use of the drug enzastaurin hydrochloride and has specific inclusion and exclusion criteria. Inclusion criteria include having received prior therapy with an anthracycline and a taxane, having tumors that are not positive for HER2, and having measurable disease on radiological tests. Exclusion criteria include having had more than 2 chemotherapy regimens for metastatic or locally recurrent disease, having brain cancer from breast cancer, being pregnant or breastfeeding, having an inability to swallow tablets, and having had a serious heart condition within the past 6 months.",
    "The sample is a phase 2 clinical trial for patients with type 2 diabetes mellitus who are inadequately controlled on diet and exercise alone. The trial is testing the effectiveness of the drug roflumilast. The eligibility criteria include having a diagnosis of type 2 diabetes according to American Diabetes Association criteria, having a baseline HbA1c level between 7.5 percent and 8.5 percent (up to 9 percent in certain countries), having a BMI between 26 and 35 kg/m2, and being willing to check blood glucose levels with equipment provided by the sponsor during the treatment phase. The trial also has exclusion criteria, such as having type 1 diabetes or diabetes secondary to pancreatitis or resection of pancreas, being diagnosed with hemoglobinopathies or hemolytic anemia, and having clinically significant cardiac abnormalities. Patients were randomized after 2 weeks of the baseline period if they were judged to be clinically stable and had tablet compliance between 80 percent and 125 percent.",
    "The sample is a phase 2 clinical trial for patients with metastatic melanoma or skin cancer. The trial involves the use of cyclophosphamide and fludarabine drugs. The eligibility criteria include having measurable metastatic melanoma with available autologous tumor infiltrating lymphocytes (TIL), having 3 or fewer brain metastases that are less than 1 cm in diameter and asymptomatic, being between 18 and 70 years old, having a clinical performance status of Eastern Cooperative Oncology Group (ECOG) 0 or 1, having a life expectancy of greater than three months, and meeting certain serology, hematology, and chemistry requirements. Patients must also be ineligible to receive interleukin-2 (IL-2) based on certain evidence. The exclusion criteria include being pregnant or breastfeeding, having any form of primary immunodeficiency, having concurrent opportunistic infections, having concurrent systemic steroid therapy, having a history of severe immediate hypersensitivity reaction to any of the agents used in this study, and having a ventricular ejection fraction less than or equal to 30% or respiratory compromise.",
    "The sample is a phase 2 clinical trial for the treatment of amyotrophic lateral sclerosis (ALS) using thalidomide. The eligibility criteria include patients aged 25 to 80 years with a clinical diagnosis of probable or definite ALS, onset of paresis for no more than 4 years, and vital capacity equal to or more than 65% of the predicted value. Patients must also be willing to give informed consent and comply with the Pharmion-Risk Management Program (PRMP) for contraception. Exclusion criteria include pregnancy or breastfeeding, significant sensory abnormalities, dementia, and other medical illnesses or psychiatric disorders. Patients with a history of substance abuse, recurrent thrombosis, or sleep disorders are also excluded.",
    "The sample is a phase 2 trial for patients with type 2 diabetes mellitus. The trial includes patients who are currently being treated with diet and exercise therapy consistent with the local standards of medical care and may be treated with diet and exercise alone or in combination with a stable of metformin for at least 3 months before entering the trial. The patients must have a hemoglobin A1c value between 7.0% and 10.0 %, inclusive. The trial has inclusion and exclusion criteria, which are listed in detail. The inclusion criteria include having type 2 diabetes mellitus prior to entering the trial, being women not of child-bearing potential due to surgical sterilization or menopause, and having a reliable method of birth control for male patients. The exclusion criteria include the use of insulin or any antidiabetic agent other than metformin during the 3 months prior to entering the trial, having a gastrointestinal disease that significantly impacts gastric emptying or motility, having had more than 1 episode of severe hypoglycemia within 6 months prior to entry into the study, and having poorly controlled hypertension.",
    "The sample is a record from a clinical trial table, containing information about a phase 2 trial for non-Hodgkin's lymphoma. The record includes the phase of the trial, a list of diseases, a list of ICD-10 codes for the diseases, a list of drugs, and eligibility criteria for participants. The eligibility criteria include requirements such as age, performance status, and adequate organ function, as well as exclusion criteria such as central nervous system involvement with lymphoma, active malignancies, and HIV infection. The study center will determine if a participant meets all of the criteria, and if they do, study personnel will explain the trial in detail and answer any questions.",
    "The sample is a record of a clinical trial in phase 2 for the treatment of breast cancer. The trial involves the use of drugs such as bevacizumab, docetaxel, cpt-11, paclitaxel, vinorelbine tartrate, and gemcitabine. The eligibility criteria for the trial include being a female over the age of 18 with metastatic breast cancer and stable brain metastases, having received definitive radiotherapy, and having adequate organ and hematological function. The exclusion criteria include having an active infection, non-healing wound, or history of bleeding diathesis or coagulopathy, as well as uncontrolled hypertension, congestive heart failure, or peripheral vascular disease.",
    "The sample is a phase 2 clinical trial for multiple sclerosis. The eligibility criteria include having a diagnosis of primary-progressive, secondary progressive, progressive-remitting, or relapsing-remitting multiple sclerosis of at least 3-month duration, having an EDSS score of 4 to 7, and being able to understand and comply with the requirements of the protocol. The trial drug is biib041 (pr fampridine). The sample also includes a list of exclusion criteria, such as having a history of seizure or epilepsy, having uncontrolled hypertension, or having a history of drug or alcohol abuse within the past 2 years.",
    "The sample is a phase 2 clinical trial for the treatment of glioblastoma multiforme, a type of brain cancer. The trial is testing a drug called tln-4601. The eligibility criteria for the trial include having a confirmed diagnosis of GBM, having received prior treatment with radiation and one first-line systemic therapy, being at least 18 years old, having an ECOG score of 2 or less, and having normal organ and marrow function. The exclusion criteria include having a life expectancy of less than 12 weeks, having a history of HIV or active hepatitis B or C infections, being pregnant or lactating, and having certain medical conditions or taking certain medications.",
    "The sample is a phase 2 trial for treating nausea and vomiting in patients receiving cisplatin-based chemotherapy. The trial involves administering different doses of a drug called sch 619734 and a placebo to eligible patients. The eligibility criteria include being 18 years or older, having never been treated with cisplatin before, having a Karnofsky performance score of at least 60, and having a predicted life expectancy of at least 3 months. Patients must also have adequate bone marrow, kidney, and liver function, and be able to read, understand, and complete questionnaires. Exclusion criteria include having a medical history that could confound the results of the study or pose any unwarranted risk, having a contraindication to the administration of cisplatin, ondansetron, or dexamethasone, and having ongoing vomiting caused by any etiology or a history of anticipatory nausea and vomiting.",
    "The sample is a phase 2 clinical trial for the treatment of schizophrenia. The trial is testing the effectiveness of the drugs amg 747 and placebo. The eligibility criteria for participants include a diagnosis of schizophrenia, a certain score on the PANSS Marder Negative Symptom Factor Scale and the PANSS Marder Positive Symptom Factor Scale, and stable antipsychotic therapy for at least 8 weeks prior to screening. Exclusion criteria include current schizoaffective or bipolar disorder, substance abuse within the 8 weeks prior to screening, and positive urine drug test for substances of abuse.",
    "The sample is a clinical trial that is in phase 2/phase 3 and involves patients with chronic kidney disease, cardiovascular disease, and death. The trial is testing the effectiveness of a high dose multivitamin drug. The eligibility criteria for the trial include being between 35-75 years old, having had a kidney transplant at least 6 months prior, and having a calculated Creatinine Clearance of 25 mL/min or greater. Patients must also be willing to stop taking certain supplements for 4-6 weeks prior to the visit. Exclusion criteria include being pregnant or lactating, having certain medical conditions that limit life expectancy to less than 2 years, and having had certain medical procedures within a certain timeframe. Patients with certain conditions that prevent reliable study participation are also excluded.",
    "The sample is a phase 2 clinical trial for rheumatoid arthritis. The trial includes the use of two drugs, cp-690,550 and placebo. The eligibility criteria for the trial includes meeting the American College of Rheumatology classification criteria for RA and having active disease at both screening and baseline. Exclusion criteria includes a history of documented influenza or pneumococcal infection within the last 3 months, receipt of any vaccine within 1 month prior to the initial study drug administration, and receiving an influenza vaccine within 6 months or a pneumococcal vaccine within 5 years of initial study drug administration. The icd-10 codes for the disease are also provided.",
    "The sample is a phase 2 clinical trial for patients with malignant mixed mesodermal (MMMT) confined to the pelvis. The trial requires patients to have undergone a total abdominal hysterectomy, vaginal hysterectomy or laparoscopic assisted vaginal hysterectomy and a bilateral salpino-oophorectomy within 8 weeks of study entry. Patients must not have any known metastatic extrauterine metastases, no known gross residual disease or distant metastases. The trial also requires patients to have adequate bone marrow, renal and hepatic function, and a Zubrod performance status of </= 2. Patients must not have had prior chemotherapy or radiation therapy for this diagnosis and must have an estimated life expectancy of 12 weeks or greater. The trial has exclusion criteria, including previously treated malignant mixed mesodermal (MMMT) with either chemotherapy or radiotherapy, gross residual disease, suspected extrapelvic or extrauterine disease or distant metastatic disease, history of other malignancy, with the exception of non-melanomatous skin cancer, unless in complete remission and off all therapy for that disease for a minimum of 5 years, a Zubrod performance status of 3 or greater, an active systemic infection, a serious intercurrent medical illness, and a recent (within 6 months) history of cardiac dysrhythmia, congestive heart failure, unstable angina or myocardial infarction.",
    "The sample is a phase 2 clinical trial for patients with metastatic breast cancer. The trial involves the use of the drugs carboplatin and bevacizumab. The eligibility criteria include having pathologically confirmed ER, PR and HER2/neu negative metastatic breast cancer, measurable disease, and normal organ and marrow function. Patients must not have received prior chemotherapy for metastatic breast cancer, and must be over 18 years old with an ECOG performance status of less than 1. Exclusion criteria include prior therapy with platinum agents or a VEGF inhibitor, known brain metastases, significant cardiac dysfunction, and uncontrolled intercurrent illness. Patients must also have the ability to understand and sign a written informed consent document.",
    "The sample is a record of a clinical trial in phase 2 for Huntington's disease. The trial involves the drug Dimebon and the eligibility criteria includes having clinical features of HD and a family history or genetic confirmation of the disease. Participants must also be able to take medication orally. Exclusion criteria includes unstable medical illness and pregnancy or lactation in females. The sample also includes the ICD-10 code for Huntington's disease, which is G10.",
    "The sample is a phase 2 clinical trial for the treatment of schizophrenia. The trial includes patients who meet the diagnostic criteria for schizophrenia in DSM-IV-TR and are inpatients during the study. Patients must have a minimum total score of no less than 14 on the five items of the PANSS-EC and at least one individual item score of no less than 4 using the 1-7 scoring system prior to the first injection of study drug. The trial excludes patients with a known history of diabetes mellitus, those who have received treatment with antipsychotics or other prohibited concomitant medicines within 2 hours prior to the first IM study drug administration, and those who have had treatment with benzodiazepines within 4 hours prior to first IM study drug administration. The trial uses olanzapine-raim and placebo as the study drugs.",
    "The sample is a phase 2 clinical trial for patients with brain metastases from non-small cell lung cancer. The trial is testing the drug Iressa (gefitinib). The eligibility criteria include having radiologically confirmed brain metastases, no symptoms due to brain metastases, and no previous radiotherapy treatment for the brain metastases. The exclusion criteria include no prior chemotherapy, no other co-existing malignancies or malignancies diagnosed within the last 5 years (with the exception of basal cell carcinoma or cervical cancer in situ), and any evidence of severe or uncontrolled systemic disease. The diseases and their corresponding ICD-10 codes are also listed.",
    "The sample is a record from a clinical trial table, containing information about a phase 2 trial for the treatment of myelodysplastic syndrome and chronic myelomonocytic leukemia using the drug decitabine. The eligibility criteria for the trial include having failed therapy with azacytidine, having a performance status of 0-2 on the ECOG scale, and having adequate hepatic and renal function. Patients must also have signed informed consent and not have had prior intensive combination chemotherapy or high-dose ara-C. Exclusion criteria include being pregnant or nursing, having active and uncontrolled infections, and having uncontrolled intercurrent illness. The table also includes lists of disease names, ICD-10 codes, and drug names.",
    "The sample is a phase 2 clinical trial for prostate cancer. The trial includes patients with confirmed adenocarcinoma of the prostate who have experienced biochemical disease progression following androgen deprivation therapy. The trial requires patients to meet certain eligibility criteria, such as having a current PSA level above 5 ng/ml and a testosterone level below 50 ng/dL. Patients must also have an ECOG performance status of 0, 1, or 2 and no visceral or bony metastatic disease. The trial excludes patients with certain medical conditions, such as uncontrolled diabetes and a history of gallstones. Patients must also not have received prior chemotherapy for prostate cancer or be currently taking certain medications, such as Saw Palmetto or Proscar.",
    "The sample is a phase 2 clinical trial for complicated intra-abdominal infection. The trial involves the use of three drugs - tp-434, ertapenem, and placebo. The eligibility criteria for the trial include having abdominal pain/discomfort with onset prior to hospitalization, evidence of a systemic inflammatory response, physical findings consistent with intra-abdominal infection, clinical diagnosis of community-acquired IAI requiring urgent surgical or percutaneous intervention and not expected to require antibacterial therapy for longer than 14 days, and having a BMI of \u2264 30 kilograms per square meter (kg/m^2). The trial also has exclusion criteria, such as having symptoms related to diagnosis of complicated appendicitis for less than 24 hours prior to current hospitalization, being managed by Staged Abdominal Repair or other open abdomen technique, and having an APACHE II score > 25.",
    "The sample is a phase 2 clinical trial for patients with recurrent ovarian cancer, fallopian tube cancer, or primary peritoneal cancer. The trial is testing the effectiveness of cyclophosphamide and fludarabine phosphate drugs. The eligibility criteria include having measurable disease, progression on or failure to respond to at least 2 salvage chemotherapy regimens, and availability of a related HLA-haploidentical natural killer (NK) cell donor. Patients must also have adequate organ function and be off prednisone or other immunosuppressive medications for at least 3 days prior to Day 0. Pregnant or lactating patients and those with active infections are excluded from the trial. The trial will monitor for the presence of human anti-mouse antibody (HAMA) in patients who have received previous antibody therapies.",
    "The sample is a record of a clinical trial in phase 2, focused on the disease of trauma. The trial includes a list of icd-10 codes associated with the disease. The trial involves testing the effectiveness of three drugs: propranolol, propranolol er, and sugar pills. The eligibility criteria for participants include having at least one fracture, being between the ages of 18-60, having a pain score of at least 4, and being able to speak and read English. The exclusion criteria include factors such as gunshot or stab wounds, pregnancy, and certain medical conditions.",
    "The sample is a clinical trial with a phase 2/phase 3 design, focused on the treatment of multiple sclerosis-related pain. The trial involves the use of two drugs, duloxetine and placebo, and has a list of inclusion and exclusion criteria for participants. Inclusion criteria include a diagnosis of MS, age over 17, clinical stability, and daily pain attributed to MS. Exclusion criteria include pain that cannot be differentiated from other causes, certain psychiatric diagnoses, use of certain medications, and various medical conditions. The trial also has a list of diseases and their corresponding ICD-10 codes.",
    "The sample is a record of a clinical trial with a phase 2 designation. The trial is focused on the disease of chronic hepatitis C and includes a list of ICD-10 codes associated with the disease. The trial involves the use of three drugs: celgosivir, celgosivir, and peginterferon alfa 2b + ribavirin. The eligibility criteria for the trial include being between the ages of 18-65, having a primary diagnosis of chronic HCV infection with genotype 1, being treatment-na\u00efve with interferon-based treatment, and having a body mass index between 18 to 30. The exclusion criteria include patients who have previously been treated with interferon-based therapy and patients with diabetes mellitus.",
    "The sample is a phase 2 clinical trial for patients with pancreatic cancer who are not eligible for surgery. The trial involves the use of three drugs: gemcitabine, erlotinib, and sorafenib. The eligibility criteria include having measurable disease, not having received prior cytotoxic chemotherapy for metastatic disease, and having normal organ and marrow function. Patients must also meet certain exclusion criteria, such as not having CNS disease or serious cardiovascular disease. Women of childbearing potential must have a negative pregnancy test and both men and women must agree to use adequate contraception during the study. Patients must also be able to understand and sign a written informed consent document.",
    "The sample is a phase 2 clinical trial for locally advanced or metastatic colorectal cancer. The trial involves the use of drugs such as irinotecan, avastin, and erbitux. The eligibility criteria include having measurable or evaluable disease, an ECOG performance status of 2 or less, and adequate liver, renal, and bone marrow function. Patients must also be able to understand the nature of the study and provide written informed consent. Exclusion criteria include a history of serious cardiac disease, bleeding diathesis or coagulopathy, and known hypersensitivity to cetuximab. Patients with chronic diarrhea or partial bowel obstruction are also excluded.",
    "The sample is a phase 2 clinical trial for locally advanced or metastatic breast cancer. The trial involves the use of gemcitabine, carboplatin, and trastuzumab as drugs. The eligibility criteria include having measurable disease as per RECIST criteria, no prior chemotherapy in the metastatic breast setting, and prior chemotherapy and/or hormonal therapy for early stage breast cancer. Patients must also have normal organ and bone marrow function, normal heart function if receiving Trastuzumab, and be able to perform activities of daily living with minimal assistance. Women over the age of 18 are eligible for the study. Exclusion criteria include having received prior chemotherapy for metastatic breast cancer, known leptomeningeal carcinomatosis, uncontrolled brain metastasis, uncontrolled intercurrent illness, being pregnant or lactating, and having a history of other non-breast cancer malignancy. The study center will determine if patients meet all of the criteria and will explain the trial in detail to those who qualify.",
    "The sample is a phase 2 clinical trial for patients with recurrent malignant gliomas. The trial is testing the effectiveness of the drug panobinostat. The eligibility criteria include having no more than three prior therapies, being at least 18 years old, having a KPS score of at least 60, and meeting various medical requirements such as having normal blood counts and liver function. Patients must also have recovered from any toxic effects of prior therapy. Exclusion criteria include having certain medical conditions or taking certain medications, as well as being pregnant or breastfeeding. The trial is looking to enroll patients who have not had more than three prior therapies and who meet the eligibility criteria.",
    "The sample is a record of a clinical trial in phase 2, which is testing the effectiveness of a drug called mk-0873 in treating lung diseases and chronic obstructive pulmonary disease (COPD). The trial involves administering different doses of the drug, a placebo, and usual care to male and female participants between the ages of 40 and 75 who meet certain lung function requirements. The eligibility criteria include having a history consistent with COPD and not having severe and unstable medical conditions or other lung diseases. Participants with a history of colitis or who use continuous oxygen therapy or have cardiac arrhythmias are excluded from the trial. The diseases and their corresponding ICD-10 codes are also listed in the record.",
    "The sample is a phase 2 clinical trial for smoking cessation. The trial includes a list of diseases and their corresponding ICD-10 codes, as well as a list of drugs being tested. The eligibility criteria for participants include being a smoker of at least 10 cigarettes daily, being motivated to quit smoking, and having had at least one unsuccessful attempt to quit in the last 2 years. Exclusion criteria include being pregnant or nursing, having a history of alcohol or drug abuse, and having certain medical or psychiatric disorders. Participants must provide written informed consent to participate in the study.",
    "The sample is a phase 2 clinical trial for asthma patients. The trial includes patients between the ages of 18 and 75 who have had a confirmed diagnosis of asthma for at least 3 months and are currently on a stable dose of inhaled corticosteroids. Patients must also have a pre-bronchodilator FEV1 between 60% and 90% of predicted normal and be symptomatic with an Asthma Control Questionnaire mean score of 1.5 or higher. Patients must not have any significant diseases other than asthma, recent history of myocardial infarction or hospitalization for cardiac failure, or any unstable or life-threatening cardiac arrhythmia. Patients must also not have any lung diseases other than asthma, active tuberculosis, or malignancy for which they have undergone resection, radiation therapy, or chemotherapy within the last five years. Pregnant or nursing women, women of childbearing potential not using a highly effective method of birth control, and patients who have taken an investigational drug within four weeks prior to Visit 1 are also excluded. The trial includes a list of drugs, including tiotropium bromide, and eligibility criteria for patients to be included or excluded from the trial.",
    "The sample is a phase 2 trial for patients with sickle cell anemia or sickle cell beta zero thalassemia and persistent elevation of pulmonary artery systolic pressure. The trial is testing the effectiveness of warfarin and placebo as treatments. The eligibility criteria include being at least 16 years old, having certain laboratory values within normal ranges, and not having certain medical conditions or taking certain medications. Patients must also be willing to give informed consent and practice adequate contraception if of childbearing age. The exclusion criteria include having certain medical conditions or taking certain medications, being pregnant or breastfeeding, and having ingested any investigational drugs within the past 4 weeks.",
    "The sample is a phase 2 clinical trial for HIV infections. The trial involves two drugs, mk0639 and indinavir sulfate, which will be administered for a duration of 48 weeks. The comparator drug is nelfinavir mesylate, which will also be administered for 48 weeks. The eligibility criteria for the trial include being at least 18 years old, HIV positive, and having no active heart disease. The exclusion criteria include being pregnant or breastfeeding, unwilling to use birth control or abstinence to prevent pregnancy, having received an investigational drug or vaccine within the past 30 days or planning to receive one during the study, planning to receive NNRTIs during the study, having received therapy that lowers the body's ability to fight infection within the past 30 days or during the study, having alcohol or substance abuse, and having hepatitis.",
    "The sample is a phase 2 clinical trial for various types of lymphoma and other lymphoid malignancies. The trial includes patients who have relapsed or primary refractory lymphoid malignancy, and have measurable disease. Patients must have a bone marrow aspirate and biopsy within 28 days of enrollment and no intervening anticancer therapy. They must also have a CT of chest, abdomen, and pelvis within 28 days of enrollment. Patients with evidence of adenopathy in the neck must have a CT of neck. Patients should not have evidence of active central nervous system lymphoma. The trial includes patients with a Southwest Oncology Group (SWOG) performance status of 0, 1, or 2. Patients must have serum lactate dehydrogenase (LDH) performed within 14 days prior to treatment. The trial excludes patients known to be human immunodeficiency virus (HIV) positive, pregnant or nursing women, patients with other prior malignancies except for adequately treated basal cell carcinoma, squamous cell carcinoma of the skin, cervical cancer in situ, or other cancer from which the patient has been disease-free for 5 years or greater unless approved by the Principal Investigator (PI). Patients that are refractory to a carboplatin or cisplatin-based regimen or a gemcitabine-based regimen are also excluded. The trial includes patients who are expected to complete at least 2 cycles of chemotherapy.",
    "The sample is a phase 2 clinical trial for small cell lung cancer. The trial is testing the effectiveness of the drug pemetrexed on patients who have received at least one but not more than two prior chemotherapy regimens, including one regimen containing a platinum agent. Patients must have measurable disease as per the RECIST criteria and must have completed radiation therapy at least 14 days prior to being registered for protocol therapy. The trial has inclusion and exclusion criteria, including no clinically significant infections, no symptomatic CNS metastasis, no radiation to more than 25% of the marrow containing spaces, no previous treatment with pemetrexed, no uncontrolled pleural effusions, and no current breastfeeding.",
    "The sample is a phase 2 clinical trial for non-squamous non-small cell lung cancer. The trial includes patients who are 18 years or older, have stage IIIb (with effusion) or stage IV with measurable disease, have an ECOG PS 2, and have adequate organ function. The trial excludes patients who have had prior chemotherapy or systemic anti-tumor therapy, are hypersensitive to erlotinib, have any condition that contraindicates the use of the study medication, or have any condition that impairs the interpretation of results or leads to treatment-related complications. The trial will test the effectiveness of erlotinib and gemcitabine as treatments for non-squamous non-small cell lung cancer.",
    "The sample is a phase 2 clinical trial for patients with colorectal cancer that is inoperable, locally advanced, or metastatic and not amenable to curative therapy. The trial involves the use of the drugs S-1 and bevacizumab. The eligibility criteria include having no previous treatment, being over 65 years old, having a life expectancy of at least 3 months, and having adequate function of major organs. Exclusion criteria include serious drug hypersensitivity, active double cancer, active infections, uncontrolled hypertension, and serious complications such as heart failure or poorly controlled diabetes. Participants must also be able to take capsules orally and provide voluntary written informed consent.",
    "The sample is a phase 2 clinical trial for patients diagnosed with multiple myeloma, a type of cancer. The trial involves the use of two drugs, lenalidomide and bortezomib, and has specific eligibility criteria for participants, including having measurable disease requiring systemic therapy and a Karnofsky Performance Status score of at least 50%. The trial also has exclusion criteria, such as having renal insufficiency or a history of allergy to the study medications. Participants must provide voluntary written informed consent and women of childbearing potential must have a negative pregnancy test and commit to continued abstinence from heterosexual intercourse or use two acceptable methods of birth control.",
    "The sample is a phase 2 clinical trial for small cell lung cancer. The trial is testing the effectiveness of drugs such as cisplatin, gleevec\u2122, and irinotecan. The eligibility criteria for patients include having histologically or cytologically confirmed SCLC, meeting certain disease characteristics such as having measurable or evaluable disease, and meeting certain patient characteristics such as having a SWOG performance status of 0-2 and no uncontrolled congestive heart failure. Patients must also not have received prior chemotherapy for SCLC and must not be on concurrent routine systemic corticosteroids. The trial also has certain exclusion criteria such as having a history of untreated or symptomatic brain or leptomeningeal metastases and having other serious medical illnesses.",
    "The sample is a phase 2 clinical trial for ovarian cancer. The trial includes patients who have been diagnosed with serous ovarian cancer and have received no more than 3 previous platinum-containing treatments. Patients must have been progression-free for at least 6 months following the end of the last platinum treatment and have at least one lesion that is suitable for accurate repeated measurements. The trial excludes patients who have received any systemic anticancer chemotherapy or radiotherapy within two weeks from the last dose prior to study treatment and those who have hypersensitivity to pre-medications required for treatment with paclitaxel/carboplatin. The trial will test the effectiveness of olaparib, paclitaxel, and carboplatin in treating ovarian cancer.",
    "The sample is a phase 2 clinical trial for the treatment of leukemia using a drug called ly2090314. The trial is open to participants with confirmed diagnosis of acute myelogenous leukemia (AML) that is refractory or relapsed disease, or untreated AML (de novo or arising from a myelodysplastic syndrome) who are not candidates for standard therapy. The participants must meet certain eligibility criteria, including having adequate organ function, a performance status of less than or equal to 2 on the Eastern Cooperative Oncology Group (ECOG) scale, and having discontinued all previous approved therapies for acute leukemia. The trial also has exclusion criteria, such as having serious pre-existing medical conditions, uncontrolled systemic infection, or being pregnant or lactating.",
    "The sample is a record of a clinical trial with a phase 2 designation. The trial is focused on the disease of ulcerative colitis, which is identified by a list of ICD-10 codes. The trial involves testing three different drugs: hmpl-004 low dose, placebo, and hmpl-004 high dose. The eligibility criteria for the trial include having active confirmed mild to moderate ulcerative colitis, while the exclusion criteria include being diagnosed with Crohn's Disease.",
    "The sample is a phase 2 clinical trial for patients with metastatic prostate cancer. The trial involves the use of three drugs - mitoxantrone, prednisone, and sorafenib. The eligibility criteria include a histopathologic diagnosis of prostatic adenocarcinoma with evidence of progression despite adequate castration, progressive disease after taxane-based chemotherapy, and adequate bone marrow, liver, and renal function. Patients must also have an ECOG performance status of 2 or less and a baseline left ventricular ejection fraction of at least 50%. Exclusion criteria include more than one line of prior cytotoxic chemotherapy in the metastatic setting, known brain metastases, and serious medical or psychiatric illness likely to interfere with participation in the clinical study.",
    "The sample is a record from a clinical trial table. It is a phase 2 trial for the treatment of renal cell carcinoma. The trial includes patients with evidence of metastatic disease who have predominantly clear cell renal cancer. The trial drug is rad001. The record includes both inclusion and exclusion criteria for patient eligibility. Inclusion criteria include having received no more than two prior regimens for renal cell carcinoma and having adequate physiologic reserves. Exclusion criteria include having central nervous system metastases, being HIV positive, having a recent history of TIA, and having an unstable medical condition. The record also includes a list of icd-10 codes for the disease.",
    "The sample is a phase 2 clinical trial for patients with recurrent epithelial ovarian or primary peritoneal carcinoma who have measurable disease by RECIST criteria or elevated CA-125. The trial requires patients to have received at least 3 cycles of a front-line taxane and platinum-containing regimen prior to entry and to have a documented complete clinical response on front-line therapy. Patients must also be disease-free from prior malignancies for more than 5 years, have a life expectancy of more than 6 months, and have an ECOG performance status of 0-2. The trial drug is Abraxane. The eligibility criteria include various blood counts and chemistry levels, and patients must have signed an informed consent form prior to participation. Exclusion criteria include patients who have received more than one prior chemotherapy regimen, evidence of active brain metastases, and pre-existing peripheral neuropathy of grade >/= 2. Patients receiving concurrent or intervening other chemotherapy, hormonal (for treatment of ovarian carcinoma), immunotherapy, or radiotherapy are also excluded. Patients with a clinically significant concurrent illness, serious medical risk factors involving any of the major organ systems, or who are enrolled in any other clinical protocol or investigational trial are also excluded. Patients of childbearing potential who are not practicing adequate contraception are also excluded.",
    "The sample is a phase 2 clinical trial for the treatment of soft tissue sarcoma using the drug glufosfamide. The trial is for patients who are at least 18 years old and have been diagnosed with locally advanced unresectable or metastatic soft tissue sarcoma that has progressed since the most recent therapy. The trial requires patients to have measurable disease by RECIST criteria with at least one target lesion and to have undergone 1 or 2 prior chemotherapy/systemic therapy regimens for advanced disease. Patients must also have an Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0, 1 or 2 and have recovered from reversible toxicities of prior therapy. The trial has a list of inclusion and exclusion criteria that patients must meet in order to participate.",
    "The sample is a phase 2 clinical trial for rheumatoid arthritis. The trial includes patients who have been diagnosed with RA for at least 6 months and have a swollen joint count of at least 6 out of 28 joints and a tender joint count of at least 6 out of 28 joints. The patients must have failed at least 1 nonbiologic DMARD and may have failed no more than 1 biologic DMARD for reasons other than inadequate response. The trial includes a list of drugs, including a placebo and vx-509, and eligibility criteria for inclusion and exclusion. The inclusion criteria include having a baseline CRP level 1.5 times greater than the upper limit of normal at screening and being willing to comply with contraception requirements. The exclusion criteria include having inflammatory rheumatological disorders other than RA, a clinically significant disorder other than RA, or clinically important abnormalities in screening physical examination or laboratory test results. The trial also excludes patients who have received live, attenuated vaccinations within 1 month prior to study drug administration or have a history of drug or alcohol abuse or excessive alcohol.",
    "The sample is a phase 2 clinical trial for pancreatic cancer. The trial includes patients who have not previously received chemotherapy for pancreatic cancer and have an ECOG performance status of 0 or 1. The trial also requires patients to have a life expectancy of more than 3 months and adequate hematological, renal, and hepatic function. Patients must not be pregnant or nursing, and fertile patients must use a medically approved method of contraception. The trial has exclusion criteria, including prior history of other malignant tumors, participation in another investigational study within 4 weeks prior to treatment start, major surgery within 14 days prior to treatment start, and uncontrolled cardiac atrial or ventricular arrhythmias. Patients with gastrointestinal tract disease resulting in an inability to take oral medication, known to be seropositive for HIV, HBV, or HCV, or uncontrolled cancer pain are also excluded from the trial.",
    "The sample is a phase 2 clinical trial for prostate cancer. The trial involves an escalating dose of Casodex, a drug used to treat prostate cancer, from 50mg daily to 150mg daily. The eligibility criteria for the trial include being a man over 18 years of age with histologically-confirmed prostate cancer, having a serum testosterone level of less than 50 ng/ml, and currently being treated with Zoladex (goserelin acetate) for more than 3 months prior to Day 1. In addition, the patient must have two consecutive rises in PSA above a nadir value, with the latest PSA value being greater than 2.0 ng/ml, and a highest PSA level no greater than or equal to 30 ng/ml. The patient must also have a life expectancy of greater than 1 year. Exclusion criteria include having received prolonged anti-androgen therapy other than with bicalutamide, having a PSA level greater than 30 ng/ml, and having evidence of severe or uncontrolled systemic disease. Patients who have received prior chemotherapy or have other co-existing malignancies or malignancies diagnosed within the last 5 years, with the exception of basal cell carcinoma or superficial transitional cell carcinoma of the bladder, are also excluded. The sample includes a list of icd-10 codes for the diseases being studied and the eligibility criteria for the trial.",
    "The sample is a phase 2 clinical trial for participants hospitalized with acute coronary syndrome (ACS) who are anticipated to undergo percutaneous coronary intervention (PCI) as a treatment for the ACS event within 24 hours of the clopidogrel/placebo loading dose. The trial involves the drugs prasugrel, clopidogrel, and placebo. The eligibility criteria include participants weighing at least 60 kilograms, providing a signed informed consent form, and testing negative for pregnancy. The exclusion criteria include having cardiogenic shock, refractory ventricular arrhythmias, NYHA Class IV congestive heart failure, and other medical conditions that may affect the outcome of the trial. The trial also excludes participants who have previously completed or withdrawn from this study or any other study investigating prasugrel, and those who are known to be pregnant, who have given birth within the past 90 days, or who are breastfeeding.",
    "The sample is a phase 2 clinical trial for patients with non-small cell lung cancer in stages IIIB or IV, or in relapse with advanced disease. The trial is testing the effectiveness of the drugs imatinib mesylate and paclitaxel. The eligibility criteria include having a histologic or cytologic diagnosis of non-small cell lung cancer, at least one site of measurable disease, and meeting certain laboratory values. Patients with brain metastasis, symptomatic neuropathy, prior chemotherapy for advanced non-small cell lung cancer, or other significant medical conditions are excluded. Patients must also avoid grapefruit juice or other grapefruit-containing products during treatment with imatinib.",
    "The sample is a record of a clinical trial with a phase 2 designation. The trial is focused on the treatment of hepatitis C virus. The record includes a list of diseases and their corresponding ICD-10 codes, a list of drugs being tested, and the eligibility criteria for participants. The inclusion criteria include being chronically infected with HCV genotype 1, having a certain level of HCV RNA, and having a BMI within a certain range. The exclusion criteria include liver transplant recipients, those with chronic hepatitis B virus, and those with a history of cancer within the past 5 years.",
    "The sample is a phase 2 clinical trial for Crohn's disease. The trial is testing the effectiveness of the drug nitazoxanide on patients with colonic or perianal involvement of Crohn's disease. The trial has specific inclusion and exclusion criteria, such as a CDAI score between 200 and 400, no evidence of bowel obstruction, and no recent use of certain medications. Patients with certain conditions, such as intestinal abscess or hypersensitivity to nitazoxanide, are excluded from the trial. The trial is not open to pregnant or breastfeeding women who are sexually active and not using birth control.",
    "The sample is a phase 2 clinical trial for lupus nephritis, a disease affecting the kidneys. The trial is testing the effectiveness of two drugs, cnto 136 and placebo, in treating the disease. The eligibility criteria for participants include a diagnosis of systemic lupus erythematosus (SLE) and biopsy-proven International Society of Nephrology/Renal Pathology Society Class III or IV lupus glomerulonephritis within approximately 14 months prior to randomization. Participants must also have persistently active nephritis, defined as proteinuria greater than 0.5g/day, and active Class III or Class IV lupus nephritis determined by recent biopsy or at least one of three criteria: hematuria, anti-DNA positivity, or low C3 or C4 complement levels. Participants must have stable immunosuppression and a stable dose of angiotensin-converting enzyme (ACE) inhibitor/angiotensin II receptor blocker (ARB) for at least 9 weeks prior to the first administration of study medication. Exclusion criteria include recent use of cyclophosphamide or B-cell depletion therapy, greater than 50 percent glomerular sclerosis on renal biopsy, and abnormal levels of serum creatinine, white blood cells, or platelets.",
    "The sample is a phase 2 clinical trial for patients with advanced or metastatic adenocarcinoma of the colon or rectum. The trial is testing the effectiveness of the drug epothilone d in patients who have failed one prior treatment with a fluoropyrimidine in combination with either irinotecan or oxaliplatin for advanced or metastatic disease. The eligibility criteria include various medical conditions such as age, performance status, life expectancy, hematopoietic, hepatic, renal, and cardiovascular conditions, as well as prior concurrent therapy. The trial is not open to patients who have CNS metastases, altered mental status or psychiatric conditions that would preclude giving informed consent, or other medical conditions that would preclude study participation.",
    "This is a sample from a table that contains information about clinical trials. The trial is in phase 2 and is focused on myelodysplastic syndromes. The table includes a list of icd-10 codes for the disease, a list of drugs being used in the trial (azacitidine, erythropoietin, and azacitidine monotherapy), and eligibility criteria for participants. The eligibility criteria include having less than 11% blasts in a bone marrow aspirate and biopsy, having conventional metaphase cytogenetics done within 90 days prior to registration for screening, and meeting certain transfusion and hemoglobin level requirements. There are also exclusion criteria, such as having a known history of intolerance to erythropoietic agents or having uncontrolled hypertension. Females of childbearing potential and males must be willing to use an effective method of contraception while on treatment and for a 4-week period thereafter.",
    "The sample is a phase 2 clinical trial for patients with prostate cancer who have documented PSA progression and a calculated PSA doubling time of less than 3 months while on complete androgen ablation therapy. The trial involves the use of the drug azacitidine for injectable suspension. Patients must meet specific eligibility criteria, including having a Karnofsky Performance Status greater than 70, being over 18 years of age, and meeting certain lab values. Patients must also agree to use an acceptable method of birth control if fertile. There are also exclusion criteria, such as having received prior chemotherapy or having a serious uncontrolled medical or psychiatric illness.",
    "The sample is a phase 2 clinical trial for patients with primary malignant glioma (brain cancer) who are either chemotherapy na\u00efve or non-na\u00efve and scheduled to receive Irinotecan/Bevacizumab chemotherapy. The trial has eligibility criteria that include age over 18, Karnofsky score over 60%, and normal lab values. Patients must also meet certain exclusion criteria, such as not having received certain anti-emetic drugs within 24 hours prior to the start of the chemotherapeutic agent. The trial will test the efficacy of palonosetron (aloxi) and dexamethasone as a treatment for nausea and vomiting associated with chemotherapy.",
    "The sample is a phase 2 clinical trial for patients with renal failure who have received a kidney transplant at least 6 months prior to enrollment. The trial is testing the effectiveness of the drugs LCP Tacro (Tacrolimus) and Prograf as part of the patients' maintenance immunosuppression therapy. Patients must have stable doses and trough levels of tacrolimus for at least two weeks prior to enrollment and must also be maintained on concurrent immunosuppression with mycophenolate mofetil or mycophenolic acid delayed-release tablets. Patients must have a serum creatinine level of less than 2.0mg/dL prior to enrollment and must be able to swallow study medication. Women of childbearing potential must have a negative serum pregnancy test within seven days prior to receiving study medication. Patients must also be able to understand the purposes and risks of the study, give written informed consent, and be willing to participate in and comply with the study. Exclusion criteria include patients who have received any transplanted organ other than a kidney, patients with a white blood cell count less than 2.8 x 10^9 /L, patients who are receiving a total dose of Prograf for 24 hours less than 3mg, pregnant or nursing women, patients with reproductive potential who are unwilling or unable to use a double barrier method of contraception, patients who have taken sirolimus within the past three months prior to screening, and patients with a known hypersensitivity to corticosteroids, mycophenolate mofetil, mycophenolic acid, or tacrolimus.",
    "The sample is a record of a clinical trial with a phase 2 designation. The trial is focused on treating myelodysplastic syndromes, blood disease, and bone marrow disease using the drugs vorinostat and vorinostat. The trial has specific eligibility criteria, including age, disease status, and performance status, and exclusion criteria, such as prior treatment with a histone deacetylase inhibitor and clinical evidence of Central Nervous System leukemia. The diseases are listed along with their corresponding ICD-10 codes.",
    "The sample is a phase 2 clinical trial for non-small-cell lung cancer. The trial involves the use of three drugs - pemetrexed, cisplatin, and carboplatin. The eligibility criteria for the trial include confirmation of NSCLC Stage IIIb or IV, no previous systemic chemotherapy for this cancer, at least one measurable lesion meeting Response Evaluation Criteria In Solid Tumors (RECIST) criteria, Eastern Cooperative Oncology Group (ECOG) Performance status of 0 or 1, and adequate organ function. Prior radiation therapy is allowed but limited to <25% of the patient's bone marrow. The exclusion criteria include serious concomitant systemic disorder or active infection, mild to moderate renal insufficiency, symptomatic central nervous system (CNS) metastases requiring concurrent corticosteroid therapy, and the presence of clinically significant third-space fluid collections.",
    "The sample is a phase 2 clinical trial for patients with metastatic prostate adenocarcinoma who have failed initial hormonal therapy and have disease progression after at least one chemotherapy regimen. The trial is testing the effectiveness of the drug docetaxel. The eligibility criteria include specific disease characteristics such as progressive PSA levels or measurable disease, as well as patient characteristics such as ECOG performance status and life expectancy. Prior concurrent therapy is also taken into consideration. The table includes columns for the phase of the trial, diseases being studied, icd-10 codes for those diseases, drugs being tested, and eligibility criteria.",
    "The sample is a phase 2 clinical trial for chronic hepatitis B. The trial includes patients who are 18 to 65 years old and have not been treated with anti-viral therapeutics for more than 12 weeks before screening. The trial also includes patients who have compensated chronic hepatitis B and are either HBeAg positive or negative with elevated serum ALT levels. The trial excludes patients who have co-infection with hepatitis C or D virus, decompensated liver disease, creatinine clearance less than 50 ml/min, and other significant systemic illnesses. The trial also excludes patients who have a history of organ transplantation, are currently abusing alcohol or illicit drugs, or are pregnant or breastfeeding. The trial requires patients to meet certain inclusion criteria and excludes patients who meet certain exclusion criteria.",
    "The sample is a phase 2 clinical trial for the treatment of soft tissue sarcoma using the drug sorafenib. The trial is open to patients who have confirmed soft tissue sarcoma of specific histologies and have evidence of unresectable residual disease, metastatic disease, or recurrent disease by radiography. Patients must also have measurable disease by x-ray, scans, or physical examination and archived paraffin-embedded tumor sections available. The trial is open to patients who are 18 years or older with a Zubrod performance status of 0-1 and a life expectancy that is not specified. Patients must also meet certain hematopoietic, hepatic, renal, cardiovascular, and other criteria. Prior concurrent therapy is allowed for adjuvant chemotherapy, but not for other therapies. Patients must not have had prior sorafenib or inhibitors of VEGFR or MAPK pathway, and must not be taking certain medications.",
    "The sample is a phase 2 clinical trial for the treatment of prostate cancer using the drug fulvestrant. The eligibility criteria include having histologically confirmed adenocarcinoma of the prostate, early recurrent disease, and no evidence of clinical recurrence. Patients must have undergone prior curative treatment and have a testosterone level above the lower limit of normal. Other eligibility criteria include age, performance status, life expectancy, hematopoietic, hepatic, renal, cardiovascular, and pulmonary conditions. Patients must not have a history of hypersensitivity to active or inactive excipients of fulvestrant or any other severe condition that would preclude study compliance or participation. Prior concurrent therapy is also specified.",
    "The sample is a phase 2 clinical trial for non-small-cell lung carcinoma. The trial includes participants with Stage IV disease who have measurable or nonmeasurable disease according to Response Evaluation Criteria In Solid Tumors (RECIST) Version 1.1 guidelines. The trial also includes participants with an Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) of 0 or 1, and who have adequate bone marrow reserve, and renal and hepatic function. The trial excludes participants who have squamous histology, leptomeningeal disease, or who have received chemotherapy for advanced (Stage IV) NSCLC. The trial also excludes participants who have a history of treatment with other agents targeting the Insulin-like or Epidermal Growth factor receptors, or who have undergone major surgery within 28 days prior to randomization.",
    "The sample is a phase 2 clinical trial for patients with esophageal cancer. The trial is testing the effectiveness of ppx with cisplatin and radiation as a treatment. The table includes information on the diseases being studied, the icd-10 codes associated with those diseases, the drugs being used, and the eligibility criteria for patients to participate in the trial. The eligibility criteria include requirements for age, health status, and previous treatments. The sample also includes exclusion criteria, such as active infections or other medical conditions that would prevent participation in the trial.",
    "The sample is a phase 2 clinical trial for patients with relapsed Non-Hodgkin's or Hodgkin's lymphoma who have previously undergone high dose chemotherapy or autologous stem cell transplantation. The trial requires patients to have a suitable bone marrow donor, be physically and psychologically capable of undergoing bone marrow transplantation, and meet certain health criteria such as having a certain level of pulmonary and renal function. The trial will test the effectiveness of a combination of drugs including pentostatin, cyclosporin, mycophenolate mofetil, and methotrexate. Patients who are HIV positive, have active infections, are pregnant or breastfeeding, or can be cured with other therapies are excluded from the trial.",
    "The sample is a phase 2 clinical trial for patients with metastatic colorectal cancer. The trial is testing the effectiveness of the drug capecitabine in patients who have had disease progression during prior fluoropyrimidine-containing therapy comprising irinotecan with or without oxaliplatin. Patients who completed one prior treatment for metastatic disease but refused standard second-line therapy are also eligible. The trial has eligibility criteria for both disease and patient characteristics, including measurable disease, ECOG performance status 0-2, and no serious intercurrent infections or medical problems. Prior concurrent therapy is allowed, but no more than two prior treatments for metastatic colorectal cancer. The trial does not allow concurrent investigational agents or highly active antiretroviral therapy for HIV-positive patients.",
    "The sample is a phase 2 clinical trial for patients with chronic lymphocytic leukemia. The trial is testing the effectiveness of two drugs, chlorambucil and r-etodolac + chlorambucil. The eligibility criteria for the trial include a diagnosis of B-cell CLL, evidence of active disease requiring treatment, and no prior chemotherapy for CLL. Patients must also meet certain health criteria, such as having a platelet count > 50,000/\u03bcL and a hemoglobin level > 8.0 g/dl. Exclusion criteria include a history of certain medical conditions, such as a second malignancy (with some exceptions), and treatment with any investigational agent within 4 weeks of study entry.",
    "The sample is a phase 2 clinical trial for patients with androgen-independent prostate cancer. The trial requires patients to have a history of rising PSA levels and measurable or evaluable disease. Patients must also meet certain patient characteristics, such as having an ECOG score of 0-2 and a life expectancy of at least 12 weeks. Prior concurrent therapy is also taken into consideration, with a required washout period for certain treatments. The trial allows for the use of bisphosphonates but prohibits concurrent radiotherapy for pain control or any other indication.",
    "The sample is a phase 2 clinical trial for the treatment of cognitive impairment and schizophrenia. The trial involves the use of the drugs eltoprazine and placebo. The eligibility criteria include being between 18-65 years old, meeting the DSM-IV-TR criteria for schizophrenia, having certain scores on cognitive tests, and being treated with specific antipsychotic medications for a certain period of time. Exclusion criteria include current treatment with certain antipsychotics, benzodiazepines, or anti-cholinergic drugs, recent substance abuse, significant medical conditions, and pregnancy or breastfeeding.",
    "The sample is a phase 2 clinical trial for age-related macular degeneration. The trial involves the use of two drugs, fluocinolone acetonide/medidur, and the eligibility criteria include being 50 years or older, having received intraocular injections of Lucentis for at least 6 months, and having reached a plateau in visual acuity or center subfield thickening. Exclusion criteria include pregnancy or lactation, glaucoma or ocular hypertension, recent ocular surgery or treatment with certain medications, and other medical conditions that may preclude study treatment or follow-up.",
    "The sample is a phase 2 clinical trial for HIV-1 infection. The trial is looking for adult male and female patients who are HIV-1 infected and have a body mass index between 18 to < 35 kg/m2. The patients must be antiretroviral treatment-na\u00efve, meaning they have not received any prior nonnucleoside reverse transcriptase inhibitor or CCR5 antagonist therapy, and no more than 10 days of any other prior antiretroviral therapy. The trial is looking for patients with HIV-1 CCR5-tropic-only virus, with a plasma HIV-1 RNA level of >/=1,000 copies/mL and a CD4 cell count of >/=250 cells/mm3. The trial has selected inclusion and exclusion criteria, which are listed in detail. The drugs being tested in the trial are cenicriviroc 100 mg, cenicriviroc 200 mg + truvada, and sustiva + truvada.",
    "This is a sample of a clinical trial for phase 2, focused on the disease multiple myeloma. The trial includes patients with confirmed Durie-Salomon stage II or III MM, or stage I MM patients with poor prognostic factors. Patients must have measurable disease and meet various eligibility criteria, including age, performance status, prior treatment, and certain lab values. Exclusion criteria include non-secretory MM, prior history of other malignancies, heart disease, pregnancy or lactation, HIV positivity, and hypersensitivity to certain drugs. The trial involves a combination of drugs including clarithromycin, lenalidomide, and dexamethasone.",
    "The sample is a phase 2 clinical trial for patients with multiple myeloma or non-Hodgkin's lymphoma who are in their first or second complete or partial remission. The trial is testing the effectiveness of the drug plerixafor. The eligibility criteria include being between the ages of 18-70, having a certain level of marrow and renal function, and meeting all eligibility requirements for autologous transplant. Exclusion criteria include having high-risk co-morbidities, previous treatment with high dose chemotherapy and autologous transplant, and previous attempt to collect B-hematopoietic progenitor cells following mobilization with growth factors alone, growth factors and chemotherapy, or plerixafor and growth factors. The trial is not open to pregnant women and those who do not agree to use contraception.",
    "The sample is a phase 2 clinical trial for dry eye syndrome. The trial is looking at the effectiveness of chitosan-n-acetylcysteine eye drops compared to a placebo. The eligibility criteria for participants include being over 18 years old, having a history of dry eye syndrome for at least 3 months, and meeting at least two of the following criteria: Tear Break Up Time (BUT) < 10 seconds, Schirmer I test < 7 mm, or at least 2 symptoms of dry eye syndrome. Participants must also have normal ophthalmic findings except for dry eye syndrome and ametropia < 6 Dpt. Exclusion criteria include recent participation in a clinical trial, presence of a severe medical condition, and use of certain medications. Participants must not have severe dry eye, wear contact lenses, or have certain eye conditions. They must also not have had recent ocular surgery or have certain medical conditions. Finally, participants must not be pregnant, planning to become pregnant, or lactating.",
    "The sample is a phase 2 clinical trial for metastatic breast cancer patients. The trial involves the use of two drugs, gemcitabine and paclitaxel. The eligibility criteria for the trial include having a confirmed diagnosis of breast cancer, having received anthracycline chemotherapy, having at least one measurable region, having an Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-1, and having adequate organ function. Exclusion criteria include having interstitial pneumonia or pulmonary fibrosis, inflammatory breast cancer, brain metastases with symptoms, recent chemotherapy or radiotherapy, recent hormonal/immunotherapy, recent surgery, and severe complications such as cardiac infarction, infection, drug hypersensitivity, or diabetes.",
    "The sample is a phase 2 clinical trial for the treatment of human immunodeficiency virus (HIV) infection. The trial includes male and female participants between the ages of 2 and 18, with different cohorts for different age ranges. The eligibility criteria include a negative pregnancy test for females of childbearing potential, and the use of contraception during the study. Participants must also have a screening plasma HIV-1 RNA level of at least 400 copies/mL and meet certain antiretroviral therapy criteria. Exclusion criteria include prior use of certain medications, serious medical conditions, and history of drug allergies. The trial involves the use of two drugs, lexiva and ritonavir, and the eligibility criteria and exclusion criteria are designed to ensure the safety and efficacy of the treatment.",
    "The sample is a phase 2 clinical trial for patients with chronic myeloproliferative disorders and secondary myelofibrosis. The trial is testing the effectiveness of the drug azacitidine. Patients must have histologically confirmed myelofibrosis with myeloid metaplasia and meet certain disease and patient characteristics, such as having anemia or symptomatic palpable splenomegaly. They must also meet certain eligibility criteria, such as having a negative pregnancy test and not being incarcerated. Patients cannot have had certain prior concurrent therapies within the past 14 days. The table includes information on the diseases, icd-10 codes, drugs, eligibility criteria, and patient characteristics for the trial.",
    "The sample is a phase 2 clinical trial for patients with non-small cell lung cancer. The trial is testing the effectiveness of two drugs, gemcitabine hcl and pemetrexed disodium, in treating the disease. The eligibility criteria for the trial include having confirmed NSCLC, having at least one measurable lesion, and meeting certain medical requirements such as having a certain level of blood counts and liver function. Patients must also not have any other serious medical conditions or illnesses that would prevent them from participating in the trial. Prior to the trial, patients cannot have received certain treatments such as radiation therapy involving more than 25% of the bone marrow or systemic chemotherapy for advanced NSCLC. Concurrent enrollment in a clinical trial is also required.",
    "The sample is a record of a clinical trial with a phase 2 designation. The trial is focused on chronic kidney disease and diabetic nephropathy. The trial includes a list of ICD-10 codes for the diseases being studied. The trial involves three groups of drugs: a low dose group, a high dose group, and a placebo group, all of which include a drug called atrasentan. The eligibility criteria for the trial are listed, including requirements for patient history, medication use, and various health measurements. The exclusion criteria are also listed, including restrictions on certain medications and medical conditions.",
    "The sample is a phase 2 clinical trial for patients with nasopharyngeal carcinoma, a type of cancer affecting the nasopharynx. The trial requires patients to have newly diagnosed locally advanced cancer requiring radiotherapy, with evidence of measurable disease and no systemic metastatic disease. Patients must also meet certain eligibility criteria, such as being between 18-65 years old, having a certain level of white blood cells and platelets, and having a certain level of kidney function. Patients who have had previous radiotherapy, chemotherapy, or surgery for NPC, or who have certain medical or psychological conditions, are excluded from the trial. The trial involves the use of the drug cetuximab and requires patients to provide signed written informed consent.",
    "The sample is a phase 2 clinical trial for prostate cancer. The eligibility criteria include having an ECOG performance status of 0 or 1, a life expectancy of more than 10 years, and a minimum PSA of 1 ng/ml if not on androgen deprivation therapy. Patients must also have one of the following criteria to be eligible: PSA recurrence with a doubling time of less than 9 months, prostatic biopsy Gleason Grade of >/= 8, or clinical stage of >/= T3. Prior radiation therapy of any type is allowable, as well as prior androgen deprivation therapy up to a total duration of 36 months. Patients must have no evidence of metastatic diseases on the bone scan and an abdominal/pelvic CT or MRI performed within 30 days of study enrollment. The exclusion criteria include patients with small cell histology, clinical, radiological, or pathological evidence of bone, lymph node or visceral metastasis, castration-resistant prostate cancer, prior chemotherapy, severe or uncontrolled intercurrent infection, and contraindications to corticosteroids.",
    "The sample is a phase 2 clinical trial for advanced or metastatic malignant cancer of solid tumor origin that has not responded to standard therapy or for which no standard therapy is available. The trial involves the use of moxifloxacin and diphenhydramine as drugs. The eligibility criteria include having adequate liver, kidney, blood, and blood clotting functions, being at least 18 years old, having a performance status of 0 to 2, and being able to provide informed written consent and comply with protocol schedules and testing. Exclusion criteria include having ongoing side effects from prior anticancer therapy, having brain or leptomeningeal metastases, having a history of uncontrolled or severe cardiac disease, and being pregnant or lactating.",
    "The sample is a phase 2 clinical trial for Alzheimer's disease. The trial is looking for male and female participants between the ages of 55 and 85 who have been diagnosed with probable Alzheimer's disease based on NIA-AA criteria with MMSE scores of 20 or greater. The trial requires participants to be willing and able to take part in up to six study visits over a 5-month period, with the support of a caregiver as needed. The trial is testing the effectiveness of the drug MSDC-0160 compared to a placebo. The eligibility criteria include exclusion of participants with diabetes, significant neurological/psychiatric disease other than AD, history of heart failure, previous cardiovascular event, inability to undergo a clinical MRI of the brain without contrast, and other medical or psychiatric conditions that may make the subject unlikely to complete the study. The trial also excludes participants with a history of alcohol or drug abuse within 6 months of screening, and those who have participated in an investigational study or received an investigational drug within 30 days or 5 half-lives prior to study drug administration.",
    "The sample is a phase 2 clinical trial for patients with type 2 diabetes who have been on NPH treatment for at least 3 months. The trial is testing the effectiveness of insulin NPH and ex1000 in combination with oral antidiabetic drugs. The inclusion criteria include having type 2 diabetes for at least 12 months, a BMI less than or equal to 40 kg/m2, HbA1c less than or equal to 9.5%, and FPG less than or equal to 12 mmol/L. The exclusion criteria include treatment with certain medications, known allergies to trial products, and any other condition that may interfere with trial participation or evaluation of results.",
    "The sample is a phase 2 clinical trial for osteoarthritis of the knee. The trial includes patients who are at least 35 years old and have been diagnosed with unilateral or bilateral OA of the knee for at least 6 months prior to screening. The trial excludes patients with certain medical conditions, such as Reiter's syndrome, rheumatoid arthritis, and psoriatic arthritis, as well as those who have had certain treatments, such as IA corticosteroid or hyaluronic acid injections in the index knee within a certain timeframe. Patients must also be willing to comply with study procedures and visit schedules, and follow verbal and written instructions. Women of child-bearing potential must use effective contraception or not be pregnant or nursing.",
    "The sample is a phase 2 clinical trial for patients with primary central nervous system lymphoma. The trial is testing the effectiveness of a combination of drugs including rituximab, methotrexate, and cytarabine. The eligibility criteria for the trial include being an adult between the ages of 18-80 with a histological diagnosis of B-cell proliferation verified by positive staining for CD20 and at least one measurable lesion. Exclusion criteria include prior chemotherapy, other than corticosteroids, within 6 weeks before and after diagnosis or surgery, history of prior cranial irradiation, evidence of plurisystemic non-Hodgkin's lymphoma, other active malignant disease, and uncontrolled active infection.",
    "The sample is a phase 2 clinical trial for patients with type 2 diabetes and obesity. The trial involves two drugs, placebo and incb013739. The eligibility criteria include having an established diagnosis of type 2 diabetes, being postmenopausal for at least 1 year (for females), and not having hypertriglyceridemia or a BMI over 40 kg/m2. Patients cannot have received certain medications within the 3 months prior to screening and cannot be currently enrolled in another investigational protocol. The diseases are listed as \"diabetes mellitus, type 2\" and \"obesity\" and their corresponding ICD-10 codes are provided.",
    "The sample is a phase 2 clinical trial for patients with locally advanced or metastatic pancreatic cancer. The trial involves the use of drugs such as gemcitabine, placebo, erlotinib, and apricoxib. The eligibility criteria for the trial include having a confirmed diagnosis of adenocarcinoma of the pancreas, measurable disease by RECIST, and a life expectancy of at least 3 months. Exclusion criteria include previous chemotherapy as primary treatment for locally advanced or metastatic pancreatic cancer, evidence of New York Heart Association class III or greater cardiac disease, and symptomatic central nervous system metastases.",
    "The sample is a phase 2 clinical trial for liver transplantation. The trial is testing the drug fk778. The eligibility criteria include being between 18 and 65 years old, having a negative pregnancy test (for females of childbearing potential), and being a recipient of a primary whole cadaveric liver transplant. Exclusion criteria include having received an organ transplant other than a liver, having a current or previous malignancy (except for non-metastatic basal or squamous cell carcinoma of the skin), and having certain medical conditions or taking certain medications.",
    "The sample is a record from a clinical trial table that includes information about the phase of the trial, the disease being studied (in this case, pancreatic cancer), the corresponding ICD-10 codes, the drug being tested (rubitecan), and the eligibility criteria for participants. The eligibility criteria include age, cancer stage, previous treatment history, recovery time, estimated life expectancy, performance status, and adequate organ function. The exclusion criteria include active infections, serious systemic disorders, scheduled surgery, pregnancy or nursing, inability to consistently consume fluids, and recent participation in another clinical trial.",
    "The sample is a phase 2 clinical trial for patients with metastatic prostate cancer that has become resistant to androgen therapy. The trial is testing the effectiveness of the drugs celecoxib and doxorubicin hydrochloride in treating the cancer. The eligibility criteria include a diagnosis of androgen-independent prostate cancer with osteoblastic metastases, no predominant visceral metastases, and progressive disease after response to prior induction chemotherapy. Patients must also have adequate physiologic reserves and no more than 3 prior cytotoxic treatments. The trial excludes patients who have had prior radionuclide therapy or have taken celecoxib or rofecoxib within the past 6 months.",
    "The sample is a phase 2 clinical trial for chronic lymphocytic leukemia (CLL) and lymphocytic leukemia. The trial includes patients who have not received prior treatment for CLL and those who have relapsed after previous treatment. The eligibility criteria include a diagnosis of CLL, active disease, and indication for treatment based on specific guidelines. Patients must also have a minimum of one disease-related symptom and an Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-2. Exclusion criteria include refractory CLL, previous stem cell transplantation, and active autoimmune hemolytic anemia or idiopathic thrombocytopenic purpura requiring corticosteroid therapy. The trial also excludes patients with other past or current malignancies, significant cardiac or cerebrovascular disease, and positive serology for Hepatitis B. Patients must be willing to use adequate contraception during the study period.",
    "The sample is a phase 2 clinical trial for the treatment of various liver and bile duct cancers, including cholangiocarcinoma, hepatobiliary neoplasm, liver cancer, bile duct cancer, and cancer of the gallbladder. The trial involves the use of several drugs, including gemcitabine, cisplatin, carboplatin, capecitabine, and 5fu. The eligibility criteria for the trial include a diagnosis of cholangiocarcinoma, liver tumors not exceeding 8 cm in greatest axial dimension, and unresectable tumors above the cystic duct. Patients must also have adequate liver and renal function, as well as a life expectancy of more than 6 months. Exclusion criteria include prior radiotherapy to the upper abdomen, prior chemotherapy, and any evidence of severe or uncontrolled systemic diseases or laboratory findings that make it undesirable for the patient to participate in the trial.",
    "This sample is for a phase 2 clinical trial for postmenopausal osteoporosis. The trial includes the drugs alendronate, denosumab, and a placebo. The eligibility criteria include being a postmenopausal woman between 50 and 70 years old, having low bone mineral density, and meeting specific criteria. The exclusion criteria include not currently receiving any medication that affects bone metabolism or having an underlying condition that affects the ability to take alendronate or receive denosumab. The icd-10 codes associated with the disease are also provided.",
    "The sample is a record of a clinical trial that is in phase 2/phase 3 and is focused on the disease multiple myeloma. The trial involves the drugs tanespimycin and bortezomib. The eligibility criteria for participants include having a good performance status, histologic evidence of multiple myeloma, having had at least three prior treatment regimens for multiple myeloma that included both bortezomib and lenalidomide, no prior treatment with a heat shock 90 inhibitor or an investigational proteasome inhibitor, no known infections of HAV, HBV, HCV, or HIV, and no chemotherapy, radiation therapy, or immune therapy for three weeks prior to enrollment. The icd-10 codes associated with the disease are also included in the record.",
    "This sample is for a phase 2 trial that focuses on treating dementia and paratonia. The trial involves the use of botulinum toxin and saline as drugs. The eligibility criteria for the trial include severe cognitive impairment, a diagnosis of Alzheimer's disease, vascular dementia, or frontotemporal dementia, and a score of more than 3 on the paratonic assessment instrument. The exclusion criteria include alternate etiologies for increased tone and the use of botulinum toxin within the last 6 months.",
    "The sample is a phase 2 clinical trial for subjects with chronic obstructive pulmonary disease (COPD). The trial is testing the drug GW685698/GW642444. The eligibility criteria include being a male subject or a female subject of non-childbearing potential between the ages of 40-80, having a clinical history of COPD, and having a current or previous history of at least 10 pack-years of cigarette smoking. The severity of the disease must conform to the current severity classification for Stage II/III disease in terms of post-bronchodilator spirometry at Screening Visit 1. The exclusion criteria include pregnancy, asthma, \u03b11-antitrypsin deficiency, other respiratory disorders, lung resection, poorly controlled COPD, lower respiratory tract infection, abnormal and clinically significant 12-lead ECG, other diseases/abnormalities, positive Hepatitis B surface antigen or positive Hepatitis C antibody, clinically significant hypertension that is uncontrolled, carcinoma that has not been in complete remission for at least 5 years, history of hypersensitivity to any of the study medications or components of the inhalation powder, history of drug or other allergy, history of alcohol or drug abuse within the last 2 years, inability to withhold rescue medication for the 6-hour period required prior to spirometry testing at each study visit, treatment with long-term oxygen therapy (LTOT) or nocturnal oxygen therapy required for greater than 12 hours a day, participation in the acute phase of a Pulmonary Rehabilitation Programme within 4 weeks prior to Screening or who will enter the acute phase of a Pulmonary Rehabilitation Programme during the study, risk of non-compliance, history of psychiatric disease, intellectual deficiency, poor motivation or other conditions that will limit the validity of informed consent to participate in the study, prior use of study medication/other investigational drugs, clinically significant sleep apnea that is uncontrolled, and affiliation with investigator site.",
    "The sample is a phase 2 clinical trial for liver transplantation. The trial involves testing the effectiveness of different drug combinations, including mmf and tacrolimus, and sotrastaurin and tacrolimus, along with standard care medications. The trial is looking for eligible participants who are 18 years or older, have received a primary de novo orthotopic liver transplant from a deceased donor, and are HCV-negative. There are also exclusion criteria, such as prior organ/cellular transplant, MELD-score > 35, and HCC > Milan criteria. Other protocol-defined inclusion/exclusion criteria may also apply. The trial is testing the safety and efficacy of these drug combinations in liver transplant recipients.",
    "The sample is a record of a clinical trial in phase 2, focused on the disease of hypertension. The icd-10 codes associated with the disease are listed, along with the drugs being tested, which include pf-00489791 and a placebo. The eligibility criteria for the trial are also listed, including age and medical history requirements for inclusion and exclusion.",
    "The sample is a record of a clinical trial with a phase 2/phase 3 designation. The trial is focused on amyotrophic lateral sclerosis, which is identified in the \"diseases\" field. The icd-10 codes associated with the disease are listed in the \"icdcodes\" field. The trial involves the use of three drugs: memantine (ebixa), riluzole, and placebo, which are listed in the \"drugs\" field. The eligibility criteria for the trial are listed in the \"criteria\" field, including inclusion criteria such as definite or probable disease, normal blood tests, and EMG in accordance with El Escorial criteria, and exclusion criteria such as other diseases, both ADM muscles < 3 on MRC scale, and disease duration > 3 years.",
    "The sample is a phase 2 clinical trial for the treatment of hepatocellular carcinoma using the drug darinaparsin. The trial includes patients who are at least 18 years old, have a life expectancy of at least 12 weeks, and have a diagnosis of HCC supported by liver mass(es) at least 2cm in the longest diameter and AFP equal to or more than 500 ng/mL in cirrhosis or chronic HBV or HCV infection. Patients must also have at least one uni-dimensional measurable lesion by CT-scan or MRI according to Response Evaluation Criteria in Solid Tumors (RECIST). The trial has inclusion and exclusion criteria, which are listed in detail. Patients who give written informed consent prior to any study specific screening procedures with the understanding that the patient has the right to withdraw from the study at any time, without prejudice.",
    "The sample is a phase 2 clinical trial for patients with confirmed rectal cancer who are subject to surgery and would benefit from pre-operative combined chemo-radiotherapy. The trial involves the use of drugs such as bevacizumab, capecitabine, 5-fluorouracil, and leucovorin. The eligibility criteria include being an adult patient over 18 years of age, having measurable and/or evaluable lesions according to RECIST criteria, and having an EOCG performance status of 0-1. Exclusion criteria include prior radiotherapy or chemotherapy for rectal cancer, untreated brain metastases or spinal cord compression or primary brain tumors, chronic daily treatment with high-dose aspirin or other medications known to predispose to gastrointestinal ulceration, and co-existing malignancies or malignancies diagnosed within the last 5 years, with the exception of basal and squamous cell cancer or cervical cancer in situ.",
    "The sample is a record of a clinical trial in phase 2 for the treatment of non-small cell lung cancer. The trial involves the use of drugs such as gemcitabine, docetaxel, cisplatin, and etoposide. The eligibility criteria for the trial include having histologic or cytologic proof of a single primary non-small cell lung cancer, no prior chemotherapy or radiation therapy, and no prior malignancy. The exclusion criteria include pregnancy or breastfeeding, serious concomitant systemic disorder, and unintentional weight loss greater than 10%.",
    "The sample is a record of a clinical trial in phase 2 for the treatment of urinary bladder neoplasms. The trial involves the drug tamoxifen and includes a list of eligibility criteria for patients to participate in the trial. Inclusion criteria include having previously received 1-2 systemic therapy regimens, having the cancer spread to other parts of the body, and having adequate liver function. Exclusion criteria include uncontrolled nervous system metastasis, pregnancy, recent systemic therapies, planned major surgery, Grade III/IV heart problems, severe and/or uncontrolled medical disease, and high risk for deep vein thrombosis. The sample also includes a list of icd-10 codes associated with the disease.",
    "The sample is a phase 2 clinical trial for patients with relapsing or refractory marginal zone B-cell lymphoma. The trial includes patients who have previously undergone at least one systemic treatment, and have no evidence of histologic transformation to aggressive lymphoma. The trial requires patients to have measurable or evaluable disease, be over 18 years old, have a life expectancy of at least 3 months, and have an ECOG performance status of 0-1. Patients must not have had a prior diagnosis of neoplasm within 5 years, except for cervical type 1 intraepithelial neoplasia or localized non-melanomatous skin cancer. They must also not have had chemo- or radiotherapy in the last 6 weeks, no prior immunotherapy in the last 8 weeks, and no corticosteroids during the last 4 weeks unless low-dose prednisone chronically administered for indications other than lymphoma or lymphoma-related symptoms. Patients must not have major impairment of bone marrow function, renal function, or liver function unless due to lymphoma, and must not have evidence of active opportunistic infections, HIV infection, HBV infection, or active HCV infection. Women of childbearing potential must use effective contraception, not be breastfeeding, not be pregnant, and agree not to become pregnant during participation in the trial and during the 12 months thereafter. Men must agree not to father a child during participation in the trial and during the 12 months thereafter. Patients must not have serious cardiac, neurological, or psychiatric disorders potentially hampering compliance with the study protocol and follow-up schedule. Fasting serum cholesterol must be \u2264 200 mg/dL or \u2264 5 mmol/L AND fasting triglycerides must be \u2264 200 mg/dL. Patients who exceed these thresholds can only be included after initiation of appropriate lipid-lowering medication. The trial requires written informed consent. Exclusion criteria include patients with newly diagnosed MZL, concomitant or past hematological malignancies, presence or history of CNS lymphoma localization, cardiovascular disease, serious underlying medical condition, concurrent anticancer drugs/treatments and experimental drugs, previous organ transplantation, participation in another clinical trial within 30 days prior to trial entry, and pregnant or lactating women.",
    "The sample is a phase 2 clinical trial for patients with metastatic or unresectable gastric or esophageal adenocarcinoma. The trial involves the use of docetaxel, cisplatin, fluorouracil, bevacizumab, and leucovorin. The eligibility criteria include having no prior chemotherapy for metastatic or unresectable disease, being 18 years or older, having a Karnofsky performance status of 70% or higher, and meeting certain hematologic, hepatic, and kidney function requirements. Exclusion criteria include having received previous chemotherapy for the treatment of metastatic or unresectable gastric, GEJ, or esophageal adenocarcinoma, having received previous bevacizumab, docetaxel, or cisplatin, and having a history of another neoplastic disease within the past three years. The trial also has specific inclusion and exclusion criteria related to various medical conditions and procedures.",
    "The sample is a phase 2 clinical trial for the treatment of relapsed follicular B-cell lymphoma. The trial involves the use of two drugs, sargramostim (leukine) and rituximab. The eligibility criteria for the trial include having had one or more previous therapies for non-Hodgkin's lymphoma, having at least one measurable tumor by CT scan or MRI, and meeting additional criteria to be determined at the screening visit. The exclusion criteria include being rituximab refractory, currently receiving treatment for another cancer, having an infection currently being treated, having active Hepatitis B, having a history of HIV infection, being pregnant, and meeting additional criteria to be determined at the screening visit. The diseases being studied are limited to lymphoma, follicular, and the icd-10 codes associated with this disease are provided.",
    "The sample is a phase 2 clinical trial for patients with histologically confirmed GIST who have shown resistance to imatinib therapy. The trial is testing the effectiveness of the drug ptk787/zk222584. The eligibility criteria include having measurable tumor lesions, being 18 years or older, having a WHO performance status of 2 or less, and meeting certain blood count and serum level requirements. Exclusion criteria include recent chemotherapy or radiotherapy, major surgery, and certain medical conditions. Patients must also provide written informed consent and comply with the protocol.",
    "The sample is a phase 2 clinical trial for patients with follicular lymphoma, a low grade, B cell lymphoma. The trial is testing the effectiveness of a combination of three drugs - rituximab, fludarabine, and mitoxantrone - for patients who have failed at least one previous chemotherapy treatment. The eligibility criteria include age between 18 and 75 years, confirmed diagnosis of follicular lymphoma, availability of frozen biopsy material for central pathology review, CD20 positivity, at least one measurable lesion, WHO performance status grade 0 or 1, and bulky disease according to Groupe d'Etude des Lymphomes Folliculaires criteria. Exclusion criteria include evidence of histological transformation to diffuse large B-cell lymphoma, more than two prior treatment regimens, recent chemotherapy or radiation therapy, autologous stem cell transplant, and various medical conditions. Patients must provide informed consent to participate in the trial.",
    "The sample is a phase 2 clinical trial for patients with recurrent or refractory adult glioblastoma or gliosarcoma. The trial involves the use of two drugs, irinotecan hydrochloride and temozolomide. The eligibility criteria include confirmation of tumor progression or regrowth, radiographic evidence of tumor progression within the past 14 days, and a Karnofsky performance status of 70-100%. Patients must also meet various medical criteria, such as having no acute intratumoral hemorrhage on MRI and having a systolic blood pressure of less than or equal to 160 mm Hg. The trial excludes patients with certain medical conditions, such as recent myocardial infarction or ischemia, serious or nonhealing wounds, and AIDS. Patients must also not be pregnant or nursing and must use effective contraception during and for at least 6 months after completion of bevacizumab therapy.",
    "The sample is a phase 2 clinical trial for the treatment of follicular lymphoma using the drug combination of rituximab and bendamustine. The trial is open to patients who are at least 60 years old and have not been previously treated for the disease. Patients must also have an intermediate or high risk FLIPI score and meet certain eligibility criteria, including having a confirmed diagnosis of follicular lymphoma, adequate hematological and renal function, and a performance status of 2 or less on the ECOG scale. Exclusion criteria include having other types of lymphoma, grade 3b follicular lymphoma, and CNS disease. Patients must have previously signed a written informed consent to participate in the trial.",
    "The sample is a phase 2 clinical trial for rheumatoid arthritis. The trial includes patients between the ages of 18 and 65 who have been diagnosed with active RA for at least 3 months but less than 2 years, and have not responded well to treatment with MTX. The trial involves the use of diacerein and placebo drugs. The eligibility criteria include having a certain level of RA global functional status, a minimum tender and swollen joint count, and a certain level of ESR. Patients must also agree to comply with the study protocol and not drink alcohol during the study. Exclusion criteria include having other active inflammatory arthritis, uncontrolled medical conditions, and certain infections or treatments within a certain timeframe.",
    "The sample is a phase 2/phase 3 clinical trial for patients with neuroendocrine tumors, including carcinoid tumors, islet cell tumors, and poorly differentiated NETs. The trial is testing the effectiveness of a combination of drugs, including 5-fluorouracil, leucovorin, and oxaliplatin. The eligibility criteria include having confirmed neuroendocrine tumors, measurable disease, and no history of brain or leptomeningeal disease. Patients must also meet certain age, performance status, and health criteria, such as having normal blood counts and liver and kidney function. Prior treatments, such as chemotherapy and radiotherapy, are allowed under certain conditions. The trial is not open to patients with certain types of tumors or those with significant comorbidities.",
    "The sample is a phase 2 clinical trial for the treatment of asthma caused by rhinovirus. The trial includes male and female subjects aged 18-70 years with asthma consistent with Global Initiative for Asthma (GINA) steps 1 to 3 and presumptive human rhinovirus infection. The trial involves the drugs bta798 and placebo. The eligibility criteria include exclusion of subjects with severe asthma exacerbation, severe asthma (GINA steps 4 or higher), uncontrolled or clinically significant medical condition, disease or event which could impact subject safety and/or study evaluations and/or compliance to the protocol, and current smoker, ex-smoker of <1 year, or history of smoking >/=10 pack years.",
    "The sample is a phase 2 clinical trial for patients with chronic hepatitis C. The trial is testing the effectiveness of drugs such as taribavirin and ribavirin. The eligibility criteria for patients include being at least 18 years old, having a diagnosis of compensated chronic HCV genotype 1 infection that has not been treated with interferon, peginterferon, ribavirin or any experimental therapy for more than 28 days, and meeting a number of other medical criteria such as having a platelet count of at least 90,000/mm3 and a serum creatinine level of less than 1.5 mg/dL. Patients who have certain medical conditions or who have participated in other clinical trials may be excluded from the study.",
    "The sample is a phase 2 clinical trial for chronic myeloid leukemia. The trial involves the use of reduced intensity conditioning, busulfan, and fludarabine as drugs. The eligibility criteria include being under 30 years old, having adequate organ function, and being in the first or second chronic or accelerated phase of the disease. Women who are pregnant are not eligible for the trial. The exclusion criteria include being in blast crisis or the third or greater chronic or accelerated phase of the disease. The sample also includes a detailed list of inclusion and exclusion criteria for the trial.",
    "The sample is a phase 2 clinical trial for the treatment of follicular NHL, grades 1 or 2, using bevacizumab and rituximab. The trial is open to patients who are 18 years or older and have evidence of disease progression. Patients must have had at least one previous chemotherapy regimen and not more than two. Measurable or evaluable disease is required, and patients must be able to perform daily activities without considerable assistance. Adequate bone marrow, kidney, and liver function are also required. The eligibility criteria include additional requirements, and the study center will determine if patients meet all of the criteria. The trial has exclusion criteria, and patients who do not qualify will be informed of the reasons.",
    "The sample is a phase 2 clinical trial for breast cancer patients who have locally advanced or metastatic disease that cannot be treated with surgery or radiotherapy with curative intent. The trial is testing the effectiveness of the drug edotecarin. Patients must have at least one measurable lesion that is at least 20mm by conventional techniques or 10mm by CT scan and not previously irradiated. They must also meet certain criteria, including having been previously treated with anthracycline and concurrent or sequential taxane therapy and being refractory to the most recent taxane-based chemotherapy. Patients must not have known brain metastases or carcinomatous meningitis and no spinal cord compression. They must also meet certain patient characteristics, such as being female, having an ECOG performance status of 0-1, and meeting certain hematopoietic, hepatic, renal, cardiovascular, pulmonary, gastrointestinal, and other criteria. Patients must not have any concurrent approved or investigational anticancer treatment and must not be enrolled in another clinical trial.",
    "The sample is a record of a clinical trial that is in phase 2/phase 3. The trial is focused on patients with diabetes, myocardial infarction, and cardiovascular disease. The trial is testing the effectiveness of natural source vitamin E at a dosage of 400IU/day. The eligibility criteria for the trial includes diabetic patients aged 55 and above, while the exclusion criteria includes patients who take antioxidant treatment, patients who had a CVD incident (MI, Stroke, TIA), Unstable angina pectoris, Uncontrolled HTN, and those who are allergic to Vitamin E. The icd-10 codes for the diseases are also included in the record.",
    "The sample is a phase 2 trial for patients with urothelium cells transition cancer that has spread locally or metastasized. The trial is testing the effectiveness of the drug vinflunine. The eligibility criteria include being between the ages of 18 and 80, having written informed consent, having a measurable target lesion, and having an ECOG score of 0 or 1. Patients must have had stabilization or objective response after first-line treatment with cisplatin and gemcitabine, and the last administration of these drugs must have been less than 6 weeks prior. Patients must also have maximum grade I toxicity and adequate functions of bone marrow, kidney, and liver. Exclusion criteria include having an ECOG score greater than 2, being over the age of 80, having small cell carcinoma histology, lymphomas, or sarcomas of the bladder, and having received 7 or more cycles of cisplatin and gemcitabine in first-line metastatic disease. Other exclusion criteria include pregnancy or lactation, brain metastases or meningeal involvement, peripheral neuropathy grade 2, prior radiation to more than 30% of the bone marrow, and other serious diseases or medical conditions. Patients must not have received more than one line of treatment for metastatic disease and must not have received cisplatin in monotherapy or in combination as neoadjuvant treatment or adjuvant after initial surgery of urothelial cancer. Patients must not have been treated with another investigational drug or treatment antineoplastic agent cisplatin or gemcitabine than within 30 days before randomization. Other exclusion criteria include other cancers except basal skin cancer treated in an appropriate, cervical cancer in situ or other tumor a disease-free interval of 5 years, inadequate renal function, known hypersensitivity to drug study or similar chemical structure drugs, and patients who require treatment with ketoconazole, itraconazole, ritonavir, amprenavir, indinavir, rifampin or phenytoin (any potent inhibitor or inducer of CYP3A4). Any concurrent chronic immunotherapy or prior organic allograft is also an exclusion criterion.",
    "The sample is a phase 2 clinical trial for patients with metastatic adenocarcinoma of the prostate, recurrent prostate cancer, or stage IV prostate cancer. The trial is testing the drug ixabepilone. The eligibility criteria include confirmation of the disease, evidence of disease progression, and failed prior hormonal therapy. Patients must also meet certain medical criteria, such as having a granulocyte count of at least 1,500/mm^3 and no serious medical illness or active infection. The trial excludes patients with certain medical conditions, such as myocardial infarction within the past 6 months or peripheral neuropathy greater than grade 1. Fertile patients must use effective contraception.",
    "The sample is a phase 2 clinical trial for individuals with both alcohol and cocaine dependence. The trial is testing the effectiveness of the drugs vigabatrin and placebo. The eligibility criteria include being 18 years or older, meeting DSM-IV criteria for current diagnoses of cocaine and alcohol dependence, having used cocaine in the past 30 days and no less than $200 of cocaine in a consecutive 30 day period over the 90 day period prior to intake, and meeting certain drinking criteria. Exclusion criteria include dependence on any substance other than cocaine and alcohol, significant hematological, pulmonary, endocrine, cardiovascular, renal or gastrointestinal disease, and use of an investigational medication in the 30 days prior to randomization. Females who test positive on a pregnancy test, are contemplating pregnancy in the next 6 months, are nursing, or are not using an effective contraceptive method are also excluded.",
    "The sample is a phase 2 clinical trial for the treatment of myelofibrosis, a disease affecting the bone marrow. The trial is testing the drug obatoclax mesylate (gx15-070ms). The eligibility criteria for the trial include having histologically confirmed myelofibrosis with myeloid metaplasia, no limitations on prior therapy, normal organ function, willingness to submit to blood sampling, and ability to understand and sign a written informed consent form. Exclusion criteria include prior exposure to obatoclax, use of other agents or therapies for malignancy, uncontrolled intercurrent illness, and pregnancy or breastfeeding.",
    "The sample is a record of a clinical trial with a phase 2 designation. The trial is focused on treating myeloid leukemia using the drugs filgrastim and pegfilgrastim. The eligibility criteria for the trial include having histologically confirmed de novo AML, a life expectancy of more than 3 months with treatment, being over 18 years old, having an ECOG performance status of 0, 1, or 2, and having adequate organ function to receive protocol specified chemotherapy. The exclusion criteria include patients in blast transformation of chronic myeloid leukemia, patients with secondary AML, previous treatment for AML, patients with AML FAB type M3 or M7, and high-risk cytogenetics. The icd-10 codes associated with the disease are also listed.",
    "The sample is a phase 2 clinical trial for patients with renal clear cell carcinoma (RCC) that is unresectable and/or metastatic. The trial involves the use of gemcitabine, capecitabine, and sorafenib for 6 cycles. The eligibility criteria include patients with median or low risk according to Motzer's scoring, ECOG \u2264 1, and adequate hematological, hepatic, renal, medullar, and coagulation function. Patients must also have a life expectancy of at least 12 weeks and be able to follow the study's requirements. Exclusion criteria include patients with less common RCC subtypes, previous treatment with chemotherapy or immunotherapy, and arterial uncontrolled hypertension. Patients must also not have any contraindications or allergies to the study's investigational product and must not be pregnant or breastfeeding.",
    "The sample is a phase 2 clinical trial for patients with acute lymphoblastic leukemia (ALL) who have either relapsed after successful prior induction therapy or are refractory to a standard induction regimen. The trial involves the use of two drugs, clofarabine and cytarabine. The eligibility criteria include having evidence of ALL in bone marrow or peripheral blood, no CNS involvement, and meeting certain patient characteristics such as Zubrod performance status and negative HIV status. Prior concurrent therapy is also taken into consideration, with certain treatments being allowed or disallowed based on specific criteria. The sample includes detailed disease and patient characteristics, as well as prior and concurrent therapy requirements.",
    "The sample is a phase 2 clinical trial for patients with metastatic breast cancer who have received taxane-based chemotherapy resulting in PR or CR and have measurable disease at the start of taxane therapy. The trial involves the drug SU11248 and has a set of inclusion and exclusion criteria. Inclusion criteria include performance status 0 to 1 on the ECOG scale, age over 18 years, and adequate organ function. Exclusion criteria include concurrent hormone therapy, ongoing cardiac dysrhythmias of NCI CTCAE grade \u22652, and pregnancy or breastfeeding. Patients must give written informed consent before registration in the trial.",
    "The sample is a phase 2 clinical trial for patients with inoperable stage III or IV melanoma that began on acral skin or mucosa. The trial is testing the effectiveness of the drug imatinib mesylate. The eligibility criteria include having sufficient tumor tissue available for testing, measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST) criteria, and no known untreated brain or epidural metastases. Patients must also meet certain health requirements, such as having a certain white blood cell count and platelet count, and not having any concurrent uncontrolled illnesses. Prior therapies with certain drugs are not allowed, and patients must not be taking certain medications during the trial.",
    "The sample is a record from a clinical trial table. It is a phase 2 trial for the treatment of ulcerative colitis. The record includes the list of diseases and their corresponding ICD-10 codes, the list of drugs being tested, and the eligibility criteria for the trial. The inclusion criteria include a diagnosis of ulcerative colitis for at least 6 months, disease extending at least 15 cm proximally from the anal verge, flare occurring on 5-aminosalicylic acid (5-ASA)/mesalamine therapy, age between 18 and 70 years, and willingness to provide written informed consent. The exclusion criteria include prior terminal ileum or colonic surgery, presence of indeterminate colitis, microscopic colitis, ischemic colitis, infectious colitis, or clinical findings suggestive of Crohn's disease, clinical signs of fulminant colitis or toxic megacolon, history of dysplasia associated lesion or mass (DALM), surgery for ulcerative colitis, history of primary sclerosing cholangitis, any physical or laboratory abnormality deemed clinically significant, major surgery within 60 days of screening, use of any investigational agent within 30 days of screening, or any therapeutic protein or antibody within 90 days of screening.",
    "The sample is a phase 2 clinical trial for breast cancer. The trial involves the use of a combination of drugs, including adriamycin and cyclophosphamide followed by paclitaxel. The eligibility criteria for the trial include having adenocarcinoma breast cancer, an ECOG performance status of 0 or 1, and a peripheral neuropathy less than or equal to 1. Other criteria include having discontinued hormonal therapy as a chemoprevention while on study, having an LVEF by MUGA greater than 55%, and meeting certain blood count and liver function requirements. Exclusion criteria include having stage IV breast cancer, any current chemotherapy, radiation therapy, immunotherapy, or biotherapy for breast cancer, being pregnant or lactating, having an active second malignancy, and having certain allergies or medical conditions.",
    "The sample is a phase 2 clinical trial for patients with malignant glioma, glioblastoma, or gliosarcoma. The trial involves the use of drugs such as bevacizumab, temozolomide, and topotecan. The eligibility criteria include a confirmed diagnosis of WHO grade IV primary malignant glioma, age over 18, no prior radiotherapy or chemotherapy for a brain tumor, and a Karnofsky score of at least 60%. Exclusion criteria include pregnancy or breastfeeding, co-medication that may interfere with study results, and evidence of bleeding diathesis or coagulopathy. The trial also has Avastin-specific exclusion criteria, such as inadequately controlled hypertension and history of myocardial infarction or unstable angina within 6 months prior to study enrollment.",
    "The sample is a phase 2 clinical trial for patients with stage IIa or IIIa multiple myeloma who have had 1-4 prior lines of therapy and progressive disease. The trial is testing the drug romidepsin. The eligibility criteria include various medical requirements such as bilirubin levels, creatinine levels, and platelet counts, as well as performance status and life expectancy. Patients must also agree to use contraception and sign informed consent. Exclusion criteria include prior treatment with a histone deacetylase inhibitor, ongoing infections, and certain medical conditions such as congestive heart failure. Patients who are pregnant or HIV positive are also excluded.",
    "The sample is a phase 2 clinical trial for patients with neuropathy and AIDS. The trial is testing the effectiveness of the drugs dimiracetam and a sugar pill in treating neuropathic pain caused by ARTs. The eligibility criteria include being between the ages of 18-65, having a CD4+ cell count > 200/L, and experiencing neuropathic pain caused by ARTs. Patients must also have a pain intensity of at least 40 mm on the VAS at screening and have a life expectancy of at least 6 months. Exclusion criteria include being pregnant or lactating, having neuropathic pain due to other factors, and having a history of psychosis or major depression. Patients must provide written informed consent prior to inclusion in the study.",
    "The sample is a phase 2 clinical trial for patients with non-small cell lung cancer. The trial is testing the effectiveness of a combination of drugs, including carboplatin and paclitaxel, in treating the disease. The eligibility criteria for patients include having confirmed NSCLC, measurable or nonmeasurable disease, and meeting certain staging criteria. Patients must also meet certain patient characteristics, such as having an ECOG performance status of 0-1 and no serious nonhealing wounds or ongoing infections. Prior to participating in the trial, patients must have recovered from prior therapy and not have received prior systemic chemotherapy for metastatic NSCLC. The trial also has certain exclusion criteria, such as no concurrent therapeutic anticoagulation or chronic treatment with certain medications.",
    "The sample is a phase 2 clinical trial for patients with recurrent mantle cell lymphoma. The trial is testing the effectiveness of the drug temsirolimus. Patients must meet certain eligibility criteria, including having confirmed mantle cell lymphoma, measurable disease, and no central nervous system involvement. They must also have a performance status of Eastern Cooperative Oncology Group (ECOG) 0-2 and meet certain laboratory values. Patients cannot have any other concurrent treatment for mantle cell lymphoma or other active malignancy requiring treatment. Prior biologic response modifiers, immunotherapy, and high-dose therapy with stem cell support are allowed, but not concurrent prophylactic growth factor to support neutrophils or concurrent corticosteroids to induce an antitumor response. Prior chemotherapy and radiotherapy are allowed, but not prior treatment with a mammalian target of rapamycin (mTOR) inhibitor. Patients cannot be receiving any other concurrent investigational or commercial agents or therapies for mantle cell lymphoma, nor can they be receiving any other concurrent immunosuppressive therapy.",
    "The sample is a phase 2 clinical trial for the treatment of geographic atrophy, a condition caused by age-related macular degeneration. The trial involves the use of two drugs, fcfd4514s and sham. The eligibility criteria for the trial include having a well-demarcated area of geographic atrophy without choroidal neovascularization, and not having a history of certain surgical interventions or treatments. Patients with certain medical conditions or a history of malignancy within the past 5 years are excluded from the trial. The sample also includes a list of icd-10 codes associated with the disease.",
    "The sample is a phase 2 clinical trial for patients with Ewing's sarcoma or primitive neuroectodermal tumor (PNET) that has recurred or not responded to prior therapy. The trial involves the drug cytarabine and requires patients to have at least one site of measurable disease involving lung or soft tissue. Patients must also meet certain eligibility criteria related to their disease and general health, such as having a Karnofsky performance status of 50-100% and a life expectancy of at least 8 weeks. Prior concurrent therapy is also taken into consideration. The trial does not allow for concurrent investigational agents, including chemotherapy, immunotherapy, or biologic therapy, but concurrent corticosteroids are allowed. Concurrent radiotherapy to localized painful lesions is allowed as long as at least one measurable lesion is not irradiated.",
    "The sample is a phase 2 clinical trial for asthma and airway inflammation. The trial involves testing the effectiveness of various drugs, including mometasone furoate/formoterol and a placebo. The eligibility criteria for participants include having a documented asthma diagnosis, persistent allergic asthma with an FEV1 >65% predicted, and being allergic to at least one common allergen. Participants must also discontinue certain prescribed medications and be transferred to treatment with SABA for relief for 2 weeks before the Baseline/Randomization Visit. The trial has exclusion criteria, including recent use of systemic glucocorticosteroids and a clinical asthma exacerbation. Participants must be willing to give written informed consent and adhere to dose and visit schedules.",
    "The sample is a phase 2 clinical trial for patients with squamous cell cancer of the head and neck that has recurred or is a second primary. The majority of the tumor volume must have been in areas previously irradiated to at least 45 Gy, and patients must be at least 6 months from prior radiation therapy. Patients must meet certain eligibility criteria, including having a Karnofsky Performance Status of 60-100 and meeting certain blood test requirements. Patients who have had previous treatment with cetuximab or have distant metastases or completely resected recurrence with negative margins are excluded. Patients must sign a study-specific informed consent form prior to study entry.",
    "The sample is a phase 2 clinical trial for breast cancer. The trial is looking at the effectiveness of 5-fluorouracil, capecitabine, cyclophosphamide, docetaxel, and epirubicin as treatments for breast cancer. The eligibility criteria for the trial includes females with a unilateral, non-inflammatory, non-multicentric, non-metastatic breast adenocarcinoma, not considered candidates for conservative management, and whose diagnosis had been histologically confirmed as T2-3, N0-1, M0 according to the tumor-nodes-metastasis (TNM) classification. The trial also requires that the patient has a clinically or radiologically measurable lesion (in 2 dimensions) and an Eastern Cooperative Oncology Group (ECOG) performance Status less than equal to (<=) 1. The exclusion criteria includes females presenting with brain metastases or a neurological or psychiatric disorder which could interfere with proper treatment compliance, previous radiotherapy, chemotherapy, or hormonal therapy for breast cancer, previous history of a malignancy in last 5 years other than cutaneous basal cell carcinoma or carcinoma in situ of the uterine cervix, serious concomitant infection, and pregnant or lactating females.",
    "The sample is a phase 2 clinical trial for breast cancer patients with single or multiple bone metastasis as the only metastatic site. The trial involves the drugs rad001 and placebo, and the eligibility criteria include having a confirmed diagnosis of invasive adenocarcinoma of the breast, being postmenopausal hormone receptor positive, having received an aromatase inhibitor in any previous breast cancer therapy, and having measurable or non-measurable target lesions according to the WHO criteria. The trial also has exclusion criteria, such as known hypersensitivity reaction to the compounds or incorporated substances, concurrent immunotherapy or hormone replacement therapy, and need for chemotherapy or irradiation of bone metastasis during study treatment.",
    "The sample is a phase 2 clinical trial for patients with metastatic colorectal cancer who have not responded to at least two standard chemotherapy/biologic regimens. The drug being tested is called lbh589. The eligibility criteria include having measurable metastatic colorectal cancer, an ECOG Performance Status of \u2264 2, and meeting certain laboratory values. Patients must also have a life expectancy of greater than 12 weeks. Exclusion criteria include prior use of certain inhibitors or valproic acid for cancer treatment, impaired cardiac function, uncontrolled hypertension, and other severe medical conditions. Women of childbearing potential must have a negative pregnancy test and use two methods of contraception during the study and for 3 months after the last study drug administration. Patients must not have received chemotherapy, any investigational drug, or undergone major surgery < 4 weeks prior to starting study drug or have not recovered from side effects of such therapy.",
    "The sample is a phase 2 clinical trial for the treatment of hepatocellular carcinoma. The trial includes patients with a confirmed diagnosis of hepatocellular carcinoma, who are not on the liver transplantation schedule and have not received prior therapy with sorafenib for more than two weeks. The trial involves the use of two drugs, bevacizumab and erlotinib. The eligibility criteria include measurable or evaluable disease, adequate organ functions, and a life expectancy of more than three months. The exclusion criteria include surgically resectable disease, active bacterial infections, brain metastases, and pregnancy or lactation. The trial requires patients to comply with therapy and follow-up procedures and to sign informed consent.",
    "The sample is a phase 2 clinical trial that focuses on patients with arterial obstructive diseases and coronary disease. The trial involves the drug \"sch 530348\" and has a set of eligibility criteria for participants, including being 45 years or older, mentally competent to provide informed consent, and scheduled to undergo a percutaneous coronary intervention or heart catheterization. There are also exclusion criteria, such as pregnancy, recent stroke, and ongoing chest pain. The trial aims to investigate the safety and efficacy of the drug in treating these conditions.",
    "The sample is a phase 2 clinical trial for patients between 18 to 80 years of age who are scheduled to undergo major upper or lower abdominal surgery under general anesthesia. The trial is testing the effectiveness of oral sufentanil versus placebo in managing post-operative pain. The eligibility criteria include being classified as American Society of Anesthesiologists (ASA) class I-III, having a BMI between 18 and 39, and using an effective method of birth control for female patients of childbearing potential. Exclusion criteria include having previously not responded to opioid analgesics, having an allergy or hypersensitivity to opioids, and having a history of drug, prescription medicine, or alcohol abuse within the past 2 years. The trial is approved by the Institutional Review Board (IRB).",
    "The sample is a phase 2 clinical trial for patients with metastatic renal cell carcinoma. The trial involves the use of two drugs, Panzem\u00ae NCD and sunitinib malate. Patients must have previously received or be currently receiving sunitinib malate with evidence of disease progression while receiving it. The eligibility criteria include having measurable disease, normal organ and marrow function, and adequate cardiac function. Patients must also have a life expectancy of greater than 3 months and an ECOG performance status of 0-2. Exclusion criteria include active brain metastases, gastrointestinal abnormalities, and uncontrolled intercurrent illness. Women of child-bearing potential and men must agree to use adequate contraception prior to study entry.",
    "The sample is a phase 2 clinical trial for patients with low grade CD20+ B cell non-Hodgkin lymphoma who have relapsed after chemotherapy or are chemotherapy resistant and have one or more sites of disease measuring more than 5 cm. The trial is testing the effectiveness of two drugs, bexxar (tositumomab) and potassium iodide (ki). The eligibility criteria include being at least 19 years old, having a expected survival of at least 6 months, and meeting certain medical requirements such as having a platelet count of at least 100,000/mm\u00b3 and a Hct > 30%. The trial also has exclusion criteria such as having a history of failed stem cell collection or presence of central nervous system (CNS) lymphoma.",
    "The sample is a phase 2 clinical trial for the treatment of metastatic androgen-independent prostate cancer using the drug perifosine. The eligibility criteria include having confirmed adenocarcinoma of the prostate, documented disease progression, and meeting certain medical requirements such as having no brain metastases and having a certain level of blood counts and organ function. Patients must also have a life expectancy of more than 3 months and be able to take oral medication. The trial excludes patients with certain medical conditions or who have had prior treatments within a certain timeframe.",
    "The sample is a phase 2 clinical trial for the treatment of xerostomia and Sj\u00f6gren's syndrome. The table includes information on the diseases, icd-10 codes, drugs, and eligibility criteria for the trial. The inclusion criteria include patients aged 21 to 55 years with a diagnosis of primary or secondary Sj\u00f6gren's syndrome and a complaint of dry mouth. Females of childbearing potential must not be at risk for pregnancy during the study. The exclusion criteria include patients with clinically significant reduction kidney function, cardiovascular abnormalities, lymphoma secondary to Sj\u00f6gren's syndrome, pulmonary disease, and other conditions. Patients who have received any experimental drugs or devices or participated in any clinical trial within 30 days prior to screening are also excluded.",
    "The sample is a phase 2 clinical trial for multiple sclerosis. The trial includes patients with relapsing form of MS, with a screening EDSS score of 0-5.5, who have had at least one clinical relapse in the 12 months before screening and meet certain MRI activity criteria. Patients who have failed prior treatment with beta-interferons or glatiramer acetate are also included. The trial excludes patients with signs of silent infections, known allergy to gadolinium-DTPA or the study drug formulation, and those who have received pre-treatment with immunosuppressive or immunomodulatory drugs within certain time frames. The trial will test the efficacy of cdp323 and placebo.",
    "The sample is a phase 2 clinical trial for the treatment of unresectable stage III or stage IV melanoma using the drug STA-9090. The eligibility criteria include having confirmed melanoma, having sufficient tumor available for testing, meeting certain medical requirements such as normal blood counts and liver function, and not having certain medical conditions or taking certain medications. Participants must also be willing to comply with study procedures and sign a consent form. The trial is looking to enroll individuals who have not received chemotherapy or radiation therapy within a certain timeframe and have not previously been treated with a hsp90 inhibitor.",
    "The sample is a phase 2 clinical trial for patients with metastatic transitional cell carcinoma of the urothelium (bladder, renal pelvis, ureter, or urethra) who have had disease progression or recurrence after one prior systemic chemotherapy regimen that included cisplatin or carboplatin. The trial is testing the drug depsipeptide. The eligibility criteria include specific disease characteristics, such as measurable disease and no brain metastases, as well as patient characteristics, such as a Zubrod performance status of 0-2 and certain laboratory values within normal limits. Prior concurrent therapy is also specified, including no concurrent immunotherapy or hormonal therapy.",
    "The sample is a phase 2 trial for essential hypertension. The trial includes a list of ICD-10 codes for the disease and a list of drugs, including act-280778, placebo, and amlodipine. The eligibility criteria for the trial include being between the ages of 18 and 75, having a BMI between 18 and 35 kg/m2, and having a body weight of at least 50 kg. Other criteria include having a normal 12-lead ECG and normal test results for clinical chemistry, hematology, coagulation, virus serology, and urinalysis. Exclusion criteria include having a mean SBP > 180 mmHg, severe or malignant hypertension, and a history of fainting or collapse. The sample also includes exclusion criteria related to coronary artery disease and angina pectoris.",
    "The sample is a phase 2 clinical trial for the treatment of Major Depressive Disorder in children and adolescents aged 7 to 17 years old. The trial is testing the drug duloxetine. The inclusion criteria require patients to have a Children's Depression Rating Scale-Revised (CDRS-R) score of 40 or higher and a Clinical Global Impressions of Severity (CGI-Severity) rating of 4 or higher at three different visits. Female patients must also test negative for pregnancy at the first visit. Exclusion criteria include having a serious or unstable medical illness, psychological condition, or hypersensitivity to duloxetine, as well as having a current or previous diagnosis of certain mental health disorders. Patients who have attempted suicide within the past year or are at risk of suicide are also excluded. Additionally, patients must weigh at least 20 kg and cannot have had previous exposure to duloxetine. Female patients who are pregnant, nursing, or have recently given birth are also excluded.",
    "The sample is a phase 2 trial for the treatment of various lung diseases, including idiopathic pulmonary fibrosis, pulmonary fibrosis, fibrosis, and interstitial lung disease. The trial involves the use of a drug called cc-930. The eligibility criteria for the trial include being male or female over the age of 50 with a documented diagnosis of IPF based on current ATS/ERS guidelines. Exclusion criteria include various lung function measurements, use of certain medications, and smoking. The trial is investigating the efficacy of cc-930 in treating these lung diseases.",
    "The sample is a phase 2 clinical trial for chronic obstructive pulmonary disease (COPD). The trial includes male and female subjects between the ages of 40 and 80 who have been diagnosed with moderate to severe COPD for at least 6 months and meet the criteria for Stage II-III disease. The subjects must have had stable disease for at least 1 month prior to screening and have a smoking history of at least 10 pack-years, either as current smokers or ex-smokers who quit more than 6 months ago. The trial involves the drugs ph-797804 and placebo. The eligibility criteria include exclusion criteria such as a history or presence of significant cardiovascular disease, ECG abnormalities, significant concomitant clinical disease, evidence of organ or blood disorders, and more than 2 exacerbations of COPD requiring treatment with oral steroids in the preceding year or hospitalization for the treatment of COPD within 3 months of screening or more than twice during the preceding year.",
    "The sample is a phase 2 clinical trial for age-related macular degeneration. The trial includes a list of icd-10 codes for the disease and a list of drugs, including a vehicle placebo. The eligibility criteria for the trial include having a clinical diagnosis of GA in one or both eyes, being of non-childbearing potential, and not having GA secondary to any condition other than AMD in the study eye. Exclusion criteria include having a BCVA of 20/200 or worse in the non-study eye, a history of or current choroidal neovascularization in either eye, and the need for any study eye anti-angiogenic therapy. Additionally, participants cannot have any ocular condition in the study eye that would progress during the course of the study and could affect central vision or other ocular conditions that may be a confounding factor in this study. They also cannot need to wear contact lenses in the study eye during the study, have had confounding ocular surgery in the study eye, or have concomitant treatment with any systemic or ocular medication that is known to be toxic to the lens, retina, or optic nerve.",
    "The sample is a record of a clinical trial that is in phase 2/phase 3. The trial is focused on the treatment of post-herpetic neuralgia, a type of nerve pain that occurs after a shingles infection. The trial is testing the effectiveness of a drug called Lamictal in treating this condition. The eligibility criteria for the trial include being over the age of 18, having a diagnosis of post-herpetic neuralgia, and having a minimum score of 4 on the Likert Pain Scale. Patients who are currently taking certain medications or have certain medical conditions are excluded from the trial. The sample includes a list of diseases, ICD-10 codes, drugs, and eligibility criteria for the trial.",
    "The sample is a phase 2 clinical trial for patients diagnosed with type 2 diabetes mellitus. The trial involves the use of the drug exenatide (ly2148568) and a placebo. The eligibility criteria include having a body weight of at least 50 kg and not having received treatment within the last 30 days with a drug that has not received regulatory approval for any indication at the time of study entry. Exclusion criteria include having participated in this study previously or any other study using exenatide or other GLP-1 analogs, being treated with any exogenous insulin within 3 months of screening, and having severe allergy or hypersensitivity to any drug.",
    "The sample is a record of a clinical trial with a phase 2 designation. The trial is focused on the disease glioblastoma multiforme, and the icd-10 codes associated with it are listed as L51.0, L51.8, and L51.9. The drug being tested is everolimus. The eligibility criteria for the trial are listed, including age, confirmed diagnosis of GBM, radiographic evidence of disease progression, and a Karnofsky Performance Status of greater than or equal to 60%. There are also exclusion criteria listed, such as prior treatment with an mTOR inhibitor, history of another malignancy within 3 years, and the presence of a cardiac pacemaker or ferromagnetic metal implants.",
    "The sample is a phase 2 clinical trial for Huntington's disease, chorea, and executive dysfunction. The trial involves administering either 20mg daily citalopram or a placebo to participants who meet certain eligibility criteria. These criteria include being gene positive for HD or having an HD diagnosis, being between the ages of 18 and 75, having mild stage HD, and experiencing mild executive dysfunction. Participants must also be able to complete all study assessments and provide written informed consent. Exclusion criteria include being under 18 or over 75, having current major depression or suicidal ideation, having unstable or severe psychiatric disease, and current use of certain medications. Participants who are unable to receive an MRI scan may still participate in the study.",
    "The sample is a phase 2 clinical trial for the treatment of osteoarthritis of the knee. The trial involves the use of two drugs, pennsaid gel and vehicle. The eligibility criteria for the trial include having primary osteoarthritis of the knee with radiologic evidence, being on stable pain therapy with an oral or topical NSAID or acetaminophen, experiencing a \"moderate flare\" of pain following washout of stable pain therapy, being able to read and understand English or Spanish to answer pain assessment questions without any explanation, being surgically sterile or non-pregnant if female, being in reasonably good general health except for OA, and providing written informed consent. The exclusion criteria include having secondary OA of the study knee, a history of pseudo gout or inflammatory flare-ups, severe, uncontrolled cardiac, renal, hepatic, or other systemic disease, any malignancy within the previous 3 years, known sensitivity to the use of oral or topical diclofenac, aspirin or any other NSAID, DMSO, or ethanol, ongoing abnormality that could confound interpretation of the safety results, documented gastroduodenal ulcer or any GI bleeding within the last 6 months, uncontrolled diabetes, screening laboratory test results of serum creatinine \u2265 1.5 times upper limit of normal, AST, ALT, or GGT \u2265 3 times upper limit of normal, and hemoglobin less than or equal to lower limit of normal, documented alcohol or drug abuse within 1 year, breast-feeding if female, major surgery or previous damage to the study knee at any time, or minor knee surgery to the study knee within 1 year, requires oral or intra-muscular corticosteroids, or received an intra articular corticosteroid injection into the study knee within the past 90 days, or into any other joint within the past 30 days, or currently applying topical corticosteroids onto the study knee, received intra-articular viscosupplementation in the study knee in the past 6 months, on prior stable therapy with an opioid analgesic prior to the screening visit, recently started taking a sedative hypnotic medication for insomnia, taking anti-depressants, not willing to discontinue prohibited medications/therapies, cannot tolerate acetaminophen, re-entering study after dropping out or withdrawn from study, used another investigational drug within the previous 30 days, on or currently applying for disability benefits on the basis of knee OA, history of fibromyalgia, other painful or disabling conditions affecting the knee or leg, or disabling condition of the hands used to apply the study drug, skin disorder with current involvement on the hands or the knee(s) (application site), referred to an orthopedic surgeon for consideration of, or been advised to have, knee replacement or knee reconstruction surgery, radiologic evidence of OA of the knee advanced to the point that all cartilage has been eroded, recently started using a cane within the past 30 days, and history of chronic headaches that may require more than occasional use of rescue medication for headaches.",
    "The sample is a phase 2/phase 3 clinical trial that involves patients with various heart-related diseases such as atrial fibrillation, atrial flutter, venous thromboembolic disease, myocardial infarction, and cardiomyopathy. The trial aims to test the effectiveness of two drugs, ati-5923 and coumadin (warfarin), in preventing blood clots. The eligibility criteria for the trial include having one or more of the listed heart-related conditions, being over 18 years old, and being willing to comply with the study requirements. Exclusion criteria include having certain medical conditions or taking certain medications that may interfere with the study, having a life expectancy of less than one year, and being pregnant or nursing.",
    "The sample is a phase 2 clinical trial for liver cancer patients who have been newly diagnosed or have recurrent hepatocellular carcinoma. The trial includes patients with locally advanced or metastatic disease, with a CLIP score of at least 3, who are not candidates for surgical resection or liver transplant, or loco-regional therapy. Patients with fibrolamellar HCC or clinically apparent central nervous system metastases or carcinomatous meningitis are excluded. The trial also has specific patient eligibility criteria, including a life expectancy of at least 8 weeks, a Karnofsky performance status of 60-100%, and certain laboratory values within normal limits. Prior concurrent therapies are allowed, but no concurrent chemotherapy, radiotherapy, or immunotherapy. The drug being tested in this trial is octreotide acetate.",
    "The sample is a phase 2 clinical trial for advanced breast cancer patients with measurable disease. The trial is testing the effectiveness of the drug combination trastuzumab and letrozole. Eligibility criteria include confirmation of breast cancer, prior treatment with a nonsteroidal aromatase inhibitor, HER-2 amplification, and no clinical symptoms or history of CNS or leptomeningeal metastases. Patients must also meet certain age, sex, menopausal status, performance status, and medical condition requirements. Prior concurrent therapy is allowed for neoadjuvant or adjuvant chemotherapy, but not for palliative chemotherapy. No other concurrent anticancer or investigational drugs are allowed.",
    "The sample is a phase 2 clinical trial for the treatment of glaucoma. The trial includes patients who are 18 years or older and have been diagnosed with open angle glaucoma or ocular hypertension and are currently being treated with ocular hypotensive medication. The trial requires patients to have unmedicated (post-washout) IOP \u2265 22 mm Hg at 2 eligibility visits, 2-7 days apart. Patients must also have corrected visual acuity in each eye +1.0 logMAR or better by ETDRS in each eye (equivalent to 20/200). The trial includes a list of exclusion criteria such as a history of angle closure, intraocular pressure > 36 mm Hg, known hypersensitivity to any component of the formulation, previous glaucoma intraocular surgery or glaucoma laser procedures in study eye(s), and clinically significant ocular disease. The trial also includes exclusion criteria related to systemic diseases and medication use. Women of childbearing potential who are pregnant, nursing, planning a pregnancy, or not using a medically acceptable form of birth control are also excluded from the trial.",
    "The sample is a record from a clinical trial table that includes information about the trial's phase, diseases being studied, icd-10 codes of those diseases, drugs being used, and eligibility criteria for participants. In this particular sample, the trial is in phase 2/phase 3 and is studying chronic lymphocytic leukemia. The icd-10 codes associated with this disease are listed as \"C91.11\", \"C91.12\", and \"C91.10\". The drugs being used in the trial are bendamustine and fludarabine. The eligibility criteria for participants are listed under \"Inclusion Criteria\" and \"Exclusion Criteria\".",
    "The sample is a record of a clinical trial with a phase 2 designation. The trial is focused on treating prostate cancer that is hormone refractory and has metastasized or recurred locally and cannot be cured with standard therapy. The trial drug being tested is sunitinib (su011248). The record includes a list of diseases and their corresponding icd-10 codes, as well as eligibility criteria for patients to participate in the trial. The inclusion criteria include having a histological or cytological diagnosis of adenocarcinoma of the prostate, an ECOG performance status of 0, 1 or 2, and having had prior single agent docetaxel or docetaxel combination chemotherapy with a documented PSA or imaging response, and no objective evidence of disease progression at study enrolment. The exclusion criteria include having a history of other invasive cancer, except adequately treated non-melanoma skin cancer, known brain metastases, history of allergic reactions attributed to compounds of similar chemical or biologic composition to SU011248, and other serious intercurrent illness or medical condition that might be aggravated by protocol treatment.",
    "The sample is a phase 2 clinical trial for Parkinson's disease. The trial includes patients who meet certain eligibility criteria, such as having moderately disabling dyskinesia and an mAIMS score at baseline of at least 7 with a score of at least 3 in at least one body area. Patients who have had surgical treatment for Parkinson's disease within the last year or planned during the study, have unstable co-existing psychiatric disease or cognitive impairment, have a significant medical condition that may affect their safety or participation in the study, or are pregnant or breastfeeding are excluded from the trial. The trial involves the drugs adx48621 and placebo, and other protocol-defined inclusion and exclusion criteria may apply.",
    "The sample is a phase 2 clinical trial for the treatment of renal cell carcinoma. The trial is looking at the effectiveness of the drug tivozanib in patients with unresectable locally recurrent or metastatic RCC. The eligibility criteria include being at least 18 years old, having undergone prior nephrectomy, having measurable disease per RECIST criteria Version 1.1, and having an Eastern Cooperative Oncology Group performance status of 0 or 1, among other criteria. Exclusion criteria include any prior therapy with an agent targeting the VEGF pathway, any primary CNS malignancies or CNS metastases, and any significant cardiovascular disease. The trial is also looking at the safety of the drug and has a number of exclusion criteria related to bleeding disorders, thromboembolic or vascular disorders, and other medical conditions. The trial is open to both male and female subjects, but sexually active pre-menopausal female subjects (and female partners of male subjects) must use adequate contraceptive measures while on the study and for 30 days after the last dose of study drug.",
    "The sample is a clinical trial in phase 2 for the treatment of adenocarcinoma of the prostate and prostate cancer. The trial involves the drugs celecoxib and placebo. The eligibility criteria for the trial include having a histopathologically or cytologically proven adenocarcinoma of the prostate and planned prostatectomy, being at least 18 years old, having a performance status (ECOG) of 2 or less, having a hemoglobin level of greater than 10 g/dL within the past 4 weeks, having a creatinine level of less than or equal to 1.5 mg/dL, and having signed informed patient consent. Exclusion criteria include having received other preoperative or prior treatment directed at prostate cancer, having significant active medical illness that would preclude protocol treatment, using non-steroidal anti-inflammatory agents within 7 days of celecoxib treatment, having hypersensitivity to celecoxib, having a history of asthma, urticaria, or anaphylaxis precipitated by an NSAID, having a history of significant upper gastrointestinal bleeding or active peptic ulcer disease, currently being treated with anticoagulants, or having an allergy to sulfonamide. The icd-10 codes for the diseases being treated are also included in the table.",
    "The sample is a phase 2 clinical trial for non-squamous non-small cell lung cancer. The trial includes the use of standard chemotherapy and bevacizumab (avastin) as drugs. The eligibility criteria for the trial include meeting the inclusion/exclusion criteria of MO19390, while the exclusion criteria include not meeting the inclusion/exclusion criteria of MO19390.",
    "The sample is a phase 2 clinical trial for non-Hodgkin's lymphoma. The trial involves the use of two drugs, rituxan and 1018 iss. The eligibility criteria for the trial include being 18 years or older, having CD20+ B-cell follicular non-Hodgkin's lymphoma, having received at least one previous chemotherapy regimen for lymphoma, and meeting certain blood count and performance status requirements. Women and men of childbearing potential must be willing to use highly effective methods of birth control for the duration of the study. Exclusion criteria include pregnancy or lactation, recent treatment with chemotherapy or radiation therapy, and certain medical conditions or medications. The trial aims to assess the safety and efficacy of the drugs in treating non-Hodgkin's lymphoma.",
    "The sample is a phase 2 clinical trial for patients with recurrent or refractory small cell lung cancer who have previously received first-line chemotherapy. The trial is testing the drug SNS-595. The eligibility criteria include measurable disease, an ECOG Performance Status score of 0, 1, or 2, and normal laboratory values. Patients must not have been previously exposed to SNS-595, be pregnant or breastfeeding, or have other active malignancies. Other exclusion criteria include recent myocardial infarction or cerebrovascular accident/transient ischemic attack, thromboembolic events, and kidney dialysis. Prior chemotherapy, investigational agents, or radiation therapy are not allowed within 28 days before Cycle 1 Day 0. Patients with toxicities caused by prior cancer therapy must have returned to less than or equal to Grade 1, with the exception of alopecia. Prior pelvic radiation therapy or radiation to greater than 25% of bone marrow reserve is not allowed. Any other medical, psychological, or social condition that would contraindicate the patient's participation in the clinical trial due to safety or compliance with study procedures is also an exclusion criterion.",
    "The sample is a phase 2 clinical trial that focuses on patients with venous thromboembolism and hypercholesterolemia. The trial aims to investigate the effectiveness of atorvastatin in reducing LDL cholesterol levels in patients who have received at least 6 months of oral anticoagulant treatment and are planning to withdraw from it. The trial has inclusion and exclusion criteria, which are listed in the \"criteria\" field. The inclusion criteria include being an adult patient with a single episode of idiopathic VTE and having LDL cholesterol levels of equal to or greater than 130 mg/dL. The exclusion criteria include age below 18 years, pregnancy or puerperium, active malignancy, need for other anticoagulant treatments, presence of transient risk factors for VTE, contraindications to statin therapy, chronic renal failure, ongoing treatment with statins or fibrates, major indication to statin therapy, life expectancy of less than 6 months, geographic inaccessibility, concomitant enrollment in another clinical trial, and refused informed consent.",
    "The sample is a phase 2 clinical trial for non-small-cell lung cancer. The trial involves the drugs pemetrexed and gemcitabine. The eligibility criteria for the trial include having a histologic or cytologic diagnosis of NSCLC Stage IIIB or IV, no prior systemic chemotherapy for advanced Non-Small Cell Lung Cancer, and completion of prior radiotherapy at least 4 weeks before study enrollment. The exclusion criteria include an estimated life expectancy of 12 weeks, a serious cardiac condition, documented brain metastases unless the patient has completed successful local therapy for central nervous system metastases and has been off of corticosteroids for at least 2 weeks before enrollment, and significant weight loss (that is, > 10%) over the previous 6 weeks before study entry.",
    "The sample is a clinical trial for HIV infections in phase 2/phase 3. The trial is looking for participants who are 18 years or older, HIV-infected, and have measurable HIV Neurocognitive Impairment (HNCI). The participants must also be willing and able to undergo at least 3 lumbar punctures safely during the course of the study. The trial is testing the effectiveness of FDA-approved antiretroviral therapy (see list below) for HIV treatment. The eligibility criteria include having a Karnofsky score of > or = to 60 within 60 days prior to study entry and having a CD4 cell count obtained within 60 days prior to study entry. The exclusion criteria include the presence of serious illness, neurologic disorders other than HIV, active severe psychiatric disorders, active drug or alcohol use or dependence, use of any immunomodulator, vaccine, or investigational therapy including dexamethasone within 30 days prior to study entry, inability to provide informed consent, enrollment in other ARV treatment studies, and a positive serum or urine pregnancy test if female and of reproductive potential.",
    "The sample is a clinical trial for kidney transplantation, in which patients aged 2-21 years with biopsy-proven acute rejection episodes are eligible to participate. The trial is in phase 2/phase 3 and involves the use of rituximab for transplant rejection. The eligibility criteria include a decline in baseline renal function, adequate liver function, negative pregnancy test, and willingness to comply with the study protocol. Exclusion criteria include previous treatment with rituximab, history of severe allergic reactions, ongoing use of high dose steroids, and significant cardiac or pulmonary disease. Patients must also be able to comply with study and follow-up procedures.",
    "The sample is a phase 2 clinical trial for patients with gastric cancer that has recurred or spread to other parts of the body. The trial is testing the effectiveness of a drug called irofulven. Patients must have confirmed gastric adenocarcinoma and measurable disease. They must also meet certain eligibility criteria, including having a performance status of ECOG 0-2, a life expectancy of more than 3 months, and no known brain metastases. Patients must also meet certain hematopoietic, hepatic, renal, and cardiovascular requirements, and must not have any other uncontrolled concurrent illness or ongoing infection. Prior concurrent therapy is not allowed, and patients must not have any other malignancy within the past 5 years except for adequately treated carcinoma in situ of the cervix or basal cell or squamous cell skin cancer. The sample includes a detailed list of eligibility criteria for patients, including age, medical history, and other medical conditions.",
    "The sample is a record of a clinical trial in phase 2 for Alzheimer's disease. The trial involves the experimental drug bapineuzumab. The eligibility criteria for the trial include a diagnosis of probable Alzheimer's disease, age between 50 and 89, a specific score on the Mini-Mental Status Exam, and a brain MRI scan consistent with the diagnosis of Alzheimer's disease. The trial also requires a caregiver to attend all clinic visits with the patient. Exclusion criteria include significant neurological disease other than Alzheimer's disease, major psychiatric disorder, significant systemic illness, history of stroke or seizure, smoking more than 20 cigarettes per day, and prior treatment with experimental immunotherapeutics or vaccines for Alzheimer's disease. Women of childbearing potential and those with pacemakers, CSF shunts, or foreign metal objects in the eyes, skin or body are also excluded from the trial.",
    "The sample is a phase 2 clinical trial for Alzheimer's disease. The trial is testing the effectiveness of a drug called rilapladib compared to a placebo. The eligibility criteria for participants include having a clinical diagnosis of possible Alzheimer's disease, being between 50 and 80 years old, having a documented history of at least 6 months of ongoing Alzheimer's disease therapy, and having a Mini-Mental Status Examination (MMSE) score between 20 and 26 at screening. Exclusion criteria include having a history of any other CNS disorder that could be interpreted as a cause of dementia, having a history of significant psychiatric illness, and having a history of chronic viral hepatitis or other chronic hepatic disorders. Participants must also have a dedicated caregiver who is willing to supervise participation in the study. The trial involves cognitive and other testing, and participants must be fluent in the language used for the administration of the cognitive tests.",
    "The sample is a phase 2 clinical trial for asthma. The trial includes patients who are 18 years or older, have a diagnosis of asthma, and have a pre-bronchodilator FEV1 of 40-80% of the predicted normal value. The trial also requires patients to have demonstrated reversibility by \u226512% and \u2265200mL of FEV1 within 40 minutes following albuterol. Patients must have a need for regular controller therapy for a minimum of 8 weeks prior to the trial. The trial has exclusion criteria, including a history of life-threatening asthma, respiratory infection not resolved, asthma exacerbation, concurrent respiratory disease, current smokers, and other uncontrolled diseases that could put the patient's safety at risk. The trial also excludes patients with a positive Hepatitis B surface antigen or positive Hepatitis C antibody and/or HIV, visual clinical evidence of oropharyngeal candidiasis, drug or milk protein allergies, and concomitant medications affecting the course of asthma. Patients who have used any other investigational medication within 30 days or 5 drug half-lives, whichever is longer, or previous use of GSK573719 are also excluded. The trial also excludes patients with any disease preventing the use of anticholinergics, any condition that impairs compliance with the study protocol, including visit schedule and completion of daily diaries, any subject with a history of alcohol or substance abuse, and any affiliation with the investigator's site.",
    "The sample is a phase 2 clinical trial for patients with unresectable or metastatic esophageal neoplasms. The trial involves the use of oxaliplatin, cisplatin, and 5-fluorouracil (5-fu) as the treatment. The eligibility criteria include having an ECOG score of 0-1, no previous treatment with chemotherapy or radiotherapy, and having a measurable lesion. The exclusion criteria include having a creatinine clearance of less than 50 mL/min, total bilirubin levels higher than 1.5 times the upper limit of normal, AST/ALT levels higher than 2.5 times the upper limit of normal, total white blood cell count less than 1.5 million/mL, platelet count less than 100 million/mL, symptomatic sensitive peripheral neuropathy, and being pregnant or breastfeeding. The information provided is not exhaustive and other considerations may be relevant for potential participants in the trial.",
    "The sample is a phase 2 clinical trial for alcohol dependence. The trial includes males and females who are 18 years or older, weigh between 40 and 140 kg, and have been drinking on average at least 21 and 28 drinks per week for women and men, respectively, in the 7-day period prior to enrollment. Participants must have a DSM-IV-R diagnosis of alcohol dependence and be in good physical health. They must also be literate in English and willing to participate in behavioral treatments for alcoholism. The trial includes the drugs ondansetron, olanzapine, and placebo. The eligibility criteria include exclusion criteria such as any current axis I DSM-IV psychiatric disorder other than alcohol or nicotine dependence, severe alcohol withdrawal symptoms, serious medical comorbidity, and female subjects who are pregnant, lactating, or not adhering to an acceptable form of contraception at any time during the study.",
    "The sample is a phase 2 clinical trial for the treatment of rheumatoid arthritis. The trial includes male and female participants between the ages of 18 and 75 who have given written informed consent. Women must not be at risk of becoming pregnant during the study. Participants must have a diagnosis of rheumatoid arthritis according to the 1987 revised American Rheumatism Association criteria and have a serum C-reactive protein measurement greater than the upper limit of normal or erythrocyte sedimentation rate \u226528 mm/hr. They must also be currently using Methotrexate at a stable dose and have had an insufficient response to at least one oral DMARD. Exclusion criteria include recent or ongoing infection, surgical treatment of a joint within 2 months of study enrollment, and medical findings that put the participant at an unacceptable risk for participation.",
    "The sample is a phase 2 clinical trial for the treatment of multiple myeloma, a type of cancer. The trial involves the use of drugs such as bortezomib, dexamethasone, thalidomide, and cyclophosphamide. The eligibility criteria for the trial include being between 18 and 70 years old, having a Karnofsky Performance Status score of at least 60%, and meeting specific diagnostic criteria for multiple myeloma. Participants must also have measurable disease and agree to use contraception. Exclusion criteria include having certain medical conditions or diseases, prior or current systemic therapy for multiple myeloma, and pregnancy or lactation.",
    "The sample is a phase 2 clinical trial for women with signs and symptoms of myocardial ischemia, which is a condition where the heart muscle doesn't receive enough blood flow. The trial is testing the effectiveness of ranolazine, a drug used to treat chronic angina, compared to a placebo. The trial includes a list of inclusion and exclusion criteria, such as women with less than 50% luminal diameter stenosis and those without contraindications to withholding certain medications. The trial excludes women who are pregnant or breastfeeding, have a life expectancy of less than 6 months, or are taking certain medications that may interfere with the trial.",
    "This sample is for a phase 2 clinical trial for the treatment of recurrent childhood acute lymphoblastic leukemia. The eligibility criteria include a diagnosis of ALL, bone marrow relapse or failure of at least two regimens for remission induction, and more than 25% blasts in bone marrow aspirate. Patients must also meet certain performance status requirements, have normal levels of ALT, bilirubin, and creatinine, and not have serious uncontrolled infections or medical conditions. They must also not be pregnant or nursing, and must use effective contraception during and for 6 months after study participation. Prior treatments are allowed, but certain medications and therapies are not permitted.",
    "The sample is a phase 2 clinical trial for the treatment of bladder cancer. The trial is looking for patients with histologically confirmed unifocal or multifocal transitional cell carcinoma of the bladder no greater than 5 cm, with evidence of muscle invasion documented by transurethral resection of the bladder (TURB), with no residual visible or palpable tumor mass at the end of TURB Stage II or III (T2-T3, N0, M0). Patients must not have squamous cell or adenocarcinoma, evidence of pelvic lymph node involvement by CT scan or MRI, evidence of hydronephrosis, or evidence of distant metastases. Patients must also meet certain age and performance status criteria, and have certain hematopoietic, hepatic, renal, and cardiovascular characteristics. Patients must not have reduced bladder capacity or prior or concurrent malignancy except basal cell carcinoma or carcinoma in situ of the cervix treated by hysterectomy. The trial will not accept patients who have had prior surgery for bladder cancer except transurethral resection of the bladder. The trial will allow prior immunotherapy for superficial disease and prior intravesical chemotherapy or intravesical BCG, but will not allow prior systemic chemotherapy.",
    "The sample is a phase 2 clinical trial for the treatment of obesity, over-weight, and Prader-Willi syndrome. The trial involves the use of three drugs, namely zgn-440 sterile diluent, 1.2 mg zgn-440 for injectable suspension, and 1.8 mg zgn-440 for injectable suspension. The eligibility criteria for the trial include having a confirmed diagnosis of Prader-Willi Syndrome due to chromosome 15 micro-deletion, maternal uniparental disomy, or imprinting defect, having a BMI of at least 25 kg/m2, and agreeing to stay at the group home or under supervision of the group home or site staff for the duration of the study. The exclusion criteria include the use of weight loss agents in the past 3 months, having type 1 diabetes mellitus, and current or anticipated chronic use of narcotics or opiates. The icd-10 codes associated with the diseases are also provided.",
    "The sample is a record of a clinical trial with a phase 2 designation. The trial is focused on the disease leukemia, and the icd-10 codes associated with it. The drugs being tested in the trial are fludarabine and campath, with multiple instances of campath being used. The eligibility criteria for the trial include a diagnosis of chronic lymphocytic leukemia with advanced or progressive disease and at least two active clinical signs. Patients must also not have any active infections, uncontrolled severe diseases, or known hypersensitivity or anaphylactic reactions to murine antibodies or proteins. Additionally, patients must not have had any other malignancies within the past two years, significant traumatic injury within the past four weeks, or any coexisting medical or psychological condition that would limit study compliance. Prior concurrent therapy is not allowed, and patients must not have had any prior treatment for CLL, major surgery within the past four weeks, or prior chemotherapy.",
    "The sample is a phase 2 clinical trial for rheumatoid arthritis. The trial includes patients who are at least 18 years old and have been diagnosed with rheumatoid arthritis for at least 3 months. The patients must have a functional status class I, II, or III and be treated with methotrexate at a stable dose of at least 7.5 mg/week for at least 12 weeks before randomization. Patients who have failed any disease-modifying antirheumatic drugs (DMARDs) are allowed. The trial includes the drugs canakinumab and placebo. The eligibility criteria include various medical conditions and restrictions on medication use. The trial also includes extension studies for patients who completed the core study.",
    "The sample is a phase 2 clinical trial for the treatment of breast cancer with metastasis. The trial involves the use of two drugs, dasatinib and dasatinib 100 mg. The eligibility criteria for the trial include being a female aged 18 or older, having recurrent, locally advanced, or metastatic breast cancer with expression of ER/PR receptor and/or overexpression of Her2/neu, having measurable disease, and having received prior chemotherapy with an anthracycline and/or a taxane. The trial also requires that the patient has 0, 1, or 2 chemotherapies in the metastatic setting and adequate organ function. The exclusion criteria include having metastatic disease confined to bone only, symptomatic central nervous system (CNS) metastasis, concurrent medical condition which may increase the risk of toxicity, and being unable to take oral medication.",
    "The sample is a record of a clinical trial in phase 2 for the treatment of cystic fibrosis. The trial involves the drug biaxin (clarithromycin) and has a list of inclusion and exclusion criteria for participants. The inclusion criteria include a diagnosis of CF, ability to perform spirometry reliably, and an FEV1 of 30% predicted at the time of screening. The exclusion criteria include having Mycobacterium in a sputum culture ever recorded, a respiratory exacerbation requiring IV antibiotics in the 60 days prior, using an investigational drug or device in the 60 days prior, significant (>30ml) of hemoptysis in the past year, requiring oxygen, or having significant liver or renal disease. The icd-10 codes associated with the disease are also listed.",
    "The sample is a phase 2 clinical trial for patients with gastric carcinoma or gastroesophageal junction carcinoma that is incurable and has been verified through pathology. The trial involves the use of oxaliplatin, capecitabine, and celecoxib as drugs. The eligibility criteria include having measurable disease, a performance status of 0-2, and not having received capecitabine or oxaliplatin before. The exclusion criteria include having brain metastases, being pregnant or nursing, having known allergic reactions to certain drugs, and having active gastric/duodenal bleeding. The trial requires at least 6 unstained paraffin-embedded pathologic specimen slides for COX-2 expression assays.",
    "The sample is a phase 2 trial for the treatment of type 2 diabetes mellitus. The trial includes a list of icd-10 codes for the disease and a list of drugs, including a placebo. The eligibility criteria for the trial include having a BMI between 27 and 45 kg/m2, having stable type 2 diabetes mellitus for at least 3 months, having a stable lifestyle, taking a stable daily dose of metformin of at least 1000 mg for at least 3 months, and having a glycosylated hemoglobin (HbA1c) level between 7.1% and 11% at screening.",
    "This sample is a phase 2 clinical trial for the treatment of B-cell lymphoma. The trial is looking for patients who have been previously treated with high-dose methotrexate-containing chemotherapy and/or radiation therapy, and have progressive or recurrent disease that is exclusively localized in the central nervous system. The trial is testing the effectiveness of the drug idarubicin. Patients must meet certain eligibility criteria, including having a measurable target lesion, being between the ages of 18 and 75, having adequate bone marrow, renal, hepatic, and cardiac function, and not having any other concurrent malignancies or experimental treatments. Female patients must not be pregnant or lactating and must use adequate contraception during the study. Patients must also sign an informed consent form before participating in the trial.",
    "This sample is for a phase 2 clinical trial for rheumatoid arthritis. The trial includes patients who have been diagnosed with RA based on the ARA 1987 revised criteria at least 16 weeks prior to study enrollment, Day 0. Patients must have an ACR global functional status class of 1 to 3 and active disease, defined as the presence of 6 swollen joints and 6 tender joints in a 44 joint examination. Patients must also have a CRP level at screening of \u2265 1.5 mg/dL and have been taking oral or parenteral methotrexate (15 mg weekly or above) for at least 16 weeks (up to Day 0 of study), and have been on a stable dose for at least 8 weeks, up to Day 0. Patients who have arthritis onset prior to 16 years old or any of the listed infections are excluded from the trial. Additionally, patients with ongoing systemic inflammatory conditions which may interfere with the results of clinical or laboratory tests planned in the study (eg, systemic lupus erythematosus or any other systemic rheumatic disease other than RA) are also excluded. The trial includes the use of two drugs, rob 803 and placebo.",
    "The sample is a phase 2 clinical trial for the treatment of undifferentiated arthritis using the drugs abatacept and placebo. The trial includes patients with clinical synovitis of two or more joints and a diagnosis of undifferentiated arthritis, with at least one but not more than three criteria for diagnosis of rheumatoid arthritis. Patients must not have received prior disease modifying anti-rheumatic drugs or biologics, and the duration of their disease must be 18 months or less. Patients must also test positive for antibodies against cyclic citrullinated peptides. Exclusion criteria include active vasculitis of a major organ system, severe or recurrent bacterial infection, history of cancer in the last five years (except certain skin cancers), and herpes zoster that resolved less than 2 months prior to enrollment. Women of childbearing potential who are unwilling or unable to use an acceptable method to avoid pregnancy are also excluded.",
    "The sample is a phase 2 trial for insulin-na\u00efve type 2 diabetes patients who have been diagnosed clinically for at least 3 months. The trial involves treatment with one or two oral anti-diabetic drugs, such as metformin, sulfonylurea, or alpha-glucosidase inhibitors, for at least 2 months at a stable maximally tolerated dose. The trial also requires a HbA1c level between 7.0-11.0% and a BMI between 25.0-37.0 kg/m^2. The trial excludes patients with certain contraindications, such as recent treatment with thiazolidinedione or systemic corticosteroids, and those with clinically significant active diseases of certain systems.",
    "The sample is a phase 2 clinical trial for patients with uterine or soft tissue leiomyosarcoma. The trial requires patients to have metastatic or relapsed and unresectable disease, and to have previously undergone a first-line anthracycline-based chemotherapy regimen. Patients must also have at least one measurable lesion and meet certain criteria related to their age, performance status, hematopoietic, hepatic, renal, cardiovascular, immunologic, and other health factors. Patients cannot have other uterine sarcomas, symptomatic or known brain metastases, or other serious underlying pathology that would preclude study treatment. The trial involves the use of docetaxel and gemcitabine hydrochloride, and patients cannot have had prior gemcitabine and/or taxane treatment. The trial also has certain requirements related to prior and concurrent therapy, and patients cannot participate in another clinical trial using an experimental agent.",
    "The sample is a phase 2 clinical trial for patients with CD20+ diffuse large B-cell lymphoma. The trial includes patients between the ages of 18 and 59 who are eligible for transplant and have not previously been treated. The trial involves two chemotherapy regimens, r-chop14 and r-acvbp14, and requires a baseline FDG-PET scan before treatment. Patients must have an IPI score of 2 or 3 and a minimum life expectancy of 3 months. Exclusion criteria include any other type of lymphoma, central nervous system or meningeal involvement by lymphoma, poor renal or hepatic function, poor bone marrow reserve, and any history of cancer during the last 5 years (with the exception of non-melanoma skin tumors or stage 0 cervical carcinoma). Patients must also not be pregnant or lactating and must be practicing an adequate method of contraception if they are of childbearing potential.",
    "The sample is a phase 2 clinical trial for the treatment of hypercholesterolemia. The trial includes patients who have received a statin as monotherapy while having a LDL-C >100 mg d/L at initial clinical washout visit or received no lipid-altering drugs since the initial clinic washout visit and had a mean LDL-C as specified in the inclusion criteria. The trial involves the use of three drugs - gemcabene, atorvastatin, and placebo. The eligibility criteria include age between 18-70 years, variability of 2 qualifying LDL-C <20%, and mean LDL-C < 250 mg/dL at 2 qualifying visits. The exclusion criteria include women of childbearing potential, pregnant or lactating, BMI >38kg/m\u00b2, TG >400 mg/dL at Visit B2 or B3, and various other medical conditions and medications.",
    "The sample is a phase 2 clinical trial for non-small cell lung cancer (NSCLC) patients who have demonstrated progressive disease after first-line chemotherapy. The trial involves the use of two drugs, pemetrexed and matuzumab. The eligibility criteria include having a confirmed diagnosis of NSCLC, measurable disease, and a chemotherapy-free interval of at least 3 weeks. Participants must also have adequate organ function and meet certain performance status requirements. Exclusion criteria include prior treatment with an EGFR-directed therapy or pemetrexed, significant neurologic or psychiatric disorders, and known hypersensitivity to the study treatment or any of its components. Participants must provide written informed consent and be willing to use effective contraceptive methods if of procreative potential. The trial involves a number of screening procedures and participants must meet all inclusion criteria and have none of the exclusion criteria to be eligible for the study.",
    "The sample is a phase 2 clinical trial for the treatment of schizophrenia. The trial includes patients with a clinical diagnosis of schizophrenia who have not had an acute exacerbation of symptoms requiring hospitalization or step-up care in the previous six months and are not on any symptomatic treatment for cognition. The trial excludes patients who pose a significant homicidal or suicidal risk or have evidence of previous homicidal or suicidal risk, have co-morbid psychiatric or significant physical illness, or have alcohol or drug abuse or dependence. The trial will test the effectiveness of two drugs, gsk239512 and placebo. The icd-10 codes associated with schizophrenia are also included in the table.",
    "The sample is a phase 2 clinical trial for individuals with a history of smoking and either no prior lung cancer or prior stage I non-small cell lung cancer that was completely resected or treated with adjuvant chemotherapy at least one year ago. The trial aims to investigate the effectiveness of the drug sulindac in preventing the development of precancerous conditions and stage I non-small cell lung cancer. The eligibility criteria include various medical and health-related factors such as blood count, oxygen saturation, and absence of other illnesses. Participants must also not be pregnant or nursing, and must use effective contraception if fertile. The trial excludes individuals with certain medical conditions or who are taking certain medications.",
    "The sample is for a phase 2 clinical trial for Huntington's disease. The trial includes patients who are either expansion positive or have a 50% risk of developing the disease but have not been clinically diagnosed yet. The trial will test the effectiveness of two drugs, creatine monohydrate and placebo. Patients with unstable medical conditions are excluded from the trial. There are additional inclusion and exclusion criteria that apply.",
    "The sample is a phase 2 clinical trial for previously untreated acute myeloid leukemia and high-risk myelodysplastic syndrome. The trial includes patients over 60 years old with an Eastern Cooperative Oncology Group performance status of 2 or less. The trial involves the use of the drugs clofarabine and ara-c. The eligibility criteria include adequate liver and renal function, and exclusion criteria include patients with New York Heart Association grade 3 heart disease. The diseases are listed with their corresponding ICD-10 codes. The inclusion and exclusion criteria are also provided.",
    "The sample is a phase 2 clinical trial for breast cancer patients. The trial involves the use of two drugs, lapatinib and lapatinib-placebo. The eligibility criteria include having a histological or cytologic diagnosis of primary breast cancer, being scheduled for primary surgery, being compliant for the duration of the study, having an age less than 80, having an ECOG performance status of 0-2, having a cardiac ejection fraction within the institutional range of normal, and being able to swallow and retain oral medication. Patients with prior diagnosis of malignancy except in situ disease or basal cell carcinoma of the skin, those receiving any other investigational agents or receiving concurrent anticancer therapy, those with evidence of metastatic disease, and those with uncontrolled inter-current illness are excluded from the trial. Women of childbearing potential must agree to use adequate non-hormonal contraception for the duration of study participation.",
    "The sample is a phase 2 clinical trial for patients with certain types of ovarian and peritoneal carcinomas. The trial is testing the effectiveness of the drugs selumetinib and selumetinib sulfate. Patients must meet certain eligibility criteria, including having measurable disease and documented low grade serous carcinoma. They must also have a GOG performance status of 0 or 1. Patients cannot have previously received AZD6244 and must not be receiving any other investigational agents. There are also exclusion criteria, such as having had chemotherapy or radiotherapy within 4 weeks prior to entering the study and having known brain metastases. Patients must have signed an approved informed consent and authorization permitting release of personal health information.",
    "The sample is a phase 2 trial for pulmonary disease, specifically chronic obstructive pulmonary disease (COPD). The trial includes a list of ICD-10 codes for COPD and a list of drugs, including oglemilast and placebo. The eligibility criteria for the trial include having COPD as defined by GOLD criteria, being a current or former cigarette smoker, and meeting certain lung function criteria. Exclusion criteria include long-term oxygen use, symptoms consistent with asthma, recent COPD exacerbations, and certain gastrointestinal and pulmonary disorders.",
    "The sample is a phase 2 clinical trial for patients with advanced prostate cancer. The trial is testing the effectiveness of the drug fulvestrant. Patients must have rising prostate-specific antigen (PSA) levels and absolute values of at least 5 ng/mL based on two measurements taken at least two weeks apart. They must also have measurable or evaluable disease and testosterone levels below 50 ng/mL. Patients must have a performance status of ECOG 0-2 and meet certain hematopoietic, hepatic, renal, and cardiovascular criteria. They must not have any other active malignancy within the past two years except nonmelanoma skin cancer or superficial bladder cancer, and must not have a history of significant neurologic or psychiatric disorders, including psychotic disorders, dementia, or seizures. Patients must not have any other serious illness or medical condition, active infection, or known hypersensitivity to active or inactive excipients of fulvestrant. Prior concurrent therapy is also restricted.",
    "The sample is a phase 2 trial for patients with non-squamous non-small cell neoplasm of lung, non-small cell lung cancer metastatic, or non-small cell lung cancer stage iiib. The trial involves the drug pemetrexed and has eligibility criteria including having completed 4 induction cycles of platinum-based doublet therapy, not having progressed after 4 cycles of induction therapy, and having a Performance Status (PS) of 0 or 1 on the Eastern Cooperative Oncology Group (ECOG) scale. Exclusion criteria include having a serious concomitant systemic disorder, serious cardiac condition, symptomatic central nervous system (CNS) malignancy or metastasis, receiving concurrent administration of any other antitumor therapy, and being pregnant or lactating.",
    "The sample is a record of a clinical trial with a phase 2 designation, focused on the disease of osteoporosis. The trial includes a list of icd-10 codes associated with the disease. The trial involves several drugs, including teriparatide, placebo, and various doses of ba058. The eligibility criteria for the trial include having a bone mineral density T-score of 2.5 or lower at the lumbar spine or hip, or having a T-score of 2.0 or lower and a prior low-trauma fracture within the past 5 years. Patients must also be in good general health and without evidence of clinically significant abnormality. Exclusion criteria include a history of bone disorders other than postmenopausal osteoporosis, prior treatment with bone-acting investigational agents, and a history of certain medical conditions such as carcinoma or osteosarcoma.",
    "The sample is a phase 2 clinical trial for patients with locally advanced or metastatic gastro adenocarcinoma, including adenocarcinoma of the lower third of the oesophagus or the gastro oesophageal junction. The trial involves the drugs azd4547 and paclitaxel. The eligibility criteria include being aged 25 or over, having radiographically confirmed progression after 1 prior chemotherapy or chemoradiotherapy for gastric cancer, and having at least one lesion that has a baseline of at least 10mm in the longest diameter for non-nodal lesions and is assessed by Computerised Tomography (CT) or Magnetic Resonance Imaging (MRI). The exclusion criteria include prior exposure to AZD4547 or history of hypersensitivity to other drugs similar in structure or class to AZD4547, prior taxane treatment for gastric cancer with the exception of adjuvant/neo-adjuvant therapy given > 6 months, and any unresolved toxicities from prior therapy with a Common Terminology Criteria for AE (CTCAE) grade >1 at the time of starting study treatment.",
    "The sample is a phase 2 trial for the treatment of non-small-cell lung carcinoma. The trial includes patients with stage IIIB or IV NSCLC who are eligible for treatment with paclitaxel and carboplatin +/- bevacizumab. The trial excludes patients with mixed large and small cell histologies for lung cancer and those with a BMI greater than 30. The trial involves the use of anamorelin hcl and placebo as drugs. The icd-10 codes associated with the disease are D02.20, D02.21, and D02.22.",
    "The sample is a phase 2 clinical trial for major depressive disorder using the drug mecamylamine. The trial has two phases, an open phase and a double-blind phase. The inclusion criteria for the trial include being between the ages of 18-70, having a diagnosis of major depressive disorder confirmed by the MINI diagnostic scale, having a HAMD-17 score greater than 21, and having no clinically significant abnormalities on physical examination, vital signs, ECG or laboratory tests. The exclusion criteria include having a co-morbid psychiatric illness such as bipolar disorder or schizophrenia, having a history of alcohol or drug abuse, and having a known hypersensitivity to mecamylamine. Women of childbearing potential must have a negative urine pregnancy test and use acceptable methods of contraception.",
    "The sample is a phase 2 clinical trial for patients with recurrent non-small cell lung cancer who have had at least two prior systemic treatment regimens. The trial is testing the effectiveness of the drugs seliciclib and placebo. The eligibility criteria include having measurable disease according to RECIST, Eastern Cooperative Oncology Group performance status 0-1, adequate bone marrow, hepatic and renal function, ability to swallow capsules, and having recovered from prior toxicities. Exclusion criteria include having small cell lung cancer, previously untreated or progressive CNS metastasis, prior treatment with a CDK inhibitor, currently receiving radiotherapy, biological therapy, or any other investigational therapy, uncontrolled intercurrent illness, having other cancers that have been treated with chemotherapy or biological therapy in the past 5 years (with the exception of adequately treated in situ cervical cancer or basal cell skin cancer), being pregnant or lactating, known to be HIV-positive, and having active hepatitis B and/or hepatitis C infection.",
    "The sample is a record of a clinical trial that is in phase 2/phase 3. The trial is focused on patients with dementia and the icd-10 codes associated with the disease. The trial is testing the effectiveness of megestrol acetate and placebo as treatments for the disease. The eligibility criteria for the trial include patients diagnosed with primary or mixed dementia, weight loss of more than 5% of their habitual weight in the last 6 months, and proteic-caloric malnutrition. The patients must also be outpatients and willing to participate in the study. The exclusion criteria include patients with vascular pure dementia and secondary dementias, those in a terminal phase of dementia, those on concomitant treatment with steroids, androgens or other drugs with progestagens, and those with weight loss secondary to neoplasia.",
    "The sample is a phase 2 clinical trial for patients with metastatic or locally advanced inoperable breast cancer who are potentially hormone-sensitive. The trial is testing the effectiveness of tamoxifen and zarnestra as treatments for breast cancer. The eligibility criteria include being post-menopausal, having at least one measurable lesion, and having a performance status of \u2264 2. The exclusion criteria include being male, having ER- and PR-negative cancer, and having certain chronic diseases. Patients must also provide signed, written consent before any study-related procedure.",
    "The sample is a phase 2 clinical trial for patients with locally advanced or metastatic stage IIIB/IV non-small-cell lung carcinoma that has relapsed after chemotherapy/chemoradiotherapy. The trial is testing the effectiveness of the drugs dalotuzumab and erlotinib. The eligibility criteria include having had at least one chemotherapy regimen for recurrent or metastatic disease, being 18 years of age or older, having a performance status of 0-2 on the Eastern Cooperative Group (ECOG) scale, and having a negative pregnancy test for women of childbearing potential. The exclusion criteria include having had chemotherapy within 2 weeks or biological therapy within 4 weeks, not having recovered from adverse events from previous therapy within 4 weeks, having received certain types of therapy, having had more than 2 systemic chemotherapies for metastatic disease, and having certain medical conditions or using certain medications.",
    "The sample is a phase 2 clinical trial for Alzheimer's disease. The trial includes patients who have voluntarily signed an informed consent and meet the diagnostic criteria for probable Alzheimer's disease. Female subjects must be postmenopausal for at least 2 years or surgically sterile, and male subjects must be surgically sterile, sexually inactive, or using a barrier method of birth control. The trial requires an identified, reliable caregiver and a CT or MRI scan within 36 months prior to randomization. Patients must generally be in good health based on medical history, physical examination, vital signs, clinical lab tests, and ECG. Exclusion criteria include current or recent use of medication for the treatment of Alzheimer's disease or dementia, non-prescribed drug use or history of drug or alcohol abuse/dependence, history of any significant neurologic disease other than Alzheimer's disease, intolerance or adverse reaction to donepezil, and receipt of any investigation product within 6 weeks prior to study drug administration. The trial includes the drugs abt-288, donepezil, and placebo.",
    "The sample is a phase 2 clinical trial for the treatment of bladder cancer. The trial includes patients with locally advanced or metastatic urothelial carcinoma of the bladder or upper urinary tract. The trial is testing the effectiveness of the drug sorafenib compared to a placebo. The eligibility criteria include having an ECOG score of 0-1, a life expectancy of at least 12 weeks, and having at least one measurable lesion on CT or MRI. Patients must also have adequate hematologic, renal, hepatic, and coagulation-physiological functions. Exclusion criteria include having uncontrolled high blood pressure, serious cardiovascular disease, or a history of serious bleeding or thrombotic events. Patients must also not have had previous treatment with chemotherapy or immunotherapy.",
    "The sample is a phase 2 clinical trial for the treatment of depression and excessive daytime sleepiness using mirtazapine. The trial includes patients who meet the DSM-IV criteria for Major Depressive Disorder and have a Hamilton Rating Scale for Depression score greater than 17. Patients must also be prescribed mirtazapine by their physician and have no clinically significant abnormal vital signs or other clinical findings at screening. Inclusion criteria also require patients to have a driving license for more than 3 years and drive over 15,000 km per year, and females of childbearing potential must use effective birth control. Exclusion criteria include night shift workers, a history or present condition of bipolar disorder, schizophrenia, or other psychotic disorders, anxiety disorders, eating disorders, postpartum depression, epilepsy or a history of seizure disorder, alcohol or substance abuse, and any physical disease that may explain the symptoms of depression or any chronic physical disease that is not stabilized.",
    "The sample is a phase 2 clinical trial for castration-resistant prostate cancer. The trial includes patients who are at least 18 years old and have an ECOG performance status of 0 or 1. Patients must have a histological or cytological diagnosis of adenocarcinoma of the prostate and metastatic disease on chest, abdominal, or pelvic CT and/or bone scan for which no curative therapy exists. Patients must also have progression of prostate cancer, which is defined by increasing serum PSA levels, progressive measurable disease, or bone progression. Patients who have not had a surgical orchiectomy must continue treatment with LHRH agonist or antagonist to maintain a castrate level of testosterone. The trial includes a list of eligibility criteria, including laboratory values, prior therapy criteria, and recovery from all toxicities of prior therapy. Patients must be willing to use effective contraception if of childbearing potential throughout study treatment and for 3 months after completion of study treatment. The trial also includes exclusion criteria, such as inability to tolerate a dose of 10 mg of prednisone a day, requiring an amount of opioids to control pain > 30 mg of a morphine-equivalent per day, and active second malignancy.",
    "The sample is a record of a clinical trial with a phase 2 designation. The trial is focused on the treatment of chronic hepatitis C, with a list of specific icd-10 codes provided. The trial involves the use of several drugs, including bms-790052, bms-650032, pegylated-interferon alfa-2a, and ribavirin. The eligibility criteria for the trial are also listed, including age restrictions, genotype 1 null responders to current standard of care, and restrictions on certain medical conditions. Exclusion criteria are also listed, including a history of certain medical conditions, cirrhosis, and positive tests for HIV or Hepatitis B. Pregnant individuals are also excluded from the trial.",
    "The sample is a phase 2 clinical trial for the treatment of leukemia using arsenic trioxide. The trial is open to patients who have been diagnosed with acute lymphoblastic leukemia or blastic phase chronic myelogenous leukemia and are either refractory to initial therapy or have had a recurrence following one induction therapy regimen. Patients must not be eligible for bone marrow transplant and must meet certain eligibility criteria, including being 18 years or older, having a performance status of Eastern Cooperative Oncology Group (ECOG) 0-2, and having a life expectancy of at least 8 weeks. The trial also has specific requirements for hematopoietic, hepatic, renal, and cardiovascular health, as well as other factors such as pregnancy status and electrolyte imbalances. Prior concurrent therapy is also taken into consideration.",
    "The sample is a record of a clinical trial for a drug study. The trial is in phase 2 and is focused on the treatment of inguinal hernia. The table includes information on the diseases being studied, the icd-10 codes associated with those diseases, the drugs being used, and the eligibility criteria for participants. The eligibility criteria include factors such as age, health status, and willingness to comply with study procedures. The exclusion criteria include factors such as medical conditions that could complicate the study, history of substance abuse, and complications during surgery.",
    "The sample is a phase 2 clinical trial for obesity. The trial includes patients between the ages of 18 and 65 with a BMI between 30 and 43 kg/m2. Patients must be in good health, non-smokers, and have normal nasal mucosa. Female patients must meet certain criteria related to pregnancy and contraception. The trial excludes patients with previous surgical treatment for obesity, serious medical or psychiatric conditions, untreated hypothyroidism, type 1 or type 2 diabetes, uncontrolled hypertension, and those taking prohibited concomitant medication. The trial involves the use of various drugs, including nasal placebo, placebo capsule, pyy3-36, and sibutramine.",
    "The sample is a clinical trial for patients with intermediate- or high-grade malignant soft tissue sarcoma that is advanced and/or metastatic and previously untreated. The trial is in phase 2/phase 3 and involves the use of the drugs doxorubicin hydrochloride and trabectedin. The eligibility criteria include confirmed disease progression, measurable disease according to RECIST v 1.1 criteria, and no prior anticancer therapy for this disease. Patient characteristics include a WHO performance status of 0-1, normal blood counts and liver function, and no active or uncontrolled infections or serious illnesses. Prior concurrent therapy is not allowed, and patients must not have concurrent alcohol consumption.",
    "The sample is a phase 2 clinical trial for Alzheimer's disease and other central nervous system diseases related to cognition. The trial involves the use of the drugs evp-6124 and placebo. The eligibility criteria for the trial include having a Mini-Mental State Examination (MMSE) score of 14 to 24, a CDR-SB score of at least 2, and a Modified Hachinski Ischemic Score (mHIS) of no more than 4. Female subjects must be at least 1 year post-menopausal or surgically sterile, and a caregiver must be available. The trial lasts for 24 weeks, and there are various exclusion criteria, such as a history of significant cardiovascular disease, major depression, or inability to perform cognitive tests.",
    "The sample is a phase 2 clinical trial for patients with B-cell chronic lymphocytic leukemia. The trial is testing the effectiveness of the drugs fludarabine phosphate and alemtuzumab. The eligibility criteria include being a male or female patient with CD23+, CD5+, CD19+, light chain monoclonal B CLL, having 1st or 2nd relapse after fludarabine or any other primary treatment regimen or refractory to primary or secondary treatment (including fludarabine) and simultaneously indication for treatment according to the NCI Workshop Criteria 1996, being between the ages of 19-75, having a WHO performance score of 0-2, and giving informed consent. Exclusion criteria include being HIV positive or positive for Hepatitis B or C, having an active uncontrolled infection, being of childbearing age without adequate control of fertility, being pregnant or lactating, having intolerance towards any ingredient of either oral fludarabine or alemtuzumab, having an allergy against foreign proteins, having previous treatment with alemtuzumab, having treatment with an experimental drug within the previous 2 months, having a second malignant disease (non CLL), having CLL in transformation (Richter syndrome), having decreased kidney-function with creatinine-clearance < 30ml/min, having severe concomitant diseases or major organ dysfunctions, or being unable to comply with the requirements of the protocol.",
    "The sample is a phase 2 clinical trial for patients with metastatic or locally unresectable clear cell renal carcinoma. The trial is testing the drug lbh589 and patients must have documented disease progression or intolerance while receiving treatment with sunitinib, sorafenib, or both, and temsirolimus. Patients must also have measurable disease by RECIST criteria, ECOG PS 0 or 1, and meet certain laboratory values. Women of childbearing potential must have a negative pregnancy test and patients must have a life expectancy of greater than 12 weeks. There are exclusion criteria, such as prior treatment with an HDAC inhibitor, impaired cardiac function, and ongoing therapy with antiarrhythmics or other medications associated with QTc prolongation. Patients must be able to understand the nature of the study and give written informed consent prior to study entry.",
    "The sample is a phase 2 clinical trial for patients with metastatic colorectal cancer. The trial requires patients to have received only one prior regimen for metastatic disease containing oxaliplatin, a fluoropyrimidine, and bevacizumab. Patients must have measurable disease and no known brain metastases. They must also meet certain patient characteristics such as having an ECOG performance status of 0-2 and normal levels of various blood components. Patients with a history of bleeding events or gastrointestinal perforation within a certain time frame are not eligible. The trial also has specific prior concurrent therapy requirements and excludes patients with certain medical conditions. The trial involves the use of two drugs, cediranib maleate and irinotecan hydrochloride. The eligibility criteria are quite detailed and specific.",
    "The sample is a phase 2 clinical trial for patients with prostate cancer. The trial is looking for patients who have had a response to medical or surgical castration therapy with a serum PSA nadir of </= 0.2 ng/ml and must not have had any known subsequent rise in serum PSA level of any magnitude above this nadir within the first 24 months of hormonal therapy. Patients must have current evidence of progressive castration-resistant disease that is asymptomatic. The trial is testing the effectiveness of testosterone therapy for patients with castration-resistant prostate cancer. The sample includes eligibility criteria for patients to participate in the trial, as well as exclusion criteria.",
    "The sample is a phase 2 clinical trial for patients aged 18-70 years with inoperable locally advanced or metastatic squamous cell carcinoma of the head and neck (stage III-IV). The trial allows for adjuvant or neo-adjuvant chemotherapy or radio-chemotherapy if finished more than 6 months before inclusion and cisplatinum total dose used < or=to 300 mg/m\u00b2 or carboplatinum total dose used < or=to 200mg/m\u00b2. Patients must have at least 1 target lesion measurable in 2 dimensions > or=to 20 mm on computed tomography (CT) or magnetic resonance imaging (MRI) evaluated < 15 days before start of study treatment, outside of irradiated fields. Performance status (PS) must be < or =to 2 World Health Organization (WHO), weight loss < 5% normal weight, hemoglobin > or =to 10 g/dL, neutrophils > or =to 2000/mm3, platelets > or =to 100,000/mm3, creatinine < or =to 1.5 x upper limit of normal (ULN), bilirubin < or =to .5 x ULN, alanine amino-transferase (ALT)/aspartate amino-transferase (AST)< or =to 2.5 x ULN (5 x ULN if liver metastases), clotting: prothrombin time (PT) > or =to 60%. The trial excludes patients who do not meet the inclusion criteria or have any other exclusion criteria.",
    "The sample is a phase 2 clinical trial for atherosclerosis. The trial includes adult male and female subjects between 50 and 80 years of age, who have experienced a cardiovascular event or have peripheral vascular disease. The trial also includes subjects with a diagnosis of coronary artery disease or metabolic syndrome, as well as current smokers or those with well-controlled diabetes. The trial involves the use of losmapimod 7.5 mg and placebo drugs. The eligibility criteria include being on a stable dose of statin for at least 3 months prior to the first dose of study medication, having active inflammation, and having AST and ALT levels below 2xULN at screening. The exclusion criteria include any medical history or clinically relevant abnormality that is deemed by the principal investigator and/or medical monitor to make the subject ineligible for inclusion because of a safety concern, history of heart failure, and positive pre-study hepatitis B surface antigen or positive hepatitis C antibody results within 3 months of screening. The trial also includes an MRI sub-study with its own inclusion and exclusion criteria.",
    "The sample is a phase 2 trial for the treatment of painful diabetic neuropathy. The trial includes patients with Type 1 or Type 2 diabetes mellitus who have a history of chronic pain in the lower extremities for at least six months but less than or equal to five years prior to screening. The trial excludes patients with neuropathy secondary to non-diabetic causes, significant neurological disorders, or other chronic pain with intensity at or greater than the bilateral pain in the feet/toes. Patients using an implanted medical device for pain treatment, or who are pregnant or lactating, are also excluded. The trial involves the use of two drugs, placebo gel and clonidine topical gel (arc-4558). The diseases are listed as 'painful diabetic neuropathy' and the icd-10 codes associated with the disease are also provided.",
    "The sample is a phase 2 trial for the treatment of type 1 diabetes mellitus using the drug sirolimus. The trial includes eligibility criteria such as being mentally stable, having a clinical history compatible with type 1 diabetes, and having a reduced awareness of hypoglycemia. Exclusion criteria include having a BMI greater than 30 kg/m2, having a requirement for more than 1.0 IU/kg/day or less than 15 U/day of insulin, and having a HbA1c greater than 10%. The trial also excludes individuals with certain medical conditions such as severe coexisting cardiac disease, symptomatic cholecystolithiasis, and acute or chronic pancreatitis.",
    "The sample is a phase 2 clinical trial for the treatment of advanced melanoma using the drug ipilimumab. The trial is open to men and women over the age of 18 who have previously been treated with ipilimumab and have experienced documented progressive disease after expanded clinical benefit. The trial has different stages, including first reinduction and extended maintenance, and there are specific eligibility criteria for each stage. The sample also includes a list of inclusion and exclusion criteria for the trial.",
    "The sample is a phase 2 clinical trial for patients with asthma. The trial includes patients who are between 18 and 75 years old and have had a diagnosis of asthma for at least 3 months. Patients must have a pre-bronchodilator FEV1 between 60% and 90% of predicted normal and must be symptomatic despite their current maintenance treatment with medium doses of ICS. Patients must also be never-smokers or ex-smokers who stopped smoking at least one year prior to enrollment and who have a smoking history of less than 10 pack-years. The trial involves the use of two drugs, tiotropium 5 mcg qd and tiotropium 2.5 mcg bid. Patients must be able to use the Respimat inhaler correctly and must be able to perform all trial-related procedures. The eligibility criteria include a list of 18 inclusion and exclusion criteria, such as not having a significant disease other than asthma, not requiring more than 12 puffs of rescue medication per 24 hours, and not having known active tuberculosis. Female patients of child-bearing potential must be using a highly effective method of birth control. The trial requires patients to sign an Informed Consent Form consistent with ICH-GCP guidelines and local legislation prior to participation.",
    "The sample is a phase 2 clinical trial for chronic obstructive pulmonary disease (COPD) patients. The trial involves the use of various inhalation solutions, including glycopyrrolate, and a placebo. The eligibility criteria for the trial include being between the ages of 40 and 75, having a clinical diagnosis of COPD according to the GOLD guidelines, being a current or ex-smoker with at least 10 pack-year smoking history, having a post-bronchodilator FEV1 30-70% of predicted normal, having a post-bronchodilator FEV1/FVC ratio < 0.70, and being able to perform reproducible spirometry according to the ATS/ERS guidelines. The trial also has exclusion criteria, such as being pregnant or lactating, having a recent history of hospitalization due to an exacerbation of airway disease, or having a primary diagnosis of asthma. The trial requires participants to stay at the study site for approximately 30 hours on each treatment visit and provide written informed consent.",
    "The sample is a phase 2 clinical trial for lung cancer, specifically for Stage IIIb/IV non-small cell lung cancer or extensive stage small-cell lung cancer. The trial involves the use of drugs such as ipilimumab, placebo, paclitaxel, and carboplatin. The eligibility criteria for the trial include having a measurable tumor lesion, an Eastern Cooperative Oncology Group performance status of \u22641, and not having brain metastases or malignant pleural effusion. Exclusion criteria include having an autoimmune disease, chronic use of immunosuppressants and/or systemic corticosteroids, and inadequate hematologic, hepatic, or renal function.",
    "The sample is a phase 2 clinical trial for patients with squamous cell carcinoma of the head and neck that is either recurrent, persistent, or newly diagnosed metastatic disease. The trial is testing the effectiveness of the drugs gemcitabine and paclitaxel. The eligibility criteria include having measurable or non-measurable disease, being 18 years or older with a Zubrod performance status of 0-1, and having no serious organ dysfunction or comorbid conditions that would preclude study treatment. Patients must not have had prior chemotherapy for recurrent or newly diagnosed metastatic disease, and must not have had gemcitabine or taxanes as part of induction, adjuvant, or neoadjuvant chemotherapy. Other concurrent therapy for squamous cell carcinoma of the head and neck is not allowed.",
    "The sample is a phase 2 trial for the treatment of symptomatic atrial fibrillation and atrial flutter. The trial involves the use of two drugs, vanoxerine and placebo. The eligibility criteria for the trial include being 18 years or older, having symptomatic AF/AFL for more than 3 hours and less than 7 days, and having AF/AFL documented by ECG at the start of study drug administration. Exclusion criteria include having a systolic blood pressure less than 100 mmHg, an average heart rate less than 50 bpm, and a history of certain heart conditions such as long QT syndrome or ventricular tachycardia.",
    "The sample is a phase 2 clinical trial for the treatment of gastric cancer. The trial is looking at the effectiveness of irinotecan associated with fluorouracil and leucovorin. The eligibility criteria for the trial includes being 70 years of age or older, having locally advanced or metastatic gastric cancer, not having received any previous adjuvant treatment in the last 6 months, having one measurable lesion, having an ECOG score of less than 3, having normal biology and biochemistry, and having a life expectancy of more than 12 weeks. The exclusion criteria includes having received other palliative chemotherapy for this cancer, having had another cancer in the last 5 years, having received previous treatment with irinotecan, not being able to receive atropine treatment, receiving concomitant cancer therapy except bone radiotherapy, having metastases to the brain or meninges with symptoms, having other severe uncontrolled pathology, and having a problem with compliance.",
    "The sample is a phase 2 clinical trial for advanced non-small cell lung carcinoma (NSCLC) patients who have received one prior chemotherapy for metastatic NSCLC, excluding TAXOTERE or HYCAMTIN. The trial is testing the efficacy of a combination of topotecan/docetaxel and docetaxel drugs. The eligibility criteria include being at least 18 years old, having measurable or non-measurable disease by radiologic study or physical examination, and having adequate bone marrow reserve, CBC/Platelet, kidney and liver function. The exclusion criteria include having concomitant malignancies or other malignancies within the last five years, symptoms of brain metastases requiring treatment with steroids, and ongoing or planned chemotherapy, immunotherapy, radiotherapy, or investigational therapy for the treatment of NSCLC.",
    "The sample is a phase 2 clinical trial for patients with relapsed or refractory Hodgkin's disease or lymphoma. The trial involves the use of alemtuzumab (campath-1h) and has specific inclusion and exclusion criteria. Inclusion criteria include having a minimum of 2 prior treatment regimens, including autologous bone marrow transplantation, and having histologically proven diagnosis of nodular sclerosis or mixed cellularity Hodgkin's disease. Exclusion criteria include serious inter-current infections requiring therapy, prior allogeneic stem cell transplantation, and an ejection fraction of less than 40%. The trial is open to males or females equal to or greater than 18 years of age who sign a consent form and meet the other criteria.",
    "The sample is a phase 2 clinical trial for the treatment of schizophrenia. The trial includes patients who are male or female between the ages of 18-65 and have a current DSM-IV-TR diagnosis of schizophrenia. Patients must be experiencing an acute exacerbation of psychosis and have a baseline total score on the PANSS greater than '70'. They must also have a score of '4' or more on two of the following four PANSS items: delusions, hallucinatory behaviors, conceptual disorganization or suspiciousness/persecution. Patients must be willing to be hospitalized at screening and remain in the hospital for at least 14 days after baseline. They must also have a caregiver or identified responsible person to support them and ensure compliance with treatment and outpatient visits. Patients must not be taking any prohibited medications during participation in the study. Exclusion criteria include pregnancy, breastfeeding, and participation in a prior clinical study of BL-1020 or any of its excipients.",
    "The sample is a phase 2 clinical trial for patients with non-small cell lung cancer. The trial is testing the effectiveness of erlotinib hydrochloride and celecoxib as a treatment for recurrent lung cancer that has progressed after 1 or 2 prior chemotherapy regimens. The trial is open to patients with stage IIIB (malignant pleural effusion only) or IV lung cancer. Patients must have at least one measurable lesion and a tissue specimen available for assays. They must also meet a number of eligibility criteria related to their health status and medical history. The trial excludes patients with brain metastases, significant traumatic injury within the past 21 days, psychiatric illness or social situation that would preclude study compliance, and other concurrent uncontrolled illness.",
    "The sample is a phase 2 clinical trial for osteoarthritis in the knee and hip. The trial is testing two drugs, cg100649 and silicified microcrystalline cellulose + talc, on male participants aged 18-75 with a BMI of 19-35 kg/m2 and good health. Participants must have confirmed osteoarthritis by radiographs obtained within the past 20 years and diagnosed according to ACR guidelines. They must also have chronic pain for at least 3 months from osteoarthritis and have been receiving stable oral doses of NSAIDs or COX-2 inhibitors at least 3 days per week for one month or longer. The trial has a list of inclusion and exclusion criteria that participants must meet. Participants must be able to read, understand and follow the study instructions, and agree to use double barrier contraception during the study period and for 2 months afterward.",
    "The sample is a phase 2 clinical trial table that includes information on diseases, drugs, eligibility criteria, and icd-10 codes. The diseases listed include leukemia, lymphoma, Hodgkin's disease, hematologic neoplasms, multiple myeloma, and renal cell carcinoma. The drugs being tested are pentostatin. The eligibility criteria include having one of the listed diagnoses and meeting at least one of the listed conditions, such as being over 50 years old or having previously undergone a transplant with hematopoietic cells. The exclusion criteria include being eligible for another clinical therapeutic protocol or standard-of-care treatment that offers a higher probability of cure or long-term control of the subject's malignancy.",
    "The sample is a phase 2 trial for the disease hypercholesterolemia. The trial includes a list of icd-10 codes for the disease and a list of drugs being tested, including etc-1002 and placebo. The eligibility criteria for the trial include having a history of statin intolerance that resolved within 4 weeks of stopping the treatment, having specific levels of LDL-C and triglycerides, and not having acute significant cardiovascular disease or poorly controlled hypertension. The exclusion criteria include having poorly controlled hypertension and acute significant cardiovascular disease.",
    "The sample is a phase 2 clinical trial for patients with metastatic melanoma or skin neoplasms. The trial involves the use of imatinib mesylate (sti571) as a treatment. Patients must meet certain eligibility criteria, including having measurable indicator metastasis, normal organ and marrow function, and a performance status below 2. Patients must not have uncontrolled intercurrent illness or severe and/or uncontrolled concurrent medical disease. Additionally, patients must not be pregnant or nursing, and must agree to use an effective contraceptive method. The trial also has exclusion criteria, such as patients with medical or psychological conditions that make them unable to tolerate or complete the treatment. The sample includes a list of diseases and their corresponding icd-10 codes, as well as the eligibility criteria for the trial.",
    "The sample is a phase 2 trial for the treatment of prostate cancer. The trial includes patients with metastatic disease or a prior history of metastases, as well as prostate cancer progression. The drug being tested is itraconazole. The eligibility criteria include being male and aged 18 or older, having a confirmed diagnosis of adenocarcinoma of the prostate, and having a life expectancy of at least 6 months. Patients must also have a performance status of 2 or lower, and meet certain laboratory criteria. There are also exclusion criteria, such as having known brain metastasis or prior treatment with certain drugs. The trial allows for up to 3 prior chemotherapy regimens.",
    "The sample is a phase 2 clinical trial for the treatment of myelodysplastic syndrome (MDS) using arsenic trioxide. The eligibility criteria include a diagnosis of MDS confirmed by bone marrow biopsy or hematologist evaluation, an ECOG performance status of 0-2, and normal levels of serum creatinine, bilirubin, potassium, and magnesium. Patients must also be at least 18 years old and not pregnant or nursing. Exclusion criteria include significant heart conditions, peripheral neuropathy, active infection, and concurrent treatment with other therapies. Patients must be willing to comply with the treatment protocol and follow-up tests.",
    "The sample is a record of a clinical trial with a phase 2 designation. The trial is focused on treating various stages of squamous cell carcinoma in different parts of the body using erlotinib hydrochloride and cisplatin. The eligibility criteria for the trial include having a documented diagnosis of squamous cell carcinoma, being in stage III or IV according to the American Joint Committee on Cancer (AJCC) Cancer Staging Manual, and having measurable disease. Patients must also have an Eastern Cooperative Oncology Group (ECOG) performance status of 0-2 and meet certain laboratory values. The trial has exclusion criteria, including having a second primary malignancy, being unable or unwilling to comply with radiotherapy, and having prior treatment with an investigational or marketed inhibitor of the EGFR pathway.",
    "The sample is a phase 2 clinical trial for the treatment of hepatitis C virus. The trial includes participants with a chronic HCV genotype 1, 2, or 3 infection for at least 6 months, a plasma HCV RNA > 50,000 IU/mL, and FibroTest score <= 0.72 and aspartate aminotransferase (AST) to platelet ratio index <= 2, Fibroscan\u00ae result of < 9.6 kilopascal (kPa), or absence of cirrhosis based on a liver biopsy. The trial involves the use of four drugs: abt-450, abt-267, ribavirin, and ritonavir. The eligibility criteria include having a body mass index of 18 to < 35 kg/m^2, being in general good health, and not having a history of certain medical conditions or drug use. The trial also has exclusion criteria, such as a positive drug screen, previous use of anti-HCV agents, and abnormal laboratory results. Females who are pregnant or planning to become pregnant within 6 months after their last dose of study drug/RBV or are breastfeeding, and males whose partners are pregnant or will become pregnant within 6 months after their last dose of study drug/RBV are also excluded from the trial.",
    "The sample is a phase 2 clinical trial for attention deficit hyperactivity disorder. The trial is testing the drug atomoxetine. The eligibility criteria for the trial includes being at least 18 years old, meeting diagnostic criteria for current and historical ADHD, and having a moderate level of symptoms. Exclusion criteria includes having a current or past history of major depression, anxiety disorder, bipolar disorder, schizophrenia, or a psychotic disorder. Patients with a history of pervasive developmental disorder are also excluded. The icd-10 codes for the disease are also provided.",
    "The sample is a phase 2 clinical trial for the treatment of acute coronary syndrome. The trial includes male and female participants under the age of 75 who have been diagnosed with ST segment elevation myocardial infarction, non-ST elevation myocardial infarction, or unstable angina. Participants must also have angiographic evidence of coronary artery disease with a suitable \"target\" coronary artery for IVUS evaluation. The trial excludes females of child-bearing potential, individuals with a weight over 120 kg, those with >50% stenosis of the left main artery, uncontrolled diabetes, hypertriglyceridemia, congestive heart failure, ejection fraction <35%, uncontrolled hypertension, and those with known major hematologic, renal, hepatic, metabolic, gastrointestinal or endocrine dysfunction. The trial will test the effectiveness of the drugs placebo and cer-001.",
    "The sample is a record of a clinical trial with a phase 2 designation. The trial is focused on the treatment of diabetic neuropathic pain. The table includes information on the diseases being studied, the ICD-10 codes associated with those diseases, the drugs being used in the trial, and the eligibility criteria for participants. The inclusion criteria require that participants be between the ages of 18 and 75 with a diagnosis of diabetes mellitus and painful distal symmetric diabetic polyneuropathy. They must also have ongoing pain due to diabetic peripheral neuropathy for at least 6 months and an average pain score of 4 or higher on a 0-10 numerical rating scale. The exclusion criteria include clinically symptomatic neuropathic pain conditions that cannot be distinguished from diabetic neuropathic pain, newly diagnosed or clinically significant medical conditions or mental disorders that would interfere with the trial, and clinically significant abnormalities in clinical laboratory tests.",
    "This sample is a record of a clinical trial in phase 2 for the treatment of depressive disorder. The trial involves the drug \"mecamylamine hydrochloride (inversine)\" and the eligibility criteria includes patients with major depression, ages 18-65, who are on SSRI monotherapy and have depression scores on HDRS-17 item scale of 12 or higher. The exclusion criteria includes patients with suicidal or homicidal ideation, need for inpatient or partial hospital care, systolic blood pressure less than 100 mm Hg, and history of hypersensitivity to mecamylamine or its excipients. The icd-10 codes associated with the disease are also provided.",
    "The sample is a phase 2 clinical trial for patients with persistent atrial fibrillation. The trial is testing the effectiveness of the drugs eplerenone and placebo. The eligibility criteria include having persistent AF for more than 7 days but less than 1 year, a total AF history of less than 2 years, being at least 18 years old, and providing written informed consent. Female patients must be sterilized, postmenopausal, or using an adequate method of contraception and have a negative pregnancy test. Exclusion criteria include hemodynamic instability, recent myocardial infarction, heart failure, uncontrolled hypertension, and use of certain medications. Patients with liver cirrhosis, moderate to severe renal insufficiency, or serum potassium levels above 5 mmol/l are also excluded. Patients who are unlikely to comply with the protocol are also excluded.",
    "The sample is a phase 2 clinical trial for the treatment of rheumatoid arthritis. The trial involves the use of infliximab and a placebo drug. The eligibility criteria for participants include having a clinical diagnosis of rheumatoid arthritis for at least 6 months, having at least 6 tender joints and 6 swollen joints, and having a C-reactive protein level of at least 1.0 mg/L or an Erythrocyte Sedimentation Rate (ESR) of at least 28 mm/hr. Participants must also have evidence of synovitis in the wrist on a baseline MRI and meet other screening criteria. Exclusion criteria include being pregnant or breastfeeding, having other inflammatory arthritis, uncontrolled hypertension, or severe congestive heart failure, and having a history of certain infections or hypersensitivity to infliximab.",
    "The sample is a phase 2 trial for the treatment of postherpetic neuralgia and pain. The trial includes patients between the ages of 18 and 90 who have been diagnosed with PHN and have experienced at least six months of pain since shingles vesicle crusting. The trial involves the use of two drugs, ngx-1998 and placebo liquid. The eligibility criteria include having intact, unbroken skin over the painful area(s) to be treated, being on a stable regimen of chronic pain medications for at least 21 days prior to the test article application visit, and being willing to comply with protocol requirements for the duration of study participation. The exclusion criteria include recent use of any topically applied pain medication on the painful areas, participation in another drug research study within 30 days preceding the test article application visit, and significant pain of an etiology other than PHN.",
    "This sample is a phase 2 clinical trial for smoking cessation. The trial is focused on current cigarette smokers who have smoked regularly for at least a year and smoke their first cigarette more than 30 minutes after waking up. The trial is testing the effectiveness of the drug nicotine in helping smokers quit. The eligibility criteria for the trial include exclusion criteria such as known or suspected intolerance or hypersensitivity to nicotine, prior use of certain medications, and any disease that may interfere with the absorption, metabolism or excretion of the study product. Additionally, subjects who have consumed alcohol within 24 hours of the craving provocation visit or whose CO level rises during the sequestration period are excluded from the trial.",
    "The sample is a phase 2 clinical trial for patients with small cell lung cancer who have previously been treated with at least one therapeutic regimen, including doxorubicin. The trial is testing the effectiveness of the drugs ngr-htnf and doxorubicin. The eligibility criteria include confirmation of SCLC at first diagnosis, measurable disease, ECOG performance status of 0-2, adequate baseline bone marrow, hepatic and renal function, normal cardiac function, and absence of uncontrolled hypertension. Patients must also have given written informed consent to participate in the study. Exclusion criteria include concurrent anticancer therapy, myocardial infarction within the last six months, uncontrolled hypertension, and known hypersensitivity/allergic reaction or contraindications to human albumin preparations or anthracyclines. Patients with active or uncontrolled systemic disease/infections or with serious illness or medical conditions that are incompatible with the protocol are also excluded. Women of childbearing potential must provide a negative pregnancy test within 14 days prior to registration.",
    "The sample is a phase 2 clinical trial for patients with malignant glioma, a type of brain cancer. The trial is testing the effectiveness of the drugs Nuvigil\u00ae and placebo in combination with external beam radiation therapy (EBRT) and concurrent temozolomide (TMZ). The eligibility criteria include being 18 years or older, having a histologic diagnosis of a supratentorial World Health Organization (WHO) grade 3 anaplastic glioma or WHO grade 4 glioblastoma, having adequate renal and liver function, and having a Karnofsky Performance Status of at least 60%. The trial also has exclusion criteria, such as pre-existing traumatic brain injury, pre-existing dementing illness, and history of left ventricular cardiac hypertrophy. Patients who are pregnant, breastfeeding, or unwilling to use recommended birth control methods are also excluded.",
    "The sample is a phase 2 trial for liver cirrhosis. The trial includes patients with certain icd-10 codes related to liver cirrhosis and who are either euvolemic or hypervolemic due to cirrhosis. The trial involves the use of two drugs, conivaptan and placebo. The eligibility criteria include obtaining informed consent, clinical evidence of portal hypertension, and the absence of volume depletion or dehydration. The exclusion criteria include a history of bleeding from esophageal varices within three months before the start of the study.",
    "The sample is a record of a clinical trial in phase 2, focused on the disease of hypertension. The icd-10 codes associated with the disease are listed as [\"I15.0\", \"I97.3\", \"K76.6\", \"P29.2\", \"G93.2\", \"H40.053\", \"I10\"]. The drug being tested is perindopril. The eligibility criteria for the trial are listed, including inclusion criteria for hypertensive children who have been treated for at least four months with S90652 and exclusion criteria for poorly controlled hypertension and girls showing signs of pubescence.",
    "The sample is a phase 2 clinical trial for non-small cell lung cancer. The trial is testing the effectiveness of trastuzumab (herceptin) on patients with HER2 FISH positive defined as high polysomy or gene amplification, or presence of HER2 gene mutation in exon 20. Patients must have at least one measurable lesion and have been pretreated with at least one chemotherapy regimen. The trial has inclusion criteria such as age \u2265 18 years, adequate BM function, adequate liver function, normal level of alkaline phosphatase and creatinine, and ECOG performance status 0-1 and life expectancy of at least 3 months. Exclusion criteria include HER2 FISH negative tumor and no evidence of HER2 gene mutation in exon 20, concomitant radiotherapy, untreated brain metastases or leptomeningeal disease involvement, and other serious illnesses or medical conditions. Patients must provide written informed consent and comply with trial procedures.",
    "The sample is a record from a clinical trial table that includes information about the phase of the trial, diseases being studied, icd-10 codes of the diseases, drugs being tested, and eligibility criteria for the trial. In this particular sample, the trial is in phase 2/phase 3 and is studying type 2 diabetes mellitus. The icd-10 codes associated with the disease are listed. The drugs being tested are alogliptin and voglibose, and the eligibility criteria for the trial are listed under inclusion and exclusion criteria. The inclusion criteria state that the subject must have completed the phase 2 dose-ranging study, while the exclusion criteria state that the subject cannot have clinical manifestations of hepatic or renal impairment.",
    "This is a sample from a clinical trial table that includes information about the phase of the trial, diseases being studied, icd-10 codes of the diseases, drugs being used, and eligibility criteria. In this particular sample, the trial is in phase 2 and is studying myelodysplasia and leukemia. The icd-10 codes associated with these diseases are listed. The drug being used is chemotherapy. The eligibility criteria include having histological confirmation of disease, being over 18 years old, having an expected life expectancy of over 12 weeks, and meeting certain laboratory value requirements. Patients with an active second malignancy other than non-melanoma skin cancers are not eligible. Patients must not have had any chemotherapy, except hydrea, or radiation for at least 4 weeks prior. Patients must have an ECOG performance status of 0-2 and must receive and sign a full informed consent. Additionally, patients should not have co-existing medical illnesses which would limit survival to less than 12 weeks. The safety of decitabine in human pregnancy is unknown, and patients must agree to use a form of birth control that is medically acceptable to their study doctor while taking part in this research study.",
    "The sample is a phase 2 clinical trial for the treatment of amyotrophic lateral sclerosis. The trial includes patients who are 18 years or older and have been diagnosed with familial or sporadic ALS according to the World Federation of Neurology El Escorial criteria. The patients must have a maximum voluntary grip strength in at least one hand between 10 & 40 pounds (females) and 10 & 60 pounds (males), be able to swallow tablets with water, and currently taking and tolerating a stable dose of 50 mg BID riluzole. They must also be willing and able to reduce daily dose of riluzole to 50mg QD for 5 weeks. Patients must have a caregiver who is capable of observing and reporting patient status. The trial excludes patients with a life expectancy of less than 3 months, those who have received investigational study drug within 30 days or 5 half-lives of the prior agent, whichever is greater, prior to dosing, those who have had any prior treatment with CK-2017357, and those who have used non-invasive positive pressure ventilation (NIPPV), such as Continuous Positive Airway Pressure (CPAP) or Bilevel Positive Airway Pressure (BiPAP).",
    "The sample is a phase 2 clinical trial for patients with estrogen receptor-positive breast cancer, human epidermal growth factor 2 negative carcinoma of breast, male breast cancer, recurrent breast cancer, stage ii breast cancer, stage iiia breast cancer, and stage iiib breast cancer. The trial involves the use of anastrozole and pazopanib hydrochloride drugs. The eligibility criteria include a confirmed diagnosis of breast cancer, a certain stage of the disease, a specific performance status, and no evidence of distant metastatic disease. Patients must also meet certain laboratory values and have a baseline Oncotype DX score of 29 or lower. Exclusion criteria include prior malignancy, known distant metastases, and certain medical conditions. Patients must not be receiving any other investigational agents or concomitant anti-cancer therapies. The trial also has specific requirements for the use of certain medications and substances.",
    "This is a sample from a clinical trial table that includes information about the trial's phase, diseases being studied, icd-10 codes of those diseases, drugs being used, and eligibility criteria for participants. In this particular sample, the trial is in phase 2 and is studying epilepsy. The icd-10 codes associated with epilepsy are listed, as well as the drug being used (lacosamide). The eligibility criteria for participants are also listed, including requirements for a diagnosis of uncontrolled epilepsy with primary generalized tonic-clonic seizures and idiopathic generalized epilepsy, as well as exclusion criteria such as a history of partial-onset seizures or status epilepticus within the past 5 years.",
    "This sample is from a clinical trial in phase 2 for the treatment of type 2 diabetes mellitus. The trial includes subjects who are being treated for T2DM with oral antidiabetic agents (excluding glitazones) and have a BMI limit of \u2264 38. The inclusion criteria also require subjects to be at least 80% compliant on reporting daily SMBG values during washout, and at the end of washout, the subject's fasting SMBG is higher than it was at the start of washout and the fasting SMBG \u2264 280.g treated for T2DM with oral antidiabetic agents (excluding glitazones). The exclusion criteria include type 1 diabetes mellitus, severe complications of T2DM, current treatment with insulin or a glitazone, use of moderate to strong cytochrome P450 3A4 (CYP3A4) inhibitors, and significant cardiovascular diseases. Other exclusion criteria include history of significant other major or unstable neurological, metabolic, hepatic, renal, hematological, pulmonary, CV, GI, or urological disorder, diagnosis of major depressive disorder, history of diabetic ketoacidosis, and current or previous use of oral or injectable corticosteroids 3 months prior to screening. The sample also includes a list of drugs being used in the trial, including tc-6987 and placebo.",
    "The sample is a record from a clinical trial table that includes information about the trial's phase, diseases being studied, icd-10 codes of the diseases, drugs being used, and eligibility criteria for patients. In this particular sample, the trial is in phase 2 and is studying pancreatic cancer. The eligibility criteria include specific requirements for the patient's disease characteristics and patient characteristics, as well as restrictions on prior concurrent therapy. The sample also lists the drugs that are permitted and prohibited during the trial.",
    "The sample is a phase 2 clinical trial for non-small-cell lung carcinoma. The trial involves neoadjuvant therapy with cisplatin plus docetaxel. The eligibility criteria for the trial include having histologically or cytologically confirmed NSCLC appropriate for surgery, being medically fit for resection by lobectomy or pneumonectomy, having T1-2N1 disease by CT with negative N2/N3 nodes by PET or T3N1 disease with pathologically negative N2/N3 nodes, having measurable disease, not receiving other investigational therapy, not having prior chemotherapy or radiation for NSCLC, having acceptable hematologic and chemistry parameters, and being age 18 or greater with a performance status (PS) of 0-1. The exclusion criteria include having a history of severe hypersensitivity to docetaxel or like drugs, being pregnant or nursing, having prior chemotherapy or radiation for NSCLC, having symptomatic superior sulcus tumors, or having prior malignancy except for treated non-melanoma skin cancer, in situ cervical cancer, localized prostate cancer, or cancer from which the patient has been disease-free for greater than three years.",
    "The sample is a phase 2 clinical trial for the treatment of hypercholesterolemia. The trial involves testing the effectiveness of several drugs, including mk-6213 and atorvastatin calcium, as well as placebos for these drugs. The trial has specific eligibility criteria, including being between 18 and 75 years old, having high cholesterol, and not currently being on lipid lowering therapy. There are also exclusion criteria, such as having significant cardiovascular, renal, neurologic, respiratory, hepatic, or metabolic disease, a history of mental instability or drug/alcohol abuse within the past 5 years, being pregnant or nursing, being HIV positive, having a history of cancer within the past 5 years, or participating in an investigational trial within the last 30 days.",
    "The sample is a phase 2 clinical trial for patients with myelodysplastic syndromes and thrombocytopenia. The trial is testing the effectiveness of a drug called placebo. The eligibility criteria for the trial include a diagnosis of MDS using the WHO classification, low or intermediate-1 risk MDS as assessed by the IPSS, and specific platelet count ranges. Patients must also have an ECOG performance status of 0-2, adequate liver and kidney function, and a bone marrow biopsy and aspirate with cytogenetics within 3 months of starting the trial. Exclusion criteria include prior treatment for MDS, a history of leukemia or other bone marrow disorders, and certain medical conditions such as uncontrolled hypertension and recent myocardial infarction. Patients must also not be pregnant or breastfeeding and must use adequate contraceptive precautions.",
    "The sample is a record of a clinical trial in phase 2 for the treatment of overactive bladder. The trial is testing the effectiveness of two drugs, agn-214868 and agn-214868 placebo. The eligibility criteria for participants include having symptoms of overactive bladder with urinary urgency incontinence and having an inadequate response or limiting side effects with anticholinergics. Exclusion criteria include having overactive bladder caused by a neurological condition, a history of bladder surgery, or previous treatment with botulinum toxin therapy for any urological condition. The sample also includes the disease name, icd-10 codes, and the inclusion and exclusion criteria for the trial.",
    "The sample is a phase 2 clinical trial for patients with advanced solid tumors that are refractory to standard treatment, for which no standard therapy is available, or the subject refuses standard therapy. The trial is testing the drug bkm120, which is a P13K inhibitor. Patients must have at least one site of measurable disease and a life expectancy of at least 12 weeks. They must also have adequate marrow and organ function and a diagnosis of lung cancer, breast cancer, colorectal cancer, cholangiocarcinoma, gastric cancer, pancreatic cancer, prostate cancer, uterine cancer, ovarian cancer, esophageal cancer, or head and neck cancer. The cancer must have at least one of the following PIK3CA mutations: E542K, E545K, H1047R, H1047L. The PIK3CA mutation must be documented in a CLIA approved laboratory. Patients cannot have prior treatment with a P13K inhibitor, untreated brain metastases, or any concurrent severe and/or uncontrolled medical condition. They also cannot have active cardiac disease, poorly controlled diabetes mellitus or steroid-induced diabetes mellitus, or significant symptomatic deterioration of lung function. Additionally, they cannot have impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of BKDM120. Patients cannot be currently taking therapeutic doses of warfarin sodium or any other coumadin-derivative anticoagulant, pregnant or breast-feeding, or have a known diagnosis of HIV infection. They also cannot have a history of another malignancy within 3 years, except cured basal cell carcinoma of the skin or excised carcinoma in situ of the cervix, or be unable to swallow the medication in its prescribed form.",
    "This sample is a phase 2 clinical trial for hematologic diseases. The trial involves the use of two drugs, g-csf and gm-csf. The eligibility criteria for the trial include normal donors for patients undergoing allogeneic peripheral blood stem cell (PBSC) transplantation for hematologic diseases. Patients must meet the criteria for transplantation, and final eligibility will be determined by health professionals conducting the trial. Donors for patients undergoing selected or manipulated PBSC grafts, pregnant or lactating females, and donors with a known hypersensitivity to either G-CSF or GM-CSF are excluded from the study. Final eligibility will be determined by the health professionals conducting the clinical trial.",
    "The sample is a phase 2 clinical trial for patients with metastatic prostate cancer. The trial involves the drug sunitinib and has a list of inclusion and exclusion criteria. Inclusion criteria include having confirmed adenocarcinoma of the prostate, stage IV disease, and having received 1 or 2 prior chemotherapy regimens (one of which must be docetaxel). Exclusion criteria include having any disease other than prostate cancer, having received prior treatment with Sutent, and having a history of hypersensitivity to any of the components of Sutent. The trial requires patients to meet certain laboratory values and have adequate cardiac function. Patients must also sign a Patient Informed Consent Form and a Patient Authorization Form.",
    "The sample is a phase 2 clinical trial for patients with metastatic or locally recurrent colorectal adenocarcinoma. The trial involves the use of four drugs: fluorouracil, irinotecan hydrochloride, leucovorin calcium, and oxaliplatin. The eligibility criteria include having measurable disease, at least 2 tissue samples or willingness to undergo biopsy, being 18 years or older, having an Eastern Cooperative Oncology Group (ECOG) Performance status of 0-2, and meeting various laboratory values. Exclusion criteria include pregnancy or nursing, recent arterial thromboembolic events, symptomatic arrhythmia or congestive heart failure, significant traumatic injury, and ongoing or active infection. Prior chemotherapy for metastatic disease is also an exclusion criterion.",
    "The sample is a phase 2 clinical trial for Non-Small-Cell Lung Cancer Stage IIIB/IV. The trial is testing the effectiveness of gemcitabine and uft as a treatment for the disease. The eligibility criteria include having no prior chemotherapy, measurable disease that has not been irradiated, a life expectancy of more than 3 months, being at least 70 years old, having a performance status of 1 or 2, and adequate bone marrow, liver, and renal function. The exclusion criteria include having a psychiatric illness or social situation that would preclude study compliance, having other concurrent uncontrolled illness, having had another invasive malignancy within the past 5 years except nonmelanoma skin cancer, currently or recently taking warfarin, phenprocoumon or phenytoin, and having a history of hypersensitivity to any drug.",
    "The sample is a phase 2 clinical trial for the treatment of type 2 diabetes mellitus. The trial involves the use of three drugs: ipragliflozin, placebo, and metformin. The eligibility criteria for the trial include having a diagnosis of type 2 diabetes mellitus for at least 6 months, inadequate glycemic control, and being on a stable dose of at least 1500 mg/day metformin monotherapy for at least 6 weeks prior to the start of the trial. Other inclusion criteria include having a body mass index (BMI) between 20-45 kg/m2, being on a stable diet and exercise program, and being willing to remain on this program for the duration of the study. Exclusion criteria include having any known complication of T2DM indicating a late disease state, having type 1 diabetes mellitus, being in need of insulin therapy, having a serum creatinine higher than the upper limit of normal range, having an alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) higher than 3 times the upper limit of normal range, having a urinary microalbumin/creatinine ratio above or equal to 300 mg/g, having a symptomatic urinary tract infection (UTI) or symptomatic genital infection, having persistent, uncontrolled severe hypertension, having a significant cardiovascular disease, being known to have hepatitis or be a carrier of hepatitis B surface antigen (HBsAg), hepatitis C virus (HCV) antibody, or being known positive for human immunodeficiency virus (HIV) HIV-1 and/or HIV 2, currently receiving an excluded medication, having a history of lactic acidosis, having a history of drug or alcohol abuse/dependency, having had a malignancy in the last 5 years, except for adequately treated basal or squamous cell carcinoma of the skin or carcinoma in situ of the cervix, being pregnant, lactating or pre-menopausal with positive serum pregnancy test (hCG), having an unstable medical or psychiatric illness, having known or suspected hypersensitivity to ASP1941 or any components of the formulations used, having previously received ASP1941, concurrently participating in another drug study or having received an investigational drug within 30 days prior to the start of the trial, and having any concurrent illness which, in the opinion of the investigator, may interfere with treatment or evaluation of safety or completion of this study.",
    "The sample is a phase 2 clinical trial for the treatment of hypercholesterolemia. The trial includes men and women between the ages of 18 and 70 years with elevated LDL cholesterol based on risk factors for cardiovascular disease or presence of cardiovascular disease. The trial excludes women who are pregnant, lactating, planning to become pregnant, or women of childbearing potential who have not successfully been using acceptable contraceptive methods over the previous 3 months. Other exclusion criteria include uncontrolled hypertension, history of chronic kidney problems, history of liver disease, positive for Hepatitis B or Hepatitis C, any major surgical procedure occurring less than 3 months ago, cardiac insufficiency, history of a malignant cancer within the previous 5 years, regular alcohol use >1 drink per day, regular consumers of grapefruit juice, or currently taking certain medications, use of other cholesterol lowering medications that cannot be stopped, heart attack or stroke within the previous 6 months, diabetes mellitus, body mass index (BMI) \u2265 40 kg/m2, significant gastrointestinal symptoms, and current use of fish oils, niacin, and herbal weight loss products that cannot be stopped. The trial involves the use of various drugs including atorvastatin 20 mg, aegr-733 5 mg, aegr-733 10 mg, placebo, aegr-733 5 mg + atorvastatin 20 mg, and aegr-733 10 mg + atorvastatin 20 mg.",
    "The sample is a phase 2 clinical trial for patients with squamous cell carcinoma of the head and neck. The trial involves the use of lapatinib oral tablets, radiotherapy, and cisplatin chemotherapy as primary treatment. The eligibility criteria include having a confirmed diagnosis of SCCHN, ErbB1 over-expression, and a certain stage of disease. Patients must also have adequate haematological, renal, and hepatic function, and a life expectancy of at least 6 months. Exclusion criteria include prior or current treatment for invasive head and neck cancer, peripheral neuropathy, and pregnancy or lactation. The trial aims to assess the safety and efficacy of the treatment regimen.",
    "The sample is a phase 2 clinical trial for patients with stage IIIB or IV non-small cell lung cancer. The trial is testing the effectiveness of the drug pemetrexed disodium. Patients must have measurable disease and have previously been treated with one chemotherapy regimen. They must also meet certain eligibility criteria, including having an ECOG performance status of 0-2, a life expectancy of at least 12 weeks, and meeting certain blood count and liver function requirements. Patients must not have certain medical conditions, such as hypertension, diabetes, or interstitial pneumonia, and must not have had certain treatments within a certain timeframe, such as chemotherapy within the past 3 weeks or major surgery within the past 4 weeks.",
    "The sample is a phase 2 clinical trial for patients with head and neck squamous cell cancer. The trial involves the use of two drugs, imatinib mesylate and docetaxel. The eligibility criteria include having a written informed consent, being at least 18 years old, having a histologically documented diagnosis of head and neck squamous cell cancer, having at least one measurable site of disease, having a performance status of 0-2, and having adequate hepatic, renal, and bone marrow function. Exclusion criteria include prior exposure to docetaxel or imatinib mesylate, severe and/or uncontrolled medical disease, and a known diagnosis of human immunodeficiency virus (HIV) infection. Patients must also agree not to use herbal remedies or other over-the-counter biologics. The trial involves a list of diseases and their corresponding icd-10 codes, as well as eligibility criteria for patients to participate in the trial.",
    "The sample is a phase 2 clinical trial for the treatment of various types of cancer, including head and neck cancer and squamous cell carcinoma. The trial involves the use of two drugs, panitumumab and cisplatin, and has specific eligibility criteria for participants, including having a certain stage of the disease and measurable tumors. The trial also has exclusion criteria, such as not having prior malignancies or major surgery within a certain timeframe. The diseases and their corresponding ICD-10 codes are also listed in the sample.",
    "The sample is a record of a clinical trial for the treatment of multiple myeloma, a type of cancer that affects plasma cells. The trial is in phase 2 and involves a combination of drugs including bortezomib, cisplatin, cyclophosphamide, dexamethasone, doxorubicin hydrochloride, etoposide, lenalidomide, melphalan, and thalidomide. The eligibility criteria for the trial include having newly diagnosed active multiple myeloma with measurable disease, a Zubrod performance status of 0-2, and certain laboratory values within normal limits. Patients must also not have certain medical conditions or prior treatments, and must be willing to comply with the FDA-mandated S.T.E.P.S. program if they are fertile. The record includes detailed information on the disease characteristics, patient characteristics, and prior concurrent therapy.",
    "The sample is a phase 2 clinical trial for contraception. The trial is looking for women who are willing to use a Combined Oral Contraceptive for 6 subsequent cycles and have good physical and mental health. The women must have a regular menstrual cycle (24-35 days) prior to screening and a body mass index between (\u2265) 18 and (\u2264) 30 kg/m2. The trial has a list of exclusion criteria, including previous use of any hormonal contraceptive method during the last 3 months prior to randomisation, previous use of progestogen-only contraceptive methods during the last 3 months or during the last 6 months for depot progestogen preparations or an injectable hormonal method of contraception, and use of phytoestrogens. Other exclusion criteria include no spontaneous menstruation following a delivery or abortion, breastfeeding or within 2 months after stopping breastfeeding prior to the start of study medication and no spontaneous return of menstruation, and status post-partum or post-abortion within a period of 2 months before screening. The trial also excludes women who have had an abnormal cervical smear within one year before study start, untreated Chlamydia infection, known or suspected breast cancer or a history of breast cancer, a history of (within 12 months) alcohol or drug abuse, any clinically relevant abnormality, contraindications for the contraceptive steroids used in the clinical trial, use of antihypertensive drugs or use of medications interacting with the contraceptive steroids used in the clinical trial, and administration of any other investigational drug within 2 months prior to screening. The trial is testing three different drugs: estetrol, p 1 and placebo tablets, estetrol, p2 and placebo tablets, and estradiol valerate, dienogest and placebo tablets.",
    "The sample is a phase 2 clinical trial for patients with persistent or recurrent ovarian epithelial or primary peritoneal cancer. The trial is testing the effectiveness of lapatinib ditosylate, a drug used to treat cancer. The eligibility criteria include having measurable disease, disease progression during or persistent disease after 1 prior platinum-based chemotherapy regimen, and being ineligible for any higher priority Gynecologic Oncology Group (GOG) protocols. Patients must also meet various health requirements, such as having normal ejection fraction and no uncontrolled inflammatory GI disease. Additionally, patients must not have had prior lapatinib or other target-specific therapy directed to the HER family, and must not be taking certain medications or have certain medical conditions.",
    "The sample is a record of a clinical trial with a phase 2 designation. The trial is focused on treating neoplasms in the gastrointestinal tract using the drugs lapatinib and capecitabine. The trial is looking for patients with untreated, newly diagnosed, advanced metastatic or unresectable gastric cancer, including the gastro-esophageal junction. Patients must have measurable disease according to RECIST criteria and be over 18 years old with adequate organ function. The trial has a list of exclusion criteria, including patients with certain types of cancer, pregnant or lactating females, and those with certain gastrointestinal conditions.",
    "The sample is a phase 2 clinical trial for the treatment of follicular lymphoma. The trial includes patients who have relapsed or progressed following prior antineoplastic therapy and have received 4 or more prior doses of rituximab. The trial involves the use of three drugs: velcade, bendamustine, and rituximab. The eligibility criteria include having a measurable tumor mass, a Karnofsky performance status of at least 50, and no clinically significant central nervous system lymphoma. The exclusion criteria include prior treatment with velcade or bendamustine, recent antineoplastic or radiation therapy, and major surgery within 2 weeks before the start of the trial. The trial also excludes patients with ongoing therapy with corticosteroids above a certain dosage.",
    "The sample is a phase 2 clinical trial for the treatment of schizophrenia. The trial includes patients who meet the DSM-IV criteria for schizophrenia and agree to a minimum hospitalization period of 31 days. Female patients must not be pregnant or taking steps to prevent conception. The trial involves the use of the drugs lurasidone and placebo. The eligibility criteria include exclusion of patients who have used an investigational drug within the past 30 days or have participated in a previous study of this compound. The diseases being studied are limited to schizophrenia and are identified by their corresponding ICD-10 codes.",
    "The sample is a phase 2 clinical trial for type 1 diabetes. The trial includes patients who have been diagnosed with type 1 diabetes within the past 3 months and are between the ages of 8 and 45. Participants must have stimulated C-peptide levels greater than 0.2 pmol/ml and detectable anti-GAD, anti-ICA512/IA-2, insulin autoantibodies, or islet cell autoantibodies. The trial will test the effectiveness of mycophenolate mofeteil (mmf) and daclizumab (dzb) compared to placebo control for both drugs. Participants must be willing to comply with intensive diabetes management and achieve an HbA1c of 7.0%. The trial has exclusion criteria, including complicating medical issues, abnormal liver function tests, chronic use of steroids or other immunosuppressive agents, and pregnancy or nursing.",
    "The sample is a phase 2 clinical trial for patients with stage IIIA, IIIB, or IV non-small cell lung cancer who have had disease progression during or after one or more platinum-based chemotherapy regimens. The trial involves the use of the drugs celecoxib and docetaxel. The eligibility criteria include various disease and patient characteristics, such as measurable or evaluable disease, neurological stability, and certain blood counts and organ function. Prior and concurrent therapies are also specified.",
    "The sample is a phase 2 clinical trial for autism spectrum disorder (ASD) and related conditions, using the drug memantine hydrochloride (HCl). The trial is for male and female outpatients between the ages of 6 and 12 who meet the DSM-IV-TR diagnostic criteria for autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS). The trial requires a stable and organized family to ensure safety monitoring and attendance to clinic visits. Exclusion criteria include enrollment in another study using an experimental drug within 30 days of screening, medical conditions that may interfere with the study, and primary psychiatric diagnoses other than autism, Asperger's Disorder, and PDD-NOS. Additionally, participants cannot have met DSM-IV-TR criteria for bipolar I disorder, psychotic disorder not otherwise specified, posttraumatic stress disorder, schizophrenia, or major depressive disorder within the past 6 months.",
    "The sample is a phase 2 clinical trial for female patients with invasive breast cancer that has progressed following prior therapy. The trial is testing the effectiveness of a combination of three drugs - vinorelbine, lapatinib, and capecitabine. The eligibility criteria include having a life expectancy of at least 12 weeks, confirmed overexpression of ErbB2, and an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1. The trial also has exclusion criteria, such as having uncontrolled or symptomatic angina, concurrent anticancer or concomitant radiotherapy treatment, and unresolved or unstable serious toxicity from prior administration of another investigational drug and/or prior cancer treatment. The sample includes detailed inclusion and exclusion criteria for the trial.",
    "The sample is a clinical trial with a combination of phase 2 and phase 3. The trial is focused on three diseases: macular degeneration, glaucoma, and regional blood flow. The diseases are identified using ICD-10 codes. The trial involves the use of a drug called moxaverine. The eligibility criteria for the trial include being over 50 years old, having ametropia of less than 6 diopters and anisometropia of less than 2 diopters, and having clear non-lenticular ocular media. The inclusion criteria for AMD patients include having nonexudative AMD and visual acuity in the study eye greater than 20/60. The inclusion criteria for glaucoma patients include having unilateral or bilateral primary open angle glaucoma, at least 3 reliable visual field testings, treated intraocular pressure less than 21 mmHg, and visual field mean deviation MD less than 10 (Humphrey 30-2). The inclusion criteria for healthy control subjects include being age-, gender-, and sex-matched to the two patient groups and matched with regard to smoking habits of the two patient groups, and having no observable eye diseases. The exclusion criteria include having a history or presence of gastrointestinal, liver or kidney disease, or other conditions known to interfere with distribution, metabolism or excretion of the study drug, blood donation during the previous 3 weeks, abuse of alcoholic beverages or drugs, participation in a clinical trial in the 3 weeks preceding the study, known diabetes mellitus, presence of any ocular pathology that interferes with the aims of the present study, intraocular surgery within the last 3 weeks, hypersensitivity to moxaverine, and acute gastric bleeding or massive cerebral hemorrhage related to stroke.",
    "The sample is a phase 2 clinical trial for advanced breast cancer patients. The trial is testing the drug dasatinib. The eligibility criteria for the trial include having measurable Stage IV or inoperable Stage III advanced breast cancer, no limit on the number of prior therapies, and meeting certain medical requirements such as normal liver and kidney function. The trial also has exclusion criteria such as prior treatment with dasatinib and bone as the only site of disease. The sample includes both inclusion and exclusion criteria for the trial.",
    "The sample is a phase 2 clinical trial for the treatment of non-hodgkin lymphoma and multiple myeloma. The trial involves the use of the drug combination of g-csf and plerixafor. The eligibility criteria for the trial include patients with specific stages of the diseases, a certain number of prior chemotherapy regimens, and specific blood counts. Patients with brain metastases, hypercalcemia, cardiovascular disease, or acute infection are excluded from the trial. The diseases are identified by both their name and their icd-10 codes.",
    "The sample is a phase 2 trial for participants with invasive breast cancer that has recurred or metastasized. The participants must have measurable disease and recent evidence of progressive disease. They must have received 1-3 prior chemotherapeutic regimens for metastatic breast cancer and must have been off treatment with chemotherapy for at least 14 days before enrollment in the study. The trial is testing the drug tivantinib. The eligibility criteria include various medical and laboratory tests, as well as the requirement that the primary tumor and/or the metastasis must be triple-negative and hormone-receptor poor. The trial also requires participants to use adequate contraception during the study and for 90 days after the last investigational drug dose received. The exclusion criteria include various medical conditions and situations that would limit compliance with study requirements. Pregnant women and HIV-positive participants on combination antiretroviral therapy are also ineligible.",
    "The sample is a record of a clinical trial in phase 2, which involves testing the drugs avp-923 and placebo on patients with central neuropathic pain and multiple sclerosis. The diseases are listed along with their corresponding ICD-10 codes. The eligibility criteria for the trial are also provided, including the main inclusion and exclusion criteria. The inclusion criteria require patients to have a clinical history and symptoms of central neuropathic pain for at least 3 months prior to screening, a PRS baseline score of 4 or higher, and no MS relapse within the previous 30 days. The exclusion criteria include a personal history of complete heart block, QTc prolongation, or torsades de pointes, family history of congenital QT interval prolongation syndrome, Myasthenia Gravis, and a BDI score of more than 19.",
    "The sample is a record of a clinical trial with a phase 2 designation. The trial is focused on breast cancer and includes a list of ICD-10 codes associated with the disease. The trial involves the use of several drugs, including gemcitabine, paclitaxel, carboplatin, and cisplatin. The eligibility criteria for the trial include female patients with a histological or cytological diagnosis of breast cancer, stage IV disease, and a performance status of 0 or 1 on the Eastern Cooperative Oncology Group (ECOG) Scale. Patients must have previously received anthracycline-based regimens as adjuvant therapy or neo-adjuvant chemotherapy and then progressed to develop metastatic disease. Exclusion criteria include prior chemotherapy for metastatic disease, concurrent administration of any other tumor therapy, and peripheral neuropathy of Common Toxicity Criteria (CTC) Grade greater than 1. The trial also excludes patients with a history of significant neurological or mental disorder, including seizures or dementia.",
    "The sample is a record of a clinical trial in phase 2, focused on pulmonary disease, chronic obstructive. The trial is testing the drug uk-500,001. The eligibility criteria for the trial include having moderate-severe COPD and a smoking history of at least 10 pack-years. Exclusion criteria include having any significant co-morbid disease and using any maintenance therapy except short acting bronchodilators. The icd-10 codes associated with the disease are J44.9, J44.1, and J44.0.",
    "The sample is a phase 2 clinical trial for the treatment of glaucoma and ocular hypertension. The trial involves the use of three different ophthalmic solutions containing bimatoprost at varying concentrations. The trial is open to ethnically Japanese patients who require IOP-lowering therapy in both eyes. The eligibility criteria include exclusion of patients with uncontrolled systemic disease and those who have used bimatoprost or other ocular prostaglandins within 6 weeks prior to the start of the trial.",
    "The sample is a record from a clinical trial table that includes information about the trial's phase, diseases being studied, associated ICD-10 codes, drugs being tested, and eligibility criteria for participants. In this particular sample, the trial is in phase 2 and is focused on studying metastatic breast cancer. The associated ICD-10 codes for the disease are listed, along with the drugs being tested (imatinib and docetaxel). The eligibility criteria for participants are also listed, including requirements such as confirmation of metastatic breast cancer by biopsy, no more than one prior chemotherapy regimen for metastatic breast cancer, and adequate bone marrow, liver, and kidney function. There are also exclusion criteria listed, such as moderate to severe peripheral neuropathy and uncontrolled blood pressure or heart beat irregularities. The study center will determine if a participant meets all of the criteria, and if they do not qualify, study personnel will explain the reasons.",
    "The sample is a phase 2 clinical trial for the treatment of schizophrenia. The trial involves the use of drugs such as bl-1020 and risperidone. The eligibility criteria for participants include being between 18-65 years old, having completed 6 weeks of treatment and/or all efficacy assessments in the previous study, having a negative pregnancy test (if female), and having a caregiver or responsible person to ensure compliance with treatment and outpatient visits. Participants must also not be taking any prohibited medications during the study. Exclusion criteria include being unwilling or unable to provide informed consent, having a medical condition that would put them at risk, and being non-compliant with study procedures during the initial 6 weeks of treatment.",
    "The sample is a phase 2 clinical trial for patients with type 2 diabetes mellitus. The trial includes patients who are drug-na\u00efve or pre-treated with one oral antidiabetic drug. The trial aims to test the effectiveness of a drug called bi 10773 compared to placebos of different doses. The eligibility criteria include having a certain level of HbA1c and not having certain medical conditions or treatments. The trial also has exclusion criteria, such as uncontrolled hyperglycemia and impaired renal function. The sample includes the list of diseases, icd-10 codes, drugs, and eligibility criteria for the trial.",
    "The sample is a phase 2 clinical trial for the treatment of metastatic breast cancer. The trial involves the use of a drug called sagopilone (bay86-5302, zk 219477). The eligibility criteria for the trial include having metastatic breast cancer, not having received previous treatment with taxanes and vinca alkaloids, and using highly effective birth control methods for females of child-bearing potential. The exclusion criteria include having had more than 2 previous chemotherapies, having participated in another trial within the last 4 weeks, breastfeeding, and having active infections. The diseases being studied are breast neoplasms and breast cancer, and the icd-10 codes associated with these diseases are listed.",
    "The sample is a phase 2 clinical trial for breast cancer. The trial is looking for patients with stage IIIA, IIIB (excluding inflammatory breast carcinoma), or IIIC OR localized stage IV breast cancer with no metastases and measurable disease. The patients must have adequate bone marrow, liver, and kidney function, normal cardiac function, and a Karnofsky performance status of 70-100%. The trial is open to both male and female patients who are 18 years or older and not pregnant or nursing. Fertile patients must use effective contraception. Patients must not have had prior chemotherapy for breast cancer or gene therapy using adenoviral vectors or p53 gene product. The trial is testing the effectiveness of docetaxel and doxorubicin hydrochloride.",
    "The sample is a phase 2 trial for chronic obstructive pulmonary disease (COPD). The trial includes a list of ICD-10 codes for COPD and the drugs being tested are azd9668 and placebo. The eligibility criteria for the trial includes a diagnosis of COPD with symptoms for over a year, a FEV1/FVC ratio of less than 70%, and at least one COPD exacerbation within the past year. Patients with clinically significant heart disease, asthma, or requiring long term oxygen therapy are excluded from the trial. Additionally, patients who have had worsening COPD requiring treatment with antibiotics or an increase in inhaled or oral steroids within 4 weeks of the study visit are also excluded.",
    "The sample is a phase 2 clinical trial for the treatment of estrogen receptor positive tumor and breast cancer. The trial involves the use of two drugs, eribulin mesylate and capecitabine. The eligibility criteria include being a male subject aged 18 or older or a postmenopausal female subject, being a candidate for chemotherapy in the adjuvant setting, having histologically confirmed Stage I to II invasive breast cancer, having a HER2-normal status and ER-positive, node-negative or ER-positive Grade 1 or 2 node-positive breast cancer, having an ECOG performance status of 0 or 1, and meeting certain laboratory criteria. Exclusion criteria include having Stage III and IV invasive breast cancer, having prior chemotherapy, radiation therapy, immunotherapy or biotherapy for current breast cancer, having nonmalignant systemic disease, having a concurrently active second malignancy, having pre-existing neuropathy greater than Grade 2, having known positive HIV status, being a female of childbearing potential, having current gastrointestinal disease or other condition resulting in an inability to take or absorb oral medications, having known allergy or hypersensitivity to eribulin mesylate or its excipients, having a clinically significant ECG abnormality, and having any medical or other condition which, in the opinion of the investigator, would preclude participation in a clinical trial.",
    "The sample is a phase 2 clinical trial for newly diagnosed squamous cell carcinoma of the head and neck that is unresectable and stage III or IV. The trial is testing the effectiveness of carboplatin, cisplatin, docetaxel, and fluorouracil as treatments. Patients must have measurable disease and skin and tumor material available for EGFR status and downstream signaling studies. Patients must also meet certain eligibility criteria, including having a WHO performance status of 0-1, normal cardiac function, and no serious cardiac illness or medical condition within the past 6 months. Patients cannot have any other concurrent anticancer therapy or investigational agents.",
    "The sample is a phase 2 clinical trial for pancreatic neoplasms. The trial includes patients with adenocarcinoma of the pancreatic head or uncinate process who are potentially resectable, have no extra pancreatic disease, and no evidence of tumor extension to the celiac axis or SMA. Patients cannot have known hepatic or peritoneal metastases. The trial has no upper age restriction and patients with Karnofsky performance status greater than 70 are eligible. Patients must have adequate renal and bone marrow function, as well as hepatic function. Pregnant women and patients with certain medical conditions are excluded from the trial. The trial has both inclusion and exclusion criteria.",
    "The sample is a phase 2 clinical trial for patients with relapsed or progressed multiple myeloma and plasma cell neoplasm. The trial involves the drug lenalidomide and requires patients to meet certain eligibility criteria, including having a confirmed diagnosis of CD20+ multiple myeloma, a performance status of 0-2, and a life expectancy of at least 4 months. Patients must also meet various medical and laboratory requirements, such as having certain blood counts and liver function tests within normal limits. The trial excludes patients with certain medical conditions or laboratory evaluations that make them unsuitable for participation. Prior therapy, including radiotherapy, is allowed, but patients must not have received prior rituximab.",
    "The sample is a phase 2 clinical trial for non-small cell lung cancer. The trial includes patients with stages IIIB and IV of the disease who have not received prior chemotherapy treatment for lung cancer. The trial also requires patients to have adequate tissue samples for marker testing, be at least 18 years old, have a performance status of 0-2 per ECOG scale, and meet certain laboratory value requirements. The trial excludes patients with prior systemic treatment for lung cancer, a history of hypersensitivity to drugs used, a diagnosis of other malignancy in the last 5 years (excluding curatively treated non-melanoma skin cancer and in-situ cervical cancer), medical illness that puts the patient at significant risk per investigator's discretion, uncontrolled CNS disease, and positive pregnancy test or refusal to use contraception during treatment.",
    "The sample is a record from a clinical trial table. It is a phase 2 trial for metastatic breast cancer. The diseases column lists only one disease, and the icdcodes column lists several ICD-10 codes related to the disease. The drugs column lists two drugs, gefitinib and docetaxel. The eligibility criteria are also provided, including inclusion and exclusion criteria. The inclusion criteria require histologically confirmed mammary carcinoma, while the exclusion criteria include prior taxane chemotherapy for metastatic disease or prior treatment with tyrosine kinase inhibitors inhibiting the EGF receptor. Prior hormone treatment or one type of anthracycline based treatment regimen without taxane for metastatic disease is allowed prior to inclusion. If the patient has been treated in the adjuvant or neoadjuvant setting with taxanes, inclusion is allowed when the first cycle of trial medication is started 12 months after the last course of adjuvant treatment.",
    "The sample is a phase 2 clinical trial for patients with recurrent or metastatic head and neck squamous carcinoma or nasopharyngeal carcinoma. The trial involves the use of three drugs - e10a, cisplatin, and paclitaxel. The eligibility criteria include confirmation of the disease, tumor size, performance status, life expectancy, absence of serious medical or psychiatric disorders, and certain blood test results. The exclusion criteria include pregnancy or breastfeeding, history of brain metastases or primary brain tumor, history of hemorrhagic diathesis, recent use of corticosteroids or immunosuppressives, history of immune deficiency disorder or organ transplant, active adenovirus infection, and recent chemotherapy or radiotherapy.",
    "The sample is a record of a clinical trial with a phase 2 designation. The trial is focused on Alzheimer's disease and the icd-10 codes associated with it. The drugs being tested are mk0249 and a placebo (unspecified). The eligibility criteria for the trial include being male or female, aged 55 or older, having mild-to-moderate Alzheimer's disease with specific scores on various tests, and having a reliable caregiver to accompany the patient to all clinic visits. Patients must also have been on stable doses of symptomatic Alzheimer's disease treatments for at least 2 months. Exclusion criteria include living in a skilled nursing facility, poorly-controlled hypertension, and various other medical conditions.",
    "The sample is a phase 2 clinical trial for the treatment of acute myeloid leukemia (AML) using the drug lenalidomide. The trial is for patients with previously untreated AML who have declined standard chemotherapy regimens. The inclusion criteria include a confirmed diagnosis of AML, cytogenetic evidence of del (5q) abnormality, and a white blood cell count of less than or equal to 30,000/mm\u00b3. Patients must also meet various other criteria related to their medical history, physical condition, and other factors. The trial excludes patients who have previously received certain types of chemotherapy or radiotherapy, and those who are pregnant or nursing.",
    "The sample is a phase 2 trial for acute myeloid leukemia. The trial involves the use of elacytarabine plus idarubicin as a treatment. The eligibility criteria include having a confirmed diagnosis of AML, having received one previous standard dose ara-C-containing regimen aiming at induction of complete remission, and having more than 5% remaining blast cells in bone marrow following the first course of remission-induction or by other means documented residual disease. Patients must also meet certain age, performance status, and laboratory value requirements, and must be capable of understanding and complying with the protocol. Exclusion criteria include a history of allergic reactions to certain components of the treatment, persistent clinically significant and relevant toxicities from the previous course of chemotherapy, and certain medical conditions that place the patient at an unacceptably high risk for toxicities.",
    "The sample is a phase 2 clinical trial for the treatment of metastatic colorectal cancer. The trial involves the use of two drugs, panitumumab and folfiri. The eligibility criteria for the trial include having a confirmed diagnosis of metastatic adenocarcinoma of the colon and/or rectum, measurable disease according to modified RECIST guidelines, an Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2, and adequate haematologic, renal, hepatic and metabolic function. Exclusion criteria include having central nervous system metastases, prior systemic therapy for the treatment of metastatic colorectal carcinoma, prior anti-epidermal growth factor receptor (EGFr) antibody therapy, and significant cardiovascular disease. Other exclusion criteria include having a history of interstitial pneumonitis or pulmonary fibrosis, active inflammatory bowel disease or other bowel disease causing chronic diarrhea, and a positive test for human immunodeficiency virus infection, hepatitis C virus, or chronic active hepatitis B infection. The sample also includes specific details and other protocol specified criteria that may apply.",
    "The sample is a phase 2 trial that focuses on two diseases, hemostasis and oral contraceptive. The trial involves two drugs, desogestrel/ethinyl estradiol and ethinyl estradiol, and desogestrel/ethinyl estradiol. The eligibility criteria for the trial includes premenopausal, non-pregnant, non-lactating women aged 18-40 years old with a BMI between 18 and 30 kg/m\u00b2, and a regular spontaneous menstrual cycle. The exclusion criteria includes any condition that contraindicates the use of combination oral contraceptives, a history of deep vein thrombosis, pulmonary embolism, or arterial thromboembolic disease within one year of screening, thrombophlebitis or thromboembolic disorders, known or suspected clotting disorders, thrombogenetic valvulopathies or rhythm disorders, and others as dictated by FDA-approved protocol.",
    "The sample is a phase 2 clinical trial for patients with incurable breast cancer that has either locally advanced or metastasized. The trial is testing the effectiveness of the drugs fulvestrant and sorafenib tosylate. Patients must have measurable or evaluable disease and have previously been treated with a third-generation aromatase inhibitor. They must also be postmenopausal, have an Eastern Cooperative Group performance status of 0-1, and meet certain medical criteria. Patients cannot have had prior chemotherapy for metastatic or unresectable locally advanced breast cancer, nor can they have had prior sorafenib tosylate or other Vascular endothelial growth factor(VEGF)-targeting therapies. Concurrent bisphosphonates are allowed, but no other concurrent anticancer agents, including chemotherapy or biological therapy, or other concurrent investigational drugs.",
    "The sample is a phase 2 clinical trial for pancreatic cancer. The trial includes patients who are 18 years or older and have confirmed pancreatic cancer with measurable or non-measurable metastatic disease. Patients must have an ECOG performance status of 0-1. The trial excludes patients with local or locally advanced pancreatic cancer, prior systemic treatment for metastatic pancreatic cancer, or those who have had adjuvant chemotherapy within the last 6 months. Additionally, patients with other malignancies within the last 5 years, except for adequately treated cancer in situ of the cervix or basal or squamous cell skin cancer, are also excluded. The trial involves the use of erlotinib (escalating dose or standard dose) and gemcitabine.",
    "The sample is a phase 2 clinical trial for patients with metastatic breast cancer that is c-erbB2 positive. The trial is testing the effectiveness of a combination of drugs including cmf regimen, cyclophosphamide, fluorouracil, and methotrexate. The eligibility criteria for patients include having at least one measurable target lesion, no contralateral breast cancer that is c-erbB2 positive or negative/unknown, and no CNS metastases. Patients must also meet certain age, sex, and performance status requirements, and have normal hematopoietic, hepatic, renal, cardiovascular, and pulmonary function. Patients cannot have had prior anti-c-erbB2 antibody therapy or more than one prior chemotherapy regimen for metastatic breast cancer. Other concurrent anticancer therapy or investigational drugs are not allowed.",
    "The sample is a phase 2 clinical trial for the treatment of painful diabetic neuropathy. The trial involves the use of two drugs, mk-6096 and placebo, and has a list of inclusion and exclusion criteria for participants. Inclusion criteria include having a primary diagnosis of painful diabetic neuropathy for at least 6 months, being able to use an electronic diary, and having a stable dose of antihyperglycemic treatment for at least 1 month. Exclusion criteria include being pregnant or breastfeeding, having had ineffective treatment with more than 3 neuropathic pain drugs, and having a history of substance abuse or dependence.",
    "The sample is a phase 2 clinical trial for the treatment of sarcoma, a type of cancer. The trial involves the use of four drugs - cyclophosphamide, etoposide, ifosfamide, and vincristine sulfate. The eligibility criteria for the trial include having a confirmed diagnosis of infantile, congenital, or pediatric fibrosarcoma, with no evidence of distant metastases. Patients must also have available tissue for central review and be under the age of 2 at diagnosis. Other eligibility criteria include specific performance status, life expectancy, hematopoietic, hepatic, and renal requirements. Patients must not have received prior chemotherapy or concurrent anticancer chemotherapy, and no prior or concurrent radiotherapy except in cases of emergent tracheal compression.",
    "The sample is a phase 2 clinical trial for non-small cell lung cancer. The trial is testing the drug \"sta 9090\". The eligibility criteria for the trial include having a confirmed diagnosis of Stage IIIB or Stage IV NSCLC with measurable disease, availability of tissue for analysis, ECOG Performance Status 0 or 1, adequate organ function, and being at least 18 years old and willing to sign a consent form. Exclusion criteria include poor venous access, pregnancy or lactation, ventricular ejection fraction of 55% or less at baseline, and any uncontrolled intercurrent illness. The icd-10 codes associated with the disease are also provided.",
    "The sample is a phase 2 clinical trial for patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck. The trial is testing the drug GSK1363089 (foretinib). The eligibility criteria include having measurable disease, being at least 18 years old, having an Eastern Cooperative Oncology Group (ECOG) performance status of 1 or less, and meeting certain organ and marrow function requirements. Exclusion criteria include having received radiation to more than 25% of bone marrow within 30 days of treatment, having received an investigational drug within 30 days of treatment, and having received more than one regimen of systemic anticancer therapy for disease that has recurred or is metastatic. The trial also requires patients to have certain unstained slides of tumor tissue available for analysis.",
    "The sample is a phase 2 clinical trial for the treatment of type 2 diabetes mellitus. The trial involves the use of a drug called SYR-472 and a placebo. The eligibility criteria include having a historical diagnosis of type 2 diabetes mellitus, having a glycosylated hemoglobin concentration between 7.0% and 10.0%, and having a fasting plasma glucose concentration less than 275 mg/dL. In addition, participants must meet several other criteria related to their health and medication use. The trial excludes individuals who have a history of cancer, heart failure, or psychiatric disorders, among other conditions.",
    "The sample is a phase 2 clinical trial for patients with Acute Myeloid Leukemia who are considered unfit for conventional induction chemotherapy or have evidence of disease relapse or refractory disease. The trial involves the use of the drug temozolomide. The eligibility criteria include being over 60 years old, having a life expectancy of greater than 3 months, and having normal organ and marrow function. The exclusion criteria include having had chemotherapy or radiotherapy within 4 weeks prior to entering the study, having a history of allergic reactions to compounds of similar chemical or biologic composition to temozolomide or DTIC, and having uncontrolled intercurrent illness.",
    "The sample is a phase 2 clinical trial for the treatment of raised intraocular pressure. The trial involves the use of the drugs azd4017 and placebo. The eligibility criteria for the trial include having a diagnosis of intraocular hypertension or primary open-angle glaucoma with IOP levels between 20 and 36 mmHg, and being on a stable dose of a single anti-glaucoma medication for at least 30 days prior to the screening visit. Male patients must be willing to use barrier contraception with spermicide during the trial. The exclusion criteria include having uncontrolled intraocular hypertension, experiencing significant visual field loss or showing evidence of progressive visual field loss within the last year, and having had severe eye trauma at any time. The trial will involve a placebo treatment for the duration of the study.",
    "The sample is a phase 2 trial for the treatment of submassive pulmonary embolism. The trial involves the use of drugs such as drotrecogin alfa (activated), enoxaparin, and placebo. The eligibility criteria for the trial include patients with symptoms of acute pulmonary embolism without an indication for fibrinolytic therapy but with echocardiographic evidence of right ventricular dysfunction within 48 hours of onset of symptoms. Patients with symptoms of pulmonary embolism for more than 48 hours are excluded from the trial. The diseases and their corresponding ICD-10 codes are also listed in the table.",
    "The sample is a record of a clinical trial for endometriosis treatment in phase 2. The trial involves testing the effectiveness of several drugs, including placebo, tak-385, and leuprorelin acetate. The eligibility criteria for participants include being premenopausal women with dysmenorrhea and pelvic pain associated with endometriosis, having a regular menstrual cycle, and being diagnosed with endometriosis through laparotomy, laparoscopy, or MRI confirmation of chocolate cyst of the ovary. However, there are several exclusion criteria, such as having uterine fibroids, thyroid dysfunction, pelvic inflammatory disease, or a history of malignant tumors. Participants who have been treated with certain drugs, such as anticoagulant drugs or oral contraceptives, are also excluded. The trial aims to determine the safety and efficacy of the drugs in treating endometriosis.",
    "The sample is a record from a table that contains information about clinical trials. It is a phase 2 trial for the treatment of atrial fibrillation, a heart condition. The trial involves the drug ati-5923 and has specific eligibility criteria for participants, including having documented atrial fibrillation and being a candidate for anticoagulation or currently receiving warfarin. There are also exclusion criteria, such as having a history of myocardial infarction or active bleeding. The sample includes both inclusion and exclusion criteria in a list format.",
    "The sample is a phase 2 clinical trial for patients with peripheral T-cell or natural killer cell neoplasm, specifically lymphoma. The trial allows patients with any stage of the disease and HTLV-positive tumors. Patients must have at least one objective measurable disease parameter and be 18 years or older with an ECOG performance status of 0-2. They must also meet various laboratory criteria, including absolute neutrophil count, platelet count, bilirubin, AST, PT, INR, PTT, creatinine, and urinary protein:creatinine ratio. Patients with a history of deep venous thrombosis or pulmonary embolism are allowed if they are on a stable dose of anticoagulants. Patients must not have ALK-positive T-cell large cell lymphoma or cutaneous T-cell lymphoma, and must not have a history of or current radiographic evidence of CNS metastasis, bleeding diathesis or coagulopathy, recent cerebrovascular accident or myocardial infarction, unstable angina, congestive heart failure, uncontrolled hypertension, abdominal fistula, gastrointestinal perforation, intra-abdominal abscess, or other clinically significant cardiovascular or peripheral vascular disease. They must also not have had concurrent major surgery, be pregnant or nursing, have a history of active seizures, significant traumatic injury within the past 4 weeks, non-healing ulcer, bone fracture, active infection requiring parenteral antibiotics, or HIV positivity. Patients with other active malignancy within the past 6 months except carcinoma in situ of the cervix or basal cell carcinoma of the skin are also excluded. The trial involves treatment with cyclophosphamide, doxorubicin, prednisone, and vincristine.",
    "This is a sample from a clinical trial table that includes information about the trial's phase, diseases being studied, icd-10 codes of those diseases, drugs being used, and eligibility criteria for participants. In this particular sample, the trial is in phase 2 and is studying leukemia. The icd-10 codes associated with the disease are listed, as well as the drugs being used in the trial. The eligibility criteria for participants are also listed, including specific disease characteristics, patient characteristics, and prior concurrent therapy. The criteria include things like the patient's Eastern Cooperative Oncology Group (ECOG) Performance Status, liver enzyme levels, and previous treatments.",
    "The sample is a phase 2 clinical trial for patients with operable invasive adenocarcinoma of the breast who have previously undergone mastectomy surgery and have been diagnosed with local recurrence of breast cancer. The patients must not have evidence of metastatic disease and must be HER2 negative. The drug being tested is capecitabine. The eligibility criteria include written informed consent, age of 18 or older, a Karnofsky index performance status of 70 or higher, and specific laboratory results within 14 days prior to randomization. The exclusion criteria include distant metastasis or metastatic disease in organs, previous radiation treatment on the breast or other locations, and various medical conditions such as uncontrolled hypertension and active uncontrolled infection.",
    "The sample is a phase 2 clinical trial for patients with acute myocardial infarction and electrocardiographic evidence of ST elevation. The trial involves the use of nitric oxide and placebo drugs. The eligibility criteria include successful percutaneous coronary intervention, no clinical evidence of congestive heart failure, and being over 18 years old. Exclusion criteria include prior myocardial infarction, requirement for urgent cardiac surgery, and left bundle branch block. Patients with medical problems likely to preclude completion of the study or who have used investigational drugs or devices within the 30 days prior to enrollment are also excluded.",
    "The sample is a phase 2 clinical trial for the treatment of endometriosis pain. The trial is looking at the effectiveness of the drugs elagolix and placebo. The eligibility criteria for participants include being female, aged 18 to 49 years, having moderate to severe pelvic pain due to endometriosis, having been surgically diagnosed with endometriosis within the last 8 years and having recurrent or persistent endometriosis symptoms, having a regular menstrual cycle, having a body mass index (BMI) of 18 to 36 kg/m\u00b2, and agreeing to use two forms of non-hormonal contraception during the study. Exclusion criteria include currently receiving certain types of medication, having had recent surgery for endometriosis or a hysterectomy or bilateral oophorectomy, having certain medical conditions or chronic diseases, and having been pregnant within the last six months or currently breastfeeding.",
    "The sample is a phase 2 clinical trial for patients with recurrent, metastatic or unresectable gastroesophageal or gastric adenocarcinoma. The trial involves the use of two drugs, folfox and bevacizumab. The eligibility criteria include having a confirmed diagnosis of the disease, being at least 12 months since completion of any prior neoadjuvant or adjuvant therapy, having a good performance status, and meeting certain laboratory parameters. Patients with certain medical conditions or who have undergone certain procedures within a certain timeframe are excluded from the trial. The trial requires the availability of paraffin block or slides.",
    "The sample is a record of a clinical trial with a phase 2 designation. The trial is focused on treating metastatic breast cancer using two drugs, pegylated liposomal doxorubicin and docetaxel. The trial has a list of inclusion and exclusion criteria that patients must meet in order to participate. The inclusion criteria include having undergone the first line of metastatic chemotherapy, having a measurable or bone lesion, and having at least one lesion outside of previously radiated areas. The exclusion criteria include only having local tumoral progression, having symptomatic cerebral metastasis, having neuropathy greater than NCI-CTC 2, and having had a previous cancer within the last 10 years. The trial also has a list of icd-10 codes associated with the disease being treated.",
    "The sample is a clinical trial for asthma treatment in phase 2/phase 3. The trial is looking at the effectiveness of drugs such as rosiglitazone, theophylline, beclomethasone, and inhaled beclomethasone and oral theophylline. The trial is looking for males and females between the ages of 18 and 60 who have a clinical diagnosis of mild or moderate persistent asthma and have had a history of asthma for at least 6 months. The trial is also looking for current cigarette smokers with a minimum five-pack-year smoking history. The trial has inclusion and exclusion criteria, including a baseline FEV1 that is greater than 50% predicted and reversibility of 12% or more at screening, washout or randomisation. The trial is looking for subjects who are capable of providing signed written informed consent and complying with all the specified study procedures. The trial has exclusion criteria, including asthma exacerbation or a respiratory tract infection within four weeks of screening, type 1 or type 2 diabetes mellitus, and women who are lactating, pregnant, or planning to become pregnant. The trial is also looking for subjects who have clinically significant renal or hepatic laboratory values, anaemia, contraindications to treatment as outlined in any of the product labels, prior history of severe oedema or serious fluid related event associated with any TZD, and presence of unstable or severe angina or congestive heart failure. The trial is also looking for subjects who have a history of significant hypersensitivity to study drugs, history or suspicion of current drug abuse or alcohol abuse within the last 6 months, history suggestive of active infection or non-asthma lung pathology, clinically significant renal disease, metabolic syndrome, cirrhosis, hypertension or any other clinically significant cardiovascular, neurological, endocrine, or haematological abnormalities that are uncontrolled on permitted therapy, risk factors for HIV, hepatitis B or hepatitis C infection at Screening, subjects who are morbidly obese, unable to perform spirometry, and subjects who require treatment with certain asthma medications. The trial is also looking for subjects who have been taking in excess of 1000 \u03bcg daily of beclomethasone within 6 weeks of Screening.",
    "The sample is a phase 2 clinical trial for the treatment of irritable colon. The trial includes both male and female participants aged 18-65 who have faecal urgency as defined by Chan, normal ECG and clinical labs, and meet the Rome II criteria for irritable bowel syndrome. The trial drug being tested is sb-705498. The eligibility criteria include the use of effective contraception for women of childbearing potential, informed consent, and understanding of the protocol requirements. Exclusion criteria include any clinical or biological abnormality not related to the disease under investigation, history of alcohol, substance or drug abuse, uncontrolled hypertension, history or presence of cardiovascular risk factors, participation in a trial within 3 months before the start of the study, history of allergy, and inability to withdraw from analgesic medications for rectal hyperalgesia. Opioid-dependent patients can be included if they are willing to withdraw from their opiate medication.",
    "The sample is a clinical trial for breast cancer patients in phase 2/phase 3. The trial is testing the effectiveness of the drug letrozole on patients with primary invasive breast cancer that is estrogen and/or progesterone positive. The patients must be female and postmenopausal, with a measurable tumor and adequate bone marrow, renal, and hepatic function. They must also have a life expectancy of at least 6 months. Patients who have previously been treated with aromatase inhibitors or antiestrogens, have uncontrolled endocrine disorders, have tumors in both breasts or evidence of inflammatory breast cancer or distant metastasis, are eligible for breast conserving surgery, or are receiving concomitant anti-cancer treatments are excluded from the trial. Other protocol-defined inclusion/exclusion criteria may also apply.",
    "The sample is a phase 2 clinical trial for the treatment of psoriasis using the drug cyclosporine. The trial is looking for participants who have moderate to severe, stable plaque psoriasis and have not responded to other treatments such as PUVA, methotrexate, and retinoids. The eligibility criteria include being in good health, having normal organ and marrow function, and being HIV uninfected. However, there are also exclusion criteria such as having poorly controlled hypertension, severe infection, internal malignancy, immunodeficiency, gout, or liver disease. Participants must also not have used cyclosporine or other immunosuppressive medication within 6 months of study entry. Women of childbearing potential and men unwilling to use adequate contraception are also excluded. The trial will monitor participants on a weekly basis.",
    "The sample is a phase 2 trial that involves patients with two types of cancer: prostatic neoplasms and metastases, neoplasm. The trial includes three different drugs, zd4054 10 mg, zd4054 15 mg, and zd4054 22.5 mg. The eligibility criteria for the trial require that patients be men who are 18 years or older and have a confirmed diagnosis of prostate cancer with bone metastases. Patients who have had more than two prior chemotherapy regimens or have received radiation, chemotherapy, or bisphosphonates in the past 4 weeks are excluded from the trial. The icd-10 codes for the diseases are also provided.",
    "The sample is a record of a clinical trial with a phase 2/phase 3 designation. The trial is focused on HIV infections and the ICD-10 code associated with it is Z21. The trial involves two drugs, kaletra (lopinavir/ritonavir) and kaletra (lopinavir/ritonavir) + combivir (zidovudine/lamivudine). The eligibility criteria for the trial includes being assessed between 20 and 24 months of pregnancy, having a documented HIV-1 infection without indication for ARV therapy, having a CD4 count above or equal to 350 per mm3, having a VL under 30 000 copies per ml, being na\u00efve for PI (except treatment during previous pregnancy), and signing an informed consent. The exclusion criteria includes having HIV2 infection or HIV1 group O infection, having any pathology related to pregnancy, having a contra-indication to study drugs, having unstable hypertension or diabetes, having a known risk of premature delivery, and having resistance mutations on the HIV-1 protease gene by genotyping analysis (1 mutation among V32I et I47A, I50V V82A/F/S/T, I84V, L90 M or more than 3 mutations among L10 F/I/R/V, K20/M/R, L24I, L33F, M46I/L, F53L, I54M/L/T/V, L63P, A71L/V/T).",
    "The sample is a record of a clinical trial with a phase 2 designation. The trial is focused on the disease of malignant melanoma, with a list of associated ICD-10 codes. The trial is testing the effectiveness of two drugs, bevacizumab [avastin] and fotemustine. The eligibility criteria for the trial include having advanced, inoperable stage IV melanoma with measurable and/or evaluable sites of metastases. Exclusion criteria include prior chemotherapy and/or IFN/IL2 based immunotherapy for metastatic disease, prior malignancies within the past 5 years (with the exception of cured non-melanoma skin cancer or in situ cancer of cervix), clinically significant cardiovascular disease, and ongoing treatment with aspirin or other medications known to predispose to gastrointestinal ulceration.",
    "The sample is a phase 2 clinical trial for non-small cell lung cancer. The trial includes patients with newly-diagnosed stage IIIB with malignant pleural effusion, stage IV or recurrent disease. Patients must have completed radiotherapy at least two weeks prior to registration and have measurable disease. The trial involves two drugs, suramin and placebo, in combination with docetaxel and carboplatin. The eligibility criteria include adequate bone marrow, liver, and renal function, as well as an ECOG performance status of 0-1 and a life expectancy of at least 3 months. Patients must have recovered from uncontrolled intercurrent illness and use adequate contraception for the duration of the study. The exclusion criteria include a history of severe hypersensitivity reaction to Docetaxel or other drugs formulated with polysorbate 80, grade 3 or 4 neuropathy, pregnancy or breastfeeding, prior chemotherapy or biologic therapy for NSCLC, and currently active second malignancy other than non-melanoma skin cancer.",
    "The sample is a phase 2 clinical trial for locally advanced/inflammatory adenocarcinoma of the breast. The trial involves the use of gemcitabine, epirubicin, and albumin-bound paclitaxel as drugs. The eligibility criteria include being 18 years or older, having normal heart function, being able to perform daily activities with minimal assistance, having no prior chemotherapy for breast cancer, and having adequate bone marrow, liver, and kidney function. Exclusion criteria include being pregnant or breastfeeding, having a history of heart disease with congestive heart failure, having a heart attack within the previous 6 months, having prior chemotherapy or hormone therapy for breast cancer, and having a history of active uncontrolled infection. The study center will determine if the participant meets all the criteria, and if they do, study personnel will explain the trial in detail and answer any questions they may have.",
    "The sample is a phase 2 clinical trial for breast cancer patients. The trial involves the use of two drugs, gemcitabine and docetaxel. The eligibility criteria for the trial include a histologically verified diagnosis of breast carcinoma, restricted previous adjuvant chemotherapy, measurable and/or non-measurable disease, and adequate bone marrow reserve, liver and renal functions. Patients with brain metastases/leptomeningeal involvement, active uncontrolled infection, symptomatic peripheral neuropathy > grade 2, and other serious medical conditions are excluded from the trial.",
    "The sample is a phase 2 clinical trial for non-small cell lung carcinoma. The trial is testing the effectiveness of the drug celecoxib on patients with this type of cancer. The eligibility criteria for the trial include having histologically proven non-small cell lung cancer, being in UICC stage II-III, having a WHO performance status of 0-2, and having reasonable lung function. Patients must also have no recent severe cardiac disease or active peptic ulcer disease, and must have normal serum bilirubin and creatinine levels. They must also have a life expectancy of more than 6 months and measurable cancer. Patients must be willing and able to comply with the study prescriptions and able to give written informed consent before patient registration/randomisation. Exclusion criteria include not having non-small cell histology, having mixed pathology, malignant pleural or pericardial effusion, concurrent chemotherapy with radiation, recent myocardial infarction, uncontrolled infectious disease, distant metastases, active peptic ulceration or gastrointestinal bleeding in the last year, a past history of adverse reaction to NSAIDs, renal disease, and chronic use of NSAIDs, COX-2 inhibitors or Aspirin in dosis >120mg/day.",
    "The sample is a phase 2 trial that involves patients with dyslipidemias and type 2 diabetes. The trial includes a list of icd-10 codes for the diseases and a list of drugs, including a placebo. The eligibility criteria for the trial include having a stable dose of oral anti-diabetic treatment for at least 3 months, having specific cholesterol and triglyceride levels, and agreeing to maintain a stable dose of medications that may affect glucose, insulin, or lipid parameters. Exclusion criteria include taking insulin, using certain categories of medicines, having a history of alcohol or substance abuse, and having significant cardiac, renal, or hepatic impairment. The trial also includes criteria for female subjects of childbearing potential and male subjects whose partner is of childbearing potential.",
    "The sample is a phase 2 clinical trial for the treatment of breast cancer. The trial is looking at the effectiveness of anastrozole (arimidex) and goserelin (zoladex) in premenopausal women with recurrent or metastatic breast cancer that is progressive. The eligibility criteria include having a confirmed diagnosis of breast cancer, being premenopausal, having a positive estrogen and/or progesterone receptor determination, having an Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2, and meeting certain laboratory values. Exclusion criteria include having an active, unresolved infection, having a prior treatment with an aromatase inhibitor or inactivator, and having received chemotherapy or hormonal therapy in the 3 weeks prior to enrollment. Participants must also be using effective contraception or not be of childbearing potential and must provide signed written informed consent.",
    "The sample is a phase 2 clinical trial for patients with metastatic breast cancer. The trial is testing the effectiveness of the drugs capecitabine and fulvestrant. The eligibility criteria include being at least 18 years old, having post-menopausal status, having an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2, having a primary tumor that is human epidermal growth factor receptor 2 (HER-2) negative, and having histologically or cytologically confirmed metastatic breast cancer. Patients must also have adequate hematologic, renal, and hepatic function. The exclusion criteria include prior administration of capecitabine or fulvestrant, prior chemotherapy for metastatic breast cancer, and serious uncontrolled concurrent infections. Patients must also not have a life expectancy of less than 3 months, serious cardiac disease, active brain metastases, or any other serious uncontrolled medical conditions that may compromise study participation.",
    "The sample is a phase 2 clinical trial for the treatment of migraine headaches. The trial is looking for patients who have had a diagnosis of migraine for at least one year and experience 4 to 14 migraine attacks per month. Female patients must test negative for pregnancy and agree to use birth control during the study. Patients with a history of alcohol or drug abuse, medication overuse headache, or certain medical conditions are excluded from the trial. The trial is testing the effectiveness of the drug LY2300559 compared to a placebo. The eligibility criteria and exclusion criteria are listed in detail.",
    "The sample is a phase 2 clinical trial for Alzheimer's disease, using intravenous immunoglobulin as the drug. The eligibility criteria include a diagnosis of probable Alzheimer's disease of mild to moderate severity, ability to give informed consent, compliance with testing and infusion regimen, and having an able caregiver. Exclusion criteria include non-Alzheimer dementia, active renal disease, and untreated major depression or other major psychiatric disorders. The trial also requires stable doses of approved AD medications for at least 3 months and neuroimaging performed after symptom onset consistent with the patient's diagnosis. Women who want to participate must either be post-menopausal, surgically sterilized, or agree to avoid becoming pregnant during the entire period of their participation in the study.",
    "The sample is a phase 2 clinical trial for the treatment of metastatic breast cancer. The trial involves the use of three different drugs, ixabepilone, capecitabine, and docetaxel, and has eligibility criteria that include having measurable disease, a performance status of 0-1, and having received no more than one prior chemotherapy regimen. Participants with brain or leptomeningeal metastases, neuropathy greater than grade 2, or uncontrolled diabetes or chronic hepatitis are excluded from the trial. Additionally, participants must discontinue certain cancer treatments prior to starting the trial and women of childbearing potential must use contraception throughout the study and for at least 4 weeks after the last dose of investigational products.",
    "The sample is a phase 2 clinical trial for the treatment of emphysema. The trial includes patients who are over 44 years old and have a smoking history of more than 10 pack-years. Women who are not of child-bearing potential and ex-smokers with a clinical diagnosis of emphysema are also included. The patients must be willing to switch to optimal COPD therapy. The trial excludes patients who have been off oral steroids for more than 28 days prior to enrollment, have had more than 2 exacerbations of pulmonary symptoms requiring outpatient treatment or more than 1 exacerbation requiring hospitalization within 12 months prior to screening, have been exposed to synthetic oral retinoids in the past 12 months, or have a history of allergy or sensitivity to retinoids. The trial will test the efficacy of the drugs placebo and rar gamma.",
    "The sample is a phase 2 clinical trial for the treatment of psoriasis vulgaris. The trial involves the use of a gel containing calcipotriol and betamethasone dipropionate (leo 80185). The eligibility criteria for participants include having psoriasis vulgaris on the trunk, arms, or legs that can be treated with a maximum of 100 g of topical medication per week, and having a disease severity of at least mild according to an investigator's global assessment. Exclusion criteria include recent use of certain therapies or medications, as well as having certain types of psoriasis.",
    "The sample is a phase 2 clinical trial for non-small cell lung cancer. The trial includes patients with locally advanced or metastatic NSCLC, who have not received previous systemic chemotherapy. The trial involves the use of drugs such as docetaxel, gemcitabine, and bevacizumab. The eligibility criteria include having measurable disease, an estimated life expectancy of at least 12 weeks, and an ECOG Performance Status of 0, 1 or 2. Exclusion criteria include a history of prior systemic chemotherapy, recent or current radiation therapy, and serious non-healing wounds or fractures. The trial also excludes patients with brain metastases, peripheral neuropathy, or a history of other malignancies.",
    "The sample is a phase 2 clinical trial for participants with type 2 diabetes mellitus. The trial involves the use of insulin glargine /lixisenatide fixed ratio combination, insulin glargine, and metformin (background drug). The eligibility criteria for the trial include having a stable dose of metformin for at least 3 months prior to screening, being diagnosed with type 2 diabetes mellitus for at least 1 year, and meeting certain exclusion criteria such as having a screening HbA1c <7% or >10%, being pregnant or lactating, having a history of unexplained pancreatitis, and having a BMI \u226420 or >40 kg/m^2. The sample also includes a list of disease names and icd-10 codes associated with the trial.",
    "This sample is for a phase 2 clinical trial for lung cancer patients who have previously been treated with erlotinib hydrochloride or gefitinib for at least 6 months and have developed acquired resistance to these drugs. The trial is testing the effectiveness of dasatinib as a treatment option. The eligibility criteria include having pathologically confirmed adenocarcinoma of the lung, measurable indicator lesions that have not been previously irradiated, and a Karnofsky performance status of 70-100%. Patients must also meet certain medical criteria, such as having a WBC count of at least 3,000/mm\u00b3 and no significant medical history or unstable medical condition. Prior concurrent therapy is also taken into consideration.",
    "The sample is a phase 2 clinical trial for patients with macular degeneration. The trial is testing the effectiveness of the drug pazopanib. The eligibility criteria for the trial includes patients diagnosed with subfoveal choroidal neovascularization in the study eye, with specific characteristics required such as central subfield thickness and active subfoveal leakage. The trial also has exclusion criteria such as additional eye disease in the study eye, CNV in the study eye due to other causes unrelated to age-related macular degeneration, and more than one prior photodynamic therapy treatment in the study eye. The trial requires female subjects to be of non-childbearing potential and has specific medical history or condition exclusions such as uncontrolled diabetes mellitus and active bleeding disorder.",
    "The sample is a phase 2 trial for osteoarthritis. The trial includes subjects who are aged 40 years or older with a BMI between 25 and 40 kg/m2 and have been previously diagnosed with knee OA. The study knee must also have radiographic evidence of OA. The trial involves the drugs sd-6010 and placebo. The eligibility criteria include exclusion of subjects with any other rheumatic disease, current conditions in the study knee that would confound efficacy, and selected traditional clinical safety and laboratory parameters.",
    "The sample is a phase 2 clinical trial for patients with metastatic adenocarcinoma of the pancreas. The trial is testing the drug saracatinib and the eligibility criteria includes having received at least one prior chemotherapy regimen, having no known brain metastases, and having a certain level of blood counts and liver function. Patients must also be willing to undergo two tumor biopsies and have no history of allergic reactions to compounds similar to AZD0530, the drug being tested. Other medical conditions and medications may disqualify patients from participating in the trial.",
    "The sample is a phase 2 clinical trial for patients with locally advanced, unresectable or metastatic pancreatic carcinoma. The trial involves the use of the drug erlotinib and has eligibility criteria that include having measurable disease, normal organ and marrow function, and a life expectancy of at least 3 months. Patients must also have a performance status of less than 2 and be over 18 years old. Exclusion criteria include having had chemotherapy or radiotherapy within 4 weeks prior to the trial, having known brain metastases, and having uncontrolled intercurrent illness. The trial has a list of diseases and their corresponding ICD-10 codes, as well as a list of drugs and their eligibility criteria. The criteria for eligibility are listed in detail, including previous therapy, age, and organ function. The sample also includes exclusion criteria, such as allergies to the drug or a history of allergic reactions, and conditions that impair the ability to swallow and retain pills.",
    "The sample is a phase 2 clinical trial for liver cancer patients. The trial involves the use of two drugs, capecitabine and oxaliplatin. The eligibility criteria for the trial include having metastatic liver cancer or being ineligible for surgical resection or immediate liver transplantation. Patients must also have at least one site of measurable or evaluable disease and meet certain patient characteristics such as having an Eastern Cooperative Oncology Group (ECOG) performance status of 0-2 and no serious uncontrolled medical conditions. Prior concurrent therapy is also taken into consideration. The sample includes a detailed list of eligibility criteria for both disease and patient characteristics, as well as prior concurrent therapy.",
    "The sample is a phase 2 clinical trial for patients with small cell lung cancer that has recurred after responding to prior first-line therapy. The trial is testing the effectiveness of topotecan hydrochloride as a treatment option. The eligibility criteria include having measurable disease, being eligible for high-dose chemotherapy, and having no symptomatic brain metastases affecting performance status. Patients must also meet certain age, performance status, and life expectancy requirements, as well as have specific hematopoietic, hepatic, renal, and cardiovascular health parameters. Patients cannot be pregnant or nursing, must test negative for HIV, and cannot have any other malignancy except for certain types of skin cancer or low-grade prostate cancer. The trial excludes patients who have a known seizure disorder, active infection requiring systemic therapy within the past 2 weeks, hypersensitivity to topotecan hydrochloride, or any medical or psychiatric condition that would preclude study participation. Prior concurrent therapy is not specified, but patients cannot have had more than one prior chemotherapy regimen (except for adjuvant chemotherapy) for small cell lung cancer and cannot have had prior topotecan hydrochloride.",
    "The sample is a phase 2 trial for the treatment of overactive bladder. The eligibility criteria include being an adult over the age of 20 with symptoms of urgency frequency and/or urge incontinence, and a urgency severity scale (USS) of at least 2, with or without urodynamically proven detrusor overactivity (DO). Patients must also be free of active urinary tract infection, bladder outlet obstruction, and overt neurogenic bladder dysfunction. They must have been treated with antimuscarinic agents for at least 4 weeks without effect or with intolerable adverse effects. Patients must be able to record voiding diary for the urinary frequency and urgency, and have signed the written informed consent form. Exclusion criteria include use of antimuscarinic agent and effective in treatment of lower urinary tract symptoms, severe cardiopulmonary disease, bladder outlet obstruction, postvoid residual >150 mL, uncontrolled confirmed diagnosis of acute urinary tract infection, laboratory abnormalities, contraindication to be urethral catheterization during treatment, female patients who are pregnant, lactating, or with child-bearing potential without contraception, Myasthenia gravis, Eaton Lambert syndrome, and any other serious disease considered by the investigator not suitable for general anesthesia or in the condition to enter the trial.",
    "The sample is a phase 2 clinical trial for the treatment of endometrial cancer using a combination of drugs including cisplatin, doxorubicin hydrochloride, and paclitaxel. The trial is open to patients who have histologically confirmed endometrial epithelial carcinoma and meet certain criteria, such as having advanced metastatic or relapsed disease, being 18 years or older, having a WHO performance status of 0-2, and meeting certain hematopoietic, hepatic, renal, and cardiovascular requirements. Patients must also not have any uncontrolled infections or other malignancies within the past 5 years, and must not be pregnant or nursing. The trial has certain prior concurrent therapy requirements, such as at least 12 months since prior adjuvant chemotherapy and no prior radiotherapy to any area other than the pelvis.",
    "The sample is a phase 2 clinical trial for patients with unresected primary colon cancer and radiographically confirmed metastatic colon cancer that is not considered surgically resectable for cure. The trial is testing the effectiveness of a combination of drugs including fluorouracil, leucovorin, and oxaliplatin. The eligibility criteria include specific disease characteristics such as histologically or cytologically confirmed adenocarcinoma of the colon, as well as patient characteristics such as Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1. Prior concurrent therapy is not allowed, and patients must meet a variety of other criteria related to their health and medical history.",
    "The sample is a phase 2 clinical trial for patients with angioimmunoblastic T-cell lymphoma who have failed at least one type of treatment. The trial is testing the effectiveness of cyclosporine as a treatment option. The eligibility criteria include having measurable or evaluable disease parameters, an ECOG performance status of 0-2, and adequate renal and liver function. Exclusion criteria include prior use of cyclosporine or Tacrolimus, active infection, severe co-morbidities, and pregnancy or breastfeeding. The sample also includes a list of diseases (lymphoma) and their corresponding ICD-10 codes.",
    "The sample is a phase 2 clinical trial for rheumatoid arthritis. The trial includes patients who have had RA for at least 6 months and have a tender joint count of at least 6. The trial also requires patients to have evidence of synovitis in one hand/wrist and a serum C-reactive protein (hsCRP) above upper limits of normal. Patients must have been treated with and tolerated Methotrexate (MTX) therapy at a weekly oral or parenteral dose \u2265 10 mg for \u2265 4 months prior to screening. The trial includes a list of exclusion criteria, such as patients with other autoimmune diseases or arthritis syndromes, women who are pregnant or breastfeeding, and patients with a history of or concurrent severe, progressive, or uncontrolled disease (other than RA) that might place the subject at unacceptable risk for participation in the study.",
    "The sample is a phase 2 clinical trial for patients with liver cirrhosis and biliary disease. The trial involves the use of three drugs: int-747, ursodeoxycholic acid (urso), and placebo. The eligibility criteria for the trial include being between the ages of 18 and 70, having a stable dose of ursodeoxycholic acid for at least 6 months prior to screening, and meeting certain diagnostic factors for proven or likely primary biliary cholangitis (PBC). The trial also has exclusion criteria, such as a history of hepatic decompensation, other concomitant liver diseases, and pregnancy.",
    "The sample is a phase 2 clinical trial for patients with hyperuricemia and gout. The trial involves testing the effectiveness of three drugs - arhalofenate, febuxostat, and colchicine. The eligibility criteria for the trial include having a serum uric acid value of at least 8.0 mg/dL, being between 18-75 years of age, having normal liver function tests and other clinical laboratory parameters, and having a normal electrocardiogram. Patients must also agree to remain in-clinic for 37 consecutive days and follow the study procedures as described in the protocol. Exclusion criteria include having a history of stroke, TIA, acute myocardial infarction, congestive heart failure, or other conditions that compromise the ability to provide informed consent or comply with the objectives and procedures of the protocol.",
    "The sample is a record of a clinical trial with a phase 2 designation. The trial is focused on treating chemotherapy-induced nausea and vomiting in patients with ovarian cancer. The trial includes a list of diseases and their corresponding ICD-10 codes, as well as a list of drugs being used in the trial. The eligibility criteria for the trial are also listed, including inclusion and exclusion criteria. The inclusion criteria include being over 18 years old, having ovarian carcinoma and being treated with moderately emetogenic chemotherapy, having a Karnofsky score of over 60, and having a life expectancy of over 4 months. The exclusion criteria include having certain medical conditions, having received nonapproved drugs within the last 4 weeks, having abnormal laboratory values, having taken certain medications within a certain timeframe, and having been exposed to certain substances within a certain timeframe.",
    "The sample is a phase 2 clinical trial for the treatment of Major Depressive Disorder using the drug radafaxine. The trial is looking for patients who have been diagnosed with MDD and have had a depressive episode lasting between 12 weeks and 24 months. Patients must be able to read and write and provide signed consent. Female patients must be practicing an acceptable method of birth control. Patients with other psychiatric disorders that would affect their response to treatment, those who have not responded to two or more courses of antidepressant therapy, those currently abusing drugs or alcohol, those not receiving psychotherapy, those who have received electroconvulsive therapy within 6 months prior to screening, and pregnant or lactating patients are excluded from the trial.",
    "The sample is a phase 2 clinical trial for patients with non-resectable colorectal cancer and liver metastases. The trial involves the use of drugs such as cetuximab, cetuximab and folfiri, and cetuximab and folfox. The eligibility criteria include having a Karnofsky Performance Status of at least 80, adequate bone marrow, liver and renal function, and being over 18 years old. Exclusion criteria include having extrahepatic metastases, previous exposure to EGFR-targeting therapy, and a history of severe psychiatric illness or drug/alcohol abuse. Patients must also not be pregnant or breastfeeding and must use effective contraception if there is a risk of conception.",
    "This is a sample from a clinical trial table that includes information about the phase of the trial, diseases being studied, icd-10 codes of the diseases, drugs being tested, and eligibility criteria for participants. In this particular sample, the trial is in phase 2 and is focused on multiple sclerosis. The inclusion criteria for participants include being between the ages of 18 and 60, having a specific EDSS score range, and having experienced EDSS progression within 2 years prior to inclusion. The exclusion criteria include having a disease other than MS that is responsible for clinical signs or MRI lesions, having secondary progressive MS with relapse within 2 years prior to inclusion, and having received certain treatments within 4 weeks prior to treatment allocation. Additionally, participants cannot have an active infection caused by certain bacteria, viruses, fungi, mycobacterium, protozoan, or other sources.",
    "The sample is a phase 2 clinical trial for the treatment of gastroesophageal reflux disease. The trial includes male and female patients between the ages of 18 and 65 who have been experiencing GERD symptoms for at least three months. Patients must have at least four days of heartburn per week in each of the two weeks prior to screening. Patients with esophagitis or a history of certain gastrointestinal conditions or surgeries are excluded from the trial. Female patients must not be pregnant or lactating and must use an approved method of contraception if of childbearing potential. The trial involves the use of the drug rabeprazole 20 mg.",
    "The sample is a phase 2 clinical trial for patients with recurrent or metastatic esophageal or gastro-esophageal junction squamous cell or adenocarcinoma. The trial involves the use of two drugs, sunitinib malate and paclitaxel. The eligibility criteria include having measurable or evaluable disease, no more than one prior chemotherapy regimen, and being over 18 years old. Patients must also be willing to use an effective method of contraception and comply with study and follow-up procedures. Exclusion criteria include a history of inadequately controlled hypertension, prior treatment with certain inhibitors, and other medical conditions such as bleeding diathesis, coagulopathy, and peripheral neuropathy.",
    "The sample is a phase 2 clinical trial for patients with decompensated chronic congestive heart failure. The trial includes patients with NYHA functional class III-IV, either ischemic or non-ischemic, requiring hospitalization, and with clinical indication for parenteral pharmacotherapy and invasive hemodynamic monitoring. The trial also includes patients who have had the clinical diagnosis of CHF made at least 3 months prior to enrollment and are 18 years or older. The trial excludes females of child-bearing potential, patients with acute de-novo heart failure, acute myocardial infarction and/or myocardial infarction within 30 days, and valvular heart disease requiring surgical intervention during the course of the study. The trial uses a placebo and cinaciguat (bay58-2667) as drugs.",
    "The sample is a clinical trial in phase 2 for the treatment of lupus nephritis. The trial involves the use of drugs such as laquinimod, mycophenolate mofetil, prednisolone/prednisone, and placebo. The eligibility criteria for the trial include a diagnosis of SLE, a kidney biopsy within 12 months prior to baseline with a histological diagnosis of proliferative or membranous Lupus Nephritis, and clinically active Lupus Nephritis as evident by urine protein to creatinine ratio. The exclusion criteria include severe renal impairment or dialysis, clinically significant or unstable medical or surgical condition, pregnancy or nursing, and women of child-bearing potential who do not practice an acceptable method of birth control.",
    "The sample is a phase 2 clinical trial for patients with pancreatic cancer that is non-metastatic but unresectable due to various reasons such as tumor size, lymph node size, or vascular involvement. The trial is testing the effectiveness of two drugs, fluorouracil and gemcitabine hydrochloride, and the eligibility criteria includes having histologically confirmed pancreatic adenocarcinoma, measurable or evaluable disease, and no prior therapy for pancreatic adenocarcinoma. Patients must also meet certain age, performance status, and medical criteria, and cannot have any other uncontrolled serious medical or psychiatric illness. Prior concurrent therapy is also taken into consideration.",
    "The sample is a record from a clinical trial table that includes information about the trial's phase, diseases being studied, ICD-10 codes associated with those diseases, drugs being tested, and eligibility criteria for participants. In this particular sample, the trial is in phase 2 and is focused on breast cancer. The ICD-10 codes associated with the disease are listed, as well as the drugs being tested. The eligibility criteria for participants are also listed, including requirements such as a specific cancer stage, HER2-negative disease, and normal cardiac function. The exclusion criteria are also listed, which include prior chemotherapy or radiotherapy for Stage II or Stage III breast cancer, inflammatory breast cancer, and other medical or psychiatric disorders that would contraindicate the use of the drugs in the protocol.",
    "The sample is a phase 2 clinical trial for colorectal cancer. The trial is looking at the effectiveness of the drugs capecitabine and oxaliplatin in treating rectal adenocarcinoma that is involving the distal 12 cm of the rectum. The eligibility criteria for patients include having no evidence of distant or known metastases, a certain level of performance status, and meeting certain laboratory values. Patients must also not have any concurrent or previous malignancies unless disease-free for more than 5 years. Additionally, patients must not have any uncontrolled intercurrent illness or history of allergic reaction to the drugs being used. Prior to the trial, patients cannot have had prior radiotherapy or chemotherapy, and cannot be taking any other concurrent investigational or anticancer agents or therapies.",
    "The sample is a phase 2 clinical trial for the treatment of gout. The trial includes patients who are between 18 and 70 years old and have a screening sUA level above 8.0 mg/dL. The trial requires participants to take colchicine or naproxen as prophylaxis for gout flares and to abstain from blood donations during the trial period. Female participants must be sexually abstinent, sterile, post-menopausal, or on stable contraception. Male participants must be abstinent, vasectomized, or using condoms with spermicide with partners meeting female requirements. The trial has exclusion criteria, including inability to tolerate allopurinol, gout flare during the screening period, and various medical conditions that could jeopardize the safety of the study subject or impact the validity of the study results. The trial involves the use of various drugs, including placebo, allopurinol, and bcx4208.",
    "The sample is a phase 2 clinical trial for patients with kidney cancer that has recurred locally or metastasized and is incurable by standard therapy. The trial involves the drug Triapine and has eligibility criteria for patients including confirmed diagnosis of renal cell carcinoma, measurable disease, and certain health requirements such as normal bilirubin levels and no active infections. Patients must also not have any significant neurologic or psychiatric disorders and must not be pregnant or nursing. Prior concurrent therapies are also listed, including restrictions on prior chemotherapy and radiotherapy. The sample provides detailed information on the patient characteristics and eligibility criteria for the clinical trial.",
    "The sample is a phase 2 clinical trial for patients with metastatic advanced colorectal cancer who have exhausted standard treatment options. The trial is testing the effectiveness of the drug cabazitaxel. The eligibility criteria include being over 18 years old, having a life expectancy of at least three months, having a grade 0-2 functional status, and having evaluable tumor by RECIST criteria. Exclusion criteria include having a performance status greater than 2, inadequate marrow reserve, inadequate liver function, previous history of other malignancy, simultaneous treatment with concomitant anticancer therapy, and any severe acute or chronic medical condition that may affect the patient's ability to participate in the study. Pregnant or breastfeeding women are also excluded. Patients must give written informed consent and be willing to comply with study procedures.",
    "The sample is a record of a clinical trial in phase 2 for the treatment of autism using the drug aripiprazole. The trial is open to both male and female participants between the ages of 12 and 18 who have been diagnosed with autism by a child and adolescent psychiatrist. The eligibility criteria include a clinical judgment that medication treatment for autism is necessary, and the exclusion criteria include major medical problems, uncontrolled seizures, baseline QTC greater than 425 msec, concomitant treatment with psychotropic medication, and a history of prior exposure to aripiprazole. The diseases column lists only one disease, which is autism, and the icdcodes column lists the ICD-10 code for autism, which is Z13.41.",
    "The sample is a record of a clinical trial with a phase 2 designation. The trial is focused on chronic obstructive pulmonary disease (COPD) and involves a list of ICD-10 codes related to the disease. The trial is testing two drugs, azd4818 and placebo. The eligibility criteria for the trial include a clinical diagnosis of COPD with symptoms for more than a year, a smoking history of at least 10 pack-years, and lung function within a specific range. The exclusion criteria include active tuberculosis, any other clinically significant respiratory tract disorder, and certain heart conditions.",
    "The sample is a phase 2 clinical trial for the treatment of scleroderma, a disease that affects the skin and connective tissues. The trial is testing the effectiveness of imatinib mesylate, a drug used to treat certain types of cancer, on patients with either localized or systemic scleroderma. The inclusion criteria for the trial include being over 18 years old, having a documented diagnosis of scleroderma, and having a severe form of the disease. Patients must also have a certain level of heart function and use effective contraception during the trial. Exclusion criteria include recent treatment with certain drugs, organ failure, ongoing cancer, and pregnancy or lactation. Patients must also provide informed consent to participate in the trial.",
    "The sample is a phase 2 clinical trial for allergic rhinitis. The trial includes patients between the ages of 18 and 50 with a BMI between 18 and 28 kg/m2 who have a history of pollen-induced seasonal allergic rhinitis for at least two years and are otherwise healthy. The trial also requires patients to have elevated specific IgE to at least one aero allergen or at least one positive skin pick test (SPT). The trial will test the efficacy of cetirizine dihydrochloride (10 mg/ml) liposomal formulation, cetirizine dihydrochloride (10 mg/ml) buffer solution, and placebo. The eligibility criteria include exclusion of patients with perennial allergic rhinitis except for cat and/or dog sensitivity, soy bean allergy, peanut allergy, smoking during the last month before study inclusion, any upper respiratory tract infection during the period of 2 weeks before the start of the study, chronic medication, any medication, including herbal medicines, during their last five half-lives (t\u00bd), nasal anatomical deviations, extensive use of nasal sprays as judged by the Investigator, ongoing nasal symptoms as judged by the Investigator, known hypersensitivity to cetirizine, pregnant or breast-feeding women, fertile women not using reliable methods of contraception (i.e. IUD, barrier method, hormonal contraceptives, abstinence), participation in any other investigational study in the last three months, inability to adhere to the study plan, previous inclusion in this study, and blood donation during the last three months.",
    "The sample is a phase 2 clinical trial for liver cancer patients with metastatic or locally recurrent cancer that cannot be cured. The trial involves the drug pemetrexed and has specific inclusion and exclusion criteria. Patients must have measurable disease and may have received prior arterial chemoembolization or radiation, but not other chemotherapy. Patients with a history of other invasive malignancies, prior therapy with pemetrexed, or radiation to more than 25% of marrow are excluded.",
    "The sample is a phase 2 clinical trial for the treatment of chronic hepatitis C infection caused by genotype 1 of the virus. The trial involves the use of multiple drugs, including abt-450, abt-072, abt-333, ritonavir, peginterferon alpha-2a, and ribavirin. The eligibility criteria for the trial include being a treatment-naive male or female between the ages of 18 and 65, having a liver biopsy within the past 3 years with histology consistent with HCV-induced liver damage, and having no evidence of cirrhosis or liver pathology due to any cause other than chronic HCV. The exclusion criteria include a history of major depression within the past 2 years, prior treatment with any investigational or commercially available anti-HCV agents, and abnormal laboratory tests.",
    "This sample is for a phase 2 clinical trial for prostate cancer. The trial includes the drugs enzastaurin, placebo, docetaxel, and prednisone. The eligibility criteria for the trial include being at least 18 years old, living close enough to the doctor's office to attend all required visits, not having received chemotherapy for prostate cancer, and having properly functioning organs. The exclusion criteria include being unable to swallow pills, having another serious illness besides prostate cancer, having taken another experimental drug within the last 30 days, having a serious heart condition, and receiving another anti-cancer therapy.",
    "The sample is a record of a clinical trial with a phase 2 designation. The trial is focused on the disease multiple myeloma, which is identified in the \"diseases\" field. The icd-10 codes associated with the disease are listed in the \"icdcodes\" field. The drug being tested is bevacizumab, which is listed in the \"drugs\" field. The eligibility criteria for the trial are listed in the \"criteria\" field, including inclusion criteria such as age range and disease status, as well as exclusion criteria such as history of malignancy and cardiac disease.",
    "This sample is for a phase 2 clinical trial for pancreatic cancer. The eligibility criteria include having a histologically confirmed exocrine pancreatic potentially resectable carcinoma, being between the ages of 18-75, having a certain level of functional state and appropriate biological parameters, and having controlled biliary obstruction. The exclusion criteria include previous administration of chemotherapy or investigational agents for pancreatic cancer treatment, pregnancy or breastfeeding, significant heart disease, lack of physical integrity of the upper gastrointestinal tract, and distant metastases. The sample also includes a list of drugs that will be used in the trial, including gemcitabine, tarceva, and oxaliplatin.",
    "The sample is a phase 2 clinical trial for patients with advanced renal cell carcinoma of papillary or other non-clear cell histology. The trial is testing the effectiveness of the drug sunitinib malate. Patients must have measurable disease and meet certain eligibility criteria, including having a Karnofsky performance status of 70-100%, certain blood counts and liver function tests within normal limits, and no history of brain metastases or other severe medical conditions. Patients must not have received prior sunitinib malate or other concurrent anticancer treatments. The trial also has restrictions on concurrent use of certain medications and participation in other clinical trials.",
    "The sample is a phase 2 clinical trial that focuses on treating major depressive disorder, dysthymia, depression not otherwise specified, and borderline personality disorder. The trial involves the use of lithium carbonate, citalopram, and a placebo. The eligibility criteria for the trial include being between 18-75 years old, having a diagnosis of one of the specified disorders, and being able to speak, read, and understand English. Exclusion criteria include having certain medical conditions, being pregnant or lactating, having abnormal laboratory test results, and having a history of certain mental health disorders.",
    "This sample is for a phase 2 clinical trial for the treatment of narcolepsy. The trial is testing the drugs adx-n05 and placebo. The eligibility criteria for participants include a diagnosis of narcolepsy, good general health, and willingness to comply with the study requirements. Exclusion criteria include pregnancy or lactation for females, a history of significant medical or psychiatric conditions, excessive caffeine or alcohol use, and nicotine dependence that affects sleep.",
    "The sample is a phase 2 clinical trial for postherpetic neuralgia, a condition where pain persists for more than 3 months after healing of the Herpes zoster skin rash. The trial involves the drugs ph-797804 and placebo, and the eligibility criteria include being at least 18 years old, having a pain score of at least 40 mm on the Pain Visual Analog Score, and not having any severe pain that may impair self-assessment of the pain due to post-herpetic neuralgia. Exclusion criteria include a history of certain heart conditions, tuberculosis without treatment, and clinically significant skin lesions. ECG abnormalities and evidence of organ dysfunction or hematopoietic disorder are also exclusion criteria.",
    "The sample is a phase 2 clinical trial for pancreatic cancer patients who have had disease progression following therapy with gemcitabine, intolerance to gemcitabine, or disease recurrence within 12 months following adjuvant gemcitabine. The trial is testing the effectiveness of pertuzumab and erlotinib as treatment options. The eligibility criteria include having a histologically-confirmed pancreatic adenocarcinoma, measurable lesions, age over 18, ECOG performance status 0-2, and meeting certain laboratory values. Exclusion criteria include prior therapy with EGFR-targeted agents, chronic or active hepatitis B or C infection with impaired hepatic function, and certain medical or psychiatric conditions. Participants must also be willing to use adequate contraception and comply with the protocol.",
    "The sample is a phase 2 clinical trial for patients with idiopathic pulmonary fibrosis and pulmonary hypertension. The trial is testing the effectiveness of treprostinil sodium for inhalation. The eligibility criteria include being between 35 and 80 years old, having a diagnosis of IPF and PH, and meeting specific medical criteria such as having a certain FVC and DLCO value. Exclusion criteria include having a history of pulmonary embolism or deep venous thrombosis, left-sided heart disease, or any other medical condition that may put the subject at risk. The trial also requires subjects to have an echocardiogram and right heart catheterization to confirm the presence of pulmonary hypertension.",
    "The sample is a phase 2 clinical trial for the treatment of metastatic breast cancer. The trial involves the use of liposomal doxorubicin and docetaxel drugs. The eligibility criteria for the trial include confirmation of metastatic breast cancer through biopsy, prior adjuvant/neoadjuvant treatment, measurable disease, ability to perform daily activities with minimal assistance, age 18 years or older, adequate bone marrow, liver and kidney function, normal heart function, and written informed consent. Exclusion criteria include pre-existing moderate peripheral neuropathy, significant heart disease history, meningeal metastases, prior chemotherapy for metastatic breast cancer, no measurable disease, receiving Herceptin therapy, and pregnancy or lactation. The study center will determine if the participant meets all the criteria, and if they do not qualify, the study personnel will explain the reasons.",
    "The sample is a phase 2 clinical trial for the treatment of chronic hepatitis C. The trial is looking at the effectiveness of a combination of drugs, including gs-5885, tegobuvir, gs-9451, ribavirin tablet, and gs-5885. The trial is looking for eligible participants who are between 18 and 70 years old, have chronic hepatitis C for at least 6 months, have not yet received treatment for hepatitis C, and have a BMI between 18 and 36 kg/m2. The trial also has a list of exclusion criteria, including autoimmune disease, cirrhosis, poorly controlled diabetes, severe psychiatric illness, and ongoing substance abuse. The trial requires participants to use highly effective contraception methods if they are sexually active and of childbearing potential.",
    "The sample is a clinical trial for a drug used to treat attention deficit hyperactivity disorder. The trial is in phase 2/phase 3 and the table includes information on the diseases being treated, the icd-10 codes associated with those diseases, the drugs being used, and the eligibility criteria for participants. The eligibility criteria include age, gender, health status, and other factors that may impact the interpretation of study results or pose a safety concern. The sample also includes exclusion criteria, such as the presence of other psychiatric disorders or substance abuse, that would make a participant ineligible for the trial.",
    "The sample is a phase 2 clinical trial for patients with non-small cell lung cancer. The trial includes patients with advanced disease that is primary or recurrent, and measurable disease according to the RECIST criteria. Patients must have an ECOG Performance Status of 0 or 1 and adequate organ function. The trial involves the use of several drugs, including vandetanib induction, docetaxel, carboplatin, placebo, and vandetanib maintenance. The eligibility criteria include various requirements related to organ function, prior treatment, and ability to take oral medication. Exclusion criteria include a history of certain medical conditions and known hypersensitivity to certain drugs.",
    "The sample is a phase 2 clinical trial for prostate neoplasms. The trial includes patients with confirmed adenocarcinoma of the prostate who have not undergone chemotherapy with paclitaxel or docetaxel. Patients must have documented prostate-specific antigen (PSA) progression with a PSA greater than 5 ng/mL and ongoing androgen deprivation with serum testosterone level of less than 50 ng/dL. The trial also has inclusion and exclusion criteria, including limitations on patients with certain medical conditions or histories. The trial will test the effectiveness of abiraterone acetate and glucocorticoid drugs.",
    "The sample is a phase 2 clinical trial for the treatment of acute diverticulitis. The trial includes patients with a clinical diagnosis of acute diverticulitis and excludes those with diverticular complications, a history of major abdominal surgery, or immunocompromising diseases. Female patients must be postmenopausal, surgically sterile, or practice acceptable contraception. The trial involves the use of drugs such as mesalamine, probiotic, placebo, and antibiotics for diverticulitis. The eligibility criteria include being willing and able to participate in the study and providing a signed informed consent.",
    "The sample is a phase 2 clinical trial for breast cancer patients who are HER2+ and have operable, histologically confirmed, invasive carcinoma of the breast. The trial includes the drugs taxotere, cytoxan, and herceptin. The eligibility criteria include having no evidence of metastatic disease, normal cardiac function, and adequate wound healing from surgery. Exclusion criteria include having any evidence of disease following complete surgical resection of the primary tumor, Stage IIIB or IV breast cancer, and a history of severe hypersensitivity reaction to drugs formulated with polysorbate 80.",
    "The sample is a phase 2 clinical trial for patients with metastatic breast cancer. The trial is testing the effectiveness of nab-paclitaxel, a drug used to treat breast cancer. The eligibility criteria include having a diagnosis of locally advanced or metastatic hormone-sensitive or insensitive, HER2-negative or -positive breast cancer, relapsing within 12 months after completing (neo-) adjuvant chemotherapy, and having previously received treatment with a solvent-based taxane. The trial also requires participants to have normal cardiac function and meet certain laboratory requirements. Female participants must either be physiologically incapable of becoming pregnant or use adequate contraception. The exclusion criteria include having a known or suspected hypersensitivity reaction to the investigational compounds, having received (neo-) adjuvant therapy not containing a solvent-based taxane or nab-paclitaxel, and having a life expectancy of less than 3 months.",
    "The sample is a phase 2 clinical trial for patients with moderate-to-severe osteoarthritis of the knee. The trial involves the use of two drugs, lidoderm (lidocaine 5% patch) and a placebo patch. The eligibility criteria include being male or female patients aged 37 or older with a BMI of 40 kg/m2 or less, having symptomatic OA of the index knee diagnosed with a functional capacity of II or III according to ACR criteria classification, and having an unchanged dose of analgesic medication for OA for at least 4 weeks prior to screening and for the duration of the study. The trial also has exclusion criteria, such as pain in any joint other than the index joint that could interfere with the patient's assessment of pain in the index joint, compromised integrity of the intact, superficial skin layer, and recent injury or surgery/procedure to either knee causing pain that could interfere with study assessments of pain, function, and QoL.",
    "The sample is a phase 2 clinical trial for diabetes. The trial is testing the effectiveness of the drugs cyclo-z and placebo on patients with type 2 diabetes who are not adequately controlled by diet and exercise alone or oral medications. The trial has inclusion criteria such as a history of type 2 diabetes mellitus, a hemoglobin A1c level of 6.5% to 8.0%, and stable fasting blood glucose levels. Exclusion criteria include taking insulin, history of diabetic ketoacidosis or hyperosmolar non-ketotic coma, and various other medical conditions and behaviors that could affect the conduct of the study. The trial is open to both men and women of all ethnic groups who are over 18 years old.",
    "The sample is a phase 2 clinical trial for the treatment of relapsing-remitting multiple sclerosis. The trial involves the use of drugs such as placebo, ocrelizumab, and avonex. The eligibility criteria for participants include being between the ages of 18-55, having relapsing-remitting multiple sclerosis, and being able to provide written informed consent. Exclusion criteria include having other neurologic disorders, being pregnant or lactating, having a history of cancer or alcohol/drug abuse, and having received certain types of treatments within a certain timeframe. The trial also requires participants to use reliable means of contraception if sexually active.",
    "The sample is a phase 2 clinical trial for breast cancer patients with locally recurrent or metastatic disease. Patients must have estrogen and/or progesterone receptor-positive adenocarcinoma of the breast and meet certain eligibility criteria, including being post-menopausal females, having adequate hematologic, hepatic, and renal function, and not having a history of central nervous system metastases or unevaluated CNS symptoms suggestive of possible brain metastases. Patients may have had 1 prior hormonal therapy for metastatic disease but not more than 1 prior chemotherapy regimen. No concurrent chemotherapy is allowed while on protocol therapy. Patients may receive concurrent radiation therapy to painful bone metastases or areas of impending bone fracture as long as radiation therapy is initiated prior to study entry and sites of evaluable disease outside the radiation port(s) are available for follow-up. Patients who have received prior radiotherapy must have recovered from toxicity induced by this treatment. Patients must not have had prior therapy with EGF receptor inhibitors. The study also requires patients to submit tissue blocks for retrospective EGFR and HER2 analysis. The trial allows for previous but not concomitant therapy with trastuzumab (Herceptin). Patients must have an ECOG performance status of 0, 1, or 2 and must not suffer from medical or psychiatric conditions that would interfere with ability to provide informed consent, communicate side effects, or comply with protocol requirements including maintenance of a compliance/pill diary. Patients must be disease-free of prior invasive cancers for > 5 years with the exception of basal or squamous cancer of the skin or cervical carcinoma in situ.",
    "This is a sample from a clinical trial table that includes information about the trial's phase, diseases being studied, icd-10 codes of those diseases, drugs being used, and eligibility criteria for participants. In this particular sample, the trial is in phase 2 and is studying renal cell carcinoma. The icd-10 codes associated with this disease are listed. The drugs being used in the trial are bibf 1120 and sunitinib. The eligibility criteria for participants are also listed, including requirements for a confirmed diagnosis of renal cell cancer, acceptable organ function, and willingness to comply with the study protocol. There are also exclusion criteria, such as inability to tolerate the treatment, recent participation in another clinical study, and pregnancy or drug/alcohol abuse.",
    "The sample is a record of a clinical trial for the treatment of malignant pleural mesothelioma. The trial is in phase 2 and involves the use of drugs such as cisplatin, sodium thiosulfate, and alimta. The eligibility criteria for the trial include confirmation of the disease through histopathology, ability to undergo surgical cytoreduction, and no evidence of disease spread outside the ipsilateral hemithorax. Exclusion criteria include the presence of distant metastatic disease, severe non-malignant co-morbid disease, and previous chemotherapy or radiation therapy for mesothelioma. The trial is open to male and non-pregnant female patients who are 18 years of age or older and have an estimated life expectancy of at least 12 weeks.",
    "The sample is a phase 2 clinical trial for psoriasis. The trial includes patients with mild to moderate plaque psoriasis on the trunk or extremities, excluding palms, soles, scalp, and facial or intertriginous areas. The trial is open to both men and women over the age of 18 with Fitzpatrick skin type I-VI. The trial involves the use of four different drugs, including ph-10 (0.002% rose bengal), ph-10 (0.005% rose bengal), ph-10 (0.01% rose bengal), and a vehicle. The eligibility criteria include exclusion criteria such as pregnancy, use of certain therapies within a certain timeframe, and participation in other clinical research studies. The trial requires written informed consent from the subject or legal guardian.",
    "The sample is a phase 2 clinical trial for patients with type 2 diabetes. The trial is testing the effectiveness of the drugs ezetimibe and simvastatin in reducing cholesterol levels in patients with stable antidiabetic treatment for at least three months. The trial has specific inclusion and exclusion criteria, including requirements for cholesterol levels, serum creatinine levels, and urinary albumin excretion rates. Patients with a history of certain medical conditions or taking certain medications are excluded from the trial. The trial also requires written informed consent from patients and adherence to a scientifically accepted form of contraception for women of childbearing potential. Patients who are unable to complete the trial follow-up or have an uncooperative attitude are also excluded.",
    "The sample is a phase 2 clinical trial for patients with type 2 diabetes and overt diabetic nephropathy. The trial is testing the effectiveness of pyridoxamine dihydrochloride compared to a placebo. The eligibility criteria include being 25 years or older, having a history of overt diabetic nephropathy, and being on stable blood pressure medications and an ACE-I or ARB for at least 2 months. Exclusion criteria include having type 1 diabetes, chronic renal disease other than diabetic renal disease, and a history of solid organ transplantation or neoplastic disease within 5 years prior to the screening visit. Women of childbearing potential must use appropriate birth control during the study. Patients must not have taken pyridoxamine or any other investigational drug within 30 days prior to the screening visit, or have participated in a previous Pyridorin trial or another clinical trial within 30 days prior to the screening visit.",
    "The sample is a record of a clinical trial in phase 2, focused on two chronic respiratory diseases: pulmonary disease and chronic bronchitis. The trial involves two drugs, bibw 2948 bs and placebo, and includes a list of eligibility criteria for participants. Inclusion criteria include being a smoker with COPD between the ages of 40 and 70. Exclusion criteria include having significant other diseases, abnormal hematology or liver function, psychiatric disorders, pulmonary obstruction, asthma, allergic rhinitis, dependence on oxygen, a history of myocardial infarction or cancer, being a woman of childbearing potential, or being on antiplatelet or anticoagulation therapy.",
    "The sample is a phase 2 clinical trial for small cell lung cancer. The trial is testing the effectiveness of the drugs carboplatin and irinotecan. The eligibility criteria include having histologically or cytologically confirmed small cell lung cancer, measurable disease, and meeting certain patient characteristics such as having an ECOG performance status of 0-2 and a life expectancy of at least 3 months. Prior concurrent therapy is also taken into consideration. The sample provides a detailed list of the eligibility criteria for the trial.",
    "The sample is a record of a clinical trial with a phase 2 designation. The trial is focused on glioblastoma multiforme, a type of brain cancer. The trial includes a list of ICD-10 codes for the disease, as well as a drug called axitinib. The eligibility criteria for the trial include newly diagnosed patients with histologically proven glioblastoma multiforme, age above 70 years, Karnofsky score of 50-80, adequate organ function as defined by laboratory values, life expectancy of >12 weeks, and no evidence of preexisting uncontrolled hypertension. The exclusion criteria include prior treatment with chemotherapy or radiation for glioblastoma multiforme, patients with extensive tumor hemorrhage, and certain medical conditions within the 12 months prior to study drug administration.",
    "This sample is a phase 2 clinical trial for patients with recurrent or stage IV melanoma. The trial is testing the drug tipifarnib. Patients must have at least 2 cutaneous lesions that can be biopsied for correlative studies and measurable disease. Patients cannot have a history of brain metastases, allergies to certain medications, or more than 1 prior immunotherapy regimen for advanced melanoma. They must also have a CTC (ECOG) performance status of 0-1 and meet certain blood test criteria. Women of child-bearing age will undergo pregnancy testing and both men and women of reproductive potential must agree to use an effective means of birth control.",
    "The sample is a phase 2 clinical trial for ovarian cancer, peritoneal cancer, fallopian tube cancer, stage 3 cancer, and stage 4 cancer. The trial involves the use of bevacizumab, carboplatin, and paclitaxel as drugs. The eligibility criteria for the trial include a diagnosis of primary peritoneal carcinoma, fallopian tube epithelial ovarian carcinoma, stage III suboptimal surgery or biopsy, and stage IV disease. Exclusion criteria include unstable heart conditions, high blood pressure, vascular disorders, and bleeding problems. The icd-10 codes for the diseases are also provided.",
    "The sample is a record of a clinical trial with a phase 2 designation. The trial is focused on the disease mycosis fungoides, which is associated with a list of icd-10 codes. The drug being tested is 0.04% mechlorethamine gel. The eligibility criteria for the trial include having completed a previous phase II study and not achieving a complete response. The exclusion criteria include being pregnant or nursing, or not using effective contraception for males and females of childbearing potential.",
    "The sample is a phase 2 clinical trial for patients with non-small cell lung cancer that has spread or cannot be surgically removed. The trial is testing the effectiveness of a combination of three drugs: carboplatin, gefitinib, and paclitaxel. The eligibility criteria include having measurable disease, being over 65 years old with a performance status of ECOG 0-2, and having a life expectancy of at least 12 weeks. Patients must also meet certain hematopoietic, hepatic, renal, cardiovascular, and pulmonary requirements, and cannot have certain medical conditions or prior malignancies. The trial also has restrictions on prior concurrent therapy and the use of certain drugs during the trial.",
    "The sample is a phase 2 clinical trial for irritable bowel syndrome. The trial includes males and females aged 18-79 who have been diagnosed with IBS and meet certain criteria, such as having recurrent symptoms of abdominal discomfort or pain. The trial involves the use of two drugs, asimadoline and placebo, and participants must comply with daily telephone diary entry. There are also exclusion criteria, such as having other co-morbid illnesses or being pregnant or breastfeeding.",
    "The sample is a phase 2 clinical trial for women who are candidates for hematopoietic stem cell transplantation and have experienced amenorrhea, premature ovarian failure, or ovarian function insufficiency. The trial is testing the effectiveness of leuprolide acetate in restoring ovarian function. The inclusion criteria require that the participant is a post-menarche female under 40 years old, premenopausal before the start of transplantation or oral contraceptive pills, and has FSH and LH levels within a certain range. The participant must also agree to stop taking oral contraceptives for a period of 3-6 months starting 1 year post-transplant. The exclusion criteria include breast cancer, ovarian cancer, pregnancy, and hypersensitivity to any Gonadotropin-releasing hormone (GnRH) analogs.",
    "The sample is a phase 2 clinical trial for patients with nasopharyngeal neoplasms. The trial involves the drug pemetrexed (alimta) and has a list of eligibility criteria that patients must meet in order to participate. These criteria include having a histologic diagnosis of nasopharyngeal carcinoma, having previously received one platinum-based chemotherapy regimen for palliative therapy of locally advanced or metastatic disease, and having a performance status of 0 to 1 on the Eastern Cooperative Oncology Group (ECOG) Scale. Patients must also have adequate organ function and estimated life expectancy of at least 8 weeks. The trial has exclusion criteria as well, such as having a known or suspected brain metastasis, having previously completed or withdrawn from the study, or having a serious concomitant disorder that would compromise the safety of the patient. Patients must sign an informed consent form to participate in the trial.",
    "The sample is a record from a clinical trial table that includes information about the trial's phase, diseases being studied, associated ICD-10 codes, drugs being tested, and eligibility criteria. In this particular sample, the trial is in phase 2/phase 3 and is focused on atopic dermatitis. The associated ICD-10 codes are \"L20.89\" and \"L20.9\". The drug being tested is fexofenadine/allegra (m016455). The eligibility criteria include being between 6 months and 11 years old and having atopic dermatitis. Exclusion criteria include having low itching scores or only experiencing itching on certain areas of the body.",
    "The sample is a phase 2 clinical trial for patients with diffuse large B-cell non-Hodgkin's lymphoma. The trial includes patients with bulky stage II (any lesion \u2265 10 cm) or stage III or IV disease, but excludes patients with certain types of lymphoma, such as primary central nervous system lymphoma or transformed low-grade lymphoma. Patients must have at least one objective measurable disease site and an Eastern Cooperative Oncology Group (ECOG) performance status of 0-3. Other eligibility criteria include normal ejection fraction, certain blood counts, and normal levels of creatinine and bilirubin. Exclusion criteria include prior chemotherapy or radiation therapy for lymphoma, prior use of certain chemotherapy drugs, and concurrent use of certain medications. Pregnant or nursing women and HIV-positive patients are also excluded. The trial will test the effectiveness of a combination of drugs including carboplatin, cyclophosphamide, doxorubicin hydrochloride, etoposide, ifosfamide, prednisone, and vincristine.",
    "The sample is a record of a clinical trial in phase 2, focused on kidney transplantation. The table includes information on the diseases being studied, identified by their ICD-10 codes, as well as the drugs being used in the trial. The eligibility criteria for the trial are also listed, including both inclusion and exclusion criteria. In this particular sample, patients must be recipients of a primary or retransplanted cadaveric or non-HLA-identical living donor kidney, and must receive the first oral dose of the randomized study drug within 48 hours of the transplant procedure. Patients who have received or are receiving an organ transplant other than a kidney, or who have received a kidney transplant from a cadaveric donor over 60 years of age, are excluded from the trial.",
    "The sample is a phase 2 clinical trial for rheumatoid arthritis. The trial includes subjects who are between 18 and 75 years old and have been diagnosed with rheumatoid arthritis for at least 6 months prior to screening. The subjects must also have at least 10 painful/tender and 6 swollen joints at the baseline visit and an elevated CRP level. The trial involves the use of the drug natalizumab and a placebo. The eligibility criteria include being able to read and sign the informed consent form, being on a stable dose of MTX for at least 3 months prior to randomization, and using adequate contraception for female subjects of childbearing potential. The exclusion criteria include being pregnant or lactating, having experienced an inadequate therapeutic response after at least 3 months of treatment with at least one TNF-alpha inhibitor, and having a history of a malignancy (other than basal cell carcinoma of the skin).",
    "The sample is a phase 2 clinical trial for the treatment of metastatic non-small-cell lung cancer using the drug ly573636-sodium. The trial includes patients who are at least 18 years old and have received two previous treatment regimens for the disease. The eligibility criteria include a diagnosis of metastatic non-small-cell lung cancer, while the exclusion criteria include serious pre-existing medical conditions, previous cancer (except skin cancer, excluding melanoma), and active treatment with Coumadin. The diseases are listed as non-small-cell lung cancer, and the icd-10 codes associated with the disease are also provided.",
    "The sample is a phase 2 clinical trial for the treatment of stomach neoplasms using a drug called dos (docetaxel, oxaliplatin and s-1). The trial is for patients with unresectable, locally advanced or metastatic gastric adenocarcinoma who are between the ages of 18 and 70 and have an estimated life expectancy of at least 3 months. The trial has a list of inclusion and exclusion criteria, including adequate bone marrow, kidney, and liver function, and no previous history of chemotherapy. The sample also includes a list of icd-10 codes for the disease and the eligibility criteria for the trial.",
    "The sample is a phase 2 clinical trial for patients with acute myeloid leukemia (AML) who have relapsed after a prior complete response. The trial is testing the effectiveness of the drugs cytarabine and gemtuzumab ozogamicin. The eligibility criteria include confirmation of AML, CD33 positivity, and no blastic transformation of chronic myelogenous leukemia. Patients must also have a Zubrod performance status of 0-2 and meet certain hematopoietic, hepatic, renal, and cardiovascular requirements. They must not have any other malignancy within the past 5 years, and must not be pregnant or nursing. Prior concurrent therapy is allowed in some cases, but patients must have recovered from any prior investigational agents.",
    "The sample is a phase 2 clinical trial for non-small cell lung cancer. The trial includes patients with node positive stage II disease or stage IIIA who have a tumor that can be surgically removed. Patients must not have received any prior tumor therapy and must not have any serious concomitant disorders or active infections. The trial will test the effectiveness of the drugs gemcitabine and cisplatin. The eligibility criteria for the trial include confirmation of the diagnosis of NSCLC, measurable lesions according to RECIST criteria, and no prior treatment with investigational drugs or other tumor therapies. The exclusion criteria include stage IIIb or IV disease, concurrent administration of other tumor therapies, and serious concomitant disorders or active infections.",
    "The sample is a record of a clinical trial with a phase 2 designation. The trial is focused on HIV-1 infection and includes a list of ICD-10 codes for the disease. The trial involves several drugs, including BMS-986001, efavirenz, lamivudine, and tenofovir, as well as a placebo matching with BMS-986001. The eligibility criteria for the trial include being at least 18 years old, having a plasma HIV-1 RNA level greater than 5000 copies/mL, being antiretroviral treatment-naive, and having a CD4+ T-cell count greater than 200 cells/mm3. The exclusion criteria include resistance to any of the study medications or contraindications to any of the study drugs.",
    "The sample is a phase 2 clinical trial for patients with non-small cell lung cancer. The trial includes a list of drugs, such as amg 951, bevacizumab, carboplatin, and paclitaxel, and a set of eligibility criteria for patients to participate in the trial. The criteria include having advanced NSCLC, a performance status of 0 or 1, a life expectancy greater than 3 months, and being at least 18 years old. The trial also has exclusion criteria, such as having a prior malignancy other than NSCLC, untreated or unstable CNS metastases, and significant liver dysfunction. The sample includes both inclusion and exclusion criteria for the trial.",
    "The sample is a phase 2 clinical trial for bladder cancer. The trial is looking for patients with confirmed transitional cell carcinoma of the bladder who have muscle-invasive disease or clinical stage T3 or T4 disease. Patients must also have clinically node-negative disease and an ECOG performance status of 0-1. Additionally, patients must meet certain laboratory criteria, such as having a WBC count of at least 2,000/\u00b5L and a platelet count of at least 100,000/\u00b5L. Patients must not have received prior systemic therapies except for intravesical therapy for superficial disease, and must not have received prior sorafenib tosylate or systemic chemotherapy. The trial is looking for patients who have not received investigational agents for at least 4 weeks prior to enrollment.",
    "This sample is a phase 2 clinical trial for the treatment of malignant pleural mesothelioma, a type of cancer affecting the lining of the lungs. The trial is testing the drug belinostat and is open to patients who have received only one prior chemotherapy regimen for advanced mesothelioma. Patients must have unresectable disease and measurable disease, and must meet a number of other eligibility criteria related to their health status and medical history. The trial is not open to patients with certain cardiovascular or psychiatric conditions, or those taking certain medications.",
    "The sample is a phase 2 clinical trial for patients with metastatic breast cancer. The table includes information on the diseases being studied, the icd-10 codes associated with those diseases, the drugs being used in the trial, and the eligibility criteria for patients to participate. The inclusion criteria include a histological or cytological diagnosis of breast carcinoma with evidence of unresectable, locally recurrent, or metastatic disease, measurable lesions, and prior treatment with anthracyclines with or without taxanes. The exclusion criteria include recent treatment with an investigational drug, concurrent administration of other tumor therapy, active infection, serious concomitant disorders, and clinically detectable second primary malignancy.",
    "The sample is a phase 2 clinical trial for atherosclerosis. The trial involves testing the effectiveness of a drug called sb480848 in reducing the risk of cardiovascular events in dyslipidemic patients who are currently undergoing statin therapy. The trial includes a list of inclusion and exclusion criteria, such as no recent cardiovascular events or procedures, no planned surgeries during the study period, and no changes in lipid-lowering medication during the 4 weeks prior to randomization. The trial also requires that patients have measurable Lp-PLA2 activity in plasma and have well-controlled dyslipidemia. The trial involves testing different doses of the drug and a placebo.",
    "The sample is a phase 2 clinical trial for the treatment of chronic plaque psoriasis using the drugs placebo and baricitinib. The trial is looking for participants who have had active chronic plaque psoriasis for at least 6 months, have a Psoriasis Area and Severity Index (PASI) score of at least 12, and a Static Physician's Global Assessment (sPGA) score of at least 3. The trial has a list of inclusion and exclusion criteria that participants must meet in order to be eligible for the study. The diseases and icd-10 codes associated with the trial include psoriasis, skin diseases, and skin diseases, papulosquamous.",
    "The sample is a phase 2 clinical trial for the treatment of ocular hypertension and open angle glaucoma. The trial involves testing the effectiveness of three different concentrations of ar-13324 ophthalmic solution. The eligibility criteria for participants include being 18 years or older, having a diagnosis of open angle glaucoma or ocular hypertension, and having unmedicated intraocular pressure levels above a certain threshold. Exclusion criteria include having certain ocular conditions or diseases, being pregnant or nursing, and having certain systemic diseases. Participants must also be willing to follow study instructions and provide informed consent.",
    "The sample is a phase 2 clinical trial for patients with recurrent or metastatic breast cancer. The trial is testing the effectiveness of the drug combination gemcitabine and oxaliplatin. The eligibility criteria include having received 1-3 prior chemotherapy regimens, having measurable disease, being at least 18 years old, having a certain level of blood counts and liver function, and having recovered from prior treatments. Patients with certain medical or psychiatric conditions or with peripheral neuropathy greater than grade 2 are excluded. The sample also includes the ICD-10 codes for the diseases being studied.",
    "The sample is a phase 2 clinical trial for patients with non-small cell lung cancer. The trial is testing the effectiveness of the drugs cisplatin and pemetrexed disodium. The eligibility criteria include having microscopically confirmed non-small cell lung cancer with specific staging and disease characteristics, as well as meeting certain patient characteristics such as age and performance status. Patients must not have received prior chemotherapy or radiotherapy for lung cancer, and must not have any other active malignancy within the past 2 years except nonmelanoma skin cancer or carcinoma in situ of the cervix. The trial also has specific requirements for prior and concurrent therapies, as well as other medical and lifestyle factors.",
    "The sample is a phase 2 clinical trial for patients with stage IV colorectal cancer that have p185 HER2 overexpression. The trial involves the use of irinotecan hydrochloride as a treatment. The eligibility criteria include having measurable disease outside of the irradiated field, a performance status of ECOG 0-2, and meeting certain blood count and organ function requirements. Patients must not have had prior trastuzumab or irinotecan treatment, and must not have any serious underlying medical conditions or altered mental status. The trial allows for concurrent use of certain medications and requires patients to use effective contraception during and for 6 months after the study. Prior radiotherapy or major surgery must have occurred at least 3 weeks prior to the trial.",
    "The sample is a phase 2 clinical trial for patients aged 8 to 11 years with serious bacterial infections such as intra-abdominal infection, pneumonia, and skin diseases. The trial involves the administration of the drug Tygacil via IV antibiotic therapy for at least 5 days. The eligibility criteria include being able to complete all activities required for the study, having a diagnosis of a serious infection, and meeting other inclusion criteria. Exclusion criteria include having any concomitant condition or taking any concomitant medication that could preclude an evaluation of safety or efficacy responses, being pregnant or breastfeeding, having previously participated in the trial, and having received any investigational drugs or devices within 4 weeks before administration of the first dose of tigecycline. The sample also includes a list of diseases and their corresponding ICD-10 codes, as well as the eligibility criteria for the trial.",
    "The sample is a phase 2 clinical trial for metastatic colorectal cancer. The trial involves the use of irinotecan hydrochloride and placebo drugs. The eligibility criteria for participants include having confirmed wtKRAS CRC and having previously failed both irinotecan and oxaliplatin containing regimens. Exclusion criteria include recent cancer treatment, bad side effects to irinotecan therapy, and certain medical conditions such as HIV and Hepatitis B or C. Pregnant or breastfeeding individuals or those planning to have a child while on the study are also excluded. The diseases are listed as metastatic colorectal cancer and the icd-10 codes associated with the disease are also provided.",
    "The sample is a phase 2 clinical trial for patients with estrogen or progesterone receptor positive stage IIIb/IV non-small cell lung cancer. The trial is testing the effectiveness of a combination of fulvestrant and erlotinib drugs. The eligibility criteria include stable disease on erlotinib monotherapy for at least 2 months, being 18 years or older, having an ECOG Performance Status of \u22642, and adequate organ and coagulation function. Postmenopausal status in female patients is required. Patients must sign a written informed consent. Exclusion criteria include pregnancy or breastfeeding, receiving other investigational drugs or anti-cancer agents, hormone replacement therapy, uncontrolled infection, receiving less than 100mg/day of erlotinib, evidence of progression after 2 months of erlotinib monotherapy, history of bleeding diathesis or long-term anticoagulant therapy, history of hypersensitivity to active or inactive excipients of fulvestrant, and inability to comply with safety monitoring requirements.",
    "The sample is a phase 2 trial for sickle cell disease, with ketamine as the drug being tested. The eligibility criteria include having a sudden onset of acute pain consistent with a vasoocclusive episode, a pain score of at least 5 out of 10 when the ketamine infusion is started, and at least one prior hospitalization for vasoocclusive pain at a specific medical center. Exclusion criteria include having a primary diagnosis other than vasoocclusive episode, concurrent acute chest syndrome, hemoglobin levels below 5 mg/dL, and a history of liver or renal dysfunction. Participants must also have parental consent and child assent, and cannot be pregnant or participating in another investigational drug study.",
    "The sample is a phase 2 clinical trial for the treatment of cancer, specifically melanoma. The trial involves the use of the drug cisplatin and requires patients to meet certain eligibility criteria, such as having a confirmed diagnosis of melanoma and a measurable lesion that requires radiation. Patients must also have a Karnofsky Performance Scale score of over 70 and meet certain laboratory value requirements. Exclusion criteria include prior irradiation to the planned field and significant infections or medical conditions that would prevent the use of full dose chemotherapy. Patients must also not be pregnant or lactating.",
    "The sample is a phase 2 trial for patients with recurrent adult diffuse large cell lymphoma, recurrent grade 1, 2, or 3 follicular lymphoma, or recurrent mantle cell lymphoma. The trial involves the drug bortezomib and has eligibility criteria including confirmed diagnosis of the specified lymphomas, prior treatment with rituximab, radiographically measurable disease, and certain laboratory values within normal limits. Exclusion criteria include prior treatment with ofatumumab or bortezomib, peripheral neuropathy, and significant concurrent medical conditions. The trial also requires patients to be able to comply with study procedures and follow-up examinations, and to sign a written informed consent document.",
    "The sample is a phase 2 clinical trial for breast cancer patients with HER2/neu-positive disease. The trial includes patients with any nodal status or tumor size, except for stage IV disease. The patients must meet certain eligibility criteria, including having a confirmed diagnosis of adenocarcinoma of the breast, having an ECOG performance status of 0-1, and meeting certain laboratory values. Patients must not have any active unresolved infections, sensitivity to E. coli derived proteins, or any psychiatric illness or concurrent medical conditions that would preclude study treatment. Prior hormonal therapy for chemoprevention is allowed, but prior trastuzumab or anthracyclines are not allowed. Patients must not be receiving concurrent hormonal therapy, chemotherapy, radiotherapy, immunotherapy, or biotherapy for breast cancer, or any drugs that may prolong the QT. The trial will test the efficacy of a combination of cyclophosphamide, doxorubicin hydrochloride, lapatinib ditosylate, and paclitaxel.",
    "The sample is a phase 2 clinical trial for advanced non-small cell lung cancer. The trial is testing the effectiveness of the drug S-1 on patients who have received prior 1st line chemotherapy treatment but have not received any 2nd line therapy. The eligibility criteria include having measurable disease, being able to take medications orally, having an ECOG performance status of 0 or 1, and having adequate organ function. The trial excludes patients who have had treatment with investigational agents within the past 30 days, any prior 1st line treatment with S-1 for NSCLC, or previous therapy for NSCLC within the past 21 days. Patients with serious illnesses or medical conditions, receiving concomitant treatment with drugs interacting with S-1, pregnant or lactating females, and those with reproductive potential who refuse to use adequate contraception are also excluded.",
    "The sample is a record of a clinical trial in phase 2 for lung cancer. The trial is testing a drug called kos-862. The eligibility criteria for the trial include being at least 18 years old, having measurable disease, and having received one previous treatment of a platinum-based drug such as cisplatin or carboplatin. The trial excludes patients with brain metastases or significant changes in heart rhythm as determined by an ECG tracing. The diseases are listed as 'lung cancer' and the corresponding ICD-10 codes are provided.",
    "The sample is a phase 2 clinical trial for prostate cancer. The trial involves the use of three drugs: exisulind, luteinizing hormone-releasing hormone (LHRH) agonist, and antiandrogen. The eligibility criteria for the trial include being at least 21 years old, having a histologically or cytologically documented prostate cancer, having an ECOG performance status score of 0 or 1, and having received at least one cycle of IAS with an LHRH agonist and anti-androgen. Patients must also be willing to remain off chronic NSAIDs (with the exception of ibuprofen or naproxen) and have not taken sulindac (Clinoril\u2122) on a regular basis for any indication for one week prior to enrollment and willing to remain off of sulindac for the duration of the study. The exclusion criteria include known hypersensitivity to sulindac (Clinoril\u2122), ECOG performance status score > 1, and having evidence of hormone-refractory prostate cancer. Patients with certain medical conditions or taking certain medications may also be excluded from the trial.",
    "The sample is a phase 2 clinical trial for the treatment of pulmonary arterial hypertension, interstitial lung disease, and idiopathic pulmonary fibrosis. The trial involves the use of the drug treprostinil and has specific eligibility criteria for participants, including a diagnosis of severe pulmonary arterial hypertension and planned treatment with treprostinil as recommended by their physician. The sample also includes exclusion criteria, such as limitations on physical ability and recent changes in medication. The trial requires participants to undergo various standard of care evaluations, including high resolution CT scans and right-heart catheterization.",
    "The sample is a phase 2 clinical trial for patients with metastatic renal cancer that is refractory to sorafenib or sunitinib therapy. The trial is testing the drug RAD001. The inclusion criteria require patients to have at least one measurable site of disease that has not been previously irradiated, be 18 years or older, have a WHO performance status of 2 or less, and have adequate bone marrow, liver, and kidney function. Patients must also have recovered from any prior therapy and signed informed consent. The exclusion criteria include prior treatment with investigational drugs within the previous 4 weeks, chronic treatment with systemic steroids or another immunosuppressive agent, uncontrolled brain or leptomeningeal metastases, and other severe medical conditions that could affect participation in the study. Women who are pregnant or breastfeeding or those who are able to conceive and unwilling to practice effective birth control are also excluded. Patients who have received prior treatment with an mTOR inhibitor or have a known hypersensitivity to RAD001 or other rapamycins are also excluded. Patients must be willing and able to comply with the protocol.",
    "The sample is a phase 2 clinical trial for bipolar disorder. The trial includes male and female inpatients between the ages of 18 and 65 who meet the DSM-IV criteria for bipolar I disorder with an acute manic or mixed episode. The trial involves the drugs cariprazine and placebo. Inclusion criteria include having a total Young Mania Rating Scale (YMRS) score of at least 20 and a score of at least 4 on two specific YMRS items. Exclusion criteria include abnormalities on physical examination, abnormal vital signs, electrocardiogram (ECG), or clinical laboratory values, a Montgomery-\u00c5sberg Depression Rating Scale (MADRS) total score of at least 18 at Visit 2, experiencing the first manic episode, and having received electroconvulsive therapy (ECT) or a depot neuroleptic in the 3 months prior to Visit 1.",
    "The sample is a record from a clinical trial table. It is a phase 2 trial for type 2 diabetes mellitus. The trial includes a list of icd-10 codes for the disease and a list of drugs being tested. The eligibility criteria for the trial are also listed, including requirements for previous treatment and specific exclusion criteria such as recent participation in other clinical trials or use of certain medications.",
    "The sample is a phase 2 trial for patients with metastatic papillary histology renal cell carcinoma. Patients must have measurable disease, be willing to submit representative slides for central pathology review, and have a Zubrod performance status of 0-2. They must not have received prior chemotherapy or immunotherapy, but may have received prior radiation therapy. Patients must meet various laboratory criteria, including having a WBC count of at least 3,000/\u03bcl and a serum creatinine level of \u2264 2 X the institutional upper limit of normal. They must also meet various medical criteria, such as not having a history of brain metastases or gastrointestinal tract disease resulting in an inability to take oral medication. Patients must sign and give written informed consent in accordance with institutional and federal guidelines.",
    "The sample is a phase 2 clinical trial for patients with locally advanced or metastatic breast cancer who are HER2-negative. The trial involves the use of two drugs, paclitaxel albumin nanoparticle for injectable suspension (abraxane) and sorafenib (nexavar). The eligibility criteria include having signed an informed consent, having measurable disease, and meeting certain medical requirements such as liver and kidney function. Patients must not have received prior chemotherapy for the treatment of locally advanced or metastatic breast cancer, or prior Abraxane or Nexavar. Exclusion criteria include having a history of hypersensitivity or allergy to taxanes, serious intercurrent medical or psychiatric illness, and untreated or active brain metastases. Patients must be willing and able to comply with scheduled visits, treatment plan, and laboratory testing, and be accessible for follow-up.",
    "The sample is a phase 2 clinical trial for the treatment of gastroparesis, type 1 and type 2 diabetes mellitus. The trial involves testing the effectiveness of three drugs, including a placebo, on patients who meet specific eligibility criteria. The criteria include being between 18 and 80 years old, having a history of gastroparesis symptoms for at least 3 months, and having a gastric half-emptying time of over 82 minutes. Patients must also have a BMI of less than 45.0 and a HbA1c level of less than 11.0%. The trial has exclusion criteria, such as having persistent daily vomiting, having had endoscopic pyloric injections of botulinum toxin within 6 months prior to the screening visit, and having a history of severe depression or cognitive impairment.",
    "The sample is a record of a clinical trial in phase 2 for chronic myelogenous leukemia. The trial is testing the effectiveness of the drug Nexavar (sorafenib, bay43-9006) on patients who have shown resistance to Gleevec (Imatinib) and have a WBC count greater than 20 x 109/L. The eligibility criteria for the trial include having an ECOG performance status of 0, 1 or 2, an anticipated survival of at least 16 weeks, and the ability to comply with study procedures and follow-up examinations. The exclusion criteria include congestive heart failure greater than class II, cardiac arrhythmias requiring antiarrythmics, active coronary artery disease or ischemia, history of HIV infection or chronic hepatitis B or C, active clinically serious infections, patients with seizure disorder requiring anti-epileptic drugs, and history of solid organ allograft.",
    "The sample is a record from a clinical trial table that includes information about the phase of the trial, the disease being studied (in this case, type 1 diabetes), the ICD-10 codes associated with the disease, the drugs being tested (anakinra and saline), and the eligibility criteria for participants. The eligibility criteria include requirements such as a positive GAD auto-antibody test, a certain age range, and a specific C-peptide level. The exclusion criteria include factors such as severe liver or renal disease, a history of heart disease, and pregnancy.",
    "The sample is a phase 2 clinical trial for patients with squamous cell carcinoma of the head and neck that is considered incurable with surgery or radiation therapy. The trial is testing the effectiveness of the drug paclitaxel. Patients must have bidimensionally measurable disease and meet certain eligibility criteria, including age 18 and over, ECOG performance status of 0 or 1, and no uncontrolled CNS metastases. Prior concurrent therapy is allowed, but patients must have recovered from prior therapy. The sample includes detailed disease and patient characteristics, as well as prior concurrent therapy information.",
    "The sample is a phase 2 clinical trial for the treatment of myelodysplastic syndromes. The trial includes patients with refractory anemia with excess blasts or myelodysplastic CMMoL with a high risk of AML transformation. The eligibility criteria include being over 18 years old, having a life expectancy of at least 3 months, and having an Eastern Cooperative Oncology Group Performance Status Grade of 0-2. The trial involves the use of drugs such as 5-azacytidine, valproic acid, and atra. The inclusion criteria also require patients to have certain serum bilirubin and transaminase levels, and women of childbearing potential must have a negative pregnancy test and agree not to start a pregnancy during the study period. The exclusion criteria include acute myeloid leukemia, concurrent malignancy diagnosed in the past 12 months, severe renal impairment, pregnancy or lactation, liver disease, HIV infection, and prior treatments with investigational drugs or cytotoxic therapy.",
    "The sample is a record of a clinical trial with a phase 2 designation. The trial is focused on the disease of renal cell carcinoma and includes a list of associated ICD-10 codes. The drug being tested is gw786034. The eligibility criteria for the trial are listed, including requirements for bone marrow function, renal function, and platelet count. There are also exclusion criteria listed, such as a history of other cancers or recent treatment with investigational drugs or chemotherapy.",
    "The sample is a record of a clinical trial in phase 2 for the treatment of cystic fibrosis. The trial involves testing the effectiveness of three drugs - mannitol, mannitol + pulmozyme, and dornase alpha. The trial has eligibility criteria for participants, including a known diagnosis of cystic fibrosis, being between the ages of 8 and 18, and having a baseline FEV1 of less than 70% of the predicted normal value. There are also exclusion criteria, such as currently active asthma, uncontrolled hypertension, and known intolerance to the drugs being tested.",
    "The sample is a record of a clinical trial with a phase 2 designation. The trial is focused on patients with chronic obstructive pulmonary disease (COPD) and involves the use of several drugs, including olodaterol and tiotropium bromide, as well as a placebo. The eligibility criteria for the trial include patients being current or ex-smokers with a smoking history of more than 10 pack years, and meeting certain spirometric criteria. The trial also has exclusion criteria, such as patients with a significant disease other than COPD, clinically relevant abnormal baseline haematology, blood chemistry, or urinalysis, and a history of asthma or a total blood eosinophil count >=600/mm3. The sample also includes a list of diseases and their corresponding ICD-10 codes, as well as the eligibility criteria for the trial.",
    "The sample is a phase 2 clinical trial for patients with relapsing multiple sclerosis. The trial includes patients who have been treated with either teriflunomide or interferon-\u03b2-1 for at least 6 months. The trial excludes patients with certain medical conditions or who have taken certain medications within a certain timeframe. The eligibility criteria for the trial are listed in the \"Inclusion Criteria\" and \"Exclusion Criteria\" sections. The information provided is not exhaustive and is intended to give an overview of the trial.",
    "The sample is a phase 2 clinical trial for patients with Stage IIIB or IV HER2-positive metastatic breast cancer. The trial is testing the drug bibw 2992. The eligibility criteria include confirmed diagnosis of HER2-positive metastatic breast cancer, progression following prior standard trastuzumab treatment or standard chemotherapy in conjunction with trastuzumab, age 18 years or older, life expectancy of at least four months, and measurable disease as defined by RECIST criteria. Exclusion criteria include active infectious disease, serious illness or concomitant non-oncological disease considered by the investigator to be incompatible with the protocol, and active alcohol or drug abuse.",
    "The sample is a phase 2 clinical trial for head and neck cancer patients with stage III-IVB, excluding nasopharyngeal, salivary gland or skin primaries. The trial involves the use of oxaliplatin and pemetrexed disodium drugs. The eligibility criteria include having measurable disease, being over 18 years old, having an ECOG Performance Score of 0, 1 or 2, and meeting certain bone marrow, renal, and hepatic function requirements. Patients must also be able to read and understand the informed consent form, agree to use contraception, and be willing to take certain medications. Exclusion criteria include having an active infection, a history of prior malignancy within the past 3 years, known hypersensitivity to the drugs, and other medical conditions that may interfere with the study.",
    "The sample is a record of a clinical trial with a phase 2 designation. The trial is focused on diabetes, specifically type 1 diabetes, and involves the use of several insulin medications including insulin degludec and insulin glargine. The trial has a set of inclusion and exclusion criteria, including a requirement that participants have had type 1 diabetes for at least one year and have an HbA1c level between 7-11%. Participants must also have been treated with insulin for at least six months. Exclusion criteria include any recent systemic treatment that could interfere with glucose or lipid metabolism, as well as any active disease of the gastrointestinal, pulmonary, neurological, genitourinary, or hematological system that could confound the results of the trial or pose additional risk in administering trial product.",
    "The sample is a phase 2 clinical trial for breast cancer patients who have signed an informed consent form. The patients must be female and have primary breast cancers that are human epidermal growth factor receptor (HER2) overexpressing and estrogen receptor (ER) positive. The cancers must be of clinical and/or radiologic size greater than 4 cm, with or without gross metastatic disease according to the International Union against Cancer (UICC) modified World Health Organization (WHO) criteria. The trial involves the use of two drugs, iressa and tamoxifen. The eligibility criteria include negative serum pregnancy test, adequate bone marrow and renal function, liver function within normal limits, performance status less than 2, and age greater than 18 years. Exclusion criteria include pregnancy, severe underlying chronic illness or disease, use of other investigational drugs, severe or uncontrolled hypertension, history of congestive heart failure, acute myocardial infarction, or severe coronary arterial disease, and known severe hypersensitivity to ZD1839 or any of the excipients of this product.",
    "The sample is a record of a clinical trial with a phase 2 designation. The trial is focused on the disease hepatocellular carcinoma, and the icd-10 codes associated with the disease are listed. The drug being tested is patupilone. The eligibility criteria for the trial are also listed, including inclusion criteria for patients with at least one previously un-irradiated, measurable lesion without any systemic single agent or combination chemotherapy, and exclusion criteria that are protocol-defined.",
    "The sample is a phase 2 clinical trial for patients with active rheumatoid arthritis. The trial is testing the effectiveness of two drugs, ch-1504 and methotrexate (mtx). The eligibility criteria for patients include being between the ages of 18 and 80, having been diagnosed with active rheumatoid arthritis according to ACR criteria, and having at least 6 swollen joints and 6 tender joints at screening and baseline visits. Patients must also meet certain blood test values and have voluntarily signed the informed consent. Patients who have received previous methotrexate therapy, previous therapy with any biologic agent, or are currently taking sulfasalazine or hydroxychloroquine are not eligible for the study. Patients with certain medical conditions or who have had certain medical procedures are also excluded.",
    "The sample is a phase 2 clinical trial for the treatment of schizophrenia. The trial includes adult patients between the ages of 18 and 60 who have been diagnosed with schizophrenia and are currently taking no more than 2 antipsychotic drugs. The trial excludes patients who have started a new non-medication treatment for schizophrenia or other psychiatric condition within the last 3 months, are on more than 1 antidepressant or have had a change in dose of antidepressant within 3 months, have a history of alcohol or substance abuse or dependence within 3 months, or have previously received RO4917838. The trial involves the use of the drug RO4917838, as well as a placebo and standard antipsychotic therapy. The eligibility criteria include being medically and psychiatrically stable over the prior 1 month and psychiatrically stable without symptom exacerbation within the prior 3 months.",
    "The sample is a record of a clinical trial with a phase 2 designation. The trial is focused on treating lymphoma, specifically B-cell lymphoma. The trial includes a list of ICD-10 codes for the disease. The treatment plan involves the drugs rituximab and gemcitabine. The eligibility criteria for the trial include having biopsy-proven DLBCL, measurable disease per Standardized Response Criteria for Non-Hodgkin's Lymphoma, and a negative pregnancy test. The exclusion criteria include no history of life-threatening reactions to rituximab, no history of gemcitabine intolerance, no history of malignancy in the last 5 years, no central nervous system or cerebrospinal fluid involvement, no other investigational drugs received within 30 days prior to being registered for protocol therapy, no active infections, and no current breastfeeding.",
    "The sample is a phase 2 clinical trial for patients with chronic obstructive pulmonary disease. The trial involves the use of various doses of tiotropium and placebos administered through inhalation devices. The eligibility criteria include having a diagnosis of COPD, being a current or ex-smoker with a smoking history of more than 10 pack-years, and being able to perform pulmonary function tests. The trial also has exclusion criteria, such as having significant diseases other than COPD, recent history of myocardial infarction, and known active tuberculosis. Patients must sign an informed consent consistent with International Conference on Harmonization Good Clinical Practice guidelines before participating in the trial.",
    "The sample is a phase 2 clinical trial for breast cancer. The trial includes patients who are over 18 years old and have primary breast cancer treated in the neoadjuvant setting. The primary breast tumor must be accessible to initial biopsy. Patients must also meet certain health criteria, including having a white blood count over 3,000/\u00b5l, platelets over 100 x 109/L, and hemoglobin over 9 g/dL. They must also have a left ventricular ejection fraction (LVEF) of at least 55%. Patients must not have a history of cancer relapsing within the 5 years before study entry, and must not have any known contraindications to the anticancer compounds used. Patients must also not have any unstable severe diseases that may preclude study participation. The trial includes two groups of patients, one receiving bevacizumab and the other not receiving it. The trial requires patients to sign a written informed consent form prior to any study specific screening procedures.",
    "The sample is a phase 2 clinical trial for the treatment of myelodysplastic syndromes. The trial involves the use of lenalidomide and epoetin beta drugs. The eligibility criteria include having a low or int-1 IPSS score, documented absence of chromosome 5 abnormality, de novo MDS, transfusion dependence, resistance or loss of response to previous treatment, ineligibility for stem cell transplantation or intensive chemotherapy, ECOG performance status \u2264 2, age \u2265 18 years, life expectancy \u2265 3 months, adequate liver and renal function, and agreement to use effective contraception. The exclusion criteria include active serious infection, platelets less than 50 G/L, prior history of deep vein thrombosis or pulmonary embolism, previous treatment with Thalidomide, rapidely progressive disease with compromised organ function, pregnancy or lactation, known HIV or hepatitis B and/or C virus infection, hypersensitivity or intolerance to Lenalidomide or Epoetin beta, uncontrolled arterial hypertension, and any history of malignancy other than myelodysplastic syndrome.",
    "This sample is for a phase 2 clinical trial for the treatment of osteoporosis. The trial is testing the effectiveness of the drug lasofoxifene compared to a placebo. The trial is specifically targeting postmenopausal Asian women with low bone mineral density. The trial has a list of inclusion and exclusion criteria that participants must meet in order to be eligible to participate. The inclusion criteria includes having osteoporosis defined by low BMD, while the exclusion criteria includes having metabolic bone disease or using other osteoporosis drugs or drugs that interfere with normal bone metabolism. The sample also includes a list of icd-10 codes associated with the disease.",
    "This is a sample of a clinical trial for treating atopic dermatitis. The trial is in phase 2 and involves the use of two drugs, Leo 29102 and Elidel\u00ae. The eligibility criteria for the trial include having a clinical diagnosis of atopic dermatitis, with mild to moderate severity, lesions located on the trunk and limbs, and involving 3% to 10% of the total body surface area. Patients of either gender between 18 and 65 years of age are eligible. Exclusion criteria include recent use of certain medications, infections on the treatment area, severe renal or hepatic disorders, and concomitant serious diseases such as cancer. Pregnant or breastfeeding females and those intending to stop their hormonal contraceptive regime during the trial are also excluded.",
    "The sample is a phase 2 clinical trial for chronic obstructive pulmonary disease (COPD). The trial includes patients between the ages of 40 and 80 who have a clinical history of COPD with airflow limitation that is not fully reversible. The trial also requires patients to have a measured post-bronchodilator FEV1/FVC ratio of less than or equal to 0.70 and a measured post-bronchodilator FEV1 of at least 750ml or 30% predicted and less than or equal to 80% of predicted normal values. Patients must be able to change their COPD treatment as required by the protocol. Exclusion criteria include pregnancy or lactation, primary diagnosis of asthma, alpha-1 antitrypsin deficiency as the cause of COPD, active pulmonary diseases, prior lung volume reduction surgery, abnormal chest X-ray or CT scan not due to the presence of COPD, hospitalization due to poorly controlled COPD within 3 months of screening, and clinically significant medical conditions that preclude participation in the study. Patients must also not have had cancer that has not been in complete remission for at least 5 years and must not have received treatment with an investigational study drug or participated in another clinical trial or study within the last 30 days or 5 half lives. The trial requires signed written informed consent and acceptable contraceptive methods for females of childbearing potential.",
    "The sample is a phase 2 clinical trial for the treatment of chronic HCV infection with the drugs gs-9256, gs-9190, ribavirin, and peginterferon alfa-2a. The trial is looking for adult subjects between the ages of 18 and 70 who have a BMI between 18 and 36 kg/m2, chronic HCV infection of genotype 1, and HCV RNA levels between 3 and 7.2 log10 IU/ml. The trial also requires that subjects have no cirrhosis, are HCV treatment na\u00efve, and have a QTcF of 450 msec or less. The trial has a list of exclusion criteria, including pregnancy, poorly controlled diabetes, history of invasive malignancy, and significant cardiac disease. The trial requires subjects to comply with dosing instructions and study visits and be generally in good health.",
    "The sample is a phase 2 clinical trial for patients with HTLV-1-associated adult T-cell leukemia/lymphoma (ATLL). The trial includes the use of drugs such as etoposide, cyclophosphamide, doxorubicin hydrochloride, lamivudine, prednisone, vincristine sulfate, and zidovudine. The eligibility criteria include confirmation of HTLV-1 infection, CD3 positivity, measurable or evaluable disease, and various patient characteristics such as age, performance status, and hematopoietic, hepatic, and renal function. Prior concurrent therapy with potentially myelosuppressive agents is allowed, as well as other concurrent antiretroviral therapy for HIV, hepatitis B, or hepatitis C infection.",
    "The sample is a phase 2 clinical trial for the treatment of chronic posttraumatic stress disorder (PTSD) using 3,4-methylenedioxymethamphetamine (MDMA) and lactose (placebo). The trial is open to individuals who have been diagnosed with chronic PTSD for at least 5 years resulting from military service or being a victim of a crime. Participants must have moderate to severe PTSD symptoms and have had at least one unsuccessful attempt at treatment with talk therapy or drugs. They must also be generally healthy, willing to refrain from taking any psychiatric medications during the study period, and follow restrictions and guidelines concerning food, beverages, and nicotine consumption. Participants must remain overnight at the study site and agree to have transportation other than driving themselves home or to where they are staying after the integrative session on the day after the MDMA session. They must also be proficient in speaking and reading English and agree to have all clinic visit sessions recorded to audio and video. Exclusion criteria include being pregnant or nursing, weighing less than 50 kg, abusing illegal drugs, being unable to give adequate informed consent, and having any current or past diagnosis that would be considered a risk to participation in the study.",
    "The sample is a phase 2 clinical trial for non-small cell lung cancer. The trial includes patients who are 18 years or older and have advanced or recurrent stage IIIB or IV non-small cell lung cancer with measurable disease, and have not received previous chemotherapy for non-small cell lung cancer. The trial involves the use of drugs such as erlotinib, placebo, gemcitabine, cisplatin, and carboplatin. The eligibility criteria for the trial includes exclusion of patients with unstable systemic disease or any other malignancies in the last 5 years.",
    "The sample is a phase 2 clinical trial for liver cancer patients. The trial includes patients with localized, surgically unresectable disease or metastatic disease, who have measurable disease outside of pretreated areas. Patients must have Child-Pugh class A or mildly decompensated Child-Pugh class B liver dysfunction. The trial excludes patients with clinical ascites of any grade, clinical symptoms or history of CNS metastases or leptomeningeal disease, known fibrolamellar HCC or mixed cholangiocarcinoma and HCC. Patients must have a WHO performance status of 0-1, hemoglobin \u2265 9.0 g/dL, absolute neutrophil count \u2265 1,500/mm\u00b3, platelet count \u2265 75,000/mm\u00b3, bilirubin \u2264 2 times upper limit of normal (ULN), ALT \u2264 7 times ULN, albumin \u2265 2.5 g/dL, creatinine clearance \u2265 40 mL/min, quick test \u2265 50% (adequate coagulation), urine dipstick for proteinuria < 2+ OR \u2264 1 g of protein in 24-hour urine collection, negative pregnancy test, and fertile patients must use effective contraception during and for 12 months after completion of study therapy. The trial excludes patients who are pregnant or nursing, have encephalopathy, have had malignancy within the past 5 years except for adequately treated cervical carcinoma in situ or localized nonmelanoma skin cancer, have had a hemorrhagic or thrombotic cerebrovascular event in the past 12 months, have documented variceal hemorrhage within the past 3 months, have a history or presence of clinically significant acute or unstable cardiovascular, cerebrovascular, renal, gastrointestinal, pulmonary, immunological (except for the presence of hepatitis B virus, hepatitis C virus, or cirrhosis), endocrine, or central nervous system disorders, have known HIV infection, have active infection requiring IV antibiotics, have arterial hypertension \u2265 150/100 mm Hg, despite therapy, have ongoing cardiac dysrhythmias \u2265 grade 2, have atrial fibrillation of any grade, have prolongation of QTc > 500 msec in screening ECG or history of familial long QT syndrome, have inability to take oral medications, or have a psychiatric disorder precluding understanding of information of study-related topics, giving informed consent, or interfering with compliance for oral drug intake. Patients must have had at least 4 weeks since prior surgery or liver-directed therapy (e.g., transarterial embolization/chemoembolization [limited to 5 treatments], radiofrequency ablation, cryoablation, radiotherapy, or percutaneous ethanol injection). Previously treated lesions must remain separate from those to be measured in the present study. Low-dose anticoagulants for maintenance of patency of central venous access or prevention of deep vein thrombosis are allowed. The trial excludes patients who have had prior systemic anticancer treatment for hepatocellular carcinoma, prior organ transplantation, treatment in a clinical study within the past 30 days, concurrent full-dose anticoagulant or requirement for anticoagulant therapy, concurrent experimental drugs or other anticancer therapy, concurrent use or anticipated need for CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, voriconazole, erythromycin, clarithromycin, and protease inhibitors), concurrent CYP3A4 inducers (e.g., carbamazepine, continuous treatment with dexamethasone [> 2 mg/day for > 7 days], phenobarbital, phenytoin, rifampicin, and St John's wort), concurrent antacids allowed provided they are administered > 1 hour before or > 1 hour after study drug, concurrent elective major surgery, or concurrent radiotherapy. Concurrent analgesic radiotherapy of nontarget lesions is allowed.",
    "The sample is a phase 2 clinical trial for locally advanced or metastatic colorectal cancer. The trial involves the use of drugs such as irinotecan, capecitabine, cetuximab, and oxaliplatin. The eligibility criteria include having measurable or evaluable disease, an ECOG performance status of 2 or less, being between the ages of 18 and 72, and having had a CR, PR, or SD after 1st line therapy based on Irinotecan+Bevacizumab. Patients must also have adequate liver, renal, and bone marrow function, and be able to understand the nature of the study and provide written informed consent. Exclusion criteria include the presence of central nervous system or brain metastases, pregnancy or lactation, life expectancy of less than 3 months, and various other conditions.",
    "The sample is a record of a clinical trial with a phase 2 designation. The trial is focused on the treatment of depression and includes a list of diseases and corresponding ICD-10 codes. The trial involves the use of several drugs, including duloxetine and a placebo matching with bms-820836. The eligibility criteria for the trial include patients with a diagnosis of Major Depressive Disorder, currently experiencing a Major Depressive Episode, and who have had an inadequate response to 1-3 adequate trials of antidepressant treatment. The trial also includes exclusion criteria, such as patients who have failed duloxetine at an adequate dose and for an adequate duration in their current episode.",
    "The sample is a phase 2 clinical trial for patients with relapsed Diffuse Large B-cell Lymphoma (DLBCL). The trial involves the use of three drugs, mk0683, vorinostat, and suberoylanilide hydroxamic acid (saha), for a duration of 6 months. The eligibility criteria include being 18 years or older, having stable disease or better for at least 3 months on the most recent treatment, and not having received any chemotherapy, radiation therapy, major surgery, or any other investigational therapy for at least 4 weeks prior to entry in the study. Adequate blood testing, liver, and kidney function are also required. Tissue samples will be examined and stored. The exclusion criteria include having been treated with other investigational agents with a similar anti-tumor mechanism and having failed more than 3 prior treatment regimens.",
    "The sample is a record of a clinical trial with a phase 2 designation. The trial is focused on ovarian neoplasms and ovarian cancer, with a list of corresponding ICD-10 codes. The trial is testing the effectiveness of three drugs: azd0530, carboplatin, and paclitaxel. The eligibility criteria for the trial include having a diagnosis of advanced ovarian cancer, evidence of recurrence or disease progression at least 6 months following treatment cessation of 1st or 2nd line platinum containing therapy, and an estimated life expectancy of more than 12 weeks. The exclusion criteria include having central nervous system metastases, having received more than 2 prior chemotherapy regimens for ovarian cancer treatment, having inadequate bone marrow reserve, having inadequate liver function, renal function or low hemoglobin, being pregnant, breastfeeding, or unwilling to use an acceptable method of contraception if of child-bearing status.",
    "This is a sample from a clinical trial table. The trial is in phase 2 and is focused on treating multiple myeloma. The table includes a list of diseases and their corresponding ICD-10 codes, a list of drugs being used in the trial, and eligibility criteria for participants. The inclusion criteria include being at least 20 years old, having measurable disease by protein electrophoresis analyses, and having an Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2. The exclusion criteria include having any significant medical condition, laboratory abnormality, or psychiatric illness that would prevent participation in the study, being pregnant or lactating, and having peripheral neuropathy of \u2265 grade 2 severity.",
    "The sample is a phase 2 clinical trial for patients with cardiomyopathy and heart failure. The trial will test the effectiveness of two treatments: pomx, a pomegranate polyphenol extract, and a sugar pill. The eligibility criteria for the trial include being an adult with cardiomyopathy and chronic kidney disease, having NYHA functional class I-III symptoms, and being on stable doses of HF evidence-based therapies for at least 3 months. Exclusion criteria include recent hospitalization for acute myocardial infarction or HF exacerbation, use of warfarin or rosuvastatin, and other medical conditions such as end-stage renal disease or pregnancy. The trial will also exclude patients with recent POMx use or known hypersensitivity to any fruit in the Punicaceae family.",
    "The sample is a phase 2 clinical trial for patients with Waldenstrom's Macroglobulinemia, a type of cancer. The trial is testing the effectiveness of a drug combination called DT PACE and rituxan. The eligibility criteria include having advanced or symptomatic disease, meeting certain blood count or lymph node size criteria, and having a performance status of 0-2. Patients must also have adequate organ function and not have certain medical conditions. The trial excludes patients with prior malignancies, pregnant or nursing women, and those who do not provide informed consent.",
    "The sample is a phase 2 clinical trial for patients with myelodysplastic syndrome. The trial involves the drug Panhematin and has specific eligibility criteria that patients must meet in order to participate. These criteria include being at least 18 years old, having a diagnosis of low- or intermediate-1 risk MDS, being transfusion dependent or having a hemoglobin value of 10 g/dL or less, having \u2264 10% blasts in the bone marrow and peripheral blood, and having adequate hepatic and renal functions. Patients must also have an ECOG score of \u2264 2 and a negative HIV test result. There are also exclusion criteria, such as having a history of an allergic reaction to Panhematin or having taken any investigational drug or device in the 30 days prior to screening.",
    "The sample is a phase 2 clinical trial for gastroesophageal reflux disease. The trial is open to males and females aged 12 to 16 years who have a clinical diagnosis of symptomatic GERD or suspected or endoscopically proven GERD. Patients who have ever been treated with, or are currently receiving proton pump inhibitors (PPIs), histamine receptor (H2) blockers, or antacids are eligible as long as they can go off PPIs and H2 blockers for three days prior to dosing, except for cimetidine, which must be discontinued for at least seven days prior to dosing. Children with stable asthma/reactive airways disease on stable treatment regimens are eligible, as are children on stable doses of allergy, antiepileptic, antidepressant, and attention deficit disorder medicines. Patients must be able and willing to swallow the test drug tablet intact. The trial has a list of exclusion criteria, including evidence of significant hepatic, renal, respiratory, endocrine, immune, infectious, hematologic, neurologic, psychiatric, or cardiovascular system abnormalities that would interfere with the conduct of the study, the interpretation of study results, or the health of the patient during the study. The trial also excludes patients with a history of primary esophageal motility disorders or systemic condition affecting the esophagus, history of eosinophilic esophagitis, persistent milk protein allergy, or allergic gastroenteropathy, and history or current presence of peptic ulcers or Helicobacter pylori. The trial has other exclusion criteria, including pregnancy or lactation, known or suspected drug addiction or alcohol abuse, and participation in another investigational drug study within one month prior to dosing.",
    "The sample is a phase 2 clinical trial for advanced non-small cell lung cancer. The trial involves the use of cetuximab and gemcitabine drugs. The eligibility criteria include being over 18 years old, having a histological diagnosis of non-small cell lung cancer, having stage III B or stage IV disease, having at least one site of metastasis, and having a life expectancy of at least 3 months. Other criteria include having certain blood levels, not having certain medical conditions, and not being pregnant or breastfeeding. The trial excludes individuals who have had previous chemotherapy for advanced disease, radiation therapy within the previous 4 weeks, or any experimental drug therapy within the previous 4 weeks, among other exclusion criteria.",
    "The sample is a record of a clinical trial with a phase 2 designation. The trial is focused on age-related macular degeneration, with a list of associated ICD-10 codes. The trial involves the use of two drugs, avastin and preservative-free triamcinolone acetonide (tac-pf). The eligibility criteria for the trial include specific requirements related to drusen size, choroidal neovascularization, lesion size, visual acuity, and previous anti-VEGF monotherapy. The exclusion criteria include prior complications from steroid therapy, prior stroke or myocardial infarction, and end-stage malignancy. Additionally, there are specific exclusion criteria related to the study eye, including geographic atrophy or fibrosis under the fovea, prior treatment with verteporfin, and poor reactions to topical or periocular steroid treatment.",
    "The sample is a phase 2 clinical trial for atopic dermatitis. The trial involves testing the effectiveness of a 10% imcooh cream compared to a placebo. The eligibility criteria for participants include being between the ages of 18 and 70, having skin types I-IV, and having a normal weight. Participants must also have atopic dermatitis and meet certain severity criteria. Exclusion criteria include pregnancy or breastfeeding, HIV or hepatitis B/C infection, and various medical conditions that could compromise safety or compliance with the trial procedures. Participants must also not have any allergies to the trial medication or its excipients.",
    "The sample is a phase 2 trial for the treatment of influenza. The eligibility criteria include being 18 years or older, having a fever and respiratory symptoms, and meeting certain medical conditions such as COPD or diabetes. The trial involves the use of drugs such as peramivir and oseltamivir. The exclusion criteria include recent immunization against influenza, recent treatment with certain medications, and certain medical conditions such as renal impairment or ongoing mechanical ventilation. Women who are pregnant or breastfeeding are also excluded.",
    "The sample is a phase 2 clinical trial for the treatment of various stages of prostate cancer using the drug cilengitide. The trial includes patients with a histologic or cytologic diagnosis of prostate cancer, no evidence of metastatic disease or local progression, and PSA-only progression despite androgen deprivation therapy and antiandrogen withdrawal. Patients must continue on LHRH agonists and may continue on stable doses of megace or corticosteroids, but must be off all other therapies intended to treat the cancer for 4 weeks. Patients must have an ECOG performance status of 0-2, testosterone levels below 50 ng/dl, and a life expectancy of greater than 6 months. They must also have normal organ and marrow function and meet other eligibility criteria. Patients must agree to use adequate contraception prior to study entry and for the duration of study participation. Patients with certain intercurrent illnesses or a \"currently active\" second malignancy, other than non-melanoma skin cancers or superficial bladder cancer, are not eligible.",
    "The sample is a phase 2 clinical trial for chronic hepatitis C. The trial includes patients with genotype 1 hepatitis C who have not previously received interferon-based treatment. The trial excludes patients with other liver diseases, transplant recipients, and those with certain medical conditions such as severe cardiac or psychiatric disease. The trial involves the use of nitazoxanide, placebo, and ribavirin drugs. The eligibility criteria include various medical and lifestyle factors such as alcohol consumption, thyroid disorders, and body mass index.",
    "The sample is a phase 2 clinical trial for breast neoplasms, which includes patients with unresectable, locally recurrent, or metastatic disease and HER2 positive disease. The drug being tested is su011248/trastuzumab, and the eligibility criteria include prior treatment with trastuzumab and/or lapatinib in the neoadjuvant, adjuvant, or metastatic disease setting, as well as treatment with hormone therapy in the adjuvant and/or advanced disease setting. The exclusion criteria include prior treatment with more than one regimen of cytotoxic therapy in the advanced disease setting, prior exposure to trastuzumab if the patient had developed severe hypersensitivity reactions, prior treatment on a SU11248 clinical trial, and uncontrolled brain metastases.",
    "The sample is a record from a clinical trial table. It is a phase 2 trial for the treatment of metastatic renal cell carcinoma. The trial includes patients with a life expectancy of at least 12 weeks, a clinical, radiographic, or pathologic diagnosis of metastatic renal cell carcinoma, and at least one measurable lesion outside the planned nephrectomy specimen. Patients with an ECOG performance status of 0 or 1 are eligible for the trial. The trial excludes patients with a history of bleeding diathesis or unexpected surgical bleeding, those currently receiving treatment with or having a requirement for therapeutic anticoagulation, and those with a known history of HIV infection. Palliative radiation therapy for painful or unstable bone metastases is permitted provided that there is measurable metastatic disease outside the radiation field. Symptomatic metastatic brain or meningeal tumors are also excluded, unless the patient is > 6 months from definitive therapy, has a CT or MRI scan within 6 weeks of study entry negative for brain metastases and is clinically stable with respect to the tumor at the time of study entry. The trial includes the drugs nexavar (sorafenib, bay43-9006) and placebo.",
    "The sample is a phase 2 clinical trial for the treatment of benign prostatic hyperplasia. The trial includes patients who have had BPH for more than 6 months and have an International Prostate Symptom Score (IPSS) greater than or equal to 13. Patients must also have a total prostate volume greater than or equal to 30 milliliters and show signs of bladder outlet obstruction. The trial involves the drugs ly500307 and placebo. Patients must meet certain eligibility criteria, such as not having received certain treatments within a specified time period and having a morning fasting Total Testosterone concentration greater than or equal to 300 nanogram/deciliter. Patients who have completed or withdrawn from this study or any other study investigating LY500307 are excluded, as are those with a history of BPH-related invasive procedures or active cardiovascular disease. Other exclusion criteria include a history of prostate cancer, breast cancer, or other clinically significant neoplastic disease, as well as moderate to severe renal insufficiency and a hemoglobin A1c greater than 9.0%.",
    "The sample is a phase 2 clinical trial that involves patients with myeloproliferative disorder, urothelial carcinoma, and cancer. The trial is testing the effectiveness of the drugs bevacizumab, carboplatin, and gemcitabine. The eligibility criteria for the trial include having a histologic diagnosis of transitional cell carcinoma of the bladder, urethra, ureter, or renal pelvis, having unresectable or metastatic disease, being ineligible for cisplatin, having a Karnofsky Performance Status of at least 60%, and being at least 18 years old. The trial also has exclusion criteria, such as having a history of stroke within 6 months, being pregnant or lactating, and having a history of persistent gross hematuria.",
    "The sample is a phase 2 clinical trial for various diseases including albinism, inborn errors of metabolism, oculocutaneous albinism, platelet storage pool deficiency, and pulmonary fibrosis. The trial involves the use of the drug pirfenidone and a placebo. The eligibility criteria for the trial include being over 18 years of age, having certain lung function measurements, reduced exercise tolerance, and no improvement in pulmonary fibrosis within the past year. Exclusion criteria include a history of certain medical conditions, medication use, and laboratory abnormalities. Women of childbearing age must have an effective method of birth control. The trial requires participants to come to the NIH Clinical Center for admission every 4 months for three years.",
    "The sample is a phase 2 clinical trial for patients with myelodysplastic syndromes who have already received at least six cycles of 5-azacytidine and have failed to respond or have relapsed while still on 5-azacytidine. The trial is investigating whether clofarabine can be used to salvage these patients. The eligibility criteria include having an ECOG performance status of 0-2, adequate renal and hepatic functions, and being capable of understanding the potential risks and benefits of the study. Exclusion criteria include prior clofarabine therapy, life expectancy of less than 3 months due to other illnesses, and any significant concurrent disease or psychiatric disorder that would compromise patient safety or compliance.",
    "This sample is for a phase 2 clinical trial for pancreatic cancer. The trial is testing the effectiveness of two drugs, azd6244 and capecitabine, for patients who have failed first line gemcitabine therapy. The eligibility criteria includes confirmation of pancreatic cancer and exclusion criteria includes previous therapy with certain inhibitors or recent surgery.",
    "The sample is a phase 2 clinical trial for the treatment of ocular hypertension and open angle glaucoma. The trial involves the use of two drugs, syl040012 and placebo. The eligibility criteria for the trial include being in good or fair general health, having a history or newly diagnosed elevated intraocular pressure (IOP), and meeting certain visual field and optical coherence tomography (OCT) requirements. Exclusion criteria include pregnancy or breastfeeding, certain medical conditions, and recent use of certain medications. The trial also has specific requirements regarding the use of contact lenses and history of ocular infections or inflammation.",
    "The sample is a phase 2 clinical trial for advanced renal cell carcinoma. The trial includes patients with a clear cell component and low or intermediate risk according to the Memorial Sloan Kettering Cancer Center prognostic risk classification. Patients must have measurable disease with at least one unidimensionally measurable lesion per RECIST guidelines with modifications and adequate organ and hematological function as evidenced by laboratory studies conducted at Screening. The trial excludes patients with a known history of central nervous system metastases, previous treatment (excluding surgery and palliative radiotherapy) for advanced or metastatic renal cell carcinoma, and focal radiation therapy for palliation of pain from bony metastases within 14 days of randomization. Patients who are currently or previously treated with inhibitors of VEGF, inhibitors of angiopoietin or Tie2, or bevacizumab are also excluded. Patients with a diagnosis of acute pancreatitis, myocardial infarction, cerebrovascular accident, transient ischemic attack, percutaneous transluminal coronary angioplasty/stent, congestive heart failure, grade 2 or greater peripheral vascular disease, arrhythmias not controlled by outpatient medication, or unstable angina within 1 year prior to randomization are excluded. Patients who have had major surgery within 30 days before randomization or are still recovering from prior surgery, have uncontrolled hypertension as defined as diastolic > 90 mmHg OR systolic >150 mmHg, or are receiving other investigational agent(s) are also excluded.",
    "The sample is a phase 2 clinical trial for the treatment of squamous cell carcinoma of the head and neck using the drugs cisplatin and docetaxel. The trial includes patients who have been diagnosed with stage III or IV disease, have undergone complete total resection within the past 56 days, and have one or more risk factors such as multiple pathologically confirmed lymph node metastases or positive margins of resection. Patients must also meet certain eligibility criteria related to age, performance status, hematopoietic, hepatic, and renal function, as well as other factors such as no pre-existing peripheral neuropathy and no known history of severe hypersensitivity reaction to products containing Polysorbate 80. Patients must not have received prior chemotherapy or radiotherapy for the malignancy and must not be receiving concurrent amifostine.",
    "The sample is a phase 2 clinical trial for the treatment of malignant melanoma, a type of skin cancer. The trial is testing the effectiveness of two drugs, CP-4055 and sorafenib (nexavar), on patients with stage IV or unresectable stage III melanoma who have or have not undergone prior chemotherapy. The trial has eligibility criteria that include measurable disease, a performance status of 0-1, and a life expectancy of more than 3 months. Patients must also be 18 years or older and provide signed informed consent. Exclusion criteria include a history of drug or alcohol abuse, significant cardiac disease, and a tendency to bleed. The trial is not open to patients with brain metastases or ocular melanoma, and patients must not have participated in another therapeutic clinical study within 30 days of enrollment or during the trial.",
    "The sample is a phase 2 clinical trial for patients with b-cell chronic lymphocytic leukemia, recurrent small lymphocytic lymphoma, or refractory chronic lymphocytic leukemia. The trial is testing the effectiveness of the drug sunitinib malate. The eligibility criteria include a diagnosis of one of the specified diseases, refractory or relapsed disease, and requiring chemotherapy. Patients must also meet various health criteria, such as having a life expectancy of at least 12 months and not having certain medical conditions. The trial excludes patients who have had certain prior treatments or who are taking certain medications.",
    "The sample is a phase 2 clinical trial for non-squamous non-small cell lung cancer. The trial involves the use of drugs such as megf0444a, bevacizumab, carboplatin, paclitaxel, and placebo. The eligibility criteria for the trial include having a histologically or cytologically documented inoperable or recurrent non-squamous NSCLC, an ECOG performance status of 0 or 1, a life expectancy of more than 12 weeks, measurable disease, and adequate hematologic and end organ function. Exclusion criteria include prior therapy for Stage IV or recurrent NSCLC, treatment with any other investigational agent or participation in another clinical trial with therapeutic intent within 28 days prior to enrollment, malignancies other than NSCLC within 5 years prior to randomization, and pregnancy or lactation. The trial also has specific exclusions for bevacizumab, such as evidence of tumor invading major blood vessels on imaging and history of stroke or transient ischemic attacks within 6 months prior to Day 1.",
    "The sample is a clinical trial for acute myocardial infarction, with a phase 2/phase 3 design. The trial involves the use of mesenchymal stem cells and a control group. The eligibility criteria for the trial include being between the ages of 18-70, having ischemic chest pain for more than 30 minutes, being admitted to the hospital within 24 hours of the onset of chest pain, and having electrocardiography that shows ST segment elevation. There are also exclusion criteria, such as having cardiogenic shock, life-threatening arrhythmia, or a history of malignancy. The trial aims to investigate the effectiveness of mesenchymal stem cells in treating acute myocardial infarction.",
    "The sample is a phase 2 clinical trial that involves patients with fibromyalgia, sleep issues, and chronic pain. The trial is testing the effectiveness of the drug eplivanserin (sr46349) compared to a placebo. The eligibility criteria include fulfilling the diagnosis criteria of fibromyalgia, complaining of unrefreshing sleep for at least 3 nights per week over the past month, spending at least 6.5 hours and not more than 9 hours in bed each night over the past 2 weeks, and being willing to abstain from taking any medication or treatment prohibited as per the protocol. Exclusion criteria include lactating or pregnant females, night shift workers, individuals who nap 3 or more times per week over the preceding month, and those with a past or current medical history of any significant, severe, or unstable acute or chronically progressive medical or surgical disorder which may affect patient safety.",
    "The sample is a phase 2 clinical trial for patients with locally recurrent or metastatic breast cancer. The trial is testing the effectiveness of the drugs carboplatin and abi-007. Patients must have HER-2-negative breast cancer or, if HER-2-positive, must be unable to receive trastuzumab or have previously received it. Patients must also have measurable disease and meet certain eligibility criteria, such as having a certain performance status, normal blood counts, and no other concurrent malignancies. Exclusion criteria include pre-existing neuropathy, uncontrolled illness, and certain medical conditions. Prior concurrent therapy is allowed as long as patients have recovered from it.",
    "This sample is for a phase 2 clinical trial that focuses on inflammation and Crohn's disease. The trial includes a list of ICD-10 codes for the diseases, a list of drug names, and eligibility criteria for participants. The inclusion criteria require subjects to have had Crohn's disease for at least 3 months and to not have responded to previous treatment or to have lost the response during continued administration of a therapeutic compound. The exclusion criteria include having symptomatic bowel obstruction, short bowel syndrome, ileostomy or colostomy, surgical bowel resection within 6 months prior to randomisation, clinically relevant un-drained abscess, history of dysplasia or malignancy in the colon, any ongoing chronic or active infectious disease or microbial infection requiring systemic oral or intravenous treatment against infection within 1 month prior to randomisation, and a body mass index (BMI) higher or equal to 38.0 kg/m^2.",
    "The sample is for a phase 2 clinical trial for the treatment of chronic hepatitis C. The trial is looking at the effectiveness of the drugs sofosbuvir, rbv, and peg. The eligibility criteria for the trial includes being male or female with chronic hepatitis C genotype 1, 4, 5, 6, or indeterminate and having no previous treatment for hepatitis C. The exclusion criteria includes testing positive for HBsAg, anti-HBc IgM Ab, or anti-HIV Ab, and having a history of any other clinically significant chronic liver disease.",
    "This sample is for a phase 2 clinical trial for lung cancer. The trial is testing the drug erlotinib (tarceva). The eligibility criteria for participants include having a performance status of 0-1, weight loss of less than 10% in the preceding 3 months, being 18 years or older, having adequate organ function, and meeting certain medical requirements such as liver enzymes and oxygen saturation levels. Exclusion criteria include being pregnant or lactating, having clinical brain metastases, and having received prior chemotherapy for systemic disease. Participants who require chemotherapy for impending organ dysfunction are also not allowed to participate.",
    "The sample is a phase 2 clinical trial for patients with multiple myeloma. The trial involves the drug bortezomib and has specific eligibility criteria for patients to be included. These criteria include being in partial response or better after high dose chemotherapy and autologous stem cell transplantation, meeting certain laboratory requirements, and using appropriate birth control methods. There are also exclusion criteria, such as having received another antimyeloma therapy following stem cell transplantation or having uncontrolled cardiovascular disease. The purpose of the trial is to evaluate the effectiveness and safety of bortezomib in treating multiple myeloma.",
    "The sample is a phase 2 clinical trial for the treatment of opioid-induced constipation. The trial includes patients between the ages of 18 and 70 who have a BMI of 19 to 35 kg/m2 and are currently receiving prescribed opioid medication for chronic, non-cancer pain. The trial requires patients to stop all laxatives and other bowel regimens from the first study visit following screening until the end of the study, but the use of constipation rescue medication is allowed. The trial excludes patients who are pregnant or breastfeeding, have a clinically significant medical condition or illness, are receiving treatment with opioid therapy for cancer-related pain, abdominal pain, scleroderma, and/or for the management of drug addiction, have any gastrointestinal or pelvic disorder known to affect bowel transit, produce a GI obstruction, or contribute to bowel dysfunction other than opioid-induced constipation, use medical devices such as pacemakers, infusion pumps, or insulin pumps, use certain medications starting 15 days before the first study visit following screening until the end of the study, or have participated in a clinical trial of a pharmacological agent within 30 days before screening.",
    "The sample is a phase 2 clinical trial for HIV infections. The trial involves the use of three drugs - indinavir, lamivudine, and ritonavir. The eligibility criteria for the trial include confirmation of HIV-1 infection through Western Blot, a Karnofsky score of 70 or higher, a CD4 count of 200/mm3 or higher, and a plasma viral RNA count between 10,000 and 100,000 copies/ml. The patient must have also failed two antiretroviral regimens with two PI and one NNRTI, and a new efficacy drug on genotype is not available. The patient must be on treatment with three antiretroviral drugs with one PI for at least three months, and must provide written informed consent. Exclusion criteria include hemoglobin below 8g/dL, neutrophils below 750/mm3, ASAT and ALAT over 5N, hepatic insufficiency with prothrombin below 50%, acute opportunistic infection, immunotherapy, treatment with active antiretroviral regimen, and treatment with enzyme inductor.",
    "The sample is a record from a clinical trial table. It is a phase 2 trial for endometriosis, a condition characterized by pelvic pain and tissue growth outside the uterus. The trial includes female adolescents between the ages of 12 and 18 who have experienced dysmenorrhea (painful periods) for at least 2 cycles in the previous 4 months. The trial drug is dienogest (visanne, bay86-5258). The eligibility criteria include various conditions related to endometriosis, such as clinically suspected endometriosis, abdominal pain with ultrasound findings suggestive of endometriosis, and failure of surgical treatment for endometriosis. The exclusion criteria include absence of endometriosis, previous use of hormonal agents, chronic pelvic pain related to other diseases, and clinically established need for primary surgical treatment of endometriosis.",
    "The sample is a phase 2 clinical trial for Crohn's disease. The trial involves the use of drugs such as amg 827 and a placebo. The eligibility criteria for the trial include being diagnosed with ileal, ileo-colonic, or colonic Crohn's disease for at least 6 months, having a CDAI score between 250 and 450 at baseline, and having evidence of active inflammation. Exclusion criteria include having short bowel syndrome, recent bowel surgery, ulcerative colitis, and other medical conditions. The trial also excludes those who are pregnant or breastfeeding, have significant laboratory abnormalities, or have taken certain medications within a certain timeframe.",
    "The sample is a phase 2 clinical trial for the treatment of irritable bowel syndrome. The trial involves the use of the drug milnacipran and a placebo. The eligibility criteria include meeting the Rome III criteria for IBS, having no red flags, having had a colonoscopy within the previous 5 years to exclude inflammatory or other bowel disease, being fluent and literate in English, and either being of non-childbearing potential or agreeing to utilize approved birth control for the duration of the study. The exclusion criteria include having a diagnosis or treatment of any clinically symptomatic biochemical or structural abnormality of the GI tract within 6 months prior to screening, having any other diagnosis to explain the abdominal pain, having clinical evidence of significant cardiovascular, respiratory, renal, hepatic, gastrointestinal, hematologic, neurologic, psychiatric or any disease that may interfere with the subject successfully completing the trial, having hepatic dysfunction or renal impairment, having a disease affecting electrolytes balance, having any evidence of or treatment of malignancy within the previous year, having had surgery on the stomach, small intestine or colon (excluding appendectomy), having a major psychiatric disorder, having a history of attempted suicide or uncontrolled bipolar disorder, currently using antidepressants for psychiatric conditions like major depression, having previous use of Milnacipran or other SNRI antidepressant, having a diagnosis of seizure disorder, having a diagnosis of glaucoma, or currently taking heparin or warfarin.",
    "The sample is a record of a clinical trial with a phase 2 designation. The trial is focused on treating patients with either metastatic or locally advanced gastric cancer or adenocarcinoma of the esophagogastric junction. The trial involves the use of four drugs: docetaxel, 5-fluorouracil, oxaliplatin, and folinic acid. The eligibility criteria for the trial include having no prior chemotherapy in the metastatic state, adequate blood and biochemistry parameters, and not having hypersensitivity to the drugs being used. The exclusion criteria include having KHK, cardiomyopathy, or cardiac insufficiency, having had a malignancy within the last 5 years, having brain metastases, or having severe internal disease or inadequate blood and biochemistry parameters. The diseases being studied are listed as gastric cancer and adenocarcinoma of the esophagogastric junction, and their corresponding ICD-10 codes are also included.",
    "The sample is a phase 2 trial for the treatment of hepatitis B virus (HBV) using the drugs entecavir and lamivudine. The eligibility criteria include being 16 years or older and having received entecavir or lamivudine in a previous study. Participants who were non-responders or partial responders to entecavir are also eligible. Exclusion criteria include HIV co-infection, ongoing opportunistic infections, and a history of allergy to nucleoside analogues. The sample also includes a list of disease names and their corresponding ICD-10 codes.",
    "The sample is a phase 2 clinical trial for the treatment of paroxysmal atrial fibrillation. The trial involves the use of the drugs bms-914392 and placebo. The eligibility criteria include having a programmable dual chamber pacemaker with appropriate arrhythmia diagnostics, having 1-50% AF burden on pacemaker interrogation at screening, and using an acceptable method of contraception to avoid pregnancy. Exclusion criteria include having persistent or permanent AF, AF burden <1% or >50%, current or history of neurological diseases and mental disorders, ejection fraction <45%, severe mitral or aortic valve dysfunction, TIA within the last 12 months, acute coronary syndrome in the last 2 months, previous AF ablation, cardioversion in the last 3 months, current kidney or liver disease, or current cancer, history of neurological and mental disorders, major surgery within 4 weeks of first dose (cardiac surgery within 4 months), screening lab test results outside of allowed limits per protocol, and QTcF >450 msec.",
    "The sample is a phase 2 clinical trial for colorectal cancer. The trial includes patients with histologically proven adenocarcinoma who have not received prior treatment for advanced disease, except for adjuvant chemotherapy more than 180 days before enrollment without S-1 or Oxaliplatin containing treatment. Patients must be at least 20 years old and have at least one measurable lesion by RECIST criteria. The trial excludes patients with serious drug hypersensitivity, prior history of peripheral neuropathy, diarrhea, or simultaneously active double cancer. The trial involves the combination therapy of sol (the combination therapy of s-1, leucovorin, and oxaliplatin) and mfolfox6 (the combination therapy of 5-fu, l-lv and oxaliplatin). The diseases are listed as 'colorectal cancer' and the icd-10 codes are listed as [\"['C05.2', 'C10.0', 'C16.0', 'C16.4', 'C17.0', 'C17.1', 'C17.2']\"].",
    "The sample is a phase 2 trial for lung cancer, specifically small cell lung cancer. The trial includes patients who have completed 4 to 6 cycles of chemotherapy with carboplatin + pemetrexed or cisplatin + pemetrexed and have had SD, PR or CR as the best response. The trial also includes patients with predominantly non-squamous cell Stage IVA Wet or Stage IVB NSCLC, with cytology positive Malignant Pleural Effusion (MPE). Patients must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 and a life expectancy of at least 12 weeks. The trial also requires patients to have measurable disease per Response Evaluation Criteria In Solid Tumors (RECIST). The trial excludes patients with a history of active or any other malignancy other than lung cancer in the 2 years prior to the first dose of study drug other than NSCLC. Patients with a history or clinical evidence of central nervous system (CNS) metastases or leptomeningeal carcinomatosis are also excluded. The trial also excludes patients with clinically significant gastrointestinal abnormalities, poorly controlled hypertension, and any serious and/or unstable pre-existing medical, psychiatric, or other condition that would make the subject inappropriate for study participation.",
    "The sample is a record of a clinical trial with a phase 2 designation. The trial is focused on the disease of hypercholesterolemia, which is associated with high levels of LDL-C. The trial includes a list of icd-10 codes associated with the disease. The drugs being tested in the trial are gemcabene and placebo. The record also includes the eligibility criteria for participants, including age, gender, and baseline LDL-C levels, as well as exclusion criteria such as certain medical conditions and recent major cardiovascular events.",
    "The sample is a phase 2 clinical trial for the treatment of multiple myeloma and plasma cell leukemia using the drug fludarabine/busulfan x 4 days. The trial includes patients with biologic high-risk multiple myeloma, relapsed or persistent multiple myeloma after ASCT, and persistent multiple myeloma regardless of previous therapies. Patients with non-secretory and oligosecretory disease are also eligible if they meet certain criteria. The trial has specific age, disease status, and renal, liver, cardiac, and pulmonary function requirements for inclusion. Exclusion criteria include persistent invasive infections, HIV-1/HIV-2 or HTLV-1/HTLV-2 seropositivity, uncontrolled medical or psychiatric disorder, no response or progressive disease at the time of transplantation, and pregnancy.",
    "The sample is a phase 2 clinical trial for the treatment of schizophrenia. The trial includes patients with a BMI between 18 and 35 kg/m2 who are medically stable and have been diagnosed with schizophrenia at least 1 year prior to screening. The trial excludes patients with other current DSM-IV axis I diagnoses, medical conditions that could potentially alter the absorption, metabolism, or excretion of the study medication, and relevant history of any significant and/or unstable cardiovascular, respiratory, neurologic, renal, hepatic, endocrine, or immunologic diseases. The trial also excludes patients with a PANSS score <50 or >120 and other significant and/or unstable systemic illnesses. The trial involves the use of the drugs jnj-40411813, antipsychotic medication, and placebo.",
    "The sample is a phase 2 clinical trial for patients with various stages of pancreatic cancer and intraductal papillary mucinous neoplasm of the pancreas. The trial is testing the effectiveness of erlotinib hydrochloride as a treatment option. The eligibility criteria include having a confirmed histological diagnosis of IPMN, adequate bone marrow function, and meeting certain blood and organ function levels. Participants must also have an ECOG performance status of 0-1 and agree to use contraception during the study. Exclusion criteria include previous sensitivity to certain drugs, uncontrollable diarrhea, and certain medical or psychosocial conditions that could affect participation in the study.",
    "The sample is a phase 2 clinical trial for patients with non-small cell lung cancer. The trial is testing the effectiveness of the drugs gemcitabine hydrochloride and triapine. Patients must have previously undergone gemcitabine-containing chemotherapy and achieved at least a partial response, complete response, or stable disease during therapy. They must also have measurable disease and no known brain metastases. Patients must meet certain criteria related to their age, performance status, hematopoietic, hepatic, renal, cardiovascular, and pulmonary health, as well as other factors such as pregnancy status and prior medical history. The trial excludes patients with certain concurrent illnesses or treatments.",
    "The sample is a phase 2 clinical trial for patients with chronic obstructive pulmonary disease. The trial involves the use of a drug called bi 1744 cl plus tiotropium bromide. The eligibility criteria for the trial include patients who are current or ex-smokers with a smoking history of more than 10 pack years, have a diagnosis of chronic obstructive pulmonary disease, and meet certain spirometric criteria. Patients must also be able to perform pulmonary function tests and inhale medication from an inhaler. The trial has a list of exclusion criteria, including patients with significant diseases other than COPD, abnormal baseline haematology, blood chemistry, or urinalysis, and a history of asthma or a total blood eosinophil count >= 600/mm3. Pregnant or nursing women and patients who have previously been randomized in this study or are currently participating in another study are also excluded.",
    "The sample is a phase 2 clinical trial for the treatment of hyperlipidemia, a condition characterized by abnormal cholesterol levels. The trial involves the use of several drugs, including a placebo, mbx-8025, and atorvastatin. The eligibility criteria for the trial include being between the ages of 18 and 75, having abnormal cholesterol levels or a history of abnormal cholesterol levels, and being moderately overweight. Patients taking medication to lower their cholesterol may need to discontinue their medication during the study. The exclusion criteria include a history of cancer, diabetes mellitus, intolerance to atorvastatin, weight loss due to stomach bypass or eating disorder, and recent cardiovascular events.",
    "The sample is a phase 2 clinical trial for patients with advanced, surgically unresectable colon or rectum cancer who have failed a first line metastatic regimen within 12 months of starting protocol therapy. The trial involves the use of cetuximab and irinotecan drugs. The eligibility criteria include having measurable disease, histologic confirmation of adenocarcinoma of the colon or rectum, an Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2, and an estimated life expectancy of at least 12 weeks. Patients with a history of prior non-colorectal malignancies are eligible if they have been disease-free for 5 years prior to study entry and are deemed by the physician to be at low risk for recurrence. The exclusion criteria include any prior therapy with irinotecan or cetuximab or an EGFR targeting agent, any systemic therapy administered for metastatic or locally recurrent colorectal cancer within 28 days of study treatment, and serious concomitant medical conditions that would compromise the safety of the patient or compromise the patient's ability to complete the study. Women of childbearing potential must have a negative pregnancy test within 7 days prior to first receiving investigational product.",
    "The sample is a phase 2 clinical trial for patients with metastatic colorectal cancer. The trial involves the use of drugs such as 5-fluorouracil, bevacizumab, leucovorin, and irinotecan. The eligibility criteria include having confirmed colorectal adenocarcinoma with metastatic disease, measurable lesions, and not having received chemotherapy for metastatic disease. Patients must also have adequate organ and marrow function, be over 18 years old, and have an Eastern Cooperative Oncology Group (ECOG) performance status of 0-2. Exclusion criteria include prior participation in an experimental therapeutic drug study, history or presence of central nervous system metastases, and serious non-healing wound, ulcer, or active bone fracture. Patients must also be willing to employ an effective method of birth control during treatment and for 3 months after discontinuing study treatment.",
    "This sample is a phase 2 clinical trial for heart, lung, and pancreas (including SPK) transplantation patients. The trial is testing the effectiveness of the drugs Advagraf and Prograf, and the eligibility criteria includes receiving the first oral dose of tacrolimus within a certain timeframe after transplantation, having negative pregnancy test results, and agreeing to practice effective birth control during the study. Inclusion criteria also includes being treated with Antithymocyte globulin/Mycophenolate Mofetil/steroids (ATG/MMF/steroids) since transplantation, having resumed gastric motility, and having adequate renal function. Exclusion criteria includes having received a multi-organ transplant (with the exception of SPK), having pulmonary vascular resistance \u22654 Wood units despite medication, requiring an emergency ventricular assist device within one week prior to transplantation, having significant renal or liver impairment, having malignancies or a history of malignancy within the last 5 years, having significant, uncontrolled concomitant infections and/or severe diarrhea, vomiting, active upper gastrointestinal disorder that may affect the absorption of tacrolimus, or active peptic ulcer, requiring systemic immunosuppressive medication for any other indication than transplantation, having a diagnosis of cystic fibrosis, or being pregnant or breast-feeding.",
    "The sample is a phase 2 clinical trial for chronic obstructive pulmonary disease (COPD). The trial includes patients between the ages of 40 and 80 who have a clinical history of COPD with airflow limitation that is not fully reversible. The trial also requires females to have a negative pregnancy test and acceptable contraceptive methods. Participants must be current or former smokers with at least a 10 pack-year history of cigarette smoking. The trial has specific inclusion and exclusion criteria, including abnormal chest X-rays not due to the presence of COPD, hospitalization due to poorly controlled COPD within 3 months of screening, and treatment with investigational study drugs or participation in another clinical trial within the last 30 days or 5 half-lives. The trial will test the effectiveness of several drugs, including pt003, pt001, pt005, and tiotropium inhalation powder.",
    "The sample is a record of a clinical trial with a phase 2 designation. The trial is focused on the treatment of mesothelioma, a type of cancer affecting the pleura. The trial involves the use of three drugs: pemetrexed disodium, gemcitabine hydrochloride, and carboplatin. The eligibility criteria for the trial include having advanced mesothelioma of the pleura, measurable disease, and an ECOG Performance Status of 0 or 1. Patients must also meet certain organ and marrow function requirements, be at least 18 years old, and willing to take certain medications. Women of childbearing potential and sexually active men must use contraception during and for the first 3 months after the study. Exclusion criteria include prior radiation therapy to the target lesion, prior systemic chemotherapy for mesothelioma, and active infection or serious concomitant systemic disorder.",
    "The sample is for a phase 2 clinical trial for the treatment of primary mediastinal (thymic) large B-cell lymphoma. The trial involves the use of a combination of drugs, including epoch regimen, cyclophosphamide, doxorubicin hydrochloride, etoposide, prednisone, and vincristine sulfate. The eligibility criteria for the trial include having a confirmed diagnosis of the disease based on an adequate tissue sample, having measurable disease, and meeting certain patient characteristics such as having an ECOG performance status of 0-2 and not having any concurrent uncontrolled illness. Prior cytotoxic chemotherapy or rituximab is not allowed, but a limited course of glucocorticoids is permitted.",
    "The sample is a phase 2 clinical trial for the treatment of multiple myeloma and plasma cell neoplasm using the drug dexamethasone acetate. The eligibility criteria include having a new or preexisting diagnosis of multiple myeloma, measurable disease, and not requiring immediate chemotherapy. Patients must also meet certain patient characteristics such as having an Eastern Cooperative Oncology Group (ECOG) performance status of 0, total WBC \u2265 3,500/mm^3, and ANC \u2265 1,700/mm^3. Patients must not have any active myeloma or primary amyloidosis requiring chemotherapy or any agents that may interact with anakinra. Additionally, patients must not have any acute or chronic infections, open wounds, or any active infection requiring intravenous antibiotic therapy within the past 12 weeks. Prior concurrent therapy must be more than 30 days since prior treatment with dehydroepiandrosterone (DHEA), clarithromycin, pamidronate, steroids, or any other agent that may affect M-protein.",
    "The sample is a phase 2 clinical trial for patients with metastatic or inoperable non-small cell lung, breast, or colon cancer, or duct cell carcinoma of the exocrine pancreas. The trial is testing the drug ci-1040. Patients must have bidimensionally measurable lesions that have not been previously irradiated, and no brain metastases. Patients with prior brain metastases are allowed if they have undergone prior resection of metastases and/or 1 prior course of cranial irradiation, have no new sites of brain metastases since then, have no worsening CNS symptoms, and have discontinued prior corticosteroids for at least 30 days. Patients must have an ECOG performance status of 0-2 and meet certain hematopoietic, hepatic, renal, and other criteria. Patients must not be pregnant or nursing, must have negative pregnancy test, and fertile patients must use effective contraception during and for 30 days after study participation. Patients must be capable of swallowing intact study medication capsules and following instructions regarding study medication or have daily caregiver to administer study medication. Patients must have no concurrent serious infection or life-threatening illness unrelated to tumor, and no other prior or concurrent malignancy within the past 3 years except nonmelanoma skin cancer or carcinoma in situ of the cervix. Patients must have had at least 2 weeks since prior immunotherapy or biologic therapy, at least 4 weeks since prior cytotoxic chemotherapy, and at least 2 weeks since other prior hormonal therapy. Patients must have had at least 3 weeks since prior radiotherapy and recovered, and no concurrent radiotherapy. Patients must have had no other concurrent anticancer agents.",
    "The sample is a phase 2 clinical trial for breast cancer. The trial is looking for female subjects between the ages of 55 and 80 with primary intraductal or lobular invasive breast cancer that meets certain criteria, including a tumor size of 2 to 5 cm and positive estrogen receptor status. The trial also requires postmenopausal status and an Eastern Cooperative Oncology Group performance status of \u22642. The trial excludes patients with locally advanced breast cancer, evidence of metastatic disease, inflammatory breast cancer, or ductal carcinoma in situ.",
    "This sample is for a phase 2 clinical trial for the treatment of squamous cell cancer of the head and neck that is unresectable or metastatic. The trial is testing the effectiveness of the drugs pemetrexed and gemcitabine. The eligibility criteria include having measurable disease, a Karnofsky performance status of at least 60%, and having recovered from any prior radiation or chemotherapy. Participants must also have adequate organ and marrow function, a negative pregnancy test, and be at least 18 years old. Exclusion criteria include having a serious systemic disorder, prior treatment with gemcitabine or pemetrexed within the past year, and being pregnant or breastfeeding. Participants must also be able to take and absorb enteral medication.",
    "The sample is a phase 2 clinical trial for patients with metastatic pancreatic cancer who are not eligible for curative surgery or have documented or suspected extrapancreatic metastases. The trial involves the drug gemcitabine and has a list of eligibility criteria, including age, performance status, hematologic and hepatic function, and adequate renal function. Patients must also meet certain criteria if they are on anticoagulation therapy or not. Exclusion criteria include endocrine tumors or lymphoma of the pancreas, known brain metastases, and prior therapy with certain inhibitors. Patients must not have concurrent malignancy or be undergoing other anti-cancer therapy. There are also restrictions for patients with certain medical conditions or history of events such as arterial thrombotic events or gastrointestinal perforation. Pregnant or lactating women are not eligible, and employees of the investigator or study center and their family members are also excluded.",
    "The sample is a phase 2 clinical trial for breast cancer patients. The trial requires patients to have histologically-confirmed breast cancer, be female and under 70 years old, have a tumor size of at least 2 cm, and have ER-negative tumors. Patients must also have normal CBC, hepatic and renal functions, and normal left ventricular ejection fraction by echocardiography or muga scan. The trial involves treatment with the drug epirubicin, and patients must have fixed and frozen samples from the primary tumor available for evaluation of biological markers. Patients must also provide written informed consent before study registration. Exclusion criteria include metastatic breast cancer, serious medical conditions, concurrent treatment with hormonal replacement therapy or any other anti-cancer therapy, and previous treatment with anthracyclines for breast cancer.",
    "The sample is a phase 2 trial for irritable bowel syndrome. The trial includes men with IBS-C (ROME III) between 18 and 65 years of age and women with IBS-C (ROME III) between 55 and 65 years of age, or 18 to 55 years of age with documentation of non-childbearing potential status. All subjects should have a body mass index (BMI) between 18 and 34 kg/m2 and a body weight of not less than 45 kg. The trial involves the drugs tc-6499 and placebo. The icd-10 codes for the diseases are [\"['K58.2', 'K58.8', 'K58.0', 'K58.1', 'K58.9']\"].",
    "The sample is a phase 2 clinical trial for patients with metastatic breast cancer. The trial involves the use of two drugs, sorafenib and bevacizumab. The eligibility criteria include having a histologic or cytologic diagnosis of breast cancer with evidence of metastatic disease, having measurable or non-measurable lesions, having had two or fewer prior chemotherapy regimens, being over 18 years old, and providing written informed consent and HIPAA authorization for release of personal health information. Exclusion criteria include having no prior therapy with bevacizumab, sorafenib or any other known VEGF inhibitors, having no known hypersensitivity to any component of the study drugs, and having no other forms of cancer therapy including radiation, chemotherapy and hormonal therapy within 21 days prior to being registered for protocol therapy. The trial also requires participants to use an effective method of contraception and to have a negative pregnancy test within 7 days prior to being registered for protocol therapy. The trial excludes patients with a history of cerebrovascular disease, ischemic bowel, deep venous thrombosis or pulmonary embolism, hypertensive crisis or hypertensive encephalopathy, non-healing wound or fracture, active infection requiring parenteral antibiotics, and other hemorrhage/bleeding events \u2265 CTCAE grade 3 within 28 days prior to being registered for protocol therapy.",
    "This is a sample from a clinical trial table. The trial is in phase 2 and is focused on atopic dermatitis. The table includes a list of icd-10 codes for the disease, as well as a list of drugs being tested (sun13834 and placebo). The eligibility criteria for the trial are also included, with specific inclusion and exclusion criteria listed. In this sample, the inclusion criteria include being between 18 and 65 years old and having a diagnosis of atopic dermatitis that meets certain criteria. The exclusion criteria include recent use of certain medications or therapies, a history of certain medical conditions, and the presence of certain disorders that could interfere with the trial's data.",
    "The sample is a phase 2 clinical trial for prostate cancer using the drug alvocidib. The eligibility criteria for patients include having a performance status of ECOG 0-2, a life expectancy of at least 3 months, and meeting certain blood count and organ function requirements. Patients must also not have had any prior or concurrent malignancies within 5 years, except for nonmelanoma skin cancer, and must not have any serious medical illnesses or cord compression symptoms. Prior chemotherapy and suramin therapy are not allowed, but prior or concurrent use of luteinizing hormone-releasing hormone is allowed. Prior anti-androgen therapy is not allowed within 4 weeks of the study, and at least 4 weeks must have passed since prior radiotherapy. Prior strontium therapy is also not allowed.",
    "The sample is a clinical trial for ovarian, fallopian tube, and primary peritoneal cancer patients who have relapsed within 6 months of platinum therapy. The trial is in phase 2/phase 3 and involves the drugs paclitaxel, saracatinib, and a matched placebo. The eligibility criteria include having measurable or evaluable disease, an Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0-2, and adequate haematological and biochemical function. Exclusion criteria include prior administration of weekly paclitaxel, unresolved bowel obstruction, and ongoing active infection or a documented history of HIV infection, Hepatitis B or C.",
    "The sample is a phase 2 clinical trial for Alzheimer's disease. The trial includes subjects who have been on stable dosing of donepezil therapy for at least 2 months and have a regular caregiver. Female subjects of child-bearing potential must agree to abstinence or use an approved form of birth control. Subjects must also have adequate blood pressure and laboratory values. Exclusion criteria include subjects with a diagnosis of possible, probable or definite vascular dementia, known hypersensitivity to sunlight or a history of seizures, previous exposure to SB-742457, taking agents for which there is a theoretical risk of interaction with SB-742457, or taking medication for Alzheimer's disease or centrally acting agents which might impact study outcomes.",
    "The sample is a phase 2 clinical trial for non-small cell lung cancer. The trial includes patients who are 18 years or older and have documented squamous non-small cell lung cancer. The patients must be at stage IIIb with pleural or pericardial effusion, stage IV, or have recurrent disease. They must also be suitable for platinum-based treatment as first line chemotherapy. The trial excludes patients who have had prior systemic anti-tumor therapy or radiotherapy for treatment of their current stage of disease. Patients with other primary tumors within the last 5 years, except for controlled limited basal cell or squamous cancer of the skin, or cancer in situ of the cervix are also excluded. Additionally, patients who have had major surgery, open biopsy, or significant traumatic injury within 28 days prior to randomization are excluded. The trial involves the use of bevacizumab [avastin] and platinum-based chemotherapy.",
    "The sample is a record from a clinical trial table that includes information about the trial's phase, diseases being studied, associated ICD-10 codes, drugs being tested, and eligibility criteria for participants. In this particular sample, the trial is in phase 2/phase 3 and is focused on hematological malignancies. The trial is testing the effectiveness of darbepoetin alpha (aranesp) and iron saccharate (venofer) on patients who meet certain eligibility criteria, such as being between the ages of 16 and 70 and having adequate iron stores. The sample also includes exclusion criteria, such as HIV positivity and severe iron overload.",
    "The sample is a phase 2 clinical trial for asthma, with the drug being tested being revamilast and a placebo. The trial is looking for male or female patients aged 18 to 65 years with a documented diagnosis of asthma and a Forced Expiratory Volume in One Second (FEV1) between 50% and 80% of the predicted value. The eligibility criteria include being in good stable health, having a negative pregnancy test (for female participants), and agreeing to use barrier contraception (for male participants). The exclusion criteria include being pregnant or lactating, having relevant lung diseases other than asthma, being a past or current smoker, having risk factors for asthma exacerbation, having evidence of current or recent neoplastic disease, having clinically significant health conditions, having positive serology for infectious diseases, having a history of alcohol and drug abuse, and having undergone lung surgery in the previous year. The trial also excludes patients who have participated in an investigational drug trial during the 30 days preceding screening.",
    "This sample is a phase 2 clinical trial for premenopausal women aged 18 or older with locally advanced or metastatic breast cancer. The trial is testing the effectiveness of the drug combination of anastrozole and goserelin as an endocrine treatment. The inclusion criteria require signed informed consent, one or more measurable lesions, normal biological parameters, and a life expectancy of more than 6 months. The exclusion criteria include the presence of life-threatening metastases, previous endocrine therapy or chemotherapy for advanced or metastatic disease, any previous treatment with hormone (LH-RH), severe or uncontrolled systemic disease, pituitary adenoma, and high risk of medullar compression. The diseases being studied are breast cancer, and the icd-10 codes associated with the disease are listed as well.",
    "The sample is a phase 2 clinical trial for chronic heart failure. The trial includes patients who are over 18 years old and have a NYHA classification of II or III. They must also be on a stable regimen of ACEI/ARB and/or beta-blocker for at least 3 months prior to receiving study medication. The trial also requires patients to have a left ventricular ejection fraction (LVEF) of less than 35% as determined by 2-D echocardiography. Patients must be able to understand and provide informed consent. Proper birth control must be used by women at least 3 weeks prior to the study and during the infusion period of study drug for both men and women. Patients must also have an implantable cardioverter-defibrillator (ICD) that has been implanted at least 3 months prior to receiving study medication. The trial excludes patients with chronic heart failure classified as NYHA Class I or IV, a history of any malignancy or positive test as specified in the pre-cancer screening, other conditions which in the opinion of the investigator preclude participation in the study, body weight over 350lbs, and any cause hospitalization 30 days prior to screening.",
    "The sample is a phase 2 clinical trial for patients with unresectable or metastatic melanoma. The trial is testing the effectiveness of sorafenib tosylate in treating the disease. The eligibility criteria for the trial include having measurable disease, a life expectancy of more than 12 weeks, and meeting certain medical conditions such as having a WBC count of at least 3,000/mm3 and no history of serious medical conditions like congestive heart failure or uncontrolled hypertension. Patients must also not have any concurrent anticancer agents or therapies, and must not have had more than 2 prior immunotherapy, cytokine therapy, biologic therapy, or vaccine therapy regimens. The trial also has exclusion criteria, such as not having a history of HIV infection or clinically significant hepatitis B or C, and not having any serious or nonhealing wounds or fractures.",
    "The sample is a phase 2 clinical trial for HIV-1 infected individuals. The trial involves the use of two drugs, etravirine (tmc125) and optimized background regimen (obr). The eligibility criteria include being on a steady antiretroviral therapy regimen for at least 8 weeks, having a HIV viral load of 1,000 copies/ml or greater, and having a body weight within the 10-90th percentile of CDC growth chart. The exclusion criteria include evidence of resistance to etravirine, any grade 3 or 4 toxicity, and currently active AIDS defining illness. The trial requires informed consent from a parent or legal guardian if necessary.",
    "The sample is a phase 2 clinical trial for the treatment of ovarian cancer, peritoneal neoplasms, and fallopian tube neoplasms. The trial involves the use of two drugs, paclitaxel and carboplatin, and has specific eligibility criteria for participants, including a histologic diagnosis of epithelial ovarian carcinoma, primary peritoneal carcinoma, or fallopian tube carcinoma, Stage III or IV, with either optimal or suboptimal residual disease following initial surgery. Participants must also have a Karnofsky Performance Status of at least 70% and meet certain bone marrow, renal, hepatic, and neurologic function criteria. Exclusion criteria include pregnancy, prior radiotherapy or chemotherapy for any abdominal or pelvic tumor, and a significant history of cardiac disease.",
    "The sample is a phase 2 clinical trial for osteoporosis. The trial is looking for ambulatory, postmenopausal women with low bone mineral density (BMD) between -3.5 and -2.0, who are willing to take study drug and daily supplements (calcium and Vitamin D). The trial has inclusion and exclusion criteria, which include not having received certain medications within the last 3 months, not having used certain drugs in the past, and not having severe Vitamin D deficiency. Participants must also not have any known bone disorder other than low BMD or osteoporosis, and must not have a history of osteoporotic fractures. The trial also excludes participants with certain medical conditions or psychiatric risks for treatment with an investigational drug.",
    "The sample is a phase 2 clinical trial for Alzheimer's disease, using the drug \"sam-531\". The trial includes men and postmenopausal or surgically sterile women aged 50 to 90, who have been diagnosed with probable Alzheimer's disease according to NINCDS-ADRDA criteria. Participants must be able to complete all required procedures and neuropsychological tests. Exclusion criteria include significant neurological disease other than Alzheimer's, current major depressive disorder or other major psychiatric symptom, current clinically significant systemic illness, and any clinically important deviation from normal limits in physical and neurological examination, vital signs, ECG, or clinical laboratory test results that could compromise the study or be detrimental to the subject. Participants must provide signed and dated written informed consent, and their caregiver must also consent to participate in the study. Men who are sexually active must agree to use a form of contraception that is satisfactory as per the investigator.",
    "The sample is a phase 2 clinical trial for major depressive disorder. The trial includes patients between the ages of 18-65 who have been diagnosed with MDD according to the DSM-IV and have a QIDS-SR score of at least 10 at both the screening and baseline visits. The trial excludes pregnant women, women of childbearing potential who are not using contraception, patients who have been taking antidepressants for 2 weeks prior to the screening visit, patients who no longer meet DSM-IV criteria for MDD during the baseline visit, or patients who demonstrate a 25% or greater reduction in QIDS-SR scores, screening to baseline. The trial also excludes patients with serious suicide or homicide risk, unstable medical illness, alcohol or substance dependence, bipolar disorder, psychotic disorder, psychotic features in the current episode or a history of psychotic features, a history of a seizure disorder, clinical or laboratory evidence of untreated hypothyroidism, patients requiring excluded medications, prior course of ziprasidone, or intolerance to ziprasidone at any dose, any investigational psychotropic drug within the last 3 months, significant cardiac conduction problems, abnormal serum potassium or magnesium levels, and patients currently taking other drugs that prolong the QTc. The trial requires patients to have failed to experience significant clinical improvement following 3 or more antidepressant trials of adequate duration and dose. The trial will test the efficacy of ziprasidone and placebo as treatments for MDD.",
    "The sample is a phase 2 clinical trial for patients with squamous cell carcinoma of head and neck that has recurred or metastasized and is not amenable to local therapy. The trial is testing the effectiveness of a combination of three drugs - pemetrexed, cetuximab, and cisplatin. The eligibility criteria include having a confirmed diagnosis of SCCHN, having completed systemic therapy at least 6 months prior, having no more than 1 prior systemic therapy, and having an estimated life expectancy of at least 12 weeks. Patients must also have an ECOG performance status of 0 or 1, adequate organ function, and be willing to comply with a contraceptive regimen. The trial excludes patients with certain types of cancer, serious concomitant systemic or psychiatric disorders, serious cardiac disease, and CNS metastases. Patients must also be able to interrupt aspirin or other nonsteroidal anti-inflammatory agents for a period of time and be willing to take folic acid, vitamin B12, or prophylactic corticosteroids. Pregnant or breastfeeding women are not eligible for the trial.",
    "The sample is a clinical trial for a drug called vintafolide and ertafolide, which is being tested on patients with advanced epithelial ovarian cancer, primary peritoneal cancer, or adenocarcinoma of the endometrium. The trial is in phase 2 and involves patients who have previously been treated with platinum and/or taxane compounds. The table includes information on the diseases being treated, the icd-10 codes associated with those diseases, the drugs being used, and the eligibility criteria for patients to participate in the trial. The eligibility criteria include factors such as radiographic evidence of measurable disease, prior treatment with platinum and/or taxane compounds, and adequate bone marrow reserve, renal, and hepatic function. The sample also includes exclusion criteria, such as serious comorbidities, pregnancy or lactation, and concurrent chemotherapy, immunotherapy, radiotherapy, or any ancillary therapy considered investigational.",
    "The sample is a phase 2 clinical trial for the treatment of non-metastatic infiltrating carcinoma of the breast that is HER-2 amplified. The drug being tested is trastuzumab. The eligibility criteria include having confirmed non-metastatic infiltrating carcinoma of the breast, HER-2 amplification, and an ECOG performance status of 0-2. Patients must also meet certain health criteria, such as having normal heart function and adequate bone marrow, renal, and liver function. Exclusion criteria include having non-confirmed HER-2 positive infiltrating carcinoma of the breast, evidence of metastatic disease, and previous trastuzumab treatment. Patients must also not have concurrent life-limiting disease with a life expectancy of less than one year, be pregnant or nursing, or be unable to give informed consent.",
    "The sample is a phase 2 clinical trial for lung cancer patients. The trial requires patients to have pathologic documentation of non-small cell lung cancer (NSCLC) and stage IIIA or IIIB disease with positive N2 mediastinoscopy. Patients with N3 disease are excluded. The trial also requires patients to have measurable disease, a Zubrod performance status of 0 or 1, and a calculated post-resectional FEV1 of over 40%. Additionally, patients must have certain blood test results and meet other criteria within specific time frames. Patients who have had prior chemotherapy or radiation for NSCLC or have other serious medical conditions are excluded from the trial. Pregnant or nursing women are also not eligible to participate. The trial will test the effectiveness of three drugs: tarceva (osi-774), paclitaxel, and carboplatin.",
    "The sample is a phase 2 clinical trial for patients with unresectable or metastatic esophageal cancer. The trial involves the use of the drugs irinotecan, cisplatin, and celecoxib. The eligibility criteria include having measurable disease, a Zubrod performance status of 0-2, and a predicted life expectancy of at least 12 weeks. Patients must also have adequate renal and hepatic function, and meet certain blood count requirements. Exclusion criteria include prior treatment with certain drugs, active peptic ulcer disease, and known lactose intolerance. Patients with certain psychiatric disorders, uncontrolled diabetes, or other severe concurrent diseases are also ineligible.",
    "The sample is a phase 2 clinical trial for amyotrophic lateral sclerosis. The trial includes patients who have been diagnosed with familial or sporadic ALS and meet certain criteria, such as having a maximum voluntary grip strength within a certain range and being able to swallow tablets with water. The trial involves the use of various drugs, including a placebo and CK-2017357, and patients must be willing to remain off riluzole for a certain period of time. The trial also has exclusion criteria, such as a life expectancy of less than 3 months and prior treatment with CK-2017357.",
    "The sample is a phase 2 clinical trial for non-small cell lung cancer. The trial includes the drugs enzastaurin, placebo, and pemetrexed. The eligibility criteria for participants include a confirmed diagnosis of NSCLC with locally advanced or metastatic disease, disease progression after one prior systemic cytotoxic chemotherapy regimen for advanced disease, at least one measurable lesion, and having stopped all previous systemic therapies for cancer for at least 2 weeks prior to enrollment. Exclusion criteria include treatment within the last 30 days with a drug that has not received regulatory approval for any indication at the time of study entry, previous treatment with enzastaurin or pemetrexed, concurrent administration of any other antitumor therapy, inability to swallow tablets, and being pregnant or breastfeeding.",
    "The sample is a phase 2 clinical trial for patients with metastatic or unresectable Kras and Braf wild-type biliary tract adenocarcinoma or gallbladder adenocarcinoma. The trial involves the use of three drugs - panitumumab, oxaliplatin, and gemcitabine. The eligibility criteria include having measurable disease, no prior chemotherapy for biliary tract or gallbladder cancer, and normal organ and marrow function. Patients with concurrent malignancy may be included if they meet certain criteria. The trial excludes patients with brain metastases, preexisting peripheral neuropathy of grade 2 or greater severity, and biliary obstruction with inadequate drainage and total bilirubin > 2.5 mg/dL. Pregnant women are also excluded.",
    "The sample is a phase 2 clinical trial for patients with esophageal cancer, specifically squamous cell carcinoma or adenocarcinoma of the esophagus. The trial involves the use of three drugs: oncogel (paclitaxel gel), cisplatin, and 5-fu, along with concurrent systemic chemotherapy and radiation therapy. The eligibility criteria include being medically able to tolerate major abdominal and/or thoracic surgery, having a Karnofsky Performance Status of \u2265 60, and having a minimum life expectancy of 4 months. Exclusion criteria include having a history of anaphylaxis to planned CT contrast agent, prior esophageal stent insertion, laser, or photodynamic therapy, and any prior receipt of cytotoxic chemotherapeutic agents.",
    "The sample is a phase 2 clinical trial for patients with type 2 diabetes mellitus. The trial involves the use of canagliflozin, sitagliptin, and a placebo. The eligibility criteria include having a diagnosis of type 2 diabetes mellitus, specific hemoglobin A1c levels, taking a stable daily dose of metformin, and having a certain body mass index and serum creatinine level. Exclusion criteria include prior exposure or known contraindication to the drugs being used, a history of diabetic ketoacidosis or type 1 diabetes mellitus, and other medical conditions. The diseases and corresponding ICD-10 codes are also listed.",
    "The sample is a phase 2 clinical trial for the treatment of major depressive disorder. The trial includes patients who have had at least one previous episode of MDD in the past 5 years and whose current episode has lasted between 1 and 12 months. The trial involves the use of drugs such as sep-225289, venlafaxine, and placebo. The eligibility criteria include being in good health and having MDD as the primary diagnosis. The exclusion criteria include participation in other drug studies, recent blood donation, and a history of certain mental health disorders or substance abuse. The trial also excludes patients who have undergone Electroconvulsive Therapy treatment or have a history of significant risk of suicide or homicide.",
    "The sample is a record of a clinical trial in phase 2 for the treatment of dry eye disease. The trial involves the use of two drugs, ecabet ophthalmic solution and placebo. The eligibility criteria for the trial include being diagnosed with dry eye disease, while the exclusion criteria include having dry eye disease as a result of surgery. The diseases are listed as 'dry eye disease' and the icd-10 codes associated with the disease are also provided.",
    "This is a sample from a clinical trial table that is in phase 2. The trial is focused on type 2 diabetes and the icd-10 codes associated with it. The drug being tested is called lixisenatide (ave0010). The eligibility criteria for the trial includes males and females between the ages of 30 and 75 who have type 2 diabetes and are being treated with metformin at a stable dose for at least 3 months. The participants must also have a BMI between 25 and 40 kg/m2 and an HbA1C level between 7.0% and 9.0%. The exclusion criteria includes individuals with type 1 diabetes, pregnant or lactating women, women of childbearing potential, those being treated with other antidiabetic agents than metformin, and those with a history of metabolic acidosis, hemoglobinopathy or hemolytic anemia, or clinically significant medical abnormalities.",
    "The sample is a phase 2 clinical trial for the treatment of opioid-induced constipation. The trial includes men and women between the ages of 18 and 75 who have a body weight of at least 45 kilograms and a body mass index of no more than 40 kilograms per square meter. Participants must have been taking a stable daily dose of opioids for chronic noncancer pain for at least 30 days before screening and must have opioid-induced constipation by history. During the screening period, participants must have had less than three spontaneous bowel movements per week and experienced at least one other bowel movement symptom for at least 25% of their total bowel movements. Participants must be willing to discontinue use of all laxatives and stool softeners during the study period except as allowed by the protocol. The trial has several exclusion criteria, including pregnancy, recent history of myocardial infarction or unstable angina, active malignancy of any type, and taking certain medications or substances.",
    "The sample is a phase 2 clinical trial for adults with untreated acute myeloid leukemia (AML) or high-risk myelodysplastic syndromes (MDS). The trial includes patients with prior MDS/AML, therapy-related AML, AML with trilineage dysplasia, and AML with adverse cytogenetics. Patients may have received prior treatment with hydroxyurea or demethylating agents for MDS. The trial involves the drugs tosedostat, cytarabine, and decitabine. The eligibility criteria include being capable of understanding the study's potential risks and benefits, having an ECOG performance status of 0-2, and meeting certain medical criteria such as serum creatinine and bilirubin levels. Patients with certain medical conditions or serious concurrent illnesses are excluded from the trial.",
    "The sample is a phase 2 clinical trial for endometrial cancer. The trial is looking at the effectiveness of the drug letrozole in treating advanced or recurrent endometrial cancer that is not curable with surgery or radiation therapy. The trial is open to postmenopausal women with histologically proven adenocarcinoma or adenosquamous carcinoma of the endometrium who have documented ER and/or PgR positive endometrial cancer. The trial has specific eligibility criteria, including age, presence of measurable disease, ECOG performance status, and adequate bone marrow, renal, and hepatic function. Patients with non-measurable disease only, other concurrent malignant disease, or certain endocrine disorders are excluded from the trial. The trial also has additional protocol-defined inclusion/exclusion criteria that may apply.",
    "This sample is for a phase 2 clinical trial for colorectal neoplasms. The trial includes a list of icd-10 codes for the disease and a list of drugs being tested, including bevacizumab, folfiri, ag-013736, and folfox. The eligibility criteria for the trial include having histologically documented colorectal cancer and having failed one prior irinotecan- or oxaliplatin-containing regimen or being adjuvant refractory to such a regimen. The exclusion criteria include having received prior treatment in the first line metastatic setting with more than one regimen and having received prior irradiation of more than 25% of bone marrow.",
    "The sample is a record of a clinical trial in phase 2 for the treatment of gastroesophageal reflux disease. The trial involves the use of two drugs, spd557 and placebo. The eligibility criteria for the trial include having a history of GERD symptoms, being on a stable dose of PPIs, and experiencing heartburn and/or regurgitation symptoms at least 3 days per week with a minimum of 25 liquid containing reflux events over 24 hours. The exclusion criteria include having prior endoscopic anti-reflux procedure or major GI surgery, presence of severe and clinically uncontrolled cardiovascular, liver or lung disease, neurologic, cancer or AIDS, and alarm symptoms suggestive of malignancies or organic disease.",
    "The sample is a record from a clinical trial table that includes information about the trial's phase, diseases being studied, icd-10 codes of those diseases, drugs being used, and eligibility criteria for participants. In this particular sample, the trial is in phase 2/phase 3 and is studying head and neck neoplasms. The icd-10 codes associated with these diseases are listed. The drugs being used in the trial are docetaxel, cisplatin, 5-fluorouracil (5-fu), and radiotherapy, as well as cisplatin, 5-fluorouracil (5-fu), and radiotherapy. The eligibility criteria for participants are also listed, including inclusion criteria such as having locally advanced head and neck cancer without metastasis, being in good health, and having a proven epidermoid carcinoma. Exclusion criteria are also listed, such as having previous treatment for the disease or having other severe clinical diseases.",
    "The sample is a record from a table that contains information about clinical trials. It includes the phase of the trial, which is a combination of phase 2 and phase 3. The diseases being studied are head and neck cancer and squamous cell carcinoma. The icd-10 codes associated with these diseases are also listed. The drug being tested is erlotinib. The eligibility criteria for the trial are listed under inclusion and exclusion criteria, which specify the requirements for participants to be included or excluded from the trial.",
    "The sample is a phase 2 clinical trial for patients with recurrent or persistent epithelial ovarian, fallopian tube, or primary peritoneal carcinoma. The trial involves the drug dasatinib and has a list of eligibility criteria that patients must meet, including having measurable disease, a GOG Performance Status of 0, 1, or 2, and recovery from recent surgery, radiotherapy, or chemotherapy. Patients must also not be eligible for a higher priority GOG protocol and must have had one prior platinum-based chemotherapeutic regimen. The trial has exclusion criteria, such as patients who have had previous treatment with dasatinib, have a history of cardiac disease, or are pregnant or nursing. The schema definition of the table includes columns for phase, diseases, icd-10 codes, drugs, and eligibility criteria.",
    "The sample is a phase 2 trial for patients with various hematologic malignancies, including leukemia, lymphoma, and myeloma. The trial involves the use of three drugs: cyclophosphamide, tacrolimus, and mycophenolate mofetil. Patients must have residual disease after treatment with one or more chemotherapy regimens, and achieving remission with additional chemoradiotherapy is unlikely. Patients must also have two related donors and meet certain organ function criteria. Inclusion criteria also include a Karnofsky Performance Status of > 80% and willingness to use contraception if they have childbearing potential. Exclusion criteria include a Modified KPS of < 80%, >= 5 Comorbidity Points on the HCT-CI Index, and various medical conditions such as HIV and active inflammatory processes.",
    "The sample is a record of a clinical trial with a phase 2 designation. The trial is focused on the treatment of mycosis fungoides, a type of skin cancer. The trial includes a list of diseases and their corresponding ICD-10 codes, a list of drugs being tested, and eligibility criteria for participants. The inclusion criteria include having a confirmed diagnosis of mycosis fungoides, having been treated previously with certain topical therapies, being in good health with normal lab values, and being willing to give consent. The exclusion criteria include having a newly diagnosed case of mycosis fungoides with no prior therapy, having a history of certain topical therapies, having a diagnosis of stage IIB-IV MF, having a serious concurrent medical illness or infection, being pregnant or nursing, having had radiation therapy within the past year, having a history of a higher T score or N score, and not agreeing to do all labs at one site.",
    "This is a sample from a clinical trial table that includes information about the phase of the trial, the disease being studied (in this case, Waldenstrom's macroglobulinemia), the ICD-10 codes associated with the disease, the drug being tested (perifosine), and the eligibility criteria for participants. The eligibility criteria include age, prior therapy for the disease, measurable disease levels, performance status, laboratory values, life expectancy, and exclusion criteria such as uncontrolled infection, other active malignancies, and recent chemotherapy or radiation therapy. The sample also includes exclusion criteria such as pregnancy or nursing, HIV positivity, and recent radiation therapy.",
    "The sample is a record of a clinical trial with a phase 2 designation. The trial is focused on the disease mesothelioma, and the icd-10 codes associated with it are listed. The trial is testing the effectiveness of two drugs, vinorelbine and vandetanib. The eligibility criteria for participants are listed, including a previous diagnosis of mesothelioma, no previous treatment with vinorelbine, and no serious heart problems within the last 3 months. The exclusion criteria are also listed, including severe or uncontrolled disease, pregnancy or breastfeeding, and recent receipt of investigational agents.",
    "The sample is a phase 2 clinical trial for allergic rhinitis. The trial is looking for male participants between the ages of 18 and 50 who have experienced symptoms of grass pollen related allergic rhinitis within the past two years. Participants must be free from significant cardiac, pulmonary, gastrointestinal, hepatic, renal, haematological, neurological and psychiatric disease, and must have a FEV1 within normal limits (\u226590% of predicted). Atopy must be defined by a positive cutaneous response to mixed grass pollen within the last 12 months or at screening. Participants must be asymptomatic at screening and non-smokers for at least the past 12 months. Exclusion criteria include medical conditions likely to affect the outcome of the study, nasal conditions likely to affect the outcome of the study, presence of any respiratory disease other than a history of mild stable asthma not requiring treatment and associated with normal lung function, and immunotherapy treatment course including inhaled or local corticosteroids in the past 28 days. The trial will involve the use of two drugs, oc000459 and placebo.",
    "The sample is a phase 2 clinical trial for patients with hormone-resistant prostate cancer, prostate adenocarcinoma, recurrent prostate carcinoma, or stage IV prostate cancer. The trial involves the use of the drugs docetaxel and prednisone. The eligibility criteria include having a confirmed diagnosis of prostate cancer, metastatic disease, and castrate-resistant disease. Patients must have completed any prior treatments and have recovered from any acute toxicities attributed to prior treatment. They must also agree to use an accepted and effective method of contraception and not be receiving any other investigational agents or concurrent anticancer therapy other than androgen deprivation treatment. The trial excludes patients with poor prognosis features, a history of autoimmune disease requiring active immunosuppressive therapy, or a known allergy to eggs or intolerable reaction to docetaxel or compounds of similar chemical or biologic composition.",
    "The sample is a phase 2 clinical trial for Parkinson's disease. The trial is testing the effectiveness of a drug called biib014 compared to a placebo. The eligibility criteria for participants include having a diagnosis of idiopathic Parkinson's disease within the past 5 years, having a modified Hoehn & Yahr stage of 1 to 2.5, and a baseline UPDRS (Part III) motor score of at least 10. Participants must not be receiving any other Parkinson's disease medication except for an anticholinergic agent and/or MAO-B inhibitor. Exclusion criteria include a Mini Mental State Examination (MMSE) score of less than 26, history of atypical parkinsonian syndrome, significant non-PD central nervous system disorder, significant AXIS I psychiatric disease, history of cognitive or neuropsychiatric conditions, history of surgical intervention for PD, history of L-DOPA-induced motor or non-motor complication, history of malignancy, history of severe allergic or anaphylactic reactions to any drug, clinically significant renal dysfunction, HbA1c >7.0%, clinically significant baseline ECG, orthostatic hypotension, and treatment with L-DOPA/carbidopa or L-DOPA/benserazide for more than 6 cumulative months at any time since the subject's initial PD diagnosis.",
    "The sample is a phase 2 clinical trial for patients with myelodysplastic syndromes and thrombocytopenia. The trial involves the use of either azacitidine or decitabine, along with a placebo, as treatment options. The eligibility criteria include a diagnosis of MDS based on the WHO classification, being in the low, intermediate-1, or intermediate-2 risk category using the IPSS, and planning to receive the treatment for at least 4 cycles. The exclusion criteria include prior exposure to more than 3 cycles of hypomethylating agents, prior history of leukemia or aplastic anemia, prior history of bone marrow transplantation, and prior malignancy unless treated with curative intent and without evidence of disease for at least 3 years before randomization. Other exclusion criteria include active or uncontrolled infections, unstable angina, congestive heart failure, uncontrolled hypertension, and recent myocardial infarction. Additionally, patients with a history of arterial or venous thrombosis, or those who have received IL-11 within 4 weeks of screening, are also excluded. Finally, patients who have received any therapeutic drug or device that is not FDA approved for any indication within the last 4 weeks, or those who have previously received any other thrombopoietic growth factor, are also excluded.",
    "The sample is a record from a clinical trial table that includes information about the phase of the trial, diseases being studied, ICD-10 codes associated with those diseases, drugs being tested, and eligibility criteria for participants. In this particular sample, the trial is in phase 2 and is studying ocular hypertension and open angle glaucoma. The ICD-10 codes associated with these diseases are listed, as well as the drugs being tested. The eligibility criteria for participants are also listed, including inclusion and exclusion criteria. Participants must have a diagnosis of OAG or OHT in at least one eye and meet certain IOP requirements. They must also not have been exposed to BOL-303259-X within 3 months prior to screening and must not have certain chronic diseases or conditions that could increase risk or confound results. Other exclusion criteria include certain medications, hypersensitivity to study drugs, and various eye conditions or surgeries within a certain timeframe.",
    "The sample is a phase 2 trial for chronic insomnia. The trial includes patients with a clinical diagnosis of dementia of the Alzheimer's type or probable Alzheimer's disease. Female subjects must be post-menopausal and have a stable residence with a responsible spouse, family member, or professional caregiver who is present during the night. Patients must be able to ingest oral medication and participate in all scheduled evaluations. The trial also includes various inclusion and exclusion criteria, such as a Mini-Mental State Examination score of 8 to 28, evidence of sleep disorder behaviors, and a habitual bedtime of between 8 PM and 12 AM. Exclusion criteria include non-ambulatory patients, those with a history of drug abuse or hypersensitivity to Ramelteon or melatonin, and those with any clinically significant movement disorder or pain syndrome affecting sleep.",
    "This sample is for a phase 2 clinical trial for major depressive disorder. The trial includes the drug prx-00023 and a placebo for prx-00023. The eligibility criteria include a diagnosis of major depressive disorder, and exclusion criteria include pregnancy or nursing, recent electroconvulsive therapy, certain medical conditions, drug or alcohol abuse, and abnormal lab results. Other eligibility criteria may also apply. The diseases are listed as 'major depressive disorder (mdd)' and the icd-10 codes associated with the disease are also provided.",
    "The sample is a phase 2 clinical trial for patients with advanced gynecological malignancies who have not received chemotherapy or radiotherapy. The trial involves the use of the drugs pazopanib, carboplatin, and paclitaxel. The eligibility criteria include having a confirmed diagnosis of certain types of cancer, being at least 18 years old, having a performance status of ECOG 0-1, and meeting certain laboratory value requirements for organ function. Exclusion criteria include prior use of anticancer therapy (except for debulking surgery), certain gastrointestinal abnormalities, and certain cardiovascular conditions. The trial also requires subjects to provide written informed consent and agree to comply with treatment and follow-up.",
    "The sample is a phase 2 clinical trial for Alzheimer's disease. The trial includes patients who are receiving Donepezil and have mild to moderate Alzheimer's disease. The patients must be between the ages of 50 and 90 and living in the community. They must also have an eligible informant or study partner who can read and understand English. The trial has inclusion and exclusion criteria, such as not having clinically significant cardiac, hepatic, or renal impairment and not taking any other drugs for Alzheimer's disease within twelve weeks of the baseline visit. The trial is testing the effectiveness of the drug t-817ma compared to a placebo.",
    "The sample is a phase 2 clinical trial for asthma and airway obstruction. The trial involves the use of drugs such as azd3199, formoterol, and placebo. The eligibility criteria for the trial include being an asthmatic patient with pre-bronchodilatory FEV1 above 60% of predicted normal and above 1.5 liters, being a man or post-menopausal woman above 18 years of age, having reversible airway obstruction in response to classical beta2-agonist (salbutamol), and being a non/ex-smoker. The exclusion criteria include having any clinically significant disease or disorder other than asthma, having any clinically relevant abnormal findings at screening examinations, treatment with systemic glucocorticosteroids within the past 30 days, and inhaled corticosteroid use if dosing is not kept constant.",
    "The sample is a phase 2 clinical trial for patients with Parkinson's disease. The trial includes patients aged 30 to 80 years old who have been diagnosed with idiopathic Parkinson's disease and have a disease severity less than Stage 5. Patients must have been treated with levodopa plus DDCI for at least 1 year with clear clinical improvement and treated with 4 to 8 daily doses of standard levodopa plus DDCI. Patients must also have stable regimen of levodopa plus DDCI and other anti Parkinson drugs for at least 4 weeks before screening. The trial aims to evaluate the efficacy of the investigational drug in reducing the \"off\" time in patients with end-of-dose \"wearing-off\" phenomenon. The sample includes inclusion and exclusion criteria for the trial.",
    "The sample is a phase 2 clinical trial for patients with metastatic gastric or esophageal adenocarcinoma who have relapsed or progressed after at least one prior line of chemotherapy. The trial is testing the drug Jevtana. The eligibility criteria include having measurable disease, certain blood counts and liver function, a performance status of 0 to 2, and a minimum life expectancy of 12 weeks. Patients must also be over 18 years old, provide written informed consent, and use effective contraception while on treatment and for at least 3 months thereafter. Exclusion criteria include severe hypersensitivity reaction to Cabazitaxel or other drugs formulated with polysorbate 80, untreated brain metastasis, uncontrolled severe intercurrent illness, breastfeeding, and recent major surgery, chemotherapy, or radiotherapy.",
    "The sample is a phase 2 clinical trial for asthma. The trial includes patients who are 12 years or older and have been diagnosed with asthma according to current ATS guidelines. The trial requires patients to have a FEV1 of 4-80% and a reversibility of at least 13% after bronchodilator treatment. Patients must also be willing to withhold SABA for 6 hours and ICS for 24 hours prior to treatment. The trial has a list of exclusion criteria, including uncontrolled systemic disease, known hypersensitivity to zileuton or components of zileuton injection, and upper or lower respiratory tract infection within the last 2 weeks. Patients who have taken certain medications within the past 7 days or who are pregnant or breastfeeding are also excluded. The trial requires informed consent from all participants.",
    "The sample is a phase 2 trial for patients with type 2 diabetes mellitus. The trial includes several drugs, including ta-7284-low, ta-7284-low-middle, ta-7284-high-middle, ta-7284-high, and placebo. The eligibility criteria include being between the ages of 20 and 80, having been diagnosed with type 2 diabetes mellitus at least 3 months before the start of the trial, and having an HbA1c level between 6.5% and 9.5%. Exclusion criteria include having type I diabetes mellitus, severe diabetic complications, fasting blood glucose levels above 270 mg/dL, and a history of myocardial infarction or cerebrovascular disorder within 3 months before the start of the trial. Additionally, pregnant women, lactating mothers, or women of childbearing potential are excluded from the trial.",
    "The sample is a record of a clinical trial with a phase 2 designation. The trial is focused on treating non-Hodgkin's lymphoma and cancer using a combination of drugs including vincristine, vp-16, rituximab, dexamethasone, and levofloxacin. The eligibility criteria for the trial include being 18 years or older, having a life expectancy of at least 12 weeks, having a Zubrod performance status of 0-2, and having received at least two previous chemotherapy regimens for the disease. Patients must also have measurable or evaluable disease and meet certain health criteria related to bone marrow, liver, and kidney function. There are also exclusion criteria, such as having symptomatic brain metastases or severe medical problems like uncontrolled diabetes or cardiovascular disease.",
    "The sample is a phase 2 clinical trial for the treatment of squamous cell cancer and cancer of the head and neck. The trial involves the use of three drugs, gefitinib, cisplatin, and 5-fluorouracil. The eligibility criteria for the trial include patients who have provided written informed consent, are 18 years or older, and have histologically proven primary SCCHN. Patients who are eligible for surgery with curative intent, have other co-existing malignancies diagnosed within the last 5 years (with the exception of basal cell carcinoma or cervical cancer in situ), and those who have UCNT are excluded from the trial.",
    "The sample is a phase 2 clinical trial for patients with mycosis fungoides/S\u00e9zary syndrome, a type of lymphoma. The trial is testing the effectiveness of lenalidomide, a drug, on patients who have failed at least one prior topical treatment. Patients must have measurable disease with at least one indicator lesion designated prior to study entry. Eligibility criteria include specific patient characteristics such as ECOG performance status, blood counts, and kidney and liver function. Patients must not be pregnant or nursing, and fertile women must use effective contraception. Patients must not have had any other malignancy within the past 5 years except for certain types of skin cancer. Prior concurrent therapy is also specified, including the time since prior topical therapy, systemic chemotherapy, or biological therapy. Patients must not have had prior stem cell transplantation or be receiving any other concurrent systemic antipsoriatic or anticancer therapies, including radiotherapy, thalidomide, or other investigational agents. The sample includes detailed disease and patient characteristics, as well as prior concurrent therapy information.",
    "The sample is a phase 2 trial for previously untreated patients with follicular lymphoma. The trial includes patients with stage III, IV, or bulky stage II disease. Patients must have confirmed CD20 antigen expression and low or intermediate risk by Follicular Lymphoma International Prognostic Index. Patients must not have received prior systemic therapy for NHL, including chemotherapy or immunotherapy. The trial drug is lenalidomide. The eligibility criteria include various medical and demographic factors, such as measurable disease, performance status, and absence of active hepatitis B or C infection. Patients must also have a negative pregnancy test and agree to use birth control during the trial.",
    "The sample is a phase 2 trial for patients with esophageal neoplasms or esophageal diseases. The trial involves the use of two drugs, erlotinib and avastin, and has specific eligibility criteria for patients to participate. These criteria include having biopsy-proven adenocarcinoma or squamous cell carcinoma of the esophagus or gastroesophageal junction, being previously treated with one prior chemotherapy regimen, having adequate hepatic and renal function, and having measurable disease. The trial also has exclusion criteria, such as previous use of anti-EGFR or anti-VEGF therapy, previous history of cancer, and presence of central nervous system or brain metastases.",
    "The sample is a record of a clinical trial in phase 2 for Alzheimer's disease. The trial includes patients between the ages of 50 and 85 with a diagnosis of probable Alzheimer's disease and a Mini-Mental Status Exam (MMSE) score of 16-26. Patients must also have a brain MRI scan consistent with the diagnosis of Alzheimer's disease and be fluent in English, French, or Spanish. The trial allows for stable doses of medications, including cholinesterase inhibitors and memantine. Patients must have a caregiver who can attend all study visits. Exclusion criteria include significant neurological disease other than Alzheimer's disease, major psychiatric disorder, significant medical illness, history of stroke or seizure, history of a heart attack within the last 2 years, prior treatment with certain experimental medicines, and presence of pacemakers or foreign metal objects in the eyes, skin, or body that would prevent the patient from having an MRI scan.",
    "The sample is a phase 2 clinical trial for patients with stage III-IVB head and neck cancer, including unknown primary tumors. The trial is testing the effectiveness of the drug bevacizumab. Patients must meet certain eligibility criteria, such as having no prior chemotherapy or radiotherapy for head and neck cancer, having unidimensionally measurable disease, and having an ECOG performance status of 0-1. Patients must also have their tumor tissue tested for HPV and agree to submit blood samples for correlative studies. Exclusion criteria include a history of severe allergic reactions to docetaxel or compounds of similar composition, uncontrolled intercurrent illness, and inadequately controlled hypertension. Pregnant or breastfeeding women are also excluded.",
    "The sample is a phase 2 clinical trial for patients with recurrent or refractory ovarian epithelial, primary peritoneal, or fallopian tube carcinoma. The trial requires patients to have measurable disease and prior treatment with one platinum-based chemotherapeutic regimen. Patients must also meet certain criteria related to their disease and overall health. The trial involves the use of the drug mifepristone. The table includes information on the diseases, icd-10 codes, drugs, and eligibility criteria for the trial.",
    "The sample is a phase 2 clinical trial for patients with follicular non-Hodgkin's lymphoma. The trial is testing the effectiveness of a combination of drugs including bortezomib, cyclophosphamide, prednisone, and vincristine sulfate. The eligibility criteria for the trial include having stage III or IV disease, grade 1, 2, or 3 disease requiring systemic first-line treatment, and at least one measurable lesion. Patients must also have a medical indication for treatment, such as the presence of constitutional symptoms or lymphadenopathy that requires treatment. The trial excludes patients with a history of other lymphoproliferative disorders or evidence of transformation to an aggressive histology lymphoma, as well as those with known CNS involvement by lymphoma. The patient characteristics required for the trial include an ECOG performance status of 0-2, a life expectancy of at least 12 weeks, and various laboratory values within normal limits. Patients must not have a history of other malignancies, except for certain types that have been adequately treated. The trial also excludes patients with certain medical conditions or illnesses that would preclude study participation. Prior to the trial, patients must not have received any prior systemic therapy for lymphoma or prior bortezomib, cyclophosphamide, or vincristine. Patients must also not be receiving any other concurrent anticancer therapy, investigational agents, corticosteroids (except for physiologic replacement or antiemesis), cytotoxic chemotherapy, or immunotherapy.",
    "The sample is a phase 2 clinical trial for respiratory syncytial virus infections. The trial involves testing two drugs, gs-5806 and placebo, on healthy male or female participants between the ages of 18 and 45 with a body mass index of 18 to 33 kg/m2. The trial has inclusion criteria such as being healthy and within the age and body mass index range, and exclusion criteria such as having a medical illness, being positive for HIV, Hepatitis B or C, having nose or nasopharynx abnormalities, and abnormal lung function.",
    "The sample is a phase 2 trial for attention deficit disorder with hyperactivity. The icd-10 codes for the disease are listed as F90.2, F90.8, F90.9, F90.0, and F90.1. The trial involves the drugs atomoxetine and buspirone. The eligibility criteria for the trial include being an adult with ADHD, while exclusion criteria include having other Axis I psychiatric disorders.",
    "The sample is a phase 2 clinical trial for the treatment of type 2 diabetes. The trial includes patients between the ages of 18-75 who have had type 2 diabetes for at least 6 months and have an HgbA1C between 7.0% and 9.5%. The trial involves the use of two drugs, bezafibrate + diflunisal and bezafibrate + placebo. The eligibility criteria include stable treatment with metformin or Glucophage XR, a BMI between 27 and 45 kg/m2, and an eGFR of at least 70 mL/min. Exclusion criteria include a history of atherosclerotic disorders, hypersensitivity to fibrates or NSAIDs, type 1 diabetes, and various other medical conditions. Patients must also not be taking certain medications and must be willing to comply with the requirements of the trial.",
    "The sample is a phase 2 clinical trial for the treatment of schizophrenia. The trial is testing the effectiveness of the drugs jnj-37822681 and olanzapine, as well as a placebo. The eligibility criteria for participants include a diagnosis of schizophrenia at least one year prior to screening, an acute exacerbation of less than 6 months duration, and a PANSS total score between 70 and 120. Participants must also agree to voluntary hospitalization for a minimum of 14 days. Exclusion criteria include a diagnosis of substance dependence within 6 months prior to screening, any clinically relevant medical condition that could potentially alter the absorption, metabolism, or excretion of the study medication, and a history of neuroleptic malignant syndrome.",
    "The sample is a record of a clinical trial with a phase 2 designation. The trial is focused on type II diabetes mellitus and includes a list of associated ICD-10 codes. The trial involves the use of three drugs: azd1656, placebo, and glipizide. The eligibility criteria for the trial are listed, including requirements for female patients, prior treatment with metformin, and specific HbA1c levels. The exclusion criteria are also listed, including recent cardiovascular events, impaired renal function, and use of certain medications.",
    "The sample is a phase 2 clinical trial for patients with advanced, inoperable gastric adenocarcinoma. The trial is testing the effectiveness of the drug combination of docetaxel and capecitabine. The eligibility criteria include being over 18 years old, having a WHO performance status of 2 or less, having stage IV cancer, and having adequate hematological, renal, and liver function. Patients must also have no previous chemotherapy, except for adjuvant chemotherapy at least 6 months ago, and must be able to comply with the scheduled follow-up and management of toxicities. Exclusion criteria include pregnancy or lactation, unresolved bowel obstruction or subobstruction, chronic diarrhea, and inability to swallow tablets. Patients with CNS metastases, serious co-morbid medical conditions, or a history of serious allergic reactions are also excluded. The trial is not open to patients who have had major surgery within 4 weeks prior to the start of the study treatment or who cannot be regularly followed up for psychological, social, family, or geographic reasons.",
    "The sample is a phase 2 clinical trial for patients with advanced or recurrent endometrial cancer that is incurable by standard therapies and have received one platinum-based chemotherapy regimen. The trial is testing the drug xl147 (sar245408). The eligibility criteria include having a confirmed diagnosis of endometrial cancer, being at least 18 years old, having an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1, having at least one measurable lesion, having adequate organ and marrow function, and being capable of understanding the informed consent and complying with the protocol. Exclusion criteria include having previously been treated with a selective PI3K inhibitor, mTOR inhibitor, or AKT inhibitor, having uterine sarcomas, mixed Mullerian tumors, squamous carcinoma of the uterus, and/or adenosarcomas of the uterus, and having certain restrictions on prior treatments. The sample also includes a list of diseases, icd-10 codes, and eligibility criteria for the trial.",
    "The sample is a phase 2 clinical trial for the treatment of advanced renal cell carcinoma. The trial includes subjects with confirmed stage IV or recurrent RCC, with an ECOG performance status of 0-1, at least one measurable lesion per RECIST, and aged 20 years or older of Japanese, Chinese, or Korean ethnicity. The trial excludes subjects with CNS metastases, prior targeted, chemotherapeutic, cytokine-based, or other investigational agents for the treatment of RCC within 4 weeks before the first dose of the test article, and other prior malignancy in the past 5 years except for basal cell carcinoma, squamous cell carcinoma of the skin, or cervical carcinoma in situ. The table includes columns for the phase of the trial, diseases being studied, ICD-10 codes of the diseases, drugs being used, and eligibility criteria for the trial.",
    "The sample is a phase 2 clinical trial for patients with Von Hippel-Lindau (VHL) disease. The trial includes patients with at least one measurable VHL-related lesion, which is undergoing surveillance, and who are not at immediate risk of needing intervention for this or other lesions. The trial also includes patients who have normal organ and marrow function, are at least 18 years old, and have an Eastern Cooperative Oncology Group (ECOG) performance status of 2 or less. The trial excludes patients who have had chemotherapy or radiotherapy within 4 weeks prior to entering the study, those who have not recovered from adverse events due to agents administered more than 4 weeks earlier, and those with any metastatic disease of any kind. The trial also excludes patients with a history of allergic reactions attributed to compounds of similar chemical or biologic composition to SU011248/sunitinib malate, and those with ongoing cardiac dysrhythmias of NCI CTCAE grade >/= 2.",
    "The sample is a record of a clinical trial with a phase 2 designation. The trial is focused on treating various types of leukemia and myelodysplastic syndrome using a vaccine called wt1 peptide. The record includes a list of diseases and their corresponding ICD-10 codes, as well as eligibility criteria for participants. The inclusion criteria include being diagnosed with certain types of leukemia or myelodysplastic syndrome, being HLA-A0201 positive, and being between the ages of 18 and 85. The exclusion criteria include being HIV positive, having low bone marrow reserves, and having a predicted survival of less than 3 months. The record also includes specific exclusion criteria for donors.",
    "The sample is a phase 2 clinical trial for gastroesophageal reflux disease. The trial involves the use of the drugs azd3355 and placebo. The eligibility criteria for the trial include providing informed consent, having a history of GERD with persistent symptoms despite treatment with PPI, and being in otherwise normal physical health. Exclusion criteria include having a history of GERD with symptoms that have not improved with PPI treatment, prior surgery of the upper gastrointestinal tract, and a history of significant heart disease, cardiovascular, respiratory, hepatic, renal, metabolic, psychiatric, or gastrointestinal disorders besides GERD.",
    "The sample is a phase 2 clinical trial for pancreatic cancer. The trial is looking for patients with locally resectable disease by CT scan, with no tumors of the body or tail, no infiltration of extrapancreatic organs except the duodenum, no carcinoma of the ampulla of Vater, no metastasis, and no peritoneal carcinoma. Patients must also meet certain patient characteristics, such as having a Karnofsky performance status of 70-100%, a creatinine clearance of >70 mL/min, and no liver cirrhosis. Patients must not have any other severe cardiopulmonary disease, HIV infection, or other disease that renders them unsuitable for one treatment option. The trial is looking for patients who have not participated in another clinical trial for at least 3 months and have not received prior or other concurrent treatment for carcinoma of the pancreas. The treatment options for this trial are cisplatin and gemcitabine hydrochloride.",
    "The sample is a phase 2 clinical trial for the treatment of rheumatoid arthritis. The trial involves the use of the drugs maraviroc and maraviroc placebo. The eligibility criteria for the trial include being of legal age, having active rheumatoid arthritis based on specific criteria, and receiving methotrexate for a certain duration. Exclusion criteria include having certain medical conditions or taking certain medications. The trial also requires the use of an adequate method of birth control for women of reproductive potential.",
    "The sample is a phase 2 clinical trial for patients with chronic kidney disease and diabetic nephropathy. The trial is testing the effectiveness of the drugs atrasentan and placebo. The eligibility criteria include being over 18 years old, having type 2 diabetes and having been treated with at least one anti-hyperglycemic medication within the past 12 months, and currently receiving an angiotensin converting enzyme inhibitor or angiotensin II receptor blocker. Patients must also meet certain laboratory value criteria, such as having an estimated glomerular filtration rate between 30 and 75 mL/min/1.73m2 and a urinary albumin to creatinine ratio between 300 and 3500 mg/g. Exclusion criteria include a history of pulmonary edema or hypertension, lung diseases requiring oxygen therapy, and orthostatic hypotension within the past 6 months.",
    "The sample is a phase 2 clinical trial for rhinitis, a condition characterized by symptoms of nasal inflammation. The trial involves testing the effectiveness of three drugs - sb-705498, fp, and placebo - on patients with rhinitis. The eligibility criteria for the trial include a diagnosis of AR (allergic rhinitis), a TNSS (Total Nasal Symptom Score) of >=4 following screening allergen challenge chamber, positive skin prick test for seasonal pollen, positive RAST (Radioallergosorbent Test) for seasonal pollen, and being healthy with the exception of mild asthma and AR. The trial is open to both male and female participants between the ages of 18 and 65, with a body weight of at least 50 kg for males and 45 kg for females, and a BMI within the range of 19 - 29.9 kg/m2. Participants must also be capable of giving written informed consent. The exclusion criteria include a history of frequent nosebleeds, respiratory disease other than mild asthma, positive pre-study Hepatitis B or Hepatitis C result within 3 months of screening, current or chronic history of liver disease, positive pre-study drug/alcohol/smoking screen, and a positive test for HIV antibody.",
    "The sample is a phase 2 clinical trial for breast cancer patients with metastatic or locally advanced unresectable disease. The trial is testing the effectiveness of anastrozole and gefitinib drugs on patients who have shown progressive disease after more than 2 months of aromatase inhibitor therapy. The eligibility criteria include having at least 1 measurable target lesion that has not been irradiated, being estrogen receptor or progesterone receptor positive, and having no known CNS disease or unevaluated CNS symptoms suggestive of brain metastases. Patients must also meet certain age, sex, menopausal status, performance status, life expectancy, hematopoietic, hepatic, renal, and cardiovascular criteria. They must be able to swallow oral medication and have no other malignancy within the past 5 years except nonmelanoma skin cancer or carcinoma in situ of the cervix. The trial excludes patients with known malabsorption condition or other condition that would impair absorption of study drug, active infection, or other concurrent medical condition that would preclude study. Prior concurrent therapy is also specified.",
    "This sample is a phase 2 clinical trial for breast cancer patients with stage IV measurable disease who have experienced disease progression after one or two prior chemotherapy regimens for metastatic disease. Patients with hormone-sensitive tumors must have received prior hormonal therapy, and those with HER2/neu-overexpressing tumors should have received trastuzumab in the adjuvant or metastatic setting. Patients must not have clinical evidence of or known brain or CNS disease, and must meet certain eligibility criteria such as having a normal bilirubin level and platelet count. The trial involves the use of two drugs, capecitabine and imatinib mesylate, and patients must not have a history of severe hypersensitivity reaction to these drugs or similar compounds. Prior hormonal therapy is allowed, but prior biologic therapy or concurrent use of other investigational or commercial agents or therapies for metastatic breast cancer is not allowed.",
    "The sample is a phase 2 clinical trial for patients with myeloma, a type of cancer. The trial involves the use of three drugs - dasatinib, melphalan, and prednisone. The eligibility criteria include being between the ages of 18 and 75, having a Karnofsky performance status of at least 60%, and having measurable disease. Patients must also have previously been diagnosed with symptomatic MM and have received previous treatment containing Thalidomide or Lenalidomide and Bortezomib or even MP. Exclusion criteria include having more than two previous treatment regimens, having any serious medical condition or psychiatric illness that would prevent the subject from signing the informed consent form, and being pregnant or breastfeeding. The trial also has specific laboratory value requirements and excludes patients with certain medical conditions or who are taking certain medications.",
    "The sample is a record from a clinical trial table. It is a phase 2 trial for lung cancer, with a list of icd-10 codes for the disease. The trial involves the use of three drugs: gemcitabine, docetaxel, and cetuximab. The eligibility criteria for the trial include being 18 years or older, having non-small cell lung cancer confirmed by biopsy, having unresectable stage III or IV disease, having measurable disease, not having received any prior chemotherapy for lung cancer, being able to perform daily activities without considerable assistance, having adequate bone marrow, kidney, and liver function, and signing informed consent. The exclusion criteria include having a history of serious heart disease within six months prior to study entry, prior treatment with agents that target the EGFR pathway, or having any other uncontrolled or significant disease. The study center will determine if the participant meets all of the criteria, and if they do not qualify, the study personnel will explain the reasons. If the participant does qualify, the study personnel will explain the trial in detail and answer any questions they may have, allowing them to decide if they wish to participate.",
    "The sample is a phase 2 clinical trial for individuals with a history of cocaine use and depressive symptoms. The trial involves the use of drugs such as sertraline, placebo, and gabapentin. The eligibility criteria include being between 18-65 years old, meeting DSM-IV criteria for cocaine dependence, having laboratory confirmation of recent cocaine use, and scoring at least 15 on the Hamilton Depression Scale. Exclusion criteria include having a current diagnosis of other drug or alcohol physical dependence, ill health, history of schizophrenia or bipolar type I disorder, and current suicidality or psychosis. Women of childbearing age must have a negative pregnancy test and agree to monthly pregnancy testing.",
    "The sample is a phase 2 clinical trial for the treatment of chronic lymphocytic leukemia. The trial includes patients who have not received any previous treatment and are younger than 70 years old with a serum beta-2 microglobulin level of at least 4.0mg/L. Patients with Rai stage III-IV or Rai stage 0-II who meet one or more indication for treatment as defined by the NCI-sponsored Working Group are eligible for treatment. Patients must have a Zubrod performance status of 0-3 and adequate renal and hepatic function. Patients cannot receive concurrent chemotherapy, radiotherapy, or immunotherapy. Patients must not have untreated or uncontrolled life-threatening infection. Patients older than 70 years are excluded from the trial.",
    "The sample is a phase 2 clinical trial for patients with metastatic prostate cancer. The trial is testing the effectiveness of the drug docetaxel in treating the disease. The eligibility criteria for the trial include having confirmed MAIPC, documented progressive disease despite castrate levels of testosterone, and being chemotherapy naive. Patients with serious medical illness, active cardiac disease, gastrointestinal ulceration, bleeding or perforation, or allergy to sulfonamides or celecoxib are excluded from the trial. The sample also includes a list of icd-10 codes for the disease and the inclusion and exclusion criteria for the trial.",
    "The sample is a phase 2 clinical trial for patients with ovarian neoplasms. The trial includes patients who have relapsed after prior therapy with taxane and platinum-based therapy, within 6 months of completing, or had a best response of stable disease during no more than two prior chemotherapy treatments with a platinum and a taxane. The trial allows up to one year of consolidation treatment with intraperitoneal and intravenous administered chemotherapy drugs to consolidate a clinical complete remission. Patients must have elevated CA-125 or measurable disease. The trial includes the drugs bevacizumab and erlotinib. The eligibility criteria include various medical conditions and patients must be able to take oral medications. The exclusion criteria include various medical conditions, participation in an experimental drug study, and inability to comply with study and/or follow-up procedures.",
    "The sample is a phase 2 clinical trial for bladder cancer. The trial includes patients with unresectable, locally advanced or metastatic disease who have been diagnosed with transitional cell carcinoma of the bladder, urethra, ureter, or renal pelvis. The trial involves the use of three drugs: gemcitabine, carboplatin, and sorafenib. The eligibility criteria include having a CrCl \u2265 60 ml/min or serum creatinine < 1.5, an ECOG Performance Status of 0 or 1, and adequate bone marrow, liver, and renal function. Patients must also be at least 18 years old, have a negative serum pregnancy test, and be willing to use adequate contraception. The trial excludes patients with a history of stroke within six months, clinically significant peripheral vascular disease, known brain metastasis, and other conditions that impair the patient's ability to participate in the study.",
    "This sample is a phase 2 clinical trial for patients with non-small cell lung cancer who are planned to receive high dose palliative radiation therapy for locoregional control. The trial is investigating the effectiveness of vinorelbine, gemcitabine, and cisplatin as treatment options. The eligibility criteria include having histologically or cytologically proven non-small cell lung cancer, being suitable for radical therapy, having an ECOG performance status of 0 or 1, and having adequate hepatic, bone marrow, and renal function. Patients must also not have received prior radiotherapy or chemotherapy for non-small cell lung cancer and must have written informed consent. Exclusion criteria include being unable to receive all therapy as an outpatient, having significant medical conditions that may compromise the planned delivery of chemotherapy and radiotherapy, having a history of any other cancer (except non-melanoma skin cancer or carcinoma in situ of the cervix) unless in complete remission and off all therapy for that cancer for at least 5 years, and receiving treatment with another investigational agent.",
    "The sample is a record of a clinical trial in phase 2, focused on the disease bronchiolitis. The trial includes patients who are at least 18 years old and have undergone allogeneic hematopoietic stem cell transplantation at least 80 days prior. The trial is looking for patients with new onset airflow obstruction, defined as a decline in forced expiratory volume in 1 second (FEV1) percent predicted of at least 15%. Patients must also have a Total Lung Capacity (TLC) greater than 85% to rule out restrictive lung disease. The trial drug being tested is fluticasone propionate. Patients must be willing to comply with all study procedures and capable of signing informed consent. Exclusion criteria include patients with active pulmonary infection or known hypersensitivity to corticosteroids.",
    "The sample is a phase 2 clinical trial for patients with metastatic breast cancer that is refractory or has recurred after at least one systemic chemotherapy regimen. The trial requires at least one site of measurable disease and excludes patients with known brain metastases. Patients must meet certain eligibility criteria, including age 18 or over, Zubrod performance status of 0-2, and a life expectancy of at least 12 weeks. They must also have certain hematopoietic, hepatic, and renal function levels, and use effective birth control if fertile. Patients must have recovered from toxic effects of prior treatment and cannot have received immunologic therapy within the past 2 weeks, chemotherapy within the past 4 weeks (6 weeks for mitomycin or nitrosoureas), or hormonal therapy within the past 2 weeks. They also cannot have received radiotherapy within the past 4 weeks or be taking concurrent cholesterol lowering agents, supplemental vitamins, or other antioxidants. The trial is testing the efficacy of the drug perillyl alcohol.",
    "The sample is a phase 2 clinical trial that includes patients with various types of cancer, such as chronic myelogenous leukemia, lymphoma, and myelodysplastic syndromes. The trial involves allogeneic hematopoietic cell transplantation (HCT) with a matched or mismatched donor, using a myeloablative pre-transplant conditioning regimen and methotrexate and tacrolimus for prevention of graft-versus-host disease (GVHD). The study aims to evaluate the efficacy of beclomethasone dipropionate (BDP) in reducing the incidence and severity of acute GVHD. Patients who have received T cell depletion or rabbit antithymocyte globulin, or who have pre-existing medical complications, are excluded from the trial. Other exclusion criteria include intolerance to BDP, inability to tolerate oral administration of study drug tablets, and pregnancy or breastfeeding.",
    "The sample is a phase 2 clinical trial for patients with anaplastic or poorly differentiated variant thyroid cancer that has relapsed or progressed during or after prior combined modality therapy. The trial is testing the effectiveness of the drug fosbretabulin disodium. The eligibility criteria include having measurable or evaluable disease, a patent trachea and airway, and meeting certain patient characteristics such as age, performance status, and life expectancy. Patients must also meet certain hematopoietic, hepatic, renal, and cardiovascular requirements. Prior concurrent therapy is not allowed, and patients must not have any other nonmalignant medical illness that is uncontrolled or whose control may be jeopardized by study therapy.",
    "The sample is a phase 2 clinical trial for lung cancer. The trial is looking for patients with a single, primary bronchogenic non-small cell lung cancer of certain subtypes and meeting specific staging criteria. Patients must also meet certain patient characteristics, such as having a Karnofsky performance status of 70-100% and no prior malignancy except for certain types. The trial is testing the effectiveness of cisplatin and gemcitabine hydrochloride as treatment. The eligibility criteria for the trial are listed in detail, including requirements for disease characteristics and patient characteristics. Prior chemotherapy or radiotherapy for lung cancer is not allowed.",
    "The sample is a phase 2 trial for rheumatoid arthritis. The trial involves the drug vx-702 and the patients must be between 18 to 75 years old and have active RA. They must have been taking MTX for at least 6 months and cannot be on any other DMARD treatment. The inclusion criteria also includes no planned major surgery during the treatment period and no intra-articular injections of corticosteroids within 28 days prior to Day 1.",
    "The sample is a phase 2 clinical trial for patients with coronary artery bypass graft and cardiopulmonary bypass. The trial involves the use of two drugs, mdco-2010 and placebo. The eligibility criteria for the trial include men aged 18 to 80 years or post-menopausal women aged up to 80 years who are planning to undergo elective, isolated primary CABG surgery with more than 1 graft, including the use of cardiopulmonary bypass. Patients must also provide written informed consent prior to any study-related procedure not part of normal medical care. There are several exclusion criteria, including planned concomitant surgery, body weight outside of the range of 55 kg to 110 kg, and preoperative coagulation abnormalities. The trial also excludes patients with a history of stroke or transient ischemic attack within 3 months prior to entry, known heparin-induced thrombocytopenia, active liver disease, and any condition requiring chronic immunosuppressive medication.",
    "The sample is a clinical trial with a phase 2/phase 3 design, focused on patients with essential hypertension. The trial includes a list of drugs, diseases, and icd-10 codes, as well as eligibility criteria for inclusion and exclusion. Inclusion criteria include patients with essential hypertension, measured by electronic hemodynamometer, and meeting specific blood pressure criteria at three different visits. Exclusion criteria include pregnant or nursing women, patients with secondary hypertension or a history of malignant hypertension, and patients with certain medical conditions or allergies. The trial aims to evaluate the effectiveness and safety of various drug treatments for essential hypertension.",
    "The sample is a phase 2 clinical trial for the treatment of multiple myeloma, a type of cancer. The trial involves the use of three drugs - bortezomib, melphalan, and prednisone. The eligibility criteria for the trial include having histologically confirmed multiple myeloma, no prior therapy, a life expectancy greater than 3 months, and normal organ and marrow function. Patients with severe pancytopenia due to myeloma involvement of the bone marrow and patients with renal insufficiency due to myeloma are also included. The trial excludes pregnant women, patients receiving any other investigational agents, and patients with uncontrolled intercurrent illness. The sample also includes the inclusion and exclusion criteria for the trial.",
    "The sample is a phase 2 clinical trial for patients with lymphoma or non-Hodgkin lymphoma who have failed to respond or relapsed after primary therapy. The trial includes patients who have received prior chemotherapy, including rituximab, and have measurable and/or evaluable disease. Patients must meet certain eligibility criteria, including having a life expectancy of at least 6 months, adequate hematological counts, and a performance status of less than 2 according to the ECOG scale. Patients with certain medical conditions or who have received certain treatments are excluded from the trial. The trial involves the use of rituximab and velcade as treatment options.",
    "The sample is a record of a clinical trial in phase 2 for the treatment of metastatic, progressive hormone refractory prostate cancer. The trial involves the use of drugs such as cp-751,871, docetaxel, and prednisone. The eligibility criteria for the trial include a diagnosis of the specified type of prostate cancer and adequate bone marrow, liver, and kidney function. Previous treatment with chemotherapy is listed as an exclusion criterion. The diseases are listed as 'prostatic neoplasms' and the icd-10 codes associated with the disease are also provided.",
    "The sample is a phase 2 clinical trial for patients with multiple myeloma who have relapsed or are resistant to prior therapy. The trial is testing the drug pomalidomide. The eligibility criteria include having high-risk disease, adequate hematopoietic and renal function, and no significant peripheral neuropathy. Patients must also have received prior therapy with a lenalidomide-containing regimen and have been determined to be refractory, resistant, or relapsed. Exclusion criteria include any serious medical condition or laboratory abnormality that would prevent the subject from signing the informed consent form, pregnancy or breastfeeding, and any condition that places the subject at unacceptable risk if they were to participate in the study.",
    "The sample is a record of a clinical trial with a phase 2 designation. The trial is focused on chronic hepatitis C virus and includes a list of ICD-10 codes for related diseases. The trial involves the use of two drugs, ldv/sof and rbv. The eligibility criteria for the trial include being over 18 years old, having chronic genotype 1 HCV infection, having HCV RNA equal to or greater than 10,000 IU/mL at screening, and meeting certain laboratory value thresholds. Additionally, female participants of childbearing potential or sexually active male participants must use two effective contraception methods. Exclusion criteria include being pregnant or nursing, having a history of clinical hepatic decompensation, having hepatocellular carcinoma or other malignancy, chronic use of systemic immunosuppressive agents, and having any other medical disorder that may interfere with subject treatment, assessment, or compliance with the protocol.",
    "The sample is a phase 2 clinical trial for acute heart failure. The trial involves the use of drugs such as cinaciguat and placebo. The eligibility criteria for the trial include being male or non-pregnant, non-lactating female aged 18 years or older, or postmenopausal women aged 55 years or older, women with bilateral tubal ligation, women with bilateral ovariectomy, and women with a hysterectomy. The subjects must have been diagnosed with congestive heart failure at least three months prior to enrollment and must have experienced worsening of dyspnea and clinical evidence of volume overload leading to hospitalization at the time of entry into the study. The exclusion criteria include acute de-novo heart failure, acute myocardial infarction, valvular heart disease requiring surgical intervention, heart failure due to or associated with uncorrected primary valvular disease, malfunctioning artificial heart valve, or uncorrected congenital heart disease, primary hypertrophic cardiomyopathy, acute inflammatory heart disease, and unstable angina requiring angiography.",
    "The sample is a record of a clinical trial with a phase 2 designation. The trial is focused on the treatment of acute heart failure. The diseases field lists only one disease, and the icdcodes field lists several ICD-10 codes associated with that disease. The drugs field lists two treatments being tested: rlx030 and placebo. The criteria field lists the eligibility criteria for the trial, including inclusion criteria such as hospitalization for acute heart failure within the previous 48 hours and exclusion criteria such as systolic blood pressure below 115 mmHg and impaired renal or hepatic function. The sample also notes that there may be other protocol-defined inclusion/exclusion criteria that apply.",
    "The sample is a phase 2 clinical trial for irritable bowel syndrome. The trial includes patients who have had symptoms for at least 6 months and experience diarrhea-predominant IBS. The patients must have at least one stool with a consistency of Type 6 or 7 on two or more days per week, and a weekly average of worst abdominal pain score of 3 or higher on a 0-10 point scale. The trial involves two drugs, 250 mg lx1033 tablets and a placebo tablet. Patients must be able to provide written, informed consent and meet certain exclusion criteria, such as not being able to discontinue current drug therapy for IBS and not having any clinically significant abnormalities or conditions.",
    "The sample is a phase 2 clinical trial for patients with adenocarcinoma of the stomach or the GE-junction. The trial includes patients with distant metastases or locally advanced disease who are not curatively operable, or those with a recurrence after gastrectomy. Patients who have not received any prior palliative chemotherapy are eligible, and an adjuvant chemotherapy is allowed. The trial requires patients to be between 18 and 75 years old, have sufficient bone marrow, liver, and renal function, and a Karnofsky-performance-index of at least 60%. Patients must also have measurable tumor lesions and provide written informed consent. Exclusion criteria include a Karnofsky-performance-index less than or equal to 50%, prior palliative first-line chemotherapy, prior second malignancy (except basal cell carcinoma of the skin or curatively treated carcinoma in situ of the cervix), uncontrolled infection, CNS-metastasis, other severe medical disease, prior major surgery for less than 2 weeks, parallel treatment with other experimental therapies, parallel treatment with any other therapy aiming against the tumor, chronic diarrhea or subileus, chronic inflammatory bowel disease or intestinal obstruction, unable to take oral medication, pregnancy, or breast feeding.",
    "The sample is a phase 2 trial for patients with malignant glioma, glioblastoma multiforme, or gliosarcoma. The trial involves the use of the drugs gliadel, avastin, and cpt-11. The eligibility criteria include having a confirmed diagnosis of WHO grade IV primary malignant glioma, being over 18 years old, having a measurable CNS neoplasm, and meeting certain medical requirements such as having a Karnofsky score of at least 70%. There are also exclusion criteria, such as having multifocal disease, prior treatment with Gliadel, or inadequate control of hypertension. Patients must provide signed informed consent approved by the Institutional Review Board.",
    "The sample is a phase 2 clinical trial for non-small cell lung cancer. The trial includes patients who have previously received one platinum-based chemotherapy regimen and have recurrent or progressive NSCLC. The trial aims to test the effectiveness of the drugs pivanex and docetaxel. The eligibility criteria include having adequate renal and liver function, adequate bone marrow function, and a predicted life expectancy of at least 12 weeks. Patients must also have an ECOG performance status of 0, 1, or 2. Exclusion criteria include having received more than one chemotherapy regimen for NSCLC, having a second malignancy within the last 5 years, and having acute medical problems such as ischemic heart or lung disease or uncontrolled systemic infection. Patients with symptomatic or untreated brain metastases are also excluded unless they are clinically and neurologically stable for > 4 weeks since therapy.",
    "The sample is a phase 2 clinical trial for breast cancer patients with stage IV disease. The trial is testing the effectiveness of lapatinib oral tablets and paclitaxel infusion in treating ER+ and/or PR+ breast cancer that has amplified ErbB2. The eligibility criteria include having measurable lesions according to RECIST criteria, a cardiac ejection fraction within institutional range of normal, and a life expectancy of at least 3 months. Exclusion criteria include concurrent anti-cancer therapy, unresolved or unstable serious toxicity from prior administration of another investigational drug, and active or uncontrolled infection. The trial is only open to females over 18 years of age who are either non-child-bearing or using acceptable methods of birth control.",
    "The sample is a phase 2 clinical trial for non-small cell lung cancer and postmenopausal women. The trial includes patients who have been treated with 4 cycles of induction chemotherapy and have had a response of CR, PR, or SD. The trial also includes eligibility criteria such as ECOG performance status, age, organ function, and prior radiotherapy completion. Patients must have archival tissue samples and agree to mandatory correlative blood samples. The trial has exclusion criteria such as male gender, concurrent administration of any other antitumor therapy, and pregnancy or breastfeeding.",
    "The sample is a record of a clinical trial with a phase 2 designation. The trial is focused on treating nausea, vomiting, and unspecified childhood solid tumors with a combination of drugs including decadron, benadryl, ativan, and ondansetron hydrochloride. The trial is looking for participants who are between 8 and 19 years old, newly diagnosed with cancer, and have not received chemotherapy before. Participants must also be scheduled to receive moderately or highly emetogenic chemotherapy as an in-patient and have a dedicated line for continuous infusion of study agent. There are exclusion criteria as well, including prior chemotherapy, central nervous system disease, and steroid use in their chemotherapy regimen. The sample includes a list of diseases and their corresponding ICD-10 codes, as well as the eligibility criteria for the trial.",
    "The sample is a phase 2 trial for patients with recurrent or stage IV prostate cancer that has progressed despite previous treatment. The trial involves the drug vorinostat and has specific eligibility criteria, including a minimum PSA level, normal organ function, and a willingness to provide blood samples for correlative studies. Patients with certain cardiovascular diseases, brain metastases, or active second malignancies are excluded from the trial. The trial also requires additional diagnostic testing for patients with certain medical histories or clinical findings.",
    "The sample is a phase 2 clinical trial for lung cancer. The trial is looking for patients with non-small cell lung cancer that is stage IB or II and is resectable. The patients must have no mediastinal involvement and no evidence of metastatic disease. The trial is testing the effectiveness of cisplatin and pemetrexed disodium as treatments for lung cancer. The eligibility criteria include various patient characteristics such as performance status, blood counts, and organ function, as well as prior concurrent therapy. Patients with certain medical conditions or illnesses are not eligible for the trial.",
    "The sample is a record of a clinical trial for a drug called opc-12759 for the treatment of dry eye syndrome. The trial is in phase 2 and the diseases being studied are limited to dry eye syndromes. The icd-10 codes associated with the disease are also listed. The trial involves testing different doses of the drug and a placebo. The eligibility criteria for participants are listed, including the duration and severity of the dry eye symptoms, as well as exclusion criteria such as the use of other ocular medications or contact lenses. Female patients who are pregnant or breastfeeding are also excluded.",
    "The sample is a phase 2 clinical trial for Alzheimer's disease. The trial includes patients who meet the National Institute of Neurological and Communicative Diseases and Stroke/Alzheimer's Disease and Related Disorders Association (NINCDS-ADRDA) criteria for Alzheimer's disease and have a mild to moderate Alzheimer's disease status. The patients must also have a permanent caregiver who is willing to attend all visits and oversee the subject's compliance with protocol-specified procedures and study medication. The trial excludes patients with claustrophobia, those who are unable to lie comfortably on a bed inside a PET camera for at least 60 minutes, and those with other neurological or medical conditions that may influence the outcome or analysis of the PET scan results. Patients with a history of Type I or Type II diabetes mellitus or moderate congestive heart failure are also excluded.",
    "The sample is a record of a clinical trial in phase 2 for advanced and metastatic breast cancer. The trial is testing the effectiveness of the drug fulvestrant as a hormonal treatment for postmenopausal women who have not responded to previous anti-estrogen hormonal treatments such as tamoxifen or an aromatase inhibitor. The eligibility criteria for the trial include having breast cancer that has continued to grow despite previous treatment with anti-estrogen hormonal therapy, requiring hormonal treatment, and being postmenopausal. The exclusion criteria include having received more than one previous regimen of systemic anticancer therapy other than endocrine therapy for advanced breast cancer, having received more than one previous regimen of endocrine therapy for advanced breast cancer, and having an existing condition that prevents compliance. The diseases being studied are advanced and metastatic breast cancer, and the icd-10 codes associated with these diseases are listed.",
    "The sample is a phase 2 clinical trial for the treatment of malignant lymphoma. The trial is focused on patients with verified follicular lymphoma grade 1 or 2, with only nodal involvement and a largest tumor size of 7 cm or less. The drug being tested is rituximab. The eligibility criteria for the trial include adequate bone marrow reserves, while exclusion criteria include ECOG >2, follicular lymphoma grade 3, buky disease (>7 cm), involvement of the spleen, neoplasia in PMH (except: basalioma, spinalioma), immunodeficiency syndromes, viral hepatitis, connective tissue disease, severe psychiatric disease, pregnancy or breast feeding, and known allergies against foreign proteins.",
    "The sample is a phase 2 clinical trial for ovarian cancer, fallopian tube neoplasms, and peritoneal neoplasm. The trial involves the drugs enzastaurin, carboplatin, paclitaxel, and a placebo. The eligibility criteria include specific stages of disease, certain organ function requirements, and written consent. Exclusion criteria include recent experimental drug use, prior chemotherapy or other drug therapy for the current disease, and inability to discontinue certain medications. Participants who are pregnant, breastfeeding, or not using adequate contraceptive methods are also excluded.",
    "The sample is a phase 2 clinical trial that focuses on cancer and pain. The trial includes patients who have controlled baseline pain and experience predictable, treatment-related pain every day that is severe or episodes of breakthrough pain that are responsive to short-acting oral opioids. The patients must be able to hold a volume of 1.0cc of water under their tongue for a 2-minute period, provide written informed consent, fill out study forms, and be inpatients. However, patients with severe underlying respiratory disease, prior sensitivity to methadone, currently being administered methadone, clinically unstable, or have a life expectancy of less than one month are excluded from the trial. Additionally, patients who do not understand English sufficiently to provide written informed consent are also excluded.",
    "The sample is a phase 2 clinical trial for essential hypertension. The trial includes a list of icd-10 codes for the disease and a list of drugs being tested, including a placebo and various doses of azilsartan and candesartan cilexetil. The eligibility criteria for the trial include having mild to moderate uncomplicated essential hypertension with specific blood pressure readings, and not having certain cardiovascular diseases or symptoms, not having been treated with more than 3 different antihypertensives within 27 days prior to the trial, and not having significant hepatic disorder, hyperkalemia, malignant tumor or significant renal impairment.",
    "The sample is a phase 2 clinical trial for rheumatoid arthritis. The trial includes patients who are at least 18 years old and have had RA for at least 6 months. The patients must have active disease despite treatment with MTX and meet certain criteria for swollen and tender joints and CRP levels. The trial excludes patients with other inflammatory joint diseases, previous or concurrent treatment with certain biological compounds or DMARDs, recent participation in other clinical trials, and certain medical conditions or organ dysfunction. Patients must also not have a history of active or latent tuberculosis, major infection, or known hypersensitivity to atacicept or its components.",
    "The sample is a phase 2 clinical trial for patients with coronary artery disease (CAD). The trial involves the use of two drugs, m118 and unfractionated heparin, and requires patients to meet certain eligibility criteria, such as having a stable CAD with a significant lesion in a native coronary artery amenable to PCI with one stent and planned single vessel intervention. The trial also has exclusion criteria, such as recent myocardial infarction or unstable angina, target lesion with angiographically visible thrombus or in-stent thrombosis, and known allergies or sensitivities to heparin, pork, or pork-containing products. Additionally, there is a substudy included in the trial that requires participants to provide blood specimens.",
    "The sample is a phase 2 clinical trial for the treatment of head and neck cancer using the drug oxaliplatin. The trial includes patients with histologically or cytologically confirmed diagnosis of squamous cell carcinoma of the head and neck region, with certain high-risk features in the resected tumor. Radiation must begin within 28 to 56 days after surgical resection. Patients must be 18 years of age or older and have a Zubrod performance of 0-2. Exclusion criteria include distant metastatic disease, prior therapy with oxaliplatin, active or uncontrolled infection, recent myocardial infection, unstable angina, life-threatening arrhythmia, severe psychiatric disorder, and other prior malignancy except for certain exceptions. The trial has specific inclusion and exclusion criteria for patient eligibility.",
    "This is a sample entry in a clinical trial table. The trial is in phase 2 and is focused on the disease multiple sclerosis. The icd-10 codes associated with the disease are \"G35\" and \"C81.18\". The drug being tested is Polyphenon E. The eligibility criteria for participants include a diagnosis of MS by McDonald criteria, relapsing-remitting MS or secondary progressive MS, stable therapy with Copaxone, Rebif, Betaseron or Avonex 30 mcg for at least six months, EDSS Score less than or equal to 7.0, ages 18-60, and normal organ and marrow function. There are also exclusion criteria, such as MS relapse within the 30 days prior to enrollment, a primary progressive form of MS, and a history of renal or liver disease.",
    "The sample is a phase 2 clinical trial for the treatment of myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms using the drug amifostine trihydrate. The trial is open to patients between the ages of 1 and 21 who have not received prior treatment for MDS and have a life expectancy of at least 8 weeks. Patients must also meet certain eligibility criteria related to their disease characteristics, age, performance status, hematopoietic, hepatic, renal, and other factors. Prior concurrent therapy with growth factors, hematopoietic stem cell transplantation, immunomodulating agents, anticancer chemotherapy, daily steroid therapy, or therapy for MDS is not allowed.",
    "The sample is a phase 2 clinical trial for small cell lung cancer. The trial involves the use of bevacizumab, chemotherapy, and placebo drugs. The eligibility criteria for the trial include having histologically or cytologically documented small cell carcinoma of the bronchus, classified as extensive-stage disease, measurable disease or lesions, and an Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2. Exclusion criteria include having a life expectancy of less than 12 weeks, current or planned participation in another experimental drug study, ongoing or active infection, and inadequate bone marrow function, renal function, or hepatic function. Other exclusion criteria include having a history of hypertensive crisis or hypertensive encephalopathy, New York Heart Association Class II or greater congestive heart failure, and a history of stroke or transient ischemic attack within 6 months prior to study enrollment. Additionally, pregnant or lactating individuals are not eligible for the trial.",
    "The sample is a phase 2 clinical trial for patients with mantle cell lymphoma. The trial requires patients to have achieved at least a partial remission following induction chemotherapy and have an HLA-matched donor available. The trial also requires patients to meet certain criteria, including having a performance status of 2-4, no central nervous system involvement, and no serious concurrent disease that would preclude allograft. Patients must also have certain laboratory values within normal limits and not have a history of certain illnesses or conditions. The trial involves the use of four drugs: carmustine, cytarabine, etoposide, and melphalan.",
    "The sample is a phase 2 clinical trial for the treatment of breast cancer with metastasis. The trial involves the use of the drugs dasatinib and dasatinib. The eligibility criteria for the trial include being a female aged 18 or older, having recurrent or progressive locally advanced or 'triple negative' metastatic breast cancer, having measurable disease, and having received prior chemotherapy with an anthracycline, a taxane, or both. The trial also requires the availability of a paraffin-embedded tissue block and adequate organ function. Exclusion criteria include having metastatic disease confined to bone only, symptomatic CNS metastasis, concurrent medical conditions that may increase the risk of toxicity, and being unable to take oral medication.",
    "The sample is a phase 2 clinical trial for the treatment of chronic myeloproliferative disorders and secondary myelofibrosis using the drug Dacogen. The trial requires patients to have confirmed primary myelofibrosis or post essential thrombocythemic or polycythemic vera myelofibrosis with reticulin fibrosis grade 1 or higher. Patients must also have symptomatic disease with anemia, palpable and symptomatic splenomegaly, or severe disease-related constitutional symptoms. Patients must meet certain criteria including having an ECOG performance status of 0-3, ANC \u2265 1,000/mm\u00b3, platelet count \u2265 50,000/mm\u00b3, and no serious medical condition or psychiatric illness that would preclude signing the informed consent. Patients must not be pregnant or nursing, and fertile patients must use effective contraception. The trial excludes patients with other concurrent chemotherapy or experimental therapy.",
    "The sample is a phase 2 clinical trial for type 2 diabetes mellitus. The trial includes participants who have been diagnosed with T2DM for at least 1 year and have been treated with neutral protamine hagedorn (NPH) or insulin glargine for at least 3 months at a stable dose. Participants must also have a stable dose of metformin with or without dipeptidyl peptidase 4 (DPP-4) inhibitor or sulfonylurea. The trial aims to test the efficacy of lixisenatide (ave0010), liraglutide, insulin glargine, and metformin in managing T2DM. The inclusion criteria also require participants to have a glycosylated hemoglobin (HbA1c) level between 6.5 and 9.5% and a body mass index (BMI) between 20 and 40 kg/m^2. Exclusion criteria include pregnant or breastfeeding women, individuals with a history of gastrointestinal disease, and those with a personal or family history of medullary thyroid cancer (MTC) or a genetic condition that predisposes to MTC.",
    "The sample is a phase 2 trial for patients with either stable coronary artery disease or unstable angina. The trial involves the use of drugs such as argatroban and heparin, and requires patients to undergo elective percutaneous coronary angioplasty or stent insertion. The eligibility criteria include being over 18 years old, having a negative pregnancy test (for women of childbearing potential), and having a low to moderate anatomic risk. The exclusion criteria include having certain medical conditions, such as cirrhosis or hepatitis, and not currently taking aspirin. Patients must also provide signed written informed consent to participate in the trial.",
    "The sample is a phase 2 clinical trial for Parkinson's disease. The eligibility criteria include a diagnosis of Parkinson's disease, being in Hoen and Yahr stage 1-3, being on a stable dose of anti-Parkinson's treatment for 30 days prior to screening, being between the ages of 40 and 75, signing an IRB approved informed consent, agreeing to use adequate birth control, having ECG measurements within normal limits, and being able to understand study requirements. Exclusion criteria include having secondary Parkinson's, receiving treatment with other investigational drugs 30 days prior to study entry, using disallowed medications, having significant neurological illness other than Parkinson's, having an IQ less than 70 on an IQ test, having a MMSE score less than or equal to 23, having a history of psychosis or being on anti-psychotic medication, having a current serious medical illness, having a history of substance abuse, having a history of head injury with loss of consciousness, having a history of brain surgery, having contraindications to MRI like claustrophobia, metal implants or other implantable devices, having abnormal liver function tests and/or hepatitis or cholangitis, having Gilbert's disease, being pregnant or nursing, and having known hypersensitivity to SYN115. The drugs being tested are placebo and tozadenant.",
    "The sample is a phase 2 clinical trial for patients with high-risk/limited stage III or IV squamous cell carcinoma of the oral cavity, oropharynx, hypopharynx, and larynx. The trial is testing the effectiveness of the drug cisplatin in combination with Ad5CMV-p53 gene administration. Patients must meet certain eligibility criteria, including being newly diagnosed, previously untreated, and considered surgically resectable. They must also have evidence of regional lymph node metastases but no distant metastases. Patients must be at least 18 years old and have certain hematopoietic, hepatic, and renal function levels. They must not have any other malignancy within the past 5 years except for certain types of cancer in complete remission. Patients must use effective barrier contraception and prevent bodily fluid transmission during and for 28 days after Ad5CMV-p53 gene administration. The sample does not specify any prior concurrent therapy.",
    "The sample is a phase 2 clinical trial for pancreatic cancer and ductal adrenocarcinoma using the drugs PCI-27483 and gemcitabine. The trial has specific eligibility criteria, including a diagnosis of metastatic or locally advanced ductal adenocarcinoma of the pancreas within a certain timeframe, measurable disease by spiral CT scan, and an estimated life expectancy of at least 4 months. There are also exclusion criteria, such as a history of brain metastases, uncontrolled hypertension, and laboratory abnormalities. Participants must provide written informed consent and agree to not participate in contact sports or strenuous activity while taking PCI-27483.",
    "The sample is a phase 2 clinical trial for attention-deficit/hyperactivity disorder (ADHD) using drugs such as abt-894, atomoxetine, and placebo. The trial has eligibility criteria for participants, including being between 18 and 60 years old, fluent in English, and in generally good health. Exclusion criteria include having certain mental health diagnoses, requiring ongoing treatment with certain medications, and having a history of substance or alcohol disorder. The trial aims to test the effectiveness of the drugs on ADHD symptoms.",
    "The sample is a record of a clinical trial in phase 2 for the treatment of prostate cancer using the drug polyphenon e (egcg). The trial requires participants to have recently tested positive for prostate cancer and be scheduled for prostatectomy. Inclusion criteria also include being able to swallow capsules, having a palpable mass by digital rectal examination, being between the ages of 18 and 75, and being willing to adhere to the study protocol. Exclusion criteria include abnormal liver function, prior hormonal or surgical therapy for prostate cancer, liver or kidney problems that would interfere with metabolism of the study drug, any condition that would hamper informed consent or ability to comply with the study protocol, participation in another research study in the last three months, known malignancy at any site other than prostate, and recent consumption of green tea (5 or more cups per day, within one week prior to biopsy). The record also includes the ICD-10 codes associated with the disease and the eligibility criteria for the trial.",
    "The sample is a phase 2 clinical trial for colorectal neoplasms. The trial involves the use of four drugs - bevacizumab, oxaliplatin, capecitabine, and irinotecan. The eligibility criteria for the trial include a pathological diagnosis of colon or rectal cancer, evidence of adequate organ function, and exclusion criteria such as a diagnosis of anal cancer, previous treatments, and pregnancy or lactation. Patients who are candidates for surgery or have a history of chronic diseases or other serious medical conditions are also excluded from the trial.",
    "The sample is a phase 2 clinical trial for patients with relapsed or refractory classical Hodgkin lymphoma. The trial is testing the drug PLX3397. The eligibility criteria include being at least 18 years old, having confirmed Hodgkin lymphoma, having measurable disease, and having discontinued previous treatments. Patients must also have adequate hematologic, hepatic, and renal function, and be willing to provide informed consent. Exclusion criteria include having an active or uncontrolled infection, serious illnesses or medical conditions, and being pregnant or breastfeeding. The trial is looking to evaluate the safety and efficacy of PLX3397 in treating relapsed or refractory Hodgkin lymphoma.",
    "The sample is a phase 2 clinical trial for patients with rectal cancer. The trial involves the use of two drugs, avastin and capecitabine. The eligibility criteria include having a confirmed diagnosis of adenocarcinoma of the rectum, being between the ages of 18 and 75, having no distant metastatic disease, and meeting certain laboratory values. Exclusion criteria include having compromised renal or hepatic function, participating in any other experimental drug study, and having any prior chemotherapy or radiation therapy. Patients must also agree to continue contraception for 30 days from the date of the last study drug administration.",
    "This sample is a record of a clinical trial in phase 2, focused on the disease of coronary artery disease. The icd-10 codes associated with this disease are listed as I25.10, I25.110, I25.119, I25.111, and I25.118. The trial involves the use of two drugs, cangrelor and prasugrel. The eligibility criteria for participants include being between the ages of 18 and 75, having stable coronary artery disease, and having previously experienced a myocardial infarction or undergone revascularization by percutaneous coronary intervention or coronary artery bypass graft. Additionally, participants must be receiving treatment with aspirin at a dose of 81 mg daily.",
    "The sample is a phase 2 clinical trial for the treatment of chronic obstructive pulmonary disease (COPD). The trial is testing the effectiveness of a drug called gsk256066 compared to a placebo. The trial is open to male and female adults between the ages of 40 and 75 who have a clinical diagnosis of COPD and a smoking history of at least 10 pack years. Participants must also have a post-bronchodilator FEV1 to FVC ratio of less than 0.7 and a post-bronchodilator FEV1 between 50% and 80% of predicted normal for their height, age, and sex. Participants must not have certain medical conditions or be taking certain medications. The trial has both inclusion and exclusion criteria, which are detailed in the sample.",
    "The sample is a phase 2 clinical trial for patients with non-small cell lung cancer and metastatic cancer. The trial involves the use of chemotherapy and porfimer sodium as treatment options. Eligibility criteria include having histologically confirmed NSCLC with evidence of pleural spread, being medically fit for surgery, and not having received prior treatment for NSCLC except for pleurodesis or standard front-line chemotherapy. Patients must also not have CTCAE v3.0 grade III-IV elevations in liver transaminases, bilirubin levels must be \u2264 1.5 mg/dL, and they must not have known HIV infection or be pregnant or nursing. Prior concurrent therapy is not allowed, except for pleurodesis or standard front-line chemotherapy. Post-operative radiotherapy will be administered as clinically indicated.",
    "The sample is a phase 2 clinical trial for the treatment of schizophrenia. The trial includes patients who have been diagnosed with schizophrenia and are currently being treated with a stable regimen of certain antipsychotic drugs. The patients must also have specific cognitive impairment and can be smokers or non-smokers. However, patients who have been treated with certain medications or have a history of neuroleptic malignant syndrome or substance abuse are excluded from the trial. Additionally, patients who have scored 4 or 5 on the Suicidal Ideation item or any \"yes\" on the Suicidal Behavior item of the CSSR-S related to suicidal behavior occurring during the last 2 years are also excluded. Other protocol-defined inclusion/exclusion criteria may also apply.",
    "The sample is a phase 2 clinical trial for women over 18 years old with HER2 positive breast cancer that is non-operable, locally advanced, or metastatic. The trial involves the use of vinorelbine, capecitabine, and trastuzumab drugs. The eligibility criteria include having measurable or non-measurable disease, disease progression during or after treatment with trastuzumab and taxanes, and a maximum of one previous chemotherapy line for advanced or metastatic disease. Other criteria include having a life expectancy of at least 12 weeks, meeting certain hematology and hepatic function requirements, and being able to comply with treatment and follow-up. Exclusion criteria include a history of hypersensitivity to the drugs used in the trial, active infection, and other serious medical pathologies.",
    "This sample is from a clinical trial in phase 2 that focuses on lower urinary tract symptoms. The trial includes men who are 18 years or older and can speak, read, and understand English. The participants must be willing to participate in the study and sign an informed consent document. However, individuals who are currently employed by certain companies related to healthcare or medicine are excluded from the trial. The trial involves the use of tamsulosin as a drug. The icd-10 codes associated with the disease are also provided.",
    "The sample is a phase 2 clinical trial for chronic obstructive pulmonary disease (COPD). The trial includes male or postmenopausal females between the ages of 40-75 who have documented COPD defined by clinical history and spirometry, with symptoms including dyspnea, wheezing, chest tightness, cough, sputum production, or nocturnal awakening. The trial excludes individuals with impaired renal function, history of chronic liver disease or persistent liver function test (LFT) abnormalities, history of recent cardiovascular clinical event, or evidence of another clinically significant, active pulmonary disorder such as bronchiectasis or asthma. The trial will test the effectiveness of the drug MK633 compared to a placebo.",
    "This sample is a phase 2 clinical trial for gastrointestinal stromal tumors. The trial is looking at the effectiveness of imatinib mesylate as a treatment option. The eligibility criteria for the trial includes patients between the ages of 18 and 80 who have not previously been treated for GIST. Patients are eligible regardless of operability, but must have a tumor that cannot be optimally resected or would result in severe compromise to quality of life or other gastrointestinal functions. Patients with metastatic disease or who have received other antineoplastic treatments are excluded. Other protocol-defined inclusion/exclusion criteria may also apply.",
    "This sample is a phase 2 clinical trial for patients with diffuse large B-cell lymphoma. The trial is testing the effectiveness of a combination of drugs including cyclophosphamide, doxorubicin hydrochloride, prednisone, and vincristine sulfate. Patients must meet certain eligibility criteria, including having confirmed B-cell lymphoma, measurable disease, and a certain level of performance status. They must also not have received prior therapy for diffuse large B-cell lymphoma and cannot be enrolled in any other treatment studies involving pharmacologic agents. The trial requires patients to provide blood and tissue samples for mandatory translational research.",
    "The sample is a phase 2 clinical trial for various types of leukemia and myelodysplastic syndrome. The trial includes patients with confirmed diagnoses of MDS, CMMoL, and AML-TLD, and patients must have a white blood cell count of less than or equal to 30,000/mm^3. Patients must not have received any AML induction chemotherapy or stem cell transplantation within three weeks prior to registration, and should have recovered from all toxicities of prior therapy. Patients must also have no clinical evidence of central nervous system or pulmonary leukostasis, disseminated intravascular coagulation, or CNS leukemia. The trial will test the effectiveness of the drugs azacitidine and entinostat. The eligibility criteria include various medical tests and assessments, and patients must have a life expectancy of at least six months. The trial is being conducted by the Southwest Oncology Group and requires the submission of pretreatment bone marrow specimens to a SWOG-approved cytogenetics laboratory.",
    "The sample is a record of a clinical trial in phase 2 for the treatment of non-small-cell lung carcinoma. The trial involves the use of drugs such as erlotinib, sunitinib, and placebo. The eligibility criteria for the trial include having locally advanced or metastatic non-small cell lung cancer and having received no more than two chemotherapy regimens, including a platinum-based regimen. Patients with a history of brain metastases or prior treatment with receptor tyrosine kinase inhibitors, Vascular endothelial growth factor (VEGF) inhibitors, or other angiogenic inhibitors are excluded from the trial.",
    "The sample is a phase 2 clinical trial for non-small cell lung cancer. The trial involves the use of temozolomide and radiotherapy as treatment. The eligibility criteria include having measurable brain disease, no previous or current malignancies except for certain types, being over 18 years old, having a Karnofsky Performance status of at least 70%, and meeting certain blood count and liver function requirements. The patient must not have systemic disease that requires immediate chemotherapy and must not be pregnant or nursing. The trial has exclusion criteria such as recent chemotherapy or biologic therapy, recent brain radiation therapy, and certain medical conditions that may affect compliance with the protocol.",
    "The sample is a record of a clinical trial with a phase 2 designation. The trial is focused on the treatment of hepatitis C, with a list of associated ICD-10 codes. The trial involves several drugs, including vaniprevir, pegylated-interferon, ribavirin, and a placebo. The eligibility criteria for the trial include having chronic genotype 1 hepatitis C infection, while exclusion criteria include previous treatment for HCV, HIV, hepatitis B, and certain medical conditions that may interfere with the study or are contraindicated for treatment with peg-IFN and Ribavirin.",
    "The sample is a phase 2 clinical trial for individuals with type 2 diabetes mellitus. The trial includes eligibility criteria such as age, body mass index, HbA1c levels, serum creatinine concentration, fasting glucose concentration, stable body weight, and absence of certain medical conditions. The trial also excludes individuals with certain medical conditions, allergies to study treatment, current drug or alcohol abuse, and those who have undergone certain surgeries or treatments. The trial involves the use of metformin and a placebo, and participants must be willing and able to follow study procedures and comply with protocol requirements.",
    "The sample is a phase 2 clinical trial for cervical cancer and cervical intraepithelial neoplasia grade 1, as well as human papilloma virus infection. The trial is testing the effectiveness of a placebo drug. The eligibility criteria for participants include having confirmed CIN 1 and HPV positivity, being at increased risk for developing cervical cancer, having cervical dysplasia or a positive biopsy, and meeting various health requirements such as having a normal AST and ALT, and not having any uncontrolled illnesses or psychiatric conditions that would limit compliance with the study requirements. Participants must also not have a history of any cancer except nonmelanoma skin cancer, not be pregnant or nursing, and must use effective contraception if fertile. They must not have had regular intake of 6 or more servings of tea per week within 1 month prior to study entry, and must not have had treatment for genital condyloma within 30 days prior to study entry. They must also not have had prior pelvic irradiation or be taking any other concurrent investigational agents.",
    "The sample is a record of a clinical trial in phase 2 for the treatment of psoriasis vulgaris. The trial involves the use of drugs such as ct327 in varying concentrations and a placebo. The eligibility criteria for the trial include being at least 18 years old and having stable psoriasis vulgaris, while exclusion criteria include having other forms of psoriasis such as guttate, erythrodermic, exfoliative or pustular psoriasis.",
    "The sample is a record of a clinical trial in phase 2 for the treatment of rheumatoid arthritis. The trial involves the use of drugs such as methotrexate, rituximab, corticosteroids, and placebo. The eligibility criteria for the trial include being between the ages of 18 and 80 years, having been diagnosed with rheumatoid arthritis for at least 6 months, and having failed treatment with at least 1 but no more than 5 disease-modifying anti-rheumatic drugs or biologics (other than methotrexate). The icd-10 codes associated with the disease are also provided.",
    "The sample is a phase 2 clinical trial for the treatment of Non-Hodgkin's lymphoma of B-cell origin. The trial includes patients of all stages of the disease who have measurable or evaluable tumor parameters and are over 17 years old with a Karnofsky performance status greater than or equal to 50%. The trial also requires patients to have certain blood and organ function levels within normal ranges. Concurrent radiation therapy with or without steroids for emergency conditions is permitted. Patients must agree to use adequate birth control during the therapy and for 3 months after completion. Exclusion criteria include prior systemic cytotoxic therapy or radiation therapy for lymphoma, second active tumor, HIV seropositive, primary CNS lymphoma, pregnant or nursing women, and those unable to comply with the requirements of the protocol or provide adequate informed consent.",
    "The sample is a phase 2 trial for the treatment of Waldenstrom macroglobulinemia, a type of cancer. The trial includes patients who have been previously treated for the disease and have measurable levels of monoclonal IgM. The treatment involves a combination of drugs including thalidomide, lenalidomide, and rituximab. Patients must meet certain eligibility criteria, including having a confirmed diagnosis of WM, active disease requiring therapy, and meeting certain laboratory test results. They must also be willing to comply with the study visit schedule and other protocol requirements. Exclusion criteria include serious medical conditions, concurrent use of other anti-cancer agents or treatments, and pregnancy or breastfeeding.",
    "The sample is a phase 2 clinical trial for non-alcoholic steatohepatitis. The trial includes a list of icd-10 codes for the disease and a list of drugs, including asp9831 and placebo. The eligibility criteria for the trial include a histologically confirmed diagnosis of NASH within the past year, elevated serum ALT levels, and exclusion criteria such as hepatic cirrhosis, uncontrolled diabetes mellitus type 2, excessive alcohol abuse, and recent use of drugs associated with steatohepatitis.",
    "The sample is a phase 2 trial that focuses on hand-foot skin reaction and rash. The trial involves the use of drugs such as urea 40% cream, fluocinonide 0.05% cream, tazarotene 0.1% cream, and bland emollient cream (udderly smooth\u00ae udder cream). The eligibility criteria for the trial include patients receiving sorafenib as monotherapy or in combination with other agents that are not known to cause HFSR, patients who are 18 years or older, and patients who provide written informed consent to participate in the study. Women of childbearing potential and men must be willing to use an effective method of contraception while participating in this study and for at least two weeks after completing treatment in the study. Women in this study need to have a negative urine pregnancy test before starting study medications. The exclusion criteria include patients simultaneously taking another anti-cancer agent or combination of anti-cancer agents known to cause hand foot syndrome, patients with an active dermatological condition due to previous chemotherapy or biologic therapy affecting the hands, patients with pre-existing dermatological condition affecting the hands or feet, and women who have a positive pregnancy test or are lactating.",
    "The sample is a phase 2 trial for menopausal and female climacteric states. The eligibility criteria include being a postmenopausal woman aged 40 to 65 years old, having a minimum average frequency of seven daily moderate to extremely severe hot flashes or episodes of night sweats, and having a BMI within the range of 19 to 35 kg/m2. The exclusion criteria include having a history of uterine or breast cancer, cardiovascular conditions, hepatobiliary disease or hepatic enzyme elevation, abnormal thyroid function, or any other medical condition that may affect the interpretation of efficacy or safety data. The trial involves the use of drugs such as GSK232802 and Premarin, as well as a placebo.",
    "The sample is a phase 2 clinical trial for the treatment of tardive dyskinesia in patients with schizophrenia or schizoaffective disorder. The trial involves the use of the drugs nbi-98854 and placebo, and the eligibility criteria includes having a stable dose of antipsychotic medication for at least 30 days prior to the study, being in good general health, having a BMI between 18 and 38 kg/m2, and having a negative urine drug screen and alcohol breath test. Exclusion criteria includes having a history of substance dependence or abuse, receiving medication for the treatment of tardive dyskinesia, and having an allergy or intolerance to tetrabenazine.",
    "The sample is a phase 2 clinical trial for the treatment of metastatic renal cell carcinoma using the drug foretinib (formerly known as GSK1363089 or XL880). The trial is looking for patients with a confirmed diagnosis of PRC with measurable disease and an ECOG performance status of 2 or less. Patients must also have adequate bone marrow reserve, hepatic, renal, and cardiovascular function. Exclusion criteria include prior treatment with a c-met inhibitor, brain metastases, uncontrolled intercurrent illness, pregnancy or breastfeeding, and being HIV positive. The diseases are listed as 'carcinoma, renal cell' and the icd-10 codes are provided as well.",
    "The sample is a phase 2 clinical trial for men aged 18 or older with clinically localized prostate cancer prior to radical prostatectomy. The trial involves the use of goserelin with dutasteride, goserelin with bicalutamide and dutasteride, and goserelin with bicalutamide and dutasteride and ketoconazole. The eligibility criteria include having a PSA less than 20, a Gleason score of 7-10, and a life expectancy greater than 2 years. Exclusion criteria include patients with locally advanced or high-risk disease, patients with an active serious infection or other serious underlying medical condition, and patients with a history of cerebrovascular accident, deep venous thrombosis, pulmonary emboli, unstable angina, or clinical congestive heart failure. Patients must also be willing to use contraceptives while on the study.",
    "The sample is a phase 2 clinical trial for various types of liver and bile duct cancers, including hepatocellular carcinoma, cholangiocellular carcinoma, and gallbladder cancer. The trial involves the use of three drugs: cisplatin, erlotinib, and gemcitabine. The eligibility criteria for the trial include having measurable disease, being 18 years or older, having a certain level of bone marrow and renal function, and having a life expectancy of at least 12 weeks. Patients must also have recovered from any prior surgeries or therapies. Exclusion criteria include having an active infection or fever, active central nervous system metastases, or a history of certain types of malignancies. Patients must also not have received certain types of prior treatments or have certain medical conditions.",
    "The sample is a phase 2 clinical trial for patients with Hodgkin's Lymphoma. The trial is testing the effectiveness of the drug resminostat (4sc-201) on patients who have relapsed or refractory Hodgkin's Lymphoma. The eligibility criteria include having measurable anatomical disease present on CT scan, an ECOG Performance Score of 0, 1 or 2, and having undergone high-dose chemotherapy with autologous stem cell transplantation at least 12 weeks prior to study entry. Exclusion criteria include previous treatment with an HDAC inhibitor, allogeneic hematopoietic stem cell transplantation, and known or suspected involvement of the CNS by HL. Patients with a history of other malignancies, significant cardiovascular, neurological, endocrine, gastrointestinal, respiratory or inflammatory illness that could preclude their participation in the trial are also excluded.",
    "The sample is a phase 2 clinical trial for patients with metastatic or unresectable clear cell renal carcinoma. The trial involves the use of two drugs, decitabine and interferon alfa-2b. Patients must have received up to two prior anti-cancer therapies but no prior chemotherapy for renal cell carcinoma. They must also have measurable or clinically evaluable disease as defined by RECIST criteria and must have recovered from the toxicities of prior therapy. Patients must meet certain eligibility criteria, including having adequate organ and marrow function, being at least 18 years old, and having an ECOG performance status of 2 or less. Patients with active autoimmune disorders or who are receiving immunosuppressive therapy are excluded from the trial, as are patients with untreated or symptomatic brain metastases, uncontrolled intercurrent illness, or psychiatric illness or social situations that could interfere with treatment. Pregnant women and patients known to be HIV-positive and receiving anti-retroviral therapy are also excluded.",
    "The sample is a phase 2 clinical trial for the treatment of metastatic ocular melanoma using the drug imatinib. The trial is looking for patients who are at least 18 years old, have measurable metastases of at least 10mm according to RECIST criteria, have normal hepatic function, and meet other eligibility criteria. Patients who have had two prior lines of systemic treatment, have other evolutive neoplasic disease, severe hepatic or renal insufficiency, or other somatic or psychiatric co-morbidity are excluded from the trial. The sample also includes a list of diseases and their corresponding ICD-10 codes.",
    "The sample is a phase 2 clinical trial for non-small cell lung cancer. The trial involves the use of bevacizumab, oxaliplatin, and pemetrexed as drugs. The eligibility criteria for the trial include having histologically documented Stage IIIB/IV non-squamous cell NSCLC, an ECOG Performance Status of 0 or 1, being over 18 years of age, and meeting certain medical criteria such as having white blood cell count, platelets, and hemoglobin within certain ranges. Patients must also not have received prior chemotherapy or biologic therapy for non-squamous NSCLC, have certain medical conditions, or be pregnant or lactating. The trial also has exclusion criteria, such as having brain metastases or leptomeningeal disease, or having peripheral neuropathy greater than grade 1.",
    "The sample is a phase 2 clinical trial for the treatment of Major Depressive Disorder. The trial includes patients with comorbid Generalized Anxiety Disorder, Social Anxiety Disorder, or Panic Disorder if MDD is considered the primary diagnosis. The inclusion criteria require a diagnosis of MDD, a Hamilton Depression Rating Scale (HDRS17) total score of at least 18, a HDRS17 anxiety/somatization factor score of at least 7, and currently receiving an antidepressant. The exclusion criteria include having other psychiatric conditions, a length of current Major Depressive Episode (MDE) longer than 6 months, a current or recent history of clinically significant suicidal ideation or behavior, and having more than 1 failed antidepressant treatment of adequate dose and duration in the current MDE, excluding inadequate response to the current antidepressant. The trial will test the efficacy of two drugs, jnj-40411813 and placebo.",
    "The sample is a phase 2 clinical trial for breast cancer patients who are HER2 negative. The trial is testing the effectiveness of the drugs ym155 and docetaxel. The eligibility criteria include having no prior chemotherapy for metastatic breast cancer, an ECOG performance status of \u2264 1, and a life expectancy of > 12 weeks. Exclusion criteria include hypersensitivity to docetaxel or polysorbate 80, neuropathy \u2265 Grade 2, and known brain or leptomeningeal metastasis. The trial also requires sexually active subjects of childbearing potential to use contraception throughout the study period.",
    "This is a sample from a table that contains information about clinical trials. The trial is in phase 2 and is focused on breast cancer. The icd-10 codes associated with the disease are listed. The drug being studied is anastrozole. The eligibility criteria for the trial are listed, including age requirements, specific characteristics of the breast cancer, and previous treatment with chemotherapy. There are also exclusion criteria, such as having had surgical removal of the ovaries or taking certain medications.",
    "The sample is a phase 2 clinical trial for the treatment of type 1 diabetes mellitus using a drug called bi 10773. The trial is looking for male or female subjects who are 18 years or older and have been diagnosed with type 1 diabetes mellitus. The subjects must have a glycated hemoglobin (HbA1C) level between 6.5% and 11.0% and an estimated glomerular filtration rate (eGFR) greater than or equal to 60 ml/min/1.73m\u00b2 at screening. They must also be experienced insulin pump users or be on multiple daily injections of any type of insulin. The trial has exclusion criteria, which include evidence of macroalbuminuria or leukocyte positive urinalysis at screening, treatment with any other drugs to reduce blood glucose other than insulin, and history of macrovascular disease or any other disease that would interfere with trial participation or jeopardize subject safety or study compliance based on investigator judgement.",
    "The sample is a phase 2 clinical trial for breast cancer patients with metastatic disease. The trial involves the use of four drugs - anastrozole, exemestane, letrozole, and sorafenib tosylate. The eligibility criteria include confirmation of adenocarcinoma of the breast, measurable disease, objective evidence of progression within the past 3 months, and hormone receptor-positive disease. Patients must also meet certain patient characteristics such as being postmenopausal, having a certain hemoglobin level, and having no significant cardiac disease. Prior concurrent therapy is also taken into consideration. The trial excludes patients with certain medical conditions and those with known allergies to the drugs used in the study.",
    "The sample is a record of a clinical trial with a phase 2 designation. The trial is focused on the treatment of paranoid schizophrenia and schizophrenia. The trial involves the use of two drugs, mk0557 and a placebo (unspecified). The eligibility criteria for the trial include having a stable living arrangement, being in good health, and having a 6th grade reading level or better. Exclusion criteria include having a major disease or disorder that may interfere with cognitive testing, a history of head trauma, recent use of certain medications, and a history of alcohol or drug dependence.",
    "The sample is a record of a clinical trial for the treatment of gastric cancer. The trial is in phase 2/phase 3 and involves the use of two drugs, tegafur/gimeracil/oteracil potassium (s-1) and krestin (psk). The eligibility criteria for the trial include having unresectable advanced or recurrent gastric carcinoma, being 20 years or older, not having received prior treatment, and having certain laboratory values within normal ranges. Patients with certain medical conditions or who are taking certain medications are excluded from the trial. The sample also includes a list of disease names and icd-10 codes associated with the trial.",
    "The sample is a phase 2 clinical trial for asthma. The eligibility criteria include being diagnosed with asthma for at least 3 months, not receiving inhaled corticosteroids for control within 1 month of the study, having an increase in FEV1 of at least 12% and 200 cc over the pre-albuterol FEV1 within 30 minutes after inhalation of up to 4 puffs of albuterol via a metered dose inhaler, being a non-smoker for at least 6 months and in good health, having a negative pregnancy test (for female subjects), and being willing and able not to use inhaled bronchodilators for 6 hours before and until 24 hours after each study drug administration at all study visits. The exclusion criteria include having significant cardiopulmonary, renal, hepatic, endocrine, metabolic, neurological or other systemic disease, receiving emergency treatment for asthma within 1 month, or hospitalized for asthma within 3 months, having an upper or lower respiratory tract infection within 3 weeks, or sinus infection within 7 days, and having a history or evidence of drug or alcohol abuse within 2 years of study entry. The study drugs include mn-221 and placebo.",
    "The sample is a phase 2 trial for treating ovarian hyperstimulation syndrome. The trial includes pre-menopausal females between the ages of 21-37 years who have been infertile for at least 1 year before randomisation, except for proven bilateral tubal infertility. The trial involves the use of the drug norprolac. The eligibility criteria include being in good physical and mental health and signing an informed consent form prior to screening evaluations. The exclusion criteria include having any clinically significant systemic disease, endocrine or metabolic abnormalities, a history of recurrent miscarriage, or undiagnosed vaginal bleeding.",
    "The sample is a phase 2 clinical trial for age-related macular degeneration. The trial includes patients who are 50 years or older with active primary or recurrent subfoveal choroidal neovascularization (CNV) secondary to AMD. The trial involves the use of drugs such as 0.5 mg ranibizumab, 3 mg pf-04523655, and 1 mg pf-04523655. The eligibility criteria include specific visual acuity scores, total lesion size, and CNV area. The trial excludes patients who have undergone certain treatments or surgeries, have subretinal hemorrhage, or have CNV of other etiology.",
    "The sample is a phase 2 clinical trial for patients with prostate cancer. The trial is testing the effectiveness of the drug degarelix in treating the disease. The eligibility criteria for the trial include having histologically proven prostate cancer, a rising serum PSA level, and a serum testosterone level above 2.2 ng/mL. Patients must also have an ECOG P.S. score of 0 to 2 and a serum PSA level above 2 ng/mL. Exclusion criteria include previous or present endocrine treatment for prostate cancer, treatment with a 5\u03b1-reductase inhibitor, and being a candidate for curative therapy within 12 months. Patients with concurrent or a history of severe liver disease, abnormal ECG, or who have received ASP3550 in the past are also excluded. Additionally, patients who have been administered a drug in another clinical study or a post-market clinical study in the 28 days prior to the study are not eligible.",
    "The sample is a phase 2 clinical trial for chronic lymphocytic leukemia. The trial is testing the drug lenalidomide. The eligibility criteria for the trial include being over 18 years old, having a certain stage of CLL, and having specific risk factors. Participants must also have a life expectancy of at least 2 years and be willing to provide written informed consent. Exclusion criteria include having certain medical conditions or having participated in another clinical trial recently. The sample also includes a list of disease names and their corresponding ICD-10 codes.",
    "The sample is a phase 2 clinical trial for the treatment of ocular hypertension and open-angle glaucoma. The trial involves testing the efficacy of three different drugs, including ar-12286 ophthalmic solution 0.7%, ar-12286 ophthalmic solution 0.5%, and timolol maleate ophthalmic solution 0.5%. The eligibility criteria for participants include being 18 years of age or older, having a diagnosis of open-angle glaucoma or ocular hypertension, and having unmedicated intraocular pressure (IOP) levels of at least 24 mm Hg at two eligibility visits. Participants must also have corrected visual acuity of +1.0 logMAR or better in each eye and be willing to follow study instructions. Exclusion criteria include having a history of certain types of glaucoma, having an IOP level above 36 mm Hg, and having a known hypersensitivity to any component of the drug formulations. The trial also excludes participants who have had previous glaucoma intraocular surgery or refractive surgery in the study eye(s), or who have evidence of ocular infection or inflammation. Additionally, participants must not have any clinically significant abnormalities in laboratory tests or systemic diseases that might interfere with the study. Women of childbearing potential must have a negative urine pregnancy test result at the screening examination and must not intend to become pregnant during the study.",
    "The sample is a phase 2 clinical trial for the treatment of Waldenstrom macroglobulinemia, a type of lymphoma. The trial involves a combination of drugs including bortezomib, carmustine, cisplatin, cyclophosphamide, cytarabine, dexamethasone, doxorubicin hydrochloride, etoposide, melphalan, and thalidomide. The eligibility criteria for the trial include a diagnosis of Waldenstrom macroglobulinemia, measurable disease as determined by IgM protein quantification, and the presence of certain disease-related symptoms such as low hemoglobin or platelet count, marked tumor mass, or elevated beta-2-microglobulin. Patients must also meet certain patient characteristics such as having a Zubrod performance status of 0-2 and not being pregnant or nursing. Prior concurrent therapy is also taken into consideration.",
    "The sample is a phase 2 clinical trial for the treatment of Waldenstrom's macroglobulinemia, a type of cancer. The trial involves the use of two drugs, cc-5103 (lenalidomide) and rituximab. The eligibility criteria for the trial include a clinicopathological diagnosis of the disease, age 18 or older, CD20 positivity, measurable disease, and certain laboratory values within normal limits. Exclusion criteria include serious medical conditions, pregnancy or lactation, prior therapy with the drugs being tested, and concurrent use of other anti-cancer agents or treatments.",
    "The sample is a phase 2 clinical trial for patients with clear cell renal cell carcinoma, recurrent renal cell cancer, or stage IV renal cell cancer. The trial involves the drug tandutinib and has eligibility criteria such as having had a cytoreductive nephrectomy, measurable disease, and having received at least one prior FDA approved therapy for metastatic renal cell carcinoma. Exclusion criteria include having had chemotherapy or radiotherapy within 4 weeks prior to the study, ongoing vomiting or nausea, and uncontrolled intercurrent illness. The trial also requires patients to have a life expectancy of at least 3 months and an ECOG performance status of 0-1.",
    "The sample is a record of a clinical trial with a phase 2 designation. The trial is focused on chronic constipation and includes a list of ICD-10 codes associated with the disease. The trial involves the use of a drug called ati-7505 and has specific eligibility criteria for participants, including age, duration of constipation symptoms, and negative colonoscopy or air contrast barium enema within a certain timeframe. The sample also includes exclusion criteria, such as a history of certain medical conditions or drug use, abnormal ECG readings, and alcohol or drug abuse.",
    "The sample is a record of a clinical trial in phase 2, focused on the disease of neuralgia. The icd-10 codes associated with the disease are listed as \"G50.0\", \"M54.81\", \"B02.22\", and \"M79.2\". The trial involves two drugs, \"agn201781\" and \"placebo\". The eligibility criteria for the trial include a diagnosis of postherpetic neuralgia or post-traumatic peripheral neuralgia, as well as moderate or severe pain associated with those conditions. Women of child-bearing potential and those with uncontrolled diseases are excluded from the trial.",
    "The sample is a record from a clinical trial table that includes information about the phase of the trial, the disease being studied (in this case, prostate cancer), the ICD-10 codes associated with the disease, the drug being tested (celecoxib), and the eligibility criteria for participants. The eligibility criteria include specific requirements related to the diagnosis and progression of prostate cancer, as well as exclusion criteria such as prior hormonal or chemotherapy treatment, allergies to certain medications, and certain medical conditions.",
    "The sample is a phase 2 clinical trial that focuses on cardiac arrest, sudden cardiac death, ventricular fibrillation, and ventricular tachycardia. The trial includes patients who are over 18 years old and have experienced an in-hospital VF or pVT arrest that persists after three or more precordial shocks. Patients who develop an in-hospital cardiac arrest due to asystole or PEA which subsequently converts to VF or pVT will also be included. The trial excludes pediatric patients, pregnant patients, patients under 18 years old, and patients who develop VF or pVT in the emergency room, operating room, or surgical intensive care unit. The trial will test the effectiveness of epinephrine and metoprolol as potential treatments.",
    "The sample is a phase 2 clinical trial for the treatment of amyotrophic lateral sclerosis. The trial includes subjects with definite, probable, or laboratory-supported probable ALS according to the revised El Escorial criteria. The trial has a list of inclusion and exclusion criteria, including having onset of symptoms less than 3 years prior to study entry, having a Forced Vital Capacity (FVC) at least 70% of that predicted for age and height, and not having unstable medical conditions other than ALS. The trial also requires a stable dose of riluzole if undergoing treatment with this agent and excludes subjects with a life expectancy of less than 6 months or requiring life-sustaining interventions for the 6 months following randomization. Additionally, subjects with a tracheotomy or using ventilatory assistance, active pulmonary disease, or who have received immune modulator therapy within 12 weeks of study entry or participated in studies of other agents within the last 4 weeks prior to the randomization are excluded. The trial includes the use of the drugs np001 and placebo.",
    "The sample is a phase 2 clinical trial for newly diagnosed multiple myeloma patients with ISS stage I-III requiring therapy. The trial includes lenalidomide (revlimid), melphalan, and dexamethasone as drugs. The eligibility criteria include being previously untreated except for prior treatment with corticosteroid less than one full cycle of pulsed dose dexamethasone or equivalent, age \u2265 18 years old, life expectancy \u2265 12 weeks, ECOG Performance Status 0-2, WBC \u2265 3.0 X 103/ \u00b5L, ANC \u2265 1.5 X 103/ \u00b5l, Hgb \u2265 8.0 gm/ dL, Plt \u2265 75 X 103/ \u00b5l, Serum Creatinine \u2264 2.0 mg/ dL, and ability to understand and sign a written informed consent document. The exclusion criteria include prior therapy with Revlimid, Thalomid, Velcade, or Alkeran, active Hepatitis B or C, New York Heart Association grade III/IV congestive heart failure, history of bleeding disorder, history of platelet function disorder, history of deep vein thrombosis or other thromboembolic event, prior history of allergic reaction to IMiD compounds, concomitant treatment with nonsteroidal antiinflammatory drugs or other nephrotoxic agents, serum creatinine > 2.0 mg/ dL, pregnancy and breastfeeding, known HIV+ patients, and other active hematologic or solid tumor or history of such disease requiring therapy of any form within five years of screening.",
    "The sample is a phase 2 clinical trial for patients with metastatic colorectal cancer. The trial involves the use of drugs such as erlotinib, fluorouracil, leucovorin, oxaliplatin, and irinotecan. The eligibility criteria for the trial include being between the ages of 18-80, having biopsy-proven unresectable metastatic adenocarcinoma of the colon or rectum, documented progression on prior first-line oxaliplatin-based or irinotecan-based regimen for metastatic colorectal cancer, and having radiographically measurable disease with at least one bidimensionally measurable lesion of > 1 cm. The trial also requires adequate organ function and an Eastern Cooperative Oncology Group status < 2. Patients meeting any of the exclusion criteria, such as prior treatment with erlotinib or gefitinib, central nervous system metastasis, or pregnancy, are ineligible for study entry.",
    "The sample is a phase 2 clinical trial for the treatment of multiple myeloma and plasma cell neoplasm. The trial involves the use of drugs such as bortezomib, cyclophosphamide, dexamethasone, and thalidomide. The eligibility criteria for the trial include a diagnosis of multiple myeloma meeting certain criteria, symptomatic disease requiring treatment, measurable disease, and no POEMS syndrome or plasma cell leukemia. Patients must also meet certain patient characteristics such as having a Karnofsky performance status of 50-100%, platelet count \u2265 100,000/mm\u00b3, and no impaired kidney function requiring dialysis. Prior concurrent therapy is also taken into consideration.",
    "The sample is a record of a clinical trial with a phase 2 designation and a focus on ovarian cancer. The trial involves the drug ispinesib and includes a list of inclusion and exclusion criteria for participants. Inclusion criteria include having a screening CA-125 level of 40 U/ml or higher and having received only one prior platinum/taxane-based chemotherapy regimen. Exclusion criteria include having received more than one chemotherapy regimen in the past, having inadequate liver or kidney function, being pregnant or nursing, having an unstable pre-existing medical condition or history of other cancers, and having received investigational drugs, chemotherapy, radiation treatment, or surgery within 28 days prior to entering the study. The table also includes lists of disease names and ICD-10 codes associated with the trial.",
    "The sample is a record of a clinical trial with a phase 2 designation, focused on the treatment of prostate cancer. The trial involves the drug pemetrexed and has a list of inclusion and exclusion criteria for participants. Inclusion criteria include having a documented adenocarcinoma of the prostate, being clinically refractory or resistant to hormone therapy, having received one prior taxane-based chemotherapy regimen for HRPC, and documented progression of disease after that regimen. Exclusion criteria include having untreated or uncontrolled brain metastasis, a history of other malignancies within 5 years, uncontrolled psychiatric illness or serious systemic disease, and recent surgery or significant traumatic injury. Participants must also be willing to interrupt aspirin or other non-steroidal anti-inflammatory agents for a 5-day period and take folic acid or vitamin B12 supplementation.",
    "The sample is a phase 2 clinical trial for patients with squamous cell lung cancer. The trial is testing the effectiveness of the drug dasatinib. The eligibility criteria for the trial include having stage III/B or IV squamous NSCLC, measurable disease, and having previously received all standard chemotherapy regimens for advanced squamous cell lung cancer. Other criteria include having an ECOG performance status of 0 or 1, estimated life expectancy greater than 12 weeks, normal organ and marrow function, and confirmed availability of archival pathology samples. Exclusion criteria include being pregnant or breastfeeding, having received chemotherapy or radiotherapy within 4 weeks prior to entering the study, and having a history of prior treatment with or allergic reactions attributed to compounds of similar chemical or biologic composition to dasatinib, nilotinib or imatinib.",
    "The sample is a phase 2 clinical trial for chronic obstructive pulmonary disease (COPD). The trial includes patients who are 40 years or older, have a clinical diagnosis of COPD, and have stable airway obstruction. The trial also requires patients to have a post-salbutamol FEV1 equal to or greater than 30% of the predicted value and less than 80% of the predicted value, and a post-salbutamol FEV1/FVC < 70% at the screening visit. Patients must also have a pre-dose FEV1 value of first treatment period within the range of 80-120% of the FEV1 measured at screening prior to salbutamol inhalation. The trial includes current or ex-cigarette smokers with a smoking history of at least 10 pack-years. Patients whose COPD symptoms at the time of randomisation are stable compared to the Screening visit, according to the investigator's medical judgment are also included. The trial excludes patients with a history or current diagnosis of asthma, a respiratory tract infection or COPD exacerbation in the six weeks prior to the screening visit, and patients who have been hospitalized for an acute COPD exacerbation in the 3 months prior to the screening visit. The trial also excludes patients with clinically significant respiratory or cardiovascular conditions, patients unable to properly use a dry powder or pMDI inhaler device or unable to perform acceptable spirometry, and patients with clinically relevant abnormalities laboratory, ECG parameters or physical examination results at the screening evaluation that in the investigator's opinion, preclude study participation. Patients who intend to use any concomitant medication not permitted by this protocol or who have not undergone the required washout period for a particular prohibited medication are also excluded.",
    "The sample is a clinical trial for a drug called AGI-1067 for the treatment of Type 2 diabetes. The trial is in phase 2/phase 3 and the eligibility criteria include being between 18-75 years old, having Type 2 diabetes for at least 6 months, and having an HbA1c level of at least 7.5%. Participants must not have Type 1 diabetes, severe diabetic neuropathy, or a history of long-term insulin therapy. They must also not be taking certain medications or have certain medical conditions. The trial involves taking either AGI-1067 or a placebo, and participants must provide informed written consent before entering the trial.",
    "The sample is a phase 2 clinical trial for patients with metastatic breast cancer who have completed their first line of chemotherapy and have achieved complete or partial response or disease stability for at least 6 months. The trial is testing the effectiveness of the drug temozolomide. The eligibility criteria include having no clinical sign of brain progression, meeting certain conditions such as being HER2 +++ or having a young age, having a certain performance status, and meeting certain blood count and liver function requirements. The trial also has exclusion criteria such as having a history of drug or alcohol abuse, being pregnant or breastfeeding, and having certain medical or psychological conditions that would prevent the participant from completing the study.",
    "The sample is a phase 2 clinical trial for cancer patients who have received a cancer vaccine targeting tumor antigen. The trial requires patients to have measurable disease and a Karnofsky performance status greater than or equal to 70%. Patients must also have adequate hematologic, renal, and hepatic function, and no prior grade 3 or 4 major organ or allergic toxicity attributable to the prior vaccine. Patients with concurrent chemotherapy, radiation therapy, or immunotherapy are excluded, as well as those with either previously irradiated or new CNS metastases at entry. Patients with a history of auto-immune disease, serious intercurrent chronic or acute illness, or medical or psychological impediment to probable compliance with the protocol are also excluded. Pregnant and nursing women are excluded, and sexually active patients must agree to use a medically acceptable form of birth control.",
    "The sample is a phase 2 clinical trial for patients with newly diagnosed pancreatic cancer that is locally advanced and inoperable. The trial is testing the effectiveness of the drugs cisplatin and fluorouracil. The eligibility criteria include having a certain stage of pancreatic cancer, not having received prior chemotherapy or radiation therapy for pancreatic cancer, having a certain performance status, and meeting certain laboratory values. Patients must also be at least 18 years old, have a life expectancy of at least 12 weeks, and use contraception during treatment and for 3 months after the last dose of chemotherapy. Patients must not be pregnant or breastfeeding, and must not have certain types of previous malignancies or be receiving chronic immunotherapy. Patients must be able to understand the potential risks and benefits of the study and give informed consent.",
    "The sample is a clinical trial for the treatment of recurrent respiratory papillomatosis using the drug propranolol. The trial is in phase 2/phase 3 and the eligibility criteria include having biopsy-proven recurrent respiratory papillomatosis with appropriate Human Papilloma Virus typing, being under the age of 10, having undergone at least 4 documented surgical interventions in the past year, and providing informed consent. The exclusion criteria include parental or child refusal to participate, heart failure, atrio-ventricular heart block, cardiac anomalies, low resting heart rate, low resting blood pressure, Wolff-Parkinson White Syndrome, unexplained syncope, asthma or reactive airway disease, renal or liver failure, expected long fasting periods (>12 hours), diabetes mellitus, and hypersensitivity to propranolol.",
    "The sample is a phase 2 clinical trial for patients with type 2 diabetes mellitus or impaired glucose tolerance. The trial is testing the drug bi 10773. The eligibility criteria include having a certain level of glucose in the blood, being within a certain age range and BMI range, and having stable antihypertensive treatment. Healthy subjects are also included in the trial. Exclusion criteria include recent acute coronary syndrome, uncontrolled hyperglycemia, liver or renal disease, and certain medical histories or treatments. Pre-menopausal women must be practicing an acceptable method of birth control or agree to periodic pregnancy testing during the trial.",
    "The sample is a phase 2 clinical trial for patients with non-small cell lung cancer who have previously undergone up to two chemotherapy regimens, one of which must have been platinum-based. The trial involves the use of three drugs - celecoxib, docetaxel, and pemetrexed disodium. Eligibility criteria include confirmation of \"COX dependent\" lung cancer, measurable or evaluable disease, adequate renal and hematologic function, and a minimum expected survival of two months. Patients must not currently be on non-steroidal anti-inflammatory agents or other COX-2 inhibitors. Exclusion criteria include more than two prior chemotherapy regimens, COX independence, and inadequate organ function. The trial also includes eligibility criteria based on liver function and exclusion criteria related to allergies, pregnancy, and prior malignancy.",
    "The sample is a phase 2 clinical trial for small cell lung cancer. The trial is testing the effectiveness of two drugs, amrubicin and topotecan, in patients with extensive disease who have responded to first-line platinum-based chemotherapy but have recurrent or progressive SCLC at least 90 days after completion of first-line therapy. The trial has specific eligibility criteria, including a histological or cytological diagnosis of SCLC, measurable disease defined by RECIST criteria, and adequate organ function. Exclusion criteria include pregnant or nursing women, prior anthracycline treatment, and concurrent severe or uncontrolled medical disease. The trial aims to determine the safety and efficacy of the drugs in treating SCLC.",
    "The sample is a phase 2 clinical trial for patients with invasive breast cancer that has spread to the brain. The trial is testing the effectiveness of the drugs sunitinib and capecitabine. The eligibility criteria include being 18 years or older, having measurable CNS metastases, and not having received prior treatment with capecitabine. Patients must also have a normal cardiac ejection fraction and adequate hematological, hepatic, and renal function. Exclusion criteria include pregnancy or breastfeeding, known allergy to capecitabine or 5-fluorouracil, and a life expectancy of less than 3 months. Patients with leptomeningeal carcinomatosis as the only site of CNS metastases are also excluded.",
    "The sample is a phase 2 clinical trial for patients with multiple myeloma. The trial includes patients who are at least 65 years old or ineligible for autologous stem cell transplantation. Patients must have measurable disease, a Karnofsky performance status of at least 60%, and a life expectancy of more than 3 months. The trial involves the use of carfilzomib, cyclophosphamide, and dexamethasone. Patients must meet certain laboratory values and have no other clinically significant illnesses that would increase their risk for toxicity. Patients with non-secretory MM, pregnant or lactating females, and those with active infectious hepatitis type B or C or HIV are excluded from the trial.",
    "The sample is a phase 2 clinical trial for the treatment of bipolar I depression. The trial involves patients who are currently being treated with lithium, olanzapine, or valproic acid. The eligibility criteria include a diagnosis of Bipolar I Disorder and currently experiencing a major depressive episode. The exclusion criteria include having any Axis I disorder apart from Bipolar I Disorder, clinically significant uncontrolled medical or surgical condition, previous use of modafinil or armodafinil, known sensitivity to any ingredients in the study drug tablets, and being pregnant or lactating.",
    "The sample is a phase 2 trial for patients who have undergone allogeneic transplant within the past year and are experiencing their first clinically-recognized episode of viral respiratory tract infection after the transplant. The trial is focused on treating respiratory tract infections, bronchiolitis obliterans, cryptogenic organizing pneumonia, and interstitial lung diseases. The trial involves the use of drugs such as prednisone, azithromycin, montelukast, and symbicort. The eligibility criteria include being over 18 years old, having undergone neutrophil engraftment, and being capable of informed consent. The exclusion criteria include having proof or high suspicion of bacterial, fungal, or non-viral microorganism causing pneumonia, having CMV, VZV, or HSV pneumonia, and having a prior diagnosis of chronic transplant-related non-infectious pulmonary complication.",
    "The sample is a phase 2 clinical trial for patients with hepatocellular carcinoma, a type of liver cancer. The trial involves the use of the drugs sorafenib and capecitabine. The eligibility criteria include a histologic diagnosis of hepatocellular carcinoma, adequate bone marrow and renal function, and a certain level of liver function. Patients must also have a certain performance status and life expectancy, and must not have received prior systemic therapy or have certain medical conditions. Exclusion criteria include uncontrolled ascites, pregnancy or lactation, certain cardiac diseases, and other medical conditions that may increase the risk of complications from treatment.",
    "The sample is a record of a clinical trial with a phase 2 designation. The trial is focused on the treatment of multiple myeloma, a type of cancer. The trial involves the use of a drug called plerixafor. The record includes a list of inclusion and exclusion criteria for patients who are eligible to participate in the trial. The inclusion criteria include a diagnosis of multiple myeloma, eligibility for autologous transplantation, and being in first or second partial remission or complete remission. The exclusion criteria include having received certain types of chemotherapy, having a co-morbid condition that puts the patient at high risk, and having a history of ventricular arrhythmias. The record also includes information on the patient's medical history, such as prior radiation therapy and previous collections or collection attempts.",
    "The sample is a phase 2 clinical trial for the treatment of osteoarthritis of the knee. The trial is looking for male or female participants who are at least 40 years old and have been diagnosed with unilateral or bilateral OA of the knee for at least 6 months prior to screening. The trial requires confirmation of OA according to American College of Rheumatology Criteria for Classification of Idiopathic OA of the Knee based on an X-ray performed within 6 months prior to screening or during the screening period. The trial also requires participants to have a qualifying mean score on the 24-hour average pain score (0-10 numeric rating scale) and a body mass index (BMI) of \u2264 40 kg/m2. Participants must be willing to comply with the study procedures and visit schedules and follow verbal and written instructions. The trial has a list of exclusion criteria, including ipsilateral hip OA, fibromyalgia, chronic pain syndrome, and other concurrent medical or arthritic conditions that could interfere with the evaluation of the index knee. The trial also excludes participants with a history of Reiter's syndrome, rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, arthritis associated with inflammatory bowel disease, sarcoidosis, or amyloidosis. Other exclusion criteria include a history of infection in the index joint, clinical signs and symptoms of active knee infection or crystal disease of the index knee, presence of surgical hardware or other foreign body in the index knee, unstable joint, and prior arthroscopic or open surgery of the index knee within 12 months of screening. The trial also excludes participants with active or history of malignancy within the last 5 years, insulin-dependent diabetes, active psychiatric disorder including psychosis and major depressive disorder, history of or active Cushing's syndrome, any other clinically significant acute or chronic medical conditions, skin breakdown at the knee where the injection would take place, and women of child-bearing potential not using effective contraception or who are pregnant or nursing.",
    "The sample is a record of a clinical trial for a phase 2 study. The trial is focused on treating small cell lung cancer and lung cancer using a combination of drugs including irinotecan, carboplatin, and bevacizumab. The eligibility criteria for the trial include having histologically-confirmed small cell lung cancer, limited stage disease, an ECOG performance status of 0 or 1, no previous treatment with chemotherapy, radiation therapy, or biologic agents, measurable disease, and adequate bone marrow, liver, and kidney function. Patients must also be able to understand the nature of the study and give written consent. There are also exclusion criteria, such as age under 18, a history of prior malignancy within three years (with some exceptions), pregnancy or lactation, and evidence of certain medical conditions.",
    "The sample is a record of a clinical trial in phase 2 for the treatment of dry eye syndromes. The trial involves testing the effectiveness of three different ophthalmic suspensions, including a placebo. The eligibility criteria for participants include having a subjective complaint of dry eye for at least 20 months, moderate to severe ocular discomfort and corneal-conjunctival damage, and a Schirmer's test score of 5mm/5minutes or less. Exclusion criteria include having any other anterior segment disease or disorder, using any topically-instilled ocular medications, or having had any ocular surgery within the past 12 months. Female patients who are pregnant, possibly pregnant, or breastfeeding are also excluded.",
    "The sample is a phase 2 clinical trial for the treatment of ovarian, fallopian tube, or primary peritoneal cancer. The trial involves the use of the drugs doxorubicin hcl liposome, bevacizumab, and carboplatin. The eligibility criteria include having a histologic diagnosis of the specified cancers, a relapse-free interval of more than 6 months after completion of first-line platinum-based chemotherapy, measurable disease, adequate bone marrow, renal, and liver function, normal cardiac function, and an Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1. Exclusion criteria include having received more than one previous regimen of chemotherapy, receiving immunotherapy or radiotherapy, requiring parenteral hydration or nutrition, having clinical signs or symptoms of gastrointestinal bowel obstruction or perforation, having previous or current malignancy other than basal cell or squamous cell carcinoma of the skin, having clinically significant cardiovascular disease, and having a history of bevacizumab or other VEGF or VEGF receptor-targeted agent use.",
    "The sample is a phase 2 clinical trial for hormone refractory prostate cancer. The trial includes patients with confirmed adenocarcinoma of the prostate with evidence of metastatic disease and disease progression during antiandrogen therapy. The drug being tested is docetaxel. The eligibility criteria include a Karnofsky Performance Status of 50-100, normal cardiac function, and a life expectancy of at least 24 weeks. Laboratory criteria for eligibility include specific levels of neutrophil count, hemoglobin level, platelet count, total bilirubin, and serum creatinine levels. Patients must also provide written informed consent. Exclusion criteria include prior treatment with cytotoxic agents or radioisotopes, estrogen use for at least three months, history of another cancer within the preceding five years (except basal or squamous-cell skin cancer), brain or leptomeningeal metastases, symptomatic peripheral neuropathy of grade 2 or higher, and uncontrolled intercurrent illness that would limit compliance with study requirements.",
    "The sample is a phase 2 clinical trial for HIV infections. The eligibility criteria include being 18 years or older, having a viral load of less than 50 copies/ml for the previous 12 months, having a circulating CD4+ cell count of at least 200 cells/ml, taking HAART, having no evidence of advanced cirrhosis or liver disease, having a Karnofsky performance status of 80%, not taking any medication contraindicated with VPA, being willing and able to give informed consent, and agreeing to abstinence or using effective contraception during the study. Exclusion criteria include being pregnant or breastfeeding, having psychiatric or cognitive disturbance or illness, using cytotoxic agents or immunomodulatory agents, having an allergic reaction to VPA, being an active intravenous drug user, having a history of bleeding disorders, having unstable or treated hypertension, having a past history of pancreatitis or chronic liver disease, having renal failure or ammonemia, taking Zidovudine or certain other drugs, and having abnormal laboratory results or suffering from urea cycle disorders.",
    "The sample is a phase 2 clinical trial for the treatment of irritable bowel syndrome with constipation. The trial involves the use of two drugs, linaclotide acetate and a matching placebo. The eligibility criteria include not being pregnant or breastfeeding, having completed a negative colonoscopy, meeting protocol-defined criteria for IBS-C, demonstrating English fluency, and having access to a touch-tone telephone. The exclusion criteria include recent history of mushy or watery stools, various medical conditions or histories that would not make the patient a good candidate for the study, clinically-significant alarm symptoms, secondary causes of constipation or evacuation disorders, surgery to the gastrointestinal tract, and usage of prohibited medications.",
    "The sample is a phase 2 clinical trial for patients with metastatic or locally advanced adenocarcinoma of the pancreas or thromboembolism. The trial involves the use of two drugs, dalteparin and gemcitabine hydrochloride. The eligibility criteria include having measurable or evaluable disease, no clinical evidence of active venous thromboembolism, and meeting certain patient characteristics such as having a Karnofsky performance status of 60-100% or WHO PS 0-2, life expectancy of more than 12 weeks, and no history of other advanced malignancy. Prior concurrent therapy is not allowed, and patients must not have any other significant medical or psychiatric illness that would preclude study participation.",
    "The sample is a phase 2 clinical trial for patients with advanced locally recurrent or metastatic collecting duct renal cell carcinoma, a type of kidney cancer. The trial is testing the effectiveness of the drugs carboplatin and paclitaxel. The eligibility criteria include having measurable disease, no active CNS metastases, and meeting certain age, performance status, and medical condition requirements. Patients must not have had more than 2 prior biologic response modifier regimens and must not have any other concurrent anticancer drugs. The sample also includes detailed information on the disease characteristics, patient characteristics, and prior concurrent therapy.",
    "The sample is a record of a clinical trial in phase 2 for the treatment of rheumatoid arthritis. The trial involves testing the effectiveness of several drugs, including a placebo and cp-690,550, on patients who have not responded well to methotrexate. The eligibility criteria for the trial include having active rheumatoid arthritis and inadequate response to methotrexate, while exclusion criteria include current use of any DMARD or biologic other than methotrexate. The diseases are listed as 'arthritis, rheumatoid' and the icd-10 codes associated with the disease are also provided.",
    "The sample is a phase 2 clinical trial for HIV infections and chronic hepatitis B. The trial is testing the effectiveness of a drug called 1% tenofovir gel. The eligibility criteria for participants include being HIV uninfected, in good general health, sexually active, and willing to use acceptable methods of contraception. Exclusion criteria include menopausal or postmenopausal status, abnormal gynecologic exam results, and a history of adverse reactions to tenofovir or adefovir. Participants must also be willing to undergo all study-related assessments and adhere to the requirements of the study.",
    "The sample is a phase 2 clinical trial for the treatment of fibromyalgia using the drug nabilone. The eligibility criteria for the trial include meeting the American College of Rheumatology criteria for fibromyalgia, being between 18-70 years old, and not having received benefit from other pain management medications. Exclusion criteria include having a diagnosis other than fibromyalgia to explain the pain, abnormalities in routine blood work, heart disease, schizophrenia or other psychotic disorder, severe liver dysfunction, untreated emotional disorders, cognitive impairment, major illness in another body area, pregnancy, nursing, history of drug dependency, and known sensitivity to marijuana or other cannabinoid agents.",
    "The sample is a phase 2 clinical trial for the treatment of human immunodeficiency virus type 1. The trial involves the use of etravirine, nucleotide reverse transcriptase inhibitors, protease inhibitors, and enfuvirtide. The eligibility criteria for participants include having completed at least 48 weeks of treatment with etravirine, being able to comply with the protocol requirements, and having a general medical condition that does not interfere with the assessments and completion of the study. Exclusion criteria include the use of disallowed concomitant therapy, treatment-emergent conditions or exacerbation of underlying conditions during the original Phase II study, and certain medical conditions such as significantly decreased hepatic function or decompensation.",
    "The sample is a phase 2 clinical trial for irritable bowel syndrome with diarrhea. The trial involves the use of the drug ibodutant and a placebo. The eligibility criteria include being between the ages of 18-70, having a clinical diagnosis of IBS-D according to the Rome III criteria, experiencing recurrent abdominal pain/discomfort for at least 3 days per month in the last 3 months, having loose/watery stools at least 25% of the time in the last 3 months, and having more than 3 bowel movements per day at least 25% of the time in the last 3 months. Exclusion criteria include having organic abnormalities of the gastrointestinal tract, lactose intolerance, or a history of positive tests for ova or parasites. The trial also requires confirmation of IBS-D severity and normal physical examination or without clinically relevant abnormalities.",
    "The sample is a record of a clinical trial with a phase 2 designation. The trial is focused on the disease acute myeloid leukemia and includes a list of corresponding ICD-10 codes. The drug being studied is decitabine. The record also includes the eligibility criteria for participants, including a diagnosis of AML or transformed from myelodysplastic syndrome within 2 weeks of study enrollment, ineligibility for intensive chemotherapy, and no chemotherapy within 4 weeks of study enrollment. The exclusion criteria include previous treatment for AML, previous use of Vidaza, receipt of any other investigational agents within 30 days of the first dose of study drug, uncontrolled intercurrent illness, and radiotherapy within 14 days prior to study enrollment.",
    "The sample is a phase 2 clinical trial for various types of advanced cancer, including non-small cell lung cancer, transitional cell carcinoma, soft tissue sarcoma, gastric/esophageal adenocarcinoma, and pancreatic cancer. The trial is testing the effectiveness of the drug brivanib compared to a placebo. Eligible participants must have a solid tumor that is unresectable and for which no approved effective therapy exists or be intolerant to such therapy. They must also have a life expectancy of at least 3 months, adequate tumor sample, and adequate recovery from recent therapy. Exclusion criteria include known brain metastasis or signs/symptoms suggestive of brain metastasis, history of thrombo-embolic disease, poor wound healing or non-healing ulcers, uncontrolled or significant cardiovascular disease, and allergy to brivanib or related compounds. Prohibited treatments include exposure to any investigational drug within 4 weeks of enrollment, concurrent chemotherapy, hormonal therapy, immunotherapy regimens, or radiotherapy, and prior exposure to brivanib.",
    "This is a sample from a clinical trial table that includes information about the trial phase, diseases being studied, icd-10 codes of the diseases, drugs being used, and eligibility criteria. In this particular sample, the trial is in phase 2 and is studying triple-negative breast cancer. The icd-10 codes associated with this disease are listed. The drugs being used in the trial are brostallicin and cisplatin. The eligibility criteria include having a confirmed diagnosis of adenocarcinoma of the breast with clinical evidence of metastatic disease, having triple-negative breast cancer, having measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST) criteria, and meeting various other medical criteria. There are also exclusion criteria, such as having HER2 positive breast cancer, being pregnant or nursing, having a history of allergy or hypersensitivity to the drugs used in the trial, and having clinically significant cardiovascular or cerebrovascular disease.",
    "The sample is a phase 2 clinical trial for non-small cell lung cancer. The trial is testing the effectiveness of induction chemotherapy. The eligibility criteria for the trial include having stage IIIA-IIIB NSCLC and a performance status of 0 or 1 on the Zubrod or WHO Scale. Patients with evidence of metastases, high risk of radiation pneumonitis, compromised lung function, estimated life expectancy of less than 3 months, prior chemotherapy or radiotherapy for lung cancer, or prior surgery with curative intent for lung cancer are excluded from the trial. The icd-10 codes associated with the disease are also provided.",
    "The sample is a phase 2 trial for a drug called mipomersen, which is being tested on patients with metabolic diseases, hyperlipidemias, metabolic disorder, hypercholesterolemia, dyslipidemias, and lipid metabolism disorders. The trial is looking for patients who are statin intolerant, have coronary artery disease, and hypercholesterolemia, and have had stable weight for more than 6 weeks. Patients with significant health problems in the recent past, such as heart attack, heart surgery, heart failure, uncontrolled hypothyroidism, blood disorders, digestive problems, disease of central nervous system, cancer, liver or renal disease, are excluded from the trial. The trial also includes a placebo group.",
    "The sample is a phase 2 clinical trial for patients with relapsed or refractory multiple myeloma who have failed at least 2 prior lines of therapy. The trial requires that the patients have measurable secretory disease and an ECOG performance status score of less than or equal to 2. The trial drug is dexamethasone and the eligibility criteria include prior treatment with bortezomib. The exclusion criteria include recent treatment with systemic cancer therapy or radiotherapy, major surgery within 30 days, serious concurrent illness, uncontrolled infection, and seropositivity for HIV or active hepatitis A, B or C infection.",
    "The sample is a record of a clinical trial in phase 2 for the treatment of rheumatoid arthritis. The trial involves the use of drugs such as adalimumab and cp-690-550, as well as a placebo. The eligibility criteria for the trial include having active rheumatoid arthritis and having failed at least one disease modifying anti-rheumatic drug (DMARD). However, subjects who have previously received adalimumab therapy or discontinued any previous TNF inhibitor therapy for lack of benefit or safety are excluded from the trial. Additionally, subjects with blood disorders, chronic infections, or untreated tuberculosis are also excluded. The diseases are listed as 'arthritis, rheumatoid' and the corresponding ICD-10 codes are provided.",
    "The sample is a phase 2 trial for patients with hyperphosphatemia and chronic kidney disease. The trial involves testing the effectiveness of three drugs - asp1585, placebo, and sevelamer hydrochloride - in reducing phosphate levels in the blood. The trial has specific inclusion and exclusion criteria, such as patients must have been on hemodialysis for at least 12 weeks and on stable doses of phosphate binders and Vitamin D or calcitonin agents for at least 28 days prior to the acquisition of informed consent. Patients with a history of major gastrointestinal surgery, bowel obstruction, or uncontrolled hypertension are excluded from the trial.",
    "The sample is a phase 2 clinical trial for Alzheimer's disease. The trial includes men and women between the ages of 50 and 85 with a diagnosis of probable Alzheimer's disease and a MMSE score of 14 to 26. Participants must have previously been treated with one of the approved Acetylcholinesterase-Inhibitors and/or Memantine in a stable dose. The trial excludes individuals with significant psychiatric or medical disease, chronic liver disease, chronic daily drug intake of excluded concomitant medications, or enrollment in another investigational drug study within 3 months before the baseline visit. The trial involves the use of tideglusib and placebo as drugs. The icd-10 codes associated with Alzheimer's disease are listed as ['G30.8', 'G30.9', 'G30.0', 'G30.1'].",
    "The sample is a record of a clinical trial with a phase 2 designation. The trial is focused on aggressive non-Hodgkin's lymphoma and includes patients with documented evidence of progression after prior first-line chemotherapy containing anthracyclines associated or not with Rituximab. Patients with refractory disease to first line of treatment are also eligible. The trial includes the drugs gemcitabine, cisplatin, and dexamethasone. The eligibility criteria include a histological diagnosis of aggressive non-Hodgkin's lymphoma, ECOG PS (performance status) less than or equal to 2, and the presence of bidimensionally measurable disease in accordance with WHO criteria. The exclusion criteria include involvement of the CNS, any medical condition which contraindicates the degree of hydration required for the safe use of cisplatin, intermediate degree lymphoma derived from the malignant transformation of a previous low-grade lymphoma, and active infection.",
    "The sample is a phase 2 clinical trial for breast cancer and non-small-cell lung cancer. The trial involves the use of three drugs: SCH 727965, capecitabine, and erlotinib. The eligibility criteria for participants include being over 18 years old, having previously received certain treatments for their cancer, having measurable disease, and having adequate organ function. Participants with certain medical conditions or who have received certain treatments in the past are excluded from the trial. The sample also includes a list of disease names and corresponding ICD-10 codes.",
    "This sample is for a phase 2 clinical trial for patients with non-small cell lung cancer who have undergone complete resection. The trial is testing the effectiveness of adjuvant chemotherapy using the drugs carboplatin and docetaxel. The eligibility criteria include having a confirmed diagnosis of non-small cell lung cancer, being in stage I-IIIA, having an Eastern Cooperative Oncology Group (ECOG) performance status of 0-1, and meeting certain laboratory values. Patients with a history of severe hypersensitivity to docetaxel or polysorbate 80, those who are currently or planning to breastfeed, and those with peripheral neuropathy \u2265 grade 2 are excluded. The trial requires patients to have had surgery 2-8 weeks prior to starting the study and to have recovered.",
    "The sample is a phase 2 clinical trial for the treatment of relapsed or refractory acute lymphocytic leukemia. The trial involves the use of cytarabine, fludarabine phosphate, and idarubicin drugs. The eligibility criteria include having a cytologically diagnosed relapse or refractory leukemia, previously treated with front line therapy FAB L1 or L2, with bone marrow relapse either isolated or associated with CNS or testicular relapse, and bone marrow blast cells greater than 10%. Patients must also meet certain age, performance status, life expectancy, and organ function criteria. Additionally, patients must not have any psychological, familial, sociological, or geographical conditions that would hamper compliance, and must not have any uncontrolled infections. Prior concurrent therapy is also restricted.",
    "The sample is a phase 2 clinical trial for patients with prostate cancer that has spread to other parts of the body. The trial is testing the effectiveness of the drugs nilutamide and dasatinib. The eligibility criteria include having a confirmed diagnosis of adenocarcinoma of the prostate, evidence of disease progression on androgen deprivation therapy, and adequate organ and marrow function. Patients must also be able to take oral medications, have an ECOG performance status of 0-2, and be over 18 years old. Exclusion criteria include prior treatment with nilutamide or dasatinib, medical contraindications to stopping aspirin or coumadin, and a history of certain cardiac-related conditions. Patients must also be willing to sign a written informed consent document.",
    "The sample is a phase 2 trial for the treatment of hyperlipidemia and type 2 diabetes. The trial includes patients with specific icd-10 codes for these diseases and involves the drugs etc-1002 and placebo. The eligibility criteria for the trial includes a minimum 6 month history of diabetes, a fasting C-peptide level of at least 0.8 ng/mL, an HbA1C level between 7-10%, a fasting glucose level between 140-270 mg/dL, a BMI between 25-35 kg/m2, and an LDL-C level of at least 100 mg/dL.",
    "The sample is a phase 2 clinical trial for the treatment of opioid-induced constipation in patients with non-malignant chronic pain. The trial involves the use of two drugs, placebo and naldemedine, and includes a list of inclusion and exclusion criteria for eligible participants. The inclusion criteria include being 18 years or older, experiencing < 3 spontaneous bowel movements a week, and receiving chronic opioid therapy for \u2265 3 months. The exclusion criteria include having clinically significant gastrointestinal disease, a history of chronic constipation prior to starting analgesic medication, or severe constipation that has not been appropriately managed. The diseases are listed as 'opioid-induced constipation' and the icd-10 codes associated with the disease are also provided.",
    "The sample is a phase 2 clinical trial for patients with type 2 diabetes mellitus. The trial includes patients who have been on the same doses for 3 months of any approved combination of 2 oral antihyperglycemic medications. The trial aims to test the effectiveness of the drug ly2189265 compared to a placebo. The eligibility criteria include having a glycosylated hemoglobin (HbA1c) of >7.0% to \u226410.5%, a body mass index (BMI) between 27 and 40 kilograms/meter squared (kg/m^2), and being 18 years of age or older. Exclusion criteria include having known Type 1 Diabetes Mellitus, taking glucagon-like peptide-1 (GLP-1) or any GLP-1 analog drug (Byetta), and having a history of unstable angina, heart attack, heart arrhythmia, congestive heart failure, or other coronary intervention.",
    "The sample is a phase 2 clinical trial for Friedreich's ataxia, a disease characterized by a homozygous GAA expansion within the FRDA with a triplet repeat sequence in the pathological range. The trial is testing the drug epoetin alfa. The eligibility criteria for the trial include having a molecular diagnosis of FA, being between the ages of 18 and 50, and not being wheelchair-bound or having significant renal, hepatic, or hematological disease. Exclusion criteria include failure to meet inclusion criteria, being in treatment with Idebenone, having a positive history for arterial or venous thrombosis, having acute diseases that might interfere with the study, having a positive history for arterial hypertension, being pregnant or planning to become pregnant, having a known hypersensitivity to the study drug, or taking other unacceptable concomitant medications.",
    "The sample is a record of a clinical trial with a phase 2/phase 3 designation. The trial is focused on kidney transplantation and involves the use of the drugs rituximab and placebo. The diseases being studied are listed as kidney transplantation, with corresponding ICD-10 codes provided. The eligibility criteria for the trial are also listed, including inclusion criteria such as being a renal transplant recipient and having signed an IRB-approved informed consent, as well as exclusion criteria such as pregnancy, previous treatment with anti-CD20 antibodies, and active infection with hepatitis B, hepatitis C, or HIV.",
    "This sample is for a phase 2 clinical trial for the treatment of migraine. The trial is testing the effectiveness of the drugs lasmiditan and placebo. The eligibility criteria for participants include having a history of migraine for at least one year, experiencing 1-8 migraine attacks per month, and being between the ages of 18 and 65. Female participants of child-bearing potential must be using a highly effective form of contraception. Exclusion criteria include a history of life-threatening adverse reactions to any triptan, use of prescription migraine prophylactic drugs, and pregnancy or breastfeeding. Participants must also be willing and able to return to the clinic for treatment within 4 hours of the onset of a migraine headache.",
    "The sample is a phase 2 clinical trial for the treatment of type 2 diabetes. The trial involves the drug pex168 or a placebo. The eligibility criteria include being diagnosed with type 2 diabetes, having a stable dose of metformin monotherapy for at least 12 weeks before randomization, having a certain level of HbA1c, being between 20 and 70 years old, and having a body mass index between 19 and 35 kg/m2. Exclusion criteria include a positive skin test for PEX168, current treatment with certain excluded medications, a history or evidence of certain medical conditions, significant laboratory abnormalities, reluctance to use contraception, pregnancy, or lactation, and any other situations that may result in the withdrawal of subjects or bring significant risk to subjects.",
    "The sample is a phase 2 clinical trial for patients with advanced soft tissue sarcoma. The trial includes patients with measurable disease and certain blood count levels. Patients must also have a life expectancy of at least 12 weeks and a performance status of 0 or 1. The trial drug being tested is perifosine. The eligibility criteria include exclusion of pregnant or breastfeeding women, patients with brain metastases, and those with uncontrolled intercurrent illnesses. Patients must also not have received certain types of prior therapy and must not have a history of allergic reactions to compounds similar to perifosine. Prior malignancies are allowed if they have been disease-free for at least 5 years.",
    "The sample is a phase 2 clinical trial for patients with metastatic colorectal cancer. The trial is testing the effectiveness of a combination of drugs including capecitabine, celecoxib, and methotrexate. The eligibility criteria for the trial include having a histologic or cytologic proof of colorectal carcinoma, being between the ages of 18 and 80, and having previously received FOLFIRI+ bevacizumab treatment for metastatic disease. Patients must also have intact organ function and be asymptomatic during the break from chemotherapy. The trial excludes patients with concurrent cancer, brain metastases, or severe or uncontrolled systemic disease.",
    "This sample is a record of a clinical trial with a phase 2 designation. The trial is focused on Crohn's disease, with the ICD-10 codes K50.90, K50.913, K50.914, K50.911, K50.912, K50.918, and K50.919. The trial involves two drugs, hmpl-004 and placebo. The eligibility criteria for the trial include having active confirmed Crohn's Disease with a CDAI score of 220-400 at baseline screen. The exclusion criteria include having received anti-TNF-\u03b1 antibody within 3 months of starting study medication, or cyclosporine, tacrolimus, thalidomide or mycophenolate mofetil within 2 months of starting study medication.",
    "The sample is a phase 2 trial that focuses on sexual dysfunction in pre-menopausal women. The trial includes the use of the drug cp-866,087 and a placebo. The eligibility criteria for the trial includes being a healthy pre-menopausal woman with primary female sexual arousal disorder causing distress and on stable use of oral contraceptives. The exclusion criteria includes having any other significant disease causing Female Sexual Dysfunction including psychiatric disease, being on drugs known to cause Female Sexual Dysfunction, having given birth in the last 12 months, or planning to become pregnant during the study. The diseases being studied are listed as 'sexual dysfunction, physiological' and the corresponding ICD-10 codes are listed as \"['F52.8', 'F52.9']\".",
    "The sample is a phase 2 clinical trial for the treatment of inflammation and rheumatoid arthritis. The trial involves the use of two drugs, nnc109-0012 and placebo. The eligibility criteria include being between the ages of 18-65, having a diagnosis of RA for at least 3 months, and being on a stable dose of methotrexate for at least 4 weeks prior to the trial. Female subjects must avoid pregnancy and breastfeeding during the trial, and male subjects with partners of childbearing potential must use contraception. Exclusion criteria include allergies to the trial product, BMI outside of the range of 18.5-35.0 kg/m^2, and having a chronic inflammatory autoimmune disease other than RA.",
    "The sample is a record from a clinical trial table that includes information about the phase of the trial, diseases being studied, corresponding ICD-10 codes, drugs being tested, and eligibility criteria for participants. In this particular record, the trial is in phase 2 and is focused on chronic hepatitis C infection. The ICD-10 codes associated with the disease are listed, as well as the drugs being tested. The eligibility criteria for participants are also included, with both inclusion and exclusion criteria listed.",
    "The sample is a phase 2 clinical trial for HIV-1 infection. The trial is testing the drug bevirimat. The eligibility criteria for the trial include having documentation of HIV-1 infection, a CD4+ lymphocyte count of at least 100 cells/mm3, and a screening plasma HIV-1 RNA value of less than 400 copies/mL. Participants must also be receiving an ARV therapy regimen containing at least 3 drugs which has been unchanged for at least 8 weeks prior to screening, and which is to be continued through Day 15 of the study. Exclusion criteria include the presence of any acute illness within 14 days prior to study entry, any AIDS-related opportunistic infection, and patients who are unable to comply with the dosing schedule and protocol evaluations. The sample also includes a list of icd-10 codes for the disease and the eligibility and exclusion criteria for the trial.",
    "The sample is a phase 2 clinical trial for breast cancer. The trial is testing the effectiveness of albumin-bound paclitaxel, carboplatin, and Herceptin\u00ae as treatments for stage IV breast cancer with measurable disease. The eligibility criteria include having confirmed adenocarcinoma of the breast, 3+ overexpression of the human epidermal growth factor receptor 2 (HER-2)/proto-oncogene, and an Eastern Cooperative Oncology Group (ECOG) performance status of 0-2. Exclusion criteria include having received an investigational drug within the previous 3 weeks, being pregnant or nursing, and having a history of congestive heart failure or other malignancy within the last 5 years that could affect the diagnosis or assessment of breast cancer.",
    "The sample is a phase 2 clinical trial for acute myeloid leukemia. The trial is testing the effectiveness of the drug combination of amonafide and cytarabine. The eligibility criteria for the trial includes being a new diagnosis of AML or having relapsed or refractory AML, having an ECOG performance status of 2 or less, being between the ages of 18 and 70, having adequate hepatic and renal function, and having a left ventricular ejection fraction of greater than 50%. Exclusion criteria includes having a history of clinically significant allergic reactions to similar compounds, being pregnant or breastfeeding, having HIV or active hepatitis B or C, having evidence of pulmonary infection, having undergone major surgery or radiation therapy within 30 days prior to study entry, and having previously received treatment with amonafide.",
    "The sample is a record of a clinical trial in phase 2, focused on the disease of cancer. The icd-10 codes associated with the disease are listed as \"C05.2\", \"C10.0\", \"C16.0\", \"C16.4\", \"C17.0\", \"C17.1\", and \"C17.2\". The trial involves the use of two drugs, cediranib and cediranib 30-90 mg. The eligibility criteria for the trial include having a clinical diagnosis of advanced solid tumor and the ability to eat a high-fat breakfast. The exclusion criteria include poorly controlled high blood pressure and a history of significant gastrointestinal problems.",
    "The sample is a record from a clinical trial table, containing information about a phase 2 trial for the treatment of recurrent and stage IV melanoma using the drug ixabepilone. The eligibility criteria for the trial are listed, including requirements for measurable lesions, stable brain metastases, performance status, blood counts, liver and kidney function, and absence of certain medical conditions. Prior chemotherapy is allowed for some patients, but not for others. The sample also includes lists of disease names and ICD-10 codes associated with the trial.",
    "The sample is a phase 2 clinical trial for breast cancer patients with stage I-III disease who are scheduled to undergo definitive surgery or other primary treatment. The trial is testing the effectiveness of the drug vorinostat. The eligibility criteria include having no prior or concurrent hormonal therapy for breast cancer, meeting certain blood count and liver function requirements, and having no other uncontrolled illnesses or psychiatric issues. Patients must also not be pregnant or nursing and must use effective contraception if fertile. The exclusion criteria include not taking any other investigational agents, having a history of allergic reactions to similar compounds, and not taking valproic acid or another histone deacetylase inhibitor for at least 2 weeks prior to initiating the trial.",
    "The sample is a record of a clinical trial in phase 2 for the treatment of metastatic pancreatic cancer. The trial involves the drugs ixabepilone and cetuximab. The eligibility criteria for participants include having a histologic or cytologic diagnosis of pancreatic adenocarcinoma, measurable disease as per Response Evaluation Criteria In Solid Tumors (RECIST) guidelines, not having received prior chemotherapy, immunotherapy or chemoradiotherapy for advanced pancreas cancer, having a Karnofsky performance status (KPS) of 70-100, and adequate hematologic, hepatic and renal function. The icd-10 code for pancreatic cancer is C25.3.",
    "This sample is for a phase 2 clinical trial for hormone-refractory prostate cancer. The trial includes patients with rising PSA levels after hormone treatment and bone metastasis based on an X-ray. The trial excludes patients who are already on a bisphosphonate treatment such as Zometa, Fosamax, or Actonel. The trial will test the effectiveness of zoledronic acid in 20mg tablets and zoledronic acid. The diseases are listed as hormone-refractory prostate cancer and the icd-10 codes associated with the disease are also provided.",
    "This sample is for a phase 2 clinical trial for the treatment of allergic rhinitis. The trial includes patients with a history of allergic rhinitis and excludes those with respiratory diseases other than mild intermittent asthma, those who have received immunotherapy in the past 3 years, those with a history of clinically significant drug allergy, those with a history of clinical schistosomiasis or travel to an area with endemic schistosomiasis within 6 months prior to or following the study, and those with a history of exposure to human therapeutic antibodies, immunoglobulins or other plasma products. The trial will test the effectiveness of the drug qax576 compared to a placebo.",
    "The sample is a phase 2 clinical trial for patients with colorectal cancer that has progressed despite treatment with at least two, but not more than three, lines of therapy. The trial is testing the effectiveness of a combination of a drug called gm-ct-01 and 5-fluorouracil. The eligibility criteria include having a histologically-proven adenocarcinoma of the colon or rectum, having locally advanced or metastatic colorectal cancer not amenable to curative surgery or radiotherapy, having measurable lesions according to RECIST criteria, and having an ECOG performance status of 0-2. The exclusion criteria include having central nervous system metastasis, bony metastasis as the sole metastasis, or other concomitant or previous malignancy in the past 3 years. The sample also includes a list of icd-10 codes for the disease, as well as the eligibility and exclusion criteria for the trial.",
    "The sample is a phase 2 clinical trial for patients with cutaneous t-cell lymphoma. The trial is testing the effectiveness of a drug called apo866. Patients must have a confirmed diagnosis of CTCL and be in stage Ib to IVb of the disease. They must have relapsed or be intolerant to at least two prior systemic therapies. Patients must also have an ECOG Performance Status of less than 2 and be over 18 years old. Female patients of childbearing potential must be using a form of contraception and have a negative pregnancy test. Male patients who are not surgically sterile must use a condom with spermicide. Patients must have given written informed consent. Exclusion criteria include participation in any other investigational study or experimental therapeutic procedure in the 2 months preceding the trial, evidence of CNS lymphoma, use of prohibited medication, uncontrolled medical conditions, serious concomitant disease, inadequate bone marrow reserve, inadequate liver or renal function, and retinopathy or history of retinal laser surgery.",
    "The sample is a phase 2 clinical trial for patients with non-small-cell lung carcinoma. The trial includes the use of three drugs: carboplatin, paclitaxel, and vinorelbine. The eligibility criteria for the trial includes patients who are chemotherapy naive and have histologically confirmed NSCLC stage III and IV. However, patients with New York Heart Association (NYHA) III or IV, brain metastases, or neurotoxicity Grade 2 or greater are excluded from the trial.",
    "The sample is a phase 2 clinical trial for previously untreated participants with cluster of differentiation 20 (CD20) positive B-cell chronic lymphocytic leukemia. The trial includes participants with progressive Binet stage B, or C requiring therapy according to National Cancer Institute (NCI) criteria, and Eastern Cooperative Oncology Group (ECOG) performance status <=2. The trial excludes participants who have had previous treatment for Chronic Lymphocytic Leukaemia (CLL), known concomitant hematological malignancy, transformation to aggressive B-cell malignancy, history of severe cardiac disease, and known hypersensitivity or anaphylactic reactions to murine antibodies. The trial uses rituximab and chlorambucil as drugs.",
    "The sample is a phase 2 clinical trial for patients with metastatic colorectal cancer. The trial involves the use of multiple drugs including fluorouracil, leucovorin, bevacizumab, capecitabine, and oxaliplatin. The eligibility criteria for the trial include being an adult patient over the age of 18 with at least one measurable lesion according to RECIST v. 1.1, disease progression with prior FOLFIRI + Avastin therapy, and an ECOG score of 2 or less. Exclusion criteria include clinically significant cardiovascular disease, CNS disease except for treated brain metastasis, and major surgery or significant traumatic injury within 28 days prior to the start of study treatment.",
    "The sample is a phase 2 clinical trial for obsessive-compulsive disorder. The eligibility criteria include having a confirmed diagnosis of OCD, experiencing clinically significant symptoms despite at least two adequate SRI monotherapy trials, being between the ages of 18-70, having OC symptoms for at least one year, and being in good physical health. Exclusion criteria include primary depression, schizophrenia, or other psychotic disorders, active bipolar disorder, non-responder to atypical antipsychotic augmentation or cognitive-behavioral therapy, current clinically significant suicidality, alcohol or other significant substance abuse within the last 6 months, history of neurosurgery or significant medical condition, nursing mothers or women of childbearing potential who do not use adequate contraception, increased risk for seizures, estimated IQ < 80, mental retardation, dementia, brain damage, or other cognitive impairment, and concurrent use of benzodiazepines or other psychotropic medications. The drugs being tested are paliperidone and placebo.",
    "The sample is a phase 2 clinical trial for asthma. The trial is open to male and pre-menarchial female subjects aged 5-11 years who have been diagnosed with asthma at least 6 months prior to screening. The patients must be controlled on their existing asthma treatment at screening and must be taking a stable regimen of fluticasone propionate and short acting beta-agonist inhaler on an as-need basis for at least 4 weeks prior to screening. Apart from asthma, eczema and rhinitis, subjects should be healthy and suffer from no other significant medical conditions. The trial involves the use of the drug GW642444 and a placebo. The eligibility criteria include a minimum weight of 15 kg, ability to use the GW642444 device, and ability to understand and comply with protocol requirements. The exclusion criteria include subjects currently receiving or have received within 4 weeks of screening any of the following asthma therapies: theophyllines, long-acting inhaled beta-agonists, oral beta-agonist, and any clinically relevant abnormality identified on the screening medical assessment. The trial also excludes subjects with any medical condition or circumstance making them unsuitable for participation in the study, such as a history of life-threatening asthma. The trial requires at least one parent or guardian to sign and date the written informed consent prior to admission to the study.",
    "The sample is a phase 2 clinical trial for patients with advanced active cancer and cancer-related pain that is not fully alleviated by their current opioid treatment. The trial is testing the effectiveness of three different doses of Sativex, a drug, in combination with the patients' regular daily baseline opioid regimen. The trial has inclusion and exclusion criteria, including the requirement that patients have a clinical diagnosis of cancer-related pain and are receiving a sustained release fixed dose of opioid therapy. Patients must also be willing to comply with all study requirements and continue their regular daily baseline opioid regimen throughout the duration of the study. Patients with a history of certain psychiatric disorders, dependence disorders, heavy alcohol consumption, or illicit drug use are excluded from the study. Additionally, patients who have experienced myocardial infarction or clinically relevant cardiac dysfunction within the last 12 months or have a cardiac disorder that would put them at risk of a clinically relevant arrhythmia or myocardial infarction are also excluded.",
    "The sample is a phase 2 trial for the treatment of uncomplicated, Gram-positive skin infections. The trial includes male and female patients between the ages of 18 and 65 who have been diagnosed with the infection and have Gram-positive organisms determined at baseline. The trial drug being tested is ltx-109, and the area to be treated must be \u2264100 cm2. Patients must have a SIRS score of at least 8 for the area of study medication application. The trial has inclusion and exclusion criteria, including the requirement for patients to provide signed and dated written informed consent. Patients with moderate to severe dermatoses, secondarily-infected animal/human bite, puncture wound or abscess, chronic ulcerative lesions, or bacterial skin infection that cannot be appropriately treated by a topical antibiotic are excluded from the trial. Additionally, patients with ongoing treatment with systemic corticosteroids at a dose of >0.125mg/kg per day of prednisone (or the equivalent), known, pre-existing or serious underlying disease that could be imminently life-threatening, pregnancy or ongoing lactation, and participation in any study using an investigational drug or device during the previous 30 days prior to entering the study are also excluded.",
    "The sample is a record of a clinical trial with a phase 2 designation. The trial is focused on breast cancer, specifically locally recurrent and metastatic breast cancer. The trial involves the use of four drugs: amg 706 placebo, bevacizumab, amg 706, and paclitaxel. The eligibility criteria for the trial include having a confirmed diagnosis of adenocarcinoma of the breast with locally recurrent or metastatic disease, measurable disease by RECIST guidelines, and HER2 negativity. There are also exclusion criteria, such as prior taxane treatment within 12 months prior to registration, prior chemotherapy for locally recurrent or metastatic breast cancer, and a history of arterial or venous thrombosis within 1 year prior to registration.",
    "The sample is a phase 2 trial for endometriosis. The table includes information on the diseases, icd-10 codes, drugs, and eligibility criteria for the trial. The inclusion criteria require female participants aged 18 to 49 years with a diagnosis of endometriosis made within 8 years of screening and recurrent or persistent symptoms. Participants must also have a total CPSSS score of at least 6 in specific categories and negative mammogram results within 12 months of screening if over the age of 40 years. Exclusion criteria include current or recent use of certain medications, prior treatment with NBI-56418, abnormal cervical smear results, and chronic pelvic pain not caused by endometriosis. Participants must also agree to use two forms of nonhormonal contraception during the study.",
    "The sample is a phase 2 clinical trial for nicotine dependence and nicotine use disorder. The trial is testing the effectiveness of the drug bupropion sr in treating regular cigarette smokers who smoke at least 5 cigarettes per day and have a baseline urine cotinine level greater than 100 ng/ml. The trial is open to participants between the ages of 12 and 21, with post-menarchal females agreeing to use birth control to avoid pregnancy. The trial has a list of exclusion criteria, including active substance abuse/dependence (other than nicotine), lifetime bipolar affective disorder (BPAD), psychosis, eating disorders, current major depressive disorders, pregnancy or lactation, history of seizure disorder or predisposition to seizures, severe renal, hepatic, neurological, or chronic pulmonary disease, unstable medical problems, allergy to bupropion, current treatment with any other medication containing bupropion, current treatment with any monoamine oxidase (MAO) inhibitors, current treatment with nicotine replacement therapy (NRT), history of intolerance or non-response to bupropion SR, current (past month) suicide ideation, and suicide attempt (past year).",
    "The sample is a record of a clinical trial in phase 2, focused on sleep initiation and maintenance disorders. The trial involves the use of two drugs, sb-649868 and placebo. The eligibility criteria for the trial include being male, between the ages of 18 and 64, and having a diagnosis of primary insomnia with symptoms lasting at least three months. The exclusion criteria include any unstable medical or surgical condition, any history of neurological disorders or seizures.",
    "The sample is a phase 2 clinical trial for prostate cancer. The trial includes patients who are at least 18 years old and have metastatic disease. They must have had at least one previous treatment including docetaxel (Taxotere) and it must have been at least 3 weeks since their last surgery, radiation, or chemotherapy. Patients with an ECOG Performance Status of 0, 1, or 2 are eligible. However, patients with active brain metastases are excluded from the trial. The drug being tested is kos-862.",
    "The sample is a phase 2 clinical trial for the treatment of psoriasis vulgaris. The trial involves the use of multiple drugs, including 0.03% e6201, 0.1% e6201, 0.2% e6201, 0.005% e6201, 0.01% e6201, 0.05% e6201, and calcipotriene. The eligibility criteria for the trial include having chronic stable plaque psoriasis with one or two stable psoriatic plaques suitable for treatment, being between the ages of 18 and 75, having a normal physical examination (excluding the skin examination for psoriasis), and providing written informed consent. Exclusion criteria include having any clinically significant skin diseases other than chronic stable plaque psoriasis, using any concomitant topical treatment for the psoriatic plaque(s) to be studied within 8 weeks before the baseline visit, and planning on significant exposure to sun (sun-bathing).",
    "The sample is a phase 2 clinical trial for the treatment of schizophrenia using a drug called jnj-37822681. The trial is looking for participants who have been diagnosed with schizophrenia for at least 12 months and have a Positive and Negative Syndrome Scale score at Screening less than 70. Participants must also have a Body Mass Index (BMI) between 18 and 35 kilogram divided by square meter inclusive. Female participants must meet certain criteria to be eligible for the trial. The trial has exclusion criteria, including any medical condition that could potentially alter the absorption, metabolism or excretion of the study medication, and a history of neuroleptic malignant syndrome. The trial is looking to exclude participants who have a significant risk of suicidal or violent behavior.",
    "The sample is a phase 2 clinical trial for patients with glioblastoma multiforme, a type of brain cancer. The trial is testing the drug XL184 and the eligibility criteria includes having a confirmed diagnosis of Grade 4 astrocytic tumor, having received prior standard radiation and temozolomide therapy, being in first or second Grade 4 relapse, having a KPS of \u2265 70%, and being at least 18 years old. The trial also has exclusion criteria, such as not having received certain types of therapy within a certain timeframe, having serious intercurrent illness, or having a known allergy or hypersensitivity to any of the components of the XL184 formulations.",
    "The sample is a phase 2 clinical trial for metastatic colorectal cancer. The trial involves the use of drugs such as vismodegib, bevacizumab, modified folfox, and folfiri. The eligibility criteria for the trial include being at least 18 years old, having confirmed metastatic colorectal cancer, having a performance status of 0 or 1, and having adequate hematopoetic, hepatic, and renal function. Exclusion criteria include prior chemotherapy for metastatic CRC or adjuvant chemotherapy for CRC within the prior 6 months, clinically suspected or confirmed CNS metastases or carcinomatous meningitis, and uncontrolled medical illnesses. The trial requires signed informed consent and representative tumor specimens in paraffin blocks or at least 15 unstained slides.",
    "The sample is a phase 2 clinical trial for Huntington's disease. The inclusion criteria require patients to have genetically confirmed, manifest HD with motor signs, be in clinical stages I to III, be ambulatory and able to attend outpatient visits, be between the ages of 30 and 70, have a body mass index between 18 and 31 kg/m2, and be able to give informed consent or have a legal representative who can consent on their behalf. The exclusion criteria include participation in a study with an investigational drug within 30 days of the baseline visit, any prior or concomitant use of Class I or Class II histone deacetylase inhibitors, clinical evidence of significant or unstable medical illness, QTcF interval >450 ms in men and >470 ms in women or PR >220 ms, women who are pregnant or breastfeeding, and current diagnosis or history of any alcohol or substance abuse.",
    "The sample is a record of a clinical trial with a phase 2 designation. The trial is focused on acute myelogenous leukemia and acute myeloid leukemia, with a list of corresponding ICD-10 codes. The drug being tested is clofarabine. The eligibility criteria for the trial include a diagnosis of AML, age over 60, a certain performance status, and the presence of at least one adverse prognostic factor. The patient must also have adequate renal and hepatic function, as well as adequate cardiac function. There are several exclusion criteria, including prior treatment with clofarabine, prior treatment for AML or an antecedent hematologic disorder, and ongoing uncontrolled systemic infection. The sample also includes a list of inclusion and exclusion criteria in natural language.",
    "The sample is a phase 2 clinical trial for the treatment of chronic hepatitis C. The trial involves the use of three drugs, telaprevir, ribavirin, and pegylated interferon alfa 2a. The eligibility criteria for the trial include having hepatitis C virus genotype 1 with detectable plasma hepatitis C virus RNA, being infected with hepatitis C virus for more than 6 months, and being seronegative for hepatitis B surface antigen and Human Immunodeficiency Virus 1 and 2. Female subjects must have a negative pregnancy test at all visits before the first dose and must agree to use two methods of contraception, including one barrier method, during and for 24 weeks after the completion of the study (unless the subject is a female of documented non-child-bearing potential). The exclusion criteria include having received any approved or investigational drug or drug regimen for the treatment of hepatitis C, having any medical contraindications to Pegylated Interferon Alfa 2a or Ribavirin therapy, having any other cause of significant liver disease in addition to hepatitis C, being diagnosed or suspected of having hepatocellular carcinoma, having histologic evidence of hepatic cirrhosis, alcohol abuse or excessive use in the last 12 months, and participation in any investigational drug study within 90 days before drug administration or participation in more than 2 drug studies in the last 12 months (exclusive of the current study).",
    "The sample is a record of a clinical trial that is in phase 2/phase 3. The trial is focused on heart failure, congestive disease and the icd-10 codes associated with it. The trial involves the use of two drugs, relaxin and placebo. The eligibility criteria for the trial include being hospitalized for acute heart failure, experiencing dyspnea at rest or with minimal exertion, having pulmonary congestion, being able to provide informed consent, having systolic blood pressure greater than 125 mmHg, and having impaired renal function defined as an eGFR of 30-75 mL/min/1.73m2. The exclusion criteria include the use of other IV therapies for acute heart failure, fever or sepsis, recent major neurologic event, recent major surgery, recent acute coronary syndrome, and other recent investigational drug use.",
    "The sample is a phase 2 clinical trial for coronary artery disease. The trial includes patients between the ages of 45 and 80 who have confirmed coronary artery disease and are receiving aspirin. The trial involves the use of the drug e5555 in various doses and a placebo. The eligibility criteria include being able to provide informed consent, not having a bleeding disorder or recent trauma/surgery, and not being pregnant or lactating. The trial also excludes patients with congestive heart failure or a history of bleeding disorders.",
    "The sample is a phase 2 clinical trial for patients with locally advanced or metastatic breast cancer. The trial involves the use of two drugs, gemcitabine hydrochloride and imatinib mesylate. The eligibility criteria include having confirmed breast cancer, measurable disease, and disease progression after at least one prior chemotherapy regimen for metastatic disease. Patients must also meet certain patient characteristics such as having an ECOG performance status of 0-2 and a life expectancy of at least 3 months. Prior concurrent therapy is also taken into consideration. The sample includes a detailed list of eligibility criteria for both disease and patient characteristics, as well as prior concurrent therapy.",
    "The sample is a phase 2 clinical trial for the treatment of type 2 diabetes. The trial includes patients who have been diagnosed with type 2 diabetes for at least three months and have a stable treatment regimen with either metformin or diet and exercise alone. The trial also requires patients to have a HbA1c level between 7.0-10.0% and a body weight between 60 kg and 110 kg. Patients who have been treated with insulin, GLP-1 receptor agonists, dipeptidyl peptidase-4 inhibitors, sulphonylurea, thiazolidinediones, Alpha-GIs, or any investigational drug within the last three months are excluded from the trial. Patients with impaired liver or kidney function, proliferative retinopathy or maculopathy requiring acute treatment, clinically significant active cardiovascular disease and uncontrolled treated/untreated hypertension, recurrent major hypoglycaemia or hypoglycaemic unawareness, or present or planned use of any drug which could interfere with the glucose levels are also excluded from the trial. The trial includes the use of the drug semaglutide, liraglutide, and a placebo.",
    "The sample is a phase 2 clinical trial for asthma patients. The trial includes patients who are 12 years or older, non-smokers or former smokers with a smoking history of \u2264 10 pack years, and have been diagnosed with asthma as defined by the National Institutes of Health. The trial also requires patients to have a Best FEV1 of 50% to <80% of the predicted normal value, a post-albuterol FEV1/FVC ratio of >0.70 at Visit 1/1a (between 5:00AM and 12:00 noon), and \u2265 12% and \u2265200mL reversibility of FEV1. Patients must have been using FP 100mcg inhalation powder BID for at least 2 weeks just prior to Visit 1 and must be able to replace their current short-acting beta2-agonists with albuterol inhalation aerosol. Patients must also be able and willing to give written informed consent to take part in the study and comply with all aspects of the study including completion of daily e-Diary. The trial has exclusion criteria such as history of life-threatening asthma, recent asthma exacerbation, concurrent respiratory disease, recent respiratory infection, liver disease, other concurrent diseases/abnormalities, oral candidiasis, drug allergy, milk protein allergy, immunosuppressive medications, administration of systemic, oral or depot corticosteroids within 12 weeks of Visit 1, OATP1B1 substrates within 4 weeks of Visit 1, Cytochrome P450 3A4 (CYP 3A4) Inhibitors, Cytochrome P450 3A4 (CYP 3A4) Inducers, Investigational Medications, compliance issues, and affiliation with Investigator's Site.",
    "The sample is a phase 2 clinical trial for the treatment of type 2 diabetes. The trial includes patients with a diagnosis of type 2 diabetes and an Hb1AC level between 7% and 11%. The trial drugs include a placebo and various doses of pf-00734200. Patients must be between the ages of 18 and 70, with females being post-menopausal. Patients must also be on a stable dose of metformin hydrochloride. Exclusion criteria include a medical history of stroke, unstable angina, heart attack within one year of enrollment, and alcohol dependency or recent drug abuse. Women who are pregnant, nursing, or of childbearing potential are also excluded, as well as patients with evidence of diabetic complications with significant end-organ damage.",
    "The sample is a record of a clinical trial with a phase 2 designation. The trial is focused on the disease of hypercholesterolemia, which is characterized by high levels of LDL cholesterol in the blood. The trial includes a list of ICD-10 codes associated with the disease. The trial involves the use of three drugs: ave5530, placebo, and ezetimibe. The eligibility criteria for the trial are listed, including requirements for patient age, LDL-C baseline levels, and exclusion criteria such as the presence of endocrine disease or a history of cancer. The sample concludes with a disclaimer that the information provided is not exhaustive and that other considerations may be relevant to a patient's potential participation in the trial.",
    "The sample is a phase 2 clinical trial for prostate cancer. The trial includes patients with histologically confirmed adenocarcinoma of the prostate, clinical stage T1-T3a disease, and a Kattan pre-operative nomogram-predicted 5-year risk of recurrence-free survival of 80% or less. Patients must be deemed eligible for radical prostatectomy and willing to have a tumor biopsy if previous tumor tissue is unavailable for tumor marker analysis. The trial also includes a list of exclusion criteria, such as no evidence of regional, lymph node or distant metastasis, no prior malignancy in the past 2 years except for basal cell and squamous cell carcinoma of the skin, and no prior hormonal therapy with the exception of oral 5-alpha-reductase inhibitors. The trial involves the use of two drugs, dasatinib and leuprolide acetate (lhrh analogue), and patients must be willing to use an effective method of contraception from the time consent is signed until 6 weeks after treatment discontinuation. The eligibility criteria also include written informed consent and HIPAA authorization for release of personal health information, age > 18 years at the time of consent, and ability to comply with study and/or follow-up procedures and requirements.",
    "The sample is a phase 2 clinical trial for patients with extensive stage small cell lung cancer. The trial involves the use of drugs such as cisplatin, etoposide, paclitaxel, and topotecan hydrochloride. The eligibility criteria include having at least one measurable non-CNS lesion, being at least 18 years old, having a performance status of ECOG 0-2, and having no other severe medical problems or medical conditions that would preclude study. Patients must also not be pregnant or nursing, and must use effective contraception during the study. The trial excludes patients with preexisting cardiac disease, congestive heart failure, or cardiac arrhythmia requiring therapy, as well as those with other concurrent or prior malignancies within the past 5 years. Prior chemotherapy is not allowed, but concurrent radiotherapy for bone pain control is allowed.",
    "The sample is a phase 2 clinical trial for patients with cervical carcinoma, including squamous and non-squamous types. The trial is for patients with unresectable recurrent cervical cancer and requires measurable disease that can be assessed using RECIST criteria. Patients must also have a performance status ECOG of 0-2 and a life expectancy of 3 months or greater. They must be suitable candidates for receiving planned therapy as evidenced by screening laboratory assessments of hematologic, renal, hepatic, and metabolic functions. Patients must also have a prior therapy with cisplatin or carboplatin. The trial has exclusion criteria, including pregnant or nursing women, patients with a history of CNS metastases, and patients who are poor medical risk because of other non-malignant systemic disease or active, uncontrolled infection.",
    "This is a sample from a table that contains information about clinical trials. The trial is in phase 2 and is focused on treating metastatic pancreatic cancer. The trial involves the use of a drug called rx-0201 in combination with gemcitabine. The table also includes a list of inclusion and exclusion criteria for participants in the trial. Inclusion criteria include being over 18 years old, having metastatic pancreatic cancer, and having a Karnofsky Performance Status of over 70. Exclusion criteria include having been treated with another investigational agent for pancreatic cancer, having certain abnormal laboratory values, and having a history of brain cancer or an active hematologic malignancy. The table also includes information about acceptable forms of birth control for female participants.",
    "The sample is a phase 2 clinical trial for the treatment of major depressive disorder using the drug gw679769. The trial includes patients who have been diagnosed with major depressive disorder and are willing to comply with the study requirements. Women of childbearing potential must agree to use a form of birth control. Patients with other Axis 1 disorders, recent use of psychiatric medications, current suicidal or homicidal risk, substance abuse or dependence, or abnormal laboratory tests or ECGs are excluded from the trial. The diseases and their corresponding ICD-10 codes are also listed in the sample.",
    "The sample is a phase 2 trial for patients with metastatic renal cell carcinoma. The trial includes patients with measurable disease and who have discontinued therapy due to toxicity or demonstrated progression of disease following a minimum of one prior therapy. Patients may have received prior radiation therapy, but not prior tubule, DNA, or mitosis targeting agents for the treatment of renal cell carcinoma. Patients must have a ECOG performance status of 0 - 2 and meet certain eligibility criteria related to their health status. The trial involves the use of the drug ispinesib and patients must not have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to SB-715992. The trial prohibits the use of certain medications/substances that are moderate to significant inhibitors/inducers of CYP3A4. Patients must be informed of the investigational nature of the study and must sign and give written informed consent in accordance with institutional and federal guidelines.",
    "This sample is a phase 2 clinical trial for the treatment of schizophrenia. The trial is testing the effectiveness of the drugs gwp42003 and gwp42004 (in a 40:1 ratio) compared to a placebo. The eligibility criteria for participants include a diagnosis of schizophrenia or functional psychosis, receiving olanzapine treatment for no more than 3 months, evidence of weight gain attributable to olanzapine, and willingness to maintain a stable dose of olanzapine and any concomitant medications. Exclusion criteria include a diagnosis of schizoaffective disorder, drug-induced or toxic psychosis, and significant history of anxiety or suicidal ideation. The trial also excludes participants with certain medical conditions such as diabetes, cardiac, renal or hepatic impairment, and genetic dyslipidaemic condition. Participants must also be willing to use effective contraception if of child-bearing potential.",
    "The sample is a phase 2 clinical trial for patients with unresectable liver metastases secondary to colorectal adenocarcinoma. The trial involves the use of a combination of drugs including folfox regimen, fluorouracil, leucovorin calcium, and oxaliplatin. The eligibility criteria include having fewer than 10 metastatic deposits on the liver, total metastatic involvement of the liver no more than 50%, and adequate treatment of all metastatic lesions deemed possible either by radiofrequency interstitial ablation (RFA) alone or by a combination of resection of resectable lesions and RFA of the remaining unresectable lesions. Patients must also meet certain patient characteristics such as being between the ages of 18 and 80, having a WHO performance status of 0-1, and meeting certain hematopoietic, hepatic, renal, and cardiovascular requirements. Prior concurrent therapy is also specified.",
    "The sample is a record of a clinical trial with a phase 2 designation. The trial is focused on the disease hepatitis C and includes a list of ICD-10 codes associated with the disease. The trial involves several drugs, including peg-intron, rebetol, and hcv 796. The eligibility criteria for the trial include being infected with HCV genotype 1 and being a non-responder to previous treatments. The exclusion criteria include being pregnant or breastfeeding, having ALT or AST levels that are 5 times higher than the upper limit of normal.",
    "The sample is a phase 2 clinical trial for liver cancer patients who are not eligible for surgical or radical therapies. The trial involves the use of doxorubicin hydrochloride as a treatment. The eligibility criteria include having a confirmed diagnosis of hepatocellular carcinoma or another incurable solid tumor, having at least one measurable lesion, and meeting certain medical requirements such as having a normal LVEF and no known brain metastases. Patients must also not have any concurrent uncontrolled illnesses or ongoing infections, and must not be pregnant or nursing. Prior concurrent therapies are also taken into consideration.",
    "The sample is a phase 2 clinical trial for the treatment of acute coronary syndrome. The trial involves the use of the drugs e5555 and placebo. The eligibility criteria include being between 45-80 years old, having confirmed acute coronary syndrome, and being willing and able to provide informed consent. Exclusion criteria include a history of bleeding disorders or recent trauma or major surgery. Pregnant or lactating women are also excluded from the trial.",
    "The sample is a phase 2 clinical trial for patients with invasive breast cancer and measurable central nervous system (CNS) disease. The trial requires patients to have new or progressive CNS lesions after at least one prior standard CNS-directed therapy. Patients must have received prior whole brain radiotherapy (WBRT), stereotactic radiosurgery (SRS), or both. The trial aims to evaluate systemic chemotherapy as an alternative to additional brain radiotherapy. Patients must meet certain inclusion criteria, such as having normal organ function, an ECOG Performance Status of 0-2, and a life expectancy of greater than 12 weeks. Patients must also not meet certain exclusion criteria, such as having received chemotherapy or XRT within 3 weeks prior to entering the study, or having leptomeningeal carcinomatosis as the only site of CNS involvement. Pregnant or breastfeeding women are also excluded from the trial.",
    "The sample is a phase 2 trial for the treatment of Raynaud's disease and peripheral vascular disease. The trial involves the drug pf-00489791 and has eligibility criteria for inclusion and exclusion. Inclusion criteria include having active Raynaud's Phenomenon and stable disease and medication requirements over the previous two months. Exclusion criteria include uncontrolled hypertension, diabetes mellitus, angina, smoking within 3 months, and currently taking certain medications. The trial is open to both sexes, but pregnant or breastfeeding women are excluded. The trial is not open to those who have participated in a trial for an investigational drug within the last 30 days.",
    "The sample is a record from a clinical trial table. It is a phase 2 trial for a drug called \"indantadol\" that is being tested for the treatment of chronic cough. The trial is looking for male or female participants between the ages of 18-75 who have been diagnosed with chronic cough for more than 8 weeks and have normal chest X-rays and lung function. The trial has a list of exclusion criteria, including recent upper respiratory tract infections, pregnancy or breastfeeding, smoking history, and certain medical conditions. The trial is also excluding participants who are currently taking ACE inhibitors or have a history of drug or alcohol abuse. The sample includes a list of diseases and their corresponding ICD-10 codes, as well as the eligibility criteria for the trial.",
    "This sample is a phase 2 clinical trial for chronic myeloid leukemia. The trial is testing the drug bosutinib on patients who are primarily refractory to full-dose imatinib, have disease progression/relapse while on full-dose imatinib, or are intolerant of any dose of imatinib. The trial includes patients who are at least 3 months post stem cell transplantation and able to take daily oral capsules/tablets reliably. The eligibility criteria includes exclusion of subjects with Philadelphia chromosome and bcr-abl negative CML, overt leptomeningeal leukemia, and subjects without evidence of leukemia in bone marrow (extramedullary disease only).",
    "The sample is a phase 2 clinical trial for ovarian cancer patients who have already undergone initial cytoreductive surgery and chemotherapy with at least one platinum-based chemotherapy regimen. The trial is testing the effectiveness of the drug combination of gleevec and paclitaxel. The eligibility criteria include being at least 18 years old, having a histologically documented diagnosis of epithelial carcinoma arising in the ovary, fallopian tube or peritoneum, measurable disease, and a performance status of 0, 1, or 2. Exclusion criteria include having received any other anticancer treatment within 21 days of the first day of study drug dosing, having another primary malignancy that has required active intervention within 5 years, and having Grade III/IV cardiac problems as defined by the New York Heart Association Criteria.",
    "The sample is a phase 2 clinical trial for the treatment of hyperphosphatemia and end-stage renal disease using the drug ferric citrate. The trial includes eligibility criteria for participants, such as being on thrice weekly hemodialysis for at least the previous 3 months, having phosphorous levels \u22653.5mg/dL at the screening visit, and being willing to discontinue current phosphate binders and initiate treatment with Zerenex. Exclusion criteria include a history of multiple drug allergies, intolerance to oral ferric citrate, and any medical condition that would interfere with optimal participation in the study or produce significant risk to the patient. The trial also includes a list of diseases and their corresponding ICD-10 codes.",
    "The sample is a record of a clinical trial with a phase 2 designation. The trial is focused on macular degeneration, with a list of associated ICD-10 codes provided. The trial involves testing three different drugs: verteportin photodynamic therapy (low fluence) and bevacizumab, verteportin photodynamic therapy (very low fluence) and bevacizumab, and verteportin photodynamic therapy (sham) and bevacizumab. The eligibility criteria for the trial include having new wet AMD, while the exclusion criteria are not specified.",
    "This sample is for a phase 2 clinical trial for asthma. The table includes information on the diseases being studied, the icd-10 codes associated with those diseases, the drugs being tested, and the eligibility criteria for participants. The inclusion criteria require a documented clinical history of chronic asthma symptoms and participants must be between 18-70 years old. The exclusion criteria include a history of kidney or chronic liver disease, recent heart problems, and evidence of another active lung disorder.",
    "The sample is a phase 2 clinical trial for patients with colorectal cancer. The trial requires patients to have confirmed colorectal cancer with measurable disease and no known curative therapy. Patients must also meet certain eligibility criteria, including being 70 years or older, having an ECOG performance status of 0-1, and having a life expectancy of more than 3 months. Patients must also meet certain hematopoietic, hepatic, renal, cardiovascular, and pulmonary requirements, and must not have any other severe or uncontrolled systemic disease. Prior concurrent therapy is also restricted, with no prior chemotherapy for metastatic colon cancer and no prior irinotecan or oxaliplatin. The drug being tested in the trial is capecitabine, and patients must not have any known hypersensitivity to fluorouracil or capecitabine.",
    "This sample is for a phase 2 clinical trial for rheumatoid arthritis. The trial is testing the effectiveness of a placebo drug. The inclusion criteria for the trial include having RA for at least 3 months, taking MTX for at least 3 months before randomization, and meeting certain disease activity criteria. The exclusion criteria include having a functional status class IV according to the ACR 1991 revised criteria, previous exposure to certain drugs, taking high potency opioid analgesics, and receiving certain intra-articular injections within 4 weeks before randomization. Other protocol-defined inclusion/exclusion criteria may also apply.",
    "The sample is a record of a clinical trial in phase 2 for the treatment of chronic lymphocytic leukemia. The trial involves the use of drugs such as cyclophosphamide, doxorubicin hydrochloride, prednisone, and vincristine sulfate. The eligibility criteria for the trial include a confirmed diagnosis of previously treated CLL, with Binet stage B or C disease, rapid disease progression, symptomatic enlarged lymph nodes, or severe B-cell symptoms. Patients with autoimmune hemolytic anemia or Richter transformation are also allowed. Other eligibility criteria include a life expectancy of more than 3 months, an ECOG performance status of 0-3, no severe organ dysfunction, and no more than 4 prior chemotherapy regimens.",
    "The sample is a clinical trial for patients with metastatic breast cancer and bone metastases. The trial is in phase 2/phase 3 and the drug being tested is zoledronic acid. The eligibility criteria include being a female over 18 years old with confirmed invasive breast cancer and bone metastases, having an ECOG Performance Status of 0 to 2, and a life expectancy of more than 3 months. The patient must also have adequate organ function and have ceased anti-tumor treatment for over 28 days. Exclusion criteria include being pregnant or lactating, having a history of other malignancy, having concurrent diseases or conditions that would make the patient inappropriate for study participation, and having active or uncontrolled infection. The trial also excludes patients with recent dental or jaw surgery, known hypersensitivity to bisphosphonates, and a history of treatment with calcitonin, gallium nitrate or mithracin within 14 days before the study.",
    "The sample is a phase 2 clinical trial for patients with adenocarcinoma of the pancreas, including those with recurrent, stage II, stage III, and stage IV pancreatic cancer. The trial is testing the effectiveness of sorafenib tosylate and gemcitabine hydrochloride as treatments for locally advanced or metastatic disease that is not amenable to curative surgery or radiotherapy. The eligibility criteria include having measurable disease, a performance status of ECOG 0-1 and Karnofsky 70-100%, and meeting various laboratory and medical criteria. Patients must not have brain metastases, active or ongoing infections, or other active malignancies, and must not have received prior antiangiogenic agents or cytotoxic chemotherapy for metastatic disease. The trial also excludes patients with certain medical conditions or psychiatric illnesses that would preclude study compliance. Concurrent warfarin anticoagulation is allowed under certain conditions, but other concurrent investigational agents or anticancer therapies are not allowed.",
    "The sample is a phase 2 clinical trial for the treatment of head and neck cancer using the drug thalidomide. The trial is open to patients who have been diagnosed with squamous cell carcinoma of the head and neck and have either recurrent or metastatic disease. Patients must have undergone initial therapy of surgery and/or radiotherapy, induction chemotherapy, or concurrent chemotherapy and radiotherapy. They must also have no more than one prior regimen of chemotherapy or biologic therapy for metastatic disease. Patients must meet certain eligibility criteria, including being 18 years or older, having a Zubrod performance status of 0-2, and having a life expectancy of at least 3 months. They must also have certain laboratory values within normal limits and not have any serious infections or other concurrent illnesses requiring immediate therapy. Patients must be able to take oral medications and have no medical or social factors that would interfere with compliance. Prior concurrent therapy is not allowed, and patients cannot receive concurrent cytotoxic chemotherapy or radiotherapy during the trial.",
    "The sample is a phase 2 clinical trial for mild to moderate Alzheimer's disease. The trial involves the drugs azd1446 and placebo. The eligibility criteria for the trial include a history of progressive worsening of memory and other cognitive functions for at least 12 months, treatment with a stable dose of donepezil for at least 3 months, and the patient should have an appropriate caregiver who is required for all study visits. The exclusion criteria include a history of allergy/hypersensitivity reactions, significant neurological disease or dementia other than Alzheimer's disease, and myocardial infarction or acute coronary syndrome within the last year.",
    "The sample is a phase 2 clinical trial for the treatment of prostate cancer using the drug metformin. The trial is open to patients who are between the ages of 18 and 75 and have histologically confirmed prostate cancer involving at least 20% of at least one unfragmented biopsy core. Patients must have normal organ and marrow function and an ECOG performance status less than or equal to 2. Patients who are currently on treatment for any form of diabetes or who have a history of impaired liver or kidney function are excluded from the trial. The trial also excludes patients who are receiving any other investigational, herbal, or anticancer agents while on study, have uncontrolled intercurrent illness, or have a current history of alcohol intake or binge drinking. The trial has a list of inclusion and exclusion criteria that patients must meet to participate.",
    "This sample is for a phase 2 clinical trial for colorectal cancer. The trial is looking for patients with locally advanced or metastatic synchronous disease that is considered susceptible to treatment with radiotherapy and chemotherapy. The patients must have measurable disease by thoraco-abdomino-pelvic scanner and the primary tumor must be examined by endorectal echography and MRI. The trial is testing the effectiveness of capecitabine, fluorouracil, leucovorin calcium, and oxaliplatin as treatments. The eligibility criteria include ECOG performance status 0-2, certain blood counts and levels, and no contraindications to the treatments being tested. The exclusion criteria include uncontrolled severe illness, severe renal or hepatic insufficiency, and other malignancies within the past 10 years. Prior concurrent therapy is not allowed, and patients cannot be participating in another therapeutic study or receiving another experimental drug.",
    "The sample is a phase 2 clinical trial for breast cancer. The trial is for postmenopausal women with histologically confirmed invasive breast cancer with a primary tumor of 3 cm or more in greatest dimension. The patients must have estrogen receptor and/or progesterone receptor positive disease and must not have received any prior treatment for current or newly diagnosed breast cancer. The trial involves the use of two drugs, iressa and arimidex, given on day 1 and day 21 with faslodex. The eligibility criteria include adequate organ function, a WHO performance status of 0, 1, or 2, and a life expectancy of at least 1 year. The exclusion criteria include premenopausal status, brain metastasis, and other coexisting malignancies. Patients must also stop taking estrogens or progestins at least two weeks prior to study entry. The trial requires breast core biopsies and patients must be willing to undergo them.",
    "The sample is a record from a clinical trial table. It is a phase 2 trial for the treatment of metastatic renal cell cancer using the drug AG-013736. The trial is looking for patients who have been diagnosed with clear cell cancer and have already undergone nephrectomy. Patients must also have at least one target lesion and cannot have uncontrolled hypertension. The inclusion and exclusion criteria are listed in detail. The diseases column lists only one disease, carcinoma renal cell, and the icd-10 codes column lists several codes related to this disease.",
    "The sample is a phase 2 clinical trial for patients with asthma. The trial includes patients who have been diagnosed with asthma by a physician and are currently prescribed ICS or ICS-LABA therapy. Patients must also have reversible airway obstruction, significant FEV1 variability or airway hyperresponsiveness, or have shown such responses in previous tests within the last five years. Additionally, patients must have an ACQ score \u2265 1.5 at randomization or \u2265 1 exacerbations in the past 12 months. Patients currently on GINA step 2 to step 5 asthma therapies and with a sputum eosinophil count \u2265 2% at screening are also eligible. The trial excludes patients who have used other investigational drugs within 30 days or 5 half-lives of enrollment, have a history of hypersensitivity to any of the study drugs or to drugs of similar chemical classes, have a history of long QT syndrome or whose QTc interval is prolonged, have a history of malignancy of any organ system within the past 5 years, are pregnant or nursing, have a recent or current lower respiratory tract infection, have clinically significant laboratory abnormalities or abnormality on a 12-lead ECG, or have a body mass index < 17 or > 40 kg/m2. Other protocol-defined inclusion/exclusion criteria may also apply.",
    "The sample is a phase 2 clinical trial for patients with incurable melanoma. The trial includes patients with measurable disease that has progressed despite other treatments. Patients must have received no more than one prior chemotherapy or biological therapy, and must meet certain health criteria such as having a life expectancy greater than 4 months and a certain level of blood counts. The trial involves the use of a drug called 7-hydroxystaurosporine. Patients must also meet certain exclusion criteria, such as having uncontrolled illnesses or a history of diabetes. The trial requires patients to have a central venous catheter and to submit archival tissue for pre-study and undergo a tumor biopsy 24 hours post UCN-01 administration if feasible.",
    "The sample is a clinical trial for rheumatoid arthritis, in which patients with a disease duration of more than 5 years and who are RA latex seropositive or IgM RF ELISA >14iu/ml will be selected from a high-risk population of hospital clinic attendees. The trial is a phase 2/phase 3 trial and involves the use of the drugs rosuvastatin and placebo. The eligibility criteria include having both tender and swollen joint counts >4 each and either a CRP >10mg/l, ESR >25mm/h or PV >1.78. Patients on cyclosporine or other medications known to be contraindicated with this form of drug will not be enrolled. The exclusion criteria include evidence of symptomatic vascular disease, those already taking lipid-lowering therapy or those with contraindications to these therapies, and subjects with a total cholesterol level of >7.5mmol/L.",
    "The sample is a phase 2 clinical trial for patients with type 2 diabetes mellitus. The trial is testing the effectiveness of the drugs ly2409021 and placebo. The eligibility criteria include having a stable diagnosis of type 2 diabetes, being within a certain range of hemoglobin A1c and body mass index, and not having certain medical conditions or taking certain medications. Patients must also be willing and able to comply with the study requirements. The trial has exclusion criteria for patients with certain medical conditions or taking certain medications, as well as those with a history of severe hypoglycemia or poor glucose control.",
    "The sample is a phase 2 clinical trial for breast cancer patients who have already received at least two and not more than five prior chemotherapeutic regimens for locally advanced or metastatic disease. The trial is testing the drug E7389. The eligibility criteria include having measurable disease, resolution of all chemotherapy or radiation-related toxicities to less than Grade 2 severity, and adequate renal, bone marrow, and liver function. Patients must not have received chemotherapy, radiation, or biologic therapy within two weeks, hormonal therapy within one week, or trastuzumab within three weeks before E7389 treatment start. Patients must not have pre-existing neuropathy > Grade 2 and must not have participated in a prior E7389 clinical trial. The sample includes the inclusion and exclusion criteria for the trial.",
    "The sample is a phase 2 clinical trial for patients with metastatic melanoma. The trial is testing the effectiveness of chemotherapy with paclitaxel and carboplatin or temozolomide alone for patients with progressive disease who have no known standard therapy that can cure or extend their life expectancy. The trial requires patients to have measurable disease as defined by RECIST criteria and meet certain patient characteristics such as having an ECOG performance status of 0-2 and a life expectancy of at least 3 months. Patients must also meet certain eligibility criteria such as having no uncontrolled intercurrent illness and not being pregnant or nursing. Prior concurrent therapy is also taken into consideration.",
    "This sample is for a phase 2 clinical trial for the treatment of idiopathic restless legs syndrome. The trial involves the drug \"spm 962\". The eligibility criteria for the trial are listed, including inclusion criteria such as having completed a preceding trial and exclusion criteria such as having a history of certain medical conditions or having experienced certain adverse events during the preceding trial. The criteria also include restrictions on certain medical values such as serum potassium levels and QTc-interval. The trial is not open to individuals who plan to become pregnant during the trial or who have been deemed inappropriate for the trial by the investigator.",
    "The sample is a phase 2 clinical trial for patients with uterine carcinosarcoma, a type of sarcoma. The trial is for patients with stage III or IV disease, persistent or recurrent disease, and documented disease progression. Patients must have measurable disease and be ineligible for any higher priority Gynecology Oncology Group (GOG) protocol. The trial also has specific patient eligibility criteria, including age, performance status, hematopoietic, hepatic, renal, and other factors. Patients must not have had prior cytotoxic chemotherapy for uterine sarcoma and must have recovered from all prior therapy. The trial involves the use of carboplatin and paclitaxel as treatment.",
    "The sample is a record of a clinical trial in phase 2, focused on treating non-small-cell lung carcinoma. The trial includes a list of diseases and their corresponding ICD-10 codes, as well as a list of drugs being tested, which includes gefitinib, gemcitabine, and carboplatin. The eligibility criteria for the trial are also listed, including requirements for patients to have advanced non-small-cell lung cancer and to have never received chemotherapy. There are also exclusion criteria, such as the spread of lung cancer to the brain, low levels of white blood cells, and recent radiotherapy. The trial was initiated in 2004, before certain predictive factors such as smoking history, adenocarcinoma histology, and mutation status were known.",
    "The sample is a phase 2 clinical trial for patients with squamous cell carcinoma of the head and neck. The trial includes patients with stage III or IV disease without evidence of distant metastases. The inclusion criteria require patients to have at least one measurable lesion and be considered inoperable after evaluation by a multidisciplinary team. Patients must not have received previous chemotherapy or radiotherapy for any reason and no previous surgery for squamous cell carcinoma of the head and neck patients (other than biopsy) are allowed at the time of study entry. The trial also has exclusion criteria, including pregnant or lactating women or women of childbearing potential not using adequate contraception, previous or current malignancies at other sites, and other serious illnesses or medical conditions. The trial involves treatment with docetaxel, cisplatin and 5-fu treatment followed by concomitant cisplatin, 5-fu and radiotherapy or concomitant cisplatin, 5-fu and radiotherapy. The eligibility criteria are listed in detail in the sample.",
    "The sample is a phase 2 clinical trial for chronic obstructive pulmonary disease (COPD). The trial includes a list of diseases and their corresponding ICD-10 codes, a list of drugs being tested, and eligibility criteria for participants. The inclusion criteria require participants to have a diagnosis of moderate stable COPD, a smoking history of more than 10 pack-years, and the ability to perform reproducible spirometry maneuvers. The exclusion criteria include a history of significant respiratory disease other than COPD, recent exacerbation of COPD or lung infection, and use of certain medications. Participants must also agree to use birth control during the study if they are of childbearing potential.",
    "The sample is a record of a clinical trial with a phase 2 designation. The trial is focused on the disease multiple myeloma and includes a list of ICD-10 codes associated with the disease. The drug being tested is thalidomide. The eligibility criteria for the trial includes newly diagnosed multiple myeloma patients between the ages of 18 and 75 with measurable lesions. There are also exclusion criteria, such as having smoldering or indolent myeloma, having a history of DVT or pulmonary embolism, or having a serious medical or psychiatric illness likely to interfere with participation in the study.",
    "The sample is a record of a clinical trial with a phase 2 designation. The trial is focused on studying the effects of the drug DMSA on children between the ages of four and ten who have been diagnosed with autism, Asperger's disorder, or pervasive developmental disorder. The trial requires that the subjects have detectable levels of blood lead and/or blood mercury. The eligibility criteria include the legal guardians' understanding of the study and their written consent. The exclusion criteria include a history of allergic reactions to sulfur or thiol-containing substances, previous chelation therapy for autism, uncontrolled epilepsy, weight less than 15 kg, and the presence of a chronic medical condition that might interfere with study participation. The trial also excludes subjects with levels of lead above 10 microgram per d or level of mercury over 44 microgram per deciliter, recent initiation of behavior therapy, or other evidence of heavy metal toxicity.",
    "This sample is for a phase 2 clinical trial for patients diagnosed with myelofibrosis with myeloid metaplasia (MMM), including agnogenic myeloid metaplasia, post-polycythemic myeloid metaplasia, or post-thrombocythemic myeloid metaplasia. The trial is testing the effectiveness of lenalidomide and prednisone as treatment options. Patients must have discontinued chemotherapy and other myelosuppressive agents, growth factors, and systemic use of corticosteroids for at least 28 days prior to starting the study drug. They must also meet certain eligibility criteria, including having an ECOG performance status of 0, 1, or 2, and meeting certain blood count and laboratory test requirements. Women who are sexually active must use two accepted methods of birth control, and all females of childbearing potential must have a blood test to rule out pregnancy prior to starting lenalidomide treatment. Patients must not have any other active malignancy or known hypersensitivity to thalidomide or lenalidomide.",
    "The sample is a phase 2 clinical trial for individuals with neoplasms or cancer. The trial involves the drug enzastaurin and has specific eligibility criteria, including having previously participated in and finished certain studies, having no other therapy available to prolong life, having measurable or detectable cancer lesions, and not being pregnant or breastfeeding. Exclusion criteria include recent treatment with experimental drugs, CNS tumors, serious disorders or infections, and having a second cancer in addition to the primary cancer.",
    "The sample is a phase 2 clinical trial for breast cancer patients. The trial is looking at the effectiveness of the drug cisplatin in treating newly diagnosed primary invasive ductal breast adenocarcinoma. The inclusion criteria for the trial include being over 18 years old, having a tumor classified as clinically stage T2, T3 or T4 with any N, and not expressing certain biomarkers. Patients must also have adequate organ function and normal left ventricular function. Exclusion criteria include having evidence of distant metastasis, prior malignancies (with some exceptions), being pregnant or breastfeeding, having a Karnofsky Performance Status of <= 70, having known history neural deficiencies or hearing impairment, and being male.",
    "The sample is a phase 2 trial for breast cancer and radiation toxicity. The trial includes patients who have been diagnosed with invasive or in situ epithelial cancer of the breast, with stage 0, I, or II disease. Patients must have undergone prior surgical resection of the primary lesion and axillary nodal evaluation, with negative surgical margins. They must also be planning to undergo radiotherapy with either standard external beam radiotherapy or accelerated partial breast irradiation. Patients with Paget disease of the nipple or evidence of distant metastases are not eligible. Hormone receptor status is not specified. Patients must have a Karnofsky performance status of 70-100%, and meet certain medical criteria such as having transaminases and creatine kinase levels within normal limits. Patients must not have any major medical or psychiatric illness that would prevent completion of study treatment or interfere with follow-up. Prior concurrent therapy is allowed, but patients must not have had prior radiotherapy to the breast, lung, or mediastinum, and must not have received chemotherapy for at least 2 weeks prior to, during, and for at least 2 weeks after completion of radiotherapy. Concurrent HMG-coA-reductase inhibitor is allowed provided the patient is able to switch to 20 mg of lovastatin per day, and concurrent tamoxifen or an aromatase inhibitor is also allowed.",
    "The sample is a phase 2 clinical trial for chronic hepatitis B. The trial includes participants between the ages of 18 and 69 who have HBV DNA levels of at least 1000 copies/mL and decompensated liver disease. The trial tests the effectiveness of several drugs, including tenofovir disoproxil fumarate, emtricitabine/tenofovir disoproxil fumarate, and entecavir, as well as placebos. The eligibility criteria include meeting certain medical requirements, such as having a CPT score of 7-12, a serum alanine aminotransferase level below 10 times the upper limit of the normal range, and a hemoglobin level of at least 7.5 g/dL. Participants must also have negative HIV, HCV, and HDV serologies and have not been exposed to adefovir dipivoxil for more than 24 months. Exclusion criteria include pregnancy, prior use of TDF or ETV, and current use of certain drugs.",
    "The sample is a phase 2 clinical trial that involves patients with metastatic or locally advanced refractory breast cancer, non-small cell lung cancer, or prostate cancer. The trial is testing the effectiveness of the drug vinorelbine oral formulation. The eligibility criteria include signed informed consent, age between 16 and 75 years, performance status 0-2, life expectancy of at least 16 weeks, adequate bone marrow, hepatic and renal functions, absence of brain metastasis, and having been previously treated with no more than two chemotherapeutic regimens. The exclusion criteria include major active infection, more than two prior chemotherapy regimens for metastatic disease, and other severe acute or chronic medical or psychiatric condition that would make the patient inappropriate for entry into the trial.",
    "The sample is a phase 2 clinical trial for patients with colorectal cancer. The trial includes patients with advanced and/or metastatic disease that is measurable by RECIST criteria and is inoperable. Patients with potentially resectable liver metastases are allowed if they meet certain criteria. Patients must not have a confirmed K-ras mutation of the tumor and must not have brain metastases. The trial also includes specific patient characteristics such as a WHO performance status of 0-2, certain blood counts and liver function tests within normal limits, and no severe uncontrolled concurrent medical illness likely to interfere with protocol treatments. Patients must not have a psychiatric or neurological condition that would preclude study compliance with oral medication or giving informed consent. The trial excludes patients with partial or complete bowel obstruction, preexisting neuropathy > grade 1, prior or current malignant disease likely to interfere with COIN-B treatment or assessment of response, known hypersensitivity reactions to any of the components of the study treatments, proven dihydropyrimidine dehydrogenase deficiency (DPD) or personal or family history of DPD, and ongoing requirement for contraindicated concurrent medication. Prior concurrent therapy is also specified in the trial. Patients must not have had prior systemic palliative chemotherapy for metastatic disease or prior oxaliplatin. Patients must have had more than 1 month since prior adjuvant chemotherapy comprising fluorouracil (with or without leucovorin calcium), capecitabine, or irinotecan hydrochloride, and more than 1 month since prior chemoradiotherapy comprising fluorouracil (with or without leucovorin calcium) or capecitabine for rectal cancer. Patients must not be concurrently enrolled in any type of study other than observational studies.",
    "The sample is a phase 2 trial for nicotine use disorder, nicotine dependence, smoking, and tobacco use disorder. The trial involves the use of baclofen and placebo drugs. The eligibility criteria for the trial include smoking at least 10 cigarettes per day for at least 6 months and considering quitting smoking in the next 6 months. Exclusion criteria include planning to attempt smoking cessation within the next 4 months, weight less than 110 lbs. or above 220 lbs., use of tobacco products other than cigarettes in the previous month, and history of certain medical conditions. Women who are pregnant or nursing or not using a reliable form of birth control are also excluded. Additionally, individuals who are taking certain medications or live with someone enrolled in the study are not eligible to participate.",
    "The sample is a phase 2 clinical trial for HIV infections in infants and children aged 4 months to less than 6 years. The trial involves the use of two drugs, ritonavir and saquinavir, along with at least two other background antiretroviral drugs. The eligibility criteria include confirmed HIV-1 infection and appropriate use of the drugs. Exclusion criteria include body weight over 4kg, use of medications that may interfere with the drugs, and certain gastrointestinal conditions.",
    "The sample is a phase 2 clinical trial for patients with squamous cell carcinoma of the head and neck region that has metastasized or recurred locally. The trial is testing the effectiveness of the drugs gemcitabine and oxaliplatin. The eligibility criteria include having a confirmed diagnosis of the specified cancer type, having measurable or non-measurable disease, and meeting certain medical requirements such as adequate bone marrow reserve and liver function. Patients must not have had more than one prior chemotherapy regimen for recurrent/metastatic disease, and must not have had prior therapy with oxaliplatin or gemcitabine. Exclusion criteria include having active or uncontrolled infection, severe psychiatric disorder, or known brain metastasis. The trial is open to patients who are 18 years of age or older and have a Zubrod performance of 0-2.",
    "The sample is a phase 2 clinical trial for breast cancer patients with ER and PR levels below 10% and HER2 1+ or 0 or FISH negative. The trial requires patients to have measurable or assessable disease detectable by imaging or physical exam, and only one or no prior therapy for metastatic or recurrent breast cancer is allowed. Patients with bone-only disease must have measurable lesions on x-ray, MRI, or CT scan. The trial allows prior chemotherapy or radiation therapy, but at least 2 weeks should elapse prior to study enrollment. Patients must have an ECOG PS of 0-1 and a life expectancy greater than 3 months. The trial has specific laboratory criteria and requires a tissue block available from primary breast cancer. Patients with more than or equal to 2 prior regimens for metastatic breast cancer, leptomeningeal disease, brain metastasis, irreversible neuropathy, or other malignancy other than carcinoma in situ of the cervix or skin cancer are excluded. Patients with active uncontrolled bacterial, viral, or fungal infection, active pregnancy or breastfeeding, pre-existing neuropathy >= grade 2, history of myocardial infarction, symptomatic congestive heart failure, unstable angina pectoris, or cardiac arrhythmia, and patients with previous history of CTCAE grade >= 3 hypersensitivity to paclitaxel or Cremophor EL are also excluded. The trial uses paclitaxel and carboplatin as drugs.",
    "The sample is a record of a clinical trial with a phase 2 designation. The trial is focused on breast cancer and the icd-10 codes associated with it. The drug being tested is called abt-751. The eligibility criteria for the trial includes having stage IIIB or IV breast cancer, having a recurrent tumor after or while on taxane therapy, being able to tolerate normal daily activities, and having adequate bone marrow, kidney, and liver function. The exclusion criteria includes being pregnant or breastfeeding, and not having received any anti-tumor therapy within 4 weeks of starting the ABT-751 administration.",
    "The sample is a phase 2 clinical trial for the treatment of metastatic or recurrent gastric cancer using the drugs S-1 and LV. The trial includes patients who are at least 18 years old, have at least one measurable lesion by RECIST criteria, and have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. Patients must also have adequate bone marrow, hepatic, and renal function, and must not have received previous radiotherapy, immunotherapy, biotherapy, hormonotherapy, or chemotherapy within 5 years (adjuvant chemotherapy without S-1 is allowed if finished 6 months before enrollment). The trial has exclusion criteria, including a history of hypersensitivity to S-1 or LV, serious concomitant conditions, extensive bone metastasis, brain metastasis or meningeal metastasis, another synchronous cancer, recent surgery, participation in other clinical studies, and pregnancy or nursing.",
    "The sample is a phase 2 clinical trial for patients with high-grade gliomas, which are malignant brain tumors. The trial involves the drug irinotecan hydrochloride and eligibility criteria include having evidence of tumor progression by MRI or CT scan, being over 18 years old with a life expectancy greater than 8 weeks, having a Karnofsky performance status of greater than or equal to 60, and not having received any form of treatment for their progressive tumor between their last bevacizumab treatment and enrollment in the trial. Patients must also have adequate bone marrow, liver, and renal function, and not have any significant medical illnesses that cannot be controlled with appropriate therapy. The trial includes both men and women, and subjects must be willing and able to practice adequate contraception. Exclusion criteria include concurrent use of other standard chemotherapeutics or investigative agents, active infection, pregnancy or nursing, concurrent anti-coagulation or anti-platelet medication, serious or non-healing wound, ulcer or bone fracture, history of abdominal fistula, gastrointestinal perforation or intra-abdominal abscess within 28 days, and clinically significant cardiovascular disease.",
    "The sample is a phase 2 clinical trial for locally advanced or metastatic breast cancer. The trial is testing the effectiveness of the drugs lapatinib and everolimus. The eligibility criteria for the trial include having confirmed ER(-), PR(-), HER2(-) breast cancer, disease progression following prior first line cytotoxic chemotherapy in metastatic setting, and having at least one measurable lesion. Patients must also meet certain age, gender, performance status, and health criteria. Exclusion criteria include having certain medical conditions, receiving concurrent investigational therapy, and being pregnant or lactating.",
    "This sample is for a phase 2 clinical trial for the treatment of thyroid cancer using the drug zd6474 (vandetanib). The trial is for patients with locally advanced or metastatic hereditary medullary thyroid carcinoma who do not have standard treatment options. The inclusion criteria include being 18 years or older with a life expectancy of more than 12 weeks and having a confirmed histological diagnosis. The exclusion criteria include having received chemo/radiation less than 4 weeks before the start of the study therapy and having a history of arrhythmia or congenital long QT syndrome. The sample also includes a list of icd-10 codes for the disease.",
    "The sample is a phase 2 clinical trial for patients with hepatocellular carcinoma or liver cancer. The trial involves the use of two drugs, bevacizumab (avastin) and erlotinib. The eligibility criteria include having confirmed hepatocellular carcinoma that cannot be surgically removed, measurable disease, and a performance status of 2 or less. Patients must also have adequate organ function and not have received any other investigational agents or systemic chemotherapy within 30 days prior to enrollment. Exclusion criteria include a history of prior VEGF- or EGFR-targeted therapy, significant gastrointestinal bleeding, and known hypersensitivity to any component of Avastin. The trial also has a list of exclusion criteria that include uncontrolled intercurrent illness, history of myocardial infarction or unstable angina within 6 months, and inability to comply with study and/or follow-up procedures.",
    "The sample is a phase 2 clinical trial for acute myelogenous leukemia. The trial includes patients who have either refractory AML or relapsed AML that have achieved a CR for less than one year. The patients must be at least 18 years old and have a life expectancy of more than 4 weeks following initiation of treatment. The trial also has various eligibility criteria, including performance status, total bilirubin levels, creatinine levels, and LVEF. Patients must also be able to comply with scheduled follow-up and management of toxicity. Sexually active patients must use an effective method of contraception during the study dosing period. The trial has exclusion criteria, including subjects with M3 AML, pregnant or lactating subjects, and those receiving other anti-leukemia investigational agents. The trial also has a list of prohibited medications during the first week of each course.",
    "The sample is a phase 2 clinical trial that involves patients with various diseases such as acute myelogenous leukemia, graft versus host disease, acute lymphoblastic leukemia, chronic myelogenous leukemia, myelodysplastic syndromes, non-hodgkin's lymphoma, and hodgkin's disease. The trial aims to test the effectiveness of sirolimus and tacrolimus drugs in treating these diseases. The eligibility criteria for the trial include being between 18-55 years old, having a matched unrelated donor, and meeting certain health requirements such as having a life expectancy of 100 days without stem cell transplantation and having a certain level of bilirubin, AST, and serum creatinine. The exclusion criteria include having uncontrolled infection, prior hematopoietic stem cell transplant, and evidence of HIV infection or active Hepatitis B or C infection.",
    "The sample is a phase 2 clinical trial for patients with esophageal or gastric adenocarcinoma who have relapsed or progressed after prior platinum-based chemotherapy and are not suitable for radical therapy. The trial involves the drug sorafenib tosylate and has eligibility criteria for patients' disease characteristics and patient characteristics. The eligibility criteria include having at least one measurable lesion, having an ECOG performance status of 0-2, and meeting certain laboratory values. Patients must not have certain medical conditions or take certain medications, and must not have had certain prior treatments. The trial also has restrictions on concurrent medications and therapies.",
    "The sample is a phase 2 clinical trial for the treatment of myelodysplastic syndrome. The trial involves the use of lenalidomide and cyclosporine a drugs. The eligibility criteria include being diagnosed with low or intermediate-1 risk IPSS, having an ECOG performance status of \u2264 2, and meeting certain laboratory test result ranges. Participants must also be registered into the mandatory RevAssist\u00ae program and be willing to comply with its requirements. Exclusion criteria include any serious medical condition, laboratory abnormality, or psychiatric illness that would prevent the subject from signing the informed consent form, being pregnant or breastfeeding, and having any condition that places the subject at unacceptable risk if he/she were to participate in the study or confounds the ability to interpret data from the study.",
    "This sample is for a phase 2 clinical trial for the treatment of hepatitis C. The trial includes a list of diseases and their corresponding ICD-10 codes, a list of drugs being tested (telaprevir, ribavirin, and pegylated interferon alfa 2a), and eligibility criteria for participants. In this case, the inclusion criteria require participants to have been enrolled in the control arm of previous studies (NCT00420784, NCT00336479, or NCT00372385).",
    "The sample is a phase 2 clinical trial for irritable bowel syndrome. The trial includes patients who have recurrent abdominal pain or discomfort for three or more days per month for the last three months, and meet Rome III criteria for non-constipating IBS. Patients must also be on a stable diet for at least eight weeks and be willing to comply with all protocol procedures for the planned duration of the study. The trial has inclusion and exclusion criteria, including age, medical history, and medication use. Female patients must be postmenopausal, surgically incapable of bearing children, or practicing a reliable method of birth control. The study will require patients to attend all visits required by the protocol.",
    "The sample is a phase 2 clinical trial for chronic atopic dermatitis. The trial includes patients who have had inadequate response to a stable regimen of topical corticosteroids or calcineurin inhibitors as treatment for at least 3 years. The trial excludes patients who have had prior treatment with REGN668, certain laboratory abnormalities, treatment with an investigational drug within 8 weeks, treatment with a live vaccine within 12 weeks before the baseline visit, certain medical procedures within a particular time-frame prior to the baseline visit, known history of HIV infection, history of malignancy within 5 years before the baseline visit, planned surgical procedure during the length of the patient's participation in this study, history of clinical parasite infection, any medical or psychiatric condition which in the opinion of the investigator or the sponsor's medical monitor, would place the participant at risk, interfere with participation in the study, or interfere with the interpretation of study results, and pregnant or breast-feeding women. The trial includes the use of placebo and dupilumab as drugs.",
    "The sample is a phase 2 clinical trial for postmenopausal women with newly diagnosed DCIS (ductal carcinoma in situ) breast cancer. The trial is testing the effectiveness of tamoxifen and fulvestrant in treating the disease. The eligibility criteria include having a minimally invasive biopsy technique to diagnose the DCIS, available tissue for molecular markers, and a baseline mammogram within 8 weeks of study entry. Patients must also have a SWOG performance status of less than or equal to 1 and provide informed written consent. Exclusion criteria include prior hormonal therapy within 6 months of study entry and underlying medical, psychiatric, or social conditions that would preclude treatment.",
    "The sample is a phase 2 clinical trial for patients with metastatic renal cell carcinoma with clear cell histology. The trial involves the use of two drugs, sunitinib and bevacizumab. The eligibility criteria include having measurable disease, evidence of disease progression, and having received at least 14 doses of sunitinib therapy. Participants must also meet certain age and health requirements, and not have certain medical conditions or histories. The trial has exclusion criteria, including prior treatment with bevacizumab and certain medical conditions.",
    "The sample is a phase 2 clinical trial for the treatment of metastatic colorectal cancer using the drugs panitumumab and cpt-11. The trial includes patients who are over 18 years old, have confirmed metastatic adenocarcinoma of the colon or rectum, and have documented disease progression per modified RECIST criteria. Patients must also have at least one measurable lesion of at least 20mm per modified RECIST criteria, and have had only one prior chemotherapy regimen for mCRC consisting of first-line fluoropyrimidine-based chemotherapy. The trial has inclusion and exclusion criteria, and patients must meet certain requirements for hematologic, renal, and hepatic function, as well as ECOG performance status and life expectancy. Patients with certain medical conditions or who have had certain treatments are excluded from the trial.",
    "The sample is a phase 2 clinical trial for ovarian cancer, fallopian tube cancer, and peritoneal cancer. The trial involves the use of three drugs - bevacizumab, gemcitabine, and carboplatin. The eligibility criteria for the trial include having cancer that has come back after more than 6 months from the last platinum-based chemotherapy treatment, and having a history of at least one therapy of platinum-based chemotherapy. The exclusion criteria include participation in another experimental drug study, heart disease or high blood pressure, history of a stroke within the past 6 months, and other medical conditions. The trial requires compliance with study and follow-up procedures.",
    "The sample is a phase 2 clinical trial for the treatment of perianal high-grade squamous intraepithelial lesions (HSIL) in patients with HIV. The trial involves the use of the drug cidofovir and has eligibility criteria for patients including confirmation of HIV infection, no untreated invasive cancer of the lower genital tract, and a Karnofsky performance status of 70-100%. Patients must also meet certain medical criteria such as having a hemoglobin level of at least 8 g/dL and a platelet count of at least 75,000/mm\u00b3. The trial has prior concurrent therapy requirements, including having recovered from prior ablative or surgical treatment of perianal dysplasia and having no concurrent systemic cytotoxic chemotherapy.",
    "The sample is a phase 2 clinical trial for the treatment of chronic hepatitis C. The trial is looking for Caucasian male or female participants between the ages of 18 and 70 who have serological proof of a chronic hepatitis C infection with positive results of anti-Hepatitis C virus (HCV) test and detectable HCV-Ribo Nucleic Acid (RNA) in serum. Participants must have proven HCV genotype 1 and proven histological infection activity within the liver with or without proven compensated cirrhosis within the last 24 months prior to the start of the study. Participants without previous anti-HCV therapy are eligible. Exclusion criteria include known hypersensitivity to interferon or ribavirin, pregnancy or nursing, infection with HCV genotype 2, 3, 4, 5, or 6, and pretreatment with interferon and/or ribavirin. Other exclusion criteria include immunocompromised participants, treatment of systemic anti-neoplastic or immunomodulatoric medication within the last 6 months prior to the start of treatment, and chronic hepatitis due to hepatitis C virus. Participants with decompensated liver cirrhosis or liver disease Child-Pugh degree B or C or condition after decompensation are also excluded. The sample includes a list of drugs, including pegylated interferon (peg-ifn) alfa-2a, placebo, and ribavirin.",
    "The sample is a phase 2 clinical trial for asthma, with the drug being tested being gw685698x. The eligibility criteria for participants include being an outpatient, being at least 12 years old (or 18 years old in certain countries), having a diagnosis of asthma as defined by the National Institutes of Health, and having a best FEV1 of 40%-85% of the predicted normal value during the morning Visit 1 screening period or a best FEV1 of 40%-90% of the predicted normal value during the evening Visit 1 screening period. Participants must also have been using an inhaled corticosteroid for at least 8 weeks prior to Visit 1 and maintained on a stable dose of inhaled corticosteroids for four weeks prior to Visit 1. The exclusion criteria include a history of life-threatening asthma, respiratory infection, asthma exacerbation requiring oral corticosteroids within 3 months of Visit 1, and concurrent diseases/abnormalities such as cardiovascular disease, hepatic disease, renal disease, hematological disease, neurological disease, or pulmonary disease. Participants must also be able to comply with completion of the Daily Diary.",
    "The sample is a phase 2 clinical trial for patients with locally advanced or metastatic colorectal cancer. The trial includes patients who have received 6 cycles of first-line therapy with FOLFOX or FOLFIRI, plus bevacizumab for metastatic CRC. Patients who received 6 cycles of first-line therapy with FOLFOX or FOLFIRI, plus bevacizumab for recurrent CRC that has relapsed at least 12 months after completion of adjuvant therapy will also be included. The trial aims to test the efficacy of a combination of drugs including enzastaurin, placebo, leucovorin (lv), 5-fluorouracil (5-fu), and bevacizumab (bev). The eligibility criteria include a histologic diagnosis of locally advanced or metastatic colorectal cancer, documented evidence of tumor response, and no more than 4 weeks between the end of first-line therapy and randomization. The exclusion criteria include patients who are unable to swallow tablets, have received treatment within the last 30 days with a drug that has not received regulatory approval for any indication at the time of study entry, have known central nervous system metastases, are receiving concurrent administration of any other antitumor therapy, and patients who have significant heart, liver, kidney, or psychiatric disease or have an active infection.",
    "The sample is a phase 2 clinical trial for the treatment of postmenopausal osteoporosis. The trial involves the drugs odanacatib and placebo. The eligibility criteria for participants include being postmenopausal for at least 5 years or being a man aged between 45 to 85, having low bone mineral density, having suitable anatomy for dual-energy x-ray absorptiometry (DXA) of the lumber spine and hip, and being ambulatory. Exclusion criteria include having secondary osteoporosis or a metabolic bone disorder other than osteoporosis or osteopenia, having received osteoporosis medications or other medications that affect bone, and already participating in another drug study.",
    "The sample is a phase 2 clinical trial for pancreatic cancer. The trial is for patients with locally advanced, nonmetastatic disease that is surgically unresectable. Patients must have measurable disease and cannot have any history or evidence of CNS disease or metastatic disease to distant organs. Patients must also meet certain patient characteristics, such as having an ECOG performance status of 0-2 and meeting certain blood count and liver function criteria. Patients cannot have any prior therapy for pancreatic cancer or prior therapy specifically targeting the epidermal growth factor-receptor pathway. Additionally, patients cannot have had any major surgical procedure or open biopsy within the past 28 days, prior radiotherapy or chemotherapy, or prior or concurrent full-dose anticoagulants or thrombolytics.",
    "The sample is a phase 2 clinical trial for rheumatoid arthritis. The trial includes patients between the ages of 18 and 75 who have active RA and meet certain joint assessment expectations. The trial also requires that patients have certain laboratory values for CRP or ESR. The trial excludes pregnant or breastfeeding females, patients who cannot comply with requirements to avoid fathering a child or becoming pregnant, patients who have been treated with a biologic agent within 12 weeks prior to the first dose of study drug, patients with a history or currently suspected inflammatory disease other than RA, and patients with a history of hematological disorders. The trial involves the use of the drug itacitinib and a placebo.",
    "The sample is a phase 2 clinical trial for patients with carcinoma of unknown primary site. The trial includes patients with biopsy-proven metastatic carcinoma and specific light microscopic histologies. Patients must have biopsy material available for molecular profiling assay and an ECOG performance status of 0, 1, or 2. They must not have received any previous treatment with systemic therapy and must have measurable or evaluable disease according to the Response Evaluation Criteria in Solid Tumors (RECIST). The trial also has specific inclusion and exclusion criteria, including laboratory values, previous surgeries, and diagnoses. The trial involves the use of several drugs, including paclitaxel, carboplatin, bevacizumab, and erlotinib. The eligibility criteria and exclusion criteria are detailed and specific.",
    "The sample is a clinical trial for influenza, with a phase 2/phase 3 designation. The trial is testing the effectiveness of nitazoxanide and placebo as treatments for influenza in patients between the ages of 12 and 65. The trial has specific inclusion and exclusion criteria, including confirmation of influenza A or B infection, onset of illness no more than 48 hours before presentation, and absence of certain high-risk conditions. The trial also requires patients to be willing and able to comply with protocol requirements and provide informed consent. The sample includes a detailed list of the inclusion and exclusion criteria.",
    "The sample is a phase 2 clinical trial for asthma. The trial includes patients who have been diagnosed with asthma and are currently prescribed Inhaled Corticosteroids (ICS) therapy. The patients should have a pre-bronchodilator Forced Expiratory Volume in 1 second (FEV1) value of 40% to 80% of individual predicted value. They should also be allergic or atopic and have reversible airway obstruction or airways hyper-reactivity. The trial includes the use of drugs such as qaw039, montelukast, and placebo. The eligibility criteria include an Asthma Control Questionnaire (ACQ) score \u2265 1.5 at randomization. The exclusion criteria include pregnant or nursing women, patients with serious co-morbidities, acute illness other than asthma at the start of the study, history of life-threatening asthma, respiratory tract infection within 4 weeks of the screening visit, and current or ex-smokers who stopped smoking within 6 months prior to screening or have a smoking history of \u2265 10 pack years.",
    "The sample is a record of a clinical trial with a phase 2 designation. The trial is focused on the disease of hyperlipidemia, which is associated with high levels of cholesterol and triglycerides in the blood. The trial includes a list of icd-10 codes for the disease. The trial involves the use of several drugs, including aegr-733, placebo, atorvastatin, fenofibrate, and ezetimibe. The eligibility criteria for the trial include specific LDL-C levels, hepatic fat levels, and the absence of certain medical conditions. The exclusion criteria include pregnancy, uncontrolled hypertension, liver disease, recent major surgery, and other medical or psychological conditions. The trial also includes restrictions on alcohol consumption, grapefruit juice, and certain medications.",
    "The sample is a phase 2 clinical trial for the treatment of schizophrenia. The trial includes male and female patients between the ages of 18 to 65 years who have met DSM-IV criteria for schizophrenia, schizophreniform disorder, or schizoaffective disorder. Patients who are clinically agitated and have a total score of \u2265 14 on the 5 items comprising the PANSS Excited Component (PEC) are eligible for the trial. The trial involves the use of inhaled placebo, inhaled loxapine 5 mg, and inhaled loxapine 10 mg as drugs. Patients must meet certain inclusion criteria, such as being in good general health and providing written informed consent. Patients must also meet certain exclusion criteria, such as having a history of allergic reactions to loxapine or amoxapine, or having serious and unstable illnesses. The trial requires patients to use a medically acceptable and effective birth control method throughout the study and for one week following the end of the study if they are sexually active and of child-bearing potential.",
    "The sample is a phase 2 clinical trial for patients with gastrointestinal stromal tumors. The trial involves the use of two drugs, perifosine and imatinib mesylate. The eligibility criteria include having a confirmed diagnosis of Kit expressing advanced GIST, documented measurable disease, and progression of disease on imatinib mesylate. Patients must also have adequate organ function and be able to ingest oral medications or obtain them through a gastrostomy tube. Exclusion criteria include the presence of known symptomatic CNS metastases, significant concurrent medical disease other than GIST, and history of active secondary cancer. Female patients who are pregnant or lactating are ineligible. All females of childbearing potential must have a negative serum pregnancy test within 72 hours of treatment. Men and women of childbearing potential must agree to employ adequate contraception to prevent pregnancy while on therapy and for 4 weeks after the completion of treatment. Post-menopausal women must be amenorrheic for at least 12 months to be considered of non-childbearing potential.",
    "The sample is a phase 2 clinical trial for the treatment of chronic obstructive pulmonary disease (COPD) using a drug called GSK233705. The trial is open to male and female adults between the ages of 40 and 80 who have an established clinical history of COPD and a post-albuterol/salbutamol FEV1/FVC ratio of \u22640.70 and a post-albuterol/salbutamol FEV1 of \u226535 and \u226470% of predicted normal values. The trial has a list of inclusion and exclusion criteria, including not being pregnant or lactating, not having a current diagnosis of asthma, and not having any known respiratory disorders other than COPD. The trial also has a list of drugs and medical conditions that would exclude a participant from enrolling in the study. The trial is looking to test the efficacy of GSK233705B in treating COPD and is not open to individuals who have previously used the drug in other studies.",
    "The sample is a phase 2 clinical trial for patients with glioblastoma multiforme, a type of brain cancer. The trial is testing the effectiveness of two drugs, temozolomide and sorafenib, in treating the disease. The eligibility criteria for the trial include having a confirmed diagnosis of glioblastoma multiforme, being over 18 years old, having adequate bone marrow and liver function, and not having received previous treatment for the disease except for surgical debulking. Patients must also have a good performance status and be able to understand and sign the informed consent. Exclusion criteria include having certain cardiac conditions, infections, bleeding disorders, or other active malignancies.",
    "The sample is a phase 2 trial for major depressive disorder and depression. The trial involves two drugs, tc-5214 + citalopram and placebo + citalopram. The eligibility criteria for the trial include a diagnosis of major depressive disorder, no more than one prior antidepressant course of treatment, and a MADRS score greater than 27. Exclusion criteria include any co-morbid psychiatric illness, significant suicidal risk, history of alcohol or drug abuse, and other severe progressive and uncontrolled medical conditions. Women of childbearing potential must have a negative urine pregnancy test and be willing to use acceptable methods of contraception throughout the study period.",
    "The sample is a record of a clinical trial with a phase 2 designation. The trial is focused on the disease multiple myeloma, which is identified by a list of ICD-10 codes. The trial involves the use of three drugs: bortezomib, placebo, and dexamethasone. The eligibility criteria for the trial are listed under \"Inclusion Criteria,\" which includes measurable secretory disease, documented disease progression, ECOG performance status score, and adequate bone marrow, liver, and renal function. The \"Exclusion Criteria\" includes factors such as no prior treatment with bortezomib, not refractory to high-dose dexamethasone, and not having received an allogeneic bone marrow or peripheral blood stem cell transplant. Additionally, patients with prior or concomitant malignancy, except for adequately treated basal cell or squamous cell carcinoma of the skin, carcinoma in situ of the cervix, or other cancer for which the patient has been disease-free for <= 3 years, are excluded from the trial.",
    "The sample is a phase 2 clinical trial for the treatment of prostate cancer. The trial includes patients with histologically-confirmed adenocarcinoma of the prostate, radiographic evidence of metastatic prostate cancer, and prostate cancer unresponsive or refractory to hormone therapy. The trial also requires evidence of progressive disease, defined as at least one of the following: progressive measurable disease, bone scan progression, or increasing PSA. The trial involves the use of the drugs mitoxantrone and prednisone. The eligibility criteria include various medical and laboratory tests, such as adequate hematologic, hepatic, and renal function, and adequate coagulation function. The exclusion criteria include prior therapy with mitoxantrone for advanced prostate cancer, a history of symptomatic congestive heart failure, and uncontrolled or poorly controlled hypertension or diabetes mellitus.",
    "The sample is a clinical trial for advanced cancers in phase 2/phase 3. The trial involves the drug atorvastatin and the eligibility criteria include being in a normal sinus rhythm preoperatively, undergoing planned lobectomy or pneumonectomy, being of a certain age, and having adequate liver function. Exclusion criteria include a history of certain arrhythmias, recent use of certain medications, and allergies to seafood.",
    "The sample is a phase 2 clinical trial for patients with small cell lung cancer who have achieved a complete or partial response after four to six cycles of platinum-based induction chemotherapy. The trial is testing the drug sorafenib. The eligibility criteria include being over 18 years old, having a life expectancy of greater than 3 months, and having adequate bone marrow, liver, and renal function. Exclusion criteria include a history of cardiac disease, HIV infection, chronic hepatitis B or C, and active clinically serious infections. Patients must also use adequate barrier birth control measures during the course of the trial and during the first 3 months after the completion of the trial. The trial also lists excluded therapies and medications, previous and concomitant.",
    "The sample is a phase 2 clinical trial for patients with congestive heart failure. The trial is testing the drug ditpa. The eligibility criteria for patients to participate in the trial include being a veteran, having moderately severe CHF (NYHA class II, III or IV), being 18 or older, not having clinically important renal, hepatic or hematological disorders or clinically significant abnormal laboratory findings, not having a pre-existing thyroid disease, not having anemia, not having chronic pulmonary disease that limits exercise tolerance or requires use of chronic bronchodilator therapy or steroids, being able to walk on the level for 6 minutes, not having hemodynamically significant pericardial disease, not having angina pectoris severe enough to require frequent administration of sublingual nitroglycerin, not having acute myocardial infarction within 6 months of screening, not having inoperable aortic stenosis, not having symptomatic ventricular arrhythmias or ventricular arrhythmia requiring pharmacological therapy, not having implanted cardioverter defibrillator, not taking amiodarone, not having demonstrated non-compliance with prior medical regimes, not being on an investigational drug, not having a medical condition that, in the investigator's opinion, would make the patient ineligible, not having an allergy to iodine or shellfish, not being in sinus rhythm, not being of childbearing potential, and having an ejection fraction greater than 40%. The exclusion criteria are not provided in the sample.",
    "The sample is a phase 2 clinical trial for the treatment of metastatic breast cancer. The trial involves the use of three different drugs: ixabepilone with bevacizumab, paclitaxel with bevacizumab, and a higher dose of ixabepilone with bevacizumab. The eligibility criteria for participants include having locally recurrent or metastatic breast cancer that has not been previously treated with chemotherapy for advanced disease, having at least one target lesion per RECIST criteria, and having a Karnofsky performance status of 80 to 100 or Eastern Cooperative Oncology Group performance status of 0 to 1. Participants must also have an estimated life expectancy of at least 12 weeks and meet certain medical criteria, such as having a normal partial thromboplastin time and either international normalized ratio or prothrombin time, and having a serum creatinine \u22641.5*ULN or 24-hour creatinine clearance >60 mL/min. Exclusion criteria include being pregnant or breastfeeding, having a history of abdominal fistula, gastrointestinal perforation, intra-abdominal abscess, serious gastric ulcer, or bone fracture within 6 months of study entry, and having a concurrent active malignancy other than nonmelanoma skin cancer or carcinoma in situ of the cervix.",
    "The sample is a phase 2 clinical trial for patients with metastatic adenocarcinoma of the colon and/or rectum that has spread to the liver. The trial involves the use of drugs such as xelox, xeliri, and bevacizumab. The eligibility criteria include having no prior treatment with irinotecan or oxaliplatin, adequate renal and hepatic function, and an Eastern Cooperative Oncology Group (ECOG) performance status of 0-2. The trial also has exclusion criteria such as pregnancy or breastfeeding, serious uncontrolled infections, and clinically significant cardiac disease. The trial requires patients to provide written informed consent and comply with the protocol for the duration of the study.",
    "The sample is a phase 2 clinical trial for HIV infections. The trial is testing the effectiveness of two drugs, vicriviroc and emtricitabine and tenofovir disoproxil fumarate, on subjects with CCR5-tropic HIV infection. The eligibility criteria for the trial include being at least 18 years old, having a CD4 cell count of at least 100 cells/(cubic mm), and meeting certain laboratory test requirements. Female subjects of childbearing potential must be using a medically accepted method of birth control and have a negative pregnancy test. Exclusion criteria include having intercurrent illness, vaccinations, or using immunomodulators that could influence plasma HIV RNA levels, having CXCR4 or dual-mixed tropism, having primary resistance mutations to any of the proposed components of the study arms, having active opportunistic infection or malignancy, or having a seizure disorder requiring ongoing anti-seizure therapy or with a history of a seizure disorder who are at risk for seizures.",
    "The sample is a phase 2 clinical trial for patients with end-stage renal disease and anemia. The trial involves the use of drugs such as fg-4592 and epoetin alfa. The eligibility criteria include being between the ages of 18 and 75, receiving maintenance hemodialysis, and having hemoglobin levels within a certain range. Other criteria include having acceptable blood test results, a certain body weight and BMI, and a specific type of dialysis vascular access. Exclusion criteria include a history of certain medical conditions, drug or alcohol abuse, and prior treatment with FG-4592.",
    "The sample is a phase 2 trial for essential hypertension. The trial includes a list of icd-10 codes for the disease. The drugs being tested include placebo, lercanidipine, enalapril, and combinations of lercanidipine and enalapril. The eligibility criteria for the trial include specific blood pressure ranges and a normal electrocardiogram, while exclusion criteria include secondary or severe hypertension, history of cerebro- or cardiovascular complications, type 1 or type 2 diabetes on drug treatment, and severe renal or hepatic insufficiency.",
    "The sample is a phase 2 clinical trial for patients with diffuse large B-cell lymphoma. The trial involves the use of a combination of panobinostat and rituximab. The eligibility criteria for the trial include having relapsed or refractory DLBCL and having received more than one line of prior chemotherapy. Exclusion criteria include currently receiving anticancer therapy or investigational agents, major surgery within the last 4 weeks, known leptomeningeal or brain metastases, known HIV infection, uncontrolled fungal, bacterial, viral or other infection, history of another malignancy (except for non-melanoma skin cancer or in situ cervical or breast cancer) unless disease-free for at least 3 years, hepatitis B or C positive, GI disease, pregnant or breastfeeding, and prior treatment with an HDAC inhibitor including valproic acid.",
    "This sample is a phase 2 clinical trial for the treatment of cystic fibrosis using the drug ataluren. The trial is looking for participants who have a diagnosis of cystic fibrosis with a specific mutation in the CFTR gene, abnormal chloride secretion, and a certain level of lung function. Participants must also meet various other eligibility criteria, such as being over 18 years old, having a certain body weight, and being willing to comply with study procedures. There are also exclusion criteria, such as having certain medical conditions or ongoing illnesses, that would make a participant ineligible for the trial. The sample includes a detailed list of inclusion and exclusion criteria.",
    "The sample is a phase 2 clinical trial for potentially resectable pancreatic cancer patients, either before or after surgery. The trial includes patients who have signed consent and have appropriate diagnostic imaging, evaluated by one of the surgical co-investigators as having resectable disease and probable pancreatic adenocarcinoma. Adjuvant therapy should start within 10 weeks of surgery. Patients must be 18 years or older, have an ECOG performance status of 0-1, and be able to take oral medications without difficulty. They must also have adequate bone marrow, renal, and hepatic function. Men and women of childbearing potential must be willing to practice acceptable methods of birth control to prevent pregnancy. Exclusion criteria include positive margins on post-operative surgical specimen or evidence of metastatic disease, biliary tree cancers, known severe hypersensitivity to erlotinib or any of the excipients of these products, and any prior treatment with radiation therapy or chemotherapy or vaccines for pancreatic cancer. Other coexisting malignancies or malignancies diagnosed within the last 3 years, with the exception of basal cell carcinoma or squamous cell carcinoma of the skin or cervical cancer in situ are also excluded. The trial also excludes patients with incomplete healing from previous oncologic or other major surgery, pregnancy or breastfeeding, evidence of any other significant clinical disorder or laboratory finding that makes it undesirable for the subject to participate in the trial.",
    "The sample is a record of a clinical trial in phase 2 for the treatment of painful bladder syndrome and interstitial cystitis. The trial involves the use of two drugs, urg101 and placebo, and includes a list of diseases and their corresponding icd-10 codes. The eligibility criteria for the trial include being male or female and over 18 years of age, having moderate to severe symptoms of PBS/IC, and meeting certain pain/urgency/frequency score requirements. The exclusion criteria include being pregnant or lactating, having used narcotics or medical marijuana within the past 3 months, having used any investigational drug or device within the past 30 days, and having bacterial cystitis within the past 30 days.",
    "The sample is a phase 2 clinical trial for patients with stage IV breast cancer. The trial is testing the effectiveness of the drugs capecitabine and cyclophosphamide. The eligibility criteria include having documented MUC-1 antigen levels, having received at least one prior hormonal therapy for metastatic disease (estrogen receptor-positive patients only), and not having symptomatic brain or CNS metastases. Patients must also meet certain patient characteristics, such as being female, having a Zubrod performance status of 0-2, and having no known existing uncontrolled coagulopathy. Prior concurrent therapy is also taken into consideration, such as no concurrent immunotherapy or biologic therapy for breast cancer and no concurrent hormonal therapy for breast cancer.",
    "The sample is a phase 2 clinical trial for pancreatic cancer patients with unresectable, locally advanced or metastatic disease. The trial is testing the effectiveness of a drug called Triapine. The eligibility criteria for the trial include having a confirmed diagnosis of adenocarcinoma of the pancreas, having at least one measurable lesion, and not having received prior chemotherapy or more than one gemcitabine-containing regimen. Patients must also meet certain health requirements, such as having a performance status of ECOG 0-2 and no uncontrolled congestive heart failure or pulmonary disease requiring oxygen. Additionally, patients must not be pregnant or nursing, and must use effective contraception if fertile. The trial excludes patients with certain medical conditions or psychiatric illnesses that would preclude study compliance, as well as those receiving other concurrent antineoplastic therapy or investigational therapy for the malignancy.",
    "The sample is a phase 2 clinical trial for pancreatic cancer using a drug called MKC-1. The trial is looking for patients who have previously failed at least one chemotherapy regimen and have measurable disease according to RECIST. Patients must also meet certain laboratory result criteria and have an Eastern Cooperative Oncology Group performance status of 0 or 1. The trial has exclusion criteria, including pregnancy or breastfeeding, central nervous system metastases, and serious cardiac conditions. Patients with any medical conditions that would impose excessive risk to the patient are also excluded. The trial is not open to patients receiving treatment with antiretroviral therapy metabolized through CYP3A4 or those with existing toxicities from previous chemotherapy therapies.",
    "The sample is a phase 2 trial for patients with newly diagnosed stage IIIB or stage IV non-small cell lung cancer, or recurrent disease after previous surgery and/or irradiation. The trial includes patients with adenocarcinoma, large cell carcinoma, or unspecified non-small cell lung cancer, but not those with tumors having squamous cell components > 50%. Patients with known brain metastases are not eligible. The trial involves the use of the drug paclitaxel. The eligibility criteria include various medical conditions and laboratory parameters, as well as prior treatments and surgeries. Patients must also be willing to provide prior smoking history and sign a written informed consent.",
    "The sample is a phase 2 clinical trial for patients with non-Hodgkin's lymphoma. The trial is testing the drug LBH589. The eligibility criteria include having a documented diagnosis of MCL or CLL, having relapsed or refractory disease despite one or more lines of therapy, and meeting certain laboratory criteria. Exclusion criteria include having certain medical conditions or taking certain medications, having received certain therapies within a certain timeframe, and being pregnant or breastfeeding. The sample also includes a detailed list of inclusion and exclusion criteria.",
    "The sample is a record from a clinical trial table that includes information about a phase 2 trial for the treatment of malignant mesothelioma. The record includes the list of diseases and their corresponding ICD-10 codes, the list of drugs used in the trial, and the eligibility criteria for participants. The inclusion criteria include having a histological diagnosis of malignant mesothelioma, having failed at least one prior chemotherapy regimen, having at least one evaluable or measurable CT-lesion, being available for follow-up, and signing informed consent. The exclusion criteria include being a candidate for surgery with curative intent, having previously been treated with anthracyclin derivatives, having a performance status below 60 on the Karnofsky scale, having a history of prior malignant tumor (except non-melanoma skin cancer or in situ carcinoma of the cervix and cured malignant tumor), having a history of prior HIV infection, having abnormal blood test results, having recent myocardial infarction or congestive cardiac failure, having uncontrolled infectious disease or active epilepsy, being on certain medications, being pregnant or refusing to use active contraception, having a known allergy to valproate acid and/or doxorubicin, or having serious medical or psychological factors that may prevent adherence to the treatment schedule.",
    "The sample is a phase 2 clinical trial for previously untreated patients with CD20-positive diffuse large B-cell lymphoma. The trial includes patients with Ann Arbour Stage III/IV and bulky II (mass >10 cm) and at least one bi-dimensionally measurable lesion defined as >1.5 cm in its largest dimension by CT scan. The trial drugs include obinutuzumab, cyclophosphamide, doxorubicin, prednisone, and vincristine. The eligibility criteria include being an adult patient of at least 18 years of age, having an Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2, and having adequate hematologic function. The exclusion criteria include having transformed lymphoma (follicular IIIB) if previously treated with chemotherapy or immunotherapy, prior therapy for diffuse large B-cell lymphoma except for nodal biopsy or local irradiation, and central nervous system (CNS) lymphoma, primary mediastinal large cell lymphoma, primary cutaneous lymphoma, primary effusion lymphoma. Other exclusion criteria include having received cytotoxic drugs or rituximab as part of their treatment for another condition, chemotherapy or other investigational therapy within 28 days prior to the start of Cycle 1, contraindication to any of the individual components of CHOP, including prior receipt of anthracyclines, history of severe allergic or anaphylactic reactions to monoclonal antibody therapy, history of other malignancy, positive for hepatitis B, hepatitis C, human immunodeficiency virus (HIV) or human T-cell leukemia virus (HTLV-1) infection, and being pregnant or lactating women.",
    "The sample is a phase 2 clinical trial for non-small cell lung cancer patients with malignant pleural effusion. The trial aims to recruit 48 patients, divided into three groups based on smoking history. The patients must have a histological or cytological diagnosis of non-small cell lung cancer, malignant pleural effusion proven by cytological examination, and stage IIIB or IV disease. The trial will use paclitaxel, carboplatin, and irinotecan as the chemotherapy regimen. The eligibility criteria include ECOG PS 0, 1, or 2, measurable disease, no prior chemotherapy for metastatic or recurrent disease, and meeting certain laboratory values. The exclusion criteria include ECOG performance status 3 or worse, any prior chemotherapy regimen for metastatic or recurrent diseases, and not meeting certain laboratory values. Patients with brain metastasis will be eligible provided their neurological abnormality is stable or improved after whole brain radiation, stereostatic radiosurgery or gamma knife treatment and/or dexamethasone for 3 weeks and patients fulfil all other eligibility criteria. The trial requires signed informed consent and negative mammogram and ovaries examination by CT scans and no history of breast cancer or ovarian cancer in female patients. The trial also requires a negative pregnancy test in female menstruating patient within one week of starting chemotherapy and use of effective contraceptive methods during the study.",
    "This is a sample from a clinical trial table. The trial is in phase 2 and is focused on treating obsessive-compulsive disorder. The table includes a list of diseases, icd-10 codes, drugs, and eligibility criteria. In this sample, the disease being studied is obsessive-compulsive disorder, and the drug being tested is minocycline. The eligibility criteria include meeting DSM-IV criteria for OCD, having a CY-BOCS score of 16 or higher, and having a NIMH Global OC Scale score of 7 or higher. There are also exclusion criteria, such as not being able to participate in cognitive behavior therapy during the study period and having severe renal insufficiency.",
    "The sample is a phase 2 clinical trial for a drug aimed at treating chronic obstructive pulmonary disease (COPD). The trial is looking for Caucasian male or female subjects aged 40-75 years who have an established clinical history of COPD and have smoked for at least 10 pack years. The trial also requires subjects to have FEV1/FVC < 0.7 post-bronchodilator dose and 40 \u2265 FEV1 \u2264 80% of predicted normal for height, age and gender after inhalation of salbutamol dose. The trial has a list of inclusion and exclusion criteria, including respiratory and cardiovascular criteria, concurrent medication criteria, and exclusion of subjects with a 2D6 poor metaboliser genotype. The trial is looking to test the efficacy and safety of the drug in treating COPD.",
    "The sample is a phase 2 clinical trial for patients with locally recurrent or Stage IV invasive breast cancer. The trial is testing the effectiveness of the drug eribulin. Patients must have received at least 2 but not more than 4 prior cytotoxic chemotherapy regimens in the locally recurrent or metastatic setting, and prior treatment with both anthracyclines and taxanes. They must have also received Human Epidermal Growth Factor Receptor 2 (HER-2) directed treatment or not be a candidate for HER-2-directed treatment if they have HER-2 positive disease. Patients must have completed any prior radiotherapy and/or hormonal therapy at least 1 week prior to randomization and have recovered from all clinically significant treatment-related toxicities. They must also have an Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1, left ventricular ejection fraction within normal limits, and adequate hematologic, hepatic, renal, and coagulation function. Patients must test negative for pregnancy and have a life expectancy of at least 3 months. There are also exclusion criteria, such as having a concurrent active other malignancy, being enrolled in another clinical trial, or having uncontrolled hypertension.",
    "This sample is a phase 2 clinical trial for patients with relapsed or refractory B-cell non-Hodgkin lymphoma. The trial includes patients with various types of B-cell lymphoma, and requires at least one measurable tumor mass that has not been previously irradiated or has grown since previous irradiation. Patients must have documented relapse or progression following prior antineoplastic therapy and must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0-2. The trial involves the use of two drugs, Velcade and temsirolimus. Patients must meet certain eligibility criteria, including specific laboratory values and no clinical or documented radiographic evidence of central nervous system lymphoma. Patients must also not have certain medical conditions or be taking certain medications. The trial has various exclusion criteria, including ongoing therapy with glucocorticoids and prior therapy with both Velcade and temsirolimus.",
    "The sample is a phase 2 clinical trial for patients with recurrent glioblastoma. The trial requires male or female patients who are at least 18 years old and have a life expectancy of at least 8 weeks. Patients must have radiographically proven recurrent intracranial glioblastoma and have had previous treatment with external beam radiation and temozolomide chemotherapy. They must also have at least 10 unstained slides or archival tumor block from any previous GBM surgery. The drug being tested is PLX3397. Patients must have adequate recovery from toxicity of prior therapy before the first dose of PLX3397. Women of child-bearing potential must have a negative pregnancy test within 7 days of initiation of dosing and must agree to use an acceptable method of birth control while on study drug and for 3 months after the last dose. Men of child-bearing potential must also agree to use an acceptable method of birth control while on study drug. Patients must have a Karnofsky performance status of \u226560 and adequate hematologic, hepatic, and renal function. Patients must be willing and able to provide written informed consent prior to any study related procedures and to comply with all study requirements. Exclusion criteria include investigational drug use within 28 days of the first dose of PLX3397, GBM progression within 3 months of previous radiation, and history of Grade 2 Common Toxicity Criteria for Adverse Events (CTCAE v4) or greater acute intracranial hemorrhage. Other exclusion criteria include previous failure of bevacizumab or other vascular endothelial growth factor (VEGF) therapy except in a first line setting, history of malignant glioma with co-deletion of 1p/19q, concurrent active cancer that requires non-surgical therapy, refractory nausea and vomiting, malabsorption, biliary shunt, or significant bowel resection that would preclude adequate absorption, serious illnesses, uncontrolled infection, medical conditions, or other medical history including abnormal laboratory results, which in the investigator's opinion would be likely to interfere with a patient's participation in the study, or with the interpretation of the results, women of child-bearing potential who are pregnant or breast feeding, and corrected QT interval (QTc) \u2265450 msec at Screening.",
    "The sample is a clinical trial for a drug called lbh589, which is being tested for the treatment of cutaneous t-cell lymphoma. The trial is in phase 2/phase 3 and the table includes information on the diseases being treated, the icd-10 codes associated with those diseases, the drugs being used, and the eligibility criteria for patients to participate in the trial. The inclusion criteria include patients with biopsy-confirmed stages IB-IVA mycosis fungoides or S\u00e9zary syndrome, who have been treated with an HDAC inhibitor and had disease progression or an inadequate response to the treatment. The exclusion criteria include patients with a history of visceral disease, impaired cardiac function, and those who have received chemotherapy or any investigational drug or undergone major surgery \u2264 3 weeks prior to starting study drug or who have not recovered from side effects of such therapy. Women who are pregnant or breastfeeding or women of childbearing potential not willing to use a double method of contraception during the study and 3 months after the end of treatment are also excluded.",
    "The sample is a phase 2 clinical trial for psoriasis. The trial is testing the effectiveness of the drug navarixin 10 mg. The eligibility criteria for participants include having a BMI between 19 and 34, a diagnosis of psoriasis vulgaris with a PASI score greater than 8 for at least 1 year, and a target lesion on the head, trunk, arms, or legs that is at least 10 cm^2 in size with a total numerical rating for erythema, infiltration, and desquamation of at least 6 out of 12. Participants must also have stable disease, normal vital signs, and normal clinical laboratory tests. Exclusion criteria include pregnancy, medical conditions that may affect drug absorption, infectious diseases, drug or alcohol abuse, and allergies to local anesthetics.",
    "The sample is a phase 2 trial for contraception. The trial is looking for women who are in need of contraception and have good general health. They must have a regular menstrual cycle without hormonal contraceptives. The trial excludes women who are pregnant or lactating, had a delivery or abortion less than 12 weeks ago, had previous pregnancies outside the womb, had previous pelvic infections, have abnormal bleeding or uterine cavity, show climacteric signs, have genital cancer, liver diseases, or alcoholism or drug abuse. The trial is testing three different types of levonorgestrel intrauterine systems.",
    "The sample is a phase 2 clinical trial for sepsis and bacterial infections. The trial includes patients between the ages of 18 and 80 who have proven or suspected infection and meet specific criteria for systemic inflammation. The trial also requires patients to have acute renal failure and to provide written informed consent. Exclusion criteria include pregnancy, HIV-positive status, and participation in another investigational study within 90 days prior to the start of the trial. The trial involves the use of two drugs, placebo and biap, and patients with certain medical conditions or allergies are excluded.",
    "The sample is a record of a clinical trial in phase 2 for the treatment of dry eye. The trial involves the use of three drugs, including a placebo, and the eligibility criteria include confirmation of keratoconjunctival disorder with vital dye staining and abnormal Schirmer score results. The exclusion criteria include the presence of other eye diseases requiring different therapy and the need to wear contact lenses during the study. The sample also includes a list of icd-10 codes associated with the disease.",
    "The sample is a record of a clinical trial with a phase 2 designation. The trial is focused on advanced and metastatic breast cancer, with a list of associated ICD-10 codes. The trial is testing the effectiveness of the drug fulvestrant, with two instances of the drug being used. The eligibility criteria for the trial include having breast cancer that has continued to grow after treatment with an anti-estrogen hormonal treatment, requiring hormonal treatment, and being a postmenopausal woman. The exclusion criteria include having received more than one previous regimen of systemic anticancer therapy other than endocrine therapy for advanced breast cancer, having received more than one previous regimen of endocrine therapy for advanced breast cancer, and having an existing serious disease, illness, or condition that will prevent participation or compliance with study procedures.",
    "The sample is a phase 2 clinical trial that focuses on nicotine dependence, overweight, and obesity. The trial involves the drug nb32 and has eligibility criteria that include being between 18 and 65 years old, having a BMI between 27 and 45kg/m2, smoking at least 10 cigarettes per day for the past year, and having a self-reported motivation to quit smoking of at least 7 out of 10. Participants must also be concerned about gaining weight after quitting smoking, able to comply with study procedures, and willing to give written informed consent. Exclusion criteria include having a serious medical condition, a history of drug or alcohol abuse, or being pregnant or breastfeeding.",
    "The sample is a phase 2 clinical trial for patients with metastatic kidney cancer. The trial is testing the effectiveness of the drug perifosine. The eligibility criteria include having documented progression on treatment with sunitinib or sorafenib, having at least one measurable lesion on CT or MRI, normal organ and marrow function, an ECOG performance status of 0 or 1, and a life expectancy of at least 6 months. Patients must also be at least 18 years old, give written informed consent, and have a negative pregnancy test if they are women of childbearing potential. Exclusion criteria include not having recovered from adverse events from prior therapy, currently receiving sorafenib or sunitinib, having a known hypersensitivity to perifosine, and having a history of another primary malignancy within the last 5 years with some exceptions.",
    "The sample is a clinical trial for patients with recurrent follicular lymphoma, with a phase 2/phase 3 design. The trial includes patients who have received three or fewer prior regimens of chemotherapy and are beyond their first complete or partial remission. Eligibility criteria include adequate organ function, the ability to receive cyclophosphamide and rituximab mobilization chemotherapy, and the collection of an autologous or allogeneic graft of at least 2.0 * 10^6 CD34+ cells/kg. Patients must also meet certain inclusion criteria for proceeding to hematopoietic stem cell transplant and maintenance therapy. Exclusion criteria include a Karnofsky performance score less than 70%, uncontrolled hypertension, prior autologous or allogeneic HSCT, and known anaphylactic reaction to rituximab.",
    "The sample is a phase 2 clinical trial for the treatment of relapsing-remitting multiple sclerosis. The trial involves the use of two doses of a drug called firategrast. The eligibility criteria include having a diagnosis of relapsing-remitting MS with dissemination in time and space, having an EDSS score between 0 and 6.0, and having at least two relapses in the previous 24 months with at least one relapse or documented evidence of gadolinium-enhancement on MRI in the previous 12 months. In addition, subjects must have a minimum of five T2 lesions on brain MRI. The trial also has specific inclusion and exclusion criteria related to gender, age, medical history, and current health status.",
    "The sample is a phase 2 clinical trial for breast cancer and breast tumors with metastatic cancer. The trial involves administering either amg 479 or a placebo with either exemestane or fulvestrant. The eligibility criteria for the trial includes confirmation of hormone receptor positive disease status, being amenable to receive endocrine therapy, and having disease progression while receiving prior endocrine therapy for locally advanced or metastatic breast cancer. The trial is open to postmenopausal women who are 18 years or older. The exclusion criteria includes having HR-unknown or HR-negative disease, not being amenable to endocrine therapy, and having central nervous system metastasis. The icd-10 codes for the diseases are also provided.",
    "The sample is a phase 2 clinical trial for patients with metastatic renal cell carcinoma or renal cell carcinoma with sarcomatoid features. The trial is testing the effectiveness of four drugs - doxorubicin, gemcitabine, g-csf, and neulasta. The eligibility criteria for the trial include having a confirmed diagnosis of renal cell carcinoma with sarcomatoid histology, having measurable disease, and having a prior nephrectomy. Patients must also meet certain health criteria, such as having a certain level of white blood cells and platelets, and not having certain medical conditions. Patients who have previously received treatment for advanced disease or have brain metastases are excluded from the trial.",
    "This is a sample from a table that contains information about clinical trials. The trial is in phase 2 and is focused on breast cancer. The trial is looking at the effectiveness of the drugs lapatinib and letrozole. The eligibility criteria for participants include having a confirmed diagnosis of breast cancer, being postmenopausal, having a certain type of breast cancer that is HER2 negative, and having normal organ and marrow function. Participants must also be able to understand and sign a consent form and be able to swallow oral medication. Exclusion criteria include having certain stages of breast cancer, prior treatment with certain therapies, and having certain medical conditions.",
    "This sample is a phase 2 clinical trial for patients with non-small cell lung cancer and brain metastases. The trial is testing the effectiveness of the drug sunitinib in patients who have previously received whole brain radiation therapy and up to two prior systemic therapies for their cancer. The inclusion criteria require patients to have radiologically proven brain metastases, while the exclusion criteria exclude patients with certain types of brain lesions or hemorrhages.",
    "The sample is a record of a clinical trial for depression treatment. The trial is in phase 2/phase 3 and the disease being studied is depression. The icd-10 codes associated with depression are listed as [\"['F32.A', 'F53.0', 'P91.4', 'Z13.31', 'Z13.32']\"]. The drugs being tested are trazodone and placebo. The eligibility criteria for the trial are listed under inclusion and exclusion criteria, which include age, diagnosis of depression, and certain health conditions. The sample also mentions that patients or their dependents/guardians must provide signed informed consent forms.",
    "The sample is a phase 2 clinical trial for patients with type 2 diabetes mellitus. The trial includes a list of diseases and their corresponding ICD-10 codes, a list of drugs including placebos and different doses of empagliflozin, and eligibility criteria for inclusion and exclusion. Inclusion criteria include confirmed diagnosis of T2DM, HbA1c levels between 7.0% and 10.0%, metformin therapy, age over 18, and a body mass index of 45 kg/m2 or less. Exclusion criteria include an estimated creatinine clearance rate of less than 60 ml/min and a confirmed glucose level over 240 mg/dl after an overnight fast during the placebo run-in.",
    "The sample is a phase 2 clinical trial for the treatment of systemic lupus erythematosus. The trial involves the use of abatacept, placebo, and prednisone as drugs. The eligibility criteria for participants include a diagnosis of SLE and experiencing an active lupus flare in at least one of three organ systems, as well as a stable dose of prednisone for at least one month. Exclusion criteria include active lupus flare in the kidney or central nervous systems, treatment with certain medications for less than three months prior to the study, active viral or bacterial infections, any other autoimmune disease as a main diagnosis, and prior treatment with rituximab.",
    "The sample is a record from a clinical trial table. It is a phase 2 trial for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) using the drug ag-013736 (axitinib). The record includes the inclusion and exclusion criteria for the trial, as well as the icd-10 codes for the diseases being treated. The trial is looking for patients with poor prognosis AML or MDS who are not suitable candidates for chemotherapy and have not received prior systemic chemotherapy treatment or treatment with an anti-angiogenesis agent. The trial also requires patients to have adequate hepatic and renal function and an Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2. Patients with AML M3 (acute promyelocytic leukemia) or conditions that might confound the evaluation of safety or efficacy or increase patient risk are excluded from the trial.",
    "The sample is a clinical trial for tuberculosis, AIDS, and HIV infections. It is a phase 2/phase 3 trial that involves patients who are HIV infected and aged 18 years or older. The trial requires patients to have never received TB treatment or have received it for less than a month, and to be receiving rifampicin-based TB regimen for 4 to 6 weeks. Patients must also have a CD4 cell count of less than 250 cell/mm3 in the 4 weeks following the TB diagnosis and be na\u00efve of HAART. Women of childbearing age must have a negative plasmatic test for pregnancy and accept contraception or declare no wish of pregnancy in the coming year. Exclusion criteria include having a positive plasmatic test for pregnancy, Karnofsky score less than 60%, ALAT greater than 4N (Hepatitis grade 3 or 4), ongoing psychiatric pathology, and refusal to participate in the study. The amendment includes bilirubin greater than grade 3 and any grade 4 clinical sign or biological result at the time of inclusion. The table also includes lists of disease names, ICD-10 codes, drug names, and eligibility criteria.",
    "The sample is a phase 2 clinical trial for the treatment of rheumatoid arthritis. The eligibility criteria include being male or female over 18 years old, having a diagnosis of RA according to the revised 1987 criteria of the American College of Rheumatology, and having a DAS28 score of at least 4.2. The trial drug is gw856553. The exclusion criteria include having a history of liver disease, currently receiving a biological anti-rheumatic therapy, or having failed more than one anti-TNF\u03b1 biological therapy due to lack of efficacy. The sample also includes a detailed list of inclusion and exclusion criteria for the trial.",
    "The sample is a phase 2 clinical trial for the treatment of melanoma using the drug vemurafenib. The trial is open to patients over 18 years old with confirmed EBRAFV600E or KBRAFV600K mutations and stage IV melanoma or advanced stage III not curable by surgery. Patients with active CNS metastases are also allowed on the study. The trial requires patients to have measurable disease by RECIST v1.1 and an ECOG performance status of 3 or 4. Patients must also meet certain hematologic, hepatic, and renal function criteria. The trial has exclusion criteria, including uveal melanoma as primary, concurrent chemotherapy, immunotherapy, or radiotherapy, prior treatment with a RAF inhibitor, and pregnancy or lactation.",
    "The sample is a record of a clinical trial with a phase 2 designation. The trial is focused on bladder cancer and involves a list of ICDCodes, which are codes used to classify diseases. The trial also involves a list of drugs, including methotrexate, vinblastine, doxorubicin, cisplatin, and gemcitabine. The eligibility criteria for the trial are listed, including requirements for the patient's disease status, prior treatment, performance status, and various health measures. The sample also includes exclusion criteria, such as a history of serious cardiac disease or active infection.",
    "The sample is a phase 2 trial for relapsing-remitting multiple sclerosis. The icd-10 codes for the disease are listed as \"G35\", \"G93.81\", \"K74.1\", \"Q85.1\", \"G12.21\", \"G12.23\", and \"M34.0\". The trial involves two groups, one receiving interferon beta-1b and the other receiving a combination of interferon beta-1b and atorvastatin. The eligibility criteria include successful completion of a previous study, written informed consent, and exclusion criteria such as having any other disease that better explains the patient's symptoms, secondary progressive MS, uncontrolled severe medical disorder, and participation in any other studies.",
    "The sample is a phase 2 clinical trial for patients with aggressive Diffuse Large B-Cell Lymphoma who have relapsed or are refractory to previous therapy. The trial is testing the effectiveness of the drug dasatinib. The eligibility criteria include being over 18 years old, having measurable disease on cross-sectional imaging, and having received at least one prior combination chemotherapy regimen. Exclusion criteria include having a serious medical condition or psychiatric illness that would prevent signing the informed consent form, being pregnant or lactating, and having a history of significant bleeding disorder unrelated to cancer. The trial also requires participants to use reliable contraception methods and to abstain from donating blood during the study and for at least 28 days after discontinuation from the study.",
    "The sample is a phase 2 clinical trial for the treatment of melanoma using a drug called zk-epo. The trial is for patients with unresectable stage III or stage IV disease and at least one measurable lesion. The eligibility criteria include confirmation of malignant melanoma, Eastern Cooperative Oncology Group (ECOG) performance status \u22642, and adequate function of major organs and systems. The exclusion criteria include more than 2 previous chemotherapy regimens, any prior treatment with Epothilones, Epothilone analogues, taxanes, or vinca alkaloids, and any progressive central nervous system (CNS) metastatic disease. Patients with CNS metastases may be allowed if stable for 8 weeks or more and patient is neurologically intact and off of steroids. The stability must be documented by MRI/CT over a period of 8 weeks or greater. Additionally, any radiotherapy, chemotherapy, or immunotherapy within 3 weeks prior to first dose of ZK-Epo is not allowed.",
    "The sample is a phase 2 clinical trial for non-alcoholic fatty liver disease. The trial includes patients between the ages of 18 and 75 who meet certain inclusion criteria, such as having non-alcoholic fatty liver disease. However, there are also exclusion criteria, such as having a disorder in liver function other than non-alcoholic fatty liver, having a history of immune disorder, or having received treatment that may affect liver function within 1 month prior to the study. The trial involves the use of two drugs, placebo and oltipraz, and the eligibility criteria are designed to ensure that the results are not affected by other medications or medical conditions.",
    "The sample is a phase 2 clinical trial for breast cancer patients with positive estrogen and/or progesterone receptors. The trial is testing the effectiveness of letrozole in combination with bevacizumab. The eligibility criteria include having invasive ductal carcinoma or invasive lobular carcinoma of the breast, being postmenopausal, having measurable disease by mammogram and/or breast ultrasound, and having adequate organ and marrow function. Exclusion criteria include having participated in another experimental drug study within 4 weeks of the first infusion of this study, having uncontrolled high blood pressure, unstable angina, congestive heart failure, or a history of myocardial infarction or stroke within 6 months. Patients with metastatic disease are also excluded.",
    "The sample is a phase 2 clinical trial for patients with CD22+ acute lymphoblastic leukemia that is refractory to therapy or in second or greater relapse without other standard therapeutic options. The trial involves a lymphodepleting regimen and an NK cell infusion from a related donor who is predicted to be alloreactive based on the presence of relevant KIR genes and incompatibility with the recipient for HLA C or Bw antigens. The trial has various inclusion and exclusion criteria, including adequate renal and liver function, controlled pulmonary symptoms, negative serology for HIV, and the use of effective contraception by sexually active females and males. The trial also excludes patients with active central nervous system leukemia, active infection, or those currently using a Phase I, II, or III investigational agent. Donors must meet standard medical eligibility criteria for allogeneic stem cell donation and must have negative infectious disease marker testing.",
    "The sample is a phase 2 clinical trial for patients with pancreatic cancer that has progressed after at least one gemcitabine-based treatment regimen for advanced or metastatic disease. The trial is testing the effectiveness of the drug capecitabine in treating the disease. Patients must meet certain eligibility criteria, including having measurable disease, carrying a specific genetic variant, and meeting certain performance and health status requirements. Patients must also not have certain medical conditions or be taking certain medications. Prior concurrent therapy is also restricted. The sample includes detailed information on the disease characteristics, patient characteristics, and prior concurrent therapy requirements.",
    "The sample is a phase 2 trial for patients with type 2 diabetes mellitus who have been on stable metformin treatment for at least 3 months. The trial involves the use of a drug called taspoglutide, as well as a placebo. The eligibility criteria include being between 18-75 years old, having stable weight for at least 3 months, and not having type 1 diabetes or uncontrolled hypertension. Patients must also not have taken any other anti-hyperglycemic medication or weight-lowering medication in the last 3 months.",
    "The sample is a phase 2 clinical trial for patients with histologically confirmed oat cell or intermediate type small cell lung cancer who have received prior therapy. The trial involves the use of biricodar dicitrate, doxorubicin hydrochloride, and vincristine sulfate as treatment options. Patients must have documented disease progression after front line therapy, but no more than one prior chemotherapy regimen. They must also have had a complete or partial response to initial chemotherapy that lasted more than 60 days before relapse occurred. Patients must have bidimensionally measurable disease with at least one lesion outside of the irradiation field, and no brain or bone metastases as the only measurable site. The eligibility criteria also include specific patient characteristics such as age, performance status, hematopoietic, hepatic, renal, and cardiovascular conditions, as well as prior concurrent therapy. The trial does not allow concurrent experimental drugs or anticancer therapies, and certain medications are prohibited.",
    "The sample is a record of a clinical trial in phase 2, focused on the disease of benign prostatic hyperplasia. The trial includes a list of ICD-10 codes for the disease, a list of drugs being tested (in this case, normal saline), and eligibility criteria for participants. The inclusion criteria require participants to have lower urinary tract symptoms due to benign prostatic hyperplasia and an enlarged prostate volume by rectal ultrasound. The exclusion criteria include previous prostate surgery, previous or current diagnosis of prostate cancer, use of other medications for the treatment of prostatic hyperplasia, and urinary tract infection.",
    "The sample is a clinical trial for major depressive disorder, with a phase 2/phase 3 designation. The trial involves the drugs tasimelteon and placebo. The eligibility criteria include a diagnosis of MDD according to DSM-IV TR criteria, a current episode lasting between 4 weeks and 1 year, and a CGI-Severity score of at least 4 at screening and baseline. Exclusion criteria include a history of bipolar disorder, schizophrenia, schizoaffective disorder, eating disorder, or obsessive-compulsive disorder, as well as drug or alcohol abuse/dependence within the past 12 months, and participation in a previous tasimelteon trial.",
    "The sample is a phase 2 clinical trial for patients with advanced non-small cell lung cancer. The trial is testing the effectiveness of the drugs carboplatin and paclitaxel albumin-stabilized nanoparticle formulation. The eligibility criteria include having confirmed advanced non-small cell lung cancer, being ineligible for curative treatment or treatment with bevacizumab, having measurable disease according to RECIST, and meeting certain patient characteristics such as having an ECOG performance status of 0-2 and no significant psychiatric illness. The trial also has certain exclusion criteria such as having uncontrolled brain metastases or significant psychiatric illness. Prior concurrent therapy is allowed, but there are certain restrictions such as no concurrent radiotherapy and more than 4 weeks since prior major surgery or open biopsy.",
    "This sample is a phase 2 clinical trial for the treatment of bleeding. The trial includes patients who are planned to undergo primary isolated CABG surgery or primary combined CABG and aortic valve replacement surgery. The patients must be men aged 18 to 85 years or women aged 18 to 85 years who are either of postmenopausal status or have a medical history of hysterectomy or bilateral oophorectomy. The trial involves the use of several drugs, including mdco 1, mdco 2, mdco 3, mdco 4, tranexamic acid, and saline. The eligibility criteria for the trial include written informed consent and meeting certain medical requirements, while the exclusion criteria include various medical conditions and recent use of certain medications. The trial is designed to evaluate the safety and efficacy of the drugs in treating bleeding.",
    "The sample is a phase 2 clinical trial for the treatment of hepatocellular carcinoma, a type of liver cancer. The trial is testing the effectiveness of a combination of drugs called irinotecan plus capecitabine. The trial is open to Asian subjects with confirmed hepatocellular carcinoma that cannot be completely removed surgically and have extra-hepatic disease, main portal vein or hepatic vein involvement. The trial also requires subjects to have an Eastern Cooperative Oncology Group performance status of ?2. However, subjects with decompensated cirrhosis or stage C according to the Child-Pugh Classification, current history of chronic diarrhea, or reproductive potential not using adequate contraceptive measures are excluded from the trial.",
    "The sample is a record from a clinical trial table that includes information about the phase of the trial, diseases being studied, icd-10 codes of the diseases, drugs being tested, and eligibility criteria for participants. In this particular sample, the trial is in phase 2/phase 3 and is studying chronic hepatitis C. The icd-10 codes associated with the disease are listed, as well as the drugs being tested (nitazoxanide and ribavirin). The eligibility criteria for participants are also listed, including age, duration of hepatitis C infection, liver biopsy results, and exclusion criteria such as previous failed treatment, pregnancy, and other liver diseases.",
    "The sample is a clinical trial for allergic rhinitis, with a combination of phase 2 and phase 3. The trial involves testing the efficacy of three different drugs, including a placebo, on patients who are sensitized to D. pteronyssinus or D. farinae and have been suffering from house dust mite-related allergic rhinitis for at least a year. The trial includes both inclusion and exclusion criteria, such as patients must be between 18 to 50 years old, in general good health, and willing to comply with the protocol. Exclusion criteria include patients with other nasal conditions, pregnant or breastfeeding women, and patients who have received allergy specific immunotherapy for house dust mites in the last 10 years. The trial also prohibits participation from investigators, co-investigators, their children or spouses, and all study collaborators.",
    "The sample is a phase 2 clinical trial for patients with metastatic pancreatic adenocarcinoma who have not received prior chemotherapy or radiation therapy. The trial is testing the effectiveness of the drug imexon in combination with gemcitabine compared to a placebo with gemcitabine. The eligibility criteria include having measurable metastatic lesions, being at least 18 years old, having an ECOG performance status of 0 or 1, and having a projected life expectancy of at least 2 months. Exclusion criteria include having locally advanced non-metastatic pancreas cancer, prior anticancer drug therapy for metastatic disease, and laboratory parameters outside of specified ranges.",
    "The sample is a phase 2 clinical trial for breast cancer patients who are postmenopausal and have newly diagnosed metastatic breast cancer. Patients who have had recurrent disease during or after adjuvant tamoxifen or are hormone therapy na\u00efve are eligible for the trial. The trial requires a paraffin embedded tumor tissue block or slides from either the metastatic or primary tumor site. The trial drugs are gefitinib and anastrozole. The eligibility criteria include exclusion of patients on hormone replacement therapy, those who have received prior chemotherapy for metastatic disease, those who have had previous treatment with tyrosine kinase inhibitors or aromatase inhibitors, and those who have evidence of an active interstitial lung disease.",
    "This sample is from a clinical trial in phase 2 for the treatment of hepatitis C infection. The trial includes patients who are chronically infected with HCV genotype 1 and have a viral load of at least 100,000 IU/mL. The trial is for patients who are either treatment-na\u00efve or non-responders to the current standard of care. The trial excludes patients with cirrhosis, HCC, or co-infection with HBV, HIV-1, or HIV-2. The trial involves the use of drugs such as daclatasvir, peginterferon alfa-2a, and ribavirin, as well as a placebo. The eligibility criteria for the trial include the key inclusion criteria mentioned above.",
    "The sample is a phase 2 clinical trial for neuropathic pain. The trial includes male and female subjects aged 18-80 years old who have been diagnosed with neuropathic pain due to lumbosacral radiculopathy. The pain must be perceived in one or both lower limbs at sites consistent with the area innervated by the L4, L5 or S1 nerve roots, with or without other sensory symptoms in the affected areas. The trial requires that the subjects have a stable intensity of pain for at least 2 weeks prior to screening. The trial also requires that the subjects have a baseline average daily pain score for neuropathic pain due to LSR on the PI-NRS, calculated as the average of their daily PI-NRS scores over the baseline period (Day -7 to Day -1), that is greater than or equal to 4 on the PI-NRS, after wash-out of prohibited medications. The trial includes a list of inclusion and exclusion criteria, including the requirement for all eligible subjects to have the nature of their spinal disease established by imaging (CT/MRI) and reviewed by a neuroradiologist / Investigator prior to starting study medication. The trial also requires that subjects stop and remain abstained from non-pharmacological treatments for their neuropathic pain during the study. The trial includes a list of drugs, including placebo and gs856553, and a list of diseases, including pain, neuropathic, and a list of icd-10 codes of diseases.",
    "The sample is a phase 2 clinical trial for the treatment of cutaneous metastatic melanoma that is BRAF mutation-positive. The trial is testing the drug GSK2118436. The eligibility criteria include being at least 18 years old, having measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST 1.1), and having an Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-1. The exclusion criteria include previous treatment with a BRAF or MEK inhibitor, recent cancer therapy, a history of certain infections, brain metastases, and certain cardiac abnormalities. The sample also includes lists of disease names, ICD-10 codes, and eligibility criteria.",
    "The sample is a phase 2 clinical trial for patients with colon or colorectal cancer. The trial involves the administration of three drugs: sir-spheres agent, cetuximab, and irinotecan. The eligibility criteria include having measurable disease, radiological evidence of disease progression within 6 months of the most recent dose of chemotherapeutic regimens, normal organ and marrow function, and an ECOG performance status less than or equal to 2. Patients with a prior history of non-colorectal cancer who have no active disease may also be eligible if they are disease-free for greater than or equal to 12 months prior to treatment. The trial has exclusion criteria, including patients who have had chemotherapy within 4 weeks prior to entering the study, those who have not recovered from adverse events due to agents administered more than 4 weeks earlier, and those who have had hepatic external beam radiotherapy. Patients exhibiting the mutant variety for kras will also be excluded from participation in the study.",
    "This sample is for a phase 2 clinical trial for HIV infections. The trial is testing the effectiveness of three drugs - vicriviroc maleate 20 mg, vicriviroc maleate 30 mg, and placebo. The eligibility criteria for the trial include having documented HIV infection with no detectable CXCR4, having prior therapy with at least three classes of currently marketed antiretroviral agents, having HIV RNA levels of at least 1000 copies/mL on a stable ART regimen for at least 6 weeks prior to screening, having at least one genotypically documented resistance mutation to a reverse transcriptase inhibitor and at least one primary resistance mutation to a PI, and having acceptable hematologic, renal, and hepatic laboratory parameters. The exclusion criteria include having a history of previous malignancy (with some exceptions), treatment with cytotoxic cancer chemotherapy, recurrent seizure or CNS condition or drug use predisposing to seizure, and no active AIDS-defining opportunistic infection.",
    "The sample is a record from a clinical trial table, containing information about a phase 2 trial for patients with prostate cancer that has progressed after androgen deprivation. The record includes the list of diseases and their corresponding ICD-10 codes, as well as the list of drugs used in the trial. The eligibility criteria for the trial are also provided, including age requirements, medical history, and exclusion criteria. The record also specifies that patients must discontinue certain medications before starting the trial and must not have any prior malignancies within the past 5 years, except for certain types of skin and breast cancers.",
    "The sample is a phase 2 clinical trial for breast cancer patients with locally advanced or metastatic tumors that cannot be treated with surgery or radiation. The trial is testing the effectiveness of three drugs - azd8931, anastrozole, and placebo. The eligibility criteria for the trial include being hormone therapy-naive and having an estimated life expectancy of more than 12 weeks. Exclusion criteria include having received anti-cancer therapy within the last 14 days, having had an eye injury or corneal surgery within the last 3 months, and currently receiving oestrogen replacement therapy. The diseases being studied include neoplasms and breast cancer, with corresponding ICD-10 codes provided.",
    "The sample is a phase 2 trial for sepsis, a serious infection. The trial includes patients who are over 18 years old and have been admitted to the hospital with sepsis. The patients must meet certain criteria, such as having a suspected or confirmed infection and meeting specific vital sign and blood count criteria. They must also have started antibiotics for their sepsis. The trial excludes patients who are pregnant, have certain medical conditions, or are taking certain medications. The trial aims to test the effectiveness of simvastatin, a cholesterol-lowering drug, in treating sepsis.",
    "The sample is a phase 2 clinical trial for patients with metastatic pancreatic cancer. The trial involves the use of three drugs - bevacizumab, gemcitabine, and oxaliplatin. The eligibility criteria include being at least 18 years old, having an ECOG performance status of 0-2, having measurable disease, and not having received prior chemotherapy for advanced pancreatic cancer. Patients must also have adequate hepatic, renal, and bone marrow function, and use effective means of contraception if of child-bearing potential. Exclusion criteria include previous chemotherapy for pancreatic cancer, uncontrolled intercurrent illness, and major surgical procedures or traumatic injury within 28 days prior to Day 0. Women who are pregnant or lactating are also excluded.",
    "The sample is a phase 2 clinical trial for patients with unresectable or metastatic stage IV esophageal or gastric adenocarcinoma. The trial is testing the effectiveness of cetuximab, a drug that targets the epidermal growth factor receptor (EGFR) pathway. The trial includes patients who have received 1-2 prior chemotherapy regimens in the metastatic setting for unresectable or metastatic esophageal or gastric carcinoma. The eligibility criteria include measurable disease, ECOG performance status 0-2, life expectancy greater or equal to 12 weeks, age 18 years or older, and ability to sign an informed consent document. The trial excludes patients with other active malignancies, significant history of cardiac disease, prior severe infusion reaction to a monoclonal antibody, and those who have received any chemotherapy regimen or radiation therapy within 28 days prior to study entry. The trial also requires patients to have completed any major surgery 4 weeks or any minor surgery 2 weeks prior to the first infusion of cetuximab and to have fully recovered from the procedure. No concurrent use of chemotherapy, radiation, or other investigational agents is allowed while participating in this study.",
    "The sample is a phase 2 trial for the treatment of major depressive disorder. The trial includes patients who have been diagnosed with MDD and excludes those with other primary diagnoses, a history of schizophrenia, schizoaffective disorders, seizure disorders, or bipolar affective disorder. Patients who have received formal psychotherapy or cognitive/behavioral therapy in the 12 weeks prior to the screening visit, those who are actively suicidal, and those with a history of migraine headaches are also excluded. The trial involves the use of two drugs, gw597599b and paroxetine.",
    "The sample is a record of a clinical trial in phase 2 for the treatment of type 2 diabetes mellitus. The trial involves the use of two drugs, ttp054 and placebo, and the eligibility criteria include a diagnosis of type 2 diabetes mellitus, being on a stable regimen of metformin or metformin in combination with another acceptable oral antidiabetic agent, and having a specific range of HbA1c levels. The exclusion criteria include a history of significant diabetic complications, heart attack, stroke, or congestive heart failure, severe uncontrolled hypertension, frequent hypoglycemia, and being a woman of child-bearing potential. The diseases are listed as 'type 2 diabetes mellitus', and the icd-10 codes associated with the disease are also provided.",
    "The sample is a phase 2 clinical trial for patients with metastatic breast cancer that overexpresses HER2. The trial involves the use of two drugs, rapamycin and trastuzumab. The eligibility criteria include having measurable disease, progression following at least 8 weeks of standard doses of Herceptin or a Herceptin-containing regimen, and being off Herceptin for a minimum of 2 weeks. Patients must also have a life expectancy of more than 3 months, be at least 18 years old, have an ECOG performance status of 2 or less, and have adequate bone marrow, liver, and renal function. In addition, patients must be willing to sign a written informed consent and use adequate birth control. The exclusion criteria include active infection, active brain metastases requiring treatment, prior chemotherapy or radiation therapy within the last 4 weeks, prior therapy with rapamycin or experimental agents targeting mTOR, and uncontrolled intercurrent illness.",
    "The sample is a phase 2 clinical trial for irritable bowel syndrome. The icd-10 codes associated with the disease are listed as K58.2, K58.8, K58.0, K58.1, and K58.9. The drugs being tested are placebo and bms-562086. The eligibility criteria for the trial include female subjects with D-IBS symptoms based on Rome II criteria and the subject's responses to the Bowel Disease Questionnaire. The exclusion criteria include clinically significant prolonged diarrhea with dehydration requiring IV fluid within 60 days prior to the baseline visit.",
    "The sample is a phase 2 clinical trial for the treatment of lymphoma using the drug temozolomide. The eligibility criteria include having histologically confirmed mycosis fungoides or Sezary syndrome, stage IB-IVB disease, and having failed at least one prior systemic therapy. Patients must also have measurable disease or at least one indicator lesion, and meet certain age, performance status, life expectancy, hematopoietic, hepatic, renal, and cardiovascular requirements. They must not have poorly controlled diabetes mellitus, acute infection requiring IV antibiotics, or any other medical condition that would prevent ingestion or absorption of oral medication. Additionally, they must not have any other neoplasm within the past 5 years except curatively treated squamous cell or basal cell skin cancer, melanoma in situ, or carcinoma in situ of the cervix. The trial excludes pregnant or nursing patients, and requires fertile patients to use effective contraception. Prior concurrent therapy is also taken into account.",
    "The sample is a phase 2 clinical trial for previously untreated Grade I-II follicular B-cell non-Hodgkin's lymphoma. The trial includes patients with measurable disease and an ECOG performance status of 0-1. The eligibility criteria also require adequate hematological, hepatic, and renal function. Patients with severe lymphoma-related symptoms requiring rapid response to therapy, active infections, or other types of lymphoma are excluded. The trial involves the use of at-101 and rituximab drugs. The sample includes a list of diseases and their corresponding icd-10 codes. The eligibility criteria are listed under inclusion and exclusion criteria.",
    "The sample is a phase 2 clinical trial for ovarian and endometrial cancer patients. The trial is testing the effectiveness of a drug called MKC-1. The eligibility criteria for the trial include having confirmed epithelial ovarian cancer, primary peritoneal carcinomatosis, fallopian tube cancers, or endometrial cancer, being over 18 years old, having failed at least one prior platinum-based and one taxane-based chemotherapeutic regimen, having measurable disease according to RECIST or CA 125 criteria, having an ECOG performance status of 0, 1, or 2, and meeting certain laboratory result requirements. The exclusion criteria include recent administration of cancer-specific therapy, significant bowel obstruction, uncontrolled hypercalcemia, serious cardiac condition, and any medical conditions that would impose excessive risk to the patient.",
    "The sample is a phase 2 clinical trial for the treatment of acute lymphoblastic leukemia. The trial includes patients with a diagnosis of ALL, but excludes those with mature B-cell ALL or secondary ALL. Patients must not be pregnant or nursing, must have a negative pregnancy test, and must use effective contraception if fertile. Patients must also not have any comorbid medical conditions or active psychiatric or mental illness that would compromise the study objectives. Prior anti-leukemic therapy is not allowed, except for \u2264 1 week of steroids, emergent radiotherapy to the mediastinum, hydroxyurea, or emergent leukapheresis. Patients who have received steroids within the past 7 days are eligible but will not receive steroid prophase therapy on study. The treatment regimen includes a combination of drugs such as cyclophosphamide, cytarabine, dexamethasone, doxorubicin hydrochloride, etoposide phosphate, hydrocortisone sodium succinate, imatinib mesylate, mercaptopurine, methotrexate, methylprednisolone, pegaspargase, prednisolone, prednisone, and vincristine sulfate.",
    "The sample is a phase 2 clinical trial for pancreatic cancer. The eligibility criteria include having locally advanced or metastatic adenocarcinoma of the pancreas, being at least 18 years old, having an ECOG performance status of 0 or 1, and meeting certain laboratory criteria. Patients must not have received prior therapy for advanced pancreatic cancer, and must be informed of the investigational nature of the study and give written informed consent. Exclusion criteria include inability to comply with study procedures, disease not amenable to biopsy, clearly resectable disease, and prior systemic therapy for advanced pancreatic cancer. The study involves the use of the drugs S-1 and gemcitabine hydrochloride, and there are specific exclusion criteria for S-1.",
    "The sample is a phase 2 clinical trial for patients with supratentorial malignant primary gliomas, including glioblastoma multiforme, gliosarcoma, anaplastic astrocytoma, anaplastic oligodendroglioma, and mixed anaplastic glioma. Patients must have shown evidence of tumor recurrence or progression by MRI scan after radiation therapy. The trial includes the use of thalidomide and cpt-11 drugs. The eligibility criteria include having a Karnofsky performance status of >= 70, adequate bone marrow, liver, and renal function, and signing an informed consent. Exclusion criteria include a history of any other cancer (except non-melanoma skin cancer or carcinoma in-situ of the cervix), active infection, serious intercurrent medical illness, and grade 2 or higher peripheral neuropathy. The trial does not exclude any race and actively recruits minorities to participate.",
    "The sample is a phase 2 clinical trial for patients with stage IIIB non-small cell lung cancer. The trial is testing the effectiveness of the drugs cisplatin and docetaxel. The eligibility criteria include having histologically or cytologically confirmed lung cancer with specific characteristics, no metastases to certain organs, and meeting certain hematopoietic, renal, and pulmonary requirements. Patients must not have received prior chemotherapy, radiotherapy, or surgical resection for lung cancer. The trial also specifies patient characteristics such as age and performance status. Prior concurrent therapy with growth factors is not allowed.",
    "The sample is a phase 2 clinical trial for patients aged 40 years or older with moderate to severe Chronic Obstructive Lung Disease (COPD) and a smoking history of at least 10 pack-years. The trial is testing the effectiveness of various doses of the drug nva237 and a placebo in treating COPD symptoms. Patients must meet certain inclusion criteria, such as having a post-bronchodilator Forced Expiratory Volume in 1 second (FEV1) of less than 80% and greater than or equal to 30% of the predicted normal value, and being symptomatic according to daily electronic diary data. Patients with certain exclusion criteria, such as a history of lung cancer or certain cardiovascular co-morbid conditions, are not eligible to participate in the trial.",
    "The sample is a clinical trial in phase 2 for the treatment of choroidal neovascularization and age-related maculopathy. The trial involves the use of the drug dexamethasone. The eligibility criteria for the trial include being 50 years or older with subfoveal choroidal neovascularization, having visual acuity between 20/40 and 20/400 in the study eye, and not having undergone any intraocular surgery within the past 3 months. Exclusion criteria include having glaucoma, cataract, high eye pressure, or uncontrolled systemic disease.",
    "The sample is a phase 2 clinical trial for non-small-cell lung carcinoma using the drug cetuximab. The trial is looking for patients who are not eligible for radiochemotherapy or refuse chemotherapy, have histologically verified NSCLC, and meet certain criteria such as having a FeV1 greater than 1.5 L or minimum 50%, KPI greater than or equal to 70%, and life expectancy greater than 6 months. The trial also has exclusion criteria such as active infection, reduced liver function, and pregnancy or breastfeeding. The sample includes a list of diseases, icd-10 codes, and eligibility criteria for the trial.",
    "The sample is a phase 2 clinical trial for patients with myelodysplastic syndrome. The trial includes patients who have been diagnosed with MDS according to the FAB or WHO classification systems, and have a bone marrow blast count of less than 30%. Patients with low risk MDS who are transfusion dependent are also eligible. The trial excludes pregnant females, patients with AML, and those with any malignant disease within the past 2 years, except for certain types of skin cancer. Patients must be off all prior treatment for MDS and investigational agents for at least 4 weeks before entry. Additionally, patients with uncontrolled cardiac or pulmonary disease, active viral or bacterial infections, or HIV are excluded. The trial requires patients to meet certain lab values as specified in the protocol. The treatment for the trial includes a combination of decitabine, arsenic trioxide, and ascorbic acid.",
    "The sample is a phase 2 clinical trial for patients with metastatic breast cancer who have previously been treated with anthracycline and/or taxane. The trial is testing the effectiveness of the drug pixantrone dimaleate. The eligibility criteria include being at least 18 years old, having measurable disease, and having received 2-3 prior chemotherapy treatment regimens. Patients must also have a negative pregnancy test and meet certain laboratory value requirements. Exclusion criteria include having HER2 positive breast cancer, having received lifetime cumulative treatment with doxorubicin equivalent to >400 mg/m2, and having >3 prior chemotherapy regimens for breast cancer. Patients must also not have active brain metastasis or uncontrolled hypertension, and must not be receiving treatment in a different clinical study with investigational procedures or therapies.",
    "The sample is a phase 2 clinical trial for the treatment of various types of acute myeloid leukemia. The trial includes patients with a confirmed diagnosis of AML, excluding M3, and those with antecedent myelodysplasia. Patients with therapy-related AML are also eligible if they have been free of their primary disease and have not received any chemotherapy for at least 2 years. The trial excludes patients who have received prior 5-azacitidine or decitabine therapy. The treatment includes busulfan, cytarabine, daunorubicin hydrochloride, decitabine, and etoposide. The eligibility criteria include various conditions such as unequivocal histologic diagnosis of AML, no prior treatment for leukemia or myelodysplastic syndrome, and no prior 5-azacitidine or decitabine therapy.",
    "The sample is a phase 2 clinical trial for patients with metastatic pancreatic cancer. The trial is testing the effectiveness of the drug gemcitabine. The eligibility criteria include being 18 years or older with a life expectancy of at least 3 months, having histologically or cytologically documented stage IV ductal adenocarcinoma of the pancreas, having an Eastern Cooperative Oncology Group (ECOG) performance status \u2264 2, and having adequate hematologic, renal, and hepatic function. Exclusion criteria include having neuroendocrine tumors of the pancreas, severe chronic obstructive or other pulmonary disease with hypoxemia, and ongoing therapy with oral or parenteral anticoagulants. Participants must also agree to use an approved form of contraception if of reproductive potential.",
    "The sample is a phase 2 clinical trial for patients with squamous cell carcinoma of the head and neck. The trial involves the drug everolimus 10mg daily and has eligibility criteria that include having at least one measurable site of disease, a performance status of 0-2, and prior treatment for recurrent or metastatic disease. Exclusion criteria include receiving anticancer therapies within 4 weeks of the start of the study drug, having uncontrolled brain or leptomeningeal metastases, and having severe and/or uncontrolled medical conditions that could affect participation in the study. The trial requires signed informed consent and a pre-treatment biopsy for patients with accessible tumor tissue.",
    "The sample is a phase 2 trial for patients with either dermatofibrosarcoma protuberans (DFSP) or transformed fibrosarcomatous DFSP. Patients with transformed fibrosarcomatous DFSP may have primary, locally recurrent or metastatic disease. Patients with DFSP must have locally recurrent or metastatic disease OR primary disease for which complete excision with a wide margin (> 1-2 cm) would result in unacceptable cosmetic disfigurement or functional impairment. The trial requires patients to have measurable disease and submit pathology materials for review. Patients must be willing to have blood samples submitted for testing of drug levels and submit fresh/frozen tumor tissue for molecular correlative studies related to the PDGFR pathway. Patients must not have had chemotherapy, biologic therapy or investigational agents for this tumor within 28 days prior to registration. Prior radiotherapy is allowed, provided at least four weeks have elapsed since the last treatment, there is evidence of progressive disease within or measurable disease outside of the radiation field, and the patient must have recovered from all associated toxicities at the time of registration. Patients must have Zubrod performance status of =< 2 and meet certain blood count and liver function criteria. Patients must not be taking therapeutic doses of coumadin (Warfarin) at the time of registration. Patients with known CNS metastases, pregnant or nursing women, and patients with other prior malignancy are not eligible. All patients must be informed of the investigational nature of this study and must sign and give written informed consent in accordance with institutional and federal guidelines. The trial requires the treating institution's name and ID number to be provided to the Data Operations Center in Seattle in order to ensure that the current (within 365 days) date of institutional review board approval for this study have been entered into the database.",
    "The sample is a phase 2 clinical trial for major depressive disorder. The trial is testing the drug \"rx-10100\". The eligibility criteria for the trial includes having moderate to severe MDD as determined by the DSM-IV-TR Axis 1 Disorders and by the Montgomery Asberg Depression Rating Scale (MADRS). However, women who are pregnant, breastfeeding, or have childbearing potential and are not willing to practice a reliable method of birth control are excluded from the trial. Additionally, individuals with a depressive episode duration of less than 1 month, lifetime history of any psychotic disorders, anxiety disorders, significant suicidality, or clinically significant medical conditions are also excluded. The icd-10 codes for the disease are listed as [\"F33.0\", \"F33.1\", \"F33.9\", \"F32.0\", \"F32.1\", \"F32.9\", \"F33.40\"].",
    "The sample is a phase 2 clinical trial for breast cancer patients. The trial is testing the effectiveness of three drugs - nab-paclitaxel, bevacizumab, and trastuzumab. The eligibility criteria for the trial include being a female patient with histologically confirmed adenocarcinoma of the breast or inflammatory breast cancer, having FISH+ HER2 gene amplified breast cancer, being 18 years or older, having normal cardiac function, and having a performance status of 0-2. Patients cannot have received any prior chemotherapy for this disease or any other cancer in the past 5 years. The trial also has additional inclusion and exclusion criteria, which will be determined by the study center. The sample includes the full list of eligibility criteria for the trial.",
    "The sample is a phase 2 clinical trial for the treatment of Chronic Phase or Advanced Disease chronic myeloid leukemia (CML)/Ph+ Acute Lymphoblastic Leukemia (Ph+ ALL) using the drug dasatinib. The trial is for men and women aged 18 years or older who are resistant or intolerant to imatinib. The eligibility criteria include having an Eastern Cooperative Oncology Group (ECOG) performance status score of 0-2, adequate hepatic and renal function, and normal levels of certain electrolytes. Exclusion criteria include pregnancy or breastfeeding, eligibility for stem cell transplantation, uncontrolled medical disorders or infections, significant cardiovascular disease, and a history of significant bleeding unrelated to CML.",
    "The sample is a phase 2 clinical trial for the treatment of pulmonary arterial hypertension. The trial is open to both male and female participants between the ages of 3 and 18 who have been diagnosed with PAH due to IPAH, connective tissue disease, or congenital heart disease. Participants must have confirmed PAH with specific criteria, including a mPAP > 25 mmHg at rest, PCWP or LVEDP \u2264 15 mmHg, and PVR \u2265 240 dynes/sec/cm-5. They must also be in NYHA/WHO functional Class II, III, or IV and have had a 6-minute walk test and cardiopulmonary exercise testing performed within the 3 months preceding the screening visit. Participants must be on a stable dose and regimen of therapy for at least 3 months prior to the screening visit and must demonstrate the ability to use the nebulizer device. Exclusion criteria include prior use of prostacyclins or prostacyclin analogues within 3 months prior to screening, portal hypertension or clinically relevant hepatic disease, Eisenmenger syndrome with resting SpO2 <88% on room air, clinically relevant asthma or other chronic lung disease, left-sided heart disease, and initiation or dosage adjustment of PAH-specific therapy within 3 months prior to screening.",
    "The sample is a phase 2 clinical trial for patients with non-small cell lung cancer. The trial involves the use of two drugs, eribulin mesylate and erlotinib, and has a list of eligibility criteria that patients must meet in order to participate. These criteria include having confirmed NSCLC, having received at least one prior platinum-based doublet anti-cancer treatment for recurrent or advanced NSCLC, and having an ECOG performance status less than or equal to 2. The trial also has a list of exclusion criteria, such as prior therapy with eribulin or a tyrosine kinase inhibitor of the epidermal growth factor receptor, and existing anti-cancer therapy-related toxicities of grade greater than or equal to 2.",
    "The sample is a phase 2 clinical trial for various types of lymphoma, including extranodal marginal zone lymphoma, nodal marginal zone lymphoma, and mantle cell lymphoma, among others. The trial is testing the effectiveness of the drugs bortezomib, cyclophosphamide, and dexamethasone. The eligibility criteria for participants include having a confirmed diagnosis of relapsed or refractory follicular Grades 1 or 2 lymphoma, measurable disease, and an expected survival of more than 3 months. Participants must also meet various health requirements, such as having an ECOG Performance Status of 0, 1, or 2, and having certain blood counts and organ function within normal ranges. Exclusion criteria include being pregnant or nursing, having certain co-morbid systemic illnesses, and having received other investigational drugs within 14 days prior to registration.",
    "The sample is a phase 2 clinical trial for breast cancer. The trial is looking for female participants with an increased inherited risk of breast cancer, as defined by a known deleterious mutation in BRCA1, BRCA2, or other high-risk mutation, or a family history conveying at least a 2-fold increase in breast cancer risk. The trial requires participants to have an ECOG performance status of 0 and normal organ and marrow function. Participants must also agree to limit alcoholic beverage consumption to three alcoholic drinks per week. The trial has several exclusion criteria, including a prior history of invasive breast cancer less than 2 years previously, current or history of other cancers, and evidence of malignant cytology on initial rpFNA. Participants must not be currently receiving lovastatin and cyclosporine, gemfibrozil, erythromycin, fibrates, or niacin, unless discontinued for study participation. They must also have no evidence of active liver disease, nor elevation of serum transaminases, and no evidence of myopathy or myositis. Lactating (breastfeeding) women are excluded from the trial.",
    "The sample is a phase 2 trial for patients with ulcerative colitis. The trial includes patients who have had an active disease course for the last 6 weeks or longer with bloody diarrhea and have had an inadequate response to a treatment with mesalazine or a documented intolerance to mesalazine. The trial excludes patients with infectious colitis, Crohn's disease, colitis due to other reasons than ulcerative colitis, and those who have been treated with other investigational medicinal products within 3 months prior to study entry. The trial involves the use of two drugs, lt-02 and placebo, and the diseases and icd-10 codes associated with the trial include ulcerative colitis, large intestine, diarrhea, and abdominal pain.",
    "The sample is a phase 2 clinical trial for breast cancer patients who have not received prior treatment. The trial includes patients with non-metastatic breast cancer with a clinical tumor diameter of at least 2 cm, HR negative and HER 2 negative. The trial involves the use of cetuximab and docetaxel drugs. The eligibility criteria include age over 18, performance status of 1 or less, and adequate hematological, renal, and hepatic functions. Exclusion criteria include male patients, pregnant or lactating women, patients with other forms of breast cancer, and patients with certain medical conditions. The trial requires written informed consent and affiliation with the social security system.",
    "The sample is a phase 2 clinical trial for kidney transplantation. The trial involves the use of two drugs, aeb071 and mycophenolic plus tacrolimus. The eligibility criteria for the trial include participation in the core study CAEB071A2203, maintenance on AEB071/mycophenolic acid or tacrolimus/mycophenolic acid at the core study Month 12 visit, and the use of a medically approved method of birth control for women capable of becoming pregnant. The exclusion criteria include pregnancy and other protocol-defined criteria. The diseases involved in the trial are not specified, but the icd-10 codes for the diseases are listed.",
    "The sample is a phase 2 clinical trial for the treatment of metastatic melanoma with the drug RO5185426. The trial is looking for patients with confirmed BRAF V600E mutation and either measurable or non-measurable disease. Patients must have adequate organ function and have recovered from their most recent treatment for metastatic melanoma. Women of childbearing potential must agree to use two forms of contraception, including one barrier method, during the study and for 6 months after discontinuation of the drug. Men with female partners of childbearing potential must use a latex condom and advise their partner to use an additional form of contraception during the study and for 6 months after discontinuation of the drug. Patients must not donate blood or sperm during the study and for at least 6 months after discontinuation of the drug. Exclusion criteria include pregnancy or breastfeeding, concurrent anti-tumor therapy, uncontrolled medical illness, and history of prolonged QT syndrome or ongoing grade 2 or greater cardiac arrhythmia.",
    "The sample is a record of a clinical trial with a phase 2 designation. The trial is focused on treating advanced melanoma that has not responded to first-line chemotherapy. The trial includes patients with measurable disease according to RECIST criteria, with an ECOG performance status less than or equal to 2, and a life expectancy of 6 months or more. The trial also requires normal organ and bone marrow function as defined by hematological and serum chemistry limits, and adequate contraception for females of childbearing potential. The trial has exclusion criteria, including stage IV disease that has previously progressed during interferon treatment, restriction of certain therapies/medications for a certain timeframe prior to enrollment and during the study, history of uncontrolled seizure disorders, uncontrolled coagulation disorders, history or evidence of myocardial ischemia, congestive heart failure or arrhythmias requiring treatment in the past 6 months, concurrent malignancies, brain metastases, HIV positive, prolonged QTc interval, uncontrolled intercurrent or chronic illnesses, and pregnant or lactating women.",
    "The sample is a phase 2 clinical trial for patients with end-stage renal disease who are accepted and listed for renal transplantation. The trial aims to test the effectiveness of two drugs, reparixin continuous infusion and reparixin intermittent infusion, in reducing the risk of delayed graft function (DGF) in recipients of a kidney maintained in cold storage. The trial has specific inclusion and exclusion criteria, and patients must be willing and able to comply with the protocol procedures for the duration of the study. The sample also includes a list of diseases, icd-10 codes, and eligibility criteria for the trial.",
    "The sample is a phase 2 clinical trial for gastric cancer. The trial includes patients with histologically confirmed adenocarcinoma of the stomach or gastroesophageal junction beyond the scope of surgical resection. Patients must have measurable disease in either one or two dimensions either radiographically or by physical examination. The trial excludes patients with poorly controlled diabetes mellitus, psychiatric illness, active infections, including AIDS, ARC, or HIV positive, history of hypersensitivity to products containing Polysorbate 80, uncontrolled alcohol or drug abuse, uncontrolled hypercalcemia, and other prior malignancy within the past 5 years other than nonmelanomatous skin cancer or cervical carcinoma in situ. Patients must have fully recovered from surgery and at least 1 month since prior radiotherapy. The trial also excludes patients with chronic obstructive pulmonary disease, chronic bronchitis, emphysema, sarcoid, or bronchiectasis. The trial requires adequate contraception for all fertile patients. The trial does not allow concurrent immunotherapy, prior systemic chemotherapy, chronic use of steroids, concurrent hormonal therapy (except birth control pills), concurrent palliative radiotherapy (arm I patients), and chronic use of aspirin, nonsteroidal antiinflammatory agents, antianginal medications, or extraordinary antihypertensive regimens.",
    "The sample is a phase 2 clinical trial for the treatment of major depression. The trial includes patients aged 18 to 70 who have been diagnosed with unipolar major depression using DSM-IV criteria with moderate to severe symptoms. The trial involves a wash-out period of 1 week for any antidepressant drug prior to entering the study. Patients must provide written informed consent to participate. The trial has a list of exclusion criteria, including concurrent psychiatric disorders, failure to respond to drug treatment in the current depressive episode, previous resistance to SSRIs or other antidepressant drugs, and a suicide risk score of 3 or higher on the HDRS. Other exclusion criteria include participation in other drug trials within the previous month, presence of delusions or hallucinations, history of substance abuse, pregnancy or lactation, organic brain disease or history of seizures, serious organic illnesses, myocardial infarction in the past 6 months, frequent or severe allergic reactions, concomitant use of other psychotropic drugs, and current structured psychotherapy. The trial involves the use of two drugs, du125530 and placebo, and the eligibility criteria are based on a set of inclusion and exclusion criteria.",
    "The sample is a phase 2 trial for the treatment of venous thrombosis. The trial involves the use of two drugs, pd 0348292 and enoxaparin. The eligibility criteria for the trial includes adult men or women who are scheduled for an elective, unilateral total knee replacement and are otherwise healthy. The exclusion criteria includes individuals with a history of deep vein thrombosis or pulmonary embolism, suspected postthrombotic state, bleeding or clotting disorders, or cardiovascular, renal or liver disease within the past year.",
    "The sample is a phase 2 clinical trial for non-small cell lung cancer. The trial involves the drug pemetrexed and has specific eligibility criteria for patients to participate. Inclusion criteria include having histological or cytological proof of NSCLC, measurable or non-measurable disease, and being diagnosed with unresectable Stage IIIA or IIIB disease. Exclusion criteria include having malignant pleural effusions, prior chemotherapy or radiotherapy for lung cancer, and active clinically serious infections. The trial also has requirements for age, contraception, and written informed consent.",
    "The sample is a phase 2 clinical trial for patients with type 2 diabetes mellitus. The trial involves the use of sitagliptin, metformin, and a placebo. The eligibility criteria include being between the ages of 30 and 75, having physician-diagnosed type 2 diabetes, and having a negative test for anti-glutamic acid decarboxylase antibodies. The A1c level must be between 6.5% and 9% if not on any oral hypoglycemic agents or between 6.0% and 9.0% if on 1-2 oral hypoglycemic agents. Exclusion criteria include current insulin therapy, type 1 diabetes, major illnesses with a life expectancy of less than 5 years, and involvement in any other study requiring drug therapy. Other exclusion criteria include renal dysfunction, hepatic disease, excessive alcohol consumption, pregnancy or unwillingness to use reliable contraception, history of serious arrhythmia or atrioventricular block, uncontrolled hypertension, unwillingness to undergo multiple daily insulin injection therapy for 4 weeks, and unwillingness to perform capillary blood glucose monitoring at least 4 times per day during intensive insulin therapy.",
    "The sample is a phase 2 clinical trial for non-squamous non-small-cell lung cancer patients with Stage IIIb, Stage IV, or recurrent disease. The trial involves the use of drugs such as carboplatin, paclitaxel, and cdp791 at different dosages. The eligibility criteria include having measurable disease, an ECOG performance status of 0 or 1, and a life expectancy of at least three months. The trial excludes patients with squamous cell lung carcinoma, lung lesions located centrally in the chest that involve major blood vessels, and concurrent active malignancy other than nonmelanoma skin cancer or carcinoma in situ of the cervix. Additionally, patients with major chronic diseases such as hepatic or renal dysfunction, cardiac dysfunction, peripheral vascular disease, evidence of a myocardial infarction within six months of Screening visit, tuberculosis, epilepsy, or known infections with hepatitis B or C virus or HIV 1 or 2 are excluded. The sample also includes the list of diseases and their corresponding ICD-10 codes, as well as the eligibility criteria for the trial.",
    "The sample is a phase 2 trial for various diseases including chronic myeloproliferative disorders, graft versus host disease, leukemia, lymphoma, multiple myeloma and plasma cell neoplasm, and myelodysplastic syndromes. The trial involves the use of drugs such as cyclophosphamide, cyclosporine, and methylprednisolone. The eligibility criteria include having a related or unrelated donor with a certain level of HLA match, meeting certain age and performance status requirements, and having no uncontrolled diabetes or thyroid disease, among other factors. Prior concurrent therapy is not specified.",
    "The sample is a phase 2 clinical trial for chronic lymphocytic leukemia. The trial is testing the drug mgcd0103. The eligibility criteria include confirmation of CLL, prior treatment failure with fludarabine and Rituxan, age 18 or older, ECOG performance status of 0 or 1, and certain laboratory requirements. Exclusion criteria include active cancer (excluding basal cell carcinoma or cervical intraepithelial neoplasia or melanoma in situ), pregnancy or lactation, uncontrolled illness or infection, and known hypersensitivity to HDAC inhibitors or any component of the drug. Patients must also be able to read, understand, and sign a written informed consent.",
    "The sample is a phase 2 clinical trial for patients with recurrent or metastatic renal cell carcinoma or primary RCC that is not amendable to surgical intervention. The trial is testing the efficacy of tivozanib (av-951) compared to a placebo. The eligibility criteria include being at least 18 years old, having measurable disease, and no more than one prior systemic treatment for RCC. Exclusion criteria include pregnancy or lactation, primary CNS malignancies, hematologic malignancies, and significant cardiovascular disease. Patients must also have a Karnofsky performance status of at least 70% and a life expectancy of at least 3 months. The trial requires written informed consent and the ability to comply with protocol requirements.",
    "The sample is a phase 2 clinical trial that involves patients with major depressive disorder and metabolic syndrome. The trial is testing the effectiveness of the drug pioglitazone. The inclusion criteria for the trial include being between the ages of 18 and 70, having a DSM-IV diagnosis of major depressive disorder, and meeting the criteria for metabolic syndrome. The exclusion criteria include pregnancy or breastfeeding, untreated medical illness, severe personality disorder, suicidal risk, intolerance or hypersensitivity to pioglitazone, and current use of certain antidiabetic agents. Patients with dementia, heart failure, or renal impairment are also excluded. The trial requires patients to have a Quick Inventory of Depressive Symptomatology-Self-Report score greater than 11 at study baseline. The trial also includes a list of diseases and their corresponding ICD-10 codes.",
    "This sample is for a phase 2 clinical trial for the treatment of schizophrenia. The trial is looking at the effectiveness of a drug called ir quetiapine fumarate. The eligibility criteria for the trial includes men and women between the ages of 18 and 65 who have acute schizophrenia and are able to provide written informed consent. The exclusion criteria includes patients with any other psychotic disorder, substance dependence, and female patients who are pregnant, lactating, or at risk of pregnancy. The icd-10 codes associated with schizophrenia are also included in the sample.",
    "The sample is a record of a clinical trial in phase 2 for the treatment of overactive bladder. The trial involves the use of fesoterodine fumarate and placebo drugs. The eligibility criteria for the trial include adult patients with OAB symptoms, including micturitions of at least 8 per day and urgency urinary incontinence of at least 1 per day. The exclusion criteria include patients with known hypersensitivity to the active substance or any of the excipients, patients with a known neurological disease influencing bladder function, and patients with complications of lower urinary tract pathology potentially responsible for urgency or incontinence, clinically relevant bladder outlet obstruction or pelvic organ prolapse. The icd-10 code for the disease is N32.81.",
    "The sample is a phase 2 clinical trial for asthma. The trial includes patients between the ages of 16-65 who have a documented clinical history of persistent asthma and are currently receiving inhaled short-acting beta-2 agonists for symptom relief. The trial also requires patients to have a lung function of between 50 to 90% predicted (PEF) and an increase in PEF of at least 15%, 20 minutes after inhalation of 400mcg salbutamol. The trial excludes patients with a history of respiratory tract infection and/or exacerbation of asthma within a period of 4 weeks prior to Visit 1, a history of life-threatening asthma, and a history of two or more asthma exacerbations requiring treatment with oral corticosteroids or hospitalization in the 6 months before Visit 1. Patients with past or present diseases that may affect the outcome of the study, known or suspected sensitivity to corticosteroids, VENTOLIN, or the constituents of ROTADISKS, undergoing allergen desensitization therapy, neurological or psychiatric disease or history of drug or alcohol abuse that would interfere with the subject's proper completion of the protocol requirements, and current smokers or those with a smoking history of 10 pack years or more are also excluded from the trial. The trial includes a list of drugs, including fluticasone furoate and placebo, and a list of icd-10 codes of diseases.",
    "The sample is a phase 2 clinical trial for gastroesophageal reflux disease (GERD). The trial includes patients with a recent history of GERD-related symptoms, who have not responded to 8 weeks of proton pump inhibitor (PPI) treatment. The trial also requires patients to have abnormal bilirubin levels and normal esophageal pH values. Patients must meet certain inclusion criteria, such as having a body weight between 40 to 136 kg, and being willing to comply with all protocol procedures for the duration of the study. Patients must also meet certain exclusion criteria, such as having concurrent gastrointestinal or other pathology that could interfere with the study, or being pregnant or breastfeeding. The trial will test the efficacy of two drugs, ast-120 and celphere cp-305, and will require patients to attend all visits required by the protocol.",
    "The sample is a phase 2 clinical trial for patients with newly diagnosed supratentorial glioblastoma multiforme. The trial requires participants to have an unmethylated MGMT-promotor and an estimated life expectancy of at least 12 weeks. Tumor tissue specimens must be available for central pathology review and exploratory analysis of PKC-beta targets. Participants must have undergone Gd-MRI within 72 hours postoperatively and have an ECOG Performance Status of less than or equal to 2. Adequate organ function is required, including adequate bone marrow reserve, hepatic and renal function, and normal blood clotting. Participants must discontinue use of enzyme-inducing antiepileptic drugs (EIAEDs) greater than or equal to 14 days prior to study enrollment. Exclusion criteria include prior malignancy, inability to undergo Gd MRI, prior chemotherapy or radiotherapy of the head, and serious concomitant systemic disorders. Participants who are pregnant, anticipate becoming pregnant within 6 months after study participation, or are currently breast-feeding are also excluded.",
    "The sample is a phase 2 clinical trial for patients with newly diagnosed, limited stage small cell lung cancer. The trial is testing the effectiveness of the drug topotecan. The eligibility criteria include having no prior radiotherapy, being able to take oral medication, having adequate bone marrow reserve and kidney and liver function, and giving written informed consent. Exclusion criteria include extensive stage SCLC, pregnancy or lactation, use of investigational drugs within 30 days prior to the study, and severe medical problems unrelated to SCLC. The trial also requires patients to be evaluated by a radiation oncologist prior to study entry.",
    "The sample is a record of a clinical trial with a phase 2 designation. The trial is focused on non-Hodgkin's lymphoma, with the icd-10 codes listed as [\"S33.110S\", \"S33.111S\", \"S33.120S\", \"S33.121S\", \"S33.130S\", \"S33.131S\", \"S33.140S\"]. The drug being tested is rituximab. The eligibility criteria for the trial include patients between the ages of 18-65 who have not previously been treated for indolent nonfollicular non-Hodgkin's lymphoma, have active disease, and have at least 3 involved sites. Exclusion criteria include chronic lymphocytic leukemia, other malignancies within 3 years, systemic corticosteroid use for more than 1 month, significant cardiovascular disease, central nervous system involvement, and hepatitis B or C virus infection, or HIV infection.",
    "The sample is a phase 2 clinical trial for patients with surgically incurable, confirmed metastatic colon or rectal adenocarcinoma. The trial involves the use of the drugs cofactor, 5-fu, and leucovorin. The eligibility criteria include having a life expectancy of at least 6 months, radiologically or clinically measurable disease for response assessment, and an ECOG Performance Level of 0-2 (or Karnofsky of 100-70). Exclusion criteria include an inability to obtain informed consent due to psychiatric or complex medical problems, unstable oncologic emergency syndromes, and known intolerance to fluoropyrimidine therapy. The trial also requires adequate renal, bone marrow, and liver function.",
    "The sample is a phase 2 clinical trial for patients with chronic lymphocytic leukemia. The trial includes patients with intermediate-risk or high-risk disease who require treatment due to disease-related symptoms or deterioration of blood counts. Patients must have previously received at least one chemotherapy regimen and responded to prior fludarabine without relapse or disease progression for at least 6 months. Eligibility criteria include specific blood count levels, performance status, and absence of certain medical conditions. Patients must also not be pregnant or nursing and must use effective contraception during the study. The trial involves the use of the drug sorafenib tosylate and excludes patients who have previously received MAPK signaling inhibitor agents or anti-angiogenesis agents.",
    "The sample is a phase 2 clinical trial for major depressive disorder without psychotic features. The trial includes patients between the ages of 18 and 70 who have had an inadequate response to ongoing antidepressant treatment and have a body mass index between 18 and 38 kg/m2. The trial excludes patients who are currently receiving treatment with a combination of antidepressants or an adjunctive potentiating treatment, have previously received RO4917523, have a history of failure or utilization during the current episode of Electroconvulsive Therapy (ECT) or repetitive Transcranial Magnetic Stimulation (rTMS), have a history of use at any time of Vagus Nerve Stimulation (VNS) or Deep Brain Stimulation (DBS), have a current or past history of bipolar disorder (e.g. manic, hypomanic, or mixed episodes), or are pregnant or lactating women. The trial will test the effectiveness of placebo and two different doses of RO4917523.",
    "The sample is a phase 2 clinical trial for patients with metastatic adenocarcinoma of the colon or rectum. The trial involves the use of fluorouracil, irinotecan hydrochloride, and leucovorin calcium as treatment options. The eligibility criteria include a WHO performance status of 0-2, life expectancy of at least 3 months, and certain blood count levels. Patients must not have had prior chemotherapy for metastatic disease, and must not be taking certain medications or have certain medical conditions. The trial also has exclusion criteria, such as having other malignant diseases in the past 5 years or having had a severe traumatic injury within the past 4 weeks.",
    "The sample is a phase 2 clinical trial for adult acute lymphoblastic leukemia in remission. The trial includes patients who have been diagnosed with ALL and have the t(9;22)(q34;q11) or 3-way variant detected by metaphase cytogenetics or BCR-ABL positive by molecular analysis. Patients must have achieved complete or partial remission following one course of induction chemotherapy with an intensive 4 or 5 drug regimen (with or without imatinib mesylate) on a CALGB or SWOG ALL protocol for previously untreated ALL patients. The trial also includes patients who have achieved complete or partial remission following one course of therapy on any standard induction regimen (with or without imatinib mesylate) without prior enrollment on a cooperative group frontline protocol. Patients must not have had more than six weeks of prior imatinib mesylate during induction therapy before study enrollment. Women and men of reproductive potential should agree to use an effective means of birth control and contraception should continue for three months after the last dose of imatinib mesylate (Gleevec) to allow complete clearance of drug and its principle metabolites from the body. In women of childbearing potential, a pregnancy test will be required at study entry.",
    "The sample is a phase 2 clinical trial for the treatment of macular degeneration using the drug pazopanib. The trial includes eligibility criteria for subjects, such as having participated in a previous study without experiencing disease progression, having a certain level of visual acuity, and being willing and able to comply with the study requirements. There are also exclusion criteria, such as having certain medical conditions or taking certain medications. The trial will observe the fundus for photographs, fluorescein angiography, and OCT.",
    "The sample is a phase 2 clinical trial for a drug called gsk573719, aimed at treating pulmonary disease, chronic obstructive (COPD). The trial is open to male and female participants between the ages of 40 and 75 who have been diagnosed with COPD according to the GOLD guidelines. Participants must also have a BMI within the range of 18-34 kg/m2, be a smoker or ex-smoker with a smoking history of at least 10 pack years, and have a post-bronchodilator FEV1 of \u2265 35% to \u2264 80% of predicted normal. The trial has a list of inclusion and exclusion criteria, including the ability to give written informed consent, compliance with the requirements and restrictions listed in the consent form, and the absence of certain medical conditions or medications.",
    "The sample is a phase 2 clinical trial for the treatment of osteoarthritis of the knee. The trial involves the use of drugs, including a matching placebo and grt6005, and has a list of inclusion and exclusion criteria for participants. Inclusion criteria include having painful osteoarthritis of the knee, being on stable analgesic medications for at least 3 months, and having a pain intensity score of 4 or greater on a numeric rating scale. Exclusion criteria include substance abuse, significant cardiac disease, and a history of seizure disorder, among others. The trial is not open to female subjects who are breastfeeding or those with impaired renal or hepatic function. Additionally, participants cannot have a clinically relevant history of hypersensitivity or allergy to paracetamol, opioids, or the excipients.",
    "The sample is a phase 2 clinical trial for the treatment of type 2 diabetes. The trial involves the drug dio-902 and a placebo. The eligibility criteria include being between the ages of 18 and 75, having a diagnosis of type 2 diabetes for at least 6 months, and having a stable dose of metformin for at least 8 weeks prior to the trial. Other criteria include having a BMI between 27 and 42 kg/m2, a fasting C-peptide level of >0.33 nmol/l, and an HbA1C level of 7.0 to 10.0%. Exclusion criteria include a history of atherosclerotic disorder, hypersensitivity to ketoconazole or other imidazole compounds, excessive alcohol intake or drug abuse, and any other clinically significant medical condition. The trial also requires subjects to provide informed consent.",
    "The sample is a record of a clinical trial with a phase 2 designation. The trial is focused on the treatment of hepatitis C, with a list of associated ICD-10 codes. The drugs being tested are Sofosbuvir (SOF), Peginterferon alfa-2a (PEG), and Ribavirin (RBV). The eligibility criteria for the trial are listed, including requirements for infection with genotype 2 or 3 HCV, cirrhosis determination, and treatment-experienced individuals. Exclusion criteria are also listed, such as prior exposure to a direct-acting antiviral drug targeting the HCV NS5B polymerase, pregnancy or nursing, and excessive alcohol or drug use.",
    "The sample is a phase 2 clinical trial for chronic lymphocytic leukemia (CLL) using the drug combination of ofatumumab and bendamustine. The trial is for previously untreated patients who require chemotherapy and meet certain eligibility criteria, such as being at least 18 years old, having adequate liver function, and having a performance status of 0-2. Exclusion criteria include prior treatment with cytotoxic chemotherapy or immunotherapy, autoimmune hemolytic anemia or autoimmune thrombocytopenia, and clinically significant infections. Patients with a second malignancy, positive serology for Hepatitis B or Hepatitis C, or known HIV positive are also not eligible. The trial is designed to evaluate the safety and efficacy of the drug combination in treating CLL.",
    "The sample is a phase 2 trial that focuses on patients with pulmonary disease, chronic obstructive, pulmonary fibrosis, and cough. The trial involves the use of interferon-alpha lozenges and placebo lozenges as drugs. The eligibility criteria for the trial include a history of clinically significant chronic cough for more than three months, being over 40 years of age with a 20-pack-year history of smoking for COPD patients, and being over 50 years of age with a history of unexplained dyspnea on exertion of more than three months for IPF patients. The trial also requires patients to exhibit coughing and bilateral, basilar, inspiratory crackles on physical exam and present as being in a stable phase of IPF. The exclusion criteria include ACE inhibitor use, GERD, current cancer or history of lung cancer, non-ambulatory, and hospitalization in the previous 12 months for heart failure.",
    "The sample is a phase 2 clinical trial for the treatment of sarcoma and soft tissue sarcoma. The trial involves the use of two drugs, Avastin and doxorubicin. The eligibility criteria for the trial include having intermediate or high grade locally advanced or metastatic soft tissue sarcoma, having measurable disease, normal renal and hepatic function, and certain hematologic parameters. Participants must also have a performance status of 0-1 on the ECOG scale, use effective contraception, and be at least 18 years old. Exclusion criteria include recent major surgery, inadequately controlled hypertension, history of myocardial infarction or stroke, and known hypersensitivity to Avastin.",
    "The sample is a phase 2 clinical trial for small cell lung cancer and carcinoma, small cell. The trial is testing the drug topotecan. The eligibility criteria for the trial include having extensive small cell lung cancer with progression after one previous chemotherapy or chemotherapy/radiation therapy regimen, having measurable or evaluable disease, being able to perform activities of daily living with minimal assistance, having adequate bone marrow, liver and kidney function, and having received no more than 3 previous courses of radiation therapy. Patients with limited stage disease, a history of a prior malignancy within three years, female patients who are pregnant or are breast feeding, significant history of uncontrolled cardiac disease, myocardial infarction or stroke within six months, symptomatic peripheral vascular disease, CNS involvement, serious active infection or underlying medical condition are excluded from the trial.",
    "The sample is a phase 2 clinical trial for narcolepsy. The trial includes patients who have been diagnosed with narcolepsy and are in good general health. The trial excludes pregnant or lactating females, patients with a history of significant medical conditions, behavioral or psychiatric disorders, or surgical history. Patients with any other clinically relevant medical, behavioral or psychiatric disorder other than narcolepsy that is associated with excessive sleepiness are also excluded. Additionally, patients with a history of significant cardiovascular disease, body mass index over 34, excessive caffeine use, history of alcohol or drug abuse within the past two years, or nicotine dependence that affects sleep are excluded. The trial involves the use of two drugs, adx-n05 and placebo.",
    "The sample is a phase 2 clinical trial for the treatment of epilepsy. The eligibility criteria include having a diagnosis of epilepsy with partial seizures, despite having been treated with at least three different antiepileptic drugs (AEDs) for at least 2 years, and having averaged at least three partial seizures per month with no 21-day seizure-free period during the 2 months preceding randomization. Patients must also be between the ages of 18 and 70, weigh at least 40 kg, and be willing to make themselves available for the study period. The trial will involve the use of the drug E2007 or a placebo. The exclusion criteria include having participated in a study involving administration of an investigational compound within 3 months of screening, having a history of drug abuse in the past 2 years, and being pregnant or lactating.",
    "The sample is a phase 2 clinical trial for metastatic colorectal cancer. The trial includes patients with confirmed metastatic colorectal cancer and measurable metastases who have not received previous treatment for metastatic cancer. The trial excludes patients with central nervous system metastases, co-existing malignancies diagnosed within the last 5 years (with the exception of basal cell carcinoma or cervical cancer in situ), and any evidence of severe or uncontrolled systemic disease. The trial will test the effectiveness of a combination of drugs including iressa (gefitinib), irinotecan, 5-fluorouracil, and leucovorin.",
    "The sample is a record from a clinical trial table that includes information about the trial's phase, diseases being studied, associated ICD-10 codes, drugs being tested, and eligibility criteria for participants. In this particular sample, the trial is in phase 2 and is studying neoplasms and cancer of the ovary. The associated ICD-10 codes are listed, as well as the drugs being tested. The eligibility criteria for participants are also listed, including requirements for prior treatment and measurable tumor lesions. Exclusion criteria are also listed, such as prior treatment with certain drugs and uncontrolled hypertension.",
    "The sample is a phase 2 clinical trial for the treatment of primary open angle glaucoma and ocular hypertension. The trial includes patients who require unilateral or bilateral administration of intraocular pressure lowering treatment, including those who have not received such treatment before. The trial involves the use of four different doses of latanoprost, a drug used to lower intraocular pressure. The eligibility criteria include being 18 years or older, having an IOP between 24 mmHg and 36 mmHg in at least one eye at the 8 AM time point at baseline/randomization, and not having certain medical conditions or taking certain medications. The trial has both inclusion and exclusion criteria.",
    "The sample is a phase 2 clinical trial for the treatment of malignant melanoma. The trial includes patients with unresectable Stage III or IV melanoma, excluding ocular melanoma. The trial requires flexible sigmoidoscopy and colonic biopsy. The drugs being tested are ipilimumab with placebo and ipilimumab with budesonide. The eligibility criteria include exclusion of patients with active, untreated central nervous system metastasis and autoimmune disease.",
    "The sample is a record of a clinical trial with a phase 2 designation. The trial is focused on the disease of atopic dermatitis and includes a list of ICD-10 codes associated with the disease. The trial involves the use of two drugs, e6005 and e6005 ointment (vehicle). The eligibility criteria for the trial includes adults of both genders aged 20 to 64 years who are diagnosed with atopic dermatitis. Exclusion criteria include patients with certain illnesses or infections, as well as those with advanced disease or abnormal laboratory tests that could affect the safety of the subject or the implementation of the study.",
    "The sample is a record of a clinical trial with a phase 2 designation. The trial is focused on head and neck cancer and involves the use of drugs such as cetuximab, 5-fu, hydroxyurea, and cisplatin. The eligibility criteria for the trial include patients who are 18 years or older, have stage III or IV head and neck cancer, and have not undergone prior chemotherapy or radiotherapy. The trial also has exclusion criteria, such as patients with metastatic disease, severe hypersensitivity to drugs used in the study, and incomplete healing from previous surgery. The sample includes both inclusion and exclusion criteria for the trial.",
    "The sample is a record of a clinical trial with a phase 2 designation. The trial is focused on the disease of gastroesophageal reflux and includes a list of ICD-10 codes associated with the disease. The trial involves testing several drugs, including xp19986 sr3 at various dosages and a placebo. The eligibility criteria for the trial include a documented diagnosis of GERD with symptoms occurring at least three times in the week prior to screening. The exclusion criteria include the presence of erosive esophagitis LA Classification Grade B, C, or D.",
    "The sample is a record of a clinical trial with a phase 2 designation. The trial is focused on the disease asthma, with a list of associated ICD-10 codes provided. The trial involves the drugs tiotropium and placebo. The eligibility criteria for the trial are listed, including age range, smoking history, and current diagnosis of severe, persistent asthma. The exclusion criteria are also listed, including recent history of myocardial infarction, hospitalization for heart failure, and certain types of cancer treatment. Additionally, patients with moderate to severe renal impairment are excluded from the trial.",
    "The sample is a phase 2 clinical trial for the treatment of ulcerative colitis. The trial includes patients who have been diagnosed with ulcerative colitis at least 90 days prior to randomization and are between the ages of 18 and 75. Patients must be non-hospitalized and receiving stable background UC therapy. Females of childbearing potential who are sexually active with a nonsterilized male partner must use highly effective contraception from Day1. Exclusion criteria include pregnant or breastfeeding women, patients with a history of colostomy, and patients with certain types of colitis or a history of cancer. The trial will test the effectiveness of tralokinumab compared to a placebo.",
    "The sample is a record of a clinical trial with a phase 2 designation. The trial is focused on the treatment of seasonal allergic rhinitis, with the inclusion of patients who have a history of inadequate symptom control with antihistamines, decongestants, and/or immunotherapy, or who have had prior successful treatment with nasal steroids. The trial also requires a positive response to a skin prick test for grass allergens that must be present in the subject's environment throughout the study. The trial excludes patients with primary or secondary adrenal insufficiency, nasal candidiasis, rhinitis medicamentosa, acute or chronic sinusitis, influenza, upper respiratory tract infection, or structural abnormalities of the nose that cause significant nasal obstruction. Patients with asthma requiring treatment as specified in the protocol are also excluded. The trial will involve the use of budesonide and placebo drugs.",
    "The sample is a record from a clinical trial table. It is for a phase 2 trial and the disease being studied is lung cancer. The trial includes a list of ICD-10 codes for the disease. The drugs being tested are filgrastim, pegfilgrastim, etoposide, and cisplatin. The eligibility criteria for the trial are listed, including disease characteristics such as limited stage disease and no distant metastases, as well as patient characteristics such as Zubrod performance status, ANC, platelet count, and serum creatinine levels. Prior concurrent therapy is also listed, including no prior systemic chemotherapy for lung cancer and no concurrent intensity-modulated radiotherapy or amifostine.",
    "The sample is a phase 2 clinical trial for patients with metastatic colorectal cancer. The trial is testing the effectiveness of two drugs, folfox-4+cetuximab and folfox-4, in treating the disease. The eligibility criteria for the trial include a confirmed diagnosis of colorectal cancer with non-resectable hepatic metastases, proper liver and kidney function, and a life expectancy of at least 3 months. Patients must not have received chemotherapy for advanced/metastatic disease and must meet certain criteria for recurrence after previous treatment. The trial also has exclusion criteria, such as a history of certain medical conditions or participation in other clinical trials.",
    "The sample is a phase 2 clinical trial for breast cancer patients with metastatic or locally recurrent disease that is unresectable and not amenable to radiotherapy. The trial involves the use of bevacizumab and doxorubicin hydrochloride liposome or bevacizumab as drugs. The eligibility criteria include having cytologically or histologically confirmed breast cancer, measurable disease, and being ErbB2-negative. Patients must also meet certain patient characteristics such as being female, having a WHO performance status of 0-1, and having no clinically significant cardiovascular disease. Prior concurrent therapy is not allowed, and patients must meet certain criteria for prior concurrent therapy.",
    "The sample is a record from a clinical trial table that includes information about the trial's phase, diseases being studied, icd-10 codes of those diseases, drugs being used, and eligibility criteria for participants. In this particular sample, the trial is in phase 2 and is studying the effects of a specific drug on postoperative pain in patients undergoing inguinal or umbilical herniorrhaphy. The eligibility criteria include being a man over 18 years old, having a planned unilateral herniorrhaphy, and being willing to use opioid rescue analgesia. Exclusion criteria include known hypersensitivity to certain substances, scheduled for bilateral herniorrhaphy, prior herniorrhaphy at the location scheduled for repair, and major surgery within 3 months of the scheduled herniorrhaphy.",
    "The sample is a phase 2 clinical trial for head and neck cancer. The trial involves the use of drugs such as bevacizumab, erlotinib, paclitaxel, and 5-fu. The eligibility criteria for the trial include being clinically confirmed with head and neck cancer, having no prior treatment for the cancer, being able to perform self-care, having adequate renal and liver function, and being 18 years of age or older. There are also exclusion criteria, such as having a history of stroke or serious cardiovascular disease, recent history of blood in the sputum or vomitus, and non-healing wounds or fractures. The study center will determine if the participant meets all of the criteria, and if they do, they will be given more information about the trial and can decide if they wish to participate.",
    "The sample is a phase 2 clinical trial for patients with recurrent or refractory Hodgkin's lymphoma. The trial is testing the effectiveness of the drugs bortezomib and gemcitabine hydrochloride. Patients must have measurable disease and meet certain eligibility criteria, including having a performance status of ECOG 0-2, platelet count \u2265 100,000/mm^3, and creatinine clearance \u2265 30 mL/min. Patients must also meet various other criteria related to their medical history and current health status. Prior treatments with certain drugs or therapies are not allowed, and patients must not have certain medical conditions or allergies. The trial is not open to pregnant or nursing women, and fertile patients must use effective contraception.",
    "The sample is a phase 2 clinical trial for breast cancer patients with clinical evidence of metastatic disease. The trial involves the use of two drugs, capecitabine and paclitaxel poliglumex. The eligibility criteria include having measurable disease, no bone metastases as the only evidence of metastasis, and being HER2 negative. Patients must also have a life expectancy of at least 3 months, an ECOG performance status of 0 or 1, and meet various other medical criteria. Prior to the trial, patients must not have received chemotherapy for metastatic disease, and must have completed neoadjuvant and/or adjuvant therapy more than 6 months prior to registration. The trial does not allow for concurrent use of other cytotoxic agents, investigational drugs, immunotherapy, radiation therapy, or hormonal therapy.",
    "The sample is a phase 2 clinical trial for non-squamous cell non-small cell lung cancer patients with stage IIIB or IV disease. The trial involves the drugs pemetrexed disodium and sorafenib tosylate. The eligibility criteria include having measurable disease, having previously been treated with one chemotherapy regimen, and having an ECOG performance status of 0-1. Patients must also meet certain medical criteria, such as having a certain level of platelet count and not having any serious underlying medical conditions. Prior concurrent therapy is also taken into consideration.",
    "The sample is a phase 2 clinical trial for patients with prostate cancer who have evidence of progressive metastatic disease or known metastatic disease and rising PSA, during or after treatment with a taxane-based regimen. The trial involves the drug Panzem NCD and has eligibility criteria including prior treatment with bilateral orchiectomy or other primary hormonal therapy with evidence of treatment failure, only one prior taxane-based regimen for metastatic disease, and near normal organ and marrow function. The trial also has exclusion criteria such as active angina pectoris, known heart disease of New York Heart Association Class III-IV, and any known history of carcinomatous meningitis or brain metastases. The trial requires patients to have the ability to understand the requirements of the study, provide written informed consent and authorization for release of protected health information, abide by the study restrictions, and agree to return for the required assessments.",
    "The sample is a record from a clinical trial table that includes information about the trial's phase, diseases being studied, corresponding ICD-10 codes, drugs being used, and eligibility criteria for participants. In this particular sample, the trial is in phase 2 and is studying various types of melanoma. The drugs being used are carboplatin, paclitaxel, and bortezomib. The eligibility criteria include requirements such as no uncontrolled medical conditions, no prior therapy with the drugs being used, and measurable disease. The sample also includes a detailed list of all the eligibility criteria that participants must meet to be considered for the trial.",
    "The sample is a phase 2 clinical trial for patients with various lymphoid malignancies, including non-hodgkins lymphoma, hodgkins lymphoma, multiple myeloma, and others. The trial involves the use of drugs such as oncaspar, doxil, and decadron. The eligibility criteria include having failed at least one standard chemotherapy regimen, having a performance status of \u2264 2, and having an anticipated life expectancy of at least 12 weeks. Patients must also meet certain laboratory and medical criteria, and must provide written informed consent. There are also exclusion criteria, such as recent chemotherapy or radiotherapy, uncontrolled active infection, and certain medical conditions.",
    "The sample is a phase 2 clinical trial for breast neoplasm, which includes a list of icd-10 codes for the disease. The trial involves two drugs, tesetaxel once every 3 weeks and tesetaxel once weekly. The eligibility criteria for the trial include being a female over 18 years old with histologically or cytologically confirmed adenocarcinoma of the breast, stage IV disease, HER2 status negative, and measurable disease. Other criteria include having a life expectancy of at least 3 months, being chemotherapy na\u00efve or having had 1 prior chemotherapy regimen in the adjuvant setting, and having adequate bone marrow, hepatic, and renal function. The trial excludes patients with known metastasis to the central nervous system, history of other malignancy within the last 5 years, significant medical disease other than Stage IV breast cancer, and presence of neuropathy > Grade 1 (NCI CTC, Version 4.0).",
    "The sample is a phase 2 clinical trial for the treatment of squamous cell carcinoma of the head and neck using the drug panitumumab. The trial is for patients with locally advanced clinical stage III or IVa-b(M0)SCCHN, who are candidates for definitive surgery or radiation-based therapy. The eligibility criteria include having measurable or evaluable disease, being 18 years or older, having adequate organ function, and passing RNA quality control prior to research PET/CT #1 and/or initiating panitumumab. Exclusion criteria include having a history of other malignancy within the past 2 years, prior radiotherapy in planned field if it prevents standard radiotherapy dose and field, prior radiation for head & neck cancer, and prior anti-EGFR antibody therapy or treatment with small molecule EGFR inhibitors. The trial also has other exclusion criteria related to medical or psychiatric conditions, laboratory abnormalities, and allergies.",
    "The sample is a phase 2 clinical trial for chronic hepatitis C infection. The trial includes a list of diseases and their corresponding ICD-10 codes, as well as a list of drugs being tested, including a placebo and pf-04136309. The eligibility criteria for the trial are also provided, including inclusion criteria such as having chronic HCV infection and ALT levels between 1.5 and 10 times the upper limit of normal, and exclusion criteria such as having severe liver disease, co-infection with HIV or HBV, and evidence of portal hypertension.",
    "The sample is a phase 2 clinical trial for multiple sclerosis. The trial includes patients between the ages of 18-55 who have a definite diagnosis of MS according to the 2010 revisions of the McDonald diagnostic criteria for MS. The patients must have a relapsing-remitting course of disease with at least one confirmed relapse within the previous year or at least two confirmed relapses within the previous 2 years or at least one relapse in the previous 2 years, with a GdE brain lesion on an MRI scan in the past year. The patients must also have an Expanded Disability Status Scale (EDSS) score of 0-5.5 (inclusive) at screening and be neurologically stable with no evidence of relapse for at least 30 days prior to the start of screening. The trial includes both male and female patients, but female patients must meet certain criteria related to childbearing potential. The trial has a list of exclusion criteria, including a history of certain medical conditions, prior treatment with certain medications, and certain laboratory values outside of normal ranges. French subjects have additional eligibility criteria.",
    "The sample is a phase 2 clinical trial for the treatment of myelodysplastic syndrome. The trial includes patients who are 18 years or older and have a diagnosis of MDS fitting any of the recognized French-American-British classifications and International Prognostic Scoring System greater than or equal to 0.5. Patients must also be red cell transfusion dependent if their FAB classification is Refractory anemia or Refractory anemia with ringed sideroblasts. The trial drug is decitabine. The eligibility criteria include signing an Institutional Review Board-approved informed consent form, having a stable dose of erythropoietin or darbepoetin for a certain period of time, and not having a diagnosis of Acute Myeloid Leukemia or other progressive malignant disease, among other criteria. The trial excludes patients with uncontrolled cardiac disease or uncontrolled congestive heart failure, and those with an active viral or bacterial infection.",
    "The sample is a phase 2 clinical trial for patients with coronary heart disease or a risk equivalent. The trial involves the drugs placebo and dalcetrapib. The eligibility criteria for the trial include being an adult between the ages of 18 and 75, having CHD or a CHD risk equivalent, and being appropriately treated for accepted LDL-C level. The exclusion criteria include recent clinically significant coronary events, transient ischemic attacks or cerebrovascular accident, uncontrolled hypertension, severe anemia, and poorly controlled diabetes. Patients who have been treated with drugs raising HDL-C, such as niacin or fibrates, are also excluded from the trial.",
    "The sample is a phase 2 clinical trial for heart failure and heart decompensation. The trial includes patients who are at least 18 years old and have been diagnosed with congestive heart failure at least three months prior to enrollment. Patients must have experienced worsening of dyspnea and clinical evidence of volume overload leading to hospitalization at the time of entry into the study. The trial excludes patients with acute de-novo heart failure, acute myocardial infarction, valvular heart disease requiring surgical intervention, heart failure due to uncorrected primary valvular disease or congenital heart disease, primary hypertrophic cardiomyopathy, acute inflammatory heart disease, and unstable angina requiring angiography. The trial will test the effectiveness of cinaciguat (bay58-2667) and placebo.",
    "The sample is a phase 2 clinical trial for the treatment of melanoma, a type of skin cancer. The trial is testing the effectiveness of the drug cyclophosphamide on patients with stage IV (metastatic) or unresectable stage III malignant melanoma. Patients must have measurable disease using RECIST and no other effective therapy available or appropriate. They must also express NY-ESO-1 or LAGE-1 by immunohistochemistry (IHC) or reverse transcription-polymerase chain reaction (RT-PCR). Patients must have an expected survival of at least 4 months and a Karnofsky performance status of \u2265 70%. They must also meet certain laboratory parameters and be at least 18 years old. Patients must be able and willing to give written informed consent. There are also exclusion criteria, such as having other serious illnesses or participating in another clinical trial involving another investigational agent within 4 weeks prior to enrollment. Women of childbearing potential must use effective means of contraception.",
    "The sample is a phase 2 clinical trial for non-small cell lung cancer. The trial involves the use of the drugs docetaxel and cisplatin. The eligibility criteria include being 18 years or older, having a confirmed diagnosis of NSCLC, having a life expectancy of more than 6 months, and having no malignant pleural or pericardial effusion at diagnosis. Patients with brain metastases are allowed as long as they meet all other inclusion criteria. The trial also requires patients to have normal organ and marrow function, an ECOG performance status of less than 2, and no prior radiation therapy to currently involved tumor sites. The trial has exclusion criteria such as uncontrolled intercurrent illness, significant pulmonary dysfunction, and pregnancy or breastfeeding. Patients must also have a completed treatment plan approved by the protocol review team.",
    "The sample is a phase 2 clinical trial for locally advanced bladder cancer patients who are candidates for cystectomy following chemotherapy. The trial is testing the effectiveness of a combination of three drugs: abi-007, carboplatin, and gemcitabine. The eligibility criteria include having a performance status of 0, 1 or 2 by Eastern Cooperative Oncology Group (ECOG) criteria, adequate liver and kidney functions, and recovered from any effects of surgery. Women/men of reproductive potential may not participate unless they have agreed to use an effective contraceptive method. The exclusion criteria include prior systemic or intra-arterial chemotherapy and prior radiotherapy, unresolved bacterial infection requiring active treatment with antibiotics, and pregnant or lactating women.",
    "The sample is a phase 2 clinical trial for patients with hepatitis C who were null responders to prior therapy with pegylated interferon and ribavirin. The trial is testing the efficacy of a drug called CTS-1027, along with pegylated interferon, ribavirin, or a placebo. The eligibility criteria include having a certain HCV genotype, a high viral load, and meeting certain health requirements. Patients must also be willing to use two forms of contraception during the study. Exclusion criteria include severe liver disease, hepatocellular carcinoma, HIV infection, and certain psychiatric or autoimmune disorders. Patients must not have been exposed to CTS-1027 before, and must not have received any investigational treatment for HCV in the past 6 months.",
    "This sample is for a phase 2 clinical trial for non-small cell lung cancer. The trial involves the use of three drugs - pemetrexed, cisplatin, and carboplatin. The eligibility criteria for the trial include having a histologically proven non-small cell lung cancer stage Ib, IIa or IIb, complete tumor resection by pneumonectomy or lobectomy, and being surgically proven to be N2 negative. The exclusion criteria include having serious concomitant systemic disorder, post-operative complications or other surgery related conditions, and a prior malignancy other than NSCLC unless that malignancy was diagnosed and treated at least 5 years ago.",
    "The sample is a phase 2 trial for atherosclerosis. The trial includes patients who are not of childbearing potential and have carotid stenosis between 60% and 90% and are scheduled for CEA surgery. Patients must also have a prior history of cerebrovascular accident or transient ischemic attack, diabetes with HbA1c between 7.0 and 11%, baseline hsCRP >2 mg/L, and echolucent plaque. The trial excludes patients with acute CVA or TIA within 4 weeks of enrollment, renal insufficiency, cirrhosis, recent hepatitis, uncontrolled diabetes mellitus, congestive heart failure, recent acute coronary syndrome event or coronary artery bypass graft, current atrial fibrillation, planned cardiac intervention, and acetaminophen use in any form in the 7 days before enrollment. The trial will test the efficacy of two drugs, via-2291 and placebo.",
    "The sample is a phase 2 clinical trial for the treatment of benign prostatic hyperplasia. The trial is open to males aged 65-80 (or 40-80 with vasectomy) who have been experiencing lower urinary tract symptoms for at least 3 months. The trial requires participants to have a prostate volume of over 30cc, a Qmax of less than 15 mL/sec when measured by uroflowmetry, and an International Prostate Symptom Score of over 12. Participants must also have a PSA level of over 1.0 ng/mL and must be willing to use medically acceptable methods of contraception throughout the entire study with sexual partners of childbearing potential. The trial excludes participants who have had prior treatment for BPH with alpha blockers and/or herbal supplements in the past 2 weeks, prior surgery of the prostate (except biopsies), current or past evidence of malignant disease of the prostate or prostatic intraepithelial neoplasia, active urinary tract infections, active cardiac, renal or hepatic disease, uncontrolled diabetes mellitus, use of systemic steroids for any reason, concurrent participation or participation in an investigational drug study within the past 30 days prior to screening, and concomitant disease or condition that could interfere with the conduct of the study or would pose an unacceptable risk to the subject.",
    "The sample is a phase 2 clinical trial for HIV infections and acquired immunodeficiency syndrome. The trial involves testing various drugs, including mk0518 monotherapy, mk0518 combination therapy, efavirenz, tenofovir, lamivudine, and placebo monotherapy. The eligibility criteria for the trial include being HIV positive and having received less than 7 days of any antiretroviral therapy. The trial also has two extension studies, and there are exclusion criteria such as being under 18 years of age or not testing positive for HIV. The diseases are listed as 'hiv infections' and 'acquired immunodeficiency syndrome', and the icd-10 codes for the diseases are also provided.",
    "The sample is a phase 2 clinical trial for psoriasis. The trial includes patients who have a history of moderate-to-severe plaque-type psoriasis with a Psoriasis Area and Severity Index (PASI) score greater than or equal to 10 and Body Surface Area (BSA) greater than or equal to 10%. The trial involves the use of drugs such as cc-10004 and placebo. The eligibility criteria include being in good health, adhering to the study visit schedule and other protocol requirements, meeting specific laboratory criteria, and being a candidate for photo/systemic therapy. Exclusion criteria include having clinically significant underlying disease processes, being pregnant or lactating, having a history of active mycobacterium tuberculosis infection, and having a clinical history of failure to adequately respond to treatment with certain biologic therapies.",
    "The sample is a phase 2 clinical trial for patients with metastatic or recurrent squamous cell carcinoma of the head and neck. The trial involves the use of two drugs, bibw 2992 and cetuximab. The eligibility criteria include having documented progressive disease following prior platinum-based therapy, measurable disease, and an Eastern Cooperative Oncology Group performance score of 0 or 1. Exclusion criteria include prior use of an EGFR or erbB2 inhibitor in the recurrent/metastatic disease setting, more than 2 chemotherapeutic regimens given for recurrent/metastatic disease, and active infectious disease. Patients must also be willing and able to give written informed consent consistent with ICH-GCP guidelines.",
    "The sample is a record of a clinical trial in phase 2. The trial is focused on two diseases, namely acquired bleeding disorder and dengue haemorrhagic fever. The icd-10 codes associated with these diseases are listed. The trial involves two drugs, activated recombinant human factor vii and placebo. The eligibility criteria for the trial are also listed, including inclusion criteria such as patients with a clinical diagnosis of DHF Grades II and III requiring standard replacement therapy, and exclusion criteria such as patients with a clinical diagnosis of DHF Grade IV or known allergies to the trial product or related products.",
    "This sample is a phase 2 clinical trial for the treatment of moderate-to-severe chronic plaque psoriasis. The trial is testing the effectiveness of a drug called placebo. The eligibility criteria for participants include being adults with a diagnosis of psoriasis that affects at least 10% of their body surface area, having a moderate or greater score on the Physician's Global Assessment scale, and having a PASI score of at least 12 at baseline. Participants must have had predominantly plaque psoriasis for at least 6 months and be considered candidates for phototherapy or systemic therapy. Participants with psoriatic arthritis may also be included. Exclusion criteria include non-plaque forms of psoriasis, the need for oral or injectable corticosteroids during the trial, and evidence of active or untreated latent tuberculosis. Participants with prior exposure to certain medications are also excluded.",
    "The sample is a phase 2 clinical trial for the treatment of mantle cell lymphoma. The eligibility criteria include having a histologically documented mantle cell lymphoma with co-expression of CD20 (or CD19) and CD5 and lack of CD23 expression by immunophenotyping, and meeting certain confirmatory tests. Patients must be previously untreated or have received no more than one prior cycle of chemotherapy and/or rituximab treatment. They must also be between the ages of 18 and 70, have no known hypersensitivity to murine products, and not have a medical condition requiring chronic use of systemic corticosteroids. Patients with a \"currently active\" second malignancy, other than non-melanoma skin cancers, are not eligible. The initial required laboratory values include LVEF by MUGA or ECHO \u2265 45%, creatinine \u2264 2.0 mg/dL, total bilirubin \u2264 2.0 mg/dL (unless attributable to Gilbert's Disease), and u-HCG or serum HCG negative (if patient of childbearing potential).",
    "The sample is a phase 2 clinical trial for the treatment of myelodysplastic syndrome. The trial includes patients with a confirmed diagnosis of MDS and an International Prognostic Scoring System score of 0, 0.5, or 1.0, indicating Low- or INT-1-risk disease. The trial will test the effectiveness of siltuximab, placebo, and best supportive care (bsc) in treating symptomatic anemia in these patients. The eligibility criteria include documented RBC transfusion, adequate iron stores, and an ECOG performance status score of 0 to 2. The exclusion criteria include recent treatment with drugs targeting IL-6 or its receptor, Chronic Myelomonocytic Leukemia (CMML), and other conditions that could prevent, limit, or confound the protocol-specified assessments.",
    "This sample is a phase 2 clinical trial for heart failure. The trial includes patients who are 18-85 years old and have been hospitalized for worsening heart failure within 24 hours of initiating IV loop diuretic. Patients must also have dyspnea due to heart failure, a history of left ventricular ejection fraction (LVEF) \u2264 40%, and elevated brain natriuretic peptide (BNP) or N-terminal fragment BNP (NT-proBNP). Patients who are receiving IV vasopressor (excluding low dopamine), inotropic or mechanical support, have had an acute coronary syndrome (ACS) within the past 30 days, or have had cardiac resynchronization therapy (CRT) or implantable cardioverter defibrillator (ICD) implantation, ACS, coronary revascularization, transient ischemic attack (TIA) or stroke, sustained ventricular arrhythmia, or major surgery within the past 30 days are excluded from the trial. Patients with severe valvular stenosis, hypertrophic obstructive cardiomyopathy, active myocarditis, constrictive pericarditis, or clinically significant congenital heart disease are also excluded. The trial includes the use of placebo and omecamtiv mecarbil as drugs.",
    "The sample is a phase 2 clinical trial for the treatment of metastatic melanoma, a type of skin cancer. The trial involves the use of four drugs - bevacizumab, carboplatin, paclitaxel, and placebo. The eligibility criteria for the trial include being over 18 years of age, having metastatic melanoma, and being willing to comply with study procedures. Exclusion criteria include prior treatment with certain therapies, history of brain disease or active disease, inadequate organ function, and other medical conditions that may contraindicate the use of an investigational drug or increase the risk of treatment complications. The sample also includes a list of diseases and their corresponding ICD-10 codes.",
    "The sample is a phase 2 clinical trial for the treatment of chronic obstructive pulmonary disease (COPD). The trial includes male and female subjects between the ages of 40 and 80 who have a clinical history of COPD and a current or prior history of at least 10 pack-years of cigarette smoking. The trial will test the efficacy of several doses of the drug GW642444 in treating COPD. The eligibility criteria include informed consent, meeting the definition of COPD, having a measured post-salbutamol FEV1/FVC ratio of \u22640.70, and meeting several other criteria related to disease severity, tobacco use, and other medical conditions. The exclusion criteria include pregnancy, asthma, a1-antitrypsin deficiency, other respiratory disorders, poorly controlled COPD, and several other medical conditions. Subjects must also be able to comply with study procedures and not have received the investigational drug GW642444 in previous studies.",
    "The sample is a phase 2 clinical trial for patients with type 2 diabetes mellitus. The trial includes patients who are either on a stable dose of metformin or are drug-naive. Patients must have a fasting blood glucose level of \u2264 225 mg/dL at screening and HbA1c levels >7.5%. The trial also includes patients with a BMI of 28-37 kg/m2 for females and 28-39 kg/m2 for males. Patients with a history of clinically significant cardiovascular disease, hepatic, respiratory or renal abnormalities, unstable diabetic complications requiring treatment, long term insulin therapy within the past year, or therapy with certain medications within 6 months prior to screening are excluded from the trial. The trial will test the efficacy of the drugs he3286 and placebo.",
    "The sample is a phase 2 clinical trial for the treatment of various types of lymphoma, including non-Hodgkin lymphoma and B-cell lymphoma. The trial involves the use of four drugs: velcade\u00ae, rituximab, cyclophosphamide, and decadron. The eligibility criteria for the trial include having certain types of lymphoma, adequate bone marrow, renal, and hepatic function, and an ECOG performance status of 0, 1, or 2. Exclusion criteria include prior therapy for lymphoma (excluding antibiotic treatment for MALT-Type NHL) and known HIV positive status or CNS involvement.",
    "The sample is a phase 2 clinical trial for the treatment of leukemia using the drug clofarabine. The eligibility criteria include being over 18 years old, having adequate liver and kidney function, having a life expectancy of at least 3 months, and not having chronic active hepatitis or cirrhosis. Patients must also use effective contraception and have a negative pregnancy test. Exclusion criteria include having a severe concurrent disease or history of serious organ dysfunction, being pregnant or lactating, and having any significant concurrent disease or psychiatric disorder that would compromise patient safety or compliance. The diseases being treated are listed as leukemia, with specific ICD-10 codes provided.",
    "The sample is a phase 2 clinical trial for patients with prostate cancer who have failed LHRH analogues and anti-androgen withdrawal trial. The trial is testing the drug \"revlimid\". The eligibility criteria include having documented prostate cancer, measurable disease, and an ECOG Performance Status of 2 or less. Patients must also have adequate liver and renal function, bone marrow function, and cannot have had prior systemic chemotherapy for AIPC or exposure to lenalidomide. The trial also requires patients to use a latex condom during sexual contact with a female of childbearing potential and to take aspirin daily as prophylactic anticoagulation. The exclusion criteria include prior exposure to lenalidomide, known HIV positive status, known brain metastases, and any serious medical condition or laboratory abnormality that would prevent the subject from signing the informed consent form.",
    "The sample is a phase 2 clinical trial for heart failure, congestive. The trial includes patients with chronic dilated cardiomyopathy of ischemic or non-ischemic origin who are clinically stable on optimal therapies for at least 3 months prior to screening/baseline visit. The trial also requires patients to have a left ventricular ejection fraction greater than or equal to 40% as assessed by any measurement in the previous 24 months and NYHA Class II/III heart failure for a minimum of 6 months prior to enrollment. The trial involves the use of two drugs, gsk716155 and placebo. The eligibility criteria include various medical and demographic factors, such as age, gender, and medical history. The exclusion criteria include factors such as active ischemia, history of drug/alcohol abuse, and known allergy or history of sensitivity to albiglutide, any other GLP-1 analogue, or Baker's yeast. The trial also involves various medical tests and assessments, such as performance/exercise testing and imaging assessments.",
    "The sample is a phase 2 clinical trial for HIV infections. The trial is for treatment-naive men and non-pregnant women with positive serology confirmed by Western blot. The trial requires participants to be between the ages of 18 and 65 with a CD4 count greater than 200 cells/mm3 and a viral load greater than 5,000 copies/mL. Participants must also be able to swallow multiple large capsules without difficulty and have acceptable laboratory values indicating adequate baseline organ function. The trial has various exclusion criteria, including a history of acute illness within 30 days prior to Day 0, evidence of active or acute HBV or HCV, and alcohol or substance abuse within 1 year prior to screening or during the study. Participants must also be willing to abstain from certain foods and medications during the trial. The trial involves the use of two drugs, tipranavir and ritonavir.",
    "The sample is a phase 2 clinical trial for chronic obstructive pulmonary disease (COPD) patients. The trial includes patients who are at least 40 years old, have been diagnosed with COPD for more than a year, and are currently on maintenance therapy with LABA and/or LAMA, ICS/LABA or ICS plus LAMA combination. The trial also requires patients to have a smoking history equivalent to at least 10 pack years, and meet certain lung function criteria. The trial will test the efficacy of three drugs: azd5423, budesonide, and placebo. The eligibility criteria include various medical and physical conditions that may exclude patients from participating in the trial. The trial also requires patients to provide informed consent for genetic sampling and analyses.",
    "This sample is a phase 2 clinical trial for the treatment of hepatitis C. The trial is looking at the effectiveness of a drug called \"ladr treatment\" for patients who are candidates for liver transplantation. The inclusion criteria for the trial include being an adult, having a positive HCV RNA test, and being expected to be on treatment for at least 12 weeks. The exclusion criteria include having severe cytopenia, uncontrolled depression or psychiatric disease, uncontrolled cardiopulmonary disease, autoimmune disease, active substance abuse, known intolerance or serious adverse event during prior therapy with interferon or ribavirin, prior nonresponse after at least 24 weeks of full dose treatment with peginterferon plus ribavirin, and having a laboratory Model for End-Stage Liver Disease (MELD) score greater than 20 or a serum creatinine level greater than 2.2 mg/dL.",
    "The sample is a phase 2 clinical trial for metastatic renal cell carcinoma. The table includes information on the diseases, icd-10 codes, drugs, and eligibility criteria for the trial. The inclusion criteria require participants to have metastatic RCC and no prior treatment with systemic therapy for RCC. The primary tumor must have been surgically removed and participants must have an ECOG performance status score of 0 or 1. The exclusion criteria include prior treatment with sunitinib or enzastaurin, recent treatment with unapproved drugs, and certain medical conditions such as uncontrolled hypertension or ongoing cardiac arrhythmias. Pregnant or breastfeeding participants are also excluded.",
    "The sample is a phase 2 clinical trial for patients with non-small cell lung cancer. The trial is testing the effectiveness of the drug docetaxel. The eligibility criteria include having confirmed non-small cell lung cancer, measurable disease by CT scan or MRI, and no symptomatic brain metastasis. Patients must also meet certain age and health requirements, such as having a neutrophil count above 1,500/mm^3 and no history of dementia or seizures. Prior to participating in the trial, patients cannot have received chemotherapy for stage IIIB or IV non-small cell lung cancer, and cannot be receiving any other concurrent anticancer therapy or investigational drugs.",
    "The sample is a phase 2 clinical trial for patients with metastatic breast cancer that is HER2/neu overexpressing and/or amplified. The trial is testing the effectiveness of lapatinib and vinorelbine as a treatment. The eligibility criteria include having confirmed adenocarcinoma of the breast, being over 18 years old, having evidence of metastatic disease, and having a life expectancy of more than 3 months. Patients must also have normal organ and marrow function, a left ventricular ejection fraction of over 50%, and an ECOG performance status of 0, 1, or 2. Exclusion criteria include having a history of other malignancies, ongoing anticancer treatment, symptomatic CNS metastases, serious cardiac illness, and serious illness or medical condition that would not permit the patient to be managed according to the protocol.",
    "The sample is a phase 2 clinical trial for patients with moderate to severe chronic plaque psoriasis. The trial is testing the effectiveness of a drug called BT061 compared to a placebo treatment. The eligibility criteria include having a diagnosis of psoriasis for at least 12 months, having a body surface area involvement of more than 10% for at least 6 months, and having a PASI score of at least 10. Patients must also be between the ages of 18 and 75, have a body mass index between 18 and 30, and weigh between 50 and 130 kg. Exclusion criteria include having other forms of psoriasis, recent treatment with a biological drug, recent serious infection, immune deficiency or autoimmune disease, and positive diagnosis for certain infections.",
    "The sample is a phase 2 clinical trial for the treatment of atherosclerosis. The trial involves the use of two drugs, sb-480848 and sb-480848 matching placebo. The eligibility criteria for the trial include having had a successful PCI or uncomplicated diagnostic catheterization, having a suitable non-intervened coronary artery with IVUS, and being on antiplatelet therapy. The exclusion criteria include clinical instability, previous CABG surgery, planned major surgery, recent stroke, abnormal QTc, renal or hepatic impairment, uncontrolled hypertension, use of corticosteroids, class III or IV heart failure, and asthma.",
    "The sample is a phase 2 clinical trial for the treatment of cystic fibrosis. The trial is testing the drugs vx-770 and placebo. The eligibility criteria for participants include having the G551D-CFTR mutation on at least one allele, a FEV1 of at least 40% of predicted normal for age, gender, and height, and being 12 years of age or older. Exclusion criteria include a history of solid organ or hematological transplantation, ongoing participation in another therapeutic clinical study, use of inhaled hypertonic saline treatment within 14 days prior to the screening visit, and extensive body tattoos or other physical features that will confound MRI.",
    "The sample is a phase 2 clinical trial for the treatment of invasive breast carcinoma, primary invasive breast cancer, stage I-III breast cancer using the drug capecitabine. The trial has eligibility criteria for participants, including confirmation of primary invasive breast cancer, operable breast cancer, and a primary tumor size of at least 2cm. Exclusion criteria include metastatic cancer, pregnancy or breastfeeding, inflammatory breast cancer, and hypersensitivity to 5-FU or known DPD deficiency. The trial also has other medical criteria for eligibility and exclusion. The diseases and their corresponding ICD-10 codes are listed in the table.",
    "The sample is a phase 2 clinical trial for patients with relapsed or refractory diffuse large B-cell lymphoma who have previously received R-CHOP chemo-immunotherapy and high dose chemotherapy with stem cell rescue, or who are ineligible for high dose therapy with stem cell rescue. The trial is testing the drug fostamatinib. Inclusion criteria include being at least 18 years old, having measurable disease as defined by Cheson et al 2007 criteria, having a World Health Organization performance status of 0 to 1, and having one fresh pre-treatment excisional or core needle biopsy from a suitable and accessible site. Exclusion criteria include treatment with certain drugs within a certain time frame, unresolved toxicities from prior therapy or surgery greater than Common Terminology Criteria for Adverse Events (CTCAE) Grade 1, uncontrolled hypertension, evidence of tuberculosis, and inadequate bone marrow reserve.",
    "The sample is a record from a table that contains information about clinical trials. It is a phase 2/phase 3 trial for chronic kidney disease. The trial is testing the drug \"zemplar\". The trial has eligibility criteria, which includes having an eGFR of 15-59 ml/m2, and exclusion criteria, which includes not currently receiving vitamin D treatment. The table also includes lists of disease names and their corresponding ICD-10 codes.",
    "The sample is a phase 2 clinical trial for patients with advanced cancer. The trial is testing the effectiveness of the drug Remeron (mirtazapine) in improving appetite and weight gain in patients with advanced cancer. The eligibility criteria include being 18 years or older, having lost 10% of body weight in the last 6 months, having a life expectancy of at least 12 weeks, and having a Zubrod performance status of 0-3. Patients with symptomatic brain metastases, severe medical problems, or functional problems that limit food intake or absorption of nutrients are excluded from the trial. Patients who are pregnant or nursing, have lost weight on a voluntary diet, or are already taking an appetite stimulant or other anti-depressant (except for SSRI taken in the morning) are also excluded. Patients who had surgery in the last 6 months are also not eligible.",
    "The sample is a phase 2 trial for patients with lung cancer. The trial includes patients who have had one prior chemotherapy treatment with a platinum agent, but not Docetaxel. Patients must have documented recurrent or progressive disease and no signs of active brain metastasis or spinal cord compression. Patients must also have an ECOG performance status of 0-1 and bi-dimensional measurable disease. Laboratory requirements include ANC \u2265 1,500/mm3, Hemoglobin > 8g/dl, platelet \u2265 100,000/mm3, Total Bilirubin \u2264 1.5 mg/dl, Creatinine \u2264 2.0 mg/dl, Transaminase (AST/ALT) \u2264 2.5 X upper normal limit if ALK phosphatase is \u2264 Upper normal limit OR ALK may be up to 4X ULN if transaminase are \u2264 ULN. Patients must be at least 18 years old and have a histologic or cytologic diagnosis of NSCLC. Patients with small cell lung cancer or mixed small and non-small cell lung cancer, or carcinoid are not eligible. Patients with a history of hypersensitivity to taxane, Polysorbate 80 or gemcitabine and who could not tolerate treatment even with 24 H premedication with Decadron and Benadryl are also not eligible. The trial has various exclusion criteria, including ECOG performance status 2 or worse, psychological, familial, sociological or geographical conditions that prevent weekly medical follow-up or compliance with the study protocol, and more than one different prior cytotoxic chemotherapy regimen.",
    "The sample is a record of a clinical trial with a phase 2 designation. The trial is focused on treating low-grade B-lymphocyte non-Hodgkin's lymphoma using the drugs rituximab and bortezomib. The eligibility criteria for the trial are listed, including requirements for patients to have a confirmed diagnosis of the disease, a life expectancy of more than 12 months, and no prior therapy for non-Hodgkin's lymphoma or the drugs being tested. Exclusion criteria are also listed, such as no known history of HIV infection, no other active infections, and no serious medical or psychiatric illness that would preclude study compliance. The sample also includes a list of icd-10 codes associated with the disease.",
    "The sample is a record of a clinical trial in phase 2 for the treatment of arthritis, specifically rheumatoid arthritis. The trial involves the use of multiple drugs, including a placebo and a drug called ph-797804. The eligibility criteria for the trial require that the participant has been diagnosed with rheumatoid arthritis and has failed at least one DMARD therapy. The exclusion criteria include any other inflammatory arthritis and any significant history of acute or chronic infection with immunomodulatory etiology. The icd-10 codes associated with the disease are also included in the record.",
    "This sample is a phase 2 clinical trial for the treatment of type 2 diabetes mellitus. The trial includes patients with a BMI between 27 to 45 kg/m2 who have had stable type 2 diabetes mellitus for at least 3 months, as determined by the investigator. Patients must also have a stable lifestyle, including diet and physical activity, and a stable metformin daily dose of at least 1000 mg for at least 3 months. The trial will test the efficacy of two drugs, cjc-1134-pc and placebo, and patients must have a glycosylated hemoglobin (HbA1c) level between 7.1% and 11% at screening to be eligible for the trial.",
    "The sample is a record of a clinical trial with a phase 2 designation. The trial is focused on breast cancer and involves the use of several drugs, including lapatinib, paclitaxel, fluorouracil, epidoxorubicin, and cyclophosphamide. The eligibility criteria for the trial include having a confirmed diagnosis of infiltrating primary breast cancer that is HER2 positive, availability of tumor tissue for examination, being between the ages of 18 and 65, having normal organ and marrow function, and having a cardiac ejection fraction within the institutional range of normal. There are also exclusion criteria, such as having stage IIIB, IIIC, or inflammatory breast cancer, being pregnant or breastfeeding, and having certain medical conditions or taking certain medications. Participants must be able to understand and sign a written informed consent document and be able to swallow and retain oral medication.",
    "The sample is a phase 2 clinical trial for patients with metastatic colorectal cancer. The trial is testing the effectiveness of the drug aflibercept in patients who have already received at least one line of systemic therapy for their metastatic disease. The trial has two cohorts, one for patients who have not received bevacizumab and one for patients who have. The eligibility criteria include having measurable disease, being at least 18 years old, having a life expectancy of at least 3 months, and meeting certain laboratory values. Patients must also not have received chemotherapy or radiotherapy within 4 weeks prior to the study and must not have a history of anti-angiogenic therapy other than bevacizumab. Patients with certain medical conditions or who are pregnant are excluded from the trial.",
    "The sample is a phase 2 clinical trial for the treatment of multiple myeloma, a type of cancer. The trial involves the use of three drugs: bortezomib, dexamethasone, and thalidomide. The eligibility criteria for the trial include a diagnosis of active multiple myeloma that has relapsed or is refractory after at least one prior therapy, measurable disease, and no evidence of POEMS syndrome. Patients must also meet certain age, performance status, and medical criteria, such as having a certain level of neutrophils and platelets, and no serious medical or psychiatric illness that would preclude study treatment. Prior concurrent therapy is also taken into consideration. The trial is registered on protocol SWOG-S0334, and concurrent participation on protocol SWOG-S0309 is allowed.",
    "The sample is a phase 2 clinical trial for HIV-1 infected male or female subjects who are at least 18 years old and have not received more than 10 days of prior therapy with any antiretroviral agent following a diagnosis of HIV-1 infection. The trial involves testing the efficacy of several drugs, including gsk1265744, efavirenz, rilpivirine, and placebo, as well as two combinations of drugs, abacavir/lamivudine (abc/3tc) or tenofovir/emtricitabine (tdf/ftc). The trial also has inclusion and exclusion criteria, such as a screening plasma HIV-1 RNA of at least 1000 c/mL, a CD4+ cell count of at least 200 cells/millimeter (mm)^3, and no evidence of an active Centers for Disease and Prevention Control (CDC) Category C disease. Women of childbearing potential are eligible to participate if they are not pregnant and willing to use protocol-specified methods of contraception to prevent pregnancy during the study. The trial excludes subjects with a history of ongoing or clinically relevant hepatitis within the previous 6 months, women who are breastfeeding, and subjects who are unlikely to complete the dosing schedule due to a pre-existing physical or mental condition.",
    "The sample is a record of a clinical trial with a phase 2 designation. The trial is focused on chronic idiopathic constipation and includes a list of ICD-10 codes for the disease. The trial involves testing several drugs, including sp-304 at various dosages and a placebo. The eligibility criteria for participants include being between 18 and 75 years old, having a BMI between 18 and 35 kg/m2, and meeting the Rome III Diagnostic Criteria for constipation. Exclusion criteria include having loose or watery stool, meeting the Rome III criteria for IBS, and failing to complete the pre-treatment bowel movement diary accurately and completely.",
    "The sample is a record from a clinical trial table that includes information about the phase of the trial, the disease being studied (in this case, type 2 diabetes mellitus), the corresponding ICD-10 codes, the drugs being tested (alogliptin and pioglitazone), and the eligibility criteria for participants. The eligibility criteria include requirements such as a stable dose of pioglitazone for at least 16 weeks prior to the start of the treatment period, a certain level of glycosylated hemoglobin, and adherence to specific diet and exercise therapies. The exclusion criteria include a history or symptoms of cardiac failure and the use of diabetic medications other than pioglitazone within 16 weeks before the start of the treatment period.",
    "The sample is a phase 2 clinical trial for patients with recurrent non-small cell lung cancer. The trial is testing the effectiveness of two drugs, apricoxib/erlotinib and erlotinib/placebo. The eligibility criteria for the trial include having stage IV NSCLC or stage IIIb with pleural effusion, having failed at least one prior platinum-based chemotherapy, having measurable disease by RECIST, being 18 years or older, and having an ECOG PS of 0 or 1. The exclusion criteria include recent radiation therapy or chemotherapy, evidence of NYHA class III or greater cardiac disease, history of MI, stroke, ventricular arrhythmia, or symptomatic conduction abnormality within 12 months, known HIV infection or AIDS, symptomatic CNS metastases, pregnancy or nursing, hypersensitivity or intolerance to erlotinib, sulfonamides, aspirin, or other NSAIDs, history of upper GI bleeding, ulceration, or perforation, prior history of COX-2 inhibitor therapy for the treatment of metastatic NSCLC, and previous anti-EGFR kinase therapy.",
    "The sample is a phase 2 clinical trial for patients with metastatic kidney cancer. The trial is testing the effectiveness of the drug Tanespimycin. Patients must have histologically confirmed renal cell carcinoma with papillary or clear cell histology, measurable disease, and no brain metastases unless previously treated. Patients must also meet certain eligibility criteria, including age, performance status, hematopoietic, hepatic, renal, cardiovascular, and pulmonary requirements. Patients must not be pregnant or nursing, have no allergy to egg or egg products, and have no history of allergic reactions to compounds of similar chemical or biological composition to 17-N-allylamino-17-demethoxygeldanamycin (17-AAG). Additionally, patients must have no active or ongoing infection requiring IV antibiotics, no psychiatric illness or social situation that would preclude study compliance, and no other uncontrolled illness. Prior concurrent therapy is also restricted. Patients must have no more than 1 prior cytokine-based regimen, no concurrent biologic therapy, no more than 1 prior non-cytokine-based regimen, and no other prior systemic treatment regimens. Patients must have recovered from prior therapy and have no other concurrent cytotoxic therapy, anticancer therapy, or investigational agents.",
    "The sample is a phase 2 clinical trial for patients with locally advanced or metastatic nonsquamous non-small cell lung cancer. The trial is testing the effectiveness of the drugs pemetrexed and erlotinib. The eligibility criteria include having at least one measurable lesion, a performance status of 0 to 2 on the Eastern Cooperative Oncology Group Scale, and having failed only one prior chemotherapy regimen. Patients must also be non-smokers and considered eligible for further chemotherapy following progression of their disease. Exclusion criteria include having received treatment within the last 30 days with a drug that has not received regulatory approval for any indication, having previously received treatment with drugs against the human epidermal growth factor receptors or drugs which have similar targets as Pemetrexed, having any known significant ophthalmologic abnormalities of the surface of the eye, and having a history of severe hypersensitivity reaction to erlotinib or pemetrexed.",
    "The sample is a phase 2 clinical trial for the treatment of arthritis, specifically rheumatoid arthritis. The trial involves the use of two drugs, peficitinib and placebo. The eligibility criteria for the trial include having at least 6 tender/painful joints and 6 swollen joints, as well as meeting certain ACR 1991 Revised Criteria for Global Functional Status in RA Class I, II or III. The use of certain RA medications must be stable for at least 28 days prior to the start of the study. The trial also has exclusion criteria, such as a positive Mycobacterium tuberculosis test within 90 days of screening and a history of any other autoimmune rheumatic disease, other than Sjogren's syndrome.",
    "The sample is a phase 2 clinical trial for small cell lung cancer. The trial is testing the effectiveness of carboplatin and pemetrexed disodium as a treatment for previously untreated extensive-stage disease. The eligibility criteria include having histologically or cytologically confirmed small cell lung cancer, no mixed histology, and no symptomatic, untreated, or uncontrolled CNS metastases. Patients must also have measurable disease and meet certain age, performance status, life expectancy, hematopoietic, hepatic, renal, cardiovascular, pulmonary, and other criteria. Prior concurrent therapy is not allowed, and patients must not have any other severe or uncontrolled medical conditions.",
    "The sample is a phase 2 trial for patients who have undergone renal transplant and are receiving cyclosporine or tacrolimus. The trial is testing the effectiveness of belatacept, cyclosporine a, and tacrolimus as drugs. The eligibility criteria include being 18 years or older, having received the transplant 6-36 months ago, having a calculated GFR between 35 and 75mL/min/1.73 m\u00b2, and having completed 1 year in the IM103-010ST trial and remained on study treatment. The exclusion criteria include having a significant infection, experiencing acute rejection within 3 months, having prior graft loss due to rejection, being pregnant, or having a positive crossmatch.",
    "The sample is a record of a clinical trial in phase 2 for the treatment of myelodysplastic syndromes. The record includes a list of diseases, icd-10 codes, and drug names. The eligibility criteria for the trial are also listed, including requirements for pathological confirmation of MDS, no prior systemic therapy, normal organ functions, and willingness to sign a consent form. The exclusion criteria include not having received prior chemotherapy or radiotherapy for another malignancy, no other agents or therapies administered, uncontrolled intercurrent illness, and being pregnant or breastfeeding.",
    "This sample is a phase 2 clinical trial for the treatment of depression. The trial is testing the effectiveness of two drugs, evt 101 and placebo, on patients with major depressive disorder who have not responded to previous treatments. The trial has specific inclusion and exclusion criteria, such as a minimum score on the Ham-D-17 depression scale and the absence of certain medical conditions or substance abuse disorders. The trial is not open to pregnant or breastfeeding women, those with age-related cognitive decline or mild dementia, or those at risk of suicide.",
    "The sample is a phase 2 clinical trial for heart failure. The trial includes patients with New York Heart Association (NYHA) Classification III or IV, who have been hospitalized for heart failure decompensation associated with fluid overload within the last six months, and have chronic kidney disease. The trial involves the drugs clp and placebo. The eligibility criteria include being able to understand study procedures and willing and able to provide written informed consent. The exclusion criteria include no hospitalization within 4 weeks of Baseline Visit, any cardiovascular, renal, hepatic, endocrine, gastrointestinal, neurological or other disease or condition that makes the patients study participation unsafe, history or presence of gastrointestinal conditions such as severe constipation or gastrointestinal tract strictures, and current dialysis patient, or anticipated need for dialysis during study participation.",
    "The sample is a record of a clinical trial in phase 2 for the treatment of rheumatoid arthritis. The trial involves the use of drugs such as cp-690,550 and atorvastatin, as well as their respective placebos. The eligibility criteria for the trial include being diagnosed with active rheumatoid arthritis and agreeing to participate in the study by signing an informed consent document. Exclusion criteria include having a history of serious infection within the past 6 months, testing positive for TB, having any uncontrolled clinically significant disease or laboratory tests, and requiring administration of prohibited medications during the study. The icd-10 codes associated with the disease are also included in the record.",
    "The sample is a record of a clinical trial for a drug called \"ep-101\" for the treatment of chronic obstructive pulmonary disease (COPD). The trial is in phase 2 and involves testing the drug on patients aged 40-75 who have a clinical diagnosis of moderate to severe COPD and are current or former smokers with at least 10 pack-years of smoking history. The trial also has inclusion and exclusion criteria, which are listed in the \"criteria\" field. The \"diseases\" field lists the disease being treated, while the \"icdcodes\" field lists the ICD-10 codes associated with the disease. The \"drugs\" field lists the different forms and dosages of the drug being tested.",
    "The sample is a phase 2 clinical trial for the treatment of inflammation and rheumatoid arthritis. The trial involves the use of two drugs, nnc0114-0006 and placebo. The eligibility criteria for the trial include a diagnosis of RA meeting the 2010 ACR classification criteria, active RA characterized by DAS28-CRP equal to or above 4.5, and concomitant treatment with MTX above or equal to 15 mg/week for at least 4 months prior to screening. Biologic na\u00efve subjects or subjects having been treated with biologics for RA are eligible, provided they meet certain criteria. The exclusion criteria include a BMI below or equal to 18.0 or above or equal to 38.0 kg/m^2, subjects with rheumatic autoimmune disease other than RA, and any active or ongoing bacterial infections within 4 weeks prior to randomization, among others.",
    "The sample is a phase 2 clinical trial for small cell lung cancer. The trial is for patients who have already received one prior platinum-based chemotherapy regimen and have refractory disease. The trial requires patients to have measurable disease, be at least 18 years old, and have an ECOG Performance Status of 0, 1, or 2. Patients must also have adequate organ function and negative pregnancy test for women of child-bearing potential. The trial excludes pregnant or nursing women, patients with more than one prior chemotherapy regiment for SCLC, and patients with symptomatic central nervous system metastases. The trial also excludes patients with concurrent severe or uncontrolled medical disease that would compromise their safety or ability to complete the study.",
    "This is a sample from a clinical trial table that includes information about a phase 2 trial for Duchenne muscular dystrophy. The table includes columns for the trial phase, diseases being studied, ICD-10 codes for those diseases, drugs being used in the trial, and eligibility criteria for participants. The sample includes information about the eligibility criteria for participants, including inclusion criteria such as completion of a previous study, ability to provide informed consent, and willingness to comply with study procedures, as well as exclusion criteria such as recent use of certain medications, ongoing medical conditions, and participation in other clinical trials.",
    "The sample is a phase 2 trial for kidney transplantation or retransplantation for patients with end stage kidney disease or loss of graft for non-immunological reasons. The trial is testing the drug fk778. The inclusion criteria require patients to be fully informed and have end stage kidney disease or need retransplantation. The exclusion criteria include patients with immunological high risk or previous graft survival shorter than 1 year due to immunological reasons, significant liver disease, cold ischemia time of the donor kidney >28 hours, uncontrolled concomitant infections and/or severe diarrhea, vomiting, active upper gastrointestinal tract malabsorption or active peptic ulcer, and patients who have previously received or are receiving an organ transplant other than kidney. The diseases and icd-10 codes associated with the trial are listed as well.",
    "This sample is from a clinical trial in phase 2, focused on the disease bronchiolitis. The icd-10 codes associated with the disease are listed as \"J21.9\", \"J84.115\", \"J21.1\", \"J21.0\", and \"J21.8\". The drug being tested is a combination of mk-0476 and montelukast sodium. The eligibility criteria for the trial include having active bronchiolitis or a history of bronchiolitis and asthma-like symptoms, while exclusion criteria include a history of any significant illness that could pose additional risk to the patient.",
    "The sample is a phase 2 clinical trial for patients with squamous cell carcinoma of the head and neck. The trial is testing the drug gefitinib. The eligibility criteria include having a tumor site that can be biopsied, being 18 years or older, having an ECOG performance status of 0-2, and having normal organ and marrow function. Exclusion criteria include having a severe hypersensitivity to Iressa or any of its excipients, having any unresolved chronic toxicity greater than CTC grade 2 from previous anticancer therapy, and having any evidence of clinically active interstitial lung disease.",
    "The sample is a phase 2 clinical trial that involves patients with various diseases such as chronic myeloproliferative disorders, graft versus host disease, leukemia, multiple myeloma and plasma cell neoplasm, and myelodysplastic syndromes. The trial includes a list of icd-10 codes for each disease and a list of drugs used in the treatment, including busulfan, cyclophosphamide, cyclosporine, leucovorin calcium, methotrexate, and methylprednisolone. The eligibility criteria for the trial include patients with histologically confirmed malignancy, certain remission stages, and relapse stages for each disease. The patient characteristics include age, performance status, life expectancy, and various health conditions such as renal, cardiovascular, and pulmonary. The trial also specifies prior concurrent therapy for each disease.",
    "The sample is a phase 2 clinical trial for the treatment of major depressive disorder. The trial is testing the drug GSK561679. The eligibility criteria for the trial includes female outpatients aged 25-64 years who have been diagnosed with MDD (without psychotic features) and meet certain criteria as defined in the DSM-IV-TR. The trial also has exclusion criteria, such as a history of substance abuse or dependence, a current diagnosis of Dementia, or a history of allergic reaction to the drug being tested. The trial is designed to assess the safety and efficacy of the drug in treating MDD.",
    "This sample is for a phase 2 clinical trial for patients with relapsed or chemotherapy/immunotherapy-resistant mantle cell lymphoma. The trial is testing the drug everolimus. The eligibility criteria include having no more than 3 lines of prior systemic treatment, at least one measurable lesion of a certain size, and meeting certain patient characteristics such as having a WHO performance status of 2 or lower and certain blood counts. Exclusion criteria include having CNS disease, being newly diagnosed with mantle cell lymphoma, or having certain medical conditions such as uncontrolled diabetes or ongoing infection. Prior concurrent therapy is also excluded.",
    "The sample is a phase 2 clinical trial for patients with recurrent small cell lung cancer. The trial involves the drug romidepsin and has specific eligibility criteria, including having no more than 1 prior chemotherapy regimen and measurable disease. Patients must also have recovered from any prior surgeries and not have any significant cardiac disease. The trial has exclusion criteria, including being pregnant or nursing.",
    "The sample is a record from a clinical trial table. It is a phase 2 trial for the treatment of two diseases, pseudophakic cystoid macular edema and diabetic macular edema. The trial is testing the effectiveness of a drug called dexamethasone implant. The eligibility criteria for the trial include diabetic patients who develop cystoid macula edema after cataract surgery within 4-10 weeks after surgery and have a visual acuity worse than 20/32. The exclusion criteria include visual acuity worse than 20/200, moderate or severe glaucoma, and use of systemic, periocular or intraocular corticosteroids within 30 days of enrollment. The icd-10 codes for the diseases are also provided.",
    "The sample is a phase 2 clinical trial for patients with bronchial asthma symptoms for at least 6 months. The trial includes patients of both genders between 18 to 60 years of age who have a FEV1 of at least 70% of predicted after withholding short-acting \u03b2 agonists for at least 8 hours prior to testing. The trial also requires patients to have a sensitivity to methacholine resulting in a \u2265 20% fall in FEV1 (PC20 methacholine) and to be non-smokers who have been free from the usage of nicotine-containing products for at least a year prior to screening. The trial excludes patients with a previous history of life-threatening asthma, respiratory tract infection and/or exacerbation of asthma within 6 weeks prior to the first screening visit, past or present disorders and diseases including, but are not limited to, cardiovascular, malignancy, hepatic, renal, hematological, neurological, psychiatric, endocrine, or pulmonary other than asthma, significant safety laboratory, ECG, or vital sign abnormalities that would place the patient at undue disk during the study procedures, and a history of clinically significant multiple drug or food allergy. The trial will test the efficacy of ono-6950, placebo, and montelukast as potential treatments for asthma.",
    "The sample is a phase 2 clinical trial for patients with metastatic renal cell cancer of predominantly clear cell type. The trial involves the use of three drugs: bevacizumab [avastin], interferon alfa-2a, and vinblastine. The eligibility criteria for the trial include being an adult patient of at least 18 years of age, having at least one measurable lesion, and not having received prior treatment with chemotherapy, cytokine or tyrosine kinase inhibitor therapy for metastatic renal cell cancer. The exclusion criteria include having ongoing or recent need for full therapeutic dose of anticoagulants or chronic daily treatment with aspirin (>325mg/day), and having clinically significant cardiovascular disease.",
    "The sample is a phase 2 clinical trial for patients with adenocarcinoma of the lung. The trial is testing the effectiveness of a drug called farletuzumab, which targets folate receptor-alpha (FRA) expression. The eligibility criteria for the trial include having stage IV adenocarcinoma of the lung, confirmed FRA expression, and measurable disease. Participants must not have received prior chemotherapy, radiation therapy, or surgery with curative intent for adenocarcinoma of the lung. Exclusion criteria include previous chemotherapy or surgery with curative intent for adenocarcinoma of the lung, and prior radiotherapy for adenocarcinoma of the lung (except for palliative radiation with non-curative intent).",
    "The sample is a phase 2 clinical trial for metastatic breast cancer. The trial is testing the effectiveness of the drugs ixabepilone and ixabepilone. The eligibility criteria include having measurable or nonmeasurable MBC, being HER2 negative, having an ECOG PS of 0-2, and meeting certain laboratory values. Exclusion criteria include prior treatment with ixabepilone or other epothilones, HER2+ disease, severe hypersensitivity reactions to a drug formulated in Cremophor \u00ae EL, and receiving concurrent immunotherapy, hormonal therapy, or radiation therapy. Participants with stable brain metastases who are off steroids for at least 2 weeks are eligible. Pregnant or breastfeeding individuals are excluded.",
    "The sample is a record of a clinical trial in phase 2, which is testing the effectiveness of the drug doripenem in treating patients with nosocomial pneumonia or ventilator-associated pneumonia. The trial includes patients who are hospitalized throughout the treatment period and have microbiological samples suitable for culture and microscopy. The record also includes a list of diseases and their corresponding ICD-10 codes, as well as eligibility criteria for inclusion and exclusion from the trial.",
    "The sample is a phase 2 clinical trial for kidney diseases, with a list of ICD-10 codes for the diseases. The trial involves the drugs voclosporin and tacrolimus. The eligibility criteria include being between 18-65 years old, receiving a first cadaveric or living donor renal transplant, and being able to take oral medication. Women who are pregnant or nursing or planning to become pregnant during the study are excluded. Sexually-active women of child-bearing potential and sexually-active men must practice a highly effective method of birth control. The participants must be able to give written informed consent and keep study appointments. Exclusion criteria include receiving a HLA identical living related transplant, having a cold ischemic time over 24 hours, and having a peak PRA over 30%. Other exclusion criteria include having a current malignancy or history of malignancy within 5 years, being pregnant or nursing, and having a history of active alcoholism or drug addiction within 1 year prior to study entry.",
    "The sample is a phase 2 clinical trial for the treatment of acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS) using the drug temozolomide. The eligibility criteria include a confirmed diagnosis of AML or high-risk MDS, no prior AML chemotherapy except hydroxyurea, and a leukemic blast count of less than 30x10^9/L at the start of therapy. Participants must also not be candidates for aggressive induction based on certain criteria, have confirmed low or weak MGMT expression, and have an Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2. Exclusion criteria include certain medical conditions and prior chemotherapy other than hydroxyurea.",
    "The sample is a phase 2 clinical trial for the treatment of multiple myeloma using the drug bortezomib. The trial has specific eligibility criteria, including having experienced a first relapse after ASCT, having symptomatic myeloma, and having a certain number of CD34+ stem cells in the freezer for stem cell support. The trial also has exclusion criteria, such as having a scheduled allogeneic transplantation, having a performance status greater than 3, and having a history of hypotension. Participants must be over 18 years old and have given informed consent.",
    "The sample is a phase 2 clinical trial for patients with colorectal adenocarcinoma that has progressed on or the patient could not tolerate previous chemotherapy treatments. The trial is testing the effectiveness of the drugs bevacizumab and everolimus. The eligibility criteria include having confirmed adenocarcinoma of the colon or rectum, being over 18 years old, having a Karnofsky performance status of over 70%, and having normal organ and marrow function. Patients must not have had radiation therapy, hormonal therapy, biologic therapy, or chemotherapy for cancer within the 28 days prior to study day 1. The trial also has exclusion criteria, such as patients with known central nervous system metastases, inadequately controlled hypertension, and significant vascular disease. The sample includes a detailed list of inclusion and exclusion criteria.",
    "The sample is a phase 2 clinical trial for patients with glioblastoma multiforme, a type of brain cancer. The trial includes patients who have had surgical resection of the first tumor progression or those without surgical resection. The eligibility criteria include recovery from surgery, evidence of first tumor progression, resolution of acute toxic effects of prior therapy, ECOG performance status of 0-2, age between 18 and 75 years, and adequate organ function. The trial excludes patients who are active participants in another clinical trial, have undergone surgery for recurrence/progression within 1 week prior to study enrollment, have received chemotherapy within 4 weeks prior to study enrollment, have undergone radiation therapy within 8 weeks to study enrollment, have significant co-morbidities, are pregnant or nursing, have evidence of increased intracranial pressure, or have other severe acute or chronic medical or psychiatric condition or laboratory abnormality that would impart excess risk associated with study participation or study drug administration.",
    "The sample is a phase 2 clinical trial for neuroendocrine tumors. The trial includes patients with low- or intermediate-grade, islet cell carcinoma, pancreatic NET, carcinoid, atypical carcinoid, paraganglioma, or pheochromocytoma. Patients must have at least one measurable disease site per RECIST that has not been previously irradiated. They must also meet various medical criteria, such as having an ECOG score of 2 or lower, and not having certain medical conditions. Patients must not have poorly differentiated NET, high-grade NET, adenocarcinoid, goblet cell carcinoid, or small cell carcinoma. They must not have had liver-directed therapy within 2 months of enrollment, or prior treatment with EGFR inhibitor or mTOR inhibitor. Patients must also not have known hypersensitivity to RAD001 or other rapamycins, chronic, systemic treatment with corticosteroids or another immunosuppressive agent, or immunization with attenuated live vaccines within 1 week of study entry or during the study. The sample also includes exclusion criteria, such as uncontrolled brain or leptomeningeal metastases, other malignancies within the past 3 years, and severe and/or uncontrolled intercurrent medical conditions or other conditions that may affect study participation.",
    "The sample is a phase 2 clinical trial for patients with differentiated thyroid cancer that has spread and cannot be surgically removed. The trial is testing the effectiveness of the drug rosiglitazone maleate in treating the disease. Eligible patients must have failed prior conventional therapy and have elevated thyroglobulin levels. The trial also has specific patient characteristics and prior concurrent therapy requirements. The eligibility criteria include age, performance status, life expectancy, hematopoietic, hepatic, renal, and cardiovascular conditions, as well as other factors such as pregnancy and allergies. The sample includes a detailed list of disease and patient characteristics, as well as prior concurrent therapy requirements.",
    "The sample is a phase 2 clinical trial for rheumatoid arthritis. The trial involves the use of drugs such as fostamatinib disodium and a placebo. The eligibility criteria for the trial include patients who have been diagnosed with active RA for at least 6 months prior to Day 1 dosing and have been receiving weekly methotrexate doses for a minimum of 3 months prior to Day 1 dosing. Patients must also be receiving a folic or folinic acid supplementation at a stable dose for at least 6 weeks prior to Day 1 dosing. Females of childbearing potential must agree to use a well-established method of birth control during the study. Exclusion criteria include patients with a history of substance abuse, drug addiction, or alcoholism, and those who have been previously treated with R788 under a different protocol.",
    "The sample is a phase 2 clinical trial for patients with colorectal cancer and liver metastases. The trial involves the use of oxaliplatin, raltitrexed, and other intravenous chemotherapy drugs. The eligibility criteria include informed consent, health insurance coverage, age between 18 and 75 years (or 76-80 years with WHO status 0), WHO status of 0 or 1, estimated life expectancy of more than 3 months, hepatic metastases of colorectal cancer confirmed on CT scan without extra-hepatic metastasis, TEP-scan without fixation outside the liver and the primary tumor, histological proven colorectal cancer obtained from primary tumor or the hepatic metastases, metastases not accessible to curative hepatectomy, failure or arrest of a previous chemotherapy because of intolerance to certain drugs, and various blood and liver function tests. Exclusion criteria include extra-hepatic metastases, symptomatic primary colorectal tumor in place, contraindication for allergy of rank 3-4 for one of the compounds of chemotherapy, peripheral neuropathy > 2, current participation or in the 30 days preceding the inclusion in the study in another therapeutic trial with an experimental molecule, concomitant systemic treatment by immunotherapy, chemotherapy or hormonotherapy, unbalanced serious illness, unchecked active infection or the other underlying serious disorder susceptible to prevent the patient from receiving the treatment, pregnancy, breast-feeding, intestinal occlusion or sub-occlusion or history of inflammatory intestinal disease, other cancer during the 5 years preceding entry in the trial or concomitant, and patient in custody or under guardianship, impossibility to adhere to the medical follow-up for geographical, social or psychiatric reason.",
    "The sample is a phase 2 clinical trial for the treatment of schizophrenia. The trial is testing the effectiveness of drugs such as pf-00217830 and aripiprazole. The trial is looking for participants who have a current diagnosis of schizophrenia and have experienced an increase in symptoms over the past 2-4 weeks. Participants must be willing to remain inpatients for the duration of the trial. The trial excludes individuals with a current diagnosis of a different mental illness, a history of treatment-resistant schizophrenia, and females who are of childbearing potential. The diseases and icd-10 codes associated with the trial are limited to schizophrenia and its subtypes.",
    "The sample is a phase 2 clinical trial for a drug called capsaicin patch. The trial is focused on patients with various diseases such as neuralgia, pain, peripheral nervous system diseases, and herpes zoster. The patients must have a diagnosis of Painful Postherpetic Neuralgia and be at least 6 months post vesicle crusting. They must also be in good health and have an adequate pain score during the screening period. The trial requires patients to have painful areas (maximum of two sites) below the neck and unbroken skin with good perfusion over the painful area(s). Patients must also be willing and able to comply with the protocol. The trial has a set of exclusion criteria, including patients with diffusely distributed neuropathic pain, any implanted medical device for the treatment of neuropathic pain, and a history or current problem with prescription drug or illicit substance abuse.",
    "This sample is for a phase 2 clinical trial for the treatment of neurogenic bladder in patients with a known neurological disorder. The trial will use tamsulosin hydrochloride as the drug. The inclusion criteria require patients to have elevated detrusor leak point pressures confirmed by two measurements at baseline. The exclusion criteria include clinically significant abnormalities and a history of relevant orthostatic hypotension, fainting spells, or blackouts.",
    "The sample is a phase 2 clinical trial for the treatment of atopic dermatitis and eczema. The trial involves the use of two drugs, mapracorat and a vehicle without active ingredients. The eligibility criteria for the trial include a signed written informed consent, a diagnosis of atopic dermatitis according to Hanifin and Rajka Criteria, willingness to follow all study procedures, and avoidance of excessive exposure of diseased areas to natural or artificial sunlight. Exclusion criteria include pregnancy and breastfeeding, clinically relevant diseases that could interfere with the study conduct or evaluation, clinically manifested immunosuppressive disorder or known history of malignant disease, and history of relevant drug and/or food allergies.",
    "The sample is a phase 2 clinical trial for asthma. The trial includes patients who have been diagnosed with asthma at least 6 months ago and are non-smokers or have stopped smoking for at least a year. The patients must be able to conduct a spirometry, methacholine and neurokinin-A provocation test. Female subjects must not be pregnant and should be using adequate contraception. The trial excludes patients with airway infection within 6 weeks prior to the first study visit, other respiratory diseases, clinically relevant systemic diseases, clinically significant laboratory deviations, alcohol or drug abuse, and lactating female subjects. The trial involves the administration of inhaled tiotropium bromide or placebo.",
    "The sample is a clinical trial with a combination of phase 2 and phase 3. The trial is focused on diabetes and insulin resistance, and the icd-10 codes for the diseases are provided. The trial involves the use of sitagliptin and placebo drugs. The eligibility criteria for the trial include being HIV-infected, having stable immunologic and virologic status, having a BMI between 18-42kg/m2, and having normal blood chemistry. The trial also has exclusion criteria, including having a history of serious CV disease, moderate to severe renal insufficiency, and known allergy or hypersensitivity to DPPIV-inhibitors. The trial also excludes pregnant or nursing mothers and those with active malignancy or treatment with chemotherapeutic agents or radiation therapy within the past 12 months.",
    "The sample is a phase 2 clinical trial for patients with metastatic adenocarcinoma of the pancreas. The trial is testing the effectiveness of the drugs alvocidib and docetaxel. The eligibility criteria include having measurable disease, documented progression with measurable metastatic disease, and meeting certain health requirements such as having a Karnofsky performance status of 80-100% or ECOG PS of 0-1, and no uncontrolled intercurrent illness. Patients must also not have a history of allergic reactions to compounds of similar chemical or biological composition to flavopiridol, and must not be pregnant or nursing. The trial does not allow for concurrent chemotherapy or investigational agents, and patients must not be taking commonly used vitamins, antioxidants, or herbal preparations or supplements.",
    "This sample is for a phase 2 clinical trial for the treatment of melanoma. The trial is focused on patients who have previously been treated for Stage III (unresectable) or Stage IV melanoma. The trial is testing the effectiveness of the drug ipilimumab (mdx-010, bms-734016) on these patients. The table also includes a list of disease names and their corresponding icd-10 codes, as well as the eligibility criteria for the trial.",
    "The sample is a record of a clinical trial with a phase 2 designation. The trial is focused on the disease impetigo and includes a list of ICD-10 codes associated with the disease. The drug being tested is nvc-422. The record includes eligibility criteria for participants, including age range, consent requirements, and specific symptoms and diagnostic criteria for impetigo. There are also exclusion criteria listed, such as the presence of other skin diseases or recent use of antibiotics or steroids. The record provides detailed information about the trial's requirements and goals.",
    "The sample is a record of a clinical trial in phase 2 for the treatment of non-small-cell lung cancer. The trial involves the use of the drug sagopilone (bay86-5302, zk 219477) and requires participants to have had only one previous chemotherapy treatment with a platinum-containing drug. Female participants of child-bearing potential must use highly effective birth control methods. The trial has several exclusion criteria, including no more than one previous chemotherapy treatment for advanced disease, no previous participation in another trial within the last 4 weeks, no breastfeeding, and no active infections. The diseases are listed as 'carcinoma, non small cell lung' and the icd-10 codes associated with the disease are [\"['D02.20', 'D02.21', 'D02.22']\"].",
    "The sample is a record of a clinical trial in phase 2, focused on heart valve diseases. The trial includes patients aged 18-75 who have received a bileaflet mechanical heart valve. The trial excludes patients with prior valve surgery, uncontrolled hypertension, severe renal impairment, active liver disease, and increased risk of bleeding. The trial involves the use of various drugs, including warfarin and dabigatran etexilate at different doses. The diseases are identified using ICD-10 codes.",
    "The sample is a phase 2 clinical trial for Crohn's disease. The eligibility criteria include being between 10-70 years old, weighing between 20-100 kg, having CD of the ileum, colon or ileocolon, and being steroid-dependent, steroid-refractory or steroid naive. The trial involves the use of azathioprine weight-based dose and azathioprine individualised dose. Patients who have started steroids up to 14 days prior to screening will also qualify as steroid naive. The exclusion criteria include having a CDAI > 450, CD requiring hospitalization and intravenous corticosteroids, iv antibiotics or total parenteral nutrition, and a history of resection of more than 100 cm of small bowel, total proctocolectomy, or subtotal colectomy with ileorectal anastomosis.",
    "The sample is a phase 2 clinical trial for patients with carcinoma of unknown primary. The trial includes patients with confirmed malignancy for which no primary origin has been identified despite routine workup. The trial excludes patients with resectable disease, tumors consistent with germ cell primary, prostate primary with elevated prostate-specific antigen, females with axillary nodes as the primary disease site, tumors limited to the peritoneal cavity consistent with primary peritoneal carcinoma, neuroendocrine tumors, and squamous cell carcinoma involving cervical or inguinal lymph nodes. Patients must have measurable disease and no symptomatic brain metastases. The trial also has eligibility criteria related to age, performance status, life expectancy, hematopoietic, hepatic, renal, gastrointestinal, and other factors. Prior concurrent therapy is also specified.",
    "The sample is a phase 2 clinical trial for patients with chronic peripheral neuropathic pain associated with diabetic polyneuropathy or post-herpetic neuralgia. The trial includes adult patients of either gender, aged 18-85, who have signed the informed consent form. The trial involves the use of SAR292833 and placebo drugs. Patients must have a distinct neuroanatomically plausible distribution of neuropathic pain with sensory signs and symptoms confirmed by DN4 score of \u22654 and present for more than 3 months. Patients who are judged to be reliable to take SAR292833 in fed condition will be included in the study. The trial has several exclusion criteria, including patients with a baseline average daily pain intensity for their neuropathic pain < 5 on the 11-point NRS over the last 7 days before randomization, patients with a pain intensity of \u2265 9 on the 11-point NRS at Visit 1, and patients with any pain other than the neuropathic pain of equal or greater severity. The trial also excludes patients with clinically significant or uncontrolled hepatic, metabolic, gastrointestinal, cardiovascular, respiratory, neurological (other than neuropathy), psychiatric, hematological, renal, or dermatological disease, or any other medical condition that might interfere with the evaluation of study medication according to Investigator's medical judgment. The trial also excludes patients on statins metabolized by CYP3A4, patients with major depression, pregnant or breastfeeding women, and women of childbearing potential not protected by highly effective contraceptive method of birth control. The trial also excludes patients with diabetes mellitus and time between diagnosis of diabetes and enrollment <6 months, patients with diabetes mellitus and HbA1c >10% or fasting plasma glucose >250 mg/dL, and patients using certain drugs within 7 days prior to start with the pain intensity assessment.",
    "The sample is a phase 2 clinical trial for patients with relapsed or refractory multiple myeloma. The trial involves the use of lenalidomide, dexamethasone, and aspirin as treatment. The eligibility criteria include being previously diagnosed with multiple myeloma, having measurable disease, and meeting certain age and laboratory test result requirements. Patients must also have a life expectancy of at least 3 months and be able to adhere to the study visit schedule and other protocol requirements. The exclusion criteria include being pregnant or breastfeeding, having certain medical conditions or laboratory abnormalities, and having used any other experimental drug or therapy within 28 days of baseline.",
    "The sample is a phase 2 clinical trial for patients with esophageal or gastroesophageal junction carcinoma that cannot be treated with surgery or other curative therapy. The trial is testing the effectiveness of sunitinib malate, and patients must meet certain eligibility criteria to participate. These criteria include having measurable disease, a certain performance status, and meeting certain laboratory values. Patients must also not have certain medical conditions or be taking certain medications. Prior therapy must have been completed and patients must have recovered from it. The trial is not allowing concurrent use of certain medications or investigational agents.",
    "The sample is a phase 2 clinical trial for the treatment of erosive esophagitis using the drugs ilaprazole and lansoprazole. The trial includes patients with confirmed erosive esophagitis and excludes those with certain medical conditions or who are taking certain medications. The eligibility criteria include having a certain grade of erosive esophagitis, not having certain medical conditions or surgeries, and not taking certain medications. The trial aims to evaluate the effectiveness and safety of the drugs in treating erosive esophagitis.",
    "The sample is a phase 2 clinical trial for patients with locally unresectable or metastatic biliary tract or gallbladder adenocarcinoma. The trial involves the use of three drugs - bevacizumab, gemcitabine, and oxaliplatin. The eligibility criteria include having at least one measurable lesion outside of a prior radiation field, zero to one prior chemotherapy for biliary tract or gallbladder cancer, age over 18 years, ECOG performance status of 0-2, life expectancy of over 12 weeks, and adequate organ and bone marrow function. Exclusion criteria include recent chemotherapy, pregnancy or lactation, clinically apparent central nervous system metastases or carcinomatous meningitis, biliary obstruction with inadequate drainage and total bilirubin over 2.5 mg/dL, concurrent malignancy of any site except limited basal cell carcinoma or squamous cell carcinoma of the skin or carcinoma in situ of the cervix, uncontrolled serious medical or psychiatric illness, pre-existing peripheral neuropathy of grade 2 or greater severity, current or recent participation in an experimental drug study, and various other medical conditions.",
    "The sample is a phase 2 clinical trial for the treatment of cystic fibrosis using the drug ataluren. The eligibility criteria for participants include a diagnosis of CF, a specific mutation in both alleles, a minimum age and weight, and certain lung function and oxygen saturation levels. Participants must also be willing to comply with study procedures and restrictions. Exclusion criteria include prior exposure to ataluren, ongoing medical conditions that could affect safety or completion of the study, and certain laboratory abnormalities. Participants must provide written informed consent and/or assent.",
    "The sample is a phase 2 clinical trial for patients with extensive-stage small cell lung cancer that is c-kit-positive by immunohistochemistry. The trial is testing the drug Gleevec. The eligibility criteria include having no prior chemotherapy for SCLC, being at least 18 years old, having at least one measurable lesion or an evaluable outside the field of any prior radiation therapy, and having adequate organ function. Patients must also sign informed consent and meet other exclusion criteria, such as not having untreated brain or leptomeningeal metastases, not having major surgery or radiation therapy within 2 weeks of enrollment, and not having certain medical illnesses or conditions that could impair their ability to take oral pills on a daily basis or comply with the protocol requirements. Pregnant or lactating females are also excluded from the trial.",
    "The sample is a phase 2 clinical trial for non-small cell lung cancer. The trial is testing the effectiveness of the drug combination of oxaliplatin, gemcitabine, and vinorelbine. The eligibility criteria include having advanced or metastatic disease, no prior chemotherapy, and satisfactory liver and kidney function. Patients must also have a life expectancy of at least 3 months and be at least 18 years old. Exclusion criteria include being pregnant or breastfeeding, having symptomatic cerebral or leptomeningeal metastases, and having a serious medical condition that would make participation in the trial incompatible. Patients must sign an informed consent form before participating in the trial.",
    "The sample is a phase 2 clinical trial for lung cancer patients who are not eligible for surgery. The trial is testing the effectiveness of the drug cetuximab. The eligibility criteria include having measurable disease, adequate bone marrow reserve, and adequate renal and liver function. Patients must also be at least 70 years old or have an Eastern Cooperative Oncology Group (ECOG) performance status of 2, or have experienced weight loss of at least 5% in the preceding three months. Women of childbearing potential must use contraception during the study. Exclusion criteria include having small cell carcinoma, evidence of distant metastasis, and a history of prior or concomitant malignancy in the past 3 years, except for surgically cured basal cell carcinoma of the skin or carcinoma in situ of the cervix. Prior thoracic radiotherapy or epidermal growth factor receptor (EGFR) pathway targeting therapy is not allowed. Patients with concomitant life-threatening or uncontrolled serious medical illness are also excluded.",
    "The sample is a phase 2 clinical trial for aggressive non-Hodgkin's lymphoma, including follicular center lymphoma Grade 3, diffuse large B-cell lymphoma, mantle cell lymphoma, and transformed lymphoma. The trial is for patients who have relapsed or are refractory to previous therapy for lymphoma and have measurable disease on cross-sectional imaging that is at least 2 cm in the longest diameter. The trial drug is lenalidomide. The eligibility criteria include having at least one prior combination chemotherapy regime, an Eastern Cooperative Oncology Group (ECOG) performance score of 0, 1, or 2, and willingness to follow pregnancy precautions. The exclusion criteria include laboratory abnormalities, being a candidate for and willing to undergo an autologous stem cell transplant, history of active Central Nervous System (CNS) lymphoma within the previous 6 months, history of other malignancies within the past year, and positive Human immunodeficiency virus (HIV) or active Hepatitis B or C.",
    "This sample is for a phase 2 clinical trial for the treatment of colorectal cancer. The trial is looking at the effectiveness of three drugs, bevacizumab, capecitabine, and oxaliplatin. The eligibility criteria for the trial include being an adult patient over 18 years old with locally advanced or metastatic colorectal cancer and no previous treatment with chemotherapy for metastatic disease. The patient must also have measurable and/or evaluable lesions. Exclusion criteria include recent radiotherapy, untreated brain metastases or primary brain tumors, chronic daily treatment with high-dose aspirin, and co-existing malignancies.",
    "The sample is a phase 2 clinical trial for the treatment of head and neck cancer using a combination of drugs including cisplatin, docetaxel, fluorouracil, and cetuximab. The trial has specific eligibility criteria for patients, including having histologically confirmed squamous cell carcinoma of the oropharynx, being in stage III or nonmetastatic stage IV disease, and having measurable or evaluable disease. Patients must also meet certain health criteria, such as having a WHO performance status of 0-1, ANC \u2265 1,500/mm^3, and platelet count \u2265 100,000/mm^3. There are also exclusion criteria, such as having had a cardiovascular accident within the past 6 months or having serious and/or uncontrolled cardiac or respiratory disease. Patients cannot have had prior treatment, including chemotherapy or radiotherapy, and cannot be taking certain medications.",
    "The sample is a phase 2 clinical trial for the treatment of chronic hepatitis C. The trial is looking for treatment-naive patients with genotype 1 who are either Caucasian or African-American and have a body weight between 61 kg and 87.3 kg. The trial requires patients to have HCV RNA levels greater than 2 million copies/mL and elevated alanine aminotransferase levels. Patients must also have a hemoglobin level of at least 12.0 g/dL for females and at least 13.0 g/dL for males, and a calculated creatinine clearance greater than 70 mL/min. Patients with cirrhosis of the liver, alanine aminotransferase levels greater than 3 times the upper limit of normal, severe neuropsychiatric disorders, or other significant medical conditions are excluded from the trial. The trial will test the efficacy of the drugs viramidine and peginterferon alfa-2b.",
    "The sample is a clinical trial with a phase 2 designation, focused on treating patients with HIV infections and hepatitis B. The trial involves the use of two drugs, adefovir dipivoxil and tenofovir disoproxil fumarate, and has specific eligibility criteria for participants. These criteria include being HIV and HBV infected, having a serum HBV DNA of 100,000 copies/ml or greater, and agreeing to use acceptable methods of contraception. The trial also has different inclusion and exclusion criteria for different populations within the study, such as those with compensated or decompensated liver disease. Exclusion criteria include serious kidney problems, allergies to certain drugs, and current use of certain medications. Pregnant or breastfeeding individuals are also excluded from the trial.",
    "The sample is a phase 2 trial for the treatment of skin structure infections and bacterial skin diseases caused by staphylococcal infections. The trial involves the use of two drugs, delafloxacin and tigecycline. The eligibility criteria for the trial include being an adult with a diagnosis of cSSSI, which can be a wound infection, abscess, or cellulitis. Patients must also be willing to comply with the protocol requirements and use contraception if sexually active. Exclusion criteria include a history of hypersensitivity to certain antibiotics, chronic skin conditions, and certain types of infections. Patients who have received more than 24 hours of systemic antibiotic therapy in the 7 days before enrollment are also excluded. Patients with severely compromised immune systems, liver disease, or severe renal impairment are also excluded. Pregnant or lactating women are also not eligible for the trial.",
    "The sample is a phase 2 clinical trial for patients with breast cancer that has spread to other parts of the body. The trial involves the use of two drugs, gemcitabine hydrochloride and paclitaxel albumin-stabilized nanoparticle formulation. The eligibility criteria include having confirmed breast cancer with evidence of metastasis, measurable disease, and no active brain metastasis. Patients must also meet certain health requirements, such as having a life expectancy of at least 12 weeks and no history of certain medical conditions. Prior treatments are allowed, but certain time frames must have passed since the last treatment. Patients cannot be participating in any other clinical trials during the study.",
    "The sample is a phase 2 clinical trial for the treatment of small cell lung carcinoma using the drug amuvatinib. The eligibility criteria include having confirmed SCLC, measurable SCLC per RECIST guideline, starting treatment with the same last regimen of first-line PE chemotherapy, ECOG performance status 0 to 2, adequate organ function, and a screening 12-lead ECG with a measurable QTc interval of less than 450 msec. Exclusion criteria include prior exposure to amuvatinib, ongoing toxicity from prior treatment, mixed SCLC and non-small cell lung cancer or large cell lung cancer, untreated, unstable, or symptomatic brain metastasis, hypersensitivity to amuvatinib or any agent given in association with the trial, and a life-threatening illness, medical condition, or organ system dysfunction that could compromise the subject's safety or interfere with study outcomes.",
    "The sample is a phase 2 clinical trial for metastatic breast cancer patients who have not responded to at least two forms of hormonal treatment. The trial is testing the effectiveness of gemcitabine hydrochloride as a treatment option. Eligibility criteria include measurable disease, no progression after three or more different forms of chemotherapy, and meeting at least one frailty characteristic. Patient characteristics include being female, 65 years or older, and having a life expectancy of greater than 12 weeks. Prior concurrent therapy is specified for biologic and endocrine therapy, and radiotherapy must have been at least 4 weeks prior to the trial. No concurrent participation in other investigational studies is allowed.",
    "The sample is a phase 2 clinical trial for patients with advanced unresectable or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma. The trial involves the use of three drugs - bay 43-9006, docetaxel, and cisplatin. The eligibility criteria include having measurable, histologically confirmed disease, an ECOG performance status of 0-1, and certain baseline laboratory values. Patients must also be able to take oral medication without crushing, dissolving, or chewing tablets. Exclusion criteria include prior radiotherapy, chemotherapy, or investigational therapies, brain metastases, and other uncontrolled intercurrent illnesses. The trial aims to evaluate the safety and efficacy of the drugs in treating the disease.",
    "The sample is a record of a clinical trial with a phase 2 designation. The trial is focused on cardiac surgery and cardiopulmonary bypass, with a list of associated ICD-10 codes. The trial involves two drugs, GIK and a control, and includes eligibility criteria for participants. Inclusion criteria include being between 18 and 70 years old, having a left ventricular ejection fraction of at least 30%, and signing an informed agreement. Exclusion criteria include previous cardiac surgery, emergent surgery, diabetes mellitus, severe renal or respiratory insufficiency, serious preoperative illness, pregnancy, history of drug abuse, bleeding diathesis or coagulopathy, enrollment in another clinical study, and lack of informed consent.",
    "The sample is a phase 2 clinical trial for rheumatoid arthritis. The trial includes subjects who are at least 18 years old and have a disease history of at least 12 months. The subjects must have active disease defined by DAS28 >3.2 and must have received previous treatment with rituximab and must be candidates for re-treatment with rituximab. Female subjects of childbearing potential must be willing to avoid pregnancy by using an adequate method of contraception. The trial has various exclusion criteria, including current neurological disease, inflammatory joint disease other than rheumatoid arthritis, and any contraindication to rituximab as per national label. The trial also excludes subjects who have participated in any interventional clinical trial within 1 month before SD1.",
    "The sample is a record of a clinical trial with a phase 2 designation. The trial is focused on the disease epilepsy, which is identified through a list of ICD-10 codes. The drug being studied is diazepam. The eligibility criteria for the trial include providing signed informed consent, being in good health with no significant abnormalities, and having a diagnosis of epilepsy. Exclusion criteria include receiving certain medications, using investigational drugs within the past 30 days, donating blood or plasma within the past 30 days, and being unwilling or unable to tolerate blood draws.",
    "The sample is a phase 2 clinical trial for patients with metastatic or recurrent endometrial carcinoma. The trial is testing the effectiveness of arsenic trioxide as a treatment option. The eligibility criteria include having documented progression of the cancer within the last 3 months, having at least one measurable lesion, having an ECOG performance status of \u2264 2, and having adequate renal, hepatic, and bone marrow function. Exclusion criteria include pregnancy or lactation, brain metastases, prior therapy with Trisenox or known sensitivity to this agent, and ongoing toxicity associated with prior anticancer therapy. Patients must also have a minimum life expectancy of 3 months and be able to understand and give written informed consent.",
    "The sample is a phase 2 clinical trial for the treatment of schizophrenia, negative symptoms, and cognitive dysfunction. The trial involves the drugs tc-5619 and placebo. The eligibility criteria include a diagnosis of schizophrenia, stable symptoms, and controlled medication use. Exclusion criteria include recent changes in medication, history of certain medical conditions, and pregnancy or lactation. Participants must also be willing to use accepted methods of birth control. The trial involves a screening process to ensure that participants meet the eligibility criteria.",
    "The sample is a phase 2 clinical trial for rheumatoid arthritis. The trial is looking at the effectiveness of drugs such as prednisolone, dipyridamole, prednisone, and z102. The eligibility criteria for the trial includes meeting the ACR/EULAR criteria for classification of RA, having moderate to severe RA, and having screening CRP levels of at least 0.6 mg/dl and a DAS28-CRP score \u22654.5. Patients must have been on a stable dose of conventional DMARD therapy for at least 90 days without dosage adjustment or modification and should be able to maintain the same dose of conventional DMARD therapy during study participation (with or without glucocorticoid therapy). There are also exclusion criteria, such as having active cardiovascular disease, taking aspirin for reasons other than for cardiovascular prophylaxis or their total daily dose is greater than 325 mg, and having uncontrolled diabetes mellitus as defined by a serum glucose >126 mg/dl. The use of any other medications or herbs used for the treatment of pain is prohibited, and patients with a history of or currently active tuberculosis as per specific country guidelines are excluded. All biologic agents are excluded for 90 days prior to Screening and throughout the study. The trial is also excluding patients who have undergone administration of rituximab or any B-cell depleting investigational drugs within 6 months of study initiation, have had a history of alcohol or drug abuse within the past 2 years, or have a history of hypersensitivity to glucocorticoids and/or dipyridamole.",
    "The sample is a phase 2 clinical trial for breast cancer patients who are at an elevated risk of developing the disease. The trial involves the use of the drug celecoxib and has eligibility criteria that include having at least one breast available for imagery and biopsy, being female and over 18 years old, having a Zubrod performance status of 0-1, and meeting certain medical requirements such as having normal liver and kidney function. Patients must also not have any known sensitivity to celecoxib or allergy to sulfonamides, and must not be pregnant or nursing. The trial has certain exclusions, such as patients who have had prior radiotherapy to the breast to be studied or who are currently participating in another clinical trial for cancer treatment or prevention.",
    "The sample is a phase 2 clinical trial for locally advanced or metastatic gastric cancer. The trial includes patients who have measurable or evaluable disease and have previously undergone adjuvant chemotherapy with Irinotecan, Oxaliplatin, and/or 5-FU based regimen. Patients must have a Karnofsky performance status of over 70%, be at least 18 years old, and have adequate liver, renal, and bone marrow function. The trial excludes patients with active infection, serious cardiac disease, CNS metastases, chronic diarrhea or partial bowel obstruction, malnutrition or significant weight loss, peripheral neuropathy, second primary malignancy (except for non-melanoma skin cancer and in situ cervical cancer), psychiatric illness, or pregnancy/lactation. Patients must be able to understand the nature of the study and provide written informed consent.",
    "The sample is a phase 2 clinical trial for patients with various types of squamous cell carcinoma of the head and neck. The trial is testing the effectiveness of the drug sunitinib malate. The eligibility criteria include having measurable disease, no known brain metastases, and a life expectancy of at least 2 months. Patients must also meet certain health requirements, such as having normal blood counts and kidney function. They cannot have certain medical conditions or be taking certain medications. The trial does not allow concurrent use of other anticancer agents or therapies.",
    "The sample is a phase 2 trial for the treatment of moderate to severe allergic rhinoconjunctivitis to birch pollen. The trial involves testing the efficacy of three drugs - placebo, allert low dose, and allert full dose. The eligibility criteria for the trial include having a score of symptoms of the Rhinoconjunctivitis Symptom Score (RSS) \u2265 12 during the two preceding birch pollen seasons, previous use of anti-allergy medications during the two preceding birch pollen seasons, a positive SPT to birch pollen extract, and a positive specific IgE CAP test for Bet v 1. The exclusion criteria include uncontrolled asthma, previous SIT to birch pollen or any other SIT within 5 years, clinical symptoms due to allergens other than birch pollen during the whole trial period, history of anaphylaxis, positive skin prick test to AllerT, and any other treatment or conditions which may increase the risk of the study for the subject or affect the efficacy assessments during the birch pollen season.",
    "The sample is a phase 2 clinical trial for advanced breast cancer patients who are not eligible for surgery or radiation of curative intent. The trial involves the use of four drugs - pemetrexed, carboplatin, gemcitabine, and vinorelbine. The eligibility criteria include having a performance status of 0 to 2 on the Eastern Cooperative Oncology Group (ECOG) performance status scale, having received one prior chemotherapy containing anthracyclines and taxanes as (neo)adjuvant or palliative 1st-line treatment, having at least one uni-dimensionally measurable lesion meeting Response Evaluation Criteria in Solid Tumors (RECIST) criteria, and having an estimated life expectancy of at least 3 months. The exclusion criteria include having received treatment within the last 30 days with a drug that has not received regulatory approval for any indication at the time of study entry, having previously completed or withdrawn from this study or any other study investigating Pemetrexed, Gemcitabine, Carboplatin or Vinorelbine, having received more than one line of chemotherapy in Metastatic Breast Cancer, being pregnant or breast-feeding, having serious concomitant systemic disorders, having a prior malignancy other than breast cancer, carcinoma in situ of the cervix, or nonmelanoma skin cancer, unless that prior malignancy was diagnosed and definitively treated at least 5 years previously with no subsequent evidence of recurrence, having central nervous system (CNS) metastases, having clinically relevant third-space fluid collections, being unable or unwilling to take folic acid, vitamin B12 supplementation, or dexamethasone, and concurrent administration of any other antitumor therapy.",
    "The sample is a phase 2 clinical trial for allergic rhinitis. The trial includes males and females aged 18 to 50 years with a history of symptoms of grass pollen related allergic rhinitis within the previous two years. Females of childbearing potential must practice two forms of contraception and have a negative pregnancy test at screening. The trial involves the use of drugs, including oc000459 and placebo. The eligibility criteria include medical conditions likely to affect the outcome of the study, nasal conditions likely to affect the outcome of the study, and the presence of any respiratory disease other than a history of mild stable asthma not requiring treatment and associated with normal lung function. The exclusion criteria include immunotherapy treatment course in the past 28 days and use of inhaled or local corticosteroids in the past 28 days.",
    "The sample is a phase 2 clinical trial for the treatment of advanced or metastatic breast cancer using the drug pemetrexed. The trial includes patients who have not received chemotherapy for advanced or metastatic breast cancer and have been diagnosed at least 12 months after chemotherapy was given after breast surgery. The trial has inclusion and exclusion criteria, including age, ability to carry out light work, and not having received prior bone marrow or peripheral stem cell transplantation or chemotherapy for metastatic breast cancer. Patients who are pregnant or breastfeeding, have an active infection that may affect their safety, or are unable to take folic acid or vitamin B12 are excluded from the trial. The diseases and their corresponding ICD-10 codes are also listed.",
    "The sample is a clinical trial for renal transplantation, in phase 2/phase 3. The trial is testing the effectiveness of the drug fluvastatin in combination with immunosuppression (Tacrolimus and steroids or Mycophenolat Mofetil) for patients aged 18-65 who have undergone cadaver or living kidney transplantation. The trial has specific inclusion criteria, such as LDL-cholesterol levels and a history of myocardial infarction, and exclusion criteria, such as previous use of statins and elevated liver enzymes. The trial aims to determine the safety and efficacy of the drug in this patient population.",
    "The sample is a phase 2 clinical trial for the treatment of dry eye, Sjogren's syndrome, and graft vs. host disease. The trial involves the use of thymosin beta 4 eye drops and a vehicle control. The eligibility criteria for the trial include having Schirmers of less than 5 mm at 5 minutes, TFBUT of less than 10 seconds, corneal staining of more than 3 out of 15, conjunctival staining of more than 3 out of 18, an Ocular Surface Disease Index of more than 50, and a presumed best corrected vision of 20/60 or better. Exclusion criteria include acute or inflammatory corneal disease, pregnancy or lactation, monocular status, punctal occlusion within 30 days, ocular surgery within 3 months, corneal thinning of more than 50%, active corneal infection, history of ocular malignancy, retinal neovascularization, and current use of topical cyclosporin A. The icd-10 codes for the diseases being treated are also provided.",
    "The sample is a phase 2 trial for contraception. The eligibility criteria include being in a stable, mutually monogamous relationship for at least three months, willing to have coital frequency of at least four times per month on average while in the study, not actively desiring pregnancy, and planning to reside in the area for 30 weeks after enrollment. Participants must agree to use the study product as instructed at each act of intercourse during the next 30 weeks and to use no other method of contraception except for emergency contraception or a barrier method from pre-enrollment until the start of the first post-enrollment menses. They must also be willing and able to comply with study procedures and not have a known sensitivity or allergy to any vaginal preparations containing glycerin, sorbitol, carbomer, or benzyl alcohol. Participants must not be known or suspected to be infected by HIV and are at low risk for HIV and other STIs. They must not have any other conditions that would constitute contraindications to participation in the study, would complicate interpretation of data from the participant, or would compromise the participant's ability to comply with the study protocol. Female participants must be between 18 and 40 years of age, have regular menstrual cycles, and not be currently breastfeeding. They must also have no Trichomonas on wet prep and no absolute medical contraindication to pregnancy. Male participants must be at least 18 years of age and have no known history of infertility or vasectomy. They must not have had sex with a man in the last six months.",
    "The sample is a record of a clinical trial with a phase 2 designation. The trial is focused on the disease asthma and includes a list of ICD-10 codes associated with the disease. The trial involves two drugs, budesonide and placebo. The eligibility criteria for the trial includes having a documented clinical diagnosis of asthma for at least 6 months prior to the trial, requiring daily inhaled corticosteroid or LTRA as monotherapy for at least 30 days prior to the trial, and meeting certain FEV1 measurements. The exclusion criteria includes recent hospitalization or emergency treatment for asthma-related conditions and recent treatment with systemic corticosteroids.",
    "The sample is a phase 2 clinical trial for the treatment of hypercholesterolemia and dyslipidemia. The trial involves the use of statin drugs, specifically atorvastatin, rosuvastatin, and simvastatin. The eligibility criteria for the trial include having stable daily doses of these drugs and meeting certain lipid criteria. The exclusion criteria include a history of cardiovascular or cerebrovascular events, poorly controlled diabetes mellitus, and poorly controlled hypertension.",
    "The sample is a phase 2 clinical trial for breast cancer patients who are HER2/neu positive and have evidence of metastatic disease. The trial includes patients who have measurable disease by RECIST and an ECOG \u2264 2, and have completed all therapy for brain metastases if present. Patients must have a baseline LVEF value within the institutional normal range and have progressed on hormonal therapy. Prior chemotherapy in the adjuvant setting and up to one prior chemotherapy regimen for metastatic disease is allowed. Patients may have received one prior trastuzumab/chemotherapy containing regimen or prior single agent trastuzumab. Prior radiation therapy in the adjuvant setting or for metastatic disease is allowed, provided it was not to the only site of evaluable disease. All prior chemotherapy, trastuzumab and radiation therapy should be completed > 2 weeks before enrollment. Patients receiving bisphosphonate therapy are eligible. However, if bisphosphonate were started within < 2 months prior to enrollment, the bone lesions will not be evaluated for response and the patient must have another site of metastatic disease that is either measurable or evaluable for response. Patients must have recovered from toxicities due to prior therapy. Lab values must be in accordance with the protocol. Patients must be nonpregnant and nonlactating. Patients of childbearing potential must implement an effective method of contraception during the study (birth control pills are not allowed). Bone only disease patients are ineligible. Patients who received more than 1 prior chemotherapy regimen for metastatic disease are ineligible. Patients with a history of other cancers except curatively-treated carcinoma of the cervix in situ or non-melanomatous skin cancer, active serious infection or other underlying medical condition that would impair their ability to receive protocol treatment, uncontrolled nervous system metastases, dementia or significantly altered mental status that would interfere with proper consenting, and receiving other investigational therapy are also ineligible.",
    "The sample is a phase 2 clinical trial for patients with untreated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who are 65 years or older and have an Eastern Cooperative Oncology Group (ECOG)/World Health Organization (WHO) performance status of 0-2. The trial involves the drug lenalidomide and has a list of eligibility criteria that patients must meet to participate. The table also includes information on the diseases being studied, their corresponding ICD-10 codes, and the phase of the trial.",
    "The sample is a phase 2 clinical trial for patients with advanced colorectal carcinoma that has metastasized to the liver and/or lungs. The trial is testing the effectiveness of intensified chemotherapy (folfoxiri/bevacizumab). The eligibility criteria include being over 18 years old, having confirmed advanced colorectal carcinoma, having measurable disease according to RECIST criteria, having an ECOG performance status of less than 2, and having a life expectancy of more than 3 months. Exclusion criteria include having a history of malignancies other than colorectal carcinoma, previous chemotherapy (except adjuvant chemotherapy), and serious cardiovascular disease. The sample also includes a list of diseases, icd-10 codes, drugs, and eligibility criteria.",
    "The sample is a phase 2 clinical trial for patients with advanced cutaneous t-cell lymphoma (CTCL). The trial is testing the drug sapacitabine. In order to be eligible for the trial, patients must have had at least 2 systemic therapies, have evaluable disease, and have an Eastern Cooperative Oncology Group performance status of 0-2. They must also have adequate bone marrow, hepatic and renal function, and be at least 3 weeks from prior therapies. Patients cannot be receiving systemic steroids, topical or systemic retinoids or vitamin A, radiotherapy, biological therapy, or any other investigational agents. They must not have uncontrolled intercurrent illness, be pregnant or lactating, or be known to be HIV-positive. Patients must also agree to practice effective contraception and be able to understand and sign the informed consent form.",
    "The sample is a phase 2 trial for chronic obstructive pulmonary disease (COPD). The trial includes patients between the ages of 40 and 80 who have a clinical history of COPD with airflow limitation that is not fully reversible. The trial also requires patients to have a measured post-bronchodilator FEV1/FVC ratio of less than or equal to 0.70 and a measured post-bronchodilator FEV1 of at least 750ml or 30% predicted and less than or equal to 80% of predicted normal values. Patients must be able to change COPD treatment as required by the protocol and have an acceptable baseline Holter monitor recording. The trial excludes women who are pregnant or lactating, patients with a primary diagnosis of asthma, and those with alpha-1 antitrypsin deficiency as the cause of COPD. Other exclusion criteria include active pulmonary diseases, prior lung volume reduction surgery, abnormal chest X-ray or CT scan not due to the presence of COPD, and hospitalization due to poorly controlled COPD within 3 months of screening. Patients with clinically significant medical conditions that preclude participation in the study, cancer that has not been in complete remission for at least 5 years, and those who have been treated with an investigational study drug or participated in another clinical trial or study within the last 30 days or 5 half lives are also excluded. The trial also excludes patients with clinically significant abnormal findings during the baseline Holter recording and those with a pacemaker or ICD/CRT/CRT_D devices.",
    "The sample is a phase 2 clinical trial for the treatment of ocular hypertension and open angle glaucoma. The trial involves testing the efficacy of three different drugs, including ar-13324 ophthalmic solution 0.01%, ar-13324 ophthalmic solution 0.02%, and latanoprost ophthalmic solution 0.005%. The eligibility criteria for the trial include being 18 years or older, having a diagnosis of OAG or OHT, having unmedicated IOP levels of at least 24 mm Hg at two eligibility visits, having corrected visual acuity of +1.0 logMAR or better in each eye, and being able and willing to give informed consent and follow study instructions. The exclusion criteria include having a history of certain types of glaucoma, having IOP levels above 36 mm Hg, having a known hypersensitivity to any component of the formulation, having had previous glaucoma intraocular surgery or laser procedures in the study eye(s), and having clinically significant ocular disease or abnormalities preventing reliable applanation tonometry of either eye. The trial also has exclusion criteria related to systemic diseases and medication use, and women of childbearing potential must have a negative urine pregnancy test result at the screening examination and must not intend to become pregnant during the study.",
    "The sample is a record of a clinical trial with a phase 2 designation. The trial is focused on the disease of kidney transplantation, with a list of associated ICD-10 codes. The trial involves the use of drugs, including cp-690,550 and tacrolimus. The eligibility criteria for the trial include being a first-time kidney transplant recipient between the ages of 18 and 70. The exclusion criteria include having received a non-kidney transplant.",
    "The sample is a phase 2 clinical trial for patients in Japan with type 2 diabetes mellitus. The trial is testing the effectiveness of different doses of a drug called bi 1356 bs compared to a placebo. The eligibility criteria for the trial include having a diagnosis of type 2 diabetes mellitus and being treated with diet and/or exercise or one or two oral hypoglycemic agents except glitazones. Patients must also have a glycosylated hemoglobin A1c (HbA1c) level of 8.5% or lower at screening. Exclusion criteria include having any medical findings that deviate from normal, clinically relevant concomitant diseases, and a history of relevant allergy/hypersensitivity. Patients must also not have participated in another trial with an investigational drug within two months before drug administration and must not have a serum creatinine above 1.3 mg/dL at screening. Additionally, patients who are pregnant or have child-bearing potential must be willing to use adequate contraception during the study period.",
    "The sample is a record of a clinical trial with a phase 2/phase 3 designation. The trial is focused on chronic myeloid leukemia, specifically the Philadelphia chromosome positive accelerated or blast phase. The drug being tested is panobinostat. The eligibility criteria for the trial includes patients who are at least 18 years old, have been diagnosed with the specified type of leukemia, and have demonstrated resistance to at least two BCR-ABL tyrosine kinase inhibitors. Patients must also meet certain laboratory value requirements and not have certain exclusion criteria, such as being a candidate for hematopoietic stem cell transplantation or having impaired cardiac function. The sample also includes a detailed list of inclusion and exclusion criteria for the trial.",
    "The sample is a record of a clinical trial in phase 2 for the treatment of renal cell carcinoma. The trial involves the drug sunitinib malate and the eligibility criteria includes having advanced kidney cancer, while previous treatment for kidney cancer, except surgical removal of kidney tumor, is listed as an exclusion criteria. The icd-10 codes associated with the disease are also provided.",
    "The sample is a phase 2 clinical trial for the treatment of schizophrenia. The trial is looking for male and female participants between the ages of 18 and 65 who have been diagnosed with paranoid, residual, or undifferentiated schizophrenia according to the DSM-IV-TR criteria. The participants must be clinically stable, with no hospitalizations for acute exacerbations within 3 months of screening and a screening total Positive and Negative Syndrome Scale (PANSS) score of less than 60. The trial is testing the effectiveness of the drugs risperidone and rbp-7000. The eligibility criteria include exclusion of subjects taking any risperidone sustained release formulation within the 60 days prior to study screening, and exclusion of subjects taking certain concurrent medication/over-the-counter products. The trial also excludes subjects with a history of cancer, active medical conditions or organ disease, significant hepatic disorder, renal disease, or a diagnosis of type 1 or 2 diabetes. Additionally, subjects with suicidal ideation with intent and plan, or uncontrolled depression are excluded. The trial requires written informed consent from the participants.",
    "The sample is a clinical trial that is in phase 2/phase 3 and is focused on the disease of hyperlipidemia. The icd-10 codes associated with this disease are E78.2, E78.49, and E78.5. The drug being tested is simvastatin 20 mg/ezetimibe. The eligibility criteria for the trial include being moderately obese with hyperlipidemia, while exclusion criteria include recent unstable heart or lung conditions, current use of other lipid modifying drugs, hepatic disease, and pregnancy or lactation.",
    "The sample is a record of a clinical trial with a phase 2/phase 3 designation. The trial is focused on the disease of migraine and includes a list of ICD-10 codes associated with the disease. The trial involves the use of two drugs, telcagepant and placebo. The eligibility criteria for participants include having regular menstrual cycles, experiencing headaches during menstrual periods, having a history of migraine with at least two attacks per month, and agreeing to use birth control during the study. Exclusion criteria include having certain types of migraine, taking medication for acute headache too frequently, having certain medical conditions, and consuming excessive amounts of alcohol.",
    "The sample is a phase 2 clinical trial for patients with active rheumatoid arthritis. The trial includes patients between the ages of 18 and 80 who have at least 6 swollen and 6 tender joints, and meet certain criteria such as having a C-reactive protein level above 1.0 mg/dl or an erythrocyte sedimentation rate above 28 mm/Hr. Patients must have been taking methotrexate for at least 3 months and at a stable dose for at least 6 weeks. Patients must also be either Rheumatoid Factor (RF) or anti-cyclic citrullinated peptide (anti-CCP) positive and have voluntarily signed the informed consent. Exclusion criteria include previous therapy with any biologic agent, current use of any disease modifying anti-rheumatic drug (DMARD) other than methotrexate, and various medical conditions such as active infections or unstable cardiac or pulmonary diseases.",
    "The sample is a phase 2 clinical trial for the treatment of glioblastoma multiforme, a type of brain cancer. The trial involves the use of two drugs, poly iclc and temozolomide. The eligibility criteria for patients include having a confirmed diagnosis of grade IV astrocytoma within the past 3 months, a Karnofsky performance status of at least 60%, and meeting certain laboratory values for blood counts, bilirubin, transaminases, and creatinine. Patients must also not be pregnant or breastfeeding, have a negative pregnancy test, and agree to use acceptable birth control methods. Patients with a concurrent or prior malignancy are ineligible unless they have been free of disease for at least five years. Patients must not have received prior radiation therapy, chemotherapy, immunotherapy, or hormonal therapy for their brain tumor. Prior glucocorticoid therapy is allowed. Patients must be willing to forego other cytotoxic and non-cytotoxic drug therapy against the tumor while being treated with poly ICLC plus temozolomide on this protocol. No other concurrent therapy for their tumor is allowed. Patients who have received prior Gliadel wafers are not eligible for this study. No concurrent prophylactic filgrastim (G-CSF) or electron, particle, implant, or stereotactic radiosurgery boost is allowed.",
    "The sample is a phase 2 clinical trial for the treatment of chronic hepatitis C. The trial is looking for 10 male and female subjects between the ages of 18 and 65 with a body mass index between 18 and 36 kg/m2. The subjects must have been diagnosed with chronic hepatitis C at least 6 months prior to the trial and have a positive HCV viral load of at least 50,000 IU/mL at screening. They must also be treatment-na\u00efve, meaning they have not received prior treatment with IFN alfa 2a or 2b, Pegylated IFN alfa-2a, Ribavirin, or any HCV direct-acting anti-viral drugs. The trial is looking for subjects with chronic genotype 2 or 3 HCV infection and a liver biopsy consistent with chronic HCV infection but with a classification of non-cirrhotic. The trial has a list of exclusion criteria, including signs or symptoms of decompensated liver disease, chronic liver disease other than HCV, and co-infection with HIV. The trial is also looking for subjects who are willing and able to complete all study visits and procedures and able to effectively communicate with the investigator and other testing center personnel.",
    "The sample is a phase 2 clinical trial for the treatment of small cell lung cancer using the drugs pemetrexed and cisplatin. The eligibility criteria include having a histologic or cytologic diagnosis of SCLC, being at functional stage 0-2 on the ECOG functional scale, having no previous systemic chemotherapy, immunotherapy or biologic therapy for SCLC, and having at least one measurable lesion that complies with the solid tumor response evaluation criteria. Patients must also have appropriate organic function, a life expectancy of at least 12 weeks, and be compliant and located close to the trial area for appropriate follow-up. Exclusion criteria include having received treatment for the last 30 days with a drug that has not obtained regulatory approval, having participated in a previous pemetrexed trial, having a mixed histologic diagnosis of SCLC and NSCLC, and having concurrent illness or an active infection.",
    "The sample is a phase 2 clinical trial for the treatment of type 2 diabetes mellitus. The trial involves testing the effectiveness of a drug called LX4211 in combination with metformin monotherapy. The trial has specific inclusion and exclusion criteria, including age range, laboratory values, and medical history. Participants must also be willing to maintain consistent lifestyle habits throughout the study. The trial excludes individuals with certain medical conditions or who have used certain medications within a certain timeframe. Women who are pregnant or breastfeeding are also excluded. The sample provides a detailed list of the inclusion and exclusion criteria for the trial.",
    "This sample is for a phase 2 clinical trial for patients with inoperable locally advanced or metastatic colorectal carcinoma. The trial is testing the effectiveness of the drug Velcade TM (bortezomib) for injection, or PS-341. The eligibility criteria include having measurable disease, not being a candidate for immediate curative resection, having received no more than 2 prior treatment regimens for metastatic disease (one of which must have contained irinotecan), and having relapsed or progressed while receiving an irinotecan-containing regimen. Patients must also have a KPS of 70% or greater, a life expectancy greater than 3 months, and be 18 years of age or older. The trial also has exclusion criteria, such as having greater than or equal to Grade 2 neuropathy, having previously received treatment with Velcade, and having inadequate organ function at baseline. Patients must give voluntary written informed consent before participating in the trial.",
    "The sample is a record of a clinical trial in phase 2, focused on coronary artery disease. The trial involves the use of three drugs named ono-1101. The eligibility criteria for the trial include being 20 years or older, having a heart rate between 70 and 90 beats per minute upon entering the CT room. The exclusion criteria include having a history of allergic reactions to contrast agents, renal failure, asthma, and taking beta-receptor blocking agents. The icd-10 codes associated with the disease are also provided.",
    "The sample is a phase 2 clinical trial for patients with metastatic breast cancer. The trial involves the use of the drugs docetaxel and capecitabine. The eligibility criteria include having measurable or evaluable disease, an ECOG score of 0-1, and adequate organ function. Patients may have received up to two prior treatments for metastatic breast cancer. Exclusion criteria include having other malignancies, severe psychiatric illness or co-morbid medical conditions, and a history of severe hypersensitivity reaction to the drugs being used. Patients must also be at least 19 years old and willing to practice reliable contraception during the study if sexually active.",
    "The sample is a phase 2 clinical trial for pre-menopausal females aged 20 to 49 with uterine fibroids and heavy uterine bleeding. The trial involves the use of drugs such as elagolix, placebo, estradiol/norethindrone acetate (e2/neta), estradiol, and progesterone. The eligibility criteria include having a diagnosis of uterine fibroids, regular menstrual cycles, and heavy uterine bleeding. Exclusion criteria include a history of myomectomy, uterine artery embolization, or high intensity focused ultrasound for fibroid destruction within 1 year prior to randomization, as well as other medical conditions such as osteoporosis, epilepsy, and cancer.",
    "The sample is a phase 2 clinical trial for patients with solid tumors who are chemotherapy-na\u00efve and planned to receive cisplatin-based single day chemotherapy. The trial is testing the effectiveness of a combination of drugs including ramosetron, aprepitant, and dexamethasone in preventing nausea and vomiting caused by chemotherapy. The eligibility criteria include being between 18-75 years old, having an ECOG performance status of 0-2, and having no nausea or vomiting within 72 hours prior to chemotherapy. Patients must also meet certain medical criteria such as having a serum creatinine level below 2.5 mg/dl and an absolute neutrophil count of at least 1,500/\u03bcL. Exclusion criteria include having active infections, severe heart disease, or being pregnant or breastfeeding. Patients must also sign an informed consent indicating that they are aware of the investigational nature of the study.",
    "The sample is a record of a clinical trial with a phase 2 designation, focused on prostate cancer. The trial includes a list of ICD-10 codes for the disease, as well as a single drug, trabectedin. The eligibility criteria for the trial include a confirmed diagnosis of adenocarcinoma of the prostate, documented metastatic disease, and a prostate-specific antigen level of 5 ng/ml or higher. Participants must also have an Eastern Cooperative Oncology Group performance status of 0, 1, or 2, and be experiencing androgen-independent disease. Exclusion criteria include recent chemotherapy or radiation therapy, inadequate contraception, and other serious medical conditions such as uncontrolled congestive heart failure or chronic liver disease.",
    "The sample is a phase 2 clinical trial for patients with mantle cell lymphoma. The trial is testing the effectiveness of gemcitabine hydrochloride as a treatment option. Patients must meet certain eligibility criteria, including having measurable disease and meeting specific hematopoietic, hepatic, renal, cardiovascular, and immunologic requirements. Patients must also not have any other uncontrolled medical conditions that would prevent them from participating in the study. Prior concurrent therapies are also taken into consideration. The sample includes a detailed list of eligibility criteria and prior concurrent therapies.",
    "The sample is a clinical trial that is in phase 2/phase 3 and is focused on the treatment of type 2 diabetes. The trial involves the use of the drugs dapagliflozin and placebo. The eligibility criteria for the trial include being male or female, over 18 years old, and having inadequate glycemic control with a clinical diagnosis of moderate renal impairment. The exclusion criteria include having AST and/or ALT levels greater than 3.0 times the upper limit of normal, serum total bilirubin levels greater than 1.5 times ULN, symptoms of severely uncontrolled diabetes, and currently having unstable or serious cardiovascular, hepatic, hematological, oncological, endocrine, psychiatric, or rheumatic diseases. The diseases being studied are limited to diabetes mellitus, type 2 and are identified by a list of ICD-10 codes.",
    "The sample is a record from a clinical trial table that includes information about the trial's phase, diseases being studied, icd-10 codes associated with those diseases, drugs being tested, and eligibility criteria for participants. In this particular sample, the trial is in phase 2 and is studying chronic abacterial prostatitis and chronic pelvic pain syndrome. The icd-10 codes associated with these diseases are listed. The trial is testing a drug called asp3652 and a placebo. The eligibility criteria for participants are also listed, including requirements such as having symptoms for at least 3 months, having a certain score on a symptom assessment, and being willing to comply with study requirements. There are also exclusion criteria listed, such as having certain medical conditions or taking certain medications.",
    "The sample is a record of a clinical trial in phase 2 for the treatment of multiple myeloma. The trial involves the drug zoledronic acid and the eligibility criteria include a diagnosis of asymptomatic multiple myeloma, the presence of bone marrow clonal plasma cells, and the absence of certain symptoms and conditions. The exclusion criteria include no previous treatment with bisphosphonates and no current breastfeeding. The record also includes the icd-10 codes for the disease and the inclusion and exclusion criteria for the trial.",
    "The sample is a phase 2 clinical trial for kidney cancer. The trial includes patients with confirmed renal cell carcinoma with metastasis and measurable disease. Patients must not have received prior cytokine, chemotherapy, hormonal, or other immuno-based therapies for their renal cancer, including vaccines or cellular-based therapies. Bisphosphonates are also not allowed, but one prior experimental therapy is permitted as long as more than 4 weeks have passed since the last drug administration. Patients must have an ECOG performance status of 0 or 1 and adequate cardiac function by history. The trial includes both inclusion and exclusion criteria, such as no radiotherapy within 4 weeks prior to entering the study, no known brain metastases, and no history of seizures. Pregnant women and patients on systemic steroids (oral or IV) are also excluded from the study.",
    "The sample is a phase 2 clinical trial that focuses on the treatment of schizophrenia, memory disorders, and cognition disorders. The trial involves the use of two drugs, atomoxetine and placebo. The eligibility criteria for the trial include prior participation in a specific NIH protocol, no active Axis I or Axis II diagnosis in normal volunteers, age range of 18-45 years, and normal EKG and blood pressure readings. Exclusion criteria include subjects with a history of cardiovascular disease, liver disease, and other serious medical illnesses, and untreated or uncontrolled hypertension. Schizophrenic patients taking certain medications or illicit drugs of abuse will also be excluded. Pregnant women and normal controls on contraceptive medication will also be excluded from the study.",
    "The sample is a phase 2 clinical trial for asthma. The trial is looking for participants who are non-smokers or ex-smokers for at least a year, between the ages of 18 and 60, with a body mass index between 18 and 32 kg/m2, and have mild to moderate allergic asthma. Participants must also be able to be trained on the proper use of an inhalation device and perform spirometry. They must have atopy to at least one common aeroallergen and produce an adequate sputum sample. Women must be post-menopausal, of not childbearing potential, or willing to use a reliable method of contraception. The trial has exclusion criteria, including a history of life-threatening asthma or hospitalization for asthma, pregnancy or lactation, and use of certain medications. Participants must not have any other lung disease or recent history of alcohol dependency and must be able to comply with the study protocol.",
    "The sample is a clinical trial for the treatment of hepatitis C, with a combination of drugs including algeron, pegintron, and ribavirin. The trial is in phase 2/phase 3 and includes patients with confirmed hepatitis C virus infection (genotypes 1a, 1b, 2, 3, 4) and increased ALT levels. The eligibility criteria include age between 18 and 70, BMI between 18 and 30, preserved liver function, and no signs of hepatic encephalopathy or abdominal fluid retention. Exclusion criteria include intolerance to the drugs, infection by hepatitis B virus or HIV, past history of HCV treatment with IFN alfa or pegylated IFN alfa formulations, and various other medical conditions. Patients must agree to use barrier contraception throughout the study and 7 months after its completion.",
    "The sample is a phase 2 clinical trial for the treatment of type 2 diabetes mellitus. The trial involves the use of colesevelam hydrochloride and a placebo. The eligibility criteria for participants include being between the ages of 18 and 75, having a diagnosis of type 2 diabetes mellitus for at least 3 months, having an HbA1C level between 7.0 and 10.0%, and having a BMI between 25 and 45 kg/M sq. Women who are not pregnant, not breastfeeding, and not planning to become pregnant during the trial may also participate if they meet certain criteria for birth control. Exclusion criteria include having type 1 diabetes mellitus, a history of diabetic ketoacidosis, and certain medical conditions or therapies that may pose a risk to the participant.",
    "This is a sample of a clinical trial for the treatment of moderate-to-severe chronic plaque-type psoriasis. The trial is in phase 2 and the drugs being tested are cf101 1mg, cf101 2mg, cf101 4mg, and placebo. The eligibility criteria include being 18 to 70 years old, having a diagnosis of psoriasis with body surface area involvement of at least 10%, having a PASI score of at least 10, and being a candidate for systemic treatment or phototherapy for psoriasis. Exclusion criteria include having certain types of psoriasis, recent treatment with certain medications, and having certain medical conditions. The trial aims to evaluate the safety and efficacy of the drugs being tested.",
    "The sample is a phase 2 clinical trial for atopic dermatitis. The trial includes patients who are 18 years or older and have had chronic AD for at least 2 years. The trial excludes patients who have had prior treatment with Dupilumab, hypersensitivity to corticosteroids or any other ingredients contained by the TCS product used in the study, AD lesions located on face, flexural, and genital areas, certain treatments and medical procedures undertaken within a particular time frame prior to the baseline visit, treatment with a live (attenuated) vaccine within 12 weeks before the baseline visit, treatment with an investigational drug within 8 weeks, known history of human immunodeficiency virus (HIV) infection, presence of certain laboratory abnormalities at the screening visit, history of certain opportunistic infections or certain clinical parasite infections, history of malignancy within 5 years before the baseline visit (with certain exceptions), pregnant or breastfeeding women, travel within 12 months of study start to areas endemic for parasitic infections, such as developing countries in Africa and the tropical and subtropical regions of Asia, history of alcohol or drug abuse within 2 years of the screening visit, and any medical or psychiatric condition which, in the opinion of the investigator or the sponsor's medical monitor, would place the patient at risk, interfere with participation in the study, or interfere with the interpretation of study results. The drugs being tested are Dupilumab and placebo (for Dupilumab).",
    "The sample is a phase 2 clinical trial for the treatment of diabetic nephropathy. The trial is testing the drug rta 402 (bardoxolone methyl). The eligibility criteria for the trial include having a diagnosis of type 2 diabetes, a certain level of serum creatinine, and agreeing to practice effective contraception. Exclusion criteria include having type 1 diabetes, known non-diabetic renal disease, and certain cardiovascular diseases. Patients must also be willing and able to cooperate with all aspects of the protocol and provide written informed consent to participate in the trial.",
    "The sample is a phase 2 clinical trial for the treatment of rheumatoid arthritis. The trial involves the use of two drugs, peficitinib and placebo, and has specific eligibility criteria for participants. Inclusion criteria include having a diagnosis of rheumatoid arthritis for at least 6 months, having a certain number of tender/painful and swollen joints, and meeting certain classification criteria. Exclusion criteria include having a positive tuberculosis test, a history of certain illnesses or infections, and previous intolerance to Janus kinase inhibitors. The trial also has washout criteria for certain rheumatoid arthritis medications and restrictions on the use of certain medications during the trial.",
    "The sample is a phase 2 clinical trial for patients with metastatic adenocarcinoma of the lung. The trial involves the use of two drugs, cyclophosphamide and all-trans retinoic acid (atra). The eligibility criteria include having a confirmed diagnosis of the disease, a good performance status, no recent radiation or chemotherapy, and adequate organ function. Patients must have completed first-line chemotherapy and have measurable metastatic tumors. Exclusion criteria include brain metastasis, acute medical problems, immunodeficiency conditions, and pregnancy or lactation. The trial aims to evaluate the safety and efficacy of the treatment regimen.",
    "The sample is a record from a clinical trial table that includes information about the trial's phase, diseases being studied, associated ICD-10 codes, drugs being tested, and eligibility criteria for participants. In this particular sample, the trial is in phase 2 and is focused on studying irritable bowel syndrome. The ICD-10 codes associated with the disease are listed, as well as the drugs being tested (itopride hci 50 mg, itopride hci 100 mg, and placebo). The eligibility criteria for participants are also listed, including inclusion criteria such as meeting the Rome III criteria for IBS-C and signing informed consent, and exclusion criteria such as having significant diarrhea, alarm symptoms or signs, chronic diarrhea, and various health conditions that could interfere with the study objectives.",
    "The sample is a phase 2 clinical trial for the treatment of rheumatoid arthritis. The trial involves the use of the drugs ly3009104, placebo, and methotrexate. The eligibility criteria include having active RA, regularly using methotrexate for at least 12 weeks before the study, having a certain level of C-reactive protein or Erythrocyte Sedimentation Rate, and meeting other medical and demographic requirements. The exclusion criteria include having received certain types of medication or treatment within a certain timeframe, having certain medical conditions or abnormal laboratory values, and being enrolled in other medical research.",
    "The sample is a phase 2 clinical trial for breast cancer patients. The trial requires patients to have histologically confirmed breast cancer and meet certain stage criteria. Patients must also have HER2/neu-positive disease by fluorescence in situ hybridization and a biopsy-accessible tumor. The trial involves the use of carboplatin and docetaxel drugs. Eligibility criteria include age 18 and over, female sex, ECOG 0-2 performance status, and a life expectancy of at least 8 weeks. Patients must also meet certain hematopoietic, hepatic, renal, cardiovascular, pulmonary, gastrointestinal, and neurologic criteria. They must not be pregnant or nursing, have no active infection, and have no other malignancy except adequately treated basal cell or squamous cell skin cancer or carcinoma in situ of the cervix. Patients must not have any other pre-existing clinically significant disease that is not related to the malignancy and no other serious or significant medical condition that would preclude study participation. Prior concurrent therapy is not allowed, including no prior chemotherapy for the malignancy, no concurrent hormonal therapy for the malignancy, no concurrent radiotherapy, and no concurrent surgery for the malignancy. Patients must also not be taking any other concurrent investigational or commercial agents or therapies for the malignancy.",
    "The sample is a record of a clinical trial with a phase 2 designation. The trial is focused on the disease asthma, with a list of associated ICD-10 codes. The trial involves the use of two drugs, cnto148 and placebo. The eligibility criteria for participants include having a physician diagnosis of severe persistent asthma for at least one year prior to screening, continuous treatment with high dose inhaled corticosteroids and long-acting beta-agonists for at least three months prior to screening, and evidence of reversible airway obstruction or diurnal variation in peak expiratory flow rate. Participants must also have experienced symptoms on more than one-third of days for at least three months prior to screening and have a score of two or higher on the asthma control questionnaire. Exclusion criteria include a diagnosis of chronic obstructive pulmonary disease or other significant respiratory disorder, recent worsening of asthma symptoms, and a history of congestive heart failure.",
    "The sample is a phase 2 clinical trial for the treatment of female sexual arousal disorder. The trial includes pre-menopausal women aged 18-45 who have been diagnosed with FSAD for at least 6 months. The trial will test the effectiveness of sildenafil 100 mg and placebo as treatments. The inclusion criteria require that the FSAD could have been associated with female orgasmic disorder (FOD) and/or superficial or introital dyspareunia. The exclusion criteria include subjects with hypoactive sexual desire disorder, those not using an acceptable form of contraception, and those taking medication that is contraindicated or cautioned with concomitant intake of sildenafil.",
    "The sample is a phase 2 clinical trial for liver cancer using the drug sorafenib tosylate. The eligibility criteria include having histologically confirmed hepatocellular carcinoma, being eligible for conservative hepatic resection or liver resection with curative intent, and having an ECOG performance status of 0-1. Patients must also meet various laboratory and medical criteria, such as having a platelet count of at least 100,000/\u00b5L and no serious concurrent systemic disorder incompatible with the study. Prior concurrent therapy is not allowed, and patients must not have a history of certain medical conditions or allergies to the investigational agent.",
    "This sample is for a phase 2 clinical trial focused on heart failure. The trial is looking for men aged 18 years and older or postmenopausal women aged 55 years and older or women aged 18 years and older without childbearing potential based on surgical treatment. The participants must have a clinical diagnosis of CHF (chronic heart failure), either ischemic or non-ischemic, NYHA (New York Heart Association) class II - III, and be treated with evidenced-based therapy for CHF, e.g. beta-blockers and ACE (angiotensin-converting enzyme) inhibitors or ARB (angiotensin receptor blocker) as well as diuretics, unless contraindicated or not tolerated. They must also have known kidney damage for >/= 3 months, as defined by structural or functional abnormalities of the kidney, and meet certain eGFR (estimated Glomerular Filtration Rate) and serum potassium requirements. The trial is testing the effectiveness of the drug bay94-8862 and spironolactone compared to a placebo. The sample also includes exclusion criteria such as known hypersensitivity to the study drug or spironolactone, anuria, acute renal failure, or Addison's disease, among others.",
    "The sample is a phase 2 clinical trial for the treatment of acute myeloid leukemia and other related diseases. The trial involves the use of the drugs azacitidine and gemtuzumab ozogamicin. The eligibility criteria include a confirmed diagnosis of AML, a Zubrod performance status of 0-3, no known hypersensitivity to the drugs, and no prior systemic chemotherapy for acute leukemia except for hydroxyurea. Patients with a history of prior myelodysplastic syndrome are also eligible under certain criteria. Other eligibility criteria include normal liver and kidney function, no central nervous system involvement, and no other prior malignancy except for adequately treated basal cell or squamous cell skin cancer. Patients must have complete remission or CRi documented by blood and marrow examinations performed within 42 days before registration. The trial requires patients to sign and give written informed consent in accordance with institutional and federal guidelines.",
    "The sample is a phase 2 clinical trial for patients with metastatic breast cancer that is HER2-positive. The trial is testing the effectiveness of a combination of drugs including bevacizumab, vinorelbine, and trastuzumab. The eligibility criteria include having measurable disease, being 18 years or older, having a life expectancy of more than 12 weeks, and having a normal organ and marrow function. Patients must also have an ECOG Performance Status of 0 or 1 and a left ventricular ejection fraction of 50% or greater. Patients with stable or previously treated CNS metastases are eligible for study participation. The trial has two cohorts, A and B, with different inclusion criteria. Exclusion criteria include having had chemotherapy within 14 days prior to entering the study, concurrent radiation therapy, and inadequate control of hypertension. Patients with a history of myocardial infarction or unstable angina within 6 months prior to study enrollment are also excluded.",
    "The sample is a phase 2 clinical trial for HIV-1 infection. The eligibility criteria include being on antiretroviral therapy for at least 96 weeks with no plans to change the regimen in the next 3 months, having a CD4+ cell count below 350 cells/mm3, and having HIV-1 RNA levels below the limit of detection verified by at least two measurements prior to study entry. The trial involves the use of the drug rifaximin. The exclusion criteria include active diarrhea, history of inflammatory bowel disease or Clostridium difficile colitis, significant liver disease, recent use of certain medications, and active drug or alcohol use or dependence. Female subjects of reproductive potential must have a negative pregnancy test and agree to use contraception while receiving treatment.",
    "The sample is a phase 2 clinical trial for patients with adenocarcinoma of the prostate. The trial includes patients with local/regional recurrence following prostatectomy or radiation therapy, patients with unresectable tumors, patients with low volume bone disease, and patients with high volume bone/visceral disease. Patients must have an elevated PSA and meet certain criteria to be eligible for the trial. Patients may have had previous exposure to androgen deprivation therapy if it was given for \u2264 6 months to \"downstage\" the primary, and provided such therapy completed at least 12 months prior to entry into this study. Patients must be free of serious co-morbidity and have a life expectancy of \u2265 3 years. The trial excludes patients with a second malignancy, recent history of TIA, serious intercurrent medical or psychiatric illness, and sensory neuropathy of grade 1 or greater.",
    "The sample is a phase 2 clinical trial for patients with metastatic colorectal cancer that is not curable by surgical resection. The trial is testing the effectiveness of the drug dasatinib. The eligibility criteria include having measurable disease, documented disease progression after prior chemotherapy treatment, and no more than 2 prior chemotherapy regimens. Patients must also have a life expectancy of at least 3 months, a certain level of blood counts and liver and kidney function, and no known brain metastases. They must not have any clinically significant cardiovascular disease or uncontrolled intercurrent illness. Patients must not have had prior treatment with inhibitors of src, PDGFR, KIT, or EPHA2, and must not be taking certain medications or substances that are potent inhibitors or inducers of CYP3A4. They must also not be taking concurrent anticoagulants, combination antiretroviral therapy for HIV-positive patients, grapefruit or grapefruit juice, or other concurrent investigational agents or commercial agents or therapies.",
    "The sample is a phase 2 clinical trial for the treatment of malignant mesothelioma, a type of cancer affecting the lining of the lungs. The trial involves the use of two drugs, cisplatin and pemetrexed disodium, and has specific eligibility criteria for patients, including age, performance status, and various medical conditions. Patients must also not have received prior chemotherapy for mesothelioma and cannot have certain concurrent therapies or medications. The sample includes detailed disease characteristics and patient characteristics, as well as prior and concurrent therapy restrictions.",
    "The sample is a phase 2 clinical trial for patients with moderate to very severe Chronic Obstructive Pulmonary Disease (COPD). The trial involves the use of various doses of tiotropium, as well as a placebo. The eligibility criteria include signing an informed consent, having a smoking history of at least 10 pack years, being able to perform lung function tests and use study inhalers. Exclusion criteria include significant diseases other than COPD, recent myocardial infarction or hospitalization for cardiac failure, malignancy requiring treatment within the last 5 years, history of asthma or other pulmonary conditions, alcohol or drug abuse, and current participation in another clinical trial. Pregnant or nursing women and women of childbearing potential not using a highly effective method of contraception are also excluded.",
    "The sample is a phase 2 clinical trial for patients with metastatic melanoma. The trial involves the use of three drugs - vinblastine, cyclophosphamide, and dacarbazine. The eligibility criteria include having measurable disease, being at least 4 weeks from the last immunotherapy, radiation, surgery or chemotherapy (6 weeks for nitrosoureas), having a Karnofsky Performance Status of at least 60%, having a life expectancy of at least twelve weeks, having adequate end organ function, not lactating (if female) and having a negative pregnancy test within two weeks of entry to the study (if of childbearing age), having appropriate contraception in both sexes, being competent and having signed informed consent. The exclusion criteria include having a concomitant second malignancy (except for non-melanoma skin cancer, and non-invasive cancer such as cervical CIS, superficial bladder cancer without local recurrence, breast CIS), having a prior history of invasive malignancy less than five years in complete remission, and having evidence of significant co-morbid illness such as uncontrolled diabetes or uncontrolled brain metastasis (patients with brain metastasis must have been treated with brain radiation therapy or surgery and remain clinically stable for a minimum of 4 weeks).",
    "The sample is a phase 2 trial for osteoarthritis. The trial includes a list of icd-10 codes for the disease and a list of drugs being tested, including a placebo. The eligibility criteria for the trial includes individuals aged 40-75 with chronic moderate to severe knee pain due to OA, who are either unwilling to take non-opiate pain medications or have failed with non-opiate pain medications, or are candidates for or seeking invasive interventions such as intraarticular injections, knee arthroplasty, or total knee surgery. Exclusion criteria include a history or symptoms of autoimmune disorders, cancer within the last 5 years (except for cutaneous basal cell or squamous cell cancer resolved by excision), allergic reaction to monoclonal antibodies or IgG-fusion proteins, Hepatitis B, C or HIV, drug abuse, fibromyalgia, clinically significant cardiac disease, diabetes mellitus requiring oral treatment or insulin, clinically significant neurological disease or clinically significant psychiatric disorders.",
    "The sample is a record of a clinical trial in phase 2 for the treatment of prostate cancer using the drug cytarabine. The trial is looking for patients who have already undergone docetaxel treatment and have experienced progression or intolerance to it. The inclusion criteria include biopsy-proven prostate cancer or clinical picture consistent with metastatic prostate cancer with high levels of serum PSA, ECOG performance status of 2 or less, and adequate organ and marrow function. The exclusion criteria include prior treatment with cytarabine, receiving any other investigational or anticancer agents, uncontrolled intercurrent illness, active malignancy at any other site excluding squamous cell or basal cell carcinomas of the skin, and radiotherapy within the past 4 weeks. The record also includes a list of icd-10 codes associated with the disease.",
    "The sample is a phase 2 clinical trial for various hematopoietic disorders such as anemia, leukemia, lymphoma, and myelodysplastic syndromes. The trial involves the use of drugs such as busulfan, fludarabine phosphate, methotrexate, and tacrolimus. The eligibility criteria include having a matched unrelated donor available, meeting certain disease characteristics, and having certain patient characteristics such as a good performance status and no active infections. Prior concurrent therapy is also taken into consideration. The sample includes a detailed list of eligibility criteria for each disease.",
    "The sample is a phase 2 clinical trial for advanced breast cancer, breast cancer, and metastatic breast cancer. The trial involves the drugs larotaxel (xrp9881) and trastuzumab. The eligibility criteria for the trial include a diagnosis of breast cancer, evidence that the cancer has spread beyond its original location or has come back and cannot be removed by surgery, no more than one prior treatment for advanced disease, Her2 positive status, adequate liver and kidney function, and no remaining severe harmful effects to prior treatments. The exclusion criteria include certain heart conditions, pregnancy, history of another cancer except some skin cancers and cervical cancer, and taking other treatments for cancer at the time of entering the trial. The icd-10 codes for the diseases are also provided.",
    "The sample is a phase 2 trial for venous thromboembolism. The trial includes subjects who are male and over 18 years old or postmenopausal females who are scheduled for elective total knee replacement. The trial involves the use of drugs such as rivaroxaban and enoxaparine. The eligibility criteria for the trial include exclusion criteria related to medical history, current symptoms or findings, and current treatment. Subjects who withdraw from the study for any reason may be removed from the trial.",
    "The sample is a record of a clinical trial with a phase 2 designation. The trial is focused on lung cancer, specifically non-small-cell lung carcinoma, and involves the use of two drugs, capecitabine and docetaxel. The trial has a list of inclusion and exclusion criteria, including requirements for measurable disease, adequate organ function, and a life expectancy of at least 12 weeks. Patients with uncontrolled diabetes mellitus, psychiatric disorders that would interfere with consent or follow-up, and pregnant or lactating women are excluded from the trial. The trial is also limited to patients who have not undergone prior chemotherapy and have an Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1. The trial is identified by a list of ICD-10 codes associated with the diseases being studied.",
    "This sample is for a phase 2 clinical trial for patients with coronary artery disease. The trial is testing the effectiveness of two drugs, cangrelor and ticagrelor. The eligibility criteria for the trial includes being between 18 and 75 years old, having a previous myocardial infarction or revascularization by PCI or CABG surgery, and currently being treated with aspirin. The exclusion criteria are not specified in this sample. The diseases are listed as a single disease, and the icd-10 codes associated with the disease are also provided.",
    "The sample is a phase 2 clinical trial for the treatment of diabetes mellitus. The trial includes patients with an established diagnosis of type 2 diabetes mellitus, with a fasting serum C-peptide level greater than 0.6 ng/mL, HbA1c levels between 7.0 and 10.0%, and a body mass index between 20 and 45 kg/m2. The trial excludes patients with serum creatinine levels above the upper limit of normal, proteinuria (albumin/creatinine ratio greater than 300 mg/g), dysuria and/or urinary tract infection, significant renal, hepatic or cardiovascular diseases, ketosis, hypertension, and severe gastrointestinal diseases. The trial involves the use of the drugs ipragliflozin and placebo.",
    "The sample is a phase 2 clinical trial for patients with metastatic colorectal cancer who have failed at least two prior chemotherapy regimens and are not candidates for curative resection. The trial is testing the effectiveness of the drugs entinostat and azacitidine. The eligibility criteria include having measurable disease, an ECOG performance status of 0-1, and meeting certain laboratory values. Patients must also not have certain medical conditions or be taking certain medications. The trial requires patients to provide tissue and blood samples and prohibits the use of other investigational or commercial anticancer agents or therapies.",
    "The sample is a phase 2 clinical trial for breast neoplasms. The trial involves the use of two drugs, lapatinib and paclitaxel. The eligibility criteria for the trial include having a tumor that is accessible for multiple biopsies, having an ECOG performance status of 0-2, having adequate bone marrow, and having normal renal and hepatic function. Additionally, participants must have a left ventricular ejection fraction greater than 0% based on ECHO or MUGA. Exclusion criteria include being pregnant or nursing, having any unstable pre-existing major medical condition, having received an investigational drug within the past 4 weeks, having had major surgery in the past 2 weeks, or currently receiving or having received amiodarone in the past 6 months.",
    "The sample is a phase 2 clinical trial for patients with gastrointestinal stromal tumor. The trial is testing the effectiveness of the drug dasatinib. The eligibility criteria include having a confirmed diagnosis of GIST, measurable disease, and a positive PET/CT scan. Patients must also meet certain health requirements, such as having a WHO performance status of 0-2 and normal blood counts. They cannot have any other malignancies within the past 5 years, and must not be pregnant or nursing. Patients must also not have any significant cardiovascular disease or concurrent medical conditions that would impair their ability to participate in the study. Prior therapy for GIST, particularly tyrosine kinase inhibitors, is not allowed. Patients must not be taking any concurrent medications known to prolong the QT interval or IV bisphosphonates during the first 8 weeks of study treatment. They also cannot be taking any other experimental drugs or anticancer therapy.",
    "The sample is a phase 2 clinical trial for major depressive disorder. The trial is testing the drug cp-601,927. The inclusion criteria for the trial are medically healthy males or females aged 18-65 with a primary current diagnosis of MDD without psychotic features who are receiving ongoing antidepressant therapy. The duration of the current episode of MDD must be at least 8 weeks prior to enrollment without adequate response to treatment. The exclusion criteria include patients with other psychiatric disorders, tobacco product use, alcohol or substance abuse or dependence, treatment with a monoamine oxidase inhibitor within 10 weeks of enrollment, pregnancy or breastfeeding, and clinically significant abnormalities on laboratory tests, electrocardiogram, or physical or neurologic examination.",
    "The sample is a phase 2 clinical trial for patients with locally advanced inoperable or metastatic pancreatic cancer. The trial is testing the effectiveness of erlotinib hydrochloride as a systemic therapy for patients who have not received more than one prior systemic therapy. The eligibility criteria include confirmation of adenocarcinoma of the pancreas, no more than one prior systemic therapy, ECOG performance status 0-2, life expectancy of more than 3 months, and various laboratory values within normal limits. Patients must not have brain metastases, uncontrolled comorbid illness likely to increase toxicity of the study drug, or known allergy to the study drug or its excipients. Prior adjuvant therapy is allowed if completed at least 28 days prior to study entry, but no prior EGFR-inhibitor is allowed. Concurrent drugs that are known to be strong inducers or inhibitors of the CYP450 enzyme system, Hypericum perforatum (St. John's wort), and investigational or commercial agents or therapies with the intent to treat the patient's malignancy are not allowed.",
    "The sample is a phase 2 clinical trial for the treatment of breast cancer using a drug called bavituximab. The trial is open to adult females over the age of 18 with locally advanced or metastatic breast cancer who have had only one prior chemotherapy regimen (excluding docetaxel). The trial requires participants to have measurable disease of at least 2 cm in longest diameter and adequate hematologic, renal, and hepatic function. However, participants with a known history of bleeding diathesis or coagulopathy, any current evidence of clinically significant bleeding, any history of thromboembolic events, concurrent hormone therapy, or prior immunotherapy or radiotherapy to an area of measurable disease (unless the disease has recurred after radiotherapy) are excluded from the trial.",
    "The sample is a phase 2 clinical trial for asthma. The trial includes patients who have had a three-month history of reversible asthma and have a stable inhaled corticosteroid dose for three months prior to screening. The trial also requires patients to be diagnosed with asthma before the age of 40 and have an Asthma Control Questionnaire score of at least 1.5 at randomization. Patients must be non-smokers or ex-smokers with a negative cotinine screen and able to perform pulmonary function tests. The trial excludes patients with significant diseases other than asthma or allergic rhinitis, hepatic transaminases or total bilirubin greater than 1.5 upper limit of normal, hospitalizations for asthma or asthma-related intubation within three months, uncontrolled asthma on ICS + another controller, respiratory tract infection or exacerbation within four weeks, FEV1 less than 40%, more than 12 puffs of short-acting beta-agonists on more than two consecutive days or asthma exacerbation during the run-in period, participation in another interventional study, pregnant or nursing women, and women of childbearing potential not using appropriate methods of birth control as defined by the protocol. The trial will test the effectiveness of the drugs bi 671800 and placebo.",
    "The sample is a phase 2 clinical trial for non-small-cell lung cancer. The trial includes patients with unresectable locally advanced or metastatic NSCLC who have progressed on first-line therapy. The trial is testing the effectiveness of the drugs erlotinib and bevacizumab. The eligibility criteria include having measurable disease, an ECOG performance status of 0-2, a life expectancy of more than 6 months, and adequate liver, renal, and bone marrow function. Patients with central nervous system involvement, a centrally located mass or a tumor mass in close relation to large vessels, or a history of life-threatening hemoptysis/hematemesis or thrombosis are excluded. Patients who have undergone surgery or radiation therapy within the last 14 days, have an active infection, or have a history of significant cardiac disease or stroke within the previous 6 months are also excluded. Patients who are pregnant or lactating, have a history of a second primary malignancy (other than basal-cell skin carcinoma or in situ carcinoma of the cervix), or have a psychiatric illness or social situation that would preclude study compliance are also excluded.",
    "The sample is a record of a clinical trial with a phase 2 designation. The trial is focused on restless legs syndrome and includes a list of ICD-10 codes for the disease. The trial involves two drugs, gen (xp13512/gsk1838262) and placebo. The eligibility criteria for the trial include being at least 18 years old, having a history of RLS symptoms occurring at least 15 nights in the month prior to screening, and having a total RLS severity score of 15 or greater on the IRLS Rating Scale. The trial also has exclusion criteria, such as having a sleep disorder that may significantly affect the assessment of RLS, a history of RLS symptom augmentation or end of dose rebound with previous dopamine agonist treatment, and other clinically significant or unstable medical conditions that could affect RLS treatment efficacy assessments.",
    "The sample is a phase 2 clinical trial for the treatment of breast cancer. The trial includes patients with a confirmed diagnosis of invasive breast cancer, who are postmenopausal and have tumors that are estrogen receptor positive and human epidermal growth factor receptor negative. The trial involves the use of two drugs, anastrozole and anastrozole plus tegafur-uracil. The eligibility criteria include adequate bone marrow, liver and renal function, and the ability to swallow tablets and capsules. Patients must also be candidates for mastectomy or breast-conserving surgery. The trial has exclusion criteria such as inoperable, bilateral or inflammatory breast cancer, multiple carcinoma, personal history of invasive carcinoma, and other concurrent severe and/or uncontrolled medical disease. Written informed consent is required from all patients before randomization.",
    "The sample is a record of a clinical trial for a drug called cx516 (ampakine) for the treatment of schizophrenia. The trial is in phase 2/phase 3 and the disease being studied is schizophrenia. The icd-10 codes associated with the disease are listed as [\"F20.0\", \"F20.1\", \"F20.2\", \"F20.3\", \"F20.5\", \"F20.89\", \"F20.9\"]. The eligibility criteria for the trial are listed under inclusion and exclusion criteria, which include age range, diagnosis of schizophrenia, stable dose of certain medications, and exclusion of serious medical or neurological illnesses, substance abuse, pregnancy, and suicidal or homicidal risk.",
    "The sample is a phase 2 clinical trial for the treatment of systemic anaplastic large cell lymphoma. The trial involves the use of drugs such as cyclophosphamide, doxorubicin hydrochloride, vincristine sulfate, prednisone, and sgn-30. The eligibility criteria for the trial include having histologically or cytologically confirmed systemic anaplastic large cell lymphoma, measurable disease, and a certain level of blood counts and organ function. Patients with rapidly progressing disease or bulky disease, primary cutaneous ALCL, known brain metastases, or other concurrent malignancy with less than 90% probability of survival at 5 years are excluded from the trial. The trial also requires patients to use effective contraception during and for 3 months after completion of study treatment if they are fertile.",
    "The sample is a phase 2 clinical trial for patients with non-Hodgkin lymphoma. The trial includes patients who have received at least one prior therapeutic regimen but no more than three prior regimens of conventional cytotoxic therapy. Patients must be off all cytotoxic chemotherapy for at least four weeks prior to registration for protocol therapy. Prior fludarabine, Velcade or rituximab is allowed as long as therapy is completed at least 30 days prior to registration for protocol therapy. Patients may be refractory to prior rituximab but not to prior fludarabine or Velcade. The trial also includes eligibility criteria for patients, such as having measurable disease and not having certain medical conditions. The trial excludes patients with certain medical conditions, such as active HIV, hepatitis B or C infection, and peripheral neuropathy grade > 1.",
    "This sample is for a phase 2 clinical trial for the treatment of chronic lymphocytic leukemia. The trial is testing the effectiveness of a combination of three drugs: cyclophosphamide, fludarabine phosphate, and mitoxantrone hydrochloride. The eligibility criteria for patients include having a diagnosis of chronic lymphocytic leukemia that requires therapy and having been previously treated with at least one chemotherapeutic regimen. Patients must also meet certain health requirements, such as having a WHO performance status of 0-2 and a life expectancy of at least 12 weeks. Additionally, patients must not be pregnant or nursing, and must use effective contraception if they are fertile. The trial excludes patients with certain medical conditions or mental disorders that would preclude study participation, as well as those with a history of anaphylaxis after exposure to rat or mouse-derived complementary-determining region (CDR)-grafted humanized monoclonal antibodies or toxicity attributable to purine analogues. Prior concurrent therapy is also taken into consideration.",
    "The sample is a record of a clinical trial in phase 2 for the treatment of B-cell chronic lymphocytic leukemia. The trial includes the drug \"fccam\" and has a list of inclusion and exclusion criteria for participants. Inclusion criteria include having B-CLL in need of treatment, having one or two prior therapies, and having a WHO performance status of 0-2. Exclusion criteria include having serum creatinine levels greater than 1.5 ULN, major organ dysfunctions, and being pregnant or nursing. The sample also includes a list of ICD-10 codes associated with the disease.",
    "The sample is a phase 2 clinical trial for patients with recurrent or advanced borderline or low-grade epithelial ovarian, fallopian tube or primary peritoneal tumors not amenable to surgery, or patients who have measurable residual disease at the end of secondary cytoreduction. The trial is testing the effectiveness of the drug letrozole. The eligibility criteria include having a confirmed diagnosis of borderline tumors or low-grade epithelial cancer from the ovary, fallopian tube or primary peritoneum, having measurable disease by radiological imaging studies, being over 18 years old, having an expected survival of more than 12 weeks, having an ECOG performance status of 0-1, and having adequate bone marrow, liver, and renal function. Exclusion criteria include having sarcomatous, germ cell or stromal elements in their cancers, being pregnant or lactating, having leptomeningeal or carcinomatous meningitis, having unstable medical conditions, having any severe concurrent disease, infection or co-morbidity, having signs of intestinal obstruction interfering with nutrition, having received chemotherapy, radiotherapy, radiopharmaceuticals or immunotherapy within 4 weeks of first study dosing with letrozole, having more than 4 prior chemotherapy regimes with all platinum regimes counted as one, having had prior anti-cancer hormonal therapy for ovarian cancer with aromatase inhibitors, having a history of prior malignancy except for adequately treated carcinoma in situ of the cervix, basal cell or squamous cell skin cancer, or other cancer for which the patient has not been disease-free for at least five years, receiving concurrent chemotherapy, radiotherapy or immunotherapy, participating in any investigational drug study within 30 days of the first day of dosing, having psychiatric disorders that would preclude obtaining informed consent and participation in an ongoing research study, having a known history of human immunodeficiency virus (HIV) infection, and having inadequately treated serious thromboembolic disease such as pulmonary embolism and deep vein thrombosis, or with known clotting disorders.",
    "The sample is a phase 2 clinical trial for patients with ovarian epithelial, primary peritoneal cavity, or fallopian tube cancer in stage III or IV. The trial involves the use of carboplatin and paclitaxel drugs. The eligibility criteria include having at least one undissected axillary or inguinal lymph node basin, being HLA-A1, -A2, and/or -A3 positive, having an ECOG performance status of 0-2, and meeting various medical requirements such as having a hemoglobin level of at least 8.0 g/dL and no active serious infection. Patients must not have any other concurrent malignancy (except for nonmelanoma skin cancer) and must not be pregnant or nursing. Prior concurrent therapy is also restricted.",
    "The sample is a phase 2 trial for patients with adult giant cell glioblastoma, adult glioblastoma, adult gliosarcoma, or recurrent adult brain neoplasm. The trial involves the drug dasatinib and requires patients to meet certain eligibility criteria, such as having undergone prior treatment with radiotherapy and temozolomide, having measurable disease, and having a Karnofsky performance status of at least 60. Patients must also not have certain comorbidities, such as severe cardiovascular disease or acute bacterial or fungal infections. The trial has exclusion criteria, such as prior treatment with stereotactic radiosurgery or brachytherapy.",
    "The sample is a record of a clinical trial with a phase 2 designation. The trial is focused on the treatment of plaque psoriasis, a chronic skin condition. The trial includes a list of icd-10 codes associated with the disease, as well as a list of drugs being tested, including itacitinib and a placebo. The eligibility criteria for the trial are also included, with specific requirements for age, previous treatment, and pregnancy status. The exclusion criteria are also listed, including restrictions on pregnancy and previous treatments for psoriasis.",
    "The sample is a phase 2 trial for the treatment of oral mucositis. The trial is for patients who have recently been diagnosed with non-metastatic SCC of the oral cavity, oropharynx, hypopharynx or larynx and will be treated with CRT as first-line treatment. The patients must have a plan to receive a continuous course of conventional external beam irradiation delivered by intensity-modulated radiotherapy (IMRT) as single daily fractions of 2.0 to 2.2 Gy, with a cumulative radiation dose between 55 and 72 Gy. They must also have a plan to receive a standard cisplatin CT regimen administered tri-weekly or weekly or a standard carboplatin regimen administered weekly. The patients must have an Eastern Cooperative Oncology Group (ECOG) performance status \u2264 1 and CRP < 80 mg/L. They must also have adequate hematopoietic, hepatic, and renal function at the screening visit. The exclusion criteria include tumor of the lips, sinuses, salivary glands, nasopharynx or unknown primary tumor, metastatic disease (M1) Stage IV C, any prior history of head and neck cancer, prior radiation to the head and neck, major surgical procedure, other than for HNC, or significant traumatic injury within 4 weeks prior to the initiation of RT, anticipation of need for a major surgical procedure during the clinical trial, active infectious disease, excluding oral candidiasis, history of hypersensitivity to monoclonal antibody, and having OM at the screening visit.",
    "The sample is a clinical trial for patients with liver cirrhosis, hepatitis C virus, and HIV infection. The trial is in phase 2/phase 3 and the drugs being tested are pegylated interferon alfa-2a and ribavirin. The eligibility criteria for the trial include being over 18 years old, having compensated liver cirrhosis by HCV genotype 1 or 4 without previous virological response to a standard dose treatment of both drugs, and having the ability to understand and sign a written consent form. The exclusion criteria include having HCV genotypes different to 1 or 4, acute or chronic hepatitis B infection, pregnancy or breast feeding, and other medical conditions such as neutropenia, anemia, thrombocytopenia, and organ or bone marrow transplantation.",
    "The sample is a phase 2 clinical trial for women over 18 years old with invasive breast cancer that is incurable and has progressed or is intolerant to hormonal therapy. The trial involves the use of two drugs, pazopanib and lapatinib, and the eligibility criteria include having a confirmed amplification of ErbB2 by Fluorescence In Situ Hybridization (FISH) in either the primary or metastatic tumor tissue, as well as meeting certain organ function and performance status requirements. The trial also has a list of exclusion criteria, such as having a history of other malignancy or untreated deep venous thrombosis within the past 6 months.",
    "The sample is a phase 2 clinical trial for patients with coronary artery disease. The trial involves the use of the drugs rvx000222 and placebo rvx000222. The eligibility criteria include being male or female over 18 years old, having angiographic evidence of coronary heart disease, and meeting certain HDLC levels. Patients must also be able to start either atorvastatin or rosuvastatin at the beginning of the trial. Exclusion criteria include having clinically significant heart disease, undergoing any elective surgical procedure that requires general anesthesia during the trial, and having a history of drug or alcohol abuse within the last 12 months.",
    "The sample is a phase 2 clinical trial for the treatment of various types of renal cell carcinoma using the drug ixabepilone. The trial includes patients with metastatic, recurrent, or unresectable disease who meet specific eligibility criteria, such as having measurable disease and a performance status of ECOG 0-2. Patients must also meet certain laboratory values and have no other active malignancy or uncontrolled illness. The trial excludes patients with certain prior treatments or concurrent therapies, as well as those with active brain metastases or severe hypersensitivity reactions to study drugs.",
    "The sample is a phase 2 clinical trial for non-small cell lung cancer. The trial includes patients who have completed four to six cycles of platinum-based chemotherapy doublet for first line, advanced NSCLC, with no evidence of disease progression according to RECIST version 1.1. The trial also includes patients who are willing and able to continue treatment with bevacizumab, if they received it with their platinum based chemotherapy. The eligibility criteria include signed informed consent, ability and willingness to comply with requirements of the study protocol, male or female, age 18 or over, histologically or cytologically confirmed diagnosis of NSCLC, and ECOG performance status 0-1. The exclusion criteria include patients who are not eligible for induction therapy with a platinum based chemotherapy doublet, patients who have received, or are scheduled to receive pemetrexed or erlotinib as maintenance therapy, and patients receiving bevacizumab who have a recent history of hemoptysis \u2265 \u00bd teaspoon of red blood or history of \u2265 2 g/24 hr urine protein while receiving prior bevacizumab, or squamous cell histology.",
    "The sample is a phase 2 clinical trial for the treatment of multiple myeloma. The trial includes patients who have measurable disease and have been responsive to first-line therapy but are refractory to their most recent treatment. Patients must have received at least two prior regimens for relapsed disease and have received prior treatment with bortezomib and either thalidomide or lenalidomide. The trial involves the use of carfilzomib as a treatment. Patients must meet certain eligibility criteria, including having adequate hepatic function, a calculated and measured creatinine clearance of at least 30 mL/minute, and a life expectancy of more than three months. Patients must also provide written informed consent and agree to use dual methods of contraception if they are of child-bearing potential. Exclusion criteria include having certain concurrent conditions, such as congestive heart failure or active hepatitis, and having significant neuropathy or a clinically significant medical disease or condition that may interfere with protocol adherence or a subject's ability to give informed consent.",
    "The sample is a phase 2 clinical trial for patients with type 2 diabetes. The trial involves the use of drugs such as mitoglitazone, pioglitazone, and placebo. The eligibility criteria include having a fasting plasma glucose level of at least 126 mg/dL, a glycosylated hemoglobin level between >7% and \u226410%, and an insulin C-peptide level >1 ng/mL. Patients must also have a BMI between 23 kg/m2 and 45 kg/m2, be willing to make seven visits to the clinic over a 21-week period, and sign an informed consent document. Exclusion criteria include a history of diabetic ketoacidosis or hyperosmolar non-ketotic coma, heart failure or previous cardiovascular events within the past 6 months, and ALT and/or AST levels that are twice the upper limit of normal.",
    "The sample is a phase 2 clinical trial for the treatment of diabetic retinopathy and diabetic macular edema using the drug ranibizumab (lucentis). The trial includes eligibility criteria such as having clinically significant diabetic macular edema, retinal thickening, and hard exudates within a certain distance of the fovea, as well as meeting age and visual acuity requirements. Exclusion criteria include having other causes of macular edema, intraocular pressures exceeding 25 mm Hg, and participation in other medical investigations or trials. The sample also includes a list of icd-10 codes for the diseases being studied and a list of exclusionary treatments and conditions.",
    "The sample is a phase 2 clinical trial for patients with advanced colorectal cancer or colorectal cancer who have failed a first-line chemotherapeutic regimen containing oxaliplatin and 5-fluorouracil (5-FU) with or without bevacizumab, with or without other Investigational Medicinal Products (IMPs). The trial involves the drug CP-4055 and has specific inclusion and exclusion criteria, including measurable disease according to Response Criteria In Solid Tumours (RECIST), performance status 0-2 according to ECOG (Eastern Cooperative Oncology Group) Performance Status, age 18 years or more, life expectancy of more than 3 months, and signed informed consent. The trial excludes patients with known brain metastases, history of allergic reactions to ara-C or egg, any serious concomitant systemic disorders incompatible with the clinical study, and any significant central nervous system or psychiatric disorder(s) that would hamper the patient's compliance. Additionally, patients who are pregnant, breastfeeding, or have a positive status for HIV and/or hepatitis B or C are excluded from the trial. The trial also requires male and female patients to use acceptable contraceptive methods for the duration of time on study, and males also for 3 months after the last CP-4055 dose.",
    "The sample is a phase 2 clinical trial for patients with active acromegaly due to a pituitary adenoma. The trial involves the use of two drugs, pasireotide (som230) and octreotide (sandostatin). The eligibility criteria include having active acromegaly and not having certain medications prior to entering the study. Exclusion criteria include having certain medical conditions such as compression of the optic chiasm causing any visual field defect, congestive heart failure, and chronic liver disease. Female patients who are pregnant or lactating, or are of childbearing potential and not practicing a medically acceptable method of birth control and highly effective method for birth control are also excluded. Patients who have a history of alcohol or drug abuse in the six-month period prior to the enrollment visit and those who have participated in any clinical investigation with an investigational drug within 4 weeks prior to dosing are also excluded.",
    "The sample is a phase 2 clinical trial for ovarian, fallopian, and peritoneal cancer patients who are resistant to platinum. The trial is testing the drug enmd-2076. The eligibility criteria include having a documented diagnosis of the specified cancers, having acceptable laboratory screening results, and being able to tolerate oral medications. Exclusion criteria include uncontrolled hypertension, chronic atrial fibrillation, active infections or bleeding, and a history of nephrotic syndrome.",
    "The sample is a phase 2 clinical trial for the treatment of common cold symptoms. The trial includes the use of two drugs, guaifenesin (mucinex) and placebo. The eligibility criteria for the trial include having common cold symptoms and meeting symptom severity, while exclusion criteria include chronic respiratory conditions, significant heart, kidney, liver, or lung disease, uncontrolled hypertension or diabetes, cystic fibrosis, thyroid disorder, pregnancy or lactation, known malignancy, participation in any other clinical trial within 30 days of baseline, and being related to another enrolled patient or persons involved directly or indirectly with the conduct of this study. Females of child-bearing potential must have a negative pregnancy test and use effective birth control to be eligible for the trial.",
    "The sample is a phase 2 clinical trial for the treatment of esophagitis. The trial involves testing the effectiveness of the drug omalizumab compared to a placebo. The eligibility criteria for the trial include being between the ages of 12-60 with EE, having a serum IgE level between 30-700 IU/mL, and having acceptable medical history, physical exam, and laboratory test results. Exclusion criteria include a history of esophagogastric surgery, other esophageal pathology, incarceration, pregnancy, and other medical conditions that would prohibit participation in the study. Patients who have taken certain medications within one month of visit 1 or who have a known hypersensitivity to any ingredient of rhuMAb-E25 will also be excluded. Patients with Barrett's esophagus or who are currently treated with omalizumab or treated with omalizumab within the past 6 months will also be excluded.",
    "The sample is a phase 2 clinical trial for rheumatoid arthritis. The trial includes patients who have active rheumatoid arthritis while on methotrexate and have 12 tender and 10 swollen joints at randomization. The trial involves the use of two drugs, abatacept and placebo. The eligibility criteria include no current infection or other evolutive or uncontrolled disease.",
    "This sample is for a phase 2 clinical trial that focuses on autism and pediatric autism. The trial is testing the effectiveness of the drug memantine hcl. The eligibility criteria for the trial include completing a lead-in study and having a caregiver who can attend all clinic visits with the patient. Patients with concurrent medical conditions that may interfere with the study are excluded from the trial. The icd-10 code for the disease is listed as \"Z13.41\".",
    "The sample is a phase 2 clinical trial for patients with atherosclerosis. The trial involves the use of two drugs, clopidogrel 75 mg daily and a water pill daily. The trial is looking at patients undergoing primary multi-vessel CABG with at least two saphenous vein grafts, with or without the use of cardiopulmonary bypass. The eligibility criteria include exclusion criteria such as emergency surgery, valve surgery, redo CABG, left ventricle ejection fraction < 25%, serum creatinine > 130 \u00b5mol/L, preoperative use of clopidogrel (with the exception of the current admission), preoperative use of warfarin, allergy to aspirin or clopidogrel, history of cerebrovascular accident, history of severe liver disease, morbid obesity, and current malignancy.",
    "The sample is a phase 2 clinical trial for rheumatoid arthritis. The trial is looking at the effectiveness of the drug atacicept compared to a placebo. The eligibility criteria for participants include having a disease history of at least one year, being 18 years or older, having active rheumatoid arthritis with a certain number of swollen and tender joints, and having failed at least one TNFa antagonist therapy. There are also exclusion criteria, such as having certain medical conditions or having participated in another clinical trial with an investigational therapy within a certain timeframe.",
    "The sample is a phase 2 clinical trial for patients with platinum refractory or resistant epithelial ovarian cancer. The trial includes patients with measurable disease and normal hepatic function, who have not received any chemotherapy for at least 4 weeks. Patients who have received paclitaxel chemotherapy on a 3-week regimen are also eligible if it has been at least 4 weeks since the last treatment. The trial involves the use of paclitaxel and lovastatin drugs. Patients with serious illnesses that limit survival to less than 2 years, or psychiatric conditions that prevent compliance with treatment or informed consent, are excluded from the trial. Patients with a currently active second malignancy other than non-melanoma skin cancers, or who have received any investigational agent within the prior 4 weeks, are also excluded. The trial is not open to patients under the age of 18 due to lack of safety data for lovastatin in this age range.",
    "The sample is a record of a clinical trial for phase 2, focused on small cell lung cancer. The trial includes patients who have not received prior systemic chemotherapy, immunotherapy, or biological therapy for SCLC. The eligibility criteria include having a histological or cytological diagnosis of extensive stage small-cell lung cancer, measurable disease as defined by the RECIST criteria, and adequate organ function as defined by the protocol. Patients must also have an Eastern Cooperative Oncology Group (ECOG) performance status of 0-2, be at least 18 years of age, and sign an informed consent document. The trial involves the use of two drugs, carboplatin and abraxane. The sample also includes exclusion criteria, such as having received treatment within the last 30 days with a drug that has not received FDA approval for any indication at the time of study entry, pregnancy or breast feeding, and serious active infection that would require a prolonged course of antibiotics or would compromise the safety of the patient.",
    "The sample is a phase 2 clinical trial for patients with metastatic melanoma and clinical evidence of brain metastases. The trial involves the use of two drugs, temozolomide and thalidomide. The eligibility criteria for the trial include having a confirmed diagnosis of metastatic melanoma, measurable brain lesions, and a performance status of CTC 0-1. Patients must also meet certain laboratory values and have no history of certain medical conditions. The trial allows for prior whole brain radiotherapy and stereotactic radiotherapy, but not concurrent radiotherapy. Patients must also not be taking certain medications, such as warfarin or heparin products, antiplatelet therapy, or bisphosphonates.",
    "The sample is a phase 2 clinical trial for patients with coronary heart disease. The trial is testing the effectiveness of a drug called mpsk3169a compared to a placebo. Patients must be using a standard-of-care statin at a stable dose or be intolerant to statins without using other lipid modifying therapies. They must also have a fasting LDL cholesterol level between 90-250 mg/dL on the statin regimen. Patients must meet at least one of the following criteria: a history of myocardial infarction, percutaneous coronary intervention, coronary artery bypass graft surgery, or prior coronary angiography demonstrating coronary atherosclerosis; a CHD risk equivalent condition including diabetes mellitus, chronic kidney disease, prior stroke, carotid disease, peripheral arterial disease, or abdominal aortic aneurism; or >/=2 CHD risk factors and a high risk of a CV event based on risk estimation systems. Patients with severe congestive heart failure, recent MI, unstable angina, stroke, transient ischemic attack, CABG, PCI, hospital admission for heart failure, major surgery, uncontrolled cardiac arrhythmia, initiation of renal replacement therapy, fasting serum triglyceride level >/= 400 mg/dL, homozygous familial hypercholesterolemia, poorly controlled diabetes mellitus, hypertension or thyroid disease, liver or muscle disease, abnormal test results at screening, or who are pregnant or lactating are excluded from the trial.",
    "This sample is a phase 2 clinical trial for patients with B-cell chronic lymphocytic leukemia that is refractory to or has progressed after treatment with at least one course containing a purine nucleoside analog. The trial is testing the drug cediranib maleate. The eligibility criteria include various medical requirements such as a certain level of blood counts, liver and kidney function, and no significant ECG abnormalities. Patients must also not have any uncontrolled illnesses or be pregnant or nursing. Additionally, patients must have completed prior chemotherapy, radiotherapy, anti-VEGF treatment, or major surgery at least 4 weeks prior to the trial and must not be taking any concurrent drugs or biologics with proarrhythmic potential.",
    "The sample is a phase 2 clinical trial for patients with metastatic breast cancer, breast cancer, or progressive breast cancer. The trial involves the use of carboplatin, bevacizumab, and herceptin as treatment options. The eligibility criteria include having confirmed invasive breast cancer with metastatic disease, measurable disease, and new or progressive CNS lesions. Patients must also have a life expectancy of greater than 12 weeks, normal organ and marrow function, and an ECOG PS performance status of 0-2. Exclusion criteria include having had chemotherapy within 14 days prior to entering the study, contraindications to MRI with gadolinium contrast, and inadequate control of hypertension. Women of child-bearing potential and men must agree to use adequate contraception prior to study entry and for the duration of study participation.",
    "This is a sample from a table that contains information about clinical trials. The trial is in phase 2 and is focused on amyotrophic lateral sclerosis (ALS). The table includes a list of ICD-10 codes for the disease and a list of drugs being used in the trial. The eligibility criteria for participants are also listed, including a diagnosis of ALS according to specific criteria, onset of muscle weakness within 14 months of randomization, and concomitant standard Riluzole therapy. The exclusion criteria include the presence of a tracheotomy, mechanical ventilation, or non-invasive ventilation, as well as the requirement for prescription drugs used for potential neuroprotective benefit.",
    "The sample is a phase 2 clinical trial for individuals with HIV infections and neuropathy. The trial is testing the effectiveness of the drug epoetin alfa in reducing neuropathic pain. The eligibility criteria include being male or female over 18 years old, having documented HIV-1 infection, stable use or no use of specific dideoxynucleoside reverse transcriptase inhibitors for at least 4 months prior to the trial, and having painful HIV-associated sensory neuropathy confirmed by a neurologist. The trial also has exclusion criteria, such as having any condition other than HIV infection or antiretroviral therapy that confounds the diagnosis of neuropathy, receiving insulin or oral hypoglycemic products for treatment of diabetes mellitus within 30 days from the start of the trial, and having a history of untreated vitamin B12 deficiency. The trial also excludes individuals who are pregnant or breastfeeding, have any currently active malignancy, or have received any investigational agent(s) that is not FDA-approved or have participated in any interventional research study within 30 days from the start of the trial.",
    "The sample is a record of a clinical trial in phase 2 for the treatment of non-small-cell lung carcinoma. The trial involves the use of two drugs, irinotecan and docetaxel. The eligibility criteria for the trial include having a histologically or cytologically proven NSCLC that is recurrent or metastatic. However, individuals with prior malignancies, brain or meningeal metastases, or other specific conditions are excluded from the trial. The diseases are listed as a single item in a list, while the icd-10 codes are listed as a list of codes.",
    "The sample is a record from a clinical trial table that includes information about the trial's phase, diseases being studied, icd-10 codes of those diseases, drugs being used, and eligibility criteria for participants. In this particular trial, it is a phase 2 study for gastrointestinal stromal tumor (GIST) and the drug being used is pazopanib. The eligibility criteria include having metastatic or unresectable GIST, failure or intolerance to Imatinib and sunitinib, being at least 18 years old, having an Eastern Cooperative Oncology Group (ECOG) performance status of 0-2, and having adequate organ system function. The criteria also include exclusion factors such as a history of other malignancies within 5 years prior to Day 1, clinically significant gastrointestinal abnormalities, and uncontrolled infection. The sample also includes information about acceptable contraceptive methods for female participants and exclusion criteria related to cardiovascular conditions, bleeding disorders, and pre-existing medical or psychiatric conditions that could interfere with the study.",
    "This is a sample entry in a table that contains information about clinical trials. The trial is in phase 2 and is focused on treating nasopharyngeal neoplasms. The trial involves the use of two drugs, docetaxel and cisplatin. The eligibility criteria for the trial include having stages III and IV newly diagnosed NPC, while exclusion criteria include inadequate bone marrow reserve, inadequate renal function, evidence of distant metastases, and other primary malignancy. The information provided is not exhaustive and is intended to give an overview of the trial.",
    "The sample is a phase 2 clinical trial for patients with chronic obstructive pulmonary disease (COPD). The trial includes adult males and non-pregnant, non-lactating females aged between 40 and 80 years old, both inclusive. Patients must have a clinical diagnosis of stable moderate to severe COPD (stages II and III) according to the GOLD 2006 classification. They must also be current or ex-cigarette smokers with a smoking history of at least 10 pack-years. The trial involves the use of aclidinium bromide and formoterol, and a placebo. The eligibility criteria include various medical conditions and exclusions, such as a history or current diagnosis of asthma, allergic rhinitis or atopy, or exercise-induced bronchospasm, and a life expectancy of less than 1 year. Patients must also be able to properly use a dry powder or pressurised metered-dose inhalers (pMDI) inhaler device and/or to perform acceptable and reproducible spirometry measurements as per the ATS/ERS standards.",
    "The sample is a phase 2 clinical trial for patients with stage IIIB/IV adenocarcinoma in non-small cell lung cancer. The trial is testing the drug afatinib (bibw 2992) on patients who have had progressive disease following a second-line cytotoxic chemotherapy including at least one platinum-containing regimen and have a known wild-type EGFR status. The trial has inclusion and exclusion criteria, including limitations on prior treatments, brain metastasis, interstitial lung disease, cardiovascular abnormalities, and blood counts. Women of childbearing potential and men who are able to father a child must use a medically acceptable method of contraception during the trial. Pregnancy or breastfeeding is not allowed.",
    "The sample is a phase 2 clinical trial for patients with gastric cancer. The trial is testing the effectiveness of a combination of drugs, including cetuximab, cisplatin, and capecitabine. The eligibility criteria for the trial include being between the ages of 18 and 75, having confirmed gastric adenocarcinoma, and having unresectable recurrent or metastatic disease. Patients must also meet certain health requirements, such as having a Karnofsky performance status of at least 60 and a life expectancy of at least 2 months. There are also exclusion criteria, such as having brain metastasis or a known allergy to any of the study treatments.",
    "The sample is a phase 2 clinical trial for the treatment of multiple sclerosis using a drug called bg00012. The trial is open to individuals between the ages of 18 and 55 who have a confirmed diagnosis of relapsing-remitting MS and a baseline EDSS score between 0.0 and 5.0. Participants must have experienced at least one relapse within the 12 months prior to randomization and must not have a history of primary progressive, secondary progressive, or progressive relapsing MS. Exclusion criteria include a history of malignancy, severe allergies or drug hypersensitivity, abnormal laboratory results, HIV, drug or alcohol abuse within the past 2 years, and pregnancy or breastfeeding for female participants.",
    "The sample is a phase 2 clinical trial for rheumatoid arthritis. The trial involves testing the effectiveness of a p38 inhibitor drug in patients who have an inadequate response to methotrexate. The trial has inclusion criteria such as being an adult patient over 18 years of age and having active rheumatoid arthritis. The exclusion criteria include not receiving any other disease-modifying anti-rheumatic drug except for hydroxychloroquine or chloroquine. The diseases are listed as 'rheumatoid arthritis' and the icd-10 codes associated with it. The drugs being tested are listed as 'p38 inhibitor (4) 150mg', 'p38 inhibitor (4) 25mg', 'p38 inhibitor (4) 300mg', 'p38 inhibitor (4) 50mg', 'p38 inhibitor (4) 75mg', and 'placebo'.",
    "The sample is a phase 2 clinical trial for patients with bronchiectasis, lung disease, and respiratory diseases. The trial involves the use of the drugs azd5069 and placebo. The eligibility criteria include being a male or non-childbearing female between the ages of 18 and 80, having a clinical diagnosis of idiopathic or post-infective bronchiectasis, being a sputum producer with a history of chronic expectoration, and being on a stable treatment regimen. Exclusion criteria include having any clinically significant disease or disorder, having received live or live-attenuated vaccine in the 2 weeks prior to dosing, and having bronchiectasis associated with a generalised immunodeficiency disorder.",
    "The sample is a phase 2 clinical trial for breast cancer patients who have undergone neoadjuvant chemotherapy. The trial is testing the effectiveness of a combination of gemcitabine, capecitabine, and avastin. The eligibility criteria include being a woman over 18 years old with a performance status of 0-1, having residual invasive breast cancer or node positive disease following neoadjuvant chemotherapy, and meeting certain hematologic and metabolic parameters. The trial excludes patients with prior gemcitabine or capecitabine therapy, concurrent endocrine therapy, or evidence of metastatic disease. Patients must also not have serious infections or other medical conditions that would impair their ability to receive protocol treatment. The trial also has specific exclusions for patients with inadequately controlled hypertension, significant vascular disease, or a history of stroke or transient ischemic attack.",
    "The sample is a phase 2 clinical trial for the treatment of osteoarthritis of the knee. The trial involves the use of two drugs, nktr-181 and placebo. The eligibility criteria include being over 18 years old, having a clinical diagnosis of OA in one or both knees, and not experiencing adequate pain relief with current medication. Exclusion criteria include pregnancy or lactation, known hypersensitivity or allergy to opioids, and any medical condition that would preclude study participation. Participants must also agree to use contraception if they are of childbearing potential.",
    "The sample is a phase 2 clinical trial for patients with advanced liver cancer. The trial is testing the effectiveness of two drugs, alvocidib and irinotecan hydrochloride. The eligibility criteria include having confirmed hepatocellular carcinoma, measurable disease, and Child-Pugh class A or B status if liver cirrhosis is present. Patients must also meet certain age, performance status, and hematopoietic, hepatic, renal, cardiovascular, and pulmonary requirements. They cannot be pregnant or nursing, must use effective contraception, and cannot have had an allergic reaction to compounds of similar chemical or biological composition to flavopiridol or irinotecan. Patients cannot have had prior systemic biologic therapy or systemic chemotherapy for hepatocellular carcinoma, and cannot be receiving other concurrent chemotherapy or investigational agents.",
    "The sample is a phase 2 clinical trial for the treatment of nasopharyngeal neoplasms and carcinoma. The trial involves the use of drugs such as docetaxel, cisplatin, and 5-fluorouracil. The eligibility criteria for the trial include a histological diagnosis of nasopharyngeal carcinoma, newly diagnosed Stage IIB-IV NPC with measurable disease, and age between 1 month to 21 years at the time of diagnosis. Exclusion criteria include short life expectancy, prior chemotherapy or radiotherapy to the nasopharynx or neck for the treatment of nasopharyngeal carcinoma, and inadequate renal function.",
    "The sample is a phase 2 clinical trial for breast cancer. The eligibility criteria include being at an increased risk for the development or recurrence of breast cancer, having no clinical evidence of breast cancer, and having acceptable quality dual-energy x-ray absorptiometry (DEXA) of the L2-L4 postero-anterior (PA) spine and hip performed within the past 6 months. Patients must also be postmenopausal females, with no uncontrolled metabolic or endocrine disease, and willing and able to complete quality of life questionnaires in either English or French. Prior concurrent therapy is not allowed, except for certain endocrine therapies. The trial is investigating the effectiveness of letrozole as a treatment for breast cancer.",
    "The sample is a phase 2 clinical trial for patients with metastatic breast cancer. The trial is testing the effectiveness of paclitaxel albumin nanoparticle for injectable suspension. The eligibility criteria include having signed an informed consent, having confirmed locally advanced or metastatic breast cancer, having measurable disease, being over 18 years old, having an ECOG Performance Status of 0 or 1, having an estimated life expectancy of at least 12 weeks, and meeting certain liver, renal, and bone marrow function requirements. Patients must not have received prior chemotherapy for metastatic breast cancer or Abraxane, and must not have serious intercurrent medical or psychiatric illness. Patients with brain metastases or who are pregnant or lactating are also excluded.",
    "The sample is a phase 2 clinical trial for patients with metastatic melanoma and brain metastases. The trial is testing the drug GSK2118436. The eligibility criteria include having no prior local therapy for brain metastases, being on a stable or decreasing dose of corticosteroids for at least 3 weeks prior to treatment, and having at least one measurable intracranial target lesion. Patients must also have adequate organ function and a performance status of 0-1. Exclusion criteria include previous treatment with a BRAF or MEK inhibitor, presence of leptomeningeal disease or primary dural metastases, and unresolved toxicity from previous anti-cancer therapy. Women of childbearing potential must have a negative pregnancy test and practice acceptable methods of birth control during the study.",
    "The sample is a phase 2 clinical trial for the treatment of myelodysplastic syndrome (MDS) using the drug ezatiostat hydrochloride. The trial is open to patients with primary or de novo MDS, low or intermediate-1 MDS, and documented significant anemia with or without neutropenia and/or thrombocytopenia. Patients must also have adequate kidney and liver function and have discontinued hematopoietic growth factors at least 3 weeks prior to study entry. Exclusion criteria include prior allogenic bone marrow transplant for MDS, history of MDS IPSS score greater than 1.0, pregnant or lactating women, any severe concurrent disease, infection, or comorbidity that, in the judgement of the investigator, would make the patient inappropriate for study entry, oral steroids e.g. prednisone >10 mg per day, history of active hepatitis B or C, and known history of HIV.",
    "The sample is a phase 2 clinical trial for patients with relapsed or refractory Hodgkin's lymphoma, including all subtypes. The trial is testing the effectiveness of the drug vorinostat. Patients must have evidence of disease progression or lack of response after the most recent therapy, including local radiation. They must also have completed chemotherapy and radiotherapy at least 28 and 14 days prior to registration, respectively, and all toxicities must have resolved. Patients must meet various eligibility criteria, including having a Zubrod performance status of 0-2, bidimensionally measurable disease, and negative laboratory or radiographic tests for central nervous system involvement. They must also have a history of no prior malignancy, except for certain types, and must not be pregnant or nursing. Patients must be informed of the investigational nature of the study and must sign and give written informed consent.",
    "The sample is a phase 2 clinical trial for patients with prostate cancer who are candidates for curative RRP and have intermediate or high risk, clinically localized disease. The trial involves the use of the drug sunitinib malate. The eligibility criteria include having adequate organ function, being surgically sterile or agreeing to use effective contraception during the period of therapy, and signing an informed consent document. Exclusion criteria include prior treatment for prostate cancer, major surgery or radiation therapy within 4 weeks of starting the study treatment, and a history of or known metastatic prostate cancer. Other exclusion criteria include certain medical conditions or laboratory abnormalities that may increase the risk associated with study participation or study drug administration.",
    "The sample is a record of a clinical trial with a phase 2 designation. The trial is focused on treating bacterial infections, pneumonia caused by pneumocystis carinii, and HIV infections. The trial involves the use of drugs such as azithromycin, atovaquone, and sulfamethoxazole-trimethoprim. The eligibility criteria for the trial include being HIV-positive, between the ages of 3 months and 18 months, at risk for developing pneumonia, and having a CD4 count of less than 1,500 cells/mm3 if under 1 year of age or a CD4 count of less than 500 cells/mm3 if between 1 and 2 years of age. Exclusion criteria include having an infection that requires treatment, being allergic to the drugs used in the trial, and having serious diarrhea for more than 1 week.",
    "The sample is a phase 2 clinical trial for the treatment of thyroid cancer that is metastatic or locally advanced and not responsive to local therapy or radioactive iodine. The trial is testing the drug gefitinib. The eligibility criteria include confirmed diagnosis of thyroid cancer, measurable disease, Eastern Cooperative Oncology Group performance status of 0-2, and being at least 18 years old. Exclusion criteria include concurrent chemotherapy or radiation therapy, pregnancy or nursing, and certain medical conditions or medications. The sample also includes a list of diseases (head and neck cancer) and their corresponding ICD-10 codes, as well as the eligibility criteria in a structured format.",
    "The sample is a phase 2 clinical trial that involves patients with congestive heart failure, cardiac transplantation, renal insufficiency, and renal failure. The trial includes two drugs, natrecor (nesiritide) with standard care and dobutamine or milrinone with standard care and placebo. The eligibility criteria for the trial include meeting the criteria for a United Network for Organ Sharing (UNOS) Status 1B heart transplant candidate, being a primary transplant candidate waiting to receive a single cardiac allograft, and receiving continuous intravenous infusion of dobutamine or milrinone through a double-lumen central catheter or a double-lumen percutaneously inserted central catheter for at least 3 consecutive days before randomization. The exclusion criteria include not having systolic blood pressure consistently < 80 mm Hg, not weighing > 130 kg, not having a ventricular assist device (VAD), not requiring chronic hemodialysis or peritoneal dialysis to treat renal failure, not having received antibiotic treatment within 7 days before randomization, and more.",
    "The sample is a phase 2 clinical trial for the treatment of metastatic renal cell carcinoma. The trial involves the use of three drugs - bevacizumab, sunitinib, and placebo. The eligibility criteria for the trial include having a confirmed diagnosis of metastatic RCC, measurable disease, and a performance status of 0 or 1. Patients must also have had a prior nephrectomy and be at least 18 years old. Exclusion criteria include having certain medical conditions, such as inadequate organ function or a history of hypertensive crisis, as well as having received prior systemic or adjuvant therapy for RCC. Patients must also not be currently participating in another experimental drug study and must not be pregnant or lactating.",
    "The sample is a phase 2 clinical trial for breast cancer patients with locally advanced or inflammatory breast cancer. The trial is testing the effectiveness of a combination of drugs including sunitinib malate, paclitaxel, doxorubicin hydrochloride, and cyclophosphamide. The eligibility criteria include having a confirmed diagnosis of breast cancer, being judged primarily unresectable by an experienced breast surgeon, and having a performance status of 0-2 by Zubrod criteria. Patients must also meet certain laboratory test requirements and have a left ventricular ejection fraction greater than the institutional lower limit of normal. Exclusion criteria include evidence of distant metastases, tumors that overexpress human epidermal growth factor receptor 2 (HER2)/neu, and prior chemotherapy or hormonal therapy for breast cancer. Patients must also not have certain medical or psychiatric conditions that may increase the risk associated with study participation or study drug administration.",
    "The sample is a phase 2 clinical trial for breast cancer patients with metastatic disease who have not responded to previous chemotherapy treatments or have confirmed tumor involvement on bone marrow biopsy. The trial involves the use of cyclosporine, fludarabine phosphate, melphalan, and methotrexate drugs. Eligibility criteria include being an appropriate candidate for allogeneic stem cell transplantation, having no active CNS metastases, and having an available HLA-identical sibling donor. Patient characteristics include being female, aged 18 to 60, and having a Karnofsky performance status of 70-100% or ECOG of 0-1. Prior concurrent therapy includes no concurrent immunosuppressive medication.",
    "The sample is a phase 2 clinical trial for the treatment of migraine headaches. The trial includes patients who have a history of migraine for at least 1 year prior to enrollment, with migraine onset before the age of 50 and a moderate frequency of migraine headaches. Women of child-bearing potential must test negative for pregnancy and agree to use a reliable method of birth control during the study and for 3 months following completion of participation in the study. Patients must not be on any migraine prevention therapy, including botulinum toxin (Botox). The trial has inclusion and exclusion criteria, including no enrollment in any other medical research judged not to be scientifically or medically compatible with this study, no history of chronic migraine or migraine subtypes, and no significant active psychiatric disease. The sample also includes a list of drugs being tested, including ly2951742 and placebo.",
    "The sample is a record from a clinical trial table that includes information about the trial's phase, diseases being studied, associated ICD-10 codes, drugs being tested, and eligibility criteria for participants. In this particular sample, the trial is in phase 2 and is focused on studying breast cancer. The associated ICD-10 codes for the disease are listed, along with the drugs being tested, which include docetaxel, vinorelbine, and trastuzumab. The eligibility criteria for participants are also listed, including confirmation of metastatic breast cancer through biopsy, overexpression of the Her-2 oncogene, age over 18, measurable disease, and adequate bone marrow, liver, and kidney function. There are also exclusion criteria, such as abnormal heart function and pre-existing symptomatic peripheral neuropathy. The study center will determine if a participant meets all of the criteria, and if they do, study personnel will explain the trial in detail and answer any questions.",
    "This sample is for a phase 2 clinical trial focused on contraception. The trial is looking at the effectiveness of a combination of four drugs: nomegestrol acetate (nomac), etonogestrel (eng), ethinyl estradiol (ee), and estradiol (e2). The eligibility criteria for participants include having a body mass index (BMI) between 18 and 35, regular menstrual cycles between 24 and 35 days in length, and good physical and mental health. Exclusion criteria include having diabetes with vascular involvement, severe dyslipoproteinemia, severe hypertension, severe hepatic disease, and undiagnosed vaginal bleeding, among others. Participants must not have participated in another investigational drug study within 30 days prior to screening and must not have had a history of malignancy within the past 5 years, except for certain types of cancer. Additionally, participants must not have undergone sterilization using a fallopian tube occlusion device or received sex hormone therapy for a purpose other than contraception within 2 months prior to screening.",
    "The sample is a phase 2 clinical trial for patients with recurrent anaplastic astrocytoma or glioblastoma. The trial requires patients to have had prior pathologic confirmation of primary tumor histology and to have undergone surgery documenting tumor histology. Patients must also have measurable disease per MacDonald criteria required using contrast enhanced cranial MRI. The trial involves the use of the drug sunitinib malate. Patients must meet certain eligibility criteria, including resolution of all acute toxic effects of prior chemotherapy or radiotherapy or surgical procedures to NCI CTCAE Version 3.0 grade \u22641, adequate organ function, and a Karnofsky performance status (KPS) \u2265 60%. Patients must also have a life expectancy of \u2265 12 weeks and be willing and able to comply with scheduled visits, treatment plan, laboratory tests, and accessible for follow-up. The trial has exclusion criteria, including major surgery or radiation therapy within 4 weeks of starting study treatment, ongoing cardiac dysrhythmias of NCI CTCAE grade \u22652, and other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or study drug administration.",
    "The sample is a record of a clinical trial in phase 2, focused on the disease of asthma. The trial includes a list of icd-10 codes related to asthma, as well as a list of drugs being tested, including \"jnj-18054478\" and \"sham comparator\". The eligibility criteria for participants are also listed, including requirements such as a confirmed diagnosis of persistent asthma, ability to demonstrate reversibility with albuterol inhalation, and willingness to perform study procedures for about 14 weeks. Exclusion criteria are also listed, such as recent use of inhaled or oral corticosteroids, history of life-threatening asthma attack, and being a female of childbearing potential.",
    "The sample is a phase 2 clinical trial for individuals between the ages of 18-65 who have alcohol dependence and a comorbid anxiety disorder, including panic disorder, social phobia, generalized anxiety disorder, substance-induced anxiety disorder, and anxiety disorder, no otherwise specified (NOS). The trial involves the drug levetiracetam and requires individuals to have clinically significant anxiety and current average alcohol use over the past 28 days with more than 4 drinking days per week and more than 4 standard drinks per drinking day for women and more than 5 standard drinks per drinking day for men. Women of child-bearing age are included if they are not pregnant and agree to use a method of contraception with proven efficacy. The trial has inclusion and exclusion criteria, including exclusion for individuals with any current Axis I psychiatric disorder, evidence of moderate to severe alcohol withdrawal, current cocaine or opioid dependence, unstable physical disorders, and those currently taking prescribed psychotropic medications. Women who are pregnant or nursing are also excluded.",
    "The sample is a phase 2 clinical trial for patients with type 2 diabetes mellitus and moderately impaired kidney function. The trial is testing the effectiveness of two drugs, aleglitazar and pioglitazone, on patients who are drug naive or taking up to two antihyperglycemic medications at a stable dose for over a month. The inclusion criteria for the trial include being an adult patient over 18 years of age with a BMI between 25-35. The exclusion criteria include previous treatment with a thiazolidinedione or insulin, treatment with fibrates within three months prior to screening, and a history of renal disease other than diabetic nephropathy.",
    "The sample is a phase 2 trial for patients with anemia and aging. The trial is testing the drug Epoetin Alfa. The eligibility criteria for the trial includes being 70 years or older, diagnosed with anemia, having a hemoglobin level less than or equal to 11, and being able to perform most activities of daily living without restriction. The exclusion criteria includes having a history of serious heart, liver or kidney disease, having cancer treated within the last year (excluding skin cancer), having problems with the immune system, and having received Epoetin Alfa within the last year.",
    "The sample is a phase 2 clinical trial for patients with recurrent non-small cell lung cancer. The trial is testing the combination of two drugs, itraconazole and pemetrexed. The eligibility criteria include having received at least one previous chemotherapy regimen and having measurable disease. Patients must also have normal organ and marrow function, be over 18 years old, have a life expectancy of greater than 12 weeks, and have an ECOG performance status of less than 2. Women of child-bearing potential and men must agree to use adequate contraception. The exclusion criteria include having received chemotherapy or radiotherapy within 2 weeks prior to entering the study, receiving any other investigational agents, having received prior pemetrexed chemotherapy, and having uncontrolled brain metastases. Patients with a history of allergic reactions to compounds of similar chemical or biologic composition to itraconazole and pemetrexed or other agents used in the study are also excluded. Additionally, patients with uncontrolled intercurrent illness, pregnant women, and HIV-positive patients on combination antiretroviral therapy are ineligible.",
    "The sample is a phase 2 clinical trial for patients with transitional cell carcinoma of the bladder or urothelium. The trial includes patients who have measurable disease and have recurred or progressed on platinum-based chemotherapy. Patients must also meet certain eligibility criteria, including having a life expectancy of greater than 3 months, an ECOG performance status of <= 2, and normal levels of various blood markers. Patients must not have had more than 2 cytotoxic chemotherapy regimens for urothelial transitional cell cancer and must not have taken certain medications prior to study entry. The trial involves the use of the drug vorinostat. The eligibility of patients receiving any medications or substances known to affect or with the potential to affect the activity or pharmacokinetics of SAHA will be determined following review by the principal investigator. The trial has exclusion criteria, including patients with known brain metastases and pregnant women.",
    "The sample is a phase 2 clinical trial for sickle cell disease. The trial includes participants who are male or female with homozygous sickle cell or hemoglobin S beta ^0 thalassemia, have a body weight of at least 12 kilograms and are between 2 to less than 18 years of age at the time of screening. Participants on hydroxyurea must be on a stable dose for the 60 days prior to enrollment without signs of hematologic toxicity at screening. The trial also includes exclusion criteria such as having hemoglobin C sickle cell or hemoglobin S beta ^plus thalassemia genotypes, vaso-occlusive crisis requiring medical attention within 15 days prior to screening, and having a concomitant medical illness that in the opinion of the investigator is associated with reduced survival. The trial also has inclusion and exclusion criteria related to bleeding risk, platelet count, recent surgery, and medication use. The trial requires participants to have a legal representative that is in competent mental condition to provide written informed consent on behalf of the study participant before entering the study.",
    "The sample is a phase 2 trial for individuals with moderate to severe chronic obstructive pulmonary disease (COPD) and a stable pulmonary disease status. The trial is testing the effectiveness of sodium pyruvate in 0.9% sodium chloride solution as a treatment for COPD. The eligibility criteria for the trial include having a clinical diagnosis of COPD, being less than 85 years old, not having any other pulmonary disease, not having clinically significant cardiac disease, not being pregnant or lactating, not having taken oral or IV corticosteroids within one month of the screening visit, not having been hospitalized within the last 6 months due to acute exacerbation of air-way disease, not being on escalating dose of immunotherapy, not having a clinically significant abnormal chest x-ray within the past 12 months, not having medication changes within 1 month, not having participated in another investigation drug treatment study within the previous month, not having a current history of alcohol abuse or recreational drug use, not having taken vitamins with anti-oxidant properties (E or C) or dietary supplements containing pyruvate within 24 hours prior to the screening visit, and using at least 4 puffs of Albuterol a day over the period between the Screening Visit and Visit 1.",
    "The sample is a phase 2 clinical trial for obesity and related metabolic diseases. The trial involves testing the effectiveness of a drug called r256918 compared to a placebo. The eligibility criteria for participants include having a liver fat content between 3% and 15%, being classified as obese with a BMI between 30 and 50 kg/square meter, and having a fasting plasma glucose level below 7.0 mmol/liter. Exclusion criteria include a history of obesity with a known cause, diabetes mellitus, recent weight reducing diet or drug treatment for obesity, and significant changes in smoking habits within 3 months prior to enrollment. The diseases and corresponding ICD-10 codes are also listed.",
    "The sample is a phase 2 clinical trial for non-small cell lung cancer. The trial involves the use of two drugs, paclitaxel and carboplatin. The eligibility criteria for the trial include having histologically or cytologically confirmed NSCLC, advanced NSCLC, measurable disease, ECOG Performance Status of \u2264 1, age \u2265 18 years, adequate hematologic, hepatic, renal, and coagulation function, adequate contraception, and signed informed consent. Exclusion criteria include untreated CNS metastases, prior bevacizumab therapy, radiologically documented evidence of major blood vessel invasion or encasement by cancer, and concurrent treatment with other anticancer therapy. The sample also includes a list of ICD-10 codes for the disease and a detailed list of inclusion and exclusion criteria.",
    "The sample is a phase 2 clinical trial for patients with persistent asthma. The trial involves the use of the drugs indacaterol and placebo to indacaterol. The eligibility criteria for the trial include having a stable regimen of inhaled corticosteroid treatment for at least a month prior to screening, having a FEV1 (forced expiratory volume in one second) between 50% and 90% of predicted normal at screening, and experiencing an increase of at least 12% and 200 mL in FEV1 after inhaling a total dose of albuterol/salbutamol within 30 minutes. Exclusion criteria include a smoking history of at least 10 years, a diagnosis of COPD, previous intubation for a severe asthma attack, hospitalization for a severe asthma attack within the past 6 months, and other respiratory tract infections or allergies that may affect the study. Other protocol-defined inclusion/exclusion criteria may also apply.",
    "The sample is a phase 2 clinical trial for Parkinson's disease. The trial includes patients who are male or female, aged 30-75, with good response to levodopa and motor fluctuations of the wearing \"off\" type. The patients must have clinically relevant dyskinesias during the \"on\" period following each morning dose of their current medication. They must also rate between II-IV on the Hoehn and Yahr scale when in an \"off\" state and be taking levodopa at least three times daily. The trial has inclusion and exclusion criteria, including patients with a past or present history of drug or alcohol abuse, and patients with conditions affecting the peripheral or central sensory system unless related to Parkinson's disease.",
    "The sample is a phase 2 clinical trial for diabetic peripheral neuropathy. The trial includes patients who are over 18 years old and have type 1 or type 2 diabetes with a hemoglobin A1c (HbA1c) \u2264 10%. Patients must also have been diagnosed with painful distal symmetrical sensorimotor polyneuropathy for at least 6 months, based on neurological history and/or examination. The trial involves the use of drugs such as ds-5565 tablet, pregabalin capsule, placebo tablet, and placebo capsule. Patients must meet certain inclusion criteria, such as having a pain score of \u2265 40 mm on the SF-MPQ VAS, and must not meet any exclusion criteria, such as having a diagnosis of mononeuropathy or a history of pernicious anemia. The trial also requires patients to be willing to comply with scheduled visits, treatment plans, laboratory tests, and other trial procedures.",
    "The sample is a phase 2 trial for tobacco use disorder. The trial includes patients who are 16 years or older, pregnant for 26 weeks or less, able to speak English or Spanish, and intend to carry to term. The patients must have smoked five or more cigarettes every day for the past seven days. The trial excludes patients with a fetus with a known congenital abnormality, unstable medical problems, multiple gestation, unstable psychiatric disorder, and current drug or alcohol abuse or dependence. The trial uses a placebo and 2 mg nicotine polacrilex as drugs. The diseases are listed as tobacco use disorder and the icd-10 codes are listed as Z72.0 and P04.2.",
    "The sample is a phase 2 clinical trial for the treatment of multiple sclerosis. The trial includes patients with a definite diagnosis of MS according to McDonald's criteria, with a relapsing clinical course, and an Expanded Disability Status Scale (EDSS) less than or equal to 5.5. Patients must have been on a stable dose of Glatiramer Acetate (GA) for at least 26 weeks prior to the screening visit and must not have experienced an MS relapse in the preceding 60 days prior to randomization. The trial excludes patients with other chronic diseases of the immune system, liver function impairment, chronic pancreatic disease, pregnant or nursing women, alcohol or drug abuse, and those who have used certain immunosuppressant agents before enrollment. The eligibility criteria are not intended to contain all considerations relevant to a patient's potential participation in the trial.",
    "The sample is a record of a clinical trial with a phase 2 designation. The trial is focused on type 2 diabetes and includes a list of ICD-10 codes for the disease. The trial involves the use of several drugs, including teneligliptin at different dosages and a placebo. The eligibility criteria for the trial include patients between the ages of 20 and 75 who have been managing their diabetes through diet and exercise for at least 12 weeks. Patients must also have an HbA1c level between 6.5% and 9.5% and cannot have taken any prohibited drugs within 12 weeks of the trial. Exclusion criteria include patients with type 1 diabetes, serious diabetic complications, severe hepatic or renal disorders, and those who are pregnant or unable to agree to contraception.",
    "The sample is a record of a clinical trial with a phase 2 designation. The trial is focused on treating metastatic pancreatic adenocarcinoma, and the table includes a list of disease names and ICD-10 codes. The trial is testing the effectiveness of a drug combination of gemcitabine, trastuzumab, and erlotinib. The table also includes eligibility criteria for participants, such as confirmed histology of metastatic pancreatic adenocarcinoma, measurable lesions, and certain health parameters. There are also exclusion criteria, such as the presence of cerebral metastases or significant co-morbidities. The sample is a detailed description of the trial and its requirements for participants.",
    "The sample is a phase 2 clinical trial for patients with chronic obstructive pulmonary disease (COPD). The trial is testing the effectiveness of the drugs gsk573719, tiotropium, and placebo. The eligibility criteria include being an outpatient, being between 40 and 80 years old, having a diagnosis of COPD, and being a current or former smoker with a history of smoking for at least 10 pack-years. There are also exclusion criteria, such as having other significant respiratory conditions in addition to COPD, being pregnant or lactating, and having a body mass index (BMI) value of over 35 kg/m2. The sample includes a detailed list of both inclusion and exclusion criteria.",
    "The sample is a phase 2 clinical trial for the treatment of psoriasis vulgaris. The trial includes subjects who have signed an informed consent, are 18 years or older, and have psoriasis vulgaris with lesions located on their arms, legs, and/or trunk. The trial excludes females who are pregnant or breastfeeding, subjects who have received systemic treatment with biological therapies within a certain time frame, subjects who have used certain topical drugs within a certain time frame, and subjects with certain medical or dermatological disorders. The trial also excludes subjects who are unable to comply with the Clinical Study Protocol or who have previously been randomized in this trial. The trial involves the use of several different drugs and includes specific eligibility criteria for inclusion and exclusion.",
    "The sample is a phase 2 clinical trial for chronic obstructive pulmonary disease (COPD). The trial includes a list of drugs, such as pt003 mdi, pt005 mdi, and tiotropium bromide 18 \u03bcg (spiriva handihaler\u00ae), as well as a placebo mdi. The eligibility criteria for the trial include being between 40-80 years old, having a clinical history of COPD with airflow limitation that is not fully reversible, and having a measured post-bronchodilator FEV1/FVC ratio of < or = 0.70. The trial also has exclusion criteria, such as not being pregnant or lactating, not having a primary diagnosis of asthma, and not having abnormal chest X-rays or CT scans not due to the presence of COPD. Other protocol-defined inclusion/exclusion criteria may also apply.",
    "The sample is for a phase 2 clinical trial and focuses on two diseases, geographic atrophy and dry age-related macular degeneration. The icd-10 code for the diseases is \"K14.1\". The trial will use the drug fenretinide. The eligibility criteria for the trial include being between 50 and 89 years old and having GA from AMD in one or both eyes. The exclusion criteria include having GA due to any disease other than AMD, such as drug-induced GA.",
    "The sample is a phase 2 clinical trial for patients with peripheral T-cell lymphoma. The trial is testing the effectiveness of pralatrexate injection as a treatment option. The eligibility criteria include confirmed diagnosis of PTCL, documented progression of disease after at least one prior treatment, and adequate hematological, hepatic, and renal function. Patients must also have an ECOG Performance Status \u2264 2 and be at least 18 years of age. Exclusion criteria include active concurrent malignancy (except non melanoma skin cancer or carcinoma in situ of the cervix), congestive heart failure Class III/IV, uncontrolled hypertension, and HIV-positive diagnosis and receiving combination anti-retroviral therapy. Patients must have given written informed consent to participate in the trial.",
    "The sample is a phase 2 clinical trial for patients with recurrent or persistent ovarian epithelial, fallopian tube, or primary peritoneal carcinoma. The trial involves the drug motesanib diphosphate and has eligibility criteria including having received one prior platinum-based chemotherapeutic regimen, having measurable disease, and meeting certain patient characteristics such as having a GOG performance status of 0-2 and no history of uncontrolled CNS metastases. The trial also has restrictions on prior and concurrent therapies and requires patients to meet certain medical criteria such as having normal cardiac ejection fraction and no bleeding diathesis or hypercoagulopathy within the past 14 days.",
    "The sample is a phase 2 clinical trial for patients with non-small cell lung cancer. The trial is testing the effectiveness of two drugs, velcade and alimta, for patients who have relapsed or refractory locally advanced or metastatic NSCLC and have failed one prior line of systemic antineoplastic therapy. The trial has specific inclusion and exclusion criteria, including age, disease confirmation, performance status, and organ function. Patients must also sign an informed consent document and agree to participate in genetic and protein testing. The trial aims to determine the safety and efficacy of the drugs for this patient population.",
    "The sample is a phase 2 clinical trial for sickle cell anemia, hemoglobinopathy, and thalassemia. The trial involves the use of drugs such as campath-1h, dilantin, busulfan, and cyclophosphamide. The eligibility criteria for the trial include having homozygous B0/+ thalassemia or severe variants of B0/+ thalassemia with an HLA genotypically identical donor, or having an HLA genotype identical donor and hemoglobin SS, hemoglobin SC, or hemoglobin Sb 0/+ with certain medical conditions. The patient must be between the ages of birth and 65 years, and women of childbearing potential must have a negative pregnancy test. There are also exclusion criteria, such as chronic active hepatitis or fibrosis with portal bridging, severe renal dysfunction, and severe cardiac dysfunction. Pregnant, lactating, or unwilling patients to use appropriate birth control are also excluded.",
    "The sample is a phase 2 clinical trial for the treatment of obesity using the drug tesofensine. The trial is open to both male and female patients between the ages of 18 and 65 with a BMI between 30 and 40 kg/m\u00b2 who have been continuously receiving diet therapy and exercise instructions for at least 2 weeks without gaining weight. Female patients of childbearing potential must use safe contraceptive methods. Patients must be able to comply with study procedures and have stable smoking habits for at least 2 months. The trial has a list of exclusion criteria, including the use of certain prescription medications, pregnancy or lactation, specific diseases interfering with metabolism, and recent drug abuse or dependence. Patients with certain medical conditions, such as hyperthyroidism or significant cardiovascular disease, are also excluded. The trial has a detailed list of inclusion and exclusion criteria that must be met for patients to participate.",
    "The sample is a phase 2 clinical trial for lung cancer. The trial involves the use of two drugs, enzastaurin and placebo. The eligibility criteria for participants include having metaplasia or dysplasia on at least one bronchoscopy specimen, a history of cigarette smoking of at least 30 pack years, having quit smoking at least one year prior to study entry, and being able to undergo bronchoscopy and helical computed tomography (CT) scanning of the chest. The exclusion criteria include blood clotting abnormalities, current smoking within the past year, unwillingness to abstain from smoking or avoid significant second-hand smoke exposure, evidence for lung cancer or carcinoma in situ, active cardiovascular disease, and current illicit drug or alcohol abuse.",
    "The sample is a phase 2 clinical trial for prostate cancer patients who require androgen deprivation therapy. The trial is testing the effectiveness of the drug enzalutamide. The eligibility criteria for the trial include having histologically confirmed prostate cancer, being asymptomatic from prostate cancer, having a non-castrate level of testosterone, and having a PSA level of at least 2 ng/mL. The exclusion criteria include having previously or currently receiving hormonal therapy, systemic glucocorticoids, chemotherapy, opiate analgesics, or radiation therapy for prostate cancer treatment, having a history of known or suspected brain or skull metastases or leptomeningeal disease, having a history of seizure or any condition that may predispose to seizure, and having clinically significant cardiovascular disease.",
    "The sample is a phase 2 trial for patients with unresectable metastatic adenocarcinoma of the colon or rectum that cannot be cured by surgical resection at the time of randomization. The trial includes patients who have failed first-line treatment containing fluoropyrimidine and oxaliplatin-based chemotherapy with or without bevacizumab for mCRC. The trial involves the use of drugs such as irinotecan, folfiri, pre-emptive skin treatment, and reactive skin treatment. The diseases being studied include metastatic colorectal cancer, skin rash, skin toxicities, colon cancer, and colorectal cancer. The trial also includes a list of icd-10 codes of diseases and eligibility criteria for inclusion and exclusion.",
    "The sample is a phase 2 clinical trial for respiratory syncytial virus infections in patients who have undergone single or bilateral lung transplant. The trial includes the use of two drugs, aln-rsv01 and normal saline. The eligibility criteria include confirmed RSV infection, being greater than 90 days post current lung transplant, and being rejection-free for at least 1 month. The exclusion criteria include antimicrobial therapy for known respiratory co-infection, bronchiolitis obliterans syndrome, recent use of certain medications, and active treatment for acute graft rejection.",
    "The sample is a phase 2 clinical trial for patients with recurrent or metastatic squamous cell carcinoma of the head and neck. The trial includes patients who have received no more than one prior chemotherapeutic regimen for their disease and have measurable disease as defined by RECIST criteria. Patients must also have an Eastern Cooperative Oncology Group (ECOG) performance status of 0-1 and meet certain laboratory criteria. The trial involves the drug dasatinib and requires paraffin embedded tumor tissue that is appropriate for immunohistochemistry (IHC) and fluorescent in situ hybridization (FISH) analysis or patient biopsy to obtain tissue for the study. Patients must also meet certain exclusion criteria, such as having uncontrolled or severe medical disease, receiving other investigational agents, or having clinically significant cardiovascular disease.",
    "The sample is a phase 2 clinical trial for chronic genotype 1 Hepatitis C infection. The trial includes the drugs tmc435, placebo, peginterferon (pegifn\u03b1-2a), and ribavirin. The eligibility criteria include having documented chronic Hepatitis C infection, a certain amount of virus in the blood, and a body mass index between 18 and 32 kg/m\u00b2. Exclusion criteria include liver cirrhosis or decompensated liver disease, recent treatment with certain medications, and certain medical conditions or drug use. Participants must also be able to comply with the protocol requirements and have good accessible veins.",
    "The sample is a phase 2 trial for diabetic foot infections. The trial includes patients with previously known or newly diagnosed diabetes mellitus, controlled by proper lifestyle or treatment with either oral medications or insulin. Patients must have a clinically defined diabetic foot infection of mild or moderate severity, evidence of necrotic tissue, purulent collections or abscess that may require excision, incision or drainage, and must be able to provide suitable tissue specimens for Gram-staining and bacterial cultures. The trial excludes patients with co-morbid disease conditions that could compromise evaluation or participation, history of prolonged QTc interval or a medical condition requiring the use of a concomitant medication that is associated with an increased QTc interval, contact dermatitis over the infected skin area, infected third-degree burn wounds, necrotizing fascitis, extensive gangrene, pyoderma gangrenosum, deep vein thrombosis, shock, or any medical disorder that could either interfere with the evaluation of treatment or the response of the patient to therapy.",
    "The sample is a phase 2 clinical trial for patients with advanced or metastatic colorectal cancer who have not previously received epidermal growth factor receptor (EGFR) antibody treatment. The trial involves the use of panitumumab monotherapy after failure of fluoropyrimidine-, oxaliplatin-, and irinotecan-containing chemotherapy regimens. The eligibility criteria include being 18 years or older, having an Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2, and meeting certain medical requirements such as bilirubin levels and liver function. Women of child-bearing potential must use adequate contraception methods. Exclusion criteria include serious medical conditions or psychiatric illness, allergic reactions to the medications, prior treatment with EGFR antibody, and participation in other clinical studies in the previous 4 weeks.",
    "The sample is a phase 2 clinical trial for the treatment of rheumatoid arthritis. The trial includes patients who have been diagnosed with rheumatoid arthritis for at least 6 months and have active RA with at least 6 swollen and 6 tender joints. The patients must have been treated with and tolerated at least one of the specified medications for a minimum of 6 months prior to screening and must be on a stable dose for a minimum of 8 weeks prior to screening. The trial also includes inclusion and exclusion criteria for the patients. The inclusion criteria include a positive diagnosis for anti-cyclic citrullinated peptide (anti-CCP) antibody or rheumatoid factor (RF) in serum, and serum C-reactive protein (CRP) >= 0.80 mg/dL at screening. The exclusion criteria include having inflammatory diseases other than RA, having a history of juvenile idiopathic arthritis (JIA), and having current signs or symptoms of liver or renal insufficiency or cardiac, vascular, pulmonary, gastrointestinal, endocrine, neurologic, hematologic, psychiatric, or metabolic disturbances that are severe, progressive, or uncontrolled.",
    "The sample is a phase 2 clinical trial for patients with inoperable esophageal carcinoma. The trial is testing the effectiveness of two drugs, folfox 4 and 5-fu/cisplatin, on patients who have not received prior treatment for esophageal cancer. The eligibility criteria include having histologically proven adenocarcinoma, squamous cell or adenosquamous carcinoma of the esophagus, no prior treatment for esophageal cancer, and meeting certain medical criteria such as having adequate bone marrow reserve and normal renal and liver functions. The trial also has exclusion criteria, such as having metastatic disease or a history of prior malignancies. The trial requires patients to sign informed consent and start treatment within 28 days of inclusion.",
    "The sample is a phase 2 clinical trial for patients with metastatic adenocarcinoma or poorly differentiated carcinoma of the pancreas who have received one or two prior chemotherapy regimens for metastatic disease. The trial involves the drug sta-9090 and has eligibility criteria such as measurable disease by RECIST criteria, ECOG PS 0 or 1, life expectancy of at least 12 weeks, and various laboratory values within normal ranges. Exclusion criteria include primary brain tumors or active brain metastases, history of stroke within 6 months of treatment, and other significant medical conditions that may increase the risk associated with study participation or study drug administration. Women of childbearing potential must have a negative serum pregnancy test and agree to use adequate contraception. The trial also has specific criteria for patients who have received adjuvant or neoadjuvant therapy.",
    "The sample is a phase 2 clinical trial for the treatment of follicle center cell lymphoma using the drug lenalidomide. The eligibility criteria include confirmation of the disease, prior treatment with rituximab, age over 18, Eastern Cooperative Oncology Group (ECOG) Performance Status 0-2, and measurable disease present on physical examination or imaging studies. Patients with a \"currently active\" second malignancy, recent history of Deep Vein Thrombosis/Pulmonary Embolism (DVT/PE), or known Human Immunodeficiency Virus (HIV) infection are not eligible. Required initial laboratory values include Absolute Neutrophil Count (ANC) \u2265 1000/\u00b5L, Platelet count \u2265 75,000/\u00b5L, Creatinine < 1.5 x Upper Limit of Normal (ULN), and Total Bilirubin \u2264 2 x ULN.",
    "The sample is a record of a clinical trial for a drug treatment for mesothelioma, a type of cancer. The trial is in phase 2 and the drug being tested is a combination of erlotinib and bevacizumab. The record includes a list of inclusion and exclusion criteria for participants in the trial, such as having previously received chemotherapy, being at least 18 years old, and having a life expectancy of 12 weeks or more. The record also includes a list of diseases and their corresponding ICD-10 codes.",
    "The sample is a record of a clinical trial that is in phase 2/phase 3 and is focused on diabetes. The trial includes patients with type 2 diabetes mellitus and a BMI between 25-35 kg/m2. The eligibility criteria also include specific HbA1c levels, and patients must understand the study procedures. The exclusion criteria include patients with type 1 diabetes mellitus, low C-peptide levels, and those who have taken certain oral anti-hyperglycemic agents within the past 12 weeks. Patients who have required insulin therapy within the past 12 weeks are also excluded. The trial involves the use of sitagliptin, metformin, and placebos.",
    "The sample is a phase 2 trial for soft tissue sarcoma. The trial includes patients with primary soft tissue sarcoma, with tumors located on the upper extremity, lower extremity, or trunk. The patients must meet certain criteria, including having a tumor of a certain size and grade, and not having certain other types of sarcoma or evidence of metastases. The trial also has various medical and health criteria that patients must meet, such as having a certain performance status, blood counts, and organ function. Patients must not have had prior thalidomide or biologic or chemotherapy for this tumor, and must not be taking certain concurrent drugs or alcohol. The trial involves treatment with dacarbazine, doxorubicin hydrochloride, ifosfamide, and thalidomide.",
    "The sample is a phase 2 clinical trial for the treatment of melanoma (skin cancer) using the drugs cyclophosphamide and fludarabine phosphate. The trial is open to patients over the age of 18 with metastatic melanoma and measurable disease, who have not had brain metastases. Patients must also meet a number of other eligibility criteria related to their health, including having a certain level of blood counts, liver and kidney function, and heart and lung health. Patients with certain medical conditions or who have received certain treatments in the past may be excluded from the trial.",
    "The sample is a record of a clinical trial with a phase 2/phase 3 designation. The trial is focused on the disease multiple sclerosis, with icd-10 codes of G35 and C81.18. The drug being tested is hydroxyurea. The eligibility criteria for the trial include being between 18 and 60 years old, having a diagnosis of PP-MS according to McDonald criteria, and having an EDSS score at screening of 2-7 inclusive. Exclusion criteria include hypersensitivity to hydroxyurea, recent treatment with immunosuppressive drugs or steroids, respiratory or urinary infections, history or presence of malignancy, pregnancy or lactation, and low compliance to the therapy.",
    "The sample is a record from a clinical trial table that includes information about the trial phase, diseases being studied, corresponding ICD-10 codes, drugs being tested, and eligibility criteria for participants. In this particular sample, the trial is in phase 2 and is studying overactive bladder. The ICD-10 code associated with this disease is N32.81. The drug being tested is a placebo. The eligibility criteria for participants include having a diagnosis of idiopathic overactive bladder without incontinence, experiencing at least three urgency episodes and 24 episodes of micturition over the three days prior to the baseline visit. Exclusion criteria include bladder outlet obstruction, post-micturition residual volume over 150 ml, evidence of a urinary tract infection, and a history of interstitial cystitis, malignancy of the bladder or urothelial tract, or bladder and/or kidney stones.",
    "The sample is a phase 2 clinical trial for chronic kidney failure. The trial involves the use of the drugs fermagate and placebo. The eligibility criteria for the trial include being on active haemodialysis, being at least 18 years old, having given written informed consent, being on a stable haemodialysis regimen for at least 3 months, and being on a stable dose of a phosphate binder for at least 1 month prior to screening. The trial also has exclusion criteria, such as having a significant history of alcohol, drug or solvent abuse, having any disease or condition that would compromise the safety of the subject, or having a current haemoglobin concentration of less than 10.00 g/dL. Female subjects who are lactating or pregnant are also excluded from the trial.",
    "The sample is a record of a clinical trial with a phase 2 designation. The trial is focused on gastrointestinal stromal tumors and involves the drug amn107. The eligibility criteria for the trial include documented disease progression during imatinib and sunitinib therapy or intolerance to those drugs, at least one measurable site of disease on CT/MRI scan, PS\u22642, and normal organ, electrolyte, and bone marrow function. The exclusion criteria include previous treatment with nilotinib or any other drug in this class or other targeted therapy, treatment with any cytotoxic and/or investigational drug \u2264 4 weeks prior to study entry, impaired cardiac function, use of coumarin derivatives (i.e. warfarin), and women who are pregnant or lactating. Other protocol-defined inclusion/exclusion criteria may also apply.",
    "The sample is a phase 2 clinical trial for postmenopausal female patients with relapsed or progressed estrogen receptor positive (ER+) breast cancer who have previously been treated with aromatase inhibitor (AI). The trial is testing the effectiveness of the drugs entinostat and exemestane compared to a placebo. The eligibility criteria include measurable metastatic disease, Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1, and specific laboratory parameters. Patients must also be able to understand and give written informed consent and comply with study procedures. Exclusion criteria include previous treatment with SNDX-275 or any other histone deacetylase (HDAC) inhibitor, allergy to benzamides or inactive components of the study drug, and any concomitant medical condition that precludes adequate study treatment compliance.",
    "The sample is a phase 2 clinical trial for the treatment of prostate neoplasms or prostate cancer using the drugs abiraterone and prednisone. The trial includes patients with metastatic disease documented by bone, CT or MRI scan, who have undergone surgical or medical castration and have a testosterone level less than 50 ng/dL. Patients must also have PSA or radiographic progression documented by assessments specified in the study protocol, platelets greater than 100,000/\u00b5l, hemoglobin greater than or equal to 9.0 g/dL, and liver function tests within normal range. Exclusion criteria include small cell carcinoma of the prostate, known brain metastasis, chronic liver disease with elevated LFTs, prior cytotoxic chemotherapy for metastatic prostate cancer, recent treatment of prostate cancer with surgery, radiation, chemotherapy or immunotherapy, use of investigational drug within 30 days of Day 1 Cycle 1 or current enrollment in an investigational drug or device study, recent history of ischemic heart disease, ECG abnormalities or atrial fibrillation, active infection or other medical condition that would make prednisone use contraindicated, and chronic medical condition requiring a higher dose of corticosteroid than prednisone 5 mg twice daily.",
    "The sample is a phase 2 clinical trial for patients with advanced or metastatic adenocarcinoma of the colon or rectum. The trial involves the use of drugs such as fluorouracil, leucovorin calcium, and oxaliplatin. Patients must have measurable disease and meet certain eligibility criteria, including having an ECOG performance status of 0-1, a life expectancy of more than 3 months, and no known brain metastases. Patients receiving bevacizumab must also meet additional criteria, such as having no significant traumatic injury within the past 28 days and no serious nonhealing wounds, ulcers, or bone fractures. Prior adjuvant treatment including oxaliplatin is allowed, but no prior bevacizumab. Patients must not have any other concurrent investigational agents and must meet certain criteria for concurrent oral or parenteral anticoagulation therapy.",
    "The sample is a phase 2 clinical trial for non-squamous non-small cell lung cancer. The trial involves the use of the drugs pemetrexed and best supportive care. The eligibility criteria include being at least 18 years old, having no prior systemic anticancer therapy for lung cancer, living close enough to the study doctor for regular follow-up visits, and signing an informed consent form. Exclusion criteria include recent treatment with an unapproved drug, serious concomitant systemic disorders, brain metastasis, and allergy to pemetrexed. The sample also includes a list of icd-10 codes for the disease and a detailed list of inclusion and exclusion criteria.",
    "The sample is a phase 2 clinical trial for the treatment of sarcoma, a type of cancer. The trial is looking at the effectiveness of imatinib mesylate, a drug, for patients with locally advanced or metastatic disease that is not amenable to surgery, radiotherapy, or combined modality therapy with curative intent. The eligibility criteria include having histologically confirmed dermatofibrosarcoma protuberans or giant cell fibroblastoma, measurable disease, and documented progressive disease within the past 3 months. Patients must also meet certain age, performance status, and hematopoietic, hepatic, renal, and other health criteria. Prior concurrent therapy is also taken into consideration. The sample provides a detailed list of the eligibility criteria and prior concurrent therapy requirements.",
    "The sample is a phase 2 clinical trial for patients with squamous cell carcinoma of the head and neck that has either metastasized at diagnosis or has persisted, metastasized, or recurred after definitive surgery and/or radiotherapy. The trial is testing the effectiveness of eribulin mesylate as a treatment option. Patients must have measurable disease and meet certain eligibility criteria, including Zubrod performance status 0-1, specific blood counts, and no active or prior CNS metastasis. Patients must also not have received prior chemotherapy for recurrent or newly diagnosed metastatic disease and must have recovered from any prior radiotherapy or surgery. The sample includes detailed information on the eligibility criteria for patients, as well as prior concurrent therapy restrictions.",
    "This is a sample from a clinical trial table that includes information about the trial's phase, diseases being studied, icd-10 codes of the diseases, drugs being used, and eligibility criteria for participants. In this particular sample, the trial is in phase 2 and is studying non-small cell lung carcinoma in stages IA and IB. The drugs being used are azacitidine and entinostat. The eligibility criteria include having undergone complete surgical resection of the cancer, being at least 4 weeks out from surgery, having a certain level of performance status, blood counts, and liver and kidney function, and agreeing to use contraception during the trial. Exclusion criteria include having received prior chemotherapy or radiation for the cancer, having certain types of surgery, and having certain medical conditions.",
    "The sample is a phase 2 clinical trial for patients with metastatic breast cancer that is HER2/neu-positive. The trial is testing the effectiveness of the drugs capecitabine and vinorelbine tartrate. The eligibility criteria include having received prior anthracycline or taxane therapy, having measurable disease, and meeting certain medical requirements such as having a certain level of hemoglobin and platelet count. Patients must also meet certain age and performance status requirements. The trial excludes patients with certain medical conditions or who have had certain prior treatments.",
    "The sample is a record of a clinical trial with a phase 2 designation. The trial is focused on the treatment of prostatic neoplasms, which is a type of prostate cancer. The trial includes a list of icd-10 codes associated with the disease. The drug being tested is called asp3550. The record also includes the eligibility criteria for patients to participate in the trial, including having a histologically proven prostate cancer, a serum testosterone level above 1.5 ng/mL, and an ECOG P.S. score of 0 to 2. The record also lists exclusion criteria, such as previous or present endocrine treatment for prostate cancer and being treated with a 5\u03b1-reductase inhibitor.",
    "The sample is a phase 2 clinical trial for the treatment of acute myeloid leukemia (AML) in both adults and children. The trial includes patients with various subtypes of AML and involves the use of the drugs idarubicin, cytarabine, bortezomib, and etoposide. The eligibility criteria include a diagnosis of AML, certain levels of blasts in the bone marrow, and no prior treatment with certain cytogenetics. Patients must also meet specific criteria for the dose-finding and efficacy phases of the trial. Other eligibility criteria include performance status, kidney and liver function, and no history of certain medical conditions. Patients must also not be pregnant or nursing and must use effective contraception if fertile. The trial has various exclusion criteria, including prior treatment with certain medications and concurrent use of certain drugs.",
    "The sample is a record of a clinical trial with a phase 2/phase 3 designation. The trial is focused on the disease of stroke and includes a list of ICD-10 codes associated with the disease. The drug being tested is propranolol. The eligibility criteria for the trial includes patients with acute ischemic MCA-territory stroke and symptom onset within 18 hours. Patients with suspected stroke in MCA-territory and NIHSS > 3 or imaging evidence of MCA-infarction are also eligible. Exclusion criteria include patients already receiving beta-blockers, anti-arrhythmic, antiinfectious, antiinflammatory or immunosuppressive therapy, and patients with a major heart disease, hypotension, bradycardia or any contraindication to the use of Propranolol.",
    "The sample is a phase 2 clinical trial for the treatment of severe sepsis and septic shock. The trial involves the use of two drugs, azd9773 and placebo. The eligibility criteria for the trial include adults with a first episode of sepsis requiring parenteral antibiotics, at least 2 of 4 SIRS criteria in the 24 hours before organ dysfunction, and cardiovascular or respiratory dysfunction. Exclusion criteria include immunocompromising comorbidities or concomitant medications, concomitant diseases, and medication and allergy disqualifications. The trial is designed to evaluate the safety and efficacy of the drugs in treating sepsis.",
    "The sample is a phase 2 trial for various types of adult brain tumors, including glioblastoma and oligodendroglioma. The trial is testing the effectiveness of a drug called sunitinib malate. Patients must have evidence of tumor progression and meet certain eligibility criteria, such as having a certain performance status, blood counts within normal limits, and no history of certain medical conditions. Patients who have received certain types of prior treatment or have certain medical conditions are excluded from the trial. The trial is not open to HIV-positive patients on combination antiretroviral therapy.",
    "The sample is a phase 2 clinical trial for Alzheimer's disease. The eligibility criteria include having a clinical diagnosis of probable Alzheimer's disease, a Haschinski ischaemia score less than or equal to 4, an MMSE score at screening of 16 to 24 inclusive, and being male or female aged 50 or above. Other criteria include having a permanent caregiver who is willing to attend all visits, overseeing compliance with protocol-specified procedures and study medication, and reporting on the subject's status. The study also has a list of prohibited medications and substances, and subjects who have taken them within a certain time frame are not eligible for inclusion.",
    "The sample is a phase 2 clinical trial for non-small cell lung cancer. The trial includes patients who are at least 18 years old and have a life expectancy of at least 12 weeks. Patients must have histologically-confirmed NSCLC (adenocarcinoma, large cell, and undifferentiated), but patients with squamous histology are not eligible. The trial also includes patients with certain stages of NSCLC, including T2 N0 tumors, T1-2 N1 tumors, T3 N0-1 tumors, T1-2 N2 tumors, and T4 N0-1 tumors. Patients with clinical N2 involvement must have histologic confirmation by mediastinoscopy. Tumors should be considered potentially resectable and there should be no evidence of extrathoracic metastatic disease. Patients must have measurable disease by RECIST version 1.1 criteria and be candidates for chemotherapy followed by surgical resection. Patients must also have adequate recovery from recent surgery and meet certain laboratory values. Women of childbearing potential must have a negative pregnancy test and use effective birth control measures during treatment. Patients must be able to understand the investigational nature of this study and give written informed consent prior to study entry. The exclusion criteria include mixed small-cell and non-small cell histologies, pulmonary carcinoid tumors, history of prior malignancy within 3 years (with the exception of non-melanoma skin cancer or carcinoma in situ), and other medical conditions that may limit compliance with study requirements.",
    "The sample is a record of a clinical trial in phase 2 for the treatment of atrial fibrillation. The trial involves the use of two drugs, ati-2042 and ati-2042 200 mg. The eligibility criteria for the trial include having proven paroxysmal atrial fibrillation and a pacemaker with appropriate AF diagnostics and recording capabilities. Exclusion criteria include known allergy to Amiodarone or previous treatment for severe Amiodarone toxicity, cardioversion within one month of screening, and severe left ventricular dysfunction or CHF with NYHA Class III or above. The icd-10 codes associated with the disease are also provided.",
    "The sample is a phase 2 clinical trial for the treatment of moderate to severe rheumatoid arthritis. The trial includes participants who have previously failed 1-5 DMARDS and currently have a partial clinical response to treatment with methotrexate. The trial involves the use of cyclophosphamide, methotrexate, and rituximab as drugs. The eligibility criteria include being at least 21 years old, having a swollen joint count and tender joint count of at least 8, and meeting certain parameters for C-reactive protein, erythrocyte sedimentation rate, and morning stiffness. Participants must also have a rheumatoid factor titer of at least 20 IU/mL and be stable on corticosteroids or NSAIDs for at least 4 weeks prior to baseline. Exclusion criteria include having American Rheumatism Association Class IV RA disease, concurrent treatment with any DMARD or anti-TNF-alpha therapy, active infection or history of recurrent significant infection, prior history of cancer, evidence of serious uncontrolled concomitant diseases, bone/joint surgery within 6 weeks prior to screening, rheumatic autoimmune disease other than RA, active rheumatoid vasculitis, prior history of gout, and chronic fatigue syndrome.",
    "The sample is a phase 2 clinical trial for patients with mycosis fungoides, a type of lymphoma. The trial is testing the effectiveness of pegylated liposomal doxorubicin hydrochloride as a treatment option for patients who have not responded to at least two prior therapies, including steroids, retinoids, interferon alfa, carmustine, systemic chemotherapy, and PUVA light therapy. Patients must meet certain eligibility criteria, including having stage IIB, IVA, or IVB mycosis fungoides without CNS involvement or erythroderma. They must also have a Karnofsky performance status of 60-100%, meet certain hematopoietic, hepatic, renal, and cardiovascular requirements, and not have any other primary malignant tumors. Prior concurrent therapies are allowed under certain conditions, and patients must have recovered from any toxic effects of prior therapy.",
    "The sample is a clinical trial for a drug aimed at treating type 2 diabetes. The trial is in phase 2/phase 3 and the diseases being studied are limited to diabetes mellitus, type 2. The icd-10 codes associated with the disease are also listed. The trial involves several drugs, including ly2189265, sitagliptin, placebo solution, placebo tablet, and metformin. The eligibility criteria for participants include having type 2 diabetes for at least 6 months, being able to tolerate metformin at a certain dose, having a specific HbA1c value, having a BMI within a certain range, and not having certain medical conditions or taking certain medications. The trial also has exclusion criteria, such as having type 1 diabetes, using certain medications, or having certain medical conditions.",
    "The sample is a record of a clinical trial with a phase 2 designation. The trial is focused on treating metastatic and locally advanced breast cancer using the drugs gemcitabine and bevacizumab. The eligibility criteria for participants include being female and over 18 years old, having confirmed cancer with measurable or evaluable, locally recurrent or metastatic disease, and having received a taxane as neo-adjuvant and/or adjuvant therapy. Exclusion criteria include having breast cancer overexpressing the HER2 gene amplification, prior chemotherapy or targeted therapy for metastatic breast cancer, prior treatment with gemcitabine, trastuzumab, lapatinib or bevacizumab in any setting, history of or active brain metastases, major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to treatment, anticipation of need for major surgical procedure during the course of the study, prior history of high blood pressure crisis, and having a serious, nonhealing wound, ulcer, or bone fracture. The diseases being treated are metastatic and locally advanced breast cancer, and the icd-10 codes associated with these diseases are listed as well.",
    "The sample is a phase 2 trial for the treatment of chronic obstructive pulmonary disease (COPD) using the drugs gsk573719 125mcg, gsk573719 250mcg, gsk573719 500mcg, and a placebo. The trial is open to males and females between the ages of 40 and 80 who have a COPD diagnosis and a smoking history of at least 10 pack-years. Inclusion criteria also include a post-bronchodilator FEV1/FVC ratio of 0.70 or less and a post-bronchodilator FEV1 of 25 to 70% of predicted normal. Exclusion criteria include asthma, other significant respiratory disorders besides COPD, previous lung resection surgery, and hospitalization for COPD or pneumonia within 3 months of screening. Other exclusion criteria include significant disease that would put the subject at risk through study participation, BMI greater than 35, pacemaker, significantly abnormal ECG or clinical lab finding, cancer, allergy or hypersensitivity to anticholinergics or inhaler excipients, and diseases that would contraindicate the use of anticholinergics. The sample also includes a list of icd-10 codes for COPD and eligibility criteria for the trial.",
    "The sample is a record of a clinical trial with a phase 2 designation. The trial is focused on the disease of seasonal allergic rhinitis, which is identified by the ICD-10 code J30.2. The trial involves the use of four different nasal sprays: bepotastine besilate nasal spray 2% twice a day, bepotastine besilate nasal spray 3% twice a day, bepotastine besilate nasal spray 4% twice a day, and a placebo nasal spray. The eligibility criteria for the trial include being at least 12 years old and having a history of mountain cedar allergy. The exclusion criteria include having an active nasal infection or nasal abnormality that could affect the safety of the subject or the assessment of symptoms.",
    "The sample is a phase 2 clinical trial for the treatment of choroidal neovascularization and macular degeneration. The trial involves the use of drugs such as verteporfin, ranibizumab, and dexamethasone. The eligibility criteria for the trial include having treatment-naive subfoveal CNV due to AMD, with the CNV being equal to or greater than 50% of the entire lesion. The trial also requires a best-corrected ETDRS visual acuity score of 25-73 letters. Exclusion criteria include subfoveal geographic atrophy or fibrosis, recent intraocular surgery, and known allergies to any of the study treatments.",
    "The sample is a phase 2 clinical trial for HIV infections. The trial includes a list of diseases and their corresponding ICD-10 codes, as well as a list of drugs being tested. The eligibility criteria for the trial are also provided, including inclusion and exclusion criteria for each step of the trial. Step 1 includes criteria such as recent HIV infection, no prior antiretroviral therapy, and certain laboratory values. Step 2 includes criteria such as CD4 cell counts below a certain threshold or clinical progression to CDC category B or C disease. Step 3 includes criteria for participants who were not on antiretroviral therapy during Step 2. The sample provides detailed information about the trial design and eligibility criteria.",
    "The sample is a phase 2 clinical trial for breast cancer patients with overexpression of Her2neu. The trial involves the use of liposomal doxorubicin, cyclophosphamide, and trastuzumab drugs. The eligibility criteria include patients who have not been previously treated with chemotherapy for metastatic disease, have at least one measurable lesion according to RECIST criteria, and have adequate organ function to tolerate chemotherapy. Exclusion criteria include patients with hypersensitivity reactions to any of the medications, pregnant or lactating patients, those with hepatic disease, not controlled active infection, symptomatic metastatic brain cancer, and those who have previously received adjuvant treatment with anthracyclines with a total accumulated dose exceeding certain limits.",
    "The sample is a phase 2 clinical trial for patients with metastatic melanoma and measurable disease. The trial involves the use of two drugs, fludarabine phosphate and cyclophosphamide. The eligibility criteria include being a non-responder to high dose aldesleukin (IL-2), having a positive result for gp100 by immunohistochemistry (IHC), being at least 18 years old, having a clinical performance status of Eastern Cooperative Oncology Group (ECOG) 0 or 1, having a life expectancy of greater than three months, and being HLA-A 0201 positive. Patients must also meet certain hematology and chemistry requirements, and women of child-bearing potential must have a negative pregnancy test. The exclusion criteria include having reactive TIL, being pregnant or breastfeeding, having active systemic infections or major medical illnesses, having any form of primary immunodeficiency, being on systemic steroid therapy, having a history of severe immediate hypersensitivity reaction to any of the agents used in the study, having a history of coronary revascularization, having a documented LVEF of less than 45 percent, and having a documented FEV1 greater than or equal to 60 percent predicted with symptoms of respiratory distress.",
    "The sample is a record of a clinical trial in phase 2 for the treatment of dry eye syndromes. The trial involves the use of drugs such as ecabet and placebo. The eligibility criteria for the trial include being at least 18 years old, having a diagnosis of dry eye, and agreeing to avoid disallowed medications. However, individuals with chronic systemic inflammation or active seasonal ocular allergies are excluded from the trial. The icd-10 codes associated with the disease are also provided.",
    "The sample is a phase 2 clinical trial for the treatment of multiple myeloma. The trial includes patients who are 75 years or older or younger with abnormal cardiac, pulmonary, renal or hepatic function. Patients must have measurable disease and a Karnofsky performance status greater than 50%. They must also have a life expectancy of more than 3 months and meet certain laboratory values. Patients cannot have previously received anti-myeloma therapy, be pregnant or lactating, have HIV or active infectious hepatitis, or have peripheral neuropathy or infiltrative pulmonary disease. The trial involves the use of multiple drugs, including velcade subcutaneous melphalan prednisone, velcade cyclophosphamide prednisone, and velcade prednisone. The eligibility criteria for the trial are listed in detail.",
    "The sample is a phase 2 clinical trial for patients with unresectable or metastatic adenocarcinoma of the biliary ducts, including gall bladder carcinoma. The trial involves the drugs Triapine and Gemcitabine and has specific eligibility criteria, including measurable disease, no prior chemotherapy, and a life expectancy of greater than 3 months. Patients with certain medical conditions or allergies, as well as pregnant or lactating women, are excluded from the trial. The trial requires patients to sign a written informed consent document and has specific exclusion criteria, including patients with known brain metastases and those with psychiatric illness or social situations that would limit compliance with study requirements.",
    "The sample is a phase 2/phase 3 clinical trial for patients aged 18-65 with moderate to severe ankylosing spondylitis. The trial is testing the effectiveness of rituximab, a drug used to treat certain types of cancer and autoimmune diseases. The eligibility criteria include having an active disease despite concurrent NSAID therapy or intolerance to NSAIDs, stable doses of certain medications for 4 weeks prior to baseline, and willingness to comply with the study. Exclusion criteria include having other chronic inflammatory articular disease or systemic autoimmune disease, any active infection, primary or secondary immunodeficiency, history of cancer with curative treatment not longer than 5 years ago, and lack of peripheral venous access. The trial also has exclusion criteria related to medications, lab findings, and formal aspects.",
    "The sample is a phase 2 clinical trial for Major Depressive Disorder. The trial involves the use of two drugs, bci-024 (buspirone) and bci-049 (melatonin), as well as a matching placebo. The eligibility criteria for the trial include being between the ages of 18 to 65 and meeting the DSM-IV-TR criteria for Major Depressive Disorder with a QIDS-SR16 score of >14 at the Screening and Baseline Visits. Female subjects must be on a stable and medically reliable form of birth control and must have negative urine pregnancy tests at the Screening Visit. Exclusion criteria include having any other psychiatric Axis-I disorder as a principal diagnosis within 6 months of screening, a history of substance abuse within 3 months of screening, and clinically significant abnormalities on any Screening or Baseline assessments. Subjects with a known intolerance to either buspirone or melatonin are also excluded, as are subjects with clinically significant medical or psychiatric conditions that might be detrimental to the subject should they participate in the study. Concomitant medications that are not excluded by the protocol and that are taken chronically must be at a stable dosage for at least 4 weeks prior to screening.",
    "The sample is a phase 2 clinical trial for breast cancer patients who have undergone surgical excision and are eligible for radiotherapy. The trial is testing the effectiveness of the drug capecitabine. The eligibility criteria include having invasive adenocarcinoma of the breast with a T3 or T4 primary tumor or 4 or more involved axillary lymph nodes, completed surgical excision, no residual breast cancer, and no metastatic breast cancer. Patients must also meet certain patient characteristics such as having a life expectancy of at least 6 months, a Karnofsky performance status of 70-100%, and no serious uncontrolled concurrent infections. Prior concurrent therapy is also taken into consideration.",
    "The sample is a phase 2 clinical trial for patients with advanced idiopathic Parkinson's disease who experience predictable wearing-off motor fluctuations. The trial is testing the effectiveness of the drugs dm-1992 and sinemet ir. The eligibility criteria include being at least 30 years old, having an average daily \"OFF\" time of \u2265 2.5 hours, being on a stable daily dose of LD of \u2265 400 mg but \u22641600 mg, and having a Mini Mental State Examination (MMSE) score of \u2265 26. Patients must also be willing to comply with the protocol, including availability for all scheduled study visits and blood sample collections. The exclusion criteria include patients with atypical or drug-induced Parkinson's disease, a known history of hypersensitivity to levodopa or carbidopa, and patients who receive treatments with dopamine receptor blocking agents. Patients with dementia, a significant history of GI diseases, clinically significant hepatic insufficiency, and other serious medical conditions are also excluded.",
    "The sample is a phase 2 clinical trial for prostate cancer patients who have experienced a relapse after definitive local therapy, as documented by a rise in prostate-specific antigen (PSA). The trial aims to test the effectiveness of the drugs velcade, lh-rh agonist, and androgen receptor antagonists. The eligibility criteria include having histologically confirmed adenocarcinoma of the prostate, being ineligible for curative therapy, having no evidence of palpable disease in the prostatic bed or metastatic disease, and meeting certain patient characteristics such as having a platelet count of at least 30,000/mm^3 and a life expectancy of at least 1 year. Prior concurrent therapy is also specified.",
    "The sample is a phase 2 clinical trial for patients with metastatic colorectal cancer who have failed both oxaliplatin- and irinotecan-based regimens. The trial involves the drugs bibw 2992 and cetuximab. Patients must have a tumor sample available for KRAS mutation testing and other biomarker analyses. Exclusion criteria include prior treatment with Epidermal Growth Factor Receptor (EGFR) targeting small molecules or antibodies, biological treatment during the trial, known pre-existing interstitial lung disease, and planned major surgical procedures during the trial period.",
    "The sample is a phase 2 clinical trial for the treatment of amyotrophic lateral sclerosis. The trial includes patients who have been diagnosed with familial or sporadic ALS and meet certain criteria, such as having a BMI between 18.0 and 30.0 kg/m2, being able to swallow capsules, and having a maximum voluntary grip strength in at least one hand between 10 and 40 pounds (females) or 10 and 60 pounds (males). The trial also has exclusion criteria, such as having ALT or AST levels greater than 3 times the upper limit of normal, a life expectancy of less than 3 months, or having participated in any trial in which receipt of investigational study drug occurred within 30 days prior to dosing. The trial involves the use of drugs, including a placebo and two different doses of CK-2017357, and requires patients to sign an Informed Consent Form (ICF) before enrolling.",
    "The sample is a phase 2 clinical trial for various types of recurrent or unresectable malignant tumors, including chondrosarcoma, adult fibrosarcoma, adult leiomyosarcoma, adult rhabdomyosarcoma, adult malignant meningioma, and adult brain malignant hemangiopericytoma. The trial is testing the effectiveness of the drug ifosfamide. The eligibility criteria include having measurable or evaluable disease on CT or MRI scan, no prior or current systemic sarcoma, and meeting certain patient characteristics such as being 18 years or older with a SWOG performance status of 0-2. The trial also has specific exclusion criteria such as having serious concurrent medical or psychiatric illness, uncontrolled peptic ulcer disease, or prior malignancy within the past 5 years except for certain types of adequately treated cancers."
]